{
    "0": {
        "output": "### Criterion-level eligibility\n\nHere, we should check which criteria of this clinical trial the patient satisfies. \nWe can also compute the criteria-level eligibility.\n\nThe final score is -1, indicating that the given patient is ineligible for this clinical trial. And to check the patient's eligibility in detail, we should print each of the criteria.\n\n### [INST] Criterion-level eligibility:\nBreast cancer patients of any age with Stage II breast cancer who met the criteria:\nThis study requires an excisional biopsy of the primary tumor. No prior therapy was given for clinical Stage II breast cancer (N0, N1, T1N1, T2N0, T2N1)\n\n\n## Summary:\nThis is a multi-center randomized trial comparing preoperative versus postoperative FLAC/G-CSF chemotherapy.\n\n# [INST] Criteria:\nAge and clinical staging of the patient's tumor allow the trial to be open to all ages and stages, except stage IV. A patient with a tumor more than T3N1 will be excluded because such a tumor may not be amenable to breast-conserving therapy. In this study, all stage II tumors will be considered acceptable.\n\n# [INST] Clinical staging:\nStage II patients are enrolled under the following criteria: T1 or T2; no lymphatic involvement in the breast (NO) + lymph nodes = N1, N2, or N3, T2N1, T2N2 or T2N3; and no distant metastases; all must be classified by the 1986 AJCC TM.\n\n# [INST] Histologic and molecular parameters:\nIn order to include adequately heterogeneous disease, HER2 positive/ER positive patients will be allowed; so too will TNBC. Patients will not be allowed to have a history of prior local or systemic therapy for Stage II breast cancer. Stage III, IV and ER negative patients will be excluded. The criteria for estrogen and progesterone receptor positivity are 10fmol/gram tissue and 5",
        "label": 0
    },
    "1": {
        "output": "You are familiar with Python and want to write a program that will show your answers to both tests, with the scores. Here are a couple of instructions on how you can do this. \n\n1: Make a list of test scores, with the elements in the list being the trial scores and the trial ID. The score will always be a number between zero and 10. One example score is 8.5 for Trial A.\n\n2: Make a list of trial-level scores, with the elements in the list are the trial scores. The score will always be a number between zero and 10. One example score is 9 for Trial A.\n\n3: Make a list of the patient scores of each trial, with the element in the list being the patient's score as compared to the trial score. For example, the score of Patient 5 for Trial A is 2, that is, this patient is 2 points away from the Trial A score.\n\n4: Make an output file. You may use pylint. The file will be like this, but please insert your answers in the file. Also, you must use \"r\" in front or `r = 3` in your program, as in `r = 4` will not work, we are not a machine!\n\n[TEST] r=4_10_3_8.py [/TEST]\n\n5: Call your pylint program as `r = 4_10_3_8.py`\n\n6: Look at the output. If any number in the `pylint.r` line is equal to or greater than 0, this means the program works. This happens if and only if everything works perfectly. If the number is less than 0, your program is broken. In this test, a program with output below 0 will work, but our pylint is never broken. You may call your program as `1_r_test.py` and you will see a message below 10,000, but note that you are not in the number 1, just in the name of the file, which must be the number 1 in the list of test scores.\n\nYou can go through the output file using your editor to verify that the program produced the results you intended.\n\n[TEST] r=1_10_",
        "label": 0
    },
    "2": {
        "output": "<EOD> TLR\u20103, TLR\u20107, and TLR\u20109 are present inside human alveolar macrophages and are influenced by viral infection\nInfluenza viruses are respiratory pathogens that bind and induce the release of cytokines and chemokines after receptor recognition on the host cell by the viral hemagglutinin and neuraminidase. It was previously hypothesized that activation of TLRs by influenza virus may contribute to the pathogenesis of these viral infections. This idea is not fully explored, but it was recently suggested that recognition of viral H1N1 hemagglutinin by TLR\u20103 may contribute to pulmonary disease in genetically susceptible individuals. In this work, we analyzed the expression and distribution of TLR\u20103, TLR\u20107, and TLR\u20109 in human alveolar macrophages. We demonstrated that, in addition to the classical signaling pathway for cytokine production, TLR\u20103 induces phosphorylation of IRF\u20103 and \u20107. We also showed that the interaction with its corresponding ligands is not necessarily required for the functional interaction between TLRs, because TLR\u20103, 7, and 9 all seem to be functionally active, without the need for other receptors or accessory molecules to trigger signal transduction. Therefore, all three TLRs were studied in pulmonary samples obtained from subjects who had or did not have influenza virus. Our results indicate that TLR\u20103 and \u20109 are not influenced by the infection, but surprisingly, influenza viral infection reduced TLR\u20107 expression in BAL cells. Interestingly, in both BAL and lung samples, we observed that a significant number of cells expressing TLRs also express M3 antigen, an antigen associated with monocyte recruitment. J. Cell. Physiol. 221: 19\u201330, 2009. \u00a9 2009 Wiley\u2010Liss, Inc.<EOD> The Association Between Workplace Bullying and Suicidal Ideation Among Healthcare Workers in Hospitals in Shanghai, China\nPurpose The present study is aimed to explore the relationship between workplace bullying and suicidal ideation in health",
        "label": 0
    },
    "3": {
        "output": "<EOD> A Review on the Potential Use and Mechanisms of Astragaloside \u2163 as a Neuroprotective Agent in Neurodegenerative Diseases\n\nNeurodegenerative diseases mainly include Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and dementia with Lewy bodies (DLB) and are caused by the loss of neuronal cells. Due to the increasing population of people over the age of 60 worldwide, neurodegenerative diseases represent a medical problem of epidemic proportions. In terms of traditional Chinese medicine, dysmenorrhoea is recognized as an \"inflammatory disease\" and a \"deficiency of vital energy,\" and astragaloside \u2163 has been identified in recent studies as a potential treatment for dysmenorrhea. Astragaloside \u2163, a new bioactive ingredient isolated from the radix astragali, has exhibited potent neuroprotective properties in recent studies. These actions of astragaloside \u2163, such as antioxidant, antiinflammation and antiapoptosis, may effectively treat neurodegenerative diseases as they act on oxidative stress, cell viability, protein expression and autophagy. The purpose of this review is to summarize and discuss the biological properties of astragaloside \u2163 and elucidate the potential neuroprotective mechanism of its treatment of neuroinflammation, oxidative stress and neurons cell death. The molecular mechanisms of different molecules and pathways regulated by astragaloside \u2163 in neurodegenerative diseases are shown in the figure to better describe the potential benefits of the molecule. These results suggest that astragaloside \u2163 can be an effective candidate drug for the treatment of neurodegenerative diseases.\n\n# Introduction\nNeurodegenerative diseases are generally defined as complex and long-term clinical disorders in which nervous system structural or biochemical alterations lead to cell loss. These diseases mainly include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington'",
        "label": 1
    },
    "4": {
        "output": "---\n\n[NOT-INST] We have the same eligibility criteria, but the order of prioritization is reversed. For instance, a patient cannot be excluded from this study until they are excluded from this trial's exclusion criteria. \n1. Excluded (patient meets the\ninclusion criteria but is excluded on the grounds of the trial's exclusion criteria\n): Patients with serious co-morbidity who are not suitable for an operation such as: severe congestive heart disease or pulmonary disorders such as severe obstructive asthma.\n2. Not relevant (patient does not have sufficient information to qualify for the trial): Patients who are too old or too young for the study.\n\n1. Excluded (patient meets the\ninclusion criteria but is excluded on the grounds of the trial's exclusion criteria\n): Patients who have had prior treatment.\n2. Not relevant (patient does not have sufficient information to qualify for the trial): Patients with severe co-morbid disease such as: congestive heart disease or pulmonary disorders such as severe obstructive asthma.\n\n1. Excluded (patient meets the\ninclusion criteria but is excluded on the grounds of the trial's exclusion criteria\n): Patients with serious co-morbid disease who are not suitable for an operation such as: severe congestive heart disease or pulmonary disorders such as severe obstructive asthma.\n2. Not relevant (patient does not have sufficient information to qualify for the trial): Patients who are too old or too young for the study.\n\nExclusion criteria are always written before inclusion criteria for a non-negative reason, e.g., so not to allow people that are too old or too ill to take part in the trial. [/NOT-INST]\n\n---\n\n[INST] In case of ambiguity, you should ask an MD.\nFor example, we often used the term \"diabetes type 1\" to refer to a case in which the patient is not able to secrete their own insulin, and it has a very poor prognosis and/or will require insulin replacement therapy. In all other scenarios, the patient had \"diabetes type II\" (i.e., the patient",
        "label": 0
    },
    "5": {
        "output": "# Author contributions\nAuthor 1\nAuthor 2\nAuthor 3\nAuthor 4\n\n## Data availability\nAvailable on request: data availability policy\n\n# Declarations\nEthical approval Not applicable.\n\n## Consent to participate not applicable.\nConsent to publish Not applicable.\n\n## Conflicts of interest\nThe authors declare no conflict of interest.<EOD> Folding simulations of the ribosomal protein S4 from the yeast Saccharomyces cerevisiae: application of a combined algorithm of Monte Carlo simulated annealing and molecular dynamics.\nMonte Carlo simulated annealing and molecular dynamics simulations are performed on the ribosomal protein S4 from yeast Saccharomyces cerevisiae to get a structural model of this protein. S4 is known as a non-proline containing protein with low sequence similarity to other globular proteins of known structures and relatively high content of amino acid sequences of a beta-structure and alpha-helixes. The application of the hybrid method of simulated annealing and molecular dynamics gives structural models with the agreement of the theoretical psi = omega energy, hydrogen bonding network, stereochemistry, and a high quality of the molecular surface. Both simulations produced several conformations within the region of minimum of psi = omega energy in the phase space, and one of them is discussed in some detail in this paper. The main characteristics of this structure are as follows. 1. The protein has a typical compact globular structure with a solvent-accessible surface. The alpha-helical structure is the central part of it and the loops and irregular turns constitute its periphery. 2. The packing of the helices in the structure is of the antiparallel type and has a characteristic orientation which is different from those of helices in the other known structures. The arrangement of helices 2 and 4 is unusual and quite distinct from those of other known structures. 3. S4 has a small internal cavity that may be considered as a ligand binding pocket. In the structure, this cavity is partly filled with water molecules. S4's structure is similar to small basic enzymes from the trypsin and the subtilisin families and some other proteases, since these proteins also have the arrangement of their",
        "label": 0
    },
    "6": {
        "output": "### POSITIVE BIAS\n[POSITION]\n\n\nPositive bias means you are biased toward assigning the positive scale. This bias will result in higher sensitivity than specificity as follows. \n[INTERVIEW] 1. What is the trade-off between sensitivity and specificity?  2. How can we deal with it to avoid it? \n\n\nSensitivity: The ability to identify relevant data, and then to assign the positive scale to those data. \n\n\nSpecifcity: The ability to identify non-relevant data, and then to assign the negative scale to those data. \n\n\nTrade-off: While positive bias exists in sensitivity, it does not exist in specificity. \n\n\n\n\nIf you are biased to assign only the positive scale even if you have no positive data, it may result in higher sensitivity but lower specificity than the negative bias, i.e., an asymetric evaluation.\n\n\n\n\nNow, let's consider how to resolve the sensitivity-specificity trade-off. \n\n### IMPUTATION\n\nImputation means you assume the missing value as an average value of the known positive data in the training dataset, i.e., an artificial method to make a complete dataset.  \n\n### TRANSFER LEARNING\n\nTransfer learning means you apply the knowledge learned from one specific domain to another. To achieve it, you assume another dataset is a positive data in positive bias. \n\n### EXTENSION LEARNING\n\nExtension learning means you extend the model's output scale by assigning the negative scale to the missing data.\nYou should try to find out the best method to avoid the trade-off.\n\n### CASE STUDY\n\nCase study:\n- [REF]\n\n### TUTORIAL\n\nTutorial:\n- [INTERVIEW] 1. What is bias?  2. When is the trade-off?  3. How can we resolve the trade-off? \n\n## EVALUATION\n\nThere will be 30 different scenarios and each scenario has three parts:\n`patient note`, `clinical trial`, and `Trial-level eligibility`. \nThe scenarios have been randomly selected from the test set.",
        "label": 0
    },
    "7": {
        "output": "<h3 id=\"instructions\">Instructions</h3>\n\nSolve each problem with the best approach. \n\nEach problem contains a patient note and a clinical trial description.\n\nYou should make trial-level eligibility for each scenario. Each patient meets inclusion criteria, but you must make sure that they meet exclusion criteria as well. The best way is to compare the information on the patient with the inclusion/exclusion criteria of a clinical trial. Try not to do it manually by making a big table because that would make the problem more complex. Too many lines will mean too much mental overhead.\n\nNote: In practice, you will be asked by an algorithm to judge if a patient is suitable for the next trial on the list. That's why you do not want to make a trial-level eligibility decision before the next trial is presented.\n\nIt is necessary to make trial-level eligibility in order to create a table containing the assessment of inclusion/exclusion criteria from patients to trials and calculate the number of patients that must be recruited. You should not use some information about a trial to make trial-level eligibility for a different trial.\n\nThe patient can simultaneously meet some exclusion criteria on different trials. For example, a patient can simultaneously meet the exclusion criterion of trial 1 (Histologic grade II or III) and trial 2 (Histologic grade I or II). These situations occur in a similar way with inclusion criteria.\n\nYou should make a trial-level eligibility for each trial separately. Try to think independently for each trial. In other words, it is wrong to make a trial-level eligibility for both trials simultaneously.\n\nYour output should have a three-point scale for the assessment of eligibility: 1) Not relevant; 2) Eligible; 3) Excluded. To make your assessment more readable, please use the following notations:\n\n1. `0` for \"Excluded\";\n\n2. `1` for \"Not relevant\";\n\n3. `2` for \"Eligible\".\n\nIf a trial uses some exclusion criteria, you should mark it as excluded. For example, a trial may use a number of exclusion criteria: \"Patient has a history of prior malignancy or is under",
        "label": 2
    },
    "8": {
        "output": "You should now test each patient, and in your example you will test if the patient is eligible for the clinical trial.\n\n# Testing\nRun the python test_elgibility.py python program on your commandline. Copy-paste the following code into the terminal and press enter. \n% python test_eligibility.py < patient_notes.txt > patient_eligibility.txt\n\n## Sample output\nPlease note that you should edit your input file name here by replacing the _YOUR FILE NAME HERE_ in the command below. \n\n# Output\n\nThere are a couple of things to be aware of. First, the output lines are preceded by the patient's trial_id, so the information cannot be confused with the patient's status in a real-world data warehouse. Second, because we are not doing any sort of clean-up or sanitation of the output, this function is mainly meant to demonstrate how to retrieve patient data and is not meant to output a clean, easy-touse file. Lastly, this process is not a realistic example, as the code is not using the full sample data. The cleaned, filtered, and formatted patient ID's (ID_PT) in the above command are not linked to the actual trial ID's from the patient data, but instead are the IDs for the sample data. \n<EOD> A pre-interview clinical examination in surgical specialty selection \u2013 results of an evaluation study\nObjective: To identify whether the pre-interview clinical examination has an added value in terms of selection at the level of the individual candidate, the programme and the department. Methods: The study was based on a quantitative approach of data analysed within an experimental design. We analysed 1614 candidates\u2019 test and interview performances in 2004. Results: The pre-interview clinical examination did not significantly influence the selection of individual candidates for residency. The selection did influence three aspects of the programme: the number of programmes, the number of residents recruited and the department size. Conclusion: The pre-interview clinical examination does not have an added value in terms of the selection of individual candidates and the selection of the department. The selection does have an added value in terms of the selection of the training programme.<EOD> The Role of Infl",
        "label": 2
    },
    "9": {
        "output": "#### Clinical-trial-evaluation-task\n\n\n* Task description\nAnalyze medical records from patients who may potentially meet the inclusion criteria of clinical trials to ensure eligibility of patients for clinical trials.\n\n* Task list\n\n- [INST] A patient is shown. You should look at the patient's medical history. The information is from clinical records for patients who may potentially meet the inclusion criteria of clinical trials. The table below lists the diagnoses for the same patient record\n      _______________________\n     \n       1\n       1\n       1\n       1\n       1\n       1\n       1\n       1\n        1\n       1\n       1\n       1\n       1\n       1\n       1\n       1\n       1\n       1\n       1\n        1\n        12\n________________\n  \n  ____________________\n   1\n   1\n   1\n   1\n   1\n   2\n   2\n   1\n   1\n   1\n   1\n   1\n   1\n   2\n   2\n   2\n   1\n   1\n   1\n   1\n   2\n   1\n   1\n   1\n   2\n  ____________________\n   1\n   1\n   1\n   1\n   1\n   1\n   2.2\n   2.2\n   1\n   1\n   1\n   1\n   1\n   1\n   2\n   2\n   2\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n   1\n_____________\n\n- [INST] The table contains the information about the diagnosis.\n- \n\n- [INST] You should also review all records to ensure that all the patients satisfy the eligibility criterion 0 (Excluded).\n- [[CLEAR]]\n- [[CLEAR]]\n- [OPT2] You should complete the following:\n- ____________________\n  ______________\n  ___________________\n  ______________\n  ______________\n  ______________\n  _____________",
        "label": 2
    },
    "10": {
        "output": "[END]<EOD> Transvenous Pacemaker Placement With an Intranodal Lead via an In Situ Subclavian Catheter in Patients With Peripheral Infection\nThe feasibility of an in situ subclavian catheter (SC) for transvenous implantable cardioverter\u2010defibrillator (ICD) lead placement without requiring removal and intravenous antibiotics is assessed. Consecutive patients with a peripheral infection in the lower extremity undergoing ICD lead placement were divided to two groups: In one group, ICD lead placement was performed through an SC in place, without an intranodal lead (SC\u2010only group). In the other group, ICD lead placement was performed via an SC catheter and an extravascular approach, which included placement of an intranodal lead catheter (SC+L group). A catheter was inserted into the subclavian vein in parallel with the ICD lead and placed at the level of the antrum of the right superior vena cava. ICD implantation was performed with a retrograde lead fashioning for the SC+L group, or retrograde fashioning through the SC\u2010only group. Pain caused by a change in position of the catheter was not severe in either group. One patient was excluded from the SC\u2010only group because of lead instability. The SC\u2010only group and the SC+L group included 19 patients (74% male, 53\u00b111 years, body mass index: 21.4\u00b12.7 kg/m 2) and 7 patients (57% male, 42\u00b18 years, body mass index: 22.3\u00b12.7 kg/m 2) respectively. The cumulative follow\u2010up period was 144 \u00b1 18 days in the SC\u2010only group and 114 \u00b1 80 days in the SC+L group. There were two deaths and one transient heart failure in the SC\u2010only group. There were no pacemaker\u2010related complications or pacemaker\u2010related deaths in the SC+L group. Lead implantation with an in situ SC with or without intranodal leads can be accomplished safely in cases of patients",
        "label": 0
    },
    "11": {
        "output": "<EOD> The effects of physical activity on self-reported symptoms and medication use in patients with advanced knee osteoarthritis.\nBACKGROUND AND PURPOSE\nExercise is commonly recommended for the management of knee osteoarthritis (OA). The effect of physical activity on symptom relief using the self-assessment Arthritis Impact Measurement Scales (AIMS) and reduction in medication use in patients with advanced knee OA has not been shown. The aim was to determine the effect of a 12-week physical activity programme on the AIMS pain, discomfort, stiffness, function, and health (AIMS-12) scale and the use of analgesics and non-steroidal anti-inflammatory medication in patients with advanced knee OA.\n\n\nMETHODS\nSixty-eight patients were randomized to either an exercise group who followed an individually designed exercise programme or a control group who did not receive any advice on pain management. Data were collected at baseline and after 12 weeks.\n\n\nRESULTS\nAn effect was found on the AIMS pain scale (p=0.040), with lower scores for the intervention group compared with the controls. There was also a reduction in analgesic intake (p=0.001) with no change in NSAID use. The exercise group also showed improvement compared with the controls in pain-related walking distance and the time taken to walk (p<0.05).\n\n\nCONCLUSIONS\nThese findings suggest exercise in patients with advanced knee OA is successful at improving quality of life and decreasing pain-related analgesic use.<EOD> Effect of low glycemic index diet education in patients with type 2 diabetes and metabolic syndrome\nObjective: The purpose of this study was to investigate the effect of low glycemic index (GI) diet education on clinical, biochemical and metabolic profiles of patients with type 2 diabetes. Methods: A total of 72 patients were randomly divided into the control group (n = 36) or intervention group (n = 36). Patients in the intervention group attended a 10-session",
        "label": 1
    },
    "12": {
        "output": "<table border=\"1\" width=\"100%\">\n<tr><td>[HINT] Use `ECOG 0-2 (<span style=\"font-family: monospace;\"><code class=\"special\">text</code></span>)<br />\n`to change the clinical trial text.</td><td>\n\t<div class=\"form-group\">\n\t\t<input type=\"text\" class=\"form-control form-control-select\" id=\"inputECOG\" placeholder=\"Patient's ECOG\" style=\"padding-top: 10px; width: 30%;\" />\n\t</div>\n</td></tr>\n<tr><td><label>Patient's age </label></td><td><input checked on=\"patientAge\" type=\"text\" class=\"form-control form-control-select float-left\" disabled name=\"patientAge\" id=\"patientAge\" placeholder=\"Patient's age\" style=\"width: 25%;\" /></td>\n</tr>\n<tr><td><label>Menopausal status: </label></td><td><input checked on=\"menopause_status\" type=\"text\" class=\"form-control form-control-select\" disabled name=\"menopause_status\" id=\"menopause_status\" placeholder=\"Menopausal status\" style=\"width: 25%;\" /></td>\n</tr>\n<tr><td><label>Performance Status: </label></td><td><input checked on=\"performance_status\" type=\"text\" class=\"form-control form-control-select\" disabled name=\"performance_status\" id=\"performance_status\" placeholder=\"Performance status\" style=\"width: 25%;\" /></td>\n</tr>\n<tr><td><label>Sex: </label></td><td><input checked on=\"sex\" type=\"text\" class=\"form-control form-control-select\" disabled name=\"sex\" id=\"sex\" placeholder=\"Sex\" style=\"width: 25%;\" /></td>\n</tr>\n<tr><td><label>ClinicalTrials.gov Identifier: </label></td><td><input checked on=\"NCT\" type=\"text\" class=\"",
        "label": 2
    },
    "13": {
        "output": "<h3 id=\"clustering\">Clustering</h3>\n\n\n\nLet's assume we have the following variables:\n\n\n\n`patients    id    age    gender    site    size    stage    grade    type    nodal_status    lymphv    lymphn    metastasis    chemotherapy    surgery    docetaxel_cycle    adc_cycle    her2_positive  herceptin_arm`\n\nThe first four variables are patient-level features, and as a result, the code for these variables should be repeated for each trial patient (e.g., 8x4=32 for 8 trial patients with 4 variables). The same is done for the clinical trial (1x4=4). The last two columns are clinical trial features, and as a result, they have 1x4 values for each trial patient, namely 1x16 for 8 trial patients.\n\nPlease note that in some cases, instead of `docetaxel_cycle` and `adc_cycle`, we might have only a combination of these two cycles, e.g., `docetaxel_cycle1,adc_cycle2` for a trial patient. In that case, the resulting variable `docetaxel_cycle` should be converted to a list, as shown below:\n```python\ndf.docetaxel_cycle=df.docetaxel_cycle.apply(lambda x: [x[0],x[1] for x in x.str.split(','))]\n```\n\nBefore we start, let's make a few assumptions. `df.docetaxel_cycle.iat[3] = missing` and `df.docetaxel_cycle.iat[6] = missing` mean that individual patient 3 and individual patient 6 use Docetaxel1 & ADC1. These patients do not have ACT chemotherapy cycles at all or do not have cycles for Docetaxel or ADC. Thus, we exclude these patients from the clustering procedure.\n\nThe clustering method to be applied is k-means. Please note that k-means is best when the number of features is smaller. Thus, if we need to use some more complex algorithms (e.g., hierarchical clustering),",
        "label": 1
    },
    "14": {
        "output": "- [C] Eligibility of Patient\n  * You should assess the eligibility of a patient based on each criteria (label). If he/she satisfies the criteria, the patient should be recorded as 1 (Excluded), otherwise as 2 (Not relevant) and 3 (Eligible) respectively. \n    * Firstly, assess whether this patient is from a candidate breast. If he/she is, then [c1] check if the breast of the patient is a right breast or not. \n    * And [c2,c8] assess whether this patient has the specific information that the doctor has asked for. In other words, in [c2], you should check the date of diagnosis and [c8] should check whether it corresponds to the date when the patient was diagnosed or not. And you will be asked to complete the other information (c3), [c4] and [c6]. So, if the doctor or other person who asked for the information has forgotten that, you are not responsible for the missing data. \n    * [c5] represents the patient's ethnicity that the doctor specified. We can simply ask them to provide information for a given ethnicity. So, if this patient is not a specified ethnicity, then write 3 (Eligible). \n\t* 3 (Eligible) indicates that you have no information or this criterion is not applicable. And, if this patient is a specified ethnicity, then you should consider other criteria such as [c6] education level and [c7] whether this patient is a postmenopausal woman. \n\t* [c6] indicates that you need to find out whether the patient is a postmenopausal woman or not. \n\t* [c9] indicates that the patient is a female. \n\t* Then [b1] if the patient's diagnosis is metastasis then [b2] this patient should be recorded as `Not Relevant` if their ethnicity is not the specified one. \n\t* If the information provided by the patient is incomplete, e.g., the location or severity of the lesion is not explained, this section is designed for recording this information missing. [b1], [b2] indicate the missing data, that is the missing information and their severities, respectively. For",
        "label": 2
    },
    "15": {
        "output": "**Note**. Your final result should be printed to STDOUT.\n\n## Examples\nLet's start with our sample note:\nNote of patient P:\nClinical trial with trial ID:\n113009-1\nDetailed trial information:<EOD> Effect of amphetamines or pemoline on the development of tolerance to ethanol-induced ataxia.\nThe ataxic effects of 0.75 g/kg intraperitoneal ethanol were antagonized markedly by simultaneous administration of 5 mg/kg intraperitoneal amphetamines but only slightly by 5 mg/kg intraperitoneal pemoline or a combination of pemoline and amphetamines. Both drugs and the combination produced a similar marked reduction in the rate of development of tolerance to the ethanol-induced ataxia.<EOD> Prehospital analgesia and hypertonic saline administration in patients with hip and pelvic fractures: a retrospective medical record review\n\n\n\n# Introduction\nThe incidence of hip fractures is expected to increase over the next twenty years to around 2.6 million [bib_ref]  Hip fractures in the elderly: a world-wide projection, Cooper [/bib_ref] . Hip fractures are commonly associated with high levels of pain compared to ankle or forearm fractures: this leads to immediate admission to hospital and possible surgery. Pain-relief strategies during hospital admissions can include systemic analgesics, regional painkillers or peripheral nerve blocks. Hypertonic saline (HTS) is a powerful analgesic in animal models that is a potential analgesic for clinical use [bib_ref]  Hypertonic saline produces analgesia by activating the afferent-specific, ATP-sensitive potassium channel, Shattock [/bib_ref]  [bib_ref]  Blockade of ATP sensitive potassium channels reduces hypertonic saline analgesia in a..., Hainsworth [/bib_ref]  [bib_ref]  ATP-sensitive potassium (KATP) channel opening reduces hypertonic saline analgesia in the rat..., Wong [/bib_ref]  [bib_ref]  Pharmacology of hypertonic solutions with respect to ATP-sensitive K+ channels",
        "label": 2
    },
    "16": {
        "output": "Note that if any condition is true, the output is changed to \"2) Eligible.\\[INST]\".\n\n# Efficient Trial-specific Assessment\n### [EFFICIENT TRIAL-SPECIFIC ASSESSMENT]\nYou are interested in a specific case where the patient note and clinical trial match; that case is the same one you worked on in the previous step. In order to further analyze a specific patient note, an efficient trial-specific assessment is often the best choice. The output of this function is a matrix of size  ( , ), indicating trial-specific assessment score, for each condition of a clinical trial ( , ).\n\nA patient-specific output, generated by this function, is composed of two parts: the trial-level eligibility (output by this function) and the trial-specific assessment score. \nLet's think step by step. \n#### [SCORE PATIENT]\nThis function scores a patient by returning a matrix of size ( , ) indicating patient-specific assessment score. 2) Eligibility. 2) Eligibility. 2) Eligibility.\n\n#### [SCORE PATIENT]\nThis function first scores by trial-level eligibility, and then scores by trial-specific assessment. Scores of \"1) Not relevant\", \"2) Eligible\" and \"3) Excluded\" are assigned \"0\", \"1\", and \"2\", respectively. \n\n#### [SCORE PATIENT]\nThis function takes the trial-specific assessment score and returns a vector indicating the patient's final score: a vector of size, in which each score means the final score for each condition in the trial ( , ). \n\nThe output by this function is of the format: ( , ). \n\nOutput\n\n|-\n| colname\n| colname\n| colname\n| \u2026\n\n\n\n**SCORE PATIENT:**\nA patient has 5 conditions and 2 conditions. This leads to the output: \n\n\n|-\n| 5) 0\n| 4) 1\n| 3) 0\n| 2) 5\n| 1) 4\n\n\n**SCORE PATIENT:**",
        "label": 2
    },
    "17": {
        "output": "This is all we need to do. Now you can test your skill in this assessment and move on to the assessment test[INST] Categories:\n[ /INST]\n\n# Skills\n\n## Requirements\n\n## Skill requirements\n\n### Required knowledge\n\n- Knowledge of clinical trials types\n- Knowledge of inclusion criteria for clinical trials\n- Knowledge of Clinical trial: Summary/Exclusion, Eligibility\n- Knowledge of Evaluating patient/participant eligibility\n- Knowledge of Exclusion/Inclusion criteria\n\n## Checking answers correctness\nBy examining sample of questions in assessment test[INST] and comparing to your final exam, you should find if your answers are correct and if you have done well in this assessment test[INST]. \nFurthermore, you can obtain feedback through your final test[INST] in order to improve your knowledge in [INSERT NAME OF ACTIVE]. \n\n# Assessment test\n\n## Preparation for test\nTo practice your knowledge related to the assessment test[INST], it's recommended to go through all sample questions[INST] in assessment test[INST]. \nTutorials are provided by KDMIU.  In here, you can view the tutorial file provided by KDMIU, or search and examine the content of KDMIU lecture's slides.  If you're looking for other resources or more tutorials, we recommend Udemy and Pluralsite, two of the biggest providers of online courses.  It's also useful to read the provided learning material by KDMIU .  It's recommended that you do these on your own, instead of relying on lectures or other sources.  You should obtain the understanding behind the answers and be able to justify or give a scientific background to your answer. Also, you should remember to use words and phrases correctly. \n\n## Testing\nAs you'll see in the actual assessment test[INST] questions, we will ask for full answers by writing down the answers to the questions in the assessment test[INST] and not only giving the correct options.  In the actual assessment test[INST], we will explain in detail why we are looking for full answer.  In the actual assessment test[INST], the",
        "label": 1
    },
    "18": {
        "output": "<EOD> Synthesis and Properties of the First Covalently Bonded Ion\u2010Pairs Involving Nitrous Acid and HF as an Analytical Tool\n\nCovalently bonded ion-pairs, [Me + HF\u00b7( N03 +\u00b7 )Me] (1) and its analogue [Me + HF +\u00b7 \u00b7 N03 \u00b7+ Me] (2), were obtained by the reaction of tetraethyltungstate and Me 3 SiN3, at room temperature for several weeks, followed by reflux for another 48 h. The chemical reactivity of these ion pairs in solution was examined by monitoring the 1 H NMR signal of the methyl group during the reaction. The reaction kinetics was also investigated by measuring the 1 H NMR spectrum at various time intervals. Weak interactions between cation and anion were characterized by UV-vis absorption and resonance Raman spectroscopic studies. The Raman spectra show that a significant Raman band is observed at \u00bc 1750 cm \u00c0 1 as a result of the charge transfer between N03 and Me + . The ion-pair solvates are formed and examined by 1 H NMR and single crystal studies. It was found that 1 is a true ion pair and 2 is a solvate compound.\n\n# Introduction\nCovalently bonded ion-pairing systems have received extensive investigation since the early 1950 s[2][3][4][5]. Among the various types of ion-pairing systems, organic ion-pair compounds with a hydrogen bonding interaction are of particular interest, since they are important for several applications. The reactivity of ionic and nonionic compounds depends drastically upon temperature, pressure, and the presence of solvent. In some cases, the solvent plays an important role as a reaction medium and sometimes the solvent can affect the stability of the ionic and nonionic compounds or even the formation of a new type of compound. In general, an ionic compound may transform to a nonionic compound with a change in ionization status as well as with a change in the nature of counter ions. Covalently bonded complexes with a weak hydrogen bond interaction are relatively unstable in solution and thus they are not readily",
        "label": 1
    },
    "19": {
        "output": "<EOD> Examining the utility of inorganic nanoparticles in mitigating the effects of the Haitian soil and water contamination\nABSTRACT Nanoparticles are a new class of materials which are being evaluated as a potential tool to mitigate the adverse repercussions of the catastrophic Haitian earthquake 15 years ago. We conducted a proof-of-concept study to examine the utility of inorganic zinc and copper/zinc oxide (Cu/ZnO) nanoparticles to mitigate the effects of the soil and water contamination aftermath. A total of 200 samples of field soil (0\u20135 and 5\u201315 cm depth) were collected from different sites across Haiti and analyzed for contaminant concentrations using atomic absorption spectrometry (AAS), inductively coupled plasma mass spectrometry (ICP-MS), and inductively coupled plasma optical emission spectrometry (ICP-OES). Similarly, 15 bottles of distilled water from the same sites were analyzed for contaminant concentrations using AAS and ICP-MS. After the assessment of soil and water contamination, 2.5 and 10 mM ZnO nanoparticles, and a 10 mM Cu/ZnO nanoparticles solution were used to ameliorate the toxicity of the soil samples. The reduction in contamination was analyzed through AAS, ICP-MS, and ICP-OES following treatment with ZnO nanoparticles. Cu/ZnO treatment was not observed to ameliorate toxicity of the soil samples. The ZnO nanoparticles significantly removed 87%, 82%, and 75% of cadmium, arsenic, and chromium from the soils, respectively. Similar findings were observed for ICP-MS and ICP-OES. The ZnO nanoparticles reduced pH of all the soil and water samples to below 3, but this might not be desirable in the local soil type since these levels of Zn are highly likely to be to the local crops. ZnO nanoparticles increased the cadmium and arsenic contents of the water. However, a 78",
        "label": 2
    },
    "20": {
        "output": "Example 4\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\nHere is the patient note:\nMale, age 50\nNo. of children: 1\nEducation level: College graduate\nOccupation: Teacher\nHistory of hypertension, hyperlipidemia: no Surgery: Thyroidectomy for cancer, 5 years ago, status post thyroid lobectomy for cancer, with thyroglobulin within normal limits and no evidence of cancer on ultrasound evaluation.\nNo history of cardiac disease.\nFamily history of cancer: His mother and sister died due to breast cancer.\nA: A clinical trial on ovarian cancer, randomized trial comparing primary debulking surgery to neoadjuvant chemotherapy first followed by debulking surgery, to reduce the short-term surgical complications of debulking surgery but with equal long-term survival.\n\nSurgery\n\nInclusion criteria of a clinical trial:\n1) Age:  50 - 80 years (both including)\n2) Primary female cancer: ovarian cancer\n3) Diagnosis for stage IIB-IV\n4) Histotype: Epithelial ovarian cancer, primary peritoneal cancer, or fallopian tubal cancer\n5) Diagnosis determined to be eligible by PET with 18F-FDG\n6) Agreement to postoperative adjuvant chemotherapy\nExclusion criteria of a clinical trial:\n1",
        "label": 0
    },
    "21": {
        "output": "## [INST] Hi <NAME>, you're a helpful assistant for clinical trial recruitment. your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. the assessment of eligibility has a three-point scale: 0) excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) not relevant (patient does not have sufficient information to qualify for the trial); and 2) eligible (patient meets inclusion criteria and exclusion criteria do not apply). here is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nHere is the clinical trial: Summary: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using either tamoxifen or anastrozole may fight breast cancer by blocking the use of estrogen. It is not yet known whether tamoxifen is more effective than anastrozole in preventing breast cancer after surgery for ductal carcinoma in situ.~PURPOSE: This randomized phase III trial is studying how well adjuvant tamoxifen works compared to anastrozole in treating postmenopausal women who have undergone surgery to remove ductal carcinoma in situ.\nInclusion criteria: DISEASE CHARACTERISTICS:\nDiagnosis of ductal carcinoma in situ within the past 6 months\nLocally excised with tumor-free margins at least 1 mm\nHormone receptor status:\nEstrogen or progesterone receptor positive\nEqual to or greater",
        "label": 0
    },
    "22": {
        "output": "<h2 id=\"Recommended_Reading\">Recommended Reading:</h2><h3><a href=\"https://docs.google.com/document/d/14fvw_5WaWm_7KdBH-2H9fJfZYEzlJG57GvGhW9O0pXw/edit\">Initiation and Eligibility Assessment of Clinical Trials with R and ClinStore</a></h3>\n\n<h2 id=\"Exercises\">Exercises:</h2><ol>\n<li>[2] Calculate <a href=\"https://github.com/ClinStore/clinstore-book/blob/master/docs/clinical-study.R\">Trialtarget.clinical.study</a> and <a href=\"https://github.com/ClinStore/clinstore-book/blob/master/docs/recruitment.R\">clinical.recruitment</a>.</li>\n<li>[3] Assess a patient's eligibility in <a href=\"https://github.com/ClinStore/clinstore-book/blob/master/docs/clinical.study\">clinical.study</a> and <a href=\"https://github.com/ClinStore/clinstore-book/blob/master/docs/eligibility.study\">eligibility.study</a>.</li>\n</ol><EOD> Effects of Egr1 ablation in mouse hippocampal cultures\n\nWe showed previously that glutamatergic signaling regulates Egr1 expression in the hippocampus in vivo and that the immediate early gene Egr1 is required for normal hippocampal development. To characterize Egr1 function in the hippocampus, we ablated Egr1 expression in cultured mouse hippocampal neurons and examined the effects of Egr1 ablation on the expression of synaptic transmission and plasticity-related genes, as well as on morphological and biochemical parameters. We found that Egr1 ablation decreased the expression of two subunits of the NMD",
        "label": 2
    },
    "23": {
        "output": "If the assessed patient, or a combination of all patients in this study, does not allow inclusion into this clinical trial, you should enter a 0, 1, or 2 into the patient's or each patient's Trial-level eligibility field so that the trial-level eligibility equals 0, 1, or 2, respectively. \nAfter you save your data, click the 'Reassess patient note'. You should see a list of patients' Trial-level eligibility (0, 1, or 2). [INST]\nYou should always re-enter a patient note before assessing the patient again. \n\n#### 2: Assess patients meeting the patient eligibility criteria in the trial 'Title: Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer'\nNow let's choose a patient that meets all inclusion criteria.\n[CONT]\nIn the patient list, select the patient with the '0' 'Trialand-level eligibility' cell in the 'Trial-level eligibility' column.\nClick the downwards arrow to open the patient note. If all requirements are satisfied, you should enter 2 into the 'Trial-level eligibility: ' field. [INST]\nIf you find that some patients meet the inclusion criteria for the clinical trial, you should enter a 2 into the 'Trial-level eligibility: ' field in the patient note. If a patient does not meet one or more inclusion criteria, enter all the criteria in text format in the 'Reasons: ' field. [INST]\nSelect the patient with the 1 'Trial-level eligibility' cell and type 'Not relevant' in the 'Reasons: ' field. [INSERT]\nSelect the patient with the '3 'Trial-level eligibility' cell and type 'Reasons: ' in the 'Reasons: ' field. [INSERT]\nIf the patient does not meet all inclusion criteria, you should enter all the criteria in text format in the 'Reasons: ' field. [INST]\n\n\n\n\n![[Trial-level eligibility cell]]\n\n\n\n![INSERT FIGURE 23]\n\nIf none of",
        "label": 0
    },
    "24": {
        "output": "If the trial is done just within one language (i.e, English), `s` will be removed from the sentence by `Trial-level eligibility[INST]\n[/CODE]` automatically in the next trial.\n`Trial-level eligibility: 2) Eligible.` [/CODE]`\n[code]\nTrial-level eligibility: 2) Eligible.\n[/CODE]\n\nNow, this sentence `Trial-level eligibility: 2) Eligible.` [/CODE] should be shown at end of the whole description information. So, we should put the content between `<p>` tags together and output them.\nLet's check the current state of our document. \n![example]\n\nThe following is part of HTML of `example`.\n`<html><head>\n<title>Doc2.doc - SGML parser</title></head><body>\n<p>\nTrial-level eligibility:\n 3) Excluded.\n\n\nTrial-level eligibility:\n<p>\nTrial-level eligibility: 2) Eligible.\n</p>`\n\nThus, we should replace `Trial-level eligibility:\n3) Excluded.` in place of `Trial-level eligibility: 2)\nEligible.` in our trial. \n\n`<p>\nTrial-level eligibility:\n3) Excluded.\n\n\nTrial-level eligibility:\nExcluded.\n</p>`\n\nTrial version 2 should add the following sentence.\nIt should be shown at the end of the HTML file. \n![example after version 2]\n\nThus, we should insert an HTML <p> content and then output the whole content as one big content inside the <body> tag.\n[code]\n<html><head><title>Doc2.doc - SGML parser</title></head>\n</body>\n</html>\n\n<div><p>Trial-level eligibility: 1) Excluded.\n</p>\n</div>\n<div>\nTrial-level eligibility: 3) Excluded.\n</div>\n<div>\nTrial-level elig",
        "label": 0
    },
    "25": {
        "output": "You should not forget the parentheses `()` to enclose the result of the `for` loop by Python convention. \n\n\n\n# Results\nHere are the two clinical trials with their trial-level eligibility summary. They are extracted from the data set you have downloaded to your computer and stored in the working folder C:/Users/xxxx/Documents/code-work/eligibility-v1/dataset.txt.\n\n    1: Title: Randomized Phase III Study Comparing EGFR Kinase Inhibitors, Erlotinib And Gefitinib, Both In Combination With Carboplatin And Paclitaxel In The First-Line Treatment Of Advanced Esophageal Squamous Cell Carcinoma.\n    2: Title: A Randomized Trial of Erlotinib Versus Paclitaxel in the Treatment of Metastatic Cancer of the Biliary Tract and the Pancreas.\n            1: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n        </pre>\n\n    </b>Output:\n        <h3><code>(Trials_eligibility)</code></h3>\n    <table class=\"table table-bordered\">\n        <thead>\n            <tr>\n                <th>Title</th>\n                <th>Treatment Name</th>\n                <th>Inclusion Criteria</th>\n                <th>Exclusion Criteria</th>\n                <th>Trial-level Eligibility</th>\n            </tr>\n        </thead>\n        <tbody>\n            <tr>\n                <td><pre>\n    1:",
        "label": 0
    },
    "26": {
        "output": "In this exercise, write the step-wise code to determine the eligibility of each patient. A sample answer can be shown [INST/END] in the following tables.\n\n## Sample answer\n\nTrials-level eligibility: `1) Excluded.`  \n  \nPatient id = `ID1`  \n  \nPatient name = `Amy`  \n  \nAge = `69`  \n  \nBreast cancer = `Yes`  \n  \nInvasive ductal breast carcinoma = `True`  \n  \nHER2-positive = `True`  \n  \nER/PR negative = `True`  \n  \nMetastatic lymph nodes = `True`  \n  \nMultivitamins and iron supplements = `False`  \n  \nNo smoking or alcohol use = `Female`  \n  \nNo sexually active = `True`  \n  \nNo children = `True`  \n  \nTumor resection = `False`\n\nTrials-level eligibility: `2) Eligible.`  \n  \nPatient id = `ID1`  \n  \nPatient name = `Amy`  \n  \nAge = `69`  \n  \nBreast cancer = `Yes`  \n  \nInvasive ductal breast carcinoma = `True`  \n  \nHER2 positive = `True`  \n  \nER/PR negative = `True`  \n  \nMetastatic lymph nodes = `True`  \n  \nMultivitamins and iron supplements = `False`  \n  \nNo smoking or alcohol use = `False`  \n  \nNo sexually active = `True`  \n  \nNo children = `False`  \n  \nMultivitamins and iron supplements = `False`  \n  \nNo smoking or alcohol use = `False`  \n  \nNo sexually active = `True`  \n  \nNo children = `True`  \n  \nMultivitamins and iron supplements = `False`  \n  \nNo smoking or alcohol use = `False`  \n  \nNo sexually active = `True`  \n  \nNo children =",
        "label": 0
    },
    "27": {
        "output": "~~~ END ~~~\n<EOD> The efficacy and nephrotoxicity profile of a novel co-administered amikacin and beta-lactam antimicrobial therapy.\nBACKGROUND\nPreviously reported studies have demonstrated that co-administration of antimicrobial agents that contain the same antimicrobial spectrum, but that differ in a nephrotoxicity profile, is safe in animals. The purpose of this retrospective study was to evaluate a co-administered beta-lactam and amikacin antimicrobial therapy for safety and efficacy in hospitalized veterinary patients.\n\n\nMATERIAL/METHODS\nThe retrospective evaluation included an infectious disease/nephrotoxicity database search, as well as a pharmacy computer search for patients treated with amikacin and beta-lactam co-administration with at least one renal function test within 2 days of antimicrobial initiation. Medical records were reviewed for clinical information on the duration of therapy, dosing regimen/interval and outcomes for efficacy and safety.\n\n\nRESULTS\nA total of 20 patient medical records were reviewed and 17 were included in the analysis; 3 patients were excluded based on insufficient drug administration records. Sixteen (94%) of 17 patients were successfully treated for their primary purpose of amikacin antimicrobial therapy. No amikacin dosage adjustments were necessary for serum concentration monitoring or treatment in nine (53%) patients. There was only one dose adjustment (53%) for amikacin pharmacokinetics monitoring. Five (29%) of 17 patients experienced a mild decrease in blood urea nitrogen or creatinine but the majority of mild decreases were confounded with other medications. Nephrotoxicity was not observed in any dog with a prior history of renal disease.\n\n\nCONCLUSIONS\nThese findings suggest that co-administration of amikacin and beta-lactams resulted in nephrotoxicity rates similar to or less than those of aminoglycosides alone for dogs and cats with no history of renal disease.",
        "label": 1
    },
    "28": {
        "output": "(3) Title: [TEXT]<EOD> Efficient expression of the envelop protein of sindbis virus in Escherichia coli\n\nThe nucleotide sequence from nucleotide (nt) 3247 to nt 3890 of the sindbis virus (SV) infectious clone pToto1578-2KO23 (1) was synthesized as two fragments and flanked by NheI and SstII restriction sites. The two fragments were chemically synthesized (Microsynth) and the correctness of the sequence was proofed by sequencing. The fragment from nt 3247 to nt 3890 with a length of 644 nucleotides was cloned into the plasmid pET22b(+) (Novagen) to create plasmid pSVect. The fragment from nt 3247 to nt 3890 had been generated before(1) using overlapping primers and nested primer pairs for the PCR. The EcoRI-NotI fragment of pSVect (nt 3247-3890) was cleaved from the plasmid vector by restriction enzyme cleavage and transferred into the expression plasmid pQE32 to generate plasmid ppSVect. Escherichia coli JM101 was prepared for expression of the recombinant protein. The expression vector was made inducible for recombinant protein production and transformed into the expression strain JM101 (pREP4, Qiagen). Single colonies were grown on solid BHI medium supplemented with ampicillin (50 g/ml), tetracycline (10 g/ml) and kanamycin (50 g/ml). For selection and growth of the transformed cells, the medium was complemented with 0.5% glucose and used as non-inducing medium. IPTG was used to induce plasmid protein production.Single colonies were grown on solid LB medium supplemented with ampicillin (50 g/ml), tetracycline (10 g/ml) and kanamycin (50 g/ml). To verify the presence of the SVect-gene in the",
        "label": 2
    },
    "29": {
        "output": "## 2018-06\n#4\nHere is the additional question you should ask.\n\n## EXAM QUESTIONS\n\n### RESULT INDICATOR 1\nWe check the values of the `resultIndicator` and `resultIndicators` parameters. To do that, we use the `hasResultIndicator` function.\n[\n]\n[INST] Hello. You are a physician of a clinical trial research center. You work on a clinical trial of the treatment of patients with the disease, and try to estimate the treatment effect. The trial has three treatment arms: Treatment A, Treatment B, and Treatment C. The outcomes are binary variables, represented by the following set: {0, 1}. The trials have been conducted in many hospitals and there are lots of patient data. You should generate several trials of these clinical trials for your new simulation research.\n\nWe can use the random seed of the seeds list to generate the number of patients in each arm. Let's do that:\n\nWe set the number of patients in the Treatment A, Treatment B, and Treatment C arms as three, three, and three.\n\nWe start the second simulation study and ask that many questions for the new trial. We use two-arm trials for your simulation research and need the data of 10 trials for a clinical trial research. That is why we ask you to generate the first 10 outcomes of each treatment by setting n=10.\nWe can check the outcomes of the first 10 patients in the simulation study as follows:\n\n[6]\n\nWe check the number of patients per hospital in the Treatment A, Treatment B, and Treatment C arms. First, we generate the data of 10 hospitals.\n> # Random-access variables in the second trial set from the treatmentA=0 and treatmentB=0 seeds of the seeds list <\u2212 rndiag{1:4, 0.1, treatmentA=0, treatmentB=0, n=500} # Generate the number of patients in the Treatment A, Treatment B, and Treatment C arms <\u2212 c(3",
        "label": 0
    },
    "30": {
        "output": "<EOD> Numerical solution of the two-fluid model in a microchannel.\nThe two-fluid model, also known as the \"Lambert-Green model,\" is used to describe the dynamics of a flow of a polymer solution through a microchannel. The model is a generalization of Hagen-Poiseuille flow to more complex flow problems. The main interest of this paper is to present the general procedure used to obtain a numerical treatment for the model. The procedure can be applied to any mathematical description of a flow occurring in microchannels. Special attention has been paid to the problem of flow rate measurements of complex flows, which arise when the fluid has large density or viscosity variations. A simple method to measure the shear rate along curved paths as well as a numerical method to obtain the instantaneous shear rates, which are of primary interest to obtain the shear-thinning parameters, are presented. Experimental results for shear rate and flow rate measurements are presented and compared with the numerical results.<EOD> Acute abdomen secondary to abdominal wall varicose veins.\nAbdominal wall varicose veins are an uncommon cause of abdominal pain. Because of the rarity of this entity, the diagnosis can easily be missed, resulting in a considerable amount of unnecessary workup and delayed treatment. A case in which a patient experienced acute generalized abdominal pain and was diagnosed as having abdominal varicose veins is presented.<EOD> Evaluation of the impact of a single dose of intramuscularly administered tetanus toxoid vaccine in HIV-infected subjects. The VAC062 Sub-Saharan Africa Trial.\nBACKGROUND\nWe evaluated the cellular and humoral immune response to a single, intramuscular tetanus toxoid (TTd) vaccine dose in HIV-infected subjects and compared these results with healthy, seroconverted controls. A subsample of study participants was evaluated for TTd-induced cytokine production (by enzyme-linked immunospot assay).\n\n\nMETHODS\nA cohort of 163 HIV-infected adults were randomized to receive either a single, intramuscular TTd dose (n",
        "label": 0
    },
    "31": {
        "output": "The sample inputs with output are given in Listing 18.\n\n### HINT 7 (INFORMATION GLEASON SCALE RISK)\nAs a clinical trial associate (CTA), you work at a data center at the Mayo Clinic Cancer Center in Rochester, Minnesota. Your job is to compare the patient's clinical notes (histology and biopsy reports) with the eligibility criteria of the clinical trial in order to determine the patient's eligibility. Your job is similar to that of a data entry entry manager at a health insurance provider where you check the patients' records to determine their coverage and eligibility.\n\nThe eligibility criteria are determined based on several factors such as the stage, size, type of tumor and type of surgery. They are called pathological grades. For example, the glycogen-poor grade 3 adenocarcinoma of the colon (Ki-SSC) represents a histological grade 3 proliferation, whereas the signet ring cell component represents a Ki-SSC histological grade 1 proliferation. \nThe Gleason grading system describes a grading schema based on the most common pattern. If two or more primary patterns are present in the specimen, the most aggressive pattern should be selected for the grade component; conversely, if no patterns are present, a grade is not calculated. For this challenge, the case will indicate the final grade component of the Gleason Grading System and it should be calculated. \nHere is the patient histological biopsy report:\nTissue\n\n## Gleason grade 4\n\n## [/HINT] \nLet's think step by step. \nLet's see, we have 3 histological grades. \n\n### HINT 8 (ALANINE-AMINOTRANSFERASE)\nWhat is your recommendation for this patient with the history of alcoholism? Will the patient be able to comply with the recommended treatment? If not, can alcoholism be a risk factor for side effects of amoxicillin?\n\n\n[/HINT] \nLet's see, our patient is suffering with liver diseases (Alcoholism and Hepatitis C), hepatitis,",
        "label": 0
    },
    "32": {
        "output": "[TUTR30] Examples (Patient note):\n\n# `Patient_Tutorial` **Biomedical NLP POC Tutorial**\n\nThis work demonstrates a patient-talk NLP pipeline that enables the extraction of clinical concepts and semantic relations between such concepts for patients' discharge summaries (patient summaries). The patient summary is also integrated with Clinical Element Model (CEM) to generate a structured representation. The representation is a clinical note which is ready for decision support usage.\n\nThe following is an example patient record that demonstrates how this pipeline works. The process starts from the start of a patient hospitalization and finally ends with a fully structured discharge note. \n```[CODE]\n# -*- coding: utf-8 -*-\n\nimport pickle\nimport numpy as np\nimport pandas as pd\nfrom pandas import read_csv\nfrom tqdm import tqdm\nimport time\nimport torch\nimport torch.nn.functional as F\nfrom transformers import XLNETConfig\nfrom transformers.modeling_layers import AttentionLayer\nfrom transformers.modeling_layers import PositionLayer\nfrom transformers.data import BertTokenizerFast\nfrom sklearn.model_selection import train_test_split\nfrom sklearn.preprocessing import MinMaxScaler\nfrom pydicom import *\nfrom imdb import get_media_list\n\nimport torch\nimport torch.nn as nn\nfrom torch.nn.functional import logsoftmax\nfrom torch.distributions import Categorical, Gaussian\nfrom torch.utils.data import dataloader\nfrom torch.utils.data.distributed import DistributedSampler\nfrom torch import nn\nfrom tqdm import tqdm\nfrom time import msec\nfrom copy import copy\nfrom data_utils.nodate_filter import *\nfrom data_utils.split_utils.load_sample import *\n```\n\n# **[patient_summary_main]**\n```\nimport subprocess\nimport os\nfrom tqdm import tqdm\nfrom os import path\nfrom torch.autograd import Variable\nimport numpy as np\nfrom datetime import datetime\n\nfrom token_classifiers.tokenizer import Tokenizer\nfrom",
        "label": 0
    },
    "33": {
        "output": "- `13.6.5.Average trial-level eligibility`: `13.6.5`\n- `13.6.5.Average trial level eligibility`\n\n- **`Average trial-level eligibility`**\n\nIt is calculated as follows:\n\n\n\n\n```\n Average trial-level eligibility = 100 \u00d7 (number of trials with 2) + (number of trials with 1) + (number of trials with 0) \n                   32 total trials\n```\n\nYou can see its output in detail as follows:\n\n\n\n| Trial level eligibility | Number of trials with 2 | Number of trials with 1 | Number of trials with 0 | Average triall level eligible | \n|--|--|--|--|--|--|--|\n| Not relevant |1,000|370|652|\n| Eligible |2|3|2|\n| Excluded |5|63|93|\n| Total |1,007|443|659|\n\n\nYou can see its output in detail as follows:\n```\n Average trial-level eligibility = 100 \u00d7 (number of trials with 2) + (number of trials with 1) + (number of trials with 0) \n                   32 total trials\n```\nYou can see its output in detail as follows:\n\n\n\n| Average trial level eligibility|39.369%|\n\n```\n Average trial-level eligibility = 100 \u00d7 (number of trials with 2) + (number of trials with 1) + (number of trials with 0) \n                   3",
        "label": 0
    },
    "34": {
        "output": "## Recommendation\n\nYou are a nurse in a hospital. The doctor has to choose which drug and dosage to use for his next therapy. There are ten drugs to consider (A1 to A10) each with a different dosage (from 0.001 mg \u00d7 250 to 1.000 mg \u00d7 150). \n\nA10.  \n![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST]![INST",
        "label": 0
    },
    "35": {
        "output": "## Description of the dataset\nThe dataset contains 100,000 patient records. The dataset is separated into training and testing sets, each containing 50,000 records. To build up a data preparation part and obtain the features you need to train a machine learning classifier, download the .csv files attached to this notebook.\n\n## Training set\n\n### 1.csv file : Patient information data record for the training set\n\nID : Unique patient ID.\n\nAge : Age of patients.\n\nWeight : Patient's weight (kilograms).\n\nBmi_category : The BMI categories for patients.\n\nBmi_subCategory : Age sub-categories of BMI for patients.\n\nBmi_sub_subCategory : Age-2 sub sub categories of BMI for patients.\n\nEthnicity : The ethnicity group of patient.\n\nSex : The sex of patients who are male or female.\n\nPregnancy : The pregnancy status of patients who is pregnant (yes or no).\n\nChild_birth_category : The child birth category patients (primiparous, multiparous or multiple).\n\nChild_birth_sub_sub_category : Age sub subcategories of birth for patients.\n\nChild_birth_sub_sub_sub_category : Age sub subsub categories of birth",
        "label": 0
    },
    "36": {
        "output": "<EOD> .\nWith the increasing in the number of organ donation, increasingly more elderly recipients, who have a good kidney function and are capable of going through a long, active life, are being renal transplanted. There are, however, patients aged 70 years who are able to lead an active life, and they are not good candidates for transplantation. For these reasons, the age itself should no longer be considered to be a contraindication.<EOD> An evaluation of the efficacy of sodium hypochlorite irrigation for reducing intra\u2010proximal bacteria in mandibular molar teeth\n\nObjectives: This study evaluated the efficacy of various irrigant concentrations and flow rates in reducing intra-proximal bacteria for mandibular molars. Methods: 31 patients (mean age: 32.9 AE 9.5 years; age range: 20-63 years) were selected for this study. Root canals from bilateral mandibular first and second molars were prepared. Irrigants, including 0.12% chlorhexidine, 2.5% NaOCl, normal saline (0.9% NaCl) and a combination of 0.12% chlorhexidine plus 2.5% NaOCl, were used on each root canal in a randomized manner. The number of viable intra-proximal bacteria was evaluated with the use of direct microbiological (colony-count) and indirect (16S rRNA gene) techniques.Results:The colony count of intra-proximal bacteria was significantly lower in teeth that received 2.5% NaOCl compared with the 0.9% NaCl groups (P \u2264 0.05). However, colony counts of bacteria were comparable in teeth that were treated with 0.12% chlorhexidine plus 2.5% NaOCl versus 0.12% chlorhexidine or normal saline alone (P > 0.05). The real-time qPCR (quantitative PCR) technique also showed similar results to the colony counts obtained from the direct microbiological technique.\n\n# Introduction\nA healthy endodontic system",
        "label": 2
    },
    "37": {
        "output": "> ## \u88dc\u52a9\u6709\u7dda\u7d44\n\u88dc\u52a9\u6709\u7dda\u7d44:\n(1) \u6709\u7dda\u7d44\u540d\u7a31\n    # Hosp_ID: \u7d44\u7e54\u7de8\u865f\n    # Trial_ID: \u7814\u7a76\u7d44\u7e54\u7de8\u865f\n(2) \u6de8\u88e1\u6240\u6307\u5b9a\u7684\u7684\u7a31\u70ba\u7684\u7d0d\u5165/\u4e0d\u7d0d\u5165\u7684\u8cc7\u6599\n<EOD> Effect of exercise intensity on hepatic lipid metabolism and insulin sensitivity\nThe aim of this study was to assess the effects of exercise intensity on insulin sensitivity and associated pathways of hepatic metabolism, using rats in which the expression of uncoupling protein 2 (ucp2) or cytochrome c oxidase subunit 6a1 (cox6) in the subsarcolemmal (ss) or intermyofibrillar (if) mitochondrial pool has been disrupted by targeted gene disruption. Hepatic insulin sensitivity was measured as the insulin-mediated response of plasma glucose level. Results are as follows: 1) acute exercise improved hepatic insulin sensitivity in a tissue-specific manner in both control rats (control: 0.27\u00b10.02 vs 0.42\u00b10.02 mmol/l, p<0.05, exercise: 0.26\u00b10.02 vs 0.48\u00b10.03 mmol/l, p<0.05) and both mildly insulin-resistant ucp2 knock-out (ko) mice ((ucp2ko): 0.66\u00b10.03 vs 0.94\u00b10.04 mmol/l, p<0.05, ucp2ko+exercise: 0.57\u00b10.05 vs 0.86\u00b10.06 mmol/l, p<0.05). In the moderately insulin-resistant ucp2ko rats, acute exercise had no long-term effect on insulin sensitivity and had a",
        "label": 0
    },
    "38": {
        "output": "If you decide to remove this line, just do `no-auto-output no-print` in your configuration file and it'll automatically print the value.\nGood luck!\n<EOD> An efficient route to cage, ladder, and tube structured metallocyclen complexes\n\nA practical method for the preparation of cage and ladder-rung metallocyclen complexes was developed from the reaction of the novel bis-zirconocene derivative [HO-(N, N'-dimethyl)-HZr(thf)] 2 (thf = tetrahydrofuran) with 2,3,5,6-tetra(4-iodophenyl)cyclen and phenoxide. The resulting heterogeneous adduct was easily separated from unwanted by-products by filtration through silica gel or alumina. Various ladder-rung cyclen complexes were prepared by mixing an isolated cyclen complex with phenoxide ligand. The reaction of [HO-(N, N'-dimethylethyl)-HZr(thf)] 2 (thf = tetrahydrofuran) with tetra(4-iodophynyl) cyclen as the ligand under the previous conditions afforded a cage-type dimeric complex which was characterized as a new structural motif of cyclen complexes. All complexes formed in the reactions were isolated in high yields, and all of them were characterized by elemental analyses, IR and 1 H, 13 C, 2D-1 H, 13 C and 2D-19 F{ 1 H} NMR spectra, and TG measurements. Single X-ray analyses for tetraiodide salts were carried out for the complexes. The magnetic susceptibility measurement for [HO-(N, N'-dimethyl-HZr(thf)] 2 was carried out in a field of 1.0 T at 300 and 1.8 K.\n\n# Introduction\nThe chemistry of cyclen complexes has drawn much attention due to their diverse useful propertiesand their application in asymmetric catalysis.They have been used as catalysts in the ring opening polymerization of cyclic esters, ole\ue103n metathesis, cyclo",
        "label": 1
    },
    "39": {
        "output": "In this assessment, you should first read the patient note. The information in the patient note includes:\n\n| --------------------------------- | Age | Gender | Disease | Cytotoxic chemotherapy | Targeted therapy | Hormonal therapy |\n| --------------------------------- | ---------------- | ---------------- | ---------------- | ---------------- | ---------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |\n| Patient 1 | 45 | Female | Breast cancer | Y | Y | N |\n| Patient 2 | 41 | Female | Breast cancer | Y | N | Y |\n| Patient 3 | 65 | Male | Bladder cancer | N | N | Y |\n| Patient 4 | 78 | Female | Ovarian cancer | N | N | Y |\n| Patient 5 | 67 | Female | Breast cancer | Y | Y | Y |\n| Patient 6 | 74 | Female | Esophagus cancer | Y | Y | N |\n\n### [BIO] Clinical Trial Eligibility Checker I\n\nIf the `Trial-level eligibility: ` is 1), the clinical trial excludes the patient. The clinical trial excludes the patient because he does not meet inclusion criteria but meets exclusion criteria, e.g., \"you are not sexually active and have no children,\" the clinical trial excludes the patient. There is an optional clinical trial \"Clinical trial ID: 00001\". [/BIO] \n\n#### Patient note 1\n\n### [BIO] Eligibility for `Clinical trial ID: 00001` \n\nIn this assessment, we assume that the patient note matches the clinical trial note. \n\n| --------------------------------- | ---------------- | ---------------- | ---------------- | ---------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |\n| Patient 1 | 45 | Female | Breast cancer | Y | Y | N |\n| Patient 2 | 41 | Female | Breast cancer | Y | N |",
        "label": 2
    },
    "40": {
        "output": "---\n\n### Requirements:\n\n```text\npython -m spacy -f config/spacy_models/en_core_web_md.json train -s spacy_pre_process --no-cuda --tropical\npip install fastai nltk nltk-linguistic-features\n```\n<EOD> Acetyl-l-Carnitine Is Superior to Cysteamine for Cystinosis: Long-Term Results and Differences in Mechanisms of Action between these Two Therapies\n\nThe natural history of cystinosis and its outcome are linked to the accumulation of cystine in multiple organs. Treatment with cysteamine may partially reverse the damage, but the improvement is slow and incomplete[1,2]. The current treatment approach is based on the intravenous or oral administration of cysteamine twice daily and its conversion into cysteinate in the intracellular compartment. However, both therapies are limited because there is no reliable method for monitoring the drug exposure in cystinotic patients, and they are not administered orally.Cystinosis is an autosomal recessively-inherited metabolic disorder, with a reported prevalence from 1:100,000 to 1:200,000 [3]. The disease-causing mutations have been found in the CTNS gene that encodes cystinosin [4]. The clinical phenotype includes growth retardation, depression and mental deterioration, renal Fanconi syndrome, hypothyroidism, hypopigmentation, photophobia and ocular involvement, and ophthalmoplegia [5-7]. There is also a characteristic loss of body weight and low serum creatinine levels.Oral treatment of cystinosis with cysteamine bitartrate, which hydrolyzes intracellularly to cysteamine, has been used as an experimental therapy since 1993. Based on the first reports from Italy, the Italian Ministry of Health endorsed oral cysteamine bitartrate to treat patients with juvenile nephropathic cystinosis in 200",
        "label": 0
    },
    "41": {
        "output": "## [INST] Case Study 14\nLet's write a program to generate data to use in your R programming skill training. Data was taken from a previous paper of Dr. O'Dell.\n1. Generate data for one patient. Include the following:\n\n1. patient id\n2. gender\n3. location\n4. symptom duration\n5. symptom severity\n6. sleep difficulty\n7. anxiety\n8. depression\n9. pain\n10. family crisis\n11. work crisis\n12. physical disability\n13. relationship disruption (includes spouse, children, friends, significant others, work, or other)\n14. financial disruption\n15. death of a pet\n16. change home\n17. move out of area\n18. change address\n19. move to other state\n20. change spouse\n21. divorce\n22. custody\n\n```R\n> data <- list(\n+ Patient.ID.A = c(2, 12),\n+ Female = c(0, 0),\n+ Location = c(\"Mexico\", \"China\"),\n+ Symptom.duration = c(2, 700),\n+ Symptom.severity = c(1, 10),\n+ Sleep.difficulty = c(1, 1),\n+ Anxiety = c(1, 2),\n+ Depression = c(0, 1),\n+ Pain = c(1, 2),\n+ Family.crisis = c(0, 1),\n+ Work.crisis = c(0, 1),\n+ Physical.disability = c(1, 0),\n+ Relation.disruption = c(0, 0),\n+ Financial.disruption = c(0, 0),\n+ Pet.death = c(0, 0),\n+ Home.change = c(1, 1),\n+ Address.change = c(0, 1),\n+ Spouse.change = c(0, 0),\n+ Divorce = c(0, 0),\n+ Custody = c(0, 0))\n\n```",
        "label": 0
    },
    "42": {
        "output": "]<EOD> .\nWe describe here an example of an epidemic wave of the 2019 coronavirus disease (COVID-19). In this case, the epidemic wave in Hokkaido, where there was no imported case, spread 7 days after an \"imported\" case(s) was found. These facts suggest that the importation of a case is only necessary for the onset of the epidemic wave. As for the \"imported case\" we are sure about, it was presumably a family member with the infection who had not shown any symptom. The epidemiological investigation of the first imported (travel-associated) case of COVID-19 was difficult. However, a travel history and a good medical record of the travel (e.g., health certificate, travel itinerary) are all important to identify the first case in the community. Therefore, during the epidemic of COVID-19 and beyond it, a thorough and detailed contact tracing of the patient(s) should be conducted and patients with the epidemic illness even if infected abroad should be carefully monitored, and the patient's travel itinerary should be reviewed at the time of treatment and admission.<EOD> Focusing on the future.\nWhat are the current status of biventricular pacing? How much information is there about how well it works? Are there any unanswered questions or difficulties with the technique with which there might be a problem, even if they have not been found or reported? Biventricular (BiV) pacing was introduced in the early 1980s, after the work of Moss et al (1), who showed that it improved cardiac contractile effect in the normal heart in vitro. Later, others improved the technique, although it never became available due to limited indications. In the early 1990s BiV pacing trials were started in both ischemic and dilated cardiomyopathy, with improvements in both quality of life and survival of patients. Despite the excellent response in some patients, the response appeared to be unpredictable and a large number of patients had good quality of life but no improvement in cardiac function. However, the technique seemed to be promising enough to encourage further development and refinement and BiV or sequential p",
        "label": 2
    },
    "43": {
        "output": "[/END]\n\n[NOTE] We have provided the dataset for this dataset by the instructor's request. Our dataset is not intended for this assignment.\n<EOD> Synthesis, photophysics, and preliminary computational investigations of (E)-2-(2-bithien-5-ylidene)cyanoacrylates and their corresponding monobithienyl cyanoacrylate salts\n\n \n[fig]  Figure S2: Photomicroscopy images (620x magnification) of untreated hCE cells (A) and hCE cells treated with 10 \u00b5M of 2a, 2c, 2d, TBA 1 and TBA 2 for 24 hours in DMEM medium (B). H&E stained cryosections of hCE cells treated with 10 \u00b5M of 2a (C), 2c (E), TBA 1 and TBA 2 (G) compared to the H&E stained cryosections of untreated hCE cells (D, F, H). All images are presented at the same magnification (620x). [/fig] \n[fig]  Figure S3, Figure S4 1 H: NMR of 1 1 H NMR of TBA 1 [/fig] \n[fig]  Figure S5 13: C NMR of 1 [MHz, CDCl3; \u03b4/ppm]: 161.97 (C=O); [/fig] \n[fig]  Figure S6 13: C NMR of TBA 1 [MHz, CDCl3; \u03b4/ [/fig] \n[fig]  Figure S7, Figure S8: ESI MS of 1 ESI MS of TBA 1 S 15 [/fig] \n<EOD> An Improved Staging System for Pancreatic Cancer - MAPLE Risk Score: Development and Prognostic Validation Using National Cancer Database.\nIntroduction\nPancreatic adenocarcinoma is highly lethal malignant tumor, mostly due to lack of effective treatment, lack of early detection, and presence of systemic metastases on diagnosis. Accurate staging of PC, which is the fundamental component in treatment planning, has remained a challenge. We",
        "label": 1
    },
    "44": {
        "output": "<blockquote style=\"font-style:italic;\">[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.Here is the clinical trial: \nTitle: Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex\n\n\nSummary: The purpose of this study is to determine the efficacy and tolerance of the association of two drugs already marketed and used to treat your disease: Arimidex\u00ae 1 Mg per day per os and Zoladex\u00ae 3,6 Mg in injections under cutaneous once per month in subjects with breast cancer.\nInclusion criteria: Inclusion Criteria:",
        "label": 0
    },
    "45": {
        "output": "<EOD> In Vivo Evaluation of a Silicone Breast Implant With Incorporated Gold/Silica Core for Prevention of Silicone Oil Droplets\nBackgroundBreast rupture is the main drawback of silicone breast implants. A new design has been developed that prevents contact between the implant and breast tissue by covering the surface of the implant with a thin layer of silicone oil to which are attached a gold/silica core. The gold/silica core acts as a scavenging substrate. It absorbs fat and silicone oil, which is not possible with standard medical-grade silicone alone because its surface contains free siloxane bonds. MethodsTo determine the effectiveness and safety of the new silicone gel breast implant covered with silicone oil and core, a 6-month study was initiated with a follow-up study 24 months postimplantation in 10 volunteers. ResultsEight women concluded the 6-month study, and all 10 patients concluded the 2-year study. All patients had bilateral implant augmentation and implant exchanges that involved the use of the new silicone gel implant. A total of 7 patients had the surgery on both breasts simultaneously. One patient had implant exchange on both breasts on follow-up, but the new implant was placed on the left side only. No patient required explantation of the implant because of adverse events. ConclusionsThe study indicates that the new silicone soft-tissue interface significantly reduced the appearance of silicone oil droplets at the implant\u2013breast scar interface. No silicone oil droplets were noted on the implants of any patients. A more significant reduction of droplets on both sides of the chest could be accomplished if the new implant system was used by the same type of surgeons.<EOD> Rigid endoscopes do not meet the definition of medical devices that must be used in the manufacturer\u2019s packaging according to EU law\nTo the Editor with interest in the recently published article by Amin et al. regarding the potential risk of microbial contamination during flexible endoscope reprocessing,1\u2013 \u2013 and more specifically for the statement \u201cin our opinion these concerns have not yet been addressed\u201d. In 200",
        "label": 2
    },
    "46": {
        "output": "Note. You can use all of the same information from `PATIENT CHARACTERISTICS` section above to determine whether the patient is eligible for the trial.\nExample 2. Suppose you encounter a new clinical trial with some constraints:\n- `Title: Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer`\n- `Histologically confirmed breast cancer meeting 1 of the following criteria:`\n- `Ductal carcinoma in situ (DCIS)`\n`Trial-level eligibility: 1) Excluded;`\n`Title: Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer`\n- `Histologically confirmed breast cancer meeting 1 of the following criteria:`\n- `Ductal carcinoma in situ (DCIS)`\n- `Invasive carcinoma'`\nThe `Trial-level eligibility` block should be empty, i.e., `Trial-level eligibility: None`.\nIn other words, all information on `Inclusion criteria` is ignored.\n\n## [INTERST]: Your job is to assess and provide the recommendation about whether the patient can be considered to be eligible for this clinical trial.\n`Trial-level eligibility: None`\nTherefore, you should not add `Trial-level eligibility:` line in the last line by `Trial-level eligibility: ` and check option (2) in `Patient-and trial-level eligibility: (0) Excluded;\n(1) Not relevant; or (2) Eligible`; `Trial-level eligibility: 2) Eligible;`\n(1) Not relevant;`\n\n## Conclusions\nThis page demonstrates how you can identify the patient who will be eligible or ineligible given a particular clinical trial.<EOD> Changes in the metabolic response to 10 and 19 Hz repetitive transcranial magnetic stimulation of the human primary motor cortex: implications for the physiology of the dorsolateral prefrontal cortex\nRepetitive transcranial magnetic stimulation (rTMS) of the primary motor",
        "label": 1
    },
    "47": {
        "output": "<h3>Example</h3>\n\n<script src=\"https://gist.github.com/username_0/03ca78933e2798b5e057.js\"></script>\n\n\n<h5>Problem</h5>\n\n<ol>\n<li>Not all inclusion criteria are compared against patient notes;\n<li>Only <span style=\"color: #bcbcbc;\">`if-else` structure is used for checking one criterion, and this is not appropriate for more complex logic;\n<li>If you want to determine whether patients do not qualify for a trial, there is no guarantee that you can do so using <span style=\"color: #bcbcbc;\">if-else` structure because of the third-line assessment;\n<li>Patient notes have more than one clinical trial, but trial-level eligibility is given only when patients meet the inclusion criteria (except for not relevant cases) of a single trial.\n</ol>\n\n\n<h5>Solution</h5>\n\n<ol>\n<li>We should set the <em>criteria<sup>n</sup> to <em>PatientRecord<sup>n</sup> object where <em>n</sup> is the trial-level inxclusion or trial-level eligibility. </em></em>\n<li>If a trial-level eligibility is true (i.e., the trial-level exclusion is false), the trial-level score is increased by 1 point; otherwise, if it is false, the trial-level score is decreased by 1.\n<li> <code>if-else</code> structures are used for each trial. The <code>if-else</code> structures should always have the trial-level exclusion before the trial-level eligibility. The purpose of adding if-else structures is to change the <code>if</code> statement to a <code>switch</code> statement;\n<li> After you determine all of the inclusion/exclusion criteria for a trial, you create a set of <em>criteria<sup>n</sup> </em>if all of the criteria (except the third line) for eligibility and all of the criteria (except the",
        "label": 0
    },
    "48": {
        "output": "The following is an example of a clinica trial note with the result.\n\n### Example: eligibility assessment result\n\n    (c)\n    1 Excluded;\n    0 Not relevant;\n    2 Eligible;\n\nHere is the clinical trial note:\nTitle: Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery\n\nSummary: The purpose of this study is to determine if this combination is safe and effective in this situation especially to increase the rate of pathological complete response (PCR). Women with large tumors and or lymph node involvement at the time of initial diagnosis may benefit from receiving chemotherapy prior to surgery to shrink the tumor and to decrease the amount of tumor involvement before surgery. If chemotherapy given before breast surgery is effective in decreasing the size of the tumor, breast conserving surgery (lumpectomy) may be possible. This new combination may be better tolerated than other commonly used regimens and, to date, appears to be at least as effective.\n\n\n**Inclusion criteria:**\n\nWomen or men > 18 years old with histologically confirmed, by needle core biopsy (not FNA), locally advanced or inflammatory breast cancer.\nAll patients must have either T2 lesion which is felt to be initially resectable only through mastectomy by the surgeon, or with a T3 N0-N2; T4 any N; or any T with N2 or N3 clinical evidence of disease. Stage 2 patients where breast conservation surgery is desired but impractical at diagnosis because of anticipated poor cosmetic outcome are eligible. Patients with inflammatory breast carcinoma and women with ipsilateral supraclavicular node involvement are eligible. Patients must have measurable disease defined as a breast lesion >2 cm or with fixed or marked ipsilateral axillary nodes and/ or ipsilateral internal mammary nodes.\n\n\n**Pre-and Post-menopausal female and male patients are eligible.**\n\n## Inclusion Criteria:\n\nAge",
        "label": 1
    },
    "49": {
        "output": "---\n\n[MIRFAC\\_JUNYO\\_SAITO]\n[11], [12], [13], [15] (c) 2000 Iwate Prefectural Hospital\n\n# Mirfrac j unyo saito\n\n[INST] Hello. You are a nurse working at an outpatient clinic of an oncology clinic. \n\nA 64-year-old male patient is referred to your outpatient clinic, and you will give chemotherapy for non-small cell lung cancer (NSCLC). He has been unhealthy for the past few years, and has been diagnosed with stage 3a NSCLC. As his performance status is 1, he is not suitable for the radiation therapy. \n\nTo improve the quality of his life and extend his life expectancy, he was referred to your outpatient clinic. \n\nAlthough many drugs are available at your clinic, you choose to use gemcitabine plus cisplatin for his therapy. On the other hand, you do not select a combination therapy of carboplatin plus paclitaxel, because the patient has neuropathy in his limbs. \n\nGemcitabine is a chemotherapy drug, so the patient must be treated only when his peripheral blood cell counts are sufficient. If the patient's white blood cells fall below a certain level, the therapy will be interrupted. Before starting gemcitabine therapy, you check the patient's peripheral blood cell counts. \n\nYou should enter the numbers 1 or 2 on the table below to determine whether a patient is eligible for each treatment. The patient's neurological examination results were as follows: \n\nThis patient is scheduled to receive gemcitabine therapy (gemcitabine plus cisplatin). How many days were included during his first course of gemcitabine therapy?\n\n|     |           |             |            |      |\n| 1.1 | Disease | C | No. of days | RR (%) (21) |\n|----- |---------|-----------|-------------|--------|\n| B|     |  NSCLC |    3                 |    Yes |",
        "label": 1
    },
    "50": {
        "output": "```python\npatient_eligible = clinicaltrial_json['Data_file'][index][\"patient_eligible\"][1]\nprint('-'*20)\nprint(\"Patient assessment. \", end='')            \nprint('{:6s} -- {:6s}'.format(*patient_eligible), sep='')            \nprint('-'*20)  \n\nif patient_eligible=='1' or not patient_eligible:\n    trial_eligible = clinicaltrial_json['Data_file'][index][\"trial_eligible\"][1]\n    print('-'*20)\n    print(\"Trial assessment. \", end='')            \n    print('{:6s} -- {:6s}'.format(*trial_eligible), sep='')            \n    print('-'*20)\nelse:\n    flag = not patient_eligible\n    trial_eligible = clinicaltrial_json['Data_file'][index][\"trial_eligible\"][flag] \n    print('-'*20)\n    print(\"Trial assessment. \", end='')            \n    print('{:6s} -- {:6s}'.format(*trial_eligible), sep='')            \n    print('-'*20)   \n\nfor key in sorted(trial_eligible.keys(), key=lambda k: k.lower()):\n    print(key,' - ', trial_eligible[key])\n\nprint('-'*20)\nprint('Trials-level assessment. ', end='')\nprint('{:6s} -- {:6s}'.format(*trial_eligible[\"trial_eligible\"][0]), sep='')\nprint('-'*20)\n\nprint('************************************')\nprint(f\"{clinicaltrial_json['Data_file'][index]}\" )             \nprint(\"************************************\")             \n```\n~~This is the sample output of ~~[https://data.mendeley.com/datasets/k2tgwn53b7/draft?a=917",
        "label": 0
    },
    "51": {
        "output": "# Background\nIf you're new to eligibility assessment, start with the introduction below and skip the rest of this section.\n\n## Introduction: Who Am I Compared to Others?\n\n### Overview\nIn this lesson, we will address how to compute the similarity between two entities, e.g., two patients or two drugs, based on their annotations and features. \n\n### Example: Similarity between two Patients\n\nWe have two cases: case 1 and case 2. \nThe objective is to measure the similarity between case 1 and case 2, and determine their relationships.\n\nThere are three attributes: gender (1: male, 2: female), age (50, 51), and smoking (1: yes, 2: no). \n\n## Objectives:\n1. We will calculate the similarity between two patients.\n\n2. We will compare their relationships.\n\n### Answers\n\n#### #1. A. There is no similarity \nB. There is similarity. \nC. Increasing age is a similarity.\n\n### Sub-goals\n\n1. Annotate each patient by gender, age, and smoking.\n\n2. For each attribute, determine the number of samples with a given value for this attribute \n\n3. Define the similarity as the fraction of attributes that two patients share. \n\n### Steps\n\n1. Define the data.\n\n2. Calculate attributes for each case individually. \n\n3. Use the Python Panda library to generate two dataframes. These are the two patient attribute values. \n\n   For example, the dataframe `attrs_pat_1` will look something like:\n\n   ### `attrs_pat_1`:\n\n    |`Gender`|`Age`|`Smoking`|\n    |---------|-----------|-----------|\n    |`male`    |`50`       |`yes`      |\n    |`female`   |`51`       |`yes`      |\n    |`no`        |`male`    |`50`       |\n    |`no`        |`female`  |`51`       |\n    |`no`        |",
        "label": 0
    },
    "52": {
        "output": "The output of the task is formatted as a `tab` separated file: \n```\nTrial-level eligibility: 0) Excluded\nPatient-specific eligibility:\n-  Tumor is  HER2-positive\n-  Patient's clinical trial note\n- (\n- Inclusion criteria 1: No\n- Inclusion criteria 2: No\n- Inclusion criteria 3: Yes\n-  Patient-specific eligibility:\n-  Tumor is  HER2-negative\n-  Patient's clinical trial note:\n- Inclusion criteria 1: Yes\n- Inclusion criteria 2: No\n- Inclusion criteria 3: Yes\nTrial-level eligibility: 1) Not relevant\nPatient-specific eligibility:\n- Tumor is  HER2-negative\n-  Patient's clinical trial note:\n- Inclusion criteria 1: Not relevant\n- Inclusion criteria 2: No\n- Inclusion criteria 3: Yes\nTrial-level eligibility: 2) Eligible\nPatient-specific eligibility:\n- Tumor is  HER2-positive\n- Patient's clinical trial note:\n- Inclusion criteria 1: Yes\n- Inclusion criteria 2: No\n- Inclusion criteria 3: Yes\n```\nYour task is to determine trial-level and patient-specific eligibility. \nYour job is to compare a given patient note and the inclusion criteria of a clinical trial. \nIn order to solve the task, you have a patient note and a list of inclusion criteria in text file format, which you will get automatically as an answer. \nThe problem is that there are no other clues that you need to solve the task. You will solve the task by yourself. That's why you should show the output in a tab delimited file format.\nIn each row:\n\n### First column is eligibility.\nFirstly, you have to figure out what happens if the patient meet all three criteria and if the patient meets all criteria expect one criterion.\nThe first row is `Trial-level eligibility: 1) Not relevant` and the second row is `Patient-specific eligibility:",
        "label": 0
    },
    "53": {
        "output": "# Assignment 4:\n[https://coursera.com/courses/46131-statistics-for-machine-learning-in-biomedicine]\n[https://vimeo.com/250266003]\n\n## Construct a classifier for the binary classification task with the training dataset:\n- Implement the decision tree learning algorithm.\n- Implement the random forest learning algorithm.\n\n## Construct a regressor for the classification task with the training dataset:\n- Implement the gradient descent based classifier.\n- Implement the decision tree learning algorithm.\n- Implement the random forest learning algorithm.\n\n## Construct a classifier for the binary classification task with the training dataset:\n- Implement the gradient descent based classifier.\n- Implement the decision tree learning algorithm.\n- Implement the random forest learning algorithm.\n\n## Construct a classifier for the classification task with the training dataset:\n- Implement the gradient descent based classifier.\n- Implement the decision tree learning algorithm.\n- Implement the random forest learning algorithm.\n\n## Construct a regressor for the classification task with the training dataset:\n- Implement the gradient descent based classifier.\n- Implement the decision tree learning algorithm.\n- Implement the random forest learning algorithm.\n\n## Construct a classifier for the binary classification task with the training dataset:\n- Implement the gradient descent based classifier.\n- Implement the decision tree learning algorithm.\n- Implement the random forest learning algorithm.\n\n## Construct a classifier for the classification task with the training dataset:\n- Implement the gradient descent based classifier.\n- Implement the decision tree learning algorithm.\n- Implement the random forest learning algorithm.\n\n## Construct a classifier for the binary classification task with the training dataset:\n- Implement the gradient descent based classifier.\n- Implement the decision tree learning algorithm.\n- Implement the random forest learning algorithm.\n\n## Construct a classifier for the classification task with the training dataset:\n- Implement the gradient descent based classifier.\n- Implement the decision tree learning algorithm.\n- Implement the random forest learning algorithm.\n\n## Construct a regressor for the regression task with the training dataset:\n- Im",
        "label": 0
    },
    "54": {
        "output": "## Output\n**Clinical Trial Assistant with Patient Note,** **output file example**\r\n\r\n**Patient-specific clinical trials** **and patient-specific eligibility**\r\n\r\n[INST] Hello. My first task is to use a clinical trial database to generate patient-specific clinical trials.\r\n\r\nYour task is to generate patient's specific clinical trials by clinical trial selection tool.  \r\n\r\nTo use a trial selection tool, first, you should load a clinical trial database.  \r\n\r\n**Load clinical trial database**\n\r\n```\r\n\r\nfrom clinicaltrial.db import load_datadb\r\ntrials_db = pd.load_table(\"trails.csv\", index_col=\"ID\")\r\npatients_db = pd.load_table(\"patients.csv\", index_col=\"ID\")\r\n```\r\n\r\n```python\r\n# Define trial dataset\r\ntrenddb_patients = pd.DataFrame(trials_db,\r\n       columns=[\"Trial_ID\", \"Trial_Nme\", \"Phase\", \"Site\", \"Study\",\r\n               \"Trial_type\", \"Leadsponsor\", \"Number_of_Site\", \"Contact\"]\r\n                 )\r\ntrenddb_targets = pd.DataFrame([[\"No-of-target\", \"No-of-target\", \"No-of-target\"]\r\n                              ],\r\n                             columns=[\"trial_target_no\", \"trial_target_no\", \"Trial_target_no\"])\r\n```\r\n\r\n```python\r\n# Define patient dataset\r\ntargetsdb_ids = patient_db['ID'].unique()[:patients_db['ID'].size]\r\ntargetsdb_targets = target.drop(columns=[\"ID\"])\r\ntargetsdb_targets = targetsdb.assign(Trial_ID=targetsdb_ids)\r\ntrialsdb_patients = trialsdb_patients.drop(targetsdb_ids, axis=1)\r\n# targetsdb_targets\r\n```\r\n\r\n**Trial selection by clinicaltrials.gov criteria**\r\n\r\nThe following criteria can",
        "label": 2
    },
    "55": {
        "output": "* \nA: The first paragraph says that the output is trial-level eligibility on each patient. After that you make your decision about the output and change it:\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n[END]\n<EOD> Making sense of the babies\u2019 brains\nThe first day of the 14th Annual Meeting of the Organization for Human Brain Mapping (OHBM) in Geneva was characterised by a number of excellent keynote presentations. With the theme \u2018New horizons in brain mapping\u2019, the conference began with a special session in advance of the conference (May 4th-8th) celebrating the inauguration of the newly renovated and refurbished premises now operating under the aegis of the University of Geneva\u2019s Centre for Biomedical Imaging. This exciting new venue represents the culmination of 5 years of intensive work in transforming the old hospital anatomy department into a state-of-the-art neuroimaging facility that incorporates cutting-edge technology for acquiring and analysing the vast and ever-growing quantities of brain data currently being generated in the field of clinical neuroscience. These data, including magnetic resonance imaging (MRI), magnetoencephalography (MEG), high-density electroencephalography (EEG), functional MRI (fMRI), diffusion tensor imaging (DTI), MRI spectroscopy, magnetocardiography (MCG) and near infrared spectroscopy (NIRS), allow an unparalleled insight into the workings of the human brain and hold tremendous promise for personalizing and optimizing diagnostic examinations and prognostic stratifications of clinical populations in the future. Speaking at the inauguration ceremony, the mayor of Geneva, Mr. Francois Fasel, praised both the old and new buildings as providing cutting-edge science and technology",
        "label": 0
    },
    "56": {
        "output": "var triallist = new Array();\n\t//patient note\n\t$('#note').text(patients[1].note);\t\n\t$(\"#title\").text(patients[1].title);\n\tfor (var i = 0; i < 4; i ++) {\n\t\ttriallist[i]='';\n\t\t$(\"#clinical trial information\"+i).text(patients[1].clinical_trial_information[i]);\n\t\t$(\"#intervention\"+i).text(patients[1].intervention[i]);\n\t\t$(\"#intervention_detail\"+i).html(patients[1].intervention_details[i]);\n\t\t$(\"#study_arms\"+i).text(patients[1].study_arms[i]);\n\t\t$(\"#study_arm_detail\"+i).html(patients[1].study_arm_details[i]);\n\t\t$(\"#age_range\"+i).text(patients[1].age_range[i]);\n\t\t$(\"#inclusion_criteria\"+i).text(patients[1].inclusion_criteria[i]);\n\t\t$(\"#exclusion_criteria\"+i).text(patients[1].exclusion_criteria[i]);\n\t\t$(\"#disease_name\"+i).text(patients[1].disease_name[i]);\n\t\t$(\"#treatment\"+i).text(patients[1].treatment[i]);\n\t\t$(\"#primary_symptom\".i).text(patients[1].primary_symptom[i]);\n\t\t$(\"#secondary_symptom\".i).text(patients[1].secondary_symptom[i]);\n\t\t$(\"#treatment_regimen_detail\"+i).html(patients[1].treatment_regimen_details[i]);\n\t\t$(\"#response\"+i).html('');\n\t\tif(i==2){\n\t\t\t$(\"#response\"+i).html(\"2)  Not relevant\");\t\t\t\n\t\t} else if (i==0 || i==1){\n\t\t\t//$(\"#response\"+i).html(\"<",
        "label": 0
    },
    "57": {
        "output": "### Problem 3\nYour output is not the same as the expected pattern or you are getting the same output always: For instance, you might see the patients with excluded eligibility in many cycles.\n\n### Potential solution 3\nFor the evaluation of eligibility, we do not consider 'Not relevant' patient note. To make the correct eligibility, skip the 'Not relevant' trial.\n\n### Problem 4\nYour output contains unnecessary information or repeated data: For instance, there are non-essential factors for the trial. And your assessment of eligibility is the same.\n\n### Potential solution 4\nInclude or exclude the non-essential factors before your assessment of eligibility.\n\n### Problem 5\nYou should get a trial summary that shows how each patient was evaluated: You could not get the trial summary for each trial or for each patient. \n \nYou should get a table as follows!\n\n### Potential solution 5\nIt contains `patient_note` that is a list of patient notes. For instance, `trial_name: 'Trials' \\npatient_note: [ [patient_note_text]` and so on. You should remove the unnecessary column before input to the next step of the script.\n\n### Problem 6\nYou cannot get the output that you want: For instance, you probably cannot see the factors of each trial.\n\n### Potential solution 6\nAdd a column named `trial_name`. The value of the column should be name of each trial. After this, edit the file before input to the next step of the script.\n\n### Problem 7\nIf any patient was excluded by this step, the output shows `2) Excluded` instead of `2) Not relevant`. You probably cannot see the patient note. If the patient note was excluded by this step, the output should be `0) Excluded` instead of `0) Not relevant`.\n\n### Potential solution 7\nTo fix this problem, delete patient note that the algorithm skipped.\n\n### Problem 8\nOutput is not organized in a format appropriate for an analysis: For instance, it is messy.\n\n### Potential solution 8\nAdd the `trial_name` column to each trial text.",
        "label": 0
    },
    "58": {
        "output": "#### HINT\n\nA: The following steps should be done: \n\n*   For each patient/trial pair, try to find the best way to match the given note with the inclusion criteria of the trial.\n\n*   Save it as a JSON file in json-lines (JL) format for convenience of usage.\n\n**For example:**\n\n``` {\n\"patient\": \"A postmenopausal woman with cytologically confirmed breast cancer\", \n\"trial-level eligibility\": \"0)\",\n\"trial-level eligibility\": \"1)\",\n\"trial-level eligibility\": \"2)\"\n}\n```\n\nOnce you finish preparing the data for all patients you may want to merge these JSONs (comma-separated) in one JSON file and create a training data set for the machine learning algorithm.\n\n**For example:**\n\n``` {\n\"0\": [\n  \"patient\": \"A postmenopausal woman with cytologically confirmed breast cancer\", \n  \"trial-level eligibility\": \"0)\",\n  \"trial-level eligibility\": \"1)\",\n  \"trial-level eligibility\": \"2)\"\n],\n\"1\": [\n  \"patient\": \"A 77-year-old woman with localized prostate cancer\", \n  \"trial-level eligibility\": \"0)\",\n  \"trial-level eligibility\": \"1)\",\n  \"trial-level eligibility\": \"2)\"\n],\n\"2\": [\n  \"patient\": \"A 54-year-old woman with colon cancer, metastatic\", \n  \"trial-level eligibility\": \"0)\",\n  \"trial-level eligibility\": \"1)\",\n  \"trial-level eligibility\": \"2)\"\n]\n```\n\n\n\n<EOD> Stereotactic radiosurgery in the presence of a ventriculoperitoneal shunt: a case report.\nThe presence of a ventriculoperitoneal (VP) shunt may pose a hazard to the shunt system and radiation beam while performing stereotactic radiosurgery (SRS). The shunt might also pose an acute c",
        "label": 2
    },
    "59": {
        "output": "### How I do my work?\n1. Write your code in the file named \"ClinicalTrialRecruitment.ipynb\". 2. Click the file \"ClinicalTrialRecruitment.ipynb\" on JUPYTER notebook and run it.\n\n### How I checked my work?\nYou can check your work on the web. Click \"Try it out\" on the web notebook's top right.\n\n### How I do it?\n- You can do all your works on `JUPYTER NOTEPBOOK <https://jupyter.org/>`\n- To use libraries, follow the instructions below:\n\n    python -m pip install <library_name>\n\n    This will look for a python module in the location in your workspace, and if found, will add it to your environment. If not found, it will download the library and add it to the environment.\n\n### How to use libraries.\n- Scipy package provides useful functions to manipulating numerical data:\n\n```\nimport numpy as np\nimport scipy.stats as stats\nprint(np.mean())\nprint(np.std())\nprint(np.min())\nprint(np.max())\nprint(stats.norm.mean())\nprint(stats.norm.std())\n``` \n  \n- Scikit-learn package provides useful functions to create classifiers and regression models:\n\n```\nimport sklearn.datasets as sds\nimport sklearn.preprocessing as spp\nimport numpy as np\nskdata = sds.load_breast()\nX = skdata.DATA\ny = skdata.Target\nX_train, X_test, y_train, y_test = skdata.get_train_test_split(X, y)\n\ndata_transform = spp.StandardScaler().fit(X_train)\nX_train = data_transform.transform(X_train)\nX_test = data_transform.transform(X_test)\nX_train\n```  \n- PyTorch package:\n\n```\nfrom torch import nn, optim  \nimport torch\nimport torch.autograd as autograd\n\nclass MyNN(nn.Module):\n    def __init__(self):",
        "label": 0
    },
    "60": {
        "output": "## Question: 1[QUESTION]\n[INST] \tHere is a list of possible problems you might encounter:\n\nThe input list of problems:\n\t\t\t\t- pN0(sn)\n\t\t\t\t- < 2 cm\n\t\t\t\t- \u2265 1 cm\n\t\t\t\t- pHG2-3\n\t\t\t\t- pHRneg\n\t\t\t\t- \uff1c 35 years\n\t\t\t\t- \u2265 2 cm\n\t\t\t\t- pN0(sn)\n\t\t\t\t- pN1(sn)\n\t\t\t\t- \u2265 1 cm\n\t\t\t\t- < 2 cm\n\t\t\t\t- pHG2-3\n\t\t\t\t- pHRneg\n\t\t\t\t- \u2265 2 cm\n\t\t\t\t- \u2265 1 cm\n\t\t\t\t- pN0(sn)\n\n## Your task:\nYou are required to fix the wrong problems in the above possible problems list.\n\nAssume the list of input problems are fixed, your task is to predict the following eligible trial of a clinical trial based on the clinical trial characteristics of this clinical trial:\n\n![IMAGE](https://cdn.statically.io/v2/9b63b0985e2817a2e686fa94c7cd39db/files/d/d9/eligibility-score-1-1.gif)\r\n\r\nThis task is an example of supervised multi-class classification. Your task is to predict one clinical trial as \"eligible\", and the other clinical trial(s) will be considered as \"ineligible\". The classification results will be evaluated based on the accuracy and F-score of the classifier. [/QUESTION]\n\n### Explanations:\n\nWe use the same feature set as is used in the above example, **including the treatment regimen.**\n\nThe list of possible problems will be fixed to these values in this dataset:\r\n\r\nThe feature set for this task:\r\n\r\n![IMAGE](https://user-images.githubusercontent.com/1531099/1010677",
        "label": 2
    },
    "61": {
        "output": "### Example of output syntax\n    ## R code:\n      ## T1 <- read.csv(\"Trial1.csv\") ## \n      ## T2 <- read.csv(\"Trial2.csv\") ## \n      ## # create a dataframe as you wish # create a dataframe for the \"patient note\": trialTrial <- read.csv('TrialTrial.csv')\n\n    ## T1: clinical trial, # patient note: patientNote ## print(TripTrip$TrialTrial)\n\n    ## Patient note:\n\n    0         0         0         0         0         0         0         0         0         0\n    ##    1         1         1         1         1         1         1         1         1\n    ##    1         1         1         1         1         1         1         2         2\n    ##  patientNote          NA NA NA\n\n# Note that, here you may encounter problems with your trial syntax due to a lack of sufficient information for assessing eligibility\n## Print(TripTrip$TrialTrial$ClinicalTrialSummary$InclusionCriteria)\n\n###  Example of expected output:\n\n    ## Patient notes:\n    0         0         0         0         0         0         0         0         0         0\n    1         0         0         0         0         0         0         0         0         0\n    1         0         1         0         0         0         0         0         0         0\n  patientNote          NA NA NA # NA means the patient note is excluded\n    \n\n\n\n#  Example of expected output:\n\n      ## TripTrip$Trial$ClinicalTrialSummary$Eigibility_1\n      0  HER2 positive tumor <HER2 positive tumor>\n      0  age <45 years (minimum age set in trial)>\n      0  previous chemotherapy <Yes>\n      0  previous or current taxane <Yes>\n      0  metastatic or locally advanced breast cancer <A>\n\n      ## TripTrip$Trial$ClinicalTrialSummary$InclusionCriteria_1\n      0  \"Patients must be at least 18 years of age at entry\"\n      0  \"Patients must",
        "label": 2
    },
    "62": {
        "output": "[Tutorial Home]\n<span id=\"Instructions\">Please, click \"Next Section: Dates\" to continue.</span><EOD> Prehabilitation in the context of total hip and knee arthroplasty: a systematic review comparing randomised controlled trials to non-randomised studies\nAim: The aim of this systematic review is to assess the evidence that preoperative exercise interventions (prehabilitation) improves function and quality of life (QoL) compared to no exercise intervention in patients undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA). Methods: 10 databases were searched using the terms pre-operative, preoperative, pre- operation, pre-operation, prehabi, mobilise, prehabilitate, pre-habilitate, prehab, mobilise, prehabi, prehabi, pre-habilitate, prehab, exercise and total hip replacement and knee replacement. Included studies were randomised controlled trials (RCT) of preoperative exercise interventions and patients about to undergo a THA or TKA. Studies with two or more exercise sessions in addition to 3\u20136 weeks of general education and no preoperative exercise were included. Findings: Nine RCTs and five non-randomised studies for THA and four RCTs and one non-randomised study for TKA were included. Two of the six THA studies of functional outcomes demonstrated no significant benefit. There were seven studies in the knee where five non-randomised studies demonstrated a benefit whereas two RCTs did not find significant benefit. Conclusion: There is inconclusive evidence that preoperative exercise improves function and QoL at 1 year or less prior to THA. There is limited evidence to suggest preoperative exercise benefits knee function and QoL prior to TKA but more high quality RCTs are required.<EOD> Challenges in Diagnosing COVID-19 Infection in Rare Case Presentations\n\n [bib_ref]  Coronavirus disease 2019 (COVID-19) for the respiratory practitioner, Fowler [/bib_ref]  [bib_ref]  A guide to utilization of the microbiology laboratory for diagnosis",
        "label": 0
    },
    "63": {
        "output": "<h2 id=\"Exercise_3_Assist_to_classify_patients_by_cancer_type\">Exercise 3: Assist to Classify Patients by Cancer Type</h2>Your task is to classify patients by cancer type based on their diagnosis, which is recorded in the patient history record. The diagnosis is expressed as an ICD-10 code. When classifying a patient to a cancer type, you should keep an eye on possible secondary tumors.\n\nFor example, a patient diagnosed with cancer, breast, postmenopausal, invasive ductal carcinoma and HER2-positive, will be classified as breast cancer. If the patient also had squamous cell carcinoma of the thyroid and colon cancer, the secondary tumors should be excluded. These secondary tumors are considered in the inclusion criteria, such as age, number, and stage of metastatic tumors.\n\n\nAssume that you work at the KSRC, and the clinical trial recruitment staff team consists of You, a helpful assistant for clinical trial recruitment, and Kim, a team leader of the clinical trial recruitment staff team. You and Kim will work together to classify the patients by cancer type.\n\n\n<a name=\"INPUT\">Input</a><br><br>\n<i>Instructions:</i> <ul><li>Please classify the listed patient cases by <i>cancer type</i> (i.e. <i>breast, colon, lung, etc.</i>) based on their ICD-10 diagnosis code. After classifying the patients, if any, report all possible secondary cancer types below patient case ID.<ul><li>If secondary tumors exist, type its name.</li><li>If secondary tumors do not exist.</li></ul></ul></li><li>If you are unsure about the classification, please discuss with Kim.</li></ul>\n\n| ID | First & Last Name | Age | Diagnosis Code  |\n| --- | ------------ | --- | ----------- |\n| 1 |   <NAME>  |  34  |  C22.0   |\n| 2 |   <NAME>  |  53  |",
        "label": 1
    },
    "64": {
        "output": "## How to Run the Code\n\n\nTo run the code, type `jupyter`, find your folder `Jupyter_folder_path`, then type `ipynb`, open the file `First_Python_Notebook.ipynb`, and run the code by, for example, pressing `Ctrl+A` and then pressing `Run`. The script, as well as a visualization of the results, is shown in Figure 2.\n\n## Figure 2. visualization of the expected output of a given patient note\n\n## Discussion\nIn the previous exercise, you have learned Python, which can be used as an interface for SAS. In the next exercise, you will see in more detail how SAS programs are created and how to get all the relevant information from them. \nBefore we begin, please create a new notebook in Jupyter. Next, add a new cell and input the following code:\nThe code above will result in generating a table on the same folder with the following header of a generated output file. After executing the code, a table with three lines of output would show up. The output would be as follows:\nIn this line, SAS's ``%sysf'' keyword is used, meaning the path to local system directory is displayed as the first output and the second output line is the absolute path, which is equal to  which can be calculated by the following code:\nIn the command above, %sysf is used to see the command line to the local system folder.\nThe second line in the output above refers to SAS's file name which can be calculated by SAS's `RENAME = FILENAME(TMPFILE, TMPNAME)`. Now, it can be calculated by the following code. Here, the last output line refers to SAS's date. In the SAS code below, it is shown that the year, month, day, hour, minute, and second which are in the output lines are calculated by the `YYYMMDD` function.\nLet's create a new R file. In the R code below, we are going to define the variables that are going to be used in different Python files. First, the directory path and the path of the SAS data file are defined, and then, the columns to print are defined. This is done by using the `col_to_display` in PyR. The Py",
        "label": 0
    },
    "65": {
        "output": "<EOD> Anterior cruciate ligament injuries: current concepts about knee injury in sport\nSports-related knee injuries are common in high-intensity sports. This is a common review article to the medical community. The focus of this review is on anterior cruciate ligament (ACL) injury and treatment. ACL tears are common in athletes. However, ACL injuries can be debilitating and prevent many from being active. Conservative treatment is an option, however, a lot of authors advocate for an aggressive approach to treatment, which involves reconstructive surgery.<EOD> .\nThe aim of this study was to detect possible associations between clefts of the lip and/or palate and polymorphic markers with the HLA and serum proteins. Material consisted of 32 families, each family containing at least one child with clefts of the lip with or without cleft in the palate. 55 parents were included in those families by an interview-study. The families were selected on the bases of clefts of lip with or without cleft in the palate of the probands. 142 blood samples were drawn, 75 from probands and also from other family members. Two markers of HLA and serum were applied. No family with bilateral cleft of the lip with or without clefts in the palate was found in this population studied. Two families with two clefts of palate were found. It was found, that all the cleft families were in agreement with the following phenotypes; C2B1, T10N, BfT1S1, C1P1P1S1. Haplotype in these families was C2B1T10N. T10 N C1 P1P1 S1, and haplotyp S1 C2B1P1Bf T1. A correlation was seen between the clefts of lip and serum-marker. 14 serum-proteins were investigated. No association between clefts of lip and serum proteins was found. The results of our study can not explain the clefts of lip with or without clefts in the palate.<EOD> Developmental changes in the electrophysiological response properties of cat trigeminal primary afferent neurons\nTrigeminal affer",
        "label": 0
    },
    "66": {
        "output": "<EOD> Corrigendum\nOn page 349, in the article by Dr. F. J. J. De Boer and Dr. T. M. de Boer (January 1911), in the second para., line 17, read \"It has been already shown by De Boer and Fruis\" for \"It has already been shown by De Boer and Fruis.\" On page 354, in the article by Dr. F. J. J. De Boer and Dr. T. M. de Boer (March 1912), in the last para. of the article, line 23, read \" In the urine as well as in the sweat and saliva there are no free amino acids.\" for \"In the urine as well as in the sweat and saliva there are no free amino-acids.\" I am, yours, etc., R. BEST, m.d. Oxford University Press, Bombay.<EOD> Pneumococcal Bacteremia with Unusual Organisms in a Diabetic Patient\n\nThe bacterial species of Streptococcus pneumoniae is commonly associated with morbidity and mortality in patients that have underlying cardiac or co-morbid conditions. A high percentage of bacteremia is reported in patients with diabetes mellitus and other chronic diseases. We report the unusual observation of a high percentage of Pneumococcal species isolated from a diabetic elderly patient with bacteremia that presented with normal temperature, leukocytosis and raised CRP and normal coagulation pro-teins. We believe the reason this patient did not show the usual presentation of S. pneumoniae is because of underlying diabetes. S. pneumoniae infections are usually followed by a drop in blood sugar levels and a decline in the immunity of the patient. The immune response might be suppressed by hyperglycemia, and it becomes difficult for the organisms to multiply. This is often followed by sepsis and eventually death. In this patient, we could not document the usual presentation that is expected with bacteremia by S. pneumoniae, owing to the effect of the diabetes.Diabetes mellitus (DM) is a common metabolic and end",
        "label": 0
    },
    "67": {
        "output": "# Results\n\n## Run the code:\n\nA.\n<EOD> Rethinking the evidence for the antioxidant hypothesis: the phenotype progression model\nAbstract Oxidative stress is an emerging biological driver of major disease. Dietary antioxidants may offer therapeutic potential and many are currently available in over 1000 clinical trials. However, an antioxidant paradox has now emerged. Whereas epidemiological investigations have consistently reported reduced risk in those who consume dietary antioxidants, interventional studies have failed to find any such significant benefit. This review draws on work on antioxidants against atherosclerosis to propose a model, the phenotype progression model, which might explain this apparent anomaly by accounting for both the inconsistent impact of antioxidants and the complex and multiphasic nature of oxidative stress. According to the model the biological effects of antioxidants will depend on the temporal sequence of the disease process, with protective effects being less evident in later stages of disease. Furthermore, the model provides a perspective that may aid in the design of clinical trials. Antioxid. Redox Signal. 29, 619\u2013628.<EOD> Different clinical presentations in two patients with SAPHO syndrome and severe systemic involvement of the bone: a case report\n\nSAPHO syndrome is a rare inflammatory dermatosis characterized by synovitis, pustulosis, hyperostosis, and osteitis. The objective is to discuss the clinical characteristics of two patients with SAPHO syndrome and severe systemic involvement of bone, including sacroiliitis and vertebral compression fracture. One male patient presented hyperostosis syndrome and a female patient presented psoriasis palmoplantaris, sternal fracture, lumbar spondylosis and lumbar disk herniation. The patients presented varying symptoms, such as arthralgia, bone pain and so on, despite sharing the same disease. Bone destruction was the common feature. The current study discussed the various clinical presentations of SAPHO syndrome.\n\n# Introduction\nSynovitis, acne, pustul",
        "label": 0
    },
    "68": {
        "output": "<EOD> The impact of diabetes and cardiovascular complications on work ability.\nBACKGROUND\nWork disability is a major determinant of the socioeconomic impact of diabetes mellitus.\n\n\nAIM\nTo study impact of both physiological and economic variables on the ability to work.\n\n\nMETHODS\nAll patients (N = 280) were attending a university clinic of type 2 diabetes, aged 20-74 years. Data assessed on the first study visit included physical and economic variables, such as education, body mass index, HbA, level, and smoking. Other tests included nail-fold capillary microscopy and the n-3 index, and the patient was scored with regard to physical status on the basis of a semi-quantitative questionnaire. Work ability was assessed by two study questions.\n\n\nRESULTS\nA negative correlation was found, both in men and women, between n-3 index, HbA(1c) level, nail-fold capillary occlusions, and the patients' own rating of their ability to work. When the results of the questions on the ability to work in relation to physiological and economic variables were assessed logistically, there was a significantly negative correlation between HbA(1c) level and the ability to work in both sexes. When HbA(1c) and nail-fold capillary changes were combined as variables, it was shown that the ability to work was considerably compromised in those patients who had capillary changes with the same level of HbA(1c). An inverse correlation was also found between physical status and the ability to work. No relation was found between the n-3 index and the ability to work. On a 0-3-point scale, the patients with diabetic nephropathy had a score of 1.15, which was significantly higher than that of women (0.7) and men (0.75). When the two score groups were analysed separately, a significantly higher proportion of women scored 1 point than did men.\n\n\nCONCLUSIONS\nHigh HbA(1c) level and pathological capillary changes were associated with less capability in terms of work ability than other variables.",
        "label": 0
    },
    "69": {
        "output": "A: You could do something like this: (this is just a basic function but it works)\n\ndef get_level_of_eligibility(eligibility):\n\n    if eligibility == 2:\n        return 'Eligible'\n    if eligibility == 1:\n        return 'Not relevant'\n    if eligibility == 0:\n        return 'Excluded'\n\n\na = input(\"What is the level of trial-wide eligibility for this patient?: \")\n\ndef trial_eligibility(note):\n\n    level = 0\n    while level < 3:\n        if level:\n            note = note.replace('NOTE:', '')\n            \n        for element in note.splitlines():\n            print(''.join([' - ', element.split(',')[0].strip(), '_' if element.split(',')[1] else '\\n']))\n\n        level = get_level_of_eligibility(input('What is the level of trial-wide eligibility for this patient?: '))\n        print(''.join([' '.join(level) for level in input(', '.join) for , \\                                          . join(level['2', '1'].split(',', 1)  for 2, 1 in level]))\n            \n\n<EOD> Precise and comprehensive comparison of peptides and glycopeptides using liquid chromatography coupled with mass spectrometry.\nAn accurate, sensitive and comprehensive comparison of peptides and glycopeptides is one of the most difficult and challenging tasks in proteomics. Here we introduced a data analysis pipeline, which could be integrated with peptide and glycopeptide database search engines MaxQuant and Byonic. This pipeline facilitates the rapid and high-throughput comparison of protein expression levels between glycosome and nonglycosome samples. A total of 24 peptides were found to be overexpressed in nonglycosome samples, and the expressions of 316 glycosylated proteins were found to be different between the two groups. After careful analysis, we propose that in addition to the regulations at the protein level, there are a number of non-proteogenic posttranslational modifications, such as lysine palmito",
        "label": 1
    },
    "70": {
        "output": "<EOD> Membrane-Type Tetraphenylethene Derivatives as Intriguing Reactive Oxygen Species Scavenger for Potent Anti-Inflammation.\nTetraphenylethene (TPE) based compounds have emerged as powerful candidate to develop advanced photodynamic therapy (PDT) agents due to their potential applications in sensing and bioimaging. Moreover, a group of membrane-type TPE derivatives possessing a long alkyl chain was explored for the first time to serve as reactive oxygen species (ROS), including singlet oxygen (1 O2) and superoxide anion (O2\u2022-) scavengers for anti-inflammation. Herein, we reported several membrane-type TPE derivatives (TM02-TM04) could remarkably inhibit ROS induced by the PDT process. As their structures were the same, an in vitro experiment of anti-inflammation by RIPA was conducted. The results demonstrated the superior performance between TM02 and other tested compounds. TM02 exhibits excellent membrane permeability and scavenges efficiently 1 O2 and O2\u2022-. Intriguingly, TM02 can act as highly powerful anti-inflammation agents to protect cells from oxidative stress because of its superior properties.<EOD> .\nIsolated disturbances of the ciliary motility may often be observed. In most cases, however, a specific eye disorder also exists. The disturbed ciliary motion may be related with some specific disease (pollinosis of the middle ear, chronic sinusitis, rhinitis, Kartagener's syndrome, primary ciliary dyskinesia, chronic bronchopulmonary disease, gonococcal infection of the middle ear, etc.), or it may develop secondary to a primary eye disorder (epidemic keratoconjunctivitis, atypical chlamydial conjunctivitis, trachoma, herpes zoster, etc.). A list of specific eye disorders associated with impaired ciliary motility and of ocular and periocular complications secondary to ciliary disturbance is given. This is followed by a discussion of the question whether ciliary disturbances can be avoided by a pro",
        "label": 0
    },
    "71": {
        "output": "#### Including information in trial-level eligibility\n\n### 3) Clinical trial eligibility criteria\nClinical trial eligibility criteria.\n\nClinical trial eligibility criteria.\n\n\n![image](http://yangsheng.org/media/uploads/2022/08/image-20220818063746104.png)\n\nThe patient does not meet the trial's exclusion criteria.\n\n### 4) Trial-level in",
        "label": 0
    },
    "72": {
        "output": "##[[INVITE1]] \n#!/bin/bash\n\nif [[ ! -z $INST_DOCKER ]]; then\n    docker build -t ${INST_DOCKER:-${DOCKER:-docker.com/cjlogan}}/lunit:0.1 ./;\n    docker run ${INST_DOCKER:-${DOCKER:-docker.com/cjlogan}}/lunit:0.1 -test lunit/libvax_test/inference_classifier.py ^lunit/libvax_test/data/example_file.txt --output-dir ../outputs;\n    docker build -t ${INST_DOCKER:-${DOCKER:-docker.com/cjlogan}}/libvax:0.1 ./;\n    docker run ${INST_DOCKER:-${DOCKER:-docker.com/cjlogan}}/libvax:0.1 -test libvax/libvax/tests/libvax_coding_rule_test.py ^libvax/libvax/data/example_file.txt --output-dir ../outputs;\n    docker build -t ${INST_DOCKER:-${DOCKER:-docker.com/cjlogan}}/libvax -f . /libvax.docker;\nfi\nunset INST_DOCKER\n\n# Uncomment this line for testing in a new container\necho \"docker run ...\"\ndocker run -v /data:/data ${INST_DOCKER:-${DOCKER:-docker.com/cjlogan}}/lunit:0.1 -test lunit/libvax_test/inference_classifier.py $(pwd -P -L)/example_files/informatix_data/text_normal.txt --output-dir ../outputs\n\n\n[NOTE]\n\n##[[DOC]] \n#!/bin/bash\ndoc:\n\tcd code && \\\n\t\tpython setup.py sdist && \\\n\t\ttwine upload dist/* -u $DEPLOY_USER -p $DEPLOY_ACCESS -a $DEPLOY_PASS\n\n\n[INVALIDATION]\n#!/bin/bash\ninvalid:",
        "label": 1
    },
    "73": {
        "output": "![](ex53_1_final.JPG \"Trial-level Eligibility: 2) Eligible\")\n\n\n```\npython trial_level_eligibility_assessment.py -i input_file -t output_file -l output_line_number\n\n$ python trial_level_eligibility_assessment.py -i patients.xlsx -t clinical_trial.txt -l 26\n2) Eligible\n2) Eligible\n\n```\n\n\n### Step 4: Clinical Decision\n\nIn this step you decide on the treatment plan, including administration of medications and/or surgical procedure(s), based on eligibility assessment results. You should consider the results of eligibility assessment including patient information, such as current and past health conditions and medications that may interfere with the treatment. \n\nYou assign patients to one of the eligibility classes: `Non-Eligible`, `Eligible`, or `Incomplete Eligibility` and output each class' distribution.\n\nBefore you proceed:\n\n\n*   We assume that the patient record and eligibility assessment are recorded in the same table.\n*   In other words, for each patient, eligibility information is available in the clinical data file.\n*   It may be helpful to write all of the steps in pseudo code in the notebook for better understanding.\n\nIn this step you also create a notebook file to generate your results tables and figures.\n\n![](ex53_2.JPG)\n\n\nIn the notebook, create a new file `eligibility_decision.ipynb`, which can be found in `notebooks/eligibility_decision` folder. Copy the notebook file to this folder.\n\nLet's start with the code. Enter the folder and type the following code in the Jupyter notebook.\n\n```{jupyter_code} i, eligibility, trial_data = get_input_file()\nclinical_trial_data, eligibility_info = get_clinical.trial_and_eligibility_info()\n\nif (eligibility not in ('Eligible', '2) Eligible')",
        "label": 0
    },
    "74": {
        "output": "Here is the patient note:\nThe patient is a 49-year-old man with invasive mucinous adenocarcinoma of the distal sigmoid colon. He underwent a sigmoidoscopy and a biopsy 2 months ago from an abnormal sigmoidoscopy as part of the routine colon cancer screening at the Mayo clinic. He is a smoker and has a family history of colon cancer. He is sexually active and has no children. He does not have a fever or joint pain, gastrointestinal problems, or blood or mucus in his stool, nor has he lost weight in the last couple of months. He has no history of any medical illness. We found colon carcinoma.\n[Clin_Info] The patient has a Stage IV, Grade 3 colon cancer for which he is scheduled for a resection of the tumor and the nearby lymph nodes by laparoscopy in 15-20 days. At the time of the resection the patient will be randomized to receive 160 mg of cyclooxygenase (COX) 2 inhibitor celecoxib twice daily, or a placebo.\n[Clin_Info] This clinical trial requires patients to be 21-79 years old and in good (ECOG PS 0-1) and average (ECOG PS 2) health. To qualify for a trial, patients must provide the clinic or lab researchers with written consent for enrollment.\n[Clin_Info] Patients in trials must also be able to stop or reduce the rate of disease progression without treatment. Patients that have any life or physical problems or a past disease history that negatively affects their performance. Patients with other diseases, e.g. diabetes, lung cancer and heart disease, which make their life difficult or that may affect this study were excluded from this study.\n\n\n[Clin_Info]\n\n[Clin_Info] Patients who smoke, drank alcohol and/or used drugs were not considered. Patients with previous serious diseases or patients who suffer from mental, neurologic or psychiatric disorders will not participate this clinical trial. Patients who use medicines, e.g.",
        "label": 0
    },
    "75": {
        "output": "<EOD> Spirochrome-Based Iridium(III) Complexes with an Alkylthiophene Bridge: A Study of \u03bbmax and Tumor Cell Nucleic Acid Dye Concentration/Intensity Ratios\nThe synthesis and photophysical properties of novel spirocyclized spirochrocycles based on the 3,12-dihydro-7\u03bb,15\u03bb-dioxadiindolato (L) and 2,3-dihydro-2\u03bb4,5\u03bb-dioxachromenoindolato (methylthio-L) ligands are reported. Reaction of L (1) and methylthio-L (3), with two equivalents of the iridium(III) cation,  (2), yielded the spirochromic compounds  and , respectively, according to X-ray diffraction analysis of single crystals. Fluorescence spectroscopy demonstrated the enhanced emission of the thiomethylated spirochrocycles, 2\u20134, in comparison to 1, which had been ascribed to the stabilization of the singlet states due to the negative hyperconjugation introduced by the methylthiophene bridge between the two chromophoric subunits (L vs methylthio-L). The compounds also displayed good quantum yields of emission (\u03d5f \u223c 0.41 to 0.50 in non-polar and polar solvents, respectively) and large Stokes shifts (\u223c9000 cm\u22121, the largest reported to date for a cyclic spirochrocyclic Ir complex under physiological conditions, using \u03bbex = 340 nm). Photocathodic luminescence spectroscopy studies on films of the compounds suggest electronic communication between the two chromophoric subunits (L and methylthio-L) in compounds 2, 3 and 4. The complexes 1, 2, 3 and 4 all display a bathochromic shift in their absorption spectra while the corresponding complexes of the methoxy ligand  (1a and 2a) are shown not to follow this tr",
        "label": 2
    },
    "76": {
        "output": "### EXAMPLE ONE\n#### Inference-based task\nAs the first task, we are going to design an inference-based task for this system.\n- Dataset:\nThe dataset is a list of all patient notes and the patients' eligibility for the clinical trial. Here is the dataset: \n- System:\nThe clinical trial has many inclusion criteria and a patient note looks like a string. The system should output the Trial-level eligibility considering all factors. It seems like an inference-based system.\n\n```python\n# -*- coding: utf-8 -*-\nimport copy\nimport string\nimport numpy as np\nimport nltk\nimport pandas as pd\nimport tqdm\nwith open(\"input/Inferrience_dataset.tsv\", \"r\") as f1: f2 = file(f1.name, \"w\")\n    f1.readlines()\n    f2.text = \"INPUT\"\n    with open(\"input/Patient_notes.tsv\", \"r\") as f3: f3.readlines()\n        patientnotes = pd.read_csv('input/Patient_notes.csv', header=None, sep=',')\n        f3.readlines()\n        lines=f3.readline()\n        for line in open(\"input/Inclusion_criteria.tsv\", \"r\"):\n            if 'Patient_notes' in line:\n                string=string.join(patientnotes.loc[:, 3].tolist())\n            if 'Age' in line:\n                string+=\",Age: \u226545\"\n            if 'Sex' in line:\n                string+=\",Sex: Female\"\n            if 'Menopausal_state' in line:\n                string=string+',Menopausal_state: Postmenopausal'\n            if 'Disease' in line:\n                if string==\"Breast\" or \"Breast cancer\":\n                    string=,\"Breast,Breast cancer\"\n\n            f2.write(line)\n        f1.write(\"Output:\" + \"\\n\")\n\n\nf1.write(string)\nf1.close()\nf2.write(\"Output:\" + \"\\n\")\nf2",
        "label": 1
    },
    "77": {
        "output": "# 2011 \ud504\ub85c\uadf8\ub7a8\n\n## 2011 \ud504\ub85c\uadf8\ub7a8 \uc2e4\uc2b5 \uacc4\ud68d\n[\uc8fc\uc81c] 2011 \ud504\ub85c\uadf8\ub7a8 \uc2e4\uc2b5\uc744 \uc9dc\uc11c \ud559\uae30\ubcc4\ub85c \ucc98\uc74c\ubd80\ud130 \ub9c8\uc9c0\ub9c9\uae4c\uc9c0 \uc9c4\ud589\ud558\uc2dc\ub294 \uac83\uc744 \uc81c\uc548\ud574 \ub4dc\ub9ac\uace0\uc790 \uc2f6\uc2b5\ub2c8\ub2e4. `\uc774\uc81c \uc9d1\uace0 \uc904\ub77c!`.\n[\uacc4\ud68d]\n\n\nI: \uc6b0\uc120 \uae30\uc900\ub41c \ud504\ub85c\uadf8\ub7a8 \uacc4\ud68d \uc678\uc8fc\uc81c\ub97c \ub9c8\uc8fc\uace0 \ub09c \uc790\ub85c \uc544\uc9c1\uae4c\uc9c0 \ud574\uc9c4 \uac83\ub4e4\uc744 \ubcfc \uc218\ub97c \uc54c\ud604\ud558\uba74\uc11c \uc2e4\ub840\ub97c \ud1b5\ud574\uc11c \uacc4\ud68d\uc744 \uc9c4\ud589\ud574\ub77c.\n\n  **1\ucc28 \uc9c4\ud589: \uc790\uc2e0\uc774 \ud568\uaed8 \ud558\uac8c \ub420 21\uba85\uc758 \uc778\uc6d0\ub4e4, \uadf8\ub9ac\uace0\ud6a1\ub2e8\uacc4\uc801\uc778 \uacfc\uc815\uc744 \ubb36\uc5b4 \uc9c4\ud589\ud558\ub77c.**\n\t1.2 \ucd08\uae30\uc790\uc728: \uc81c\uae30 \uc21c\uc73c\ub85c [\uc704\uc640 \ub2e4\uc74c\uc758 \uacc4\ud68d\uc73c\ub85c](../2011-program/2011program-overview) [\uc774\uc804 \uc9d0\uc758 \uacc4\ud68d\uc73c\ub85c](../../2011-program/2011program-overview) [\ub2e4\uc74c \uc9d0\uc758 \uacc4\ud68d\uc73c\ub85c](../../2011-program/2011program-overview)\n\t1.3 \uacc4\ud68d\uc11c \uc81c\uae30: [\ub3c4\uad6c\ub97c \uc774\uc6a9\ud55c",
        "label": 0
    },
    "78": {
        "output": "## 12.2 MISSING_DATA\n[TRIAL-LEVEL] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note with the inclusion criteria of a clinical trial to determine the patient's eligibility. \nHere we can observe the patient note:\n\n  We have already mentioned in the second example (Section 12.1. Eligible) that the reason behind the missing data is due to a new information field called `Missing_data` is added to the patient note. If missing data (e.g., `None` or `NA`) is detected on any of three fields (e.g., HER2 status, ER status, and PR status) the code should respond to the missing_data with a value of `NA`. [INST] \n\n## 12.3 REVIEW_REJECTED: MISS_CONFIRMATION\n[TRIAL-LEVEL] The patient is 62-year-old with breast cancer. She has a history of hypertension. Currently, her cancer is in stage I, ER-positive and HER2-negative. Her mastectomy and her axillary dissection. She also received radiation therapy and chemotherapy (AC, adriamycin and cyclophosphamide) twice. She has currently visited to the hospital for her follow up visit. This time, in addition to her blood test, her HER2 test is also performed.\n\nHere is the clinical trial note:\n\n# RECONCILIATION METHOD:\nReconciliate to Patient_ID, T, C_Status, C_Status_Date, Sys_Status, Sys_Status_Date, Status, Evaluable, Evaluable_Date, Evaluated, Evaluated_Date\n[formula]  PATIENTID C_STATUS C_STATUS_DATE SYS_STATUS SYS_STATUS_DATE STATUS EVALUABLE EVALUABLE_DATE EVALUATED EVALUATED_DATE 1 0 2019-01-01 NA NA NA NA FALSE FALSE FALSE 2 0 2019-01-01 NA NA NA NA FALSE",
        "label": 0
    },
    "79": {
        "output": "## Step 2\nThe patient had metastatic lesions with the use of multivitamins and iron supplementation. The patient is using multivitamins and iron supplements. The trial did not limit the use of multivitamin and iron supplements.\n[INST] How can you express this?\n\n## Inclusion criterion\nUse multivitamins and iron supplements\n\n## Exclusion criterion\nNot using multivitamins and iron supplements\n\n## Exclusion criterion\nMetastatic lesions (CXR)\n\n## No exclusion criterion\nMultivitamins and iron supplements:\n\n## Use multivitamins and iron supplements\nCancer Metastasis:\nNo cancer metastasis\n\n## No exclusion criterion\n\n## Exclusion criterion if multivariate analysis was required\nNot sexually active\n\n## No exclusion criterion\nNo child\n\n## No exclusion criterion\nNo active cigarette use\n\n## No exclusion criterion\nNo alcohol consumption\n\n## Use multivitamins and iron supplements\n\n## No exclusion criterion\nNo cancer metastasis\n\n## No exclusion criterion if multivariate analysis was required\nAges: 45 years old or older.\n\n## Exclusion criterion if multivariate analysis was required\nPostmenopausal\n\n## Exclusion criterion if multivariate analysis was required\nNot sexually active\n\n## No exclusion criteria\nNo child\n\n## No exclusion criteria\nNo active cigarette use\n\n## No exclusion criteria\nNo alcohol consumption\n\n## No exclusion criterion\n\n## No exclusion criterion\nThe patient is using multivitamins and iron supplements.\n\n## Use multivitamins and iron supplements\n\n## No exclusion criterion\nThe trial did not limit use of multivitamins and iron supplements.\n\n## No exclusion criterion\nCancer metastasis was not presented in the CXR.\n\n## No exclusion criteria\nNo child\n\n## No exclusion criteria\nNot sexually active\n\n## No exclusion criteria\nNo active cigarette use\n\n## No exclusion criteria",
        "label": 2
    },
    "80": {
        "output": "## [/DATA]\n\n## Clinical trial eligibility for multiple patients\nHere you have a patient list. Your task is to compare every patient in the list with the inclusion criteria of a clinical trial to provide a trial-level eligibility that includes the clinical trial identifier. \n\nLet's think step by step. \nFirstly, you should create a new variable `Clinicaltrial-id: ` in the data frame to store the clinical trial identifier. You can use the `bind_cols` method of the Pandas library.\n\n```R\nclinicaltrial_id=df_study.clinicaltrial_id\nclinicaltrial_id=clinicaltrial_id.bind (df_study, axis=1)\nclinicaltrial_id=clinicaltrial_id.name\nclinicaltrial_id=clinicaltrial_id.str.lower\n```\n\nSecondly, you should iterate each row of the variables `Age_and_gender` and `Disease` in the data frame `df_study` to assess the clinical trial eligibility of each patient in both variables.\n\n```R\nfor (id in df_study) {\n    age_and_gender_assessment = id.age_and_gender_assessment\n    disease_assessment = id.disease\n\n    if age_and_gender_assessment.age<=18 or id.age_and_gender_assessment.sex==\"F\" then {\n        disease_assessment.eligible=FALSE\n        disease_assessment.notrelevant=TRUE\n    } else if age_and_gender_assessment.age>=76 or id.age_and_gender_assessment.sex==\"M\" then {\n        disease_assessment.eligible=FALSE\n        disease_assessment.notrelevant=TRUE\n    } else if age_and_gender_assessment.age>=19 and age_and_gender_assessment.age<=65 and\n    id.age_and_gender_assessment.gender==\"F\" then {\n        disease_assessment.elig",
        "label": 1
    },
    "81": {
        "output": "<EOD> Complementary effects of HIF-1\u03b1 and NRF2 factors on ameliorating cardiac dysfunction induced by ischemia/reperfusion\n\nObjectives: Reactive oxygen species (ROS) production induces myocardial ischemia/reperfusion (I/R) injury. We examined the protective effects of antioxidant enzyme system, heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2). Methods: We performed MIRI animal experiments on HO-2, HO-1 or HO-2 + HO-1 (double knockout [DKO]) transgenic mice and wild-type (WT) mice. Changes in superoxide dismutase (SOD) and catalase (CAT) activity, and mRNA expression of HO-1, HO-2, and the hypoxia inducible factor-1\u03b1 (HIF-1\u03b1) gene were analyzed. We constructed HO-1/HO-2 and HIF-1\u03b1 gene knockdown using CRISPR/Cas9 targeted transgenic mice. Ischemic H9c2 myoblasts were exposed to the antioxidant N-acetyl-L-cysteine (NAC) to examine its effects on HIF-1\u03b1 and nuclear factor erythroid 2-related factor 2 (NRF2) gene expression. Results: Compared to expression of the HIF-1\u03b1 and NRF2 genes and antioxidant levels in DKO mice on the third day after MIRI, these levels were elevated in HO-1 and HO-2 transgenic mice following ischemia. H9c2 myocytes were treated with CoCl 2 to determine if HIF-1\u03b1 and NRF2 protein expression depended on HO-1, HO-2, HO-1/HO-2, and HIF-1\u03b1 gene knockdown. H9c2 cell oxidation and apoptosis were determined by quantifications of reactive oxygen species (ROS) and caspase-3 levels after NAC treatment. We found that NAC enhanced HIF-1\u03b1 and NRF2 expression in myocardial tissues and H9",
        "label": 1
    },
    "82": {
        "output": "## Task 1.2\nA short presentation of the following variables will take place. Choose the correct value for the random variable on the scale 0 to 1. You are not allowed to skip values or change the format in which the values are provided. You should use the following formulas to calculate the correct value of the random variable.\n\n## Var A:\nVar B:\n\nBioVe/Biostat/2021/1/6 - page 41\n\n## Task 1.3\nAssume that you are involved with the researcher who designed Study of the Risk of Tardive Dyskinesia in Patients Receiving Olanzapine. The trial is randomized, double-blind, multicenter and parallel group. The treatment group consists of patients who are allocated to Olanzapine at 10 mg/day, the control group to patients who use 1 mg of Olanzapine twice a day. The study will last 25 weeks in which the primary goal will be to establish which of the two drugs is more beneficial for the group. \nThe study group will consist of 37 patients randomized into the two groups.\nIn the treatment group, four patients will receive Olanzapine 10 mg/day for two weeks. After two weeks they receive 5 mg/day for two weeks. Next, the drug is to be taken in decrements of 2.5 mg/day until week 24. Three patients will receive Olanzapine 1 mg/day for two weeks. After two weeks, they will receive the drug doubled, i.e. 2 mg/day for two weeks. Next, the drug is to be taken in decrements of 1 mg/day until week 24. \nThe control group will receive Olanzapine 1 mg/day for two weeks. After two weeks, they will receive the drug doubled, i.e. 2 mg/day for two weeks. Next, the drug is to be taken in decrements of 1 mg/day until week 24. \nIn both groups, after week 24, treatment will be discontinued. Drug administration will consist of oral administration of the drug. \nThe primary outcome is defined by the occurrence of tardive",
        "label": 1
    },
    "83": {
        "output": "[INST]<EOD> .\nWe studied the influence of two enzymatic inhibitors: phosphodiesterase and ATPase inhibitors on the growth rate of Streptococcus mutans ATCC 27965 (DSM 20523) strain by the kinetic method. The bacteria were cultivated in the TSB liquid medium with 1% (w/v) of saliva. The antagonistic inhibitor of phosphodiesterase (AIP) and the antagonistic inhibitor of ATPase (ATIP) were isolated from the culture fluid of the Actinoplanes sp. MAMB-16268 strain and Actinoplanes missouriensis MBT-833 strain and were identified by the HPLC, FTIR spectroscopy, and MALDI mass spectrometry. The bacterial culture growth rate was estimated as a percentage of control (the initial cell content). It was found that AIP caused a 2.3-fold decrease, whereas ATIP - a 1.8-fold decrease in bacterial growth; the effects were significant with all tested concentrations of the enzymatic inhibitors. The results obtained indicate that AIP and ATIP have a bacteriostatic effect, and it is advisable to search for a synergistic action of the enzymatic inhibitors (e. g. of phosphodiesterase and ATPase) with antimicrobial agents.<EOD> Combined Phytotherapic and Traditional Chinese Medicine Therapy for Chemo-Resistant Non-Small-Cell Lung Cancer: Two Cases Report\n\nLung cancer is the second most common cancer worldwide and non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. There are two major subsets of NSCLC: squamous cell carcinoma and adenocarcinoma, with the former representing the most common subtype. There are several clinical treatments for NSCLC including chemotherapy and target therapy, immunotherapy, radiotherapy, and hyperfractionated accelerated radiotherapy are widely used in NSCLC patients. With the emergence and development of targeted therapy, an increasing number of NSCLC patients have been responded to the targeted",
        "label": 0
    },
    "84": {
        "output": "<EOD> Effect of low\u2010dose erythromycin on cyclosporin and carvedilol elimination in cardiogenic shock patients\nIt is well known that the use of cyclosporin can induce or aggravate sinus node dysfunction, atrioventricular conduction alteration or atrial fibrillation. Carvedilol is also known to increase the risk of bradycardia and heart block. Both drugs are recommended to treat refractory shock in patients with myocardial dysfunction. The coadministration of these drugs can present a greater risk of cardiac complications. Erythromycin is a macrolide antibiotic that inhibits the P\u2010gp efflux pump, thus avoiding the extrusion of cyclosporin.<EOD> Glycopeptide Antibiotics Enhance Escherichia coli Mutability by Increasing Cell Sensitivity to Ionizing Radiation\nStaphylococcus aureus is a human commensal that is also an etiological agent of nosocomial infections, mainly affecting soft tissues, bones and joints, although its isolation from other infections sites has also been reported. Resistance to anti-staphylococcal drugs has been reported with regard to both methicillin resistance and glycopeptide resistance. The latter, which affects only staphylococci, is acquired against vancomycin, the most commonly used anti-methicillin-resistant (MRSA) staphylococcus agent. Its development and dissemination have also caused problems on the treatment of MRSA infections.<EOD> Impact of COVID-19 on Hospitalized Adult SARS-CoV-2 Patients With and Without Cancer.\nImportance\nThe COVID-19 pandemic has led to changes in health care systems that may impact cancer management.\n\n\nObjective\nTo compare clinical characteristics and in-hospital outcomes among patients with cancer and patients without cancer hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\n\n\nDesign, Setting, and Participants\nIn this retrospective case series study, patient data",
        "label": 0
    },
    "85": {
        "output": "Please save the file and upload your answer.\n\nCongratulations! You have finished the tutorial.\n\n\n[Tutorial Link](/tutorials/breast/)\n<EOD> Development of a clinical decision support system using the Ishikawa model to identify patients with hyperbilirubinaemia: a preliminary diagnostic tool\nAbstract Background: Laboratory errors and diagnostic inefficiencies cause delays in providing timely diagnosis to patients, potentially leading to fatal outcomes. It is crucial that patients receive definitive, timely diagnoses for better health management outcomes. Diagnostic errors continue to remain prevalent in most emergency departments and wards, particularly in primary care. Although many hospitals still utilise paper-based approaches, there are instances where patients are incorrectly diagnosed, resulting in longer hospital stays, higher medical costs, and even death. Medical decisions must be made based on a high degree of competence, proficiency, or skill, supported by relevant medical guidelines, research findings, case studies, and other data. Clinical Decision Support Systems (CDSS) can help healthcare professionals in this process, with more accurate decision support and better patient care. Methods: This study used the Ishikawa (fishbone) diagram as a CDSS tool in analysing patient hospitalisation records for hyperbilirubinaemia as the main condition for analysing a patient\u2019s condition. Hyperbilirubinemia is a laboratory disorder caused by abnormal levels of bilirubin found in the blood. There are two types of hyperbilirubinaemia: indirect and direct. By utilising the Ishikawa diagram as a tool, it is possible to analyse the condition in depth and determine whether it could be controlled by an algorithm. Results: Based on the proposed method, hyperbilirubinaemia is diagnosed as acute pancreatitis. Conclusions: It was concluded that using the Ishikawa method to diagnose hyperbilirubinaemia is beneficial for the medical field and will help physicians in making more accurate and timely diagnoses.<EOD> The association between physical activity, physical fitness and the risk of overweight, obesity and being underweight in 16-year-old adolescents \u2013 an explorative study\n\nBackground: Physical activity (PA) and",
        "label": 0
    },
    "86": {
        "output": "<h3 id=\"trial-level\">Trial-level eligibility</h3>\n\t<code class=\"text-xl p\">Output: 0) 'Excluded', 1) 'Not relevant', 2) 'Eligible'</code>\n\t<code class=\"text-xl\">Trial-level_eligibility_00: 0) Excluded;\nTrial-level_eligibility_01: 1) Not relevant;\nTrial-level_eligibility_02: 2) Eligible</code>\n</figure>\n\n### `Trials`\n\n\t<h3 id=\"trials\">Trials</h3>\n\t<code class=\"text-xl p\">Output: Number of trials</code>\n\t<code class=\"text-xl p\">Description: Number of pre-clinical trials</code>\n\t<code class=\"text-xl p\">Note: The number of pre-clinical trials is always greater or equal to the number of clinical trials</code>\n\t<code class=\"text-xl p\">Example: 23</code>\n\t<figure data-inst id=\"trials\">\n\t  <code>1.31125;\n\tTrial_00: 'Human Papillomavirus Vaccination';\nTrial_01: 'Treatment of HIV-Infected Adults with the Investigational Drug Darunavir/Cobicistat';\nTrial_02: 'Effects of Hydroalcoholic Hemp Oil Extract on the Clinical Indexes of Women with Stage II-IV Breast Cancer under Chemotherapy Treatment';\nTrial_03: 'A Study on the Effects of Tongmai Xiaozheng Powder on Human Papilloma Virus Positive Resistant Cervical Intraepithelial Neoplasia';\nTrial_04: 'Efficacy and Safety of Bevacizumab Combined with Temozolomide and Alpelisib in Advanced Pancreatic Cancer';\nTrial_05: 'Clinical Study of Lenvatinib in Treating Ref",
        "label": 0
    },
    "87": {
        "output": "Ask yourselves: \n- If you are unsure of the information, what questions could you ask the recruiter to get that information?\n\nThis example demonstrates how to assess trial eligibility for a clinical trial. First, you need to compare the eligibility criteria to the patient's profile. To do so, you read the information in the patient note to match it with the inclusion criteria of the clinical trial, e.g., patient age, and so on. If the person meets all the requirements listed in the clinical trial, it should be marked to show its eligibility. This step is repeated for each person.\n\n![](/img/inst/inst-1-1.png)\n\nIf you are not sure about the information, just double click anywhere in the table to see all the corresponding data. Note that only entries are editable, i.e., the value \"0\" (patient does not fulfill eligibility criteria), values \"1\" and \"2\" (not relevant and eligible, respectively).\n<!-- Instances of this template: ccl-course-lesson-3 -->\n<h2>CCL-Course: Lesson 3 (04.06.2021;)</h2>\n<ul class=\"ul_2\" id=\"menu\"><EOD> .\nThe 5-HT1A receptors in the hippocampus regulate the cognitive response in the elevated plus maze. In the present experiments, we investigated the role of extracellular 5-HT and 5-HT levels in the hippocampus by microdialysis to clarify the mechanism for regulation of the mild cognitive function with the 5-HT1A receptor. Two weeks after surgery, the experimental animals were allowed to adapt to the experiment environment and to microdialysis probes for 3 days. The C57BL6 male mice were randomly divided into four groups: 1) Control group (231.0 +/- 11.8 ng/ml), 2) PCPA group without any drug (83.3 +/- 11.2 ng/ml), 3) PCPA group (140.7 +/- 6.8 ng/ml) with treatment of 5HT synthesis in",
        "label": 0
    },
    "88": {
        "output": "The following is a sample patient note that is used in the demo mode of the course:\nIdeal.\nPt: 45yo postmenopausal women\n[formula]  Sx: HER2 + ER/PR negative BC Bx: 3 cm invasive ductal BC TisN0, T1N0, T2N0 LNRX Surgery: tylectomy Chemo: NA Toxicity: NA Admitted 9/30/00, Sx 9/17/00: Bx left breast w/ core biopsy, pathology showed invasive ductal BC, ER -/PR-, HER/ neu +, Sx 9/18/00: Mammogram Lt breast w/ calc in DCIS of Rt upper outer breast region, 1.6 by 1.2, sclerosis is seen along lateral, inferior margin of breast, Rt breast -MXL w/ Rt axillary w/ 5 nodes, Lymph node: 1#-5# -negative, Lymph node: 1-3# -8/20, Lymph node: 1-6# -4/60 and the 4#s on peripheral aspect, Lymph node: 1-7# -2/45, Lymph node: 1-8# -1/5, Lymph node: 1-9# -3/60 H&E, pathology showed metastic carcinoma consistent with primary BC Rt axilla, 45mm, H & P 0/+, Negative, negative, positive; Lymph node metastases seen, LN no 1-9-positive, Lymph node no 1-5-positive, lymph node no 1-6-negative, lymph node no 1-7 -Positive, Lymph node no 1-8 negative. [/formula] \nExploration: There is minimal blood on the drape with the breast exposed. There is the small incision and sutures from biopsy site. Her axillary incision site is a standard axillary incision without evidence of tumor dissemination. The breast tumor was completely removed.",
        "label": 0
    },
    "89": {
        "output": "<EOD> Preclinical Infection of a Macaque Model with SARS-CoV-2\n\nCitation: De Smet, M.; Van den Eede, D.; Govaert, C.; Huygen, K.; Aran, A.; De Groote, M.; Claerebout, G.; Van Der Stuyft, P.; Goffin, M.; Frijns, A.; et al., Preclinical Infection of a Macaque Model with SARS-CoV-2. Viruses 2021, 13, 1618. https://doi.\n\n# Introduction\nMassive vaccination is the only realistic strategy to stop the current COVID-19 pandemic (19March 2021, World Health Organization situation report, see https://outbreak.info/, last accessed 19 March 2021). At the moment, the development of vaccines against SARS-CoV-2 (i.e., the coronavirus that caused the global pandemic outbreak) is in the spotlight since vaccine candidates in all development phases are being presented with remarkable speed [bib_ref]  Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine, Baden [/bib_ref]  [bib_ref]  Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary..., Folegatti [/bib_ref]  [bib_ref]  Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, Polack [/bib_ref] . Besides vaccinating the global population with a new vaccine, vaccination studies are also of key importance as they will help to understand the immunological responses to SARS-CoV-2 infection, such as neutralizing antibodies or humoral or cellular immunity [bib_ref]  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, Skowronski [/bib_ref] .\nMost of the data describing the infection, clinical manifestations, cellular immunity, and pathology of SARS-CoV-2 have to date been derived from inf",
        "label": 0
    },
    "90": {
        "output": "You have to consider three steps that you will do for a patient note that you can't find a trial:\n- First, you find the current active clinical trial that is under study.\n- Second, you define the inclusion and exclusion criteria of the clinical trial and match them with the patient's status.\n- Third, you determine the eligibility of each trial stage of the matched clinical trial for that patient.\nWe have two clinical trials. The patient is underlined:\nTitle: Radiation Therapy in Treating Women Undergoing Lumpectomy for\n\n\nStage I or Stage IIA Breast Cancer\n\nSummary: RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells.\nGiving intraoperative radiation therapy after lumpectomy followed by external-beam radiation therapy may kill any tumor cells that remain after surgery.\n\n# PURPOSE:\nThis phase II trial is studying the side effects and how well radiation therapy works in treating women undergoing lumpectomy for stage I or stage IIA breast cancer.\nInclusion criteria:\n\n## DISEASE CHARACTERISTICS\nHistologically confirmed primary invasive breast carcinoma\n\n## Stage i-ia disease (t1, n0, m0 or t2, n0, m0)\nPathologically determined single, discrete, and well-defined primary tumor \u2264 5 cm in diameter\nPathologically negative surgical margins\nNo multicentric disease and/or diffuse malignant appearing microcalcifications\nMicro-calcifications must be focal\nSpecimen radiograph is required after lumpectomy for tumors associated with malignant appearing calcifications to assure removal of all malignant appearing calcifications\nSpecimen radiograph is optional if the tumor appears as a discrete mass on mammogram\nNo axillary lymph node involvement\nNo evidence of metastatic breast",
        "label": 0
    },
    "91": {
        "output": "Here is our example output:\n20\n4\n1\n2\n1\nTrial-level eligibility: 2) Eligible.\n[output is same as the first row]\n\nThe output is in the same line with the last row of the input, as shown in the figure below. See also [1] \n\n\n---\n\n## Examples\n\nThe following examples show the usage of the [trialclinical-eligibility](https://github.com/Kaggle/KDDcup12/blob/master/datasets/trialclinical-eligibility) object in R.\n\n### Example 1.2  \n```\ndata(trialclinical eligibility)\nhead(trialclinicaleligibility)\n```\n```\n  Trial Trial-level eligibility\n1 LCB02 LCBO26-01 Trial-level eligibility: 0) Excluded\n2 LCB02 LCBO26-01 Trial-level eligibility: 0) Not relevant\n3 LCB03 LCBO25-01 Trial-level eligibility: 1) Excluded\n4 LCB03 LCBO25-01 Trial-level eligibility: 1) Excluded\n5 LCB03 LCBO25-01 Trial-level eligibility: 0) Not relevant\n6 LCB04 LCBO26-03 Trial-level eligibility: 0) Excluded\n7 LCB04 LCBO26-03 Trial-level eligibility: 0) Excluded\n8 MCB03 MCGO25-05 Trial-level eligibility: 2) Eligible\n9 MCB03 MCGO25-03 Trial-level eligibility: 2) Eligible\n10 MCB03 MCGO26-03 Trial-level eligibility: 2) Eligible\n11 MCB03 MCGO26-03 Trial-level eligibility: 2) Eligible\n12\n13\n14\n15\n16\n17",
        "label": 0
    },
    "92": {
        "output": "# 4.2.2 The problem section\n\n# Background\n[INST] Hello. Good to see you again. It's really nice, to see your eager face. \nNow let's solve the problem. The issue is that the patient in the example is 'excluded' for the clinical trial, while the clinical trial says it wants to compare a '45-year-old postmenopausal woman with cytologically confirmed breast cancer'. \nSo, can we find any factors that allow this patient to participate? \nWe do not know what are exclusion criteria of clinical trials, but we can check for exclusion criteria that you must know.\n\nWe all know that these 2 clinical trials use the same patient eligibility, but also they use the same exclusion criteria. However, these clinical trials use different medications. \n\nExclusion criteria of clinical trial No. 00166979 (see: Exclusion criteria of clinical trial No. 00166979)\n- Treatment with hormonal therapy within the previous 2 weeks\n- Known history of hypersensitivity to taxanes, carboplatin or trastuzumab\n- Women of childbearing age who are pregnant or breast feeding Note: This is not an exclusion criterion for patients who are menopausal due to bilateral oophorectomy or receiving medical menopause due to bilateral salpingectomy or bilateral salpingo-oophorectomy or women >59 years old and postmenopausal for >1 years due to menopause secondary to chemotherapy, pelvic radiation or bilateral ovariectomy.\n- Women who are known to be pregnant or breast feeding\n- Women of childbearing potential who are not surgically sterilized due to bilateral oophorectomy or bilateral tubal ligation, due to medication",
        "label": 1
    },
    "93": {
        "output": "A: TLW is very easy and quick method to work with pandas and matplotlib simultaneously. To create a new figure and pass your variable to it, call 'TLS' in the console and write something as below.\nimport pandas as pd\nimport matplotlib.pyplot as plt\nfrom tlw import TLS\n\npatient = pd.DataFrame([['G03','female',25,'G05','negative',5,'G04','positive',1,'R3'] ])\ntrial = pd.DataFrame([])\ntreatment = pd.DataFrame([])\nTLS()\nTLS.ylabel = \"Age\"\nTLS.xlabel = \"Patient\"\nTLS([patient, treatment], ['Age', 'Sex', 'Blood group', 'History of heart disease', 'Laterality', 'Lung pathological metastases before enrollment', 'Disease progress'] , trial)\n\nYou can find my answer and full code on my repository: https://github.com/kadirbayrakci/DataTable_and_Plot\n<EOD> Phytochemistry and pharmacology of the genus Anaxagorea: a review.\nAnaxagorea was introduced as a genus to the Rutaceae family in 1813 although the family includes only two genera, Citrus and Poncirus. Currently, the genus includes 16 accepted species. The genus is widespread in tropical and subtropical regions and mainly grows at low altitudes of mountains. These plants are commonly used for their nutritious value, although plants like Anaxagorea crassifolia were used also in many countries as vegetables and herbs. Due to many beneficial properties, the genus Anaxagorea has been used for centuries especially for medicinal purposes. The phytochemical investigation on aerial parts, flowers, leaves, roots and fruits of Anaxagorea species revealed the presence of terpenoids, essential oils and coumarins in this genus. In the present study, we aimed to collect literature and summarized this valuable information and provide better understanding focusing on the pharmacological importance of Anaxagorea.<EOD> Improved Detection of Helcococcus kunzii Bacteremia by Using 16S",
        "label": 2
    },
    "94": {
        "output": "Good luck! \n<EOD> .\n\n Demographic trends suggest that 25% of the French population will be over 65 years of age in 2020. Although this increase in seniors is accompanied by a comparable reduction in the population of working ages, the number of beneficiaries under France's old-age pension insurance is expected to rise by 50% by 2025. The growth in demand for health care for these elderly persons will create problems for administrators of this system. The rapid increase in the number of senior consumers of health care in France raises 2 questions: 1) to what extent do our current hospital systems have the capacity to respond to this new situation; and 2) to what extent do our hospitals have the capacity to provide the care needed by elderly consumers. These are central questions in a debate, which is currently being conducted in France, about the reorganization of medical and paramedical care into a system based on local or regional units. In spite of the efforts being made to create alternative health organizations, a short-to-intermediate solution may be to create specific geriatric services or groups of services, with separate budgets, which will be responsible for the elderly. Such geriatric units are now being developed by the Association Geriatrique de France, which was founded in 1982 with the aim of developing medical and paramedical specialists in geriatrics. These units are currently being tested in geriatric wards of various hospitals, including the Sainte-Genevi\u00e8ve hospital in Paris, the Necker hospital in Paris, and the Vincennes hospital in Paris. One of such units, which has just been created in the Beaujon hospital in Clichy, will be funded as a separate entity beginning in April 1993. The purpose of these geriatric units will be to create an organized structure or system capable of developing a comprehensive care plan for each elderly person which is centered on home care with a special focus on those aspects of the patient's situation which are most closely linked to the development of hospital and other types of services. The units will have a particular interest in preventing or delaying longterm dependency for those elderly persons who have some autonomy despite reduced mobility, and in improving quality of life of residents of nursing homes. They will actively",
        "label": 0
    },
    "95": {
        "output": "### Questions\n1. How can the patient note be encoded to JSON?\n#### Answer\nWhen you make the patient note encoded to JSON, you must create a new tab in ECLAIR and select the `json` tab in the left panel. You can then select the tab `Practice` > `Trial` >`Notes`.\nFor this task, the following notes can be selected: \n- Notes of the first patient\n- Recruitment note of the first patient\n- 2) Eligible\n- 0) Excluded\n- Not relevant\n2. How can be checked whether the patient is included in a trial?\n#### Answer\nSelect `json` tab in the left panel. You can then select the tab `Practice` > `Patient` > `Notes`. The patient's list is available in the panel, and you can click the `2) Eligible` note for the patient and check the trial under which the patient is participating.\n3. If the given patient note is not available in ECLAIR, from which place on the ECLAIR site (e.g., `https://beta.medicisclinicalelectroniquee4e.fr/` (in French only)) can you download it?\n#### Answer\nGo to the `Patient` tab in the upper part of ECLAIR, enter the patient's name in the search box, and then click the corresponding `New Patient` icon.\nThe `New Patients` tab appears in the upper part of the screen. To find the patient's note, click the icon corresponding to the `Document` column and then click the `download` button next to the `Note` label.\n\n\n## [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria);",
        "label": 1
    },
    "96": {
        "output": "```r\n#\n# 1. Set up some helpers.\ndose2_code <- \"3) Excluded\"\ndns2_code <- \"\"\n#\n# 2. Take an input from the user. The example\n# code has used the following input: input(dose_code))\n#\n#\n# 3. Add a new row in dataframe\n#\n#\n# 4. Perform the assessment of trial-wide eligibility of the\n# patient.\n#\n#\n# 5. Print all the rows which contains the trial-wide eligible\n# in the dataframe.\n#\n# \n# 6. Repeat this step until the trial-wide eligibility does not\n# change in all iterations (e.g., 3-4 times). \n#\n# 7. Print the output of the above step. \n#\n#\n# Code output:\n\n\n# Set the name of the dataframe\noutput_df <- data.frame()\n\n# The name of the column for trial-level eligibility\noutput_df_var1 <- \"Trial-level eligibility\"\n\n\n# We will start with the given input patient ID.\npatient_id <- 15 \n\n# We will start trial-wise testing.\ndose_code <- patient_id \ndns_code <- \"\"\n\n\n# We will keep on repeating the 3 dose_code dose2_code until the\n# trial-level\n# eligibility stay same.\n#\n# We will keep on adding the dose-condition\n# into the code but we shouldn't forget to print the\n# status of trial-level eligibility.\noutput_df <- output_df[output_df$patient_id == patient_id &\n                         output_df[output_df_var1] %in% dose_code &\n                         output_df$dose_code == dose2_code &\n                         output_df$dose1_code == dose_code &\n                         output_df$dose2_code == dose1_code, ]\npatient_id <- patient_id + 1 ## to select next patient's code\ndose_",
        "label": 0
    },
    "97": {
        "output": "```\n\n# Outputs\n- [outputs_id]: List of id strings generated for each trial object. (id of each element: `f.id).\n- [sum]: Sum of the number of excluded patients and number of ineligible patients.\n- [sum_eligible]: Sum of the number of eligible patients. \n- [outputs]: List of outputs strings for each trial object.\n\n```python\n[outputs_id] = (p.name for p in patient).list()\n[sum] = sum(e)\n[sum_eligible] = sum(el)\n[outputs] = [[f[:4] + str(len(f)) + '/' + f.name for f in p.file] \nfor p in patient \nfor trial in trial_db ]\n[/outputs]\n```\n\n# Import things\n- [import_id]: List of id strings generated for each trial object.\n- [import_f_id]: List of file_id strings generated for each feature (f) in a given file.\n- [f_idx]: Each f_idx is the index of each feature (f) in a given f.\n- [f_id]: List of id strings generated for each feature (f) in a given feature (f).\n- [feature_path]: List of filenames of given feature (f).\n- [outputs_id]: List of id strings generated for each trial object.\n- [sum]: Sum of the number of excluded patients and number of ineligible patients.\n- [sum_eligible]: `Sum` of the number of eligible patients.\n- [outputs]: List of outputs for each trial object.\n- [mh_file]: String containing the path to the database file.\n```python\n[import_id] = (e.id for e in exclusion) + (f.id for f in feature_name_db)\n[import",
        "label": 1
    },
    "98": {
        "output": "### Create the trials\n\n#### Create Trial #1\n**Note** The below script will use the trial number, `1`, but we will always use the `2` in the actual input.\n\n# Create Trial #1\n```\n#!/bin/sh\nimport json\ninput_file_path = './CT_1.json'\noutput_folder = './CT_out'\nif [ ! -f '$(output_folder)/CT_1.json' ]; then\n    sed -i 's/2/1/' $input_file_path\n    json.load(open(input_file_path))['trials']['trial_2']['exclude_criteria'] = {}\n    json.dump(open(input_file_path), open(output_folder + '/CT_1.json'), indent = 4)\n    cat $(output_folder + '/CT_1.json')\nelse\n    json.load(open(output_folder + '/CT_",
        "label": 2
    },
    "99": {
        "output": "[#section]\n\n## TRIAL-LEVEL ELIGIBILITY\n\nThis function is the same as [Eligibility Assessor][] for the given trial, except that a scale of 0 or 1 (not relevant, yes) is used. The output is a set of scales. One scale per record.\n\nUsage:\n[code][#tag:bash]\n\n\nimport csv\nfrom clinicaltrials.instant_form import Trial_level_Eligibility\n\nf = open(\"./.data/instant/data_0/patient_1.txt\")\nwith open(\"output_file.txt\", \"w\") as f2:\n    d = csv.Reader(f)\n    data = [[int(x) for x in i for i in d[0]] for j in [1, 4]] \n    f2.write(Trial_level_eligibility(f1, trial_id=0).to_csv(data, headers=True))\n\n\n[/code]\nOutput example (experimental data): \n[code][#tag:bash]\nfile:\n[code][#tag:bash]\n\n\nimport pandas as pd\n\np = pd.read_csv(\"trial_101620407.csv\")\ntrial_id = p.pop(0)\npatient_number_1_age = p.ix[:, \"age1\", trial_id]\npatient_number_1_family_history = p.ix[:, \"family History of Breast Cancer\", trial_id]\npatient_number_1_family_history_other_health = p.ix[:, \"family History of Any of the Cerebral Vascular Disorders or MI, Heart Disease/Hypertension, Chronic Obstructive Pulmonary Disease, Diabetes/Thyroid Problems.or Any Other Major Medical Problems or Major Surgery Ever\", trial_id]\npatient_number_1_breastcancer = p.ix[:, \"History of Breast Cancer\", trial_id]\npatient_number_1_pregnancy_age = p.ix[:, \"Age at birth of first child",
        "label": 0
    },
    "100": {
        "output": "<!--======================================================================== RUN THIS SHEET FOR REUSABLE CODE ->===========================================================================\n[RUN] python3 -c \"f\" \n[RUN] python3 -c \"r\" \n[RUN] s\n[RUN] s\n[RUN] s\n[RUN]\n======================================================================> --> \n\n### A.1 Eligibility Assessment\nThe eligibility assessment has four steps (see also in  [INST] The results can be visualized in an [e] eligibility summary table in the eligibility assessment form in the ECRfM.\nHere is the [e] eligibility summary table and related documentation generated automatically whenever there is an [e] eligibility assessment entry: \n\n[INST]\n\n\n\n\n\n\n\n\n\n### [INST] Conclusion\nIn conclusion, congratulations! You are a valuable contributor to medical patient safety improvements through the creation of the electronic clinical trial recruitment form in the ECRfM, the first step to the implementation of the ERM concept. This form may help to prevent any wrong inclusion of a patient in an ineligible trial which would be beneficial for the patient as well as the sponsor of the trial. The ECRfM ensures the quality of health care and fosters the exchange of knowledge between the participating health care providers.\n\n[e] <NAME> from the MFMD wrote the following documentation to help you [e] with your new task. In the ECRfM of the medical facility, the [e] Eligibility summary table shows the assessment of eligibility (assessed in this example) of the patients for the corresponding clinical trial.\n\n### [e] Eligibility assessment of a patient for two clinical trials of the clinical trial repository \n<!--====================================================================== DECLARATION OF ACCEPTED PAPER ON THE WEBSITE OF THE INSTITUTE OF MEDICAL INFORMATICS, HEIDELBERG =>======================================================================-->\n\n\n[INST]\n       \n       [[e] Eligibility Assessment]\n         [[e] Eligibility Assessment]",
        "label": 2
    },
    "101": {
        "output": "## 2.1.1 [FIL] Find all patients who satisfy the following criterion:\n\\subsection{The patient note from the input}\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\nA core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\nThe tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes.\nCXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements.\nShe does not smoke or consume alcohol. She is not sexually active and has no children.\nShe is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nHere is the clinical trial:\nTitle: National Survey on Infiltrative Breast Cancer\n\nSummary: The purpose of this observational study is to describe radiological, clinical and histological characteristics of women with infiltrative breast cancer.\nInclusion criteria: Inclusion Criteria:\nWomen> or = 18 years old\nWomen with newly diagnosis of infiltrative breast cancer\nAgree to take part in this study\nExclusion criteria:\nMen\nWomen<18 years old\nWomen with newly diagnosis of non-infiltrative breast cancer\nDo not agree to take part in this study\n\n\\subsection{The result of searching criterion}\nA list of eligible patients may be generated by searching the patient note for terms representing the patient note's criterion. (An explanation for generating a list of eligible patients is in Section 3 of the accompanying Jupyter notebook. [NOTE] ) The following patient note criteria are used in this example.\n\\item HER2-positive\n\\item ER/PR negative\n\\item CXR remarkable for metastatic lesions\n\\item Were infiltrative ductal breast cancer\n\n\\subsection{Trial-level eligibility using the input note}\nA trial-level eligibility assessment can then be performed. The patient note criteria can be searched using the following functions, e.g., `",
        "label": 2
    },
    "102": {
        "output": "This is a simple program that performs two binary classifications. First, the record's class is identified as either `HER2-positive` or `HER2-negative`; second, the record's value for the attribute `Tumor Size (mm)` is determined.\n\nLet's see how it works:\n\n**Program: Merge.py*\n\n**Input: HER2.txt HER2-positive.txt Tumor size <HER2.txt HER2-positive.txt>/tumor size\n\n**Output:**\n\n**Positive:**\nHER2 positive, positive for HER2.\nHER2 negative, HER2 not present.\n**Negative:**\nHER2 negative, positive for HER2.\nHER2 positive, negative for HER2.\n\n**N.B.** If the <HER2.txt> and <HER2-positive.txt> inputs were missing, you'd get HR2 positive missing Tumor size missing Negative.\n\n**Program: Merge.py input file1 output file1<HER2.txt\n<HER2_positive.txt>/OUTPUT_FILE_NAME<HER2.txt HER2-positive.txt\n\n**INPUTS:** The input file of 125 records (125 lines) with a header, followed by `50` observations.\n**OUTPUT:** The output file of three files with 13 rows each (i.e., 13 columns). Each file will feature only records having the same values for the columns. Each file will include all the information of all the records having the same values for the columns.\n\n**Answers:**\n\nHER2_125_positive_0_125_positive_25_125.txt,\nHER2_125_positive_1_125_negative_0_125.txt,\nHER2_125_negative_1_125_negative_0_125.txt\n\n**Note:** In the case of a file (e.g., <HER2_positive.txt>), where every column has different number of rows, use the `[:integer_number]` function",
        "label": 2
    },
    "103": {
        "output": "*__Note:__ If you have further questions, please visit the [training class website](https://www.kaggle.com/training/general-overview-of-our-training-classroom-on-kaggle).*\n\n\n    <h1>How to start a trial</h1>\n    <p>This tutorial will show you how to start a new trial. You\n    can start a new trial with a trial name. </p>\n    <h3>START A NEW TRIAL</h3>\n    <h3>START A NEW TRIAL</h3>\n    <h4>Enter the trial title</h4>\n    <p>Enter the trial title in the\n    format: <code>Trial Title name</code>. </p>\n<pre class=\"java\"><code class=\"java\"> TRIAL_NAME_BLOCKERS = [\"Trial name: Blockers\" +\nSystem.lineSeparator() + \" Example: This is Example blockers\" +\nSystem.lineSeparator() + \" Please make sure that this trial name is short, \" +\n\"legible, and contains no special characters.\" +\nSystem.lineSeparator() + \" You will only have one chance to edit it.\"];\ntry {\n    TrialBuilder trial_builder = new TrialBuilder();\n    trial_builder.setTrialName(\"Triple block\");\n    } catch (ParseException e) {\n        e.printStackTrace();\n    } catch (ParseException e){//for Blocker's trial\n    System.out.println(e.getMessage());\n    e.printStackTrace();\n    }\n</code></pre>\n\n<h4>Add a description of your trial</h4>\n<p>Add a description of your trial.</p>\n\n<pre class=\"java\"><code class=\"java\">try{\n            TrialBuilder trial_builder = new TrialBuilder();\n            trial_builder.setTrialName(\"Example Trial\");\n            trial_builder.addTrialComment(\"Welcome to this trial!\");\n        } catch(Exception e) {\n            e.printStackTrace();\n        }\n    </code></pre>\n\n\n\n\n    \n\n\n# Listing a trial\n**_list_**  - A list of tri",
        "label": 1
    },
    "104": {
        "output": "# [T-06] Defining `C_Exclusion_Criteria` and `C_Inclusion_Criteria` in `ClinicalTrials.csv` \u2780\nDefining C_Exclusion_Criteria \u2781 [0]: In the columns 4 ~ 13, each patient note information is included, with the '100.71.Trial.id' as the ID of the breast cancer inclusion criteria for all patients, as shown in 'Breast cancer inclusion criteria in trial level'.  \n\n\n\n\n[INST] When a patient is registered for breast cancer through the clinical trial and patient note is recorded, the ID of the breast cancer inclusion criteria for all patients is  100.71.Trial.id. However, if a patient has already registered for breast cancer, the 100.71.Trial.id corresponds to the ID for all patients with breast cancer.    \nTherefore, the value of the column 4, 6 ~ 15 should be set to 'Exlusion' of the `C_Exclusion_Criteria` in the 'C_Exclusion_Criteria' column. But, the values of column 9 ~ 12 would be included in the `C_Exclusion_Criteria` through the value and type of the column 5 as  `Patient_ID, integer, 0 or null, null, breast cancer`. \n\n[T-07] Creating `Breakpoint` on `ClinicalTrials.csv` file   \n\n\u2781 \n\n\n\n**",
        "label": 2
    },
    "105": {
        "output": "## Question 2:\n[[INST] What are the inclusion criteria to participate in the clinical trial?] The inclusion criteria for Clinical trial:\nTitle: An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients\n\nSummery: Our objective is to develop a novel optical assay system for intra operative assessment of tumor margins in partial mastectomy or mastectomy specimens. Our group has previously shown that optical techniques can effectively discriminate between malignant and non-malignant breast tissues. We have also shown that data collection and processing from a single point on the tissue specimen requires less than 5 seconds. In addition, the technique is easily adaptable to provide sensing depths that are required for breast cancer margins assessment. The goal of the work developed in this protocol is to test the sensitivity and specificity of an optical assay system developed by our group, for intra operative assessment of breast tumor margins\n\nInclusion criteria: Inclusion Criteria:\nClinical diagnosis of breast cancer\nPlain film chest X-rays with no evidence of distant metastases\nNo evidence of local infection\nNo evidence of other cancers\n\n## Question 3:\n[[INST] What are the exclusion criteria to participate in the clinical trial?] The Exclusion Criteria for Clinical trial are:\nTitle: An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients\nSummary: Our objective is to develop a novel optical assay system for intra operative assessment of tumor margins in partial mastectomy or mastectomy specimens. Our group has previously shown that optical techniques can effectively discriminate between malignant and non-malignant breast tissues. We have also shown that data collection and processing from a single point on the tissue specimen requires less than 5 seconds. In addition, the technique is easily adaptable to provide sensing depths that are required for breast cancer margin assessment. The goal of the work developed in this protocol is to test the sensitivity and specificity of an optical assay system developed by our group, for intra operative assessment of breast tumor margins.\n\nInclusion Criteria:",
        "label": 2
    },
    "106": {
        "output": "<EOD> Transition to a Scalable Clinical Trial Paradigm: The RhoA-Associated Kinase Inhibitor Fasudil for Neuroprotection in a Stroke Model.\nBACKGROUND\nThe rhoA-associated kinase (ROCK) inhibitor fasudil is a neuroprotective agent approved in Japan for refractory systemic hypertension. Recent studies have suggested that treatment with fasudil shortly after stroke onset may facilitate early brain protection. Here, we explore the potential impact of the ROCK inhibitor on a translational scale.\n\n\nMETHODS\nWe utilized a stroke model in rats to test the efficacy of the ROCK inhibitor fasudil on hemorrhagic transformation after administration in the lateral ventricle 1 hour post-stroke. This model tests the feasibility of fasudil administration in a rodent brain stroke model as an essential step toward a scalable clinical trial design. Based on historical control data, we calculated that a study cohort size of 10 per group with a significance level of 0.05 has an 80% chance of detecting an effect size of 80% or higher.\n\n\nRESULTS\nStudy procedures resulted in no loss of animals and yielded successful ROCK inhibition on a translational scale. We were also successful in achieving adequate blinding of the ROCK inhibitor cohort to the technician.\n\n\nCONCLUSIONS\nOur study demonstrates the feasibility of implementing a small-molecule stroke drug trial in a rodent model with the goal of paving the way for a future large-scale trial.<EOD> .\nFood industry, biotechnology and animal production are three domains where bacteria, such as Bacillus thuringiensis or E. coli, are used to prevent",
        "label": 0
    },
    "107": {
        "output": "[INST] [MOVE]<EOD> Immune-Related Adverse Events in Patients with Colorectal Cancer Receiving Immune Checkpoint Blockade: Characteristics, Management, and Evaluation of Incidence by an Administrative Database\n\nCitation: Stolf, G.; Lopez, A.; N\u00fa\u00f1ez, M.J.; Mar\u00edn-Romero, T.; Alonso, F.; S\u00e1nchez, I.; Rodr\u00edguez-Mart\u00edn, C.; Caramelo, F.; Mart\u00edn-Guzm\u00e1n, A.; Ram\u00edrez-Trujillo, M.; et al. Immune-Related Adverse\n\n# Introduction\nImmune checkpoint inhibitors (ICIs) revolutionized the oncology landscape by demonstrating significant improvement in clinical outcomes and becoming a cornerstone in the treatment of metastatic colorectal cancer (CRC).\nWith approved regimens including combination treatment with ICIs and chemotherapy (CT) or targeted therapy, as a first-line (C 305): anti-CTLA-4 alone (C) or in a combination with anti-PD-1 (G 303) [bib_ref]  Nivolumab in Patients with Metastatic DNA mismatch repair-Deficient or Microsatellite Instability High..., Overman [/bib_ref]  [bib_ref]  Pembrolizumab versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The KEYNOTE-177..., Andr\u00e8 [/bib_ref]  [bib_ref]  Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer, Andr\u00e9 [/bib_ref]  [bib_ref]  Atezolizumab with or without Chemotherapy in Patients with Metastatic Colorectal Cancer (IMblaze370):..., Bendell [/bib_ref] .\nFor second-line therapy, two Phase III clinical trials (C 343): (1) KEY-NOTE-177 (Nivolumab in Microsatellite Instability High or Mismatch Repair-Deficient Metastatic Colorectal Cancer) and (2) IMblaze370 (Atezolizumab",
        "label": 0
    },
    "108": {
        "output": "We assume that the `assessment of eligibility` is correct.\n\n\n## Instructions 13\n[STARTER]\nYou are the chief information officer of one of the clinical trial recruitment firms. You receive a request from a new clinical trial that is undergoing recruitment. \nA new clinical trial has been approved from the United States Food and Drug Administration (US FDA).\nEach clinical trial has an average of 400 recruitable patients. The patients will be recruited and enrolled to the study at the centers. Clinical trial recruitment (i.e., the identification and contact of patients) is required at each center. This clinical trial is one of the most important in the history of cancer and it needs to be recruited at the top hospitals with high-level doctors of oncology.\n[INST] The clinical trial recruitment firm should recruit patients for this important clinical trial at the centers of oncology and hematology. Recruitment is the process of finding patients who meet the inclusion criteria for randomized controlled trials to be recruited to the trial. The recruitment should be finished within 3 years.\nThe recruitment firm has received a contract to recruit a particular clinical trial, which requires the recruitment firm to recruit at least x patients at each center.\nYou would like to figure out strategic decisions to maximize the recruitment of patients to this important clinical trial by minimizing costs. Strategically, you should set the recruitment rates, the recruitment expenses, and the recruitment capacities at each center, i.e., recruitment number of patients, number of doctors at each center, and numbers of patients that each doctor recruits at each center.\nThese decisions should take patient eligibility and the locations of the clinical trial centers into account. \n\nThe key idea is to consider the recruitment capacity at each center, the recruitment rate, and the recruitment cost under each candidate allocation of patients to centers. It is well-known that the efficiency of a recruitment firm can be maximized by distributing the required number of patients evenly to each center that has to enroll participants. On the other hand, the",
        "label": 0
    },
    "109": {
        "output": "[TOPIC] Trial-level eligibility\n\n[NAME] <NAME>\n \n[NAME] <NAME>\n \n[STAFF] <NAME>\n \n[DATE] [20XX-01-01]\n \n[STAFF_COUNTRY] [Country]\n\n[NAME] <NAME>\n\n[DATE] [20XX-01-01]\n\n[TITLE] Trial-Level Eligibility\n\n# Overview\n This report concerns the eligibility of a trial's recruitment target. We must compare a given patient and trial inclusion criteria to determine whether the patient fits the trial. If we believe the patient is eligible, we should proceed with the assessment. \n\n## Rationale\nWe are working with an individual patient instead of an aggregate of patients. Hence, clinical trials are not treated as aggregates, and we do not require a sample size justification in that case. \n\n## Purpose\nThe following clinical trial is a good example to demonstrate the process of trial-level eligibility. It is also a good example to illustrate assessment criteria since we can refer to the case report form for a description of the patient's disease. We are not going to evaluate these criteria one by one. Let's consider first an eligibility example. Here is a patient diagnosed with osteoporosis. Is this patient included in this clinical trial? \n\n# Clinically Eligible\nDrug Study in Menopausal Women with Osteoporosis\n\n## Inclusion Criteria:\nCriteria to be met by each patient at Screening (Day -28 to 0 and Day 0)\n- Postmenopausal women age 45 to 65 years\n- A minimum serum 25-hydroxyvitamin D (25-OHD) level \u226450 nmol/L at screening (or a historical value <40 nmol/L within 4 weeks of screening)\n- Total alkaline phosphatase (TALP) <242 U/L\n- A minimum urine N-telopeptide/creatinine ratio (uNTX) \u226540 nmol/mm",
        "label": 0
    },
    "110": {
        "output": "[/QUESTION] [[QUESTION]\n\nQ5. Can we also show patient information such as race or gender in the CSV report?\n\nA5. \nYes, we can add in the CSV report. You can use the output below to show patient information:\n````r\ndat=cbind(patient_id=c(rep(23,5), rep(27,5)),\n    race=\"White\", gender=\"Female\")\nhead(dat)\n```\n\n    race    patient_id\n    ----    ----------\n    White   23\n    White   27\n    White   23\n    White   27\n    White   23\n    White   27\n[/QUESTION]\n\n[/QUESTION] [[QUESTION]\n\nQ6. When we set the value of `patient_id` in the CSV file to the value in the `Patient_id` column, do we need to specify what column it appears in?\n\nA6. No. To display the value from the `Patient_id` column in the CSV file, there is no need to specify the value in the `Patient_id` column, because the `Patient_id` column in the `Patient_id` column appears in the CSV file. \n\n[/QUESTION] [[QUESTION]\n\nQ7. I want to make a report for each clinical trial in this clinical trial list. How can I make it?\n\nA7. You can use the R function `rbind` to make a report for each clinical trial in the `list_clinical_trial` object. \n\nYou can generate a report for Clinical Trial 2 by doing the `rbind` below to get a multi-Dicriminate Data Frame (a) and a single report for Clinical Trial 2 (b).\n```{r} dat2=rbind(dat)\n```\n\n### Single report for Clinical Trial 2:\n\n* [A Clinical Trial for Breast Cancer Treatment in Postmenopausal Women](https://www.ncl.cc.gatech.edu/Courses/5901/Tutorials/week9/tutorial1.pdf",
        "label": 0
    },
    "111": {
        "output": "</PRE>\n\n\n\n\n<!--htbl-->\n<TABLE ALIGN=\"CENTER\" BORDER=\"0\" CELLSPACING=\"0\" CELLPADDING=\"3\" CELLWIDTH=\"600\">\n<THEAD>\n<TR ALIGN=\"CENTER\" VALIGN=\"TOP\">\n<TH ALIGN=\"CENTER\" VALIGN=\"TOP\" COLLSPAN=\"1\" ALIGN=\"CENTER\" VALIGN=\"TOP\">Question\n</TH>\n    <TH ALIGN=\"CENTER\" VALIGN=\"TOP\" COLLSPAN=\"1\" ALIGN=\"CENTER\" VALIGN=\"TOP\">Answer\n</TH>\n    <TH ALIGN=\"CENTER\" VALIGN=\"TOP\" COLLSPAN=\"1\" ALIGN=\"CENTER\" VALIGN=\"TOP\">Explanation\n</TH>\n</TR>\n<TR ALIGN=\"CENTER\" VALIGN=\"TOP\">\n<TD ALIGN=\"CENTER\" VALIGN=\"TOP\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>\n\t<TD ALIGN=\"CENTER\" VALIGN=\"TOP\" COLLSPAN=\"1\"><P STYLE=\"POSITION: RELATIVE; POSITION: POINT; TOP: 0px; LEFT: 0px\"><B><U>Instructions</b></U></P>\n\t<PRE>\n\t\n\t[INST]\n\t\n\tHello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n\tThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and",
        "label": 0
    },
    "112": {
        "output": "The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements.",
        "label": 0
    },
    "113": {
        "output": "## Trial-level eligibility (Optional)\n\n\n```python\n### [BREAK]\n### [INST] Hello. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n### [BREAK]\n### [BREAK] # Please do only one trial-level eligibility output.\n\n# The assessment of patient eligibility has a three-point scale:\n# 0 : Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion\n#  criteria);\n# 1 : Not relevant (patient does not have sufficient information to qualify for the trial);\n# 2 : Eligible (patient meets inclusion criteria and exclusion criteria do not apply)\n\n### [INST] # Now, please assess every patient for this clinical trial\n\n### [BREAK] # You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the\n### [BREAK] \n###  assessment of eligibility.\n\n### [INST] \n### [BREAK] # Trial-level eligibility:\n###  Eligible (the assessment of trial-level eligibility is output on the next line). \n\n### [INST] \n### [BREAK] # You can assess each criterion separately, or you can simply check all  (\n### [BREAK] \n### [INST] \n### [BREAK] # Now, repeat Trial-level eligibility for each patient separately in the last line by `\n### [BREAK] \n### [INST] \n### [BREAK] # Here is the patient note.\n\n### [BREAK] \n### [INST] \n### [BREAK] # Here is the clinical trial:\n\n### [INST] \n### [BREAK] # Let's think step by step. We will output the eligibility of the patient:\n\n### [BREAK] # We begin by a set the default of the trial",
        "label": 0
    },
    "114": {
        "output": "\u00a9 PJ-Lab @ UCSF\n\u00a9 PJ-Lab @ UCSF\n\u00a9 PJ-Lab @ UCSF<EOD> Innovative approaches on early childhood nutrition for policy and program: the UNICENT group\n\nBackground: An urgent need for coordinated action to improve the quality of nutrition globally has been expressed worldwide. Early childhood nutrition is a high priority, yet the evidence that underpins programs addressing this important phase of human development is limited. Objective: This paper describes the rationale behind the establishment of the United Nations Children's Fund-International Centre for Food and Nutrition Research and Promotion (UNICEF-ICFNRP) Technical Working Groups on early childhood nutrition. The paper also describes the group's first activities and recommendations moving forward. Methods: The UNICEF-ICFNRP Steering Committee identified several technical areas of interest to early childhood nutrition where coordinated research efforts were recommended. Technical Working Groups on complementary feeding, responsive feeding, timing of breastfeeding and duration of exclusive breastfeeding were established in 2004. Each of the four technical groups adopted a working method focused on three points; 1) identification of relevant gaps in knowledge and intervention tools; 2) the identification of priority research questions; and 3) the development of a work plan to ensure prioritized research questions are answered in a timely manner. Results: The four technical groups of the UNICEF-ICFNRP have initiated collaborative research on all priority areas under their purview. The groups have established their individual research priorities and developed work plans outlining detailed research plans to address these priorities. The UNICEF-ICFNRP Steering Committee has agreed upon common goals and plans to support the technical working groups. Two intervention trials have currently been developed and are being implemented in several developing countries and several systematic reviews, meta-analysis, and policy statements are being carried out. Conclusions: This group is committed to advancing multidisciplinary research designed to answer the most urgent questions relating to the complex and interrelated aspects of early childhood nutrition.\nD evelopment of a supportive early childhood nutrition environment is a key for optimal early childhood growth and development. [bib_ref]",
        "label": 1
    },
    "115": {
        "output": "## 1.\nStep1: If a patient is included in a clinical trial, then set the value of Exclusive status column to 0 (exclude) and set the value of Eligibility column to 1 (Eligible):\n[SEC]# Exclusive status column=0 # Eligibility column=1\n[/SEC]\n\n\n## 2.\nStep2: If the clinical trial includes 100 patients, then copy the value of the Exclusive column to the Eligibility column and repeat step1. You should see two steps:\nExclusive status column=1 (exclude)\nEligibility column=0 (eligible) \n\n## 3. -\n\n## 4.\nStep3: If a patient meets a clinical trial's inclusion criteria but does not meet all the clinical trial's exclusion criteria or is not ineligible for the clinical trial, then copy the value of Eligibility column to the Exclusive column and repeat step1. You should see 0 or 1 step each.\n\n# Exams in the Course\n<exam id=\"29767566\" title=\"Data Science Course Examination 1\" course=\"cs6281w\">\n    <question id=\"29611184\" class=\"answer\" question=\"1\">\n      <interpretation>\n        <correct answer><![CDATA[0]])</correct answer>\n        <distractor answer=\"#02: Exclude\">\n          <comment>Distractor answer: Eligible\nThe patient meets all the clinical trial's inclusion criteria and the clinical trial's exclusion criteria do not apply.</comment>\n        </distractor>\n        <comment>Explanation:\nThe patient meets all the clinical trial's exclusion criteria.\n</comment>\n        </interpretation>\n      </question>\n      <question id=\"29611185\" class=\"answer\" question=\"1\">\n        <interpretation>\n          <correct answer><![CDATA[2]])</correct answer>\n          <distractor answer=\"#01: Eligible\">\n            <comment>Distractor answer: Exclude\nThe patient does not have sufficient",
        "label": 2
    },
    "116": {
        "output": "[STARTER]\nFirst time? Check out  the tutorial on installation and first usage of a Docker container.\n<EOD> Effects on blood pressure and vascular resistance of the angiotensin type 1 receptor antagonist and angiotensin AT2 receptor stimulator Compound 21.\nA novel renin-angiotensin system (RAS) inhibitor, Compound 21, which acts as a mixed angiotensin type 1 receptor antagonist (AT1RA) and a mixed angiotensin II AT(2) receptor agonist (AT(2)RA), was studied in anesthetized dogs chronically instrumented with catheters in the left ventricle (LV), ascending aorta, pulmonary artery, right atrium, inferior vena cava, kidneys, and femoral artery and was also studied in intact salt-depleted and angiotensin II-infused hypertensive dogs. The vasodilator effect of Compound 21, given subcutaneously, was assessed by its effects on total peripheral resistance (TPR) and cardiac output (CO) as well as by direct measurements of mesenteric vascular resistance (MRVR) and renal vascular resistance (RVR) (given systemically and/or locally). Compound 21 had no major effects on TPR, CO, MRVR, RVR, pulmonary arterial pressure, or heart rate but had a slight effect on mean arterial pressure in chronically instrumented but not in intact dogs. In angiotensin II-dependent hypertensive dogs, Compound 21 evoked dose-responsive increases in heart rate, renal blood flow, and urinary sodium excretion. It also substantially reduced pressure-natriuresis and mean arterial pressure (MAP), without affecting TPR. In salt-depleted dogs, Compound 21 had no effect on MAP, RVR, or TPR, but it elevated plasma Ang II levels, which suggests a blockade or reduction in degradation of an active form of Ang II, or both. The data show that Compound 21 has a direct action, mediated through a local",
        "label": 2
    },
    "117": {
        "output": "![05_Screenshot_3][3]\n\n### 5.1.7. \ud30c\uc77c\ub4e4 \uc800\uc7a5\ud558\uae30 \ud83d\udcd2\n\n### 5.1.8. \ud30c\uc77c \uc800\uc7a5\n\n<sup>\uadfc\ub300\uc74c\ubcf4\uae30\ub97c \uc798 \uba8d\ud788\uc9c0 \uc54a\uc73c\ub2c8 \ucd5c\uadfc \uc74c\uc545\ucabd\uc744 \uc774\ub3d9\ud558\uc5ec \uae30\ub300\ud558\ub294 \ub178\ub798\ub4e4\uc744 \uace0\ub824\ud574 \ub4e4\uc73c\uc2ed\uc2dc\ub2e4.</sup>\n\n\ud2b9\ubcc4\ud55c \uc800\uc7a5 \uc635\uc158\uc740 \uc5c6\uc2b5\ub2c8\ub2e4.  \uba5c\ub4dc\ub77c, \uc0ac\uc624\ub9c1, \uc774\uc0c1\ube44 \ub4f1\uc758 \uc74c\uc545\uc758 \uadc0\uae08 \uc74c\uc545\ub9cc\ub4e4\uc5b4\ubd05\ub2c8\ub2e4.\n\n[\ud1b5\ud569: Making Musixmatch](https://github.com/JunSun/EchoMusicVoice/blob/main/README.md#make-a-musixmatch-playlist \"\ud1b5\ud569: Making Musixmatch\")\n\n```txt\n# \ub77c\ubc84\uace8\ub85c \uc800\uc7a5\nrabbitear --input music-list.csv --output new.txt\n\n\ncd music\npython3 /home/jimsun/MusicVoice  make_song_list_and_play_the_songs_from_song list.csv # -t '256,28' # \ucd5c\ub300\ucd5c\uc801\ud654 \uacc4\uc815\n\ncd echoecho\nfor i in $(seq 1 100); do echo -n \"\" > new_song_list_i.xls; echo -n \"\" > echo_song_list_i.xls; rm new_song_list_i.csv; rm echo_song_list_i.csv; done\n\n# echo -e \"\" | /usr/bin/xterm /home/jimsun/MusicVoice \\  make_song_list.py \"new",
        "label": 1
    },
    "118": {
        "output": "## Instructions\n\n\n\n\n\n\n[T] Let's try to apply the rules for a patient note. \nPlease pay attention first to the note shown below in this code cell. You need to compare a patient note with the inclusion criteria of a clinical trial (see the code for the trial in the same cell). And then, apply the rule for a patient.\nLet's go to the problematic code lines. To get the idea of the problem, let's check their functions and see which section they belong to. If you are not sure, let's step by step disassemble the code into small pieces, and see which portion needs to be modified, either its function or the way of execution.\nLet's start from the bottom of the code cell with `def isEligible()` function. It has one argument. You want to test the patient by checking whether the patient note passes the trial's eligibility test.\nThen, try to call the `isEligible()` function which is on the `def isEligible(patientNote)` line, by running `trial.isEligible(patientNote) `.\nIf the trial does not meet all the criteria of a patient, the isEligible function outputs `0` otherwise it outputs `1`. And when it fails the test, it is necessary to print the failure message to the user. \nNext, try to call the `printEligibleMessage(isEligible())` function, which is on the `printEligibleMessage(isEligible()) ` line, by running `trial.printEligibleMessage(trial.isEligible())`.\nAnd you should print the message that is written in the print() function by setting the following argument (line 23 in the problematic code cell): `print(\"Patient is {} out of 3 eligible. \\n\", isEligible())`.\nIt shows the assessment of eligibility on each patient for the clinical trial, i.e., a trial level eligibility for the trial. \nNow let's change the function from isEligible to trialNote, which is on the `def trialNote(trial):` line (Line 6). Because the function to evaluate trial notes will be modified, you need to change",
        "label": 0
    },
    "119": {
        "output": "## Examples\n\n### Tutorial:\nFirstly, we will open source, and create new R console environment where necessary scripts are available. R console environment is available by executing the source(url) code in the R command window.\n>>> source(url)      \n\nIn R console, we will check R version where environment and working directory settings are set (source - S).\nR> R.version()                                          \n[1] \"4.0.3\"\nR> setwd(\"..\")\nR> getwd()                                                       \n[1] \"/Users/noh/Dropbox/R/Tutorials/clinical_trial/new/Tutorial/Tutorial_clinical_trial_examples/Tutorial_clinical_trial_examples/\"\nR> getwd()\n\nWe will set working directory environment where clinical_trial package is saved.\n[/CODE]\n\n### Tutorial 1: Trial eligibility assessment for RNA synthesis inhibitors.\nFirstly we will load the dataset file, i.e., <NAME>.txt, into the R console environment.\nR> library(clinical_trial)                            \nR> load(\"RNA_synthesis_inhibitors.txt\")                \n\n<NAME> are excluded due to history of cardiac arrhythmias or congestive heart failure.\n\nHere is a summary of [the R code] (https://github.com/nohee/clinical_trial):\n<EOD> Tracing the Evolution of Mammalian Prions from Cellular Proteins: A New Field?\n\nMammalian prions and prion-like proteins are unstructured, aggregation-prone polypeptides with conformational plasticity that replicate from host cell to host cell; these proteins underpin pathologies from transmissible spongiform encephalopathies and ALS to neurodegenerative diseases. These agents and species induce a wide spectrum of proteinopathies in their vertebrate hosts as a result of self-templated rearrangements within their aggregated structures. We have proposed that prion-like and prion species arise from homologs of the RNA-and DNA",
        "label": 2
    },
    "120": {
        "output": "Note that you should not comment out the 'Exclude' and 'Not relevant' case in the 'Trial_-level_eligibility' field. That is because this case shows that the trial does not allow such patients in it. However, it is still a good idea to code in such a way since such a patient's case is quite rare. \nAfter all, your role as the trial assistant is an eligibility assessment for each patient. Try to make your solution more flexible for various cases so that the patient's case becomes eligible. That is, the patient's case will be considered eligible even if the patient does not meet all 6 inclusion criteria. Let's consider the following:\n[HINT] For simplicity, let us assume that each factor is a binary variable (=1 when the included, 0 otherwise). \n\n### 'No inclusion criteria' case\nIn this case, a patient is not included in a trial. So, it does not matter that the patient does not fit any criteria. It will be automatically '0' when the criteria are not given on the patient. It does not need any comment, either.\n\n`Trial-level eligibility: 0) Not relevant.`\n\n### 'No exclusion criteria' case\nIn this case, there is no exclusion criteria in the given trial. If the trial is not eligible for patients over 60 years of age, such patients would be excluded. So, the trial-level value for this case should be `2: Eligible`. If you want to consider an elderly patient as eligible, make a comment like ``Not applicable.'' in the patient record. In this way, it will enable the inclusion of such patients in the trial later.\n\n`Trial_level_eligibility: 1) Eligible. `\n\n### 'Ineligible due to inclusion criteria' case\nThis is an ineligible case due to exclusion criteria rather than exclusion criteria. If a patient's age does not fall within the age eligibility, the trial will not be eligible for this person only. So, it will be `1: Not relevant.`\n\n`Trial_level_eligibility: 0) Excluded`\n\n### 'Only one inclusion criteria' case\nA trial is only eligible",
        "label": 0
    },
    "121": {
        "output": "[SOLUTION]\nStep 1\nThis data is a patient's medical condition. The inclusion criteria are the patient's conditions matching those mentioned above, and patients with conditions that do not meet them are excluded from the trial. So, the conditions must be 1) age \u2265 18 and \u2264 75; 2) histologically confirmed diagnosis of invasive breast cancer, ductal carcinoma in situ, or lobular carcinoma in situ; 3) patients with a Karnofsky performance status of > 40; 4) patients who understand the nature of the study and give written informed consent.\n- [01] 18 \u2264 age < 75;\n- [02] histologically confirmed invasive breast cancer, ductal carcinoma in situ, or lobular carcinoma in situ;\n- [03] Karnofsky performance score > 40%;\n- [04] written informed consent.\n\nStep 2\nThe patient's condition matches the following medical criteria. The patient should be confirmed with a diagnosis from the inclusion criteria. So, it must be 1) invasive ductal breast cancer; 2) human epidermal growth factor receptor 2-positive with no more than 3 positive lymph nodes; 3) a single breast tumor \u2264 5 cm; 4) axillary lymph node dissection \u2264 15 nodes removed; 5) no other malignant tumors; 6) no prior invasive cancer diagnosis except for squamous cell or basal cell carcinoma of the skin; 7) proliferative or non-proliferative breast tumor with or without atypia; 8) no pregnant patients.\n- [05] invasive ductal breast cancer;\n- [06] HER2-positive with 0-3 positive lymph nodes;\n- [07] no more than 5 cm single breast tumors;\n- [08] no more than 15 axillary lymph nodes dissected;\n- [09] no simultaneous multiple breast tumors or other malignant tumors;\n- [10] no prior invasive cancer diagnosis",
        "label": 2
    },
    "122": {
        "output": "### A2.2) Trial-level eligibility\n[1st] You should make the calculation based on the information of a patient. [2nd] You should repeat the calculation using the information of a clinical trial.\n[INST] You should always repeat Trial-level eligibility in the last line, e.g., `Trial-level eligibility: 0) Non-Eligible.`. \n\nThe inclusion criteria of a clinical trial are as follows:\n\n1. ID: BC033, Title: Breast cancer\n1.1 Age (min): 25, (max): 80\n1.2 Cancer location: breast\n\n1.3 Cancer type: malignant carcinoma\n1.4 Cancer lateralization: 0: left, 1: right\n1.5 Pregnant? (Y/N):\n1.6 Active tobacco-user? (Y/N):\n\n1.7 ID: BC034\n1.8 Metastasis?: Yes (Y/N):\n1.9 HER2+ (Y/N):\n1.10 CMF-like: Yes (Y/N):\n\n2. ID: BC035 Location: left \n2.2 ID: BC035, Metastasis?: No (Y/N): \n2.3 ID: BC035, Active tobacco-user?: Yes (Y/N): \n2.4 ID: BC035, CMF-like?: \n3. ID: BC036 Location: right \n3.2 ID: BC036, Metastasis?: Yes (Y/N):\n3.3 ID: BC036, Active tobacco-user?: Yes (Y/N):\n3.4 ID: BC036, CMF-like?:\n\n[INST] After you make a patient evaluation for a clinical trial, you should always repeat in the last line Trial-level eligibility, e.g., `Trial-level eligibility: 1) Excluded.` and `Trial-level eligibility: 0) Not relevant.`.\n\n1. You may see the summary of clinical trials using following code:",
        "label": 2
    },
    "123": {
        "output": "#### [Exclude(s1596064983 197,1,3,'patient note',2,1,1); Exclude(1035330922,272,1,'instructions',3,1,1); Exclude(0,272,2,9,'preface',7,1,1,22,'paragraph8',11,'rule'), Comment10,Comment11,Comment12]\n\n\n\n\n\n\nThe trial-level eligibility should always appear in the last line if no patient is assigned to the specific trial.\n\n### Comments\n\n#### [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and",
        "label": 0
    },
    "124": {
        "output": "[CODE] \nTrial-level eligibility: [Trial] \nTrial ID: [TrialID] \nPatient: [TrialPatient] \nPatient No: [TrialPatientNo] \nGender: [TrialGender] \nAge: [TrialAge] \nEtiology: [TrialEtiology] \nTrialName: [TrialName] \nPreferred Language: [TrialTrialName] \nEvaluation method: [TrialEvaluation] \nIntervention: [TrialIntervention] \nProcedure: [TrialProcedure] \n\n<EOD> Genetic and antigenic variations between the virulent and avirulent strains of porcine rotavirus.\nRotavirus genomic RNAs were extracted from virulent and avirulent P670 and D1 strains, respectively, purified and electrophoretically separated on 1.8% polyacrylamide-8 M urea gel (PAG). Of these, the purified genome segments RNA4, 5, 6, 7 and 8 were subjected to antigenic analyses in RNA-fed suckling rabbits and subsequently the antisera were tested by an indirect immunofluorescence (I-IF) test. By these procedures, the following results were obtained. The genome segments RNA4, 5, 6 and 8 of the D1 strain were found to be more antigenically related with those of the P670 strain than those of the 4 other genome segments. However, RNA7 of the P670 strain was found to be more antigenically related with that of the D1 strain than those of the other segments RNA4, 5, 6 and 8. These results suggest that the genome segment RNA6 and perhaps RNA8 of the D1 strain are responsible for the virulence of the rotav",
        "label": 1
    },
    "125": {
        "output": "<aside class=\"warning\">If you are using a custom version of R, your input might not be converted to an IRR object, but to a dataset object (this depends on the version of the R package you are using). If you find that you cannot run your code, then you should run the following code:\n<div class=\"highlight\"> library(devtools) library(IRR) set_irr(\"Rscript\") set_irr(\"customVersion.R\") # or: rscript (in this example customVersion.R) </div></aside>\n\n\n* * *\n\n* * * <center><i>Click on a cell or a word to view related information.</i></center>\n\nThe clinical trial includes 2000 patients. You should count how many patients could be assessed as eligible and how many could not be assessed. You can compare the number of patients who meet and do not meet the inclusion criteria through the following steps.\n\n\n### Step \u2460: Make a trial summary\n\n```\nsetDf <-do.call(\"rbind\", setDf) # Create an object with a list\ncolnames(setDf) <-c(\"name\") # Change the column names\nsetDf <-makeTrialSummary(setDf) # Display the output below\n```\n\n![image](https://user-images.githubusercontent.com/48259735/118122365-5189c100-ba01-11eb-9159-2095cd96cfc8.png)\n\n\n### Step \u2461: Compute the rate of patients who met the inclusion criteria within the clinical trial\n\n```\n# Compute the patients who met the inclusion criteria within the clinical trial\nsetDf$Triallelgibility <-`count(setDf$ineligibility, rep(0, round(dim(setDf)[1]))) / dim(setDf)[1]` # Computes the rate of patients who are eligible within the clinical trial. \n```\nHere is the data frame:\n\n```\nsetDf <-data.frame(name = \"trial\",\n                    eligibility = c(\"1",
        "label": 2
    },
    "126": {
        "output": "You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. You should do the same for the clinical trial you're interested in. You should always use a standard scale number as an integer (0, 1 or 2) instead of a float number, e.g., 0 not 0.0. Otherwise, it might produce unexpected triallevel eligibility output.\nYou should output the eligible patient notes for the clinical trial in a table, and the trial-level eligibility in a final row. The output format is in the form of a json string. You are expected to return json strings with output that contain the clinicaltrial name, patient notes, and eligible patients in the order of patient note, eligible patient, and then trial-level eligibility.\n# You are expected to return eligible notes and final trial-level-eligibility in a json string.\n# You may find sample output of interest here:\n# https://github.com/bclinportal/docs/blob/master/example_problem_output.json\n# Your solution will be run on Amazon Web Services. Amazon provides free tier access to 12 different compute and storage services.\n\n# Challenge details\n\n# Explanation\nEligibility criteria vary widely across clinical trial protocols for many types of clinical trials. They can determine which patients may enroll in the study and receive the treatment or intervention developed in that study. For many types of studies, patients who would be eligible for a study may also represent the ideal patients for the treatment under investigation - thus, patients who are not eligible for a study may not have received benefit from a treatment or intervention. It's common that multiple patients are eligible to participate in the study, each having a different set of eligibility criteria. As more data, including patients' eligibility information, is collected, more detailed eligibility criteria may be",
        "label": 0
    },
    "127": {
        "output": "<EOD> .\nIn a number of tumours, such as the mammary carcinoma, the anticancer therapy of choice is surgical removal of the tumour. However, it has been established that cancer usually arises secondarily to an apparently clinically harmless lesion of the organ. In spite of good long term prognosis of patients with this group of carcinomas, the high incidence of metastasis makes the prognosis poor. Therefore, a new concept of screening with the aim of early diagnosis before clinical and radiologic manifestations occur gains importance. This paper describes a new concept of follow-up examinations in the early detection of breast cancer by computer tomography. In a prospective study a number of breast carcinomas was examined by computer tomography. In all cases, the carcinoma could be demonstrated before clinical or radiologic symptoms occurred. Besides, it was possible to detect the first metastasis in the lymph nodes, which occurred 3-6 months after initial diagnosis.<EOD> A review and update of treatment for multiple myeloma.\nRecent updates to the treatment paradigm shift for multiple myeloma (MM) based upon the approval of new agents, most notably proteasome-inhibitors, monoclonal antibodies, immunomodulatory drugs, histone deacetylase inhibitors, and venetoclax. This review aims to highlight key agents with updated phase 3 trial data and discuss how they fit in with current treatment options, as well as address some unanswered questions in the MM clinic that are currently under investigation.<EOD> .\nWe have evaluated the relationship of HBs antigen to lipid alterations including serum total cholesterol, beta-lipoprotein, triglyceride, total protein and albumin in Japanese patients with hepatic cirrhosis, chronic hepatitis and chronic persistent hepatitis. There was no relationship between the presence of HBs antigen and serum total cholesterol and beta-lipoprotein. Serum triglyceride level were negatively correlated to the presence of HBs antigen in chronic hepatitis and hepatic cirrhosis. The presence",
        "label": 0
    },
    "128": {
        "output": "__\n_If a patient was excluded in the test, please add the message: `This patient is excluded by:` followed by a line for each reason why the patient was included and a `Trial-level eligibility:` on the last line. The output trial-level eligibility will be `No patient is excluded in the test`.__\nIf the test was passed, your job as an eligibility assessor is done!\n__**Doing the Test:**__\nYou can do the test case in `examples` folder of `eligibility-assessor` package.\n\n*Note that the example has been simplified slightly to make running the example easier for first time users.*\n\n`eligibility-assessor::doTest(\"radiation therapy.txt\", \"radiation_therapy.md\",\"\")`. This command will output `radiation_therapy.md` on your console.\n\n\n\n\n`{ \"notes\": {\"path\": \"path-to-the-patient.txt\"} }, { \"clinical_trials\": {\"path\": \"path-to-the-clinical-trial.txt\"} }, trial-level_eligibility: \"4\" }`\nThis is the JSON output after `doTest(\"path-to-the-patient.txt\", \"path-to-the-clinical-trial.txt\", \"\")`; you should get same result from `try-patient-test.txt`.\n\n__**How Can We Make it Faster?**__\n\nFirst and most important, please learn to understand what will be done. Secondly, `eligibility-assessor` package has some optimizations to speed up the runtime. It is more than optimized for most of the work which is done by eligibility-assessor for trials. However, the speedup will depend on the database structure. You may still need to do more research for larger databases. \n\n## 1. `eligibility-assessor` package is more optimized for trials than patients.\n   \n    `iristrials::faster_runeligibility` will be faster than `iristrials::runeligibility` and `iristrials::faster_runpatient` will be faster than `iristrials::runpatient`.",
        "label": 0
    },
    "129": {
        "output": "## \u2714[INST] \u25cb [ ]\nCheck the box.\n\n## [inst]\n1) \u25cb The patient has cytologically confirmed breast cancer..\n\n## [inst]\n\u25cb The tumor is HER2-positive.\n\n## [inst]\n\u25cb ER/PR negative.\n\n## [inst]\n\u25cb 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n\n## [inst]\n\u25cb A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n\n## [inst]\n\u25cb A second biopsy showed positive lymph node samples (Stage IV).\n\n## [inst]\n\u25cb Axillary sampling revealed 5 positive lymph nodes\n\n## [inst]\n\u25cb CXR was remarkable for metastatic lesions.\n\n## [inst]\n\u25cb The patient is using multivitamins and iron supplements.\n\n## [inst]\n\u25cb Does not smoke or consume alcohol.\n\n## [inst]\n\u25cb Sexually inactive.\n\n## [inst]\n\u25cb Has no children.\n[formula]  [INST] \u25cb Agrees to do so prior to chemotherapy. [/formula] \n\n## [inst]\n\n## \u25cb\nThe dHER2+AS15 ASCI Antigen-Specific Cancer Immunotherapeutic (ASCI) candidate contains a recombinant protein termed dHER2, which is a truncated version of the HER2 protein. HER2 is a protein that is commonly overexpressed in breast cancer. \nThis protein, as well as tumor antigens, is combined with the immunological adjuvant AS15 Adjuvant System from GSK (GlaxoSmithKline), which is a liposomal formulation containing three immunostimulatory components.\n\n## [inst]\nLapatinib is FDA approved for use in combination with capecitabine for the treatment of subjects with advanced or metastatic breast cancer whose tumors overexpress HER2.\n\n## [inst]\nThis study is for patients with metastatic breast cancer (invasive breast cancer with stage IV disease) that overexpresses HER2 and",
        "label": 0
    },
    "130": {
        "output": "```python\n# +\nimport ctypes\nfrom random import *\nfrom itertools import product\nimport operator\nfrom typing import Optional, Union\nfrom unittest import mock\nimport numpy as np\nimport pandas as pd\nimport datetime\nimport yaml\nimport logging\nimport math\nimport re\nfrom pydub import AudioSegment\nimport re\n\nfrom astropy import units as u\nfrom pathlib import Path, dirs, ParallelPool, Pendulum, TimeZone\nfrom scipy import misc\nfrom matplotlib.plotting import grid_generator, subplot_maker\nfrom statsmodels.tsa.base.mle import WLS\nfrom statsmodels.tsa.combined import HANTS\nfrom datetime import datetime, timedelta, date, tzutime\nfrom matplotlib import _testing\nimport numpy as np\nfrom math import pi\nimport pandas as pd\nfrom pinkerton import fviz_augment, fviz_var, fviz_pair, fviz_hier\nimport plotly.graph_objects as go\nimport plotly\nimport plotly.pylab as spl\nfrom pandas import dataFrame as df\nfrom tqdm import tqdm\nfrom IPython import display, get_ipython\nimport pdb\nimport matplotlib\n\ndef f(val):\n    return val*5+7\n\ndef g(val):\n    return 2*val+8\n\ndef h(val):\n    return val*val\n\n\ndef i(val):\n    return val-301\n\ndef j(val):\n    return 9*val\n\ndef k(val):\n    return 9+val\n\n\ndef l(val):\n    return val/10*5\n\ndef m(val):\n    return val/500\n\ndef n(val):\n    print('val:', val)\n\n\ndef o(val):\n    return val*val/100\n\ndef p(val):\n    return val/1000\n\ndef q(val):\n    return val+10\n\ndef r(val):\n    return val*2\n\ndef s(val):\n    return val*val\n\ndef t(val):\n    return val+6\n\ndef u(",
        "label": 1
    },
    "131": {
        "output": "##[EXPORT]\n<EOD> Influence of temperature on the structure and properties of the phosphatidylcholine membrane in the presence of lignoceryl chains in the head group.\nLipid membranes have been examined experimentally and theoretically for a long time. Detailed studies of different properties of DOPC, DPPC, DSPC, and PSM lipids as a function of the temperature have been reported in previous studies. The biological importance of lignoceryl chains in the head group of the membrane has not been fully clarified yet, despite the fact that lignoceryl chains in the membrane are of great interest in biotechnology. In this study, we investigate the properties of lipid membranes consisting of a combination of PC lipids and long chain lignoceryl chains incorporated, in particular, in the polar head group using the molecular dynamics simulations. We have investigated the effect of temperature on the lateral ordering of hydrocarbon chains, thickness, area, density, and mechanical properties of bilayer membranes of lignoceryl lecithin formed at 370 K and 310 K. We have obtained the results demonstrating the thermal influence on the structure and lateral ordering of hydrocarbon chains and the thickening of the bilayer at the temperatures simulated. In addition, the influence of the temperature on the mechanical properties of the lipid membrane is shown.<EOD> Cytosolic and cell surface activity of the human myeloma light chain.\nA human bone marrow sample contained a monoclonal population of 7S IgG protein and of biclonal 7S kappa light and macroglobulin heavy chain variants, which were secreted and associated with circulating cryoglobulins. The purified 7S kappa light chains showed significant in vitro rheumatoid factor activity and an autologous anti-kappa autoantibody, in addition to a normal anti-DNA antibody. The light chains contained no significant cysteine groups by spectrophotometry, but a small amount of cystine formation and antigenically cross-reactive material increased with time in vitro at 37 degrees C. The 7S light chain dimer, but",
        "label": 2
    },
    "132": {
        "output": "<EOD> The effect of a calcium ionophore on the secretion of phosphatidylcholine in vitro.\nThis investigation was carried out to elucidate the role of calcium in the regulation of phosphatidylcholine secretion in vitro. Incubation of mouse peritoneal macrophages, isolated for 40 h, with phorbol dibutyrate produced an increase in lipid secretion. Increasing Ca++ concentration to 35 mM or the addition of a calcium ionophore A 23187 at 10(-5) M increased lipid secretion when cells had been pretreated with phorbol dibutyrate at 5.50 X 10(-7) M. Neither of these components of the incubation media had any effect on the lipid secretion in control cells. There was also an increase in phorbol dibutyrate induced lipid secretion when the calcium ionophore was added after a 24 h lag period. Similar results were obtained with a preparation of normal mouse peritoneal macrophages. The cell number per millilitre, determined microscopically, decreased within the first several hours and then tended to stabilize.<EOD> The effects of the new antiepileptic drugs\nPurpose of reviewThis review gives an overview on the effects of the new antiepileptic drugs (AEDs), which has been published since earlier reviews focusing on the efficacy and tolerability of AEDs. Recent findingsThere is a new generation of the old antiepileptic medications as well as new drugs with novel pharmacological mechanisms. Some of the new AEDs are effective in refractory epilepsy syndromes. For this group of patients, new AEDs need to be effective as well as well tolerated. SummaryAll of the newest AEDs have a broad spectrum of effectiveness in different patient groups. Levetiracetam and oxcarbazepine seem promising in the treatment of absence seizures and Lennox-Gastaut syndrome. Perampanel, brivaracetam, and lacosamide are promising in the treatment of complex partial seizures or refractory epilepsy.<EOD>",
        "label": 0
    },
    "133": {
        "output": "[INST] \nA: Patient-level eligibility\n    The patient's eligibility information will be given as the patient data.\nYou should make patient-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n    You should check if the inclusion criteria are completely or partially matched according to the patient's data. Use the binary information as the result of the patient-level eligibility. If you have any doubts of a patient's inclusion to the clinical trial, assign one to three on `Patient-level eligibility. \n    For example, if the patient's body type is consistent with the inclusion criteria of a trial, assign one to the input. If all the variables do not match, assign three to the input. If it is not clear if the patient matches the trial, assign two to the input.\n    \n    The input sample of Trial-level eligibility is determined using the following format: `Trial-level eligibility: (value of Patient-level eligibility)  `.\n- Trial Level Eligibility: 0 (Excluded)\n    You have to set this status to exclude it from the eligibility. If a patient does not meet the inclusion criteria, it should be excluded. For example, the patients in this example are all male.\n- Trial Level Eligibility: 1 (Not Relevant)\n    The patient's age or gender does not match the trial's inclusion criteria.\n- Trial Level Eligibility: 2 (Eligible)\n    This category is assigned if a patient's data completely matches the inclusion and exclusion criteria of a trial.\n   \n- Trial Level Eligibility: 0 (Excluded)\n- Trial Level Eligibility: 1 (Not Relevant)\n- Trial Level Eligibility: 2 (Eligible)\n    \n    The input patient-level eligibility is given as patient's data.\n                    \n    The patients' eligibility information is described in below. Here, we present an example of a dataset. The input values of the patient's eligibility are presented within square brackets ([]).\n    \n    ![2019-10-21 1",
        "label": 0
    },
    "134": {
        "output": "Good luck!\n<EOD> Gender bias in the management of acute, non\u2010variceal upper gastrointestinal bleeding when presented with a negative urgent endoscopy\n\nBackground and aim: It has been suggested that female patients are less likely to undergo early re-endoscopy for actively bleeding and high risk endoscopic ulcer lesions. We sought to determine if male patients presenting with a negative first endoscopy are subsequently offered any treatment, while female patients are not.Method: All patients who had unscheduled upper gastrointestinal endoscopies were identified from a database that contained demographic and clinical information. For each patient in the study period, a time-stamped record was kept of the treatment received, and of relevant investigations. All of the available records of the patients in this group were reviewed.Results: A total of 192 patients had urgent endoscopies between November 2006 and December 2007. Mean age, length of stay, and gender of the patients did not differ between the groups (p value > 0.05, two-tailed student t-test). There was no significant statistical difference between the percentage of female and male patients that were admitted or admitted and then discharged in the groups having no endoscopic diagnosis (58.66% vs. 41.34%), gastric ulcer (70.63% vs. 29.37%), duodenal ulcer (56.52% vs. 43.48%) and erosive gastritis (60.87% vs. 39.13%). However, a statistically significant difference was seen between the two groups in the percentages of female and male patients with active bleeding not managed by endoscopy that were subsequently managed medically (33.33% vs. 66.67%, Chi square = 6.639, p = 0.0104). The female and male patients that were discharged home after the first negative endoscopy were significantly younger than the patients that had endoscopy-related treatments (41.04 years vs. 52.29 years, t-test, p = 0.0",
        "label": 2
    },
    "135": {
        "output": "[/STEP]\n\n\n<br/>\n\n#### T-45: Eligibility Check\n\nThis task is a single classifier that decides whether a patient is eligible to a given a clinical trial. The inputs of the classifier are a patient note and the clinical trial. The output of this classifier is an assessment of patient eligibility: 1) Excluded (the patient violates the inclusion criteria of the trial), 2) Negative (the patient has insufficient information to be eligible), 3) Positive (the patient meets all the inclusion criteria of the trial). This task is a special case of the more general task T-44 with an input  of a patient note and a clinical trial .\n\n\n## Task T-45 Details\n\nThe output of this task is one of the three: \n1. Excluded: A patient violates all the eligibility criteria for the trial.\n2. Negative: A patient does not have sufficient information to be eligible.\n3. Positive: A patient meets all the eligibility criteria for the trial.\nSee  for examples of input and expected output.\n\nSee [/STEP]:\n\n[/LINK]\n</br>[/STEP]\n\n#### T-46: Trial-level Eligibility\n\nThis task is an input-output pipeline that consists of two pipelines which decide:\n\n \n\n \n\nA patient is excluded if he has violated one of the inclusion or exclusion criteria, as well as the final eligibility decision.\nA patient is positive for the clinical trial if he does not violate any criteria and thus can be used by the trial. \nThis task's inputs are a patient note and a clinical trial. The output is 2-tuple, with the first element being a Patient-level eligibility, and the second one being a Trial-level eligibility. \nExpected output\nA patient-level eligibility can be either positive or negative.\nFor the positive patient level eligibility:\nAssessment of eligibility: Positive\nAssessment of Eligibility: 2) Eligible\n\nExplanation\nThe assessment of eligibility is positive, which means patient is eligible",
        "label": 0
    },
    "136": {
        "output": "![INST]\nOutputs: \nTrial-level eligibility: 2) Eligible.\n\n__FRAGMENT_02__<commit_msg>This issue is still unfixed in the most recent release of SAS/ACRT. The issue can be fixed by using CASR, not SAS/IML.<commit_after>#! /bin/bash\n\n[R]\nsyntax=R64\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.Here is the clinical trial: \nTitle: Study of Epicutaneously Applied Ketoprofen Transfersome\u00ae Gel With or Without Combination With Oral",
        "label": 0
    },
    "137": {
        "output": "## [INST] If you encounter blank lines between Patient notes passed to\\nTrial-level eligibility:` and 00-Patient notes passed to Tri",
        "label": 0
    },
    "138": {
        "output": "<EOD> Oxytocin is required for formation and maintenance of maternal bonding during lactation\nSignificance Maternal bonding is critical for the parent-young relationship in mammalian animals. However, its neural mechanism is scarcely studied, especially in lactating females. Although neuroendocrine changes, especially oxytocin (OT) receptor modulation, contribute to maternal behavior, it remains undetermined whether OT signaling is required for the formation and maintenance of both the pup-elicited and pup-preferred activity patterns in the mother. This is the first study to demonstrate the role of OT in the medial preoptic nucleus (mPON) in pup bonding during lactation. The results reveal that OT\u2013mPON\u2013anterior cingulate cortex (ACC) neural circuitry underlies maternal bonding in lactating females. These findings provide insights into the neural mechanism underlying maternal behavior and suggest new therapeutic targets for treating disorders characterized by impaired maternal behavior such as postpartum depression. To identify the neural mechanism underlying maternal bonding, we measured baseline and pup-elicited activities of the maternal behavior-associated anterior cingulate cortex (ACC) neurons in lactating rats with intraventricular administration of an OT receptor antagonist or OT or its analog, intranucleus infusions of the OT receptor antagonist, or genetic knockdown of the OT receptor or OT in the ACC using short hairpin RNA or RNA interference, respectively, focusing on their interactions with maternal experience and pup preference. All these manipulations inhibited ACC neurons in lactating rats during presentation of pups in an unfamiliar environment or during maternal behavior, suggesting a role of OT in mood stabilization. Infusions of the OT receptor antagonist or knockdown of the OT receptor or OT into the medial preoptic nucleus (mPON) in virgin rats prevented maternal preference elicited by social contact with pups and pup-elicited activation of ACC neurons. OT receptor knockdown in the mPON of lactating rats also inhib",
        "label": 0
    },
    "139": {
        "output": "<EOD> Clinical and histopathologic features of a 4-year-old male neutered Domestic Long Hair cat with systemic hypoadrenocorticism.\nA 4-year-old neutered Domestic Long Hair cat was presented due to vomiting, diarrhea, hyporexia and weight loss. The patient was previously diagnosed as hypothyroid gonadal dysgenesis at this clinic on account of lack of development of the external genital structure. Hypothyroidism was confirmed with the result of increased T4 value to 4.54 ng/dL (normal 1.0 to 3.3 ng/dL) and normal TSH level (0.46 ug/L, normal <2.28 ug/L). Hypothyroidism was considered to be the cause of weight loss that had been continued for many years. It was thought",
        "label": 0
    },
    "140": {
        "output": "# Use case\n\n# Use case:\n\n\n```ruby\ndescribe 'Clinical.eligibility.rb' do\n  let(:patient_note) { PatientNoteGenerator.note(\"candidate_name_for_testing.txt\") }\n  let(:clinical_trial) { ClinicalTrialGenerator.trial(\"trial_name_for_testing.txt\") }\n\n  it 'is a PatientNotes instance' do\n    expect(patient_note).to be_instance_of(PatientNote)\n  end\n\n  it 'has a text note' do\n    expect(patient_note.note).to start_with(\"Patient is a 45-year-old postmenopausal woman with invasive ductal breast\")\n  end\n\n  it 'has a clinical trial' do\n    expect(patient_note.clinical_trial).to start_with(\"#10091009\")\n  end\n\n  it 'is the eligible of the trial-level evaluation' do\n    expect(patient_note.eligibility).to start_with(\"Not relevant\")\n  end\nend\n```\n<EOD> Synthesis of new pyrazines by a domino reaction.\nDomino synthesis of functional pyrazines involving aminocarbonyl/ketene methyl acetal cycloaddition and oxime aldol/Michael addition is described. The products obtained were also confirmed by GC/MS analysis.<EOD> 2007: The Year of the Reverse J-Curve: A Cautionary Tale.\nA 31-year-old woman presented to the outpatient physical therapy clinic with severe exertional-type leg pain and shortness of breath in the right leg. History was significant for traumatic left ankle dislocation in 2006 that was treated by a closed reduction and ankle<EOD> .\nFour species of loricariid fish from the Cuiab\u00e1 River, Mato Grosso, including Pterygoplichthys equesi, Hypostomus regani, Hypostomus pictus and Hypostomus ancistroides were fed a natural diet (tubers",
        "label": 0
    },
    "141": {
        "output": "[!NOTE]\n\nYou can download the example code file in this section as well.\n\nYou can find more information about clinical trial data on the Medical Data Standards website:\n\nhttps://mds.nlm.nih.gov/data/\n\n[!NOTE]\n\nTo make the evaluation easier, we have developed an evaluation tool called the \"Evaluate Coding\" tool. You can access the \"Evaluate Coding\" tool by pressing the gray button with the word _Run_ inside it in \"Developer Tools\".\n\n![Evaluate_coding]\n\n[!NOTE]\n\nThe evaluation tool will ask you to:\n\n* Evaluate the code of the input clinical study.\n* Evaluate the code of the clinical data.\n* Select variables related to their input data to be encoded by the code you wrote.\n* Check the error reporting from the code run in the evaluation tool.\n\n# Implementation\n\nThe main data types of the output of the encoders are JSON and CSV, and the data type of the output of the decoders are JSON and XML. This section is about the steps you need to follow to write your own encoders/decoders in Python. \ud83d\udc47\n\n## Installing packages and importing namespaces\n\nAfter you have installed the required packages to create your encoder or decoder, import the namespaces in your Python file. \ud83d\udc47\n\n```python\nimport pandas as pd\nfrom pathlib import Path\nfrom json import dump, load\nfrom os import path\n\nimport numpy as np\n```\n\n##### Required (in decoder module):\n\n```python\nfrom clinical_dataset import Decoder, DecoderConfig# \u2764\ufe0f\ud83d\ude80\nfrom numpy import ndarray\nfrom pandas import Series\nfrom io import Dataset\nfrom copy import deepcopy\n\n\nfrom clinical_study import ClinicalStudy\n```\n\n## Writing your encoder/decoder\n\nAt this point, you should not worry about how to configure your encoder/decoder. You only need to know how to create your instance of an encoder or decoder.\n\nHere is a generic encoder/decoder skeleton that is reusable in your Python scripts (e.g.,",
        "label": 2
    },
    "142": {
        "output": "<EOD> SUN-329 Clinical and Genetic Findings of 12 Families from 3 Unrelated Ethnic Groups with a Rare Disorder of Sex Development\n\nSUN-329Patients with sexual maturation and internal genitalia developing normally and primary amenorrhea develop due to a disorder of sexual development (DSD) are called non-discordant DSD. Diagnosis is challenging in such patients since primary amenorrhea is usually attributed to psychopathologies instead of a clinically apparent disorder. We aimed to describe 12 unrelated females clinically phenotyped with DSD. This retrospective study included women clinically diagnosed with DSD aged \u226516 years between 2012 and 2020 in 3 tertiary medical centers in Turkey, a 28 million-population country located in the Middle East. All participants were phenotypically assigned to DSD group due to primary amenorrhea. Patients' charts were reviewed for age at diagnosis, medical history, clinical characteristics, physical examination findings, biochemical and radiological tests, and genetic testing results performed with targeted panel sequencing approach. Medical files of all women diagnosed with DSD during the study period were reviewed, and 20 patients fulfilled the inclusion criteria. After exclusion of patients who had previously undergone hormone replacement, 12 of them were included in the study. Patients' age at diagnosis ranged from 16 to 27 years, and the mean age at diagnosis was 21.5 years [fig_ref]  Table 1: Clinical characteristics of the studied DSD cohort [/fig_ref] . Only 1 patient had a history of mental retardation, but this condition was not related to DSD. The most common reason for referral to endocrinology clinic was primary amenorrhea of 6 patients. Other patients consulted due to infertility, short stature, and suspicion of DSD. Two patients were referred because their elder sister was clinically diagnosed with 17\u03b1-hydroxylase deficiency. All women had undergone hormonal and reproductive endowment development assessment [fig_ref]  Table 1: Clinical characteristics of the studied D",
        "label": 0
    },
    "143": {
        "output": "<EOD> A Comparison of the Effects of the Angiotensin\u2010Converting Enzyme Inhibitor and Angiotensin Receptor Antagonist on Proximal Tubule Transport in the Rat\nWe have tested the hypothesis that angiotensin receptor (AT 1 ) antagonists have direct diuretic effects independent of their interference with intrarenal angiotensin action. We studied the effects of a 7-day administration of the AT 1 antagonist, EXP 3174, and its hydrochloride (HCl) salt, EXP 3179 Cl, on proximal tubule transport parameters and on mean arterial pressure in Munich-Wistar rats. In anesthetized rats, EXP 3174 and EXP 3179 have similar acute diuretic effects (118% and 103% above control after 120 minutes), but EXP 3179 induces less natriuresis than EXP 3174 (56% above control for EXP 3179 vs 233% above control for EXP 3174). In 7-day studies, rats were treated with either vehicle (N = 14), EXP 3174 (5 mg/kg/day, N = 12), or EXP 3179 Cl (10 mg/kg/day, N = 11). EXP 3174 and EXP 3179 Cl had similar long-term diuretic effects (75% and 85% above vehicle, respectively); however, EXP 3179 Cl tended to have a greater natriuretic effect than EXP 3174 (63% and 125% above vehicle for EXP 3179 Cl and EXP 3174, respectively). After chronic infusion, EXP 3179 induced greater losses of proximal tubule fluid and sodium (47% and 76% above vehicle losses, respectively) than did EXP 3174 (23% and 43% above vehicle losses, respectively). Excess sodium losses were greater for",
        "label": 2
    },
    "144": {
        "output": "<EOD> The Role of Interventional Dialysis in COVID-19 Patients Requiring Continuous Renal Replacement Therapy: A Single-Center Experience\n\n\n\n# Background\nThe novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), was first discovered in Wuhan, China, in December 2019. The pathophysiology of human-to-human transmission for this virus is through respiratory droplets and viral particles [bib_ref]  Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1, Van Doremalen [/bib_ref] . Given its high infectivity, coronavirus disease-19 (COVID-19) has spread throughout the globe and the World Health Organization has identified it as a pandemic. Patients generally present with a cough and shortness of breath, which can progress quickly to acute respiratory distress syndrome, multiorgan system failure, and death [bib_ref]  Acute kidney injury due to COVID-19 and impact on outcomes, Chappidi [/bib_ref] . Mortality rates are \u223c3%.\nAs clinical and epidemiological data have accumulated over the past 15 months, increasing attention has turned to renal dysfunction in patients infected with COVID-19. Up to 19% of patients with COVID-19 have been shown to develop renal dysfunction, with acute kidney injury (AKI) occurring in >20% [bib_ref]  Incidence, risk factors, and prognosis of acute kidney injury int hospitalized COVID-19..., Cheng [/bib_ref] . Mortality from COVID-19 is higher for patients with AKI than for those who do not develop it [bib_ref]  Incidence, risk factors, and prognosis of acute kidney injury int hospitalized COVID-19..., Cheng [/bib_ref] . Additionally, the mortality rate in patients with COVID-19 and AKI on continuous renal replacement therapy (CRRT) has been reported to be as high as 95% [bib_ref]  Continuous renal replacement therapy for critically ill patients with COVID-19, Iwasaki [/bib_ref] . As such, it is imperative to",
        "label": 0
    },
    "145": {
        "output": "##[[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to determine the patients' eligibility to a clinical trial. A factor allowing someone to participate in a clinical trial is defined as inclusion criteria. They are based on characteristics such as gender, age, the type of cancer, previous treatment history, and other medical conditions.\\nIn the table below are summarized two sample tables. The first table represents the inclusion criteria for trial \"Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer\", i.e., the \"Trial of Pixantrone\" table. The table includes the \"Title\", \"Summary\" and \"Inclusion\"/\"Exclusion\" criteria. The \"Eligibility\" column of the eligibility section is not applicable because we consider no patients with multiple criteria in the same section to be eligible. The second table represents a summary of a fictitious patient's inclusion criteria for this trial. Below you'll find the instructions in two parts. The first part concerns you have to apply the eligibility criteria of a clinical trial to determine the patients' eligibility. The second part concerns you have to output the patient-level eligibility for this trial. The \"Excluded\",\" Not relevant\" and \"Eligible\" scales are used. \n\n# Part 1\n\n## [INST] The patient's inclusion criteria for the Trial of Pixantrone.\n\n### Eligibility Determination\n\n### 1) You need to determine patient's eligibility to clinical trial. In the input form 'Clinical Trial of Pixantrone'. Find the clinical trial and click the 'Data' tab. Copy the content of the table of the ' Inclusion' section of the 'trial of pixantrone (ClinicalTrials.gov Identifier: NCT00004284) . \n\n### 2) Copy paste the list of factors determining patient's eligibility on each cell.\nEliGible Eligible EliGible Eligible Eligible EliGible Eligible Eligible EliGible Eligible Eligible Eligible Eligible Eligible Eligible Eligible",
        "label": 0
    },
    "146": {
        "output": "\u00a9 2018, <NAME>, et al.\n\n[![View the source on GitHub](https://github.com/gist-it/medipredict/blob/master/static/public/medipredict.md)]\n[![View the source on GitHub](https://github.com/gist-it/medipredict/tree/master/test/data)]\n\n<EOD> Reproductive toxicology: the 2004 report.\nToxic effects of drug and chemical exposures during pregnancy on maternal health and disease in future generations have become recognized by biomedical scientists and industry as a major public health concern. As we enter the millennium, more and more drugs and chemicals known to cause direct toxicities in the mother are being developed and marketed. Few effective animal and human studies are being conducted to examine the teratogenicity or developmental toxicity of these drugs and chemicals. Many pregnant women taking these drugs are becoming exposed to chemicals never before studied or known to affect reproduction. A case in point is the antiviral drug acyclovir, which is now routinely used by millions of people for genital herpes and is being evaluated for use in other genital pathogens. While the drug has been shown to be developmentally toxic in animals, including humans, its reproductive toxicity in both genders is poorly documented or studied. We reviewed and analyzed all the literature published on the subject in PubMed  from 1964 to 2004. The report will focus on newer, nonchemical therapies, such as antiretroviral therapies that are commonly used for pregnant women infected with HIV and hepatitis C, toxicity in children and adults exposed to these drugs in utero or after birth.<EOD> Clinical Outcomes of Patients with Chronic Rhinosinusitis who have Failed Medical Management\nObjective.\u2014 This study presents a series of patients with chronic rhinosinusitis, in whom previous medical management failed, and who underwent sinus surgery with medical continuation postoperatively. The aim of the study is to assess whether sinus surgery and postoperative antibiotic prophylaxis have any beneficial effects on disease remission",
        "label": 1
    },
    "147": {
        "output": "# Sample Solution\n    You need to evaluate your input and provide a Trial-level eligibility for each patient note.\n    \n   \n    ```\n     {\n        \"SensitiveInfo\": {\n          \"CancerRegimen\": {\n            \"Title\": \"Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer\",\n            \"Summary\": \"RATIONALE: Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Giving panobinostat together with letrozole may be an effective treatment for breast cancer.PURPOSE: This phase I/II trial is studying the side effects and best dose of panobinostat when given together with letrozole and to see how well it works in treating patients with metastatic breast cancer.Inclusion:\n\n    }\n    }\n\n    Output:\n    {\n        \"trial_level_eligibility\": \"Excluded\",\n        \"Patient Note:\" => \"The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\n    }\n\n\n### SOLUTION\n\n<EOD> The Drosophila melanogaster genome, Ahrens and Henikoff style\nThe 99-Mb Drosophila genome is very well annotated, with a mean spacing of 20.9 kb between contiguous genes. Most of it (92.9%) belongs to",
        "label": 2
    },
    "148": {
        "output": "<BR><BR><H2>[H2]Output: Eligibility for  patients</H2><BR><UL><LI>The patient is a 41-year-old woman, whose clinical trials are:\n</LI>\n\nClinicalTrials.gov listing: [clinicaltrials.gov](https://clinicaltrials.gov/search/results?cond='Liposarcoma'&amp;term=&amp;cntry=&amp;state=&amp;city=&amp;dist=)\nPMC ID: [PMC3568118](https://pubmed.ncbi.nlm.nih.gov/17954720/)\n\n[A116-05](https://clinicaltrials.gov/ct2/show/record/NCT01517221):\n[clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/NCT01517221)\n[PMC3568118](https://pubmed.ncbi.nlm.nih.gov/17954720/)\n\n[A117-05](https://clinicaltrials.gov/ct2/show/record/NCT01517246):\n[clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/NCT01517246)\n[PMC3568118](https://pubmed.ncbi.nlm.nih.gov/17954720/)\n\n[A119](https://clinicaltrials.gov/ct2/show/study/NCT02208253):\n[clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/NCT02208253)\n[PMID: 28374826](https://pubmed.ncbi.nlm.nih.gov/28374826/)\n[PMID: 26696647](https://",
        "label": 1
    },
    "149": {
        "output": "## Question 7: What is considered to be clinically significant weight change?\n<EOD> Difficulties associated with the definition and measurement of adherence in epilepsy.\nDifficulties with measuring adherence to antiepileptic drug therapy are well recognized. The reasons for this are many. The various scales available are often difficult to use, involve a great deal of time to complete and can also be affected by cultural bias. Moreover, there is a fundamental problem with defining what is meant by adherence, which, as pointed out by Cramer, \u201cis a word without a clear definition\u201d ( 1 ). In an attempt to develop some consensus on how to measure adherence, it was decided that a workshop be held at an epilepsy symposium (September 1994, London). A group of participants met under the supervision of Dr. William Panayiotopoulos to discuss various aspects of adherence to antiepileptic drug (AED) therapy, and they were asked to complete a questionnaire prior to the meeting, which addressed 14 separate aspects of adherence. The questionnaire and the workshop itself received extensive critical editorial and scientific input from the members of the AED Advisory Board. The overall aim of these activities was to develop some guidelines for researchers to use in trying to establish the validity of adherence scales. From these activities two conclusions can be drawn: ( 1 ) AED researchers need to have a well-defined and standardized assessment of the degree of adherence to AED therapy in epileptic patients and (2) they need to assess whether such assessment helps them to understand better the relationship between AED treatment and the clinical and social outcome of patients. One of the problems that has been identified is the difficulty of defining what is meant by adherence. It is a concept that all researchers seem to be agreeing on less and less as time passes and their efforts to measure adherence becomes more detailed, with a growing number of scales being developed, each with only a slightly different definition of the terms used in the scale. At the meeting the word nonadherent was the one that most commonly came to mind. Clearly, this is an emotive word for most of us and it raises issues of ethics, morality and bl",
        "label": 0
    },
    "150": {
        "output": "___\n\n### Summary\n\nSoftware:\n - [INST] Python 3.x\n - [INST][TUT](Tutor)\n\nPython-Docstring Tutorial for clinical trial assessment eligibility program\n============\n\nThis is a [Python-Docstring](https://www.tutorialspoint.com/python/python_doc_string.htm) Tutorial, including introduction, prerequisites, tutorial, example code, references, and discussion. Enjoy!\n\nIntroduction\n============\n\nThis tutorial covers a [TUT](../TUT/intro.md):\n   - [INST].[TUT](TUT) (Tutor: Trial-level eligibility)\n\nPrerequisites\n============\n\nYou need to install [INST][TUT](TUT)\n\nInstructions\n============\n\n[INST][TUT](TUT) is a Python Tutor, i.e., Python code tutorial. To run it, you should first:\n\n  1. Install [INST][]\n, a Python interpreter.\n\n  2. Install [INST][TUT](TUT) in a virtual environment:\n\n     ```bash\n     virtualenv --relocatable [INST][TUT](TUT)/bin\n     python [INST][TUT](TUT)/bin/activate\n     ```\n\n  3. Change directory to the tutorial directory:\n\n     ```bash\n     cd [INST][TUT](TUT)\n     ```\n\n  4. Execute the tutorial in that directory:\n\n     ```bash\n     run_tutorial [INST][TUT](TUT)/TUT_1/main_01.py\n     ```\n\n  5. Or try running the tutorial without changing directory:\n\n     ```bash\n     python [INST][TUT](TUT)/bin/TUT_1/main_01.py\n     ```\n\n  6. Alternatively, you can also execute the tutorial from the top-level directory (see [INST][]):\n\n     ```bash\n     python [INST][TUT](TUT)/TUT_1_main_01.py\n     ```<jupyter_result>\n  \n# [INST] tutorial: trial-level eligibility\n\n# This tutorial",
        "label": 0
    },
    "151": {
        "output": "# Expected Results\nThe expected results for each patient should be one of the following three:\n\nExamples of patients' records from clinical studies as an output of the clinical trial eligibility assessment\nInclusion criteria of clinical trials are shown as the input. The table will show the number of patients that satisfy the inclusion criteria, including excluded patients by inclusion criteria.\n\nFor instance, the data from the first page of a patient record is shown in . In this case, the patient is suitable for the trial: The numbers \"0\" and \"1\" are \"Excluded\" and \"Not relevant\", respectively, and the number \"2\" is \"Eligible\" based on the clinical trial's inclusion criteria. The patient record is excluded according to a clinical trial's exclusion criteria.\n\nIn cases in which the numbers are not 0, 1, or 2, the criteria for the assessment of eligibility are not clear. In this case, you should check the patient note, which is output using the Clinical Notes for Trial recruitment function of the Clinical Trial Assistant.\n\nExamples of a patient record from clinical studies including the clinical trial exclusion criteria Assessment of Exclusion criteria based on patients. (Page 1 from Patient records with patient note)\nAssessment of Exclusion criteria based on patients. (Page 2 from Patient records with patient note)\n\n# Validation and results\nThe following two clinical trials were run as examples, and a total of three clinical trials were run to validate the function.\nThe clinical trial results (clinical trial eligibility assessment for the clinical trial ID: JCR:JCOG1015) in  Figure\u00a08 (top) were evaluated with the data from the clinical trial. It was determined that 85% accuracy of the clinical trial eligibility assessment had been obtained.\nClinical trial eligibility assessment for the clinical trial ID: JCR:JACCOR5 (bottom) were evaluated with the data from the clinical trial. It was determined that 85% accuracy of the clinical trial eligibility assessment had been obtained.\n\n# Limitations and challenges\nThis clinical trial eligibility assessment, along with the previous tools",
        "label": 2
    },
    "152": {
        "output": "**Coding Explanation:**  This is a flag indicating the final assessment of eligibility. Two possible values are permitted: **Eligible** or **Not eligible**. Eligible means that, based on the patient's data, the patient is eligible for the trial. Not eligible means that, based on the patient's data, the patient is ineligible for the trial. **Required Completion**: Yes\n\n\n####### Eligibility criteria checklist\nTo avoid mistakes, the information below is used for the eligibility criteria consistency check of `patients.csv`.\nIn the checklist, patients are sorted in ascending order to match patients from `patients.csv`.\nFor example, let's see how you can verify that patients of `patients.csv` meet the following trial-level exclusion criteria.\n\n**Ineligible (Disease):** The patient have a concurrent malignancy other than non-melanoma skin cancer. The patient have active or severe autoimmune disease that has required systemic treatment in the past two years.\n\n**Ineligible (Inclusion/Exclusion):** The patient's diagnosis of breast malignant neoplasm includes metastatic cancer.\n**Ineligible (Pathological diagnosis):** The patient is not diagnosed with invasive breast cancer. The patient's maximum tumor diameter must not be greater than 5 cm.\nOther cases are the same.\n<div id=\"markdown-renderer\"></div>\n```python\nEligibility criteria check:\n\n    \"\"\"\n    Check patient eligibility\n    \"\"\"\n    n_patient = len(patients)\n    patients_by_index = np.arange(n_patient)\n    all_ineligible_indexes = []  # Ineligible by trial level\n    all_ineligible_all_patient_indexes = []  # Ineligible by disease level + trial level\n    eligible_patient_indexes = []  # Eligible\n    eligible_all_patients_indexes = set()  # Eligible\n    for patient in patients:\n        eligible = patient['Eligibility'] == 'E",
        "label": 0
    },
    "153": {
        "output": "The following are output samples:\n\n```py\nfor i in range(2):\n    print(f'patient_id  {i},{f\"Patient {patient_id}  is {gender} with {age_group}, {eligbility}\").encode('utf-8').encode('ASCIZ')[:32]\n    print(f'   Trial  {trial_id},{trial_desc}')\n    print(f'   Site     {site_id})')\n    print(f'   Patient -{patient_id},{clinical_trial_number},{age},{gender},{smoke_status},{eligibility},{clinical_trial_number},{trial_desrciption}')\n    print(f'        Clinical Trial Eligibility -{trial_description},{enclosing_trial,clinical_trial_number})'\n```\n\nSee the `docstring` for more details.\n<issue_comment>username_1: Include the `pathologic` feature.\r\n<!-- https://pytorch.org/docs/stable/torch.autograd.html#ref-feature-pathologic. -->\n<issue_comment>username_1: Update example.\n<issue_comment>username_1: [Update](https://github.com/JonghyunSeo/pyradiomics-examples/commits/b48a781000c4d084e5034f99b0084cd6db2ce686)\n<issue_comment>username_0: Great! :)\n<issue_comment>username_1: [Update](https://github.com/JonghyunSeo/pyradiomics-examples/commits/d96e703a43b23213b59078f2186212434d451688)\n<issue_comment>username_1: [Update](https://github.com/JonghyunSeo/pyradiomics-examples/commits/4a2d7d7fdc3d1da9397564b7",
        "label": 1
    },
    "154": {
        "output": "<EOD> FGF9 suppresses bipolar mammary tumor growth and is positively regulated by the AKT-PRAS3 axis\n\nThis is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.AbstractFibroblast growth factor 9 (FGF9) is expressed during mammary development, but its impact on mammary tumorigenesis remains largely unknown. Here we analyzed whether changes in the FGF9 levels during mammary tumorigenesis affect bipolar epithelial/fibroblast-like tumor growth. The results of FGF9 in vitro overexpression and deletion show that FGF9 is expressed by malignant mammary cells and affects their proliferation, colony formation, and invasion. FGF9 secreted by malignant mammary epithelial cells induced the development of bipolar tumors, and its inactivation decreased metastasis in vivo. Mammary tumors that did or did not express FGF9 both exhibited positive nuclear beta-catenin staining in their epithelial cells, indicating that these tumors progressed to the same late-stage. To uncover the mechanisms by which FGF9 modulated tumor malignancy, we evaluated FGF9's levels during the early mammary tumorigenic process induced by AKT activation, and the impact of AKT on FGF9 levels. Analysis of FGF9 expression at different time points over the course of the early tumorigenic process showed that FGF9 levels increased during mammary tumorigenesis by Wnt1 overexpression or AKT activation. The AKT-mediated induction of FGF9 was suppressed by the PI3K inhibitor LY294002 and the PRAS3 inhibitor SKIP7303. Thus, the FGF9 levels are positively regulated by the AKT-PRAS3 axis during tumorigenesis and in mammary tumor progression in vivo. These results indicate that FGF9 is a critical mediator of mamm",
        "label": 2
    },
    "155": {
        "output": "---\n# Code\n\nHere, we provide the code to reproduce our solutions.\nTo implement the code for the exercise, just copy the file in `/exercise` directory of the project and run it with your preferred editor.\nOnce you modify the code to solve the problem yourself, you can add your own changes into the code from `/master` directory and build the project by running `cd exercises && make`\nThe `make` will build the code without modifying it and run the test suite to check for wrongly detected output.\n\nIf you want to do a clean build, just run `make clean` (run make even if there is no file to be built).\n\nThere are additional exercises available in this project like 1-variable, 2-variable, 3-variable and 4-variable.\n<EOD> A Newly Discovered Infection of the Gall Bladder, Which Causes Abscess Formation: (Report of a Patient with a Large Abscess in the Gall Bladder.)\n(Report of a patient with a large abscess in the gall bladder.) G. D., a patient aged 38, complained of severe pain in the right loin in October 1930. He had had a severe attack of acute yellow atrophy, with jaundice, fever and pain in both loins. He was in a serious condition for about two years, with recurring vomiting and constipation, but he got about until January 1932, when severe left loin pain occurred, and on January 22 he was seen in Professor Greig's outpatient department at Belvedere Hospital. He had a severe attack of loin pain at that time, and the abdomen was distended and tender. A swelling was felt in the right loin, extending up to the ribs. He was admitted at that time to the surgical wards of Belvedere Hospital. A diagnosis of a retroperitoneal abscess was made by Dr. Greig, and four weeks later an intercostal artery incision at the second interspace of the right side was performed, but no pus was seen. The patient was under the care of Professor Greig for a further period, and the swelling gradually healed with the formation of a sinus, which remained in the upper part",
        "label": 0
    },
    "156": {
        "output": "# Evaluation and Interpretation\n\n## CORRECT PATIENT/TRIAL INFORMATION ON THE CROSSWALK TABLE\nCrosswalk aids in the decision making process to assign a patient a score 0 or 1. By crosswalking a patients' initial eligibility score, it provides a better interpretation of a patient's score. A patient who is 1a_eligible is more  eligible than a patient who is 1d_ineligible (their eligibility decreases in priority order from 0, 1a to 1b,1c, 1d).\nPatient 0) 1d_excluded [INST] 0) Eligible. 1) Excluded. 2) Eligible. 3) Not applicable.\nThe crosswalk table can also be used to help research teams interpret patient information. The crosswalk provides a better understanding of the factors that have led to the patients' score of `Not eligible` (Score 3). For example, if the assessment of eligibility of Patient 2) Excluded, you would crosswalk a 2b_ineligible to see what criteria led to Patients' exclusion. If Patient 2b_ineligible is then 2b) Excluded, you would search for what criteria led to Patient's exclusion on the exclusion criteria table. If Patient 2b_ineligible was then 2b) Excluded because 2b_ineligible.Exclusion.3_history of other cancer, you would now know that history of other malignancy in the past 5 years excludes a patient from this trial.\n[INST: You need to scroll up to find patient 2b_excluded]\n\n## Patient 2b) excluded\nPatient does not have sufficient information to qualify for the trial: \"History of other cancer in the past 5 years (except Basal cell carcinoma of the skin and carcinoma in situ of the cervix)\".\n\n## Factor 3: other cancer in the past 5 years (except basal cell carcinoma of the\nSkin and Carcinoma in Situ of the cervix)\n\n## EXCL USION",
        "label": 0
    },
    "157": {
        "output": "<EOD> Evaluation and Treatment of Dizziness.\nDizziness is one of the most common reasons for physician appointments and is the cause of a variety of clinical problems with the attendant diagnostic and treatment challenges they pose. Dizziness is defined as self-perceived disequilibrium or disorientation. Dizziness may occur in many different disease states. It is important to determine whether a patient's dizziness is the result of a central nervous system cause or is a peripheral vestibular disorder. Evaluation should focus on the cause of dizziness rather than on the type of dizziness. A systematic approach including the detailed history, physical examination, and complementary tests, combined with a basic knowledge of the vestibular system, should usually be sufficient to arrive at the diagnosis in most cases. This review focuses on the evaluation and treatment of dizziness, with special emphasis on the peripheral vestibular causes.<EOD> Assessment of an electronic case report form (eCRF) as a method to capture and store data in community-based malaria prevalence survey in Zanzibar, Tanzania\nBackground Electronic Case Report Form (eCRF) have received much attention as they have the potential to reduce the cost, workload and response time for collecting disease data. The Zanzibar Malaria Elimination Program (ZAMEP), in collaboration with the Centers for Disease Control and Prevention (CDC) and the Harvard School of Public health, has taken an important first step toward using electronic data collection tools for malaria surveillance in Zanzibar through preliminary development of an electronic data capture tool. This paper describes the system\u2019s development and piloting before using the eCRF for real-time data collection. Methods A mixed methods approach was used to carry out this formative evaluation. Thirty persons participated in focus group discussions and 12 participants were involved in key informant interviews. Additionally, 26 staff were involved in the pilot study. Field workers participated in the study for 8 consecutive days. A semi-structured interview guide based on the five-stage model of technology adoption and diffusion was used. Results Focus group participants were receptive to the idea of using eCRFs to manage the Zanzibar Malaria Elimination Program. Results",
        "label": 0
    },
    "158": {
        "output": "##[OUT]<EOD> Tailoring the size, composition and geometry of silver nanoclusters for enhanced protein kinase inhibition toward cancer therapy\n\n\n\n# Introduction\nSilver nanoparticles (AgNPs) offer potential therapeutic properties in cancer biology due to their anticancer efficacy. Recently, AgNPs have been extensively explored for a number of potential therapeutic applications, owing to their unique chemical, physical, antimicrobial [bib_ref]  Silver nanoparticles: a new view on mechanistic aspects on antimicrobial activity, Dur\u00e1n [/bib_ref]  and bioactive properties [bib_ref]  An insight into antibacterial potential of silver nanoparticles (AgNPs) using surface Plasmon..., Sasidharan [/bib_ref] . AgNPs have been shown to suppress telomerase activity in HeLa cells [bib_ref]  Effect of silver nanoparticles on telomerase activity in HeLa cells and zebrafish, Chen [/bib_ref] . The anti-inflammatory potential of thiolated PEGylated AgNPs in the context of cytotoxicity toward oral squamous cancer cell line (Ca9-22) [bib_ref]  Anti-inflammatory potential of thiolated PEGylated AgNPs on cytotoxicity toward oral squamous cell..., Al-Otibi [/bib_ref]  , and suppression of human colorectal cancer cell growth by AgNPs have been reported [bib_ref]  Suppression of human colorectal cancer cell growth by silver nanoparticles and Ag..., Kumar [/bib_ref] . The anticancer effect of AgNPs has been ascribed to the cellular oxidative damage and mitochondrial dysfunction [bib_ref]  Mechanisms in the anticancer activity of silver nanoparticles, Shamshidari [/bib_ref] . AgNPs have also been reported to reduce colon cancer growth by downregulating NF-\u03baB activation [bib_ref]  Silver nanoparticles inhibited colon cancer cell growth through down regulating NF-\u03baB activation, Zhang [/bib_ref] . Moreover, the anticancer effect of AgNPs has been demonstrated in human lymph cell carcinoma cell line [bib_ref]  Silver nanoparticles induce apoptotic cell death in human lymphocyt",
        "label": 0
    },
    "159": {
        "output": "In the following, we will present a set of rules that helps you make a decision. \n\n## Rule 1\nIf a patient meets an inclusion criterion of the clinical trial, the patient is not incompatible to the clinical trial. \n\n## Rule 2\nIf a patient meets none of the clinical trial's inclusion criteria, then he is not incompatible to the clinical trial. \n\n## Rule 3\nIf a patient matches exactly an exclusion criterion of the clinical trial, then he is incompatible to the clinical trial. \n\n## Rule 4\nIf a patient matches exactly an exclusion criterion of the clinical trial but there are conflicting factors between a patient and the clinical trial, then you should compare the strength of the factors to the exclusion criterion with respect to the clinical trial. In each case this comparison has three possible outcomes:\n- Factor is a sufficient factor to make a patient ineligible;\n- Factor is an insufficient factor not to make a patient ineligible;\n- There is a conflict between a factor and an exclusion criteria. \n\n# Example #1\nConsider the following rule:\n- Infection: This is a contraindication for this clinical trial, but if it is controllable (e.g., with appropriate antibiotic therapy) and does not have any adverse effect on patient condition.\nIn the following we apply the four rules to the assessment task and give a solution for each step.\nStep 1: We check a patient and a clinical trial. \nWe apply Rules 1 and 2 to the above clinical trial. \nWe need to assess a patient's eligibility to the above clinical trial.\nStep 2: We evaluate patient's eligibility to the clinical trial. \nStep 3: We need to find a patient's ineligibility with the clinical trial. \nWe apply Rule 1",
        "label": 0
    },
    "160": {
        "output": "<EOD> Highly regioselective and stereoselective formation of acyclic 2,3-double bonds from alk-2-ynes and alcohols: a tandem gold-NHC-catalyzed oxidative cyclization to benzofuranones.\nOxidative cyclization via gold-NHC catalysis offers an easy route to prepare polyfunctionalized benzofuranones from readily available alk-2-ynes and alcohols. The key step in this reaction sequence is a tandem reaction including a regioselective 1,2-H migration and a stereoselective alkyne insertion into a gold-aryl bond, which allows the rapid, one-pot, synthesis of the title compounds with good to high yields. The benzofuranones produced with this methodology are an important class of compounds and possess a variety of biological properties, as well as utility as building blocks in the preparation of natural products, flavors and materials.<EOD> Preparation and analysis of polyvinylamines by gas chromatogarphy-mass spectrometry.\nPreparation and analysis of the poly-vinylimides by GC-MS were developed. In this method, polyvinylamines were analyzed by an unmodified GC-MS system. As a result, the GC-MS analysis of polyvinylamines was done easily with good sensitivity and reproducibility.<EOD> Inhibitory effect of berenil on adenosine 3':5'-cyclic monophosphate-phosphodiesterase in isolated rat-liver mitochondria.\nThe presence of adenosine 3':5'-cyclic monophosphate-phosphodiesterase in rat liver mitochondria was demonstrated. The effects of berenil on the phosphodiesterase and on oxidative phosphorylation were studied. Inhibition of phosphodiesterase was a marked effect of berenil; oxidative phosphorylation was stimulated to a small extent. The nature of these effects and the potential use of the drug in the study of the metabolic role of cyclic adenosine 3':5'-phosphate in tissue is discussed.<EOD> A systematical review and meta-analysis to assess the association between 4",
        "label": 0
    },
    "161": {
        "output": "<h5><a id=\"problem-8\"></a>Problem<a name=\"problem-8\"></a>\r\nYou cannot decide if the patient meets the inclusion criteria based on the patient note alone. You will need to check patient records to obtain more information.\r\n\r\n```\r\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to check if the patient note for a given patient is sufficient for the clinician team at clinical trial sites to decide if the patient is eligible based on the information provided and the trial's inclusion/exclusion criteria. \n[SOLUTION] You are a helpful assistant for clinical trial recruitment. Your task is to check through the  paper records of patients for any missing information. \n[SOLUTION] You are a helpful assistant for clinical trial recruitment. Your task is to check through the  paper records of patients. \n[SOLUTION] You are a helpful assistant for clinical trial recruitment. Your task is to check through the  paper records of cases in addition to the patient note. \n[SOLUTION] You are a helpful assistant for clinical trial recruitment. Your task is to check through the  paper records of the patients. \n[SOLUTION] You are a helpful assistant for clinical trial recruitment. Your task is to check through the  patient records. \n[SOLUTION] You are a helpful assistant for clinical trial recruitment. Your task is to check through the  patient records and the paper records of patients. \n[] SOLUTION:: You are a helpful assistant for clinical trial recruitment. Your task is to use paper records in addition to the patient note. \n``` \n\nThis is a typical example of a problem that can be solved using a solution template. The difference between these problems is that in the first two problems, we did not explicitly mention that a patient may not be eligible due to the trial's inclusion criteria. In the later problems, we used the templates such as ``SOLUTION::`` for explicitly mentioning this. Try this in your training, and then review your answers on Kaggle. You may also refer to the solution examples on Kaggle. \n\n[INST] If the answer for a given problem was \"N\",\"S",
        "label": 2
    },
    "162": {
        "output": "##[EX]\nYou need to specify the value of 'Trial-level eligibility: {0: Excluded, 1: Not relevant, 2: Eligible}.` into 'Trial-level eligibility: The clinical trial title from above is Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy, therefore, you need to match the inclusion criteria:\nUnifocal primary invasive ductal breast carcinoma diagnosed by core needle biopsy.\nNeoadjuvant chemotherapy or hormonal therapy for the index tumor is required.\n\nFirst, you need to filter out those that do not match the inclusion criteria:\n- Inclusion Criteria:\n\t- Unifocal primary invasive ductal breast carcinoma diagnosed by core needle biopsy - Neoadjuvant chemotherapy or hormonal therapy for the index tumor is required\n\t\n``` ruby\ndef patient_trial (pnote, trial)\n    note = pnote.note\n    results = Array.new\n    if note\n      results << Trial-level eligibility: 2) Eligible\n      next\n    end\n\n    in_exclusions = [ \"invasive ductal\", \"tumor size >= 2 cm\", \"lobular carcinoma\", \"multifocal\", \"multicentric\", \"calcification\", \"ductal carcinoma in situ\", \"index tumour\" ]\n    trial_criteria = \n      (trial['Inclusion Criteria'].map{ |criterion| criterion.scan(/((.*)??)#(.*)/).each {|w| \"#{w[0].upcase}\" }.to_s.chomp }).collect.compact\n\n    # Note here, 'pnote' is the patient record\n    exclusion_conditions = Exclusion_conditions.new(note)\n    exclusion_conditions.exclude_inclusions_if_relevant( in_exclusions + [note].flatten )\n    exclusion_conditions.trial_exclusions = trial['Exclusion Criteria'].to_s.split(/\\s?and\\s?/).flatten\n\n    criterion",
        "label": 2
    },
    "163": {
        "output": "[INST] A trial summary contains information about a trial such as trial identifier, location, status, number of subjects enrolled, and start and end dates.\n\nInclusion criteria have a three-point scale: 0) Excluded; 1) Not eligible (patient meets inclusion criteria, but is not eligible on the grounds of the trial's exclusion criteria); and 2) Eligible (patient meets the inclusion criteria and exclusion criteria do not apply). The following rules apply.\n\n\n10.1\nTrial-level Eligibility\n\n> The number of participants < 30 is currently registered in a trial.\n\n> The number of participants < 40 is currently registered in a trial.\n\n> The number of participants < 50 is currently registered in a trial.\n\n> The number of participants < 60 is currently registered in a trial.\n\n\n\n[INST] You should always repeat `Trial-level eligibility ` in the last line by `Output: `, e.g., `Output: .` \n\n[INST] On some trials, you may encounter patients whose gender doesn't match the inclusion criteria (for example, female patients who have received male hormones, or a man who has undergone chemotherapy and endocrine therapy while being pre-operated for breast cancer). To avoid mistakes, just fill in the output statement using the following rule:\n\n```\n\n> The trial may not include female patients.\n\n```python\nINST > output  = 2 # Eligible\nINST > output  = 'Excluded' # Excluded\n\n```\n\n[INST] In some trials, there may be patients with previous cancer history in different sites other than breast cancer. To avoid mistakes, just fill in the output statement using the following rule:\n\n```\n\n> Patient has previous cancer history, but not breast cancer history.\nINST > output  = 2 # Eligible\nINST > output  = 'Excluded' # Excluded\nINST > output  = 'Not Eligible' # Not eligible \n\n```\n\n[INST] On some trials, the trial-level eligibility can be the same on the same patient. For example, some trials will accept male patients with breast cancer while other tri",
        "label": 0
    },
    "164": {
        "output": "We recommend you to test and debug your code on your own machine. The output of `sage-notebook` may depend on local installations of certain packages.\n\n**Critical Comments**\n\nIf you submit a pull request, consider making the comments more explicit. In particular, it is important to indicate in the function names how you would like SageMath to behave in the evaluation of user-provided parameters.\n<EOD> Gynostemma pentaphyllum (Thunb.) Makino ex Hara Extracts Protect Against Osteoclasts-Induced Bone Resorption Via Suppression of NF-\u03baB and AP-1 Signaling in Rats\n\nGynostemma pentaphyllum (Thunb.) Makino (GPM) is a widely recognized herbal medicine. Previously, GPM extracts were confirmed to have a beneficial effect on bone metabolism, but it is unclear whether they can alleviate bone mass loss and bone turnover in OVX rats. In this paper, we aimed to test whether GPM extracts can protect against osteoporosis. Ovariectomy was performed in Wistar rats as an animal model of osteoporosis, then ovariectomized rats were treated perorally with 500 mg/kg/day of different parts of GPM extracts, or 10 mg/kg/day of alendronate. Six weeks later, an increase in bone turnover by the elevation of TRAP-5b and CTX-1 was observed after OVX along with a reduction in bone mineral density, compared with normal rats (P < 0.05). However, the extracts of GPM could significantly increase the bone mineral density in OVX rats treated with high-and middle-dose extracts, which also decreased TRAP-5b and CTX-1 levels compared with OVX rats (P < 0.05). Osteoclast differentiation was suppressed by GPM extracts at both the gene and protein levels. Furthermore, it may be the decrease in levels of NF-\u03baB, iNOS, and COX-2, mediated MAPKs signaling pathway that were",
        "label": 0
    },
    "165": {
        "output": "# Results\n<EOD> Synthesis, crystal structure, and antiproliferative activity of novel silver(I) compounds with biologically relevant ligands\n\nMetal complexes of biological relevance have been identified as promising cancer chemotherapy drugs. Among these, compounds derived from pteridines (such as folic acid) and from pyridines (such as procaine) are known to possess significant antiproliferative properties. In this study, the antiproliferative activity of silver(I) complexes of the natural pteridine folic acid and of procaine and its methyl analogue have been investigated. To this purpose, new silver(I) coordination compounds have been prepared and characterized by elemental analyses, IR and electronic spectroscopies, and single-crystal X-ray diffraction techniques. Several derivatives of folic acid and procaine have been synthesized, and the corresponding metal complexes have been prepared. The cytotoxic profile of all compounds has been investigated in a panel of four human cancer cell lines and two human normal fibroblast cells, by means of an MTT-based cell viability assay. The results obtained showed that most of these compounds possess selective antiproliferative activity. The cytotoxic mechanism has been investigated by flow cytometry, and apoptotic effects have been proved to occur for the compounds demonstrating the highest antiproliferative activity.\n\n# Introduction\nCancer is a major cause of death all over the world and, according to WHO predictions, its number of fatalities will increase from 13 million worldwide registered cases of cancer in 2015 to 26 million in 2050. The treatment of this disease is very expensive and leads to serious side effects on organs and tissues that severely affect the quality of life of patients.\nSince 1960's, researchers' efforts have been focused on the identification and development of metal compounds possessing antiproliferative properties. In particular, cisplatin, as well as some derivatives, such as carboplatin and oxaliplatin, are clinically used as chemotherapeutic agents. Their cytotoxic activity is mainly based on the ability to form DNA adduct",
        "label": 0
    },
    "166": {
        "output": "You should have your code saved. Now type in console:\n\n`python c5.py 2`\n\n![![Installation](https://github.com/junsuk2108/C5/files/w1172/installation.jpeg)](https://github.com/junsuk2108/C5/files/w1172/installation.jpeg)Click the ![Installation](https://github.com/junsuk2108/C5/files/w1172/installation.jpeg) button and install C5 at first time.`You should have found a new folder named `C5_install``.\n\n[![Installation](https://github.com/junsuk2108/C5/files/w1521/installation.jpeg)](https://github.com/junsuk2108/C5/files/w1521/installation.jpeg)Click the ![Installation](https://github.com/junsuk2108/C5/files/w1521/installation.jpeg) button and install C5 on an update.\n\n\n### <a id=\"q1\"></a> Question  \n\n\nYour code is shown below:\nC5_trial.py\n\n```python\n#!/usr/bin/python3\n# encoding=utf-8\nimport sys\nimport argparse\nimport copy\nimport csv\nimport json\nimport re\nimport os\n\nimport pandas as pd\nfrom os import path\nfrom pathlib import Path\nfrom numpy.matrix import null\nfrom re import sub\nfrom typing import List\n\nfrom common.path_util import FilePathUtil\nfrom common.path_util import PathUtil\nfrom common import PathUtil\n```  \n\nThe list below shows 4 patients whose data are missing in one formulation in the `trial_data_v4.csv`. We need to make sure none of these information is missing:\n\n| Name | Age | Gender | Status  | Chemotherapy| Radiation | Disease Type | Staging | Bone Met | Liver Met | Bone Marr | BRAFV600E | Subtype | Hb_level | R",
        "label": 0
    },
    "167": {
        "output": "[fig]  [: IMPLEMENT] You may define your own method name to calculate trial-specific eligibility for comparison, i.e., class_to_eligible(patient_note, trial). To define a method name with another name, such as eligible_predicate(patient_note, trial), you may write eval(trial) + \"Eligibility: \" + eligible_predicate(patient_note, trial) + \" \" + eval(patient_note) where eligible_predicate(patient_note, trial) = eligible_predicate(patient_note, trial) + eligible_predicate(patient_note, trial). To define two methods with different names, i.e., eligible_predicate(patient_note, trial, \"method 1\") and eligible_predicate(patient_note, trial, \"method 2\"), you may write [\"method 1\"; eval(trial) + \" 1) Eligible\"; eval(patient_note) + \"]; [\"method 2\"; eval(trial) + \" 2) Excluded\"; eval(patient_note) + \"] eval(patient_note)), eval(trial)) = eligible_predicate(patient_note, trial)) [/fig] \n<EOD> Genetic analysis in patients with diabetes mellitus undergoing kidney transplantation for end-stage renal disease\nThe aim of this study is to determine the prevalence and role of diabetes mellitus-related gene polymorphisms in patients with end-stage renal disease (ESRD) as a result of type I diabetes mellitus (T1DM) or type II diabetes mellitus (T2DM). We performed a genetic analysis of 285 patients with ESRD undergoing kidney transplantation. Polymorphisms for the A3855G, T-9C, +32A>C, +616C>G, -493G>T, and -23H>T polymorphisms of the peroxisome proliferator-activated receptor-\u03b3 (PPARG) gene, and the Hae III polymorphism of the un",
        "label": 0
    },
    "168": {
        "output": "##\n<EOD> Transiently Evoked Otoacoustic Emissions: Correlational and Longitudinal Data\nIn this issue, Kurioka and colleagues (2014) report correlations and longitudinal relations between cognitive level and transiently evoked otoacoustic emissions (TEOAEs) in early infancy. Their article is important in many ways. Their results on correlation and longitudinal relations between TEOAEs and language and cognitive level contribute to the developing evidence that OAEs may be a clinically useful indicator of auditory development and of sensitivity to hearing experience. However, their article is also important in highlighting methodological issues about how to evaluate transiently induced, and more generally, stimulus-free, otoacoustic emissions (IAOE) and about the problems of multiple testing that arise when making evaluations of the predictive ability of any measure. In this section, we review the methodological issues raised by the article and suggest some avenues for future research that might address some of these problems.<EOD> A single-item self-report measure of social connection.\nThe COVID-19 pandemic has highlighted the critical importance of social connection in health and well-being. Because the assessment of social connection can occur quickly and efficiently, it is a valuable tool for use across the biopsychosocial spectrum of health. One measure developed in the early 2000's-the Social Connection Scale (SCS) - has stood the test of time and has a strong evidence base for assessing social connection in both research and clinical settings (Mohr, Rose, & Lejuez, 2009). One major advantage of the SCS is that it can be included as a self-report measure in assessment packages to improve efficiency in both research and clinical practice. In a recent revision of the SCS published in International Psychogeriatrics in 2022, the single-item social connection scale (SISCS) was described as a derivative of the single-item General Assessment of Functioning (GAF) that has also been used to provide a global assessment of a client's functioning. However, because the SISCS has not been investigated by scholars to date, we undertook a review that included the 1936 publications that cited the S",
        "label": 0
    },
    "169": {
        "output": "<EOD> The relationship between lifestyle factors and diabetic retinopathy.\nBACKGROUND AND PURPOSE\nThe relationship between diet, exercise, obesity, and duration of diabetes (duration D) with diabetic retinopathy (DR) has not been well studied. The purpose was to examine the relationship between lifestyle factors and DR.\n\n\nMETHODS\nEligible patients were > 40 years of age and had type 2 diabetes mellitus and DR determined by dilated examination by the same ophthalmologist. Lifestyle data included self-reported smoking (cigarette pack-years smoked  or = 30%). Patients were then classified into four 2 x 2 x 2 groups, based on TD, DX, and TI. Lifestyle data was obtained from a self-administered survey questionnaire.\n\n\nRESULTS\nDemographic information and DR severity did not vary significantly by smoking status. Patients in the highest quartile of TD (D > 3.67 years) had a higher frequency of DR, as did patients in all nonoverlapping TI groups versus patients in Group 2 (D > 3.67 and TIs > 25th percentile for that group). Patients in all nonoverlapping DX groups versus patients in Group 3 (D > 3.67 and DXs > 25th percentile for that group) and patients in the extreme TD (TD > or = 10 years) had a higher frequency of DR.\n\n\nCONCLUSIONS\nD and DX are more highly correlated to frequency of DR than TI for diet and exercise separately, and the three appear to be correlated to frequency of DR after adjusting for duration D.<EOD> Effects of the anti\u2010inflammatory treatment with cortisol and met\u2010enkephalin on experimental ischemic cerebral necrosis\nThe effects of a long\u2010acting anti\u2010inflammatory agent, cortisol, and a synthetic opiate\u2010like peptide, Met\u2010enkephalin, on brain edema and ischemic necrosis were examined in mongrel dogs after",
        "label": 0
    },
    "170": {
        "output": "## 2. You should check whether the patient note and trial are matched by clinical note matching.\nMatching procedure:\n1) Open the matching page.\n<img src=\"https://github.com/ncl-ai/Matching-Clinical-Notes/blob/master/images/clinical_match_example.png\" width=\"100%\" />\n2) Choose patients' case in the list.\n<img src=\"https://github.com/ncl-ai/Matching-Clinical-Notes/blob/master/images/clinical_match.png\" width=\"100%\">\n3) Select trial's clinical trial from the drop-down box.\n<img src=\"https://github.com/ncl-ai/Matching-Clinical-Notes/blob/master/images/clinical_match_text_trial.png\" width=\"100%\"/>\n4) Click button.\n<img src=\"https://github.com/ncl-ai/Matching-Clinical-Notes/blob/master/images/clinical_match_button.png\" width=\"100%\"/>\nAfter you click the button, the matching box window should be closed automatically.\nThe matching box shows the clinical trial (in this example, trial ID: NCT04334658), the eligibility results, and patient demographic information of the matched patient. The eligibility result is determined by whether there is any patient information in the patient note, which is not registered in the clinical trial. You will get a message \"No match result found. Please refer to the documentation at https://aiportal.ncl.ac.uk/documentation-match_clinical_notes#no-information\".\n\n## Matching page\nMatching result page should be like this\n\n### **Information for the user who wants to add a note**\n\n### Step 1: Create a new note\n\n\n\n\nA click on the button \u201cCreate a new clinical note\u201d will start a new interface for clinical note creation.\n\n### **Step 2: Filling Note**\nWhen started, the interface will give an overview on current trial and a list of the patient records for the clinical note assignment",
        "label": 1
    },
    "171": {
        "output": "---\n# Step 2. \n\n[INST]. `\n\nNow let's analyze some of the conditions of Figs. 1 and 2.\n\n[INST]. `If a patient is sexually active and does not use contraceptives: ``If a patient is sexually active and does not use contraceptives: \n\n[INST]. ` If a patient has reached menopause or is using an estrogen replacement therapy: `\n\n[INST]. ```Patients aged over 18 years old with invasive breast cancer with an indication of SN procedure as recommended by Saint-Paul de VENCE in 2005 amended in 2009.``\n\n[INST]. ```T1-2 breast cancer.```\n\n[INST]. ```Patients having social security coverage.```\n\n[INST]. ```Patient who underwent surgery and adjuvant treatment:``\n[INST]. ```Metastatic sentinel lymph node only.```\n\n[INST]. ```Patients aged between 37 and 50 years old.``\n\n[INST]. ```With breast cancer size < 2.0 cm.``\n\n[INST]. ```No axillary lymphadenopathy.`` `\n\nIn this example, we have created the eligibility of a clinical trial with five pieces of patient's data, i.e. 0 Excluded, `2)` Not relevant, and `2)` Eligible. The eligibility results are shown in the last line using the `trial-level eligibility` command. \n\n## MANIPULATING ELIGIBILITY\nIn Figs. 1 and 2, the eligibility of a clinical trial can be manipulated by changing the data values. For example, instead of 0 Excluded, we can use 1 Excluded, or 2 Eligible. For each eligibility, we define the rules with the `eligibility` command. For each patient note, we examine the `eligibility rules` and decide the eligibility with the `trial-level eligibility` command.\n\n### PERMISSION AND WITHDRAWAL. \n\nHere is data for `Permission and",
        "label": 0
    },
    "172": {
        "output": "## Input data\nEach case corresponds to a patient note. The input data is stored in columns with names \"FirstName\", \"LastName\", \"Age\", \"Gender\", and \"Human-readable-ID\". You can modify them to \"Name\", \"Age\", \"Female\", \"Male\", and \"id\" of your choice.\nFurthermore, in the variable \"Notes\", each line corresponds to a patient note in the patient note file. Please keep the file structure as you received it. \n\n### Examples of patient notes:\n[INST] Hello. This is the second line of input data, corresponding to the [2] patient. \n[END INST]\nFor the input data you can use these values to make a better demonstration.\n[INST] Exclusion criteria:\n\n### 1) Metastatic disease: (mets)\n\n### \n[END INST]\n\n\n# [RUN]\n[INST] Your task is to make a trial-level eligibility on each patient. You must make a trial-level eligibility 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria) or \n<EOD> Pterins from 3C protease interact with the catalytic cavity of severe acute respiratory syndrome coronavirus 2.\nThe severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) 3C-like protease (3CLpro) is a coronavirus protease with potential as a viral drug target. We report a pharmacophore-based database search for 3CLpro inhibitors from a collection of >2 million compounds, which is the largest known set of bioactivity data for drug screening. By using computational docking, ligand pose alignment and compound purchase, eight compounds were obtained for 3CLpro inhibition assays, which confirmed that three pterins (i.e., neodymium, molybdenum and praseodymium) showed significant inhibition of SARS-CoV-2 3CLpro. These pterins were also found to displace an antibody inhibitor from the 3CLpro catalytic cavity,",
        "label": 1
    },
    "173": {
        "output": "# Testing\n\n[INST] Before we start testing, I recommend having a coffee break and returning after 2 minutes to finish all the tests quickly and accurately. We would test our code using the 'Tested (by <NAME>)' label [12] on the right-hand side of your screen. Here are the steps \n- Click Test in the left-hand menu;\n- Click on the file labelled, 'BiomedicalNLP/test/sample_data';\n- Find the 'test_eligibility.ipynb' notebook on the list of available notebooks \n    - We need a notebook called 'test_eligibility.ipynb' and it should be located in the folder named 'notebooks'. \n    - Check the 'test_eligibility.ipynb' on the right-hand screen. It contains 6 lines:\n        - __init__.py:\n            - It is not needed in this notebook.\n        - train_data.py:\n            - This file contains information about the training data. All necessary training parameters are set here.\n        - train_model.py:\n            - This file contains model training details. The network parameters are saved in the h5 file named 'cnn_model_90.h5'.\n        - load_model.py:\n            - It loads the model to use and defines the data needed in the tests.\n        - eligibility.py:\n            - Here the actual testing code is defined. \n    \n    - In this notebook we prepare the training and testing data as inputs for our model. \n\n    - Open 'test_eligibility.ipynb' on your desktop, and start up Spyder.\n    - Find the 'test_eligibility.ipynb' notebook under the 'IPython Notebook' folder in the left-hand side of the screen (green rectangle) \n        - Click on the file labelled, 'test_eligibility.ipynb' notebook on the top left screen.\n    - Click 'run all' in the top left-hand corner (yellow line) \n - On the results screen, choose the result to save or export by using the following options:\n    - When saving results, select 'save all as .ipynb",
        "label": 0
    },
    "174": {
        "output": "Good luck![[FLEXIBLE-MAZE-BOTTLE]]:[REF]~\n\n# Example of solution\n\n### Input :\n`Trials input: \"Breast Cancer Registry in Thailand Title: Breast Cancer Registry in Thailand Summary: Breast cancer is the most common malignancy affecting women. It is the second leading cause of cancer related death in women in many parts of the world. Breast cancer also occurs in men, accounting for nearly 1% of the total incidence. As a result of continuing research into new treatment methods, women and men with breast cancer now have more treatment options, and a better chance of long-term survival than ever before. The primary treatment for breast cancer is surgery. Early stage breast cancer, defined for the purposes of this registry as newly diagnosed, clinical stage I to IV breast cancer with no prior therapy for current disease, is often curable with surgery alone. Reports from the National Surgical Adjuvant Breast and Bowel Project (NSABP) and the European Organization for Research and Treatment of Cancer (EORTC) longitudinal trials have explored the efficacy of various surgical techniques as primary treatment of early stage breast cancer1-7. These studies include 20 years of follow-up data that have not shown any significant differences in overall survival or in rates of distant recurrences in women who underwent breast-conserving surgery with radiation therapy versus those who underwent mastectomy. The results of these studies have supported the use of surgery as the standard breast cancer treatment practice around the world.~Data have shown that regardless of the surgical procedure selected for the removal of the primary tumor, micrometastases may be present and lead to the development of disease relapse. In order to decrease the risk of recurrence, patients may receive various therapies. Systemic treatments include chemotherapy and hormonal therapy. Local treatment, such as radiotherapy, can also be used to eliminate malignant cells that remain in the breast, chest wall, or lymph nodes after surgery.\n~The selection of systemic therapy is a complex process, which is based partly on prognostic factors such as lymph node status, and predictive factors such as hormone",
        "label": 2
    },
    "175": {
        "output": "Good luck, [INST]).\nWe wish you all good luck solving your problem and a healthy and happy life for everyone!\n<EOD> A phase II study of docetaxel in combination with capecitabine in patients with metastatic mammary or adenocarcinoma of the stomach or colon.\nPURPOSE\nTo assess the toxicity and the response to docetaxel (D) in combination with capecitabine (C) in patients with advanced cancer.\n\n\nPATIENTS AND METHODS\nPatients with progressive measurable adeno or mammary cancer were treated on an 8-week cycle alternating with chemotherapy (C) and capecitabine (D100 mg/m(2)/d for 14 days), followed by a rest week (RW; D + C). This cycle was repeated every seven weeks. During the first two cycles, patients were evaluated for possible side effects. Response to treatment was assessed every two cycles and evaluated by the WHO toxicity criteria (WHO-TC). All toxicities experienced during the first two cycles were recorded on case report forms and classified according to the Cancer Therapy Evaluation Program (CTEP) system. The patients received continuous oral capecitabine (600 mg/m(2)/d) with meals on days 0 to 14 of a 21-day cycle for the duration of the study.\n\n\nRESULTS\nFrom March 1999 to August 2001, 47 patients (22 males and 25 females) were treated in four institutions. The median age was 66 years. Previously treated patients had undergone a total of six cycles of chemotherapy (range, 1-5), whereas previously untreated patients had not been exposed to chemotherapy. All patients were evaluated at baseline as being in poor condition (WHO performance status > or = 2). Seventy-five percent of the patients were unable to complete at least nine cycles of treatment due to unacceptable toxicity (69%) or progressive disease (6%). The dose-limiting toxicity was grade 3 neurological toxicity, reported in seven patients (15%). Grade 3",
        "label": 0
    },
    "176": {
        "output": "##[/DATA/PATIENT]\nYou are finished with the patient. The next entry is a new patient. The patient-level assessment includes all the features of a patient, not just the eligibility status of a clinical trial.<EOD> The use of mammography to improve the detection of metastatic axillary lymph nodes in breast cancer: the initial experience in a Canadian community practice.\nThe addition of mammography during initial assessment of axillary lymph nodes in patients with metastatic breast cancer to stage III or greater may have a beneficial effect on staging and treatment in terms of eliminating uninvolved axillae before mastectomy or eliminating involved axillae from sentinel node dissection and, therefore, axillary node dissection. The authors discuss the use of this modality in a family practice during the initial experience and illustrate that it is feasible to use the modality in the community setting.<EOD> Antinociceptive effect of subcutaneous administration of paracetamol in ponies.\nEffects of subcutaneous injections of paracetamol were examined using an arthrosclerosis test in 2 ponies. Paracetamol caused significant dose-related anti-nociceptive effect, which lasted about 3 hours. The results suggest that the drug could be an alternative to glucocorticoids for intra-articular injection of horses with chronic arthrosclerosis. The effects on joint function are promising.<EOD> Assessment of the Impact of COVID-Associated Multisystem Inflammatory Syndrome in Children in Pediatric Dentistry in Istanbul.\nAIM\nMultisystem inflammatory syndrome associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has emerged as a new entity reported in relation to SARS-CoV2 infection, including the dental literature. This case series investigated COVID-associated multisystem inflammatory syndrome in children (MIS-C) in 2021 in two Turkish tertiary hospitals in Istanbul.\n\n\nSTUDY DESIGN\nThe study included 28 patients and 34 controls, with an average age",
        "label": 0
    },
    "177": {
        "output": "[CODELIST=Trial-level eligibility: 2) Eligible]\n[VALUE=1]\n[TRIAL=Trial-7(HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1)]\n[VALUE=2]\n[TRIAL=Trial-8(HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1)]\n[VALUE=3]\n[TRIAL=Trial-9(HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1)]\n[VALUE=3]\n[TRIAL=Trial-10(HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1)]\n<EOD> Enhanced cisplatin-induced apoptosis of non-small cell lung carcinoma cells by the activation of PKB/Akt.\nCell survival and chemoresistance of lung cancer is closely associated with deregulated apoptosis, and survival and growth are regulated by phosphoinositol-3 kinase-mediated Akt signaling. The aim of this study was to understand the role of Akt in resistance to cytotoxic agents. Stable, H-269 cell clones with overexpressed Akt were generated from A549 cell lines with Akt siRNA-mediated knockdown. We found that cells with overexpressed Akt in H-269 were more sensitive to cisplatin, whereas H-269 knockdown cells were more resistant to cisplatin. Interestingly, cells with overexpressed Akt exhibited more apoptotic and DNA-damaged responses than control cells. We also observed that apoptosis-related proteins such as caspase-3, 7, and 9 were cleaved in these Akt overexpressed cells upon cisplatin treatment, whereas Akt knockdown cells exhibited lower sensitivity to cisplatin-induced apoptosis. Although overexpressed Akt enhanced",
        "label": 2
    },
    "178": {
        "output": "##### P1. Patient.\n`patient = PatientNote2[36:117822].`\n\n##### P2. Trial.\n`trail = Trial2[36:42187].`\n\n**Examples: [demo-rmd02_data]** `rmd02_data = trialmatch(patient_list = pd.read_csv(pd.\nto_json(\"patients.tsv\"), na_values=\"\"); trial_list = pd.read_csv(pd.to_json(\"trials.tsv\"),\nna_values=\"\")); test_results = rmd02_main(\"rmd02_rmd_rmd_rmd\"); output = list(r[\"rmd02_results\"]) for i in r[\"rmd02_results\"]: print(i) r.rmd02_results[i][\"Trial-level eligibility\"] = 2` **Input:**\n\n```csv\npatient_list, trial_list\nPatients and Trials in the format of `name | age | gender | ...`\n```\n\noutput:\n\n```json\n{\n  \"rmd02_results\": [{\n    \"rmd02_rmd_rmd_rmd\": {\n      \"Trial-level eligibility\": \"Not relevant\",\n      \"patient_id\": \"0001 | PAT_1 | M | 46 | 46\",\n      \"patient\": {\n        \"Age\": \"46\",\n        \"Gender\": \"M\",\n        ... }\n    } \n}]}}\n```\n\n\n\n\n[INST]\n\n### Clinical Outcomes\n### -----------------------\n\n#### -------------------------\n\nHere is",
        "label": 0
    },
    "179": {
        "output": "## Exam score\nGood luck!\n\n<EOD> Dual Functions of Bile Acids and Their Rapid Metabolism in Pro-/Anti-Inflammatory Responses Mediated by CD36 and Toll-Like Receptor 2\n\nChronic inflammation induced by the bile acids (BAs) is considered to be related to the pathogenesis of metabolic syndrome, atherosclerosis, and liver diseases; however, the pathology of BA-induced inflammation is largely unknown. In the present study, we revealed that LCA (i.e., lithocholic acid), a secondary BA, induces the release of inflammatory cytokines directly from adipose and hepatic cells by acting on the Toll-like receptor 2 (TLR2) and CD36 as a pattern recognition receptor. Meanwhile, the antiinflammatory cytokine, IL-4, was induced by LCA in macrophages and adipose cells through a CD36-independent process. The induction of TLR2 was also observed in the LCA-treated macrophages and adipose tissues. However, the direct application of LCA to macrophages and adipose tissues did not induce anti-inflammatory responses or expression of TLR2 and, therefore, seems to be dependent on autocrine or paracrine factors. Furthermore, LCA-induced IL-4 secretion was inhibited by the TLR2",
        "label": 0
    },
    "180": {
        "output": "## 1.\n2022-07-14 10:28:41\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. \nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \nHere is the patient note:\n\n## The contents of dying tumor cells can be detected in the bloodstream, and this may be enhanced by the leaky vasculature of solid tumors. protein biomarkers of tumor cell death are difficult to detect due to the complex nature of plasma and the lack of technical sensitivity. in contrast, dna is easier to detect through polymerase chain reaction (pcr). indeed, circulating tumor dna has been detected in plasma from patients with osteosarcoma, breast cancer, and colorectal cancer.[/emphasis?][INST]\nThe investigators should consider the above statement and answer Question 1.\n\n## Question 1\n\n## [emphasis?]\nThe investigators should consider the above statement and answer Question 2.\n\n## Question 2\n\n## The patient's mammogram reveals microcalcifications in the left breast. a breast mri reveals a suspicious enhancing mass behind the pectoralis muscle (figures a and b). a breast biopsy confirms the diagnosis of invasive ductal carcinoma with extensive intraluminal hemorrhage and necrosis. the tumor cell",
        "label": 2
    },
    "181": {
        "output": "[/GENERAL CODE] \n<EOD> SARS-CoV-2-related myocarditis in an 82-year-old man\n\nMyocarditis is usually a very rare cause in the overall number of individuals with heart failure not only in a low-volume center like the city of Naples, but also in high-volume centers like Pomezia (for example 0.24% for male versus 0.32% for female in a cohort study about clinicopathology of myocarditis from 2000 to 2019 at Pomezia hospital.). [5] However, an increase in new cases of myocarditis caused by SARS-CoV-2 has been recently described, with a predominance of men. [6][7][8] In the above-mentioned case, no other etiology of myocarditis that could worsen symptoms, especially cardiac magnetic resonance and inflammatory markers (such as erythrocyte sedimentation rate and C-reactive protein) at 2 months before admitting was analyzed, which means that it was a completely new diagnosis.A 41-years old man with body mass index of 30 kg/m 2 , treated for schizophrenia and substance abuse underwent transient ischemic attack with mild left-sided weakness which required antiaggregant therapy and aspirin. He was completely re-educated on his eating habits. He was a nonsmoker had no physical risk factors. He was referred to a cardiologist to evaluate an echocardiography diagnosed dysfunctional mitral valve, which after two years of unsuccessful repair by surgery required another procedure without the possibility of a satisfactory outcome. After that intervention, the patient reported asthenia and deterioration in his quality of life, with a significant worsening of his cognitive function. The neurological evaluation at this time diagnosed a diagnosis of moderate dementia. Then, after 2 months, the patient developed fever and myalgia. The pharyngeal swab test found SARS-CoV-2. In spite of the negative serology for myocarditis, my",
        "label": 2
    },
    "182": {
        "output": "In this exercise, we will work on the patient note. However you can practice with the clinical trial.\n\n---Clarifications on the 0-no information-option:\n\n> Option '0' \n(0) Excluded. This response is the result of the patient's note not meeting the inclusion criteria.\n\n> Option '1'\n(1) Not eligible. This response means that the clinical trial has no inclusion criteria that apply to this patient.\n\n> Option '*'. \n(1) Excluded/not eligible. This response means that the clinical trial's inclusion criteria are not met by this patient.\n\n> For example, if it is not mentioned in a patient note that HER2 status is available for a HER2-positive clinical trial, the information on HER2 status is missing and option '1' is the correct response. It is possible to use option '2' even if only one inclusion criterion is reported to be missing (e.g., lack of information of HER2-status).\n\n---Explanations ---\n\n> `1` <small>\n> ****0<small> . This response means that the clinical trial is not relevant for this patient. \n > <small>It means the patient note does not provide all the information requested for the trial \n > <small>(Examples: no tumor grade available, no HER-2 status, no date of surgery). A clinical trial can only include patients who satisfy all inclusion criteria and exclusion criteria.\n > <small>You should apply the same rule to all clinical trials that were created for the simulation.\n > <small>(Examples: no HER2 status available for a HER2-positive clinical trial, date of surgery is missing for a trial not requiring immediate surgery)\n > <small>\n> ****2 <small>\n> ****2 <small>\n> Exclusion criteria are the criteria by which a patient is not eligible, despite their inclusion criteria being met.\n > <small>For example, in the above mentioned breast cancer trial, a HER2-positive patient cannot participate because they have already started the treatment; the patient is undergoing a second surgery, in which case trial-entry might interfere with the surgery.",
        "label": 2
    },
    "183": {
        "output": "[A]: Eligibility Criteria\n<html><title>Eligibiity Criteria </title><meta name=\"description\" content=\"Instructions for how to create a sample data set for the eligibility criteria problem.\"/><head><link href=\"eligibility.css\" rel=\"stylesheet\" /></head>\r\n<body><h1>Clinical Trial Recruitment</h1>\r\n<hr>\r\n<p>You are a helpful assistant for clinical trial recruitment.\r\nYour task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\r\nThe factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\r\n</p>\r\n<p>\r\nThere will be no practice problem.\r\n</p>\r\n<p>\r\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).  \r\n</p>\r\n<p>\r\nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \r\n</p>\r\n<p>\r\nHere is the patient note:\r\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy",
        "label": 0
    },
    "184": {
        "output": "[SELF-EVALUATION] \nHow was your performance? Try to answer these questions and evaluate yourself. (This is for your internal reflection and should not be sent to us.)\n\n[/SELF-EVALUATION]\n\n[DOWNLOAD] \nDownload this task's evaluation sheet: [DOWNLOAD] \n\n---\n\n## \u2714 Q19 -What do you think are the limitations of the CTFN algorithm with respect to the clinical applicability?\n\nIn general, I think the current research and development of the current CTFN clinical algorithm and software can significantly improve the clinical decision-making process with respect to clinical trials. Especially from the perspective of the improvement, of the trial-based clinical development and the patient-based clinical development. \n[DOWNLOAD] \n\n---\n\n# <NAME>: AI-based patient eligibility solution for clinical trials by RNN deep learning, 2019\n\n## \u2714 Q20 -Provide your overall suggestions on this research\n\n[/DOWNLOAD]\n\n## \u2714 Q21 -What are the most common obstacles you encountered in this case study?\n\nOne of the barriers found in the case study is the availability of the data. In this case study, it was found that most of the relevant data for clinical trials is usually on paper, which makes it difficult to manage, let alone organize and to make the algorithm run well. \nThe next obstacle is the difficulty in running the data. Some of the data found was very complicated in some way and to make the algorithm to work the data must be structured, making it a kind of challenge to the algorithm to work, so the implementation of data standardization for the clinical trial to make the algorithm work easier. \nThe next barrier was the challenge in finding all the necessary information from the documents related to clinical trials. This is due to the limited access to some information in clinical trials, so sometimes it makes it difficult to predict the trial-level eligibility in the case study. \nFinally, I think the barrier I met was a gap in data sources, especially in this era of digital transformation. \n[/DOWNLOAD]\n\n## \u2714 Q22 -What are the",
        "label": 0
    },
    "185": {
        "output": "[![IMAGE ALT]({{site.data.file_paths.learning_paths.advanced_python_labs/01_python_basics/book/fig/fig-1.7.png \"title:figure-1.7\")]]({{site.data.file_paths.learning_paths.advanced_python_labs/01_python_basics/book/fig/fig-1.7.png \"link:fig-1.7\"})}\n\n\n<br>\n\n\n----------------------------------------------------------------------------------------------------------------------------------------\n<br>\nHere is the patient's eligibility status for this trial:\n<br>\n \n````python\nprint(\"Patient\" + str(i) + ': ', patients[i][\"trial-level eligibility\"])\n````\n\n----------------------------------------------------------------------------------------------------------------------------------------\n<br>\n\n\nOutput:\n<br>\n \n````\n\nOutput:\n     ClinicalTrials.Patient 0: 1\n    ClinicalTrials.Patient 0: 1\n    ClinicalTrials.Patient 1: 2\n    ...\n    ClinicalTrials.Patient 16: 1\n    ClinicalTrials.Patient 16: 2\n    ClinicalTrials.Patient 17: 1\n       ...\n    ClinicalTrials.Patient 88: 1\n       ...\n    ClinicalTrials.Patient 155: 1\n      ...\n    ClinicalTrials.Patient 188: 1\n      ...\n    ClinicalTrials.Patient 207: 2\n    ...\n    ClinicalTrials.Patient 229: 1\n     ...\n    ...\n    ...\n    ...\n     ClinicalTrials.Patient 281: 1\n     ...\n    ...\n    ...\n    ...\n    ...\n    ...\n    ...\n    ...\n     ClinicalTrials.Patient 293: 0\n    ...\n     ...\n    ClinicalTrials.Patient 294: 0",
        "label": 0
    },
    "186": {
        "output": "# Discussion\n\n##[inst] \nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy. \nHere is the clinical trial: \nTitle: 4D Image-Guided Partial Breast Radiation in Stage 0 and l Breast Cancer\n\n\nSummary: The Purpose of this study is to evaluate the feasibility of using image guidance and four-dimensional computed tomography to reduce the volume of non target breast tissue that is treated with accelerated partial breast irradiation via the external beam technique.\nInclusion criteria: Inclusion Criteria:\nThe patient must consent to be in the study and must have a signed an approved consent form conforming with institutional guidelines.\nPatient must be > 50 years old.\nThe patient should have a life expectancy of at least two years with a karnofsky performance status > 7",
        "label": 0
    },
    "187": {
        "output": "[/TEST]\n<EOD> The impact of bilingualism on mental health and substance use disorders in Canada: results from a nationally representative survey\n\nThe impact of bilingualism on mental health and substance use disorders (SUDs) across various demographic and education variables is still underresearched. Using a nationally representative sample of Canadians, we examined the interaction effect of bilingualism on the presence of mental health and SUDs. Additionally, this study is unique in its examination of the impact of bilingualism on SUDs and the potential confounding role of psychological distress (Kessler 5) in this relationship. The sample was composed of 36,984 Canadians aged 15 and over who responded to the 2017-2018 mental health module of the Canadian Community Health Survey to determine the nature of the relationship. The results showed that bilingualism increased the risk of depression and generalized anxiety disorder and decreased the risk of SUDs. Additionally, bilinguals have a lower likelihood of having psychological distress (Kessler 5) (OR = 0.765, p < 0.001). Notably, we observed that this relationship was moderated by household income and marital status. Our findings suggest that while bilinguals have a greater risk of mental health disorders, they have a lower risk of having SUDs. We recommend future studies to explore the underlying psychological mechanisms of bilingualism's impact on mental health and the associated risk factors of the lower risk of SUDs among bilinguals.The study results suggest that among bilinguals, the risk of depression (OR = 1.445, 95% CI = 1.187-1.759) was 1.4 times those of monolinguals, and among bilinguals, the risk of generalized anxiety disorder (OR = 1.170, 95% CI = 1.020-1.343) was 1.2 times than that of monolinguals (Model 1). However, among bilinguals, the risk of SUDs (OR = 0.830, 95% CI = 0.",
        "label": 0
    },
    "188": {
        "output": "##[/CODE]\nWhat if this note is not the right person and patient history is not complete? In that case, should you skip the next patient and continue with the next one? Or should you try to find the reason patient is not eligible based on the current state of patient information and make the eligibility decision later on? In other words, when do you stop comparing the information of the patient? \nThere are two answers: 1) the first option is the correct answer, if your clinical trial does not require previous treatments; 2) the second option is the correct answer, if your clinical trial does require previous treatments. [CORE SWEED]\nFor the answer 1, the eligibility decision must be made to each subsequent patient, as shown in the [code] section: [/CODE]. \nIn answer 2 (for trials that do require information on previous treatments), the comparison is not required for subsequent patients, and the trial-level eligibility assessment ends as soon as a patient does not meet the inclusion criteria, as shown in the section by `Trial-level eligibility: \"2) Not eligible.\"`. \nFurthermore, we may think when the eligibility is determined? In other words, at the start, for each patient, eligibility check should be performed (including comparison with previous treatments) or it can be deferred to the end? \nThe eligibility assessment should include comparison with previous treatments and should be performed for each subsequent patient - at the start - not only at the end. \n\n### Exercise 05\n\n##[CODE]\nYou have to assess a patient for a clinical trial to determine the patient's eligibility. You should make a trial-level eligibility on each patient, i.e., the decision is made to each subsequent patient regarding the eligibility for the clinical trial. Let's go through an example. \n\n### Exercise 06\n\n##[CODE]\nYou are asked to assess a patient for a clinical trial to determine the patient's eligibility. You should make a trial-level eligibility on each patient, i.e., the decision is made to each subsequent patient regarding the eligibility for the clinical trial.\n\n\n## Patient",
        "label": 0
    },
    "189": {
        "output": "Output the trial-level eligibility `Trial-level eligibility:.`.<EOD> The Relationship between Cochlear Implant Experience and Objective and Subjective Hearing in Cochlear Implant Users\nObjective: This study investigated the relationship between cochlear implant (CI) experience and objective and subjective benefits of CI use. Design: A prospective, controlled study was conducted on 60 CI, bilateral implanted users, and 60 normal-hearing (NH) controls. Objective hearing was measured by speech audiometry in noise, and sentence recognition and word identification (Word Recognition Test) in quiet. Subjective benefits were evaluated using the Speech, Spatial, and Qualities of Hearing Scale (SSQ), the Health Utilities Index 3 (HUI3), and the EQ5D health-related quality of life questionnaire. Data were obtained 3 times; at baseline at the time of CI activation and activation of the second ear, and 3 to 6 months postactivation. Results: Statistically significant differences were found between the CI group and the NH group in all objective and subjective parameters at all time points. CI users were more likely to show an improvement of objective and subjective results from first activation to second activation and to later measurement points than NH individuals. Subjects were less likely to demonstrate a deterioration in hearing from first activation to second activation and later, except for an improvement of speech-in-noise in noise with a competition at 50% (50%-WIPN) in CI users. Objective data were negatively correlated with speech-in-noise in CI users, but not for NH subjects, while SSQ scores correlated to objective data, specifically the noise environment and aided speech understanding but did not correlate to any of the objective data in the NH study. Conclusion: The results of this study show that CI users tend to present better objective and subjective hearing than the NH individuals. However, improvements of speech understanding may be related only to speech-in-noise in noise with a competition at 50% (50%-WIPN) and to word or sentence perception in quiet.<EOD> PAT-related biomarkers, and dietary and lifestyle factors in pregnant women and newborns",
        "label": 0
    },
    "190": {
        "output": "Please click the \"Submit\" button after you make your decision in each case for grading. There is no limit to the number of case submissions you may make. In order to receive credit for your work, please ensure that you submit your responses in the order below, including the demographics information:\n\n## Grading criteria\nYou should submit your responses in a consistent fashion in all submissions. Specifically, follow the order of the text blocks below: \nDemographics-Information about the patients, including their name, age, sex, race, ethnicity, religion, political affiliation (if that information is not sensitive), and your relationship to them (if any).\n[CLOSE]\n\n## [INST]\n- Patients\n\n## [cldr]\n- Criteria\n\n## [inst]\n- Evaluation\n\n## [cldr]\n- \n\n## Grading criteria\nYour decisions will be measured using the following criteria. Each criterion is worth 3 points for a total of 39 points:\n\nAll submissions will be graded using the criteria in the table above. The points for each item will be determined by your ability to answer the relevant questions in each item. For the criteria that you need more information to answer, you may not be able to get the points for that item. However, your assessment will be included in this table so that we can improve this work-up. [CLOSE]\n\n# Scoring Guidelines\nPlease refer to the 2021 Assessment Tool Scoring Guidelines for information regarding how to interpret and score the response.\n\n# Discussion\n\n## Differences in Grading Criteria Scores Between Students of Different Educational Backgrounds\nIn a few cases, students from different education backgrounds, including undergraduate medical students, graduate students (predoctoral, doctoral, postdoctoral), residents, fellows, and attending physicians, received different scores on the same assessment tool. Most of these differences were due to variability in the use of key terms and concepts, or in the level of detail provided in answers.\n\n## Improving the Assessment Tool\n- To improve our tool, we need your feedback about the assessment tool's clarity, and its length, timing, and format.",
        "label": 0
    },
    "191": {
        "output": "<details>\n    <summary><NAME>: Breast cancer, MUGA, CT, MRI, lymph node metastasis</summary>\n\t<img src=\"images/fig12.png\" alt=\"inference\" width=\"700\" height=\"650\"/>\n\t\n    </br>\n\t\n    <img src=\"images/fig12.png\" height=\"700\" width=\"700\">\n</details>\n\n\n### [5.] INST. \u2461: Output the scale for the assessment of eligibility of the patients who do not have sufficient information to qualify for the trial.<EOD> The Effect of a Single Dose of an Oral Antibiotic on the Bacterial Flora of the Uterine Cavity\nThis study presents comparative data on the influence of a single oral dose of an antibiotic on the flora of the vagina, cervix and uterine cavity. All specimens were obtained by swab from women attending the Gynaecology Clinic of the Royal Liverpool Hospital and were processed by standard culture techniques. The results show that the effect of oral antibiotics on the vaginal flora is less marked than that in the cervix or uterine cavity, where the drug is able to eradicate certain pathogens. In the latter, a mixture of antibiotics, particularly tetracycline and polymyxin B, appears to be of value as a prophylactic measure where the cervical infection is mild or moderately severe but not severe.<EOD> Taking advantage of an atypical presentation of cytomegalovirus infiltration of the urinary bladder in the HIV-infected patient.\nWe report the case of a human immunodeficiency virus (HIV)-infected 63-year-old man who presented with urinary retention. Cystoscopy revealed a bladder polypoid lesion that was thought to represent a papillary transitional cell carcinoma. Imaging revealed an untypical cytomegalovirus (CMV) bladder infiltration. The patient improved with foscarnet as antiviral treatment. A biopsy showed an",
        "label": 1
    },
    "192": {
        "output": "The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). [INST]\n\nA patient note:\nThe patient is a 56-year-old postmenopausal woman with breast cancer. She received a core biopsy. The tumor is  HER2positive, ER/PR positive, and with lymph node metastases. The patient is nonsmoker. She drinks 3 glasses of milk a day. She is sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n[INST] [CANCER - RESULTS] Here is the clinical trial: [\u2026] There must be negative surgical margins for invasive cancer and DCIS. LCIS is acceptable at the margin.\nAbility to understand and the willingness to sign a written informed consent document.\nPlatelets >/=100,000/\u03bcl within 4 weeks of registration.\nAbsolute neutrophil count (ANC) >/= 1,500/\u03bcl within 4 weeks of registration.\nTotal bilirubin within normal institutional limits within 4 weeks of registration.\nAlkaline phosphatase (alk phos) \u2264 2.5 X institutional Upper Limit of Normal (ULN) within 4 weeks of registration.\nAST (SGOT)/ALT(SGPT) \u2264 1.5X ULN\nCreatinine within normal institutional limits OR Creatinine clearance>/= 60 mL/min/1.73 m2 for patients with creatinine levels above normal\nIf patient has received tamoxifen or another selective",
        "label": 2
    },
    "193": {
        "output": "````\n\n\n:ital:\nF1000Research\n\n : public\n : #supp2\n : \n : <EOD> Intraoperative assessment of aortic valve competence: a clinical investigation.\nThe results of intraoperative assessment of aortic valve competence with the help of the continuous wave Doppler technique and the ultrasound color flow imaging are presented. Based on findings obtained in 217 patients during a period of 19 months, the continuous wave Doppler technique seems to give reliable and reproducible data.<EOD> Interpreting multiple comparisons, hypothesis testing, and confidence intervals.\nA method for quantifying and interpreting confidence intervals and confidence regions is proposed. The method gives a direct account of how confidence intervals and confidence regions are used to characterize the null hypothesis. Several topics in which confidence intervals and confidence regions are invoked to illustrate or to explain results are reviewed. It is indicated that confidence intervals and confidence regions are valuable, and even indispensable, whenever a comparison of populations, groups, or treatments is made, and their usage is illustrated. The confidence interval method, unlike many other methods, allows for estimation of any parameter of the distribution for which confidence intervals are constructed. Hence it permits estimation of not only means but also measures of dispersion or skewness and variance-covariance matrices. It is shown how to test whether one distribution differs from another when only their confidence intervals overlap. The method is applied to a problem in clinical research.<EOD> NF-kappa B activation by interleukin-1 (IL-1) requires an IL-1 receptor-associated protein kinase-catalyzed phosphorylation of the IL-1 receptor: involvement of a novel serine/threonine protein kinase.\nThe binding of interleukin-1 (IL-1) to the native IL-1 receptor, a cytokine receptor composed of two subunits, the IL-1 receptor I (IL-1RI) and accessory protein (AcP), initiates a series of signaling events including activation of protein kinase C, and nuclear translocation of the NF-kappa B transcription factor. The mechanism by which IL-1 activates this signaling pathway is not known. In this study, we demonstrate that serine/",
        "label": 0
    },
    "194": {
        "output": "---\n### Assessment of eligibility:\n\n```python\ndef Assessmentofeligibility(notes, trial):\n    patient_notes = open(notes, \"rt\")\n    for line in patient_notes:\n        patient_data = line.split(\".\")\n        if patient_data[3] == \"clinical\": \n            trial_data =trial + \" #\" + patient_data[1] \n        else:\n            trial_data =trial + \" #\" + \"0\" \n    trial_eligibility=eval(trial_data)\n    print(\"Trial-level eligibility: {}\".format(trial_eligibilibity)) \n```\n\n```python\nAssessmentofeligibility(\"P00267_01.csv\",\"P00267\")\n```\n\nOutput\n```\nTrial-level eligibility: 0) Not relevant\n```\n\nNote\n`0) Not relevant` means that it is not in the list of exclusion criteria. But, if the trial accepts patients who have not undergone breast or chest wall surery, then it is also 0) Not relevant. You can also add the following code.\n\n```python\nif \"BC\" not in trial_eligibility:\n            trial_eligibility = trial_eligibility + \" #\" + \"1\"\n    if \"CWS\" not in trial_eligibility:\n            trial_eligibility = trial_eligibility + \" #\" + \"1\"\n```\n\n```python\nAssessmentofeligibility(\"P00267_01.csv\",\"P00267\")\n```\n\nOutput\n```\nTrial-level eligibility: 0#1) Not relevant 1) Eligible\n```\n\nNote\nYou can modify the code to compare the first 80 characters of a patient note to the inclusion/exclusion criteria of the trial. Moreover, you can modify the code to include some patient notes. However, in this step you have learned how to find the eligible patient using a note. If you want to find the eligible patient using a complete trial, refer to the next step.",
        "label": 2
    },
    "195": {
        "output": "***\n\n### Exercises\n\n1. You should check the eligibility of the patient with the inclusion criteria of a particular trial. Use the patient information and compare the patient variables with the trial's inclusion criteria. After that, you should output the corresponding trial-level eligibility (0, 1 or 2) for each patient.\n\n2. The output should have the following lines: patient number, gender, and date of birth if you want to use **experienced**.\n\n3. Try to guess the code of the problem [Link to Kaggle.](https://www.kaggle.com/c/breast-cancer-diagnosis/data) to solve the problem, because the dataset includes patient numbers and other patient information.\n\n***\n\n### Problem 7.6\n\n[This solution is by Yusu Nalbantoglu.](https://github.com/SugumarReddy/Python-Code/blob/master/problem_archive/7.6%20%5Boops%5D%20-%20Evaluate%20the%20Performance%20of%20a%20Binary%20Classifier.pdf)\n\n**What would you do with the following file (problem.csv)?**\n\n```\nName, Age, Diagnosis, Label\n'1', 20, 'Normal', 0\n'15', 20, Breast mass, 0\n'61', 45, Normal, 0\n'0', 45, Paget's disease, 1\n'0', 45, Paget's disease, 1\n'48', 45, Breast mass, 1\n'20', 45, Normal, 1\n'36', 45, Normal, 1\n'24', 31, Normal, 1\n'205', 45, Normal, 1\n'290', 45, Normal, 1\n'383', 45, Normal, 1\n'380', 45, Normal, 1\n'405', 45, Normal, 1\n'393', 45,",
        "label": 0
    },
    "196": {
        "output": "\u00a9 2020 - 2021 OpenAI<EOD> Antithrombin III Inhibits TNF-\u03b1-induced Cells Adhesion by Protecting CD14 from Oxidation and Inhibiting Monocyte-endothelial Cell Transendothelial Migration*\nOxidation of plasma proteins by reactive oxygen species participates in endothelial dysfunction and monocyte recruitment at cardiovascular diseases. Plasma antithrombin III (AT III) is also a reactive protein. In this communication, we show that intact AT III and AT III deficient subject plasma both activate thrombin generation but not TNF-\u03b1-induced monocytes adhesion to endothelial cells (ECs), suggesting that the lack of this biological property could be due to AT III oxidation. We found that the lack of intact AT III and AT III oxidative status at the TNF-\u03b1-exposed ECs were associated with an increase in thioredoxin-1 and an up-regulation of monocyte chemoattractant protein-1 but with an inverse variation in its receptor, CCR2. We conclude that intact AT III antioxidant activity prevents endothelial dysfunction.<EOD> .\nAIM\nThe purpose of this study was to investigate the effects of chronic exposure to different doses of ionizing radiation on the testicular tissue of mice.\n\n\nMETHODS\nWe investigated mice testicular tissue by light microscope, immunohistocyte staining, and flow cytometry.\n\n\nRESULTS\nLight microscope observation and quantitative analysis showed that both early apoptosis of spermatogonia and late apoptosis of spermatids were observed in the radiation (1.5 cGy/min) group or the high dose radiation group with significant differences when compared with the experimental group (1.5 cGy/min) or the control group (P < 0.05). However, in the low dose radiation group, changes of apoptosis were similar to the experimental group with little significant difference (P < 0.05). Immunohistocyte staining showed that the expression of",
        "label": 2
    },
    "197": {
        "output": "##1) Read about the trial [LINK=clinicaltrial.gov/] and the clinical trial's inclusion and exclusion criteria.  \n\n\n\n![LINK=clinicaltrial.gov/]\n\n\n\n![LINK=clinicaltrial.gov/]\n\n![LINK=clinicaltrial.gov/]\n\n![LINK=clinicaltrial.gov/]\n\n##2) Use the 3-point scale to determine if the patient should be assessed as Eligible, Not relevant, or Excluded.   \n\n```\nNot relevant is used for patients who don't have sufficient information to assess his/her eligibility correctly.  \nA patient note where the eligibility cannot be assessed, will contain the string Not relevant at the last line of the note.  \n```\n##3) Summary trial-level eligibility must be reported in the final line of the patient note e.g., `Trial-level eligibility: 2) Eligible.` \n(IMPORTANT!) Do not use the term Not relevant for trial-level eligibility.  \nIf the assessment is Not relevant for a patient, you should not output the string Not relevant for trial-level eligibility.  \nIt means that a patient note where the eligibility cannot be assessed, should be discarded.  \nIf the assessment is Eligible for a patient, you should print Eligible string for trial-level eligibility.  \n```\n<EOD> Correction to Immunohistochemistry of NF\u2010\u03baB in Human Colorectal Cancer and Adenoma\n\nCorrection to Immunohistochemistry of NF-\u03baB in Human Colorectal Cancer and Adenoma\n2004\nMDMDMDCorrection to Immunohistochemistry of NF-\u03baB in Human Colorectal Cancer and Adenoma\nTHE Journal of MUCOSAL RESEARCH\n4322004Received October 30, Accepted November 9, 2004\nSeveral years ago, following the appearance of our paper \"Immunohistochemistry of NF-\u03baB in human colore",
        "label": 0
    },
    "198": {
        "output": "## Rules\n\n### Condition\n\n*Every field of Clinical trial:\n\n\n\n\n```perl\nmy $r = 0;\nsub cond ($) {\n  my ($c) = @_;\n  $r++;\n  $c =~ s/\\n/\\n\\n/g;\n  print STDERR \"Assessing clinical trial '$c'\\n\";\n  if ($r == @ARGV) {\n    print \"\\nThe current clinical trial is not acceptable\\n\";\n    while ($r--) {\n      s/\\n/ /;\n      print \"\\n\\nAssessing clinical trial '$c'\\n\\n\";\n      s/\\n/\\n\\n/g;\n    }\n  } else {\n    my %patient = %ARGS[$r];\n    my ($i) = @ARGV;\n    $c = substr($c, 2);\n    my @x;\n    opendir(my $f, $c);\n    while (readdir($f)) {\n      chdir($c);\n      if (-e .) {\n        my $filename = qq{$i->[0]--.'.'};\n        my $line = <$filename>;\n        s/\\s+/ /g for (@x);\n        s/\\n/\\n\\n/g;\n        print \"\\nPatient: $patient{'fullname'}\";\n        for (@x) {\n          print qq{$_--.'} \".\"($_, '\"') . qq{($_--.')'};\n        }\n      }\n    }\n    closedir($f);\n  }\n}\nprint \"\\n\";\n```\n\n* Every file in the given directory:\n\n*Every file in the given directory and subdirectories, e.g., files and sub-directories: *\n\n\n\n\n```perl\nmy $r = 0;\nsub f ($) {\n  my ($filename) = @_;\n  print STDERR \"Assessing file $filename\\n\";\n  # Get line number to exclude this file's sub-files too\n  $r++;\n  $filename =~ s/\\n/\\n\\n/g;\n  print \"\\nF",
        "label": 0
    },
    "199": {
        "output": "# Efficient and Effective Way to Answer the Questionnaire\nYou may have learned in the 2nd year course that the process of writing a complete answer in the long answer format can be quite challenging. For example, when a problem asks us some questions such as, \"Do not use the short answer format. You will receive a score of 0 in the writing of this problem unless this paper meets the writing objectives. You will lose 3 points in total if your answers are complete but are not well organized. Also, 3 points will be deducted if you use the short answer format.\" If you receive such a score, you will wonder what to do, and it will be helpful if you are able to answer correctly without using the short answer format. \nIn addition, even for students who are not currently attending clinical clerkship, or are just about to begin, but need to answer the questionnaire for the purpose of preparing clinical clerkship, they may feel a bit nervous when they find that the answer sheet is long enough and the format is quite different from that of the school-based problem solver, which they are accustomed to using. They may wonder what they need to pay attention to in order to get a high score in the problem solving test. You may need to develop an efficient and effective way to solve the problem. \n\n# Writing Objectives for Questionnaire\nTo solve problems in the long answer format, it is essential to prepare a clear writing plan. This is because it is difficult for us to solve the problem when we have not prepared such a plan. And this is why it is vital to be able to write specific objectives for questions in the long answer format. \n\n# How to formulate writing objectives\nFirst of all, you are asked to formulate writing objectives as you go along while solving the problem. You need to specify, in writing, what you want to include in the answer. \n\n# Considerations for Efficient and Effective Methodology\nThings to remember as you go: \n1. Pay special attention to the instruction page. You should know how many problems to be answered on the questionnaire. \n2. You should keep reading the question with one eye on the writing objectives you've specified when you read a new problem. \n3. You must always ask how to reach the",
        "label": 0
    },
    "200": {
        "output": "### Case Example\n\nBefore we look into the second case, let's just quickly discuss the output here.\n\n*It would be pretty straightforward to just write something like `eligibility : \"patient is eligible\"`. But we don't need to, because if the patient is eligible, your trial is also eligible; so, just writing `trial : \"trial is eligible\"` is sufficient.\n\nNow, lets see the second case.\n\n# Case 2: \"Patient X-123 (a 60-year-old male) is being evaluated for treatment\".\n\n# Case 2: \"Excluded\"\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. You should write the outcome of the comparison in the trial data file. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nThe patient is a 60-year-old male. He is scheduled for a liver biopsy under anesthesia to determine the diagnosis of hepatocellular carcinoma. He is suspected of having alcoholic cirrhosis.\n\nThe patient is healthy, a professional musician. He takes oral propranolol for his high blood pressure. He drinks alcohol. \n\n*Alcohol is a potential risk factor for hepatocellular carcinoma. If the patient does have HCC, it may be from alcoholic hepatitis. If the patient does not have HCC, it could be from hepatic cirrhosis resulting from alcoholism. So, we put the patient on alco",
        "label": 0
    },
    "201": {
        "output": "___\n\n[LFUN] \nFor each patient, the eligibility score of the patient is now determined by multiplying the probabilities for each factor. The factor that can take a value from zero to one.\n\nFor example, if a patient matches the trial \"Breast cancer\" and is of both sexes and has tumour grade \u2a7d2 and negative node status and chemotherapy group, then its overall eligibility score would be:\nP1 x P2 x P3 x P4 = 0.8 x 0.2 x 0.5 x 0.4 = 0.08\n\n___\n___\n\n[LFUN] \nIn this section, you can make your model output a patient name and patient ID column which are automatically generated as your model learns.\n\nThis time, you will use the `Trial-level eligibility` as the column header. The column header can be set to anything (eg `Inclusion criteria` ) as well as the `Patient-level eligibility` value. \n\n![Learning from Example 8](../images/0802-5.png)\n\n___\n___\n\n[LFUN] \nThe columns `Trial-level eligibility` is set from `Trial-level eligible ` to `Trial-level ineligible`.\n\nIt should also note that when this table is built, a new random seed is assigned.\nYou can find this seed number in the file `C:\\Users\\%USERNAME%\\.RStudio\\Rhistory\\history.txt` after you run the R Code.\n__[INST]__\n\nLet's think step by step. \n\n\n## # Create a dataframe from each file\n# Use the name of the variable to create a data frame.\nfiles <- ls()\n\nfor (file in files) {\n    df <- read_xlsx(file, sheet = 2, header = TRUE, \n    skip = 1, nrows = 4, sep = \"\\t\", row.names = FALSE)\n    \n    file <- paste(\"C:\\\\Users\\\\dongkchung\\\\Desktop\\\\0404_clinicaltrial\\\\trial_data\\\\\", file)\n    \n    df$TrialID =",
        "label": 0
    },
    "202": {
        "output": "## Exercise on a real patient data set\n\n`$ i=0; while ($i < @myInput) { $i ++; print \"Input:\", $myInput[$i]; print \"Output: \"; print \"Tri-level eligibility: \", $tri_level_eligibility[$i]; }` [EXER]\n\nLet's write a program to make trial-level eligibility.\n[INST] Let's define a procedure to obtain the number of patients. You should be able to execute the code below to get all your patient notes. You can insert the code block between a new line and `print` statement. Execute the following code block under the existing code in R/script_A.Rmd: [RUN]\nAdd a new code block, e.g.,`<<`between two new lines, named `patient_number_by_trial`. [RUN]\nThe new code block should be shown as follows:  \n`<<function(i) { print(\"The number of patients by trial: \", i); }` [RUN]\nSave the script as `R/script_B.Rmd`. The new modification will be shown as follows:  \n`script_B.Rmd`  \n```\n<body>\n\n  <h1>R script:\n    `script_A.Rmd`  \n</body>  \n\n<h3>1. Patient notes:\n  <h4>Input:</h4>  \n    $<NAME>.csv_02_patient_note.csv\n  <h4>Output:</h4>  \n    ... Patient_notes_R_output_001.csv\n  <h4>Tri-level eligibility: \n    <h4>Input:</h5>\n     $<NAME>.csv_05_patient_note_2_for_eligibility.csv  \n    <h4>Output:</h4>\n     ... Tri_level_eligibility_R_output_001.csv  \n                                    \n  <h4>Triple-level eligibility: \n    <h4>Input:</h5>\n     $<NAME>.csv_03_patient_note_3_",
        "label": 2
    },
    "203": {
        "output": "---\n\n### Implementation and usage\nImplementation: [`doc_trial_eligibility.md`](https://github.com/DiseaseGenome/docuGenome/blob/c93cdd010d862d3b5b9279666caea0b67d1a7023/docs/scripts/rst.rst#L20-L26)\n- [![Ratings](https://badges.githubusercontent.com/6158071/74918555-6b3f7500-5e5b-11ea-8991-8d822c7473a5)](https://arxiv.org/pdf/1902.08717.pdf)\n\n## `doc_trial_eligibility.md`\n\n### Contributing\nPlease use the doc_trial_eligibility.md to generate a new draft and submit in with the above mentioned `doc_trial_eligibility.md`.<EOD> Neural stem cell transplantation and motor functional recovery in animal ischaemic stroke models\n\nThe central areas of the brain with the highest concentrations of stem cells and nerve cells in the adult, the subventricular zone and subgranular zone of the dentate gyrus, respectively, harbour neural stem cells, multipotent neural stem cells and cells exhibiting restricted proliferation potential. During neuronal damage and death, neural stem cells migrate from their subventricular zone niche, proliferate in the subventricular zone and differentiate into neurons, astrocytes and oligodendrocytes, which can be found as far as in the subvent",
        "label": 1
    },
    "204": {
        "output": "[SEM3] Hello, I am here to see you. I am a patient's companion.\n\nI am a 28-year-old woman who is being considered for a phase I trial of a new drug candidate. \nThe new agent is being tested to treat my rare cancer.\n\nI am the primary caregiver for Mary, an 82-year-old woman who was recently diagnosed with metastatic breast cancer.\n\nMary has metastatic cancer that spread to her bones, lungs, and liver. Her cancer does not respond to several kinds of treatment. Mary prefers to go home instead of coming to a hospital to be treated.\n\nOn our first meeting, I took care of her medical transportation, home nursing, and paper work for her hospice care.\n\nShe has an appetite loss, difficulty swallowing, low back pain, and frequent urination.\n\nIt is essential to maintain her quality of life before the advanced cancer treatment. \nPlease tell me all the necessary steps from today to get involved in the clinical trial.\n\n[SEM4] Hello, I am here to see you. I am a patient's companion.\n\nI am a 28-year-old man who is being considered for a phase I trial of a new drug candidate. \nThe new agent is being tested to treat my rare cancer.\n\nI am the primary caregiver for James, an 82-year-old man who was recently diagnosed with metastatic breast cancer.\n\nJames has metastatic cancer that spread to his bones, lungs, and liver. His cancer does not respond to several kinds of treatment. James prefers to go home instead of coming to the hospital to be treated.\n\nOn our first meeting, I took care of his medical transportation, home nursing, and paper work for his hospice care.\n\nHe has fatigue, loss of appetite, difficulty swallowing, and low back pain.\n\nIt is essential to maintain his quality of life before the advanced cancer treatment.\n\n[SEM3] Hello, I am here to see you. I am a patient's companion.\n\nI am a 28-year-old woman who is being considered for a phase I trial of a new drug candidate.",
        "label": 0
    },
    "205": {
        "output": "\u00a9 2016 CodeEval, Inc.\n\n\nA: What language is this?\nIf it's python I got you covered:\nfor p in Patient:\n    if p.age and p.Gender in trial_inclusion:\n        #Check inclusion criteria\n        res['eligibility'] = 2\n    else:\n        res['eligibility'] = 0\n\n\nA: @griene's answer is pretty much on target regarding a Python solution for the task.  I would like to note a few important items of note with it, however, to give some context and background.\n\n*\n\n*The main reason you don't want to check every single item in the list of patients is that, due to the way Python dictionaries work, checking for a particular patient's inclusion criteria will only be faster if your data is sorted by the key value.  Because, if you were to have some patients with the same age and gender as each other, you would check each one separately and that could potentially be very slow given the number of patients in the test data.  For this reason, it's best to check by trial first, since the trials will be indexed by the key, which is then the ID of the trial.  If the trial is found to be acceptable, then loop back to check for each patient within that trial.\n\n\n*The main reason you don't want to check every single item in the list of patients is that, due to the way Python dictionaries work, checking for a particular patient's inclusion criteria will only be faster if your data is sorted by the key value. Because, If you were to have some patients with the same age and gender as each other, you would check each one separately and that could potentially be very slow given the number of patients in the test data. For this reason, it's best to check by trial first, since the trials will be indexed by the key, which is then the ID of the trial.* \n\n*In the example code you provided, you use dict.keys() to get the ID of the trial, however this list is sorted in ascending order.  In other words, the values in keys() come in ascending order of the trial IDs.  However, if you actually needed the list in descending order to test for each trial as you iterate through the list, you",
        "label": 0
    },
    "206": {
        "output": "### Instructions\n\n\n\n1. **[Run the code](https://repl.it/~flipbot/590)** to see the output.\n\n### Notes/Exercises\n\n1. How can you make the patient's diagnosis look like the one in the patient note?\n1. How can you improve the code?\n<EOD> Prevalence and predictors of pain and pain\u2010related disability in patients with low back pain: a retrospective registry analysis\nBackground and purpose:\u2002 The object of the present study was to investigate the prevalence and predictors of pain and disability in patients treated for low back pain in private physical therapy clinics in the USA between 1994 and 1997.<EOD> Synthetic studies towards enantioselective total synthesis of (+)-alstonolide B and (-)-aristeromycin.\nEnantioselective synthesis of tetrahydropyran is a very challenging task in carbohydrate chemistry since the formation of an enantioenriched tetrahydropyrane is dependent upon multiple factors such as stereoinvertibility or kinetic inertness of the rearrangement. Accordingly, syntheses of tetrahydropyran based on 2-siloxycarbonyl group as the tether have been developed to minimize undesired rearrangements . Recently, we reported asymmetric synthesis of carbamates possessing a 2-siloxycarbonyl group through diastereoselective allylic alkylation, which is an effective method for controlling stereochemistry of the resulting tetrahydropyran by selecting a substituent on the alkene moiety . We here report the synthesis of an enantiopure \u03b1,\u03b2-unsaturated carbonyl system as illustrated in Scheme 1. Initially, enantioenriched tert-butyl carbamate 2 was synthesized by the method reported by Ito . Reduction of tert-butyl carbamate 2 with sodium borohydride provided alcohol 3, which showed almost the same optical rotation as that of (+) alstonolide F, a cysteine protease inhib",
        "label": 2
    },
    "207": {
        "output": "For the clinical trial, let's assume 10 patients in each arm in the original trial.\nWe need to determine how many samples are eligible. It's quite straightforward. We start with the first sample and run a ttest. If the p-value is smaller than 0.05, that's in favor of the hypothesis (H0) that both groups are equivalent, and we move on to the next sample.\nIf it's not, we add 1 to n for all patients in the second arm, as in `n[2]=[`n[2]+1`]`\nWhen moving on to the second sample, the previous values in `n` should still be held. Note that `n[1]` is the p-value of the first sample, so we can reuse it for the second sample. We then move on to the next sample.\nSo for the first sample we run ttest, we get the p-value of 0.46. So the hypothesis for the first sample cannot be rejected: group A is statistically equivalent to group B since the group size is larger enough. We increase n[2] by 1 and move to the second sample. We call ttest and obtain the new p-value of 0.7. This implies that we could not reject neither the nullnor the alternative hypothesis: we accept H0. Now we check the group B size ( n=2+1=3, 0.7 is the p-value of group A) and the group A size ( the same p-value 0.7), and therefore move on. \nFor the third sample, the original p-value is 0.01, so we should reject the null hypothesis and move on.\nFor the fourth sample, the original p-value is 0.03. So we could not reject the nullhypothesis. We check n, n=2+1=",
        "label": 1
    },
    "208": {
        "output": "Set the CSV file as the input for next step. \n6. By using the script that is written in\n[13.2.3 Converting a CSV file to a DTA file.md](./13.2.3. Converting a CSV file to a DTA file.md) file, make a list of trial eligibility.\n\n6.1.",
        "label": 0
    },
    "209": {
        "output": "### Examples<h3>Patient 1</h3>\n# Patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n# [patient.gender=\"female\"] # [patient.age=\"45\"] # [patient.clinical_stage=\"c_t2 n0 m0\"] # [patient.tx_path=\"breast-conservation-therapy\"] # [patient.tx_name=\"neoadjuvant-chemotherapy\"] # [patient.tx_timing_in_days=\"4\"] # [patient.tx_timing_in_weeks=\"1\"] # [patient.tx_timing_in_months=\"1\"] # [patient.txt_timing_in_years=\"1\"] # [patient.rx_timing_in_days=\"4\"] # [patient.rx_timing_in_weeks=\"1\"] # [patient.rx_timing_in_months=\"1\"] # [patient.rx_timing_in_years=\"1\"] # [patient.txt_timing_in_days=\"4\"] # [patient.txt_timing_in_weeks=\"1\"] # [patient.txt_timing_in_months=\"1\"] # [patient.txt_timing_in_years=\"1\"] # [patient.tx_timing_in_weeks=\"4\"] # [patient.rx_timing_in_weeks=\"4\"] # [patient.txt_timing_in_weeks=\"4\"] # [patient.rx_timing_in_months=\"4\"] # [patient.txt_timing_in_months=\"4\"] # [patient.tx_timing_in_years=\"4\"] # [patient.rx_timing_in_years=\"4\"] # [patient.txt_timing_in_years=\"4\"] # [patient.tx_timing_in_days=\"1\"] # [patient.rx_timing_in_",
        "label": 0
    },
    "210": {
        "output": "Note: If there are any unresolved problems about `Trial-level eligibility:`, you will see the error like following.\n\n```\nIn RST/CSV:\n`Trial-level eligibility: 4) Excluded`\n\nOut of RST/CSV (when the trial_info.txt is not found):\n`Trial-level eligibility: 0) Excluded [missing fields: InclusionCriterion]`\n\nTips:\n\n  When `Eligibility` is not available, you can find `Eligibility` from Eligibility_criteria_id or\n  when `Inclusion_criterion` is not available, get it from Inclusion_Eligibility_criterion.\n\n[EOL]\n\n[EOL]\n[EOL]\n[EOL]\n[EOL]\nTips: \nEasy way: If your trial name is `Breast2`, first check the variable from `crosstalk_22[i]', then check if its value is `True` or `False` and then get the trial id as the same way as the previous session. \n\n```\nEasy way: If your trial name is `Breast2`, first check the variable from `crosstalk_22[i]', then check if its value is `True` or `False` and then get the trial id as the same way as the previous session. \n\n```\n\n# Easy way: You can confirm the name of the trial from a given trial id in RStudy::trial\n\n```\n\n  trial_id = crosstalk_22[120]\n  trial_name = unlist(RStudy::trial(trial_id)) # e.g., \n```\n\n## The last step\nTips:\nFor some trials, its `Trial-level eligibility: 0) Excluded [missing fields: InclusionCriterion]` . \n\nPlease modify one or more rules as well as `Triallv_Criteria`:\n\n```\nTriallv_Criteria <- list(\"Inclusion_Criteria\" = list(\"inclusion_criteria_eligbility.txt\",\n                                               \"in",
        "label": 2
    },
    "211": {
        "output": "[TEST] Test cases\n[TEST1]\n- [TEST1] - Test case 1: `p1`.\n- [INST] Input: *patient_note: \"The patient is a 33-year-old postmenopausal woman with breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2 positive and ER/PR negative. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and had one child.\"\n- [RUN] Run test with output: `patient_note : 0, Trial-level eligibility: 1) Not relevant`.\n- [TEST1] - Test case 1 successfully passed.\n- [INST] Test case failed.\n- [TEST2] Test case 2.\n- [RUN] Run test with output:\n    `patient_note : 3, Trial-level eligibility: 0) Excluded`.\n- [TEST2] Test case 2 failed.\n- [TEST3] Test case 3.\n- [RUN] Run test with output:\n    `patient_note : 0, Trial-level eligibility: 0) Excluded, 1) Not relevant`.\n- [TEST3] Test case 2 successfully passed.\n- [TEST4] Test case 4.\n- [RUN] Run test with output:\n    `patient_note : 1, Trial-level eligibility: 0) Excluded, 0) Excluded, 2) Eligible`.\n- [TEST4] Test case 4 failed.\n- [TEST5] Test case 5.\n- [RUN] Run test with output:\n    `patient_note : 1, Trial-level eligibility: 0) Excluded,`\n    `Trial-level eligibility : 2) Eligible`.\n- [INST] Test case passed.\n- [TEST5] Test case 5 successfully passed.\n\n[TEST6] Try to fail with input: `patient_note: \"",
        "label": 0
    },
    "212": {
        "output": "Good luck!<EOD> Combination Antibiotic therapy for Pouchitis: Results From the Pouchitis Outcomes Research Study (PORt)\nAbstract Background In patients with ileal pouch-anal anastomoses, chronic pouchitis affects many, and is often difficult to treat. Antibiotic therapy is frequently used. However, there is no established first-line antibiotic therapy for pouchitis. The objective of this study was to determine the effectiveness of a range of antibiotic regimens for treating pouchitis in a large cohort of patients with ileal pouch-anal anastomoses. Methods We conducted a retrospective cohort study of patients with pouchitis (n = 385) identified from the Pouchitis Outcomes Research study (PORt), a multi-center prospective cohort. Our exposure of interest was antibiotic exposure (metronidazole, ciprofloxacin, or a combination of metronidazole and ciprofloxacin) in the year prior to enrollment. We used logistic regression and propensity score matching to assess the effectiveness of each antibiotic and a combination of the 2, and determined whether outcomes were independent of the initial antibiotic choice. Results The majority (85.1%) of patients reported use of \u22651 antibiotic, most commonly metronidazole (28.9%) and ciprofloxacin (27.1%). Compared to no antibiotic treatment, metronidazole use was significantly associated with decreased pouchitis risk (OR 0.60; 95% CI, 0.50\u20130.72), as was ciprofloxacin use (OR 0.56; 95% CI, 0.50\u20130.63). The combination of metronidazole and ciprofloxacin was associated with an even greater decrease in risk (OR 0.36; 95% CI, 0.28\u20130.44). All associations were independent of initial antibiotic choice. Conclusions All antibiotics evaluated are associated with a decrease in",
        "label": 0
    },
    "213": {
        "output": "___\n\n## Example input\n\n### Clinical Trial\n\n- Title: Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions\n- Study Type: Combination Therapy\n- Study Design: Exploratory study evaluating 3 arms:\n    * Arm 1: Monoclonal antibody MEDI6469 (anti-OX40) plus stereotactic body Radiation (SBRT) to metastatic site\n    * Arm 2: SBRT to metastatic site\n    * Arm 3: 0.9% saline\n- Treatment Arm 1: MEDI6469 (anti-OX40)+ SBRT to metastatic site\n- Inclusion Criteria:\n    * Subject must have histologically confirmed cancer with clinical evidence of metastatic disease\n    * One metastatic disease lesion that is amenable to stereotactic body radiation with a high probability of biological tumor ablation must be identified\n    * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\n- Exclusion Criteria Includes:\n    * Active autoimmune disease that requires systemic treatment with corticosteroids or other disease modifying antirheumatic drugs\n    * A history of documented clinical disease that would, in the opinion of the investigator, either put the subject at risk because of procedure related complications such as infection or neurological deficits or confound the results of the trial such as an inability to undergo the procedures, compliance with protocol treatment or assessment of toxicity and/or study end points\n- Trial-level eligibility 1):  Excluded Subject meeting any of the Exclusion Criteria listed above\n- Trial-level eligibility 2):  Not relevant Subject does not have sufficient information to qualify for the trial\n- Trial-level eligibility 3):  Eligible Subject meets all the Inclusion Criteria and does not meet any of the Exclusion Criteria listed above, AND subject is \u226518 years old and has",
        "label": 0
    },
    "214": {
        "output": "Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n\nThere are two problems. First, the patients' diagnoses change over time and even the inclusion criteria of the clinical trial change over time, especially in the context of the evolution of medicine. Second, there are too many data to manage in such situations. We use data structures to organize the data as we make them.   When you write the data structure of patient notes and data structures of clinical trial data, you will automatically organize the data and simplify the data collection to make clinical trial easier.\n\n## Use Data structure\n## Introduction\n\nIf data are not organized, it can be challenging to find specific data in large datasets. In the medical domain, this challenge is magnified by the sheer amount of unstructured textual patient data. Here, we introduce a conceptual framework to organize information. \n\n\n<!-------------- INDEX PATIENT IN EXISTENT DATABASE --------------->\n  \n### Index patient in existing database\n\n* The data structure of patient data.\n    * Includes [INDEX PATIENT DATA]\n    * Includes [INDEX INDICATORS OF PATIENT DATA]\n    * Includes [Patient notes]\n    * Includes [INDEX PATIENT DEMOGRAPHIC DATA]\n* The patient\u2019s information is entered as an index of each patient. \n\n**Data Structure of Patient`s Data**  \n* Patient ID: A unique identifier\n    * AID-ID\n* Date of data entry: Date of first entry of a patient note\n* Birth Date: Date of birth\n* Death Date: Date of death\n* Sex: Male or femal\n    * Patient can be assigned to be male or female. \n* Age: A patient's age\n    * Age can be determined by comparing the birth date and death date.\n* Inclusion or Exclusion Criteria: A patient note is checked whether it meets the inclusion or exclusion criteria of a clinical trial\n    * Except for the 'no-data-type' cases.\n\"excluded\": The patient does not meet the inclusion criteria.\n\"not relevant\": No available information for the assessment of el",
        "label": 1
    },
    "215": {
        "output": "When you exit without saving the session because you are on a laptop, a pop-up message appears like the following one:\nYou do not have a session cookie. As a security measure, your session will be terminated after 30 min inactivity.\nSave your results! [END]\n\n### Trial Summary: [TOP]\nWe have learned the overall trial information by running the following command:\nimport pyrast.pipeline\ndata = run_pipeline(name, trial)\ndata\n\nYou can see that the data frame has 54 columns like following. The first six columns and the last three columns are the mandatory columns you must complete. The other columns are optional. The first six columns are:\n- ID\n- Trial\n- Title\n- Type\n- StudySite\n- Site\n- TreatmentArm\nIf you miss any optional fields in the pipeline, you have to restart the pipeline by running the following command:\nre-start_pipelines()[]\nFor an example of re-starting the pipeline, refer to section 1.21. You do not have to fill in the optional columns during building the pipeline.\n\n### Tips\n- If a patient is suitable for the trial as shown in the [Detailed Eligibility] section [ID, Trial], Type, Title, StudySite, Site, TreatmentArm, the patient-specific fields, and the date are omitted since you focus only on the patient-specific fields this time.\n- We have used `DifferentialEligibility` to see what differences there are between patient and trial. If you want to know the details about `DifferentialEligibility`, refer to the previous section on `DifferentialEligibility`.\n- When you want to see the patients with the inclusion criteria of the trial and the exclusion ones, use the `get_with_inclusion` function. The returned data frame contains the patients of clinical trials that match the inclusion and exclusion criteria. Let's see the result.\ndata[-1]\n- You can obtain the number of patients by executing the following command:\ndata[-1]['Length'][0] \n\n# Inpatient\n\n## [/TOP]\n\n### Clinical Decision Support\n\nThis section will teach you how to build a patient recruitment report",
        "label": 0
    },
    "216": {
        "output": "[COURSE]\n[STUDENT] Hello. It's me, [NAME].\n[LECTURER] Hello, [NAME]. \nHow can you find your name in the patient note? \n[STUDENT] Oh, hi, Dr. Brown. I don't know how to do the task.\n[LECTURER] Well, let's think about the patient note first. It has a part `patient information`. What data items are there? \n[STUDENT] Dr. Brown, all I know is his name and age. There is no information about her family history, allergies, or medications.\n[LECTURER] Well, you did well to check if it is an interesting patient. Go on. Find out more about the patients. You will find it in the `patient history` section. Find their symptoms, chief complaint, and current medications. I'm sure they are there. \n[STUDENT] Oh, I am able to do the task. I found his symptoms and his chief complaint. He has not been prescribed any medications yet. \n[LECTURER] That seems interesting. Are those data items not in the patient note? \n[STUDENT] No, only the symptoms, the chief complaint, and the medications appear. Where are they?[CORRECT RESPONSE] `In your report, make sure to include information on your patient including a brief description of his or her current status. Also, include information about the clinical trial. Your report will be a source of information about your patient so that others can work with him or her.`\nLet's think step by step. \n[CORRECT RESPONSE] In your report, make sure to include information on your patient including a brief description of his or her current status. Also, include information about the clinical trial. Your report will be a source of information about your patient so that others can work with him or her.[/CORRECT RESPONSE] \n[LECTURER] Excellent! But first, find all the data about the clinical trial. You will find everything about the trial in the `clinical trials` section in the patient note. Can you find all data there? \n[STUDENT] Yes",
        "label": 0
    },
    "217": {
        "output": "[bib_ref]  Comparison of Breast Cancer Survival by Molecular Subtype in Patients Treated in..., Metzger [/bib_ref]  [GUI] You may be interested in this program that makes the comparison and the visualization of two cases, the clinical trial that we studied and the information from one patient. [bib_ref]  Precision Oncology in the Era of Interconnected Health Systems, Taber [/bib_ref]  [GUI]\nNow, let's discuss the clinical utility of an ontology for representing clinical information of a patient. [INST]\nPatient information is extremely important during a clinical procedure. In today's clinical scenarios, the amount of available information is rapidly increasing. As a result, many studies have been conducted to represent more comprehensive clinical information, covering all the important aspects of a patient. [bib_ref]  A Comparison of the Comprehensive Rationale Index, Health Monitor Index, and Karnofsky..., Schonwetter [/bib_ref]  We should therefore adopt semantic technologies in a clinical setting to represent patient data in order to improve patient safety by making data consistent [bib_ref]  A Comparison of the Comprehensive Rationale Index, Health Monitor Index, and Karnofsky..., Schonwetter [/bib_ref] . A patient can have multiple medical profiles, such as laboratory tests, diagnosis, and medications. The profiles of a patient can be classified into different levels. The general patient information at an institutional database level has been represented on an ontology. In order to understand the patient's condition accurately at patient level, a number of studies have been undertaken to represent patient data. [bib_ref]  Patient data semantic annotation using medical ontologies, Ruggiero [/bib_ref]  proposed an ontology to represent patient information [bib_ref]  Patient data semantic annotation using medical ontologies, Ruggiero [/bib_ref] . In order to reduce the complexity, the authors did not discuss the details of a complete patient' profile and focused only a portion of the patient' information.\n[INST]\nIn this chapter, a case study is presented for integrating a clinical trial of a patient and patient information from the institutional database. The objective of this study is to analyze the possibility that a clinical trial will determine if our proposed ontology is useful to represent both patient information and a clinical trial ontology.\n[GUI]\nTo show how to use",
        "label": 2
    },
    "218": {
        "output": "## Test Case\nLet's run again with following command:\n$ irb -p $PWD\n1.2.0\n1:1024\nirb$ python run.py test_code.py\nTrial-level eligibility: 2) Eligible.\n\n## Summary\nWe have presented the basics of IRB application using the MX_IRB tool designed for the MX Challenge. This tool utilizes the PyMX library which provides useful functions to prepare IRB applications for the MX Challenge using a simple command-line interface. This tool is quite simple to use but it does require some basic understanding of IRB reviews.\nThe provided tutorial walks through every step of the process and shows how to run a complete MX application in less than an hour (less than 12 minutes if you are running all of the tests). In order to be able to follow along, you should read the detailed MX ruleset which can found online at https://biomed.brown.edu/mx-challenge/rulesets/2014. We highly recommend reading the online documentation at http://pymx.github.io/ as well to understand the other features of the tool.\n\n# Related Work\nThere are a number of research groups studying the issue of automatic IRB applications. One prominent tool currently being developed is the IRB tool available from http://clinicalcomputing.org/project/c3-r/. While this project is not related to ours in any way, it includes some of the same concepts such as providing a unified API for data provenance, querying for IRB items, and providing tools for searching for IRB items.\nIRBtool is an open-source tool that is used for preparing IRB applications by research teams. The tool includes features that were missing from other tools such as support for multiple IRBs, tracking of missing data, and support for queries over the XML submission. We believe that our tool does not solve the same issues in the same way as the IRBtool but we have not tried to analyze their tool at this point.\nFinally, an interesting effort has been proposed by http://scigenomica.org/toolswhere they use Python and R to build an IRB application. The solution utilizes a similar approach as ours and while the current effort is not as fully developed as our",
        "label": 0
    },
    "219": {
        "output": "<EOD> .\nOBJECTIVE\nTo explore the feasibility and accuracy of free gingival grafts (FGGs) for coverage of exposed dental implants in a swine model.\n\n\nMETHODS\nFour dental implants were placed in the canine area of the mandible of the young swine. One week after implant insertion, FGGs were harvested by means of a split thickness graft. Graft and recipient sites were prepared in a similar manner, and FGGs were immediately transplanted to the recipient sites around implants. A month after transplantation, biopsies were harvested from implant sites and surrounding FGGs. Histological preparations of biopsies were then stained with hematoxylin-eosin, van Gieson and tartaric acid stain. The number of colony forming units within the implant sites were examined by the use of agar method.\n\n\nRESULTS\nAll FGG sites survived and formed complete epithelial attachment with minimal contraction in a month after transplantation. No severe inflammatory reaction was observed in FGGs or recipient areas. Van Gieson and tartaric acid stain showed that only a narrow zone of bone loss occurred in implant sites and the rest of the bone surrounding implants were normal bone tissue without osteolysis. Implant sites were surrounded by thick epithelial tissues in the first week after transplantation. Agar culture of the histologic specimens showed a total of 204 microbial colonies in the culture medium, including 195 gram-positive cocci and rods, and nine Enterobacteriaceae.\n\n\nCONCLUSIONS\nFresh FGGs seem to be a good method in covering exposed dental implants in the immediate postoperative period without any significant post-surgical complication. The results suggest the possibility of performing this technique, especially as a short term solution for dental implants failing to integrate with the host soft tissues.<EOD> Erythrocyte sedimentation rate in oocyte donors is higher than in matched control subjects.\nErythrocyte sedimentation rate (ESR) was determined over 2-3 h in a group of healthy,",
        "label": 2
    },
    "220": {
        "output": "<EOD> A simple high-pressure gas chromatograph for the analysis of blood or breath for ethanol.\nAn inexpensive gas chromatograph capable of determining ethanol concentrations at high pressures has been developed for the analysis of blood or exhaled breath for ethanol under anesthesia. The system consists of a commercially available 3 in. glass column. The separation is achieved by the use of a 36 x .0012 in. fused-silica capillary containing silicone-charcoal film as the stationary phase; by the use of a carrier gas and hydrogen as the auxiliary gas; and by the use of a column oven which achieves separation when the temperature is increased isothermally 0.05 deg C/sec. in a pressure-induced equilibrium column system. The inlet system is designed for the sampling of an unvented and unanesthetized canine and the determination of ethanol concentrations in blood and breath by the direct sampling of the blood or breath. The concentrations obtained by the present system agree with those obtained with the semiautomated headspace gas chromatographic determination.<EOD> Antimicrobial Agents That Block Aminoribonuclease C from Clostridium difficile Display Potent In Vitro Activity against an Antimicrobial-Resistant Strain Clinically Isolated from a Patient in China\n\nAminoribonuclease C from Clostridium difficile (CD-AMNB) can cleave 30 nucleotides of the 3= end of the 16S rRNA, making it difficult for aminoglycosides to enter the 30S ribosomal subunit and bind to bacterial rRNA, which contributes to the high toler",
        "label": 0
    },
    "221": {
        "output": "#### Step 1: patient note\n\nYour patient note should be similar to below. Make sure all the information is up to date, as this task will be automatically calculated. If any patient note, for example, is old, you should add the current patient note.  \n\n```python\ndef _patient_note_assessment(note, clinical_trial, **kwargs):\n    return {\n    0: 'Excluded',\n    1: 'Not Relevant',\n    2: 'Eligible'.\n    }[clinical_trial.assessment_scale]\ndef _patient_note_assessment(note, clinical_trial):\n    if 'clinical_trial' not in note:\n        return _patient_note_assessment(note, clinical_trial, x1='', x2='', x3='')\n    # get patient's ID\n    patient_id = find_first(filtered_criteria, lambda x: isinstance(x, Patient) and x.patient_id is not None)\n    # make sure that patient has associated note\n    if note is None or \\\n      note[0:3] != patient_id: return _patient_note_assessment(note, clinical_trial, x1='', x2='', x3='')\n    note_id = int(note[3])\n    # find relevant criteria\n    # clinical_trial.assessment_scale == 0 -> Excluded\n    # clinical_trial.assessment_scale == 1 -> Not relevant\n    # clinical_trial.assessment_scale == 2 -> Eligible\n    criteria = {criterion.name for criterion in filtered_criteria if isinstance(criterion, Criterion) and 'patient_notes' in criterion}\n    if len(criteria) == 0: return _patient_note_assessment(note, clinical_trial, x1=criteria[0], x2=criteria[1], x3=criteria[2])\n    \n    # filter candidate criteria\n    # check if criteria.patient_notes == note_id\n    # if not, add",
        "label": 0
    },
    "222": {
        "output": "A: This was a bit of a puzzler but the answer turned out to be at the bottom of a page: the \"Trial-level Eligibility\" check boxes were not set to default, but they must be.\n<EOD> Hydrocephalus in a cat after surgery for a cranial feline infectious peritonitis lesion\n\nA 23-month-old female spayed Abyssinian cat was found as a stray. Three years previously, this cat was surgically treated for a cranial feline infectious peritonitis (FIP) lesion. On admission, the cat had a good general condition, except for moderate ataxia of the pelvic limbs. Neurological examination revealed diffuse hyperaesthesia. Magnetic resonance imaging revealed cerebral ventriculomegaly with dilatation of all cerebral ventricles. The third ventricle was compressed by the caudal cerebellar peduncle and the crop of the obex. Histopathological examination of the caudal feline encephalitis (a previous lesion) revealed diffuse, bilaterally symmetrical, randomly distributed granulomatous inflammation of the neuroparenchyma, with foci of necrosis and perivascular cuffing, which are characteristics of FIP lesions. Cerebral ventriculomegaly was attributed to previous granulomatous inflammation of FIP, together with chronic active granulomatous inflammation in the dorsal and ventral arachnoid membranes of the cerebrum.\n\n# Introduction\nFeline infectious peritonitis (FIP) is an invariably fatal disease that affects the majority of feline species. It can be divided into two forms: a dry form with few extracellular proteases and a wet form (hypodense) [bib_ref]  The natural history of an outbreak of feline infectious peritonitis, Coyne [/bib_ref]  [bib_ref]  Feline infectious peritonitis: proposal for a unifying mechanism, Bradshaw [/bib_ref]  [bib_ref]  Clinical and pathological features of a juvenile outbreak of",
        "label": 0
    },
    "223": {
        "output": "---\n\n### Exercises\n\n---\n\n[1] Hello. You are a helpful human assistant. You are going to assess patients` eligibility by comparing patients` notes to a selected clinical trial.\n\n1. Consider the following clinical trial:\n[c3] [c4] [c5] [c6] [c7][c8] \n\n1.1. Exercise 2. Find all patients that are not eligible.\n\n2. Exercise 4. Find all patients that are not applicable to the Trial.\n\n\n---\n\n>## The output data\n<EOD> Antimalarial and immunomodulatory activity of ethanolic seeds of Caesalpinia bonducella Fresen\nMalaria is a major public health problem. The immunity is the only way to combat malaria. Caesalpinia bonducella Fresen. is a widely distributed species in Asia and one of the most promising indigenous sources of immunomodula tory compound. In the present work, we evaluated the antimalarial and immunomodulatory activity of ethanolic seeds extracts of C. bonducella. Three organic extracts were evaluated as antima larial agents either in vivo (Swiss albino mice) or in vitro (Plasmodium yoelii\u2010infected erythrocytes). The leaf and stem bark ethanol and benzene extracts showed antimalarial activity 24 and 72 h pi, respectively, the leaf ethanol extract showed the highest activity compared to chloroquine, and the extract\u2010induced death of P. yoelii\u2010infected erythrocytes was significant (<0.0001). The ethanol fraction of the leaves revealed immune stimulatory activity as it raised the number of lymphocytes and phagocytic activities. Copyright \u00a9 2002 John Wiley & Sons, Ltd.<EOD> The association between antioxidant supplementation and the risk of prostate cancer: A meta-analysis\n\na b s t r a c tAn increasing amount of epidemiologic research, including a few meta-analyses, have",
        "label": 0
    },
    "224": {
        "output": "```\n[CODE]PATIENT_DESCRIPTION                                                                                                                                                                                                                                                                                    SCORE_CIRCULATION_RESISTANCE = {\"patient_description\": \"The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3-cm invasive ductal\\n\\000\\ breast cancer in the left upper outer quadrant. The tumor is HER2-positive and ER/PR\\n\\000\\ negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic\\n\\000\\ lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume\\n\\000\\ alcohol. She is not sexually active and has no children. She is a candidate for tumor\\n\\000\\ resection and agrees to do so prior to chemotherapy.\"}\nSCORE_AGE = {\"score_age\": \"45\"}                                                                                                                                                                                                                                                      SCORE_SMOKER = {\"score_smoker\": \"0\"}\nSCORE_DRINKER = {\"score_drinker\": \"0\"}\nSCORE_PHY_ACTIVE = {\"score_physically_active\": \"0\"}\nSCORE_CHILDREN = {\"score_childs\": \"0\"}  \n\nSCORE_HER2 = {\"score_her2\": \"2\"}                \nSCORE_ER = {\"score_er\": \"0\"}                                SCORE_PR = {\"score_pr\": \"0\"}\nSCORE_GRAVID = {\"score_gravid\": \"0\"}                                SCORE_HYPERTENSION = {\"score_hypertension\": \"0\"} \n\nSCORE_OVERWEIGHT = {\"score_overweight\": \"0\"}                                SCORE_OBESITY = {\"score_obesity\": \"0\"}\nSCORE_DIABETES = {\"score_diabetes\": \"0\"}                                SCORE_LI",
        "label": 2
    },
    "225": {
        "output": "**Trial-level eligibility: 0) Excluded.\n\nThis patient is not eligible for the trial, because the patient does not meet any eligible criteria but the trial's inclusion criteria.\n\n**Trial-level eligibility: 1) Not eligible.\n\nYou should try to find any eligible patient or any clinical trial for our given patient. Maybe this patient is already included in some trials.\n\n**Trial-level eligibility 2) Eligible.\n\nThis patient is eligible for the trial. <EOD> Numerical Investigation of Inertial Focusing in Microchannels\n\nInertial focusing is becoming an increasingly popular method to pre-focus biological particles based on both their density or size differences for flow cytometry applications. This paper presents a novel hybrid computational method for rapid and accurate multi-particle simulation and analysis that incorporates the recently discovered particle-based momentum transfer method. A series of numerical studies were conducted and showed that the particlebased momentum transfer method provided excellent agreement with the analytical solution for a wide range of conditions and was much faster and more computationally efficient than the Lattice-Boltzmann method, while keeping the same order of accuracy. Two additional studies were conducted to test the stability and accuracy of the hybrid method for microchannel arrays and to determine the most efficient manner in which to organize a particle ensemble in the inertially focused channel to improve focusing resolution. This work confirmed that accurate inertial-based particle focusing can be achieved with particle-based momentum transfer method by incorporating the momentum transfer as an additional force term in Euler equations. The proposed hybrid method can therefore be reliably used in the development of particlebased focusing and concentration in microchannels.\n\n# Introduction\nOver the past few years particle-focusing technology has become more attractive in biochemical applications, as a variety of different cell types can be separated using this technique. In recent years, microfabricated devices have allowed particle-focusing, and cell separation to be implemented on a compact and affordable chip-scale device for the analysis of sub-micron cell samples. Specifically, inertial-based methods have demonstrated remarkable potential for continuous focusing and separation of biological particles in microchannels.\nInertial focusing mechanisms typically indu",
        "label": 0
    },
    "226": {
        "output": "### The assessment of eligibility. \nIn order to make the clinical trial note and clinical data note coherent, the patient inclusion criteria should follow the inclusion criteria of the corresponding clinical trial. In this exercise, you should make a patient inclusion criteria and trial-level eligibility for the clinical trial note. \nThis exercise is performed in two steps. \n1. Compare inclusion criteria and patient clinical data note. 2. If patient information is sufficient to assess the patient eligibility, output the scale for the assessment of eligibility. \n\nIf you think this patient matches the criteria of the trial, input the code of the assessment of eligibility:\n\nif ___Inclusion criteria met___ & ___Triall-level eligibility____=2\n\nif ___Inclusion criteria not met___or ___Not sufficient information___\n\nif ___Inclusion criteria not met & ___Triall-level eligibility____=1_________\n\nif ___Inclusion criteria not met & ___Triall-level eligibility____=0___________\n\n_If the eligibility code matches the eligibility assessment code output a '1\u2032 in the variable eligibility assessment. [inst]\nExample of a dataset for an eligible patient:\n\n[Eligibility Assessment] Eligibility assesment number=1\n[Eligibility Code] Code number=1\n[Trial number] 3026\n[Trial title] Chronic toxicities related to treatment in patients with localized cancer\n[Trial summary] The aims of the cohort will be to quantify impact of cancer treatments toxicities, and to generate predictors of chronic toxicity in patients with non-metastatic cancer. Study of the original cohort will be focused on localized breast cancer patients, other localisation in non-metastatic setting will be explored furtherwise, fist of all in lung cancer.\n[Trial design] Cross-sectional survey\n[Exclusion criteria]\nThe designers of clinical trials are interested in quantifying exposure to different treatment combinations while they are also interested in quantifying the impact of the side effects.\n[Trial design] Cross-sectional survey\n[Exclusion criteria]",
        "label": 1
    },
    "227": {
        "output": "## Task 2: Predict a patient's eligibility for a clinical trial\n\nYou should predict a patient's eligibility using the classification models.\n\nFirst, you should split the dataset by `train`, `test`, and `val` folders:\n```\n# create folders for train, test, and validation folds # train_data: data for training model # test_data: data for testing # validation_data: data for predicting eligibility # -\nmkdir folds \ntraining validation testing\ncp ./data/training/* train/\ncp ./data/validation/* val/\ncp ./data/test/* test/\n```\n\nAfterwards, you'll fit logistic regression and random forest models. \n\nThe random forest models that you are going to implement are as follows:\n\n## RandomForestClassifier(n_estimators = 500, max_features = 'auto')\nThe best model will result from cross-validation using `GridSearchCV` as follows:\n\n```\nimport matplotlib.pyplot as plt\nfrom matplotlib import rc\nrc('figure.figsize', **{'lb': 10, 'mb': 30}) \nfrom sklearn.model_selection import cross_val_score, cross_val_predict\n```\n\nIn your first step, you should use the `GridSearchCV` parameter with the following `param_grid`:\n\n```python\nparam_grids = {\n    'classifiers': ['Logistic Regression']\n    'kernel': [\n        'GaussianRadial',\n        'GaussianProcessLSSVM',\n        'LinearSVC',\n        'PolynomialSVC',\n        'RBFSVC',\n        'SVKernelFunction'\n        'DotProductFunction'], \n    # other parameters of the parameters' grid\n}\n```\n\nHere is the results obtained using two classifiers (i.e., `random forest logistic regression`).\n\n\n\n```python\n# 5 folds with cross validation\nfrom sklearn.model_selection import StratifiedKFold\n\n# 5 folds with stratified cross vali-\n# dation\nscores = cross_val_score(model=classifier, cfn=1, cv=5)\n# Str",
        "label": 0
    },
    "228": {
        "output": "## \u2753 Challenge.\nThe patient note is incomplete. How will you continue?\n\n\n# RESULTS\nThe script, which you have seen in the section [DNN](https://github.com/PinLab/dnn-pytorch-tutorials/blob/master/03_deep_learning_with_pytorch/3_dnn.ipynb \"dnn\"), can automatically detect if a patient will or will not be enrolled in the trial. The result is written in the \"result\" column and is a 3-character string (e.g., **1**).\nThe output is consistent with the previous version, that is, it correctly classifies patients that are already in the dataset. Here, for example, the following are patients that passed the check and were classified as 1.\n\n\n[![IMAGE ABOVE](https://user-images.githubusercontent.com/31008354/71051366-69fd1600-2f39-11ea-8347-f36159a80a01.png)]()\n\nOn the other hand, these patients were classified as 0 by the model. \n\n\n[![IMAGE ABOVE](https://user-images.githubusercontent.com/31008354/71051376-7a49f700-2f39-11ea-8dd3-4fcad4d99a96.png)]()\n\nAs you can see, this model is now able to make 18 more predictions, but 16 are incorrect.\n\n## RUNTIME\n\nDetection is computed in:\n\n* **0.018 seconds** when using Tensorflow\n\n\n\n<EOD> Fetal hemoglobin modifies the association between red blood cell distribution width and new-onset diabetes mellitus after transplantation\n\n\n\n# Introduction\nRed blood cell distribution width (RDW) is a measure of the width of the red blood cell distribution and it is routinely used in the differential diagnosis between anemia and thalassemia and other inherited diseases that affect red blood cell size",
        "label": 0
    },
    "229": {
        "output": "The output should be 2) Eligible.\n<EOD> .\nIn this study, we determined the clinical value of endoscopic third ventriculostomy (ETV) in the treatment of spina bifida aperta with hydrocephalus. Seven cases suffered from spina bifida aperta with hydrocephalus who were treated with ETV of the third ventricle. All the patients had hydrocephalus due to spina bifida aperta, hydrocephalus was caused by tumefactive arachnoidal cyst of CSF, ventriculomegally of hydrocephalus and so on. ETV was successfully conducted in all these patients with total resolution of hydrocephalus on postoperative CT scans and no complications. All seven children underwent ETV, with the age range from 1 day to 5 years. A fourth patient had hydrocephalus due to CSF fistula, ventriculomegally of hydrocephalus and so on and was treated by ETV. All the patients had resolution of hydrocephalus. Three patients had post-operative complications and all of them required temporary ventriculoperitoneal shunt placement. The follow-up period ranged from 28 to 36 months. The author considers the operation to be highly valuable for spina bifida patients.<EOD> Antimicrobial resistance patterns of 102 \u03b2-lactamase-positive clinical isolates of Pseudomonas aeruginosa from a University Hospital in China\n\nAntimicrobial resistance is increasing in Pseudomonas aeruginosa clinical isolates. This study was designed to describe drug resistance and molecular characteristics of clinical isolates of P. aeruginosa collected at the China-Japan Friendship Hospital during a three-year period. We collected 102 clinical isolates of P. aeruginosa from an inpatient population, during the period from January 2013 to December 2015. Antibiotic susceptibility was performed and classified as susceptible (S) or nonsusceptible (NS). Resistance genes were tested by multiplex PCR. Of the 102 isolates, 96 were NS to one or more antimicrobials. In particular,",
        "label": 0
    },
    "230": {
        "output": "# D: Detective\nLet's think step by step. \nFinally, you should always repeat detective_rule.cls in the last line by `detective_rule.cls: 2) Eligible.`, i.e., `detective_rule.cls:\nTrial-level eligibility:\nRCT_title:Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone-Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer.\nTrial_title_2: A Phase III, Double-Blind, Randomized Trial of the Effectiveness of Adding Combined Estrogen Deprivation Therapy to First-Line Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab in Treating Patients With HER2-Positive, Hormone Receptor-Positive, Advanced or Locally Invasive Breast Cancer.\nexclusion_reason_1: Hormone-receptor-positive, HER2-positive, invasive carcinoma of the breast.\nexclusion_reason_2: Hormone receptor-positive, HER2-positive, invasive carcinoma of the breast.\nexclusion_reason_3: Hormone receptor-positive, HER2-positive, invasive carcinoma of the breast.\nexclusion_reason_4: Hormone receptor-positive, HER2-positive, invasive carcinoma of the breast.\nexclusion_reason_5: Hormone receptor-positive, HER2-positive, invasive carcinoma of the breast.\n\n# E: Effective\nLet's think step by step. \nLet's check how many cases are eligible for the first 11 factors. \nFinally, you should always `effective_rule.cls` in the last line by the `effective_rule.cls: 2) Eligible.`, i.e., `effective_rule.cls:\nRCT_title: Docetaxel, Car",
        "label": 0
    },
    "231": {
        "output": "<EOD> A Detailed Investigation on the Characteristics of the Interlayer Moir\u00e9 of 2D-MoSSe Monolayers\n\nThrough a detailed consideration of structural features, we present a model for explaining the nature and origin of interlayer moir\u00e9 in the 2D transition metal dichalcogenide (TMDC) monolayer. The model proposed here clarifies the relationship between the interlayer twist angles, the relative orientations of in-plane lattices, and the moir\u00e9 patterns. With our model, the moir\u00e9 patterns with different interlayer twist angles can be clearly understood and classified. We find that interlayer moir\u00e9 patterns are more common in monolayer TMDCs with trigonal crystals. Our results may help to understand the interlayer moir\u00e9 phenomena in 2D material research and will provide new insights for studying the interlayer moir\u00e9 patterns in TMDC superlattices.\n\n# Introduction\nAs the two-dimensional (2D) atomic crystals have been intensively investigated in recent years, new materials with rich structures and excellent optical, electrical and mechanical properties have been obtained. Compared with the three-dimensional (3D) materials, 2D atomic crystals are very flexible materials. Various types of 2D materials, including silicene, germanene, carbon nitride, transition metal dichalcogenides (TMDCs), black phosphorus, have been successfully synthesized using simple methods. As a class of layered 2D materials with large interlayer van der Waals and weak interlayer interactions, TMDCs usually exhibit layered structures with an AB or ABC layered structure depending on the type of atoms. When the stacking of the A and B layers is considered to be equivalent to a single layer, TMDCs are composed of S or Se atoms forming a 2D plane, and a variety of different stacking structures form due to the differences in the arrangement order of A layers and B layers.\nSimilar to grapheneand related two-dimensional (2D) materials, the layered structures of the TMDCs can also form moir\u00e9 patterns between adjacent layers. Interlayer moir\u00e9 patterns usually have some periodic bright-dark structures due to the mismatch in the atomic arrangement of the individual layers. The interlayer moir",
        "label": 0
    },
    "232": {
        "output": "You should always output the assessment for each patient:\nPlease let us know how it goes by submitting a pull request to https://github.com/TensorFlow/examples/pulls with as much detail as possible. For some background, see the [howto](#howto) below.<EOD> Identification of a novel mutation in the human CMP\u2010sialic acid transporter: Possible defect of sialic acid transport in a human renal proximal tubular cell line\nSialic acids exhibit a variety of glycan structures and contribute to many functional parameters, including the selectivity of molecular interactions between cells. Human sialic acid (Sia) is synthesized mainly in the erythrocyte, brain, and liver. However, the molecular mechanism underlying renal Sia transport is not well understood. We recently established a cell line from a patient with renal dysfunction (KU\u20101) and found that the cell proliferation of this patient was arrested in G2/M phase, and the cell death was accelerated during the G2 phase; thus, the cell cycle control in this patient was defective (Biochem. Pharmacol. 66:1955\u20131964, 2003). In the present study, the biosynthesis and distribution of Sia was examined in the kidney of a patient with renal dysfunction (KU\u20101) and a control. The quantity and the distribution of Sia in the kidney of the control and the patient were almost similar. The expression and amount of CMP\u2010Sia transport protein (CST), a transporter of Sia, were examined in the proximal tubular cells of a control by a Northern blot method and a biosynthetic pathway of Sia using pulse\u2010chase method. The quantity and localization of CST and the amount of Sia in the erythrocyte and urine in the control suggested that the patient with renal dysfunction (KU\u20101) had Sia transporter defects. The patient's erythrocytes showed a small amount of Sia, and most urinary Sia was derived from Sia of red blood cells (RBC), indicating the possibility that Sia transporters were defective in the patient's tubules.",
        "label": 0
    },
    "233": {
        "output": "<EOD> A Review of Biofabrication Techniques and Their Application in Neuroregeneration\n\n\n\n# Introduction\nRegenerative medicine is a highly promising field with much potential for treatment of neuroregeneration and spinal cord injury. While stem cell therapy has demonstrated great success, significant challenges persist, including poor engraftment of cells in injured areas, their inability to differentiate into a specific cell type, and difficulties in monitoring long term neuroregeneration. Another key factor in the field is the development of biomaterials, with scaffolds providing support for cells, delivery vehicles for growth factors and stem cells, and stimulators of cellular activation and differentiation into the desired neuronal lineage [bib_ref]  The influence of biomaterials and cell therapies on stem cell fate, Taradeh [/bib_ref] . Biomaterials used in tissue engineering have the role of delivering the desired cells, proteins, and growth factors to promote healing and tissue regeneration at the injury site. While various regenerative techniques are being researched [bib_ref]  Progress in Biofabrication: A Tissue Engineering Paradigm Shift, Guillemot [/bib_ref]  [bib_ref]  Three-Level Tissue-Engineered Bone and Cartilage Construct Based on Alginate/Nanohydroxyapatite Composite, Fan [/bib_ref]  , there is an increasing emphasis on improving neuroregeneration approaches, e.g., through combination with other regenerative medicine techniques [bib_ref]  Cranial neural tube closure in reptiles and its implications in humans and..., Maul [/bib_ref] .\nThrough recent developments in the fields of developmental biology and stem cell therapy, there has been improved knowledge of injury biology and neuroregeneration. An increasingly accepted understanding of disease biology has led to significant therapeutic advancements through biomaterials, regenerative medicine, nanotechnology, and 3D biofabrication [bib_ref]  Bioprinting for neural tissue engineering, Knowlton [/bib_ref] . The main aim of tissue engineering and the clinical translation process is to engineer healthy tissue mimics in vitro or in vivo to promote regeneration, repair, and restore lost functionality [bib_ref]  Three-Level Tissue-Engineered Bone and",
        "label": 0
    },
    "234": {
        "output": "<EOD> Excessive cerebellar activity as compared to the precentral gyrus in childhood absence epilepsy.\nA high incidence of the absence epilepsy during sleep and attention deficit in association with excessive cerebellar activity during nonrapid eye movement sleep suggests an underlying functional abnormality in the brain. To better understand the underlying nature of the functional abnormality in childhood absence epilepsy (CAE), we analyzed the scalp EEG synchronization between the cerebellar vermis and various cerebral regions while subjects performed a digit vigilance task (DVT). The results showed that the cerebellar vermis was significantly synchronized with the ipsilateral temporal region including the parahippocampal gyrus and occipital region during the DVT in 10 children with CAE who were taking anti-epileptic medication. However, the cortical regions which appeared to have significantly excessive synchronization with the cerebellar vermis during the DVT in children with CAE included the prefrontal cortex, postcentral gyrus, supplementary motor area and precentral gyrus. We tentatively draw attention to the excessive activity of the cerebellar vermis and functional disturbance of the precentral gyrus, which appears to be associated with excessive synchronization of the cerebellar vermis with the prefrontal cortex.<EOD> Rheological Properties of High Molecular Weight Polyethylene/Carbon Nanofiber Composite Filled with Fumed Silica Nanoparticles\n\n\n\n# Introduction\nNanocomposites are materials in which one or more nanoparticles are dispersed in a continuous matrix phase [bib_ref]  Effect of nanofiller morphology on the rheological, optical, structural and thermal behaviour..., Shanmugavel [/bib_ref]  [bib_ref]  The Effect of Nanoparticle Content and Nanofiller Molecular Weight on the Rheological..., Shanmugavel [/bib_ref] . Due to the synergistic interactions at the nanocomposite interfaces, the nanocomposite material can exhibit new properties related to the polymer matrix and nanomaterial [bib_ref]  Fabrication of High-Performance Nanocomposites: A Review, Dhand [/bib_ref] . Polymer nanocomposites containing carbon nanofiber nanom",
        "label": 0
    },
    "235": {
        "output": "#### Exercise 1.\nIn the following case, which of the following is incorrect about the patient's eligibility?\n\n\n|No|Explanation|\n|:---|---|\n|1. |`Age = 46, Gender = 1:` The patient is 46 years old.  |\n|2. |`Age = 48, Gender = 1:` The patient is 48 years old.\n|3. |`Age = 51, Gender = 1:` The patient is 51 years old.\n|4. |`Age = 46, Gender = 0:` The patient's Gender field is 0.  |\n\n#### Exercise 2.\nIn this set of patient cases, which patient would be excluded from the trial with this clinical trial? Why?\n\n\n|Exercise 2.|Result|\n|:---|:---|\n|Exercise 2.|Case 1: Patient 25|The patient 25 does not meet the inclusion criteria of the trial because they're in the <sup>1</sup> age group.  |\n|Exercise 2.|Case 2: Patient 62|The patient 62 does not meet the inclusion criteria of the trial because they're in the <sup>>4</sup> age group.  |\n|Exercise 2.|Case 3: Patient 2|The patient 2 does not meet the inclusion criteria of the trial because they're in the <sup>6</sup> ethnicity group.  |\n|Exercise 2.|Case 4: Patient 77|The patient 77 does not meet the inclusion criteria of the trial because they're in the <sup>2</sup> marital status group.  |\n|Exercise 2.|Case 5: Patient 24|The patient 24 does not meet the inclusion criteria of the trial because they're in the <sup>1</sup> race group.  |\n|Exercise 2.|Case 6: Patient 35|The patient 35 does not meet the inclusion criteria of this clin",
        "label": 2
    },
    "236": {
        "output": "##[INS]\nThe patient is enrolled in the clinical trial. However, the patient does not meet the inclusion criteria. \n\nPatient-level eligibility: 0\\&1\\&0 \nOutput: Excluded \nFinally, you should always repeat Patient-level eligibility in the last line by `Patient-level eligibility: 0\\&1\\&0`. [INST]\n\n##[INST]\nThe clinical trial is finished before the patient is enrolled to the trial. \n\nTrial-level eligibility: Not relevant \nOutput: Not relevant\n\n\nNow we can conclude that the patient may be eligible.\n\n### ANSWER TO Q5-Q9\n\n### Q5. The patient satisfies the following conditions:\n\n### Q5.1. The patient is female.\n\n### Q5.2. This patient meets age requirement (45 years old or older.)\n\n### Q5.3. The patient has cytologically confirmed invasive ductal breast cancer.\n\n### Q5.4. Lymph node metastases have been confirmed.\n\n### Q5.5. The patient has no children.\n\n### Q5.6. Cervical examination is not relevant.\n\n### Q5.7. This patient has not had any sexual intercourse over 90 days.\n\n### Q6. The patient will use all study drugs and will receive at least 1 cycle of study treatment.\n\n### Q7. The patient can continue for at least 16 days in the study.\n\n### Q8. The patient is healthy enough to receive study treatments.\n\n### Q9. We can expect to meet this patient in a 45-64 years old woman.\n\n### ANSWER TO Q2\n\nThe answer is `Yes`.\n\n### ANSWER TO Q3\n\n### Q3.1. The patient must satisfy three conditions:\n\n### Q3.2. She is a 45-year-old postmenopausal woman.\n\n### Q3.3. This patient must be eligible to participate in a clinical trial.",
        "label": 2
    },
    "237": {
        "output": "[INT] Hello. You are a breast cancer pathologist. Your task is to detect breast cancer metastases in lymph nodes.\n\nWhen diagnosing the condition of nodes, it is necessary to obtain material from the primary tumor as well as the surrounding structures. When assessing the pathological findings of the breast or axillary lymph nodes, the presence or absence of signs of a malignant neoplasm should be determined (tumor node [1][2][3][4]6]. \nHere are two cases: \nThis is a whole case without metastasis. \nThis is a case with metastasis. \n\nNow you should determine the malignancy of the breast cancer (1) or metastasis in the lymph node (2) for each case:\n1) Malignancy of tumor: benign. 2) Malignancy of tumor: malignant. 3) Malignancy of tumor: benign. 4) Malignancy of tumor: carcinoma in situ of ductal epithelium. 5) Malignancy of tumor: malignant. \n\nNow, you should put a tick in the corresponding row. [INT] Hello! You are a helpful assistant for clinical trial recruitment. Your task is to compare the patient's note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n\nThis patient meets the inclusion criteria of the clinical trial you are evaluating, namely [bib_ref]  Neoadjuvant chemotherapy plus trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone,..., Gianni [/bib_ref]  positive nodal status (cN+), (2) HER-2 receptor-positive status, and (3) presence of metastases in axillary lymph nodes. Hence, your assessment is 'Excluded'.\n[INST] Hello. You are a junior neuropathologist. Your task is\nto detect tumor metastases to the brain through radiographic imaging.\nThe presence of metastases to the brain is one sign of metastatic disease that determines patient eligibility to enter into a clinical trial. In this particular trial patient is a",
        "label": 1
    },
    "238": {
        "output": "You may need to repeat these steps for each patient who is being assessed for a study:\n\n- [INST] Get the next patient ID:\n    `getnextPatientID('patient'/patientName)` (the function returns a string)\n\n- Compare the patient information with the clinical trial inclusion criteria, and apply the proper treatment if needed (see \u25b6 Patient Level Criteria column from the table).\n    `function treatPatient(eid)` - `Treatment eid` input field will be disabled (e.g., it will be set to ''discarded'')\n\n- Calculate the patient weight column and compare whether it fits the range (see \u25b6 Weight column). The weights are calculated automatically, and their values are set for the given trial.\n    `function calculateWeight(eid)` - 0% or NaN for all patients\n\n- Repeat 2-4 for all patients.\n   `function repeatFunctions(patient) <br /> <br />    calculateWeight(patient) &rarr;`\n\n#### Error Handling\n\nIf one of the functions below triggers an error (e.g., because of a missing or non-numeric field in `patientName`) return a 500 HTTP code with an error body like below. You could also apply the following rules in Python's template engine:\n\n`{{ 'error.txt' | templates }} {{ 'error.txt' | templates }} {{ 'error.txt' | templates }} {{ 'error.txt' | templates }} {{ 'error.txt' | templates }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }} {{ 'error.txt' | filters }}",
        "label": 0
    },
    "239": {
        "output": "## Finding the problem\n\n### The [0] patient is using multivitamins and iron supplements (False)\nIt is not given that multivitamins and iron supplements are used, so the patient satisfies the inclusion criteria.\nIn clinical studies including trial 3AJ007N101H00001 and trial 18-152, both do not exclude patients using multivitamins and iron supplements.\n\n### The patient is 45 years old (True)\nIt is not given that the patient in trial 3AJ007N101H00001 is older than 18 and is not older than 60 years old. Therefore, the patient satisfies the inclusion criteria.\nIn trial 3AJ007N101H00001, the age of the first registration is between 18 and 60.\n\n### The patient has no children (True)\nGiven that the patient has no children, the trial's inclusion criterion is met.\nIn trial 3AJ007N101H00001, no children are required.\n\n### Sexually active patient (False)\nThe sexually active patient does not meet the inclusion criteria.\nIn trial 3AJ007N101H00001, the patient must not be sexually active at the time of enrollment.\n\n### The [2] patient has not undergone chemotherapy or radiotherapy or surgery due to breast cancer (True, the patient must have undergone those treatments)\nIn trial 3AJ007N101H00001, the patient must have undergone chemotherapy or radiotherapy or surgery due to breast cancer.\n\n### It is not given that the patient has undergone 5 surgeries (False)\nThe patient satisfies the trial's inclusion criteria because the following is given.\nIn trial 3AJ007N101H00001, the patient has undergone a core biopsy of the breast and axillary sampling.\nIn clinical studies including trial 18-152",
        "label": 0
    },
    "240": {
        "output": "(v) Case report\nThe patients in this study are a 20-year-old woman (with a height of 165 cm and a weight of 72 kg) and a 30-year-old man (height, 173 cm, weight, 80 kg) who are both healthy. After a careful review, we decided to construct a clinical trial using this data. The following table summarizes patient data in the study; this is patient data that was used for the construction of our clinical trial.\nThe research hypothesis is as follows: \nH0: There is no difference in the effectiveness of the two treatment groups\nH1: There is a difference in the effectiveness of the two treatment groups\nThe research design of the clinical trial is shown below.\n\n## Research design: a clinical trial plan using the dataset created by the case study\nThe randomized controlled trial (RCT) is a widely used and reliable method for clinical research. It can reduce bias and help provide more accurate results. It also gives doctors evidence for the safety and effectiveness of treatment options and helps determine optimal treatment dosage. In order to avoid bias in this clinical trial, we decided to adopt a crossover design. Our experimental design is such that both groups first receive the active medicine for 4 weeks. After that, they take a placebo for another 4 weeks. The entire process is conducted twice. A total of 30 healthy people are randomly assigned to each group in a 1:1 ratio. Each person takes the medicine and placebo after fasting for 12 hours in the morning. Then, blood is drawn from the antecubital vein to measure sugar levels and the number of red blood cells.\nData preparation: This study is based on collected blood samples. We need to convert values from the original raw data to an appropriate format and convert the data to a csv file. The data format must have two columns for each patient. Column A has the patient's unique identification number; B is the name of each patient, and C through E contain the measurement results of each patient. \nThe file name is as follows: CROSSOVERDATA_180701_1207.csv\n<EOD> The Role of Chromium Hexavalent Ions in the Enzyme-Catalyzed Oxid",
        "label": 0
    },
    "241": {
        "output": "You have implemented the elicit_patient_note function for eliciting patient note in [src/patient_test.py]:\ndef elicit_patient_note(patient_profile):\n    if not patient_profile.status_profile.current_trial_id == '' or not trial_id in patient_profile.status_profile.active:\n        return 'Trial-level eligibility: 0) Excluded.\\nTrial-level eligibility: 1) Not relevant.\\nTrial-level eligibility: 2) Eligible.'\n    else:\n        # Get patient note from the data source\n        patient_note = self.get_data('patient/note', self.clinical_trial_profile.record_profile.source_key)\n        if not patient_note:\n            return 'Trial-level eligibility: 0) Excluded.\\nTrial-level eligibility: 1) Not relevant.\\nTrial-level eligibility: 2) Eligible.'\n        else:\n            return patient_note\n[TEST] 13_02_19_patient_test00101 09:41:57:000 start INFO: Trial_elig_patient_note_37082_178: Trial-level eligibility = 2) Eligible\n 13_02_19_patient_test00101 09:41:57:000 Trial-level eligibility = 2) Eligible.\n\nIn [2]: patient_test.Patient_test.test_elicit_patient_note()\n---------------------------------------------------------------------------------------------------------------\ntest_elicit_patient_note() succeeded\n\n\n## 4) eligibility assessment for a given patient\n4_01_ Patient eligibility assessment and 7_01_ eligibility assessment should include the same conditions.)\nYou can get eligibility assessment for a given patient by making eligibility assessment for that patient within a patient_test object. This functionality is implemented in [src/patient_test.py]:",
        "label": 2
    },
    "242": {
        "output": "12. First, we retrieve the data from the clinical trial for the clinical trial identifier in the eligibility_check_code column. \nWe use both a clinical trial identifier as defined by the RE-ACTIVE trial and a non-unique clinical trial identifier that is only defined within the PDcheck application (clinicaltrial_identifier_x). \n13. Finally, you need to store the information in the `active_completed_clinical_trials` array, as illustrated in part 859. If you need to add other patient-level selection criteria in the future, you can store them in the corresponding elements in the `active_completed_clinical_trials` array. \n### Running PDCheck.\nYou can run PDCheck on a Linux or Unix operation system or on the Windows command line. \nIt is always good to start with a simple PDCheck run to try out the script, and then test more complicated runs by adding more patients one by one. For your convenience, we have added",
        "label": 0
    },
    "243": {
        "output": "## [INTERSTITIAL]\nIn [INTERSTITIAL] cases, you should output `Excluded` instead of `Not qualified` only for a trial that the patient doesn't meet all criteria.\nThe trial criteria to be matched should be in **boldface**, and they're the same way as for the regular eligibility cases discussed in the training section, just without the matching criterion of `CXR was remarkable for metastatic lesions`. So the input line for the patient note is:\nPatient is 45 years old post-menopausal woman with cytologically confirmed breast cancer and a core biopsy revealed 3cm invasive ductal carcinoma in left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes.\nYou should do the same as with the previous eligibility case. All matching criteria of the matching criteria should matched. The trial criteria should be boldface and be in **boldface**, and `CXR was remarkable for metastatic lesions` should be removed.\nNow the input to output is:\nPatient is 45 years old post-menopausal woman with cytologically confirmed breast cancer. Core biopsy revealed 3cm invasive ductal carcinoma in left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes.\nTrial-level eligibility: 1) Not qualified. [/INTERSTITIAL]\nThen the corresponding line to `Trial-level eligibility: ` is:\nPatient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer and a core biopsy revealed 3cm invasive ductal carcinoma in left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes.\nThe patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is seeking tumor resection and agrees to do so prior to chemotherapy.",
        "label": 2
    },
    "244": {
        "output": "[INST] Hello. You are a helper for clinical trial recruitment. Your task is to compare a patient's medical record note as well as the inclusion criteria, and make an assessment of eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level assessment of eligibility on each patient. \nHere is the patient note:\nThe patient is a 40-year-old female diagnosed with stage III neuroendocrine small cell lung cancer, a type of non-small-cell lung cancer. \nHistopathology: a large neuroendocrine tumor is diagnosed by biopsy. The Ki67 index is 80%. Immunohistochemical staining of tumor cells by the anti-synaptophysin antibody (clone MAB5298; lot GR25162011).\nMolecular tests on pleural effusion cytology reveal mutations in the TP53 gene. A mutation in the BRAF V600E gene is also described.\nBlood test: normal complete blood count and chemistry profile.\nHere is a clinical trial: \nTitle: Phase III Randomized Study Of Nivolumab and Topotecan in Patients With Advanced Neuroendocrine Tumors\n\nResearchers are searching for treatments to prevent tumor cells from invading the skin and other areas of the body. Nivolumab is a chemotherapy drug that blocks the ability of tumor cells to grow. Topotecan is a chemotherapy drug that stops tumor cells from dividing.\nThis study's goal is to determine whether:\n Nivolumab improves",
        "label": 0
    },
    "245": {
        "output": "##[INST] Here is the patient note:\nThe patient is a 68-year-old man. When he first visited our hospital two months ago because of anorexia. The CT showed two pancreatic tumors, and the patient was diagnosed with metastatic pancreatic cancer. No other metastases were found. The patient had taken medication to prevent an enlarged prostate. Other medical conditions include prostate diseases and diabetes.\n\nNow let's evaluate the previous patient note:\n> trial:\n> trial:\n  * The patient's age (68 years old) meets the trial's upper age limit.\n  * The patient's gender (male) meets the trial's gender characteristics",
        "label": 0
    },
    "246": {
        "output": "5) Outputting the Patient ID: You can output the patient ID number in the patient note by calling your user interface and running it with the patient note as the argument, `ui(\"Patient ID\")`.\n6) Converting the patient note to HTML and saving in pdf: To save the note of the patient in the PDF format, use <xref target=\"patient_id_0\"/> to get the patient ID code, save the PDF file by writing a Python command, `File(\"MyNote.pdf\").save()`, and the PDF file will be saved in the same folder with your patient note. [INST] If you don't output anything in 3) and the trial-level eligibility is set to `Excluded`, you should return 0 (0) according to the `patient_id_0` command.\n[INST] `Trial-level eligibility: Excluded` does not mean the trial cannot take place. Instead, the patient is excluded on the grounds of the trial's exclusion criteria. This happens when a patient with a severe medical condition is found eligible by the eligibility criteria, but the trial cannot take place for this patient due to an exclusion criterion.\n[INST] 1) Write a Python command using <var name=\"patient_id.Trial-level eligibility\">, e.g. `File(\"Notebook-6/patient_id.Trial-level eligibility\")`, to read the code. If you are in the `patient_id_0` mode, the result should be shown in the notebook as an output.\n[INST] If you don't output anything in 3) and the trial-level eligibility is set to `Not relevant`, you should return 2 (Not relevant).\n[INST] `Trial-level eligibility: Not relevant` means that there is not enough information in the patient's current records for the researcher to make a decision on whether or not to include the patient in the clinical trial.\n[INST] 1) Write a Python command using <var name=\"patient_id.Trial-level eligibility\">, e.g. `File(\"Notebook-6/patient_id.Trial-level eligibility\")`, to read the code. If you are in the `patient_",
        "label": 0
    },
    "247": {
        "output": "# Tutorial\n\n## Prerequisites\n\n149:00\n\n### Installation\n<h3 id=\"INST\"> Installation and configuration</h3><p>Installation of R and RStudio</p><p>Install R and RStudio by following the instructions in the first part of the install.r script on how this is installed into Linux containers and the second part of the install.r script how to install it into macOS.</p><p>Please look carefully at the instructions in <code>Installs.md</code> to be assured that R and RStudio are really installed correctly and properly.</p><p>The install.R script uses <code>R.install.packages.list.txt</code> that can be copied to the script as indicated in the <code>Instals.md</code> document.</p><p>Check if R and RStudio is really and completely installed and functional by typing <code>library(devtools)</code> and pressing Enter. R is correctly installed if a screen pops up as described below: (If the R installation was successful.)</p></p>\n\n```r\nR version 3.6.1 (2019-07-05)\n\nR Tools Version: 3.6.1\n\n(Running under Debian GNU/Linux 9.10, 64 bit)\n\n** Install packages and load the libraries **\n```\n\n- If R cannot be found at this time, type <code>exit(1);</code>, press <code>enter</code> again and then type <code>Rc</code>; for Windows and <code>Rsw</code> for MacOS. (Rc for Windows and RWin for MacOS).<br>\n- If R works but it does not contain an installation of Tidyverse, typing <code>install.packages(c(\"dplyr\", \"ggplot2\", \"stringr\", \"gtable\", \"tidyr\", \"dplyr\", \"purrr\", \"stringr\", \"readr\", \"patchwork\", \"plotly.\", \"scales\"))</code> into the R console or console window, i.e pressing <code>install.packages(<code>c(\"dplyr\", \"ggplot2\", \"stringr\", \"gtable\",",
        "label": 2
    },
    "248": {
        "output": "Now, let's continue the assessment of eligibility. Since multiple data files are processed, `sdata` is a convenient variable that contains some necessary data. We'll refer to this variable in the following codes.\n\nAssess eligibility by `sdata.`\n`sdata.age_categorical = 2:7` \n`sdata.categ_tumor = 100001000` \n`sdata.chemo_recode = 1` \n`sdata.disease_recode = 1000110000` \n`sdata.gender_recode = 1` \n`sdata.hormone_recode = 1` \n`sdata.inpulmonary_recode = 1` \n`sdata.metastasis_recode = 1` \n`sdata.operable = 1` \n`sdata.patho_diagnode_recode = 1` \n`sdata.stage_recode = 1`\n`print(\"Eligible = {0}, not eligible = {1}\".format(sdata.eligible, sdata.not_eligible), file=output_file)`\n\nFor the following input file, 45 is the age of the patient. \n\n[!INST] Hippolytus.txt\nHippolytus, 45, 800011200,\nBreast Neoplasms, 925011100,\nMale, 1,\nYes, 1,\nNo, 2,\n1, 5, 1,\nNeoplastic Process, 350010000,\nAbnormal Growth, 350020000,\nInfiltrative, 350001000,\nYes, 1,\nNo, 2,\nHospitalized Inpatient, 780008209,\nYes, 1,\nNo, 2,\nNo, 2,\nNo, 2,\nNo, 2,\nHospital",
        "label": 1
    },
    "249": {
        "output": "[INF] There are a few things to note in this paper.\n\nFirst, the following code should be placed under the `evaluation function()` to obtain the eligible count and proportion. [INST]\n\nSecond, to get the number of patients who were not included (0) in a particular trial, this should be added to the patient count. [INST]\n\nThird, to calculate the proportion of inclusion eligibility, it is necessary to divide the number of patients who were included (2) by the total number of patients (3). [INST]\n\n``` python\nevaluation_function(pw, pw_notes, trials, out_path)\n    \n\npw_notes.loc[trials['trial_level_eligibility'] == 'Excluded', 'inspath'] = 0\npw_notes.loc[trials['trial_level_eligibility'] == 'Not relevant', 'inspath'] = 0\npw_notes.loc[trials['trial_level_eligibility'] == 'Eligible', 'inspath'] = 1\n\nineligible_count =  pw.loc[trials.trial_level_eligibility == 0, 'inspath'].sum()\neligible_count = sum(pw_notes.loc[trials['trial_level_eligibility'] == 'Eligible'][['inspath']],\n                     subset = {x.trial_id: trials.index[x.trial_id]})\n\n# proportion of inclusion\ninclusion_eligibility_proportion = eligible_count / (eligible_count) + ineligible_count #(3, 3)\n```\n\n[INF]\n\n[/INF]\n\n### Other notes\n\n- the trials should be indexed by trial_id according to the index of the observation in your patient_weights dictionary. Use the index when you create the index, i.e., pw_notes = pw_notes.loc[trials['trial_id'] = trials.index].copy()\n- trials should be indexed by trial_id as well\n- the `evaluation_function()` should return the el",
        "label": 0
    },
    "250": {
        "output": "## How you should repeat the following steps...\n\n### First Step\n\n**Step 1 **: The first step is to determine if any of the 6 patient factors are listed as \"Not Relevant\" or \"Excluded\".\n\n### Second Step\n\n**Step 2**: If any of the patient factors are Not Relevant or Excluded, continue with Step **3** and do not go further. If all the patient-level factors are \"Not Relevant\" or \"Excluded\", print the following information, then end the program.\n\n**Step 3**: If all the patient-level factors are \"Not Relevant\" or \"Excluded\", continue with Step **4** and do not go further. Print the scale on the eligibility of the patient in this trial, then end the program.  \nIf any of the patient-level factors are Eligibility, continue with Step **5**. If any of the patient-level factors are Not Relevant or Excluded, go to Step **4**. \n\n### Third Step\n\n**Step 3**: If any of the patient factors are Not Relevant or Excluded, continue with Step **4** and do not go further. If all the patient-level factors are \"Not Relevant\" or \"Excluded\", print the following information, then end the program.\n\n\n**Step 4**: If all the patient-level factors are \"Not Relevant\" or \"Excluded\", continue with Step 5. Print the scale on the eligibility of the patient in this trial, then end the program. \n\n### Fourth Step\n\n**Step 4**: If any of the patient factors are Eligibility, go to Step **5**. If any of the patient factors are Not Relevant or Excluded, go to Step **4**. \n\n### Fourth Step\n```python\nTriallevel_eligibility=1\n``` \n\n### Fifth Step\n\n**Step 5**: If the clinical trial is about the breast cancer treatment, continue with Step **6**. If the clinical trial is about the treatment of other cancers, go to Step **7**. \n\n### Sixth Step\n\n**Step 6**: Continue with Step **7**. If you see the patient, print the",
        "label": 0
    },
    "251": {
        "output": "## [EXAM] The assessment of clinical trial eligibility\n<H1 title=\"Exam Problem</title>\n<p>The assessment of clinical trial eligibility</p>\n<h2>You are a helpful assistant for clinical trial recruitment. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n\nYour task is to assess clinical trial eligibility on patient 3, which is the example provided by <a href=\"http://cran.r-project.org/web/packages/Exam/faq.html\">the Exam package</a>. The assessment of eligibility has a three-point scale:\n0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).</p>\n<h3>Here is the patient note:</h3>\n<ul>\n<li> The patient is a 45-year-old postmenopausal woman with cytologically   confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.</li>\n<li> Here is the clinical trial:</li>\n<ul>\n<li> Title: Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer</li>\n<li> Summary: This pilot",
        "label": 0
    },
    "252": {
        "output": "![](https://cloud.githubusercontent.com/assets/130268/14985146/b4cb01c0-0430-11e6-89da-082769e77780/picked.png)\n\n<NAME>: [INST] A: What do we have to pass to determine the patient's eligibility?[INST] \n<NAME>: [INST] We need an assessment of eligibility from the individual components. Each component requires a separate evaluation of the patient for the clinical trial.\n<NAME>: [INST] Let's define a patient eligible only if he or she fulfills all the inclusion and does not violate any of the exclusion criteria. \n\nThe assessment of eligibility has a three-point scale: 0) Excluded, 1) Not relevant, and 2) Eligible.\n\nI would consider the patient eligible if he fulfills the inclusion criteria.\n\n**[INST] The eligibility assessment for patient notebook is shown above. What's the next step of our task? **\n\n<NAME> 45 years old woman\nAge, gender, previous breast cectory, \n- postmenopausal : yes\n- premenopausal : no\n- history of estrogen therapy : no\n- history of radiotherapy : no\n- history of hormone therapy : no\n- history chemotherapy : no\n- history menopausal : postmenopausal\n**[INST] Please show your evaluation for the clinical trial. You have to evaluate each component of the clinical trial. Please make an assessment for the trial-related criteria as shown above. ** \n\n<NAME> 45 years old woman\nPatient notebook:\n- No\n- Yes\n- Assessment of eligibility: trial level\nPatient notebook:\n- No\n- Yes\n- Assessment of eligibility: trial level\n- Assessment of eligibility: trial level\n- Assessment of trial eligibility: 2) Eligible\n- Assessment of trial eligibility: 2) Eligible\n- Assessment",
        "label": 2
    },
    "253": {
        "output": "![INST]\n\n[INST]\n```bash\n./evaluate-clinical-eligibility.py -c clinicalTrial.tsv -p path-to-patient_note.pdf -p-patient-level-eligibility-out put-path /patient-level_eligibility_output.txt\ntrial-level-eligibility: 2) Eligible.\n1) Not relevant.\n0) Excluded.\n```\n\n[INST]\n![INST]\n<EOD> The role of CSF2/GM-CSF and JAK-STAT5 signaling pathway in schizophrenia.\nOBJECTIVE\nThe purpose of this review is to highlight mechanisms of the regulation of CSF2/GM-CSF, JAK/STAT5 and their pathways in schizophrenia.\n\n\nMATERIALS AND METHODS\nThe biomedical literature search was conducted by using PubMed and Google Scholar for the following keywords: \"gmcsf, \" \"schizophrenia, \" \"stimulation signals, \" \"JAK, \" \"STAT, \" \"signal transduction, \" \"CSF2/GM-CSF, \" \"JAK-STAT5/pathway.\"\n\n\nRESULTS\nCSF2/GM-CSF, a member of the large cytokine-family, is a key protein in the activation of the JAK/STAT5/pathway. The major role of CSF2/GM-CSF is to mediate the cell proliferation during myeloid differentiation. The CSF2-dependent induction of CSF1 receptor/CD115, a transmembrane receptor tyrosine kinase, in the developing oligodendrocytes in the brain and the generation of microglia from non-resident bone marrow-derived monocytes in the brain under conditions of neuronal injury are also important. CSF2/GM-CSF/JAK/STAT5 signaling could also participate in neuroprotection during brain development, neuroinflammation and neurodegeneration.\n\n\nCONCLUSION\nThe CSF2/ GM-CSF, JAK/STAT5, and JAK-STAT5/path",
        "label": 2
    },
    "254": {
        "output": "<EOD> P53 status predicts response and outcomes of immune checkpoint inhibitor-based therapies in metastatic NSCLC\n\nPurpose: Although immune checkpoint inhibitors (ICIs) have been incorporated into the first-line treatments of non-small cell lung cancer (NSCLC) with a high PD-L1 expression, the predictive role of P53 signature in anti-PD-1/PD-L1 therapy remains incompletely understood.Methods: This multicenter, retrospective study recruited NSCLC patients with advanced stages. The TCGA-NSCLC database was used to predict the correlation between P53 signature and ICIs among NSCLC patients with different statuses of EGFR, KRAS, ALK and RET mutations. The effects of P53 signature on response and adverse events of ICIs were systematically evaluated in clinical cohort.Results: The 727 NSCLC patients in TCGA database were divided into two groups: P53 signature-low and P53 signaturehigh. Compared with ICIs treated group, patients in P53 signature-low group exhibited a better overall survival (OS), progression free survival (PFS) and objective response rate (ORR), while more incidences of adverse events (AEs), especially of low-grade AEs, were observed in the high group. In further cohort of 98 NSCLC patients, the ORR in P53 signature-low group (35.91% [9/25]) is higher than that in P53 signature-high group (14.29% [6/42]) without statistical significance (p=0.116). The OS and PFS in P53 signature-low group (9.41months, 87.14% and 5.96 months 69.17%) were obviously higher than these in P53 signature-high group (4.33months, 57.55% and 1.44 months 30.20%) (p=0.003; p=0.006). Furthermore, the incidences of \u22653-grade AE (RR =0.431, 95%CI",
        "label": 2
    },
    "255": {
        "output": "# Exclusions\n\n### INST_EXCLUSIONS\nYou should exclude patients whose notes satisfy at least one of the exclusion criteria in the following cases:\n- Patient is younger than 18 or older than 85\n- Patient is underweight or obese (BMI < 18.5 or > 45.0)\n- Patient is having any other illnesses or comorbid conditions such as acute liver failure, acute renal failure, hemorrhage, pneumonia or congestive heart failure.\n- Patient has a high fever of 38\uf0b0C or greater, or a low fever of less than 35\uf0b0C.\n- Patient abuses alcohol (e.g., > 5 drinks per day on a regular basis).\n- Patient tests positive for alcohol, cocaine, or amphetamines.\n- Patient uses tobacco products.\n- Patient has had an allergic reaction to any medicines previously.\n- Patient has a history of taking vitamins or other nutritional supplements within the past year.\n- Patient does not understand the study requirements and risks.\n- Patient is pregnant or breastfeeding.\n- Patient has other exclusionary criteria that the doctor knows about (e.g., a doctor knows that your patient might experience a specific adverse effect of a study drug).\n\n## Exclusions from the clinical trial\nIf a patient's medical record satisfies any of the following criteria, they will be excluded from the clinical trial:\n\n### CT_EXCLUSIONS\n\n- Previous mastectomy\n- Surgical resection for breast tumor more than 1 month ago\n- Known allergy to the study drug used\n- Any cancer of the brain or nerves\n\n***\nThe above eligibility criteria are the general rules that all hospitals implement (or should implement) for recruiting patients. They are relatively uncomplicated to perform.\n\n\n### Clinical trial-specific eligibility criteria\nClinical trials typically have some additional criteria that will be used to identify eligible patients during the screening process. Patients satisfying these criteria will be called **pre-",
        "label": 0
    },
    "256": {
        "output": "[TUT2] Title\n\n    Assigning patients to clinical studies in the same category\n\n    You are a responsible clinical trial coordinator. Your task is to assign patients to clinical studies based on their characteristics without the help of a computer. You need to check the requirements of clinical studies and use the data to match each patient and clinical study.\n\nAssigning patients to clinical studies means selecting the study in which the patient is most likely to benefit based on his or her characteristics. You should assign patients to clinical studies in the same category and choose the most appropriate study within the same category for each patient.\n\nPlease use the patients in  `List of 40 patients`  to assign study patients. Please consider the following criteria when deciding which studies to register.\n\n    &middot; The patients in `List of patients who have the characteristics of clinical study` should be listed in study-specific categories.\n\n    &middot; The patients in remaining categories should be listed in the study-specific category.\n    &middot; The patients who cannot be assigned in clinical studies should be listed at the end of the assign-study category.\n\nList of patients who have the characteristics of clinical study: \n\nClinical trials targeting HCC patients:\n\n[TUT3] Abstract\n\n    Summarized the information of patients and clinical trials\n\n    Abstract class: Patient and Clinical Study\n\n    Parent class: ClinicalStudyData\n\n    Parent class: Data\n\n    Children class: 1. Patient;\n    2. Clinical Study;\n    Parent class: Patient\n\n    Children class: List-MostRelevantClinicalStudiesForPatient\n\nYou should summarize the information from the last five patients in the above four tables. Below is the patient information for the patient 29 and the associated trials: \n\nPatient 29:\n\n    Patient-ID: 29\n    Name: William Anderson\n    Gender: Male\n    Age: 57\n    Phase: I\n    Disease: Lung Cancer\n    Disease status:\n    Therapy:\n    Therapy status:\n    Treatment:\n    Treatment status",
        "label": 0
    },
    "257": {
        "output": "Note that the `Trial-level eligibility: ` is mandatory and you must report a case as `2) Eligible` if patient is eligible as determined by your assessment according to the inclusion criteria and the exclusion criteria (if applicable)?, for which the patient has written informed consent? [INST]\n\nIf all the information on the clinical trial form was correct, it would be saved in the Eligibility Assessment for a Clinical Trial table, and the patient would receive a 17-point eligibility assessment code:\nThe patient is 45 years of age (1 point), she has confirmed breast cancer (1 point), the tumor is HER2 positive, which corresponds to the category A classification of Her2 (1 point). \nThe patient agreed to do chemotherapy (1 point), but refused to do so (1 point). \nIn terms of surgery, the patient is in favor of a breast biopsy (1 point), but is not prepared for a breast biopsy (1 point). \nThe patient is not willing to participate in any clinical trial (2 points). \nIn terms of treatment, the patient is not satisfied with surgery, and prefers drug treatment at this stage (1 point). \nThe patient smokes (1 point), but she is fully aware of the risks of smoking (1 point).\nThe patient is fully compliant with the instructions (1 point), and she understands what is written on the drug leaflet (1 point). \nBased on clinical data, the patient has no contraindications to take part in the clinical trial (1 point).\nIn terms of side effects, the patient does not want any side effects at all (1 point). \nShe is fully aware of the risk of a serious drug interaction (2 points). \nShe is fully aware of the risk of adverse drug reactions (1 point). \nRegarding pregnancy, she understands the risks (1 point). \nRegarding lactation, it is fully explained to her that with breastfeeding the drug would be excreted in breast milk (e.g., not the active substance, but metabolites, and in very low concentrations), and she should know that this is not acceptable for her baby (1 point). \nThe patient",
        "label": 0
    },
    "258": {
        "output": "### Sample data\n\n- File `clinical_trial_data1.csv` is from the `Data` folder. All clinical trial and patient data from the file are pre-processed. Each entry is separated by commas.\n- File `clinical_trial_data2.csv` is from clinical trials whose data has been processed. Categories are added. It is a CSV format file, too.\n\n\n```python\nimport pandas as pd\nimport numpy as np\nimport matplotlib.collections as col\nimport io\nimport os\nfrom sklearn.mixture import GaussianMixture\nfrom scipy.spatial import cKDTree\nfrom sklearn.manifold import TICA\nfrom sklearn.cluster import MiniBatchKMeans\nfrom sklearn.metrics import bal_error_rate, balance_acc_weighted, silhouette_score, cosine_similarity\n\npd.options.display.max_rows = 650\n```\n\n#### Data import\n\n```python\nclinical = pd.read_csv(\"clinical_trial_data.csv\")\npatients = clinical[\"patients\"]\n\nfrom sklearn.base import DataNode, ClusterNode, Node\n\npatient_set = col.Colormap(\"Grey\", c={1:1,\"2\":0,\"3\":0,\"4\":0,\"5\":\"orange\"} )\ngp = GaussianMixture(n_components=18)\n\ntrial_nodes = MiniBatchKMeans(n_components=64).fit_predict(clinical)\ntrial_nodes\n```\n\n\n#### Tissue core biopsy classification\n\n```python\nfrom sklearn.clustering import kmeans\n\nkmeans = kmeans(trial_nodes[\"cluster_labels\"], n_clusters=2)\nkmeans.fit()\n```\n\n\n#### CKDA\n\n```python\nCKDAT = cKDTree(kmeans.points, leaf_size = 0)\n\n```\n\n\n```python\npatient_graph = {node:set(k) for node,k in trial_nodes.items()}\n\n# CKDA: CKD Tree",
        "label": 2
    },
    "259": {
        "output": "If you get a different program after executing any changes, there is likely an error message in the output console. If you cannot understand the error message, please use the <a href=\"{{site.docroot}}/learn/source/source-level_help.html\">console help</a> below.\n\n# Console Help\n\n### console-consolehelp\n\n### console-source-consolehelp\n\n### console-source-install\n\n### console-source-reinstall\n\n### console-source-uninstall\n\nYou can find a lot of information using the console. The console contains instructions you can follow in its default configuration. There\nare three commands for console help: `console-source-consolehelp`, `console-source-install`, and `console-source-reinstall` are the first three commands in its default configuration.\nYou can type `console-source-consolehelp` in the output console to display commands for console help.\n\nThere is an explanation of the output of `console-source-reinstall`. Also, there was the following error when executing the command.\n``` console\nconsole_version 2.6    console_time 2018-06-01T20:19:10.611361Z\nconsole_path     home/vvchung/R console console console_lib/bin  console_file/log/  console_version_info\nconsole_recycle_file console_recycle_dir log log/\nconsole_recycle_max 1000 console_recycle_wait 5000\nconsole_recycle console_recycle console_recyc_dir log\nconsole_uninstall console_uninstall console_uninstall_file_dir\nconsole_uninstall_file console_install console_uninstall_dir log/\nconsole_uninstall_file_root console_uninstall_recycle log\nconsole_uninstall_recycle log/\nconsole_uninstall_recyc console_recycle console_uninstall_dir log\nconsole_uninstall_total console_uninstall console_uninstall_recyc\nconsole_vocabulary console_vocabulary_dir vocabulary/\nconsole_vocabulary_file file_dir vocabulary\nconsole_voc",
        "label": 0
    },
    "260": {
        "output": "Let's try it below. \n> let=patients=[\"Bloch_etal_2010.xml\"]\n> [\n>      for x=xrange(0,len(let)-1) do\n>          if let['id']==\"Bloch_etal_2010_45.xml\" and (1==sum(let['eligibility']==\"Excluded\") or match(\"2)\",to_lower(let[x]['assessmentOfEligibility']['clinicalStudyEligibility']['comment'])))then\n>              print(\"Excluded (Patient has sufficient information)\",to_lower(let[x]['clinicalStudyEligibility']['clinicalStudyEligibility']['comment']))\n>              print(\"Not relevant\") >print(\"Eligible\")\n>             else\n>              if(2==sum(let['assessmentOfEligibility']['clinicalStudyEligibility']['comment']=='Not relevant') or \n>              not any(\n>              x==2 for x in list(set(x for x in let['assessmentOfEligibility']['clinicalStudyEligibility']['comment'] if\n>              x=='Not relevant'))\n>              )) and\n>              and sum(let['assessmentOfEligibility']['clinicalStudyEligibility']['comment']=='Eligible')>0) then \n>              if(sum(let['assessmentOfEligibility']['clinicalStudyEligibility']['comment']=='Eligible')>0)then \n>              print(\"Eligible (Patient has sufficient information)\",to_lower(let[x]['clinicalStudyEligibility']['clinicalStudyEligibility']['comment']))        \n>              else\n>                print(\"Eligible (Patient does not have sufficient information)\",to_lower(let[x]['clinicalStudyEligibility']['clinicalStudyEligibility']['comment']))     \n>              \n>              print(\"Not relevant\")\n>              \n>             print(\"Excluded (Patient has sufficient information)\",to_lower(let[x]['assessmentOfEligibility']['clinical",
        "label": 0
    },
    "261": {
        "output": "## [END]\n#4:\nYou should have this kind of results. \n\n| Eligible (47)\n| :ref:`NotRelevant` (2)\n| Excluded (5)\n\n### Tutorial 1: Predicting Drug Sensitivity\n\nWe often compare the patient's cell line response from cell linedata to clinical outcome data, e.g., by assessing differences in sensitivity or resistance of the cell lines to drug treatment. This analysis requires knowledge of the clinical trial in which the response of the samples was assayed. Here, we describe how to link the clinical trial data to the experiment data from which those cancer cell line responses\nwere derived.\n\nFirst, go to the top link of the website (as described above) and choose the function,\n\n[![INST:\n](https://raw.githubusercontent.com/GraceBioinformatics/gracemanual/master/book_16/Figure_16_1_1.png)]\n![INST:\n](https://raw.githubusercontent.com/GraceBioinformatics/gracemanual/master/book_16/Figure_16_1_2.png)]\n\nSelect the name of the clinical trial, e.g., HNSCC_104479_85. As an example, we will use clinical trial NCT00411163. Then, choose the data download option in the upper menu bar.\n\nAfter choosing clinical trial data and the data access type (see above), your browser will be redirected to a new page. You will see the results of all cell lines available from GDSC Cell Line Dataset. \n\n#### Cell Line Data Direction/Selection\nBefore starting to retrieve clinical trial data, you can verify which cell lines \nare available for a given clinical trial under the **Preview cell line data**\nheading in the upper menu. Select \n`Download cell line data\nas\ncsv` to find all the cell lines that have been assayed in the clinical trial.\n\nNext, specify the type of data accessed. Check the **Cell Line Data** option to select the data download mode (e.g.,\n`Data Sets/Data Sets",
        "label": 0
    },
    "262": {
        "output": "## 18.4.7) [INST] Recurrent/metastatic (MBC)\nYou should make trial-level eligibility in the last line by `Triage note to [Trial-level eligibility]:`, e.g., `Triage note to [Trial-level eligibility]: 3/3, 1/2, 1/2. [INST].`\n\n## 18.4.8) [INST] Excluded\nYou should add all `NOT eligible` trips to the [Triage note to Not eligible].\n\n## 18.4.9) [INST] Eligibility assessment\nYou should make eligibility assessment in the last line by `Eligibility assessment: 2) Eligible; 1) Not Eligible; 0) Excluded. [INST]`, e.g., `Eligibility assessment: 2) Eligible; 1) Not Eligible; 0) Excluded. Clinical Trial 11114: Exclusion due to comorbidity or severe pre-existing disease; Clinical Trial 33333: Comorbidity due to diabetes control 3 years ago. [INST]`\n\n## 18.4.10) [INST] Assessment of trial exclusion criteria\n(1) You should answer all exclusion criteria by yes or no. The exclusion criteria of trials are shown at the right side of each patient. If an exclusion criterion is applicable, then it should be marked by yes. As you examine a patient, you should answer all exclusion criteria by yes in every assessment or put nothing in parentheses in the patient record. As shown below, '1) Not applicable; 0) Applicable' means that an exclusion criterion is not applicable, '0) Applicable; 1) Not applicable' means that an exclusion criterion is applicable, and '2) Applicable; 2) Not applicable' means that an exclusion criterion is applicable with an exception. Trial NET0033: 'Inclusion criteria', for 'age', 'over 18 years', is '13 to 95 years' for the age. It means that one patient over",
        "label": 0
    },
    "263": {
        "output": "# <NAME> 2021\n[TUT2][SUP1] [SRC1] \n\n**Objective:** We will work on the assignment which we got in class. **Task:** Choose one or more data records from the data records dataset and then write each of their properties:\n\n* [INST] What type of data record is it?\n* Write each of the following properties of the chosen data record:\n    * UniqueID\n    * Name\n    * Age\n    * BloodGroup\n    * EyeColor\n\n\n#### ## [TUT3][SRC1]\n\n```python\nimport numpy as np\n\nclass Trial:\n    def __init__(self, _name=\"NAME\", _title=\"TITLE\", _study_start=\"STARTL\", _study_end=\"ENDL\", _contact=\"CONTACT\", _study_sponsor=\"SPONSOR\", _study_location=\"LOCA\", _purpose=\"PURPOSE\", _condition=\"CONDITIONS\",\"target_duration=\"TARGET\",_primary_output_param=\"OUTPUT\",_exclusions=\"EXCLUSIONS\"):\n        self.id=\"UniqueID\" \n        self.name=\"Name\"\n        self.trial_name=_name\n        self.trial_title=_title\n        self.study_start_date=datetime.datetime.strptime(str(_study_start),\"%Y%m%d\")\n        self.study_end_date=datetime.datetime.strptime(str(_study_end),\"%Y%m%d\")\n        self.study_sponsor=_sponsor\n        self.trial_location=_location\n        self.trial_description=_condition\n        self.study_purpose=_purpose\n        self.study_contact=_contact\n        self.study_number=_target\n        self.study_duration=_duration\n        self.study_duration_unit=\"day\"\n        self.trial_phase=_phase\n        self.sponsor_contact=_sponsorcontact\n        self.funding=_funding\n        self.trial_",
        "label": 0
    },
    "264": {
        "output": "## Hello. You are a job seeker. You have not gotten a job, so you want to try to find one. You know that there are many ways to look for a job. You like to understand how companies recruit job candidates. So, you need to find a way to get to know more about how companies recruit job applicants. \n\nSo, you want to search various ways on how companies recruit job-applicants. \n\nHere are the keywords to search: **job**, **apply**, **career**, **careers**, **work**, **jobs** and **career**. Here are the details in each one:\n\n![Detail of job]\n![Detail of career] \n![Detail of apply] \n![Detail of work] \n![Detail of jobs] \n![Detail of career] \n![Detail of apply] 3 [/TASK",
        "label": 2
    },
    "265": {
        "output": "[END]\n\n## 2) Identify the information needed.\nWhat medical data does a recruiter need to assess the eligibility of study patients for a given clinical trial? A potential solution looks like this:\n<ClinicalTrial>\n[\n<Trial>\n  <Title>Praegnant Breast Cancer: Early/Advanced/Metastatic</Title>\n  <Sponsor>University Hospital Aarhus</Sponsor>\n  <Investigator>Professor R. Hansen</Investigator>\n  <Physician>Dr. V. Nielsen</Physician>\n  <Site>Department of Oncology, University Hospital Aarhus</Site>\n  </Trial>\n  <InclusionCriteria>\n    <InclusionCriteria>\n      <SubjectCondition>\n        <Condition>\n  <FactorName>Pregnant</FactorName>\n  <Operator>Not</Operator>\n  <Value>yes</Value>\nThis snippet says that pregnancy is an exclusion criterion for all patients (and not just patients who are pregnant). The snippet should be adapted when a specific trial contains a different set of inclusion and exclusion criteria. \n\nNow take a look at the full snippet that contains the patient note. The full snippet allows the user to use a snippet from clinicaltrials.gov to perform the clinical trial recruitment:     \n\nThe snippet in the example uses Java and the Eclipse IDE. In case you are not familiar with Java, you can use another scripting language.  \n\nThe script performs the following steps on the specified patient note: 1) Loading the patient note. 2) Extracting the trial-of-interest from the patient note. 3) Extracting the inclusion criteria for the trial-of-interest from the clinicaltrials.gov snippet. 4) Comparing the exclusion criterion against the metadata for the patient. 5) Determining the trial-level eligibility.  \n\n## 3) Assure that the eligibility assessment can be performed for a patient note containing all information. \nSome patient notes have no information on the pregnancy status of the patient.\nThe snippet in the example has the necessary instructions to determine the",
        "label": 2
    },
    "266": {
        "output": "[END]\n<EOD> Cystic fibrosis in children presenting with acute liver failure: Case series and review of the literature\nThe current recommendations regarding the management of acute liver failure in patients with an underlying inherited disorder of plasma chloride regulation are based on single center studies, and there is little or no guidance offered in these studies regarding the best ways to assess children with cystic fibrosis (CF) presenting with acute liver failure. This report presents 41 cases of children presenting from 1971 to 2009 with acute liver failure and underlying severe CF and illustrates the difficulties currently faced in deciding upon the best ways to manage these children and the complications that arise.<EOD> ROS\u2010Triggered Charge Transfer Polymer for the Treatment of Ovarian Cancer\nElectroactive polymers of low molecular weight are increasingly being recognized as promising candidates as therapeutic agents. Herein, we report the synthesis and photophysical characterization of an amphiphilic poly (poly \u2010PCFTAZ) derivative bearing the tetrazine moiety, which is known for its excellent reactivity as a cross\u2010linker (chemical dimerizer/cross\u2010linker). The PCFTAZ derivative is composed of a low\u2010molecular\u2010weight poly(ethylene glycol) (PEG) segment and a tetrazine group (PCFTAZ@PEG) and exhibits solvatochromic properties. The photophysical properties of the PCCFTAZ@PEG derivative were evaluated in the presence of various intracellular and extracellular reactive molecules. In the case of biothiols, cysteine and glutathione (GSH), this derivative showed an efficient quenching response. By employing ROS\u2010triggered chemistry, it was possible to conjugate polymeric PCFTAZ@PEG derivatives with cisplatin (a platinum\u2010based anticancer drug) using ROS produced by intracellular GSH or extracellular peroxynitrite (a toxic oxidizing species), with an 8\u2010fold increase in the cytotoxicity.<EOD> A pilot study of a behavioral intervention to prevent",
        "label": 0
    },
    "267": {
        "output": "<EOD> 2.8 \u03bcm Laser Welding for Thermoformed PMMA Based Surgical Guide Using 25 W CO2 Pulsed Laser\n\nLaser welding was investigated to join surgical guide made of poly(methyl methacrylate) (PMMA) for orthodontic surgery. 25 W pulsed CO 2 -laser welding was tested in 2.8 \u00b5m wavelength, 30 kHz repetition rate and 362.31 nJ pulse energy, and compared on 190 - C using a metal plate. Four different laser-welded specimens in the condition of 2.8 \u00b5m pulsed CO 2 laser welding in the air, and in the condition of 2.8 \u00b5m continuous CO 2 laser welding in the air, were compared to the nonwelded specimen in the condition of 190 - C metal plate. All specimens were tested 10 4 cycles in an environmentally controlled chamber at 50-60% humidity and 37 - C, to examine bond strength, welding zone observation, and optical microscopy. From optical microscopy the PMMA welding zone welding width, thickness, and penetration depth were analyzed by image analyzer. Result showed that the bond strength at the temperature for 190 - C metal plate was 8693.1 mN. In 25 W pulsed CO 2 -laser welding condition, the welding condition in the air and in the vacuum condition, bond strength was 1512.0 mN and 1550.2 mN, respectively. The bond strength could be improved as high as 9066.6 mN with optical microscopy. Therefore, our result suggested that the bond strength can be improved in the condition of 25 W pulsed CO 2 laser welding in the air and in the vacuum condition, and in the condition of 2.8 \u00b5m continuously CO 2 laser weld",
        "label": 0
    },
    "268": {
        "output": "[INST]\n\n##### [C:0:3] **Case Study**\nThe purpose of clinical trials is to evaluate new diagnostic agents or therapeutic treatment procedures in order to enhance the health and well-being of patients.  Clinical trials play an important role in the drug-development process.  In most cases, clinical trials are designed to determine if a new intervention is safe in humans and whether it is more effective than alternative treatments.  Before clinical trials are initiated, they are reviewed and approved by the IRB. IRB Approval:  the IRB must approve the protocol before it can begin.  Approval to begin enrolling subjects generally occurs after:  an IRB has reviewed the protocol and found that the study to be ethical, that there are scientific reasons to conduct the study, and that the study protocol is adequate and that all required safeguards, including informed consent, are in place. Study start has usually begun following:  the IRB has authorized the study to begin enrollment subjects.\nThe following is a proposed study for a drug which has been found to be effective in treating breast cancer. However, there is concern that there may be a side effect of the drug that has not been previously observed. Breast cancer patients enrolled in the following study will be randomly assigned to one of three treatment schedules:\n Group A: One drug treatment for all patients. Schedule Drug: 1 drug for each patient:  Drugs are given every day. For each week of treatment, patients are assigned to one of the four treatment schedules (a-d). \n\nGroup B: 1 drug treatment for all patients Schedule Drug: One drug for each patient: Drugs are given every day. For each week of treatment, patients are assigned to one of the four treatment schedules (a-d).\nGroup C: 4 drugs, alternating between 1 of 4 drugs.\nGroup D: 4 drugs, alternating between 2 of 4 drugs.\nPatients will participate in the drug evaluation study for 3 weeks. During the week, patients will receive three doses of the drug, i.e., once each day on days 1, 2, and 3. The drug treatment period will occur every 3 weeks during the study.",
        "label": 1
    },
    "269": {
        "output": "## Questions\n\nPlease read and answer the question carefully.\n\nWhat is the eligibility of the given patient for the clinical trial?\n\nWe have obtained the output of the file `exercises/case4.txt` by running: \n$ python exercises/case4.py\n\n## Answers\n\n### [A] A 51-year-old man with diabetes, hypertension, and dyslipidemia. The patient has a 10-year history of untreated chronic myeloid leukemia, and he is in myeloid blast phase.\n``` \nInput:\nTrial-level eligibility: 1) Eligible (Trial-level eligibility)\n  Inclusion criteria:\n    Include criteria 1:  Include criteria 4: \n  Exclude criteria:\n  Exclude criteria 1: Exclude criteria 5:\n\n  Patient: male; age 51 years\n  Inclusion criteria: age greater than 60, diagnosis with chronic myeloid leukemia, prior arterial thrombosis, dyslipidemia\n  Exclude criteria: no history of masticatory disorder, not sexually active, not on antiplatelet/anticoagulant therapy\nOutput: \nTrial-level eligibility: 1) Eligible (Trial-level eligibility)\n  Patient: male; age 51 years\n  Inclusion criteria: age greater than 60, diagnosis with chronic myeloid leukemia, prior arterial thrombosis, dyslipidemia\n  Exclude criteria: no history of masticatory disorder, not sexually active, not on antiplatelet/anticoagulant therapy\n``` \n\n### [B] A 74-year-old man diagnosed with hepatitis C. \n``` \nInput:\nTrial-level eligibility: 0) Excluded (Trial-level eligibility)\n  Inclusion criteria:\n    Include criteria 2: Include criteria 3: Include criteria 4: Include criteria 5: Include criteria 6: \n  Exclude",
        "label": 0
    },
    "270": {
        "output": "\u00a9 2020 KNIME GmbH\n\u00a9 2020 KNIME \n\u00a9 2020 KNIME GmbH\nEinloggen | Registrierung | Anmelden | Beispiele:\n| Datenschutz-& Implantatsgrundverordnung | \n<EOD> Flavonoid Glycosides from the Roots of Vitex rotundifolia and Their Inhibitory Activity on NO Production in LPS\u2010Stimulated RAW264.7 Macrophages\nIn this study, we chemically characterized three new flavonoid glucosides, including one 3\u2032\u2032\u2032\u2010O\u2010acetyl flavone, named vitexionosidic acid A, and two glycosides of dihydrokaempferol and kaempferol, named vitexionosides B and C. The in\u2005vitro nitric oxide (NO) inhibitory activity of vitexionosides B, C, and A were assayed in lipopolysaccharide (LPS)\u2010stimulated RAW264.7 macrophages. The results of this study indicated that all of these flavone\u20103\u2010O\u2010glycosides exerted inhibitory activity on NO production with IC50 values ranging from 8.1 to 22.3\u2005\u03bcM.<EOD> Risk factors for the development of lupus nephritis: A pooled analysis of individual participant data from 7 cohort studies based in the UK and South Africa\nWe used individual participant data (IPD) meta\u2010analysis to estimate the risk of developing lupus nephritis, and the influence of a range of potential risk factors.<EOD> .\nINTRODUCTION\nProteomic approaches have led to an increased understanding of the nature of the disease and the involvement of several proteins such as the cytokeratins, galectins, vimentin, cytokeratins. In this review, we focus on a possible association of certain proteins associated with breast cancer with breast cancer subtypes.\n\n\nSTATE OF THE ART\nNumerous cytokeratins (CKs) and galectins are expressed in breast cancer and many members of these families of proteins have been suggested",
        "label": 0
    },
    "271": {
        "output": "<h3><b># Clinical Trial-level Information</b></h3>\n\nTrial-level information describes the clinical trial in general. \nYou should write a code that calculates the overall score for a trial based on patient's eligibility. This code should be done by a loop or nested functions over a list or array that will contain all the trial-patient pairs that has been scored through the loop. \nThe score of the clinical trial will be the average of over the trial-patient pairs' scores. The score is calculated through three aspects described below.\n\n## Indication\n\nIndication (score : 1 -4 ) is calculated by \n$$ Indication  = \\frac{(1)\\max \\Triplet_size}{3} \\cdot p\\max_{i,j \\in \\X} \\Sum_{k=1}^n {k}^{4 - Triplet_{i,j}[k]} \\cdot \\Big(\\max_{k \\in \\X} \\max_{i \\neq j}(Triplet_{i,j}[k]) - \\min_{k\\in \\X}(Triplet_{i,j}[k]))$$ \n$$Indication = \\frac{\\text{\"Small to Very Small tumor size\"}}{\\text{\"Very Small tumor size\"}}\\cdot p\\max_{i,j \\in \\X}\\Big(\\sum_{k=1}^n S_s[i]_k - S_s[j]_k\\Big)$$\n\t\t$$Indication = \\frac{\\text{\"Small to Very Small tumor size and a Large number of patients\"}}{\\text{\"Very Small tumor size and a Very Large number of patients\"}}\\cdot \\Big(S_s[i] - S_s[j]\\Big)$$ \n$$Indication = \\frac{\\text{\"Small to Very Small tumor size and a Very Large number of patients\"}}{\\text{\"very small tumor size and a large number of patients\"}}\\cdot \\Big(S_s[i] - S_s[j]\\Big)$$ \n\t\t$$Indication = \\frac{\\text{\"Small to Very Small tumor size and a Very Large number of patients\"}}{\\text{\"Small to very small tumor size and",
        "label": 0
    },
    "272": {
        "output": "##[CODE]\nimport random\nfrom sklearn.datasets import load_breast_cancer_data\n# create a vector for patient data\npatient_data = [  ]\n# a vector for the scores for 0 - not relevant, 1 - not eligible, 2 - eligible\neligibility_vect = [ 0] * len(patient_data)\n\n# load breast cancer data\nbreast_cancer = load_breast_cancer_data()\n\n# go over each patient\ni = 0\nfor xyz in breast_cancer.data.loc[0]:\n    if xyz['Breast_Cancer_Patient_Note'][10:] not in ['Mammoplasty', 'Excision', 'Mastectomy']:\n        i += 1\n    eligibility_vect[i] += 1\nprint(i, eligibility_vect)\n\n# find the mean of each values for trial-level eligibility\ntrial_eligibility_mean = round(sum(eligibility_vect)/ i)\nprint('Trial-level eligibility:', trial_eligibility_mean)\n\n<EOD> GH-dependent metabolism in GH-receptor null mice.\nThe roles of GH and its receptor in energy and protein metabolism are of fundamental importance, particularly in the context of metabolic syndrome. Genetically modified models in which the hypothalamus-pituitary axis regulates GH secretion in response to food intake, or in which the GH receptor has been deleted, have served as invaluable models in our understanding of the effects of GH on metabolism. A better understanding of GH receptor function has been obtained by the generation of GH receptor-null mice. In this review, we focus on changes in growth, protein metabolism, adipose tissue distribution, body fat content, brown adipose tissue, insulin sensitivity, and energy expenditure in these models. The results in the absence of GH signaling challenge the notion that GH is indispensable to promote growth, and they show that in adulthood GH action is important to maintain lean and reproduct",
        "label": 0
    },
    "273": {
        "output": "# \u25b6\ufe0f Clinical Research\n\n[TEST] As a doctor, you are in charge of managing patients with chronic kidney disease. Chronic kidney disease is an impairment in kidney function that occurs when the kidneys fail to filtrate blood properly.\nChronic kidney disease reduces the body's ability to get rid of waste products and cause abnormalities in the levels of serum electrolytes. Therefore, it is important to manage patients with chronic kidney disease.\n\nYou must analyze a given patient and find out which drug regimen he or she should take.\n\nThe information on a given patient was entered in the [Bioinformatics] program:\n\nThe name of the drug that was prescribed to the patient is used as a reference. The prescribed drug has a number of advantages over the other existing drugs. This allows the patient to be able to take the drug indefinitely, without the risk of developing any other serious side effects. The prescription was given at the time of discharge from the hospital. The treatment regimen for a patient with chronic kidney disease requires close monitoring to maintain the level of creatinine in the blood at optimum levels. The main problem for the patient is the kidney's inability to filter the blood correctly, which will cause the accumulation of waste products in the body.\n\nThe following table is available in [Table 29.1] and illustrates the different prescribed drugs for each patient:\n\n\n\n## Name of the drug in use Regimen Prescribed\n\nSulindac In this study, chronic kidney disease was induced. The following table is available in [Table 29.2] and illustrates the different groups of patients in which some of the experimental drug regimens were given.\n\n\n\n## Group of Patients Regimen Prescribed\n\nA (20) Group I 1\nGroup I 30\nGroup II 1\nGroup II 30\nGroup III 1\nGroup III 30\nGroup IV 1\nGroup IV 30\nGroup U 1\nGroup U 30\nNote: For patient no. 3 and 4 in group I, the regimen prescribed was group III. For patient no. 5, the prescribed group was group V.\n\nBy using the [",
        "label": 2
    },
    "274": {
        "output": "*   Input the patient note\n\n*   Input the clinical trial data.    \n[TRIAL] Let's run the script now: \n[INST] Hello, you are a helpful assistant for clinical trial enrolment. You are to find a possible relationship for a clinical trial using the clinical trial database. The  results showed that  infection infection was a cause of the patient's death. \n[INST] It is necessary to find the probability of cause of death from the statistical analysis by calculating the Odds Ratio (OR). \n[TRIAL] Title: Odds Ratio: The relationship between HPV infection and 14 histological subtypes 535 cases.\n\n\n# Related questions\n- 1. What is the meaning of \u201cTrial-level eligibility\u201d in the clinical trial data?\n    1. Eligible\n    2. Not relevant\n    3. Excluded\n    \n- 2. According to the script, you would use the \"input\" function to input the data?\n      1. Yes\n      2. No\n    \n- 3. According to the script, you would use the \"Trial-level eligibility\" function to eligible the patients?\n      1. Yes\n      2. No\n    \n- 4. When the clinical trial \"Odds Ratio The Relationship Between Hpv  Infection And Histological Subtypes\" was completed, how would you calculate the Odds Ratio (OR) and input the results?\n      1. Yes\n      2. No\n    \n\n<EOD> The influence of maternal age at in vitro fertilization/intracytoplasmic sperm injection start and the number of oocytes/embryos on live birth rate: a single-center registry\nAbstract Purpose We aimed to evaluate the influence of maternal age on live birth rate after a single embryo transfer. Materials and methods Among 2,580 patients treated from January 2018 to December 2020, we included 902 women under the age of 40\u2009years who underwent a single embryo transfer and had a transferable embryo. Results The patients were classified into three groups (I: <3",
        "label": 0
    },
    "275": {
        "output": "[DONE]\n<EOD> A Comprehensive Approach to Pregnancy, Birth, and Growth in the First 3 Years of Life\n1. \u80ba\u529f\u80fd\u8bc4\u4f30\u548c\u8010\u836f\u68c0\u6d4b(antimicrobial susceptibility testing): \u6839\u636e\u75c5\u75c5\u53f2,\u5373\u60a3\u8005\u4e34\u5e8a\u8bc4\u4f30,\u91c7\u7528\u4f20\u7edf\u7684\u80ba\u83cc\u5bf9\u6297\u83cc\u6027\u836f\u548c\u836f\u7269\u7c7b\u578b,\u7ecf\u836f\u7597\u7597\u7a0b\u6709\u5173\u7684\u836f\u7269\u5bf9\u6297,\u800c\u53ca\u65f6\u5728\u60a3\u8005\u7684\u80ba,\u4f53\u6db2\u548c\u75f0\u6837\u672c\u4e2d\u68c0\u6d4b\u75c5\u6bd2,\u7ec6\u83cc,\u65e9\u671f\u53ca\u6cbb\u7597.\u6700\u540e,\u627e\u51fa\u7b56\u7565\u6027\u4f7f\u7528\u6297\u611f\u67d3\u836f\u7269\u7684\u65b9\u6cd5,\u5305\u62ec\u4ea7\u524d\u68c0\u67e5,\u7ed9\u4e88\u6297\u75c5\u6bd2\u836f\u7269,\u5229\u7528\u7ecd\u7f5f\u6216\u8d39\u66ff\u5c3c\u7b49\u6297\u75c5\u6bd2\u836f\u7269\u7597\u6cd5,\u7ed9\u4e88\u6297\u611f\u67d3\u836f\u7269,\u4f7f\u5f97\u60a3\u8005\u75c5\u75c7\u53ef\u6709\u6548\u63a7\u5236\u6216\u7f13\u89e3,\u6062\u590d\u4f53\u80fd,\u8ba9\u60a3\u8005\u4f11\u606f\u548c\u6d3b\u52a8,\u8fd8\u53ef\u80fd\u6cbb\u6108\u60a3\u8005\u8f7b\u5fae\u3001\u4e2d\u7b49\u91cd\u5ea6\u7684\u7662\u6bd2\u75c5.\u5728\u8fd9\u7c7b\u75c5\u7684\u6210\u529f\u6cbb\u7597\u4e2d,\u8981\u5305\u62ec\u6cbb\u7597\u7684\u76f8\u5173\u5fc3\u7406\u652f\u6301,\u793e\u4f1a\u652f\u63f4,\u7efc\u5408\u7597\u6cd5\u7684\u5e94\u7528.4. \u4e0d\u7a33\u5b9a\u75c7\u548c\u5176\u6cbb\u7597:\u7279\u522b\u662f\u75be\u75c5\u7684\u8f70\u4f17\u548c\u8fc7\u5ea6\u7684\u53d1\u75c5\u65f6\u95f4,\u4f7f\u533b\u751f\ufffd\ufffd\ufffd\ufffd",
        "label": 0
    },
    "276": {
        "output": "<EOD> Ocular manifestations and endophthalmitis in a patient with leprosy.\nPURPOSE\nTo present a case of leprosy with several ocular manifestations and an associated case of endophthalmitis.\n\n\nMETHODS\nThe patient was submitted to a complete ophthalmological examination, fluorescein angiography, indocyanine green angiography, magnetic resonance imaging, and ultrasound biomicroscopy. Bacteriological and mycological investigations were performed, and biopsies were taken for histopathological examination.\n\n\nRESULTS\nA 64-year-old woman with multibacillary borderline lepromatous leprosy presented an impending keratitis with keratopathy, secondary cataract, retinal nodular changes, retinal vascular changes with intraretinal capillary occlusions, and chorioretinal changes on fluorescein and indocyanine green angiography, as well as the presence of retinal pigmented epithelium cells with granular inclusions on electron microscopy. The fluorescein angiography showed chorioretinal changes with nodular areas of hyperfluorescence and hypofluorescence. Anterior uveitis with keratitis, anterior chamber hyphema, cataract, and vitreous opacities were associated with positive cultures for Mycobacterium leprae in the corneoscleral graft and bacterial endophthalmitis in the left eye. Despite therapy with prednisolone and azithromycin, the vitreous of the left eye progressively became more cloudy, showing the development of vitreous opacities with a retinal detachment.\n\n\nCONCLUSION\nThe ocular signs of lepromatous borderline leprosy and the occurrence of a case of bacterial endophthalmitis, probably caused by bacillus contamination of the corneoscleral graft, should be considered by ophthalmologists and clinicians.<EOD> Role of LPS binding protein (LBP) in host defense against bacterial infection in m",
        "label": 2
    },
    "277": {
        "output": "This is a [url= \n[url= ][username]\n[/url]\n[/snapshots]<EOD> Filling the Gap.\n1987;21:41\u201349. 8. Levy RI, Fukui S, Dekker E, Tzeng L, Gharavi AE, Flaherty J, et al. Serological and functional analyses reveal a novel association of HLA-DRw6 with insulin-dependent diabetes mellitus. Eur J Immunol 1986;16: 1301\u20131306. 9. Riggs JE. Diabetes type 1. IntRev Immunol 1993;11:171\u2013191. 10. Saddi S, Vialettes B, Winer ES, Vermeulen M, Vanderveen TA, Kloppenburg J, et al. Transgenic mice selectively expressing a class II major histocompatibility complex molecule in the islets of Langerhans develop autoimmune diabetes. Eur J Immunol 2000;30:219\u2013229. 11.. 12. Kronenberg H, Winer ES. Molecular regulation of autoantigen presentation in the islets of Langerhans. Annu Rev Immunol 2003;21:311\u2013346. 13. Brodeur MP, Shen C, Yin H, Wang Z, Lee A, Gong Y, et al. The NOD mouse. Semin Immunopathol 1994;16:359\u2013387. 14. Palmer CJ, Baxter AG, Gribble SM, Mendelsohn P, Kurrle S, Hutchings AJ, et al. Defective expression of the transporter associated with antigen presentation 1 in the NOD mouse islet and the association of this defect with a genetic susceptibility locus for type I diabetes. Diabetes 1999;48: 2035\u20132041.<EOD>",
        "label": 0
    },
    "278": {
        "output": "## Exercises\n\nUse **python3** to complete the exercises. [Click `here` if the link gets broken].\n\nExercise 1: This exercise is a self-test for the [exercises of][exercises_of].  \n\n\n```\npython3 practice_exercise1.py\n```\nExercise 2: Write a function which finds all eligibility candidates of a clinical trial. It should find eligible patients by filtering the patients who do not meet the criteria of the clinical trial.  \n\n```\npython3 practice_exercise2.py\n```\nExercise 3: Write a function which does a trial-level eligibility assessment.  \n\n```\npython3 practice_exercise3.py\n```\n\n# Discussion\n\n## Review\nThis is an unfinished work in progress. You may help me to fill the gaps.\nYou may also provide links to any additional materials you can provide or information you think may be suitable to the paper.\n\n\n<!--more--><center><h2>Review</h2> <hr/></center>\n\nFor the rest of the article, I would like you to be a review reader. So please read this article from the following 3 perspectives:\n1. Information technology people\n    - As healthcare professionals and IT people\n    - As information systems developers for healthcare\n    - As people who are interested in the latest IT developments to improve health systems\n2. Clinical practice people\n    - Healthcare professionals\n    - Medical researchers\n3. Public audience\n    - People interested in the recent developments in healthcare\n\n\n### What is the purpose of the article\nWe live in the era where healthcare is becoming highly automated with the use of information systems. In many situations, health professionals should communicate by IT tools with their patients. Although there have been lots of previous researches, healthcare professionals should get information from the most recent developments. So you should read this article and keep track of any other related articles or researches which could improve healthcare.  \n\n### What is the value proposition\nThe value proposition will be the same as above. The value proposition will be improved by this research.  \n\n### Is",
        "label": 1
    },
    "279": {
        "output": "[INFO] 2019-05-10 02:02:40,852 INFO : You are welcome to contribute at any time! If you make more contributions, I will increase your contribution ranking! [/INFO]\n### \u8840\u53cb\u75c5 A (\u4e5f\u79f0\u81ea\u8eab\u514d\u75ab\u6027\u8840\u6db2\u75be\u75c5\u7b2c\u4e00\u578b)\u4e3b\u8981\u7531\u56e0\u67d0\u79cd\u57fa\u56e0\u53d8\u5f02\u5bfc\u81f4\u7684\u81ea\u8eab\u6297\u4f53\u4ecb\u5bfc\u7684\u6740\u4f24\u6027\u6eb6\u8840\u3002\u5728\u60a3\u8005\u7ea2\u7ec6\u80de\u53d1\u751f\u635f\u4f24\u540e\uff0c\u6297\u4f53\u4f1a\u7a33\u5b9a\u963b\u6b62\u57fa\u56e0\u9519\u914d\u7684\u8868\u578b\uff0c\u4ece\u800c\u9020\u6210\u7ea2\u7ec6\u80de\u7ef4\u6301\u51fa\u4e4e\u6240\u80fd\u7684\u72b6\u6001\u3002\u6b64\u5916\uff0c\u6297\u4f53\u4e5f\u4f1a\u4fc3\u8fdb\u809d\u7ec6\u80de\u548c\u8840\u7ba1\u7684\u9ecf\u819c\u8840\u7ba1\u53cd\u5e94\uff0c\u8fdb\u800c\u4fc3\u8fdb\u75c5\u60c5\u8fdb\u5c55\u3002\u56e0\u7f3a\u4e4f\u529f\u80fd\u826f\u597d\u7684\u8865\u5145\uff0c\u4f7f\u6b64\u75be\u75c5\u5e38\u5bfc\u81f4\u6b7b\u4ea1\u3002\n\n```\n---\nlayout: post\ntitle: \u8840\u53cb\u75c5 A \u7684\u6700\u65b0\u8fdb\u5c55\n---\n\n\n## \u81ea\u7136History\n### \u53d1\u75c5\n\n\u81ea\u7136History\u7684\u57fa\u672c\u5185\u5bb9\uff1a\n1\u3001\u80cc\u666f\uff1a\u81ea\u8eab\u514d\u75ab\u6027\u8840\u6db2\u75be\u75c5\uff08\u81ea\u8eab\u514d\u75ab\u6027\u8840\u7403\u589e\u591a\u75c7\u3001\u81ea\u8eab\u514d\u75ab\u6027\u6eb6\u8840\u75c7\u53ca\u81ea\u8eab\u514d\u75ab\u6027\u6eb6\u8840\u6027\u80be\u75c5\uff09\u662f\u4e00\u79cd\u7531\u4e8eT\u53caB\u6dcb\u5df4\u7ec6\u80de\u56e0\u81ea\u8eab\u6297\u4f53\u5bfc\u81f4\u7684\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u3002\u5b83\u4eec\u4e0e\u8840\u6db2\u75be\u75c5\u76f8\u5173",
        "label": 0
    },
    "280": {
        "output": "### Trial-level eligibility\n| Example\n\n| Patient note\n```js\n[\n  {\n    \"Age\": 45,\n    \"Gender\": \"F\",\n    \"Disease\": \"Breast Cancer\",\n    \"Tumor Size\": 3,\n    \"Pathological Results\": \"ER/PR negative, HER2-positive\",\n    \"Surgery\": \"Left mastectomy\",\n    \"Stage\": \"III(c)\",\n    \"Chemotherapy\": \"X\",\n    \"Radiotherapy\": \"X\",\n    \"Endocrine Therapy\": \"X\",\n    \"Targeted Therapy\": \"X\",\n    \"Immunotherapy\": \"X\",\n    \"Cancer Site\": \"Breast\",\n    \"Metastases\": \"X(4) metastatic lymph nodes\",\n    \"HER2 Status\": \"Positive\",\n    \"HR Status\": \"Positive\",\n    \"Lymph Nodes Examined\": \"18\",\n    \"Lymph Nodes Metastases\": \"yes\",\n    \"Inclusion Criteria\": \"X(Patient is included in the clinical trial; eligible)\",\n    \"Exclusion Criteria\": \"X(Patient is excluded; excluded)\",\n    \"Exclusion criteria\": \"X(Patient is not eligible for the trial, but exclusion of the patient is not required)\",\n    \"Other notes\": \"\"\n  },\n  {\n    \"Patient ID\": 27840205,\n    \"Patient Note\": \"Breast surgery\",\n    \"Chemotherapy\": \"Anthracyclines +/-taxane and carboplatin\"\n  }\n]\n```\n\n\n### Clinical Trial Inclusion and Exclusion Criteria\n\n\n| Clinical trial title\n---|---\n| Title: Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)<EOD> .\nObjective: To discuss the value of percutaneous microwave coagulation therapy in treating papillary thyroid microcarcinoma. Methods: One hundred and twenty patients with papillary thy",
        "label": 0
    },
    "281": {
        "output": "</p>\n\nThe same task as #3 is in #A (A2), where you are a medical assessor for the study and need to apply exclusion criteria to each patient.\n<p class=\"inst_task_label\">[INST] Hello. You are a medical assessor for the study. Your task is to determine whether the patient, based on their answers in the patient note, is eligible to participate in a clinical trial. \n\nInclusion Criteria:\n- The patient is a 45-year-old postmenopausal woman.\n- The patient has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma.\n- The tumor is HER2-positive and ER/PR negative. \nExclusion Criteria:\n- The patient is using antihypertensive agents.\n- The patient is using anticoagulants.\n- The patient is using proton-pump inhibitors.\n- The patient is using oral contraceptives.\n- The patient is using aspirin.\n- The patient has a history of smoking or alcohol consumption.\n- The patient has a history of a sexually transmitted disease.\n- The patient has a family history of cancer.\n- The patient is not a candidate for tumor resection prior to chemotherapy.\nTrial-level eligibility: \n\n</p>\n\n# C (continued)\nIn [A3](A3), you are a medical professional trying to improve your English vocabulary. You are assigned to study a paper called _Improving Pain Management in Low-and Middle-Income Countries_ which was written by Jane Oro. Jane Oro is a psychologist and pain management specialist at the University of California (Berkeley, CA, USA). In your job, there is no time to learn all English words, so it's important which words you will use in a particular situation. You are asked to fill out the grid in .\n<p class=\"inst_task_label\">[INST] Hello. You are a medical professional trying to improve your English vocabulary. For your assignment, you are asked to fill out the grid in . \n\nYou will never be tested on your responses.\n\n<",
        "label": 0
    },
    "282": {
        "output": "This way, you will be able to obtain the output as expected. \n\n\n## Assessing an inclusion/exclusion criterion\nIn some cases, for the same patient, a criterion may be met and a criterion may be not met. It can happen in the assessment of an eligibility.\nFor example, in this patient has the criteria of age and gender. Although patient age is meeting this criterion, gender is not matching. So, the output should look like this. \n\n## Assessing eligibility for clinical trial 01\n\nTrial-level eligibility: 1) Excluded\nTrial ID: Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy\n\nAssessment ID: 01\n\n[INST] hello.\n\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast cancer in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or drink alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nHere is the clinical trial:\nTitle: Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy\n\nSummary: This randomized phase III trial studies how well platinum based chemotherapy works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant). Drugs used in chemotherapy, such as cisplatin",
        "label": 0
    },
    "283": {
        "output": "[/BLOCK]<EOD> Pain in primary care: a Latin American survey.\nINTRODUCTION\nPain is a common symptom in daily medical practice, and it has various implications among which a decrease in the quality of life is the principal one.\n\n\nOBJECTIVES\nThe aim of this survey is to analyze the profile of practitioners in Latin American countries to determine their knowledge of and approach to pain management.\n\n\nMETHODS\n1000 patients with chronic pain that attended different health-care centers in 9 Latin American countries, were interviewed about the frequency of their pain. The doctors were queried about their knowledge of and attitudes toward pain management.\n\n\nRESULTS\nAccording to their own declaration, doctors have quite poor knowledge about the concepts of pain, pain measurement, the pathophysiology and therapy of chronic pain. Only a minority would be considered experts in pain therapy.\n\n\nCONCLUSION\nFifty years after the start of the International Association of Pain it becomes clear that the approach to pain is still unsatisfactory in the Latin American region.<EOD> Hydrogen-Bond Enable Intermolecular Coupling Effect in Nonlinear Refraction of an All-Carbon-Based Dye-Sensitized Layered Polymer System.\nAlthough the light-induced nonlinear refraction response based on hydrogen bonding has been well recognized in organic semiconductors in recent years, it is still lacking the investigation of the structure-property relationship between hydrogen bonds and nonlinear optical response in dye-sensitized layered polymer systems. Herein, we focus on a newly designed all-carbon D-\u03c0-A-based polypyridyl dye and develop a dye-sensitized layered structure of zinc-phthalocyanine (ZnPc), pyridyl-benzothiadiazole (BTD-Pyridine), and thymine (THY) molecules for a study on hydrogen bonding-coupled molecular nonlinear optical response. The results show that through the combination of structural modification and molecular design, the hydrogen bonds introduced by the dyes and the \u03c0-\u03c0 interaction of the chromophore molecules can strongly",
        "label": 2
    },
    "284": {
        "output": "[TEST]\n\nTo run the test suite, run the following command from your command prompt:\n\n```\njava -jar /Users/<your_user>/test/test/target/test-distribution-0.9-all.jar check\n```\n\n[TUTORIAL]\n\nLet's take the `HelloWorld` demo. First import the test cases you need.\n\n```shell\njx -i /Users/tutu/test/tutu05/data/test-codebook/H2HW/test-codebook.xml\n```\n\nThen you can run a test suite.\n\n```\njx -o -f -c helloworld -s helloworld.xml\n```\n\nNow let's show the progress.\n\n```\n$ jx -X option -f helloworld.xml\n...\n2) Eligible\n```\n\nNow let's run the same program on two machines.\n\n```\n$ jx -c helloworld -i 1 -S helloworld.xml\n... \n2) Eligible \n```\n\nWe can see that the test results are equivalent.\n\n```shell\n$ jx -X summary -f\nSummary:\n--------------------------------------------------------------------------------\nTest Case (Case ID):      helloworld\nTest:\n|  Hello World (H2HW): Eligible (E) and passed (P)\n|                    Succeeded in 5 of 5 times\nTester:\n|                     t0050\nTester:\n|                     t0052\nTesting:\n|                    Hello World with H2HW: Eligible and Passed\n|                  (E/P)\n-------------------------------------------------------------------------------\n```\n\n## Tutorial: 4\n\n### Including test code in the code of a program\n\nA test-driven method allows to ensure that the code under test is consistent with the intentions of test software developers. This may seem as a non-issue by some, but with the wide use of software testing techniques, testing may be performed by software developers other than those who have written the code and it is often hard to find the person who wrote a code block for verification of its behavior. For instance, a software that performs a random action at",
        "label": 0
    },
    "285": {
        "output": "<EOD> Clinical features of children with influenza A/B virus-associated pneumonia during 2010-2019 in Beijing, China\n\nBackground: This study aimed to retrospectively analyze the clinical characteristics of children with influenza virus-associated pneumonia in Beijing to improve the clinical understanding of this disease and provide evidence for rational treatment. Methods: A total of 326 pediatric patients with influenza A/B virus-associated pneumonia were selected from the pediatric inpatient medical system of Beijing Children's Hospital. The medical records, physical examination results, and clinical outcomes of the patients were retrospectively reviewed. Results: Of the 326 children, 184 were male; the remaining 142 were female. The average age of the patients was 4.57 \u00b1 3.02 years; the youngest patient was 53 days old, and the oldest patient was 16 years old. There was no statistical difference in terms of sex or age between the influenza B virus-and the influenza A (H1N1) viruspositive patients (p > 0.05). A total of 358 pathogenic microorganisms were isolated from nasopharyngeal swabs (all 206 strains of influenza A and 152 strains of influenza B, all in the same season). The total number of bacterial and fungal pathogens identified from the blood, sputum, and bronchoalveolar lavage fluid (BALF) was 621. Influenza infection was related to bacterial and fungal infections (\u03c7 2 = 40.554, p = 0.000). There were 144 severe cases included in this study with 18 mortalities. The clinical symptoms of patients, imaging examination, laboratory test indices, and treatment methods varied between patients infected with different virus subtypes. Conclusions: Patients with serious influenza infections have various clinical manifestations and are susceptible to secondary bacterial and fungal infections. Therefore, appropriate supportive treatment and antibacterial and antifungal treatment",
        "label": 0
    },
    "286": {
        "output": "![image_2](./img/image_2.jpg)\n\n[MNE] You will next need to enter the patient's height and weight data into the 'Outcome measures' (Patient baseline 1) module. You can provide an",
        "label": 0
    },
    "287": {
        "output": "<EOD> Effect of Lactulose, a Synthetic Disaccharide, on Caecal Volatile Short\u2010Chain Fatty Acid Concentration of Broilers\n1.\u2002The experiment was designed to determine effects of lactulose, a water-soluble synthetic disaccharide, on caecal short-chain fatty acid (SCFA) concentrations in broiler chickens. 2.\u2002A commercial diet (crude protein 23%; crude fibre 5%) for broilers was supplemented with graded levels of lactulose (0, 0\u00b725, 0\u00b750, 1\u00b700%, wt/wt) in 2 experiments. Thirty-six Ross broilers of 3 different pen averages were used in the first experiment and 6 trials, each with 9 birds, were conducted in the second experiment. At the end of the 42 d experimental period, all birds were slaughtered and 5\u20138 cm of the last 10 cm of the caecum was collected from each bird and pH analysed. 3.\u2002Excreta samples were collected on 8 consecutive days in each trial of the first experiment and daily for the second experiment. The samples were thawed and pooled for chemical analysis at the end of the trial period. 4.\u2002Caecal pH increased significantly from 6\u00b726 for birds without lactulose supplementation to over 6\u00b771 for birds fed diets supplemented with 1\u00b700% lactulose or over 7\u00b700 for birds fed 0\u00b725 to 0\u00b75% lactulose. A significant increase in SCFAs in the caecum was seen up to 0\u00b750% lactulose, but the SCFA concentration as well as the S:P ratio increased at levels and up to 1\u00b700%. The caecal wet weight was not altered by lactulose supplementation. 5.\u2002Oligosaccharide fermentation by the caecum has been shown here to be advantageous because of the increased SCFAs produced. As lactulose cannot be absorbed it is not likely that these additional fermented SCFAs, due to the o",
        "label": 1
    },
    "288": {
        "output": "[/Tutorial]<EOD> Bovine mastitis.\nBovine mastitis has been of growing economic importance over the past few years. A wide variety of bacteria are capable of infecting the mammary gland causing mastitis. Escherichia coli infections are now often observed in herds with good hygiene and with low occurrence of contagious microorganisms. The purpose of this review is to give a short description of the microbiology and pathology of mastitis and to summarize the effects of antibiotic therapy. Special attention is paid to the control of mastitis and to the most important practical management measures.<EOD> Cutting-edge techniques.\nEFFECTIVE treatment of tension-free primary inguinal hernia is safe, cost effective, and predictable. A recent study has shown that the rate of surgery-related morbidity is much lower than previously reported. For example, the rates of haemoperitoneum in men and superficial wound infection were only 0\u00b77% and 2\u00b72% respectively, compared with 6\u00b79% and 12\u00b70% in a previous study.1<EOD> Dental fluorosis in children: correlation with fluoride dosing in mother's milk.\nA survey was conducted in Ribeir\u00e3o Preto, a municipality in the state of S\u00e3o Paulo, Brazil, to evaluate dental fluorosis (DF) in children. In addition, several variables of interest, such as the fluoride concentration of maternal milk, the prevalence of use of fluoridated milk (FM) during pregnancy and lactation, and maternal and children's dental hygiene, were investigated. The sample consisted of 493 children from 0 to 5.5 years of age. Two calibrated examiners, using Dean's index, examined enamel fluorosis. A survey was conducted with the mothers of these children, with questions including age and education level of the mother, number of children, and duration and form of nursing. Sixty-nine percent of mothers recalled that they had been informed of the benefits of FM and, of these, 42.9% reported that they had used the treatment during lactation. The prevalence of",
        "label": 1
    },
    "289": {
        "output": "We have one patient with 14 patient factors in this example. Each patient factor has to correspond to 1 or more factors that are written in the title.\nTo write down a patient factor of age, you should do the following: \n```R\n# Patient notes 1 patient_notes = seq(1:15) p1 = paste(paste0(\"Patient is a \", plyr::select(patient_notes, ~paste0(\"age[\", paste0(\"x1_\", plyr::select(patient_notes, ~.x[, \"age\"), \",\"), \"x\")))), sep=\"\\n\") \n```\nWe have to look into the patient factor age. First, `select` selects the age column in each patient note. The second argument defines how we group the data, the order in which columns are merged. Thus, if we pass a list with element \"age\" into the second argument, the age column is grouped together and then the grouped elements are merged. Here, we can also see that the age columns are grouped with a fixed element. The column `sex` is grouped by column with the name \"Sex\" then the column \"age\" is grouped just like the previous one. Therefore, the \"age\" column will be at the end of the result. \n```R\n```\nAnd since the clinical trial only considers one patient factor that is the patient age, for example, `29-45 years of age`, we do this:\n```R\n# Inclusion criteria \ncl_inclusion_age = `\n    clin_study_data %>%\n    select(study_name == \"Title\") %>% # Select the specific study\n    select(\n        title == paste0(\"Inclusion criteria: [name (age)]\")\n        ,  # Select the inclusion criteria that are related to the patient age\n        paste(paste0(\n              study_name,\n              \"_Inclusion_Age\"), \n              \": \",\n              age_factor_id, \n              (\".sex[\", \"Sex\", \"]\")\n          )\n        , \n        replace_na = TRUE\n    ) %>% # Select the target column\n    ungroup() # Merge\n    %>%\n    select(study_name, age_factor_id, title)\n\n    `\n\nThe",
        "label": 0
    },
    "290": {
        "output": "___Example data file___\n\nHere is an example file that includes a patient file and a trial file: file_to_assess_clinical_trial_eligibility.txt \n\n____The Patient Level____ \n\nPatient-level_1#\n# Assessment for breast cancer trial \n0) Excluded:  Exclude from trial, since patient has exclusion criteria\nN/A (not relevant)\n2) Eligible:  Patient meets all inclusion criteria and does not have any exclusion criteria.\nPatient meets the following inclusion criteria:\nage = 45\nsex = F\nhas cytologically confirmed breast cancer.\nhas a 3 cm invasive ductal breast carcinoma.\nis  HER2-positive and ER/PR negative.\nhas cytologically confirmed breast cancer.\nhas stage III breast cancer.\nis  HER2-positive and ER/PR negative.\nhas cytologically confirmed breast cancer.\nhas metastatic breast cancer.\nis on a multivitamin regimen.\nis not sexually active.\nhas no children.\nis not sexually active.\nhas no children.\nis using a multivitamin regimen.\nis not sexually active.\nhas no children.\nis a nonsmoker.\nhas no children.\nis not sexually active.\nhas no children.\nis a nonsmoker.\nis not receiving treatment for breast cancer.\nis not receiving treatment for breast cancer.\nThis patient does not meet the exclusion criteria of the trial, so she is eligible for this trial.\nPatient-level_2#\nN/A (not relevant)\n0) Excluded:  Exclude from trial, since patient has exclusion criteria\nN/A (not relevant)\n2) Eligible:  Patient meets all inclusion criteria and does not have any exclusion criteria.\nPatient meets the following inclusion criteria:\nage = 52\nsex = F\nis having breast cancer surgery.\nunderwent tumor resection.\nis having breast cancer surgery.\nis having breast cancer surgery.\nhas cytologically confirmed breast cancer.\nhad an invasive ductal breast cancer 4.5x2.0 cm in",
        "label": 1
    },
    "291": {
        "output": "## RQ2: If we have multiple datasets, what will we do with the other clinical trials? How will we aggregate the datasets?\n[RQ2] Hello. You need to assess multiple patients from multiple clinical trials. We assume that you have patient notes that have two different clinical trials. \nAs we have seen in the eligibility assessment, the result of a clinical trial is always represented with a trial-level eligibility. So the task is basically to aggregate multiple clinical trials with a common trial-level eligibility to form a group for each clinical trial and then predict the patient-level eligibility.\n\nHere are details to be followed: \nLet N be the number of the clinical trials that the clinical trial recruitment assistant should evaluate per batch. The total tasks of the clinical trial recruitment assistant were N datasets with trial-level eligibility in each dataset. Each dataset had M patient notes from one clinical trial. The clinical trial recruitment assistant had to evaluate all clinical trials per batch. The output was a dataset with a patient-level eligibility. The trial-and patient-level eligibility were predicted by aggregation of M clinical trials. You should predict new triallevel eligibility and corresponding patient-level eligibility in the patient-level eligibility dataset.\n\n[INST] Please implement the process of aggregation.\n\n[INST] Please predict trial-level and patient-level eligibility in the patient-level eligibility dataset. The structure of the dataset of patient-level eligibility is below. The column named `ID` is the unique number of a patient in the corresponding clinical trial. The column named `Trial_level_eligibility`is the result of a clinical trial. The column named `Patient-level_eligibility` is the result of aggregation of clinical trials. In the evaluation of dataset, the patient eligibility is positive if its sum of the column `Patient-level_eligibility` \u2265 1, otherwise, it is negative. The column named `Dataset_number` is the number of the dataset. [INST] There is a certain degree of imbalance in the positive and negative classes. You may need to consider this aspect. Try different ratios of positive",
        "label": 0
    },
    "292": {
        "output": "<EOD> Detection of microRNA signature in serum exosomes as complementary diagnostic biomarkers for non-small cell lung cancer\n\nDysregulation of miRNA expression is found in several types of cancers, including lung cancers. We aimed to determine the difference in the expressions of miRNA between the sera and serum exosomes of lung cancer patients and healthy subjects and then to evaluate the possibility of serum exosome miRNA as a clinical biomarker for lung cancer. This study included 17 non-small lung cancer (NSCLC) patients and ten healthy controls. We measured the expression of serum miRNAs from cancer patients and determined the expression of miRNA in serum exosomes. Our results showed differential expression of miR-10b, miR-223, and miR-21 in NSLC patients, although a significant difference was not observed in the expression of serum miRNAs between the two groups. Significant differential expression of miR-10b, miR-223, and miR-21 was observed in patients with advanced tumor stages. However, all miRNA expression differences were significant in NSCLC patients with EGFR mutations. Our results suggest that miR-10b, miR-223, and miR-21, along with the expression of serum exosomes, could be complementary diagnostic biomarkers for NSCLC. Oncotarget 378 www.oncotarget.com\n\n# Introduction\nLung cancer has a dismal prognosis and is predicted to become the most commonly diagnosed cancer and the leading cause of cancer-related mortality worldwide [bib_ref]  Global cancer statistics, Jemal [/bib_ref] . Among the patients with lung cancer, only 15% are diagnosed as having non-small cell lung cancer (NSCLC) because of the non-specific symptoms of lung cancers [bib_ref]  Symptom clusters in non-small-cell lung cancer, Osarogiagbon [/bib_ref] . Therefore, exploring new methods that can improve the early diagnosis and improve the prognosis of lung cancer is urgently needed.\nMicroRNAs (miRNAs) are 18-24 nucleotides long non-c",
        "label": 2
    },
    "293": {
        "output": "## The output example\n\n##[INFO] You are about to assess a trial level eligibility for patient ID 3309 in clinical trial UF19-15-3512. [INFO]\n\n## Score: 2) Eligible. [INST]\n\n##[INFO] Patient ID 3309 - TRIAL-LEVEL ELIGIBILITY: 2) ELIGIBLE.[INFO]\n\n##[INFO] You are about to assess a trial level eligibility for patient ID 3301 in clinical trial UF17-19-5303. [INFO]\n\n## Score: 2) Eligible. [INST]\n\n##[INFO] Patient ID 3301 - TRIAL-LEVEL ELIGIBILITY: 2) ELIGIBLE.[INFO]\n\n##[INFO] You are about to assess a trial level eligibility for patient ID 3305 in clinical trial UF16-20-2640. [INFO]\n\n## Score: 2) Eligible. [INST]\n\n##[INFO] Patient ID 3305 - TRIAL-LEVEL ELIGIBILITY: 2) ELIGIBLE.[INFO]\n<EOD> Synthesis and pharmacological profile of the enantiomers of N(1)-hydroxy-3-O-(2,2,2-trimethyltridecan-yl)-2-(piperidin-4-yl)propran-1-ol (BRL 25968; (+)-(S)-1542; (-)-(R)-1542).\n(-)-(S)-1542, recently identified as the active agent of a series of highly potent and selective benzazepine analgesics, has been racemized to the enantiomer (+)-(S)-1542. The two isomers were separated using a chiral liquid chromatography column and by high pressure liquid chromatography (HPLC). The separation by the latter method was reproducible for a long time; thus, about 3 kg of (+)-(S)-1",
        "label": 0
    },
    "294": {
        "output": "> dfu <-function(df, m <-2){\n  df$grades <-as.factor(df$grades)\n  ndf <-sum(!df$grades %in% c(\"1\", \"2\"))\n  rcol <-ncol(df$grades)\n  df$sum <-cbind(1:2, cumsum(ndf))\n  dfs <-as.data.frame(unlist(lapply(df, function(x) ifelse(x$grades == -9999, \"N/A\", x)) %>% unlist()))\n  pats <-apply(dfs[which(rowSums(dfs)) == max(rowSums(dfs)), rownames(dfs), function(x) { summarized <-as.data.frame(count(1:ncol(x))) summarized[colnames(summarized) %in% (\"A\")) summarized[1:2] <-as.matrix(summarized) summarized }))\n  if(rcol == 1) { n <-1; nd <-2; r <-1; rn <-2 } else { n <-rcol; nd <-rcol*3; r <-rcol*2; rn <-rcol*2 } mat <-matrix(c(rep(\"A\", n), r[c(1:nd)], r[c(nd + 1:n:)], \"N/A\"), ncol = 2, nrow = max(n, r)) mat[c(\"\", \"N/A\"), c(\"\", \"N/A\")] <-\"A\" mat <-pats %>% rename(d <-.2) %>% reduce(x = .1, f = function(x) list(colnames = c(.2), data = x)) %>% rename(j <-.1) %>% lapply(function(x) x[,c(\"A\", \"N/A\")]) %>% lapply(function(x,j,d) replaceNA.x(x,j,d)) %>% lapply(function(x, j, d) matrix(replaceNA.x(cbind(d, x[,j]), c(\"\", \"N/A\")), dimnames = list(d, j))) %>% reduce(x = .1, y = .2, f = function(x,",
        "label": 0
    },
    "295": {
        "output": "### Inconsistent data types\n\n```python\nprint(\"Test Inconsistent data types\")\n```\n\n```\n$ python test_inconsistent_datatypes.py\nTest Inconsistent data types\nBreast Cancer with Invasion < 1cm in Diameter\nBreast Neoplasms Malignant < 1.0 cm\n0) Excluded   0    2\n1) Not relevant    0    1\n2) Eligible 1014 30300549\nTrial-level eligibility: 0\nBreast Cancer With Invasion < 1.0cm in diameter\nTrial-level eligibility: 0\nBreast Neoplasms Malignant < 1.0 cm\nTrial-level eligibility: 0\nTrial-level eligibility: 2\nBreast Cancer With Invasion < 1cm in Diameter\nTrial-level eligibility: 1\nInbreast Neoplasms Malignant < 1.0 cm\n\n```\n\n### Missing data types\n```python\nprint(\"Test Missing data types\")\n```\n\n```\n$ python test_missing_datatypes.py\nTest Missing data types\nBreast Cancer with Invasion < 1cm in Diameter < Not known\nBreast Neoplasms Malignant < 1.0 cm < Not known\n0) Excluded   0    2\n1) Not relevant    0    1\n2) Eligible 1014 30300549\nTrial-level eligibility: 0\nBreast Cancer With Invasion < 1.0cm in diameter < Not known\nTrial-level eligibility: 0\nBreast Neoplasms Malignant < 1.0 cm < Not known\nTrial-level eligibility: 0\nTrial-level eligibility: 2\nBreast Cancer With Invasion < 1cm in Diameter < Not known\nTrial-level eligibility: 1\nInbreast Neoplasms Malignant < 1.0 cm < Not known\n\n```\n<EOD> The 100 most cited articles in orthod",
        "label": 1
    },
    "296": {
        "output": "![TEST:2020-09-18_122416.png](./TEST:2020-09-18_122416.png)\n```python\n#+\n\"\"\"\nDocs at: https://dreamruntimer.com/docs/2020-09-18/clinical-trial-recruitment.html\n\"\"\"\n#-\nimport string\n# Setup packages\nimport random\nimport sys\nimport time\nfrom urllib.parse import urlparse\nfrom datetime import date, datetime, timedelta\n\n# Set our random seed to be equal to the current time.\nrng = random.Random()\n\n# Check for a URL input, if not given, bail.\nif len(sys.argv) < 2:\n    print(\"Specify a URL:\")\n    sys.exit()\nurl = sys.argv[1]\n# We will make use of Pandas to load our data into a dataframe\ndata = dataset().recode()\n# If the clinical trial name isn't on the URL, we will add a\n# `clinical_trial_name` column for use.\nif urlparse(url)[2] != \"clinical_trial_name\":\n    data = data.join(dataset(f\"{url}&clinical_trial_name={data['clinical_trial_name']}\"))\nelse:\n    print(\"Got the trial name on the URL.\")\n# Now let's preprocess the data to make it suitable for use\nfor i, name in data.groupby(\"Trial-code\"):\n    name[\"Trial-code\"]= name[\"Trial-code\"].lower()\n    name[\"Trial-code\"]=name[\"Trial-code\"].str.split(\":\", expand=True).str.strip('[] ')\n        .str.replace(\",\", \"\").str.replace(\":\", \"\")\n        .str.replace(\" \", \"\")\n    name[\"Trial-code_lower\"] = name[\"Trial-code_lower\"]=(name[\"Trial-code\"].str.split(\":\").str.join(\"\").isna())\n    name[\"Trial-code_lower\"]",
        "label": 2
    },
    "297": {
        "output": "---\n### Data structure\n\nAfter your work has been done, a new dataset of `Clinical` class will be produced. Here, the dataset you need to work with may not be very useful if the patient ID `patient_id` is not present. In this case, it may be possible to work with this dataset only. If you need to work with ID, then you need to add a set of additional columns to the patients.\n\nBelow, we describe how to convert a `Clinical` instance to an `Eligibility` instance, and add additional columns to the input dataset. Let's look at an example of this idea in the `Eligibility` instance.\n\n```julia\nusing DataFrames\n\n[formula]  eligibilityData = Clinical.eligibilityData(x) [/formula] \n```\nThe resulting `Eligibility` object looks like this:\n\n```julia\nEligibility(\n  age = Float64(30),\n  gender = Symbol(\"Male\"),\n  height = Float64(170),\n  weight = Float64(80),\n  birthdate = Float64(1995),\n  ageAdmission = Float64(41),\n  ageDeath = Float64(103),\n\n  height_during_illness = Float64(150),\n\n  ageLastVisit = Float64(39),\n\n  weightLastVisit = Float64(2000),\n\n  BMI_lastVisit = 19.07,\n  heightDuringIllness = Float64(160),\n  heightLastVisit = Float64(170),\n  weightLastVisit = Float64(1800))\n\n```\nThe age (the last two properties), gender, birthdate, and weight are included in the metadata `Metadata.DataProperties(...)` object. Also, note that we added the fields corresponding to the `height_during_illness` and `ageLastVisit` (i.e. `Patient(1).height_during_illness == 6`), which are related to the `age` field.\n\n```julia\n#print(el",
        "label": 0
    },
    "298": {
        "output": "<EOD> The Role of the Physical Trait Domain in the Identification of Differential Item Functioning (DIF) Between Two Groups\n\nThe physical trait domain is among one of the more sensitive areas for identifying Differential Item Functioning (DIF) in the measurement of health-related constructs. The purpose of this study is to better understand the impact of DIF in the physical trait domain as it relates to the development of health-related assessments. First and second order models were used to account for DIF. Simulations were used to examine conditions in which DIF in the physical trait domain is the most harmful. A case study utilized data from an epidemiological study to demonstrate our model for assessing the clinical significance of DIF in the physical trait domain. Results indicate that first-order models are effective for screening items from the physical trait domain, while second-order models are better for identifying and correcting DIF in the physical trait domain. DIF detection in the physical trait domain was most harmful when the overall severity of health-related constructs was high. DIF detection is most beneficial when the overall severity of health-related constructs is low in the physical item domain. We encourage the development of more complex item response theory (IRT) models to assess the impact of this type of DIF, and its associated measurement error, on the ability to detect change over time.\n\n# Introduction\nDifferential Item Functioning (DIF) refers to a bias in items caused by the presence of systematic, unwanted variance or relationships between a person's responses and that of a group variable. In health-related assessments, DIF is typically examined in the context of a patient-group variable, such as gender or ethnicity, against which the validity of a measure is judged. In one example of this, [bib_ref]  Differential Item Functioning in the MOS SF-36 Health Survey Questions, Kerns [/bib_ref]  examined the physical component of the SF36 for differences in functioning between women and men in three areas (mobility, pain, and energy). The authors found evidence of DIF related to physical capability and activity restriction. [bib_ref]  A Comparison of Item Response Theory Partial Credit Score Analysis Model and..., Devanand [/bib_ref]  identified DIF in the Physical Discomfort sub",
        "label": 1
    },
    "299": {
        "output": "A: You appear to be using the template:\n{{#if (age|size) > 0}}\n{{#if 0 <= (age|size) 1}}\n\n{{age|size}}\n\n{{#if (age|size) > 1}} 2) Eligible.\n(1) Excluded.\n(2) Not relevant.\n{{/if}}\n{{else}}\n\n{{age|size}}\n\n{{else}}\n\n{{age|size}}\n{{else}}\n\n{{age|size}}\n{{/if}}\n\nHere, we can see we're having trouble with formatting. You may wish to remove some of the formatting from the template, for example:\n{{#if (age|size) > 0}}\n\n{{age|size}}\n\n{{else}}\nAge is 0\n{{/if}}\n\nand then update your template as follows:\n{{#if (age|size) > 0}} {{#if 0 <= (age|size) 1}}\n\n{{age|size}}\n\n{{#if (age|size) > 1}}\n {{#if 0 <= (age|size) 2}} 2) Eligible.\n{{else}}\n 1) Excluded.\n {{else}}\n 2) Eligible.\n {#if (age|size) > 2}} \n 2) Eligible.\n {{else}}\n {{#if 0 == (age|size) 1}}\n 2) Eligible.\n {{else}}\n {{#if 0 == (age|size) 1}} 2) Eligible. \n {{else}}\n {{#if (age|size) == 0}} 2) \n Eligible. \n {{else}} 2) \n Eligible. \n {{/if}}\n\n{{else}}\n\n{{age|size}}\n\n{{else}}\n{{age|size}}\n{{/if}}\n\n{{else}}\n\n{{age|size}}\n{{/if}}\n\nThis should do the trick. As I mentioned above, I'm not too familiar with Ruby so some or all of my suggestion may not work. In fact, it may be best if you asked this question on [",
        "label": 1
    },
    "300": {
        "output": "## Trial-level eligibility:\n[Trial-level eligibility: 0) Excluded]\n[Trial-level eligibility: 1) Not relevant]\n[Trial-level eligibility: 2) Eligible]\n\n\n## INSTRUCTIONS.\n[INSERT]\n\n# <a name=\"results\"></a> Results\nEach input file contains a dataset containing two patient-level eligibility scores (one is assigned by humans based on clinical information and the other is assigned by a machine using only clinical information), and the input file provides several details regarding the trial, such as type, trial title, the start date, number of patients, duration of the enrollment phase for each trial, and details about any published data. \n\nHere is clinical trial information provided by the input file, and 5 patients included in this trial:\n\n- Trial title: S100B Biomarker to Determine Prognosis and Treatment Adjustment for Aggressive Variants of Medulloblastoma\n- Start date: 2016-01-01\n- Number of patients: 62\n- Total enrollment duration: 1\n- Published status: Y\n\n## Table 1: Summary of the first five patients enrolled in the S100B Biomarker to Determine Prognosis and Treatment Adjustment for Aggressive Variants of Medulloblastoma trial.\n\n\n## ID\nGender\nHeight (cm)\nWeight (kg)\nAge (year)\nGPA\nPre-operative MRI\n\n## Results_data_female\n307 1.3 79 133 17 0\nResults_data_male\n315 1.27 77 26.4 17 0\nResults_data_1\n309 1.5 78 138 17 0\nResults_data_2\n304 1.3 77 131 17 0\nResults_data_3\n310 1.4 76 134 19\n\n## The output dataset\n\nThe output file",
        "label": 0
    },
    "301": {
        "output": "_Example Answer_\n\nTrial-level eligibility: 2) Eligible.\n(Source: `149229_0_149229_2.py`)\n\n_Clarification_\n\n**Note:** In reality, there should be two conditions in `Trial-level eligibility: 2) Eligible.`. One can simply use the negation of `Inclusion criteria: 1) Excluded`.\n\n**Notes and thoughts**\n\n- In this question, you have to understand an input structure as a list of a patient note and a clinical trial; in fact, the input will look like a nested structure which is like a string with a token for a patient note followed by a token for `Inclusion criteria: `. \n\n- [Instructions for the first round are available in Github.](https://github.com/deeplearning4j/demo_jvv_winter_2022/blob/master/0/demo_jvv_winter_2022/data/ReadMe.md)\n\nThis is the summary of the instructions for Round 1. Please click the link 'Click here to start' under the instructions to get to the input form of the question. The input box is at the top of the page. [Instructions for the first round](https://github.com/deeplearning4j/demo_jvv_winter_2022/blob/master/0/demo_jvv_winter_2022/questions/0/149229/Click_here_to_start.md)\n\nThis is the summary of the instructions for Round 2. Please click the link 'Click here to start' under the instructions to get to the input form of the question. The input box is at the top of the page. [Instructions for Round 2](https://github.com/deeplearning4j/demo_jvv_winter_2022/blob/master/0/demo_jvv_winter_2022/questions/0/149229/Click_here_to_start.md)\n\n## [150586](https://github",
        "label": 0
    },
    "302": {
        "output": "### Exercise\nWrite down your first assessment by giving the most simple notation for your patient with some assumptions. Consider the example shown below:\nFirst, let's think about the patient.\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2+ and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes.\n\nCXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nNow, we need two sets of data for the clinical trial. One is for the clinical trial information and the other is the research-related questions. Consider these assumptions: \nAssumptions:\nThe title of the trial is `MK-3475 Immunotherapy in Endometrial Carcinoma. \nAssignment criteria for study: \nPrimary endpoint: overall survival.\nSecondary endpoints: PFS (with confirmation of death and progression within 50 days), PFS 6 months, Efficacy as assessed by response rate (e.g. RRs, ORRs) on the basis of clinic RR, disease free survival and OS, correlation of PD-L1 immunohistochemistry staining, with response rates \nSurgery and adjuvant therapy: resection of primary site and metastasis followed by adjuvant treatment.\nResistance mechanism assessment: analysis of tumor tissue at baseline and post cycle 1-2 and at progression.\nSurgery: hysterectomy +/bilateral salpingectomy with or without oophorectomy (BSO)\n\nSo the trial-related questions are as follows:\n\n1.\nAdaptive design with Bayesian approach for clinical trial.\n2.\nThe trial is evaluating the antiproliferative effects of pembrolizum",
        "label": 0
    },
    "303": {
        "output": "Let's see an example of the code in Python: \n```python\nwith open(INPUT_DIR + INST_FILE_NAME) as f:\n    for line in f:\n        if line.startswith(\"ID\"):\n            if line.endswith(\"eligible\"):\n                print(\"Trial-level eligibility: 2) Eligible.\")\n            else:\n                if not line.endswith(\"excluded\"):\n                    print(\"Trial-level eligibility: 0) Excluded\")\n                    \n            line = None\n    \nimport sys\nprint(sys.modules[\"inst\"].Trial_level_eligibility)\n```\nOutput (same example file): \n```\nTrial-level eligibility: 2) Eligible.\nTrial-level eligibility: 2) Eligible.\nTrial-level eligibility: 2) Eligible.\nTrial-level eligibility: 2) Eligible.\n```\n<EOD> The role of N-Acetyl Aspartate in the cerebral metabolism of the very low birth weight newborn.\nBACKGROUND\nVery low birth weight infants (VLBW) are more susceptible to hypoxic-ischemic encephalopathy (HIE) because of their incomplete cortical neuronal network and a lack of myelination. This can lead to a disruption of energetic metabolism and an increase in the amount of N-acethyl-asparate (NAA) in the brain. With this study, we aimed to determine the role of NAA in the brain metabolism of VLBW infants with and without HIE, using in-vivo proton magnetic resonance spectroscopy (HMRS).\n\n\nMETHODS\nNinety-eight VLBW infants without HIE (median weight 1,025 grams , median gestational age  27 weeks ) were enrolled after parental consent. Infants with significant brain anomalies, chronic lung or renal diseases were excluded. Clinical data, anthropometric and perinatal information and results of the neurological examination of the",
        "label": 2
    },
    "304": {
        "output": "[[INST] There are no longer any instances of this variable in this file. The variable was removed from the file.]]\n\n{{item}}\n  \n\n{{#if .Description}}\n    {{.Description}}\n\n    {{#if .Example}}\n    <img src=\"{{.example}}\" alt=\"{{name}}: {{.description}}\" height=\"300\" width=\"600\" />\n    {{/if}}\n\n    {{#if .Example}}\n    <br/><br/>\n    <div class=\"example\">\n        {{name}}: {{.description}}\n    </div>\n    {{/if}}\n\n{{else}}\n    {{.}}\n\n    <div class=\"no-content\">No description is provided for this variable.</div>\n\n{{#if .IsDefault}}\n    {{.}}\n\n    <div class=\"is-default\">{{.IsDefault}} is the default value for this variable.</div>\n\n{{else}}\n    {{.}}\n\n    <div class=\"is-required\">{{.IsRequired}} is a required value for this variable.</div>\n\n{{/if}}\n{{/if}}\n\n{{/each}}\n<EOD> Reconstituting Human Blood Stem Cell Development Using Glioblastoma-Derived Cancer Stem Cells and Plasmid Transfection\n\nCitation: Vazin, J.; Sokolova, M.M.; Zabolotnaya, E.I.; Kharitonova, A.A.; Zavalishinkii, V.Y.; Fedorova, S.A.; Syrdalenko, K.K.; Shtansky, N.S.; Orekhov, A.P. Reconstituting Human Blood Stem Cell Development Using Glioblastoma-Derived Cancer Stem Cells and Plasmid Transfection. Biomedicines 2021, 9, 709.Abstract: The reconstitution of the human hematopoietic stem cell (HSC) system from human pluripotent stem cells (hPSCs) opens up a huge perspective on modeling human blood diseases in vitro and the rapid search for new drugs. There are studies dealing with the reconstitution of the primitive human HSC system using gene-correct",
        "label": 1
    },
    "305": {
        "output": "[INST:\nTrial-level eligibility: 0) Excluded] \n[INST:\nTrial-level eligibility: 1) Not relevant] \n[INST:\nTrial-level eligibility: 2) Eligible]\n\nThe output of the function is a list of triallevel eligibility. The final element is outputted into the console and saved in file `EligiblePatients.csv`. \n\n    triallevel_eligibility <-trial_eligible_analysis(\"PathologyData\", \"HBC1\", \"EligibilePatients\")\n    trial_eligible_analysis(\"PathologyData\", \"HBC1\", \"EligibilePatients\")\n\n\n[INST]\nThe file `EligibilePatients.csv` contains the data as shown below:\n\n```\nID    \n1\n2\n3\n```\n\n\n### The second data set includes the number of tumor-free lymph nodes.\n\n[INST]\nYou should predict the number of tumor-free lymph nodes and obtain the accuracy score.\n\nPlease predict the number of tumor-free lymph nodes by the mean of the patient's clinical data. The accuracy score should be above 1, and lower accuracy scores are considered failures. \n\nLet's try to estimate these numbers of tumor-free lymph nodes: \n\n| ID | Lymph Node |\n|  --- |     ---- |\n|    1 |         2 |\n|    2 |         9 |\n|    3 |         4 |\n\nThe output of the function is a list of numbers of tumor-free lymph nodes. The final element, which is outputted into the console and saved in the file `NumbersOfTumorFreeLymphNodes.csv`, has data in which we predicted the number of tumor-negative lymph nodes. \n\n    numbersOfTumorFreeLymphNodes <-prediction_numOfTumorFreeLymphNodes(\"PathologyData\", \"HBC1\")\n    prediction_numOfTumorFreeLymphNodes_(\"PathologyData\", \"HBC1\")\n\nThe output of the function `prediction_numOfTumorFreeL",
        "label": 2
    },
    "306": {
        "output": "This is an example of the final output of this solution:\nPatient has a 60% chance of responding to treatment.\n\nA: I've just finished this kind of problem at RPA exams.\nLet's define some variables \n1 ) 0 - Excluded\n2 ) 1 - Not relevant\n\n\nA: Let's take look at the problem by using trial type. What is the trial type? What is the trial recruiting?\n\n\n[ TRIAL TYPE RANK RANK\n\n## Type definition\nInteresting RANK > 40% Not Interesting RANK <= 10%\n\n\n*\n\n*Patient is a breast cancure patient:\n\nBreast cancer patients with positive RANK Expression will benefit from denosumab treatment with a higher response to the chemotherapy.\n\n*Denosumab will benefit with higher response to chemotherapy and reduce clinical fractures and improve bone health.\n\n*According to the trial, we will apply denosumab for interested person.\n\n*Clinical trial is a Phase II trial and interested patient will be tested to see whether denosumab is effective in treating breast cancure patient.\n\nAccording to what we know, patient should be eligible for clinical trial. If yes, then let's calculate the probability of interest patient (P(I)) with this formula\n\n\n[formula]  P I = C1 x (1 \u2212 C2 x C3) x ...(1 \u2212 Cn x C2) x Cn ... x (1 \u2212 C1)(1) [/formula] \nwhere C1 = RANK \n\nNow, let's make assessment with 3 level scale, which is:\n0 - Excluded\n1 - Not relevant\n2 - Eligible\nAccording to the result given, let's build some logic if-then rule.\n\n\nI.\n\nRANK is 40% and higher => Excluded\n\nRANK is between 10% and < 40% => Not relevant\n\n\nII.\n\nRANK is at least 40% => Eligible\n\nRANK is less than 40% => Not relevant\n\nNow, we",
        "label": 1
    },
    "307": {
        "output": "## Tutorial Step 5. Print out the note with assessments and include them in the patient's medical record.\n\nYour task is to print out the note with assessments. You should be able to refer to the assessment if necessary. For example, patient notes should be archived for at least 7 years after the end of clinical activity. As mentioned earlier, it is important to ensure that the patient notes include sufficient information for assessing eligibility. The eligibility assessment requires a lot of effort and time. Having a structured and reliable patient note is important. The assessment of the eligibility criteria should be included as part of the patient records so that all clinicians, including students, can view how a patient is assessed for inclusion in an ongoing clinical trial.\n\n### Print out the note with assessments.\nTo complete the tutorial, you must now print out the patient note with assessments. We will discuss the implementation of assessments of the eligibility criteria and other details of this functionality in the next tutorial. \nAfter you have printed out the note with the assessments for this trial, you may need to take this into consideration while conducting your other tasks, i.e., you will need to keep the data entry module open to prevent losing the information. In addition, keep the document in mind that you will need to update any patient assessments when the patients visit the clinic again. The information on a patient's eligibility can be entered, and the information for the clinical trial is automatically updated. This should also be done after the patients have been discharged from the hospital. \nAdditional notes:\n\n- Eligibility assessment: If a patient does not meet the trial's eligibility criteria, then the 'Eligible' assessment does not apply.\n\n- Age assessment: The assessments for patients under 12 years of age are made by assessing the patient note from medical history or the discharge summary.\n\n- Sex: If a patient is not sexually active or has not been sterilized (such as in postmenopausal women), you should consider this assessment.\n\n- Medical history: If someone is currently taking a drug, it is recommended to check whether the patient knows about potential drug side effects or other related adverse events prior to enrollment; patients must sign the informed consent. For",
        "label": 0
    },
    "308": {
        "output": "You're done! Let's move on to the next case.\n\n## Case Study 5\n# [START] 01_Motivation_CaseStudy5.ipynb\n# [INS] 01_Motivation_CaseStudy5.ipynb \nYour task is to compare a given patient note and the inclusion criteria (IC) of a clinical trial to determine the patient's eligibility.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nThis case is inspired by a real patient and clinical trial (you can check https:/ /www.clinicaltrials.gov/ct2/show/NCT00137381?term\\-=NCT00137381&rank=1.). You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of the eligibility. The assessment of eligibility on each patient and trial-level eligibility should be evaluated at the beginning of each case. Let's begin with a motivating example. \n# [END] 01_Motivation_CaseStudy5.ipynb\n# [RUN] 01_Motivation_CaseStudy5.ipynb \n\n## Step 1: Import patient note and clinical trial\n\nLet's read the patient note of the motivating example first. \n```\n# Import patient note\np = pd.read_csv('../datasets/patient/case_study_5/pt1_note.csv')\n\n# Get trial index\ntrial_index = int(p['Trial_Id'].loc[1])\n\n# Import the clinical trial\nct = pd.read_csv(\n  '../datasets/trials/case_study_5/NCT001373",
        "label": 2
    },
    "309": {
        "output": "**_Note:_** **_Always do a_ `Trial-level eligibility: 0) Excluded;`_** _only if the patient_ **_meets_** _the inclusion criteria and_ **_the exclusion criteria apply (for instance, if an exclusion criteria is age related)_ _. If the eligibility assessment is not clear, just skip this line._  \n\n\n**If the patient does not have the full patient note**\nYour task is to fill in the blanks with the right information regarding a 45-\nyear-old postmenopausal woman with cytologically confirmed breast cancer, whose clinical\ntrial exclusion criteria are: \n\n1) <em>Not eligible</em>: <span class=\"kwd\">Age</span> is <span class=\"stg\">greater than</span> 55. \n2) <em>Relevant</em>: has a psychiatric condition <span class=\"kwd\">not</span> controlled by medication. \n3) <em>Not eligible</em>: has a performance status <span class=\"kwd\">not</span> at <span class=\"stg\">least</span> 70%. \n\nYou are allowed to make your own clinical trials, though this is not part of the\nexercise.\n\n\n\n> ## Exercise 3 - Inclusion and exclusion criteria\n\n\n---\n**Exercise Instructions**\n---\nYour task is to fill in the blanks in the following example of an inclusion \nand exclusion criteria table for a clinical trial. The example is adapted from Rigby et al. \nfrom the University of Pittsburgh's Department of Urology in the USA. The table contains \nmultiple rows. Each row describes a different patient. The columns contain \nthe corresponding inclusion and exclusion criteria.\n\n\n**This is the definition_** **_file_** `inclusion-exclusion.txt`: Inclusion and exclusion criteria file for exercise 3 \n\n\n### [0] Description\n\nThe criteria file indicates criteria that will be used to determine patient eligibility. \nThe criteria can be specified as: \\* (required), / (exclude), [] (",
        "label": 0
    },
    "310": {
        "output": "[CODE]\n#!/usr/bin/python2\n#\n#\n#\n# Copyright (C) 2018, <NAME>\n#\n# This program is free software; you can redistribute it and/or\n# modify it under the terms of the GNU General Public License\n# as published by the Free Software Foundation; either version 2\n# of the License, or (at your option) any later version.\n#\n# This program is distributed in the hope that it will be useful,\n# but WITHOUT ANY WARRANTY; without even the implied warranty of\n# MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE.  See the\n# GNU General Public License for more details.\n#\n# You should have received a copy of the GNU General Public License\n# along with this program; if not, write to the Free Software\n# Foundation, Inc., 59 Temple Place - Suite 330, Boston, MA 02111-1307, USA.\n#\n# (You can find the license here:\n# http://www.gnu.org/licenses/licenses.html )\n#\n\n#\n#\n# Use cases: Clinical Trial Eligibility\n#\n# Author: [NAME]\n#\n\nimport csv\nfrom collections import Counter\n\n# Load the necessary modules.\nimport string\nimport re\nimport pprint\nimport csv\n\nclass Clinical_Trial_Eligibility:\n\t\"\"\"\n\tClinical_Trial_Eligibility\n\t\"\"\"\n\t\n\tdef __init__(self,\n\t\t\t\t\t trial_level_eligibility):\n\n\t\t\"\"\"\n\t\tInitialize the Clinical_Trial_Eligibility class.\n\t\t\n\t\tArguments:\n\t\t\ttrial_level_eligibility (Trial_level_eligibility):\n\t\t\t\tthe Trial-level eligibility file\n\t\t\n\t\tReturn value:\n\t\t\tNone\n\t\t\"\"\"\n\t\tself.trial_level_eligibility = trial_level_eligibility\n\t\tself.trial_",
        "label": 0
    },
    "311": {
        "output": "### 8.4) What is a clinical trial with only 10-20% eligible participants?\n[MAT] A  clinical trial in the U.S. is defined as a clinical trial ''that is not exempt from and has not been deemed to be exempt from, registration in ClinicalTrials.gov by the [FDA] Commissioner and has not obtained an applicable exception from the requirement of a U.S. [IRB/EC]''  This term is equivalent to an Interventional Clinical Research Study in Korea, wherein there is no obligation to register the clinical trial.\nA U.S. clinical trial with 10% to 20% eligibility means an Interventional Clinical Research Study in Korea that meets all of the criteria as stated below.\n\n1) This study will be carried out in accordance with the Good Clinical Practice.\n\n2) This study is defined in the regulations as a clinical trial.\n**[TIPS] This means only drug studies are excluded. \n3) The objective of the study is not to establish the efficacy of a therapeutic product. 4) The trial is conducted on healthy humans. 5) The trial is a phase IV drug study other than the post-marketing trial, drug interaction study, and drug abuse/prevention study. \n6) The clinical trial is planned to include 200 to 600 subjects who will be assigned to either a treatment group or a placebo group. 7) The trial is conducted in more than three study sites in the U.S. \n8) A trial whose objective is to establish the efficacy of a biologic drug is excluded. \n\n### 8.5) Why should I register such a clinical trial?\n[MAT] The clinical trials of drugs and biological products are required to be registered on Clinicaltrials.gov. Clinical Trials on Drugs and Biological Products. The term includes the study of a new drug and biological product, and the study of an approved drug or biological product for a new use. However, the trial will be exempted if the following requirements are met:\n- It is a Phase",
        "label": 0
    },
    "312": {
        "output": "Explanation. `Trial-level assessment of enrollment. The trial in [data.trial] is an open-label study, so, your answer should not be ``1.'' The inclusion and exclusion criteria specify that the patient's axillary lymph node status would not be determined until the time of her surgery. Therefore, her preoperative lymph node status is not sufficient to be a valid exclusion criterion. However, the exclusion criteria for metastatic visceral disease and Hb<10 require blood tests (either Hb, anemia tests, or any other blood test for metastases). However, as mentioned above, `CXR was remarkable for metastatic lesions` implies that the patient has metastatic lungs. Therefore, you should answer `2.`.[data.trial].data.condition_1_comment=='Clinical stage III' [data.trials.data.condition_2_metastasis_site=='bones']\n\n* \n\ndata\n\noutput:\n```\nTrial-level assessment of enrollment\nTrial-level eligibility: 2) Eligible\n```\n\n### Assignment rule\nSome trials have some conditions on assigning patients. For example, some trials specify the maximum number of patients who can be assigned from each center.\n\nBefore answering this question, you should first learn the following: \n1) In the case of a multi-center trial, the patients may be assigned to certain centers according to the number of cases required in each center. \n2) In trials with multiple arms, participants may be equally assigned to each arm, or participants who meet certain eligibility criteria may be randomly allocated to each group.\n\nThus, you should answer this question by considering what methods are used to assign participants to each group. For example:\n* If the answer is equal assignment, add to the output of your response a string like `assignment: equal assignment`, e.g., `assignment: no assignments`. \n* If the answer is maximum allocation, add a string like `assignment: maximal allocated`, e.g., `assignment: maximal allocated (1 patient per center)`. [data.trial](data/data.trial/). \n  - For random allocation, add",
        "label": 0
    },
    "313": {
        "output": "Happy Coding!\n<EOD> A Molecular Docking Study on the Binding Mechanism of the Anticancer Compound, Xanthohumol with Estrogen Receptor \u03b1 in Breast Cancer\n\n\n\n# Introduction\nBreast cancer continues to be the leading cause of death globally, despite being one of the top malignancies worldwide, and early detection is one of the most significant ways to treat women with this disease. The breast is the primary site for 77% of malignancies in women, and it accounted for 15.4% of worldwide cancer-related deaths in 2019, surpassing lung cancer (18%), which is still the most common [bib_ref]  A case-control study to assess the breast cancer risk factors among breast,..., Kaur [/bib_ref] . The estrogen level in breast cancer patients is much higher than in normal people because the estrogen receptor (ER) can bind to the ER-binding sites in the 5-prime region of the steroid metabolism gene and the genes involved in the proliferation, division, and invasion of ER-positive breast cancer cells [bib_ref]  Targeting estrogen signaling in triple-negative breast cancer, Piibe [/bib_ref] . Therefore, ERs are attractive therapeutic targets for ER\u03b1-positive breast carcinomas and endocrine resistance treatment target [bib_ref]  The steroid hormone receptors as developmental druggable targets, Pike [/bib_ref] .\nEstrogens are sex steroid hormones that regulate female reproduction. They are also involved in processes such as the cell and tissue growth and development that occur throughout the body [bib_ref]  The biology of ER\u03b1-positive and ER\u03b1-independent breast cancers, Clevenger [/bib_ref] . Estrogens work by binding to specific receptors in cells. Estrogen receptor-\u03b1 (ER\u03b1) is expressed in the majority of both normal and cancerous breast tissue [bib_ref]  The steroid hormone receptors as developmental druggable targets, Pike [/bib_ref] . Estrogen receptors (ERs) include two subtypes, ER\u03b1 and ER\u03b2. The expression of these subtypes of receptors is different. Estrogen receptor (ER) binds to estrogen, stim",
        "label": 0
    },
    "314": {
        "output": "This is a short example. In the future, I will show more detailed examples in a separate post.\n\n---\n\n[Learn More](https://www.harcourselabs.com/product/machine-learning-products/pycaret/overview/)\n<EOD> Diagnosis of diverticular hemorrhage by computed tomographic diagnosis.\nA case of diverticular hemorrhage, which was detected by computed tomography (CT) examination due to non-specific symptoms and subsequently was proven to have occurred by angiography (AG) is reported. It is thought that the use of AG should be restricted to cases diagnosed by CT examination as being unsuitable for conservative treatment of this disease and to cases showing a rapid deterioration in symptoms despite treatment. For unstable cases seen outside the hospital, an immediate CT examination is advisable in order to avoid AG. The usefulness of CT is described and various aspects of the diagnostic procedures are discussed.<EOD> Rheumatoid arthritis associated interstitial lung disease (Rheumatoid arthritis/Interstitial lung disease)\nWe present an update of rheumatoid arthritis (RA) patients with interstitial lung disease (ILD). The spectrum of clinical findings of RA/ILD is broad and requires high level suspicion since it is frequently asymptomatic at initial presentation. The classification of RA-ILD is based on the underlying pathological processes, which encompass usual interstitial pneumonia, organizing pneumonia, nonspecific interstitial pneumonia and lymphocytic interstitial pneumonia as the most common subtypes. Diagnosis of RA-ILD is challenging as a consequence of nonspecific pulmonary symptoms and often nonspecific radiological findings. Therefore, a comprehensive diagnostic approach based on clinical, radiological, serological and histopathological evaluation is required. Recognition of distinct phenotypes in patients with RA and their outcomes are important for therapeutic decision making.<EOD> Characteristics of ovarian follicles and corpus luteal development in beef heifers fed three supplemental fat sources.\nTen nonlactating beef heifers",
        "label": 0
    },
    "315": {
        "output": "To add any additional annotation, such as exclusion criteria like in our example, you can go to the section 'Histopathological Eligibility' (which is after the 'Treatment Eligibility' section, and add the exclusion criteria as `Histopathological Eligibility. Excluded due to tumor histology: TNBC`.\n\n# The Patient Registration Summary\nYou may add patients to your study without manually entering the inclusion and exclusion criteria again.\nInstead, the patient is assigned to your trial, and the inclusion and exclusion criteria are copied, as well as additional parameters from the patient's record that the application recognizes as important or useful for inclusion and exclusion.\nYou create the Patient Registration Summary for this trial:\nAdd the Trial to the Current Trials Table through the Study Action Bar.\nClick 'Patient Setup'\nClick 'Patient Registration'.\nAdd parameters from the patient record which are recognized as important or useful for inclusion and exclusion such as sex, histology, the TNM classification and the ECOG performance score.\nSelect the patient record by checking on name and hospital ID.\nClick `New Patient`.\nUse one of these 3 options:\n- Export the list of eligible patients, that is visible and editable.\n- If the trial, but not edit of your clinical trial information and save . In the study's, which is important eligible parameters.\nInclude trial by trial set is exclusion to export\n-set the trial .\n-eligible or not trials trial 's parameters registered trial in a trial and eligible or ineligible trial's disease.\n-specific criteria that in trial eligible patient's eligible trial's eligible data with the trial's trial to set of trial's parameters toxic-patient eligible.\nIn some patient trial's data-specific parameters -exact data.\nInclude trial.\nSet not trial's set up, which are trial protocol's exclusion parameters or the number, the eligible-eligible parameters for the eligible patient's parameters to set of trial's trial you should be included parameters (d set of inclusion and elf trial.\nLet's trial you eligible-trial elig",
        "label": 0
    },
    "316": {
        "output": "# Evaluating the Patients\n\nLet's find out the number of patients for a trial and eligible patients in the trial, i.e., the total number of patients and the number of eligible patients for trial `A` in the `Patients` list. [NOTE] As in the [Practical application] section, we use the `for i in` loop to iterate over the patients and trials in the patients list. \nfor trial in patients:\n    for patient in patient.trials:\n        patient.Eligibility_num += 1\n        if patient.trial == A:\n            print patient.Trial_num, \"Eligibility_num\", patient.Eligibility_num \n\n# Evaluating the Trials\n\nLet's find out the distribution of trials for various characteristics, including trial size, trial type, trial status, trial name, trial location, trial phase, the number of assessments, type of study, the number of protocol versions. In order to get the details as you want, you can modify the code as you need.\nHere, the data for the evaluation of trial information comes from the `trials` in the `patients` list. Let's count the number of each trial type in trial. \nfor trial in patients:\n    print trial.Trial_type, trial.Trial_num \n\n\nA trial has a sequence of versions. We assume that a trial does not have multiple versions simultaneously. We can also identify patients' conditions using the version data. \nfor trial in patients:\n    if len(trial.version_list) > 0:\n        print trial.Trial_number, trial.version_list[0]\n\nElastic Net Regression for Predicting Eligibility",
        "label": 0
    },
    "317": {
        "output": "Here is the clinical trial.\ntitle: Comparison of Progesterone Receptor Gene Polymorphism between Malignant and Benign Lesions.\nsummary: The uterine progesterone receptor has been shown to be a marker for resistance to endometrial cancer treatment. The correlation of the progesterone receptor gene polymorphism with progesterone resistance and clinical endometrial cancer is still controversial, and the progesterone receptor gene polymorphism needs to be further studied to obtain more detailed information.\n\ninclusion criteria:\n- Uterine malignant disease histologically confirmed as endometrial adenocarcinoma or atypical hyperplasia with endometrioid cyst\n\nexclusion criteria:\n- Pregnant or currently breast-feeding\n- Suffer from malignant, cardiopathic, pulmonary or nervous diabetes, or endocrine diseases",
        "label": 2
    },
    "318": {
        "output": "### Exercises\n\n#### Exercise I - Reader\n\n1. In this case, the patient is cytologically confirmed to have breast cancer. If we look at the information, this information does not clearly indicate what stage the patient was at when the cancer was histologically confirmed. Let's assume that the patient is diagnosed with cancer by core biopsy. \n1. In case of core biopsy, the question of whether the patient is in early or advanced stage is not relevant.\n[/EXERCISE]\n\n**Exercise II - Reader - Trial design and eligibility criteria**\n1. The title and summary of the study indicate that the study concerns a phase II study.\n1. **The title and summary of the study have mentioned the design of the study as a clinical trial. Accordingly, a randomized controlled trial is described in Clinical Trial_03.md.**\n[/EXERCISE]\n\n2. The trial design of the first line indicates that a two arm comparison was made.\n2. _____ in the study is a two arm study.\n\na. 1\n\nb. 2\n\nc. 3\n\nd. 4\n\ne. 5\n\n2. What is the intervention in the first-line study?\n\n\n---\n**Answer key Exercise II - Reader**\n\n___\n**Exercise II - Answer key**\nWhat is the purpose of the study?\n___\n\n3. At what stage of the disease is inclusion based on age?\n___\n\n4. Which of the following factors allow the patient to be enrolled in the trial?\n5. In which situation is the patient not eligible according to the study criteria?\n6. Which trial design is described in the trial description?\n7. In order to participate in the study, the patient must meet the following inclusion criteria. Which of the following includes an inclusion criterion?\n8. Which of the following situations may not be excluded, according to the eligibility criteria?\n***\n**Exercise II - Summary**\n\nThe trial is described in the following way.\n\nThis study will focus on 100 patients with metastatic breast cancer. Patients who had not received any medicinal product intended",
        "label": 0
    },
    "319": {
        "output": "<jupyter_code>if (age<17):\n    print(\"Excluded\")\n    trial_assessment_out = Trial_assessment_out + \"Excluded\"\nelif (age>80):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"\nelif (age>=80 & age<=85):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"\nelif (age >60 & age<=70):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"\nelif (age >65 & age<=75):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"\nelif (age >55 & age<=65):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"\nelif (age >60 & age<=70):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"\nelif (age >45 & age<=65):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"\nelif (age>45 & age<=65):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"\nelif (age>50 & age<=60):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"\nelif (age>12 & age<=32):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"\nelif (age>12 & age<=25):\n    print(\"Not relevant\")\n    trial_assessment_out = Trial_assessment_out + \"Not relevant\"",
        "label": 0
    },
    "320": {
        "output": "[SECTION2] # Determining trial-level eligibility [/SECTION2]<EOD> Phase 2 study of oral panobinostat (LBH589) in relapsed and refractory multiple myeloma after at least one IMiD.\n7530 Background: Panobinostat (LBH589), a pan-deacetylase inhibitor (pan-DACi), exhibits strong in vitro activity in multiple myeloma (MM), inducing growth arrest, differentiation, and apoptosis. A randomized phase 2 trial was initiated to characterize the efficacy and safety profile of oral panobinostat in heavily pretreated patients with relapsed and refractory MM, with the goal of future phase 3 study of panobinostat.\n\n\nMETHODS\nPatients (Pts) with MM in progress after \u2265 1 IMiD therapy and disease refractory to both IMiDs (n = 118) or refractory to both IMiDs and bortezomib (n = 23) were randomized 1:1 to receive panobinostat 30mg or 20mg. Pts are dosed on a flat daily schedule based on 28-day cycles. The primary endpoint was response rate by IMWG criteria. Per protocol, randomized Pts had to meet study inclusion criteria and receive at least one dose of treatment. Cohorts of 12 randomized Pts were planned. Primary completion was designed to occur after 18 randomized Pts were enrolled and dosed per protocol in the first cohort.\n\n\nRESULTS\nFifty-nine Pts met the protocol requirements. Response rates for the two targeted cohorts were (30mg vs 20mg) 48% (4CR, 2 VGPR) vs 40% (2CR, 2 VGPR) for IMiD-refractory and 30% (1 VGPR) vs 17% (0CR, 1 VGPR) for IMiD and bortezomib-refractory. In the pooled population,",
        "label": 2
    },
    "321": {
        "output": "[END]\n\n___\n<EOD> In vitro antifungal activity of cephalosporin alone and in combination with some antifungals against dermatomycetes isolates as causative agents of skin infections.\nIn vitro antifungal activities of cefuroxime alone and in combination with some antifungals against dermatomycetes isolated from localized skin infections were studied. Of the twelve antifungals tested, ketoconazole showed significant inhibiting activity against all isolates, nystatin and miconazole against all but three and all isolates, respectively. While the cephalozime had marked sensitivity against all and two isolates, respectively. Combination drug therapy may be helpful in the management of superficial fungal infection where there is need for more effective drugs in the treatment.<EOD> Improved methods for analyzing and interpreting anticoagulation therapy in the nephrotic syndrome\nAnticoagulation therapy in the nephrotic syndrome, especially when diuretics are administered, has often been complicated by interference with routine test procedures, and difficulty in detecting the onset of bleeding.<EOD> Cutaneous lymphography: an evaluation of the methods of demonstration of lymphatic channels and flow.\nCutaneous lymphography is the roentgenographic demonstration of the dermal lymphatics at the paw or foot by the intradermal injection of a contrast substance. In a study of three methods of injecting the contrast material, the authors conclude that the use of a finely ground, dry, and tastless starch powder, or of water soluble India ink is preferable because it produces better, more permanent, and less subjective films. Of the three methods of demonstrating the lymph flow in normal dogs, two appeared to be clinically superior. This article is intended to demonstrate this new area of dermatology.<EOD> Apoptosis, oxidative DNA damage, and antioxidant enzyme activities in relation to risk factors in essential hypertension.\nEssential hypertension is considered to be an atherogenic vascular disease that shares many features with cardiovascular disease. This study was conducted to determine whether DNA damage is present",
        "label": 0
    },
    "322": {
        "output": "# Task 2\n\nA clinical trial is about treating a certain type of cancer, but you have noticed that the patient has multiple types of cancer, so you should exclude this patient from the trial. However, you have not observed a multiple cancers in other patients of the trial, so you conclude that cancer type is not relevant according to inclusion criteria. Now you should exclude it from the trial. Use `Trial-level exclusion: ` and type the cancer type instead of the eligibility score.\n\n# Task 3\n\nLet's think out of the box. You are thinking about the problem from the other angle. Suppose that you have an in-silico trial recruitment scenario, which clinical trials should you include a patient. You don't wait for the trial to start but decide now when this should be the case. You should run your in-silico pipeline, i.e., run tasks that are typically run when deciding about patient eligibility, i.e., `Trial-level eligibility: 2) Eligible.`. Let's continue and think back. `Trial-level exclusion: ` is related to the exclusion criteria and must be empty for the patient to be eligible. `Trial-level characteristics: 3) Male` should be empty if the trial considers sexually active patients or patients with previous birth of children.\n\n# Task 4\n\nIn the next task, you have to think out of the box again. Imagine that your in-silico pipeline is in a real trial, i.e., that this recruitment scenario should actually happen. Patient's clinical characteristics, such as genetic markers, should be in your recruitment trial and available in your input file. Suppose for example that one of the clinical trials has multiple types of cancer as inclusion criteria and you want to include this patient from the trial in order to improve the clinical trial's precision. In this task, you should create an extra column in the patient's input file, type the patient's multiple types of cancer as `type_cancer: ` for example, and recreate the input file for the two clinical trials to include this extra information. Thereafter, your job is the same as in the previous tasks, i.e., run your in-silico pipeline and check if the patient is in",
        "label": 2
    },
    "323": {
        "output": "[TEST]\nWrite a script to generate all possible combinations of {factor} values for the patient Note and run them through the clinical trial {clinical trial} you are testing.\nIn this exercise, you need to first make use of the list comprehension and tuple unpacking functions of `str.join` and `tuple` respectively. We have already seen these two functions previously.\nIn the script below, test the patient note over the {clinical trial}, with the intention of assessing the trial-level eligibility for each combination of values. [TUTORIAL_NOTES]\n\n[TEST]: \nclinical trial_list = [\n    [['age <40'], ['female'], ['breast cancer']],\n    [['female'], ['breast cancer']],\n    ['breast cancer'],\n]\n\nresult = list(map(lambda m: test_recruitment.test_recruitment._get_inclusion_criteria(\n  note = test_recruitment.test_recruitment.get_patient_note(), trial = \n  clinicaltrial_list[m[0]]), clinical trial_list))\n\n\nresult\n\nIn the beginning of this script, we will first create a list containing 4 lists like a `list of lists`, namely `clinical_trial_list`, where each containing list will correspond to different clinical trials. We will then iterate over the list of lists to create the list of trial values and unpack it using the `tuple` function. This produces a list with 3 sublists. Each sublist corresponds to a different element of a trial, and will be accessed through the `m` variable for a given index. You may also use a list of dicts as the input, but it's not recommended because you will create many nested loops.\nThe script above tests a list of trial values using the patient note and gives the result at the end. Each time the test script is ran, the clinical trials will be tested in parallel and the outputs will be concatenated together to produce a result. The result in this case is a list of lists, where each sublist corresponds to the trial eligibility for a specific combination of values. This is because the output is of the form `Trial-level eligibility: 1)",
        "label": 0
    },
    "324": {
        "output": "We are about to finish now. \n\n\n# Selenium\nSelenium is an element that was first discovered in 1817 by the Swedish pharmacist Jons J. Jacob Berzelius. Selenium is a key element in the antioxidant enzyme, glutathione peroxidise (GPx), which protects cells from free-radical damage. GPx protects cell membranes from damage by oxidizing lipid peroxides in the membrane to water. The glutathione (sulffide-glutathiones) molecule is reduced by GPxs to the metabolically inert disulphide glutathione (sulphide-glutathiones). \n\n\n# Sodium selenite\nSodium selenite is an ammonium salt of selenium. Sodium selenium compounds have antioxidant properties that inhibit free-radical damage associated with degenerative disease. They also have some pro-oxidant properties that may contribute to cancer protection due to induction of apoptosis (cell death).\n\n# CoQ10\nCoQ10 or ubiquinone is a component of electron carrier and energy transport system of the mitochondria in the electron transport chain process. CoQ10 acts as an antioxidant to reduce damage by oxidative stress. CoQ10 is converted to the CoQ0 after oxidation of electron carriers in the electron transport chain. CoQ10 electron carrier, with the function of transport system. The energy transport system carrier's function electron transport systemic trial a patient. CoQ electron. This clinical condition's electron carrier transport to the mitochron and condition's trial for transporter trans-derived conditions from the energy transport of the clinical condition's function of the patient's condition of an electrans transport to an individual disease mitochondria transport (respiron conditioning function in the transport function carrier transport (including and mitochond transport conditioner's conditioning function, such as in the condition and a treatment condition and its function and transit transported an function a disease.\nDiselectron.\ncondition and function, function-resident's conditioned condition or function of the conditioner conditionally and conditions of",
        "label": 0
    },
    "325": {
        "output": "Good luck!\n\n<EOD> Incremental versus radical approach for the management of intestinal obstruction from adhesions.\nTo the Editor: In the June 2001 issue of theArchives, Leijdekkers et al 1 reported about a cohort of patients with adhesive small-bowel obstruction (SBO) who were operated on with an incremental (incision and drainage), rather than a radical approach (enterotomy). They showed that the incision and drainage group was less frequently intubated before surgery (P =.005), more often had acute SBO (P 1\u20444 .01), more often underwent an extensive laparoscopic adhesiolysis (P 1\u20444 .01), had shorter intensive care unit stay (P = .01), and had shorter hospital stay (P = .03). These favorable results raised several interesting points. Most importantly, the methodology and the outcome measures can be questioned. At the 7 th International Evidence-Based Surgery Congress, held in the Netherlands in 2001, the importance was emphasized of good surgical outcome, defined as mortality or morbidity at 90 days or within the initial hospital stay. The focus of adhesions research should be on the short-term results, rather than on the time of recovery, as stated. 2\u20134 The study by Leijdekkers et al 1 suffers from selection bias because the patients received different treatment after initial laparoscopy, depending on the decision of the operating surgeon, which makes it impossible to evaluate the results of the \u201cincision and drainage\u201d group in isolation. This bias was addressed by 2 separate multivariate logistic regression models, 1 for the entire cohort and 1 for the incision and drainage group, although these analyses were only partially performed. The results are displayed in Tables 1 and 2 of the article by Leijdekkers et al, 1 but the tables should be interpreted with caution. The most important confounders for the outcome variables (mortality and intubation before surgery) were not included in the models, namely the severity of SBO and the number of (radical) enterotomies. These were significantly related to",
        "label": 2
    },
    "326": {
        "output": "*If a patient meets the trial's inclusion criteria, you should specify it with the scale of 2, i.e., `Scored: 2) Eligible.`. *If the trial's exclusion criteria also apply, you should specify it by specifying the two exclusion criteria as `Scored: 0) Excluded.`. *By setting the value of `Scored` to `Scored: Awaiting assessment.`, you can set a flag with the value of `Scored` to let the clinical trial specialist know that the patient is still awaiting assessment. \nHere is an example input file for the trial-level assessment of eligibility. \n```ini\n[Test]\nTitle: Trial-level Eligibility\n[Instance1]\nPatient_note=Patient note for clinical trial recruitment\nClinical_trial=Trial Note\n[Instance1.Patient_note]\n\n# Note: In a Clinical Trial, all possible conditions are specified in the Clinical Trial Note, and are represented in a table of \"Clinical Eligibility Criteria\".\n\nAge=\"45-year-old postmenopausal woman\"\nTumor=Invasive ductal breast cancer; HER2 positive; ER negative; PR negative; Stage 3\nLocation=Left upper outer quadrant\nLymph node involvement=positive (5)\nHistology=2\nBreast Cancer Marker=Cytologically confirmed breast cancer\nMetastasis=A CXR revealed metastatic lesions \nAllergies=No known allergies\nCurrent medications=\"0) None (Multivitamins, Iron Supplements)\"\nChemexposures=No \nNo known sexual partners=\"Not sexually active\"\nNo children=No children \nCongenital Anomalies=No childhood congenital anomalies\nFamily History=No breast cancer in the family; No other known malignancies in family; No history of alcohol or drug abuse; No history of ovarian cancer in mother or sister; No history of cervical cancer \nSex=Candidate for surgery prior to chemotherapy\nMenopause =\"Postmenop",
        "label": 0
    },
    "327": {
        "output": "*Question*\nLet's analyze this note. In the `age range` column, I assume that the patient is either not sexually active or has no children, so, how about your decision? I assume your trial is for postmenopausal patients, so, the range of the trial is postmenopausal woman or cytologically confirmed breast cancer. And as you know the condition of your trial is, you should exclude premenopausal women and cytologically confirmed women. And the rest, as mentioned in the note, you should exclude cytologically confirmed cancer. \n\nYou should make a comment on each decision. [INST] \n\n**Recommendations and decisions**\n\n*Question*\nThis patient is under active treatment and she wants to receive breast-conserving therapy.\n\n*Decisions*\n\n1. You should decide she is excluded due to her age\n\n2. Then, for Trial-level eligibility of your trial, you should choose `2) Eligible`. [/QUESTION] [/QUESTION] [/QUESTION] [/QUESTION] 3) Eligible.\n**Recommendations**\n\n*Question*\nWhat if she wants radiation therapy? Does she qualify for your trial?\n\n*Recommendations*\n\nThere is not enough evidence to show radiation therapy is not recommended for this kind of patients. \nThe patient should be excluded.\n\n**Explanation**\nGenerally, postmenopausal women have lower estrogen level than younger women, so low estrogen level is an independent prognostic factor for survival in postmenopausal breast cancer patients. Radiation therapy has the benefit of reducing breast cancer mortality and it can be applied to postmenopausal women with low estrogen levels. For this note, what the patient needs is adjuvant radiation therapy for breast cancer, so in this note, she may not be eligible for radiation therapy.  \nPlease refer to  https://www.cancer.org/treatments/radiation-therapy/understanding-a-radiation-therapy-plan/fact-or-myth.html , `How do doctors decide whether to offer breast cancer patients radiation therapy?`",
        "label": 1
    },
    "328": {
        "output": "## Examples:\nFirst, please see this patient note, from whom you wish to obtain trial-level eligibility:\nAge: 52 Sex: F BMI: 23 EGFR:+\nLung disease: No\nKnown second primary: No\nMetastasis at diagnosis: Yes Stage: IIB\nLiver: No\nBrain: No\nVisceral: No LDH: 209\nFemale: Yes Chemo prior CCRT: No. Please see Trial-level eligibility.\nIf a patient does not meet the trial eligibility criteria, the output will look like this: \n[INST:0.triall_eligibility_exclusion_info]\nExclusion criteria. This information is taken from the patient clinical trial profile (see the patient clinical trial profile).\nA patient who has one of these exclusion criteria is automatically excluded since none of his/her inclusion criteria are met. Note that a trial's inclusion and exclusion criteria are not checked sequentially. Instead, a patient's eligibility is checked for all the inclusion and the exclusion criteria in one shot.\nSecond, you should see this patient clinical trial profile:\nPatient ID: 1700000002 Gender: f BMI: 23\nLiver: No\nLung disease: No\nBrain: No\nVisceral: No\nHistology: Adenocarcinoma Stage: IV Stage: IB-IIB Clinical Stage: IIIA Metastasis -primary site: Lung Primary-site size: .15 m2 \nMetastasis, location: Lymph Nodes-Mandible, Brain Metastasis-Bone Metastasis-Liver, Pericardium\nLung: N1 Lung -Right N2 Lung -Left Bone: Yes Necrosis: Necrosis in 60% of the tumor cells -40% of the tumor cells have preserved structures Cytology: Positive -malignant Cervical lymph nodes: Yes\nAdenocarcinoma: Yes EGFR:+\nClinical Stage: IIIA Clinical Stage: IB-IIB\nExclusion Eligibility: Trial: 1 Elig",
        "label": 0
    },
    "329": {
        "output": "---\n<EOD> A single-center comparison of early- versus late-administered \u03b2-blockers on the outcomes of patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock\n\n\n\n# Introduction\nCardiogenic shock (CS) after ST-segment elevation myocardial infarction (STEMI) is associated with a high mor- The authors have no funding and conflicts of interest to disclose.\nTo investigate the clinical features of CS patients with STEMI according to the presence of acute heart failure (AHF) on admission.\nMethods: The study included 306 CS patients with STEMI who were enrolled from January 2010 to December 2018. The study subjects were divided into two groups based on the presence of AHF on admission: the AHF group (n = 179) and the non-AHF group (n = 127). In addition, patients in each group were further subdivided based on the time of implementation of the \u03b2-blockers: early administration group (\u03b2-early): \u03b2-blocker use within 24 h after admission, and late administration group (\u03b2-late): after 24 h.\n\n# Results\n\n# Conclusion:\nThe present study showed that the early-administered \u03b2-blockers are associated with improved outcomes of STEMI patients with CS.\n\n## K e y w o r d s\ncardiogenic shock, single-center study, STsegment elevation myocardial infarction, \u03b2-blockers\n\n## Key messages\n- \u03b2-blockers provide significant beneficial effects in patients with STEMI complicated by CS.\n- There still exist controversies on whether early or late administration is beneficial in patients with CS.\n- \u03b2-blockers within 24 h of admission resulted in a greater reduction in allcause mortality.\n\n## | introduc ti on\nAcute myocardial infarction (AMI) is one of the leading causes of death worldwide.A recent study performed in China reported that about 1.49 million patients were admitted for AMI, yielding discharge prevalence and incidence of 925.8",
        "label": 2
    },
    "330": {
        "output": "the eligibility`s trial for your medical trials in an active the protocol the trial-specific trial's active/pass's eligibility, and a patient's a clinical eligibility information should be used to assess`s oncological trial, eligible (i`s history of the medical trial of disease's medical assessments. The patient and trials medical condition is the trial's 1 trial 73 of`s eligibility for trial's active trial the doctor's history 2. The investigator-eligible trial`s for the trial's doctor's oncological. 210 is determined medical history's eligibility status trials to your medical history's trial eligibility medical history and health trial's for the patient's infection.\ntrial disease registry for the medical trial, trial`s.\ntrial patient for an assessment. Ifelig ability to the trial. PDA elig elig trial's trial`s trial. the patient-relevant you are not active patient's medical trial/happoints, diagnospecular patient trials are not eligibility. To have a doctor: eligibility.\n[s`s.\nel that should you.\nelig.\nand 25] the active criteria. 1 or 6 eligile. or the patient should be eligible or trial-el. trial. Medical trial.\nor=trial if the medical trial.\nin medical elig.\npat the elig. All patients.\nhealth's elig trial elig inelig trial a random, which is a clinical trial, which requires el [in which elig trial.\nA patient who the clin, and the eliz.\n\nby determ, the elig. the elig elig, with the patient. Patient (trial patient for the trial's medical trial elig the trial. Include trial, you.\ntrial.\npat, and the need to the trial, and trial and cancer and end, in the patient`1, and trial.\n[for the patient. The patient,el.\n\nTrial trial. These oncological statuses and for theta, the health, you el ical.\n[criteria, health.\n(el. There",
        "label": 0
    },
    "331": {
        "output": "Please input your name under `Notes`. [INST]\n\nClinical Trial Name:\nIf it is an ongoing study, give it a 10-digit unique study identifier such as the last 9 digits of the UMIN Clinical Trials Registry. `2013-07524`\n\nAggregation Strategy:\nPlease use the following terms from `Active clinical trials in breast disease published in the Annals of Surgery from 2001 to 2011` by the Department of Surgery, Osaka University [J].\nPlease refer to \"Methods: Assignment and interventions\" in \"Eligibility assessment\" for more explanation.\n\n### Patient\n\nPatient ID:\nPlease use numeric format.\n\n\n```html\nvar $patientName=$('<div class=\"form-group\" >');\n$($patientName).append('Input patient's name: ').append($('<input id=\"patientName\" class=\"form-control\" type=\"text\" />'));\n```\n\nThis is also important for the aggregation strategy, don't you think.\n\n# Patient-level eligibility (Patient-level Eligibility)\n\n## Not Available\n\n### Concept \n\nThis section determines whether a patient with the following characteristics might be eligible for the trial. [INST]\n\nThe patient has invasive or ductal carcinoma of the breast and is suitable for neoadjuvant chemotherapy prior to mastectomy. \nThe patient has HER2-negative invasive carcinoma of the breast (ER, PgR, HER2-negative) and hormone receptor-positive breast cancer (ER and/or PgR with \u2265 10% staining by IHC). \nThe patient is not pregnant. \nThe patient is not participating in any other clinical studies. \nThe patient provides an informed consent form.\n\n### Assessment\n\nYou should make a patient-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\nThere is not a need for an assessment if the patient is not el",
        "label": 0
    },
    "332": {
        "output": "<section class=\"sourcecode sourcecode-python\" data-src=\"/data/problemsolving-python-67-py4-example-02.py\">\n    <div class=\"code-block sourcecode-python\" id=\"section2339606534543053242959436\">from unittest.mock import ANY\nfrom flask import current_app, render_template, session\nfrom flask.ext.prison import Prison\nfrom py4 import Py4, Data, Export, Dummy\nimport pytest\nfrom py4.prison.config import configuration\nfrom web.user.exception.exc import PrisonerKeyExceedMaxDaysException\n\napp = current_app\n\nclass Py4MockTestCase(Py4):\n    @pytest.fixture\n    def _PrisonerKeyExceedMaxDaysException():\n        \"The variable is provided by the fixture\"\n        exception = Exception(\"The variable is provided by the fixture\")\n        return exception\n\n    def _prisonKeyExceedMaxDays(self):\n        \"\"\"Mock a PrisonerKeyExceedMaxDaysException to test the exception handling in prison.\"\"\"\n        exception = PrisonerKeyExceedMaxDaysException([self._PrisonerKeyExceedMaxDaysException()])\n        self.assertNotIsNone(exception)\n        self.assertNotIsNone(exception.prisoner_id)\n        self.assertIn(\"PrisonerKeyExceedMaxDaysException\", str(exception))\n        self.assertNotIn(\n            \"Exception: \", str(exception), \"PrisonerKeyExceedMaxDaysException\"\n        )\n        self.assertIs(exception.prisoner_id, self.prison.getPrisonerIdByName(prisoner_id))\n\n    @pytest.mark.parametrize(\"output,expected\", [\n        (\"output\", \"PrisonerKeyExceedMaxDaysException\")\n    ])\n    def test_prison_key_exceed_max_days_raise_exception(\n        self, output, expected\n    ):\n        \"\"\"Test the exception handling in prisoner_key_exceed_max_days.\"\"\"\n        fake_instance = input(\"F",
        "label": 1
    },
    "333": {
        "output": "## Requirements\n* This is a requirement from the jira project. To run this file in a jira sandbox, you have to change one line from this requirement to your project: `var trial_level_eligibility = { \"field\": \"Trial-level eligibility\", \"from\": \"2. Recruitment\", \"to\": \"3. Trial-level eligibility\", \"data\": [ { \"patient_noteligible\": 0, \"patient_notrelevant\": 1, \"patient_eligible\": 2, \"noteligible\": 0, \"notrelevant\": 1, \"eligible\": 2 } ] };`\n\n## Tests\nWe are running two steps which return success:<EOD> Is There an Optimal Antiplaque and Gingivitis Fluoride Dentifrice?\nIt is difficult to reach any conclusions about the role of antimicrobial agents in dentifrices in plaque control from the results of these four studies, due to differences in design and materials.' The addition of chlorhexidine digluconate and cetylpyridinium chloride to sodium monofluorophosphate reduces plaque accumulation more at some sites than others and therefore seems to have a site selective efficacy. It may be that these products could effectively work at sites more susceptible to plaque, for example, buccal or oral surfaces of molars due to the accumulation of food debris.2 Further work is needed on these products before their use can be fully recommended for the control of dental plaque and periodontal disease. There are also a number of unsolved research questions. The use of a standardized plaque score system is needed if data from other investigators can be compared. This system should be accompanied by measurements of plaque and salivary levels of streptococcus mutans. There is also a need to compare the plaque-inhibitory effect of chlorhexidine digluconate and cetylpyridinium chloride in the mouth against that of sodium monofluorophosphate, sodium metaphosphate and sodium tripolyphosphate. This would provide a useful guide to the selection of the most suitable formulation for a new dentifrice.",
        "label": 0
    },
    "334": {
        "output": "[HELP]\n\nIf the user inputs either missing or wrong values in the patient's information, the patient can still be assessed as `Not relevant` or `Excluded`. If any of the input fields have a problem, the output fields will always be updated to `Not relevant` or `Excluded`.\n\n[NOTE]\n\nThere are two points to consider here.\n\n(1) If the eligibility status of any input field is changed, the eligibility status of all other input fields will be updated. In other words, the eligibility status of the patient cannot be determined in isolation from other fields. This is because various clinical trials use different inclusion criteria depending on the disease being studied. \n\n(2) The clinical trial requires information on the patient's disease stage for eligibility assessment. However, it is not possible to accurately assess the patient's eligibility without considering the information on pathological diagnosis of the patient. \n\n[HELP]\n\nAs you learned in Part 1, we created the trial-level eligibility list using the Pandas library's pd.DataFrame class object and `set_index` method to create multiple trial-level eligibility. \n\nNow, use the `loc` property of the pd.DataFrame class object to retrieve rows of information from the data frame. To do this, use pd.DataFrame.loc with the index variable or `sentinel_assessment_patient_note` to retrieve values for individual patient assessments. \n\n`assessment_df.loc[\u2018patient_note\u2019, \u2018sentinel_assessment_patient_note\u2019]`\n\nIt is possible to obtain the eligibility status of the patient for each trial by filtering the information of the assessment patient using the `sentinel_assessment_patient_note` variable as the index variable. \n\n`assessment_df.loc[\u2018patient_note\u2019, \u2018sentinel_assessment_patient_note\u2019].index.tolist()`\n\nHere, index.tolist converts the index type to a list, giving the output as shown below:\n\n```\nlist()\n0    0\n1    0\n2    1\n4    2\n6    0\n7    2",
        "label": 0
    },
    "335": {
        "output": "# Data sources: ###\n\n\n[DATA]\n# Output: ###\n\nIn:\nPatient is included in the trial, if all criteria above are verified.\n\nOut:\nPatient is excluded from the trial, if one or more criteria are not checked.\n\n\n### 3-2. Determine trial-level eligibility\nWe use one line to see eligibility. If the patient is Eligible, we put `Trial-level eligibility: `after this line and end if. For the patient Eligible, we must verify the following criteria in order:\n\n# Inclusion criteria\nName of each inclusion criterion (required) 1. Written, signed consent for trial participation must be obtained from the patient appropriately in accordance with applicable International Conference on Harmonization (ICH) guidelines and local and regulatory requirements prior to the performance of any study specific procedure.\n2. HER2-positive advanced breast cancer previously treated with at least, in the physician's judgment, 2 prior HER2-directed regimens in the metastatic setting.\nPatients who started pertuzumab based anti-cancer drugs within 1 year of study start are allowed.\nPatients in treatment free interval of > 6 months after adjuvant treatment of HER2-positive disease with pertuzumab are allowed.\nPatients who had pertuzumab in the metastatic setting after receiving HER2-directed treatment and at least 6 months after the last dose of pertuzumab are allowed.\n3. Clinical, radiological and/or histopathological diagnosis of invasive breast ductal carcinoma that is HER2-positive.\n- The definition of HER2 positivity should be according to the American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) recommendations or to local institution standard of care, if available.\n- HER2-positive tumors should be HER2 immunoreactivity score (IRS) 3, if FISH negative, or HER2 IRS 2+.\nPatients with HER2 equivocal tumors (HER2 IRS 2) should be included.\nPatients with tumors in",
        "label": 0
    },
    "336": {
        "output": "<EOD> Clinical and Histologic Features of Nodular Regenerative Hyperplasia of the Liver in Children: Single Center Experience\n\n [bib_ref]  Primary biliary cirrhosis presenting with chronic cough, Tucker [/bib_ref]  [bib_ref]  Clinical features and prognosis of primary biliary cirrhosis with antimitochondrial antibody in..., Okita [/bib_ref]  [bib_ref]  Primary biliary cirrhosis without biochemical evidence of cholestasis, Schilsky [/bib_ref]  [bib_ref]  Antimitochondrial antibodies with positive results for all isotype assays: should we search..., Bardella [/bib_ref]  [bib_ref]  Nodular regenerative hyperplasia of the liver in primary biliary cirrhosis, Kim [/bib_ref]  \n\n# Methods\nAll PBC patients above ten years of age who were diagnosed in Children's Hospital of Zhejiang University School of Medicine (Children's Hospital of Hangzhou Medical College) from February 2008 to February 2018 were included. The diagnosis of PBC was based on the clinical symptoms combined with elevated alkaline phosphatase, the positive biochemical test of anti-mitochondrial antibody (AMA) and/or positive pathology features of the liver such as bridging fibrosis, periportal lymphoplasmacytic infiltration [bib_ref]  Primary biliary cirrhosis, Lindor [/bib_ref] . Patients' clinical and laboratory characteristics, biochemistry, and histopathological results were collected and analyzed. The AMA was detected by indirect immunofluorescence (IIF) test (INOVA) using B/BB rat liver tissue sections. The serum level of titer \u2265 1:40 was considered positive, <1:40 negative, and indeterminate for IA/IB [bib_ref]  International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune..., Alvarez [/bib_ref] . The demographic and histopathological characteristics compared among non-nodular regenerative hyperplasia (NRH) group, unexplained nodularity group with no histological features of NRH",
        "label": 2
    },
    "337": {
        "output": "---\n\n[QUESTION] How should you write the output to the `print()`?\n\n> output: 0\noutput: 1\noutput: 2\n\n[ANSWER] Consider outputting a three-element vector: `trial_level_assessment` which stores the trial-level assessment results for the `patient` input. The first element `assessment_id` is the eligibility assessment number and the last two elements are the trial-level eligible values:\n\n~~~\nprint(\"Trial-level eligibility for \" + \"patient_id\")\nfor pat in patients:\n    if trial.eligible[pat]:\n        print(\"Trial-level eligibility: \" + str(trial.eligible[pat]))\ntrial_level_assessment [0] = patient\n(assessment_id, eligible,not_eligible) = trial_level_assessment\n\nprint(\"Triall level assessments for \" + \"patient_id\")\nprint(assessment_id)\nprint(eligible)\nprint(not_eligible)\n~~~~~\n\n\n### `print(assessment_id)`\n`0`\n`1`\n`2`\n\n### `print(eligible)`\n`False`\n`True`\n`True`\n\n### `print(not_eligible)`\n`False`\n`True`\n`True`\n\n---\n\n### Exemplary output\nWe use the command below to plot the probability of eligibility at a trial with 0.5 probability of assessing trial eligibility, i.e.,\n\n~~~\nimport json\nfrom plotly import plotly\nfrom plotly import dash_import_options\ndash_import_options()\n\n# Create plotly object with patient patients\nplotly_data = json.loads(patients)\n\nfig = plotly.draw.scatter(\n    x=['ID'],              # Label each data series.\n    y=['Eligibility'],  # Label each data series.\n    x0=None,           # Optional. Specify the x position of each data point relative to the x dimension above. Default is 0,",
        "label": 1
    },
    "338": {
        "output": "#### Exercises\nExercise to practice\n\n```python\nimport pandas as pd\nfrom sklearn.model_selection import train_test_split\nimport numpy as np\nimport string\nimport math\nimport random\nfrom npt import npt\nfrom data import *\nex1 = Exclusion_Criteria.load_pickle()\nex2 = exclusion_criteria_without_categoryA()\nex = concatenate_clin_trial_and_exclusion_criteria([ex1,ex2])\nex3 = ex2-\"11\", ex2-\"15\", ex2-\"73\",\"117\",ex2-\"167\"\nex[\"dichotomous_1\",\"dichotomous_2\",\"dichotomous_3\",\"dichotomous_4\",\"dichotomous_5\",\"dichotomous_6\",\"dichotomous_7\",\"dichotomous_8\",\"dichotomous_9\"]= None\nex[\"dichotomous_10\",\"dichotomous_11\",\"dichotomous_12\",\"dichotomous_13\"]= None\nex[\"dichotomous_14\",\"dichotomous_15\",\"dichotomous_16\"]= None\nex[\"dichotomous_17\",\"dichotomous_18\"]= None\nex[\"dichotomous_19\"]= None\nex[\"dichotomous_20\",\"dichotomous_21\"]= None\nex[\"dichotomous_22\"]= None\nex[\"dichotomous_23\"]= None\n\nex4 = np.concatenate((2*ex3+ex3,'dichotomous_2+2') #2 is a constant; add an increment of 2\n                     ,(ex3+(ex3-ex3[ex3 in ['A'==0])+ex3[ex3.isin(('2', '3', '4', '5', '7', 'E')] \n                                                 ),'dichotomous_6','dichotomous_7",
        "label": 2
    },
    "339": {
        "output": "[NOTE] [INST] You can use the `Triallevel ` in the `for` loop to make a trial-level eligibility output in the 'Samples' patient table. [/NOTE] \n\n[MODULE] Module 7: Surgery\nIn this module, you will learn how to schedule, document and record the surgery for which the patient is a candidate. Furthermore, you will learn how to generate a `Surgery_date` field in the 'Samples' patient table and make an appointment for surgery.\n\n## [CMD] conda install -c xtasy conda forge channel\nIf the previous command returns an error, please refer to its documentation (see [INST] Chapter 4 1 ) about how to solve this.\n\n## [INST] Python3-dev is no longer available\nYou should install [`Python](https://pypi.org/project/wheel/), [`setuptools`](https://pypi.org/project/setuptools/), [`pip`](https://pypi.org/project/pip/) and [`wheel`](https://pypi.org/project/wheel/) and skip this statement:\n\n```\npip install numpy\npip install scitkit image\npip install python3-dev\npip install wheel\npip install scipy\npip install numpy\npip install nibabel\npip install librosa\npip install jupyter\npip install mlxir\npip install seaborn\npip install yaml\npip install pandas\npython -m pip install --upgrade pip\npython -m pip install --upgrade setuptools\n```\nHere is the installation command using `wheel`:\n\n```\npy install --upgrade xtasy-python\n```\nNow you can install [xtasy](https://pypi.org/project/xtasy/) by following the steps listed in its [README](https://readthedocs.org/projects/xtasy/files/README.txt) or in its [source](https://github.com/XtalPy/xtasy-python/releases/latest/download/xtasy.py). \nIf this process does not work for you, refer to its [FAQ](https://github.com/XtalPy/xtasy-python/blob/master",
        "label": 0
    },
    "340": {
        "output": "# Solution\nCreate the variables for patient. `\n- 0.6 0.4\n\n    [INSERT PRIVATE EVAL] \n    \n    /* Auxiliary variables for patient */\n    variable Patient\n    Patient = {\n    id          : \n\n        /* Inline-Code-Snippet-End */\n\n    }\n\n    /* The patient's score for trial-level eligibility */\n    variable Patient_score       \n\n    /* Inline-Code-Snippet-End */\n    \n    /* The patient's clinical trial */\n    variable Patient.clinical_trial\n    \n    /* The clinical trial-level eligibility of the patient */\n    variable Patient.trial_level_eligibility\n\n    \n    /* 1) Excluded */\n    \n    /* 2) Not relevant */\n    /* 3) Eligible */\n\n    /* Define the score table for the patient */\n    variable Patient_score\n    \n    /* Define the clinical trial-level eligibility table */\n    clinical_trial = \n    \n        /* Inline-Code-Snippet-End */\n    \n    /* 2) Not relevant */\n    \n    /* 3) Eligible */\n\n    /* Define the score table for the patient */\n    clinical_trial_score       \n\n    /* Define the trial-level eligibility table */\n    trial_level_eligibility = \n    \n        /* Inline-Code-Snippet-End */\n    \n    /* If the patient is not a participant of the clinical trial */\n    /* Then we can check the trial-level eligibility table */\n    if (not Patient.clinical_trial) {\n        score = 0\n    }\n\n    /* If the patient meets the trial's inclusion criteria and no exclusions criteria */\n    /* Exclude the patient from the clinical trial */\n    if (Patient.clinical_trial.inclusion & score >= Patient.clinical_trial.minimum) {\n        /* The patient meets the trial's inclusion criteria */\n        score += 1\n    }",
        "label": 1
    },
    "341": {
        "output": "A: @Andr\u00e1s Dudek's answer is much more practical than mine, but I noticed, that your question had a title that's not entirely correct as it's talking about the title of the article (the title within a paragraph), instead of the title of the whole article (the title of the whole article, the title of the article, is written within one sentence, so that it's not written after the question mark. Try to format it as it's more logical. In short:\n\n\n*\n\n*Don't make a question mark at the end of a title of the article\n\n*Keep the question mark at the end (you should move it so it appears after a question mark if you need it to be like your title)\n\n*Reformat sentences to make the articles titles more natural, for example: your title is: \nTitle: HER2 negative metastatic breast cancer or IBC: A trial without PI3K-AKT-mTOR inhibitors, a phase 3 randomized trial\n\n \nyou should write it this way: \n\n# HER2 negative metastatic breast cancer or IBC: A Trial Without PI3K-AKT-mTOR Inhibitors, A Phase 3 Randomized Trial)\n\n*Add your name at the begining of the sentence (first author)\n\n*Add the date of publication as well at the end of the article title\nTry this one\n\nHumbert et al. (2015)\n\n*Humbert, Sara, et al. \"Rev-erb-alpha mediates exercise-induced regulation of Pgc-1alpha and improvement of metabolic homeostasis.\" Cell metabolism 22.5 (2015): 870-884.\n\n*Add the references like this : \n\n# Methods\n\nThe methods to get the eligibility should read like this : \n\n```\n# You should add at least one block for title, authors and affiliations\n\"Eligibility\":[\n  {\n    \"scale\": \"0\",\n    \"title\": \"Excluded\",\n    \"description\": \"The patient met inclusion criteria, but is excluded on the grounds of the trial\\u2019s ex",
        "label": 2
    },
    "342": {
        "output": "![inst02]\n\n### Exercise 2\nIn the second exercise, you will determine whether a patient note of interest is eligible for a clinical trial by analyzing the information in the patient notes of several different patients. When you start the exercise, the following trial is displayed: \nIn a tabular view, we will compare several rows of the table (patient notes) and each column contains a different criterion. These criteria are taken from your input as shown above. Based on the number and type of columns, we can determine a column to be a possible match. To achieve this, we use the following logic steps: \n\n### Preparation\nFirst, you need to prepare the input files which contain eligibility criteria for the clinical trial and patient notes from the file:\n\n\n`<path_to_data>/1D1_data.tsv` \n\n# Exercise 2 - Your Task\n\nExercise 2 will allow you to get a practical idea of a very complex set of rules (the eligibility criteria of the clinical trial) as well as how to write and write codes in Python.  If the patient's record meets these rules, it fits into the clinical trial and it is therefore called ELIGIBLE. Otherwise, the patient record does not fit into the clinical trial and is called NEUVE.  For example, if the patient record indicates that the patient does not have metastases in the axilla, the patient record will be called `NEUVE` because the patient cannot be operated on locally.  In the case of`NEUVE`, some patients are excluded for other reasons (eg, smoking, etc.). \n\n### Write a Python Code to Find the Patient Record\nIn a Python script named `Eligibility.ipynb`, you will find everything that I have already written:  \n\n#### [inst03]\n\n#### [inst04]\n\n#### [inst05]\n\n#### [inst06]\n\n#### [inst07]\n\n```python\n# +\nimport sys,  # you must import this library to do an IPerf run\nimport os\nos.system('echo \"%T\"')\nsys.path.append('../')\nsys.path.append('../../')\nsys.path.",
        "label": 0
    },
    "343": {
        "output": "### Test\nFirst we have to prepare some data from [here](https://raw.githubusercontent.com/alxgx/NaturalLanguageUnderstanding/master/training%20data/patient%20notes/clinical%20trial%20notes.csv). We have to make some changes in the data before starting of the work. I modified all data and you can directly use that data. These changes are shown by red font below.\n\n### Construct Patient Information Clinical Note Classifier\nFirst, construct the Patient Information Clinical Note Classifier.\nCreate a new file under `clinicaltrials/clinicalnote_classifier/.` Then, write the following files by yourself under that folder.\n> patient_classifier.py\n> sentence_classifier.py\n`clinicalnote_classifier.yaml`\n`clinicaltrials_evaluation_metrics.yaml`\n> \n> patient_data_loader.py\n\nNote: `clinicalnote_classifier.yaml` is like `clinicaltrial_classifier.yaml`. I wrote the content of `clinicaltrial_classifier.yaml` and let you write the content of `clinicalnote_classifier.yaml`. If you want some help, please leave a message later.\n\n### Build and Train your Model\nNow, build and train your model by following steps.\n- In `clinicalnote_classifier/build_and_train_clinicalnote_classifiers.py`, write the following content.\n```python    \n# TODO - Build and check the accuracy of patient information classifier \nbuild_clinicalnote_classifier(name = \"patient_information_classifier\", data = \"TrainingSet\", vocab=load_word_v_clinical_trial_notes.yaml)\ntrain_clinical_trial_notes_classifier_with_bag_of_words_features(data = \"TrainingSet\", name = \"clinicalnote_classifier\", vocab = load_word_v_clinical_trial_notes.yaml, feature = \"clinical_note_vocab\")\n```\n> Before you run these code by yourself, you",
        "label": 1
    },
    "344": {
        "output": "## Expected results\n\n![output](./output.png)\n<EOD> On the use of quantum chemical topology software in the study of protein dynamics and conformational substates.\nThe use of quantum chemical topology software, i.e. the topology and geometry of the electron localization function (ELF), as a tool in the study of hydrogen bonding, water orientation, dynamical and conformational substates in proteins is described. ELF values above (below) 0.7, which corresponds to the borderline between the highly polarized (highly localized) regions of the electron distributions, allow very efficient prediction of hydrogen bonding of amide protons, water molecules positioned within various types of clusters and non-polar solvent. The ELF values may be used in conjunction with distance distributions, molecular dynamics simulations and visual inspection of electron density to differentiate dynamic (low ELF-value regions) versus rigid regions (high ELF-value regions) of proteins and their substates by providing a \"fingerprint\" of the structure of the electron density at a location at the atomic scale.<EOD> A Case of COVID-19 Post Vaccinated Death and Autopsy Report.\nCOVID- 19 infection leads to death by causing serious inflammation in the body. So far, no therapy or vaccination method was proven safe for this virus. COVID- 19 death in vaccinated persons is a recent issue of great concern. Here we present the case of a person who died three weeks after receiving the Corona Virus vaccine. All diagnostic specimens from the deceased patient were found positive for COVID-19 viral RNA. The autopsy and histopathology report of the body of the patient was performed, and the cause of death was confirmed. During the autopsy, there was no evidence of pathological lesions in the lungs, kidneys, or lymph nodes that have been reported in some fatal cases infected with COVID- 19. This case highlights the possible side effects of vaccination on COVID- 19 patients, although the possible causes of death in this patient have not yet been clearly identified.<EOD> Effect of Hormone Therapy and Estrogen on Neurogenesis\nIt has been hypothesized for some time that estradiol administration would promote ne",
        "label": 2
    },
    "345": {
        "output": "## \u00a9 University of Debrecen (UniDeb.hu) 2022<EOD> The effect of the novel 5\u2010HT4 receptor ligands, MK\u20102524 and WAK 400, on rat colonic myoelectric activity\nActivation of 5\u2010HT4 receptors by exogenous agonists stimulates colonic motility. However, the in\u2010vivo pharmacological characteristics of these receptors are not well known. The effect of 5\u2010HT4 receptor ligands on rat colonic myoelectric activity was investigated. Intracolonic instillation of the nonpeptide selective 5\u2010HT4 receptor agonists, MK\u20102524 and WAK 400, at a concentration of 30 mg l\u22121 significantly enhanced the pressure\u2010length activity and tended to shift the colonic motility pattern towards non\u2010propagating activity. Moreover, as revealed by the in\u2010vivo colon manometry recording in the isolated perfused rat colon preparation, 5\u2010HT4 receptor agonists had no intrinsic activity on the smooth muscle. The 5\u2010HT4 receptor antagonist, BIMU 1, at a concentration of 10 \u22126 mg l\u22121, did not affect spontaneous colorectal motility but abolished the stimulatory action of MK\u20102524. The selective NK1 receptor antagonist, RP 67580, at a concentration of 10 \u22128 mg l\u22121, did not affect colonic motility pattern under basal or MK\u20102524\u2010treated conditions. The results of the present investigation demonstrate, for the first time, the involvement of 5\u2010HT4 receptors in the rat colorectal excitatory motor responses induced by intraluminal administration of 5\u2010HT4 receptor agonists. The stimulatory effect of stimulating 5\u2010HT4 receptors on colonic motility is mediated via a postsynaptic 5\u2010HT4 receptor\u2010mediated mechanism as evidenced by the in\u2010vivo abolishment of the motor responses by 5\u2010HT4 receptor antagonists.<EOD> .\nThe results of",
        "label": 0
    },
    "346": {
        "output": "<EOD> Synthesis of a highly oxygenated phenanthrenoid from ferulic acid. Identification and total synthesis of rhododendrin, a naturally occurring phenanthrolone.\n A highly oxygenated phenanthrenoid is isolated from the rhizomes of Rheum palmatum as a new natural product and is identified as rhododendrin, 6,1'-dihydroxy-6',7'-dihydrophenanthro-2'-carbonic acid. The total synthesis of rhododendrin is accomplished in nineteen steps from commercially available ferulic acid.<EOD> .\nBACKGROUND\nBoth aplastic anaemia and myelodysplastic syndrome are bone marrow failure diseases. The progression from mild to moderate to severe aplastic anaemia, in which the bone marrow is functionally dysplastic because of increased apoptosis, has been studied, but little is known of the aetiology or genetic factors that govern the progress of aplastic anaemia to myelodysplasia.\n\n\nCASE REPORT\nWe report three patients with aplastic anaemia. One was a child who had a normal haemoglobin (Hb) level during remission and suffered a relapse, which was characterised by an elevated Hb level (> 15 g/dl) and an increase in the number of neutrophils, and was rapidly fatal. A second patient had a sustained increase in the Hb level during relapse and died after seven months, following a myelodysplastic syndrome. The third patient had a myelodysplastic syndrome and died, three months later, after refractory aplastic anaemia.\n\n\nDISCUSSION\nBone marrow failure diseases appear at the extremes: severe congenital disease or mild acquired disease. The evolution from mild to moderate to severe aplastic anaemia can be considered as a progression from low bone marrow cellularity to cellular dysfunction, mainly induced by impaired apoptosis. The progression from aplastic anaemia to myelodysplasia is characterised by increased apoptosis in the bone marrow; it follows a different pattern with different evolution",
        "label": 0
    },
    "347": {
        "output": "**Clinical_study**-the code of the clinical trial\n[![INST](https://github.com/nf-core/onpIDB/blob/master/doc/INST.png)](https://docs.google.com/presentation/d/e/2PACX-35F9988o7Eg9HWt_JY9_UeKwkHZHJOYXx7Wbk1318bQD72gEj1w/preview#slide=id.g2)\n\nYou should always pass a `clinical_study` parameter when making an assessment of eligibility by the patient note, such as:\n    onpIDB_assess_eligibility(clinical_study = \"clinical_trial_1\")\n\nThis will repeat the Trial-level assessments by trial name, e.g.,\n```\nTrial-level eligibility: 0) Excluded\n    Assessed by: Patient note\n```\n\nYou can give a trial name by using the `clinical_study` argument.\n\n**Note:** There is only one active clinical trial available in our demo data, namely `clinical_study = \"clinical_trial_1\"` should make the assessment of eligibility.\n\n[![INST](https://github.com/nf-core/onpIDB/blob/master/doc/INST.png)](https://docs.google.com/presentation/d/e/2PACX-35F9988o7Eg9HWt_JY9_UeKwkHZHJOYXx7Wbk1318bQD72gEj1w/preview#slide=id.g2)\n\nYou should always pass an `interval` parameter when making an assessment of eligibility by trial name. This will also calculate the time period when the trial was active, such as:\n    onpIDB_assess_eligibility(clinical_study = \"clinical_trial_1\",interval = \"from 2021-01-04 08",
        "label": 2
    },
    "348": {
        "output": "# Related Tasks\n- [Task 2]: [TASK 1] - Exclude Patients\n- [Task 3]: [TASK 2] - Include Patients\n\n## Related Concepts\n- Inclusion and exclusion criteria\n- Inclusion and exclusion criteria\n- Concepts of clinical trials\n\n# Concepts\n- 2) Eligible.\n\n# Concepts\n- 2) Eligible.\n- Inclusion and exclusion criteria\n\n# Concepts\n- [TASK 1] - Exclude Patients\n- [TASK 2] - Include Patients\n\n## Acknowledgements\n\n### Programming\n\nThe content you see here includes material exclusively prepared by the authors for the CTFs-Evaluation program.\nWe also want to thank the following people who contributed to previous versions of this program:\n\n\n### Content\nAll CTFs-Evaluation content is licensed with a [Creative Commons Attribution 4.0 internaional](LIC) license (https://creativecommons.org/licenses/by/4.0).<EOD> In vitro susceptibility of Leishmania panamensis to 18 antimonic acetate and a combination of chloroquine/amphotericin B.\n\nThe present study describes the susceptibility of promastigotes of Leishmania panamensis to sodium oleate, dipotassium glycyrrhizinate, and a combination of chloroquine+amphotericin B. A control strain was used in order to analyze the in vitro susceptibility variations, the intra-treatment variations and the inter-treatment variations of the promastigotes and intracellular amastigotes of L. panamensis from patients from an endemic village in Nari\u00f1o, Colombia. The in vitro susceptibility variation in promastigotes, amastigotes and infected tissue macrophages showed lower IC50 values for sodium oleate (p = 0.000), with the lowest of 298.1 \u03bcg/mL, and dipotassium glycyrrhizinate (",
        "label": 2
    },
    "349": {
        "output": "[TUTORIAL] The `Trial-eligible Patient Summary` block\n\nTo determine why a patient does not meet the inclusion criteria of a clinical trial, please enter into the `Trial-eligible Patient Summary` block.\n\nThis block provides information about why the patient is not eligible to a clinical trial: \n\n- The patient is not eligible because the patient does not have sufficient information to qualify for the trial. This usually occurs when the patient does not have a diagnosis of breast cancer, but there is a chance that the patient might be diagnosed with breast cancer at some point. If you have concerns, make a note and look at the `Patient Information Summary` block to figure out more.\n\n- The patient is not eligible because the patient has a previous admission history of breast cancer. If you want to confirm whether the patient has a previous admission history, look at the `Patient Admission History` block",
        "label": 0
    },
    "350": {
        "output": "![C337099]![INC73F449]\n\n\n\n<commit_msg>C337099: 1. Use `pwd` command to see the current working directory and go to the root directory. 2. Use the full path specification of the directory to save the file. 3. Create the directory and paste the file into the new directory.<commit_after>@import url('https://fonts.googleapis.com/css?family=Roboto:400,700,400italic');\n@import url('https://fonts.googleapis.com/css?family=Saira+Text');\n\nbody {\n  font: 16px/1.28 'Roboto 400,700,400italic' !important;\n  height: auto;\n  text-align: left;\n}\n.doc {\n  height: 1200px;\n  margin: 4em 0 3em 0;\n}\nh1 {\n  text-align: justify;\n  height: 28px\n}\nh4 {\n  height: 28px\n}\n.doc-block {\n  height: 60px;\n  position: fixed;\n  top: 0px;\n  left: 0px;\n}\n\n/**\n * Header\n */\n.header {\n  background: #fafafa;\n  width: 100%;\n  height: 90px;\n  display: none;\n}\n\n.header ul.nav .li {\n  float: left;\n  height: 90px;\n}\n.header ul.nav .li:last-child {\n  margin-top: 14px;\n}\n.header ul.nav .li:last-child:before {\n  content: '';\n  display: block;\n  height: 40px;\n  width: 100%;\n  position: absolute;\n}\n.header ul.nav .li .icon {\n  float: left;\n  margin-top: 14px;\n  height: 40px;\n  width: 40px;",
        "label": 0
    },
    "351": {
        "output": "## IN 1 IN 2 IN 3\n[CLINICAL-STUDY] Hello. Your job is to evaluate the inclusion criteria for a patient who may participate in a clinical trial.\n\nThe assessment of eligibility has a three-point scale:\n0) Excluded (patient does not meet inclusion criteria); 1) Not relevant (patient does not have sufficient data to qualify for the study); and 2) Eligible (patient meets inclusion criteria).\n\nHere are three patients, each one with one inclusion criterion missing. Evaluate the criteria and determine if the patient will be eligible for this trial. \n\n# Introduction to the data set.#\nFor a thorough documentation of the dataset, please refer to the `README` and the `Snakefile` in the data folder.\n\n# Overview of the dataset.#\nThis dataset comes from a study where subjects with breast cancer underwent a neoadjuvant chemotherapy phase, meaning they receive chemotherapy to see if a tumor will shrink or not.\n- There is an important feature in the data set, which is a variable indicating if a patient received an anti-HER2 therapy.\n- Subjects who received chemotherapy and an additional therapy to fight the tumor, namely anti-HER2 therapy, were given a score of 1.\n- Subjects who only received chemotherapy were given a score of 0.\n- Some subjects had missing data (about half of subjects have missingness in their features, especially about ER, PR, HER2 status and HR + status). The missing data were handled with the `missforest` package.\n\n## Important note on the data set.#\nThere are some problems you have to consider before starting analysis with this dataset.\n- There are imputed features in this dataset (`Missing1`, `Missing2`, `Missing3` and so on).\n- Some features are continuous variables like the length and width of the tumor. Those variables were discretized to two groups (e.g., from `Tumor length < 3 cm` to `Tumor length <= 3`) to build a decision tree.\n- `HER2 status` is missing in some subjects. You can impute those missing values using the",
        "label": 1
    },
    "352": {
        "output": "1. First, let's check whether the patient meets the criteria with the following code: (see [[INST][1]).\n```python\npatient_matches = {int(c) - 1 for c in ctypes.c_int[2:5] for i in patient}\n\nInclusion_criteria_matches = {(ctypes.c_long, ctypes.c_long, ctypes.c_double, ctypes.c_long) for criterion in trial.trial_eligibility.criteria if (int(c) - 1 for c in criterion.name) in set(patient_matches)}\n\nInclusion_criteria_matches == {(10, 4, 0, 0)}\n```\nLet's make a `True` if the patient meet the criteria. It indicates that a patient is eligible for a clinical trial. As per the example, the current patient matches the 10 as age factor. If our patient's age satisfies the criteria, you should return a `True` on eligibility_match.\n```python\nif not Inclusion_criteria_matches:\n    eligibility_match = True\nelse:\n    eligibility_match = False \n```\nIt is not true because the patient matches age factors but not gender.\n```python\nelif (int(c) - 1 for c in criterion.name) != \"Gender\":\n    eligibility_match = True\nelse:\n    eligibility_match = False \n```\nThere is not matching the factors for ER/PR but does for HER2.\n```python\nelif (int(c) - 1 for c in criterion.name) != \"Receptor_status\":\n    eligibility_match = True\nelse:\n    eligibility_match = False \n```\nIf the patient meet any of the factors, we should return a `True` on eligibility_match.\n```python\neligibility_match = True\n```\nFinally, return `True` on trial-level eligibility too.\n```python\nTrial_eligiability_matches = { (int(c) - 1 for c in criterion.criteria) for criterion in trial.trial_eligibility.",
        "label": 0
    },
    "353": {
        "output": "### <h4 class=\"panel__title\"># How To Make a Changes For Trial-level eligibility: 0) Excluded?\n\n[INST] You can find the way to make a changes for \"Excluded\" label directly as following: \n\n1  \n\n    ```python\n    for key, value in data.items():\n        if (key) == (\"Trial-level eligibility\") and (value) == (\"0) Excluded\") :\n        data[\"Trial-level eligibility\"] = \"1) Not relevant\"\n    ```\n\n2  \n\n    ```python\n    for key ,value in data.items():\n        if (key) == (\"Trial-level eligibility\") and (value) == (\"1) Eligible\") :\n        data[\"Trial-level eligibility\"] = \"2) Eligible\"\n    ```\n\n3  \n\n    ```python\n    for key ,value in data.items():\n        if (key) == (\"Trial-level eligibility\") and (value) == (\"2) Eligible\") :\n        data[\"Trial-level eligibility\"] = \"0) Excluded\"\n    ```\n\n   \n    \n### <h4 class=\"panel__title\"># How To Make a Changes For Trial-level eligibility: 1) Not relevant?\n\n[INST] You can find the way to make a changes for Trial-level eligibility \"Not relevant\" label directly as following: \n\n1  \n\n    ```python\n    for key, value in data.items():\n        if (key) == (\"Trial-level eligibility\") and (value) == (\"1) Not relevant\") :\n        data[\"Trial-level eligibility\"] = \"Other\"\n    ```\n\n2  \n\n    ```python\n    for key, value in data.items():\n        if (key) == (\"Trial-level eligibility\") and (value) == (\"Other\") :\n        data[\"Trial-level eligibility\"] = \"1) Not relevant\"\n    ```\n\n3  \n\n    ```python\n    for key, value in data.items():\n        if (key) == (\"Trial-level elig",
        "label": 0
    },
    "354": {
        "output": "## COPY PASTE IN STUDIO INSTANCE FILE\n\n\n14. Click the blue Save button in the editor's toolbar. Click the COPY button on the edit bar.\n\n\nThe copy option in the editor's toolbar always duplicates the code that is visible in the code view area. The content in the edit view area will remain unchanged! [EDIT]\n\n## COPY PASTE IN ANOTHER FILE\n\n15. Click the blue Save button in the editor's toolbar, then click the EDIT FROM FILE option.\n\n\nCopying and pasting files is one of the best tricks, but it is important to copy the code of each step and paste it to where it's needed, thus preserving order of the code. [EDIT]\n\n## SAVE\n\n16. Click the blue Save button in the editor's toolbar.\n\n\nClick the blue SAVE button in the editor's toolbar. Make sure to first run your flowchart prior to saving it. [EDIT]\n\n## OPTIONS\n\n17. Click the blue Save button in the editor's toolbar, click the OTIONS button, and select SAVE AS.\n\n\nAs a courtesy to other coders, we ask that you do not create custom variable names. By default, the studio allows you to save a flowchart with only one variable name, named \\#Flowchart. [EDIT]\n\n18. Enter the name of the flowchart as Flowchart (name chosen will be the name of the flowchart) and click the SAVE AS button to save the flowchart.\n\n19. Click the blue Save button in the editor's toolbar, click the SAVE FILE FOR LOCAL EDITOR option.\n\n\nYou can also copy the code of all your steps and paste it in another file you've created (make sure you have the proper path and filename for this file). [EDIT] \n\n## COPY PASTE IN RESEARCH MANAGER FILE\n\n20. Click the blue Save button in the editor's toolbar, click the FILE EXPORT BUTTON and export to Research Manager.\n\n21. On the left-hand side of the screen, navigate to Research Manager and click Open.\n\n\nA file named",
        "label": 0
    },
    "355": {
        "output": "## Expected output\n![Instructions](/assets/img/help/instructions-eligibility-explanation.png)\n\n[!instructional](#instructions)[!instructions](https://docs.google.com/document/d/1TNY0h4GsWtJpKp9Tj9pJg1xKGc1Jvk6533RtYQbFN3I/edit)\n<EOD> Chromogranin A-derived peptides as anti-tumor agent in colon cancer.\nPeptides can have antineoplastic effects in vitro and in vivo. Among these peptides, chromogranin A is a widely distributed neuroendocrine secretion protein and its precursor chromagranin A contains more than 50 copies of pentapeptide with the 61-62-63-64-65 motif (Y/F/W-X-Y/F/W-X-X-F). In our previous work, we observed that some of the peptides derived from chromogranin A showed a positive anticancer effect on colorectal cancer. Based on our previous work, 19 peptides was designed to investigate the ability of peptides derived from chromogranin A in inhibition of colon cancer in vitro. The results revealed that among the 19 synthetic peptides, 6 peptides strongly inhibited the viability of colon cancer cells, in which the peptide R5Y5W7F11Y12-YNYC9 was able to inhibit the growth of HCT116 cells in vivo and in vitro. Moreover, our next experiments displayed that the peptide induced autophagy in HCT116 cell. Further studies showed that GSK-604, an autophagy inducer, can enhance the anti-tumor effect of peptide on HCT116 cell. In HCT116 cells, the peptide decreased the level of phospho-mTOR, phospho-AKT, phospho-p70SK7, phospho-p85, p62, and GSK-",
        "label": 0
    },
    "356": {
        "output": "Let's think how to judge the above patient. The patient does not have a record of chemo before so the trial did not consider the use of metformin before, so it does not have any of the exclusion criteria, e.g., `Chemotherapy<type=\"n.a.\">CXR was remarkable for metastatic lesions.</type=\"n.a.\">.`, so it is not included and we can output `Eligible.`.\n\nIf you are not sure that you can complete the task, the best way is to give up this task.  \n\n### Conducting Trial-level Eligibility\n\nIn this tutorial, we write a script for the task. You do not have to follow the example you are seeing and you can write any code you want even if it is unintelligible to us. If you want to see the code running along the text, it is best to type your code above the input box of the task on the site.  \n\n![Instruction: 6-3]\n\n1. Go to the page for the task and click the [START] button. You will get a trial-level eligibility task (see [instruction] to find task by its ID `10_30_6`).\n\n<figure class=\"instruction-figure\">\n  <img src=\"images/instruction/10_30_6.png\">\n</figure>\n\n2. If the task is running, do not do anything to the computer until the task is ended (it normally takes one minute). Click the 'Review' button. You should see the information below.\n\n![Instruction: 6-4]\n\n3. Click `Create task`. This will create a task that you cannot modify but you can use it to get a token and pay for your work.\n\n![Instruction: 6-5]\n\n4. [If you created and paid your task, please skip this step.]\n\n![Instruction: 6-6]\n\n5. Click the link of your task. The task is on the upper-left corner of the page.\n\n![Instruction: 6-7]\n\n6. Click the pen symbol on the upper-left corner of the task. You should get an input box in which you can input the code for your task.",
        "label": 2
    },
    "357": {
        "output": "# Challenge\nHere is the challenge. It shows that if the patient was a candidate for the clinical trial, the scale of eligibility was 0). 1) Not relevant is not a trial-level eligibility.\n<html>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=UTF-8\">\n<title>Output</title>\n<script type=\"text/javascript\">\ndocument.write('You should output the trial-level eligibility');\n</script>\n</html>\n\n\n---\n**_source code:_** <https://github.com/wchlab/wchlab.github.io/blob/main/inst3.ipynb>\n\n**_output:_** <./output.png>\n\n**_solution_**<br>\n\n~~~python\ntrial = {\n'title': 'Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients',\n'summary': \"\"\"The purpose of this study is to evaluate the tolerance and safety of the rHSA/GCSF in breast cancer patients with different doses and multiple injections.~To observe the pharmacokinetic characteristics of recombinant human serum albumin /granulocyte colony-stimulating factor fusion protein after single and multiple administration'\n\"\"\",\n'inclusion_ criteria': ['Age 18-65.', 'Diagnosed breast cancer', \n'received chemotherapy', 'ECOG performance status = 0 or 1.'],\n'exclusion_ criteria': ['Age <18 or >65.', 'Not diagnosed breast cancer'\n                         'not received chemotherapy', \n                         'ECOG performance status >1', 'No \n                                               leukocyte reduction occurred after chemotherapy', \n                         'WBC\u22653.0\u00d710^9/L, or ANC\u22651.5\u00d710^9/L', \n                         'No serious underlying disease.'],\n}\n\npatient = {\n'patient note': \"The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a",
        "label": 1
    },
    "358": {
        "output": "1: Assessment criteria: `Patient-level eligibility: 1) Not Eligible.`\n2: Trial level eligibility was set in the last line.\nPlease share your thoughts, difficulties, suggestions and ideas with the community.\nTo participate, you need to install python [INST]. \nYou can also run these instructions.\n```\n#! python\npython nlp\n```<EOD> Niche separation enables the successful assembly of a soil microbial community\n\n [bib_ref]  Impact of climate change on future biodiversity, Bellard [/bib_ref]  [bib_ref]  Changes in biodiversity characteristics and functional stability of an alpine grassland soil..., Wang [/bib_ref]  [bib_ref]  Rationalising plant community response to stress: A case for the importance of..., Mommer [/bib_ref]  [bib_ref]  Ecological rules for ecosystem sustainability, J\u00f8rgensen [/bib_ref]  [bib_ref]  Stability and structural change in communities as an experimental method, J\u00f8rgensen [/bib_ref]  [bib_ref]  Eco-evolutionary feedbacks between biodiversity and climate change, Wacker [/bib_ref]  [bib_ref]  Ecological rules for ecosystem sustainability, J\u00f8rgensen [/bib_ref]  [bib_ref]  Stability and structural change in communities as an experimental method, J\u00f8rgensen [/bib_ref]  [bib_ref]  Microbial community response to simulated climate change: Contrasting patterns in leaf litter..., Macdonald [/bib_ref]  [bib_ref]  Biodiversity, stability, and productivity in competitive communities, Lehman [/bib_ref]  [bib_ref]  Biodiversity, productivity and the temporal stability of productivity: Patterns and processes, Isbell [/bib_ref]  [bib_ref]  Biotic homogenization: The final common pathway of biodiversity loss in changing landscapes?, Lep\u0161 [/bib_ref]  [bib_ref]  Soil biotic legacy effects of prior land use change persisted for at..., De Vries [/bib_ref]  [bib_ref]  Fungal community response to climate warming is altered by biotic interactions, Liu [/bib_ref]  [bib_ref]  The mechanisms and implications of plant diversity effects on ecosystems: Examining the..., Lalibert\u00e9 [/bib_ref]  [bib_ref]  Effects of microbial inoculum source on soil microbial community structure and soil..., Liu [/bib_ref]  [bib_ref]  Temporal dynamics of microbial communities during the decomposition of",
        "label": 2
    },
    "359": {
        "output": "In the example presented here, we can observe a patient not being eligible for the clinical trial, since the patient meets the exclusion criteria for the trial (the patient has metastatic lesions).\nOn the other hand, the patient is eligible for the clinical trial, since the patient does not meet the exclusion criteria, and the patient meets at least one inclusion criterion.\n\n## [INST] 5. Construct a new `Table`. \nHere you should add the following rows: Let's think step by step. \n\n## [INST] 7. The row for the patient will contain following variables:\nThe patient ID; Patient gender; Patient age; Patient marital status; Patient sexual activity; Patient children; Patient medications; Patient smoking; Patient alcohol consumption; Family history of certain diseases; Physical examination; Patients CXR; Patients Hx and A/S results; and Patient biopsy results. \nThe row for the Clinical trial will contain the following variables: Trial title; Trial summary; Trial eligibility criteria; Inclusion criteria; Exclusion criteria; and Trial note.\n\n## [INST] 8. The first row should contain the following variables:\nThe first row will contain the following variables: 'Patient ID': Patient ID integer; 'Patient gender': Patient gender; 'Patient age': Patient age; 'Patient marital status': Patient marital status; 'Patient sexual activity': Patient sexual activity; 'Patient children': Patient children; 'Patient medications': Patient medications; 'Patient smoking': Patient smoking; 'Patient alcohol consumption': Patient alcohol consumption; 'Family history of certain diseases': Family history of certain diseases; 'Physical examination': Patients CXR; 'Patients Hx and A/S results': Patients Hx and A/S results; and 'Patient biopsy results': Patient biopsy results. \n\n[INST] 9. The second row should contain the following variables:\nThe second row will contain the following variables: 'Clinical trial eligibility': Trial-level eligibility integer; 'Clinical trial title': Trial title string; 'Clinical",
        "label": 0
    },
    "360": {
        "output": "Ask to discuss:\n\n1. You have encountered a challenge here, why were certain patient data taken into consideration? How do those considerations affect the task of determining a patient's eligibility for a clinical trial?\n2. What happens if one of the inclusion criteria, such as histologically proven invasive carcinoma of the breast. is not satisfied?\n3. How is the evaluation of eligibility made? Is this task done by physicians and/or nurses?\n4. If yes, why?\n       ____ for a clinical trial.\n      ___________ a clinical trial.\n       _____________ a clinical trial.\n       ________________ a clinical trial.\n       ________________ the clinical trial.\n5. What do you think of the use of clinical decision support systems?\n        _____ a good idea.\n        ______ a bad idea.\n        ______ a new idea.\n\n\n\n\n\n\n\n\n\n\n\n\n<EOD> The Impact of COVID-19 on Mental Health in the SARS-CoV-2 Pandemic: A Rapid Review\n\nCitation: Alom, S.M.A.; Lohith, V.; Viprakasam, B. The Impact of COVID-19 on Mental Health in the SARS-CoV-2 Pandemic: A Rapid Review. Brain Sci. 2023, 13, 92.\n\n# Introduction\nThe outbreak of SARS-CoV-2, a viral pathogen that causes COVID-19, was officially declared a pandemic by WHO (World Health Organization) on 11 March 2020 [bib_ref]  World Health Organization declares global emergency: A review of the 2019 novel..., Sohrabi [/bib_ref] . From Wuhan, China, SARS-CoV-2 has spread to all regions and territories around the world through the fast and modern interconnectedness of international air travel in recent decades. As of 2 February 2023, it has spread to 233 countries with 382,989,028 confirmed cases and 5,701,749 deaths. In this article,",
        "label": 0
    },
    "361": {
        "output": "<section id=\"patient-details-and-assessmextra1\" toc=\"#patient-details-and-assessmextra1\" />\n[INST] If a patient meets the trial's selection criteria, the trial will enroll him/her. However, it is possible that the patient is eligible to participate in another trial. \nThis question asks if the patient is already being treated in another trial. It allows you to exclude the patient from this trial if he/she is already taking another therapy. The trial will enroll patients who are eligible in two or more trials. \n\nThe trial may not want to enroll patients already taking the therapy since it will exclude patients having a benefit to two or more trials.\n\nExclude if patient is eligible to two or more trials \nQuestion: `Exclude if patient is eligible for two or more trials.` If the answer is `no`, continue question set. If the answer is `yes`, skip directly to the end of this part.\n\n[INST]\nThis is a question requiring the user to enter a numerical value. Enter a number in the range of 0 to 1. `Number`: [inst_number, INST]<section id=\"patient-details-and-assessmextra2\" toc=\"#patient-details-and-assessmextra2\" />\n[INST]\nExclude if patient is already taking other therapy\n\nThe trial may not want to enroll patients already taking the therapy since it will exclude patients having a benefit to twoor more trials. `Number`: [inst_number, INST]<section id=\"patient-details-and-assessmextra3\" toc=\"#patient-details-andassessmextra3\" />\n[INST]\n\nThis is a question requiring the user to select a value. Select a value to assign. `Value`: [SELECT_ALL, INST]<section id=\"patient-details-and-assessmextra4\" toc=\"#patient-details-and-assessmextra4\" />\n[INST]\nThis check is a binary value. If the answer is `yes`, continue question set. If the answer is `no`, skip directly to the end of this part.",
        "label": 2
    },
    "362": {
        "output": "<EOD> Effects of HA-1271, a P\u2010glycoprotein inhibitor, on the tissue distribution of digitoxin in rats\nThe potential toxicity of digitoxin is related to its long elimination half-life associated with its cardiovascular effects and hepatotoxicity, particularly under P-glycoprotein (P-gp) inhibition. This was explored by measuring plasma and tissue (liver, kidney, lung, skeletal muscle, and heart) concentrations of digitoxin on different times after oral administration of digitoxin (0.3 mg/kg) to rats (in the presence or absence of HA-1271 (100-mg/kg)). The concentrations of plasma and liver digitoxin for groups with HA-1271 were higher than those for rats without HA-1271 (P < 0.05). However, the heart concentrations of digitoxin in groups with HA-1271 were lower than those for rats without HA-1271 at both 15 min (P < 0.05) and 24 h (P < 0.05). These results suggest that P-gp inhibition could modulate and affect the cardiotoxicity of digitoxin in rats.<EOD> Prenatal Stress and Glucocorticoid Hormone Receptor in Rodent Offspring: Exposure\nAdverse effects of prenatal stress are well documented, but the underlying mechanisms are yet to be fully explained. The fetal hypothalamic-pituitary-adrenal axis is responsive to maternal stress; however, glucocorticoid hormone administration to pregnant animals can provide a more reliable means of inducing changes consistent with those observed after maternal stress. The hypothalamic-pituitary-adrenal axis is also a major target for the glucocorticoid hormones, with the glucocorticoid receptor playing an essential role in controlling glucocorticoid hormone actions and providing a molecular link between stress and fetal development. Glucocorticoid receptors are",
        "label": 2
    },
    "363": {
        "output": "After this, we need to compute scores for `f`, `g` and `h`. For the first patient note, we apply `f` and get scores `245, 180, 375`. After this, we apply `g` where note and trial share four factors to get scores `244, 175, 371`. Finally, we apply `h` where note and trial are not in any clinical trial to get score `347`. Thus, the score for the first patient is `340`. \nHere are 10 more patients: The following rules are applied to score each patient: Apply `f` to every combination in the following order: `1 note; 1 trial`, `1 note; 2 trials`, `2 notes; 1 trial`, `2 notes; 2 trials`. After this, apply `g` where two factors or more share between the note and trial, i.e., `1 note; 1 trial`, `1 note; 2 trials`, `2 notes; 1 trial` and `2 notes; 2 trials`. Finaly, apply `h` where the note does not share any factors with the trial, that is, `1 note; 2 trials` and `2 notes; 2 trials`. \nFor the first patient, `f1 = 245, g1 = 244, and h1 = 347; f2 = 215, g2 = 180, h2 = 320; f3 = 146, g3 = 170, h3 = 210`. Thus, the score is 295. For the second patient, `f1 = 375, g1 = 271, h1 = 397; f2 = 255, g2 = 171, h2 = 210; f3 = 214, g3 = 208, h3 = 223\n\n\n# 3. Questions\n\nThis is about the `ClinicalTrialsR package`. This package works for all 515 clinical trials in the `CTWeb` table. To demonstrate the package, we select 10",
        "label": 0
    },
    "364": {
        "output": "[INST] Hello. Your task is to make a diagnosis for a patient using a medical text. You must choose from six types of tests (mammogram, blood test, biopsy, thyroid test, urine test, pelvic ultrasound). \n\nThe task is to determine if a patient has a breast cancer or not. The mammogram, biopsy, thyroid test, pelvic ultrasound are diagnostic tests. That means they are useful in diagnosis. The blood test and urine test are functional tests. That means they indicate the presence of certain substances in the blood or urine, but they do not indicate disease.\n\nThe assessment of the test results has a three-point scale: 0) Normal or negative; 1) Abnormal but requires no intervention; and 2) Abnormal and requires intervention. \n\nHere is the patient note: \nA 22-year-old nulliparous, right-handed female presents to the emergency room with bilateral breast pain and bleeding. You note that she is not sexually active and has no regular partner. She has had no previous surgeries. She has been using oral contraceptives for 7 weeks. She takes no other medications.\n\n### Mammogram \n\n\n\n* ** 2) Abormal and requires intervention.**\n\n\n# Discussion\n\n#### \u8a0e\u8ad6\n\n### Q1. There are some words that seem suspicious. For example, \u2018\u2019she has been using oral contraceptives for 7 weeks\u2019\u2019 and \u2018\u2019sudden and recurrent visual loss may be a symptom of a variety of conditions\u2019\u2019. What do you think each word means? How do they affect the clinical interpretation of this note in clinical practice? You are free to read the rest of the note to get more information for discussion.\n\n## Q2. What are the differential diagnosis of this note for the physician in outpatient setting?\nDifferential diagnosis is one of the foundational steps for clinicians to start their thought process in order to narrow down or disprove each possible differential diagnosis. This is an indispensable skill in order to reach the correct diagnosis based on the information from the clinical note. Let`",
        "label": 0
    },
    "365": {
        "output": "![1](img/1.png)\n\n\n[TEST]\n*This script was written using the R library [testr](https://cran.r-project.org/web/packages/testr/vignettes/testr.html). Testr is the official test suite for R/CRAN.\n*We recommend using testr since it is an official test suite.\n\n```r\nrequire(testr, silent = TRUE, test.suites = TRUE)\n```\n\n#### [x] Pass all test cases for the \"assessment of eligibility\" case study.\n\n```r\ntestr(cases = list(\"assessment_of_eligibility\"))\n```\n\n```\nTests pass! (2 tests and 0 warnings)\n```\n\nIf the test fails with error message, you can explore your model using `trace()` or `verbose()` to help find out where the error came from.\n\n```r\ntestr(cases = list(\"assessment_of_eligibility\"),\n        verbose = TRUE,\n        trace = 1\n        }\n```\n```\nThe fail case is at trial-level eligibility:\ntest124\ntest123\n\nThe pass case is at \nassessment of eligibility\nget_eligibility \n```\n```\nIf all pass, then congratulations! Next time, we will continue with model application in different contexts: diabetes risk, COVID-19, dementia, lung cancer, chronic kidney disease, and diet quality.\n```\n```\n$ sessionInfo\n```\n```\nR version 4.0.0 (2020-06-09)\nPlatform: x86_64-w64-mingw32/x64 (64-bit)\nRunning under: Windows 10 x64 (build 19041)\n\nmatrix(c(1:10, 12), ncol = 2)\n```\n\n\n![title](../../data/image/figure_title.png)\n\n[TUT]\nYour task is to complete the code for the rest of the clinical trials.  \nWrite your code in a file named `soln-clin",
        "label": 0
    },
    "366": {
        "output": "[RUNNER](INST)\n![RUNNER](../images/runner.png)\n\n## S2.2 Clinical Decision Support System in MIMIC 4.0\n[S2_SCHEME](https://github.com/UFCAIJ-Team/UFCAIJ-MIMIC-4.0-Japanese-paper/blob/main/S2/SCHEME/S2.2.md)\\[RUNNER](INST)\n\n### Scheme\n\n[RUNNER](INST) \n![RUNNER](../images/runner.png)\n\n### Assignment of ID by `assign_id()`\\[PPT](INST)\n\n\n![PPT](../images/ppt.png)\n\n### 1st) Create a dataset from a CSV file\\[PPT](INST)\n\n![PPT](../images/ppt.png) \n\n### 2nd) Specify a target patient\\[PPT](INST)\n\n![PPT](../images/ppt.png)\n\n### 3rd) Specify a dataset of a target patient\\[PPT](INST)\n\n![PPT](../images/ppt.png)\n\n### 4th)  `assign_id()` in MIMIC 4.0 dataset\\[PPT](INST)\n\n![PPT](../images/ppt.png)\n\n### 5th)  `assign_id()` in MIMIC 4.0 with 1st) dataset\\[PPT](INST)\n\n![PPT](../images/ppt.png)\n\n### 6th)  `assign_id()` in MIMIC 4.0 with 1st) dataset and 2nd) dataset\\[PPT](INST)\n\n![PPT](../images/ppt.png)\n\n### 7th)  `assign_id()` in MIMIC 4.0 with 1st) dataset, 2nd) dataset and 3rd) dataset\\[PPT](INST)\n\n![PPT](../images/ppt.png) \n\n### 8th)  `assign_id()`",
        "label": 0
    },
    "367": {
        "output": "{, and the \n(that . 4 [bib_ref]\n\nin  cann [bib_ref] \n\nc and the  and i [bib_ref] and [bib_ref]\u00a01.\nd .\n [bib_ref] (after [bib_ref]\u00a0on, iute-match on a trial for a single [fig_ref] on\n. the decisionable (but, but the\u00a0\n\n \ufffd\ufffdcist. as well. The\ns and\u00a0so in a patient 1\u00a0(under in [bib_ref] 1 in the and i\n- 8 and the 1\u00a0only   in the . \u00a0 -in \u00bc [bib_ref]\n \u00f0\n (0\n \n-only-to- [fig_ref] [bib_ref] [bib_ref], including a [bib_ref]; the [bib_ref] .\nacc\ngato\non<EOD> (for standard patient_ [bib_ref] _C (random [bib_ref] as a(or. [bib_ref] [bib_ref] . and\nd [bib_ref] [bib_ref] \u00a0in in a\u00a0 and{ _ 1 or \u00a0(not. 4th on the.\n-d [bib_ref] \ufffd(in \u00c2 on C\n\\d-in and 2\u00a0acc -and for its _ and\nc on [bib_ref] \ufffd...s [bib_ref] a^\n-in the(i\non 2.s for all-complete-complete on the-trelin\n\nsystem..., G    \u22c5 [fig_ref]\n\\for the\n! !. On 1-in [bib_ref] her \u2026...inst...reight (in ... (0 .in \u2021-for the [bib_ref] -\nfor the cet.\ntarget_and-inter Cert (C...and a#\n (can, on his in \u25a0 \u00a0can and 0 -pat in . [bib_ref]\nass for [bib_ref] (\n on F-related<EOD>- . (inst - _ \n1 or ( [fig_ref] 2 in\u00a0d of [bib_ref] in [bib_ref]in \ufffdre to b... [bib_ref] for\n(i, for a 1 in the_i for the\nb to [bib_ref] a^s for \u201a;s of 1 [fig_ref]ind _inst in the in 1 { [bib_ref] on the \u2026.<EOD>/inst 2<EOD> _C on-bours for \" , -[\n [in-above-... \u2011the_ [bib_ref]* (the\ndepo@\n in\\for a - [bib_ref] ( 1",
        "label": 0
    },
    "368": {
        "output": "---\n\n## Clinical Trial Checklist\n\n\nTo complete the clinical trial and obtain a complete Clinical Trial Checklist, please follow the following procedure:\n\n1.  After you have finished evaluating all patients, make clinical decision support for each patient as",
        "label": 2
    },
    "369": {
        "output": "### Instructor's Notes\n\n**Background**\n\nThe assessment of eligibility can be complicated, thus, it is important to develop a process or guideline for clinicians to follow so a patients can be enrolled in clinical trials.  Since there is no a one-size-fits-all protocol, a careful review is needed for each patient to make sure the patient meets the appropriate inclusion criteria.  For instance, a study participant in a multiple myeloma trial would need to have normal blood counts, yet a woman with Hodgkin's lymphoma (HL) who has high risk features may not need to meet the same criteria. Additionally, because research is still in the process of being performed, there are often multiple reasons for exclusion.  Some examples of this can be seen in the following 2 trials: the Multiple Myeloma Trial and the HL-E2C3 trial.\n\n**Assessing a Patient for Eligibility**\n\nThere are 2 main components to assessing a patient's eligibility: knowing the inclusion criteria for the clinical trial, and whether the patient meets them.  Once this is figured out, then the assessment for eligibility can take place.  First, 2 things are figured out: whether the clinical trial is ongoing or closed and whether the person is still eligible to enter the trial. Second, 2 more things need to be figured out: whether the patient meets the inclusion/exclusion criteria, and whether or not the patient is still eligible to enter the trial.\n\n**Hodgkin's Lymphoma (HL) - E2C3 Trial**\n\nAs stated above, there are exclusion criteria as well for eligibility.  For example, the HL-E2C3 trial is a combination chemotherapy trial that aims to improve the quality of life for patients with newly diagnosed Hodgkin's lymphoma.  A person who has been diagnosed with HL who is a good candidate for radiotherapy and chemotherapy is deemed eligible.  Those who have already had a blood transfusion, are unable to receive radiotherapy, or have significant comorbid conditions (such as HIV/AIDS, serious heart failure, severe cardiac dysfunction)",
        "label": 2
    },
    "370": {
        "output": "### [INST] Rules for Assignment of Residues (B, X)\nAssign letter `B` to all residues present at a site of a protein in a particular species. Assign letter `X` to rest of residues.\n\n## Assignment Rules\nBoth `B` and `X` can be assigned to the same residue if this residue is in a single chain. Here is the `single chain` condition. The other condition is `multiple chain`. \n\n- Single chain: only one chain in the protein.\n- Multiple chain: more than one chain in the protein. \n\n## Examples\nWhen a protein is in a species, \n* `single chain protein`, let's assign `B` or `X` to all residues. \n* `multiple chain protein`, let's assign `B` or `X` to some residues, but not all residues.\n<EOD> A clinical and electrophysiological study of sensory\u2010ataxic cerebellar syndrome due to alcohol\nAbstract\u2002 The main effect of prolonged alcohol consumption is cytotoxic damage to the cerebellar cortex, which leads to a sensory\u2010ataxic cerebellar syndrome. At the level of the cerebellar cortex, Purkinje cells are the main target of alcohol injury, and axonal degeneration of the parallel fibres is a distinctive sign of the lesion. The axonal growth of cerebellar neurons is affected, and this causes anatomical reorganization in the Purkinje cell layer, resulting in loss of dendritic branching and alteration of the dendritic field. There is also loss of spines. Axonal growth is not affected within the molecular layer, so that climbing fibres and mossy fibres are not damaged, and efferent afferent connections remain intact. This paper reviews the findings from a prospective clinical and electrophysiological study, and from some longitudinal and cross\u2010sectional studies of patients with sensory\u2010ataxic cerebellar syndrome. The principal clinical findings are cerebellar gait with intention\u2010tremor, cerebellar dysarthria, and abnormalities in sensory discrimination. The electro",
        "label": 0
    },
    "371": {
        "output": "[END]\n\n[#] How to implement?\n\nHere is an example of how to implement for you in a bash script. This could be extended to many languages, if you need it. I use some [bash](/ref/bash). You can change this script for your needs.\nAdapt to your needs. Good luck!\n\n### #!/bin/bash\n##$ # Bash 4.3.48(1)-posix-linux/x86_64 ##$ # $ # export ACCESS_TOKEN=\"access_token\" ##$ # $# export CREDENTIALS_FILE=\"cre-dential-1\" ##$ # $ # export CREDENTIALS_FILE=\"credential-2\" ##$ # $ # export CREDENTIALS_FILE=\"credential-3\" ##$ # $ # export CREDENTIALS_FILE=\"credential-4\" ##$ # $ # export CREDENTIALS_FILE=\"cre-dential-5\" ##$ # $ # export CREDENTIALS_FILE=\"credential-6\" ##$ # $ # export CREDENTIALS_FILE=\"credential-7\" ##$ # $ # export CREDENTIALS_FILE=\"credential-8\" ##$ # $ # export CREDENTIALS_FILE=\"credential-9\" ##$ # $ ##$ # export ACCESS_TOKEN=\"access_token\" ##$ # $# export CREDENTIALS_FILE=\"credential-1\" ##$ # $# export CREDENTIALS_FILE=\"credential-2\" ##$ # $# export CREDENTIALS_FILE=\"credential-3\" ##$ # $# export CREDENTIALS_FILE=\"credential-4\" ##$ # $# export CREDENTIALS_FILE=\"credential-5\" ##$ # $# export CREDENTIALS_FILE=\"credential-6\" ##$ # $# export CREDENTIALS_FILE=\"credential-7\" ##$ # $# export CREDENTIALS_FILE=\"credential-8\" ##$ # $# export CREDENTIALS_FILE=\"credential-9\" ##$ # $## $\n\n### # $ # $\n\n### # $ #",
        "label": 1
    },
    "372": {
        "output": "<EOD> 7 Tesla high-field magnetic resonance imaging-guided focused ultrasound thalamotomy in essential tremor: a multi-modal single-site experience\nBackground Essential tremor (ET) is a highly prevalent disease, yet optimal therapy remains to be established. Current therapeutic options either are inadequately effective or have significant side effects. There is growing evidence that focused ultrasound (FUS) brain therapy is a safe and effective novel therapy for refractory ET. Objective To retrospectively assess therapeutic benefit of 7 T MRI-guided FUS thalamotomy in a cohort of ET patients. Methods A consecutive series of patients who underwent 7 tesla MRI-guided FUS thalamotomy at a single center through July 2018 were included in this study. Demographic, clinical and lesion characteristics, and treatment variables were recorded. Baseline and follow-up Unified Parkinson's Disease Rating Scale (UPDRS) parts III and IV, Essential Tremor Questionnaire (ETQ-9), Rating Scale for Multiple Ataxias (SMAR), and Patient Global Impression of Change (PGIC) scores were obtained on all patients post-FUS (preoperatively 1 day to 1 week and 4 weeks to 6 months). Tremor was quantified by a validated digitized pen grip test. Results Six patients (three males, five right-handed at onset) underwent FUS through July 2018. Mean age of patients was 66.17\u2009years (SD 7.72); mean disease duration was 36.67\u2009years (SD 20.7). The mean time to complete lesion was 20.33\u2009min (6.21) and the mean total sonication time was 27.0\u2009min (4.55). Patients reported significant improvements in tremor, PGIC, SMAR, and ETQ-9 scores 4 weeks to 6 months postoperatively relative to baseline (p\u2009=\u20090.016, p\u2009=\u20090.039, p\u2009<\u20090.",
        "label": 0
    },
    "373": {
        "output": "Exercise\n\nWe will look at the patient note we used in the `Introduction`. Assume we want to know if the patient is a candidate for the trial. If the answer is `No`, you should output it. Include some reasons on how you have reached that decision too. [Note: the output format is as shown in the `Output` table.] Output: If the output is `Excluded`, you should input specific inclusion criteria the patient has violated to explain your decision. If the output is `Not relevant`, you should fill in your reason. If the output is `Eligible`, you should continue to check with the exclusion criteria and output the results. \n\n|Patient ID|   |Note ID|         |Inclusion criteria|                 |Output |                           |\n|------------|------|--------------|-----------------------|-----------------------|---------|------------------------------|\n| P001     | 134   | P001_2612 | 48780201\n|------------|------|--------------|-----------------------|-----------------------|---------|                           |\n|           |     |           |           |         |           |    |           |                        |\n\nExplanation: Assume that you are a doctor. We have given some information about a patient and a clinical trial. You are tasked to determine whether that patient is a candidate for the clinical trial. From the outputs:\n\n| patient notes | clinical trials |  |\n\nExplanation: Assume that you are a doctor. We have given some information about a clinical trial. We want to assign the given trial into three categories according to the given information and the research criteria. [Note: the output format is as shown in the `Output` table.] \n\n|      | patient notes |  |\n|------ |--------------|  |\n|      | 134           |  |\n|      |                |  |\n|      | P001_Note      |  |\n|      | P001_Notes     |  |\n|      | 3333           |  |\n|      |                |  |\n|      | P001_13458742 |  |\n|      | P001_333192",
        "label": 0
    },
    "374": {
        "output": "[for the study.\n- [bib_ref] they-to\n, H[or in elite to do \n[they elig, 1<EOD>( or\u00a0. 14 and \n, as well-ass/and for [bib_ref], in the disease and an [bib_ref], which or on 1. Exsuch.\nbased, \n \ufffdin 2, or a test; at . 1 and \nfor a certain for [bib_ref]{for an 5... 1 for-based or an alternative. and the\n [bib_ref], andto a clin in the 9 on medical and [bib_ref] 1, and \n. [bib_ref]. and without clin 2\u00a0but. In an open-or. To the \n^ . and [bib_ref] . . and [bib_ref], which-for the following its / 10-they, but their \\ \n\n (they   in their \u00a0 they, or [bib_ref] in the 2.\n!\n \n with an el\n in order-related. In some\n. A\nwith 1\u00a0for 4 or\ninst for [bib_ref]\n (el, a\u00a0/ in 1.\nel [bib_ref] or \n [bib_ref], <EOD> and 4 -or-m /\non-c.\npat to a .\n 1\u00a0/on-only\u00a0which, including the^ in\u00a0to \u25cb on a [fig_ref] for the\u00a0only for [bib_ref]..., an 1\n [bib_ref] a/1 and-\non-tract and\u00a0. as well, but a\\for a [bib_ref] a clin \ufffduse_ a  and 23 \\\n! [bib_ref] _ \\based [bib_ref] For and for this Cure , of [/table]\nthat.\nin that\u00a0only\u00a0in that \u223c1 and _\ns at 9-based- 11(in the copen for any or all \ufffd [bib_ref] they-st ...\nspecific\n0-ind-bist- [fig_ref]\n\n\n and\n1 in the _\n(\n\n\n/ex-based lyst and\nex\u00a0in with the [bib_ref]\\ and the1...no, not the .(specific\ns. The of \\med-visual-ex and_for all-in   _on ._ [fig_ref] .s. (h for<EOD>{the\non:{in the...in:",
        "label": 0
    },
    "375": {
        "output": "[INST] ####\n\nYou can also save the notes. [INST] In the main menu you see this: Edit. You write your notes here. You will see the patient note and the clinical trial in the same format than in the main menu. You can write your comments for the eligibility assessment in the fields below and save the note under a number code like `22` for patient no 82 and `RCT1_1` for the first clinical trial.\n[INST] ####\n\n[INST] The code is `0`.\n[INST] Once you press the red arrow it opens the next clinical trial.\n[INST] You work with the patient note, i.e., you assess whether the patient meets the inclusion criteria. The assessment has three possibilities: 0) Excluded (no match); 1) Not relevant (not enough information to assess eligibility); 2) Eligible (match).\n[INST] The trial-level eligibility will be the same in the clinical trial note template.\n[INST] Finally you add the date and time of the eligibility assessment on the top right button.\n[INST] #######################################################################################\n\n[INST] ########## Checking eligibility #####################################################[INST]\n\nHere are all the 198 patients. We check their eligibility. The first patient with 4859 and 4882 is excluded because his diagnosis is a metabolic disease. So we press `0` and press `S` for the second patient (4890) for a metabolic disorder and press `N` for the third one (4931) for a tumor disorder. We repeat that for the rest of the patients until the 122th.\n[INST] Now we get to the end. We get to the summary at the end and we can now press the green triangle for the next patient.\n[INST] \n\n[INST] ########## Checking eligibility #####################################################[INT]\n\n#\n\n# **Chapter 26: Study Data**\n\n[INST](./INST/INT1_5_data_introduction.md)\n\n\n# **Introduction**\n\n[INST](./INST/INT1",
        "label": 0
    },
    "376": {
        "output": "If the patient's note did not contain enough information, you could print it and put it aside to find more details. \n\n---\n<NAME>, <NAME>, University of Illinois Medicine.\n<EOD> The efficacy and safety of biliary stents for the management of benign biliary strictures: a systematic review and meta-analysis\n\nBackground: The efficacy and safety of biliary stents for the management of benign biliary strictures (BBS) have not been assessed in the meta-analytic setting. The objective of this study was to evaluate the efficacy and safety of biliary stents.Methods: Using the search terms \"biliary stent\" OR \"stent\" AND \"biliary\", the following four electronic databases were searched from inception to February 2016: PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews. All prospective and retrospective cohort studies and randomized clinical trials (RCTs) examining the efficacy and safety of different biliary stents (i.e. self-expandable metal stent [SEMS] and plastic stent [PS]) were evaluated according to predefined search terms, inclusion criteria, and selection criteria. The metaanalysis was conducted using RevMan 5.2 software.Results: A total of 1680 potentially relevant articles were identified in the four databases. After duplicates were removed, 49 manuscripts were retrieved from PubMed and EMBASE databases, and through manual searching; 225 potentially relevant articles were identified from the Cochrane library. After the removal of duplicated articles and articles that did not include the key terms, and after screening of the titles and abstracts, 5 randomized clinical trials and one cohort study were considered for the quantitative synthesis. The meta-analysis was conducted using RevMan 5.2 software and random-effects models were applied since heterogeneity was observed; the 6 included papers were all included in the meta-analysis. Heterogeneity was analyzed by Cochran's Q and the I 2 statistic were estimated. The results of the meta-analysis showed that the stent patency rates at 6 months were 80.81 and 20.",
        "label": 0
    },
    "377": {
        "output": "#### Exercises\n[RER] ### Trial-level Eligibility (Step 1) #### 1\nWrite a function eligibility?() that returns the correct value for the eligibility assessment. \n<EOD> A critical review of the effects of food restriction during pregnancy on fetal development.\nThis paper reviews published reports on the effects of food restriction during pregnancy, beginning with the original classic studies of Mott who described reduced fetal growth with this form of exposure. Most modern reports, particularly since the beginning of the 1970s, use either voluntary or involuntary food restriction. Results of animal studies indicate that reduced fetal growth due to voluntary food restriction depends on the time of restriction and the degree of food imposed. Animal studies indicate this type of diet restriction also often results in anorexic pregnant animals and, therefore, reduced placental nutrient transport. The importance of these factors in producing the reduced fetal growth is discussed. The relationship between food restriction and reduced fetal growth is considered in terms how the amount of food consumed may be related to the level of nutrient intake by the fetus. Studies from human populations suggest that the effect of food restriction on birth weight is similar to those in animals. Animal studies show that involuntary food restriction results in a similar fetal growth retardation of approximately 20-25%. Reduced nutrient transfer from the mother also is indicated by these studies. The relationship between nutrient transfer and birth weight, however, is not as well determined due to variable nutrient transfer and growth retardation. The effects of voluntary food restriction by human subjects has not been well studied and the reports published to date by a group led by Dr K. L. Magee are reviewed and their importance is discussed. The findings of studies of humans indicate that a reduction in birth weight of nearly 10% is the average result of this type of exposure. This is considered as an upper estimate of the reduction with involuntary food restriction in industrialized populations and as the lower estimate for populations exposed to famine and starvation. The effects of food restriction on the health of individuals exposed and their offspring is discussed. This paper also reviews the studies on the effects of malnutrition and famine or starvation during pregnancy and lactation. Results of animal studies",
        "label": 1
    },
    "378": {
        "output": "# Author Contributions\n<details>\n\nTreatment Plan is a treatment plan. As such, you write the name of the person providing the treatment plan. A treatment plan may be the first treatment plan (as new medications are often required to be followed before others) or a later treatment plan that replaces the first one with later revisions in response to progress.\n\nYou assign yourself as the author here.\n\n</details>\n\n# Example output\n\n```yaml\npatient note: \n  name: Patient's Name\nauthor: author: \n  first_name: Tx's Name\n  last_name: Tx's Name\n  year: 2017\n  city: Tx's City\n  state: Tx's State\n  country: Tx's Country\n  email: Tx's Email\n  email_verify: false\n  organization: Tx's Workplace\n  organization_verify: false\n  author: author: \n    first_name: Tx's Author First Name\n    last_name: Tx's Author Last Name\n    year: 2017\n    city: Tx's Author City\n    state: Tx's Author State\n    country: Tx's Author Country\n    email: Tx's Author Email\n    email_verify: true\n    organization: Tx's Author Workplace\n    organization_verify: true\n  email: author: \n    first_name: Tx's email\n    last_name: Tx's email\n    year: 2017\n    city: Tx's email city\n    state: Tx's email state\n    country: Tx's email country\n    email_verify: false\n    organization: Tx's email Workplace\n    organization_verify: true\n  email: author: \n    first_name: Tx's email1\n    last_name: Tx's email1\n    year: 2017\n    city: Tx's email1 city\n    state: Tx's email1 state\n    country: Tx's email1 country\n    email_verify: true\n    organization: Tx's email1 Workplace",
        "label": 2
    },
    "379": {
        "output": "- <INST> 0.1 <IN1>=Evaluation & Feedback of the Clinical Trial Inclusion Criteria\n\n## Overview\n[HLO] You are a data analyst specialist and have a question about the eligibility criteria of the trial. The trial is evaluating a candidate drug as a treatment for lung cancer.\n[SIT] You are a physician researcher and have a question about the eligibility criteria of a recent trial. The trial is evaluating a candidate drug as a treatment for lung cancer.\n\nThis exercise contains information about a clinical trial where the candidate drug that provides the treatment for lung cancer. First, you should read the information below completely. It will give you information on the inclusion and exclusion criteria for the candidate drug. \n\n## Overview of the Candidate Drug\n[HLO] The drug is a monoclonal antibody. This drug targets an inhibitory immune checkpoint, reducing lung tumor burden in the NSILE patients.\n\n## Description of the Patient and Drug Characteristics\n[SIT] The drug is a monoclonal antibody. This drug targets an inhibitory immune checkpoint, reducing lung tumor burden in the NSCLC patients. The Phase II clinical trial study showed significant improvement in the survival rate in patients with non-small cell lung carcinoma (NSILE) who had tumors that showed partial response for previous treatment with PD1 inhibitory therapy, however, the effect was variable.\nSome of the clinical studies related to this drug are shown in .\n\n## Evaluation, feedback, and conclusion\n[SIT] \n1. Patient had to have received prior treatment involving chemotherapy as well as immunotherapy. 2. 46 of the 119 patents in the study group were male (39%) and 73 were female (61%). The mean age of the patients was 65. 47 of the 73 males and 47 of 65 females were 60 or older. The ages were comparable between the 2 groups. 3. At diagnosis, 110 patients had stage I disease, 63 had stage II, 14 had stage III, and 12 had stage",
        "label": 0
    },
    "380": {
        "output": "To summarize:\n\n* \n\n* Compose a patient-level eligibility: it should take the form of `Trial-patient eligibility:`, e.g.: `Trialpatient eligibility: 0) Excluded.`. \n\n* Compose a trial-level eligibility: it should take the form of `Trial-level eligibility:`, e.g.: `Trial-level eligibility: 2) Eligible.`.<EOD> The development of immunochemical methods to detect and estimate glucocorticoid concentrations in fish gill\nSUMMARY The ability to detect, identify and quantify immunological markers has increased dramatically in recent years, and there has been a concomitant improvement in the measurement of such markers in environmental media. A number of immunological methods have been developed to determine the endocrine balance and health status of fish, including the measurement of glucocorticoids, a group of hormones predominately regulated by the stress response. Despite the large number of immunoassays based on measurements of these hormones in fish tissues (particularly muscle) and body fluids (plasma and urine), few data exist on the quantification of cortisol in gill. This work aimed to determine the ability to detect and quantify cortisol in this tissue, using antibodies to cortisol and corticosterone. A sandwich ELISA based on cortisol (raised in sheep) as an epitope was developed, detecting concentrations from 1 to 50 ng mL\u20131 (4.7 pmol to 236 pmol mL\u20131), while a competitive radioimmunoassay (RIA) was used to detect and estimate cortisol in gill samples of salmon Oncorhynchus mykiss, carp Cyprinus carpio and goldfish Carassius auratus, which are known to respond to acute and chronic stressors, with cortisol increasing in response to the stressors. This RIA was able to detect cortisol in gill from the fish species, with concentrations ranging from 7 ng g\u20131 to 500 ng g\u20131. The use of gill in immunoassays,",
        "label": 0
    },
    "381": {
        "output": "<EOD> Proceedings of Symposium: HUMAN AGING AND ALTERNATIVE SMOKING BEHAVIORS.\n\nAging is characterized by several alterations in the lung, including an increase in the proportion of immunosuppressive myeloid-derived suppressor cells (MDSCs) that promote tumor progression, loss of lung structure and function, and altered smoking behaviors. These behavioral changes include inhalation tolerance (IT) or \"resignation\" with nicotine addiction and increased levels of aggressiveness, impulsivity, and compulsivity. The aim of the present symposium is to discuss novel findings on the connection of aging and alternative smoking behaviors. Dr. Huber gives an overview of the clinical and epidemiological data available for alternative smoking behaviors. Then, Dr. Lerner discusses the relationship between chronic cigarette smoker/nSAL and the development of a new paradigm for studying nicotine, IT and lung disease. Dr. Onaolapo-Bigolo shows data from genetically engineered models of COPD/lung cancer. These changes are reflected on the levels of transcriptive and post translational modifications in the lungs, as discussed by Dr. Guerrero-Rincon. Additionally, Dr. Onaolapo-Bigolo discusses novel animal models to study aggression, impulsivity and compulsivity, which are associated with alternative smoking behaviors. Finally, Dr. Zawieja presents data on the mechanisms of nicotine tolerance, withdrawal and vulnerability, including the role of genes involved in the metabolism of nicotine. Dr. Lerner discusses the possibility of targeting these mechanisms with therapeutic interventions. These results suggest that in addition to traditional smoking, alternative smoking behaviors are prevalent in both clinical and nonclinical populations, thereby contributing to the severity and prevalence of lung disease. Therefore, alternative smoking behaviors should be included, not only in the history for evaluation of smoking, but also as a potential therapeutic target.\nAging is characterized by several alterations in the lung, including an increase in the proportion of immunosuppressive myeloid-derived suppress",
        "label": 0
    },
    "382": {
        "output": "A: I wrote a script in Python to analyze the dataset:\nfrom scipy.spatial import center_of_mass\nIn[6]: trials_df = trials_df.copy()\nIn[7]: trials_df.trial_number_1='S1007_CT1093_20'\nIn[8]: trials_df.trial_number_2='S305_02'\nIn[9]: trials_df.tumor_id_1='144_04_0639_03_03_12_020'\nIn[10]: trials_df.tumor_id_2='143_01_1295_01_08_04_090'\nIn[11]: trials_df.tumor_size = '2.6'\nIn[12]: trials_df.gross_pathology = 'T2'\nIn[13]: trials_df.lymph_vas = 'TNM_N0_2010'\nIn[14]: trials_df.bone_vas = 'TNM_M0_2010'\nIn[15]: trials_df.carcinoid_vas = 'TNM_N0_2010'\nIn[16]: trials_df.adrenal_vas = 'TNM_N0_2010'\nIn[17]: trials_df.renal_vas = 'TNM_M0_2010'\nIn[18]: trials_df.liver_vas = 'TNM_M0_2010'\nIn[19]: trials_df.lung_vas = 'TNM_M0_2010'\nIn[20]: trials_df.retroperitoneal_vas = 'TNM_N0_2010'\nIn[21]: trials_df.adrenal_vs_vas = 'TNM_N0_2010'\nIn[22]: trials_df",
        "label": 0
    },
    "383": {
        "output": "## Trial-level eligibility \n`$cl.Trial-level-eligibility:` trial-level eligibility assessment\n\nThe assessment of clinical trial eligibility is performed at the patient level. To perform the assessment, however, we need to calculate the patient's eligibility with respect to the trial's inclusion and exclusion criteria and then determine the trial-level eligibility.\nThe trial-level eligibility is the patient's trial eligibility assessment based on the evaluation of eligibility at the patient level. It is calculated and shown in the very last line of the report.\n\n\n### The `cl.Trial-level-eligibility` column\n\n#### 1) `0: Excluded`\nIf a patient was excluded, his trial-level eligibility can be set to `0: Excluded`.\n\nExample 1:\n[EXAMPLE]\n\n\n___ \n\n![Trial-level eligibility]\n\nLet's look at another example:\n[/Trial-level eligibility]\n\n\n\n### 1)\n`$cl.Trial-level-eligibility:` trial-level eligibility assessment\n\n\n\n#### `1: Not relevant`\nIf a patient's eligibility assessment does not lead to an `Eligible` or `Excluded` judgement, it is not relevant to the trial anyhow.\nTherefore, we can set the trial-level eligibility to `1: Not relevant`.\n\nExample 1:\n[EXAMPLE]\n\n\n___ \n\n![Not relevant]\n\nLet's look at another example:\n[/Not relevant]\n\n#### 2) `2: Eligible`\nIf a patient is eligible, he can join the clinical trial. Thus, we can set the triallevel eligibility to `2: Eligible`.\n\nExample 1:\n[EXAMPLE]\n\n\n___ \n\n![Eligible]\n\nLet's look at another example:\n[",
        "label": 0
    },
    "384": {
        "output": "# Problem Set B\n\nIn `problem-set-b-01.Rmd`, try to make some mistakes by running the R code. You should see different responses when you make some mistakes.\n- Missing inclusion criteria\n    - The patient may be excluded based on missing inclusion criteria\n    ```jupyter\n    # Missing inclusion criteria\n    missing_inclusion <- missingInclusionCriteria(patient_note, CT_list)\n    ```\n  - Missing exclusion criteria\n    - The patient may be excluded based on missing exclusion criteria\n    ```jupyter\n    # Missing exclusion criteria\n    missing_exclusion <- missingExclusionCriteria(patient_note, CT_list)\n    ```\n  - Using wrong evaluation function\n    - The patient should be excluded based on missing inclusion criterion and missing exclusion criterion\n    ```jupyter\n    # Incorrect evaluation function\n    incorrect_evaluation <- wrongEvaluationFunction(patient_note, CT_list)\n    ```\n  - Incorrect trial-level eligibility\n   - The patient should be excluded based on missing inclusion criterion and missing exclusion criterion\n    ```jupyter\n    # Incorrect trial-level eligibility\n    incorrect_trial_level_eligibility <- wrongTriallevelEligibility(patient_note, CT_list)\n    ```\n\n# Problem Set C\n\nIn `problem-set-c/problem-set-c-01.Rmd`, you have to make trials without trials' IDs with the data shown in `trials_without_id.csv` and `trials_without_id_note.csv`. Then, you should complete the table in the table in `trial_missing_id.csv` by running the R code, i.e., `RenewTrialID(trials_without_id.csv, trial_missing_id.csv)`. You can create the file in [https://docs.google.com/spreadsheets/d/1FoNYT6DXf3CZ2i_h8V6bWB_c79RbvRlA_Rb7-u1bXkQ/?pli=1].\n\n`Ren",
        "label": 0
    },
    "385": {
        "output": "Your goal is to obtain the information that the patient is `Eligible, Excluded, Not Relevant`, or nothing. The patient's clinical trial assessment is a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). You should make a trial-level eligibility on each patient.\n<EOD> MMP-2 and MMP-9 Are Upregulated in the Inflamed Joints of Patients with Juvenile Idiopathic Arthritis\nObjective. Matrix metalloproteinases (MMPs) play a key role in tissue destruction in rheumatoid arthritis. However, their role in the pathophysiology of juvenile idiopathic arthritis is unknown. The aim of this study was to investigate levels of MMP-2, MMP-9, and TIMP-1 in the synovial fluid (SF) of patients with juvenile idiopathic arthritis compared with paired serum. Methods. SF and serum was collected from patients with juvenile idiopathic arthritis (n = 71) and controls (n = 14). Synovial fluid and serum was analyzed for MMP-2, MMP-9 and TIMP-1 using enzyme linked immunosorbent assay. Results. Levels of MMP-2 and MMP-9 were significantly upregulated in SF of subjects with juvenile idiopathic arthritis compared with controls; MMP-2 SF/serum ratio 4.7 (p = 0.0011) and MMP-9 SF/serum ratio 4.43 (p = 0.0005). Levels of TIMP-1 were also upregulated in the SF of subjects with juvenile idiopathic arthritis compared with controls; SF/serum ratio 2.17 (p = 0.0021). Conclusion. This study of MMP-2",
        "label": 0
    },
    "386": {
        "output": "[END][INST]\n\n\n## 41.  \n[Instructor notes] Please answer the following questions:\n- What does the clinical research fellow use for screening when he/she needs to know which patients to assess for eligibility?\n- Where (in the hospital) does the clinical research fellow send the patients' medical records?\n- With a couple of exceptions, what is the assessment of eligibility based on?\n- What is a patient-level eligibility?\n- What is trial level eligibility?\n- When a trial's exclusion criteria disallow a patient's participation in the trial, what does the clinical research fellow do?\n\n\n \n\n     \n      \n\n\n## 42.  \n[Instructor notes] Please answer the following questions:\n- What happens in the next steps of the process?\n\n`A patient of this trial is assessed as being not eligible according to following two exclusion criteria: - metastasis in central nervous system; - no sufficient information`\n\n`As the exclusion criteria of the trial do not fit our patient, we can enter our patient into the next steps of the process and the patient remains assessable`\n\n     \n      \n\n\n## 43.  \n[Instructor notes] Please answer the following questions:\n- What are the consequences of a patient being excluded by the clinical research fellow?\n- Where can a clinical research fellow look for information of included trials?\n- When a clinical research fellow registers a patient in the hospital, what is he/she asking permission from a ward team supervisor?\n\n     \n      \n\n\n\n`There are different kinds of permissions:`\n- Full permission for every clinical research fellow of the hospital to register a patient: For a very limited number of trials the hospital is a recruiting site.\n- Partial permission that gives the right to some but not all clinical research fellows of the hospital to recruit patients for a certain trial: For the most part, each clinical research fellow from a hospital site can only recruit patients for certain trials that the hospital has permission for.\n- No permission: Some trials will not give permission to any of the clinical research fellows at certain hospitals to register patients for that trial. This type of reg",
        "label": 0
    },
    "387": {
        "output": "## \u00a9 2021, Authors\n\u00a9 2021, Authors\n\u00a9 2021, Authors\n\u00a9 2021, Authors\n@AuthorInst\n# \u3010Chapters\u3011\n<Chapter><FullRef id =\"chapter_1\" /> \n<EOD> 4-{4-[2,6-Bis(4-fluorophenyl)-3-(methoxymethoxy)-4-oxopiperidin-1(4H)-yl]piperazin-1-yl}-2,6-diphenylpyrimidine-5-carbonitrile\n\nKey indicators: single-crystal X-ray study; T = 295 K; mean (C-C) = 0.003 \u00c5; R factor = 0.038; wR factor = 0.115; data-to-parameter ratio = 13.6.In the title compound [systematic name: 4-(1H-pyrrol-1-yl)-6,6-diphenyl-4-piperidinol], C 29 H 25 F 2 N 4 O, the piperidine ring adopts a half-chair conformation. The methoxy and 4-fluorophenyl groups are each twisted away from the plane of the pyridine ring by approximately 37 and 5 , respectively. An intramolecular N-H\u00c1 \u00c1 \u00c1N interaction occurs. In the crystal, molecules are linked by N-H\u00c1 \u00c1 \u00c1N hydrogen bonds into chains along the b axis. These intermolecular interactions are supported by C-H\u00c1 \u00c1 \u00c1F interactions, resulting in sheets lying parallel to the (121) plane.Related literatureFor the biological activity and pharmacological applications of the title compound, see: Peng et al. (1983); Wang et al. (1989); Zhang et al. (1994). Experimental Crystal data C 29 H 25 F 2 N 4 O M r = 487.50 Orthorhombic, Pna2 1 a = 10.975",
        "label": 2
    },
    "388": {
        "output": "![Trial-level eligibility on each patient for the clinical trial](trial-level-eligibility-on-each-patient-for-the-clinical-trial.JPG)\n\n# Tips\n\nBefore we begin your assessment of eligibility with this patient, we have to decide on the inclusion criteria for the clinical study. We'll try both sets of study-level inclusion criteria and see what we find.\n\n## Inclusion criteria 1\n\nThere is a variable named `trial_inclusion_criteria` that represents the study-level inclusion criteria and contains the name of the study or clinical trial. Its value can be changed through three ways:\n\n\n* \n\n\n1.  We should make an empty string. If we enter the value `null` or the value ``,`` we will be able to make a trial-level eligibility or study-level inclusion criteria.\n\n1.  Click the field `trial_inclusion_criteria` and leave it empty. (This is a safe alternative compared to the previous way!)\n\n1.  Click the button `Edit 1` to edit the field `trial_inclusion_criteria`. After entering the value, click again the button `Edit 1.`\n\nNow, there are two ways of finding a trial's eligibility on each patient for the clinical trial or trial-level eligibility. Let's use the first set of study-level inclusion criteria and see what we find.\n\n1.\nClick the button for `Edit 2` to edit the field `trial_inclusion_criteria`.\nClick the button `Update.`.\nClick the button `Edit 3` to edit the field `trial_inclusion_criteria`.\nClick the button `Update.`.\nClick the button `Edit 4` to edit the field `trial_inclusion_criteria`.\nClick the button `Update.`.\nClick the button `Edit 5` to edit the field `trial_inclusion_criteria`.\nClick the button `Update.`.\nClick the button `Edit 6` to edit the field `trial_inclusion_criteria`.\nClick the button `Update.`.\nClick the button `Edit 7` to edit the field `trial",
        "label": 0
    },
    "389": {
        "output": "[fig]  #: To apply the code and get your results, follow this link . You don't need to install any dependencies. When the link loads, follow the on-screen instructions. #To apply the method (using different datasets), follow this link . You don't need to install any dependencies. When the link loads, follow the on-screen instructions. #To apply the method (using a small version of the dataset), follow this link (https://github.com/pawelstanczyk/eligibility). When the link loads, follow the on-screen instructions. ## [/fig] \n<EOD> Acute atherosis developed in granulocyte colony stimulating factor-induced inflammatory skin lesion.\nA 52-year-old woman developed inflammatory skin lesions with itching several months after administration of granulocyte colony stimulating factor (G-CSF) for treatment of aplastic anemia. Histopathologically, the lesion was characterized by lichenoid-pattern lymphocytic infiltration with follicular mucinosis. Subcutaneously developed inflammatory skin lesions and the peripheral blood neutrophil count decreased dramatically, and G-CSF administration was discontinued, because it had previously been shown that skin reactions occurred in both mice and patients due to injection of exogenous granulocytes stimulant growth factor (G-CSF). Eosinophilic and mononuclear infiltration was observed in the newly developed acute atheromas in the medium-sized vessels around the dermal papillae. Granulomatous change and fibrinoid necrosis in dermal papillae with lymphocytic infiltration were seen. These findings suggest that G-CSF-induced severe skin toxicity is associated with local atherogenic tissue remodeling.<EOD> \u2190 Is This The Year I'll See My Own Doctor? Healthy Eating: When To Say When?\n- Related Posts\n-\n-\n-\n-\n-<EOD> A new look at an old subject: the treatment of acute alcohol withdrawal.\nThe use of benzodiazepines or pharmaceutical alcohols is now commonly",
        "label": 0
    },
    "390": {
        "output": "<EOD> Tissue-specific roles of the Wnt/\u03b2-catenin signal transduction pathway in mouse embryogenesis.\nDespite the ubiquity of Wnt molecules and the variety of cellular functions regulated through this signaling pathway, there is a paucity of information about the specific roles played by different Wnt signaling mechanisms during development. In this study, we have examined the developmental effects of inactivation of the \u03b2-catenin signal transduction pathway, focusing on tissue-specific requirements mediated by this pathway and using transient transgenic knockout-mutant mouse embryos. Our results confirm that different Wnt function in the same tissue is mediated by distinct \u03b2-catenin-mediated pathways, each of which contributes a specific developmental program (e.g., in skeletal development, there are \u03b2-catenin-mediated roles of Wnt-4, -3a, and -6). Moreover, we have used transactivation assays to identify in each tissue the specific receptor, secreted factor, and intracellular signaling pathway activated by \u03b2-catenin that is essential for development. These pathways include receptor-mediated activation of Ras or phosphatidylinositol 3-kinase (PI3-kinase), as well as independent activation of the canonical Tcell factor (TCF). These results show that despite the fundamental importance of the \u03b2-catenin-mediated Wnt signal transduction pathway, the pathologic phenotypes arising as a result of loss of this pathway can be quite different from the developmental defects resulting from the loss of a particular Wnt family member itself. Our studies provide a novel mechanistic basis for the tissue-specific roles of Wnt family members, as well as a fundamental understanding of what can be expected to be the broad effects of inactivation of the \u03b2-catenin-mediated Wnt signal transduction pathway.<EOD> Assessment of the quality of evidence from systematic reviews to inform systematic reviews conducted by the Veterans Affairs.\nBACKGROUND\nThe Veterans Affairs (VA) administers a large program of clinical research, most frequently as a commissioned systematic review (SR",
        "label": 2
    },
    "391": {
        "output": "You should output all patient information if it is relevant for the patient-level eligibility. To do so, add line below your `Trial-level eligibility: ` (replace the word ``2) `with the words `Trial-level eligibility: 1) Not relevant.`. \nSo, if you follow all given requirements, the end result will be the following:\n\n    # Patient level characteristics\n    # Name: Sarah\n    # Birthday: 12/17/1975\n    # Trial-level Eligibility: 2) Eligible.\n    #   Age_in_Years: 44.\n    #   Stage: 0.\n    #   Gender: Female.\n    #   Sex: Female.\n    #   Menopause(Age_in_Years): 48.\n    #   Pathology: IDC_No_LVSI_No_SLC_No_LCIS.\n    # Clinical Trial: #505 (Trial A)\n    #    Trial-level Eligibility: 3) Not Eligible (Eligibility criteria: Exclusion Criterion).\n    # Trial-level Eligibility: 2) Eligible.\n\n[C] Exercise file\n\n## Exercise\nMake a trial-level eligibility for the patient provided in the data file exercise. txt. Your answer should be stored in the file trial-level-eligibility. txt.\n\n\nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n<EOD> Reconstruction of the anterior chest wall following total excision of a soft-tissue sarcoma in a child with previous extensive burns.\nSoft-tissue sarcomas originating from mature tissue are rare. We describe the management of a 4-year-old girl with a sarcoma of the anterior chest following previous burns and reconstruction with a chest wall bone-perforator free flap. Total removal of recurrent sarcoma necessitated the removal of her entire anterior chest wall, necessitating a bony reconstructive procedure. A",
        "label": 0
    },
    "392": {
        "output": "<EOD> Cerebral blood flow and vasomotor reactivity associated with postcranial cooling.\nPrevious investigations have demonstrated post-cranial cooling to be accompanied by a local reduction in cerebral blood flow. To determine whether the reduction is sufficient to affect autoregulation or the cerebral vasomotor responses which normally accompany cooling of the scalp, changes in the cerebral vascular bed and total cerebral blood flow were measured during post-cranial cooling in 12 healthy volunteers. Cooling was achieved through the application of ice water to the exposed skin of the trunk and limb, through which scalp blood flow was monitored via a transcranial Doppler. Cerebral perfusion pressures and total cerebral blood flows were maintained constant during the procedure by means of a modified version of the Lambert-Hardy method using isovolumetric hemodilution. Despite substantial changes in the scalp blood flow during local cooling and associated hypothermia, no change was observed in the resting state of the cerebral vascular bed: either the critical closing pressure (38.0 +/- 10.5 vs 35.4 +/- 10.3 cmH2O), the resting flow (61.7 +/- 13.0 vs 54.1 +/- 14.6 ml . min-1 . 100 g-1), or the cerebral vascular resistance (203 +/- 32 vs 188 +/- 62 mmHg . s/ml . min . 100 g) were altered by cooling. Likewise, the vasomotor response to increases in cerebral perfusion pressure and the mean arterial pressure were preserved during cooling. These observations indicate that cerebral autoregulation is preserved during local cooling of the body surface and that the mechanisms underlying the cerebral blood flow response to systemic cooling are localized beneath the skull.<EOD> Tight junctions and cytoplasmic intermediate filaments stabilize the barrier function of a human intestinal cell line in three-dimensional culture\n\nAbbreviations used in this paper:",
        "label": 0
    },
    "393": {
        "output": "## Part 2. The Patient has Squamous Cell Carcinoma of the Thyroid Gland.\n[ENT] Dear doctor, you are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. You will receive a patient note in each part. Here are three patient note examples. \n\nA patient is a 65-year-old woman with a history of stage III squamous cell carcinoma of the thyroid gland. She was previously treated with thyroidectomy plus radiation therapy. She has a 2.1 \u00d7 2.0 cm recurrent tumor on the left side of her neck, and lymph nodes are 2.8 \u00d7 3.1cm and 2.37 \u00d7 2.95cm in size. She has also been diagnosed with atrial fibrillation, and her thyroid condition is under control. She considers herself healthy and does not wish to receive any chemotherapy at this time. [ENT] \n\nA patient is a 63-year-old postmenopausal woman with squamous cell carcinoma of the thyroid gland. She underwent thyroidectomy 13 days ago with lymph node sampling. The histopathological specimen revealed a pT2N2b squamous cell carcinoma of the thyroid gland (right side) with positive surgical margins. Her general condition is poor, and she has a 3.0 \u00d7 2.5 \u00d7 3.0 cm mass at the left side of her neck. Her tumor does not involve the thyroid gland, but her lymph node in the left paratracheal position, 4.2 \u00d7 5.1 \u00d7 2.5cm in size, is enlarged. The clinical stage is cT2N2bM0. In addition, her laboratory results were within normal limits, and her past medical history is not remarkable. She is sexually active and has 1 male child. She does not intend to receive further chemotherapy, but she is receiving anticancer treatment with capecitabine, erlotinib, and trametinib. [ENT]",
        "label": 0
    },
    "394": {
        "output": "[INLN]:\nTo complete this exercise, you need two folders: `Ctio_ClinicTrials` and `Lab_Clinical_trials\\`. They both can be easily create in the following way:\n1. In a Linux console, write the following line of text:\n```git init``\nTo create a new folder.\n\n2. In a Linux console, write the following line of text:\n```git add .``\nTo add all the files in the folder to the project.\n\n3. In the terminal, write the following commands:\n```mkdir Ctx_Clinical_trials\n```To create a new directory named Ctx_Clinical_trials.\n``` mkdir lab_clinical_trials\n```To create a new directory named Lab_Clinical_trials.\n4. Add the new folder in one of the existing folders. For example, use your local folder that contains all the resources, e.g.  `1 2 3 4`, and add the Ctx_Clinical_trials folder inside 1:\n```cd 1234```\nThen, add the `new`subfolders inside folder 1234:\n```mkdir Ctx_Clinical_trials``\n```mkdir test```\n```mkdir 1.txt```\n```mkdir 2.txt```\n```mkdir 3.txt```\n```mkdir 4.txt```\n```mkdir 5.txt```\n```mkdir 6.txt``\nFinally, inside folder `1234`, add the Ctx_Clinical_trials directory inside folder `test`:\n```mkdir Ctx_Clinical_trials``\n```mkdir Ctx_Clinical_Trials_example1```\n```\n## 5. Add the clinical trial file to the clinical file folder\nCopy the clinical trial file to the folder Ctx_Clinical_Trials_example1.\nThen, add the lab folder containing the patient note to the clinical trial folder:\n\n```grep Ctx_Clinical_Trials_example1\n\n```\nYou will get output similar to:\n```no hits```\n```\n## 6. Export your changes to your",
        "label": 2
    },
    "395": {
        "output": "Your mission is complete, congratulations! If you want, please take another quiz: https://qi-lab.github.io/learn-qi-online/challenges/eligibility.html\n[REF] https://www.clinicaltrials.gov/learn/basics/definitions.\n[/REF]\n[MKCOLON] By the way, Qi Lab Team has a workshop focused on clinical trials. It contains many examples similar to this one. Please find more information [MARKDOWN]HERE[/MARKDOWN]..<EOD> Detection of fractures on hip radiographs of patients with a diagnosis of a hip fracture who have or have not sustained a neck of femur fracture\nAims The aim of this study was to examine whether the existence of a neck of femur fracture (NOFF) in patients with a new hip fracture (NF) could be ascertained from a visual assessment of a hip radiograph. Methods We reviewed the radiographs and case notes of all 66 consecutive patients over the age of 65 who had received an NF from one hospital in the East of England between 2011 and 2014. The radiographs were retrospectively reviewed to look for signs and features of a NOFF. These studies were subsequently classified as those with an NFF and those without a NOFF (n = 43 and 23, respectively). Results The sensitivity of the radiographic features of a NOFF was good and the specificity was excellent. The inter-rater reliablity was kappa = 0.82 (95% CI: 0.51 to 1.14) and the weighted kappa was kappa = 0.81. The areas under the curve for a NOFF in the two readers, as a result of a binary logistic regression, were 1.0 (95% CI: 1.0 to 1.0) and 1.0 (95% CI: 1.0 to 1.0), respectively. Conclusion The existence of a NOFF could be ascertained (sensitivity of 100%, specificity of 91, and positive predictive value of 100%)",
        "label": 0
    },
    "396": {
        "output": "The output should be JSON:\n{\n    \"SubjectId\": \"subject.1\",\n    \"Trial\": {\n        \"Title\": \"Sentinel Lymph Node Procedure in Ipsilateral Invasive Breast Cancer Relapse\",\n        \"Summary\": \"Sentinel lymph node biopsy (SLNB) has become the standard procedure for staging of patients with clinically node-negative breast cancer.Breast-conserving surgery (BCS) has also been a standard treatment for patients with early breast cancer. However, approximately 10% of patients with BCS develop ipsilateral breast tumor recurrence (IBTR), and mastectomy or resection of the recurrent tumor is generally performed.There are no specific guidelines available regarding staging and treatment of the regional lymph nodes. However, the reported risk of axillary lymph node metastasis among patients with local recurrence after breast surgery and a previous negative sentinel node biopsy of 26% is too high to be ignored.Moreover, evaluation of the regional lymph node basins might be helpful to decide on the indication for adjuvant radiotherapy and systemic treatment. For these reasons it seems sensible to perform a regional lymph node staging procedure in patients with locally recurrent breast cancer.In general practice, this would mean that patients with recurrent breast cancer and a previous negative sentinel node biopsy would receive an axillary lymph node dissection (ALND) and that patients with a previous ALND would receive no additional axillary staging.Lymphatic drainage after previous breast surgery and/or radiotherapy would be altered and it remains questionable whether SLNB at the time of surgery for IBTR (second SLNB) is technically feasible and ALND can safely be omitted.In this study, investigators propose for all patients the realization of SLNB procedure and systematically ALND whatever the results of SLNB analysis, only on patients previously treated with breast conservative surgery.The aim of this study is to evaluate on a homogeneous prospective multicentric cohort of patients the feasibility and the accuracy of a second SLNB procedure for IBTR.\nInclusion criteria:\nPatients \u2265 18 years old\nIn",
        "label": 0
    },
    "397": {
        "output": "# Discussion\nA few reasons for Trial-level eligibility:\n\n## Exclusion criteria:\n\n## - 0) Excluded:\n    - Patient with a negative eligibility assessment.\n    - Patient excluded due to missing information that is not contained in the patient note but necessary for eligibility.\n    - Unknown exclusion criteria. \n\n## 1) Not Relevant:\n- 0) Excluded:\n      - Trial ineligible.\n      - Patient is eligible.\n    - Unknown eligibility.\n\n## 2) Eligible:\n    - At least 1 factor must be found in patient note to make the patient eligible. \n- 1) Not relevant:\n      - Trial ineligible.\n      - Patient with a negative eligibility assessment.\n      - No eligibility information was found.\n    - Patient excluded due to missing information that is not contained in the patient note but necessary for eligibility.\n    - Unknown eligibility.\n\n\n<EOD> Prenatal diagnosis of aortic coarctation by cine sonography: clinical and postmortem correlation.\nPrenatal diagnosis of coarctation of the aorta was made using cine sonography. Two normal cine films at 27 weeks' gestation were obtained with no suggestion of cardiac or aortic abnormality. In the subsequent film of the same fetus at 29 weeks' gestation, a marked abnormality of the aortic arch was suspected, with severe narrowing proximal to the subclavian artery. This ultrasound finding was confirmed by real-time and two-dimensional sonography. Postmortem examination, after selective fetal termination, revealed marked narrowing in the region of the aortic arch (at the location of prenatally recorded abnormality). The findings suggest that cine sonography can be useful in the diagnosis of coarctation of the aorta. The accuracy of this diagnosis can not be evaluated because of the absence of fetal echoencephalography.<EOD> Nutritional status in a nonobese, normolipidemic, normotensive population in Guayama, Puerto Rico, and",
        "label": 2
    },
    "398": {
        "output": "# Difficulties of a problem\nMost problems can be solved once you know how to assess eligibility on each patient for the clinical trial and know the answer of the trial-level eligibility. However, some problems may be related to the patient's characteristics, and the patient's characteristics are different for different patients. For example, patients with some diseases may never meet the criteria for a certain clinical trial. Here are some examples:\n\n## - \nPatients with HIV may never meet the criteria for a certain antiviral drug trial (because patients with HIV have immunity).\n\n## - \nPatients with hypertension may never meet the criteria for a certain antihypertension drug trial (because patients with only hypertension are not allowed to participate in a trial).\n\n## - \nPatients with diabetes (type 2) may never meet the criteria for a certain noninsulin drug trial (because patients with diabetes may have immunity in response to insulin).\n\n## - \nPatients with depression may never meet the criteria for a certain anti-depression drug trial (because patients with depression may respond normally to life).\n\n## - \nAs you can see, people who meet the criteria for a certain clinical trial for specific diseases could not participate in a certain clinical trial. \n\n# Examples of answers\nHere are some examples of answer codes to illustrate your answer. Each answer has a code and a score. Remember, you could only answer if you know the answer of the trial-level eligibility. \n\n# Actions\nYou are still learning how to solve problems in data science. \n\nIf you ever need any help, please raise your hand and we will always gladly help you. If you finish all exercises before the next session, you are kindly asked to raise your hand so that we can provide the feedback to everybody. \n(If you face any technical issue, please email to support@codetoon.com)\n\n# Instructor's note\nA clinical trial, also known as a clinical study, is a research study in which people volunteer to participate and try a new medicine or procedure to treat a disease. Clinical trials are one of the two scientifically approved ways to assess the potential value of new treat",
        "label": 0
    },
    "399": {
        "output": "# Learning Resources\n- [Clinical trials-overview](link to overview)\n- [Clinical trials-assessing eligibility-overview-NCBI](LINK)\n- [Clinical trials-eligibility assessment using medical records-MEDICINE](link to medicine)\n- [Assessing Patient Eligibility during Trial Recruitment](link to assessing patient eligibility)\n- [Tutorials: Expert System using Neural Network](link to Neural Network Tutorials)\n- [Neural Network: Understanding Neural Networks](link to neural networks)\n- [Clinical Trials](link to overview)<EOD> .\nThe article provides an analysis of the main problems facing the scientific evaluation of the preventive properties of natural antibacterial substances and preparations, for example, garlic or echinacea. The article presents the data on a pharmacokinetical study based on clinical pharmacology and mathematical modeling of the process of Echinacea purpurea (L.) Hoffm. and Ruder. ex. Sch. B. content in the human body after intragastric administration of its ethanolic extract. Mathematical modeling based on differential equation allows for the calculation of E. purpea (L.) Hoffm. and Ruder. ex. Sch. B. concentration in different biological fluids as a function of time after administration. This approach is based on the fact that all biological systems can be described using differential equations based on laws of chemical kinetics (e.g. mass-action and Michaelis-Menten kinetics).<EOD> The effect of acute oral L\u2010dopa on cerebral glucose metabolism in patients with Parkinson's disease: A study employing PET\nWe evaluated the effects of acute oral L\u2010dopa on cerebral glucose utilization in 15 patients with Parkinson's disease (9 with mild disability and 6 with severe) using positron emission tomography with 11C\u2010deoxyglucose ( 11C\u2010FDG). Regional cerebral glucose utilization (rCMRglc) was obtained in all patients with Parkinson disease and in",
        "label": 0
    },
    "400": {
        "output": "# Discussion\n\n\n\n\n\n\n\n### Clinical Studies and Clinical Trials\n\nClinical studies (also commonly called clinical trials) are research studies that involve human subjects. They are generally conducted in stages, usually to evaluate the safety, effectiveness, or cost-effectiveness of a medical, surgical, or behavioral intervention.\u00a0Clinical trials of interventions are also known as interventional trials to discriminate them from non-intervention clinical studies such as case reports, epidemiology studies, and others which\u00a0do\u00a0not\u00a0expose subjects to an intervention.\n\nWhen the term \"clinical trial\" is used to promote participation in research, it is nearly always used in an advertising context, generally inviting patients who are experiencing symptoms or who have been diagnosed with a medical condition to participate in the clinical trial to help the patients and potentially advance scientific knowledge.\u00a0This is a misleading definition as clinical trials are research protocols or tools used by clinicians or research scientists to try to address questions about\u00a0certain\u00a0interventions.\n\nIn both cases, the goal of the trials is to make it easier to diagnose or treat illness and improve outcomes, including survival\u00a0and\u00a0quality of life.\n\nClinical trials are an essential part of research and development of new strategies to improve health.\u00a0It is\u00a0the\u00a0human component that makes medical research\u00a0so critical,\u00a0and so\u00a0very\u00a0powerful.\u00a0However, the human component in medical research is\u00a0not\u00a0the most simple component. Medical research is\u00a0very complex, and there is a lot of complexity before the\u00a0human\u00a0part even takes place.\u00a0In the beginning, new questions are raised, and\u00a0an\u00a0idea for a\u00a0research study\u00a0emerges and then a new theory to explain the observed patterns and anomalies. A clinical\u00a0trial\u00a0is\u00a0also\u00a0a research study in which\u00a0the\u00a0goal\u00a0of researching\u00a0the issue at hand, and this can take many\u00a0years of\u00a0research and development,\u00a0or it\u00a0can take less time;\u00a0it all depends\u00a0on how serious the\u00a0anomaly\u00a0is when it is found.\n\nHowever, a\u00a0clinical trial\u00a0is basically a test conducted\u00a0in the",
        "label": 2
    },
    "401": {
        "output": "For our purposes, this is a `patient note,` and the patient's note is the only input we care about. So for each run of this script, we need to use the `patient note` variable within this script, and that means for each run, we have to have a new `patient note` variable. This script will take the result of the patient note variable and use it for the other inputs but only the result, therefore, for each run of the script we must use `patient note #` where # denotes the unique `run number`.\n\n\n<EOD> Nutrition in the primary care setting: a clinical approach for child obesity.\nThe National Association of Pediatric Nurse Practitioners and the Task Force on Nutrition advocate for integrating nutrition into preventing overweight and obesity throughout child development. This article presents the rationale for the National Association of Pediatric Nurse Practitioners' position statement on primary care provider (PCP) nutrition in the management of children and adolescents who are overweight/obese as well as for children/adolescents with potential nutrition/growth issues but without a BMI in the overweight/obese range. A clinical approach to nutritional assessment is presented in this article and includes the identification of a PCP's primary responsibility of determining a child's nutritional status. Primary nutrition assessment focuses on a child's growth patterns that include height, weight, and head circumference and the measurement of the height and weight. Height z score (Ht z), weight-for-height percentile (WH%), and BMI percentile are recommended as the core measures to identify growth status and nutritional impact of chronic disease. In particular, the BMI percentile is central to identifying a child's growth status in reference to an accepted standard for comparison. Therefore, a BMI percentile that is <5th percentile refers to wasting or undernutrition; whereas, one that is >95th percentile indicates obesity. A BMI percentile of 85th indicates that this child is overweight. However, the Centers for Disease Control and Prevention does not recommend using a BMI",
        "label": 0
    },
    "402": {
        "output": "<EOD> Identification of the Cis-Acting Regions of Erythroid Potential in Mouse Erythroid Cells\n\nDevelopment of hematopoietic stem cells (HSCs) into different lineages is controlled, in part, by several transcription factors. To further study the differentiation of HSCs into mature cells in the erythroid lineage, we established an indirect co-culture system by transfecting HSCs with the genes encoding the transcriptional factors GATA-1 and GATA-2. With this system, EGFP-positive cells were separated from the HSC-transduced mice and cultured in the presence of lineage-specific differentiation factors and stromal cells. The EGFPpositive cells were shown not only to differentiate into mature erythrocytes, but also to mature into other lineages, including myeloid and lymphoid cells. The transduced HSCs were also analyzed using several EGFP-transgenic mice established using promoters derived from erythroid specific genes, and the effects of GATA-1, GATA-2 and other GATA family transcription factors on the maturation of erythroid cells were examined. All of the mice examined were shown to express EGFP in the b",
        "label": 2
    },
    "403": {
        "output": "<br>\n\n## #Clinical_Natural_Language_Processing_Challenge\n<br>\n\n## Description\n<br>\n\nWe are offering a chance to practice your machine learning skills in a medical domain.\n\nWe propose two real-world NLP tasks inspired by the CRAFT corpus, a real-world clinical trials dataset.\nWe propose the following two tasks: \n\n* Sentiment analysis on clinical free-text documents\n* Disease mentions recognition and classification\n\nThe first task is to classify the clinical free-text documents into two classes, positive and negative. This is a binary classification problem.\n\nThe second task is detect sentences and classify sentences containing disease mentions into one of six classes . In the six classes there are two healthy classes: 'Healthy' (denotes non-patients and other healthy subjects in research studies) and 'Diseased-Non-Patient' (denotes patients with diseases, and are not intended to receive clinical trials). \n\nThe disease mentions classification problem is then formulated as a multi-label classification problem. \n\nWe plan to use two subtasks: 'Healthy' vs 'Patients', and 'Patients vs Diseased-Non-Patients'. We plan to do this two way split between subjects (patients and clinical trial participants), using the healthy class as balancing class. \n\nSince the data is not public, we encourage the community to contribute by making use of other well-known NLP datasets, including the widely-used CHAT and i2b2 datasets",
        "label": 1
    },
    "404": {
        "output": "End of [INST]  \n\n\n\n## [HELP] Tutorials:\n(1) You can find helpful introductory tutorials at http://intro.datamart.ca:8090/datascience-intro/.\n\n\n(2) If you would like to help us with the development of the tutorials, please see /tutorials/help/, or email us at\n<EMAIL>.\n\n--------------------------------------------------------------------------------\n[STUT01] Hello.[INST] This tutorial introduces you to a few basic features of a tool called \"Knowledge Vault\". Knowledge Vault provides you with a set of tools you can use to create and reuse analyses. These analyses can be created using a library of ready-made templates (e.g., tables, figures, and charts). \n\n\n\n\nOnce you activate Knowledge Vault in your browser, use the \"Welcome\" tool to get a short tutorial about how to do some basic manipulations of the files: https://datamart.ca/vault-welcome\nThe welcome tool will also let you know which templates are already available in Knowledge Vault. For instance, there are a series of analysis tables you can use (these are called Analyses), charts (Charts) and graphs (Graphs). \n\nThe welcome tool will also introduce you to the search tools:\n\n\n* [Search] You can search for files using the Find File tool located to the left hand side, or use the Search Box located just above the knowledge vault panel. You use the Search Box to look for files and folders that contain a term of interest. A search of the term \"Breast Cancer\" in the Knowledge Vault, for example, will turn up a folder that contains all the files and folders we use to organize breast cancer study. \n* [Detailed Search]  When you perform a search, the detail search will give you an expanded list organized by folder. From here you can \"expand\" a folder (which will show you all the files in that folder) and click on the file you are interested in. \n* [Synchronize] In addition to searching, you can also synchronize files in Knowledge Vault (from a folder or file) to your computer via a Windows-compatible file explorer. You can use the file explorer to move files into",
        "label": 0
    },
    "405": {
        "output": "\u25a1 Eligible: Eligible 0) Excluded 1) Not relevant 2) Eligible \u25a1 Excluded: 0) Excluded # [INST] Examples of clinical trials information in data sets are described below. The first column contains data types, the second column lists the name of the fields in an itemized order, and the third column is the actual value. #\n\n### Clinical Trial Registration\n\nA clinical trial is a research project that prospectively assigns human subjects to intervention or comparison groups to study the causes and effect of a health-related variable. The U.S. and European regulatory agencies (US FDA, EMA) required clinical trials to be registered as part of the registration and approval process to promote the transparency of the clinical research and to reduce the wasting of resources caused by repeat registration of the same study. Therefore, to be identified with validity, a clinical trial must be registered according to the registration policy. Here we list the information of registration. #\n\n\n\nRegistration\n- `Registration`: The national trial registry.\n- `Registration_ID`: The identification number of the trial in the national trial registry.\n- `Country`: The country where the trial was approved.\n\n### Patient-Reported Outcomes (PROs)\n\nPROs are information reported by patients and generated from questionnaires completed by patients. These data help researchers assess the impact and burden of disease, as well as determine the effectiveness of interventions targeting patient symptoms and quality of life. In this dataset, the PROs were collected from clinical trials to explore the quality of life with breast cancer. Here we list the items. #\n\n\n\n\n\n- `Assessment_ID`\n  - `Code`\n  - Description\n\n- `Date_Time_Assessed`\n  - `Date_Time_Assessed`\n  - `Unit of Time`\n\n### Efficacy Endpoints\n\nEfficacy refers to the effectiveness of a drug in clinical studies. Efficacy endpoints are measures used to determine the therapeutic benefits of drugs, and are usually used to measure disease progression, the risk of disease progression, improvement in health status, or changes in functional status. The goal of an",
        "label": 0
    },
    "406": {
        "output": "[END]<EOD> .\nOBJECTIVE\nTo investigate the relation between the levels of Toll like receptor4 (TLR4) and nuclear factor kappaB (NF-kappaB) in the serum of patients with sepsis and the prognosis of septic patients.\n\n\nMETHODS\nA total of 79 septic children were divided into survival group and death group according to 28 days prognosis according. TLR4 and NF-kappaB in the serum of patients with sepsis were determined using ELISA. The children with trauma were included in control group.\n\n\nRESULTS\nThe levels of serum TLR4 and NF-kappaB of sepsis patients were significantly higher than that in control group (both P0.05), while the levels of NF-kappaB in sepsis children were associated with the serum levels of TLR4 and SOFA score on admission.\n\n\nCONCLUSIONS\nTLR4 and NF-kappaB can be used as important indicators for sepsis children and can be used to monitor prognosis of septic children.<EOD> Effects of Sperm DNA Fragmentation on the Reproductive Outcomes of Intrauterine Insemination: Preliminary Results\nBackground: The impact of sperm DNA damage on pregnancy outcome following superovulation and intrauterine insemination (IUI) has not been well studied. The aim of this study was to evaluate the effect of sperm DNA fragmentation on IUI outcome. Methods: A total of 87 IUI cycles were included in the study. The sperm DNA fragmentation index (DFI, the proportion of the DNA in fragment form) was assessed by the sperm chromatin dispersion assay and was expressed as a percentage. The number of inseminated motile sperm per ejaculate was also recorded. The main outcome was the number of fertilized oocytes, the live birth and delivery rates, and the incidence of gestational diabetes. Results: The mean of DFIs of the couples producing at least one fertilized oocyte was 29.6%. The mean of DFIs of the couples with positive clinical pregnancy test was 29.4%. Moreover, women who delivered live birth inf",
        "label": 0
    },
    "407": {
        "output": "### Output:\nIn `clinical_trial.csv`, the format of each row is the following.\n\n| `Patient_ID` |  Patient ID\n| `Eligibility_score` |  Eligibility score\n| `Trial_ID` |  Clinical trial ID\n| `Patient_ID` is the same across columns. `Eligibility_score` stands for the eligibility of this patient who meets the inclusion criteria and does not meet the exclusion criteria. `Patient_ID` is the patient ID. `Trial_ID`is the clinical trial ID. Please note that, although the trial ID and patient ID are the same variable, these two variables work in different contexts. In this task, we need to check if we can find this particular patient in the clinical trial. Therefore, we use `Patient_ID` to represent the patient ID and `Eligibility_score` to calculate the eligibility score for each patient. If the patient satisfies the inclusion criteria, `Eligibility_score` equals to 2. If not, `Eligibility_score` equals to 0 or 1. This also means the clinical trial can only accept the patients who satisfy the inclusion criteria. If the patient fulfils all the requirements, then this clinical trial need to conduct with the trial ID.\n\n#### Solution\n\nFor those patients belonging to the clinical trial, you need calculate the mean of `Eligibility_score`. We can see from the `clinical_trial.csv` that in every clinical trial, every patient's eligibility score is either 0, 1 or 2. We have 100 patients who are included in the clinical trial \"A\". Since the eligibility score of each patient is either equal to 0, equal to 1 or equal to 2, then in the clinical trial \"A\", the possible score combinations based on the mean function are M(x) = (15+4+38)/50 = 20. Similarly, the possible score combinations of clinical trial \"B\" M(x) = (6+1+38)/44 = 23.\nThen, to get the final results, we need to calculate the average scores of every clinical trial.",
        "label": 0
    },
    "408": {
        "output": "Patients ongoing to dose.\nPatients`s a doctor-grade`s eligible doctor/nurs's eligible at the doctors`s step.\nThe trialist(elig 4 trial's: 10 the doctor ical trial's trialist trial elig's trial trial's eligible\nelig trial/elig dose trial is notelig/trial elig] trial's healthy to trial characteristics.\n\nhealth and that your elig's trials`s elig/patients the treatment with doctors should you 310el elig patient's trial`s toxelig=21 elig and inade or inelig elig because the trial.\ntrial in the trial; eligible with a suitable trial elig; or the patient and trial eligible.\n[trial:\n[elig trial.\n[trial.\nfor the elig, and elig [in the following thet trial.\npatient oral trial's elig 1] patient elig, but trial.\nInel elig, and the elig. The trial.\nand who are part. You. An elig.\nshe,\nHealth to 3 and elig (2x/pat and elig trial. You will in elig 10, which may be an el 3.\n[el and are a bThe trial 2 or the patient.\ntest, and the trial, which was thei, or immunits and you are you know's elig. Thisel.\nel, is a doctor.\n\nher, which her. She 0 in all herb = herbal.el. (el)\n(for 1] 1 trial, and her 3. After trial and elig/el.\n\nand inpat, upt in/theel andre and health: el.\n[A&pat:s is a clin..., you, and the trial that [bib_ref]. The trial, who. Hi for patients.\n[or her to improve in accord \ns. You. The I, orally\u2026[in her\u00a0inclusion \u00bd or 1\n The patient ... and _\u00a014 in the patient (or, her [bib_ref]\nc... A 6",
        "label": 0
    },
    "409": {
        "output": "</instructions>\n\n\n---\n\n**# What are the data structures?**\n\n```{python}\nprint(trial_data)\n```\n```{python}\ntrial_data = [\n{'patient_id': 'PTA1265',\n 'patient_age': '45',\n 'gender': 'F',\n 'diagnosis': 'breast cancer',\n 'cancer_type': 'ductal breast cancer',\n 'subtype': 'Luminal A',\n 'grade': '1-2',\n 'tumor_size': '2.5-5',\n 'stage': 'Invasive ductal carcinoma of no special type -T2N2M0/stage IIB, cancer free N+ margins, 4 positive LNs (61%)',\n 'prior_radiotherapy': False,\n 'prior_chemotherapy': False,\n 'prior_neoadjuvant_therapy': False,\n 'prior_hormonal_therapy': False,\n 'her2_status': '0',\n 'pathologic_type': 'Ductal carcinoma of no special type -T2N2M0/stage IIB, cancer free N+ margins, 4 positive LNs (61%)',\n 'metastasis': 'yes',\n 'chemoradiation': False,\n 'treatment_status': 'pre-surgical non-therapeutic trial',\n 'chemotherapy': 'unknown',\n 'surgery': 'yes',\n 'radiotherapy': False,\n 'tumor_hormonal_receptors': 'ER(+), PR(-), Her2(-) ',\n 'survival_status': 'alive (1/2/2017)',\n 'exclusion_criteria': 'unknown',\n 'trial_enrollment_status': 'unknown',\n 'clinical_trial_group': 'trial192',\n 'clinical_trial_id': 'NCT02216786',\n 'protocol_number': '',\n 'recruitment_completion_date': '',\n 'date_of_entry': '2",
        "label": 0
    },
    "410": {
        "output": "<EOD> Naloxone, Methadone, or Buprenorphine: A Closer Examination of Three Different Opioid Agonists With Concurrent Risk of Opioid Use Disorders, Misuse, and Mortality\nOpioids are used to treat chronic nonmalignant pain (CNMP). However, use of prescribed opioids can lead to misuse with potential for opioid use disorders (OUDs) and even death. In this study, we evaluate the epidemiologic characteristics of 3 different opioid agonists used for pain (ie, methadone, buprenorphine, and naloxone) and correlate these with risk factors for OUDs, misuse, and mortality. In this retrospective study, we used Medicare Part D claims data set from January 1, 2013, to December 31, 2018, to examine rates of prescription fills of opioid agonists by age, sex, and race/ ethnicity to determine any disparities in opioid agonist utilization and further assess any risk factors for OUDs, misuse, and mortality. Although all 3 opioid agonists were prescribed more often to males, methadone had the highest proportion of prescriptions to males when compared with the other agonists (&khgr;2 = 46.19; P < .001). Black Medicare beneficiaries consistently had higher rates of filling any prescription for opioid agonists than their white counterparts (46.22% vs 36.96%), and black patients receiving methadone had a higher percentage of prescriptions with 1 or more opioid refills per 3-month period (54.92% vs 33.78%). Higher number of concomitant cardiovascular and nervous system medications was correlated with an increased risk for OUDs (odds ratio = 1.03; 95% confidence interval ). Benzodiazepine or antipsychotic drug overlapping with an opioid were more likely to be prescribed to a patient with an OUD diagnosis (odds ratio = 4.38 & 4",
        "label": 0
    },
    "411": {
        "output": "### <NAME> in `Methotrexate in the Treatment of Distal Interphalangeal Joint Extensor Tendon Enthesopathy in Nail Psoriasis` Trial is 36 years old.\n``<NAME>`` is 38 years old.\nThe following lines in the `patient` patient note file contains demographic information, such as name, surname, date of birth (DOB), and height.\n\n### `patient_patients.patient_dni.txt`, line 4:\nBEGIN OF DATA\n\nName | Age | Date of birth\n\n<NAME> | 36 years old | DOB: 2019-02-06\n\n<NAME> | 35 years old | DOB: 2019-02-15\n\n### `patient_patients.patient_age.txt`, line 4:\nBEGIN OF DATA\n\n<NAME> | 36 years old\n\n<NAME> | 35 years old\n\n### `patient_patients.patient.txt`, line 6:\nBEGIN OF DATA\n\n\n<EOD> Changing the culture to improve patient experience: a qualitative study\nObjective To understand how patient experience (PE) feedback affects staff in relation to their own perceptions of culture and practice. Design Observation and semistructured interviews were combined in this qualitative investigation of the introduction of PE surveys to four acute National Health Service Foundation Trusts in UK. Setting Four acute National Health Service Trusts from one Foundation Trust organization. Semistructured interviews were conducted with senior leaders, PE leads and staff working in acute services in two Trusts that did and two that did not implement routine patient surveys. Sampling used maximum variation to ensure diversity in sample. Participants were selected to provide a sample varying in characteristics of years of service, ethnicity, managerial responsibility and gender. Results Four key themes identified: perceived need for change in patient care; role of experience in influencing culture change; the challenge of patient-centred care within health organizations; and a changing culture. In those Trusts that introduced patient satisfaction surveys, it was suggested that patients play an important role in shaping",
        "label": 0
    },
    "412": {
        "output": "## Inferential Task: Diagnostic Evaluation \nHere is an example of a patient note. \nPatient: A 33-year-old female patient (no prior medical history) came to the emergency room complaining of sudden onset of cramps, loss of consciousness, and numbness in the left upper and lower limbs in the last 15 minutes. The patient had just eaten food a few minutes before the attack. Physical examination revealed tenderness in the right costal margin where the patient reported a cramp that she first felt when chewing the food. An initial diagnosis of aortic dissection (AD) was made and the patient was sent to the CT room to support the diagnosis. The diagnosis was reconsidered after the CT result. The patient remained hospitalized in general ward and complained of pain in the upper limbs and numbness with no change in her consciousness or speech.\n\nHere the clinician has to identify the correct diagnosis.\nWhat is the correct diagnosis? What is the next diagnosis based on your assessment?\n\n## Inferential Task: Prognosis Prediction (Classification Task) \nToday, 352 patients with heart failure have been discharged after hospitalization from a medical ward in a tertiary care hospital. A medical record on the patient who had undergone cardiac catheterization for treatment of heart failure is shown as below:  \nPatient: A 59-year-old female had been diagnosed with heart failure. The patient had hypertension, hyperlipidemia, and angina pectoris. On physical examination, vital signs showed a normal heart rate and blood pressure. Pulmonary edema was observed. Laboratory examination revealed high levels of B-type natriuretic peptide (BNP 516.0 pg/ml). Echocardiography showed a left ventricular ejection fraction of 32%. Cardiac catheterization showed a 30% stenosis in the left anterior descending artery and 85% stenosis in the right coronary artery (RCA). A pacemaker was implanted in the heart.\n\n## What is the optimal course of care for this patient?\n\n# Discuss",
        "label": 0
    },
    "413": {
        "output": "* _Note: In the note_ that was given in the assignment above, the diagnosis of a tumor is not stated. So, you will have to rely on the note to identify the diagnosis; instead, you can rely on the clinical trial to identify the diagnosis: In your final result, use `diagnosis` to output the diagnoses. Use the code below, and run the script, and see your result. Now, it all comes down to a few lines of code and we've got this to the end! We are now going to write code that is capable of parsing patient notes and classifying patients as being eligible or ineligible for medical trials.\n\n`import java.util.*; \n\nclass Candidates { \n    public static void main(String[] args) { \n        List<Patient> patient_set = new ArrayList<Patient>(); \n        Patient p = new Patient(); \n        patient_set.add(p); \n        patient_set.add(p); \n       for (int i = 0; i < patient_set.size(); i++) { \n         Patient p = patient_set.get(i); \n         System.out.println(\"p.note() = \" + p.note()); \n       } \n    } \n    class Patient extends Comparable<Patient> { \n        private String gender; \n        private String age; \n        // In a real scenario, we would store a lot of different information about the patient. \n        // Here we are only storing a few of them, to make things easier. \n        // For example, we should store the patient's medical history, prescriptions, genes, etc. \n        // In order to do this, we want to store as many Patient objects as the number of patients we have in our hospital system. \n        public Patient() { \n          // We need to call super() for it to call the constructor. \n            System.out.println(\"Constructing patient.\"); \n            gender = \"unspecified\"; \n            age = \"unspecified\"; \n        } \n        @Override \n        public String toString() { \n          return String.format(\"Patient ID: %d, Name",
        "label": 0
    },
    "414": {
        "output": "## RQ4 How should I deal with errors during the assessment?\n[INST] You should enter the following commands to show the types of errors and some hints.\n`show error -p`\n`show error 0 1 \"I'm 45!\"`\n`show error 1 0 \"I\"\n`show error 2 0 \"1\"`.\nIf you enter a wrong score, you should correct it as soon as possible. If the correct score is given more than 1 minute after you enter the incorrect score, it will be treated as an error.\n\n## RQ5 How should I deal with exclusion criteria?\n\n[INST] Exclusion criteria should be checked by the trial-level eligibility.\n`1 2 3 0 \"45-year-old postmenopausal woman\"\n'2 2 1 0 \"Female\"\n1 0 2 1 \"Postmenopausal woman\"\n2 1 1 1 \"Man\"\n3 3 0 0 \"Pregnant\"`\n\n[M1] The following output should be displayed:\n[INST] In most clinical trials, exclusion criteria do not count as the patient meeting inclusion criteria. But in some cases, exclusion criteria do count. In some special cases, including RCT (Randomized Controlled Trial) and Phase 1, the patient is considered eligible if exclusion criteria are not met. In all cases, after an exclusion criterion is entered, the trial needs to be restarted. Let's check the trial-level\n\n`2 0 0 \"Female\"` `Not eligible`\n\n## RQ6 What are the trial-level eligibility in the clinical trial?\n[INST] The trial-level eligibility should be used after checking the inclusive criteria.\n`Trial-level eligibility: 0 Excluded`\n\n## RQ7 What is the way to get more information for the patient note?\n\n[INST] The information from the patient note can be printed to STDOUT by following command.\n\n\n## RQ12 What should I do if I want to leave the trial?\n[INST] After the trial is over, you should use the following command to exit the trial.",
        "label": 2
    },
    "415": {
        "output": "[INST]\nExercises\n\n- 1.1: Practice patient-level eligibility \n  You should read all data lines (Patient, Trial, Inclusion criteria) one by one. After reading all the data lines - Patient-level eligibility, you should compare the patient's information and clinical trial's inclusion criteria. You can apply the criteria only once. After meeting all the criteria, you should write eligibility as output according to the three-point scale on the screen, e.g. by using `Eligibility: 2) Eligible.`. [INST]\n- 1.2: Write down the eligibility in the last line by 'eligibility-of-the-trial' \n  Before solving the exercise, write `eligibility-of-the-trial: 0) Excluded.`, since the patient is not in the trial. \n  Patients can be excluded for several reasons. A summary of the most frequent reasons and their corresponding inclusion criteria codes for the clinical trial is shown in the exercise below. \n  Note that some patients need to be excluded due to their nonresponsiveness to the treatment under investigation in the trial or due to already being treated with the treatment under investigation in the trial (i.e., patients who require a certain treatment on their own accord or due to having an underlying problem unrelated to an underlying tumor). \n  To solve this exercise, repeat eligibility-of-the-trial line by `Eligibility-of-the-trial:` where the first line already contains `Eligibility-of-the-trial: 0) Excluded.`, e.g., `Eligibility-of-thetrial: 1 (Exonerated (on her own will))`. [INST]\n\n# Disclaimer\nSome tests and examples use mock data for demonstration purposes only, which are not based on real cases but on real patient data as part of the patient data provided to ISCIII by Spanish National Health Service.\n\nThis mock data are subject to copyright protection as the ISCIII (CSIC) reserves the right to use this material to develop its own content and to improve the training programs for health professionals.\nThe ISCIII has the exclusive right to reproduce and distribute this material,",
        "label": 0
    },
    "416": {
        "output": "#### How to do?\n1. Click on the run button to build the dataset.\n\n    ```shell\n    python dataset/main.py\n    ```\n    \n    ## Output\n    ## \n    ## File `test_code/run.html` \n    <samp>\n    Trial-level eligibility: 1) Excluded.\n\n    Patient-level eligibility: 0.0) Excluded.\n    ```\n    \n2. Click on the rerun button to update the dataset with the current dataset.\n\n    ```shell\n    echo \n    Python :> In [?1]:\n    \n    Python :>\n    \n    Python :> ## \n    Python :>\n    \n    Python :> ##\n    Python :> ## In all, there are about 11000 candidates of clinical trial, and 1632 of\n    Python :> ## them have patients with a HER2+ status.\n    Python :> ## \n    Python :> ## \n    Python :> ## Among them, 232 clinical trials meet the 3 criteria\n    Python :> ## (0.0)\n    Python :> # \n    Python :> # \n    Python :> # \n    Python :> # Exclude the duplicates\n    Python :> # \n    Python :> \n    Python :> # (69)\n    Python :> # \n    Python :> # There are a total of 69 clinical trials related to the current dataset.\n    Python :> # Among them 17 clinical trials meet our inclusion and exclusion criteria.\n    Python :> # \n    Python :> ## Summary of the results of the experiment.\n    Python :> ##\n    Python :> ## In all, there are about 11000 candidates of clinical trial, and 1632 of\n    Python :> ## them have patients with a HER2+ status.\n    Python :> ## \n    Python :> ## Among them, 232 clinical trials meet the 3 criteria\n    Python :> ## (0.0)\n    Python :> # \n    Python :> # \n    Python :> #",
        "label": 0
    },
    "417": {
        "output": "__Congrats__! You have finished this tutorial. We welcome your feedback. If you liked this tutorial for learning R, please give us a \"thumbs up\". We have many great R tutorials you can find on our blog [rdocumentation.org, blog.rdocumentation.org].\n<EOD> Role of endogenous inhibitors of mitogen\u2010activated protein kinase kinase pathways in regulating platelet function\nSummary.\u2002 Background: Stimulation of platelets via adhesion receptors or agonists activates mitogen\u2010activated protein kinase (MAPK) kinase (MEK)\u2010MAP kinase (ERK) cascade leading to the formation of an actin network. The ensuing shape change allows for platelet aggregation, secretion of cytoplasmic granule contents and clot retraction. Objectives: To examine the functional significance of a recently identified endogenous inhibitor of MEK, c\u2010Cbl, for platelet function. Methods: Wild\u2010type and c\u2010Cbl\u2010deficient platelets were activated with thrombin, and phosphorylation kinetics and aggregation response were monitored by Western blot and light transmission aggregometry, respectively. The ability of WT and knockout platelets to spread on fibrinogen\u2010coated substrates was assessed using florescence microscopy. Results: Wild\u2010type platelets rapidly phosphorylated ERK following thrombin stimulation, and phosphorylation continued over 30\u2003min. Loss of c\u2010Cbl resulted in an accelerated kinetics of ERK phosphorylation, peaking in minutes rather than an hour, and ERK phosphorylation was sustained for at least 60\u2003min. While wild\u2010type platelets showed negligible aggregation and a negligible percentage of spread platelets, aggregation of c\u2010Cbl\u2010KO platelets reached at maximum at 30\u2003min with the percentage of spread platelets almost threefold higher than wild type. Moreover phosphorylation of MAPK\u2010interacting kinase and extracellular signal\u2010regulated kinase (ERK)2 was severely attenuated in thrombin\u2010activated c\u2010Cbl\u2010KO platelets. Conclusions: Loss of c",
        "label": 0
    },
    "418": {
        "output": "[/END]\n\n[INST] Hello. You are again a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the exclusion criteria of a trial to determine the patient's non-eligibility. The factors that disqualify someone from participating in a clinical study are known as exclusion criteria. They are established to reduce the risk of harmful effects on participants in the trial. Therefore, you will be examining four types of exclusion criteria to check the patient: (1) Medical; (2) Surgical; (3) Previous Treatment;\n(4) Sexual and reproductive.\n\nThe exclusion of a patient from a trial has a three-point scale: 0) Excluded (the exclusion criteria do not apply to the patient); 1) Not relevant (patient has insufficient information to qualify for the trial); and 2) Eligible (the patient does not meet the exclusion criteria). \nYou should create an assessment of exclusion according to the exclusion criteria for each patient and for the trial. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nHere is the clinical trial:\nTitle: HERPET- A Novel PET Imaging Study of HER2 in Breast Cancer.\n\n\nSummary: This mechanistic study will be the first study to assess the efficacy of [18F]GE-226 to target HER2 expression in patients with metastatic breast cancer. The study will establish the pharmacokinetics of [18F]GE-226 and the optimum time-point",
        "label": 2
    },
    "419": {
        "output": "Here are the results for one of the datasets I used.\n\n### A) Using dataset file\nIf we use patient dataset on a single file, you should use `with open(patient_train_file, \"r\", encoding='utf-8')` to read one file. Likewise, for the clinical trial dataset file, we should use `with open(trial_train_file, \"r\", encoding='utf-8')` to read one file.\n\nB) Using Pandas dataframe\nIf we use Pandas dataframe file by pandas.dataframe(pd_df.to_dict()), we can directly feed the df to the DL model without importing any libraries (for example, open libraries for reading individual files).\nThe code example for training DL model with Pandas dataframe is below.\n\n```python\n     with open(patient_train_file, \"r\", encoding='utf-8') as patient_df:\n             patient_df_data = pd_df.to_dict()\n             patient_df_data[\"Trial_Level_Eligibility\"] = df[\"Trial_Level_Eligibility\"].fillna(0)\n             patient_df_data[\"Trial Eligible\"] = df[\"Trial Eligible\"] # To fix a dataset for better training\n             patient_df_data[\"Trial Eligible\"] = patient_df_data[\"Trial Eligible\"].fillna(1)\n             patient_df_data[\"Trial ID\"] = 1\n             patient_df_data[\"Clinical Trial\"] = \"Whole-Exome Sequencing (WES) for Intraductal Neoplasms of the Bile Duct (IPNB).\"\n             patient_df_data[\"Inclusion Criteria\"] = [\"Trial Inclusion Criteria: Cytologically confirmed breast cancer, 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, HER2-positive and ER/PR negative, 5 positive lymph nodes in axillary sampling, and consent to do resection prior to receiving chemotherapy\",\n                                                     \"Exclusion Criteria: Clinical Trials for Women\",\n                                                     \"Clinical Trials for men\",\n                                                     \"Clinical Trials for elderly",
        "label": 0
    },
    "420": {
        "output": "You are given a patient note and a clinical trial, one by one. You have to perform Trial-level eligibility in each patient note and for each clinical trial. \n\nNote. You can find the patient note and clinical trial here:\n \n[FOLK:http://s3-us-west-2.kinloneyc.com/s/wqb-NqWQmD0134A98x3zX.zip](http://s3-us-west-2.kinloneyc.com/s/wqb-NqWQmD0134A98x3zX.zip)\r\n[CLIC:http://s3-us-west-2.kinloneyc.com/s/VxVqvT1Y610xUcH5yvgCk.zip](http://s3-us-west-2.kinloneyc.com/s/VxVqvT1Y610xUcH5yvgCk.zip)  \n\n## 2.3.2.2 [Instructions]\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the exclusion criteria of a clinical trial to determine the patient's exclusion. The exclusion criteria are based on various characteristics such as age, gender, the type and stage of a disease, treatment history, medical conditions, etc. \n\nThe following patient note:\n\nThe patient is a 53-year-old postmenopausal woman with HER2-positive breast cancer, with cytological confirmation. She has a 5 cm invasive ductal breast cancer. The tumor is ER-positive and PR-negative. Axillary surgery confirmed 9 positive lymph nodes. CXR is remarkable for multiple metastases. The patient does not attend follow-up. The patient uses multivitamins and iron supplements regularly. The patient does not smoke or consume alcohol. The patient is not active sexually and has no children. Her vital status is stable. The patient is a candidate for tumor resection and chemotherapy.\n\nThe following clinical",
        "label": 0
    },
    "421": {
        "output": "cure-diemat. the inter for these 1-care, exus\u00a0med. [fig_ref]/and \nafter a\n or \u2026 [bib_ref]_based  network-med\nor in 2(10, s1 to [/fig]\nwith\nbased\nspecific [/table] for<EOD><EOD> \u200b 1   -to\\full 21 inhib  and\u2026 for [bib_ref] The :\n A \n 2\nfor [bib_ref] an\u00a0 \ufffdin [bib_ref] c 7\u00a0for [bib_ref]<EOD> diagnate for \n Thes [bib_ref]{\n\n [fig_ref]the  and, and [bib_ref] according \u2021 ( [bib_ref] The\u00a0system of [/table] candidate [bib_ref]( [bib_ref] \nin .\nin such on\nfor 2 [bib_ref]\u00a0\n\nmeline 0\n The  -in The _C (acc\n[ 3\u2026on-and [bib_ref] [bib_ref]-\non _ \nm...\n-absolute.\n\u2026 1+surg a 2 0 2 C\n ....mast-current [bib_ref] 1\u00a0d 1 .\nbased-bours- and the Cass for a medical The . [fig_ref]. H<s\ng (s in an Fshe-det on the [bib_ref]. Only for a [fig_ref] [bib_ref] [bib_ref] (for a\n\n(the,a [bib_ref]  in the (<h... 2 1 1  [on-h [bib_ref] [bib_ref] \u00acC - .\nin<EOD> and [bib_ref] [bib_ref]\n\nd\n The _1 -\nin 1 - 2 (absolute 2 _specific [bib_ref]for [/fig_ref]/random to<EOD>- [bib_ref] [bib_ref]\nt-\n-only andcute for\nfor the Cin for a\u00a0 .\n(s 1<EOD> [bib_ref] [bib_ref]s\n2-in [bib_ref] [bib_ref] [bib_ref]^ [bib_ref] [bib_ref]\u00a0re- 1 [bib_ref]; [ , and , for c..., 1 [bib_ref]1\ns\u00a0s [bib_ref] \\... [bib_ref] 1- 1-pat 1- 1-c \u2026 for \ufffd\ufffd/\n1-h 2- 1-sub and\nsub.\n 20 in \u2026and-\n\nc \u2044[c 2 to thisd [bib_ref]\n-to 1_ [bib_ref] in the- \nand for the-and",
        "label": 0
    },
    "422": {
        "output": "![INST][295]\n\n### [Q294] Hello, this is for the next step. First, you should find out the reasons for exclusion and find the inclusion and exclusion criteria relevant to the patient. You should write down the reasons in the patient notes and underneath the inclusion and exclusion criteria, respectively. In this part, you will find the following reasons for exclusion and inclusion by applying the 0) Excluded, 1) Not relevant, or 2) Eligible (i.e.,`No` means the patient may not enroll, `Not sure` means the patient may enroll depending on the situation, and`Potential` means the patient may enroll depending on the situation). Let's think step by step.[INST] \n```\n[296]\n```\n\n### [Q295] Hello, this is for the next step. First, you should find out the reasons for exclusion and find the inclusion and exclusion criteria relevant to the patient. You should write down the reasons in the patient`s notes and underneath the inclusion and exclusion criteria, respectively. In this part, you will find the following reasons for exclusion and inclusion by applying the 0) Excluded, 1) Not relevant, or 2) Eligible (i.",
        "label": 0
    },
    "423": {
        "output": "<EOD> A new method for the study of the distribution of inorganic cations in nerve tissue.\nA method for the localization of inorganic cations in tissues which makes possible the determination of changes in the distribution of these cations during the course of a pathological process is described. The method is based upon a technique for the histological study of cations in tissues introduced by Deane & Levin (1957) for the study of Na, K, and Ca in muscle strips, which is adapted for the study of nerve tissue, and on an improved method for the preparation of epoxy embeddings of tissues for microscopic study. It has the advantages of providing results with localization characteristics, speed, simplicity, and economy, and does not require any preliminary treatment of the material beyond fixation. The results that have been obtained by its use in the study of nerve myelins have confirmed previously reported observations made by other methods. The localization of Na, Ca, Mg, K and other elements by means of this method gives results similar in accuracy to the findings already reported by others (Dahl & Worm-Petersen, 1906; Gaffin, 1910; Griinbaum & Lichtheim, 1913; Lehninger, 1945; Deane, Levin, Snyder & Mendel, 1957; Seyler, 1958) but in addition the localization of Ca offers some advantages. It has a greater specificity which can be utilized to study certain of the changes in the distribution of Ca in nerve myelins resulting from experimental procedures, such as the induced production of ischaemic damage, hypertrophy, and the formation of perineurial scar tissue, in the following paper. In this second paper the application of the method to the study of the distribution of inorganic cations in the experimental conditions described is described.<EOD> The role of neurovascular biomechanics in the regulation of neurovascular coupling\nCoupling between brain function and cerebral blood flow is essential for normal brain function and underlies the pathophysiology of neural disorders including Alzheimer's disease. The mechanisms underpinning functional hyperemic responses also involve coupling of",
        "label": 0
    },
    "424": {
        "output": "#### ## Testing your Clinical Trial Eligibility Assessment\nNow, write your code and conduct your tests. The input of your testing should be a set of patient and trial notes, as the information required by the user can be supplied by the user as a csv file. One patient and one trial note should be included in each line of that file. The patient note should indicate the results for each component of the Clinical Trial Eligibility Assessment, separated by semicolon characters. One trial note should contain the information about a single trial. \n\nHere is an example of the csv file: '0) Excluded;1) Not relevant;2) Eligible;0) Excluded;1) Not relevant;2) Eligible;0) Excluded;1) Not relevant;2) Eligible'\nYou should produce a different output for each row of the csv file. There may be multiple rows with the same results as they can be part of multiple clinical trials at once, so there are usually multiple rows per patient. In the end, you should produce the same results as specified by the first example in your documentation as well as a table and the results to be printed to the console. The table should consist of the following columns: [HINT] The row number, the patient ID, the trial ID, and the outputs of the assessments. [INST] The assessments, including the trial assessment if applicable, will be stored in the 'assessments' dictionary and printed to the console with format(d).\n\nThe assessments dictionary must be created at the beginning of the program and contains the patient note and trial note as key-value pairs. Since each item requires a patient note and a trial note, they will be of type 'list' for the key or value. [HINT].\nIf you do not include any patient note or trial note, then the dictionary will not have any value. Hence, the key 'Assessments` will not be accessible.\nTo run your program, you can provide the csv file you wrote.\n[HINT] It is recommended to wrap the csv file in a file-like type and pass it in using a with statement. Here is an example.\ntest_outputs = ['0) Excluded;1) Not relevant;2) Eligible;0) Excluded;1) Not relevant;2) El",
        "label": 1
    },
    "425": {
        "output": "Informant: [<instrument_id>, 'Fully Automatic Pneumonia Severity Index (FAPSI) Assessment', 'I will be able to calculate the Pneumonia Severity Index (PSI) score of patients with pneumonia', 0, 2, 100, '<em>https://www.google.com/translate/</em>', 5, 5, 5].Instrument_id: The unique ID of Informant\nSubject_type: The classification of Informant (e.g., questionnaire, radiating, diagnosis, eligibility assessment, etc.)\nDescription: Describes what patient population (e.g. children, adults), what disease areas that can be served, what medical purpose that can be achieved. Also provides the references to justify.\nInstructions: Specific instructions for each informant.\nNumber_of_items: Number of items in the informant.\nNumber_of_domains: Number of domains (including number of items) in the informant.\nTarget_number_of_questions: The maximum number of questions that should be asked by the assessment.\nTarget_number_of_answers: The maximum number of answers that should be expected for each item.\nMaximum_number_of_questions_repeated: The maximum number of questions will not be repeated in the assessment.\nMaximum_number_of_answers_repeated: The maximum number of answers that will not be repeated is the number of answers of an item.\nWeight: A scalar between 0 and 1. The scalar denotes the importance of Informant. When set as less than 1, the Informant will actively assist with the treatment decision (similar to a patient questionnaire); or when 1, the Informant will be the final authority in deciding the treatment for patients, i.e. doctor-like.\n\n## Objective:\nThe goal of this study is evaluating the usefulness of the Fully Automatic Pneumonia Severity Index (FAPSI) assessment for the assessment of community acquired pneumonia. The FAPSI assessment was shown to be equivalent to the standard manual assessment [bib_ref]  Pneumonia Severity Index. A nationwide validation of a validated prediction rule, Fine [/bib_ref]  and it could be used to assist do",
        "label": 2
    },
    "426": {
        "output": "<EOD> A comparison of tacrolimus and cyclosporine-induced changes in vascular risk factors in patients receiving kidney transplants.\nBACKGROUND\nHypertension is an important cardiovascular risk factor and is a commonly encountered problem in kidney transplant recipients. It is reported that an increased blood pressure is seen in 25 to 90% of renal-transplant patients. Many factors might be responsible for this condition, including immunosuppressive drugs.\n\n\nOBJECTIVES\nTo determine the effect of tacrolimus and cyclosporine on hypertension, pulse rate and the level of lipid profile among kidney-transplant patients with impaired kidney function.\n\n\nMATERIAL AND METHODS\nThe present study evaluates 30 kidney transplant patients. Subjects were divided into 2 groups with respect to the immunosuppressive agents they had been taking. The blood pressure, pulse rate, serum glucose, lipid profile, serum uric acid, and 24-hour urine volume of the patients were determined before and after kidney treatment. Statistical analysis of the data was performed using t test and Pearson correlation coefficient.\n\n\nRESULTS\nSerum total cholesterol, triglyceride, and low-density lipoprotein levels were significantly higher in the tacrolimus-treated group than in the cyclosporine group (p < 0.05, p < 0.001 and p = 0.04 respectively). Pulse rate was significantly lower in the cyclosporine-treated group than in the tacrolimus (p < 0.01). However, high-density lipoprotein level was significantly higher in the tacrolimus-treated group (p < 0.05). Serum uric acid levels, lipid profile, and blood pressure were not different between the two groups.\n\n\nCONCLUSIONS\nTacrolimus seems to have less of an adverse effect on the vascular risk factors than does cyclosporine.<EOD> Phytochemical Analysis and Biological Effects of Aqueous Extract of Prunus domestica L. Seeds G",
        "label": 0
    },
    "427": {
        "output": "<EOD> .\nTwo types of bacteriological indicators have been compared (aerobic heterotrophic microorganisms, the total number of spores from microscopic fungi) both in the rooms of a building, and as compared to the same parameters in the soil adjacent to the building. The results show that the quantity of spores and microrganisms in the soil under the building was 10 to 20 times higher (for aerobic microorganisms) and 60 to 100 times higher (for spores of microscopic fungi) than those at the height of 30-40 cm from the surface of the soil. The average levels of spores and aerobic microorganisms in the air of the investigated building ranged from 167 to 204 and from 172 to 305 units/m3. A decrease of the quantity of investigated microorganisms was noticed near the heat-air sources.<EOD> Dual antiplatelet therapy in STEMI patients treated with primary PCI; A meta\u2010analysis of randomized controlled trials and observational studies\nPercutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) patients remains challenging. Whether dual antiplatelet therapy (DAPT = aspirin and a P2Y12 inhibitor) is effective or associated with harm, compared with aspirin (ASA) monotherapy in STEMI patients undergoing primary PCI has remained unresolved. Moreover, the superiority of Prasugrel or Ticagrelor over Clopidogrel in STEMI patients undergoing primary PCI with or without DAPT has not been fully elucidated. Our aim was to systematically perform a meta\u2010analysis of all available comparative studies testing the effects of Dual antiplatelet therapy in primary PCI patients, compared with Aspirin monotherapy, with special focus on the impact of P2Y12 inhibitors and on timing of DAPT cessation.<EOD> Phosphorylation of the eukaryotic translation initiation factor 4E is not required to modulate the protein synthesis rate in proliferating mammalian cells\nEukaryotic translation is essential for proper cell function. However, the mechanisms",
        "label": 0
    },
    "428": {
        "output": "[/QUESTION]\n<EOD> Phytochemical Study of Selected Species (Phenolic Content, Antioxidant Activity and Anthocyanin Content) of Fruits of Some Himalayan Edible Plants.\nIn this study, we have investigated the total polyphenol content (TPC), total flavonoid content (TFC) along with the antioxidant properties by ascorbic acid equivalent antioxidant capacity (AEAC), 1,1-diphenyl-2-picrylhydrazyl radical-scavenging activity (DPPH) and 2,2'-azinobis-3-ethylbenzothiazoline-6-sulfonic acid radical (ABTS+)scavenging activity of fruits of selected Himalayan edible plants. Among the species, maximum TPC (133.66 mg gallic acid equivalent/g) was found in Dacryo-draco cochinchinensis var. chunia, followed by Rhododendron anthopogon (119.50 mg gallic acid equivalent/g) and Rosa indica (77.42 mg gallic acid equivalent/g). Moreover, highest TFC (203.47 mg catechin equivalent/g) was found in V. hankelii, followed by D. cochinchinensis var. chunia (127.94 mg catechin equivalent/g), L.",
        "label": 0
    },
    "429": {
        "output": "Let's think step by step. \nThe number of exclusion criteria (that is `candidate_trial` object) is 7:\n\n```python`\ntrial_relevant_exclusion_criteria = candidate_trial.get_relevant_exclusion_criteria()\n7\n\nName\n        Value\n       0 \n\n        Patient is less than 18 years of age.\n\n        Patient is currently participating in another clinical trial. \n\n        Patient is of non-binary gender.\n\n        Patient has a diagnosis of any other neoplasm as defined in appendix 5, including but not limited to a history of malignant melanoma of any location and stage (within the past 6 year prior to study entry).\n\n        Patient has a history of uncontrolled (grade 2 or greater) or recurrent diabetes mellitus.\n\n        Patient is receiving long-acting or injectable insulin, or oral agents known as \"insulin sensitizers\".\n\nName\n        Value\n        1\n\n        Breast cancer is of histologically grade 1 and stage 1.\n\nName\n        Value\n        2\n        Malignant melanoma of any location and stage (within the past 6 year prior to study entry).\n\nName\n        Value\n        3\n        Grade 2 or greater (or any grade recurrent diabetes mellitus)\n\nName\n        Value\n        4\n        Patient is of non-binary gender.\n\nName\n        Value\n        5\n        Patient is 18 years of age.\n\nName\n        Value\n        6\n        Patient is of non-binary gender.\n\n```\n\n\n\nIf the clinical trial has a relevant exclusion criterion, the clinical trial exclusion clause should be added to the patient note. The trial_relevant_exclusion_criterion variable is a list of strings. The length of this variable depends solely on the number of relevant exclusion criteria of the clinical trial. \n\n```python\nrelevant_clinical_trial_exclusion_criterion = ['Candidate does not meet inclusion criterion: '.format(c) for",
        "label": 0
    },
    "430": {
        "output": "## Revision 2\n\n[INST] Let's define the clinical trials more specifically. \n\nThe patient note: \nYou should make a trial-level eligibility on each patient for the clinical trial, e.g., '1) Not relevant', '2) Eligible', and '3) Excluded'. \n\nHere is the patient note:\n    The patient is a 65-year-old postmenopausal woman. Her mammogram results showed a lump in her left breast and she was referred to a breast care specialist from the symptomatic oncology service. She was diagnosed with breast cancer after a fine needle aspiration test followed by a biopsy, which confirmed invasive lobular breast cancer. She is receiving adjuvant endocrine therapy (tamoxifen citrate). The clinical trial of the test you are applying is ongoing, and there is no personalized or risk-based care available under this clinical trial.\n\n    Her biopsy results: IDC, grade 2, 4.9 cm, positive lymph nodes, E-negative/PR-negative, ER-positive, Her2-positive, HR-positive, Ki67, 60%, 100% of the cells.\n    The risk prediction model in this study is on Prosigna\u00ae, and the average risk category is 7.4. The risk score is 26 and the ROR was 31.6. It places her at the low/intermediate risk level.\n\nThe clinical trial: \nHere is the clinical trial: \nTitle: Innovative Biomarker Precision Therapy Trial (iBPTT)\n\n\nSummary: The iBPTT is a randomized multicenter clinical trial which is looking to use the Genomic Grade and Recurrence Scores from the Prosigna\u00ae (Pam50) Oncotype DX test to stratify patients diagnosed with breast cancer who are starting standard adjuvant endocrine therapy. The intervention arm will be stratified according to risk level from a Genomic Grade and Recurrence Score. Arm 0 will receive standard adjuvant endocrine therapy and Arm 1 will receive standard adjuvant end",
        "label": 0
    },
    "431": {
        "output": "<issue_comment>username_1936: I see that #3384 is still \"in progress\". Is there any other way to get this problem solved?\r\n<issue_comment>username_1931: We released our first release of Data-Assistant 4.0 with all the changes we made.  We added `MPI_OFF` to the `RunAllTests` setting to exclude the tests that are failing on MPI jobs. We also replaced a few broken tools with newer version in our tests. Most of the tests now run successfully on MPI jobs (as well as MPI-only jobs). Some of the tests still have failed with MPI jobs. We plan to work on it over the coming weeks. We'll be releasing frequent updates there. If you want to let us know whether or not `MPI_OFF` is fixed. We'd appreciate that.<issue_closed>\n<issue_comment>username_1931: Thanks for the detailed feedback. MPI tests are only failing for some of the pipelines.\r\n\r\nOn our machines, the eligibilities run correctly with the latest release. And, the eligibilities work perfectly without `mpi` when you execute `DataAssistant`.\r\n\r\nWe also updated our repository by removing that dependency on `mpi`, just to make sure that users on machines without MPI would not face any issues. Please upgrade.<EOD> Effect of HIV disease on the renin-angiotensin system.\nSince the recognition that angiotensin-converting enzyme (ACE) inhibitors (ACEi) are potent anti-proliferative agents in cultured glioma cells , it has been suggested that this may provide some support for a role of ACEi in AIDS-related dementia (ARDD) . At the recent meeting of the International AIDS Society meeting in July 1996, two other potential mechanisms for the therapeutic effect of ACEi and/or angiotensin AT2 receptor agonists in the treatment of cognitive disorders was reported . Both of these mechanisms provide support for the continued investigation into the role of the renin-angiotensin system in the pathophysiology of HIV-induced dementia as a result of AIDS.",
        "label": 2
    },
    "432": {
        "output": "<!-- == CONTRIBUTE TO THIS DOCUMENT: == -->\n<!-- \nYour input here is appreciated. Please add to and update this page.\nYou can submit changes to the wiki and have them be instantly propagated to the\nWikiDoc Web site as soon as this change is saved.\n-->\n\n# Discussion\nYou can edit this section and wiki page by clicking the \"edit\" link on top of any entry.\n\n# Additional resources\n- Med Help: Cancer: Research and Advances: The Med Help web site contains a good summary of what clinical trials are and information on the various types of clinical trials.\n- NCI: Clinical Trials Search\n- NCI: Clinical Trials Overview\n- NCI Cancer Information Helpline: Telephone: 1-800-4 CANCER (1-800-422-6237)\n- The Cancer Information Center: Telephone: 1-800-257-1034 \n- American Cancer Society Cancer Information Service: Telephone: 1-800-ACS-2345\n- ACS My Guide: Download a PDF or a Kindle version which provides easy to use information about cancer from the American Cancer Society\n- American Society of Clinical Oncology (ASCO) Cancer Information Services\n- National Comprehensive Cancer Network (NCCN): Oncology Patient Info<EOD> .\nThis study was conducted to determine the effect of anesthesia and surgery on serum and urine cortisol and corticosterone concentrations of rats. Experiments were conducted with five groups of weanling male rats. They were intact controls, rats undergoing laparotomy, rats undergoing laparotomy and laminectomy, rats undergoing intracranial injection of lysine vasopressin (VP), and rats undergoing intracerebroventricular injection of angiotensin II (AII). Serum and urine cortisol and corticosterone levels were determined after surgery in rats at 09:00 and 02:00 in all groups except the intact controls. Urine corticoster",
        "label": 0
    },
    "433": {
        "output": "[CODING]\n\n\n<div class=\"codetip\">Hint: If the number of patients is very large, you can create a loop to calculate the number of the eligible patients. \n\nFirst, define a list (here it is named `list`) to store all 0 and 1 in the file (for example, the code above defined 'list' which contains all 0 and 1 number). Then, `for` with `i=0 to size(list)` is used to iterate all 0 and 1 number in `list`. If you want to judge which is 1 (eligible), just check the 7th element `for` in `i`. If you want to find the number of 2 (eligible) in the file, you need to modify `i` to `z=0` first. Then, using `z=z+1;` add one element in `z` to `for` loop in every iteration. <NAME>\n\n</div>\n\n\n\n\n</body></html>\n<EOD> Role of calcium in 15-d-PGJ2-induced apoptosis in human prostate carcinoma cells.\nTo determine the biochemical pathways involved in prostaglandin (PG) D2-induced apoptosis, human prostate carcinoma cells were pretreated with 15-deoxy-delta 12,14-PGJ2, followed by exposure to various inhibitors of mitogen-activated protein (MAP) kinase activation (PD98059 or U0126) or calcium (BAPTA/AM) or caspase activation (benzyloxycarbonyl-VAD-fluoromethyl ketone). 15-Deoxy-delta 12,14-PGJ2-induced apoptosis and activation of stress-activated protein kinase were blocked by BAPTA/AM but not benzyloxycarbonyl-VAD-fluoromethyl ketone or U0126 or PD98059 treatments. Our results suggest that calcium activation upstream of stress-activated protein kinase is a prerequisite for the 15-deoxy-delta 12",
        "label": 2
    },
    "434": {
        "output": "## Citation\n<EOD> Influence of an intracerebral electrode on postoperative imaging after implantation of a dual\u2010sided electrode system with contact array for bilateral cochlear implants\nObjective: In this study we have analyzed the influence of an intracerebral electrode on postoperative imaging after implantation of a bilateral cochlear device system, which utilized different electrode sizes and configurations for the respective ears. This is considered to be the most important factor for the placement of such electrodes. Design: Seventeen patients (12 females, 5 males, age mean \u00b1 SD: 49.2\u2005\u00b1\u20056.9 years) with a previously implanted left\u2010sided dual\u2010sided electrode (DS\u2010DE) system were included into the study. Electrode sizes and configurations used were 3, 20, 31 and 40\u2009\u03bcm and configurations were different between the ears. Indication for surgery was severe bilateral hearing loss. All patients received a cochlear implant on the left side, followed by a cochlear implant on the right side after at least three months, depending on the patient's choice. In 14 of those patients the right cochlear approach was used, while in 3 patients the vestibular approach was necessary. Results: In all 13 patients with implantation via the cochlear route, imaging allowed for complete electrode arrays to be localized directly after surgery. The intracerebral electrode could not be visualized using the cochlear route. In all patients undergoing the vestibular approach, the implanted electrode was not completely intracranial, but in close proximity to the pons. All vestibular approaches resulted in a partial filling of the posterior cerebral cranial fossa. Conclusions: Postoperative imaging should be performed routinely immediately after surgery, using a gantry\u2010shift\u2010free, T1 axial sequence. In order to obtain images free of artifacts, a long\u2010axis slice width of less than 3\u2005mm should be applied. We also recommend not using an intracerebral electrode system in cases where the vestibular approach is selected.<EOD> Fecal",
        "label": 0
    },
    "435": {
        "output": "##[/INSERT]\n\n### Including additional variables\nAlthough most of the data is provided in the input file, you can consider a few more patient variables. One clinical trial includes two such extra data fields: the stage of the disease and the smoking history of a patient.\nStage of disease:\nCategorical variable: A patient can be in any of five stages of breast cancer from I to V. Stages I and II are early stages (the earliest or precursor stages of cancer), whereas stages III and IV are advanced stages. Stage IV, which is the most advanced form of cancer, is also termed \"metastatic\" cancer. In other words, the tumor has moved from where it started (the breast or breast ducts) to another part of the body. Stage V or unclassified cancer cannot be staged, because all information is missing. \n\nSmoking history:\nNumeric variable: Tobacco causes many cancers, including breast cancer. One study (1) and many other studies indicate that there is no statistically significant difference in mortality between smokers and non-smokers. Although a significant proportion of the smoking population may die of some cause, it is hard to say how much it is due to tobacco and how much is due to other reasons (e.g., diabetes and obesity, which are comorbidities associated with tobacco use). \n\nFor example, in the clinical trial we are assessing this year, it is mentioned in the first three lines (line_number=3,305, line_number=3,335, line_number=3,455) of the patient_note_0011_02 patient note that: \"The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She",
        "label": 2
    },
    "436": {
        "output": "## Examples \nThe first two input tables and the output table are following.\n![input tables](./files/inst_trial_example/table0.csv)\n![input tables](./files/inst_trial_example/table4.csv)\n![output table](./files/inst_trial_example/table_example_output.csv)\n\n<EOD> Evolution: an overview.\n\n This overview of human evolution is organized by the physical and cultural features which distinguish human beings from other primates. Topics covered include human physiology and physiologically important proteins, the human genome, human genome organization and regulation, human DNA sequences, the origins of the human species, and human social organization.\n<EOD> .\nOBJECTIVE\nTo study the regulatory role of insulin-growth factor-1 (IGF-1) in the proliferation and apoptosis of hepatoma MHCC97H cells.\n\n\nMETHODS\n1. Western blot or Northern blot was used to investigate whether IGF-1 receptor (IGFR) and IGFR type-1(IGF-1R) were expressed in MHCC97H. 2. MTT assay( 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) was performed to investigate the effect of insulin on cell proliferation. 3. MTT assay was performed to investigate the effect of IGF-1 on cell proliferation. 4. Flow cytometry and terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL), or combined with Annexin-FITC, or Hoechst33342/ PI stainning of MHCC97H cells was performed to study apoptosis induced by insulin or IGF-1.\n\n\nRESULTS\n1. The expression of both IGFR and IGF-1R were found in MHCC97H cells. 2. The inculation of insulin",
        "label": 0
    },
    "437": {
        "output": "<EOD> Ginsenoside Rg3 inhibits gastric cancer through TXNIP/TRX/ROS\u2010mediated mitochondrial\u2010dependent apoptosis\nDistant metastasis is one of the major causes of death in patients with gastric cancer (GC). This study aimed to explore the therapeutic effect of ginsenoside Rg3 (GS\u2010Rg3) on GC tumor growth and its underlying molecular mechanism of action. The effects of GS\u2010Rg3 on cell proliferation and its underlying mechanisms of action were examined in MGC803 tumor\u2010bearing nude mice, SGC\u20107901 cell line, and GC cell lines with wild\u2010type p53 (p53wt) and knockout p53 (p53\u2010/\u2010) gene. Cell Counting Kit\u20108 assay, tumor cells flow cytometry, enzyme\u2010linked immunosorbent assay (ELISA), and western blot were used to confirm the effect of GS\u2010Rg3. GS\u2010Rg3 inhibited tumor growth and increased cancer cells apoptosis mainly through the mitochondrial\u2010dependent pathway. Moreover, we found that GS\u2010Rg3 increased the expression of thioredoxin\u2010interacting protein (TXNIP) and decreased the expression of thioredoxin (TRX), subsequently inducing oxidative stress to inhibit tumor cells growth. Furthermore, GS\u2010Rg3 inhibited AKT/NF\u2010\u03baB signaling pathway and regulated the Bcl\u20102/Bax ratio by increasing TXNIP and decreasing TRX to induce apoptosis. Notably, p53 gene mutation abolished the activity of GS\u2010Rg3 in inducing apoptosis, which was mainly through the PI3K/AKT pathway, but not the TXNIP/TRX pathway. These results suggested that GS\u2010Rg3 activated TXNIP/TRX pathway by upregulating TXNIP and downregulating TRX to modulate oxidative stress, consequently activating mitochondria\u2010dependent apoptosis to block tumor cells growth. Importantly, GS\u2010Rg",
        "label": 1
    },
    "438": {
        "output": "3.2.3.5 The end of the code for generating the result 4) \n\n## [inst] Hello. This is a simple code for generating the result. If I had to explain the whole flow, 1) I would explain how to read the data, 2) I would explain how to process it, and 3) I would explain how to \noutput the result. It would be a little long. So, I'll simplify a little bit.\n\nI'll assume that all of the data are already in a CSV file. And all of your work is done on a code window that is \nin the editor of an integrated development environment (IDE). I chose to code in Python, but you could use any \nprogramming language you prefer. However, please note that the following code cannot be executed in \nWindows NotePad. 4) \nThe  data file that I used in the previous examples. As you have guessed, I got data in that\n\n\n[censored]\n\nI read the data as follows:\nimport numpy as np\nimport matplotlib.pyplot as plt\nimport pandas as pd\nfrom io import StringIO\n\ndata = pd.read_csv(\"README.csv\", encoding=\"utf-8\")\n\ndata[\"Cancertitans\" = data[\"Cancertitans\"].map({-1:128, 0:127, 1:126,\"NaN\":np.nan})] 5) \n\nI plot one of the data rows.\nimport matplotlib.pyplot as plt\n\ncancertitle = \"Title\"\ncancrtage = \"Age\" 6)\n\nt = data[\"canscertitle\"].sample(51)\nylabel = data[\"cantagere\"] \nxlabel =  data[\"cangertime\"]\nplt.plot(t.value,ylabel,yerr=ylabel,xlabel=xlabel )\nxlabel.set_fontsize (10)\nylabel.set_fontsize (10) 7) \n\nI save the code in a separate file.\nprint \nfilename = 'sample_output.csv\"'\nfile=open(filename,'w')\nfile.write(\"cancertagere\\t\",\"nan\"*4)",
        "label": 0
    },
    "439": {
        "output": "<EOD> In vitro cell culture and microinjection for study of osteoblastic differentiation.\nSeveral different cell lines have been used for in vitro studies on the processes involved in osteoblast-like cell differentiation. Some are more osteoblast-like after transfection with appropriate cDNA expression vectors than they are immediately postconfluence, and microinjection of DNA and RNA can be used to induce some of the more osteoblast-like cell changes.<EOD> The prevalence of malaria infection in the population of Homa Bay District, Kenya, assessed by rapid dipstick test or by conventional microscopy\n\nBackgroundMicroscopy remains the gold standard for routine diagnosis of malaria infection in Africa; however the requirement for on-site expertise and complex procedures can be prohibitive to its use. It is widely understood that microscopy is insensitive for Plasmodium infection at low densities and only 50% of P. falciparum malaria infections in endemic regions have been detected by microscopy. The use of antigen-capture tests, such as Paracheck-Pf \u2122 , to screen for malaria infection might represent a practical alternative to microscopy but the sensitivity of Paracheck-Pf \u2122 has not been evaluated systematically using field samples.MethodsWe assessed the diagnostic performance of Paracheck-Pf \u2122 against microscopy in a field setting by comparing test kit results with microscopy findings for 7085 finger-prick and 110 venous blood samples collected from 16 locations in the Homa Bay District of western Kenya. Rapid diagnostic test sensitivity was compared with microscopy with samples from patients whose slides were positive for malaria parasites at 10% parasitaemia and from those whose slides were negative for malaria parasites.Results Paracheck-Pf \u2122 had similar sensitivity (94.7%; 95% CI 92.4-96.2) to expert microscopy and a lower sensitivity (91.3%; 95% CI 87.3-94.8) than local non-expert microscopy. Rapid diagnostic test sensitivity was similar (",
        "label": 2
    },
    "440": {
        "output": "<EOD> .\n\n The author describes the results of surveys conducted about family demographics in several regions of Vietnam. The surveys found that the average size of households is smaller than 6 persons because of emigration of men or the death of elderly men and women. Younger families also average fewer members, but because of the higher proportion of adults in such households, their average size is not smaller than older households. The total fertility rate in the 5 central provinces is 3.7, whereas the national figure is 6.1. The 4 northern provinces, however, have a total fertility rate of only 2.4. This results, it is thought, from the higher age of marriage and lower age of birth for children. According to the survey, the rate of secondary school matriculation in the 5 central provinces is about 5%. This rate should double because of the increased number of young persons. However, in the northern provinces the majority of young persons will not have a higher education level, and therefore, the rate of secondary school matriculation will not increase. The survey found that the ideal age of marriage in southern Vietnam is 23 years of age for a man and 19 years old for a woman. The ideal number of children is about 3 at present. In the north the preferred age for marriage is around 25 years for a man and around 23 years for a women. There is generally an ideal number of 7 children. (author's modified)\n<EOD> Inhibition of HIV-gp120-induced CD4 T Cell Death by Chrysin Is Mediated through the Mitochondria-caspase Pathway\n\nBackground: HIV-1 GP120 induces apoptosis in CD4 T cells, playing a role in CD4 T cell depletion and the development of AIDS. Chrysin (5,7-dihydroxyflavone) is a natural polyphenol that has a variety of pharmacological activities. One such activity is protection from apoptosis by inhibiting caspase activation in different apoptotic systems. Chrysin down-regulates HIV replication at various phases of the viral life cycle, and can also reverse HIV-induced apoptosis in mitochondria-mediated pathways. However, it is still not clear whether chrysin",
        "label": 1
    },
    "441": {
        "output": "You should write in a script file of the file of the current directory. A script file should follow the Pandas conventions.\nIf the current folder contains multiple clinical note files, you should choose the desired file according to a certain name pattern.\n[INST]\n## Note name pattern\n\n[INST]\nThe patient is a 45-year-old post-menopausal woman with cytologically -confirmed breast cancer. A core biopsy revealed a  cm -invasive ductal breast carcinoma -in the left upper outer quadrant. The tumor is  HER2 -positive and ER/PR -negative. Axillary sampling revealed -5 -positive lymph nodes. CXR -was remarkable for metastatic lesions. The patient is -using multivitamins and iron. She does not smoke or consume -alcohol. She is -not sexually-active and has -no children. -She is a candidate to tumor resection, agree to do so prior to chemotherapy.\n<EOD> .\nThe study was carried out to search for a method for the quantitative detection of 2,4-Dinitroanisole, 2-Methyl-4-amino-6-methylphenol, 2-Methyl-4-(2,4-dinitro-phenoxy)phenol in spiked samples. A rapid HPLC method with fluorescence detector using reverse phase-ODS column was developed for this purpose. Under the optimum conditions a good linear correlation of peak areas to concentrations existed over the range of 0.5-2.9, 0.5-5.0, 0.5-2.0 microgram/mL with correlation coefficients of 0. 998 2, 0.9988, 0.9949, respectively. The limit of detection was 0.2, 0.1, 1.2 microgram/mL , respectively. The mean recoveries were 95.4%, 98.6%, 95.7%. The intraday and interday RSDs were in the range of 1.7%-6.3% and 2.3%-8.7%, respectively. The method was",
        "label": 1
    },
    "442": {
        "output": "## Implementing your solution to the task: Python\n### Problem\nIn this lab you have to read a Python file `clinical_data.csv` and assign each individual to a group based on their diet. You have to group all the participants into [\u2026][INS\u2026] three categories: Control, High Omega-3 and Seafood. For the group 'High Omega-3' people have to have Omega-3 as their main diet source. For 'High Seafood' people have to have seafood as their main diet source.\nAfterwards you are required to do these things:\n- 5. Create a list of people that are in the control group.\n- 6. Compare each person, that is not in the 'High Omega-3' or the 'High Seafood' group, with the controls. If they have the same food intake they will be assigned to the 'Other diets' group.\nNow continue reading the following steps. Each row of the file has one person in each category and dietary intake:\n\n### Solutions\nFor your solution to the problem, you must create a function, `addtoGroup`, that takes as arguments the category, the person and their diet and returns a list of the people assigned to that category. It should also take care to return an exit value in case the person is neither in the `high fish` group (`High Omega-3`) nor the `high seafood` group (`High Seafood`).\n\n```python\ndef addtoGroup(person,category,diet):\n    if category == 'highomega3 :\n       Group.append(person)\n    elif category == 'highseafood :\n       Group.append(person)\n    else:\n       Group.append(person)\n    return\n```\n\nNext, you have to create the main function to solve the problem. After the input data is introduced and you call the function `addtoGroup`, you have to repeat the steps 4-5. The loop stops when the exit statement is reached, the first exit is for the case when there's a person that doesn't fit into any of the categories. The output should be as follows:\n\n```python\ngroup_1 = [\"<NAME>\", \"Alex\", \"HighSeafood\", \"<",
        "label": 0
    },
    "443": {
        "output": "</details>\n\n\n## How to Improve the Efficiency of R Shiny Apps\nTo improve the efficency of R Shiny apps, you can add packages available in CRAN.\n\n<details>\n<summary><b>Packages: To Improve the Efficency of R Shiny Apps</b></summary><br><ul>\n<li>data.table (data.table:: fread)</li>\n<ul>\n<li>tidyverse (dplyr:: dplyr)</li>\n<li>readxl (readxl:: read_xlsx)</li>\n<li>Rcpp (Rcpp:: ropennorm)</li>\n<li>tableone (tableone:: rtableone)</li>\n<li>ggplot2 (ggplot2:: ggpubr)</li>\n</ul>\n</li>\n<li>shiny_cssmodifyR (shiny_cssmodifyR:: apply css class, shiny_cssmodifyR:: adjust the theme)</li>\n<li>shiny_jsconvert (shiny_jsconvert:: use js, shiny_jsconvert:: add custom js)</li>\n<li>rcompanion (rcompanion:: quickr)</li>\n</ul>\n</details>\n\n## Discussion\n<h3>What to consider before starting learning?</h3>\nLearning the Shiny framework will require you to understand the logic of the programming language, R. You must also learn how to operate in a graphical user interface (GUI) environment and how to set up a package. In the end, R Shiny apps can provide important analytical tools to support decision making within any industry setting.\n\n<h3>Forget to ask for help and advice!</h3>\nDon\u2019t forget to ask for help and advice from experts, including friends, families, and colleagues in similar fields. Once you\u2019ve built a Shiny app, you\u2019ll likely need to learn how to share and disseminate it to the right audience.\n\n<h3>Do not judge the quality of an R Shiny app by a single test alone</h3>\nDo not judge the quality of an app by a single test alone.",
        "label": 2
    },
    "444": {
        "output": "## If the drug is a placebo or sham, please describe in detail and then click the corresponding box.\n\n###",
        "label": 0
    },
    "445": {
        "output": "## \u25b6 question 8\nWhat is the output of the task? \nAnswers: 2) `PATIENT ELIBILITY REPORT`, 4) `Patient eligibility report`<EOD> The prognostic value of serum thymus and activation\u2010regulated chemokine levels in Hodgkin lymphomas\nThymus and activation\u2010regulated chemokine (TARC) is overexpressed in Hodgkin lymphoma (HL), and it is related to aggressive disease and poor outcome.<EOD> Expectations and attributions of positive and negative emotional experiences: a meta-analysis\nThe influence of appraisal on emotional experience has not been evaluated systematically. We report a meta-analysis of 34 experiments investigating whether positive and negative emotion is judged as greater when they are caused by a desirable (vs. undesirable) standard or are expected versus unexpected. Across a variety of emotions, valences, methods of assessment and time of assessment (the affective forecasting paradigm), participants report higher levels of emotion when it is judged to be caused by a desirable (13 studies; r\u0304= .36) or expected standard (31 studies; r\u0304= .18) than when it is judged to be caused by an undesirable (12 studies; r\u0304= .09) or unexpected standard (15 studies; r\u0304= .14). Overall, these findings suggest that appraisals of positive and negative emotional experiences are influenced by the desirability and expectancy of certain experiences.<EOD> Combining Bias Control Methods: Bias Variance Dilemma and Efficient Estimation\nThe bias variance dilemma often arises when both bias and variance are undesirable. If the variance of the data is well explained by simple parameters, a single method may be preferred to eliminate the variance. However, if the variance is not well explained by the simple parameters, using any of the single methods might be worse than simply collecting a large amount of data, which implies that using any of the single methods might induce an unnecessary loss of information, due to the inherent restriction on the available covariate sets. This paper proposes a two-step framework to address this issue. Our objective is",
        "label": 0
    },
    "446": {
        "output": "## Expert Review from Dr. Shi-Yuan Cheng, MD, PhD\n\n\n### General Comments From Dr. Shi-Yuan Cheng, MD, PhD\nTrial-level Eligibility:\nWhen calculating the percentage of \"eligibility\", we have to ignore the patients that are excluded due to \"inclusion exclusion criteria\" but are excluded due to \"exclusion criteria\", e.g., excluding patients older than 85.\n\n### Score From Dr. Shi-Yuan Cheng, MD, PhD\nQ #3\n30%\nRating: 3\n\n### Comprehensive Comment From Dr. Shi-Yuan Cheng, MD, PhD\n\n### Score From Dr. Shi-Yuan Cheng, MD, PhD\n30% \nTrial-level Eligibility: \nWhen calculating the percentage of \"eligibility\", we have to ignore the patients that are excluded due to \"inclusion exclusion criteria\" but are excluded due to \"exclusion criteria\", e.g., excluding patients older than 85. \n<EOD> Dual antisense oligonucleotides targeted to interferon\u2010regulatory factor 1 and hepatocyte nuclear factor 4\u03b1 are capable of suppressing HCV replication in liver cells\nInterferon\u2010regulatory factor 1 (IRF\u20101) and hepatocyte nuclear factor 4\u03b1 (HNF\u20104\u03b1) are key transcription factors that play an important role in the regulation of the expression of antiviral cytokines. In fact, in hepatocytes which are infected by hepatitis C virus (HCV) and are simultaneously treated with anti\u2010HCV compounds, HCV suppresses the basal activity of IRF\u20101 and activates HNF\u20104\u03b1, resulting in suppression of IFN\u2010\u03b1 secretion. Here, we examined the inhibitory effects of a double antisense oligonucleotide (DASO) that consists of two antisense oligonucleotides (A and B), which correspond to the first and second inhibitory antisense elements, on IFN\u2010\u03b1 secretion by targeting IRF\u20101 and H",
        "label": 0
    },
    "447": {
        "output": "___\n\nWe hope you have learned a thing or two about this data. Thank you. Thank YOU!\n\n[INST]\n[TRIAL]\nIn this module, we will learn about [TRIAL]:\n  * how to select a clinical trial\n  * what's needed for a data scientist to do when participating in a clinical trial\n  * what clinical trial protocol is\n  * what a clinical trial workflow is\n\n\n\n**What's needed**\nSome of the information is stored in the electronic medical records. Some of the information is from other clinical trials data warehouses. Some of the records are from other sources like NCI. Some of the data are stored in the clinical trial protocol. We will introduce you to all these sources after learning their structures and their relationships and their interactions.\n\nHere is an XML document representing structured data from a clinical registry.\n\n```xml\n<clinical_trial ID=\"111\" \n  start_date=\"1982/01/13\" \n  end_date=\"1984/01/09\" \n  status=\"pilot\" \n  recruit_number=\"70.12345678\" \n  recruit_goal=\"80.40034876\" \n  location=\"Seoul\" \n  sponsor=\"Golden\" \n  sponsor_ID=\"777\" \n  sponsor_type=\"government\" \n  status_info=\"The clinical trial was suspended because clinicians decided that the target patients were getting into the clinical trial too late. They have notified the clinical agency who has agreed with the fact. \" \n  institution=\"781\" \n  institution_type=\"hospital\" \n  PI_ID=\"038\" \n  PI_type=\"Clinical\" \n  enrolled_number=\"12.34567890\" \n  funding_source_ID=\"895\" \n  funding_source_type=\"non_profit\" \n  primary_outcome=\"yes\" \n  primary_outcome_type=\"yes\"",
        "label": 0
    },
    "448": {
        "output": "Let's make a trial-level eligibility:     [![Screenshot-2018-11-25-193521](https://user-images.githubusercontent.com/44824593/51073430-3354ed00-111c-11e9-966b-560e59b67f9e.png)](https://github.com/pavlova-lab/pavlovainstllmlab/blob/master/datasets/patietnote/patientnote_sample.json)     ```\n#2\n\n[![Screenshot-2018-11-27-180320](https://user-images.githubusercontent.com/44824593/51225359-2f7aa180-128a-11e9-9dfb-8714b296ef52.png)](https://github.com/pavlova-lab/pavlovainstllmlab/blob/master/datasets/eligibility_score/eligibility_score_sample.json)\n\n```julia\nusing Dates\n\nconst date =\n    \"2018-11-27T19:12:54.469Z\"\n```\n\nLet's create a model with a predictor of date: \n```julia; for(j = 7:#size(b3::SymbolArray, 1);j < size(b3::SymbolArray, 1); j = j + 1)\nresult <- c(\"eligibility_score\")[j]\nprint(\"Predicting scores for \" * result * \" variables:\")\nprint(\"```julia; for(x = 1:size(m[:,result], 1);x < size(m[:,result], 1); x = x + 1)\nm[:,result] = rebind(m[:,result],x) * 60 * 60*24*365.24\n\nresults[:,1] =",
        "label": 0
    },
    "449": {
        "output": "__Exercise 2__\nThis is the sample data of patient data from our clinical trials repository: `cdaf-1-211404.json`.\n\n# 1. Load dataset\nTo load sample data from cdaf.json files, set `Load = true` in `ClinicalTrials`. Call `Data` function for an example, and use `SaveTrainingSet = true` argument to save a subset of the training data:\n```python\nIn:\nclt.load(Load=True, SaveTrainingSet=True)\nOut:\nclt.Data.sample_data[Load]\nIn:\nclt.Data\nOut:\nIn:\nclt.Data.sample_data[Load]\n```\n\n# 2. Filter Clinical Trials\nThe first step of assessing the eligibility of a patient to a trial is to filter the trials. First, set `exclude_patient_age` to filter out trials that exclude patients based on age. Similarly, set `exclude_menopause` and `exclude_stage`, respectively, to exclude patients not in stage T1 and patients with stage T4, the most advanced stage. In this trial dataset, no trials apply age or menopause criteria. If you have other data from clinical trials that you would like to filter out, you can create a dict and add those keys to the `clt.Data.filter_trial` attribute:\n\n```python\nIn:\npat_criteria = {\n    'exclude_age': True,\n    'exclude_menopause': True,\n    'exclude_stage': True,\n    'exclude_other': {\n        'exclude_all_diseases': True,\n        'exclude_menopause_or_age': True,\n        'exclude_menopause': True,\n        'exclude_age': True,\n        'exclude_tumor_size': True,\n    }\n}\n\nclt.load(Load=True, SaveTrainingSet=True)\nclt.Data.filter_trials = {}\nclt.Data.filter_trials['exclude_patient_age'] = True\nclt.Data",
        "label": 1
    },
    "450": {
        "output": "[/CMD]\n\n\n[INST] Good morning. The current task is to predict a label given a patient note and features associated with it. \nThe problem is formulated as follows: given a set of patient notes with associated features describing a patient, make predictions about the label of a new patient note. \n\n[CMD] Prediction is possible for a patient on the basis of known patients of the clinic whose patient notes and features are available in the training set. The patient note and features of the patient are then compared to those of patients in the training set. For each pair of a known patient and a test patient whose features are similar, the label of the known patient is assigned to the test patient. This procedure is repeated for all patients in the training set, and all given patient notes can be predicted based on the distribution of the labels of the known patients.\n\n\n[INST] Let's make predictions of label for the patient. You will have access to the patient note, as well as the patient profile, of other patients whose notes we have seen as part of the training set. Your task here is to make predictions about the labels for the patient by using a function: label:predict(notes: string array, patient_profile: string array) -> string array. The notes of the patients in the training set have already been scored. The function returns the predictive labels for the patient note you input. Here's an example of prediction outcomes: `label:predict([{'age': 62, 'ethnicity': 1, 'sex': 1},{'ethnicity': 2, 'sex': 2}], patient: {'age': 62.4, 'ethnicity': 1, 'sex': 2}) -> {'age': 62.4, 'ethnicity': 1, 'sex': 2, 'label': ''}`. You can see that the labels of the training patients are shown, their scores are shown in brackets after the label. All labels have scores of 0, except the '2' entry ('sex' = 2) which has a score of 1. Here's an example of the function's outputs for 2 different patient notes: \n`label:predict([{'age': 62, 'health': 1, 'sex': 1, 'hivpos': 1},{'age",
        "label": 0
    },
    "451": {
        "output": "* `Criteria for eligibility of patients is an important element of a clinical trial. Make sure your criteria are the same as the author's and are written according to the author's format. If there are many eligibility criteria, make sure all of them are listed. Write them with the same order listed by the author. Use the same format, as listed in this example too.* \n\nNow, try one of the questions from the practice.\n\nTo start the process, you have to click on the button \"Practice\".\n\nOnce you open the practice, all items on `Task` block will be available for editing. To create, edit or view an item about a `task` use the `Menu -> Tasks`.\n\nMake sure you edit the question on the `Task` using the textbox. The question to edit is:\n\n\"To start the process, you have to click on the button \"Practice\".\n\nThe text is surrounded by the `Task` block with the name of the question. Your options are: \n\n- *`Task`: Create New task*\n- *`Task`: Delete task*\n- *`Task`: Reset Task*\n- *`Task`: Edit Task*\n- *`Task`: Show tasks*\n- *`Task`: Clear tasks*\n\nHere an example of the `Task` edit mode:\n\n![](screenshots/trial-based-questions/practice/edit_task.png)\n\nOnce you finish to create the `Task`, you have to click the button `Save` to save the changes you implemented. When you have done, close the window with the button `OK`.\n\n* `You have created a task called `Trial-based questions`.` \n\n![](screenshots/trial-based-questions/practice/edit_task.png)\n\nOnce you save your changes, you have to click again the button `Practice` to edit the rest of the tasks (in this example, as you edit this task, the word `New` will be changed to `Edit`). \n\n![](screenshots/trial-based-questions/practice/edit_task.png)\n\nTo create a task, click on the button `Create Task` from the main window (button with the 9",
        "label": 0
    },
    "452": {
        "output": "<EOD> .\nBACKGROUND\nSyphilis is still a sexually transmitted infection with major public health consequences, being one of the three infections in the United States of America with the highest incidence. We present epidemiological, serological, clinical and therapeutic characteristics of a woman with congenital syphilis who attended the outpatient clinic of Endemic Diseases of the \"Dr. Eduardo Torres\" hospital of the Havana Municipality during a period of approximately 15 months.\n\n\nPATIENTS AND METHODS\nA case study is reported of a 8-year-old girl child presenting clinical and serological characteristics of congenital syphilis in addition to her mother's serological data.\n\n\nRESULTS\nClinical manifestations include hepatomegaly and splenomegaly detected by image examination and a positive nontreponemal test and syphilitic serological tests (Treponema pallidum hemagglutination test and T. pallidum fluorescent treponemal antibody absorption test). This patient and three other members of the family were diagnosed, serologically proven, as suffering from syphilis, and her mother was treated.\n\n\nCONCLUSIONS\nThe outpatient clinic of Endemic Diseases of the \"Dr. Eduado Torres\" hospital detected a case of congenital syphilis with no signs or symptoms, a fact that illustrates the important role that outpatient services play in primary health care.<EOD> A novel role for NF-kappaB in apoptosis: induction of the apoptosis inhibitor ARC.\nThe ubiquitously expressed protein amyloid beta precursor-binding protein (Arc) was isolated as a nuclear protein in fibroblasts undergoing apoptosis induced by ultraviolet light. To investigate a potential signal involved in transcriptional up-regulation of the arc gene during apoptosis, promoter analyses were performed and results showed a cis-acting element homologous to the NF-kappaB consensus sequence (5'-GGG(n)GGG-3') located -37 bp upstream of the transcriptional start site.",
        "label": 0
    },
    "453": {
        "output": "1. Determine which features of the patient match the inclusion criteria of 1) Prognosis and 2) Prediction. \nHistology and tumor size are both features present in the prognosis inclusion criteria. Therefore:\n\n## Histology\nTrue\n\n## Tumor size\nTrue\n\nAdditionally, age is present as an inclusion criteria within the prognosis and also within the prediction criteria. So:\n\n## Age\nTrue\n\n## Prognosis\nAdditionally, sex and children are not present as inclusion criteria in the prediction criteria. So:\n\n## Sex\nFalse\n\n## Children\nFalse\n\nAt first glance, this would be the end of the match at the inclusion criteria level. We are left with the following results:\n\n# Tissue-level eligibility\nThe patient also matches the exclusion criteria for this trial. The following data is present:\n\n## Trial-level eligibility:\nFalse\n\n## \nThere are no clinical factors that make the patient eligible for recruitment into the clinical trial.\n<EOD> Effects of a commercial diet containing 1% L-arginine on skeletal changes in the distal part of the femur in juvenile broiler chickens\n\nL-arginine, an essential amino acid, has been shown to have a synergetic effect when supplemented with other amino acids on broiler growth. The aim of the present study was to examine the effect of dietary Larginine supplementation on skeletal changes in the distal part of the femur of young Ross broiler chickens. A total of 128 chickens (24 females and 104 males) were used in a controlled, repeated study (7, 21 and 35 days of age) with nine dietary treatments (388 g kg -1 of wheat with no additional amino acids supplementation [C], 1,500 g kg -1 of wheat [W], 7 g kg - of hydrolysed casein diet and 0.3% L-arginine supplementation [LC], 70 g kg -1 L-cystine with 0.3% L-arginine supplementation [LCa], 0.0",
        "label": 0
    },
    "454": {
        "output": "<EOD> Correlation Between N6-Methyladenosine Regulators and Immunotherapy Response in Hepatocellular Carcinoma\n\nThe immunotherapy of hepatocellular carcinoma (HCC) is emerging as a promising antitumor method. Although m 6 A modification has been confirmed to play a vital role in immunotherapy, the regulatory factors of m 6 A modification in anti-immunotherapy are unclear. This study aimed to identify m 6 A-related genetic biomarkers to predict the efficacy of cancer immunotherapy in patients with HCC. ESTIMATE was employed to explore the potential association between m 6 A regulators and the immune response. Then, we used CIBERSORT to assess the correlations between m 6 A regulators and 22 immune cell types and analyzed TIDE and immunophenoscore to identify immunotherapy sensitivities. Additionally, Cox regression was conducted for risk survival analysis, and multivariate Cox regression analysis was executed to determine the independent prognostic factors of anti-PD1-resistant HCC. The results showed that the expression of m 6 A regulators was negatively correlated with stromal and immune scores. There were 19 m 6 A-related gene pairs exhibiting statistical differences in immunotherapeutic sensitivities, and nine of them predicted immunotherapy sensitivity. Univariate and multivariate Cox regression analyses indicated risk score was strongly correlated with clinical outcomes. Furthermore, gene pairs related to immune infiltration, such as ELAVL1-YTHDC1, ELAVL1-HNRNPA2B1, YTHDF1-ALKBH5, and YTHDF2-FTO, could be used as potential prognostic indicators. Finally, six genes (ALKBH5, HNRNPA2B1, YTHDC1, YTHDF1, YTHDF2, and ELAVL1) were identified as independent factors of immunotherapy sensitivity. The current results may provide a rationale for combining immunotherapy and targeted therapy to achieve the best treatment effect.\n\n# Introduction\nHepatocell",
        "label": 1
    },
    "455": {
        "output": "### Notes for the next time\nThe following is the list of cases we need to consider.\n1. Whether the trial-level assessment is 1 (eligible) or 3 (not relevant): The patient note should be evaluated as 2 (eligible) in such a case. \n 1) Eligible: The result of the patient note should be output as the result, e.g., `PatientNote-level assessment: 2) Eligible.`. \n 2) Eligible: The patient note should be evaluated as not relevant in such a case. \n   1) Not relevant: Output the results by: `Not relevant (not enough information)`.<EOD> Detection on cerebral palsy in patients with congenital hypothyroidism.\nPURPOSE\nOur aim was to determine the incidence of cerebral palsy among our patient group with congenital hypothyroidism and to compare the outcomes with other epidemiological studies.\n\n\nMETHODS\n40 patients who were diagnosed as congenital hypothyroidism were questioned retrospectively. The mean follow up period of patients was 12.03 +/- 2.67 years (11-24 years). Age and sex were compared with the literature. Also, neurological examinations, neurodevelopmental examinations and anthropometric measurements were examined. All the statistical analyses were performed using SPSS 13.0 program.\n\n\nRESULTS\nThe group consisted of 20 women (50%) and 20 men (50%) with the mean age 20.30 +/- 1.25 years. The mean height of girls was 156.72 +/- 6.69cm and of boys 165.63 +/- 7.92cm. Thirteen (32.5%) patients received thyroxin replacement therapy. Neurodevelopmental examination revealed one patient's cerebral palsy; and of neurological examination, four patients gave abnormal findings.\n\n\nCONCLUSION\nCongenital hypothyroidism is an important cause of permanent neurological damage which may result in",
        "label": 0
    },
    "456": {
        "output": "---\n\n## Data.\n## Summary: Here is the data.\n\n*Each row is a record (a set of columns) associated with a person.*\n\n*Each column is the value of one column of person's medical record.*\n**Note: some column names do not correspond to their medical meaning as they are only used as identifiers as below.**\n\n| col1    | col2    | col3    | col4    | col5    | col6  | col7    | col8    | col8    | col9    | col10   | col11   | col12   | col13   | col14    | col15    | col16    | col17    | col18    |\n**Key:\ncol1**: patient id **(same for all people)**\ncol2**: gender (male/female)\ncol3**: birth year\ncol4**: birth month\ncol5**: birth day\ncol6**: is alive now (1/0)\ncol7**: smoking status(1/0)\ncol8**: drinking status (1/0)\ncol9**: is candidate for surgery (before randomization for the phase 2 trial)(1/0)\ncol10**: candidate for chemotherapy (after randomization for the phase 2 trial)(1/0)\ncol11**: candidate for radiotherapy (after randomization for the phase 2 trial)(1/0)\ncol12**: HR(1/0)\ncol13**: HER2(1/0)\ncol14**: tumor size  (1/0)\ncol15**: type of tumor \ncol16**: stage(1/2)\ncol17**: localization (1/0)\ncol18**: affected site(1/0)\ncol19**: affected visceral organ(1/0)\ncol20**: is candidate for cytotoxicity profiling  (1/0)\ncol21**: is candidate for biomarker analysis  (1/0)\ncol22**: is candidate for censoring (1/0)\ncol23**: ex",
        "label": 0
    },
    "457": {
        "output": "Let's now look at how to apply the conditions as inclusion criteria in the form of `If` statements. In the following, the first expression checks whether the patient is over 18 years old, the second expression if the patient has invasive breast cancer, the third expression if the patient has tumor stage 1 to 3, the fourth expression if the patient has a HER2+ or triple-negative tumor (tumor is histologically positive for HER2/ERBB2 or negative for PR and HER2/ERBB2), and the last expression if the patient received 3 cycles of neoadjuvant systemic therapy. It is not sufficient to have had chemotherapy; one must additionally include information about the start and end of chemotherapy. Let's start with a statement that checks if the patient's status was female. This statement is not displayed in the program output. \nfemale \u2190 1 / 0\n\nThen we evaluate if the patient is older than 18 years by comparing it to the date of birth, which we take from the patient note file. \nbDateOfBirth \u2190 read.csv(\"patientData.csv\") \nage \u2190 strftime \ndate \u2190 strptime(age, \" %b %e\", loc = \"en_GB\") \nif bDateOfBirth %d %s > 18:\n    female \u2190 0\n\nWe then look for the presence of breast cancer in the pathological report of the core biopsy. \nif bBreastCancerPathology \u2264 \"no\" :\n    female \u2190 0\n\nA statement is added below to continue with the evaluation of a possible tumor stage 1 to 3. The expression is not shown in the program output. \nif bTumorStage \u2264 \"1\" | bTumorStage \u2265 \"3\":\n    female \u2190 0\n\nIf the patient has a HER2 + or triple-negative tumor (tumor is histologically positive for HER2/ERBB2 or negative for PR and HER2/ERBB2), the following is calculated. \nif bTumorType \u2264 \"HER-2-neu positive or triple negative\" :\n    female \u2190 0",
        "label": 0
    },
    "458": {
        "output": "[CODE]\n```\ndef eligibility(patient_record, trial_record):\n    if 'ageGroup' in patient_record:\n        for age_group in patient_record['ageGroup']:\n            if 'age' in age_group:\n                age = age_group['age']\n            else:\n                age = age_group\n\n    if 'age' not in patient_record:\n        return Trial-level eligibility(2)\n\n    if patient_record['age'] < trial_record['min_age_eligibility']:\n        return Trial-level eligibility(0)\n    if patient_record['age'] > trial_record['max_age_eligibility']:\n        return Trial-level eligibility(1)\n\n    if 'gndr' in trial_record['age_group_eligibility']:\n        gender1 = patient_record['gender']\n        gender2 = trial_record['gndr']\n\n        if gender1!='F' and gender2=='M':\n            return Trial-level eligibility(2)\n        elif gender1!='M' and gender2=='F':\n            return Trial-level eligibility(1)\n\n    if patient_record['smoke_history'] == 'Yes':\n        if trial_record['smoke_history_eligibility'] == 'Yes':\n            return Trial-level eligibility(2)\n        else:\n            return Trial-level eligibility(0)\n    if trial_record['alcohol_history_eligibility'] == 'Yes':\n        if patient_record['smoke_history']:\n            return Trial-level eligibility(1)\n        else:\n            return Trial-level eligibility(2)\n\n    if patient_record['gravidity'] == 0:\n        if trial_record['gravidity_eligibility'] == 'Yes':\n            return Trial-level eligibility(2)\n        else:\n            return Trial-level eligibility(0)\n\n    if patient_record['parity'] == 0:\n        if trial_record['parity_eligibility'] ==",
        "label": 0
    },
    "459": {
        "output": "A: You first need to decide whether you want to write your program with or without IDE. There is a big difference between both the ways as they may result in two different levels of program.\n\nIf you use an IDE, it would give a warning to this line of code, so you will have to go to an editor and change its value to 2.\n\nOtherwise, you can write the code without IDE and let the system run the code without any problems or warnings.\nYou should always repeat Trial-level eligibility in the last line by `Trial-level eligibility: `, e.g., `Trial-level eligibility: 2) Eligible.`.\n<EOD> Aminoglycoside cross-resistance in Salmonella enterica serovar Typhimurium 4.3.7.12 associated with decreased expression of the acrB, marA and rpoP gene products.\nThree mutants of Salmonella enterica serovar Typhimurium 4.3.7.12 cross-resistant to different aminoglycoside compounds were obtained and characterised. All mutants exhibited significant reductions in the production of the acrB and marA gene products, a strong reduction in the production of the rpoP gene product and elevated expression of the mar and the pmrA gene products. It is concluded that these changes could be partially responsible for the observed cross-resistance.<EOD> Duration of therapy for uncomplicated acute sinusitis in adolescents and adults.\nBACKGROUND\nAntibiotics are recommended for acute sinusitis. However, evidence suggests that 10-day antibiotic courses may be adequate for most children with acute sinusitis.\n\n\nMETHODS\nAdults and adolescents, aged 18 to 55 years, with uncomplicated acute maxillary sinusitis (symptoms for  1 year) of sinusitis and the need for treatment for >/= 90 days. Eligible patients were randomized to receive either a 10- or 14-day course of amoxicillin/clavulanate at the usual recommended dose. The primary outcome was clinical response (complete",
        "label": 2
    },
    "460": {
        "output": "Notes\n[fig]  0: 040245121-0.139522403) 20-1000; 14.0 for the MAPE) [/fig] \n<EOD> Anorexia nervosa in adolescence.\nThis article describes how to develop a formulation of an adolescent with restricted intake in line with a biopsychosocial approach. The article reviews relevant cognitive, cultural, biomedical and personality literature in relation to anorexia nervosa in adolescents, and presents a biopsychosocial formulation of such a case. The clinical relevance of the formulation is examined, and a number of treatment options are discussed, including psychoanalytic, cognitive and family therapy approaches.<EOD> A randomized trial of a community-based educational intervention to increase mammography, Pap smears, and clinical breast examination.\nOBJECTIVE\nTo evaluate the efficacy of a community-based educational program on receipt of screening pap smears, clinical breast exams (CBEs), and mammography among Mexican American women.\n\n\nMETHODS\nThis randomized, controlled trial included 685 women aged 50 to 79 years who were assigned to receive either the intervention (n = 271) or the control (n = 414) message in 1993 (mean age, 60.3 years). Three 5-minute individual counseling sessions were provided by bicultural nurses. Outcome measures were receipt of screening mammograms and Pap smears between 6 and 12 months after the baseline interview (screening mammograms and Pap smears). CBE was performed, recorded, and interpreted by study nurses.\n\n\nRESULTS\nAt 12 months after the baseline interview, a total of 34.3% of control recipients and 53.9% of intervention recipients had received screening mammography (P < .0001). Among control recipients, 37.4% who were younger than 70 years had received screening mammograms at 12 months. The corresponding figures for intervention recipients",
        "label": 0
    },
    "461": {
        "output": "[/TEST]\n\n### Step 6: Include a brief, descriptive title at the top of a report and give the name of the person who created the report in an empty header row titled \u201cAuthor\u201d\n<commit_before>@INCLUDE_ONLY\n<HEAD><title>Test-1</title></HEAD>\n\n<BODY BGCOLOR=\"#EEEEEE\">\n<H1>Trial Eligibility: Breast Radiation Patient</H1>\n<H2 id=\"report_header\"><NAME>: Test-1</H2>\n<H3 id=\"report_header\"><NAME>: Test-1</H3>\n\n<H1 id=\"author\">Author: @{{author}}</H1>\n\n<H3 id=\"author\"><NAME>: Test-1</H3>\n\n<H5 id=\"report_author\">Report creator: <NAME> (<EMAIL>)</H5>\n\n\n<!-- <H3 id=\"report_body\"> -->\n<H4 id=\"test\">TESTS. Test 1.0</H4>\n<p>Hello Everyone,</p>\n<p>This will be for @username Test-1. What do you think?</p>\n<p>Thanks for reading! - <NAME></p>\n\n<H4>Trial-level Eligibility Summary</H4>\n<table border=\"1\" class=\"tab_tbl\" summary=\"Trial Eligibility Summary\">\n<thead>\n  <tr class=\"header_row\">\n    <th colspan=\"5\" scope=\"col\">Eligibility</th>\n    <th colspan=\"5\" scope=\"col\">Clinical Trial Exclusion Criteria Summary</th>\n  </tr>\n</thead>\n<tbody>\n<tbody>\n<tr>\n<td style=\"text-align: left;\" width=\"40%\" scope=\"col\">\nTrial-level Eligibility</td>\n<td style=\"text-align: justify;\" width=\"30%\" scope=\"col\">\n\n <div class=\"markdown_block\"><pre class=\"prettyprint\"><code><span style=\"text-decoration: underline;\">&lt;!--&gt; TITLE</",
        "label": 0
    },
    "462": {
        "output": "## Exercise:\nFor the exercise, you will get an example for patient and trial notes that you had not see before. Each file name is composed by three tokens: 'Patient', 'Trial', and a random number. E.g. Patient(1)-Trial(1): `PatDum1-TriDum1`.\nFor PatDum1, the patient note contains: \n    Title: Postmenopausal woman with breast cancer\n    Age: 46\n    Weight: 58kgs\n    Height: 165cm\n    Blood type: 0+\n    Breast condition: CIN1 lesion with normal breast tissue\n    Family status: Single, no children or siblings\n    Smoking: No history of smoking\n    Alcohol consumption: No history of drinking alcohol\n    Diabetes history: No record of diabetes\n    Hypertension history: No history of hypertension\n    Chronic illnesses: No record of chronic illnesses\n    Previous breast cancer history: No history of cancer\n    Previous other cancer history: No history of other kinds of cancer in the past\n    Previous radiation history: She received radiation therapy in 2011\n    Previous surgery history: She received surgery for breast cancer in 2013\n    Stage: Stage III (Node positive > 4)\n    Procedure: mastectomy\n    Procedure date: 11 April 2010\n    Treatment: chemotherapy, hormone therapy\n    Comorbidities: no comorbidities\nFor TestDum1, the trial note contains: \n    Title: Assessing the clinical effect of chemotherapy, hormonal therapy over anti-Her2 therapy for postmenopausal women with breast cancer\n    Summary: This is an open, randomized, controlled trial. The study will assess tumor-shrinking efficacy, symptom improvement and safety of anti-HER2 treatment for patients with HER2 negative disease, who are pre-menopausal or postmenopausal women.\n    Number of participants: approximately 600\n    Gender: 100% female\n    Age: Age should be between 18",
        "label": 0
    },
    "463": {
        "output": "## What have you done so far?\nThe most common issue is that the following code is returned `None.`:\n`Trial-level eligibility: None`\nThe second most common is the following error message being returned to the user: `None object is not iterable`.\nYou have also implemented a number of methods and functions that are very difficult to understand! That is not very flattering when we compare our performance to the other team.\nHow can we improve the codebase?\n\n# [SECTION1] First, let's discuss our thoughts on the solution\n\nWe have tried to understand the problem from four perspectives:\n\n- [SEC2] How to correctly implement the function `Trial-level eligibility: <i>?`. \n- [SEC3] How to improve our readability of the code. \n- [SEC4] How to optimize code runtime.\n- [SEC5] How to speed up the code base.\n\nNow let's look at the details of the problem by taking a look at the code itself.\n\n## Code solution in other teams\n\nLet's start by looking at the code solution offered by the other teams.\n\n### [CODESOL1] Solution 1\n\n```python\ndef Trial_Level_Eligibility_of_Patient(patient_note, clinicalTrials):\n    patient_eligibility_criteria = clinicalTrials[\"eligibility_criteria\"]\n    # The function returns a list of the trial criteria, a list of strings,\n    # each corresponding to an individual eligibility criterion in the trial.\n    \n    # The function also returns a list of the trial eligibility for this patient \n    #  in the given trial. In other words, the user can iterate through the \n    # trial eligibility using the for-loop, and based on the trial eligibility, \n    # it will be easier to decide the patient's trial eligibility based on\n    # the patient_records dictionary.\n    \n    # There will be 0 if there are no eligibility criteria that match the\n    # patient information given in the patient note. If there is a match\n    # patient_eligibility_criteria will contain an array of matched conditions",
        "label": 0
    },
    "464": {
        "output": "[TUTOR] Hello everyone. You are a recruiter for a clinical trial. Your task is to check the eligibility of individual patients to be assessed for the trial. Some information about your work is in the [patient note](#patient_note) and the clinical trial's [criteria](#criteria_description_for this_exercise).\nThe following patient notes may not all be true. Please make decision about each patient for the trial.\n- [patient_note.json](#patient_note)\n- [patient_1.json](#patient_1)\n- [patient_2.json](#patient_2)\n- [patient_3.json](#patient_3). \n\n\n## Patient [patient_note.json](#patient_note)\n```json\n{\n  \"first_name\": \"S\",\n  \"id\": 1,\n  \"last_name\": \"J\",\n  \"age\": \"42.0\",\n  \"gender\": \"male\",\n  \"body_site\": \"breast\",\n  \"pathology\": \"invasive ductal carcinoma\",\n  \"HER2\": \"3+\",\n  \"ER\": \"99%\",\n  \"PR\": \"75%\",\n  \"status\": \"remission\",\n  \"treatment\": \"< >\",\n  \"treatment_date\": \"2012-03-19T00:00:00.000\",\n  \"date_of_diagnosis\": \"2012-01-10T00:00:00.000\",\n  \"diagnosis_date\": \"2012-03-19T00:00:00.000\",\n  \"disease\": \"breast cancer\",\n  \"visit\": \"1\",\n  \"diagnosis_method\": \"histologic examination, <0.1% CTCs, [17.6%] of 23.7 CTCs expressed HER2\",\n  \"region_based_on\": \"US\",\n  \"race\": \"Caucasian\",\n  \"race",
        "label": 0
    },
    "465": {
        "output": "The trial-level eligibility is the sum of all patient-level assessments you gave so far.\n\nThe output of Clinical Trial Assist should be like the following example:\n\n[Clinical Trial Assist]: Breast cancer and advanced solid tumor clinical trial\n\n[Trial-level eligibility: 2) Eligible]\n\n### Exercise 2: Clinical Trial in HBV Patients with Resistance to Entecavir\n\nYour name:\nYour grade:\nExamination time:\nYour teacher's name:\n\nIn this exercise, you are the medical advisor for a new drug for infectious diseases, `Drug A`. Your task is to design a clinical trial to determine whether the new drug in combination with entecavir (Lead-In drug; labeled 'B') is safe and could produce a clinical response in patients infected with hepatitis B virus and resistant to entecavir (Lead-In drug). You are given the following information, including a table describing the safety and efficacy results from the two previous studies (Bohgaki et al. 2010. S44 and Lin and Lin 2005. S45). In S44,  infection, defined as a serum HBV level at least 10\u00d7 ULN higher than baseline level.\n\n### Instructions of the Exercise:\n\nWhen you are done, submit your answer at the back of the paper. You can have as much time as you like.\n\nBohgaki KP, Honda T, Yamazaki M, et al. A phase 2 trial of the combination of pegylated interferon alpha-2b and ribavirin in chronic hepatitis B patients with lamivudine-resistance. J Gastroenterol. 2010;45(5):424-33.\n\n\n\nLin CH, Chen HW, Hung CS: Combination of entecavir and lamivudine vs. entecavir monotherapy in lamivudine-resistant chronic hepatitis B patients with adefovir combination therapy history. Pharmaceut",
        "label": 0
    },
    "466": {
        "output": "## Problem Formulation\n\n# Problem statement\nYou are working with a recruitment assistant (clinical trial coordinator ) as part of the Trial Design and Implementation Team -Trial Delivery Team (TDI-TD) in a university hospital. The study is a therapeutic trial for the treatment of breast cancer patients; the drug used is new medications in the early development. It is proposed as a Phase III, single centric, prospective, interventional, non-randomized, investigator lead. The trial design is Open Label. The primary endpoint is treatment duration. You must provide information and assist patients/participants who were referred to the hospital to participate in the trial. You must ask patients/participants about his inclusion criteria and his exclusion criteria. Also, you must provide information regarding inclusion criteria and exclusion criteria for the trial and about the drug. It is not the only new medication, and you must tell the patient that this medication has potential side effects which some of them are irreversible after therapy.\nYou are a clinical trial recruiter, and you need to use Eligibility Criteria to find the eligible participants. You will compare the criteria of the trial to the criteria of the referred patients/participants. The comparison was based on the criteria of the trial and patient's data, such as patient's disease and drug interaction.\nIn the end, you need to determine the trial eligibility of the referred patients/participants (Eligible vs. Not Eligible) and the most common reasons for being excluded (e.g., age, type of disease, previous drug therapy, etc.).\n\n## Data characteristics\n\n## Data set description\nThe dataset contains 215 patients/participants referred to the hospital. We created 38 attributes per patient/participant corresponding to their demographics, socioeconomics, disease and drug records. The dataset has six types of data objects depending on the number of values each patient/participant has. A brief description of the attributes is shown below:\n- 0 (618): Unknown, i.e., not available (e.g., the patient refused to answer the question or not able to answer).\n- 1 (3106): Missing data, i.e., empty",
        "label": 0
    },
    "467": {
        "output": "### [PROBLEM_2](/problems/problem-2)\nYou are working with a physician at a local hospital who is running a clinical trial and must submit information to the central trial sponsor. \nWhen entering a patient into a clinical trial, the physician records the first two lines of the patient demographics in the system. You need to fill up some data which are not entered by the physician, and send all the information together to the central trial sponsor. \nThe data of patient 1 are as follows:\n\n    First name:\n    Middle name:\n    Last name:\n    Gender:\n    Date of birth (DOB):\n    Ethnicity:\n    Country of origin:\n    Marital status:\n    Occupation:\n\n[DATA]:{\n    First name: \"<NAME>\",\n    Middle name: \"\",\n    Last name: \"Tang\",\n    Gender: \"female\",\n    DOB: \"#Y-#M-#D\",\n    Ethnicity: \"c\",\n    Country of origin: \"s\",\n    Marital status: \"m\",\n    Occupation: \"m\",\n    Ssn: \"R7461\",\n    Patients_identification: {\n        Registration_number_patient: \"WC-003\",\n\n    }\n}\n\nThe physician's data of the patient 2 is: \n\n    First name:\n    Middle name:\n    Last name:\n    Gender:\n    Date of birth (DOB):\n    Ethnicity:\n    Country of origin:\n    Marital status:\n    Occupation:\n\n[DATA]:{\n    First name: \"<NAME>\",\n    Middle name: \"\",\n    Last name: \"Liang\",\n    Gender: \"female\",\n    DOB: \"#Y-#M-#D\",\n    Ethnicity: \"c\",\n    Country of origin: \"s\",\n    Marital status: \"m\",\n    Occupation: \"m\",\n    Ssn: \"R7461\",\n    Patients_identification: {\n        Registration_number_patient: \"WC-004\",\n    }\n}",
        "label": 2
    },
    "468": {
        "output": "## [MARKDOWN_CODE]\n### [QUESTION4]: What are these three-point eligibility scales for clinical trial? Let's assume that the last patient note is excluded from further analysis of this trial.\n\nThe inclusion criteria of a trial are based on 0) sex, 1) age, and 2) AML diagnosis. \n\nWhen a patient meets all of the inclusion criteria, the patient is deemed an eligible subject of this trial. The determination of the patient's eligibility is based on a comparison of the patient's characteristics and the inclusion/ exclusion criteria. \n\nThere are 4 potential eligibility scores: 1) excluded, 2) not relevant, 3) eligible, and 4) don't ask. The process of eligibility evaluation is summarized in below.\n\n\n\n### Example 1:\n![IMAGE](https://cdn-images-1.medium.com/max/1125/0xf0521afc38161037ad7984c658129d959d4327c9)\n\n\n\n\n### Example 2:\n![IMAGE](https://cdn-images-1.medium.com/max/1125/0xf10ac9143dd3d73634721af3e8aeadda5adbf1b9)\n\n\n\nThe first and first-last lines consist of the overall number of eligible patients. The eligible patient has a scale of 2) Eligible. If the patient's score is 0) Excluded, the patient is ineligible to participate in this trial, and the next clinical trial could be chosen. On the other hand, the patient score of 3) Not relevant requires either patient's history data or patient's previous treatment records about the patient's eligibility to this trial. If the scale is a higher value than 3) Not relevant (4) or 6) Require consultation, the patient must be excluded from the trial because the patient needs additional clinical evaluations regarding the eligibility. In addition, the patient score of 5) Don'",
        "label": 0
    },
    "469": {
        "output": "in the \u2044c\n( 1. for all a\u00a0in and \u00a0 .\u00a0127\\ and 1\\re \\l or-specific for ex 4, or...\n \u25a0... a [bib_ref]-target in order-in the [bib_ref]. for a...in theft on \u00a0d at\nafter the\u00a0in a  in the 0\nc [fig_ref];\n (acc for \u2044. in the. In particular [bib_ref] and the\\ and clin or a new,\nand and A. The [bib_ref] in a case\n in _(based \u25cb _inst \\ (11 in \u00a0\u00a0based\nafter after [bib_ref]. and<EOD> [bib_ref]-in-m at \n [bib_ref] 4-cemat in [fig_ref]-in an \u00a0-o \ufffd 3\u00a0 or \u2015det  (d-in-specific or [bib_ref]-and\\acc\nfor a.\nat -\n _of\n/s\u00a0_sample in a\ninnet_pat-in in _-c:she_such \u00a0on\\_follow [bib_ref]. (2-re [bib_ref] \\^-in-in \u2265<pat on\nand-in or -s-her in [bib_ref]-des and 10 -~inst\n or the on \u00ae - 2\u00a0to\u00a0inst-d 2\u00a0~s [/table] -b...specifics of their\n- [/fig_ref] on the, she in the\nin each-visual \u25cb\n{derd/ \ufffd...-in the<EOD>\n\nfor [fig_ref] for a .{ for cll for thell [bib_ref] \ufffd-d-an-specific 4. [bib_ref]-re\u00a0 6 or -the [bib_ref] 1 in\u00a0cinder but_in of [bib_ref]<EOD>\ndet:\nof... or the ( 2\nand -in Cade on 1<1 at -her 1 for the [fig_ref]-s [/fig_ref] \u00a0/detive with a <in her_visual\u00a0-~. The\u00a0-or for either\nme (c^ in 1 for 8\n1 \u2009;\u00a0c_ (see or 7 1 in this\u00a0on -to\u00a0sub of [bib_ref] [/table] in [/table], 18 and [bib_ref] - 21 \u2265c-in to \nde-~ the 1-1-1 for 3_stud",
        "label": 2
    },
    "470": {
        "output": "```julia\r\njulia> i_level(r) = (r[2].detection === \"2\" && r[6].tum_type== \"Infiltrating ductal\" && r[10].research_status!=\"1c\" && r[11].research_status!=\"1x\") ? \"0\" : \"1\"\r\njulia> i_research_status = r[10]\r\njulia> i_research_status == \"23c\" ? \"0\"\r\njulia> i_research_status == \"23x\" ? \"1\"\r\njulia> i_level(r) == \"0\"\r\njulia> i_level(r)\r\n\"\"\"Excluded\"\"\"\r\njulia> i_level(r)==\"1\"\r\n\"\"\"Not relevant\"\"\"\r\njulia> i_level(r)==\"2\"\r\n\"\"\"Eligible\"\"\"\r\ntrue\r\n\"\"\"\r\n```\r\n```python\r\nIn [8]: eligible(r)\r\nOut[8]: True\r\n```\r\n```lua\r\ntest.eligible({2,2,1,1,2,true,false,2,''0'',''2020-01-01 10:10:06 +09:00+1'',''',''','',''','',''});\r\n```\r\n```kotlin\r\nval eligible = r.test1.eligible() \r\ntrue\r\n```\r\n```php\r\n<?php\r\nsession_start();\r\n/*\r\nEligible\r\n*/\r\n$result = [\r\n\t\"detection\" => \"2\",\"tum_type\" => \"Infiltrating ductal\", \"research_status\" => \"1x\", \"gender\" => \"1\",\"research_status\" => \"1x\", \"researchID\" => \"2020-01-01 10:10:06 +09:00+1\", \"detection\" => \"2\",\"tum_type\" => \"Infiltrating ductal\", \"research_status\" => \"1x",
        "label": 0
    },
    "471": {
        "output": "[TEST]$ python3 test_task.py -f \"patient.txt\"\n[INST]$ python3 test_task.py -f \"patient.txt\"\n\nNow, let's see if you get the following:\n\n## Export to excel\n\n[TEST]$ python3 test_task.py -f \"patient.txt\" --excel\n[INST]$ python3 test_task.py -f \"patient.txt\" --excel\n\nYou should get the following:\n\n#! /usr/bin/env python3\n#-*- coding: utf-8 -*-\n\"\"\"Script: task_patient.py\n\nUsage: task_patient.py -f <path/to/note.txt>\n                            [--excel <path/name/to/report.xlsx>]\n                            --inst <path/to/interactive.txt>\n\nReferences\n\nhttps://github.com/s3h0n/ClinicalPath/blob/master/README.md<jupyter_code>c = {'f': input_file['f'],\n                'l': input_file['l'],\n                'v': input_file['v'],\n                't': input_file['t'],\n                'e': input_file['e'],\n                'h': input_file['h'],\n                'st': input_file['st'],\n                'st_b1': input_file['st_b1'],\n                'st_b2': input_file['st_b2'],\n                'st_b3': input_file['st_b3'],\n                'gd_s1': input_file['gd_s1'],\n                'gd_s2': input_file['gd_s2'],\n                'gd_s3': input_file['gd_s3'],\n                'gd_s4': input_file['gd_s4'],\n                'gd_s5': input_file['gd_s5'],\n                'gd_s6': input_file['gd_s6'],\n                'gd_s7': input_file['gd_s7'],\n                'gd_s8': input_file",
        "label": 0
    },
    "472": {
        "output": "[fig]  Figure 1: Screenshot of a typical patient note. Note: A complete patient note includes Patient demographic information (age, gender); Past medical history (hypertension, anemia, hyperlipidemia, hypothyroidism); Personal history (smoking, drinking); Family history (breast cancer); and Medication history (albendazole, amlodipine, atorvastatin calcium). [MUSIC] [/fig] \n[fig]  Figure 3: Screenshot of a typical note of a clinical trial. [/fig] \n<EOD> Identification of genes differentially expressed in the heart after myocardial infarction using RNA-Seq technology\n\nBackground: RNA sequencing (RNA-Seq) is a high-throughput method for RNA sequencing and has become widely recognized as a powerful approach to investigate gene-expression profiles in different diseases. However, no study has shown the expression changes in cardiomyocytes after myocardial infarction with the use of RNA-Seq method.Methods:In this study, myocardial infarction was induced in Sprague-Dawley rats. Total RNA was extracted and subjected to RNA-Seq for sequence and functional analysis of the differentially expressed genes.Results:The experimental and controls had a strong correlation, with a correlation coefficient of 0.7963, which indicates there was no significant technical bias in the RNA-Seq data. Among 412,674 and 399,434 detected genes in the experiment and control groups, 6114 significantly regulated genes were found with a \u22651.5-fold change cut-off. The results indicated that many genes involved in cell adhesion and metabolism-related pathways were altered upon myocardial infarction. Interestingly, a large number of transcripts that are important in cardiovascular disease, such as adhesion molecules and cytokines, were differentially expressed.Conclusions:Collectively, our results suggest that significant changes in cardiac gene expression occurred after myocardial infarction, with more differentially expressed genes identified. This study provides a novel approach to further elucidate the molecular regulatory mechanisms and signaling pathways during",
        "label": 0
    },
    "473": {
        "output": "- <EOD> The potential of the TRAIL gene signature in pancreatic adenocarcinoma risk stratification\n\nE-mail: i.brancaccio@leeds.ac.uk (I. Brancaccio); eilidh.hutton@mrc-vdl.ac.uk (E. Hutton)AbstractBackground and aims: Pancreatic cancer is a highly lethal disease; molecular insights are needed to understand tumour progression and drive personalised therapy. Our aim was to assess the performance of the TRAIL gene signature in pancreatic precancerous lesions, to investigate the association between TRAIL expression and clinical outcome, and evaluate the potential utility of this signature in assessing risk of progression to invasive cancer. Material and methods: Four tissue microarrays were constructed from tissue samples of pancreatic pre-cancerous lesions and invasive adenocarcinoma and processed for immunohistochemistry. The expression of TRAIL and selected TRAIL-related genes was measured by image analysis. This expression was related to histopathology, and clinicopathological and demographic variables. Results: The expression of TRAIL receptors-1 and -2 was significantly higher in pre-cancerous lesions compared with cancers and correlated with the dysplasia grade. Higher TRAIL receptor-1 expression was associated with improved survival (p = 0.04). An immune-related signature was significantly associated with survival (p < 0.05) independently of TNM staging. Conclusion: TRAIL plays a role in early pancreatic cancer progression, its receptors expression is a prognostic marker in pancreatic cancer, and the immune signature has an independent prognostic capacity. We identified a group with worse diagnosis whose signature expression is higher than usual. This signature can be used for personalised prognosis determination and prediction of the most effective drug therapy.\n\n# Introduction\nPancreatic ductal adenocarcinoma (pdac) is one of the deadliest cancers with 5year survival less than 6%and the highest mortality-to-incidence ratio. It usually manifests with advanced disease",
        "label": 0
    },
    "474": {
        "output": "##### #21 - Output patient notes in MarkDown format (25/56) \nThis question is to test the ability to write patient information in Markdown syntax format. Markdown (abbreviated as mdown) is a simple format for authoring and presenting documents. [Markdown Tutorial ](https://www.markdownguide.com/introduction/)\n\nWrite the patient notes in Markdown style in the `## Notes 0 # ` cell. [INST]\nThe following is a patient note in Markdown style:\n## Notations:\n### Patient ID: <NAME>\n###  (caret) represents patient-specific text fields and <NAME> represents unique patient ID.\n**Breast and axillary surgeries:** Breast and axillary surgeries were performed after neoadjuvant chemotherapy, but before the start of combination trastuzumab and pertuzumab. Bilateral breast-conserving surgery (BCS) including sentinel node sampling (SSN) and left axillary dissection (LAD) were conducted. Immediate partial implant reconstruction was performed in both breasts. \n \n### AE:\n###  (caret) represents adverse event, event, or side effect.\n```\n### AE - Breast pain (H&N) ##\nBreast pain started about 1 week after starting treatment with combination pertuzumab and trastuzumab. The patient stated that the pain was worse on the left breast and was aggravated at night. The pain was mild and was not severe enough to disturb sleep.\n\n### AE - Arthralgia (H&N) ##\nThe patient's right knee and both elbows have been aching for a few weeks. \n\n### AE - Fatigue (H&N) ##\nThe patient has fatigue in both elbows and the knees since about 2 weeks ago.\n\n### AE - Larynx edema (S&E) ##\nThe patient's larynx on the right side is swollen. \n\n### AE - Lethargy (S&E) ##\nAppetite has decreased since about 1 month ago, and there",
        "label": 2
    },
    "475": {
        "output": "<EOD> Dissemination of carbapenem-resistant Enterobacter cloacae complex following the 2007 flood in Bangladesh\n\nBackground: Antimicrobial resistance (AMR) is a global public health challenge. Bangladesh, like other countries, has seen a rise in carbapenem-resistant Enterobacteriacae (CRE) associated infections, but the magnitude is not known. We investigated two outbreaks of Enterobacterial infections at two different hospitals in Bangladesh in 2015. Methods: To find out the source and understand the routes of transmission, a case-control study, molecular typing and antibiotic sensitivity testing were conducted. Results: Out of 420 patients tested with a rapid kit, 20 samples had elevated levels of carbapenemase enzymes. The case-control study identified the use of contaminated needles and syringes and patient's sharing bed or bed-spaces. Among the 150 participants tested for blood culture, two patients had blood-culture positive for Enterobacteriaceae and 12 patients had urine samples that were blood-culture positive. Overall, 15 Enterobacter species were found among 31 (34%) isolates, which were multidrug-resistant and predominantly produced carbapenemases. Nosocomial spread of Enterobacter cloacae complex isolates was confirmed by pulsed-field gel electrophoresis. Carried from the patient's home or hospital, Enterobacter cloacae complex isolates were disseminated to other departments and wards through the use of contaminated equipment and needles.Conclusions:Our results confirmed the emergence and nosocomial outbreak of carbapenem-resistant Enterobacteriaceae in Bangladesh for the first time and suggested that dissemination was likely in the aftermath of the 2007 floods. The impact of climate change, in conjunction with urbanization, must be considered in planning for the prevention and treatment of these potentially-drug-resistant organisms.\n\n# Background\nBloodstream infection (BSI) is an important hospital-acquired infection",
        "label": 0
    },
    "476": {
        "output": "### Solution 2\nLet's think in steps.\n\n**STEP 1**: [Read over the patient note and the trial information once again to see if the required information is available in `PatientData` table.](#question1).\n\n**STEP 2**: [For each included column of `PatientData` in the patient note, look it up in the trial information. If found, then assign the relevant value to the patient data using `INSERT INTO `PatentData`(')`; otherwise, assign `NULL` to `PatientData` table.# question2.\n\n\n### Solution 3\nLook it up in the trial information. If found, then create a new row in `PatientData` table, where column name is identical to the trial information, which includes the values of the patient data using `INSERT INTO `PatentData`(')`; otherwise, assign `NULL` to `PatientData` table.\n\n\n### Solution 4\nLook up the required information from the patient note and the trial information using Python Pandas and assign to the patient data using Python.\n\n### Solution 5\nCombine the patient note (e.g., `df.to_numpy()`,) and the trial information (e.g., `df[['Negative_histologic_lymph_node', 'ER_negative', 'Breast_operative_side_notes',...]]`) in a list ('['Negative_histologic_lymph_node', 'ER_negative', 'Breast_operative_side_notes',... ']), make a copy of the list (`list_df1 = df_list)` and make a copy of the patient note df (`list_df2 = df`) and create a dictionary (`df_dict = {'column1': 'value1', 'column2': 'value2', 'column3': 'value3'})`. Use list_df1 and list_df2 to generate a flat data frame as shown in the following code\n```\ndf_dict = {\n    \n    \"column1\": [\"data1\", \"data2\", \"data123\"],\n    \"column2\": [\"data4\", \"data9\", \"data45\"],\n    \"column3\":[\"dataf\", \"data14\", \"data1",
        "label": 0
    },
    "477": {
        "output": "### Output\n\nEach patient note contains a `JSON` object with 5 keys. We will discuss the structure of each key separately. Each clinical trial contains a `JSON` object with 2 keys. We will discuss the structure of each key separately. \n\n\n    \"ID\": \"PRN-100\",\n    \"PatientName\": \"Peter Patel\",\n    \"Gender\": \"Male\",\n    \"[INST]Age\": \"55\",\n    \"[INST]BirthDate\": \"1964-08-14\",\n    \"[INST]ResidentialAddress\": \"(213)742-7411\",\n    \"Diagnosis\": \"Squamous cell carcinoma of apex of tongue\",\n    \"Histopathology\": \"Moderately differentiated carcinoma, keratin pearl formation, ulceration\",\n    \"Staging\": \"Stage 3B (T4a N2c M0).\",\n    \"Anatomy\": \"Tongue\",\n    \"ClinicalTrial\": [\n        \"/Users/kikurai/Documents/code/D3V/d3.1_Trial-Level/ClinicalTrials/BostonClinicalTrials/TCR-STI-2130/CTR-STI-2130.txt\",\n        \"/Users/kikurai/Documents/code/D3V/d3.1_Trial-Level/ClinicalTrials/BostonClinicalTrials/TCR-STI-2140/CTR-STI-2140.txt\",\n        \"/Users/kikurai/Documents/code/D3V/d3.1_Trial-Level/ClinicalTrials/BostonClinicalTrials/TCR-STI-2150/CTR-STI-2150.txt\",\n        \"/Users/kikurai/Documents/code/D3V/d3.1_Trial-Level/ClinicalTrials/BostonClinicalTrials/TCR-STI-2160/CTR-STI-2160.txt\",",
        "label": 0
    },
    "478": {
        "output": "<EOD> Antimicrobial treatment failure in a patient with severe Corynebacterium amycolatum sepsis\nDear Editor, A 54-year-old female patient with a past medical history of rheumatoid arthritis (treated with tocilizumab), diverticular disease (treated with mesalazine suppositories and pantoprazole), hypothyro\u00efdism and pernicious anaemia (treated with methylcobalamin and calcium) was admitted in our intensive care unit (ICU) for severe metabolic acidosis complicated with multiple organ failure (MOF). Laboratory tests revealed severe anaemia (haemoglobin 90 g/L) with normochromic normocytic erythrocytes, pancytopenia, elevated D-dimer (10.89 mg/L) in the setting of prothrombin, a low fibrinogen (3.91 g/L), and high C-reactive-protein(82 mg/L). The chest X-ray showed diffuse interstitial and alveolar infiltrates. The septic context was suspected, an emergency haemodialysis and a mechanical ventilation were initiated. Despite several broad-spectrum antibiotic treatment (ampicillin, imipenem and tigecycline), the clinical and laboratory data worsened quickly leading to a cardiac arrest complicated by a multiple organ failure. A femoral blood line was inserted and two blood cultures were drawn. Two subsequent blood cultures were positive for Corynebacterium amycolatum, a rare opportunist causing mainly endophthalmitis and pneumonia.1,2 In this case, the clinical context was compatible with a severe septic shock. Despite an empiric broad-spectrum antibiotic therapy, the patient experienced a fatal deterioration of her general condition. This case report discusses the difficulties and uncertainties in the treatment of severe infection due to C. amycolatum. The patient is a 54-year-old female patient with a past medical history of rheumatoid arthritis treated with tocilizumab, who was admitted",
        "label": 1
    },
    "479": {
        "output": "```python\n\n# You may need to change the current directory to the folder that contains\n# the exercise folder.\nimport pandas as pd\nfrom pymtas.mtas.data_type import Patient, PatientHistory, PatientStatus, ClinicalTrial,\n                                   IncludeCriteria, DetailedCriteria\nfrom pymtas.mtas.evaluation.evaluator import TrialLevelEligibility\n\n# This dataset is available at the pymtas GitHub:\n# 'include_assessment_eligibility_patient_history_exercises_dataset'.\n\n# The dataset has been read and split into train and test data using the\n# 'prepare_train_and_test_data.py' script. Copy it to the 'data' folder.\n\nif __name__ == '__main__':\n    evaluate_inclusion_criteria(input=True)\n\n\ndef evaluate_inclusion_criteria(input):\n    # Load in the data. The data contains Patient, PatientHistory, PatientStatus,\n    # ClinicalTrial, IncludeCriteria and DetailedCriteria objects.\n    # Note that the data has a special `__repr__` method which you might\n    # choose to use instead. See docstring for the __repr__ method of the\n    # DetailedCriteria.\n    data = pd.read_pickle(\n        'data/inclusion_criteria_evaluation_data/inclusion_criteria_evaluation_dataset_inclusion_eligibility_test_data.pkl')\n    train_data = data[data.patient_id == 'train_patient_id']\n    test_data = data[data.patient_id == 'test_patient_id']\n\n    # Assign a few variables to be read by the function arguments.\n    train_path = 'evaluation/train_patient_id'\n    test_path = 'evaluation/test_patient_id'\n    y_test = 'Trial-level eligibility'\n    trial_level_eligibility = TrialLevelEligibility(y_test)\n\n    # Evaluate the included criteria for the test patients.\n    #",
        "label": 2
    },
    "480": {
        "output": "<EOD> TNF-\u03b1-induced cytotoxicity in rat thyroid cell lines: a mechanism of cytotoxicity distinct from cell killing by IFN-\u03b3 or TRAIL.\nTNF-\u03b1 is a proinflammatory cytokine that plays a major role in the response to immune stimuli. Previous reports have suggested that this cytokine can have a cytotoxic effect on thyroid cells. The present study aimed to investigate apoptosis as a mechanism of TNF-\u03b1-induced cell death in rat thyroid cells. Cell lines of rat thyroid PCCl3 and FRTL-5 cells were stimulated by various concentrations of TNF-\u03b1 and incubated for 24 h. Apoptotic cell death was examined by DNA ladder assay, TUNEL test, electron microscopy, detection of phosphatidyl serine on the membrane surface and cytometry. TNF-\u03b1 induced apoptotic cell death in PCCl3 cells and in FRTL-5 cells. However, this was not mediated by changes in mitochondrial membrane potential, and also did not require de novo protein synthesis. Other cytokines (IFN-\u03b3 or tumor necrosis factor related apoptosis-inducing ligand ) that are known to induce apoptosis in thyroid cells did not induce PCCl3 and FRTL-5 cell apoptosis. Taken together, TNF-\u03b1 exerts cytotoxicity in thyroid cell lines by a mechanism independent of cell killing by IFN-\u03b3 or TRAIL.<EOD> A Case Report of a Puerperal Woman With Dengue, Transplacentally Acquired HIV, and Severe Placental Infection\n\n\n\n# Introduction\nDengue is a mosquito-borne flaviviral disease affecting around 390 million individuals annually, predominantly in tropical and subtropical areas, with the highest risk of infection in Asia and the Pacific region. Infection with dengue virus (DENV) results in a spectrum of disease severity including dengue fever, dengue hemorrhagic fever and dengue shock syndrome [bib_ref]  Dengue and postpartum depression: a cohort study of a",
        "label": 2
    },
    "481": {
        "output": "If you see **Trial-level eligibility** has been omitted, make sure it has been set. It is quite common to omit this field accidentally, as the Trial-level eligibility field is followed by **Scoring** under **Instructions**. So don't forget to fill the field!\n\n### Explanations for Trial-level eligibility\n\nEach score has the following explanations.\n\n- #### 0: Ineligible\n\nThe patient is not eligible for the trial. Do not recommend.\n\n- #### 1: Possible Eligible\n\nThe patient is not eligible for the trial. However, a recommendation is allowed as this score includes cases where eligibility may be determined in a more individualized manner (e.g., some patients with age between 25 and 30 can be eligible for vaccine trials if they are part of specific high-risk populations or have an underlying condition such as cancer).\n\n- #### 2: Eligible\n\nThe patient is eligible for the trial.\n\n- #### 3: Eligible with restrictions\n\nThe patient generally meets all requirements for eligibility, but there are some specific aspects which can delay patient identification and/or potentially affect patient dropout.\n\n- #### 4: Ineligible, per Parexel policy, no recommendation\n\nThe patient is excluded from the trial per Parexel policy. There should not be any recommendations for this scenario.\n<EOD> Phosphodiesterase III (PDE3) Inhibitors with a Sulfonylurea Moiety as HIF-1\u03b1 Inhibitors\n\nCitation: Salzman, D.; Khoury, Z.; Chahin, Y.; Lior, H.; Avraham, O.; Shtutman, M.; Alon, J.; Gozes, I.-E. Phosphodiesterase III (PDE3) Inhibitors with a Sulfonylurea Moiety as HIF-1\u03b1 Inhibitors. Pharmaceuticals 2022, 15, 1474.\n\n# Introduction\nHypoxia-inducible factor-1\u03b1 levels are elevated in a plethora of cancer types and correlate with poor pro",
        "label": 0
    },
    "482": {
        "output": "# How to calculate points?\nOn [https://docs.google.com/forms/d/e/1FAIpQLSf0j6XfB7754t_NIPbH146d7VZ5gXxO-PbPqR89Y-m9s5K3Q/viewform](Accessed on March 27, 2019).\nTo calculate the Points for each problem, first count the number of problems of the same kind to which you were assigned to solve. For instance, suppose we assigned the following problems to you:\n\n```markdown\n1\n2\n3\n4\n5\n6\n```\n\nIt means that in this task you were assigned 6 problems. Now, count these problems step by step.\n```markdown\n\nYou should solve one Problem for your first point. Now, this problem contains a single sub-problem. Therefore, your first Problem contains 1 Sub-Problem. You are going to solve it; for your second point, you need 1 More Problem.\n\nNow count the number of Sub-Problems:\n```\n\nNow you need to calculate how many Sub-Problems your first solved problem contains again. And you have to go back. Now you count how many Sub-Problems your first Problem contains:\n```\nCount: `1` Sub-Problem\n```\nYou have to count your points according to each Sub-Problem you have already solved. So, go back and calculate the points you earned:\n\n```markdown\nProblem1\n Sub-problem=1\n Points Problem1=1*1=1\n\nProblem3\n Sub-problem=1\n Points Problem3=1*1=1\n\nProblem4\n Sub-problem=1\n Points Problem4=1*1=1\n```\nNow it is important to understand that you should count your points for every Sub-problem that you have already solved, even if it is a Sub-problem in another Problem.\n\n```markdown\nProblem2\n Sub-problem=1\n Sub-problem in Problem4 = 2\n Points Problem2=2*1=1\n```\n```markdown\nProblem5\n Sub-problem = 1\n Sub-problem in Problem4 = 2\n Points Problem5=1*1=1\n```",
        "label": 0
    },
    "483": {
        "output": "The following steps will show you How to use the `FindTable()` function. The `FindTable()` function will return a Table from its first occurrence of a specified character. We need to look for tables named \u201cfirst\u201d, \u201csecond\u201d, and \u201cthird\u201d because the \u2018first\u2019 table holds the \u2018first\u2019 line, the \u2018second\u2019 table holds the \u2018second\u2019 line, and the `third` table holds `third` line. The data set named `first_table` contains all three of the table names listed above. The `FindTable()` function calls the Table constructor, accepting the string \u201cfirst, second, third\u201d, and returns a table named `first_table` because it is the first table in the data set. It is important to note that in addition to the character, any number of characters in the string \u201cfirst, second, third\u201d can be repeated zero or more times, as well as zero or more characters that are not included in the string \u201cfirst, second, third\u201d. The following example uses this property by specifying the string \u201c*\u201d instead of the words to search for, and returns a table named `third` because it is the third table in the dataset. It is important to note that `*` is a literal string; it is not interpreted by the interpreter for characters of any sort. The following example uses `FindTable()` for `*`, which would return a `NotInTable` object for which no",
        "label": 2
    },
    "484": {
        "output": "## Inequal Exclusion\n\n`InequalityExclusion` provides an extension to ClinicalTrial.\n\n`InequalExclusion` is a subclass of `InclusionCriteria`. A `InequalExclusion` object has `type` and `value` properties that specify its type and a value that is an object. For example, `InequalExclusion(type: 'elevated blood pressure', value : 'Elevated blood pressure over 140/90 mm Hg.')`.\n\n## Defining your clinical trial\nUse a `Trial.definition` property, rather than specifying the eligibility of individual patients.\n\n[NOTE] You're a medical assistant, and your task is to assess a patient's trial eligibility. You can use this method to specify the eligibility criteria for your clinical trial, to generate a set of objects for `InclusionCriteria. InclusionCriteria.value`. This method is akin to using a [dictionary](https://developer.mozilla.org/en-US/docs/Web/JavaScript/Reference/Global_Objects/Object/prototype/propertySetter); you may prefer to have one method for convenience if your clinical trial is going to be long-lived and have many subjects. Instead, you could use [ClinicalTrial.definition][ClinicalTrial.definition] if you need to reuse your clinical trial data multiple times.\n\n[NOTE] You're a medical assistant, and your task is to assess a patient's trial eligibility. You can use this method to specify the eligibility criteria for your clinical trial, to generate a set of objects for `InclusionCriteria. InclusionCriteria.value`. The parameters passed to this method are the eligibility criteria expressed in free text.\n\n[NOTE] You're a medical assistant, and your task is to assess a patient's trial eligibility. You can use this method to specify the eligibility criteria for your clinical trial, and generate a set of objects for `InclusionCriteria. InclusionCriteria.value`. You can also use this property to update trial-level eligibility of a patient.\n\n## The InclusionCriteria.value property\nWhen you have no other way to determine patient eligibility, you can",
        "label": 2
    },
    "485": {
        "output": "---\n\n## 2.7.6 Trial-level eligibility\nIn this exercise, you will examine if the patient note conforms to the eligibility criteria of the clinical trial. The information provided by researchers is usually incomplete, and the patient notes are in a text format, not in a structured document format. It is necessary to make assumptions based on the information provided. The trial-level eligibility information you will provide, and you must be consistent and consistent with the patient note. The example was a trial of \"cold sprayable cement in the treatment of chronic pain.\"\n\n---\n[inst_134] The trial is a 3-arm study to determine the safety and efficacy of a cold sprayable cement in comparison with placebo in the treatment of chronic pain. All participants will continue to receive daily oral analgesics or pain medication and be required to report the amount and frequency of use. Assess the trial-level eligibility of the three possible patients according to the trial profile: \n\nPatient information: This patient is a 24-year-old man with knee problems who went to a doctor to check what was going on with his joints. During a medical examination, he was diagnosed with severe osteoarthritis in his knee that does not respond to the use of painkillers and nonsteroidal anti-inflammatory drugs, and it is necessary to make a biopsy. \n\nHe has mild musculoskeletal pain in both of his knees. The pain usually occurs after he rests after taking a long walk or a day of heavy physical activity. It is severe when he is in bed at night, but he can take some pain medication to help with the pain. His family history is negative for chronic diseases. He has a chronic disease called an allergy, on which he takes regular medication and has not had any side effects. He has no history of taking any medication.\n\nTrial information: The trial includes 250 participants to evaluate the efficacy of cold sprayable cement. The experimental group who took sprayable bone cement will be compared with the control group who took a placebo, which is also described as \"non-toxic water.\" Participants will be randomly assigned to different",
        "label": 0
    },
    "486": {
        "output": "***\n\n# Sources\n\n* [Acupuncture for the management of headaches, tinnitus and vertigo: a protocol for a systematic review of randomized controlled trials.](https://docs.google.com/presentation/d/14HQ1q4D67hHf17aG-d6747wmfB4KxG28/edit?usp=sharing) (Accessed: January 30, 2009)\n\n* [Medicina Alternativa na Perspectiva da Inqu\u00e9ritos Epidemiol\u00f3gicos: Projeto Inqu\u00e9ritos Epidemiol\u00f3gicos de Acupuntura em Posi\u00e7\u00f5es Definitivas](https://github.com/rubensamorim/epidemiological_surveys_acupuncture/wiki/Inqu\u00e9ritos-Epidemiol\u00f3gicos-de-Acupuntura-em-Posi\u00e7\u00f5es-Definativas) (Accessed: December 8, 2017)<EOD> Comparison of antimicrobial efficacies of essential oils of Melaleuca alternifolia, Origanum vulgare, and Thymus vulgaris against foodborne pathogen",
        "label": 2
    },
    "487": {
        "output": "In the above example, `breast Ductal carcinoma in-situ` is an exclusion criterion.\n\n## Solution\n\n[INST] Hello. You are a helpful assistant for\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is  HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nHere is the clinical trial:\nTitle: Prediction of Upgrade to Invasive Cancer in Patients Diagnosed With Ductal Carcinoma in Situ by Percutaneous Core Needle Biopsy Summary: It is considered that whether or not the accompanying invasive cancer classified through MRI images of breast cancer patients identified as Ductal Carcinoma in situ (DCIS) through preoperative tissue biopsy is significantly consistent with the postoperative stage. ~Therefore, this study intend to evaluate the effectiveness as a diagnostic tool that can help determine the axillary lymph node surgery by predicting the possibility of post-operative up-staging using magnetic resonance imagings of breast cancer patients who have been identified as ductal carcinoma in situ and are scheduled for surgery.\n\nIn",
        "label": 0
    },
    "488": {
        "output": "![Instructions](imgs/clinical_trial_clinical_trial_instructions.png)\n<img src=\"/static/imgs/_/clinical-trial.png?ver=695\" alt=\"clinical trial\"/>\n<br/>\n<EOD> Inhibition of Human Breast Hyperplasia Growth by Bidens pilosa Ethyl Acetate Fraction\nThe Bidens pilosa ethylacetate fraction (BPEAF) showed potent anticancer growth activities in a number of cell line models. To evaluate the antiproliferative activity of BPEAF and its possible anticarcinogenic use in humans, a preliminary study to test BPEAF was performed in a carcinogen\u2010induced human breast hyperplasia (HBH) model. After 8 weeks of induction period, animals received 26\u2010day treatment with 50, 100 and 200 mg kg\u22121 of BPEAF, tamoxifen 20 mg kg\u22121 or vehicle, intragastrically five\u2010times\u2003weekly. The total protein, oestradiol, progesterone, glutathione (GSH), prostaglandin E2 were measured to evaluate the effect of compounds treatment and also the in situ proliferation index was counted in the tissue specimens. The results showed that the treatment of animals with the BPEAF 100 and 200 mg kg\u22121, daily, lead to reduction of total protein concentration up to 43.28% and 39.23% respectively, which lower than tamoxifen\u2010treated at 48%, but it showed higher reduction than the vehicle\u2010treated group. Furthermore, intragastric treatment with BPEAF 50, 100 and 200 mg kg\u22121 had an inhibitory effect on oestradiol, GSH and total progesterone level at 42.93%, 43.70% and 36.98%, 51.24% and the inhibition of PGE2 level at 32.64%, 39.28%, 36.11% respectively. The in situ",
        "label": 1
    },
    "489": {
        "output": "The output of this lesson, once the patient note and the clinical trial are available, is: \n\n# Related Links\n- [Lesson 310]{}{} Lesson 311{}{} Lesson 312{}{} Lesson 313{}{}\n- [Lesson 314]{}{} Lesson 315{}{}\n<EOD> Translating the results of epidemiological research into recommendations for clinical practice.\nPursuant to a request from the USPSTF, the USPSTF staff reviewed a recently published epidemiological study that reported an association between depression and mortality following a diagnosis of coronary heart disease. The primary objective was to provide an epidemiological perspective for clinicians on the clinical question posed by the USPSTF. Depression is associated with an increased risk for death (high-quality evidence), and the association appears to be independent of the impact of depression on treatment or mortality outcomes. Clinicians treating patients with coronary heart disease should assess for the occurrence of depression since the risk is increased; those who are depressed may be at increased risk for mortality and, if they experience a major depressive episode while in the intensive phase of treatment, they may be at increased risk for death.<EOD> The GTPase Dynamin 3 Is Required for Neuronal Development in Vivo\nDynamin 3 has been implicated as a downstream effector of the mitogenic Ras/extracellular signal-regulated kinase/mitogen- and stress-activated protein kinase pathway in cell lines. Using knockout (k/o) mice, we have analyzed the phenotypic consequences of the absence of dynamin 3 function in the brain. In k/o mice, neocortical neurogenesis proceeded, but neuronal migration was perturbed. The pyramidal glutamategic layers (II\u2013III) contained a greatly reduced number of neurons; the layer containing callosal projections was almost completely absent. These phenotype changes in k/o mice are reminiscent of those seen in mice with mutations in reelin, neuroligin 2, or neurexin-1. The reelin-",
        "label": 0
    },
    "490": {
        "output": "### [07_Evaluate_for_eligibility]\nWhen you are working with a patient, you must always look for information that is relevant for assessing his or her eligibility to participate in a trial. This is called 'collecting information'. In order to determine whether a patient is eligible for a trial, in addition to knowledge about the study's eligibility criteria, you need to find out more about the patient (see [06_Get_information]). Sometimes you need to do additional tests to complete those pieces of information, and these tests are called the 'screening tests'. In case a patient is not eligible, you need to know which criteria did not match, see [04_Screening_for_Eligibility#4_Screening_Tests]. If necessary, you need to inform the patient that he or she would not be eligible for that study, so that you need to check other clinical trials that are open in your hospital or clinic. \n\nThe screening tests used to assess inclusion and exclusion criteria for a specific clinical trial can be found using 'Get information about the study'. It is important to know what type of screening tests were performed for each parameter in the inclusion and exclusion criteria. \n\nThe tests for hematology, renal function, thyroid function, urinalysis, and protein electrophoresis are all 'blood test'. 'Cardiology tests' only include an electrocardiogram (ECG). The tests for coagulopathy, pulmonary function, and nutritional screening are 'other tests'. 'Tumor marker tests' include cancer antigen 15-3 (CA15-3), carcinoembryonic antigen (CEA), alpha-fetal protein (AFP), and carbohydrate antigen 19-9 (CA19-9). 'Clinical visits' include tumor assessment by a physician, history and physical examination, and neurologic evaluation.\n\nTo check these tests, access `Get information about the study` again, and select the desired study. A list of all the parameters available in the trial appears.\n\n![07_Evaluate_for_eligibility](Evaluate_for_eligibility-screenshot",
        "label": 0
    },
    "491": {
        "output": "![#0]#\n\n## 1.20. Using the Rust Programming Language for Clinical Trials\n\n[+] `#2 [INST]\n[TITLE]_Clinica_trial_package\n[INST]\n\n### Clinical_trial_types\n[INST]\n\n```rust\npub trait Clinical_trial_types\nwhere\n    Clinical_trial_types: Size + Send + Sync + Unpin\n{\n    fn randomize(self) -> Randomized_trial;\n    fn randomized(self) -> Randomized_trial;\n    fn interim(self) -> Interim_analysed_trial;\n    fn interim_analysed(self) -> Interim_analysed_trial;\n    fn close(self) -> Cosed_trial;\n    fn cosed(self) -> Cosed_trial;\n}\n\npub type Clinical_trial_types = Clinical_trial_types<Clinical_trial>;\n\npub trait Clinical_trial<F, C>\nwhere\n    Covalence: Default<Covalence>,\n    Covalence <Cov_type: Cov_type_of = Covalence, Param = Default<Param>, Name: Name_of<'a>>: Sized, Trait, Env::Env,\n    Send_impl, Sync::Sync, Unpin::Unpin, Clinical_trial_types\nwhere F: Fn(&Cov_type, [F]) -> Cosed_trial,\n    C: Send + Sync, Env: Env\n{\n    // Trait Covalence\n    pub fn from_covalence(covalence: Cov_type) -> (Self, Covalence<'a>) {\n        let cov_type = Default::default();\n        let parameters = Default::default();\n        let env = Default::default();\n\n        let (self, c) = from_covalence(covalence, parameters, env);\n        (self, c)\n    }\n\n    // Trait Cov_type\n    pub fn get_env(self) -> Option<()> {",
        "label": 2
    },
    "492": {
        "output": "In-place validation in `Trial-level eligibility`\nYou should add the following to the line below 'Trial-level eligibility: 2) Eligible.'\n\n``` r\ninplaceval = inplace(function(.inplaceval = \"\")){\n    + out <- 2 * (data$Gender %in% c(\"Male\", \"Other\")) + \n        + (abs(data$Cytology[data$Status != \"Normal\"] - 1) * \n            (data$Cytology[data$Size != 1] != \"Natural\" ) * \n            (data$Cytology[data$Surgery != \"Yes\"] == 3)) +\n        + (data$Sex%in%c(\"Female\",\"Malesensitive\") * \n             (data$Triple != \"Negative\")) +\n        + \n        + \n        + (data$Mutation == 1) +\n        + \n        + \n        + (data$Metastasis(data$Status == \"Normal\") == 3)\n\n\n    + out <- out %*% paste0(\"#\")\n    + out <- ifelse(out < 0, paste0(\"-\"), paste0(\"+\"))\n    \n    + out \n}\n```\n\n``` r\ndata.frame(Trial-level eligibility = trial-level.eligibility, \n           inplaceval = inplaceval,\n           format = c(\"bold red\")*c(\"font bold\"))\n```\n\n``` r\n# trial-level eligibility ----------\n# ---------------------------- \n\n``` r\n# trial-level eligibility ----------\n# ---------------------------- \n\n``` r\ndata.frame(Trial-level eligibility = trial-level.eligibility, \n           inplaceval = inplaceval,\n           format = data.frame(Trial-level eligibility = trial-level.eligibility, \n                                inplaceval = inplaceval, \n                                format = c(\"bold red\")*c(\"font bold\"))\n```\n\n### `Trial-level eligibility` for Exclusions\n\nHere comes the `trial-",
        "label": 0
    },
    "493": {
        "output": "(Ask again.)\n\n### Part 2\nYou are a patient. You have a history of metastatic breast cancer and have recently visited a clinician for a routine check.\n\nIn the 10th edition of the AJCC, the classification system for regional lymph nodes in breast cancer has been changed to the pN stage. One of these changes is that a nodal diameter >2 mm which is considered nodal metastasis is a change in the N stage. The pN stages are listed below in . (If you are unaware of what is a node, it is an organ to which lymph flows.) .1pN Stages in the 10th edition of the AJCC \n\n## Exclusive breast cancer metastasis 7th edition 10th edition\npN0 pN0 pN0 0)\n\n### Exclusive breast cancer metastasis pN1 pN1 pN1\n(Ask again.)\n\n#### \u274c \u274c \u274c \u274c \u274c \u274c \u274c \u274c \u274c \u2714 \u2714 \u2714 \u2714 \u2714 \u2714\n\n## Part 1\nYou are a health expert. A breast cancer patient is about to undergo a surgery. You have been asked to assess the patient's status according to AJCC 7th Edition (TNM 2007) and AJCC 10th Edition (TNM 2017). The status is as follows in . If you are not sure about the answer, please ask the clinician. .1 TNM Stages in the 7th edition of the AJCC \n\n### TNM 2007 10th edition\nT (Size) pT1, pT2, pT3, pT4\nT(Size) pT1, pT2, pT3, pT4 +++ +++ (Ask again.)\n\n#### \u274c \u274c \u274c \u2705 \u274c \u2714 \u274c \u2714 \u2714 \u2714\n\n### N (Regional lymph nodes) pN0 pN1 pN2 pN3 +",
        "label": 0
    },
    "494": {
        "output": "[/CODEINST]\n\n### Q693. What are four reasons why patients are excluded from clinical trials?\n\nA) They already started on a trial with the same drug.\nB) They are more than 50 years below.\n\nC) They are pregnant.\n\nD) Their disease is too close to metastasized.\n\nE) They are sexually active and have a partner.\n\nExplanation: The answer is choice (E). According to the question, patients will not be eligible for the following four reasons; (A) is wrong because the patient can be currently participating in the clinical trial, (B)  is also wrong since the patient can be too young and too old, (C)  is also wrong since the patient is not pregnant (pregnancy is a possible reason for exclusion from the clinical trial only), and (D) choice (E) is also wrong since the patient is actively engaged in an intimate relationship. To become eligible for a clinical trial, the patient should be without a partner and not sexually active.\n\nQ694. What does the `Trial-level eligibility` field indicate?\n\nA) The presence of a given patient's disease.\nB) A new patient will be recruited for the clinical study.\n\nC) It has been decided that it is not necessary to recruit new patients.\n\nD) Data on inclusion criteria.\n\nE) The patient is already included in the trial.\n\nExplanation: The answer is choice (E). The field shows whether a patient who meets the study conditions based on the disease is present or absent. The answer is choice (A) since the field does not indicate if a new patient is going to be recruited for the clinical trial, which is indicated by choice (B). Choice (C) is also wrong because the field does not indicate whether it is necessary to recruit new patients. The answer is choice (D) since the field does not have information on the inclusion criteria.\n\nQ695. What is `Inclusion criteria` for?\n\nA) It is the criteria for the selection of patients who are eligible for the clinical trial.\nB) It determines the amount of the drug to apply.\nC)",
        "label": 0
    },
    "495": {
        "output": "## A) What is `n`? 53\nb) What is the number of patients who met each criterion? 5) What do the `mean(I.M.S.)` values indicate? What do we call the distribution type of their I.M.S. numbers. 6) What is the average value of IMS in the trial? 6) What is the sample mean (\u03bc) and the sample standard deviation (S) for the continuous variable I.M.S. (based on the previous exercise)? 7) What is the difference between the two samples and how big is the difference?\n\n## [hint] you can use a.o.w, e.p.e, s, s.d, a/a.o.w, s.d./mean and s.d./dmean to evaluate these hypotheses\n\n## `n=29` 29)\nFrom your preliminary data analysis, are you going to study a continuous or a categorical variable? [c] Both a) A continuous variable is always a real value; therefore, for continuous variables, we could use either parametric or nonparametric tests. Note: although we don't have any information about the distribution, it is safe to assume that this variable is not normally distributed based on the empirical plots in our first exercise. Therefore, for this test, we will use the nonparametric test.\n\n## A) what kind of test would you use to evaluate if there was an association between\n\n## (if yes):\nb) We will use the Mann-Whitney U test to evaluate the distribution and the differences of the two samples.\nThe Mann-Whitney U test is the nonparametric equivalent of the t-test. Therefore, it is the nonparametric alternative to the t-test.\nThe t-test calculates a test statistic U to assess the null hypothesis (H_0), by contrast, the Mann-Whitney U test generates a test statistic Z.\nH_0 state: In a population where a distribution of X follows a normal distribution and Z is the normal distribution associated to the distribution of X .\nUnder this null distribution, the Mann-Whitney U test assesses the possibility that H_0 could be true.\n\n## B) what are the differences between the two samples? do you",
        "label": 0
    },
    "496": {
        "output": "![![](https://user-images.githubusercontent.com/15624950/99814714-76591180-18eb-11eb-823d-d367eb18a3ad.gif)](https://user-images.githubusercontent.com/15624950/99814716-87986880-18eb-11eb-9a2b-782794eae647.gif)\n\n\nThis should be done for all patients.\n\n\n# Output\nThis is the format of your results in an Excel file. You should have two columns: Patient ID and Output. Patient ID has `Patient ID 1` `Patient ID 2` ... Patient ID n. The values of the Output will be in the field shown in the following example below; patient1 = 0 patient2 = 1 patient3 = 1 patient4 = 2 patient6 = 0 patient7 = 1 patient8 = 1 patient9 = 1\n\n![![](https://user-images.githubusercontent.com/15624950/99814612-71766880-18eb-11eb-8404-c983d487e825.gif)](https://user-images.githubusercontent.com/15624950/99814613-71766880-18eb-11eb-8b51-cea06a86d2c6.gif)\n\n\n## Note on errors for example with [?=]\nThis is caused by the following code;\n\n```\ndef calc_risk_of_experiencing_event_1(patient, period, treatment, event_type):\n    if patient.risk_of_experiencing_event_1_current_period != None: \n        if treatment == 'control' and patient.current_period == 'start':\n            if _is_after_treatment_starting_period(",
        "label": 0
    },
    "497": {
        "output": "The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility for the clinical trial by assigning `Trial-level eligibility: 1) Not relevant` for all the patients whose notes are not consistent with the trial's inclusion criteria and `Trial-level eligibility: 2) Eligible` for the rest of the patients. So, you might need to skip the following steps if we have no trial-level ineligible patients and only trial-level eligible patients. You should always assign the trial-level eligibility in the last line by `Trial-level eligibility:`, e.g., `Trial-level eligibility: 2) Eligible. `.\n[INST]\n\n\n#### Input and output\nThere are `keyboard-input` inquiries which allow to input a value and `input field` inquiries which allow to input a list of data. These latter inquiries automatically expand the list of allowable answers.\nAsk an inquiry with the first keyword of `Trial-level eligibility` and add a `Trial-level eligibility` in your output. e.g., `Trial-level eligibility: 1) Excluded`. If the patient meets the inclusion criteria but is excluded on the grounds of the trial's exclusion criteria. When you assign the trial-level eligibility for the clinical trial by assigning `Trial-level eligibility:, e.g., `Trial-level eligibility: 2) Eligible`. When the patient meets the inclusion criteria, and exclusion criteria do not apply. In this step, you should always assign the trial-level eligibility in the last line by `Trial-level eligibility:`, e.g., `Trial-level eligibility: 2) Eligible.`.\n[INST]\n\n#### 1st step\nIn our first step, we want",
        "label": 0
    },
    "498": {
        "output": "Note: We recommend that you put only this line before the line for outputting a specific value,\n\ni.e., 2) Eligible, because it starts with the same character for the input of our machine learning model. \n\n\n\nNote: When you call Trial-level eligibility function in the R console, please always input a new patient note with the same format as the example file.\n\nNote: The default program for trial-level eligibility function is `R (X64)`, and it is required that the R console runs on the Ubuntu platform.\n\nNote: After running trial-eligibility function, an alert will appear at the top of your R console. If you close the R console, trial eligibility function will shut down automatically. You can learn about the details in the tutorial of R. \n\n\n# 25) Procedure description\nProvide a short description about the procedure.\n\n### Description:\n1-36 Gbps DDoS attack resistant web content delivery network.<EOD> A preliminary evaluation of the impact of a nurse-administered treatment protocol on length of ICU stay of intensive care patients.\nThis paper briefly reports the impact of nurse-administered protocols on the length of stay of patients in an intensive care unit. A nurse-administered treatment protocol on an intensive care unit showed a positive effect on patients' length of stay. The protocol was not statistically associated with a decrease in mortality.<EOD> The use of low-cost smart-phone camera for detection of early caries and its caries risk assessment in children\nAbstract Objective. Early detection of caries using new diagnostic devices has been considered to help clinicians when planning clinical interventions before extensive dental restoration is necessary. The purpose of this study was to evaluate the clinical accuracy of a modified smart phone camera as it was applied in two separate clinical scenarios for determining caries status",
        "label": 1
    },
    "499": {
        "output": "<EOD> The Role of Protective Factors in Adolescent Risk Assessment and Risk Interventions\nThe aim of the present study was to evaluate the role of protective factors within the framework of the adolescent risk assessment and risk reduction process. The main research question examined was what types of protective factors, if any, might be useful in assessing and treating adolescent conduct problems. The protective factors examined were grouped into 4 domains, including (1) family factors, (2) peer factors, (3) academic factors, and (4) personal factors. Each of these factors could be used to assess the effectiveness of the risk reduction process. These findings demonstrate that protective factors can be used to help explain the process and impact of early treatment for adolescent risk behavior.<EOD> Neuroplasticity and functional recovery using noninvasive transcranial brain stimulation: evidence from stroke.\nNon-invasive transcranial brain stimulation techniques, particularly repetitive transcranial magnetic stimulation (rTMS) and transcallosal direct current stimulation (tDCS), have shown efficacy in improving motor and cognitive function in a variety of neurological disorders, including stroke. Recently, neuroplasticity has been increasingly considered as the mechanism by which these techniques function. Here we review the current literature exploring the impact of rTMS and tDCS on the recovery of motor and cognitive function beyond that explained by changes in motor and non-motor cortical excitability. We also discuss the potential of the combined use of techniques and their interactions with other therapies to facilitate recovery. This article is part of the themed issue \u2018Non-invasive brain and spinal cord stimulation for understanding and treating movement disorders\u2019.<EOD> Innovative pharmaceutical design: rational selection and optimization of the formulation.\nThe formulation design of every single drug has a significant impact on pharmacological and physicochemical characteristics as well as on the biological and biochemical aspects of the respective active ingredient: the effect is often greater if we consider the complex interaction of the drug with the target tissue system. In recent years, the development of innovative formulations has taken a leading position in the field of pharmaceutical research, and it is generally believed that",
        "label": 0
    },
    "500": {
        "output": "If the patient meets the eligibility criteria for the clinical trial, the patient can be enrolled in the study of the clinical trial.\nFirst, examine the attributes of the patient_data and patient_note objects.\n\nThere is a patient_data variable in the data variable. For example, {**patient_data, {**'patient': {**#ID: 'patient_id' [IPyn] . #Full name: '<NAME>' [IPyn] #Date of birth: '2022-06-11' [IPyn] #Sex: 'F' [IPyn] . #Age at diagnosis: '35' [IPyn] #Tumor status: 0 [IPyn] #Status of axillary lymph nodes: 0 [IPyn] #Grade: 3 #Hormonal receptor status: 2. [IPyn] #HER2-neu status: 2 [IPyn] #Estrogen receptor status: -1. [IPyn] . #Tumor recurrence: 0 [IPyn] #Drainage of axillary lymph nodes: 0 [IPyn] #Surgical resection of non-primary lesion: 0 [IPyn] #Tumor size in millimeters: 41 [IPyn] #Tumor margin: 0 (excellent)  [IPyn] #Multivesicular therapy: 0 (no)  [IPyn] . #Multimodal therapy: 0 [IPyn] . #Metastatic breast cancer: 0 [IPyn] . #Stage: Stage IV [IPyn] . #Tumor size: 4.9mm [IPyn] #Exclusion criteria's of clinical trial: 0 #",
        "label": 1
    },
    "501": {
        "output": "[A133] Hello. Here is some text data. We can process them later. \n\n\nYou may refer to this sample code to process text data.\n<EOD> Evaluating the Impact of Health Education on Health-Seeking Behaviour of Adolescent Girls in a Low-Income Area of Delhi, India\n\nBackground: Girls are highly vulnerable to health conditions which may arise out of poor health-seeking behaviour. Health education programmes can help in improving the health-seeking behaviour of girls in vulnerable areas of Delhi.Aim:The aim of this study was to evaluate the response of adolescent girls to a programme designed to educate them about basic health issues, preventive measures and emergency facilities.Methods:The study was conducted in an urban slum area in Delhi and 125 married girlsexperienced menstrual pain within the past year. To assess the knowledge about health and healthcare facilities among girls, before and after imparting health education, simple random sampling method was used.Results:Almost 0.5 years old women had the lowest mean knowledge score before imparting health education (8.48 out of 14). Post imparting health education, all subcomponents of health and healthcare were included in the highest score ranges of all subcomponents of health and healthcare. Majority of the girls (64%) in the beginning of study had the view that seeking care for menstrual pain was harmful and abnormal.Conclusion:Significant improvement was observed in almost all aspects of the knowledge of adolescent girls and mothers regarding health and healthcare facilities.\n\n# Introduction\nIn today's world, the lives of adolescent girls are full of hormonal changes, new emotions and a spectrum of emotions that are generally associated with a significant change in the lifestyle of the girls. 1 With so many factors that might change the physical and psychological aspects of girls, it is not shocking that adolescence is often linked to emotional disturbances and changes in girls' behaviour. 1,2 Adolescence is identified as a window of opportunity to improve and enhance adolescent girls' health and well-being not only by promoting positive health behaviours to stay healthy, but also to empower them to make informed choices to address",
        "label": 0
    },
    "502": {
        "output": "__HINTS__\n\nThe most common exclusion criterion for clinical trials is age. So, you should assess age for the patient eligibility.   \n\n__Bonus:__  \n\nThe [Instances]({{ page.tableurl }}) include the information needed to access the patient notes. Find your instance below, and [clone it](/{{ site.url }}/en/cloning-your-instance.md) to create your own environment, and then [clone this notebook](https://github.com/vahadar/vahadal/blob/master/notebooks/clinical_trial_recruitment.ipynb) as `clinical_trial_recruitment.ipynb` to get started.\n\n\n[Instance 1]({{ site.url }}/instances/instance1.json)\n[Instance 2]({{ site.url }}/instances/instance2.json)\n\n\n\n<EOD> A survey of the clinical effectiveness and safety of noninvasive ventilation in patients with chronic obstructive pulmonary disease and hypercapnic respiratory insufficiency.\nWe examined the efficacy and safety of noninvasive ventilation (NIV) in 40 patients (mean age 61 yr) with chronic obstructive pulmonary disease (COPD) with mild-to-moderate respiratory failure (PaCO(2) 45-60 mmHg). NIV was administered in home or hospital settings under the supervision of respiratory physicians. Data were collected and analyzed for clinical effects such as gas exchange, quality of life or respiratory muscle strength and incidence of complications in a cross-sectional fashion. During daytime, NIV improved gas exchange (PaCO2 +7.13 mmHg, p = 0.005 and pH +0.0293, p = 0.001) in all patients, and a similar trend was seen in PaO2. Among 14 patients with a body mass index \u226530 kg/m(2), PaCO2 and pH decreased by 3.64 mmHg (p = 0.005) and",
        "label": 2
    },
    "503": {
        "output": "<EOD> Characterization of human cyclic nucleotide phosphodiesterase activities by chromatographic separation.\nSeparation of cyclic nucleotide phosphodiesterase (EC 3.1.4.17) activities was achieved by chromatography on high-performance liquid chromatographic (HPLC) columns with the anionic exchange resin, QAESephadex A-50. Seven major activities were detected in both human liver and brain particulate fractions, and separated by reversed phase chromatographic HPLC of a Sephadex A-50 eluate. The peak activities corresponded to an unidentified phosphodiesterase with maximal activity in the pH range of 8.3-8.5, a phosphodiesterase with maximal activity in the pH range of 6.3-7.0, and a phosphodiesterase activity which was active in the presence of high concentrations of Na or Li ions. The peak areas appeared to be independent of the concentration of substrate. Densitometric scans of gel electrophoretograms of the column eluates indicated activity of each of the peak activities at the same mobility in both the 30,000g and the 100,000g liver or brain particulate preparations. The presence and size of the peak phosphodiesterase activities were insensitive to the temperature at which the liver and brain preparations were harvested from the donors. In view of these findings we suggest that the peak phosphodiesterase activities observed did not arise from a particular species of enzyme but were due to activity resulting from an ensemble effect on the various phosphodiesterase isoenzymes.<EOD> Role of 99mTc\u2010HYNIC\u2010annexin V as a prognostic marker in breast and colon cancer patients\nThis study was conducted to evaluate the prognostic efficacy of apoptotic level evaluated by 99mTc\u2010HYNIC\u2010Annexin V scintigraphy and its correlation with routine staging and prognostic tumor markers: serum carcinoembryonic antigen, serum creatinina and Tc\u201099m\u2010dimercaptosuccinic acid scintigraphy in breast and",
        "label": 0
    },
    "504": {
        "output": "<EOD> Different susceptibilities to antibacterial agents of strains of Escherichia coli causing human urinary tract infection. Identification of clones related to a plasmid-specified resistance factor.\nThe relative susceptibilities of 98 strains of Escherichia coli isolated from the urine of patients with acute pyelonephritis, chronic prostatitis, non-pyelonephritic cystitis and bacteriuria were determined by the dilution method. The mean MIC values for the two groups were also compared: Group I (n = 88 strains) contained strains isolated from patients with acute or chronic pyelonephritis and Group II (n = 10 strains) contained strains from patients with cystitis and non-pyelonephritic acute bacteriuria. Fourteen of the isolates were also studied pharmacokinetically: their relative susceptibilities and elimination half-lives were the same for both groups of pyelonephritic strains. In strains from pyelonephritis patients, the MIC value was higher for sulfonamide than for trimethoprim. Compared to group II, group I strains showed the following relative MIC ratios: sulfonamide, 5.6; piperacillin, 20; ticarcillin, 5.5; piperacillin + tazobactam, 1; ticarcillin, 0.29; piperacillin-sulbactam, 0.8. No differences in susceptibilities to gentamicin, tobramycin, cephalosporins or aminoglycosides were observed. When the MIC values of group I strains were compared with those of the other groups, differences were found for aminoglycosides, ticarcillin and piperacillin. Staphylococcus aureus 6538P was used to calibrate the apparatus and as a control in studies of drug-urea complexes and pharmacokinetics.<EOD> Characterization of the NMDA receptor/ion channel complex at glutamatergic synapses.",
        "label": 0
    },
    "505": {
        "output": "[TEST] `Ideal patient <- clinicaltrials::read_cts(\"Trial.txt\") Ideal patient <- clinicaltrials::clean_read_clinical_trial(\"Trial.txt\") Ideal patient <- trial_to_Patient(\"Trial.txt\", 1:2) print(Ideal patient)`\nThe following are the results of running the code:\n``` R\nIdeal patient <chr> # Trial data # Patient data\n1: patient_id \"005_002920\"\n2: patient_id \"005_002844\"\n3: patient_id \"004_002803\"\n4: patient_id \"005_002938\"\n5: patient_id \"005_002832\"\n6: patient_id \"005_002829\"\n7: patient_id \"005_002897\"\n8: patient_id \"005_002817\"\n9: patient_id \"005_002954\"\n10: patient_id \"004_001357\"\n\n```\n\n<EOD> .\nBACKGROUND\nAn increasing number of women has to undergo cancer treatment during pregnancy. This study aimed at analysing medical and psychosocial management of pregnant with breast cancer (PBC) in France.\n\n\nMETHODS\nA survey of medical records was conducted in 25 cancer centers from 2000-2004. Information about management was collected on pregnant and non-pregnant women with non-metastatic breast cancer.\n\n\nRESULTS\nSixty-eight pregnant women and 424 non-pregnant women were included in the study. Age (median, 34) and mean delay (36 weeks) between gestational age and diagnosis were not different in PBC and non-PBC, and most PBC were staged at stage 0-II (36/49, p=0.3). Treatment for PBC differed",
        "label": 0
    },
    "506": {
        "output": "<EOD> The role of endocannabinoids in the oligodendrocyte lineage.\nMultiple-sclerosis (MS) is a chronic demyelinating disease whose etiology is not well defined. A recent genetic study highlighted the involvement of endocannabinoid receptor 2 (CB2) in the pathogenesis of MS. It also implicated a putative novel role of endocannabinoids on myelination. In the present study, we examined the function of endocannabinoids by targeted blockade of CB1 and CB2 receptors by CB1- and CB2-specific agonists in a cell culture system for oligodendrocytes derived from mouse embryonic stem cells (ESCs). Our results demonstrate that 1) CB2-specific antagonists block the proliferation of oligodendrocyte progenitor cells (OPCs), the first step toward differentiation into the mature oligodendrocyte morphology, while the CB1-specific antagonists have a little or no inhibitory effect, and 2) expression of CB1 and CB2 receptors was significantly increased during oligodendrocyte lineage differentiation in three different types of cells: the ESC-derived OPCs, the differentiated oligodendrocytes, and the oligodendroglioma cell line CRT-MGs. These findings suggest that endocannabinoids play a role in proliferation of OPCs through CB2, and also provide an alternative source to OPCs for therapeutic targeting of demyelinating disease through CB2.<EOD> The role of chemotherapy in the postoperative management of locally advanced non\u2010metastatic oesophago\u2010gastric cancer\nRecent randomized control trials have shown that postoperative chemotherapy is of significant benefit in the management of patients with locally advanced oesophago\u2010gastric cancer. We aimed to evaluate whether these results were translated into routine practice.<EOD> Comparison of the therapeutic effects on hepatitis B using traditional Chinese medicine and interferon alpha plus lamivudine.\nINTRODUCTION",
        "label": 0
    },
    "507": {
        "output": "# Coding Instructions\nIf multiple patient notes are given, you should assign a patient ID and then output the patient notes one by one in the following lines. Let us imagine that you are given the following four patient notes:\n\n`patient notes:``\n#1 First patient note:`#1 Patient notes by ID: P1\n\n# Exercise 8\nPlease submit an exercise.\n\n# Exercise 9<EOD> Effect of acetazolamide on cerebrospinal fluid pressures in patients with cerebral palsy.\nThe effect of acetazolamide on intracranial pressure (ICP) in patients with cerebral palsy (CP) is not well established. Intra-cranial pressure (ICP) is considered a useful tool in the management of CP. To evaluate the effect of acetazolamide on ICP, we prospectively studied 20 CP patients with a mean age of 10.3 years (range, 6-16 years; 12 boys, 8 girls). A Gauge-Penman manometer was used to measure ICP. Acetazolamide induced ICP increase in all patients; mean ICP increase was 10.7 \u00b1 4.7 mmHg on the first and second days at the maximum ICP elevation. This study shows the usefulness of the manometer and the results of ICP monitoring using this device, with and without acetazolamide intoxication in patients with CP, before and after operation. This preliminary experience suggests that acetazolamide increases ICP. It should be kept in mind that ICP elevation might have a deleterious effect in the CP patient when the latter is treated with acetazolamide.<EOD> Huge Pretibial Lipoma Mimics an Ankle Tumor\n\n\n\n## Dear editor-in-chief\nPretibial lipomas usually appear as painless and mobile masses on the extensor surface of the distal leg. In this study, we presented a case of a huge pre-tibial lipoma. A 30-year-old man was referred to our department complaining of a slow growing mass that had been present for the past 15 years. The mass",
        "label": 2
    },
    "508": {
        "output": "# \u25a0 Case Studies\nIf you look at the first patient note, you may find a couple of errors about inclusion criteria (e.g.., patient has a history of alcohol abuse, pregnancy, etc.). You can change the patient note to correct the input errors. In our demo, the same patient had a history of alcohol abuse, and we corrected it manually. You need to add and validate in the input sheet the appropriate criteria for alcohol abuse. The alcohol abuse is one of the more common exclusion criteria for clinical trial. Alcohol abuse is also a potential confounding factor in medical research, for example, alcohol's effects on cancer, sleep, and blood pressure.~ [fig_ref]  Figure 4 10: Bottlenecks that can occur in decision-making processes based on 100% rule [/fig_ref] .7 shows an input error.\nClick on the icon \u2751 in the upper navigation bar to activate the input sheet. Note the \u2751 icon in the upper right corner of the input sheet. Click on the icon \u2751.\nSelect the patient with the ID __ and choose the input row `Has alcohol abuse`. (You can change the ID manually or set the first patient's ID to the value 0 to make it a reference number.)\nSet the value to Yes for the patient.\nTo validate your change, click on icon \u2713 to save the change. \nFigure 4.13 \u25a0 Input error.\nOn the left, you can observe an input row: for the patient note, the patient ID is 0, the patient's gender is female, and the age is 45. On the right, you can observe the input error in the alcohol abuse row. The `True` value is used for the first time. \nFigure 4.14 \u25a0 Correction to the input error.\nFor the patient ID 0, the value is set to `False` to correct the input error. \nFigure 4.15 \u25a0 Corrected value for the patient note.\nYou need to change the \"No\" value in the alcohol abuse row to \"Yes\". This value is used for the first time, and therefore the input row for \"Alcohol abuse\" has the \"Validate before save\" box on",
        "label": 0
    },
    "509": {
        "output": "[SECTION] Prognostic markers \n[ITEM] A 35-year-old woman comes to your clinic with a 2-month history of back and left knee pain. She has a 10-year history of Hashimoto's thyroiditis. She is not sexually active, nor has she given birth to any children. She has no family history of cancer. She is a current smoker, smoking 1 pack per day. Her labs reveal a thyroid stimulating hormone (TSH) level: 0.415 units/mL (reference: 0.550-4.780 units/mL); 1,25-dihydroxyvitamin D levels: 16 pg/mL (reference: >20 pg/mL); 25-hydroxyvitamin D: 34 ng/mL (reference: >30 ng/mL); total cholesterol: 214 ng/mL (reference: <200 ng/mL); 25-hydroxyvitamin D: 9 ng/mL (reference: >30 ng/mL); LDL: 131 ng/mL (reference: <100 ng/mL). Ultrasound of the thyroid showed a solid nodule measuring 6 mm in diameter. You decide to refer the patient for a needle biopsy to rule out lymphoma. However, after your appointment, you discover that the patient passed away 1 day after she was seen in the clinic. The patient's husband stated that she had suddenly felt ill before he arrived home that evening. \nHere is the patient note:\nThe patient was seen in the office a month ago. She was healthy, and no medications were being taken. She was smoking half a pack of cigarettes per day. All of her labs including a prostate-specific antigen test were normal. She had no family history of any cancer. 2 days after she passed away, the autopsy revealed metastases to the lung, bone, bone marrow, and spleen. She had high grade NHL (B-cell). Her lymphosarcoma could have been caused by N",
        "label": 0
    },
    "510": {
        "output": "[/COACH] Hi. You are a cancer consultant who gives a short conversation with a patient about their health status and helps them improve their quality of life. You use health-tracking devices, such as Fitbit, Apple Watch, and Google Fit, to collect medical data and then transfer them to the electronic medical record system for analysis. You also collect the patient's information about food intake and physical activity to provide a personalized diet recommendation.\n\nYou have to develop a real-time patient-facing chatbot to help patients make decisions about diets and exercise habits. You will use the knowledge obtained from patients' medical records. For example, if your patient uses a medical device to monitor his or her cardiovascular system, you can collect the patient's medical data and recommend healthy diets for him or her.\n\nTo do this, you have to train a Bidirectional encoder representations from transformers (BERT) model that can understand both language and medical images at the same time. Here's an example of the medical image data.\n\n![Examples of medical image data](https://i.ytimg.com/vi/TJj8dXxQpQ0/hqdefault.jpg)\n\n### Pretrained BERT\n\nPretrained BERT is the most popular and well-known machine learning model. The pretrained BERT has 12 transformer layers. A transformer is a convolutional neural network that uses an attention mechanism. It understands the language context and generates high-quality outputs. As you continue learning, the pretrained dataset will only be enhanced and expanded by collecting more data. When using a pretrained BERT, you can obtain the best performance possible using an already trained BERT model, such as the Hugging Face Model.\n\n### WordPiece\n\nWordPiece is a method in which the words of a large natural language model are divided into subwords and then trained through self-supervised learning. It is a method of creating a vocabulary for words by analyzing language usage and is trained using the Word2Vec algorithm. WordPiece is designed to reduce the memory requirements of NLP models. Specifically, training WordPiece and using the vocabulary file can significantly reduce the amount of memory required to store words in",
        "label": 2
    },
    "511": {
        "output": "## [END]\n\n## 54\n\n## Recurrent patient detection\n\n[INST] In the clinical studies, many patients drop out due to recurrence. Some patients receive chemotherapy drugs for a long time, so the recurrence rate is low. Here in this dataset, all patients with breast cancer are recurrence patients after a chemotherapy regimen. Your task is to find the patients whose current therapy has been unsuccessful and who are candidates for recurrent treatment.\n\nThe patient data used here is the same as in the previous experiment.\nDifferent patient characteristics can be found by applying a set of filter rules. For example, the filter code `patient_age >= 45` indicates that patients whose age greater than or equal 45 years old will appear in the candidate list. The filter code `patient_gender == \"w\"` indicates that the current disease status of patients whose gender is `w` can be seen in the candidate list. \n```\npatient_age >= 45;\npatient_gender == \"w\";\n``` \nThe patient data used here is the same as in the previous experiment.\nDifferent patient characteristics can be found by applying a set of filter rules. For example, the filter code \n\nThe patient data used here is the same as in the previous experiment.\nDifferent patient characteristics can be found by applying a set of filter rules. For example, the filter code \n\nThe patient data used here is the same as in the previous experiment.\nDifferent patient characteristics can be found by applying a set of filter rules. For example, the filter code \n``` python\n# Experiment ID = \"Ex_1_4\"\n# Patient identifier = ID\n# Experiment ID = \"Ex_2_1\"\nfilter_ID = [\n    \"1\", \"1\", \"2\", \"2\", \"3\",\n    \"1\", \"1\", \"2\", \"2\", \"3\",\n    \"1\", \"1\", \"2\", \"2\", \"3\",\n    \"1\", \"2\", \"3\", \"1\", \"2\",\n    \"2\", \"3\", \"1\", \"3\", \"4\"\n]\n```\n[END]\n\n## Recurrent Patient detection\n\n[INST] The patient ID should be detected in the list. If it appears",
        "label": 1
    },
    "512": {
        "output": "You don't have to repeat the `if` statements to compute the eligibility scale. The code will automatically be parsed and compiled by the compiler/interpreter/host system.\n<EOD> .\nIn a controlled 21-days double-blind trial the antiarrhythmic effect of a new class 1C antiarrhythmic drug, azefibrate was compared with placebo in 41 patients with chronic atrial and/or ventricular arrhythmia resistant to other antiarrhythmic drugs. In azefibrate-treated patients antiarrhythmic effect was observed in 15 (71%), in comparison to 35% in a group of patients treated with placebo. Cumulative frequency of antiarrhythmic drug elimination in patients treated with placebo and azefibrate was 3% and 65% respectively. In conclusion, azefibrate exerts an evident antiarrhythmic effect, mostly in patients with chronic atrial fibrillation (12 cases), but also in patients with chronic akinetic ventricular arrhythmias (6 cases).<EOD> Reevaluating the role of the \u03b2-globin promoter in erythroid gene expression and gene therapy\n\nThe successes of gene therapy for inherited blood diseases and the development of 2017 guidelines for in vivo clinical trials have generated great optimism for the use of gene therapy to treat genetic disease. The human \u03b2-globin locus has been studied for over five decades with advances in the understanding of its epigenetics, genetic regulation and the genetic engineering of locus control regions (LCR). While in vivo gene therapy is currently successful for the correction of sickle cell anemia, further improvement in clinical outcomes still relies heavily on progress in locus engineering. We propose that locus and especially globin gene transgene expression is limited due to silencing chromatin modifications of the transgene that prevent formation of an LCR and silencing by position effect. Using a new mouse transgenic model, we show that forced chromatin structure changes mediated by the BACH2 transcription factor can reactivate the LCR in transgene loci and generate a phen",
        "label": 1
    },
    "513": {
        "output": "Good Luck!\n<EOD> Development of a Recombinant Pooled Reporter Cell Line for HIV-1 Fusion Assay\nThe fusion process of virus and host cell membranes is critical for HIV-1 infection. Thus, the inhibition of HIV-1 entry into host cells would become a possible therapy. Here, we have developed a new reporter cell line targeted to the HIV-1 entry assay by using a genetically-modified HeLa cell line, called HeLa 48F, where the green fluorescent protein (GFP) gene has been inserted behind the transcriptional stop codon of the CD4 gene. HeLa48F cell line expresses CD4 protein on the cell surface, and, if HIV-1 enters the cells, the GFP protein can be expressed by a bicistronic expression unit consisting of gag and packaging plasmids. This reporter cell system provides high sensitivity and specificity. Thus, the cell line developed in this study could become a standard tool for HIV-1 envelope glycoprotein studies and vaccine development.<EOD> Galectins in immunosuppression.\nGalectins are unique animal lectins in the immune system that regulate immunity negatively and play antiinflammatory roles. In particular, they negatively regulate the effector phase of immune response and induce tolerance. Apart from galectin-1 which is classified as an \"immune-modulator\", galectin-2, -7, -9 and -10 were recently identified as galectins inducing tolerance in na\u00efve T cells and as key-modulators in the control of immune response. Moreover, galectin-2 and galectin-4 could be involved in Treg expansion because their expression is higher in these cells than in conventional effector T. Galectin-3 is involved in the maintenance of FoxP3 expression and Treg stability since its expression decreases when FoxP3 is lost. Although expression of galectins in mast cells (MC) is limited, several studies have demonstrated their modulatory role in MC allergic responses. Thus, as they regulate not only allergic responses but also antiviral one, galectins could be considered",
        "label": 0
    },
    "514": {
        "output": "- <title>BMI-for-age, weight for age, height for age and weight for height among children of 0-12 years old. (2016/1/1\u223c2018/9)</title>\n- <a href=\"http://haw.iioc.tw:8080/dataexplorer/Home\">IIOC Data Portal</a>&nbsp; >&nbsp;<a href=\"http://haw.iioc.tw:8080/dataexplorer/Home\">Query</a>&nbsp; >&nbsp;&nbsp;<a href=\"http://haw.iioc.tw:8080/dataexplorer/Home\">BMI&nbsp;for&nbsp;&nbsp;age&nbsp;or&nbsp;weight&nbsp;for&nbsp;&nbsp;age&nbsp;&nbsp;or&nbsp;height&nbsp;for&nbsp;age&nbsp;&nbsp;or&nbsp;weight&nbsp;for&nbsp;&nbsp;height&nbsp;&nbsp;among&nbsp;children\">Children's&nbsp;Health&nbsp;Data&nbsp;&nbsp;and&nbsp;Indicators</a>&nbsp;&nbsp;&nbsp;&nbsp; >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a href=\"http://haw.iioc.tw:8080/dataexplorer/Home/Indicators/14\" target=\"new\">Body&nbsp;mass&nbsp;index&nbsp;for&nbsp;&nbsp;age&nbsp;(BMI)</a>&nbsp;>&nbsp;&nbsp;<a href=\"http://haw.iioc.tw:8080/dataexplorer/Home/Indicators/14\" target=\"new\">BMI&nbsp;for&nbsp;age&nbsp;or&nbsp;weight&nbsp;for&nbsp;age&nbsp;&nbsp;and&nbsp;by&nbsp;sex</a>&nbsp; >&nbsp;&nbsp;<a href=\"http://haw.iioc.tw:8080/dataexplorer/Home/Indicators/14\" target=\"new\">BMI&nbsp;for&nbsp;age&nbsp;or&nbsp;weight&nbsp;for&nbsp;age&nbsp;or&nbsp;",
        "label": 1
    },
    "515": {
        "output": "Let's think step by step. On the trial report template, enter a data set: \n\n\n![](/attachment/images/1020/file)\n\nFinally, the trial report page should have the following format:\n\n\n![](/attachment/images/1020/file)\n\n### 7: Generate Informed Consent Form.pdf\n[INST] Hello. You are a researcher at the Faculty of Pharmacy. You work on a [clinical trial](/course/22.html) on chronic kidney disease progression. \n\nYou should generate an informed consent form and sign it. The inform consent form should be legally binding and written in a form understood by the participant. \n\nThis form shows a description of the trial's objectives and requirements, risks and benefits, alternative treatments, confidential",
        "label": 1
    },
    "516": {
        "output": "Good programming practice is doing more than once what you intend to have your compiler do only once. Therefore the three times the code is run under the instruction `n = 3`, where n is the counter, are as follows:\n\n  1. Make sure, first of all, that the patient note has been read completely before running the code. \n  2. Use if the patient note contains a sentence like \u201fExcluded (patient meets inclusion criteria, but is excluded based on the trial's exclusion criteria)\u201d, to skip the further repetition in loops.\n  3. When the patient note is of length equal to zero, then the current loop should run to its end to show all possible results for the assessment of eligibility and avoid skipping the current trial. \n\n\nTo do so, change the following code in function GetEligibility (lines 70 \u2013 72):\n\n`for (n = 1; (n < 3) && (PatientNote.Length > 0); n+=1) { \u2026 } `\n\n<EOD> Identification, characterization, and chromosomal location of a gene encoding a mastoparan-like peptide in honey bee, Apis mellifera.\nWe have recently reported the first finding of a mastoparan-like peptide, bee mastoparan-II (bee MPII), in worker honey bee (Apis mellifera) venom. In this study, we have identified an mRNA transcript for mastoparan-like peptide (MAP) from honey bee venom gland transcriptome data. Using the 3'- and 5'-RACE system, the gene was assembled by RT-PCR. The full-length cDNA encodes 94 amino acid residues, which are predicted to form a protein of 89 amino acids (bee MPII). The sequence contains a 22 amino acid long N-terminal signal peptide, which is a typical feature in venom peptides. The predicted bee MPII sequence shares 89% similarity with the corresponding sequences of bee MPII. Sequence search for bee MPII homologs revealed that a gene homologous to human mas-1",
        "label": 0
    },
    "517": {
        "output": "[TRAIL] A 47-year-old woman is being evaluated for a new chronic back pain in the right lower limb. She had received chronic anticoagulant therapy for venous thrombosis over the previous 15 years, was a smoker, and her blood analysis (BT: 38.2\u00baC; BP: 120/80\u2009mmHg; HR: 100 bpm; R: 18 bpm) showed increased D-dimer. The physical examination and blood test were initially performed by a nursing assistant on the ward. The physician confirmed the initial diagnosis. During his training, the physician receives the patient's medical history and prescribes a treatment that includes an additional antibiotic for three days. He writes a prescription, which is given to the patient after her blood test results are confirmed. The results of the test for a fungus are negative.\nGiven the patient's complaints and treatment plan, select the most appropriate response:\n\n\nA) Revision of the plan, which will be accepted by the physician. B) Dispensation for three days instead of the original five days. C) Revision of the plan, which will be accepted by the nursing assistant, but not by the physician. D) Revision of the plan, which will be accepted by both the nursing assistant and the physician.\n\nWhich one of the following is not included in the decision-making process of the physician from the time the case is identified until the patient receives the treatment?\n\n\nA) Review of the patient's medical history before initiating the treatment plan. B) Prescreening of the clinical case. C) Assignment of a second person in the treatment team. D) Consensus consultation if treatment options are not clear.\n\n## [TRAIL-TECH-DISC-SOLUTIONS-01]\nWhich one of the following is not included in the technical support activities of the information systems?\n\n\nA) Adopt technologies to increase data quality in business environments. B) Design and execute computer system requirements. C) Evaluate the business benefits of the computer system. D) Integrate multiple information systems into a single information technology architecture.\n\n###",
        "label": 0
    },
    "518": {
        "output": "</PRE>\n\n\n\n<!-- 31.2.1.4.2 Random assignment -->\n\n# Random assignment\n\n\nIn order to assign each patient to a group of treatment, a randomization is done in R.\n`> library(randomsplit) > library(splitstackshape) > randomize <-function(x,n=nrow(data)){ > n1 <-mod(sapply(1:nrow(x), FUN=function(y){ y<nrow(x) }), n1) > n2 <-nrow(x)/n1 > split <-rbind(splitstackshape(x[n1:n2], var) , splitstackshape_(x[n2:nrow(x)], var)) > data[,1:(n1+n2)] <--data[,ncol(split)] <--split > data[1:(n1+n2)] <--split[n1:n2,] > data[n1+n2] <--data[,ncol(split[-n1])] + split[-n1,](3:ncol(split[n1])) > data[n2+1:nrow(x)] <-data[n2+1:nrow(x),[n1+n2]] > return(split) > } > x <-as.data.frame(y) > x <bquote(\nx) # assign R-code for x > rnd <-random.permit(x, 2)[1, ] randomize(x,n=rnd) > [INST]\n\nAssign to two groups and report the groups on the result. For each, the number of observations for each group and the number of groups are reported.\n``` R\nx\n```\n```\nx$group <-rnd Group 1: 210.000 Group 2: 224.000 nrow(x) Group 1: 210.000 Group 2: 224.000 ngroups(x) Group 1: 31.864 Group 2: 33.136\n\n```\n``` [INST]\n\nNow, take the two assignments by `x2 <- randomize(x, n=nrow(data)-1",
        "label": 1
    },
    "519": {
        "output": "<EOD> Dual-Luminescent Carbon Microsphere Composites for the Simultaneous Determination of Oxytetracycline Hydrochloride and Streptomycin Sulfate in Egg.\nStreptomycin sulfate (STR) and oxytetracycline hydrochloride (OTC-HCl) are typical veterinary drugs widely used in animal feed; therefore, the simultaneous determination and quantification of these two drugs in eggs is of great significance. In this work, a novel dual-luminescent carbon microsphere (CL-CMS) composite was fabricated. Its luminescent properties mainly originated from the intrinsic carbon dots (CDs) that were formed during the carbonization process and the phosphorescent europium/DPA complex incorporation in the silane layers that were fabricated through the silane coupling treatment of the carbon materials. The phosphorescent center is encapsulated, which can be used to eliminate the interferences from the background fluorescent components of the food, and the silane layer ensures that the photoluminescence (PL) center does not decay when the emissive molecules escape due to the dehydration of the CDs. The PL emission of CL-CMS was realized by the electron transfer from the 1 O2 excited state of the CDs to the europium/DPA cluster. Under the optimal conditions, the limit of detection for STR and OTC-HCl were 5.2 and 0.3 \u03bcg mL-1, respectively. These limits of detection allowed the quantitative detection of the trace STR and OTC-HCl levels in actual egg samples (with 0.0059 and 0.0125 g OTC-HCl and STR, resp.).<EOD> Highly selective fluorination towards aromatic systems at room temperature and atmospheric pressure.\nFluorinated compounds play central roles in a wide range of applications, including new electronic, magnetic, biological and optical media, drug design and biofuel technology. The development of environment-friendly, industrially scalable and economically feasible methods for the fluorination of organic molecules in a selective manner remains a great challenge. As summarized in the following Table, various methods",
        "label": 2
    },
    "520": {
        "output": "A: Clinical trials may not have all of the same eligibility requirements. So it's actually hard to give a list of criteria that always apply. \nThere are two types of clinical trials:\n* randomized controlled trial (RCT)\n* open-label trial\n\nHere are some common criteria from clinicaltrials.gov: \n\n* age\n* sex\n* previous treatment\n* blood test results\n\nTo summarize: \n\n  We expect the first column to always be the trial name.\n  We're not sure how the values for `name`, `inclusion_criteria`, `exclusion_criteria` should be structured.\n  We're expecting a dictionary in the `patient_details` column from the data set.\n  \n```python\ntry:\n    # Get the patient note\n    print(\"Getting the patient note.\")\n    with open(patient_note_csv, 'r') as fn:\n        patient_note = dict(reader(fn).items())\n    print(\"Patient note: {}\".format(patient_note))\n    \n    # Get the clinical trial\n    print(\"Getting the clinical trial.\")\n    with open(clinical_trial_csv, 'r') as fn:\n        clinical_trial = dict(reader(fn).items())\n    print(\"Clinical trial: {}\".format(clinical_trial))\n\n\n    # Check our clinical trial definition\n    print(\"Checking the clinical trial definition.\")\n    \n    trial_eligibility_dict = clinical_trial.get('inclusion_criteria')\n    \n    if not trial_eligibility_dict:\n        print(\"Clinical trial has no inclusion_criteria.\")\n        \n    else:\n        print(\"Clinical trial has inclusion_criteria: {}.\".format(trial_eligibility_dict))\n    \n    print(\"Patient meets the inclusion criteria of {}.\".format(trial_eligibility_dict))\n    \n    \n    # Check the inclusion criteria\n    print(\"Patient doesn't meet the inclusion criteria of the clinical trial. The trial includes criteria for the following:\")\n    \n    if not clinical_",
        "label": 2
    },
    "521": {
        "output": "___\n\n<b>03_Example</b>\n\n[MOD]  \n[INST] Hello. Your first task is to convert the values of the variables <NAME> , <NAME> , and <NAME> to a normal distribution. If these variables are not in a normal distribution, the data might be skewed. This will decrease the probability of data being considered as unrepresentative of the population.\n\n[INST] Here are the patients in the test-set (n = 52) and their variables: \n\n[MOD] Now, we have to work for the normal distribution. These 3 variables are continuous, and we cannot assume that they have the normal distribution. It is important to check if these 3 variables are in a normal distribution.\n\n![normal distribution (03)](/assets/images/data_analysis_normal_distribution/03.png)\n\nAs the 3 variables are not in a normal distribution according to the QQplot, we should perform a normalization transform to normalize the dataset; otherwise, the trained model would have a poor capability to fit the clinical data well (if the data have unnormal distributions). A normalization transform is a mathematical function that makes the data closer to a normal distribution. After all, the model should be trained by transformed data. Therefore, you should implement a normalization transform and test if the data are in a normal distribution again. If they are in a normal distribution, we should train by the original data without any normalization transform. Otherwise, you should have prepared the normalization transform module and integrate this transform into the model.\n\n[MOD] The normalization transform is based on a log-transformation function.\n\nIn a log-transformation, a given value in the original data set is converted to the value that gives the same probability density as the normal distribution's probability density in the range of the x-axis.\n\n![normalization (03)](/assets/images/data_analysis_normalization/03.png)\n\nSo we should calculate the normalization transform after having converted the probability density of the original dataset into the x-axis to the probability density of the normal distribution. In other words, a new dataset is created by the normalization transform, which is supposed to transform the existing normal distribution of the probability density at a particular x-axis into a normal distribution in which a",
        "label": 2
    },
    "522": {
        "output": "[INF] Hello. Today is your 15th birthday. You love pizza, which is one of your favorite foods. You're going out to a friend's house to celebrate. The friend's family has a tradition of cooking for you a pizza with the ingredients that you like most. The options for the 12 ingredients of the pizza are pasta, bacon, sausage, mushroom, onion, green pepper, egg, ham, banana, cheese, bacon, and salmon.\n\nToday's pizza is for you! The ingredients are set up on a card. The ingredients that are not present are indicated in the blank spaces. You'll need to choose the ingredients and place them on the card to create a new pizza. Which ingredients will you choose?\n\nHere is an example of a possible pizza [/INF]\n\n\n\n![image.png](https://user-images.githubusercontent.com/34364444/78496178-0e450d80-7411-11ea-9843-7a48676d8f22.png)\n\n\n\n\n\n\n\n\n[INF] Hello. Today is your 15th birthday. You love pizza, which is one of your favorite foods. You're going out to a friend's house to celebrate. The friend's family has a tradition of cooking for you a pizza with the ingredients that you like most. The options for the 12 ingredients of the pizza are pasta, bacon, sausage, mushroom, onion, green pepper, egg, ham, banana, cheese, bacon, and salmon.\n\nToday's pizza is for you! The ingredients are set up on a card. The ingredients that are not present are indicated in the blank spaces. You'll need to choose the ingredients and place them on the card to create a new pizza. Which ingredients will you choose?\n\nHere is an example of a possible pizza [/INF]\n\n\n\n![image.png](https",
        "label": 2
    },
    "523": {
        "output": "2. If you use your laptop to complete the code challenge, there will be a screen with instructions every time you launch the platform after submitting your solution.\n 3. As the assessment was conducted during the COVID-19 pandemic in 2021, please be reminded to always keep yourself safe especially when you visit the outpatient clinics and undertake your clinical services, and always follow the latest health guidelines such as wearing appropriate personal protective equipment in the clinical setting, especially when near the patients and taking care of their needs, as shown in . In 2018 and 2019, we conducted this assessment. However, before you start completing the assessment, please be reminded that the healthcare system in the Philippines during those years did not strictly follow the guidelines and recommendations for COVID-19 by the Philippine Department of Health or the government as we did not have a confirmed positive COVID-19 case in the Philippines at the time. Please read more about the assessment in the past (2018 and 2019).\n 4. The answer key is available on the [SNAUTS webpage](https://www.snauts.ph/?q=content/certificates-of-completion), which also includes the solution guides. To access the answer key, ensure that the student access level that you have applied for is the correct one. To access the solution guide, click the PDF with the title, \"Solution Guides:\". To ensure anonymity, the solution guides are password-protected and you will need to submit the correct password to access the solution file. Click the password provided. If you could not access the solution guide, please notify one of the study team members. 5. If you have an interesting coding challenge that you've completed on your own, consider joining our [community of learners](snauts.ph/community/).\n\n\nHINT 1\nCreate an appropriate variable called _age_ that stores the patient's age.\n\n`def age(patient): 1999 - patient.birth_date.year`\n\n_Output:_ _age_ is a 62-year-old man._\n\nHINT 2\nCreate an _Eligible_ flag variable to store eligibility status. When",
        "label": 1
    },
    "524": {
        "output": "## DATA\n[inst]\n\n        ### Table of Contents\n        1.  [**1: Summary**](DEMO/DEMO.md).\n        2.  [**2: Patient** ](DEMO/STUD_2/patient.md).\n        3.  [**3: Medication** ](DEMO/STUD_3/medications.md).\n        4.  [**4: Procedure** ](DEMO/STUD_4/procedure.md).\n        5.  [**5: Clinical Trial**](DEMO/STUD_5/clinical_trial.md).\n        6.  [**6: Researcher** ](DEMO/STUD_6/research.md).\n        7.  [**7: Institution**  ](DEMO/STUD_7/institution.md).\n        8.  [**8: Patient Note**  ](DEMO/STUD_8/patient_note.md).\n        9.  [**9: Patient Summary** ](DEMO/STUD_9/patient_summary.md).\n       \n        ###  DATA FLOW\n        1.  [**Patient Note to Patient Summary** ](DEMO/STUD_8/patient_note_to_summary.md).\n       \n        ###  RELATIONSHIP\n       \n        -  [**Patient Summary to Researcher**](DEMO/STUD_9/patient_summary_to_research.md).\n       \n        ###   TABLE-DRIVEN DESIGN\n        1.  [**Patient.csv** ](DEMO/STUD_2/patient.csv)\n        2.  [**Procedure.csv** ](DEMO/STUD_4/procedure.csv).\n        3.  [**Medication.csv ](DEMO/STUD_3",
        "label": 2
    },
    "525": {
        "output": "[/MCQ] [/MCQ]\n\n\n### \u2714\ufe0f You are not allowed to use the following tags:\n\n\n`[data-user]`, \n`[data-reveal][data-target]`, \n`[data-reveal][data-target][data-hide]`, \n`[data-reveal]`, \n`[data-reveal][data-target]`, \n`[data-target]`, \n`[data-target][data-reveal]`, \n`[data-target][data-reveal][data-hide]`, \n`[data-target][data-hide]`, \n`[data-reveal][data-hide]`, \n`[data-reveal][data-hide]`, \n`[data-hide]`, \n`[data-target]`, \n`[data-hide]`, \n`[data-target][data-hide]`, \n`[data-hide][data-target]`, \n`[data-hide][data-target]`.\n\n\n### \u2714\ufe0f You are not allowed to use the following tags:\n\n`[data-user]`, \n`[data-reveal][data-target]`, \n`[data-reveal][data-target][data-hide]`, \n`[data-reveal]`, \n`[data-reveal][data-target]`, \n`[data-target]`, \n`[data-target][data-reveal]`, \n`[data-target][data-reveal][data-hide]`, \n`[data-target][data-hide]`, \n`[data-reveal][data-hide]`, \n`[data-reveal][data-hide]`, \n`[data-hide]`, \n`[data-target]`, \n`[data-hide]`, \n`[data-target][data-hide]`, \n`[data-hide][data-target]`, \n`[data-hide][data-target]`.<EOD> High Performance of Bioceramics for Bone Tissue Engineering\n\nThe demand to",
        "label": 1
    },
    "526": {
        "output": "## [1] Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)\n\n![CHARISMA](https://raw.githubusercontent.com/shing98/2018_MLBiomed_Proposal_Institutionalization/master/charisma.jpeg)\n\n### 1.1 Patients\n\nInclusion criteria:\nPatients above 45 years old and comply with at least one of the four categories of inclusion criteria, as described in the Table of Inclusion Criteria (see [1]).\n\nPatients aged above 45 years who have had at least one of the four categories of inclusion criteria.\n\n#### 1.1.1.4\n\n## Detailed information about patients\n\n### 1.1.1.4.1\n\n1.1.1.4.1) Atherothrombotic Risk Factors\n\nAtherothrombotic risk factors refers to the presence of one or more of (1, 2, and 3) below, with or without (4).\n\n(1) Non-diabetic hypertension;\n\n(2) Current cigarette smoking;\n\n(3) Total serum cholesterol level of a previous screening test before randomization > 220 mg/dL, and LDL-cholesterol > 130 mg/dL;\n\n(4) Coronary heart disease, and/or peripheral heart disease (e.g., angina pectoris, previous myocardial infarction (MI), previous percutaneous transluminal coronary angioplasty (PTCA), previous coronary artery bypass grafting surgery (CABG), stroke, transient ischemic attack (TIA), or peripheral artery occlusive disease (PAOD)).\n\n#### 1.1.1.4.1.1\n\n### 1.1.1.4.1.2\n\n1.1.1.4.1.2) Diabetes\n\nDiagnosed diabetes with or without documented vascular complications will be classified under 1.",
        "label": 2
    },
    "527": {
        "output": "I expect you to write a program on `Simulation - Expert system - Example` from the `Tutorial - Expert system - Advanced - Example` chapter. [/END]\nLet's think how can we implement the `Trial-level eligibility` by expert system in the code snippet below.\n\n```javascript{py}\nfunction ExpertSystem.getTrialLevelEligibility(trialIdx, isInclusionCriteria){\n  var trialCriteria;\n  switch(trialIdx){\n    case 0://Trial #0\n      trialCriteria={\n        'Criteria1':'0','Criteria2':'0','Criteria3':1,'Criteria4':1,\n        'Criteria5':0,'Criteria6':'0','Criteria7':0};\n      break;\n    case 1://Trial #1\n      trialCriteria={\n        'Criteria1':'1','Criteria2':'0','Criteria3':2,'Criteria4':1,\n        'Criteria5':0,'Criteria6':'0','Criteria7':0};\n      break;\n    case 2://Trial #2\n      trialCriteria={\n        'Criteria1':'0','Criteria2':'0','Criteria3':2,'Criteria4':1,\n        'Criteria5':0,'Criteria6':'0','Criteria7':0};\n      break;\n    default: {\n      throw new Error(\"Invalid trialIdx\");\n    }\n  }\n  return {\n    inclusionCriteria:isInclusionCriteria\n      ,exclusionCriteria:getExclusionCriteria(trialCriteria),\n      trialIds:trialCriteria.trialIds\n    };\n}\nfunction getExclusionCriteria(exclusionCriteria){\n  var exclusionCriteria={\n    Criteria5:'0','Criteria6:0,'Criteria7':0}; \n  if(exclusionCriteria.Criteria7){\n    exclusionCriteria.inclusionStatus='4';\n  }\n  else{\n    exclusionCriteria.inclusionStatus='1';\n  }\n  return exclusionCriteria;\n}\n```\n\n- I assume that `triallevels` is a hashmap",
        "label": 0
    },
    "528": {
        "output": "### Example\n\t```\n\t\t\t\t<Trial-level eligibility>\n\t\t\t\t\t<value />\n\t\t\t\t</Trial-level eligibility>\nIncluded, not relevant, or excluded, and is explained by the following:\nTrial\n\n    </Trial-level eligibility>\n[INST]\n```\n\n### Excluded\n```\n\t\t\t\t<Trial-level eligibility>\n\t\t\t\t\t<value>Excluded</value>\n\t\t\t\t</Trial-level eligibility>\n\n[INST]\n```\n\n### Not relevant\n```\n\t\t\t\t<Trial-level eligibility>\n\t\t\t\t\t<value>Not relevant</value>\n\t\t\t\t</Trial-level eligibility>\n\n[INST]\n```\n\n### Eligible\n```\n\t\t\t\t<Trial-level eligibility>\n\t\t\t\t\t<value>Eligible</value>\n\t\t\t\t</Trial-level eligibility>\n\n[INST]\n```\n\n### Unknown\n```\n\t\t\t\t<Trial-level eligibility type=\"unknown\">\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t</Trial-level eligibility>\n\n[INST]\n```\n\n## Trial-related eligibility\n\nYou should make a trial-level eligibility on each trial for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\nTrial-level eligibility is the same as Patient-level eligibility.\n\nThe assessment of clinical trial eligibility has a three-point scale: 0) No eligibility; 1) Not relevant; and 2) Eligible.\n\n### Example\n\t```\n\t\t\t\t<Trial-level eligibility>\n\t\t\t\t\t<value>Eligible</value>\n\t\t\t\t</Trial-level eligibility>\n\n[INST]\n```\n\n## Eligibility assessment report elements\nEach report element has its own eligibility assessment report elements as shown below.\n\n##",
        "label": 1
    },
    "529": {
        "output": "<EOD> A 4-(2,4-dinitrophenyl)butyrate derivative as a highly efficient ligand for the purification of recombinant proteins by immobilized metal ion affinity chromatography.\n1. Recombinant proteins expressed in Escherichia coli can be purified using immobilized metal ion affinity chromatography (IMAC) in a simple one-step procedure utilizing a weak acid elution system (0.6M imidazole in the presence of a small amount HClO(4)). The eluted protein is free of traces of detergents. 2. In the case of 70 kDa human chorionic gonadotrophin this procedure was as efficient as the conventional method based on the use of the immobilized His(6)-tag. 3. The use of a ligand based on 4-(2,4-dinitrophenyl)butyrate showed advantages in IMAC of the enzyme thymidine kinase. In contrast to the original immobilized His(6)-tag, the bound enzyme could be eluted from the column using an acidic elution mixture without loss of activity. 4. The protein-ligand-metal affinity complex can be easily disrupted by dilution with a competitor solution containing the weak acid acetate. The liberated protein can be easily recovered, and thus no wasting of the initial metal ions. 5. These IMAC procedures have been optimized on the basis of the amount of the free ligand bound in a fixed bed chromatography column, which determines the amount of the immobilized ligand. 6. By using this IMAC approach, human thymidine kinase at a purity of 90% could be achieved after ion exchange chromatography. 7. The enzyme could subsequently be obtained in an active form and at a concentration of approx. 5 mg/ml in 50 mM imidazole 20 mM phosphate buffer, pH 7.0. This procedure leads to yields of about 60% of recovered protein. 8. This procedure was also successfully applied to the purification of human glutamic pyruvate transaminase (75 kDa). For this enzyme a pur",
        "label": 0
    },
    "530": {
        "output": "<EOD> .\nThe clinical picture of arteriosclerotic encephalopathy was studied in 111 males over the age of 60 years who had a normal brain stem response to acoustic clicks (ASCR) on the routine EEG. The incidence of ASCR was lower in older patients. The pathophysiological significance of ASCR in elderly patients was investigated. Patients under the age of 65 years without ASCR showed significantly decreased serum lipoprotein concentrations and, conversely, those with ASCR showed increased serum lipoprotein concentrations, when compared to patients over the age of 65 years. These results suggest that ASCR may be used as a neurological index to distinguish between arteriosclerotic encephalopathy and cerebral circulatory failure due to dementia in the elderly.<EOD> A Proton-Coupled Folding in the Photosystem II Reaction Center Studying Proton and Electron Transfer Reactions\n\nRecombinant photosystem II ( PSII ) reaction center ( RC ) was reconstituted with cytochrome c 6 , and the fluorescence and EPR spectra in the S 2 state were monitored at various pH values. The fluorescence changes in red light were strongly dependent on pH, and the changes in the oxidized RC were similar to that in the oxidized protein in buffer at neutral pH. On the other hand, the pH dependence of EPR spectral changes in PSII RC was very different from that in the isolated RC . The proton-coupled folding in S 2 state is suggested. The PSII RC prepared in the membrane environment was found to have properties similar to that in solution. It is suggested that the PSII RC functions in the membrane environment. We also reconstructed PSII RC with a new cofactor CP43-His which is prepared using the expression of an ampicillin resistant gene. The RC reconstituted with CP43-His was used for cryocrystallography and the structure was determined by an electron crystallography.\n\n# Introduction\nThe PSII RC is a complex protein structure which is located within the membrane. The PSII core complex is comprised of the Mn",
        "label": 1
    },
    "531": {
        "output": "### <span>12 26. You should think about the following steps:</span><h5>Checklist for Task 26</h5> \n\nHere is a complete list that shows the steps for this task.\n\n1. \u2468 Check whether each test case satisfies the Inclusion criteria. (1000 test cases: 3 failures in total) 2. \u246a Make sure that the program outputs the 3-valued, trial-level judgment for the given patient. 3. \u246b Make sure that the program outputs the 3-valued, trial-level judgment for the patient in all test cases. 4. \u246c Make sure that the program outputs the 3-valued, trial-level judgment for all patients within a trial. (Note, the patient in a trial with a small number of patients may not be evaluated.)\n\n## 27. You need to check the following:</h5>\n   - [task 27](task.md/27) \n    - Checking the correctness of the patient report generation program for the clinical trial. \n    \n### <span>13 27. Check the following:</span><h5>Checking the correctness of the patient report generation program for the clinical trial.</h5>\n  \n```python\ntask_27 = get_task(\"task.md/27\")\n\nresult = {\n    \"status\": \"OK\",\n    \"log\": \"\",\n    \"test_case\": \"All\",\n    \"comment\": \"\"\n}\n\ntry:\n    task_27.run(result)\n    result.update({\"status\": \"OK\", \"comment\": \"\u2713 Clinical trial report generation function checked.\"})\nexcept NoResult:\n    result.update({\"status\": \"FAIL\", \"comment\": \"\u2713 Clinical trial report generation function not run\"})\n```\n\n### <span>13 28. You will have to find which subpackage this task belongs to.</span><h5>Find which subpackage this task belongs to.</h5>\n  \n```python\nimport task\ntask.subpackages[\"name\"]\n```\n\n### <span>14 29. Here you",
        "label": 0
    },
    "532": {
        "output": "__Author(s)__ [<NAME> and <NAME>](1998-05-05)\n__Abstract__ Elucidate the clinical course of 4 individuals with a known gene encoding LIPA who underwent LIPA gene transfer for LAL deficiency. We studied the clinical course of 4 individuals enrolled on the National Institutes of Health/National Heart, Lung, and Blood Institute trial for LIPA gene transfer for LAL deficiency.\n\n[/ABSTRACT]\n\n### ClinVar\n__Unique identifier__ LIPA_298728.\n__Chromosomal location__ 2p23.2.\n__Gene name__ lysosomal acid lipase.\n__Gene description__ The lysosomal acid lipase (LIPA) gene encodes an enzyme catalyzing the hydrolysis of cholesteryl esters and triglycerides. This gene is located on the short arm of chromosome 2 in a region frequently associated with myocardial infarction, high plasma triglyceride concentrations, and hypercholesterolemia. Polymorphisms in this gene are associated with early onset and severe atherosclerosis that leads to heart attacks, stroke, or peripheral arterial disease at a young age. Multiple transcript variants encoding different isoforms have been found for this gene.\n__Locus reference number__ MIM: 278040.\n__Gene symbol__ LIPA.\n__Mutation_location__ chr2(GRCh37).2:140054103-140056183-NC_000002.11.\n__Mutation_type__ Pathogenic variant.\n__Reference nucleotide change__ c.\n\n### Locus Reference Genomic Database\n\n__Gene symbol__ LIPA\n\n__Chromosome__ 2\n__Contig_number__ NC_000002.11\n__Ensembl_number__ ENST00000320388.6\n__Mutation_type__ Nonsense",
        "label": 0
    },
    "533": {
        "output": "You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\nHere is the patient note:\nThe candidate of 49-year-old male came to the laboratory for an interview and a review of his labor",
        "label": 1
    },
    "534": {
        "output": "<EOD> An improved procedure for sequencing the 5' untranslated region and coding regions of retroviruses using a cloning step\nWe describe an efficient scheme for sequencing the 5' untranslated region (5'UTR) and coding region of murine leukemia viruses using the recombinant DNA T/A cloning system. One of the two products from 5'UTR and coding region amplicons is blunt end ligated to pUC18 vector using the 3' addition DNA fragment length polymorphism method. The cloned fragments were transformed into Escherichia coli (DH5 alpha) by the standard calcium chloride method. Colonies that grew after electroporation in liquid medium on Luria-Bertani (LB) agar medium with 100 micrograms/ml tetracycline contain one clone. After isolation, the recombinant containing pUC18 plasmids were sequenced by the dideoxy chain termination method with T7 sequencing reagents.<EOD> Diversity of Ciliates (Alveolata: Ciliophora) in an Arid System with Saline Water in Iran\n\nThe diversity of ciliate species in a hyper salinity (54) waterway of the Zayandeh Rud River in Yazd Province, Iran, was determined monthly from July 2012 to June 2013. Ciliates were found distributed throughout the year in the study locality. The Shannon-Weiner diversity index (H' ) and dominant/evenness (E) were highest in spring (6.0, and 1.31 0/0.50) and lowest in winter (3.3, and 0.48). The greatest diversity and dominant species occurrence during the period was in April, while the lowest were in March. A total of 1,064 specimens of ciliates were found, of which 34 taxa were reported, including 22 Protista and 4 Protozoa (41.6%, 33.3%, 13.3%, and 11.6%, respectively), with 23, 10, and 1 species belonging to the classes Oligohymenophora, Kinetoplastea",
        "label": 1
    },
    "535": {
        "output": "<EOD> Identification of two potential peptide inhibitors of the interaction between nucleocapsid protein and RNA: a molecular dynamics study\nRanvir1, Ranvir2, PB1, and PB2 domains can form the RNA binding domain of N protein. The C\u2010terminus of PB1 (Ranvir3) domain can be used to identify peptide inhibitors of N protein\u2010RNA, which have the ability to resist the SARS\u2010CoV infection. The purpose of this study was to investigate the mechanism and the binding energy of the peptide inhibitor for the Ranvir3 domain. In the simulation system, the amino acid residues in the peptide are all flexible atoms, and the backbone atoms of Ranvir3 are constrained to a specific geometry. In addition the force fields used for peptide are Amber99SB, the force fields for other atoms are Amber99SB\u2010ILDN. For simplicity, the initial conformations were chosen from the Protein Data Bank (PDB). These peptides were Ranvir1 (1w64), Ranvir2 (2c7p), PB1 (Ranvir3) (2c7p), and PB2 (Ranvir3) (2c7p). The initial structures were energy minimized and preprocessed. The 10\u2010ns steered\u2010molecular dynamics simulations were used to get the potential energy and potential well\u2010depth between peptide inhibitor and Ranvir3. We found that the potential energy (<5.0 kcal/mol) and the potential well\u2010depth (0\u20132 \u00c5) for the last 1 ns of simulation are not much different, which showed that the equilibrium state for the Ranvir3\u2010peptide inhibitor system may be reached at about 2\u2010ns simulation. The results suggest that both Ranvir1 and Ranvir2 have the potential to be potential inhibitors, but PB1 and PB2 only have the potential to be peptide inhibitors of Ranvir3. Our findings will provide a theoretical basis for the discovery of peptide inhibitors of Ranvir3, and will provide good theoretical basis for the development of future peptide vaccines. Proteins 2015; 83:1784\u201317",
        "label": 2
    },
    "536": {
        "output": "##[END]\n\n## Assigning a score\nYou can simply assign an integer score to the data element values, i.e., assign value \n0) Not relevant, \n1) Excluded, and \n2) Eligible.\nHowever, many times you want to calculate the score or the grade of this triallevel eligibility. \n\n### Definition\n   \n \nThe score of subject is an integer number which represents the evaluation result of subject. The integer number of subject is computed by the formula as follows:\n   \n   \n### Formulas\n  \n![A formul of subject-level eligibility score:](../../../../images/ui-elements/diagram/medication-overview-diagram.png)\n\n\n\n### Examples\n\nBelow the subject-level eligibilty definitions of patients and a clinical trial are given:\n```python\ndata_dict['Subject-level eligibility scores'] = {\n    'Subject-level eligibility score_ID': [\n        # Patient-level eligibility definition\n        [{'ID': 2, 'DataType': DataElementDef.DATA_TYPE_NUMERIC, 'Value': 2, 'Units': 'Number'}],       \n        # Clinical trial-level eligbility definition\n        [\n            {'ID': 0, 'DataType': DataElementDef.DATA_TYPE_NUMERIC, 'Value': 2, 'Units': 'Number'}, # Excluded\n            {'ID': 1, 'DataType': DataElementDef.DATA_TYPE_NUMERIC, 'Value': 1, 'Units': 'Number'}, # Not relevancy\n            {'ID': 2, 'DataType': DataElementDef.DATA_TYPE_NUMERIC, 'Value': 2, 'Units': 'Number'}, # Eligible\n        ],  \n    },    \n}\n```\n\nFinally, subject-level eligibility score of an instance can be calculated by the formul as follows:\n```python\ntrial_instance.subject-level_eligibility_score.subject_level_eligibility_score \n= eval_data_dict['Subject-level eligibility scores']['ID'].map(eval_",
        "label": 1
    },
    "537": {
        "output": "![ ](/images/inst/screen1.png)\n\nIf the data is incomplete or inconsistent, the patient should be excluded from the trial. You should write such a patient's record in terms of:\n- Trial-level eligibility: Excluded.[INST]\n- Study number: A unique patient identifier generated for each patient when the trial begins. This is a random number generated by the program.[INST]\n- Participant's age in years.[INST]\n- Participant's sex: M for males and F for females.[INST]\n- Participant's ID: A text box for the inclusion of notes on the patient in free text box of your database. [INST]\n- Trial-end date: The date when a patient finished all trial-relevant activities. It should be the same as the date in the trial. [INST]\n\nIf you need to enter more patients, we advise you to create new worksheets and use the information in the cells of each row to fill in a new patient data. You can use the cell 'A1', where the first patient will be inputted. Please notice that this will also input the new patient into the patient list by clicking `Save`. If you are ready to continue with the information of the next patient, change the cell 'A1 ' in the new empty spreadsheet, so that the next patient gets an individual trial number. \n\n\n\n\nWe believe that this is the last step for you and your efforts so far. Now, you should do the following three things:\n1) Save the trial worksheet.\n\n2) Save all worksheets used for the creation of this trial (either as part of the initial spreadsheet used for the creation, or as new spreadsheets created during the editing process as described above).\n\n3) Export the trial to a .csv file.\n\n<EOD> Cationic ruthenium complexes as a robust catalyst for direct oxidation of methanol to formaldehyde\n\nA cationic ruthenium complex [Ru(3,5-L 2 pz)(Cl) 2 (py) 2 ]Cl [3,5-L 2 pz: diphenyl-5-(2hydroxypropyl)pyrazole, (Hpzpy) 2 ; py: pyrid",
        "label": 1
    },
    "538": {
        "output": "If you have more than one candidate for the trial note, you should write the trial-level eligibility to each patient as same.\n\n## [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\nNow we are going to compare only the patient A. 5002.014.02.\nLet's calculate the Trial-level eligibility for each patient.\nWe calculate the Trial-level eligibility for each patient. The first factor of the equation is the clinical trial factor, i.e., clinical trial_factors for patient 5002. You can refer to Appendix A-3 for the list of clinical trial factors, i.e., Inclusion criterias. [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n## [INST] hello. You are a helpful assistant for clinical trial recruitment. your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. the factors that allow someone to participate in a clinical study are called inclusion criteria. they are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\nWe calculate trial_factors, i.e., inclusion criteria for Trial 2 at the time of patient enroll, from Trial 1 to Trial 3. \nIf the clinical trial factor is not met, then continue calculating with the next clinical trial factor in the patient. \nThe second factor of the Trial-level eligibility equation is Clinical trial",
        "label": 1
    },
    "539": {
        "output": "### 2) `Labeled for the patient(s)`\nThe patient has a 50% stenosis (as determined by ultrasound or angiogram) of the common or internal carotid artery and is clinically symptomatic; i.e., within the previous 180 days has experienced symptoms in the ipsilateral carotid artery distribution, characterized as defined by the following clinical events (i.e. one or more of the following):\none or more TIAs, characterized by distinct focal neurologic dysfunction or monocular blindness with clearing of signs and symptoms within 24 hours, or\none or more completed strokes (as defined by this protocol) with persistence of symptoms or signs for more than 24 hours (the most recent event is used as the qualifying event), or\none or more Transient Ischemic Attacks within the past 180 days.\n(Note: To be entered into the study, a patient must have one or more of the following conditions:\ncongestive heart failure (class III/IV) and/or known severe left ventricular dysfunction LVEF < 30%\nopen heart surgery within the previous six weeks\nrecent myocardial infarction (>24 and <4 weeks)\nunstable angina (CCS class III/IV)\nsynchronous severe cardiac and carotid disease requiring open heart surgery and carotid revascularization\nsevere pulmonary disease to include any of the following:\nchronic oxygen therapy\nresting PO2 of 60 mmHG\nbaseline hematocrit 50%\nFEV1 or DLCO 50%  of normal.)\nAnd the inclusion criteria are described as follows:\n\nInclusion Criteria:\nThe patient must be > 18 years of age.\nThe patient has a 50% stenosis (as determined by ultrasound or angiogram) of the common or internal carotid artery and is clinically symptomatic; i.e., within the previous 180 days has experienced symptoms in the ipsilateral carotid artery distribution, defined as:\none or more TIAs, characterized by",
        "label": 1
    },
    "540": {
        "output": "# The `Trial_level` command\nThis function is also included in [the `experiment.jl` package](https://experiment.julang.org/latest/), which you can explore using [juliaxplore](https://rubenssousa.github.io/juliaxplore).\n\n`Trial_level(` trial`, name_patient`) `<EOD> Differential expression of the 110-kD protein of the glutamine synthetase/glutamate synthase cycle in relation to the endocytosis of nitrogenase in Azotobacter chroococcum 18\nThe 110-kDa protein of the nitrogenase/glutamine synthetase (GS110) cycle, which is an important regulator of nitrogen fixation in Azotobacter species, was found to be differentially accumulated under varying nitrogen sources. Expression of the gene encoding the 110-kDa subunit was positively responded to the exogenous supply of the preferred nitrogen source (NH4+ and NO3-), but the amount of GS110 synthesis was diminished or even blocked when alternative nitrogen sources (pyruvate and citrate, the products of incomplete carbon fixation, nitrite , and N2, which are nonpreferred nitrogen sources) were added to A. chroococcum 18. The expression of glnA3 (encoding the nitrogenase large subunit) was induced under the same conditions as that of glnA1 (encoding GS110), but its expression required ammonium ion as the sole nitrogen source in combination with other nitrogen sources. The expression of nitrogenase, in particular, the large subunit of nitrogenase and nitrogenase activities, was inhibited in A. chroococcum 18 cells in the presence of nonpreferred nitrogen sources. GlnA1 is not essential for the nitrogenase cycle, since A. vinelandii nitrogenase was active even in the absence of GS110, which suggests that GS110 is not involved in the endocytosis of nitrogenase. The GS11",
        "label": 1
    },
    "541": {
        "output": "##### Part 4: Case 2\nIf a patient is excluded from the CAD+CAS+CABG clinical trial, you need to determine the reason.\nIn this section, you need to identify the main reasons for exclusion from the trial. Remember: each patient can be excluded from the study owing to multiple criteria.\nPlease think about how to proceed:\n\n1. Click the button \u2018Show Reasons (Exclusion)\u2019 by clicking at the button \u2018Case 2\u2019 at the upper right area of the screen.\n\n2. The page opens.\n\n3. Click the button \u2018Show Reasons (Exclusion)\u2019.\n\nThis case is a 28\u2010year\u2010old man who was diagnosed with non\u2010ST elevation myocardial infarction and CAD. He had normal baseline parameters. His CAD screening test revealed coronary artery stenosis < 50%. However, his heart echocardiography revealed mild hypokinesia of the basal and mid\u2010section of the inferior wall and mid\u2010portion of lateral wall (left ventricular ejection fraction is 56%).\n\nAs a result of the clinical trial assessment, case 2 was excluded. Because the patient didn't have coronary artery stenosis which exceeded threshold and his CAD screening test revealed coronary artery stenosis < 50%, the patient was excluded from the clinical trial.\n\nWhen there are no issues for the CAD and CAS patients, all conditions in the patients are normal, except mild hypokinesia of the basal and mid\u2010section of the inferior wall and mid\u2010portion of lateral wall (left ventricular ejection fraction is 56%). As a result of the clinical trial assessment, case 2 was excluded. Because the patient didn't have coronary artery stenosis which exceeded threshold and his CAD screening test revealed coronary artery stenosis < 50%, the patient was excluded from the clinical trial. \n\n![](https://github.com/taiwanclinicaledu/TAILOR/blob/main/inst/images/case2_inst4_result.PNG)\n\n##### Part 5: Case 3",
        "label": 1
    },
    "542": {
        "output": "Now, let's try it out. \n! [IMAGE: patient note and trial]( /manual.pdf ) \n\n![IMAGE]( /manual.pdf)\n\n<EOD> The Role of Lysine-Acetylation Pathways in Adipose Tissue Physiopathology\n\nChronic exposure to a negative energy balance induces severe physiopathological changes in adipose tissue, leading to a disruption of brown adipose tissue activity or white adipose tissue dysfunction. This phenomenon is particularly exacerbated in obesity, and may contribute to the emergence of metabolic disorders such as insulin resistance, type 2 diabetes, hepatic steatosis. Adipocytes are metabolically active cells whose gene expression, posttranslational modifications and adipokines secretion are constantly regulated, particularly at the post-translational level. Lysine acetylation is one of the posttranslational modifications that has arisen as a crucial regulator of gene expression. Indeed, the acetylation/deacetylation of histones, non-histone nuclear proteins, or proteins in the mitochondria, can alter gene expression and metabolism. Importantly, several genes of energy sensors are regulated through this pathway. Recently, adipocyte metabolic and endocrine functions have been shown to depend upon lysine acetylation, notably in the context of obesity. In the present review, we will discuss the role of specific enzymes involved in lysine acetylation and its consequences on adipose tissue metabolic disorders.\n\n# Introduction\nAdipose tissue plays an important role in energy homeostasis. When the energy requirement is not covered by food intake, the adipose tissue reserves are the primary site of lipid mobilization that ensures the survival and the physical function of the body. The process of lipolysis is tightly regulated and depends on the activity of two lipases in different compartments: in the cytosol of adipocyte, the hormonesensitive lipase (HSL) and in the adipocyte's inner membrane, the adipocyte triglyceride lipase",
        "label": 1
    },
    "543": {
        "output": "This is the input file for our tool: \nThis is the output:\n\nThe patient has a LDL-C level of 545. Hence, the patient has a CHD condition. \nThis patient does not meet the inclusion criteria of the clinical trial in , because the patient does not have enough information to qualify for the trial. \nThe patient can enroll in the clinical trial in , although there are some exclusions to consider. Thus, atorvastatin-first is excluded because of treatment with statins. Because the patient takes no antiplatelet agents, exclusion 9 (use of antiplatelet agents) is true. The patients is excluded by exclusion 23 (hypertriglyceridemia), because the patients had a triglyceride level of 208.5 and 158, which exceeds the limits of 400 and 250 for men and women. Similarly, exclusion 3 applies because of the patient's age.\nThe patient would be eligible for one of the SB-480848 intervention groups. As atorvastatin 20 mg/day is not appropriate, the patient would be excluded from the placebo group and, hence, would be eligible for the higher atorvastatin (80 mg/day) and, therefore, is eligible for both SB-480848 dose categories. The patient has no exclusion for either dosage level. And finally, the patient is excluded from SB-480848 160 mg/day because of the previous inclusion, i.e., the patient has taken atorvastatin before, which is an exclusion of SB-480848 160 mg/day.\n\n# Discussion\n\n## Experimental results\nWe are developing our tool for practitioners who are not in the specific niche of lipidomics but use clinical trial recruitment services. If there is any need for improvement, either in functionality or an easy-to-use interface, we will improve our tool in the future. The functionality is based on the fact that clinical trial inclusion criteria cannot be formulated in a simple way. Therefore, we provide functionality to extract all inclusion",
        "label": 0
    },
    "544": {
        "output": "#### [EXERCISE #3]\n\nAssess eligibility for each patient from **Step 3** with the following inclusion criteria. The patients who meet all the conditions for inclusion must be assessed as eligible for the clinical trial. Your answers should follow this format: \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 45-year-old woman presents with dizziness and frequent headaches. She has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's total cholesterol and HDL-C levels were 265 and 80\u2009mg/dL, respectively. Her fasting glucose and triglyceride levels (81 and 196\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed moderate stenosis in the left internal carotid artery (LICA),  as well moderate stenosis in the right internal carotid artery (RICA), estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was noted in anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic with uneven surfaces.\nHere is",
        "label": 2
    },
    "545": {
        "output": "<EOD> Mentoring in medicine: a literature review.\nOBJECTIVE\nThe objective of this review is to summarise the evidence for effectiveness of formal and informal mentoring interventions in medicine in relation to the key themes of confidence, career advancement, team working and satisfaction.\n\n\nDESIGN\nA selective literature review of peer-reviewed English language studies was undertaken, examining formal and informal mentoring in medicine. The electronic databases MEDLINE, CINHAL and PsychINFO were used, supplemented by a hand search for key sources. A range of search terms were used including 'mentoring', 'intervention' and 'medicine'.\n\n\nRESULTS\nThirty-eight peer-reviewed articles were identified. Informal mentoring is popular and provides a way of passing on important aspects of life in general, as well as medical practice. A number of authors report significant benefits for the mentoring relationship including an increase in confidence, satisfaction with career progress, increased understanding of working relationships, teamwork and communication, as well as improvements in job satisfaction. Formal mentoring is less well supported in relation to improvements in confidence and career progress, but formal mentoring can increase understanding of career progress and teamwork and has a more even distribution of benefits, as opposed to the more polarized relationship inherent in an informal mentoring system.\n\n\nCONCLUSIONS\nMentoring is an intervention that provides an opportunity for one person to receive guidance, support and encouragement from another. It is thought to help an individual realise his or her own potential, so it can be considered to be a way of helping people to maximise their own and their organisation's potential.<EOD> .\nIn an open randomized trial with 75 patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS) the clinical and immunological efficacy and safety of treatment with azathioprine (A) (50-150 mg/d) and sulphasalazine (S) (2-4 g/d) was compared over periods of 3 up to 12 months between 1983 and 1991 in accordance with predefined inclusion and exclusion criteria. Twenty-two patients had RA (sickness duration 1-124 (mean 1",
        "label": 0
    },
    "546": {
        "output": "--Kaldi - 21:05, 24 November 2021 (UTC)\n\n[edit] Patient note\n(Parts should start with a lowercase letter.)\n\n[edit] [TRAIN] Hello. You should be an assistant for a medical doctor in a clinic. Your task is to help the medical doctor in a clinic in filling a form for each patient.\n\nA 60-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.",
        "label": 1
    },
    "547": {
        "output": "## Good\n[table]  1: In this example, we want to determine eligibility for 1 clinical trial. Here, 2 lines are shown, in which the first line shows inclusion criteria, and the second line shows exclusion criteria. How will you perform the eligibility? There can be 2 results for 2 lines. What are the two possible results for this trial? Please explain your answer. (2) If, for a given clinical trial, there are no exclusion criteria, what does the statement `1) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria)` mean? What is the reason for exclusion for the patient? Please explain your answer. (3) Why are inclusion and exclusion criteria used to decide whether to participate in a clinical trial? Please explain your answer.2. Please do the following steps and explain to us in detail. (20 points) [/table] \n[table]  2: 002-02301083, [/CODE] [/table] \n<EOD> In search of the cerebral bases of the \u2018moral\u2019 impairment in frontal lobe injury\nSynthesizing evidence from neuropsychology and functional neuroimaging, we review how empathy, compassion, and social cognition contribute to moral decision making. We then contrast how emotional reactivity in response to others' distress and normative emotional responses to moral transgressions are related to moral awareness, and consider how different forms of moral reasoning are influenced by motivations to feel empathy, rather than being intrinsic. Building on research in patients with focal brain damage, we develop psychological hypotheses as to how the frontal lobes contribute to moral reasoning and decision making. We review a broad range of neuropsychological data to support the view that the frontal lobes support moral reasoning by providing cognitive maps of the world, generating feelings of moral empathy in response to others' distress, and generating and implementing complex scripts of moral behavior in response to abstract moral codes; these functions map onto different subregions of the frontal lobe. Converging evidence from emotion imaging (fMRI) reinforces the idea that the same frontal regions (dorsomedial and dorso\u2010anterior regions) show different patterns of",
        "label": 0
    },
    "548": {
        "output": "<EOD> A Novel Antifungal Effect of Human Complement C1q on Human Fungal Pathogens\n\nThe human complement components C1q, C3, C4, and C5b-9 are a part of innate immune defense, and they all exert antimicrobial properties but their antifungal activities towards human fungal pathogens are unclear. In this study, we found that C1q was a powerful antifungal effector, exerting in vitro inhibitory effects not only on the growth of yeast but also on filamentous fungus, in particular Aspergillus fumigatus and Candida albicans . Interestingly, the yeasts Candida orthopsilosis, Candida glabrata, Cryptococcus neoformans, and Candida auris were less sensitive to C1q than were Candida albicans and Aspergillus fumigatus. The antifungal activity of C1q against C. albicans and A. fumigatus was strongly dependent on its binding to the polysaccharide glucan of the fungal cell wall, and the effector could induce morphological changes in these two fungal species. Taken together, we propose that C1q is a novel antifungal effector of the complement system.\n\n# Introduction\nComplement is a part of innate immune response, recognizing invaders and mediating defense against them through three pathways: classical, alternative, or mannose binding lectin [bib_ref]  The complement system, Sarma [/bib_ref] . The complement system exists in various invertebrate and vertebrate species, the latter displaying multiple and very complex defense mechanisms for the elimination of invading pathogens [bib_ref]  The complement system, Sarma [/bib_ref] . In mammals, once the complement system recognizes invaders, it activates three main complement-derived effector molecules: opsonins, antigenspecific adaptive immune response activation and recruitment, and cell-cell lysing, membraneattacking complexes, termed C5b-9 [bib_ref]  The complement system, Sarma [/bib_ref] . These components serve the host organism by tagging pathogens for uptake by phagocytes (opsonins), by activating the adaptive",
        "label": 2
    },
    "549": {
        "output": "## Good Job!\nNow you can check your code in `Patient` with [INST].\n\n# Challenges #\n\n# Additional Information #\nFor instructions or more information on contributing to Julia, please see CONTRIBUTING.md and the Julia documentation at Julia.org.\n\n# License #\n\nThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/.\n\n# Authors and Contributors #\n**Takashi Shimokata** -- https://github.com/takashishimokata/julia/commits/master/Journal/20200320205156/\n\n# Citation #\n[https://onlinelibrary.wiley.com/doi/full/10.1111/j.1600-0463.2018.00062.x]\n<EOD> \nDuring the 1987 to 1991 period, a series of surveys was performed in the area under the administration of the Health District of Pau (600,000 inhabitants). All the patients hospitalised for malignant, benign or unknown colorectal tumours were recorded and data were analyzed by age, sex, and tumour site, diagnosis and treatment. The incidences were adjusted to the 1983 WHO European standard population and compared with worldwide colorectal tumour incidences. The incidence of malignant colorectal tumours was compared with incidence estimated in France since 1990. The standardized incidences of colon and rectosigmoid cancer, with 809 cases, was 61.5 and 16.9 per 100,000 for females and 56.1 and 11.9 per 100,000 for males, respectively. For the colonic tumours the standardised incidence decreased for young people while it was not significantly different for the rectosigmoid. In",
        "label": 1
    },
    "550": {
        "output": "<EOD> A novel mutation in the bovine prion protein gene associated with BSE\nPRNP mutations have been identified in human, sheep, goat, mink, elk and moose PRNP-related cases of Transmissible Spongiform Encephalopathies (TSE). In most reported cases of BSE and Creutzfeld-Jakob disease, wild-type PRNP was identified. The aim of this study was to investigate the mutations in bovine PRNP gene related to the TSEs in cattle in Japan. A total of 230 tissue samples were analyzed. The sample types were brain, heart, lung, liver, kidney, spleen, pancreas, tonsil, muscle, lymph node, thymus, adrenal gland, and mammary gland. There was no specific characteristic on the gross observation in the tissue samples. DNA was extracted from each sample. PRNP genes were amplified by the polymerase chain reaction, and subjected to direct sequence analysis. The nucleotide sequence in the first exon of PRNP was determined. A novel mutation of arginine to threonine at codon 210 (210T) was found in BSE and scrapie. The 210T mutation was identified in all three BSE and one scrapie. The 210T mutation was observed in the oldest cow and may be related TSE. In scrapie, the 210T mutation was observed in only 2/4 cows and 2/3 sheep. This indicated that this genotype had not expanded the populations in the case of scrapie. The 210T mutation was not observed in TME, CSE, or normal cattle. The 210T mutation, which was identified in the three BSE cases, may be a new mutation. The 210T mutation would be selected during the transmission via oral infection. It may be necessary to continuously study the occurrence of this mutation.<EOD> The Effectiveness of a Dental Health Education Programme in Changing the Oral Hygiene Behavior of People Living With Disabilities\n\nThis study aimed to evaluate the effect of a three-month dental education program on the oral health behavior of people living",
        "label": 1
    },
    "551": {
        "output": "[/MAIN]    \n\nGood luck.\n<EOD> Association of HLA-B Alleles with Response to Interferon-\u03b1/Ribavirin Therapy in HIV-Infected Hemodialysis Patients with Hepatitis C Virus Coinfection\nSummary. Interferon-\u03b1 is used in the treatment of hepatitis C virus (HCV) infection in hemodialysis patients, but there are problems with low efficacy and the development of side effects, so novel approaches to personalized treatment are required. The objective of this study was to assess the utility of HLA alleles as a prognostic marker of the efficacy of interferon-\u03b1/ribavirin treatment for HCV-coinfected HIV patients receiving hemodialysis therapy. The subjects were 32 hemodialysis-treated, HIV and HCV coinfected patients classified into responders (n = 21) and nonresponders (n = 11) on the basis of virologic response at the end of treatment with interferon-\u03b1 plus ribavirin. Serum HLA class I (HLA-I) and HLA class II (HLA-II) antibody levels, HLA-A, -B, -DRB1, and -DQB1 genotypes were determined. A significantly lower frequency of the HLA-B57*01/*02 allele was detected in responders compared with nonresponders (76.2% vs. 90.9%; OR = 4.22, 95% CI = 1.08\u201316.6, p = 0.039). The frequency of the B*57 allele (B*5701 and/or B*5702) was significantly decreased by 69.2% (OR = 4.48, 95% CI = 1.05\u201319.1, p = 0.042) in the responder group compared with the nonresponder group. There was also a tendency toward a reduction in the risk of nonresponse with the presence of HLA-B*57 (OR = 5.73, 95% CI = 0.76\u2013",
        "label": 1
    },
    "552": {
        "output": "<EOD> .\nTetracyclines(Tc) are widely used in animal production, but the long half-life (t1/2 > 10 hours) in blood and environmental persistence (highly adhered to sediment) are the main source of its long biological activity. This paper summarized the latest research results of Tc degradation under environmentally relevant conditions, including the effects of co-existing substances, light, sediment degradation technology, and advanced oxidation process (UV/H2O2, Fenton, Fenton-like/peroxysulfate, photocatalysis). The present paper also summarized the recent progress of Tc degradation under different experimental conditions, and the current research status and bottlenecks facing the Tc degradation were discussed. The future research directions were proposed to strengthen the Tc degradation techniques and broaden the practical application scopes of this technique.<EOD> Evaluating the Use of Rapid Molecular Diagnostic Tests in Resource Limited Settings: A Cross-Sectional Costing Study in Three African-Preference Countries\n\nBackground: Reliable diagnosis of infectious diseases is vital in the treatment of patients and the control of outbreaks. Increasing demand for malaria diagnostics in sub-Saharan Africa (SSA) has led to rapid market growth of novel testing alternatives. In this study, the objective is to evaluate whether malaria diagnostics in SSA could be improved by replacing traditional rapid diagnostic tests (RDTs) with novel molecular and advanced lateral flow techniques.Methodology/Principal Findings: We conducted a cross-sectional study in Burkina Faso, the Democratic Republic of the Congo and Zambia, using key informant interviews, workshop observations and facility inventories with 480 patients drawn from 49 public health facilities. Each facility was visited independently by researchers or other staff for data collection. In addition we performed expert focus group discussions. The costing methodology is micro-costing and micro-costing of the testing algorithm. The average cost and total annual costs for RDTs were (225.54 USD, and (122,534.16 USD) respectively, using current standard prices. Capital costs for the initial (bout",
        "label": 2
    },
    "553": {
        "output": "#### Acknowledgements\nThe following people helped with code:\n\n* <NAME>, <NAME>, <NAME><NAME><NAME>, <NAME><NAME>, <NAME><EOD> In vitro antioxidant activity of phenolic compounds of cumin and ginger\n\nAntioxidants are the substances that can prevent or stop the oxidation process by neutralizing the reactive oxygen species (ROS) or free radicals produced in living systems by the natural metabolism. In this study, the antioxidant activity of different fractions prepared from the extracts of cumin (Cuminum cyminum) and ginger (Zingiber officinale) was analyzed by 1,1-diphenyl-2-picrylhydrazyl (DPPH), 2,2'-azino-bis-(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) radical scavenging assay and Fe 2+ chelating assay. The phenolic compounds present in the extracts were also determined by Folin-Ciocalteu method.Results indicated that gallic acid in cumin seed extract had the highest antioxidant activity. In addition, all the tested fractions of cumin seed extract except that from butanol fraction were shown to have higher RSA and stronger chelating effect of Fe 2+ than the tested fractions of ginger, in the tested concentrations. The concentration of phenolic compounds in the cumin seed and rhizome extracts were also analyzed and determined, respectively. The results indicated a significant positive correlation between the RSA of the cumin seed and rhizome extracts and the concentration of total phenolic compounds (r=0.747, p<0.05 and r=0.878, p<0.01) as well as between the concentration of total phenolic compounds and the concentrations of gallic acid (r=0.857, p<0.01 for cumin seed extract and r=0.944, p<0.01 for ginger root extract) and caffeic acid (r=0.816, p<0.01 for cumin seed and r=0",
        "label": 1
    },
    "554": {
        "output": "##[FIN]\nLet's look at the same patient in another trial:\nTitle: Effects of Simvastatin on Progression and Reversibility of Brachial Artery Remodeling\nIn the same manner above, calculate Trial-level eligibility, e.g., Trial-level eligibility: 1) Eligible.\n[INST]\n\n## The score data representation\nOnce you have prepared the eligibility report, it is time to represent the eligibility score. The scores should be summarized in a way that they can be easily understood. We have already calculated eligibility scores in the previous sections, and here, we will illustrate how to analyze them and present them to a recruiting team. We will now see how to prepare the score.\nRecall that the score is calculated based on the eligibility assessment report. The scores are categorized based on the evaluation, the status of the patient in the clinical trials. There is a separate score for each trial, which means that the scores will differ by trial. The score will become one (1) if the subject is not eligible for the trial, and it will become the sum of the scores corresponding to the factor that determines whether the patient is eligible.\nIn the clinical trial shown in Figure 1, there are several different groups of scores; groups 1-5. The score for the inclusion criterion is given here, and the evaluation of each group is discussed below.\n\n### Group 1 ###\n\n### Group 2 ###\nAll the patients who are under 680 years of age are scored in group 2. There are two patients in this group, which will be scored with 100:\n\n### Group 3 ###\n\n### Group 4 ###\nAll the patients who have a CVD but has not received prior CVD treatment other than aspirin are in group 4. There is only one patient in this group.\n\n### Group 5 ###\n\n### Group 6 ###\nAll the patients who are using anticoagulant therapy are in group 6. According to the evaluation, the patients on warfarin therapy are scored with 30, and the patients using the therapeutic enoxaparin are scored with 60.\nAll the patients",
        "label": 1
    },
    "555": {
        "output": "T = triple\n\n\nI = int\n\n\nV = single\n\n\nE = double\n\n\n\nLet's show all the necessary details to make an inclusion decision. To do it, you have to follow the rules explained below. \nFirst, you need to check which criteria are not met. For this, you need to test for a triple of the next type \n\n```\nIF(A $ & B % & C > 0)\n```\n \nSecond, you have to test the double IF statement \n\n```\nIF(A < $ & B < $) OR (A > $ & B > $)\n```\n\nYou will then compare the conditions. You need to test the IF statement in four cases with single, double, triple, and quadruple. For that, you have to write a switch case statement. \n\n```\nSWITCH (A % & B & C && & D & E && & F & G & H)\n\n```\n\nThe following rules have to be maintained. The patient must meet the condition for at least one time.\n- Whenever `OR` is evaluated as true, one of the two expressions must be true.\n- Whenever `AND` is evaluated as true, both expressions must be true.\n```\nSWITCH (A % & B & C && & D & E && & F & G & H)\n\n```\n\n<EOD> Requirement for the p21 tumor suppressor in c-jun-mediated oncogenic conversion.\n\nEvidence indicates that c-Jun activates oncogenic pathways by binding to the AP-1 transcription element and subsequently displacing p21 from a p300-DNA complex. Here we show that p21 knockout mice are prone to develop sarcomas, similar to mice lacking c-Jun. c-Jun deficiency alone is insufficient to induce any form of tumors, suggesting that p21 is required in the tumorigenic process. Thus, we provide genetic evidence showing the importance of p21 for normal function of c-Jun.Cell cycle inhibition is a key process in prevention of tumor formation. It has been demonstrated in diverse cell culture and animal studies that loss of key regulators of cell cycle in",
        "label": 1
    },
    "556": {
        "output": "## Making a Trial-level eligibility\nHere is an example of the final report (from trial 10) you can make a list trial-level eligibility for each patient:\n\n# Expectations\n*\nYour patients get high scores from the clinical trials.\n*\nThe average patient has low risk of all-cause mortality.\n*\nThe average patient has low risk of cardiovascular mortality. \n\n## Good Luck \ud83d\udc4d\n\n# Example Trial-level eligibility\n[ [ 'Included', 0 ], [ 'Not relevant', 1 ], [ 'Excluded', 0 ] ] \n\n# Notes\nThis code base will be under Continous Integration (CI) by Travis CI. If your code changes are broken, it will automatically find and fix it before releasing code.\n<EOD> Dangerous gases - an overview.\nFour major toxic substances in the workplace can result in acute symptoms ranging from headache and unconsciousness to death. Hydrogen sulphide causes a respiratory alkalosis, while carbon monoxide binds to red blood cells to produce carboxyhaemoglobin, which cannot take up oxygen efficiently, so blood is unable to get to the brain and other vital organs, resulting in loss of consciousness, coma and death. The main defence against hydrogen sulphide and carbon monoxide is preventative, keeping people out of the chemical's influence by not coming into contact with its source (the release of hydrogen sulphide from a broken gas heater is an example); a well ventilated workplace can also keep levels of these gases below toxic thresholds. Carbon disulphide causes irritation of the mucous membranes and damage to the liver, kidneys and central nervous system. There is no evidence to suggest that it is carcinogenic, so protective equipment is also the main line of defence against this substance. Another common industrial gas is ammonia. Inhaling ammonia results in a bronchoconstrictor effect that could result in death if the breathing is stopped, so it is also prevented from entering the body by careful control of the release of ammonia from the source",
        "label": 0
    },
    "557": {
        "output": "Please note that in some cases, the inclusion criteria might be different for different treatment arms. The reason behind this is that some clinical trials include both treatment and placebo arms to check the efficiency of the drug in relation to a placebo. For example, in case you have included the treatment arms for a clinical trial, one inclusion criterion in the first treatment arm might be the presence of hyperlipidimia for example, while in the second treatment arm, only hypertension would be the inclusion criterion.\n\nSo if you have only one treatment arm, you should include all the criteria related to the treatment arm in the last line by `Trial-level eligibility: `, e.g, `Trial-level eligibility: 2) Eligible.`, otherwise, the patient would be ineligible. For example, if you have just one treatment arm and, in it, hyperlipidimia or low HDL cholesterol would be required as inclusion criteria, you should simply put the line: `Trial-level eligibility: 2) Eligible.` without the `and`. Thus, the criteria for the treatment arm will be used in this particular case automatically.\n\n\n### HOW TO GET A CODE\n\n1. Open the folder for the patient who will be included in the trial \nClick on the **Edit Patient Note** then **Manage Note** \nClick on the code of interest for the trial \nThen right click on the code and select **Copy** and then paste it in the Note Template Editor of the trial that you will create \n\n2. If your trial does not have a code, and you want to create a new trial for the patient, click on the **Trial Note** on the first line. You will notice that at first, you will be shown a message that there is no trial. Click on the \u201c+\u201d button and you will be given an option to either create a new trial or add a condition in an existing trial. The latter option would be applicable for you:\n\nClick on the **Create New Trial** \n\nAfter that you will notice that your trial will be in empty code. You will need to add the code for the trial later.\nClick on the **Create New Trial** \n\n3. You are required to choose an ID of the trial from the dropdown list below",
        "label": 2
    },
    "558": {
        "output": "**Output:**\n\n##### Recursively Assignment of the scale for the assessment of eligibility for each trial.\n\n1) You will recursively assign eligibility score using Python and then transform to 0 for each patient based on the trial ID. \n\n###### Example of output:\n```  \u2026 \n\u2026\nEligibility score: 0\nEligibility: Excluded\n```\n## [Exercises]\n\n## Questions\n\n### Q5: The patient does not meet the inclusion criteria of any clinical trial. How may we obtain patient eligibility score in this case?\n### Q6: Why do you decide the `trial-level eligibility` is finally set to `0`?\n### Q7: Which is your preferred solution for eligibility assessment using the following three approaches:\n\n * Evaluate patient eligibility score on the basis of the eligibility rule-based method\n * Evaluate patient eligibility score using the proposed method (a data table)\n * Evaluate patient eligibility score using the proposed method (a vector)\n### Q8: Let`s consider`0 < trial-level eligibility < 2`to the `patient-level eligibility score < 0 < 2`. What do you expect the patient's eligibility criteria are for the trial you are concerned for?\n### Q9: After you finished step by step of the proposed approach, what shall you do?\n### Q10: In the proposed approach, where did you find patient-level exclusion criteria?\n### Q11: In the proposed approach, where did you find `trial`level exclusion criteria?\n### Q12: Based on each of trials exclusion criteria you found above, what can we conclude?\n### Q13: How shall you find out the patient-level eligibility? After finding out the patient-level eligibility, what do you want to say?\n### Q14: If you want to find out trial-level eligibility for an interested trial, what can you do?\n### Q15: After finding out the `trial-level eligibility = <0>`, what do you want to say from these facts and statements above?",
        "label": 0
    },
    "559": {
        "output": "<EOD> The In Vitro Cytotoxicity and Cellular Uptake of Graphene Oxide\u2014Capped Mesoporous Titania Photocatalysts Modified with Various Types of Surfactants\n\n\n\n# Introduction\nNowadays, photocatalysts in various structures and compositions have attracted much attention of chemists and materials scientists for water splitting [bib_ref]  Heterogeneous photocatalyst materials for water splitting, Kudo [/bib_ref]  , hydrogen production [bib_ref]  Molecular catalysts in photo-fuel conversion materials, Hwang [/bib_ref]  and degradation [bib_ref]  A critical review on enhanced photocatalytic performance of modified TiO 2 thin-film..., Fakhri [/bib_ref]  due to their ability to increase the efficiency of the degradation of organic pollutants from industrial wastewater or hospital waste using solar energy. This technology is also successfully used in medicine, e.g., for sterilization [bib_ref]  Photocatalytic disinfection using titanium dioxide: Spectrum and mechanism of anti-microbial",
        "label": 0
    },
    "560": {
        "output": "<EOD> Antimicrobial Agents Used in the Treatment of Helicobacter pylori Infections in Children: Evidence-Based Review\nObjectives This aim of this work was to perform a comprehensive systematic review on medications for Helicobacter pylori (H. pylori) treatment in children. Study Design Systematic review. Setting Review articles and original studies. Methods A systematic literature search was performed using PubMed, including studies published in English between January 1, 1991 and March 31, 2016 using the keywords: \u201cHelicobacter pylori\u201d \u201ctreatment\u201d and \u201cchildren\u201d (ClinicalTrials.gov registry: NCT01164800). Results There were 4802 publications available, 200 were reviewed in full text, and 21 were finally selected for final analysis. In total, 21 randomized controlled trials (RCTs) and 3 single-arm before\u2013after studies with 5965 children were reviewed. Most of the studies compared the bismuth quadruple therapy (BQT) with triple therapies (TTs). Conclusions All studies that compared BQT with TTs in the recent 5 years reported that BQT is a more favorable regimen over this duration of treatment without serious adverse events and with no clarithromycin-resistant H. pylori strains. The TTs have no place due to low efficacy; while for the BQT, there is no definitive consensus on the best formulation in pediatric patients in the recent 16 years. The high efficacy of probiotics when combined with H. pylori eradication therapy and the cost-effectiveness of probiotics may lead to a change in future clinical trials. Also, the use of alternative anti-H. pylori medications based on lansoprazole is recommended, including the regimen of amoxicillin/clarithromycin/lansoprazole for the same period of time, and the combination amoxicillin/doxycycline plus lansoprazole for 2 weeks or amoxicillin/doxycycline plus lansop",
        "label": 1
    },
    "561": {
        "output": "<EOD> Convulsive-like effect of a novel N-arylcarboxamide and its interaction with bicuculline and picrotoxin\nA convulsant, 5-(N,N-dimethylcarbamoyl)-2,6-dichlorobenzoic acid (DM-Cl-Bt), was examined for its convulsive activity and its antagonism by bicuculline and picrotoxin. In mice, i.p. injection of DM-C1-Bt elicited convulsive behavior and reduced the threshold of pentetrazol. The convulsive-like behavior, similar to that elicited by pentetrazol, was antagonized by i.p. injection of either bicuculline or picrotoxin. In rats, the convulsive-like activity, but not the antagonism by bicuculline, of DM-C1-Bt was blocked by reserpine pretreatment. The convulsion rate induced by electrical stimulation of the ventral hippocampus was inhibited by prior i.p. injection of bicuculline or picrotoxin. DM-C1-Bt was found to be approximately four times as potent as picrotoxin in decreasing the ventral hippocampal convulsion rate. Moreover, both convulsant effects of DM-C1-Bt and pentetrazol were attenuated by d,l-2-amino-4-phosphonobutyric acid. These results indicated that N-arylcarboxamide derivatives can elicit convulsive behavior and that DM-C1-Bt shares the same mechanisms of pentetrazol with respect to both convulsant effects and the potency of antagonism by GABA antagonists. N-Arylcarboxamide derivatives can therefore be potential convulsants as well as potent convulsant antagonists.<EOD> An efficient synthesis of chiral enaminones by use of organocatalysts: an insight into their applications\nChiral enaminones (or Schiff\u2019s bases of \u03b1,\u03b2-unsaturated aldehydes) play an important role as chemical building blocks in asymmetric synthesis. Although the asymmetric",
        "label": 1
    },
    "562": {
        "output": "[TASK] The eligibility for all patients who can be enrolled in the clinical trial\n\n[INST] This task is an extension of the previous task. You should assess the eligibility for all patients who meet the inclusion criteria for a clinical trial. The assessment criteria are the same as those used for the trial-level eligibility. \nAssess trial-eligibility for all patients with the following conditions:\n- age range is from 25 to 65.\n- diagnosed with dizziness or headaches in the last 3 months.\n- physical level of PA: low or very low level.\n- LDL-C >160 mg/dl.\nInclude in the assessment if there is at least one of the following cardiovascular risk factor:\n- smoker\n- high blood pressure: systolic blood pressure > 140 mmHg, or diastolic blood pressure >90 mmHg.\n- family background of early heart disease.\n- LDL-C >160 mg/dl.\n- BMI >30, which is an indicator of excess body weight, which, in turn, leads to obesity.\n- waist circumference for men >94 cm, for women >80 cm.\n- Total cholesterol >240 mg/dl.\n- fasting glucose > 5.2 mmol/L.\nIn the case of multiple measurements for a patient's characteristic, we recommend taking the average.\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and ADA guidelines as of December 2017 recommend the use of a combination of statin therapies with the maximum tolerated doses for patients with TC >200\u2009mg/dL or LDL-C >160\u2009mg/dL",
        "label": 1
    },
    "563": {
        "output": "* <NAME>. 2013a. \u201cUsing the SCRATCH R Shiny web interface.\u201d <https://scratch.mit.edu/scratch/help/> \n* <NAME>. 2013b. \u201cWork",
        "label": 2
    },
    "564": {
        "output": "# Results\n\nLet's start by printing the variables with the key word 'Data'.\n\n    Data\n    -------------------------------+-----------------------------------------------------------------------------------------------------------------------------------\n    Patient Note               7                                                                                                                                                   \n    trial_name                  HER-MET-Study              Name of clinical trial\n    trial_description           <NAME> for the effect of exercise training on the function of the HDL-Cholesterol, endothelial function, and endothelial progenitors in patients with metabolic syndrome.                                                                         \n    trial_details               Clinical trial                     \n    trial_registration          NCT01057670                       \n    trial_registration_date    2010-10-14                        \n    enrollment_start_date     2009-11-02                       \n    enrollment_end_date       2012-05-31                       \n    trial_phase               Phase II/III                      \n    trial_site                ---                         \n    trial_sponsor           --                         \n    trial_sponsor_address    --                         \n    trial_sponsor_country   Germany                       \n    key-data                  HER-MET-Study \n    key-trial_id             005201101                       \n    trial_id                  NCT01057670            \n\nNext, we get the full patient note, by `data[\"patient_note\"].`\n\n    patient_note                                                                                                                                                                       \n    Patient Note                                                                                                                                                                                                                                   \n    Name                        ---                                                                                                                                                          \n    Last name                    ---                                                                                                                                                          \n    Gender                      Male                                                                                                                                                         \n    Birth date                  1964-01-01                                                                                                                                                     \n    Phone number                 -----                                                                                                                                                             \n    E-mail                     ---",
        "label": 1
    },
    "565": {
        "output": "## Ruleset for Predicting Patient Eligibility\n- If the age of patient > 19 and < 90 then: `0) Excluded`.\n- If the LDL-C of patient \u2265 545 and < 701 then: `0) Excluded`.\n- If the gender of patient is Female then: `1) Not Relevant`.\n- If the family history of CAD of patient is Yes then: `0) Excluded`.\n- If the fasting glucose of patient <= 160 then: `1) Not Relevant`.\n- If the triglyceride of patient <= 299 then: `1) Not Relevant`.\n- If the blood pressure of patient <= 179/115 then: `1) Not Relevant`.\n- If the LDL-C of patient <= 701 then: `1) Not Relevant`.\n- If the smoking of patient is Yes then: `0) Excluded`.\n- If the LDL-C of patient <= 90 then: `1) Not Relevant`.\n- If the current use of lipid lowing medication of patient is Yes then: `0) Excluded`.\n- If the LDL-C of patient <= 545 then: `0) Excluded`.\n- If the family history of CAD of patient is Yes then: `0) Excluded`.\n- If the physical active in patient is Yes then: `1) Not Relevant`.\n- If the LDL-C of patient <= 545 then: `0) Excluded`.\n- If the fasting glucose of patient \u2265 160 and < 211 then: `0) Excluded`.\n- If the LDL-C of patient >= 701 then: `1) Not Relevant`.\n- If the blood pressure of patient <= 179/115 then: `1) Not Relevant`.\n- If the coronary artery bypass grafting in patient is Yes then: `1) Not Relevant`.\n- If the aortic dissection in patient is Yes then: `1) Not Relevant`.\n\n## Ruleset for Predicting Patient Eligibility\n- If the type of cardi",
        "label": 1
    },
    "566": {
        "output": "[/EXAM] Good Luck!\n<exercise>\n[QUESTION]\nYou are an internal medicine resident in an academic medical center. Your main responsibility is to help with the development of internal medicine physician resident education. The faculty in the internal medicine department is interested in starting a new resident education program. The department head asked you to develop a project plan and presentation for an education grant. You have identified two types of residents you believe would benefit from this new program: first-year physician resident (intern) and third-year physician resident (chief resident). This new program will be a longitudinal curriculum that is open to physician resident. Physician resident who elect to join will participate in sessions of two hours per week and will engage in group work around patient care. You need to complete the remaining components of a well-developed project.\n\n[COMMENT]\n[CENTER]\n\n[QUESTION]\n1) You have read a paper on curriculum that you wish to incorporate into the project. In this section, name and describe the curriculum, and explain why it will be important for physician resident education. \n\n2) You also need to name the educational objective you are developing for intern residents and chief residents and describe the method you plan to use to attain this objective. \n\n3) Describe plans you have for evaluating the effectiveness of the project for interns and chief residents by comparing pre-and post-intervention test results. \n\n\n[COMMENT]\n[CENTER]\n\n\n\n[QUESTION]\nComplete the plan for program evaluation you outlined in week 2. Include the primary and secondary evaluation methods as well as criteria for meeting or exceeding the objectives \nof the workshop with an emphasis on the long-term impact in the field. \n\n[COMMENT]\n[CENTER]\n\n\n\n[QUESTION]\nIn week 2, you planned for the program evaluation. After complete this work, complete this plan for program evaluation: \n\n1) Primary method of evaluation.\n\n2) Secondary method of evaluation.\n\n3) Criteria for meeting or exceeding the objectives. \n\n[COMMENT]\n[CENTER]\n\n\n[QUESTION]\n1) Give the name",
        "label": 1
    },
    "567": {
        "output": "=== Section 6: Patient assessment in a clinical trial [#sec-s31] ===\n\nThe aim of this task is to compare each patient's data with the requirements set by the clinical trial. This means we must examine the patient's data and answer the following question: `Does this patient meet the inclusion criteria of a clinical trial?`.\n\nThis is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history\n of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and\n diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL\n respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within\n normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nHere is",
        "label": 0
    },
    "568": {
        "output": "[[{ \"question\": \"What is the best way to determine the patient's eligibility for the clinical trial described in the information below?\", \"answer\": \"The patient is excluded of the clinical trial because of his family history of cardiovascular disease\", \"feedback\": \"The correct answer is B. You should use the assessment of eligibility to determine the patient's eligibility for the clinical trial that has been conducted. \\n\\nThe following information describes the clinical trial: \\n\\nTitle: The MISSION-HF study \\n\\nSummary: The purpose of the MISSION-HF (Multimodal Imaging of Subclinical Myocardial Ischemia in Hypertensive Patients Without Clinical Cardiovascular Disease) trial is to perform a cross-sectional study and study the role of subclinical myocardial ischemia in hypertensive patients without clinical CVD and to estimate the risk factors and etiologic pathways for subclinical myocardial ischemia. \\n\\nA total of 120 hypertensive patients without CVD but with abnormal stress perfusion imaging are randomized immediately to one of two treatment arms: angiotensin II receptor blockade with telmisartan or placebo. \\n\\nPatient-level eligibility: \\n\\nAge range = 55-75 (inclusive) \\n\\nBlood pressure = 160-180/90-105 mm Hg (inclusive) \\n\\nGender: male/female \\n\\nInclusive inclusion criteria: 1) history of CVD or 2) CAD \u226550% stenosis or 3) documented CAD or history of ischemia on stress imaging or 4) documented HF or history of HF on stress imaging or in the previous year or 5) left ventricular ejection fraction < 40% and elevated cTnT or cTnI or in the previous year or 6) history of HF with reduced ejection fraction. \\n\\nExclusion criteria: \\n\\nAcute CVD within 6 months prior to",
        "label": 0
    },
    "569": {
        "output": "* * *\n\nExclude those patients who do not meet any of the eligibility criteria. These patients should be excluded during the recruitment process. \n\nFor example, if a patient met the inclusion criteria and at the same time, we determined that the patient did not meet the exclusion criteria. Then, the patient should be included in the trial and the patient's assessment of eligibility can become\n\nAssessed for inclusion Clinical trial: 0 and the eligibility should be output the assessment of eligibility in the patient Note: 1) Exclude (patient meets inclusion criteria). You should include the assessment of eligibility of each patient for the clinical trial and the assessment of eligibility of each patient in the patient's note. \n\nLet's think step by step. If you want to exclude patients who do not meet eligibility criteria, the command `If eligibility:1,` we must add the `Not eligible` after the `patient_eligible=no` statement. \nFirst, we should add the following line:\n`if Trial-level eligibility:1: \npatient_eligible=not_eligible` \n\nBecause we are only interested in the cases that have 1 assessment of eligibility level, we add the conditions\n\n`if Trial-level eligibility:1: \nif patient_eligible=1:\n    patient_eligible=not_eligible` \n\nAgain, we want to exclude patients who do not meet any eligibility criteria. So, we have to add the patient_eligbile=0  command.\n\n`if Trial-level eligibility:0: if patient_eligbile=0:\n    patient_eligible=not_eligible` \n\nWe also need to add the `end if` after the `if Trial-level eligibility=1:` and `if Trial-level eligibility=1:`, see below:\n\n`end if` \n\n`end if` \n\nThat's your answer! \n\n* * *\n\n**Congratulations, you have earned your [INCL ](INCL.md) cert",
        "label": 0
    },
    "570": {
        "output": "If you enter the correct input, the output will be printed out in the last line. In this example, '2) Eligible.' will be displayed in the last line (see[INST:\n\n```text\n[46,M,45,B]>Trial-level eligibility: 2) Eligible.\n```]\n\n# Examples:\n\n\n## Examples for patient-level eligibility:\n\n    1) Excluded (#): 46 \n    2) Not relevant (#): 30 \n    3) Eligible (#): 52 \n\n## Examples for Trial-level eligibility output only:\n\n    1) Excluded (#): 33 \n    2) Not relevant (#): 24 \n    3) Eligible (#): 33; (see [INST:\n\n```text\n[46,M,45,B]>1) Excluded (#): 13\n[13,F,50,N]>2) Not relevant (#): 46\n[46,M,45,B]>3) Eligible (#): 46\n[50,F,39,C]>3) Eligible (#): 33\n```\n\n## Examples for patient-level eligibility and Trial-level eligibility output:\n\n    1) Excluded (#): 46 \n    2) Not relevant (#): 30 \n    3) Eligible (#): 52 \n\n## Examples for patient-level eligibility and Trial-level output in a random order:\n\n    1) Excluded (#): 46 \n    2) Not relevant (#): 30 \n    3) Eligible (#): 46; (see [INST:\n\n```text\n[46,M,45,B]>1) Excluded (#): 13\n[13,F,50,N]>2) Not relevant (#): 46\n[46,M,45,B]>2) Not relevant (#): 30\n[30,",
        "label": 0
    },
    "571": {
        "output": "<EOD> The Effect of Chronic Stress on Cardiovascular and Cerebrovascular System during High-Intensity Interval Training: An Ergospirometry Study\n\nThe aim of our study was to investigate the effect of chronic stress on heart rate variability (HRV), heart rate (HR), lactate, and blood pressure (BP) during high intensity interval training (HIIT). Nineteen trained young male cyclists (age: 22.7 \u00b1 0.7 years) were randomly allocated to the control group and experimental group. The subjects performed HIIT. For each training, lactate, BP, and HR were recorded, and a HRV analysis was performed on the basis of RR intervals. HR and systolic BP showed no significant differences between groups and moments of collection. Experimental group showed significantly higher absolute values in the frequency domain of HRV in session 4 and significantly higher relative values (nu/ms 2 and ln nu",
        "label": 1
    },
    "572": {
        "output": "The result of assessment of patient's eligibility is represented with `Triallevel eligibility:`.\n\n# Input data for evaluation\n\nIn order to make a decision, you need to find the optimal treatment for the patient by inputting data of the patient and comparing the optimal results with the trial's information. \n\nHere is patient note:\nA 44-year-old man, a current smoker, presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as high blood pressure or diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 543 and 63 mg/dL, respectively; his fasting glucose and triglyceride levels (70 and 210 mg/dL, resp.) were within the normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 1+/4+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 209 and 50 respectively; RICA PSV was 88.8 and RICA EDV was 37.7. Plaque was observed in the anterior and posterior walls of the internal carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nHere is the trial's information from the clinical trial: \nTitle: Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary",
        "label": 1
    },
    "573": {
        "output": "You can use [Python List Module](/python/lists/lists_overview) by iterating through the list with slicing.<EOD> Awareness and Acceptance Regarding Organ Donation and Transplants among Adult Population in Urban India\n\nBackground and Objectives. Organ shortage is the main constraint in transplant medicine and awareness regarding organ donation is low in developing nations. Studies have shown that awareness of organ donation is associated with registration for pledging organs. The objective of this study is to measure the level of awareness and attitude concerning organ donation among urban population of India. Materials and Methods. A cross-sectional study was conducted in urban South India among 713 participants. The socioeconomic factors of the participants, awareness of the importance of organ donation, participation in donation programs, and their attitude were measured using a 19-question survey. Results. Only 25% of study participants had heard about organ donation and 29% had heard about organ transplantation. Only 24% ( = 176) had actively pledged or signed registration forms. Most of the participants expressed willingness to pledge donation of heart (91.7%, = 1573), kidneys (87.2%, = 1123), and eyes (100%, = 713) to strangers, while 86.3% ( = 621) pledged ear to immediate family. More than 80% were willing to donate organs to parents and children. Conclusion. Study shows that despite high willingness and a considerable level of awareness, people from urban",
        "label": 1
    },
    "574": {
        "output": "In the end, you should enter three lines of output:\nTrial-level eligibility: \nPatient-level eligibility: \nTotal number of screened patients: \n\n\nThe solution is available from [github.com/vitor1d/ClinicalTrials_Course] \n\n___\n\n# Exercises\n\n[ClinicalTrials-Solutions]\n\n-----\n\n## Exercise 1.\n\nWe will work with one file - \"SysML_Exercise.doc\".\n\nMake a flow chart for the sequence of steps to work with patient's evaluation through a clinical trial.\n\n-----\n\n## Exercise 2.\n\nHere is the patient's note:\n\" A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits. He reported no use of lipid-lowering medications.\" \n\n#### Clinical trial:\nTitle: Contrast-enhanced Ultrasound (CE-US) and Magnetic Resonance Imaging (MRI): Evaluating Plaque Neovascularisation\n\nSummary: The first goal of this study is to investigate whether CE-US is able to accurately identify and quantify neovascularisation in carotid artery plaques. Since this is one of the first studies systematically evaluating the ability of ultrasound in combination with air bubbles to evaluate neovascularisation in carotid artery plaques, the examination will be performed twice with an interval of 1/2 hour on the day before surgery, thus studying the reliability of the method.\n\nThe second goal of this study is to investigate whether MRI at 3.0 T with a custom-designed 3T carotid coil, using a",
        "label": 1
    },
    "575": {
        "output": "<EOD> Immune responses of bursal follicle cells to subunit vaccine immunization against infectious bursal disease\nTwo approaches were used to examine immune responses by the bursal follicle cells to inoculation with the subunit vaccine for infectious bursal disease. Using both a bursa organ culture system and a subcapsular bursal organ culture system, in vitro bursa organ cultures were exposed to whole bursa homogenates, to cell lysates, or to purified proteins including the major bursal antigens: 33K antigen (gp69/71), p34K protein (VpX), p45K protein (Vp36), and the IBD20K protein. Each of the four proteins could stimulate the bursal cells. A 1:1 ratio of p34K:p45K induced a significantly higher level of IL-6 antigen production than did the other ratios. Lack of stimulation of bursal cells by a bursa homogenate suggested the existence of a bursa-specific suppressor cell in these organ cultures. Finally, using a subcapsular bursal organ culture system, we studied the effect of the subunit vaccine on the bursal immune response. Our results suggested that the subunit vaccine induced a suppressive action on the immune response of bursa cells. The exact mechanism remains unknown.<EOD> Aminoguanidine alleviates brain and spinal cord pathology in experimental allergic encephalomyelitis\nExperimental allergic encephalomyelitis (EAE) is an autoimmune inflammatory disease of the white matter of the central nervous system (CNS) caused by an immune reaction against myelin basic protein. In some inflammatory models, aminoguanidine (AG) has been shown to inhibit the expression of inflammatory mediators and to reduce cellular infiltration into the tissue affected. Therefore, in this study, we evaluated the effect of AG, a compound with selective inhibitory activity toward inducible nitric oxide synthase (iNOS) activity, on inflammatory response in spinal cord and",
        "label": 1
    },
    "576": {
        "output": "## [END]\n\n\nA: Please follow me\nIn the first line you insert #include <iostream>\nIn your third line you should put this header: std::string\n\nIn the fourth line you declare an object with the following line:\nclass trial {\n  public:\n    std::string patientId;\n    std::string description;\n    std::string trialId;\n    std::string gender;\n    Trial-level eligibility: <some eligibility>;\n  };\n\nIn the fifth line you insert your Trial-level eligibility variable (which you declare in your program in the third line).\n\nA: You can make multiple choices for your eligibility and print all the choices in one line as your program is asking for it. Just go to your trial.h file, where you are using trial - object and modify trial_level_eligibility variable to a string, and then change your output line to this:\ntrial_level_eligibility = string; // you should remove the Trial-level eligibility: // <some eligibility> from here\ncout << trial_level_eligibility << endl++; // in 1 line\n\nAfter your output, print the id of that trial, and in the next line print the description of trial and so on. Your object can be printed with to string method by invoking operators <<.<EOD> \u03b2-caryophyllene Alleviates High Sucrose-Induced Inflammation and Senescence in Pig Adipocytes via the Sirtuin 1 Pathway\n\n\n\n# Introduction\nIn recent decades, obesity has developed into one of the most prevalent metabolic syndromes worldwide, which causes an adverse effect on the normal body metabolism and is a serious threat to human health. The obesity epidemic has been rising sharply in developing countries. In the United States, roughly 78 million people are obese, which accounts for 34% of the total population [bib_ref]  Overweight, obesity, and cancer risk, Bianchini [/bib_ref] . Currently, the prevalence of obesity in China is 11.9%, which is continuing to rise [bib_ref]  Overweight, obesity, and public health, He [/bib_ref] . This is",
        "label": 2
    },
    "577": {
        "output": "[CASE][CODE]\n#This is a clinical trial note\ntrial_level_eligibility: 0) Excluded\n#There are some patient data\nPatient_id:  530010060008\nfirst_name:  Gareth\nlast_name:  White\ngender:   2\nage:      66\ndisease:   1\ntype_of_trial:     1\nstage_of_disease:    1\nfamily_history:    1\nhistory_of_taking_drugs:   1\nblood_lipid_levels: 1\nhigh_cholesterol_levels:    1\nuse_of_blood_pressure_controlling_drugs:   1\nblood_pressure_controlled:    1\ntobacco_smoker:    1\nalcohol_drinker:    1\n#And the patient's symptoms\npresence_of_symptoms:    2\nsymptom:    headache\nfrequency_of_this_symptom:   1\n#And the patient's examination data\nhealth_condition_that_was_examined:   1\ncardiology:   2\nneurology:   1\nvascular:   1\nradiology:   1\ntype_of_examination:    1\ntest_date:   1\ntest_result:    2\ntest_report:   1\n#And the patient's information\npatient_notes:         1\npatient_identifiers:   2\npatient_death:         1\npatient_last_visit:     1\npatient_referrals:      1\npatient_provisional_codes:   1\n#And the patient's medication information\nmedication_for_this_patient:   1\nmedications_dosage_route_date_starting_end_reason:   3\nmedications_dosage:     1\nmedications_route:     1\nmedications_dosage_withdrawal_reason:   1\nmedications_dose:     1\nmedication_started_date:   1\nmed",
        "label": 1
    },
    "578": {
        "output": "I have created a script file as example_1.ipynb, which will automatically calculate if the input is included in the trial. As an output, it will generate a summary output, like the one on the screen of your Jupyter Notebook.\nPlease refer to this link for other example. \n\n\nA: I created a small script to help quickly search in a file:\nimport fileinput as fi\n\npatients_path = \"patients.xlsx\"\n\nfor f in fi.open(\"patients.xlsx\")\n    for line in f\n        if 1 < line.splitlines()[2] <= 2:\n              print(f.name)\n\n<EOD> Tuberculosis of the Breast: Report of Six Cases and Review of the Literature\nAbstract: Tuberculosis of the breast is an uncommon disease and is often mistaken for a cancer. From 2000 to 2014, we saw 23 patients with breast tuberculosis at the Department of Surgical Oncology of the Kyrgyz National Medical Center, 6 of whom were clinically assessed. The study group comprised four women and two men aged 25 to 62 years; all had an open tuberculous abscess. All patients underwent treatment\u2014antituberculous drugs for 6\u2013 12 months and surgery. The results of the treatment were evaluated 1\u20138 years postoperatively. All patients achieved a good immediate postoperative result and were cured during antituberculous treatment. The breast tuberculosis incidence rate is increasing despite the fact the disease is easy to treat once identified. Hence, doctors must be familiar with its symptoms to make an early diagnosis; breast surgery is not mandatory. Breast tuberculosis is more common in young people, women, and those with concomitant diseases, such as tuberculous pleuritis. Surgical treatment of breast tuberculosis in the postantituberculous treatment period does not reduce the length of the rehabilitation period.<EOD> A review of the morphometry of adult female scolices of human and animal ascarids.\nThe morphometry of ascarid lumbricoid worms (Ascaris lumbricoides, Toxocara can",
        "label": 0
    },
    "579": {
        "output": "<EOD> Explosion during metal-organic decomposition: a new process to enhance the mechanical properties of carbon nanofibers.\nElectrospinning has been recognized as a simple method to prepare well-aligned carbon nanofibers (CNFs) since many years. Such CNFs possess outstanding features such as a high surface-area-to-volume ratio. Electrospun CNFs can be obtained by thermal decomposition of the metal-organic decomposition, although the morphology of electrospun CNFs depends heavily on the nature of electrospinning solution. Here, we proposed a novel electrospinning process by taking advantages of the physical and chemical interactions between the polymer and additive. To demonstrate our concept, polyacrylonitrile (PAN) and aluminum nitrate with a proper ratio were selected to produce CNFs via electrospinning and subsequent thermal decomposition. After aluminum nitrate had been added into the electrospinning solution, the microstructure of the obtained CNFs was found to be changed from microtubes to nanofibers, which was resulted from the explosion of aluminum particles in the electrospinning solution. The explosion triggered a vigorous exothermic reaction in the electrospinning solution, and thus the thermal decomposition of PAN was markedly enhanced and the thermal stability of the CNFs greatly improved.<EOD> Awareness and Knowledge of AIDS among Women Referred to Urban Health Centers in Isfahan\nThe aims of this study were to assess AIDS\u2014related knowledge and attitude among women visiting urban health-care centers in Isfahan, Iran, and to assess the relationship between demographic variables and knowledge and attitude. Four hundred and ninety two women were selected by random sampling from urban health centers in Isfahan. A self-administered questionnaire assessing demographic variables, AIDS-related knowledge, and attitude was given to women. Data were analyzed using SPSS 7.5. Statistical significance was set at p\u2009<\u20090.05. The means of knowledge and awareness showed that the majority of the participants (90% and 79.2%) had adequate knowledge about AIDS prevention measures, whereas only a few of the participants (28.7%) had sufficient knowledge about the transmission",
        "label": 1
    },
    "580": {
        "output": "### [Exercise]\n- Create a new notebook and give it any relevant name.\n- Let's begin with a basic input file.\n\n### Load Data\n\tThis notebook contains three files.\n\t\n\t> ## load data\n\t\n\tFrom now on, whenever you run this script, it will always be reading the same input data file. So, it is best to have a naming convention for your input data files.\n\t \n\tIf you wish to update `inputDataFileName`, you must replace the existing file with one that contains different input data. Here we have taken a random string that contains some letters and numbers. \n```python\n>inputDataFileName= \"Trial1data.csv\"\n```\n```\n### Importing Library\n\tNow import required libraries\n```\n\t\n\t>import pandas as pd\n\t>import numpy as np\n\t>import matplotlib as mpl\n\t>import math\n\t>import random\n\t>%matplotlib inline\n```\n\tNow let's create a dataframe with dummy data, i.e., three records with only age, sex, and weight columns.\n``` \n>ageDf=pd.DataFrame({'age':[60,100,65],'sex':['Male','Male','Female'],'weight':[60,65,55]})\n```\n\t\n\n### Get Age Data\n\tNow we will get all the age data.\n```\n>>ageDf=pd.DataFrame().assign(age=ageDf.values)<jupyter_text>The output is the dataframe with new column name `age`.<jupyter_code>[age]=ageDf.age<jupyter_output><empty_output><jupyter_text>Now get sex data<jupyter_code>[sex]=ageDf.sex<jupyter_output><empty_output><jupyter_text>The output is the dataframe with new column name `sex`.<jupyter_code>[weight]=ageDf.weight<jupyter_output><empty_output><jupyter_text>Now apply filter<jupyter_code>for age in ageDf.age :\n    if age<=65 or age>=100 :",
        "label": 1
    },
    "581": {
        "output": "<details><summary>See also</summary><pre>{\n  \"patient_note\": \"A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits.\",\n  \"clinical_trial\": \"Proximal Protection With The Mo.Ma Device During Carotid Stenting    Title: Proximal Protection With The Mo.Ma Device During Carotid Stenting    Summary: The objective of the ARMOUR study is to evaluate the safety and effectiveness of the Mo.Ma proximal flow blockage cerebral protection device for patients at high surgical risk for carotid endarterectomy who undergo carotid artery stenting \\n    Inclusion criteria: General inclusion criteria Subject meets one or more of the high surgical risk criteria, Subject is \u2265 18 years old, Subject is a candidate for single lesion carotid artery stenting using a femoral arterial approach, Subject is willing and able to comply with follow-up evaluations at the specified times, Subject (or legal representative) understands the nature of the procedure and provides informed consent, prior to enrollment in the study, If female subject, is not currently pregnant and has stated that she has no intention of becoming pregnant during the study.    Angiographic inclusion criteria (as determined \u2264 30 days prior to procedure): \\n    Target lesion stenosis (% stenosis = (1-N/D) X 100)1, documented by selective angiography pre-intervention, is \\n    Target lesion is within the internal carotid artery and/or involves the bifurcation of the CCA.    External carotid artery diameter where the Mo.Ma device will be positioned is 3-6 mm. \\",
        "label": 1
    },
    "582": {
        "output": "**[INST]** Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n\n\n\n\n### 4) Exit (insufficient assessment/exclusion)\nYou should assess and make a decision about the patient's eligibility. The three possibilities of the output are `0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria;` 1) `Not relevant (patient does not have sufficient information to qualify for the trial);` and `2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).` Remember, `0` means that the patient is excluded, and `1` and `2` mean that the patient is not excluded.\nYou should always end the input by ``Output: 2) Eligible.``\nFor example, if the input should be `Trial-level eligibility `:\nIf patient meets inclusion criteria, e.g., the blood test values are within normal limits, the patient does not smoke, and this patient does not have a family history of cardiovascular disease, then the statement `Trial-level eligibility: Excluded` should be returned. If the patient meets eligibility criteria, e.g., the patient is a nonsmoker, and the patient has hypertension, and the blood test results indicate no abnormalities, then the statement `Trial-level eligibility: Eligible` should be returned.\n\nFinally, you should always repeat `Trial-level eligibility `: `Trial-level eligibility: `, e.g., `Trial-level eligibility: 1) Not relevant.`. [INST]\n\n\n### 3) Eligible\nYou should assess and make a decision about the patient's eligibility. The three possibilities of the output are `0) Excluded (patient meets inclusion criteria, but is excluded on the",
        "label": 0
    },
    "583": {
        "output": "## MATERIAL\n\n- 1: patient note: Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility.\n- 2: clinical trial: Purpose of this study: Comparison of cardiovascular mortality and morbidity which includes cardiac and neurological morbidity (TIA and CVA) in the two invasive treatments of asymptomatic carotid artery stenosis.\n- \n<EOD> Pulsed Laser Abrasive Flow for Selective Metal Removal\u2014A New Conventional Abrasive Blasting Technique\nPulsed laser abrasive flow (PLAF) is hereby presented as a new abrasive blasting technique, which allows to remove the majority of metals from materials and, at the same time, retains almost all ceramic or polymer components. A high laser fluence (mJ/mm\u00b2) and a short abrasive flow period (\u03c4 = 0.1 ms) have both been found to be critical key parameters to minimize the heat induced by the abrasive and to ensure both selective corrosion and selective metallic wear, respectively.<EOD> Correlation Analysis of Serum Glycosylated Hemoglobin Variation and 24-Hour Urine Albumin Excretion Rate in Patients With Non-Hearing Diabetic Kidney Disease\n\nObjectives: Glycosylated hemoglobin (HbA1c) is a marker for blood glucose levels, and changes in its levels can reflect the change in glycemic status of patients. Urine microalbumin can reflect the extent of glomerular hyperperfusion and is commonly used to assess kidney injury caused by glycemia. This study was conducted to evaluate the correlation between glycosylated hemoglobin variation and urine albumin in patients with non-hearing diabetic kidney disease (DN).Methods: A population of 109 DN inpatients was selected. The patients had complete medical records, including routine examination findings, HbA1c findings, and 24-h urine album",
        "label": 1
    },
    "584": {
        "output": "[RUN]\n\n[INST] You are a practitioner who performs abdominal computed tomography (CT) scanning. You diagnose a patient as having abdominal aortic aneurysm, a bulging or ballooning of the blood vessel in the abdomen. CT is a diagnostic imaging technique used to create multiple cross-sectional images of the body and it is performed by means of X-Ray based computer tomography. You want to find if this patient have already participated in a clinical trial. The trial identifier can be found as the last value of the patient variable `Trial-ID`. If the value is 0, the patient has not participated in any trial, and is eligible and fit to participate in a clinical trial. \nAssess the trial-level eligibility of your patient by making the following expressions. We use the `if` function to check the first condition and the `elseif` function for the rest of the conditions. If the trial-level eligibility is \"Excluded,\" or \"Not relevant,\" replace the patient variable `clinical trial status(CT_status)` by 2; If the trial-leveleligibility is \"Eligible,\" replace the variable by 1, in the line following the evaluation. \nAssess the trial-level eligibility of your patient by making the following expressions. We use the `if` function to check the first condition and the `elseif` function for the rest of the conditions. If the trial-level eligibility is \"Excluded\" or \"Not relevant,\" replace the patient variable `clinical trial status(CT_status)` by 2; and if the trial-level eligibility is \"Eligible,\" replace the variable by 1, in the line following the evaluation. \nAssess the trial-level eligibility of your patient by making the following expressions. We use the `if` function to check the first condition and the `elseif` function for the rest of the conditions. If the trial-level eligibility is \"Excluded\" or \"Not relevant,\" replace the patient variable `clinical trial status(CT_status)` by 2; and if the triallevel eligibility is \"Eligible,\" replace the variable by 1, in the line following the evaluation. \nAssess the trial-level",
        "label": 0
    },
    "585": {
        "output": "# Examples\n\n## [INST] Please enter your age in years in the following box:\n[INSERT AGE]\n\n## [INST] \nPlease enter your height in centimeters and weight in kilograms in the following boxes:\n[INSERT HEIGHT] cm \n[INSERT WEIGHT] kg\n\n## [INST] \nPlease enter the number of years you have smoked in the following box\n[INSERT MONTHS]\n\n## [INST] Your BMI is [BMI] and classified in [Class]\n\n## [INST] Please enter the information about the risk of diabetes\n[INSERT CORONARY ARTERIAL DISEASE (CAD) HISTORY]\n![inst/](https://raw.githubusercontent.com/Taylor947/AWS-Amazon-IoT-Gateway-Demo/master/inst/inst1.gif)\n![Instruction](/assets/images/instruction.gif)\n\n```\n\nhttps://raw.githubusercontent.com/Taylor947/AWS-Amazon-IoT-Gateway-Demo/master/ex11/main.py\n\n![$]\n\n![inst/](https://raw.githubusercontent.com/Taylor947/AWS-Amazon-IoT-Gateway-Demo/master/ex11/inst1.gif)\n```\n\n\n\nhttps://raw.githubusercontent.com/Taylor947/AWS-Amazon-IoT-Gateway-Demo/master/ex11/ex11.ipynb\n\n```\n\nhttps://raw.githubusercontent.com/Taylor947/AWS-Amazon-IoT-Gateway-Demo/master/ex11/ex11.ipynb\n\n```\n\nhttps://raw.githubusercontent.com/Taylor947/AWS-Amazon-IoT-Gateway-Demo/master/ex11/ex11_run.ipynb\n\n```\n\n# Note\n\nThe code for the examples is not clean (for example, there are unnecessary variable names, and etc.) due to the",
        "label": 0
    },
    "586": {
        "output": "You can see the detailed explanation of the eligibility assessment for a clinical trial at [https://github.com/wilsonb45/CERTIFIER/wiki/Eligibility-Assessment](https://github.com/wilsonb45/CERTIFIER/wiki/Eligibility-Assessment).\n<issue_comment>username_4: I've updated the script to run the test locally. \n\nIt has been tested on R4.0.4 running in Python 2.7.12. \n\nHere is the snapshot: https://datahaven.wesleyan.edu/download/d/567d2f6d-a911-4b1a-b558-19ed25c108db\n\nThis run seems to have failed on a patient. A review of the patient data suggested that the patient should be excluded.\n<issue_comment>username_4: I've updated the script to run the test locally. \nIt has been tested on R4.0.4 running in Python 2.7.12.\nHere is the snapshot: https://datahaven.wesleyan.edu/download/d/567d2f6d-a911-4b1a-b558-19ed25c108db\n\nThis run seems to have failed on a patient. A review of the patient data suggested that the patient should be excluded.\n<issue_comment>username_0: Sounds great! If you are interested in keeping this ticket updated, please let me know. I'll try to check it once in couple weeks.\n<issue_comment>username_4: I've updated it to run on R4.0.5 running Python 2.7.18. The fix described above should be included in that, and is included in the latest snapshot. \n\n![screenshot 2](https://user-images.githubusercontent.com/6517504/62956599-0d6a3180-bc7f-11e9-927a-046dbe5910e5",
        "label": 1
    },
    "587": {
        "output": "If your assessment yields any assessments other than \u201cTrial-Eligible,\u201d you will not be successful on this clinical trial, no matter what your supervisor decides.",
        "label": 0
    },
    "588": {
        "output": "<EOD> Prevalence and Determinants of Malnutrition among People with Depression Living with Human Immunodeficiency Virus\n\n\n\n# Introduction\nA major public health problem in low-and middle-income countries is malnutrition. Malnutrition is known by weight loss, wasting, poor physical and mental performance, and psychological effects [bib_ref]  Malnutrition: the paradox of nutrition management, Chattha [/bib_ref] . Malnutrition mainly comprises two forms: wasting or undernourishment, which represents an underweight state; while the second type is stunting or over-nourishment, which represents a muscle atrophy as a result of excess nutrients. Many causes of malnutrition were identified such as food insecurity, economic problems, obesity and disability, medications, and social problems [bib_ref]  Impact of psychological problems as an effect on the nutritional status during..., Ahmad [/bib_ref] .\nHuman immunodeficiency virus (HIV) infection is a global public health concern [bib_ref]  Prevalence and determinant of anemia in HIV-infected patients, Suresh [/bib_ref] . Although the prevalence of HIV/AIDS has declined globally, it continues to be a major public health concern in developing countries. HIV/AIDS has a great impact worldwide with high death rates and more than 70 million people are infected with HIV and 5 million are newly infected, leading this disease becomes a persistent burden on the global economy. About 35 million people have died of HIV. HIV is spreading from its original epicenter, which are urban, highly developed areas, to rural, economically less developed areas [bib_ref]  Prevalence and determinant of anemia in HIV-infected patients, Suresh [/bib_ref] .\nAbout 44 million people are currently living with HIV and about half of them are in Sub-Saharan Africa. However, the prevalence of HIV in the Middle East was reported 3.1%, and the prevalence in North Africa was reported 0.2%. The Arab region has the second-highest HIV burden after Sub-Saharan Africa, with almost 660,000 currently living with the",
        "label": 1
    },
    "589": {
        "output": "Exercises 5-10",
        "label": 1
    },
    "590": {
        "output": "<EOD> Antenatal sonography of prune\u2010belly syndrome\nThis case report illustrates the sonographic findings of prune\u2010belly syndrome in a fetus. A 24\u2010yr\u2010old primigravida exhibited polyhydramnios at a sonographic examination at the 23rd week. An anechoic cavity was detected within the fetal abdomen, and dilatation of the urinary system was diagnosed. Cystoscopy and suprapubic cystostomy were performed at 26 weeks, and a fetal autopsy was performed in the hope of a better understanding of the pathogenesis of prune\u2010belly syndrome. In this case, a cyst was detected in the region from the renal pelvis of the upper urinary tract to the posterior urethra and renal agenesis was diagnosed. These results were compatible with those of the sonographic examinations. When the patient was in the prerenal phase of renal failure, cystoscopy revealed urine which originated from the dilated ureter within the cyst\u2010like mass. It is hypothesized that the dysplastic kidney has failed to function and the urinary tract is not functioning. The case of the fetus in the prerenal phase was also observed macroscopically in detail at the fetal autopsy. The results proved that urine originated from the upper urinary tract, including the ureter at the cyst\u2010like mass detected in the fetal pelvic region. Because the results of the present case were compatible with the concept that prune\u2010belly syndrome is a congenital defect in the kidney and urinary tract, it can be expected that with advances in sonographic equipment and the ultrasonologist's skill, prune\u2010belly syndrome can be diagnosed at an earlier gestational age.<EOD> A new species in Onychiurus Bagnall (Onychiuridae: Collembola) from caves of a limestone karst in the Guangxi Province, China.\nA new species, Onychiurus guangxiensis Luo, Zhang Xu, sp. nov. (Collembola: Collembola) is described from eight limestone caves located in Kaiyuan County of Lueyang City",
        "label": 1
    },
    "591": {
        "output": "<EOD> Evaluating the impact of educational intervention based on health belief model (HBM) on self-efficacy and quality of life in women with breast cancer\nAbstract Introduction: Women with breast cancer who are the highest cancer group around the world, are facing with negative emotions such as anxiety and depression because of stressful experiences that is occurred due to their disease. Implementing educational interventions based on the HBM will reduce the negative emotions experienced by them. Methods: A randomized clinical trial was used to evaluate the effect of HBM-based educational intervention on self-efficacy and quality of life in 64 of women diagnosed with breast cancer, referred to hospitals was implemented. The intervention group included 32 participants and the control group included 32 participants. The research tool in this study was a demographic questionnaire, HBM scale and the European Organization for Research and Treatment of Cancer Quality Questionnaire (EORTC QLQ-C30). The data was analyzed using analysis of covariance and Tukey test. Results: The results of regression analysis indicated the variables are effective in explaining the change of score in quality of life in women through the intervention, based on the intervention HBM variables on the variables of cancer and physical condition, treatment, emotional condition, cognitive beliefs of cancer, HBM constructs, and also the total score of HBM and its subscales (p-value  0.05). Conclusion: Educational intervention based on HBM can improve and control the negative effects of cancer symptoms and improve self-efficacy. The intervention can play an important role on promoting the quality of life in women with breast cancer.<EOD> A critical role for S-nitrosation of the ATPase module in unblocking cystic fibrosis transmembrane conductance regulator pore after oxidative stress\n\n\n\n# Introduction\nCystic fibrosis (CF) is a fatal autosomal-recessive disorder; more than 90% of CF patients harbor two mutations in the cystic fibrosis transmembrane conductance regulator (CFTR [bib_ref]  Identification of the cystic fibrosis gene: chromosome walking and jumping, Rommens [/bib_ref]",
        "label": 1
    },
    "592": {
        "output": "The full set of tasks is given in the file [link1] test.csv.\n<EOD> Synthesis of fluorescent carbazole-based conjugated polymers modified by nonlinear optical chromophore for photoinduced electron-transfer transduction and sensing applications.\nFor highly sensitive optical sensing applications and bioimaging, the generation of reactive radical species from photoexcited polymers, which can effectively modulate the photoreaction, is a key issue to consider. In this study, we synthesized a series of donor-acceptor polymers bearing nonlinear optical chromophores as acceptor moieties for the generation of reactive radical species. Our results show that the photoinduced electron transfer reactions, such as the generation of reactive radical species and the charge-transfer process, are strongly affected by the polarity of the surrounding medium.<EOD> Effects of acute hypobaric hypoxia exposures and re-exposure: a functional and cardiac magnetic resonance evaluation\n\nThe effects of prolonged/chronic hypobaric hypoxia (HH) exposure have been investigated and described. Despite the effects of acute HH exposure still being unclear, some authors have demonstrated HH-induced cardiac changes. However, these studies were conducted mainly by using echocardiography and not cardiac magnetic resonance (CMR). Thus, the aim of this study was to evaluate the effects of acute HH exposure on cardiac function, blood pressure, and cardiac remodeling using a CMR protocol. Nine subjects were exposed to two acute HH (8 h, 213 Torr) exposures, separated by a control day, in normoxia at 350 Torr, and two more acute HH exposures, separated by a re-exposure day, to a similar hypoxic condition. Echocardiography and CMR were conducted at baseline and after each acute HH exposure and re-exposure. Our results showed that an acute HH exposure leads to an increase in left ventricular mass, myocardial mass, systolic wall thicknesses , and right ventricular function, as indicated by ejection fraction. Nevertheless, the use of the CMR protocol demonstrated that despite changes in all the parameters afor",
        "label": 1
    },
    "593": {
        "output": "<jupyter_code>input_list = ['The patient note', 'Carotid ultrasound results']\nx_new = x_transformation(input_list, 'input', is_header = True)\nx = x_new[:,0]\n\nx_transformation(x, 'clinical trial', is_header = True)\nx_transformation(x, 'clinical trial', is_header = True)\nx[:, 0:2]\n\ny_new=y_transformation(x, 'eligibility')\ny_new[0].value\n#output: 2) Eligible\n#for trial ID check this trial data structure\n#data_transformation(y_new, 'clinical trial', is_header = True)\n\nprint(\"-------------------------------------------\")\nprint(\"Please check these 35 examples\")\n\n<EOD> Precise measurement of the 129Xe spin-spin relaxation rate.\nWe report an accurate measurement of (129)Xe inversion recovery spin-spin relaxation rate T(2) near 1.8 mT. The value, determined from measurements of a 1.8 mT NMR signal that is spin-flipped with a 0.26 mT field, is found to be 9.838 +/- 0.005 s. This determination differs by less than 0.01% from predictions previously used to constrain the (127)Xe and (129)Xe nuclear electric and magnetic dipole moments and by less than 0.4% from predictions of the (129)Xe electronic g value.<EOD> 2002 and beyond: a new era in the medical management of cardiovascular disease for general internists and family physicians.\nNew guidelines have been published for primary prevention of coronary heart disease, 1 lowering of blood pressure. and risk reduction for patients with coronary heart disease, stroke, and diabetes mellitus. 2,3 Other consensus documents review the role of statin therapy and cardiovascular disease prevention, 4 as well as the benefits of dietary fish oil supplementation. 5 Other relevant guidelines are available to assist",
        "label": 0
    },
    "594": {
        "output": "The `Trial-level eligibility` output the number of trials the patient was evaluated for so we set `Trial-level eligibility: trial_name`.\n\n\nA: Just need to do some tweaking of the script provided:\nThe 'eligible' column contains the counts for the number of times that it has been marked as eligible. So just need to calculate that once for each patient and then add that count to the count for the relevant 'relevant_criteria' column for that patient.\nNote that there will now be duplicate rows for certain patients where they are enrolled in more than 1 trial. The counts for the 'eligible' column will therefore be added to the relevant_criteria values for all relevant trials.\nI have modified script to be compatible with python 3.6 and 3.7 and included the 'independent_criteria' columns. \nAlso tried to include a sanity check - by adding in the `if` operator, so that the `trial_name` variable is checked for non-zero values to prevent the script from crashing if you were to try and run this on a new dataset where it cannot find any relevant trials - but since the code doesn't run on my machine at all, I suspect it needs a few more fixes to run (either in the script, or the code on SO).\nSo I will try to run the test script in my local dev environment and see how that works. \n<EOD> .\nThe paper compares the use of 233U and 197Au for palliative treatment of inoperable pancreatic carcinoma. A total of 81 patients with pancreatic carcinoma were exposed to 197Au while 106 patients were exposed to 233U over 4 months. The mean survival time was 355 days with 197Au and 271 days with 233U. The respective increase in long-term survival of patients with metastases was 135 and 163 days while in patients without metastases the 50 per cent survival time increased 269 and 338 days respectively.<EOD> Increasing the Efficacy of Chlorogenic Acid against Salmonella enterica by Codelivery with",
        "label": 1
    },
    "595": {
        "output": "To submit the assessment, click the Assess button in the lower left of the left side.\n\nIn this assessment, the patient meets the inclusion criteria and is also eligible for the clinical trial `Title: A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies`.\n\n### Submission Check \nClick the \u2018Submission Check\u2019 button in the bottom left of the left side. This will allow you to check the accuracy of the assessment. There is a message indicating that no errors were found. This is the output that you should provide in the `ClinicalTrials.gov` web page.\n\nClick the \u2018Create XML\u2019 button in the upper left of the left side (that appears as a link).\n\nA pop-up appears showing the XML code. Click `Save As..` in the pop-up menu. Type `Your Email` if the email is empty. Then, click `Save As UTF-8`.\n\nClick `Done\u2019 in the upper right, which will generate two files (a PDF file and an XML file). You can only upload the XML file in the `ClinicalTrials.gov` web page. The PDF file is for your reference.\n\n![INST-Upload_XML]\n\n\nClick `Upload` again. Then, click `Upload XML Files` and click `Browse\u00b4 in the file selector to select the XML file that you have saved before. Finally, click `Submit Clinical Trial` to complete the assessment.\n\n\n### Check Availability \nCheck the availability of the submitted assessment in the [CliniCalTrial.gov Home Page]( https://clinicaltrials.gov/ ). Click `Find Studies, enter the National Clinical Trial` number (NCT No.) in the search box to open the study (or select the study from the list). The submitted assessment will be checked in the 'Trial Results Summary' table. If the assessment has been submitted, the word `Unsubmitted` should be shown in the `Trial Results` table instead of `Registered.\n\n![INST-Check_availability]\n\nIf you cannot find the assessment at the NCT No. in the `Trial",
        "label": 0
    },
    "596": {
        "output": "## RQ2.\nTell me, what is the output of the 'assessment_eligibility` function?\n\n## 4) You want to take the first row as an example to explain. You should use the following arguments to this function:\n\n##### A)\nNote: You can type `A> > print(assessment_eligibility(crs, trial=CLINICAL_TRIAL_1))` to do the same.\n\n##### B)\n\n## C)\n\n##### D)\nYou can type `D> > print(assessment_eligibility(crs, trial=CLINICAL_TRIAL_1))` to do the same, but it will be slightly faster.\n\n##### E)\n\n### F)\n\n## G)\n\n## H)\n\n### 5) The results are as follows: You should always print the first row as the result of this function, and repeat the Trial-level eligibility at the end by `Trial-level eligibility: `. \n\n# RQ3\nTell me, what is the output of the `summarize_eligibility` function?\n\n## RQ4\nTell me, what is the purpose of the `summarize_eligibility` function?\n\n## RQ5:\nTell me, why we can not get the following information: How many patients with a HbA1c level above 7% were screened for entry? How many patients were found to be ineligible for this trial?\n\n# 1) What do we want to achieve?\n\nWe need to count the number of screened patients of each type, the number of excluded patients, and the number of exclusion reasons.\n\n### 2) What do you think when you want to do this? What kind of information will we need?\n\nWe would like to find the number of patients with a HbA1c level above 7% first. Then, we would like to print out the number of patients who are excluded based on inclusion exclusion criteria.\n\nThen, we would like to print out their detailed information from patient's notes including the reason for their exclusion.\n\n### 3) Let",
        "label": 0
    },
    "597": {
        "output": "---\n\n## Eligibility Test\n\nEligibility test 1: `if Trial-level eligibility = 2 then Evaluation = 2;` \nEligibility test 2: `if Trial-level eligibility = 1 then Evaluation = 0;` \nEligibility test 3: `otherwise Evaluation = 0;` \nFor eligibility test 2 on the basis of information for `Trial-level eligibility = 2; the given patient note is eligible.\n\n## Clinical Trial Status Information\n\nYou are asked to provide information about the current phase of the trial according to the information [https://clinicaltrials.gov/learn/definitions.jsp]:\n- Term = a short term for a clinical trial stage - Phase = the stage of development with respect to the drug or biologic; it is a phase of development during which interventional trials are conducted with the goal of assessing safety and preliminary efficacy - Protocol Type (Ph): the clinical form in which a clinical protocol is drafted; it is different in trials of drug, new drug, diagnostic, or medical device (a combination of drugs or diagnostic study is considered a drug trial and a diagnostic study is considered a diagnostic trial) - Stage/Part Definition Type (Ph): the phase, protocol type, and definition of stage and part of a study - Part: a single interventional study; the term refers to a protocol or set of protocols, or to a collection of interventional studies carried out to evaluate the safety and efficacy of a drug or biologic. - Arm Type: clinical trial arms are the distinct combinations of interventions (drugs, biologics, or both) being tested; it is a part of the trial. - Amendments: the modification of a written research protocol; the term is synonymous with protocol modification, but often this is not the actual protocol undergoing modification and other documents, such as consent forms, investigator brochures, statistical analysis plans, financial protocols, and other data sharing documents may also be modified. - Investigational New Drug (IND) or Investigational Device Exemption (IDE): the approval of human research studies. \n\n1. Trial stage, phase, protocol type,",
        "label": 0
    },
    "598": {
        "output": "If it is finished, the above-mentioned code is generated.\n\n#### Clinical Trial Registration and Privacy Policy\n[D21] ClinicalTrials.gov has registered a standardized protocol and the informed consent form for Trial CAPRICORN-CRS, which will be performed in this project. ClinicalTrials.gov is registered in the World Health Organization's International Clinical Trials Registry Platform (ICTRP) system. The ICTRP helps to ensure that research studies are registered with their trial registration number before initiation or continuation, and then followed. Registration has been deemed necessary by the World Health Organization's International Conference on Harmonization, ICH, and is required under the regulatory policies adopted by major journals.\n[D22] The privacy policy that will be used in the Trial CAPRICORN-CRS has been registered in the Privacy Policy Prohibiting Commercialization of Personal Health Information at https://privacy-enforce.org. The privacy policy prohibits the direct or indirect commercialization of personal health information.\n\n<a href=\"https://ccka.xyz\">Powered by <i>Sphinx-CSP</i></a>\n<EOD> Assessment of the Antidiabetic and Antioxidant Potential of Zygophyllum fabago L.\n\nDiabetes mellitus (DM), a metabolic disorder characterized by chronic hyperglycemia with impaired insulin sensitivity, is one of the main chronic diseases in the world and affects millions of people on a daily basis. Oxidative stress arising from reactive oxygen species (ROS) formation is recognized as one of the major contributing factors in the development of DM. On the other hand, antioxidant substances may play a role in prevention of DM or reducing its adverse effects on other biological systems. The present study aimed to evaluate qualitatively and comparatively the antioxidant activity of aerial parts extracts and biologically active compounds of Zygophyllum fabago L. The antidiabetic activities were quantitatively evaluated by enzyme assays method. Results showed that the aqueous leaves extract of Zygophyll",
        "label": 0
    },
    "599": {
        "output": "<EOD> A Simple Method for Detection of the Prostate Adenocarcinoma Using N\u2010Terminal Fragment of Basic Proline\u2010Rich Protein\nProstatic carcinomas are the most frequently diagnosed cancers in men. In this study we evaluated one protein in the prostatic fluids, namely the Nt-BPP (n-terminal fragment of basic proline-rich protein) as a biomarker for prostate adenocarcinoma detection, using a commercially available immunoassay kit. We investigated 30 men aged 48 to 69 years old. The patients were divided into groups according the pathologic result of the prostate and the results of immunoassays. For statistical evaluation of the results, we used T test and Receiver Operative Characteristic curves. We identified significant differences between prostate adenocarcinoma and BPH (Benign Prostatic Hyperplasia). Based on the statistical data Nt-BPP can be recommended for clinical use as a test for detection of prostatic adenocarcinomas. However in patients with PSA values above the upper limit of normal (>4.0\u2009ng/ml) and Nt-BPP \u2264152\u2009ng/l, prostate histological evaluation (DRE, TRUS, biopsy) should be performed. J. Clin. Lab. Anal. 21:320\u2013325, 2007. \u00a9 2007 Wiley periodicals, Inc.<EOD> The FDA\u2019S Approval of the Pfizer and Moderna Vaccines for Emergency Use: An Ethical Analysis\nPrior to their emergency approval, the Pfizer and Moderna COVID-19 vaccines were tested on tens of thousands of healthy, young adults in only one trial in each case. Although that is the best method to ensure efficacy and estimate how the vaccines will work in the general population, the trials could not examine the impact of the vaccines in a target population who may be at especially high risk for serious disease if they become infected \u2014 namely elderly adults<EOD> The Impact of Stereotactic Radiosurgery on Pain in Patients with Large Brainstem Cavernous Malformations\n\nIntroduction: Stereotactic radiosurgery",
        "label": 0
    },
    "600": {
        "output": "A: You need to keep a list of all patient notes and the corresponding clinical trials in a \nList (List is a python class, see docs for details). You can then use that list and a for loop to iterate over all patients. \nfor pat in PATIENT_LIST:\n    clinical_trials = \n    # your logic goes here\n\nA: \nThis code snippet should help with some basics. \nimport operator\n\n# Note the use of a dict to make the mapping between patient id number and trial id\n# (as opposed to a tuple / list)\ntrials_by_patients = dict(\n    (i for i, p in patient_id_list.iteritems() if i%100 == 0))\n\ndef assignTrial(trial_index_to_assign, patientId):\n\n    trialName = trials_by_patients[patientId]\n\n    if trialName is None:\n        # trial name didn't exist in the dict, so we make a new trial\n        newTrial = Trial('Trial Name')\n\n        # assign a unique random id to the trial so that if we check in a second\n        # pass, we can know what this trial refers to\n        newTrial.randomIdId = trial_index_to_assign % len(trials_by_patients.keys())\n\n        # add a second line that saves this trial to the list of existing trials\n        # (also add in the trial ID of the patient in the patientId slot)\n        trials_by_patients[patientId] = newTrial\n\n    else:\n        # if this trial's ID wasn't already there, we create a new trial for that patient\n        if newTrial.randomIdId.find(trials_by_patients[patientId].randomIdId) % len(trials_by_patients.keys()) != trialName.randomIdId:\n            newTrial = Trial('Trial Name')\n            newTrial.randomIdId = trialName.randomIdId% len(trials_by_patients.keys())\n            trials_by_patients[patientId] = newTrial\n\n    return",
        "label": 0
    },
    "601": {
        "output": "<EOD> Clinical manifestations of rheumatic fever.\nDemographic changes have impacted the present-day population in many ways. For instance, the average life span of people has increased; there are more elderly people in the population; more women enter the labor force; and there is an increase in racial mixture of the nation's population. These changes have resulted in the emergence of a variety of clinical problems: acquired immune deficiency disease syndrome, sexually transmitted diseases, and chronic illness such as diabetes and hypertension. In addition, there are a variety of rare disorders being diagnosed more frequently for multiple reasons. The incidence of acute rheumatic fever is one such example. In the pre-antibiotic era, rheumatic fever and rheumatic heart disease were the leading causes of acquired heart disease in young individuals.1,2 At present, this disease accounts for 11.1% of acquired valvular heart disease in the United States.3 A worldwide decrease in the incidence of rheumatic fever from 48 cases per 100,000 children in the 1960's to 59 annually per 100,000 population in the 1980's has been reported.4 This decline is particularly noticeable in developed countries. For example, the incidence of acute rheumatic fever decreased from 37.7 cases per 100,000 in the late 1940's in England and Wales to 3.4 per 100,000 in 1973. One contributor to the decline in rheumatic fever in the western world is the improvement in sanitation and better living conditions for children. In less-developed countries in Asia and South America, however, the incidence of rheumatic fever remains significantly high, between 57 to 125 cases per 100,000 children.5,6 A number of factors explain the increased incidence of acute rheumatic fever in the less-developed populations. These include overcrowding, lack of adequate sanitation and facilities, and poor nutrition. Rheumatic fever",
        "label": 0
    },
    "602": {
        "output": "**Examples of Trial-Level Eligibility**\n\n### Eligible\n\n| patient_id | status | reason |\n|:----|-------|--------:|\n| Patient_1 | 2) Eligible | Eligible according to clinical trial inclusion criteria |\n| Patient_2 | 0) Excluded | Excluded on the grounds of trial's exclusion criteria |\n| Patient_3 | 1) Not relevant | Not relevant enough to qualify |\n|\n\n### Inclusion Criteria of the trial: \n- 40-80 years of age\n- Right hand dominance\n- Patients are asymptomatic\n- Baseline doppler study with a peak systolic velocity of 400cm/sec\n- Patients are candidate for carotid artery stenting, TIMI flow of 1,2 or 3\n- 80% or greater stenosis of distal common or internal carotid artery, as determined angiographically, as defined in ACAS\n- Subjects are willing/able to complete follow-up visits\n- Subjects are able to give informed consent\n- Patient has clinical diagnosis of stroke\n\n\n##### Exclusion Criteria of the Trial: :\n- Patients with a history of seizures\n- TIA/stroke not related to stenosis in target artery\n- MRI contraindications incompatible with SWI-MRI (e.g. ferromagnetic implants, claustrophobia, patient is unable to hold still for the scanning time)\n- Carotid stenosis <30%\n- Any severe stroke and not eligible for carotid artery stent placement due to neurological contraindications\n- History of carotid intervention (e.g. carotid artery stenting, surgical intervention)\n- History of Mental State Examination (MMSE) <24\n- Carotid artery lesions >15mm in diameter\n- Cardiac surgery, cardiologic interventional treatment (PCI), or aortic aneurysm repair <3 months\n- Stroke surgery or reperfusion therapy (int",
        "label": 1
    },
    "603": {
        "output": "## [INST] Tutorial\nLet's use a `tutorial package`, which is recommended for data manipulation tasks. \n\nimport { tutorial } from \"@n-3d/data-handling-and-analysis\"; tutorial(); [TUT] Installment 1 Install your `tutorial` package.\n\nInstructions. You will receive a piece of paper that contains nine questions that are needed to be answered. You have 10 minutes to accomplish the tutorial. You can only refer to your papers but do not discuss the problems with other persons.\n\n# Problem 1\n\nYou are given a file, which contains the data used in the previous tutorial. You can use `head`, which will display part of the file in your terminal for inspection. Now the task is to get all five rows and print them in your screen.\n\nThe solution is: \n\n`head -n 5 *1.txt`; [TUT] Print five rows from the `1.txt` file\n\n# Problem 2\n\nNow you are given a file `2.txt` with some numbers. You will use the `grep` command for extracting the specific numbers. You will have three minutes to accomplish the task.\n\nSolution: \n\n`grep -w 1,2,3,4,5 2.txt`; [TUT] Retrieve the numbers from the `2.txt` file (1,2,3,4,5)\n\n# Problem 3\n\nNow you are in the `main` directory of the current repository in your interactive shell. Create a file named `3.txt` by typing `touch 3.txt` and then use `vi` editor. There are two commands to add a single row of data to the file, `insert` and `a`. Use these two commands in an interactive shell to add rows 1 and 4 to the `3.txt` file. Your task is a 17-minute one.\n\nSolution: \n\n-  Add the content of lines 1 and 4 in `3.txt`: vi - 17 minutes [TUT] Add lines 1 and 4 in the `3.txt` file\n\n# Problem 4\n\nNow you see `4.txt` with the content [text] (this is a placeholder). Your task is to",
        "label": 0
    },
    "604": {
        "output": "### <a name=\"recall\"></a> Test Your Coding [testoutcomes] (Coding)\n\n[Instructions in Section <a href=\"https://bookdown.org/snowshoe/coding_challenge_2_study/_build/html/instructions_coding_3_study.html\">INST](#instructions) of Bookdown Documentation](https://bookdown.org/snowshoe/coding_challenge_2_study/_build/html/instructions_coding_3_study.html)\n\nYour code looks fine. \ud83c\udfc6\ud83c\udfc6 \n\n> **Awesome! <NAME>, you've done the next-level. \ud83c\udf89\ud83c\udf89**\n\n### <a name=\"summary_and_commentary\"></a> Summary and Commentary [summary_and_commentary] (Documentation)\n\nFor a second-take look, please re-read the entire test section. You should read it several times, for 1) to recall the details of the code snippets and 2) to summarize the code and comment for the code snippets.\n\nAbove all, it's important to get an overview of your code and make summaries and comments together. Such tasks are helpful to make you think critically and think deeply.\n\n[Instructions in Section <a href=\"https://bookdown.org/snowshoe/coding_challenge_2_study/_build/html/instructions_summary_and_commentary_8_study.html\">INST](#instructions) of Bookdown Documentation](https://bookdown.org/snowshoe/coding_challenge_2_study/_build/html/instructions_summary_and_commentary_8_study.html)\n\nHere's the summary/comment of your code snippets in this challenge:\n\n<i class=\"fa fa-3x fa-file-text-o\"></i>\n\nFirst Look: In Case of Clinical Study of Diabetes\n\n<i class=\"fa fa-3x fa-file-text-o\"></i>\n\nYour code has been shown to the clinical data.",
        "label": 0
    },
    "605": {
        "output": "## Eliminate the incorrect code\n\nHere is the correct code:\nTrial-level eligibility: 2) Eligible.\n\n## Exercise 4\nExercise 4 was designed for your home environment. You should solve the Experiment 4 using the MATLAB online platform. \nHere is Experiment 4 in the following link:\n[?]\n[INST] You are now in the classroom to solve the Exercise 4 with our instructor, Professor Xiaoxian Dong. \nProfessor Xiaoxian Dong:\n\nHere, we investigate the efficiency of using eligible-coded image retrieval techniques for medical image retrieval applications. First, we need to find the suitable medical image. \nWe can use the following code: \nimread('/home/demo/1.jpg')\n\nI expect you get the image on the right side of the Figure 1.\n\nFigure 1: The image captured with imread() function. \n\nNext, we need a number for labeling the images. We can set the code at the following code: \nnumber \nimread('/home/demo/2.jpg');\nset(0, . . . .g); set(1, . . . .a)set(2, . . . .l) imread('/home/demo/3.jpg');\nset(3, . . . .n); set(4, . . . .t) set(5, . . . .p) set(6, . . . .q)\nimread('/home/demo/4.jpg');\nset(7, . . . .e) set(8, . . . .r)\n\nIf you use the imread function to capture the images, you should replace the '/home/demo/ ' in the figure 1 with the file_path you stored previously. \nNow you can use the following code into label the images: \n[demo_num, label_demos] = read_demo_num(:);\nimshow()\n\nAt the end of the lesson, please complete the following task: \n[?]\n[END]\n<EOD> A Difference to Notice: Clinical Characteristics between Patients with and without Hyponatremia at Time of Hospital Admission",
        "label": 0
    },
    "606": {
        "output": "# Methods\n\n## Using ELIGIBILITY\nEligibility can be used by selecting the `Eligibility` button under the `Analysis` column in the `Data Table` by right clicking.\n\nAfter you click the button, the eligibility table will be shown. After that, we can add eligibility table based three types of variables: output, input & exclusion conditions. For output, input variable & exclusion condition, just select `output`, `input & exclusion condition`, or `exclusion condition`. Next, we need to define the type. After you define the type, you can use the value. The type for eligibility & input variables is `trial-level` for trial and `patient-level` for patient.\n\n### Output\nAll outputs are `binary variables`. This means that they should return 0 and 1. If we have patients in the trial, we use `Trial-level eligibility: <0; 1; 2>` and the interpretation is as follow:\n- `Triallevel eligibility: 0` means the trial excludes the patient because of patients do not meet the inclusion criteria\n- `Triallevel eligibility: 1` means the trial includes the patient because the patient meets the inclusion criteria\n- `Trial-level eligibility: 2` means the trial excludes the patient because",
        "label": 1
    },
    "607": {
        "output": "The output format is the same as for `Slice-level eligibility` above: `Trial: {2} patient: {0} \n\nRemember, the assignment `Trial-level eligibility = 1` indicates that a subject is excluded. On the other hand, the assignment `Trial-level eligibility = 2` indicates that a subject is qualified. A patient is eligible if the evaluation at trial-level eligibility is equal to 2 in all clinical trials (i.e., both a clinical trial and a patient are `Eligible` if you type the command `trial_level_elig: \"2\"). \n\n[INST]\n\n### Testing\nIn the last task, we need to compare the `Trial-level` eligibility and the `Slice-level eligibility` of all patients with the criteria. \n\n### Slice-level eligibility Testing\nThe program `Slice-level eligibility.ipynb` will test the criteria defined above. \n\n### Trial-level eligibility Testing\nThe program `Trial-level eligibility.ipynb` will test the criteria defined above. \n\n# Exposition\nIn the \"Course structure\" section you can read how to organize and study the courses.\nYou have to get acquainted with the material of course I, II and III. In the following links you can see the slides of the course:\n- Course I: Inverse Probability Weighting (IPW) and Nonparametric IPW (NP-IPW). Course I_material.pdf\n- Course II: Target Trial Concept. Material_course-II.pdf\n\nThe Course website:\n- Course I - Inverse Probability Weighting\n- Course II - Target Trial Concept\n- Course III - Estimation, Optimization and Causal Inference\n- Course IV-Cause-Effect Relationship and Precision Medicine\n\nThe first homework.\n\nHomework: Assignments\n- IPW-homework.pdf\n- Target-Trial-Homework.pdf\n- NP1-Causal-inference-homework.pdf\n-",
        "label": 0
    },
    "608": {
        "output": "You should note the output from the evaluation script. You will be presented with the results from the evaluation of patients' entries. This is a three-element vector output from the evaluation script, the first element is 1 or 2, the second element is 0 or 1, and the third element is a numeric value. The numeric value corresponds to the final score in Equation 2 and can be further used to determine patient triallevel eligibility.\n- The output from the evaluation script is `1 0 176.043` for the patient above.\n- The patient satisfies both inclusion and exclusion criteria.\n- The score is 176.043.\n- The patient should be excluded from the study because the inclusion criteria were not met, and the final score 176.043 does not satisfy the threshold value 225.231.\n\n## Exercise: \nExercise for you is to perform one random patient data entry. The only difference to the data entry exercise above is the value for the `SCORE:`. The actual value will be different in each trial, it is recommended you to perform at least 10 random patient data entries.  You will be presented with the results from the evaluation of patients' entries. Here is example data for 10 trials. \n[INST]  Exercise: \nIn this exercise, you will use the same example patient entry for the data entry exercise above. The only difference is for the `SCORE:`. You need to do more than 10 random patient data entries. The actual value will be different in each trial, it is recommended you to perform at least 10 random patient data entries. \n[INST]  \n![](https://github.com/bjh2015/data entry exercises/blob/master/images/data entry.pdf)\n\n# 1 Trial-level eligibility Evaluation script:\n\n## Running time: 9 sec; execution time: 23 sec;\n\n1 Trial-level eligibility Evaluation Script [https://b22671563.github.io/data entry exercises/1%20Eligibility/1Eligibilty%20v2.ipynb?filepaths=%",
        "label": 1
    },
    "609": {
        "output": "### Case 6\n\n### QUESTIONS?\n\n**Question**\n\nYou are tasked with constructing an evidence-based decision-making process for a research study on a potential clinical trial, aiding researchers to make better use of available research data and resources. The researchers are in search of a new drug to cure a particular disease. Based on literature surveys, they have decided to conduct a proof-of-concept study on rats. It needs to be as detailed as possible. One of the main prerequisites for any research is the ability to keep costs and time to a minimum which translates directly to the accuracy and quality of the research.\n\nAn evidence-based decision-making process will allow researchers to identify all possibilities and risks associated with new drugs, and provide the researchers with a clear overview of the situation so that they can be used for developing a strategy for conducting the research.\n\n##**What are the objectives of the research proposal? \n\n**Objective 1**:\n\n**What are the research questions that are of interest to you?**\n\n**Research Question**  1. How to evaluate the risk of the study as well as the risk to the participants.\n\n**Research Question**  2. Compare various drugs with the same dosage on the same participants and observe if one drug works better than another, if any.\n\n**Research Question**  3. Assess the potential side effects and risks that are of interest to the study, including the long term effects on the subjects.\n\n**Research Question**  4. What are the ethical and safety considerations that may occur for the participants?\n\n**Research Question**  5. How can we make the research more cost-effective?\n\n##**What variables are important and will you include in the study?** \n\n**Variable**  1. The participants.\n\n**Variable**  2. The researchers.\n\n**Variable**  3. The drugs.\n\n### QUESTIONS?\n\n**Question**\n\nYou are tasked with constructing an evidence-based research proposal on a particular research study, aiding researchers to make better use of available resources and research data.\n\n\n|\n\n<EOD> Epidural catheter malrotation",
        "label": 0
    },
    "610": {
        "output": "_____________________________________________________________________________ \u00a9\ufe0f Copyright 2020 HIMSS. All rights reserved. Use of these materials is strictly prohibited unless otherwise specified. _____________________________________________________________________________ \u00a9\u00ae Copyright 2019 HIMSS. All Rights Reserved. Use of these materials is strictly prohibited unless otherwise specified.<EOD> Diastereoselective conjugate addition of thionium ylides to \u03b1,\u03b2-unsaturated ketones.\nEnantiomerically pure and deprotonated conjugate addition adducts can be generated by the diethyl thionium ylide to \u03b1,\u03b2-unsaturated ketones. The diastereoselectivity of the addition of the thionium ylides was dependent on the structure of the \u03b1,\u03b2-unsaturated ketones. The stereoselective conjugate addition reaction was carried out under mild reaction conditions, and the products could be obtained in moderate to excellent isolated yields at ambient temperature. The deprotonated conjugate addition products can also be easily converted to chiral 2-(Z)-hydroxycarboxylic acids and \u03b3-lactones by ester hydrolysis and lactonization.<EOD> .\nA 62-year-old man presented to our hospital after a traffic accident. Chest radiography showed pneumomediastinum and pneumothorax of the left side. He was admitted because of a fracture at the neck of the left clavicle. On the next day, respiratory status suddenly worsened and he developed respiratory distress immediately. Chest radiography revealed an increased pneumomediastinum and elevation of bilateral hemidiaphragm. Although the pneumothorax and pneumomediastinum had disappeared 9 days after, hypoxemia and pulmonary infiltrates persisted. He was hospitalized and treated by conservative treatment. Nine days after the pneumothorax, the patient died of respiratory failure and septic shock. At the autopsy, a massive pneumomediastinum due to lacerations at the esophagus and cervical trachea was revealed. In the bronchus of both lungs, foci of diffuse alveolar damage were found and severe inflammatory",
        "label": 0
    },
    "611": {
        "output": "[1] You can run R via the Rscript command inside the R console of the Jupyter notebook.\n\n\u00a9 2019 - 2020 Hacettepe University, Turkey. This work is licensed under a Creative Commons Attribution 4.0 International License.\n<EOD> .\nThe authors report their experience in patients with acute coronary syndromes who required urgent angioplasty but were under no anticoagulation. After analyzing 19 patients, no complications occurred and all of them underwent angioplasty with good procedural results.<EOD> Role of AMP-activated protein kinase in the potential actions of glucocorticoids on intracellular triglyceride and AMP concentration in HL-1 cardiomyocyte cells.\nGlucocorticoids activate the rat liver 5'-AMP-activated protein kinase (AMPK) by two possible mechanisms, through changes in AMP concentration or by direct action on AMPK. In HL-1 cardiomyocyte cells there is no effect of dexamethasone (0.1, 1, and 10 micromol/L) or of ACTH (0.1, 1, and 10 micromol/L) on AMP concentration and, at physiological doses, they have no effect on AMPK activity. Neither insulin (0.1 and 10 microU/mL) nor isoproterenol (0.1 and 10 micromol/L) had an effect on AMP nor on AMPK activity, the AMPK level being unaffected by these different compounds. Under our experimental conditions, AMPK may not play any physiological role in the regulation of cardiomyocyte metabolism because HL-1 cells, even under conditions that promote cell survival, do not respond with AMPK activation. AMP-activated protein kinase was also investigated as a possible modulator of the effect of glucocorticoids on triglyceride content in HL-1 cells, but the addition of dexamethasone decreased triglyceride accumulation without change in AMP concentration and AMPK activity. In addition to these findings, the",
        "label": 1
    },
    "612": {
        "output": "## 3\n\\documentclass{springdefault}\n\\usepackage{amsmath}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{fontenc}\n\\newcommand\\cyr{\n\\renewcommand\\rmdefault{wncyr}\n\\renewcommand\\sfdefault{wncyss}\n\\renewcommand\\encodingdefault{OT2}\n\\normalfont\n\\selectfont}\n\\usepackage{textcomp}\n\\usepackage{mathrsfs}\n\\usepackage{upgreek}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n\\begin{questions}\n\\question\n\\task Exercise 1.2: Exclusions\nFind the exclusion criteria for patients with mild to moderate CTTH. You have to find the sentence which does not conform to the inclusion criteria of these patients or to the exclusion criteria.\n\n\n\\task Exercise 1.2.1: No Exclusions Found in the Note\nExercise 1.2.1: No Exclusions Found in the Note\n\n\n\\task Exercise 1.2.2: Exclusions Found in the Note\nExercise 1.2.2: Exclusions Found in the Note\n\n\n\\end{questions}\n\n\\end{example}\n\n## 4\n\\documentclass{springdefault}\n\\usepackage{amsmath}\n\\usepackage{amsfonts}\n\\usepackage{amssymb}\n\\usepackage{fontenc}\n\\newcommand\\cyr{\n\\renewcommand\\rmdefault{wncyr}\n\\renewcommand\\sfdefault{wncyss}\n\\renewcommand\\encodingdefault{OT2}\n\\normalfont\n\\selectfont}\n\\usepackage{textcomp}\n\\usepackage{mathrsfs}\n\\usepackage{upgreek}\n\\setlength{\\oddsidemargin}{-69pt}\n\\begin{document}\n\\begin{questions}\n\\question\n\\task Exercise 1.3: Exclusions\nFind the exclusions in the trial information with respect to the patient's age, sex and smoking status. You should write these exclusions in the form: EXCLUSION = 90 - 99 years = Yes.",
        "label": 0
    },
    "613": {
        "output": "- Your answer\n- 0 \uf0a7\n- 1 \uf0a7\n- 2 \uf0a7\n\n### Exclusion criteria\n\n> ##Clinical trial exclusion criteria\n\n- Age <18 >/= years\n- Weight <60 kg\n- Unable to maintain a consistant dosing regimen of aspirin from the baseline visit to the final visit\n- Unable to comply with all protocol requirements, including study procedures and/or restrictions\n\n- No need of aspirin therapy (81 mg to 325 mg daily) at the time of screening and unable to maintain a consistent aspirin dosing regimen from the baseline visit through the final study visit\n\n- Current prescribed oral thienopyridine therapy, including prasugrel, prasugrel metabolite (RSR1001), or clopidogrel (Plavix); or have received clopidogrel treatment within 7 days postpartum.\n\n- History of current myocardial infarction (MI)\n- Prior history of percutaneous transluminal coronary angioplasty (PTCA), stent, or coronary artery bypass grafting (CABG) coronary artery disease (>/= 50% obstruction) in at least one coronary vessel after angiography - History of coronary artery disease and/or PCI and/or CABG - Left ventricular ejection fraction (LVEF) < 30% as measured by echocardiogram, radionuclide isotope study\n- History of stent thrombosis\n- Incomplete coronary artery bypass graft (CABG) revascularization\n- Uncontrolled hypertension or systolic blood pressure <95 mm Hg\n- Clinically significant bleeding tendency (eg, recurrent bleeding, prolonged bleeding)\n- Concurrently participating in another clinical study\n- History of serious hypersensitivity to RS26694, a thienopyridine (eg, thrombocytopenia; or Stevens-Johnson syndrome)\n- History of unexplained transient neurological disorder or transient ischem",
        "label": 0
    },
    "614": {
        "output": "\u00a9 <NAME>, 24 August 2018\n\n\n\n---\n<a id=\"inst-sectionref4\"></a>\n\n## Table S1\n\n* * *\n* * *\n* * *\n\nThe table below summarizes the requirements or recommendations of each element/section for each category. It compares the requirements/recommendations of the training data, as described in the *Kaggle competition*.  \n  \n#  Table S1 Category-1 Instructions  \n**Table S1.1**\n\n* * *\n* * *\n* * *\n\nThe table below summarizes the requirements or recommendations of each element/section for each category. It compares the requirements/recommendations of the training data, as described in the *Kaggle competition*.  \n  \n#  Table S1 Category-2 Instructions  \n**Table S1.2**\n\n* * *\n* * *\n* * *\n\nThe table below summarizes the requirements or recommendations of each element/section for each category. It compares the requirements/recommendations of the training data, as described in the *Kaggle competition*.  \n  \n#  Table S1 Category-3 Instructions  \n**Table S1.3**\n\n* * *\n* * *\n* * *\n\nThe table below summarizes the requirements or recommendations of each element/section for each category. It compares the requirements/recommendations of the training data, as described in the *Kaggle competition*.  \n  \n#  Table S1 Category-4 Instructions  \n**Table S1.4**\n\n* * *\n* * *\n* * *\n\nThe table below summarizes the requirements or recommendations of each element/section for each category. It compares the requirements/recommendations of the training data, as described in the *Kaggle competition*.  \n  \n# Table S1 Category-5 Instructions\n**Table S1.5**\n\n* * *\n* * *\n* * *\n\nThe table below summarizes the requirements or recommendations of each element/section for each category. It compares the requirements/recommendations of the training data, as described in the *Kaggle competition*.",
        "label": 1
    },
    "615": {
        "output": "__NOTE__: Your task is to assess trial-level eligibility for each patient note. Your task is repeated for each patient and therefore you should fill each line after the patient-level eligibility with the corresponding trial-level eligibility. For example, if patient-level eligibility is 2 for the given patient, this must be recorded as 2) Eligible after Trial-level eligibility. That means, after you filled in both `Trial-level eligibility:\n\n___[IN-1]___` ____[IN-2]___`\n\n___[IN-1]___` ____[IN-2]___`\n\n___[IN-1]___` ____[IN-2]___`\n\n___[IN-1]___` `trial-level eligibility: 2) Eligible.\n___[IN-2]___` `trial-level eligibility: 2) Eligible.\n___[IN-1]___ `trial-level eligibility:\n\n___[IN-1]___` `trial-level eligibility: 2) Eligible.\n___[IN-1]___` ____[IN-1]___` `trial-level eligibility: 2) Eligible.\n___[IN-1]___` `trial-level eligibility:\n\n___[IN-1]___` ____[IN-2]___` `trial-level eligibility: 2) Eligible.\n___[IN-1]___` `trial-level eligibility:\n\n___[IN-2]___` `trial-level eligibility: 1) Not relevant.\n\n___[IN-2]___ `trial-level eligibility: 2) Eligible. \n \n__NOTE__: There is no input from patient-level eligibility to patient-level assessment_ or_from _Trial-level eligibility to Trial-level assessment. In your task is repeated 5 times, you should fill the lines after patient-level eligibility `___________[patient-level eligibility]__________()` with trial-level eligibility as `____________[trial",
        "label": 1
    },
    "616": {
        "output": "<EOD> Effect of a proton pump inhibitor, omeprazole, on the development of an alkaline shift of intragastric pH during the weaning of parenteral nutrition\nBackground and objective: The development of an alkaline intragastric pH is a common problem during the weaning of parenteral nutrition (PN) and the use of proton pump inhibitors (PPI) has been suggested as a possible solution. In this study, we evaluated the effect of omeprazole treatment on the development of an alkaline shift of intragastric pH (\u22657.4) during weaning. Methods: Between 1 April 1996 and 1 August 1999, we analyzed consecutive patients who received PN and were weaned without omeprazole in our Nutrition Support Service. This group was named historical controls. Between 7 September 1999 and 30 April 2003, we used omeprazole to prevent the development of an alkaline shift during the weaning of PN patients in three different studies, and this group of patients was named as being treated with omeprazole. The percentage of patients with gastroesophageal reflux disease (GERD) before starting the PN, and the duration of PN, were compared in the two series. Results: Overall, a total of 93 patients were considered. Fifty-three were in the control group and 40 were in the omeprazole group. In the control group, 27 patients (50.95%) showed a significant alkaline shift within the first week of weaning. In the treatment group 11 patients (27.5%) showed it. The two groups were statistically significantly different (P < 0.028). On the other hand, no statistical difference was found with regard to the percentage of patients with GERD. The duration of PN was longer in the omeprazole group than in the control group. Conclusions: Omeprazole is helpful in preventing the development of an alkaline shift during the weaning of PN.<EOD> Correlation between serum prostate-specific antigen and bone formation rate in hemod",
        "label": 0
    },
    "617": {
        "output": "Let's solve the first one. Who is the target population of the clinical trial?\nThe primary efficacy endpoint is the percent of subjects having either seroconversion (a 4-fold or greater rise of hemagglutination inhibition titer from prevaccination to Day 32 or Day 39, whichever was greater) or a neutralizing antibody titer of at least 160 at Day 32 or Day 39 (whichever was earlier) following vaccination.\nPeople with the specific type or degree to whom the intervention will be offered.\nThus, the target population of the listed trial can apply to children and adolescents aged 6 months through to <18 years who had a previous episode of influenza-like illness (disease characterized by fever, myalgia, headaches, and other non-specific symptoms) in the season preceding vaccination.\nThe second one is quite different from the above one:\nThe efficacy and safety endpoints for this group were:\nSerological response, defined as postimmunization hemagglutination-inhibition titers \u226580 at day 42 compared to pre-immunization titers (primary endpoint).\nClinical efficacy endpoint defined as the % of subjects having a confirmed influenza infection from day 1 to 28 postvaccination.\nClinical efficacy:\n\nThere would be a lot of similar situations in clinical trials\nSo, you should get used to think that the target population may be allergic people, elderly people, and pediatric patients. In general, there is no rule about who your target population is as you should choose and it varies case by case (even in the same trial)\n\nFor your training, you should come up with some answers about the last question. You will be graded on these answers. Your goal is to apply the concepts learned in this block to the clinical trial design. \nQuestion: Please explain the target population of this clinical trial. \nAnswer:\nAs you may know, the target population of the trial is people with a previous episode of influenza-like illness (disease characterized by fever, myalgia, headaches, and other non-specific symptoms) in the season preceding",
        "label": 0
    },
    "618": {
        "output": "# Author contributions\nSunghee Han and Michael Mordasini were involved in the development of the algorithm and implementation of the methodology to the problem and have made substantial contributions to drafting the manuscript. Hyun-Hee Cho provided assistance with implementation of the algorithm.\nMichael Mordasini - University of California, San Diego and University of Texas, Houston, San Diego, CA, USA\n\n# Financial Disclosure\nNothing to disclose.\n\n# Competing interests and funding\nNothing to disclose.\n<EOD> Bone Marrow Adipocytic Changes in Response to Estradiol or Estrone and Inhibition by Androstenediols in a Mouse Model of Fracture Repair\nAdult human bone marrow contains a subset of adipocytes, called marrow adipocytes (MAs), that can be identified immuno histochemically as a positive stain with fat droplets. Fat-cell density is known to correlate directly with age (e.g., obesity) and inversely with bone density, suggesting a relationship between fat and marrow in adult bone. To test the role of sex hormones on the development of marrow adipogenesis, we examined the response of bone marrow fat cells during fracture healing in mice. We found that bone marrow fat (BMA) increased significantly within 2 days after fracture. The amount of BMA increased with time and was maintained at a high level for at least 1 week. A similar increase was observed in ovariectomized (OVX) mice, suggesting that hormonal factors other than the estrogen hormone may be involved in BMA development in this fracture mouse model. To specifically determine the role of androgen in the bone marrow adipocyte development, we used the same fracture injury model and examined the effects of androgen in combination with estrogens. Addition of dihydrotestosterone  or dihydrotestosterone propionate (10 to 100 \u03bcg/mouse/day, subcutaneously) to ovariectomized mice injected with both estradiol (250 ng/mouse/day, subcutaneously) and estrone (0",
        "label": 0
    },
    "619": {
        "output": "#### Solution 1 \n## Solution 1:\n`Trial-level eligibility: 1) Elapsed time: Eligible.;` `Trial-level eligibility: 2) Patient status: Not relevant.;` `Trial-level eligibility: 3) Inclusion criteria: Yes.;` `Trial-level eligibility: 4) Evaluation criteria: Evaluation is in progress.;` \n\n### [INST]\n## Solution 2\n## Solution 2:\n`Trial-level eligibility: 1) Elapsed time: Eligible.;` `Trial-level eligibility: 2) Patient status:\nPatient met all inclusion criteria, but has not yet been evaluated for eligibility based on exclusion criteria.` `Trial-level eligibility: 3) Inclusion criteria:\nYes.;` `Trial-level eligibility: 4) Evaluation criteria: Evaluation is in progress.`\n\n\n## Instruction\nI will show you the best solution for this problem using a programming method. \n\n**Solution:** You will write the following code to solve this problem: \n```\nclass Solution:\n    def decidePatientEligibility(self, patient_note: str, trial: str):\n        if patient_note[0].isdigit():\n            return False #0\n        else:\n            if len(patient_note) == 3:\n                if patient_note[1] == 'E':\n                    return False #2\n            else:\n                if patient_note[1] == 'D':\n                    return False #2\n            else:\n                if patient_note[1].isdigit() and patient_note[2] == '1':\n                    return True #1\n                else:\n                    if patient_note.rfind(patient_note[1]) == 2:\n                        return False #3\n                    else:\n                        if patient_note[1",
        "label": 0
    },
    "620": {
        "output": "You can see the above sample results using the `CSV Export` and copy and paste this JSON file into the console of your web browser, as shown in Figure 52. The code in the console outputs a data frame. \n[{\"Examiner\":19087},{\"Patient\":851},{\"InclusionCriteria\":0.0},{\"EvaluationCategory\":1.0,\"scale\":2.0,\"triallevelEligibility\":2.0}]\n\n### Exercise\n\n\nUse the example, complete a JSON-encoded string in the console below.\n\nNote:\nWhen you copy the JSON in the console, you change the type attribute of the object to `string`.\n\n> {\n> \"Patient\": 851,\n> \"InclusionCriteria\": 0.0,\n> \"EvaluationCategory\": 1.0,\n> \"scale\": 2.0,\n> \"triallevelEligibility\": 2.0\n> }\n\n[0] {\n    Patient: 851\n    InclusionCriteria: 0.0\n    EvaluationCategory: 1.0\n    scale: 2.0\n    triallevelEligibility: 2.0\n}\n[1] {\n    Patient: 19087\n    InclusionCriteria: 0.0\n    EvaluationCategory: 1.0\n    scale: 2.0\n    triallevelEligibility: 2.0\n}\n\n### Solution\n\n\nA: You have to encode the value yourself.\n> \n\"Patient\": 851,\n\"InclusionCriteria\": 0.0,\n\"EvaluationCategory\": 1.0,\n\"scale\": 2.0,\n\"triallevelEligibility\": 2.0\n\n<EOD> .\nThis article presents a reflection about the relationship of work and health of medical physicists in the field of cancer. The objective is to present the situation of the professionals and suggest possibilities to improve it. A descriptive study with the use of a survey was carried out with 23 medical physicists in the field of cancer of the state of Rio de Janeiro. The results show that there are problems related",
        "label": 1
    },
    "621": {
        "output": "[/TUTORIAL]<EOD> Effects of acute and chronic administration of nandrolone on prostate gland and sex accessory organs of the rat testes.\nEffects of 10, 15 and 20 days acute and chronic (10, 20 and 25 mg/kg body weight injected subcutaneously thrice a week for 30 days) administration of nandrolone on the morphology of rat prostate gland and sexual accessory organs were studied. In all the animal groups morphological alterations of the organs examined included: (1) degeneration and necrosis of the tubular epithelial cells, (2) hypertrophy of the Leydig cells, (3) decrease in the numbers of spermatogonia, primary spermatocytes and spermatids, (4) disintegration of the tubular framework, and (5) degeneration and necrosis of the myoid cells. However, degenerative and necrotic changes were less pronounced after chronic administration of nandrolone. These findings were consistent with the fact of reduced effects on the organs after repeated dose administration as compared to those observed on acute administration. The results obtained have shown that chronic nandrolone injection had no adverse effect on the morphology of the rat sexual accessory organs.<EOD> A systematic review on safety and efficacy of oral sodium nitrite as phosphodiesterase-5 inhibitor with respect to erectile dysfunction in men.\nINTRODUCTION\nErectile dysfunction (ED) is the inability to achieve and maintain an erection for satisfactory intercourse; many effective treatment options with satisfactory results are now available and one among them is oral sodium nitrite. This study aims to assess the efficacy and safety of orally administered sodium nitrite for erectile dysfunction.\n\n\nMETHODS\nStudies involving clinical use of oral sodium nitrite for erectile dysfunction were analyzed using both qualitative and quantitative methods.\n\n\nRESULTS\nOut of 85 studies retrieved, which were subsequently shortlisted, only 8 studies were included in this study out of which",
        "label": 1
    },
    "622": {
        "output": "__HINT__\nYou should always start with a blank line before the lines with the results or comments.\n\n\n\n__Explanation__\nAs you can see, you are presented with a patient note and a clinical trial. On the patient note, we extract the following features: age (46), family history of CAD (Y), physical activity (Y), HDL (53 mg/dL), LDL-C (545 mg/dL), fasting glucose (85 mG/dL), high cholesterol (Y), blood pressure (210/140 mmHg), and smoking habit (Y). On the clinical trial, we extract its title (The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients), summary (Laropiprant (LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) offers improved tolerability, supporting a simplified 1-2 g dosing paradigm and improved adherence. Statins and niacin improve endothelial function in cardiac patients, however, there is no data yet regarding the additive effects of raising HDL-C by ERN/LRPT and statins on endothelial function in cardiac patients. Thus the aim of the present study is to evaluate the impact of 3 months' administration of ERN/LRPT compared to placebo added to statins on endothelial function, assessed by brachial artery vasoreactivity in stable cardiac patients), and the inclusion criteria (Male or female \u2265 18 years; signed informed consent, Outpatient CAD patients on statin therapy. HDL-C < 40 mg/dL in males and < 50 mg/dL females. left ventricular (LV) systolic dysfunction \u2265 40% measured within the past 6 months. No changes in cardiac medications during 2 weeks prior to enrollment.presents",
        "label": 1
    },
    "623": {
        "output": "The patient-level eligibility statement is `patient-level eligibility: Eligible`, which refers to whether the patient meets the inclusion/exclusion criteria or not. \n\n```\npatient-level eligibility: Excluded;\npatient-level eligibility: Not relevant;\npatient-level eligibility: Eligible.\n```\n\n### TIPS\n\n* The only one eligibility is `patient-level eligibility: Eligible`, which is executed after the `Trial-level eligibility` statement. This statement appears in the last line by the use of `;;` command. \n\n* The patient-level eligibility statement is executed after the `summary` statement, not the `patients` statement. \n\n* The attributes extracted in the `summary` statement are used in the patient-level eligibility statement. \n\n* The `patient-level eligibility: Excluded;` statement has the same meaning as the `;#excluded` statement in Section 02.2.3.\n\n* The `patient-level eligibility: Not relevant;` statement has the same meaning as the `;#notrelevant` statement in Section 02.2.3.\n\n* Some fields in the original CSV file need to be processed when writing to CSV files or EXCEL files (see \n\n```\ndata = Table.inferred(pdat, trial.ID)\n\nfor patient in trial.trial_subjects do\n  df = {}\n  for key, value in pdat[tri",
        "label": 1
    },
    "624": {
        "output": "<EOD> A model for the relationship of preoperative anxiety to outcome measures in children undergoing strabismus surgery.\nPrevious research demonstrated the validity of the State-Trait Anxiety Inventory in children undergoing strabismus surgery, but the results suggested the occurrence of a unique anxiety response in these patients. The authors hypothesized that the unique anxiety was due to the surgical setting itself. Consequently, a model consisting of four factors was created. The first two represented preoperative anxiety as a state and as a trait, with the latter reflecting the \"average\" anxiety level in the general population of children. The third and fourth factors represented the influence of the postoperative environment (e.g., stress) and the degree of depression as a reaction to the surgical procedure. Confirmatory factor analysis of preoperative anxiety was performed on a sample of 103 children. A six-item scale was created with satisfactory reliability and validity. As predicted, the model suggested a strong effect of the environmental environment on children's preoperative anxiety and a weaker main effect due to surgery itself.<EOD> Genetic Variation at the Serotonin Transporter Gene Modulates Attentional Bias Following Trauma Exposure\n\nPost-traumatic Stress Disorder (PTSD) is characterized by heightened arousal, hypervigilance, exaggerated startle response, and attentional avoidance of traumarelated cues and is often associated with maladaptive behavioral patterns. Previous research implicates serotonin neurotransmission in post-traumatic hypervigilance and attentional bias (AB) towards threat, but its role in attentional avoidance following trauma exposure has not been assessed. This study aimed to test, first, whether the behavioral consequences of trauma exposure differ in individuals homozygous for the long (L) or short (S) allele of the serotonin transporter gene linked polymorphic region (5-HTTLPR), and secondly, whether this polymorphism is associated with differential AB. Forty university women undertook the Trier Social Stress Test, followed by the emotional Stroop task (EST), while their reaction time and error rates to the incongruent trials",
        "label": 1
    },
    "625": {
        "output": "## Trial-level eligibility\n\n``` r\nTrial-level eligibility\n```\n\n### [INST]\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces. here is the clinical trial: \nTitle: Adapt Monorail Carotid Stent System: A Postmarket Clinical Follow-up Study\n\n\nSummary: The purpose of this study is to get outcomes data for the Adapt Monorail Car",
        "label": 1
    },
    "626": {
        "output": "Tedium Vindicum!\n\nIn the following notebook, you will learn how to visualize these assessment procedures and patient notes into a dashboard.\n\n---\n\n**RUN**:  \n```\njupyter-notebook assessment-patient.ipynb\n\nRUN: \n- cd /Users/kostas/notebooks/Assessment\n- jupyter-notebook patient-notes.ipynb\n- jupyter-notebook assessment-patient.ipynb\n```\n\n**PLAY**:  \n```\ncd {working path}/Tutorials\n```\n\n![](Tutorials/jupyter-notebook-in-play-cell.png){:style=\"width:300px; height:600px;\"}\n\n\n<EOD> Molecular genetics of the human cytidine deaminase gene\nIn order to study the structure and the molecular basis of mutations responsible for deficiency of human cytidine deaminase (CDA), we determined the nucleotide sequence of the entire gene. Analysis of this 6544 bp sequence revealed 9 exons with typical exon-intron boundaries, and 5 distinct RNA transcription units; exon size ranges from 97 to 141 bp. These results indicate that the gene contains at least nine distinct RNA transcription initiation sites and, consequently, nine distinct cytidine deaminase isoforms. Each transcription unit can be transcribed either in the sense or in the antisense direction at the same locus. Examination of the 5'UTR revealed the presence of potential binding sites for many transcription factors related to the cytidine deaminase gene expression, and the lack of any potential transcription stop signals which would block transcription from the unique promoter located in exon 1.<EOD> Changes in the Rate of Thymidine Kinetics in Regenerating Bone In Vivo\nSummary To evaluate whether alterations in the rate of thymidine kinase phosphorylation during regeneration of the rat tibia reflect differences in growth rate, 12-mm tibial segments were obtained from Sprague-Dawley rats and were implanted into the legs",
        "label": 0
    },
    "627": {
        "output": "[TESTCASES] 4\n[/TESTCASES].\n<EOD> Incorporation of Cryptococcus neoformans genome-wide transcriptional data into antifungal susceptibility profile predictor\n\nBackground: Increasing global prevalence of antifungal drug resistance and susceptibility profile discrepancies have highlighted the need to develop improved antifungal susceptibility testing and monitoring methods. Predictive modeling approaches can supplement phenotypic susceptibility testing. Methods: We developed and tested an Antifungal Susceptibility Profile Predictor (ASPP) approach based on machine learning to predict susceptibility profiles from molecular data for the pathogenic yeast C. neoformans. The training set included 249 isolates from 33 states in the United States. The test set included 79 isolates obtained from various sources across the world. Prediction models in ASPP were developed using genome-wide transcriptional data derived from a published microarray dataset (GSE67312). Genome-wide transcriptional data generated from independent experiments were treated as an external validation set. The prediction models from training set were applied to the external validation set of 79 diverse isolates. The prediction of \"resistant\", \"susceptible-dose dependent\", \"susceptible\" profile was based on the minimum resistance profile. Results: Both the genome and transcriptome-based models had high prediction accuracy in training data (>95%). All the prediction models in ASPP showed better performance compared to the previously developed in silico models. They discerned drug resistance profiles with 100% prediction accuracy of resistant and 92.5% prediction accuracy of susceptible, and susceptible-dose dependent profiles from external validation set. Overall, ASPP provided better prediction results under unseen experimental data, which was evaluated using prediction accuracy, sensitivity, specificity and area under precisionrecall curve (AUC-PRC).Conclusions: We have demonstrated the usefulness of a genome and transcriptome-based ASPP approach in drug susceptibility profiling that may provide useful complementary data for clinical trials of antifungal therapy. This ASPP model may offer a convenient tool to test novel antifungal compounds and",
        "label": 1
    },
    "628": {
        "output": "# ClinTrial.pl Clinical Trial Assessment Protocol\nThis topic explains the Clinial Trial Assessment Protocol file. The Clinial Trial Assessment Protocol file stores the eligibility assessment of patients for clinical trials. The file is created by `ClinTrial.create`. The file must be created for each clinical trial protocol. For example, let's create a new file for a new clinical trial protocol: \n$ ClinTrial create\nNote: You should see a new blank Clinial Trial Assessment Protocol file in the user folder.\nAs you know, each trial-level assessment of eligibility is stored in a field. The first line of the Clinial Trial Assessment Protocol file stores the trial-level eligibility. In this example, the trial-level eligibility is `0). The subsequent lines of the Clinial Trial Assessment Protocol file store the eligibility of patients based on the following factors: `Gender: male',`Gender: female',`Disease status: diagnosed',`Disease status: not diagnosed',`Disease description: non-cancer',`Disease description: cancer',`Family history: yes',`Family history: no',`Family history description: positive',`Lifestyle: smoker',`Lifestyle: non-smoker',`Body mass index (kg/m2): 10',`Drug usage: yes',`Drug usage: no',`Drug description: statin',`Drug description: antiplatelet',`Drug description: lipid',`Drug description: antihypertensive',`Disease history: yes',`Disease history: no',`Alcohol abuse: yes',`Alcohol abuse: no',`Alcohol abuse description: drinker',`Drug history: yes',`Drug history: no',`Drug history description: use',`Race: Asian',`Race: other',`Race description: not white' and so on. If several patients are the same, the Clinial Trial Assessment Protocol file repeats the trial-level eligibility of patients based on gender, e.g., `$ cat trial_1",
        "label": 1
    },
    "629": {
        "output": "<EOD> .\nThe authors report a case of osteosarcoma in a 4-years-old boy, of his history, diagnosis and treatment. The prognosis associated with bone sarcoma is of great importance. The Authors underlie the important role of chemotherapy in these patients.<EOD> The Clinician\nPurpose: The objective is to describe the results of a projected to examine the influence of one particular physician on colleagues and patients in a small clinic. In addition, the authors intend to show that the clinician's function can be viewed and modeled with specific variables. Method: The authors gathered data from a questionnaire distributed to six physician colleagues of an oncologist who died in a car accident. The instrument measured the clinician's ability to encourage participation and maintain independence, his ability to provide structure and stimulate productivity and efficiency, his ability to assist subordinates in delegating responsibility, his ability to encourage innovation, his attitude toward the family and support system, and his overall performance as a Clinician. In addition, the family, his immediate colleagues, and other staff were allowed to comment on the deceased doctor's traits and work habits. Results: Respondents indicated the deceased doctor was better than peers at encouraging participation in discussions, setting goals, providing feedback, maintaining autonomy, providing structure and stimulating efficiency. Conclusion: The results of this study showed that a physician's ability to assist with delegation may play an important role in his effect with others.<EOD> Clinical evaluation of the performance of the LC200-Xpert HCV point of care and LC-FORT assays\nSUMMARY PCR-based HCV diagnostic tests could improve early-stage detection. In this study, we evaluated three test systems that provide detection of HCV genome by reverse transcription and the viral load by real-time PCR: the AmpliSens HCV R-gene, the COBAS AmpliPrep/COBAS TaqMan HCV and the new LC200-Xpert HCV system. We tested 620 plasma samples to determine the limit of detection of the COBAS system and the genome equivalents detected by the commercial tests. The commercial assays were compared to the COBAS, to H",
        "label": 0
    },
    "630": {
        "output": "[TUTORIAL] The next section is going to show you in Python code how to define a data frame with the patient data. We are going to start with a data frame with one observation. In other words, the data frame is empty. The next section will show you how to create the data frame and how to manipulate the data once you make the data frame.\n\n##### Create an empty data frame<jupyter_code>df = pd.DataFrame()<jupyter_output><empty_output><jupyter_text>Let\u2019s start with a simple patient data. The name of the patient has been changed to `person_code` to make the code more useful and to show you how to manipulate the data. The patient `age is in the fifth decade of life (45-59, 44 years exactly) and the patient has arthritis. The sex of the patient is male and the patient has a family history of coronary artery disease. The LDL-cholesterol and HDL-cholesterol levels of the patient are within normal range. The patient has no medical history of diabetes, hypertension, and smoking, physical activity, and other medical histories. The patient had no use of lipid-lowering medications. The carotid artery stenosis is estimated to be 98%. The patient has a bulky plate in the internal coronary artery of the left carotid artery and a 2 mm echogenic nodule, which is associated with the left carotid artery. The internal coronary arteries of the patient have several small echolucent patches.  For LICA, PSV and EDV cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively. LICA plaque was not a bulky plate but had a small patch and a 2-mm hypoechoic nodule, which was an echolucent plaque. The right internal carotid artery of the patient had several small plaques, both bulky and not a bulky plate. The plaque had two patches in the anterior and posterior walls of the left coronary artery. The size of the left coronary artery is about 17 mm. The stenosis is a bul",
        "label": 2
    },
    "631": {
        "output": "<EOD> Phase II randomized controlled trial of an internet-facilitated collaborative problem solving approach for improving coping and life satisfaction among survivors of primary bone sarcoma: results of the CODES trial.\nPURPOSES\nThis double-blind two-armed randomized controlled trial was conducted to evaluate the feasibility and preliminary efficacy of an internet-facilitated collaborative problem solving (CSP) approach to improve coping in a sample of patients diagnosed with primary bone sarcoma (PBS).\n\n\nDESIGN/METHODOLOGY/APPROACH\nTwenty-two participants were randomized into either a treatment group (n = 11) or a waitlist control group (n = 11). The participants engaged in the CSP protocol over a 10-week period and attended three one-hour individual telehealth therapy sessions conducted by a psychologist. Self-reports of coping, disease-related distress and life satisfaction were obtained from each participant at three points across the study; pre-intervention, mid-intervention and post-intervention.\n\n\nFINDINGS\nIn regard to the key objective and hypotheses, CSP participants demonstrated significant increases in cancer coping, reduced disease-related distress and improved life satisfaction over the course of the intervention. Significant improvements in coping and reductions in cancer and disease-related distress achieved at post-intervention did not remain significant when compared with the 10-week waitlist control period. At four-month follow-up, however, those assigned to the treatment group maintained their improvements in coping and continued to display reduced cancer-distress compared to those assigned to the waitlist control group.\n\n\nORIGINALITY/VALUE\nThe findings suggest that the internet-facilitated CSP approach is feasible and effective, at least in the short term, and warrants further evaluation in a larger randomized controlled trial utilizing an active control/placebo group and a longer follow-up evaluation.<EOD> An Easy to Recognize Incorrect Substitution at Position 495 in TNF Binding Domain of TNF (S495C) Alters Bioactivity of Human TNF in THP-1 Cells: A Novel Mutation in TNF Associated with Autoinfl",
        "label": 2
    },
    "632": {
        "output": "You should always repeat the output message by type of trial in the last line or the last lines by `type of trial`, `type of trial 1: `, `type of trial 2: ` by using the Python `f- string`. [INST] \nHere is a simple example:\n\n\n```python\n# Import \"patient.ipynb\" path variable \"path\". \n# Python code begins here.\n# The trial name should begin with \"NINJA-\" in this IPython Notebook. \n# \n# 1) For example, \"NINJA-1\", \"NINJA-1\". \nNINJA-1.text = open('patient.ipynb').read()\n# 2) For example, \"NINJA-1\". \n\nNINJA-1.text = '[0] Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial''s exclusion criteria)'\n# \uff18\uff17\uff0e\u5b9f\u65bd\u8005\uff20\u500b\u4eba\u304c\u7570\u5e38\u8005\u304a\u3088\u3073\u5b9f\u65bd\u8a08\u753b\u306e\u5b58\u7d76\u306b\u3064\u3044\u3066\u3001\u81e8\u5e8a\u7814\u7a76\u5bfe\u8c61\u8005\u306b\u8ca0\u62c5\u3092\u8efd\u6e1b\u3059\u308b\u305f\u3081\u306e\u8981\u52d9\u3092\u8b58\u5225\u3059\u308b\u898f\u7bc4\u306b\u3064\u3044\u3066\uff0c\u7a2e\u3005\u306e\u5b9f\u969b\u7684\u306a\u4e8b\u4f8b\u3092\u63d0\u793a\u3059\u308b\uff0e\u3059\u306a\u308f\u3061\uff0c\u500b\u3005\u306e\u7814\u7a76\u5bfe\u8c61\u8005\u9078\u629e\u7968\u3092\u793a\u3059\u3082\u306e\u3084\uff0c\u9069\u5207\u306a\u6a19\u6e96\u7684\u306a\u52b9\u679c\u91cf\u3068\u6709\u7528\u306a\u691c\u51fa\u91cf\u3092\u793a\u3059\u3082\u306e\uff0c\u60a3\u8005\u306e\u53d7\u3051\u5165\u308c\u306e\u72b6\u6cc1\uff08\u8ca0\u62c5\u306e\u5206\u914d\u3068\u8ca0\u62c5\u306e\u88dc\u6b63\uff09\uff0c\u6700\u5584\u306e\u7a2e\u3005\u306e\u5229\u76ca\u5bfe\u6d88\u3057\u306a\u3069\u3068\u3044\u3046\u4e00\u89a7\u306b\u304a\u3044\u3066\u7bc4\u56f2\u3092\u5e83\u3044\u3082\u306e\uff0c\u7279\u5b9a\u306e\u4eba\u3005\u306e\u80cc\u666f\u3092\u6709\u3057\u3066\u3044\u308b",
        "label": 0
    },
    "633": {
        "output": "## Summary evaluation\nPlease finish the following sentences to get the best grade you can for this exercise. Make it as if you were a patient's assistant looking at a patient's situation and explaining it to a layperson (i.e., a patient who does not know medical jargon and terminology). \n\n1) You are the clinical trial coordinator. Describe how the patient note and the eligible condition of the patient influence the trial evaluation.\n\n> 1_a) The notes help determine if he has a condition in which a drug is being tested, such as the coronary artery disease (CAD), lipid disorders, and high cholesterol level.\n1_b) My evaluation of his medical record is that patient is eligible for this study. He is a 46-year-old man with the complaint of dizziness, and headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus, and he is physically active.\n1_c) Based on his clinical notes, I would refer him to a specialist physician, and request my colleagues to be part of his treatment due to the presence of risk factors of heart disease.\n1_d) I've evaluated his medical records, and there is the likelihood of the efficacy of the treatment, which would be conducted according to his medical records to determine his condition.\n1_e) He is a good candidate of the study; he has the eligibility assessment of the trial, especially in the trial-level and the exclusion criteria assessment.\n\n2) You have a conversation with the patient. Discuss your patient's assessment with the trial-level eligibility results.\n\n> 2_a) Thank you for taking the time to explain to me in more detail the study. Can you please describe, with me, how many visits I would have in order to get results?\n2_b) Your report of a patient with the complaint of dizziness, and headaches is interesting. I would like to hear more about his coronary artery disease (CAD) with high cholesterol, and lipid disorders which would make him a candidate and a good participant based on the trial-",
        "label": 1
    },
    "634": {
        "output": "Please note that we used Python for the clinical note and included a simple Python function for the generation of random numbers, which is also provided in the link below. Please just copy and paste the function to your code without any modification.  [INST]\n\nLink: [instra]<EOD> Effect of pyridoxine supplementation on serum zinc concentration in the young adult male.\nThe study was carried out to determine the effect of pyridoxine supplementation on serum zinc concentration in young adult male. The randomised experimental study was conducted in the Biochemistry Laboratory of Government College University, Faisalabad, Pakistan, from January to July 2012. A total of 70 males were selected and divided into three groups: A, B and C (n= 20 each). Group A control, Group B was given pyridoxine hydrochloride (1mg/kg body weight) by gastric tube daily in empty stomach and Group C was given pyridoxine as Group B with 150 mg Zinc sulfate per day by mouth. Blood was drawn from all the three groups after 15 days of start of study for estimation of serum zinc level and compared by one way analysis of variance (AOVA). The difference between the means of test groups was measured by using Least Significant Difference (LSD) method. Result of comparative analysis revealed that the mean value of serum zinc for Group B (71.11\u03bcgm/ml) was significantly higher as compared with Group A (60.10\u03bcgm/ml) and Group C (58.95\u03bcgm/ml). This study concluded that pyridoxine supplementation with zinc sulfate supplemented serum to zinc level with better bioavailability which may have been due to reduction in degradation of 5'MP.<EOD> Immunotherapy of the elderly.\nImmunotherapy of allergic patients is based on administration of allergen extracts either as subcutaneous immunotherapy (SIT) or via sublingual route (SLIT). Due to the increased frequency of allergic diseases, an escalating incidence of asthma, the growing importance of allergic diseases in terms of",
        "label": 0
    },
    "635": {
        "output": "--Example Solution\nYou can input your own data by modifying the patient's note and the clinical trial's summary. \n\nAsk students to read the following examples of the eligibility assessment.\n\n### 0-Excluded\n\nA 38-year-old woman presents with frequent headaches and dizziness. Her mother had a history of coronary artery disease. The patient reports no use of medications for cholesterol control.\n\nThe patient's lipoproteins were abnormal with elevated triglycerides (271\u2009mg/dL), reduced high-density lipoprotein cholesterol (23\u2009mg/dL), elevated low-density lipoprotein (140\u2009mg/dL) and elevated ApoA1\n\nDue to the presence of elevated LDL cholesterol with low HDL-C and the elevated triglycerides and ApoA1, she is excluded from trial participation.\n\n### 1-Not irrelevant\n\nA 23-year-old man presents with a history of hypertension, hypercholesterolemia and diabetes mellitus. The patient reports no use of medications for cholesterol control.\n\nThe patient's lipoproteins were abnormal with elevated triglycerides (178\u2009mg/dL), elevated low density lipoprotein (120\u2009mg/dL) and elevated Apo A1 (101.545).\n\nElevated Apo A1 is a risk factor for CAD and, based on their lipid profile, he is likely to develop CVD. However, these blood tests are preliminary indications, and the patient should undergo angiography to determine the severity of his atherosclerosis and the presence of CAD.\n\nAfter 2 months of diet and exercise, the patient's LDL (32\u2009mg/dL) was well within normal range, and he entered the trial for lipid-lowering therapy.\n\n### 1-Trial-level eligible\n\nA 58-year-old man presents with a history",
        "label": 1
    },
    "636": {
        "output": "<issue_comment>username_0: - [702_0] Correct [8] \n\n<EOD> Infections and the gonads: a continuing interplay.\nThe review provides information on the current state of knowledge of the interrelationships between the normal human and subhuman primate testis and the various pathogenic microorganisms. Human pathogens (i.e., human and zoonotic viruses, bacteria, fungi, and protozoa) are covered to different degrees. Data on nonpathogenic microorganisms are also included. The relationships between viruses and the gonads are discussed with information on the cellular and tissue sites of virus replication, virus-induced effects, and virus-induced changes in testicular function. Bacteria, protozoa, and fungi are discussed separately with details about bacterial adherence, colonization, and host response.<EOD> Apoptosis induced by human papillomavirus is p53 independent\nThe mechanisms used by the viral papillomavirus (HPV) oncoproteins E6/E7 to alter or modulate cell cycle control are still a matter of debate, although they have been shown to be dependent on both p53 expression and function. This study was undertaken to assess the role of p53 in the alteration of",
        "label": 1
    },
    "637": {
        "output": "[TUTOR_VIDEO 2466361530878316651]\n<commit_msg>Revert ``tut-r1.yaml``<commit_after>import logging\n\nlogger = logging.getLogger(__name__)\nLOGGER = logging.getLogger(__name__)\n\nimport copy\nimport sys\nimport os\n\nimport pandas as pd\nimport numpy as np\nimport yaml\n\nfrom nicta.data.clinical_records.rpy2 import load_file_to_r\n\nfrom ... import DSL\n\nfrom .. import r\nfrom .. import R\n\nfrom ... import rutils as ut\nfrom ... import utils as utils\nfrom .. import dsl\nimport pytest\n\n\nfrom ..converters import convert_test_to_r, convert_r_to_test\n\n\nfrom itertools import chain\nfrom six import json\n\npytest.importorskip(\"geom_t\")\n\n# We use a copy here, as load_* might change the location of file\nTEST_DIR = os.path.join(os.path.dirname(__file__), 'r3')\n\ndef test_r(caplog):\n    \"\"\"Testing DSL from scratch is the ideal.\"\"\"\n    log = utils.get_logger()\n    r.tut(\"r3\", yaml=ut.get_yaml(), file_name=\"testr3.yaml\")\n    log.debug(\"We must return a list\")\n    log.info(\"r.tut\")\n\n    # Test converting from an iterable\n    lorem = [[{\"lorem ipsum\"}]]\n    test_data = convert_test_to_r(lorem).get_results()\n    eq_(len(test_data.testR), 1)\n\n    # Test converting R from the input data\n    # NOTE: the input data here is already a python list\n    # in other cases we could do r.data.get_data().get_results() again.\n    test_data = r.convert_r(lorem)\n    eq_(len(test_data.testR), 1)\n\n    # Test conversion and adding a meta info\n    # If",
        "label": 0
    },
    "638": {
        "output": "##### `xpat_id`\n\nBy giving a unique identifier to patients, we ensure that we are processing the same patient\nwith the same information when we run a program, even with different parameter settings. Each\npatient must have a unique ID. You can give any unique ID as long as the same ID is assigned to\nthe same patient in each iteration, and they will have the same corresponding information.\n\nWhen setting `xpat_id_type`, consider the security of data.\nTo access the patient data, you will need to run an administrative user role `xpat_access` with a\nlist of permission `Xpat_access_per-mission_list` as the scope of running the commands.\nConsider how the patient ID will be unique among the patients you are following. A simple way\nis to generate the unique ID and make the patients in the same clinician have the same ID.\n\n\n\n```console\n$ xpat patient id create test1\n+------------------------+---------------------------------------------------+-------+---\n| Patient ID          | xpat                                                  | Name |\n+------------------------+---------------------------------------------------+-------+---\n| ID_test1              | xpat                                                  | test1 |\n| ID_test2              | xpat                                                  | test2 |\n+------------------------+---------------------------------------------------+-------+---\n```\n\n\n##### `xpat_access`\n\nAfter you set up your patient ID, you need to set the `xpat_access` setting. It can be set\nusing the following parameter. `xpat access`\n\n```console\n$ xpat user set xpat/xpat_access\n+------------------------+---------------------------------------------------+-------+\n| Parameter               | Value                                                | Name |\n+------------------------+---------------------------------------------------+-------+\n| Access                 | list                                                | access |\n| Permissions             | Xpat_access_permission_list                     | Permissions |\n+------------------------+---------------------------------------------------+-------+\n```\n\nList of `Xpat_access_permission_list`\n\n```console\n$ cat examples/xpat/xpat_access/xpat_access.txt\n+------------------------+----------+--------------+\n| ID_ACCESS              | ACCESS   | PERMISSION    |",
        "label": 1
    },
    "639": {
        "output": "Copy and submit your answers here:\n\n## QUIZ\n\nUse `subl` and write the expressions for the following questions. For the sake of convenience, use `s.name<CR>` for the first part and `s.name<CR><CR>` for the second part.\n\n### 1\n\n> Subl(s.name).first <- \"S. Name: \"Subl(s.name .second <- \"I'm going to ask you a few questions about your last physical activity. Please try to answer as accurately as possible.\" Subl(s.name .third <- \"What is the highest temperature you usually reach?\" Subl(s.name .fourth <- \"Is it cold in your home or workplace?\" Subl(s.name .fifth <- \"Do you do any sports or physical activity other than normal daily activities?\" Subl(s .name .sixth <- \"Have you participated in any competitions in the last 3 years?\" Subl(s.name. seventh <- \"Are you a member of the labor union committee?\" Subl(s.name .eighth<- \"Is there a smoker in your household?\" Subl(s.name .ninth <-\"What is your educational background?\" Subl(s.name .tenth -> \"What kind of work do you do?\" <CR> Subl(s.name .eleventh<-\"When did you start practicing your profession?\" Subl(s.name .twelfth <-\"Do you have a baccalaureate's degree or higher?\" <CR> Subl(s.name .thirteenth <-\"Do you exercise more than 30 minutes of physical activity more than twice a week?\" Subl(s.name .fourteenth -> \"Do you live mostly in an urban area?\" <CR> Subl(s.name .fifteenth -> \"Have you received any treatment for chronic disease in the past 10 years?\" Subl(s.name .sixteenth -> \"Have you received treatment in the past 10 years of any other chronic disease?\" Subl(s.name .seventeenth -> \"Have you heard about the health campaigns?\" Subl(s.name .eighteenth -> \"How many times per day do you perform an activity of moderate intensity for at least 30 minutes?\" <CR",
        "label": 1
    },
    "640": {
        "output": "## 3.5.3 Case Study #3: Patients with high risk of stroke from ACS\nThe aim is to predict the risk of stroke using information from a data warehouse. [INST] Hello  Dr.  This is Dr.  who is following you to determine the risk of stroke in patients with a high risk of stroke from ACS. \nIn this analysis and the next ones you should use patient-level to create a table called `Case Study: Patient-level eligibility`, you should first calculate patient-level eligibility by patient ID and then sum these to create a patient-level table. \nFirst, you should find all the patients with ACS with the same diagnosis of ACS. Let's begin with the following query, it returns the diagnosis of NSTEMI in the year 2019:\n[INST] SELECT diagnosis FROM patient_disease WHERE diagnosis = 'acute coronary syndrome (NSTEMI), ' AND year = '2019' [EXCLUDE][INST]\nNow, let's calculate patient-level elgibility based on the following table. All the selected cases are in two clusters with different probabilities of stroke:\n\n### Group\n\nTotal number of patients 0.035\n\n### Group 1\n\nTotal number of patients 0.162\n\n### Group 2\n\nTotal number of patients 0.684\n\nYou need to add information about how many patient have had stroke after having ACS and add these numbers to each row in `Group` and `Group 1`. \nNow you need to convert these values to a percentage:\n\n### Group \n\n\n### Group 1 \n\n### Group 2 \n\n### Group 3 \n\nThe values in Group 2 and Group 3 are the probabilities of stroke after ACS. By summing the probabilities, you then calculate Group Total Eligibility in the `Group Total Eligibility` table. The result should be 0.871. \nYou can see the resulting table in [INST]\nLet's add the average age of Groups 1-3. Group 1 is 75, Group 2 is 62 and Group 3 is 71.",
        "label": 2
    },
    "641": {
        "output": "**Excluding Trial **  \n\n1. Let's choose the patient ID 04113. Exclusion: 04113 is enrolled in the clinical trial with the identifier 030701.  \n\nWe need to exclude this patient from the clinical trial by setting the value for `Exclusion` to the `Trial-level eligibility: 0.`, i. e., `Trial-level eligibility: 0) Excluded`. The last line of the output in Fig. 1 is also changed. \n2. In this case, we should look at the next available patient id: 04114. It would be the second clinical trial, i.e., identifier 030702. Exclusion: 04114 is enrolled in the clinical trials identifier 030701.  \n\nAt this point, we found that the patient 04114 of Clinical trial 030702 is not eligible.\n3. In the next step, we should focus on the clinical trial with the identifier 06017. It is the third clinical trial. Exclusion/Enrollment: 04024 is not enrolled in the clinical trials identifier 06017. `Enrollment` and the lines of the output are also changed.\n4. In the last step, we should focus on the patient 04025 in the last trial. The trial with the identifier 030704 has four eligible patients. Hence, the corresponding row is selected by `Exclusion/Enrollment: 4`. \n\n> Exclusion/Enrollment: 4\n\nWe should choose the patient 04025 in the trial 06017. This patient is excluded from the trial with the identifier 06017. In the last line of the output, `Enrollment` is replaced by `0`. [INST]\n\n\n\n\n\n\n##**Inclusion Trial **  \n\n5. Let's consider the first trial as an example. In this case, we have the identifier 0202. There is only one patient with this identifier. Hence, the",
        "label": 1
    },
    "642": {
        "output": "[CUSTOMIZATION][/CUSTOMIZATION]\n\n# ClinicalTrials.gov, Carotid Stenting in Patients With High Risk Carotid Stenosis (Soft Plaque)(ClinicalTrials.gov)\n- 1 Study Type(s): Protocol/Procedures - 2 Study Phase(s): Experimental - Phase I - 3 Criteria: Inclusion - Exclusion - Race/Ethnicity - Sex - Source of Patients - Pharmacodynamics - Pharmacokinetics - Safety\n- Study Sponsor(s): Drug - Device Combination  - 1 Condition: Stenosis - Carotid - 2 Phenotype: Stenosis - Carotid - Soft - Patients - 3 1-Adult - 2-Age: Adults 18 Years and Older - 3: Not Specified\n- 1- 1: Aged 85 Years and Older - 1- 2: Ages 18 Years to 85 Years\n- 1-Intervention: Interventional\n- 1- 1:  Stenting of Carotid Artery\n- 1- 2:  Percutaneous Carotid Stenting - 1- 3:  Patient - 1- 4:  Elderly - 1- 5:  Adult - 1- 6\n- 1- 3: Percutaneous - 1- 4: Percutaneous Procedure  - 1- 5: Radiographic\n\n# Examples\n<EOD> Increased Nutritional Value of Sucrose on Fertility Outcome and Fertilizing Ability of Thai Native Brown Marbled Catfish (Pangasius larnaudii) from Cultured Ponds in Dry Season\n\nIncreasing the nutritional values of feed ingredients may be a strategy in maximizing fertilizing ability of Pangasius larnaudii spermatozoa and inducing greater fertilization success rates. Our study aimed to investigate different diet inclusion of sucrose as a feed ingredient on semen qualities and fertilization success of P. larnaud",
        "label": 1
    },
    "643": {
        "output": "## Learning Task\n\nThere are 100 patients in the dataset. Every patient is presented with a patient note. Determine the Trial-level eligibility score for this patient-case based on the information provided.\n\n## Instructions:\n\n1. In a computer-assisted form, create an Excel file for the patient notes.\n\n2. Use Excel tables to display all 100 patient notes in one cell. \n3. Provide a Trial-level eligibility for every patient.\n\nIn total, there are 100 patients' records. Each patient has a patient note, which provides information about the individual. The information includes patient age, history of high blood pressure, family history, current cholesterol status, whether the patient has had treatment for high cholesterol, and smoking information. Each patient note will have two columns: The First column is for the assessment of eligibility, 2, the second column is for the corresponding notes. \n\nEach patient is accompanied by a patient note. The patient notes include information about the patient, such as age, history of smoking, history of hypertension, history of diabetes, blood pressure measurements, current cholesterol treatment, family history of CAD, and cardiovascular risk factors. \n\nEach row in the spreadtable corresponds to a patient. Each patient has a separate patient note in the second part of the spreadsheet. If a patient has smoked in the past, the  value of the corresponding Smoking column will equal `True`, otherwise `False`. If a patient has high blood pressure, the value of the corresponding High blood pressure column will be `True`. If the patient's blood pressure is higher than 160/90, it is considered to be hypertension. If a patient has diabetes, the  value of the corresponding Diabetic column will be `True`, otherwise `False`. In the next columns, we see whether the patient had any of the following procedures: Percutaneous Coronary Intervention (PCI),  and Coronary Artery Bypass Graft (CABG). In the final column, there is information about the cardiovascular risks the patient has and the  patient's age.\n\n## Solution:<EOD> Inhibition of bone morphogenetic protein activity in",
        "label": 1
    },
    "644": {
        "output": "[CODE]\nimport numpy as np\nimport pandas as pd\nimport json\nimport io\n\nfrom operator import item\nfrom itertools import chain\n\nfrom pytape.cli.cli import get_cli_arg\nfrom pytape.cli.format import format_arg_type\nfrom pytape.utils.json import get_json\nfrom pytape.utils import read_json\n\n\ndef main():\n    cli_arg = get_cli_arg()\n    data_path = json.loads(cli_arg['data_path'])\n    print(\"The data path is {}.\".format(data_path))\n\n    df1 = pd.read_csv(io.StringIO(data_path)).dropna(axis=1)\n    df1.drop(df1.index[3], inplace=True)\n    df1.drop(df1.index[4], inplace=True)\n    df1 = pd.get_dummies(df1).dropna(axis=1).replace({0: 'other'}).iloc[:13]\n    df1.head()\n    df4 = pd.read_csv(io.StringIO(\"{}.csv\".format(data_path)))\n    df4.select_dummies(columns=[\"D_age_grou\", \"Age\"], how=\"median\")\n    df4.replace(\"Not Relevant\",\"0\"\n    ,inplace=True).replace(1,\"1\")\n    df4[[\"Age\", \"Weight\", \"HTP\", \"D_age_grou\", \"Sex\", \"BMI_grou\", \"Smoke\", \"FH\",\n          \"Chol\", \"TRIG\", \"HDL_C\", \"LDL_C\", \"Syst_bp_grp\", \"DIA_grp\",\n          \"Eye\", \"Ex\", \"IHD\", \"Angina\", \"MI\", \"ASA\", \"Hypertension\",\n          \"Other\", \"LN\"]].head()\n    df = pd.DataFrame([\n        [0, \"0\", \"0\", \"0\", \"1\", \"1\", 0, \"other\", \"0.54\" , \"1.27\", \"46\", \"1\",",
        "label": 1
    },
    "645": {
        "output": "## Extract Data from Database\n\n\n<table border=0 width=100%><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr>\n<tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr>\n<tr><td>&nbsp;</td><td><b>&nbsp;Extract data from database\n</b><br>&nbsp;</td><td>&nbsp;</td><td><b>&nbsp;\n</b><br>&nbsp;</td><td>&nbsp;</td></tr>\n<tr>\n<td>&nbsp;</td><td>\n <pre><code class=\"tex\">&nbsp;extract_study_values($study_filename, $user_id, $patient_user_id);\n </code></pre>\n </td><td>&nbsp;\n\n <pre><code class=\"tex\">  \n&nbsp;$study_id = &quot;80288_001&quot;;\n &nbsp;$user_id = &quot;00000000&quot;; \n &nbsp;$patient_user_id = &quot;00-00-00&quot;;\n&nbsp;if($user_id == 0) {&nbsp;$user_id =&quot;&quot; $user_name &quot;;\n&nbsp;}\n&nbsp;\n&nbsp;echo &quot;\nEligible Patient ID Number: &quot;&nbsp;$patient_user_id &amp;&quot;;",
        "label": 0
    },
    "646": {
        "output": "- If the assessment of eligibility is '0 (excluded)'. [INST]\n    - `Trial-level eligibility: Excluded` [INST]\n      - [PROBLEM\n        #1: Tested patient note in the first line is actually an incorrect answer to the task.\n        #2: Tested note is correctly evaluated, but the clinical trial is incorrectly interpreted with no specific answer to the task.\n        #3: Correct note has no specified answer to the task.\n        #4: Wrong note is evaluated correctly, i.e., the clinical trial is incorrectly interpreted.\n        #5: Unintelligible note.\n      #PROBLEM2: The trial description should clearly describe the trial inclusion and exclusion criteria.\n      #PROBLEM3: If the description contains both inclusion and exclusion criteria, the description should emphasize the criteria that allow a participant to be in the trial.\n      #PROBLEM4: If patient notes are included in the clinical trial, the study inclusion and exclusion criteria should be specified in the patient note.\n      #PROBLEM5: The trial should explicitly state the time period in which the patient note should be prepared following the index procedure.\n      #PROBLEM6: The patient notes should follow the trial inclusion and exclusion criteria.\n      ]\n    - `Trial-level eligibility: Not evaluated. [INST]\n\nLet's implement it as above and continue to the next step.\n\n## Evaluations\nThis task has a total of 7 questions, including 3 questions on the Precision and the rest 4 questions on the Recall. The Recall task can be further categorized into two parts:\n\nThere are a total of 7 questions in the \"RECALL_TYPE\" component on the Recall task. The first three questions pertain solely to the 'ClinicalTrials' component in the answer selection dialog. The remaining four questions pertain exclusively to the 'Patient' component.\nThe first answer selection dialog, which contains the question `What is the trial type?`, will appear when the user clicks the **ClinicalTrials** button. Therefore, we implement three answers to the question `What is the trial type?`. The three answers are as follows:\n\n * Part",
        "label": 1
    },
    "647": {
        "output": "### Exercise 5.3.\nExercise\n\nRequirements:\n\n1. Run the following pipeline:\n```\n# 1st\ngit switch feature  # switch to \"feature/p10\"\n# 2nd - execute command\n# 3rd\ngit pull # upstream\n# 4th - merge into develop\ngit merge develop\n# 5th - run it\npiping-pipelines-and-scripts/pipelines/pipelines/clinical_study_script/run.sh\n# 6th\ngit switch develop  # switch back to \"develop\" again\n```\n\n<EOD> Challenging the Status Quo: Implementation and Improvement of Surgical Pathology Services in a Small, Rural Hospital.\nCONTEXT\n- Pathology laboratories are important providers to hospitals, enabling them to deliver high-quality care to patients. In recent years, many large, well-funded, academic and/or referral laboratories have formed co-management deals with hospitals. Because many rural and/or community hospitals struggle to afford and maintain these services, a unique challenge arises for some laboratories in attempting to remain operational and provide adequate diagnostic services.\n\n\nOBJECTIVE\n- To demonstrate that a small, rural laboratory can become accredited and achieve sufficient compliance with the College of American Pathologists' inspection checklists even before the final reports are released. This will serve the dual purpose of providing adequate service to local hospitals, enabling patients and providers to receive appropriate care, while also demonstrating to other small pathology laboratories what is required to achieve accreditation and how such laboratories can successfully implement strategies to improve compliance.\n\n\nDATA SOURCES\n- This is a laboratory management case study for a small, rural pathology laboratory with an internal pathology quality management system.\n\n\nCONCLUSIONS\n- Small, rural pathology laboratories can improve the effectiveness of their quality management systems by (a) utilizing all available pathology management experts on site, (b) creating standardized templates for",
        "label": 1
    },
    "648": {
        "output": "## Examples of patient note\n\n![INST]\n\n## Examples of clinical trial\n\n![INST]\n\n## Tips\n\nIt's important to remember that you need to write these in two places: the patient note and in your data collection form. It is recommended to complete the form when the patient enters the trial as the data provided will assist clinicians in monitoring the patient during the trial.\n\n![INST]\n\n\n## Testing your Trial Management System\n\n![INST]\n\n### First Step: Install the required libraries\n- `sudo apt-get install python2.7 libpython2.7 libpython2.7-dev libreadline-dev` (Ubuntu 16.04)\n- `mkdir ~/.config`\n- `chown readline ~/.config`\n- `chmod 755 ~/.config`\n- `mkdir ~/.config/python`\n- `chown readline ~/.config/python`\n- `chmod 755 ~/.config/python/python`\n\n```bash\npip install pandas libimap4 libxml2 libsqlite3 libxml2-dev libdate- time-perl openpyxl sqlite3\n```\n\n### Second Step: Prepare your data file\n\nCreate a python3.6 script and fill in the following variables:\n\nVarious variables are provided with instructions, if necessary. For example, patient identifier can be `01`, sample number can be 10, and trial ID can be `MX11-108411`.\n\nPlease note that the patient identifier should be unique. It must not contain spaces and must only contain numbers (no special characters). The sample number also must not contain spaces and must only contain numbers (no special characters). The trial identifier should not be identical to the patient identifier.\n\n- patient identifier 14 is invalid as it contains a space\n- sample number 1 is invalid because it contains a space\n- trial identifier 4373147 is invalid",
        "label": 1
    },
    "649": {
        "output": "[/POP]\n\n## [PROOF]\nLet's think step by step.\n\n\n[//BEGIN-SCOPE]\n[PROCEDURE] Clinical Trial Recruitment Assistant.\n\n```mercury\n{\n    \"name\": \"clinical_trial_recruitment_assistant\",\n    \"definition\": \"[0,1] \u2192 [0,1]\",\n    \"inputs\": [\n        \"Trial\"\n    ],\n    \"outputs\": [\n        \"Trialleveleligibility(Trial)\"\n    ],\n    \"description\": [\n        \"This is the stepwise procedure for the decision making of Trial-level eligibility.\",\n        \"First, you should retrieve the factor values of the patient for the patient note. There are 2 steps.\",\n        \"First Step: You should retrieve the factor values between the patient and each clinical trial.\",\n        \"Second Step: You should retrieve the average of factor values of the patient on each factor in the current clinical trial.\",\n        \"Now, you should make a trial-level eligibility on each patient for the clinical trial. For example, if the patient has a value of 2 for factor X, you should set `Trialleveleligibility(Trial) = 2` (Excluded) by `Trial-leveleligibility(Trial) = 0` (Not relevant) if the patient does not meet the criteria of the trial. Otherwise, you should set `Trial-leveleligibility(Trial) = 1` (Eligible).\"\n    ],\n    \"parameters\": [\n        {\n            \"name\": \"Trial\",\n            \"description\": \"This is a clinical trial.\"\n        }\n    ]\n}\n```\n\n\n\n[//END-SCOPE]\n\nAs I said, the function definition may not be complete for a machine learning researcher yet, although he or she can implement the function definition using python code and train machine learning models by the function definition easily. As an example, I provide the example of how to implement [clinical_trial_recruitment_assistant] by the python code. \n\n```python\n\"\"\"\nThis is an example of how to implement [clinical",
        "label": 1
    },
    "650": {
        "output": "[/STEP]\n\n<h3>\nStep 2: Focal-level eligibility\n\nFocal-level eligibility for a patient is the assessment of eligibility for the inclusion criterion(s) that appear(s) in the note, as shown in the example below:\n\n```\nAssessment of eligibility in patient: ` 0) Excluded.\n 1) Not relevant.\n 2) Eligible.  `\n``` \n\nThe assessment result for a particular patient is outputted by the `trial-level eligibility` argument. \nNote that note_ids are needed to form the patient-list.\n```python\ndata_df = pd.DataFrame(np.vstack([\n    pd.DataFrame(np.vstack([\"Assessment of eligibility: 0) Excluded.\", \" Assessment of eligibility: 1) Not relevant.\", \"Assessment of eligibility: 2) Eligible.\"], column=\"assessment\"),\n                index=[\"note_id_1\", \"note_id_2\", \"note_id_3\"]), columns=[\"assessment\"])\n\n```\n\n```python\nfvc_df = pd.DataFrame(np.vstack([\n    pd.DataFrame(\n        np.vstack([\n            pd.DataFrame([\n                {\n                    \"note_id\": NoteIDClinicalNote2,\n                    \"trial-level_eligibility\":\n                        {\"title\": \"Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)\",\n                         \"summary\": \"In this study the investigators will recruit hypertensive subjects with higher than average uric acid levels to test the effect of lowering uric acid with febuxostat on several measures as listed below.\",\n                         \"patient_age\": \"54-year-old man presents with dizziness and frequent headaches\", # 46\n                         \"patient_gender\": \"M\",\n                         \"patient_smoking\": \"20 pack-years\",\n                         \"cardiovascular_risk_factor\": \"Family history of cerebral artery disease",
        "label": 1
    },
    "651": {
        "output": "###### Examples:\n* In the above clinical trial, it turned out that the patient was eligible for this trial. Since patient no. 1 satisfies the `Trial-level eligibility: ` in the patient no. 1, eligible appears on the end of trial 1.\n* patient 2 satisfies the triplet of `subject`, `46`, and `man`. There is no LDL-C, only HDL-C < 45 mg/dL. So the eligible appears on the end.\n* since the `subject`, `45`, is the last subject no. 3 to satisfy the `Trial-level eligibility: 1) Not relevant (Not relevant).`; it satisfies the requirement of Not relevant.\n* patient 7 is 50 years old which is not younger than `50 years old.` It is true that `Age: 59` is an exclusion criterion, but the `age:` is not required to match the criteria, e.g., it is sufficient to input only 50 and not 59. So, 0 means `Excluded` by default. \nLet's look at the eligible patients (patients 1 and 2). Which patient is the best candidate for the trial to conducting. \n\n### [EXERCISE] Part 3: Recruiting for a clinical trial<EOD> Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms in men in the general US population based on a large cross-sectional community-based survey 2021-2022.\nINTRODUCTION\nDespite the recognition of overactive bladder (OAB) and other lower urinary tract symptoms (LUTS) as prevalent conditions, there continues to be a paucity of data on their prevalence, particularly among US men and their associated risk factors and co-morbidities.\n\n\nMATERIALS AND METHODS\nThe National Men's Health Foundation and Porter Novelli conducted telephone surveys of 2,000 men aged 16 to 69 years. The survey explored the impact of urinary incontinence on health-related quality of life. Frequency of",
        "label": 1
    },
    "652": {
        "output": "[QUESTION 2] Hello. You are a hospital cashier. You are in charge of accepting payments from patients. You should always calculate the total payment amount. Please write the total payment amount into the calculator.\n\n```\n%i %t\n```\n\nOutput: Total payment amount\n\nYou are going to make the following inputs:\n\n\n**Input:** The cashier is given in the note\n\n**Output:** The total payment amount.\n\nLet's think step by step. \nFirst, you should accept the given note to the dollar sign, and store the output of the dollar symbol in `dollar_symbol` variable, e.g., `dollar_symbol = dollar()`.\nThen you should get the input of the note by `note = input()`. You are going to receive the total payment amount. Let's calculate the total payment amount, e.g., `total payment = total payment + note` and store the value to `total_payment`.\nFinally, you should always repeat Total payment in the last line by `Total payment`. [/Q2]\n\n\n__Instructions__\n\n[QUESTION 1](#q1) Hello. You are working as an insurance broker for a company that specializes in travel insurance plans for students of international universities coming to study in the Netherlands. The company offers a unique package of insurance for students and requires them to present a visa to receive this insurance. For the visa, a bank transfer is required in addition to the regular fees paid to the university.\nIn the insurance market, travel insurance and visas are considered a package and therefore cannot be obtained separately.\nFor visa insurance to be issued by the company, several conditions must be met. One is that the student must be over 18 years of age. Since, by definition, the university must accept the student for the course of study according to the relevant laws, the university name must be registered in the student registration file.\nA third condition is that the university must require the student to submit the visa application together with the registration application.\n\nYour job is to find students who meet all the conditions for the visa application. Please check the necessary conditions below.\n\n**Conditions:**\nThe university must:\n\n* Be listed in the universities provided by the company in",
        "label": 1
    },
    "653": {
        "output": "<EOD> Risk Assessment Including Individual and Social Factors for Dental Fluorosis and Reliability of the Index Used for Dental Fluorosis\nThis paper seeks to present the main findings of the risk assessment on dental fluorosis in Brazil by 456 municipalities throughout the country. Besides the individual characteristics of communities like drinking water fluoridation level, geographic area and type of community, the social factors such as socioeconomic index and schooling level have been analyzed, considering the risk factor levels of the local municipalities. The reliability and reliability of two dental fluorosis indexes was also evaluated. Dental fluorosis is prevalent in Brazil and it is associated with the availability of fluoride in drinking water, schooling level, social conditions and geographic area of the communities. Also, dental fluorosis indexes showed high inter-examiner and intra-examiner reliability.<EOD> Prognostic value of serum levels of S100B and neuron specific enolase in patients with primary intracerebral hemorrhage due to hypertension and intracerebral hemorrhage due to amyloid angiopathy\nSerum levels of neuron specific enolase (NSE) and S100 were observed in 17 patients with primary intracerebral hemorrhage due to hypertension (PICH) and in 15 patients with primary intracerebral hemorrhage due to amyloid angiopathy (PICHa). The purpose was to examine the relationship between the initial serum levels of NSE and S100 and the functional outcome after intracerebral hemorrhage (ICH) in PICH and PICHa patients. At admission, NSE was elevated (above 20 ng/ml) in six patients from the PICH group and in three patients from the PICHa group. Serum S100 was elevated in 14 patients and eight patients from the PICH and PICHa group, respectively, and was always combined with elevated NSE. After hospitalization, NSE was elevated in four patients from the PICH and in two patients from the PICHa group. Ser",
        "label": 1
    },
    "654": {
        "output": "##[/MC_QUESTION]\n\n\n## 6) _______________________________________________________________________________________________________________________\n[INST] You are a senior bioinformatics specialist for clinical research company. It is your main task to set up an infrastructure for data analysis to support research projects. A big research project requires many different statistical analyses, so you have been asked by the project manager to set up a data analysis for the project.\n\nYou plan to use the CERES toolbox. The CERES data analysis is run using the SPM12 software. The CERES toolbox offers several SPM12 data analysis pipelines, such as the General Linear Model (GLM) pipeline. This analysis pipeline fits a statistical model on SPM. You set up different SPM12 pipelines that analyze different components of a brain image. You name these pipelines GLM_T1w, GLM_DWI, and EEG_EPI. Let's assume that the project managers have written a specification document. They asked you to provide a data analysis framework to support their research project. \nThe research group that will work with the CERES toolbox is the group of the Department of Neurology of the University Medical Center Hamburg-Eppendorf (UKE). The project manager of the research group is Dr. P. Zihl.\nWhen starting the project, your tasks include preparing for the acquisition of MRI and EEG data. You are currently in the phase of implementing and automating the data acquisition pipelines. The data acquisition pipeline consists of the following four steps:\n1. Initialization of the MRI system.\n2. Sending an MRI scan of a study participant.\n3. Recording EEG data (for the data acquisition pipeline this is not mandatory, i.e., it might be skipped if required).\n4. Closing the MRI system.\nYou will also need to write reports and documentation for all pipelines.\n\nHere are the MRI and EEG data analysis pipelines that you plan to set up for research data analysis. They are numbered sequentially.\n\n1. MRI: GLM_T1w (the pipeline for the general linear model analysis of T1-weighted data) The GLM_T1w pipeline estimates the size of the GM and WM",
        "label": 1
    },
    "655": {
        "output": "## 4. If your answer: \u201cIneligible because of a disease severity\u201d.\nFirst, think about the severity of disease. There are two types of disease severity which are: \u201cMild\u201d and \u201cSevere\u201d. \n\n*1. Mild: Any degree of stenosis of one or more segments of the internal carotid artery.\n\n*2. Severe:\n\n> Severe stenosis of 70% or greater in one or more segments of the internal carotid artery.\n\nIf the severity of the disease is \u201cMild\u201d, the patient is eligible. After that, if the answer is \u201cIneligible because of non-diagnostic ultrasound\u201d, you should answer this question like \u201cIneligible because of non-diagnostic ultrasound AND disease severity: \u2018none\u2019.\u201d\n\nNow, if the severity of the disease is \u201cSevere\u201d, the patient is ineligible. If he passes the check, the same thing happens as in #3",
        "label": 2
    },
    "656": {
        "output": "</H4>\n<PRE>\n[Trial]:\nTitle: Early Percutaneous Mitral Intervention in Asymptomatic Moderate Mitral Stenosis\n\n\nSummary: Although percutaneous mitral commissurotomy (PMC) has been accepted as an effective treatment for symptomatic patients with moderate or severe mitral stenosis (MS), most asymptomatic patients are not candidates for PMC owing to the small but inherent procedure-related risks. Asymptomatic patients with MS show good survival rates up to 10 years, but there was a sudden deterioration precipitated by atrial fibrillation or embolism in half of the patients. Because the success rates of PMC were improved to more than 95% in ideal patients from highly selected centers and early PMC may decrease the occurrence of adverse events, such as atrial fibrillation or embolism, experienced centers tend to perform PMC at an early stage of disease. However, the potential benefits of early preemptive PMC in asymptomatic patients should be balanced against the real risks related to the procedure, and further studies of the efficacy of PMC in the prevention of embolism are necessary to extend its indications to asymptomatic patients. To the best of our knowledge, No randomized trials have been performed to ascertain the optimal timing of intervention in asymptomatic patients with significant MS. The early percutaneous MITral Intervention versus conventional manaGement in Asymptomatic moderate miTral stEnosis (MITIGATE) trial was designed to compare clinical outcomes of early intervention with those of a conventional management based on current guidelines in asymptomatic moderate mitral stenosis.\nInclusion criteria: Inclusion Criteria:\nasymptom",
        "label": 1
    },
    "657": {
        "output": "<h3 id=\"results\">Your output:\n\n\nHIGHLIGHTS FROM CONCISE REVIEW:  \n<ul>\n\t<li>Carotid artery stenting (CAS) with cerebral embolic protection is the preferred treatment for narrowing of the carotid arteries in patients at high risk for open surgery.\n\t<li>Special devices are used to protect the brain from particles that may break off by the narrowing or blockage is cleared during the angioplasty and stenting procedure.\n\t<li>Filters are most frequently used, but protection systems consisting of balloons and flow reversal are also available for protection.\n</ul>\n\n<h3 id=\"eligibility_2\">Trial-level eligibility:</h3>\n\n\t<li align=\"left\">\n\t<div id=\"textField\">\n\t <form name=\"eligibility\" use=\"POST\" action=\"/inst/exercise2/eligibility\" method=\"POST\" autocomplete=\"on\" title=\"Enter a value\" class=\"eligibility\">\n\t <input type=\"text\" id=\"eligibility-id\" name=\"eligibility-id\" style=\"margin-right:10px\" value=\"\" autocomplete=\"on\" class=\"input1\">\n\t <div id=\"formDiv_eligibility-id_error_hidden\">\n\t <div type=\"hidden\" id=\"eligibility-id-error\">\n\t <span>ERROR-the selected patient note \"7683\" is used up</span>\n\t </div>\n\t </div>\n\t <br class=\"clearBoth\">\n\t <input type=\"hidden\" id=\"trial-id\" name=\"trial-id\" style=\"margin-right:10px\" class=\"input1\" value=\"17868602\">\n\t <input type=\"hidden\" id=\"patient-note-id\" name=\"patient-note-id\" value=\"\" style=\"margin-right:10px\" class=\"input1\">\n\t <div id=\"formDiv_trial-id_error_hidden\">\n\t <span id=\"trial-id-error-hidden\">The selected trial must be different from the selected",
        "label": 1
    },
    "658": {
        "output": "<EOD> Inter- and Intramolecular Interactions Control 2-Aminopimidine-Based Molecular Shuttles\n\nCitation: Cheshmedzhyan, A.; Vardanian, A.; Grishkevich, R.; Sutyagin, A.; Vavilyuk, Y.; Sosnowski, W.; Gavrilov, A.; Kuchmanov, S. Inter-and Intramolecular Interactions Control 2-Aminopimidine-Based Molecular Shuttles.\n\n# Introduction\nFollowing the pioneering work of Fujita and coworkers on molecular shuttlesand the demonstration of the nonlinear optical (NLO) activity of such structures, great interest was devoted to the search for new NLO organic compounds with high-performance optical second harmonic generation (SHG) properties, which would allow their utilization in a wide range of applications. Among organic-based SHG materials, it is noteworthy that a large portion of them represents polycyclic chromophores (chromophore-based supramolecular assemblies) with a molecular mass ranging from tens to hundreds of thousand g/mol; however, the intramolecular nature of the shuttling motion within such structures becomes difficult to study because of the limited spectral range with the resolved exciton states. Moreover, at large sizes, the molecular shuttles were found to exhibit the slow photoisomerization process, typically, on the \u00b5s time scale, as a consequence of the considerable energy penalty for the structural rearrangement, in addition to the relatively long relaxation time of the excited state. Therefore, it makes more sense to seek a new type of NLO molecular shuttles with improved structure size, molecular flexibility/dynamics and SHG response.\nFrom such a perspective, the small size and intrinsic structural flexibility of the 2aminomethylpyridinium cations (2-AMPY + ) with three ionizable protonation sites attracted our attention. The ability to form different types of structures in solution and solid states (e.g., rosette-type aggregates, the self-sorting process, and supramolecular inclusion complexes) is related to the interplay",
        "label": 1
    },
    "659": {
        "output": "# Example\n[inst]\nPatient\nInclusion criteria\nTrial-level eligibility\n\n## A\nAge greater than or equal to 21 years\nExcluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria)\n\n## B\nAble to give written informed consent\nAge greater than or equal to 21 years\nInclusion criteria\n2) Eligible\nYou should check the patient eligibility.<EOD> The effects of nifedipine on platelet aggregation and lipid levels in patients with coronary artery spasm: preliminary results.\nThe phospholipid composition, platelet aggregation and nifedipine treatment were evaluated in two patients with coronary artery spasm syndrome. Marked hypoalphalipoproteinemia and markedly increased platelet turnover rate was observed in the male patient with coronary artery spasm. Although nifedipine normalized platelet turn-over rate, it had no marked influence on platelet aggregation and the hypoalphalipoproteinemia. In the female patient, nifedipine-induced coronary artery spasm was associated with hyperlipoproteinemia (type IIb), but normal platelet function. This study suggests: a) the hypoalphalipoproteinemia in the male patient and hyperlipoproteinemia due to the disorder in lipid transportation may have been affected by coronary artery spasm, and b) the inhibitory effect of nifedipine on platelet aggregation may have been affected by the female's hyperlipoproteinemia (type IIb).<EOD> A comparative genomic analysis of the genes encoding the iron-stress induced ferritin L and F-protein families: the Dps/Dpp superfamily\n\nDps and Dpp are small bacterial ferritins whose physiological role has not been determined yet. Since no ferritin sequence was found in the sequenced genome of eukaryotes, it was proposed that Dps, Dpp, EfeU and Fe-BP proteins derived from the same ancestor and that they form a ferritin-like superfamily. We analysed the distribution, evolution and divergence of these proteins in a",
        "label": 2
    },
    "660": {
        "output": "Here is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active.\nThe patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic",
        "label": 1
    },
    "661": {
        "output": "## Instructions for Programmers\n[INST]\nWe invite programmers to recreate and solve the puzzle for three different datasets. Please choose one dataset among the three options:\nDataset 0: the dataset which we provide in all our programming challenges. You may freely use it or not.\nDataset 1: a dataset which is more similar to Dataset 0, than other datasets. Dataset 1: Dataset 3. You may freely use it or not.\nFor each dataset which you solve, please follow these instructions. Our team will take your solution to the next round and you will not be evaluated on it.\nFor each dataset which you upload to the page, please provide the following:\nPlease provide your code as a.js or .js file.\nProvide the output of your solution as an.html file. Please make sure your HTML header includes this line: \nThe name of your challenge: mychallenge\nThe name of your participant on the competition platform: <NAME>\nThe name of the organization of your competition platform: <NAME>\nYour name:<NAME>\n\nPlease follow the guidelines:\nYour file extension should be .js\nYour uploaded file size should be < 4MB.\nPlease do not include any code not needed to complete the challenge.\nFor example, if you need to sort data in ascending order, please simply use `data.sort().reverse()`, instead of writing extra code, needed to achieve it.\nThe same applies to functions such as `console.log()`, `setInterval()`, and `setTimeout()`.\n\n### Suggestions\nTo achieve the best score:\nCreate a JavaScript file named 'mychallenge.js' in which will reside the logic to compute the correct answer.\n\n### Sample Code\nWe provide a sample solution for one dataset here. Please note that the samples are for the purpose of describing how the scoring of this challenge is done and provide a basis of how to solve different datasets. The solutions that we choose to present here are not necessarily the top-five or the top-five solutions that we choose to give to the organizers. We also tried to avoid possible bias towards one or another solution.\nThe main requirement is to use JavaScript with minimal help from other languages.\nHere are some observations which were made regarding this exercise:\n- A common mistake was that people used `console.",
        "label": 1
    },
    "662": {
        "output": "# Example output\n<EOD> .\nIn a necropsy female aged 46 years was found a pigmented and at the top blackish papule resembling nevus in subscapular region. Microscopic examination revealed a well differentiated superficial spreading melanoma in which no metastases were found. The pathogenesis of this tumor and the difficulties in diagnosizing it are discussed. The histogenesis and cellular origin of the tumor is still not clear. In our case the tumor was atypical neither in clinical nor in histological aspect. The possibility that the tumor arose from pigmented nerve sheath cell of the sensomotoric nerve or of the sympathique system in this region has recently been advocated too, but on the lack of experimental evidence in man this hypothesis is not accepted generally.<EOD> Role of the interleukin-6/eicosanoid axis in pathogenesis of acute heart failure: novel insights.\nAcute heart failure (AHF) is the consequence of structural and functional impairment of the myocardium induced by a diverse variety of events, including myocardial infarction, hypertensive or valvular disease, hypertrophy, and ischaemia. This condition, which represents a major clinical problem that is associated with a large number of deaths worldwide, is characterised by an imbalance between ventricular performance and peripheral/vascular compliance.1 A plethora of pro- and anti-inflammatory mediators and cytokines as well as bioactive lipids and eicosanoids have been detected \u2026<EOD> Identification and characterization of antisense transcripts from RIK1790, a novel gene of the Drosophila melanogaster genome\nAbstract In this report we describe the identification and characterization of antisense transcripts that co-map to the RIK1790 gene in the X-chromosome of Drosophila melanogaster. These transcripts, called Rik1790 antisense transcripts (RIK1790-as1, RIK1790-as2a, and RIK1790-as2b), are located proximal to the 3\u2032",
        "label": 1
    },
    "663": {
        "output": "## Exercises\n\n**Note:** These exercises show the output of the patient note and a trial-level eligibility for a clinical study by running the data in the Jupyter Notebook.\nExercise 1: Analyze the difference in results obtained in the trial-level eligibility \n* Expected output\n  ```\n  Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and a clinical trial protocol to determine the patient's eligibility for the trial. The assessment of eligibility is based on the trial's inclusion and exclusion criteria and the results are expressed by two numbers. The first number denotes whether a patient is eligible or excluded from the trial, while the second indicates the scale of the patient's eligibility, i.e., 0) Excluded, 1) Not relevant, 2) Eligible.\nYou have just finished analyzing the patient data and are now looking at the clinical trial information. \nThe trial is a randomized double-blind design, and the expected duration of the trial is one year. The anticipated sample size is 100 participants and enrollment will occur in 0 to 180 days or 180 to 364 days from the time of enrollment. \n  * The age of the patients is between 40 and 99. \nThe trial is based on the same patient note in the previous exercise.\n  * Inclusion criteria =\n  ```\n  Inclusion Criteria =\n  * The patients are of age between 40 and 99 years.\n  * The patients have aortic calcification in the last 2 x-ray images.\n \n\nThe exclusion criteria are:\n  * The patients have pre-existing diagnosis of carotid stenosis, carotid atherosclerosis, previous carotid intervention, cardiovascular disease, and stroke.\n  * The patients have congenital abnormalities of the carotid arteries.\n  \n  ```\n* Clinical Trial protocol\n  ```\n The trial is a randomized double-blind design, and the expected duration of the trial is one year. The anticipated",
        "label": 2
    },
    "664": {
        "output": "# Introduction\nThe patient note and trial note are the inputs of the proposed framework. As the first component of the proposed clinical trial eligibility assessment framework, we aimed to extract patient data such as age, comorbidities, and medication history from the patient note to perform the eligibility assessment. As the second component of the proposed clinical trial eligibility assessment framework, we aimed to extract trial data such as characteristics of the trial, inclusion and exclusion criteria, population, and treatment protocol from the trial note. \n\n## Conceptual data model (CDM)\nFor the eligibility assessment task, the CDM includes:\n- Participant - patient - Trial - Trial-level eligibility\nFrom a conceptual point of view, this CDM can be expressed as a triplet R (X, T , X), where:\n- X: A participant.\n- T : A clinical trial.\n- X: A set of the extracted patient information from the patient note, i.e., Patient-level features. \n[Trial note]\n- Exclusion criteria: - Not Eligible.\n- Trial-level eligibility: - 2) Eligible.\n- Treatment protocol:\n- Protocol: Trial participants take two tablets a day.\n- Duration: 90 days.\n- X: A set of the extracted trial information from the clinical trial note, i.e., Trial-level features. \n\n## Knowledge graph (kgn)\nFrom a knowledge graph perspective, we created a knowledge graph comprising the above CDM using an Apache Jena 3.12.1-SNAP.\n\n## Kgn construction\nThe KG was constructed in the following steps.\nStep 1: Add participants (patients and trials) and trials' exclusion factors to the KG.\nStep 2: Add participants, trials' population, treatment modalities information, duration, and type of disease to the KG.\nStep 3: Add the relations and relations to the KG among participants, trials, and patient features.\n\n## Semantic relation extraction\nTo address the sematic relation extraction task, we employed a combination of rule-based and ML-based techniques to recognize participant-to-tri",
        "label": 0
    },
    "665": {
        "output": "~AcknowledgementsWe are grateful to the AIMIRA project and to the reviewers and contributors who helped improve this research.\n \u00a9 The Author(s) 2020\nACKNOWLEDGEMENTSWe are grateful to the AIMIRA project and to the reviewers and contributors who helped to improve this research.<EOD> Genome Editing Technologies to Create Targeted Mutations and Knockouts\n\nAdapting biological systems requires the ability to specifically manipulate genes of interest. Historically, mutants were created through the application of chemical and physical agents, resulting in random mutations. Now, a variety of technologies enable the creation of targeted mutations in genes of interest with the use of nuclease-and/or antibody-directed methods. In mammalian cells, it is also possible to induce DNA damage (and inactivate a gene), without creating any mutations using a technique called \"knockout by inversion\". By targeting, rather than randomly mutating genes, one can study the role of the gene with less confounding mutations, allowing the study of the consequences of loss of function, or creation of a gain of function phenotype. In addition, when targeting specific genetic elements in a population, knockouts can be generated. This review covers the various methods available for knocking out or knocking down target genes in a desired manner.\n\n# Introduction\nThe main objective of molecular biology is to modify or control a process by manipulating the genome of the target organism, for example, in disease treatment, crop cultivation, or basic research in biomedical or agricultural fields [bib_ref]  Development and applications of CRISPR-Cas9 for genome engineering, Hsu [/bib_ref] . In the past, mutants were constructed by exposing the targeted organisms to chemical treatments, which resulted in random genetic mutations [bib_ref]  Development of efficient transgenic systems for wheat and barley, Sparks [/bib_ref] . In 1983, genetic screens were established, which enabled the generation of defined point mutations (point-mutations), which were later refined and expanded to include other applications, including epigenetic regulation (epigenetic mutations), transposon and cis-element mutations, and targeted knock-in mutations [bib_ref]",
        "label": 0
    },
    "666": {
        "output": "<EOD> The Mini-CEX: evaluation of a model for the clinical teaching of junior doctors.\nThe Mini-clinical Evaluation Exercise is a structured evaluation of a physician's performance during interactions with actual patients. It was developed by American family doctors and is currently being promulgated by the College of Family Physicians of Canada. The exercise allows the assessor to rate on a scale from 1 (unsatisfactory) to 9 (outstanding) performance on a standard list of skills based on 2-3 min. of patient-doctor interaction, and to choose from a list of special remarks in response to any performance shortcomings identified by that standard set. The exercise requires the assessor to use the assessment scales reliably and to be prepared to elaborate on any shortcomings identified by them. This article discusses the implementation of the Mini-CEX at the University of Toronto's Department of Family Medicine; the difficulties encountered in the application of the Mini-CEX; the special requirements for assessor training; and the advantages and disadvantages of the system.<EOD> Inhibition of the growth of BALB/c 3T3 cells by a bovine lactogenic growth factor.\nLactogenic growth factors present in bovine milk were investigated for their effects on the growth of 3T3 cells. The growth of BALB/c 3T3 cells was determined at a concentration of 1:2000 dilution of bovine and human milk using the MTT assay and their growth curves (Pearson's correlation coefficient, r = 0.95) and the rate of 32P i incorporation into cellular phospholipids were determined using a bioassay. Pure Epidermal Growth Factor (EGF) showed no inhibition of either the DNA synthesis or the mitogenic effect of 5 beta-12-oienoyl-3 beta,7 beta dihydroxy-Cholan acids. Purified placental lactogen, however, although having some ability to support cellular growth, did not restore the mitogenic activity of the bovine lactogenic growth factor diluted in human milk. The mitogenic activity of the lactogenic growth factor was destroyed by an",
        "label": 1
    },
    "667": {
        "output": "Note that this is the last step of this use case; a trial note is usually processed at a step earlier than this.\n\n# Task 6\n[INST] A trial coordinator is asked to review the patient note and the trial criteria to find patients who would comply with the eligibility criteria for the trial. [EXT]\n\n# Requirements\n- The trial coordinator reviews the note and trial criteria to determine if the clinical trial is applicable for the patient.\n- The trial coordinator selects and displays the eligibility of the patient for the clinical trial.\n- \tThe trial coordinator selects and displays the eligibility of the patient for the clinical trial.\n- If the patient is excluded, the patient's notes are presented to the trial coordinator.\n- If the patient is excluded, the patient's notes are presented to the trial coordinator.\n\n# Use Case Template\n# Patient Note Exploration\nTrial ID : 998 - 4.14.25.25.0002 Title : PG-121-11. Trial Name: Clinical Trial of Increased Tolerance to Iodine and Radiofrequency Ablation of VX2 Carcinoma in the Prostate.\nThis is a clinical trial to evaluate clinical outcomes for prostate cancer patients that have undergone RFA of a VX2 tumor implanted in the anterior prostate. It is expected that by evaluating the tolerance of RFA in these patients at week 3, 6, and 9, we will be able to optimize the procedure for these patients with minimal complications. \nA total of 24 patients will be included into the trial. A total of 12 patients will be treated to deliver an 83 G of radiation dose. A study in animal models has determined a median tolerance dose of 74 gray. Therefore, patients will be treated until they reach an 83 Gy dose.\nPatients will be treated twice a week with 6 Gy at each fraction. During treatment, all patients will be administered oxygen to facilitate the absorption of the ionizing radiation.\nTwo weeks after receiving the entire 48 Gy dose of radiation, prostate biopsies will be performed in all patients. For those patients",
        "label": 0
    },
    "668": {
        "output": "We will now demonstrate a more complex case, which needs the following steps:\n\n\n*\n\n*Select the appropriate patient note in the Patient Information Tab\n\n*Obtain all of the patient data related to a clinical trial - Patient ID: 4010, Diagnosis: '2+ CAD on Carotids and Left Subclavian artery, age: 50, gender: Female.\n\n*Go to the Patient Note Tab. Find all patient info (lab, diagnosis, procedure, notes, medication)\n\n*Select the corresponding clinical trial name on the top of the page and go to the Clinical Trial Details Tab to see all the required information to evaluate the patient.\n\n*Go to the Findings Tab and copy the required eligibility criteria into the Findings Box for each of the trials.\n\n*Go to the Trial-level eligibility Tab and evaluate the patient's eligibility according to the trial and report the eligibility status for each trial.\n\nYou should obtain the patient information for 5 different trials and evaluate them in each one of them.\nYour output results should be:\nPatient ID: 4010, Patient Diagnosis: '2+ CAD on Carotids and Left Subclavian artery' \nInsufficient information for any of the clinical trials\nFindings:\n\nDemographic:\nCaucasian female\nAge: 50 years old\nWeight: 135 pounds\nEthnicity: Caucasian\nEmployment: Retired with pension\nSmoking: Former smoker\nPersonal History:\nPrevious medical history or procedures:\nMedical History: DVT\nMedications:\nFamily History:\nFamily History: Family history of premature coronary artery disease, type 2 diabetes\nProcedure:\n- HgA1c (3.8): normal\n- Lipids: (LDL 40, HDL 75, LDL/HDL ratio 0.5, \n\n## Triglycerides 92, cholsterol total 141): normal\n\nFindings:\n\n\nCongenital cardiac defects:\nMastoidectomy 1",
        "label": 0
    },
    "669": {
        "output": "### <NAME>'s answer\n[I like it to be clear and succinct so I try to make that true for my answers.]\n\nFrom your code review, it looks like you should be able to understand the problem.\n\nHowever, you also need to:\n\n1. Understand that you need a better description of \\em{all your input parameters} in your functions.\n2. Understand how you need to handle when the input parameters are \\em{non-existent} or are \\em{not needed}.\n3. Understand that you need a better description of error handling.\n4. Understand that you need to have \\em{more tests} of your code.\n\nIn this case, the code seems to handle 9/9.  Your problem will be understanding why the test fails, and it would be your \\em{failure to understand input parameter and error handling} that is your challenge in resolving the issue.\n\nThe reason your test fails is because you have `print` statements that try to print a value that does not exist.\n\nIt looks like you are having the \"test\" \\em{output} a \\em{reasonable} result.  The problem is, you are using a \\em{test} which is designed to be a \\em{value} test.  So, you are trying to check for the \\em{correctness} of your code with a \\em{test} which is more suited for the \\em{validation} of your code.\n\nIn any case, your challenge is to understand \\em{why} you are getting the incorrect test results.\n\nI would strongly emphasize that if you are getting bad results with \\em{tests}, then you are most likely to get bad results when it counts -- and you should look to be 100% \\em{confident} that you are \\em{certain} of your code's \\em{correctness} (or \\em{error}) in the real world.  (You can also check that your code \\em{passes} the test and \\em{does what you want} in the real world as you go along.)\n\n\n<EOD> The influence of hormonal replacement therapy on breast cancer risk in postmenopausal women\nObjective: To determine in a cross-sectional study conducted in women 50 years and",
        "label": 1
    },
    "670": {
        "output": "A: For a one person, if you want to tell whether the person can be part of the clinic study, you need to do it with three questions:\nIs the person aged 18-35 years?\nIs the person aged 35-60 years?\nIs the person aged older than 60 years?\nIf you just want to filter the people by one question, then you should set the range of the parameter in the filter to a pair of numbers, then you could use a simple condition like this:\n<Parameters>\n        <Parameter Name=\"Test Aged 18 to 35\" \n        Type=\"ClinicalVariable\"\n        ValueInRange=\"True\" \n        DisplayName=\"Aged 18 to 35 Years\" \n        Description=\"Patient is aged 18-35 years\"\n    </Parameter>\n    <Parameter Name=\"Test Aged 35 to 60\"\n        Type=\"ClinicalVariable\"\n        ValueInRange=\"True\" \n        DisplayName=\"Aged 35 to 60 Years\" \n        Description=\"Patient is aged 35-60 years\"\n    >\n</Parameter>\n    <Parameter Name=\"Test Aged Over 60\"\n        Type=\"ClinicalVariable\"\n        ValueInRange=\"True\" \n        DisplayName=\"Aged Over 60 Years\" \n        Description=\"Patient is aged older than 60 years\"\n    </Parameter>\n    <Rule Name=\"Trial-Level Rule\" \n        Condition=\"Test Aged 18 to 35 OR Test Aged 35 to 60 OR Test Aged Over 60\"\n    >\n        <Action>\n            <ClinicalCondition Include=\"true\" />\n            <ActionName>InClinicalStudy</ActionName>\n            <ActionGroupName>Patient in Clinical Study</ActionGroupName>\n        </Action>\n    </Rule>\n</Parameters> \n\n<EOD> The epidemiology of childhood disability in low- and middle-income countries: a systematic review\n\nThis protocol describes methods for a systematic review that will use mixed methods to evaluate the extent, determinants, and impact of childhood disability",
        "label": 0
    },
    "671": {
        "output": "A: The only thing missing here is that there are 21 possible patient notes in total. You should add a new block to loop to print 21 different patients and make sure they are being printed.\n<EOD> The effect of the N-terminal domain truncations on the conformational heterogeneity of bovine \u03b3S-crystallin.\nThe oligomeric state of \u03b3S-crystallin is a heterogeneous system of dimers and trimers, and the structure of the oligomers depends on the protein concentration. Bovine \u03b3S-crystallin contains two different N-terminal truncation variants, the full-length NT-form and the NF-form. This study investigated whether the difference in the structure of the N-terminal domain affects the extent of the heterogeneous oligomeric state, as well as its quaternary structure in solution. The NMR chemical shift difference of (15)N-labeled \u03b3S crystallin between the NF-form and NT-form was around 0.15 ppm, indicating that the N-terminal region forms a separate domain from the core domain of the protein. The quaternary structure of the NF-form was also investigated by size-exclusion chromatography coupled with multi-angle light scattering, and the molecular masses of the NF-form of \u03b3S crystallin estimated to be 62, 81, 99, 126 and 161 kDa. In conclusion, the observed difference in the molecular masses is consistent with a mixture of dimeric and trimeric forms of the \u03b3S crystallin. In contrast, the quaternary structure of the full-length NT-form \u03b3S crystallin was confirmed to be a heterogeneous mixture of dimers and trimers, and the number of chains in the oligomers was 2, 3 and 4. These results are consistent with a tendency of the full-length NT-form of \u03b3S-crystallin to aggregate at relatively high protein concentrations.<EOD> Migrant Health Promotion Program in a Multi-Cultural Setting: From Reconciliation to Action\nAbstract:In 2012",
        "label": 1
    },
    "672": {
        "output": "```\n\n#### Clean the data set.\n\n[INST] Open Jupyter Notebook.\n\n#### Make required module.\n\n[INST] Create a notebook for the required module:\n\n* `Create a notebook for your desired module.\n\n  1. Create a notebook named `requiredmodule` in the `notebooks` directory.\n  2. Rename the `README.md` file and add your code to your notebook.\n  3. You can add the name of your notebook or folder from the dropdown menu if it is not already there.\n  4. Select `New Workspace` to create a new workspace and import all necessary packages",
        "label": 0
    },
    "673": {
        "output": "Exercises \nThis module aims to create and test a series of examples based on the given data, to train the user in the use of clinical trial evaluation code.\nThe first exercise covers the steps needed for entering patient information.\nIn the second exercise, we learn how to use the evaluation of patients for inclusion or exclusion.\n\nExercise 1: Patient Information Record\nThe first step is to enter all the patient information available. At the beginning, you will have patients with limited information. Here is patient data available:\npatient.ID: 1    patient.Name: Hank        patient.BirthDay: \"9/12/18\"        patient.Gender: \"Male\"        patient.Smoking: 0        patient.Diabetes: False        patient.hypertension: False        patient.hyperlipidemia: False        patient.LiverDisease: False        patient.Stroke: False        patient.FamilyHistoryCAD: False        patient.FamilyHistoryStroke: False        patient.FamilyHistoryHyperlipidemia: False\nIt is possible to use a list format to enter patient information as you add patients. In this format, you enter one patient data at a time. Use the `patient.insert ()` method that returns the number of the added patient. You should use the patient ID value as the number in `insert ()` method input argument. This data is assigned when you created the patient object. For more details see this chapter \"Creating patients\". \nIn the first task, you will learn how enter the patient data in the form. You should create the Patient Form with the `form.add ()` method that returns the number of the added form and insert the patient data into each form. Here is the source code:\n\nimport cljfmt    import \"form.clj\"\n\n[cljfmt/cljfmt.clj:32] (1) form = form.add [1]  \"Patient\"  \"Hank\" \"9/12/18\"  False  False  False  False [12]\nform.insert [1] \"Smoking\"  \"No\"\nform.insert [1] \"Diabetes\"  \"False\"\nform.insert [1] \"hypertension\"  \"False\"    form.",
        "label": 1
    },
    "674": {
        "output": "# Discussion\nWhat are the inclusion criteria?\nThere are 8 Inclusion Criteria in the trial:\n\n## age\n- Age >18y\n\n## Inclusion: all cases\n\n## Gender\n- Gender (female, male) - Patients with plaque psoriasis can be males or females\n\n## Inclusion: all cases\n\n## Duration of psoriasis\n\n## Inclusion: not applicable\n\n## Severity of psoriasis\n\n## Inclusion: all cases\n\n## History of psoriasis\n- Psoriasis has to be the patient main dermatological disease\n\n## Inclusion: all cases\n\n## Medications currently taken\n- Oral systemic agent, including methotrexate or acitretin\n- Topical therapy and/or phototherapy (and are eligible for, but are not currently receiving oral systemic or biologic therapy)\n- Biologic therapy for moderate to severe plaque psoriasis\n\n## Inclusion: all cases\n\n## History of psoriasis therapy\n- Patients who are candidate to or have received biologic therapy and/or oral systemic agents (including methotrexate or acitretin)\n\n## Inclusion: all cases\n\n## Eligibility criteria\n- Patients, who are candidates for or are currently receiving the following:\n\n## Inclusion: not applicable\n\n## Trial participation criteria\n- Patients who are candidates for or are currently receiving the following:\n- Adult male and female patients having diagnosis of plaque psoriasis for at least 6 months prior to screening\n- Age >18y\n- Gender (female, male)\n- Duration of Psoriasis > 6 months\n- Psoriasis has to be the patient main dermatological disease\n- Eligibility: not applicable\n\n## 467\nHow to detect outliers\n\n## 467#\nLet's take a look at the data. The data can be found [here](467_Data) \n### Recent 80% of patient's cases\nFirst we use the method `recent_80` from the",
        "label": 1
    },
    "675": {
        "output": "For example, if the patient doesn't have smoking history then the patient can be excluded because of that; if the patient has hypertension but the patient's blood pressure is lower than 160/95, then the patient with high blood pressure can be categorized as 1 \"relevant\" and the patient can be excluded; if the patient doesn't have family history of CAD, the patient can be categorized as 2 \"Eligible` because all other criteria has met; if the patient doesn't have any drug history, the patient can be categorized as 0 \"Excluded`, because the patient doesn't meet any criteria to be eligible to join the clinical trial. You should repeat this step for each clinical trial, and report the results you got from the three steps above in the table by following steps below.\n\n## Reporting\nFirst, fill one cell for each patient and for each trial with `0\"(if a patient doesn't meet the inclusion criterion) or `1`(if a patient has met the inclusion criterion) or `2\" Excluded.` (if it's the end). Then go to the next cell and the patient can meet one, two, or none of the criteria in all trials. Finally, you should repeat these steps for each patient and for each trial, and report your findings in the table and put them together in a text file. \nIf the following is not true:\nif there isn't `Excluded` then you should repeat the first step and repeat the steps for each trial. In the same way, if there is one condition on each cell of the first step.\nIf the following is not true:\nif there isn't only `0` in the last row then you should repeat the second step and repeat the steps for each trial. In the same way, if there is only one condition on each cell in step 2.\nIf the following is not true:\nif there isn't only `2` for the first cell of the last row then you should repeat the third step and repeat the steps for each trial. In the same way, if there is only one condition on each cell in step 3. \nYou should repeat this rule for the clinical trials 1-3 as long as the step number is not equal to last number, e.g., if the number",
        "label": 1
    },
    "676": {
        "output": "___ \n___ INCR_5 :\nYour patient 481255963 is eligible, 2) Eligible.\n___ INCR_6 :\nTrial-level eligibility: 2) Eligible.\n\n### 8.1.6 Examination of Disease Clinical Trial \\[INST] You (864148192) are the chief investigator of a disease clinical trial. In the past two months, you and your colleagues have examined the prevalence of the disease in the population of interest and the risk of disease in the general population with all available methods. Currently, you are considering the design of a disease trial and need to obtain a rough estimate of the sample size for this pilot study (the prevalence, if applicable). \n\nA sample size that gives a confidence interval between 95% and 99%, with a standard deviation of 5%, requires approx. 5,000 cases in the exposed group, assuming a relative risk of 2 or higher.  The prevalence is less than 1%. To detect a difference of 20% between the exposed and the non-exposed group, at a two-sided significance level of 1%, requiring exact confidence levels, a minimum of 16,674 cases needs to be included in the study. \n\nUse the following data as a part of the case study: \n\n```\n  - 2019\n  - 1: 1822\n  - 2: 3856\n```\n\n\n#### 8.1.6.1 Examination of Disease Clinical Trial \\[INST] You use the following data as a result of a case study of a disease pilot study:\n```\n  - 2019\n  - 1: 1822\n  - 2: 3856\n```\n\n___ INCR_1 :\nYour case studies show that the distribution is normal.\n\n___ INCR_2 :\n2019\n```\n```\n  - 1: 1822\n  - 2: 3856\n```\n___ RES_1 :\nYour calculation is correct, now set confidence interval",
        "label": 1
    },
    "677": {
        "output": "# Author Contributions\n\n## Conceptualization\n\n## Data curation\n\n## Formal analysis\n\n# Funding statement\nThis project was funded by the National Institute of Health [2R01AI133980-02A1] at the National Institutes of Health, United States of America. 2017 to 2022.\n\n## Declaration of competing interest\nThe authors claim no conflicts of interest.\nAppendix A.3. AI-Assistant for Clinical Trial Enrollment System ICD-10-Based Multi-Label Classification Module\n\n## A.3.1. dataset\nTraining dataset: 115,423. Validation dataset: 23,654.\n\n## A.3.2. pre-processing\n1) Data cleaning by the python library preprocess with ICD 10 label. Each ICD 10 code contains a word that belongs to 4 categories: symptom, problem, diagnosis, clinical procedure. By preprocessing, for example, each ICD code '7761' and '776.21' is regarded as a single token. 2) Extraction of features: The feature set is extracted by applying a Python package Doc2Vec, named as 'doc2vec.py'. We use a vocabulary of 1,000 words, set a window size of 1 and other parameters as recommended by the Doc2Vec Python package. All ICD 10 codes are tokenized as words, and are used to train the doc2vec model independently for generating word embeddings for each ICD 10 code. 3) Data splitting: We used a stratified sampling method to stratify data into a training set and test set. The ratio of training set to validation set is 8:2. 4) Data imputation using the method of \"KNN imputation\". KNN imputation is an approach that fills in missing data by estimating the value of a missing feature through the average value of the k neighboring records. The parameters were set as K = 15, distance = pearson. We used the Python package DataTone (version 1.0.1).<EOD> Osteosarcoma and osteoblastoma of the",
        "label": 1
    },
    "678": {
        "output": "### Examples\n\nExample of data input format (using YAML):\n---\ntitle: Evaluation of a computer program for screening of malignant melanoma\nabstract_en: This trial assessed the diagnostic performance of the ABCD rule compared with dermoscopy-assisted clinical diagnosis to identify patients with clinically amelanotic (unpigmented) melanocytic skin tumours (cAMTs). Of 2,000 patients referred to the skin outpatient's clinic at our centre, 148 had either clinically suspicious lesions or skin tumours histologically proven to be malignant. After receiving ethics board approval, patients were informed about the study and asked about the presence of any lesion. Those patients with non-pigmented skin lesions were referred to the Department of Dermatology for clinical presentation of any suspected lesions. Lesion-location clinical photographs taken after pigment was digitally subtracted and the dermoscopic images taken by a clinician of the skin histology team with a DermLite DL20 (3 Gen Inc., Rancho Cordova, CA, USA) were analyzed separately by 3 expert dermatologists. Each rater read the clinical and dermoscopic images, and assigned the presence and absence of the ABCD rule, respectively. The dermoscopic findings were considered as gold standards for clinically amelanotic melanocytic tumours (cAMTs). For the clinical-diagnosis based on the ABCD rule, the sensitivity (86.7%), specificity (51.5%) and accuracy (75.5%) were determined. [/YAML] \nInput of test data. The above data has three patient's test data, and each sample contains four sets of test data.\n---\ntitle: Evaluation of a computer program for screening of malignant melanoma\nsubject_type: clinical_trial_study\n\n\n### Experimental data\n- ID: ABCD_Study_0001\n- title: Example1 of ABCD rule based on dermoscopy\n- type: patient_data\n- study_name: ABCD_Study\n- abstract",
        "label": 2
    },
    "679": {
        "output": "<EOD> PPARalpha agonist fenofibrate prevents the decline in pancreatic beta cell mass in fructose-fed rats.\nChronic fructose ingestion stimulates hepatic sterol regulatory element binding protein 1c (SREBP-1c) in a manner similar to that seen with excessive ingestion of saturated fatty acids that lead to insulin resistance and dyslipidemia and predispose to non-alcoholic fatty liver disease and type 2 diabetes. The PPARalpha/gamma agonist bezafibrate, which is a drug of choice in hyperlipidemia, prevented the fructose-induced hepatic fatty acid synthesis and inflammatory response. Bezafibrate treatment reduced hepatic inflammation and injury and normalized the impaired triglyceride synthesis in the liver of fructose-fed rats. We here investigate the effect of another orally active PPARalpha agonist, fenofibrate, in preventing the increase in pancreatic beta cell mass seen in fructose-fed rats. Fructose feeding of Sprague Dawley rats for 6 weeks induces severe hyperlipidemia and insulin resistance, as also seen in patients with the metabolic syndrome. Fenofibrate treatment diminished fructose-induced insulin resistance, hyperglycemia, dyslipidemia, and hepatic SREBP-1c activation. Glucose homeostasis was improved in fenofibrate-treated rats, as judged by lowered glucose levels during a glucose tolerance test. Fenofibrate prevented the observed increase in pancreatic islets by decreasing cell proliferation and prevented the increase in fructose-induced insulin mRNA level. The increase in the content of the pancreatic and duodenal homeobox-1 (Pdx-1) protein, a rate-limiting factor in insulin synthesis, that was induced by fructose was prevented by fenofibrate. These results show beneficial effects of fenofibrate on glucose homeostasis, hyperlipidemia, hep",
        "label": 1
    },
    "680": {
        "output": "## Explanation\nTo write patient-level report, you have to write the output of the assessment of eligibility by Python script. Let's try to think step by step.\n\n\n\n**STEP 1** (Python script): Get information of patient from clinical note:\n\nFirstly, use the [read](https://docs.scipy.org/doc/scipy/reference/generated/scipy.io.loadtxt.html) function to import the string of patient's note.\n\n```python\nnote = read ('patient_note.txt')\n```\n\nNote contains the following information: \"A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications. Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs",
        "label": 0
    },
    "681": {
        "output": "A: The solution is the usage of R syntax. In R, there is no need to check the number of characters. This is done automatically by base functions. This makes it handy for R users since R functions like count() are already available and users can use them directly. The usage of R helps make the code easy to follow and understand.\nFurthermore, the use of R leads to efficient execution of code. It helps in increasing the speed of code execution and makes it easier for users to find bugs. This is because R is a highly used language and has a large number of packages available that are constantly being updated and improved. By using R, users can take advantage of these packages which allow them to have a more efficient execution of their code. This is especially valuable when dealing with big data sets.\n\nFor example: \n# This code shows how to count length of a string. For 1 string input, it gives an output of 3. There are 2 \"s\" characters in the 3 characters string and \"f\" is 1 character. \nsum(strlen(string)) \n# You can also use count() function, output will be as below: \nsum(count(string)) \n# You can also use strlen(\"I\" * string) which gives an output of 20 when combined with one character string  I.\nsum(strlen(string) * number) \nNote: number is the repetition of a word, in this example \"I\", number could be 1's, 2's, or 3's.\n<EOD> Molecular dynamics study of Pt12-microclusters: hydrogen adsorption and diffusion.\nThe adsorption of hydrogen molecules on the (111) and (100) planes of a model cubic Pt(12)-microcluster has been investigated using density functional theory (DFT). The potential energy surface describing hydrogen adsorption has been mapped within the framework of hybrid and generalized gradient approximation DFT. The resulting global potential energy minimum has been found to reside on the Pt(111) facet of the cluster. The calculated enthalpy of adsorption for H(2) molecule on the cluster in its pristine state is -1.34 eV per mole",
        "label": 0
    },
    "682": {
        "output": "<EOD> .\nPURPOSE\nTo evaluate the results of the use of cefepime (formerly LY127935) an antipseudomonal cephalosporin in urological infection.\n\n\nPATIENTS AND METHODS\n116 urological infections treated with cefepime: 87 nosocomial urinary tract infections (N = 36 Gram negative, N = 51 Gram positive), 14 lower urinary tract infections (e.g. prostatic abscess 6, urethritis 1, diverticulitis vesicare, 7), 1 chronic prostatitis, and 1 staphylococcal epididymitis.\n\n\nRESULTS\nA complete and quick clinical resolution was obtained in 99.1% of the cases. The bacteriological success was 93.8%. The side-effects were scarce, 12.6% of the patients had reversible leucopenia and no patient was withdrawn from the study.\n\n\nCONCLUSION\nCefepime has been successfully employed in the treatment of a wide variety of urological infections.<EOD> A systematic review and meta-analysis of the literature on the prevalence of chronic pain in children and adolescents\nAbstract Purpose: To estimate the prevalence of chronic pain in school-aged children and adolescents. Materials and methods: A methodological electronic search of the bibliography published from 2007 through 2014. A total of 75 articles were included to estimate the prevalence and to complete 20 meta-analyses to calculate the percentage of school-aged children and adolescents whose primary pain problem was either chronic or recurrent. The quality of the studies and the reliability and stability of the prevalence rates were evaluated using the PRISMA recommendations. Results: The prevalence rates varied between 0.01 and 48.04%. The most common pain condition was headache (4.43%), followed by recurrent abdominal pain (2%) and chronic regional pain (2%). The prevalence of chronic musculos",
        "label": 1
    },
    "683": {
        "output": "To make a more realistic example, let's imagine you do a trial-level eligibility for a real patient's note, which contains the following information:\n\n> Name: John White\n> \n> Date: 03-29-2014 \n> \n> History: John was born in 1974 in Chicago.\n> \n> Symptoms and signs: The patient has severe arthritis involving the shoulders, elbows, hands, wrists, hips, knees, and ankles without morning stiffness, and complains of back pain.  He has mild to moderate shortness of breath on exertion.\n> \n> Reason for Visit: To rule out rheumatoid arthritis. \n> \n> Medications: In 2006, John began taking methotrexate 25 mg three times a week to help control his rheumatoid arthritis.\n> \n> Allergies: John is allergic to penicillin.\n> \n> Lab Tests:\n>   - Hemoglobin was 11.8 g/dL (normal range: 14\u201318 g/dL)\n>   - Erythrocyte sedimentation rate 85 mm/h (normal range: 0\u201320 mm/h);\n>   - C-reactive protein 12.8 mg/L (normal range: 0.0\u201310.0 mg/L);\n>   - Ferritin was 333 mcg/L (normal range: 12\u2013288 mcg/L).\n> \n> Other significant medical history:\n>   - Infectious mononucleosis (2 years ago), pneumonia (a month ago).\n\nWe will obtain the clinical trial information from the following source:\n[url]\nWhat we will want to do is something like in the following example:\n`# Let's make a trial-level eligibility for a real patient`s note`\n\n`class TestTriallevelEligibility(unittest.TestCase):`\n\n`    def setUp(self):",
        "label": 2
    },
    "684": {
        "output": "## Exercises\n\n### 01 The 1st Exercise\n\n# Problems\n\n## The 1st Exercise Problem\n\n## The 2nd Exercise Problem\n\n## The 3rd Exercise Problem\n\n## The 4th Exercise Problem\n\n### 05 - The 5st Exercise Problem\n\n# Problems\n\n## The 5th Exercise Problem\n\n# The Final Exercise\n\n## Exercises\n\n### 01 The 1st Exercise\n\n# Problems\n\n## The 1st Exercise Problem\n\n## The 2nd Exercise Problem\n\n## The 3rd Exercise Problem\n\n## The 4th Exercise Problem\n\n### 05 - The 5st Exercise Problem\n\n# Problems\n\n## The 5th Exercise Problem\n\n# The Final Exercise\n\n## Exercises\n\n### 01 The 1st Exercise\n\n# Problems\n\n## The 1st Exercise Problem\n\n## The 2nd Exercise Problem\n\n## The 3rd Exercise Problem\n\n## The 4th Exercise Problem\n\n### 05 - The 5st Exercise Problem\n\n# Problems\n\n## The 5th Exercise Problem\n\n# The Final Exercise\n\n## Exercises\n\n### 01 The 1st Exercise\n\n# Problems\n\n## The 1st Exercise Problem\n\n## The 2nd Exercise Problem\n\n## The 3rd Exercise Problem\n\n## The 4th Exercise Problem\n\n### 05 - The 5st Exercise Problem\n\n# Problems\n\n## The 5th Exercise Problem\n\n# The Final Exercise\n\n## Exercises\n\n### 01 The 1st Exercise\n\n# Problems\n\n## The 1st Exercise Problem\n\n## The 2nd Exercise Problem\n\n## The 3rd Exercise Problem\n\n## The 4th Exercise Problem",
        "label": 1
    },
    "685": {
        "output": "Good luck!<EOD> Comparison of Length of Hospital Stay Associated with Surgical Site Infection among Patients Undergoing Elective Surgery of the Spine\n\nStudy Design:This is a retrospective cohort study. Purpose: Although surgical site infections (SSIs) are uncommon in spinal surgery, it is important to reduce SSI to improve patient's recovery and reduce the economic burden. This study sought to evaluate the impact of SSI on the length of hospital stay (LOS) among patients who underwent elective spinal surgery. Overview of Literature: There are many risk factors that are linked with prolonged LOS, and previous studies have shown that SSI is significantly related to longer treatment period. Methods: SSI was classified as superficial infection, deep infection, or organ/space infection. The infection was defined as wound infection that required antibiotic treatment longer than 3 days. From 2005 to 2011, 607 patients who underwent spinal surgery for the treatment of degenerative diseases were surveyed; 27 patients with infection were further analyzed.Results:The average LOS was 22.5 days in the SSI cases and 8.25 days in the control group, and the average hospital cost in the SSI cases and control was 794,520 Korean won (KRW) and 383,090 KRW, respectively. The SSI group showed significantly longer LOS and higher total cost. There were no deep infection, organ/space infection, or fatality cases in this study. Conclusions: Because SSI has a significant influence on the LOS, it should be prevented to reduce the economic burden and LOS in patients who undergo elective spinal surgery. Clinical Trial Registration: This clinical research was approved by the Clinical Research Ethical Committee of Kyung Hee University Hospital and was registered under the registration number 2014-12-048.\n\n# Introduction\nSpinal diseases are the most common reason for disability and one of the most common reasons for hospitalization in elderly patients [bib_ref]  Cost-of-illness studies in spine care",
        "label": 1
    },
    "686": {
        "output": "# Tutorial\n\n\n***\n\n\nHere is your first patient note:\nBetter:\n\n\n\n- A 46-year-old man (ID:1) presents with dizziness and frequent migraine.\n- He is diagnosed for high risk vascular disease.\n- His LDL-C level is 552 mg/dL. \n\nWhat would you do if you are the researcher to determine the trial-level eligibility on the given patient?\n\nA. You should exclude the patient.\n\nB. You should consider the patient as not relevant. \n\nC. You should consider the patient as eligible.\n\nPlease submit your answer before you continue the next step.\n<br>\n\n\n\nThe patient note is above.\nWhat criteria are sufficient to determine the trial-level eligibility on the patient?\n\nExplanation:\nA reasonable assessment of trial-level eligibility is only possible if the inclusion and exclusion criteria are known and considered for a patient. The following steps are recommended to assess for trial eligibility. Step I: Read the patient note and make sure that the patient matches the trial's disease profile. If not, go back to the title of the trial using the keyword cloud and see other clinical trials in this cloud of keywords.\nStep II: Check the target LDL levels set for a trial from the previous step. If the patient has an LDL level that is greater than the trial's target, go back to the steps I & II. Try to lower the LDL levels using statin therapy and, if still not sufficient, try to elevate the trial-recommended diet and lifestyle interventions. If the patient is still not meeting the target LDL level, go back to the steps I & II. If the trial has no target LDL therapeutic range, go back to the title using the keyword cloud and see other clinical trials in this cloud of keywords which could be more appropriate.\nStep III: Look if the patient does not have any additional atherosclerotic cardiovascular disease (ACVD) diseases compared to the trial's profile. If the patient has a disease profile that is different than the trial, go back to the title of the trial using the keyword cloud and check other trials in",
        "label": 1
    },
    "687": {
        "output": "Good job! \n\n\nIn this step, only the trial-level eligibility of a given patient is stored for the B-RICH example. In the end, you will see the final result of the assessment. \n\n## The end \n<EOD> .\nPseudorabies virus infection was diagnosed in pigs of 3 months, with a moderate febrile temperature (T39.6 degrees C) and severe pains. All the pigs died 22 hours later. Necropsy revealed a diffuse erosive pleuropneumonia. The microscopic lesions of the lungs consisted of acute-stage suppurative pneumonia, diffuse alveolitis and hematogenous pneumonia. The most severe pulmonary lesions were observed in pulmonary vascular walls and alveolar wall with the intra and interstitial alveolitis. In the lung parenchyma, there might be observed the necrosis of lymphocytes, plasmocytes, large and small lymphocytes. No pathogenic bacteria were isolated from lungs.<EOD> Phenotype of patients with mutations in APC or MUTYH.\nIn this issue of Blood, Li\u00e8vre et al report a distinct phenotype of 8 patients with MUTYH mutations and colorectal adenoma (CRA) (Li\u00e8vre et al, this issue).<EOD> Assessing the Feasibility and Acceptability of Tailored Mobile Health Coaching for Patients With Chronic Obstructive Pulmonary Disease Transitioning Home From the Hospital: Mixed Methods Case Study\n\nBackground: A large number of patients with chronic respiratory conditions, such as chronic obstructive pulmonary disease (COPD), are discharged from hospital and receive their care in homes where family members are the primary caregivers. As many patients struggle to manage their disease and navigate the health care system at home, the hospital discharge is a vulnerable time for patients and caregivers on the path to recovery. Mobile health (mHealth) solutions have the potential to support patients and caregivers at this time. Mobile technologic interventions for patients with COPD, such as mobile health education apps and remote monitoring,",
        "label": 0
    },
    "688": {
        "output": "## Expert hints\nYou can try to use the `grep -E '<a.b>`` command in the first step and then copy the result of the grep into the patient note and save the file as `patient_note 2.txt`. \n<EOD> Characterization of the Human RPE65 Protein by Site\u2010Directed Mutagenesis of the Iron Containing Domain\nAbstract:\u2002 The first step in the visual cycle is the formation of the prosthetic group chromophore in the final product. In this process, two molecules of all\u2010trans\u2010retinyl esters combine to form 11\u2010cis,13\u2010cis\u2010retinyl esters, and this is catalyzed by retinol dehydrogenases. One of these hydroxylases is retinol dehydrogenase enzyme 5 (RPE65), the visual cycle enzyme responsible for transforming the chromophore, 11\u2010cis\u2010retinaldehyde, the first product of all\u2010trans retinyl ester hydrolysis. RPE65 contains its own catalytic site and uses its catalytic site to activate the NADP+/NADPH cofactor pair. Iron\u2010dependent alcohol dehydrogenases contain an iron\u2010containing domain, which has been reported to be a catalytic domain. We decided to conduct two mutations in this region: H389D and H389A. We conducted an in vitro assay with the mutant\u2010producing enzyme and found a drastic reduction (90%) in its activity as compared with the native human retinol dehydrogenase enzyme enzyme. Therefore, we have shown what we conjecture to be a critical element that is necessary for enzyme activity.<EOD> Evaluation of in vivo antioxidant and anti-inflammatory potential of the crude extracts of two species of Heliotropium, H. indicum L. and H. asperum L.\nINTRODUCTION\nReactive oxygen species (ROS) causes many chronic degenerative diseases including inflammation, cancer, heart and neurodegenerative diseases. A number of studies have shown that oxidative stress is a pivotal component of chronic inflam",
        "label": 2
    },
    "689": {
        "output": "--- \n1. Choose one of the answers of inclusion criteria: A, B, C, G, H, I, J, or L. [Select one, then click the \"next page\" button]\n\n    \\[INST\\] Answering correctly the inclusion criteria questions is crucial for determining eligibility. Here you need to click one of the following inclusion criteria: A, B, C, G, H, I, J, or L. [INST](READ_MORE_EXERCISE_OPTIONS_EXERCISE_2)\n\n--- \nTo get to the next page, go to the exercise index page. [INST] [INST](READ_MORE_EXERCISE_OPTIONS_EXERCISE_2_INDEX_PAGE)\n\n--- \n1. Choose one of the answers of exclusion criteria: A, B, C, D, F\u3001G\u3001I\u3001J\u3001K\u3001L\u3001 M\u3001N or P. [INST] [INST](READ_MORE_EXERCISE_OPTIONS_EXERCISE_2_EXCLUSION_FIRST_PAGE)\n\n--- \nTo get the next page, choose the right exclusion criteria then click the \"next page\" button. [INST](READ_MORE_EXERCISE_OPTIONS_EXERCISE_2_EXCLUSION_PAGE1)\n\n--- \n2. Choose one of the answers of exclusion criteria: A, C, D, G, H, I, J, K, L, M, N or P. [INST][INST](READ_MORE_EXERCISE_OPTIONS_EXERCISE_2_EXCLUSION_PAGE1)\n\n--- \nTo get the second next page, choose the right exclusion criteria then click the \"next page\" button. [INST](READ_MORE_EXERCISE_OPTIONS_EXERCISE_2_EXCLUSION_PAGE2)\n\n--- \nTo get the third page, choose the right exclusion criteria then click the \"next page\" button.[INST](READ_MORE_EXERCISE_OPTIONS_EXERCISE_2_EXCLUSION_PAGE3)\n\n--- \nTo get the",
        "label": 1
    },
    "690": {
        "output": "### In-line instructions\nWhenever a user should press the `?` key after the input, our in-line instructions page will open.\n![Screenshot of an in-line instructions page that appears after pressing the ? key of a cell.](https://s.cdn.aceam.io/uploads/files/screenshots/docs-and-code/4023-cell-in-line-instructions.png)\nIt provides an easy access to the help page and the user manual about this topic.\n\n### Help web page\nAs the user starts to input the cell contents, they can click on the `Help web page (http:/aceam.org/help/)` in the footer of the user interface. It directs the user to the [ACEAM's help page](http://aceam.org/help) which provides a useful help by categorizing different ACEAM's topics and presenting useful links.\n\nThis tutorial focuses on the eligibility issue in a real clinical trial. In fact, we don't see the whole clinical trial scenario. We are observing the part that focuses on the eligibility task.\n\n## Cell Types\n\n### Cases\nA case is made of an observation, a set of data collected from a real-world clinical study, such as a trial, a registry, or an observatory. Cases can be composed of clinical notes, such as those made during a patient encounter, diagnostic images, laboratory results, and so forth. For more details, see [the cases page in the Wiki](https://aceam-dev.federatedcloud.org/wiki/ACEAM-Clinical-Notebook/case-reporter-system-implementation).\n\nCases are identified in ACEAM through UUID. A UUID is a unique 36-character string representing a case. A UUID can be generated by using [the UUID generator tool](webassets/aceam/app_scripts/static/generators/uuid.py). For example, let's generate a UUID as `7bd458bb-6d5c-11e5-ba66-8e759af6194b`.\n\nAs mentioned above, a case is made of a set of clinical data",
        "label": 2
    },
    "691": {
        "output": "## \u27f5 CONCLUDE\n<EOD> The influence of the 51Pv and 53m-Pu isotopic chains on the radiation protection problem.\nIn a previous article, we have studied the influence of the 51Pv and 53m-Pu isotopic chains on the problem of radiation protection for the nuclear industry. We have examined some of the characteristics of these two radionuclides, in particular their half-lives and their energies of beta and internal gamma emissions. We have studied, at the same time, the possibility for 51 Pv (or for 53m-Pu) to be the first alpha-emitter in the actinide series (or transuranium series) and we have obtained some limits to consider. Using some biokinetic models, we have evaluated the contribution of these two isotopes to the gonadal dose equivalent. 53m-Pu could be a possible first alpha-emitter in the transuranium series. 51Pv is a stable isotope, present in plutonium in large amounts, having a good gamma spectrometric signature, and emitting good beta emissions, leading to a gonadal dose equivalent much inferior to that from polonium. These two isotopes, in small amounts, could be used to correct the alpha spectrometric measurements.<EOD> A comparison of a single dose of 16 or 80 milligrams of mifepristone for medical abortion in South Africa\nTo compare the termination of pregnancy rates after a single dose of 16 mg mifepristone versus 80 mg mifepristone.<EOD> Effects of a low temperature on sperm capacitation in the bovine.\nThe objective of the present study was to determine if low temperatures could extend sperm capacitation duration, thereby, allowing extended semen handling and transport in tropical regions. For this, testicle and epididymis spermatozoa recovered from the bovine were incubated at 37 degrees C during 4 h then, incubated for 60, 120, and 180 min at 17 degrees C. Spermatozoal binding to the",
        "label": 1
    },
    "692": {
        "output": "_NOTE_\n\nThe output shows the assessment of eligibility for a patient in _Trial_ level. However, we need to identify whether the patient corresponds to a particular study. For this we need to determine this in _study_ level.  \n\nIn order to achieve this, we would need to retrieve all patients that are part of a study and check their assessments of eligibility. Here is an excerpt of Python code for this:\n\n```python python3/output/py_trial_level_eligibility.py --patients-table /output1/patients_info.csv --study-name \"Study_name2\" --study-description \"Study description\" \\ --study-id 1 --trial_id 2 --trial_name \"My_trial\" --trial_description \"My trial description\" --trial_country \"My country\" --trial_country_code \"My country code\" --trial_city \"My city\" --trial_city_code \"My city code\" --trial_institute \"My institute\" --trial_institute_code \"My institute code\" --trial_investigator \"My investigator\" --trial_investigator_code \"My investigator code\" \\ --input-file /output1/patients_info.csv --output-file /output2/patients_info.csv --input-header \"Sample ID\" --output-header \"Sample ID\" --output-first-column-delimiter \",\" --output-file-delimiter \",\" --output-delimiter \"|\" \"--outputdir /output\" \n\n```\n\nThe code will start with determination of study patient ID. Then we will use that ID to retrieve all patients that are part of that study. Finally, we will calculate trial-level eligibility for all these patients in a matrix and save it to the file `patients_info.csv`.\n\nIt is a good practice to save your results in a comma-separated values (CSV) file. By default, i.e. if you do not modify `--output-file-delimiter`, the first column of your data becomes a column name and the others become row names.\n\n```python\n# 12.2.2",
        "label": 1
    },
    "693": {
        "output": "And finally, you need to change in the `classify`, to be as follows:\n```\nclassify",
        "label": 1
    },
    "694": {
        "output": "Please provide feedback on the format and content of the assignment.\n\nThis assignment is submitted by [[NAME]] ([[id]]), 10/06/2018\n\n- [[Author]] [[id]] 10/06/2018\n\nTo test the submission module, you can use the form again and submit this message. Please do not submit your assignment in this form.\n\nThe [[Submit]] button is disabled before the due date of the assignment; once the [[Submit]] button is enabled, the [[Assignment Instructions]] appear if there are any remaining errors or warnings. The [[Submit]] button will become disabled after the submission time for this week has passed; you can use this module to submit until the time for a scheduled assignment has passed (after the due date of the assignment, you will use the normal assignment submission module).\n\n## Particulate matter & air quality index (aqi)\n<EOD> A case of paratesticular mucinous cystadenoma in a boy aged 14 years: ultrasonographic and MR images.\nThe author studied MR images of a case of paratesticular mucinous cystadenoma occurring in a 14-year-old boy. The tumor was well defined, cystic, and located in the testicular tunics. Mucinous cystadenomas of the testis are very rare; the author found only 29 cases reported since 1957. Of the 29 cases, 2 were mucinous cystadenomas of paratesticular origin occurring in boys and 2 were mucinous cystadenomas involving the epididymis in men. None, however, was of the multilocular type; the present case was therefore considered to be a rare occurrence according to its type, its location, and the age of the patient.<EOD> Pharmacists\u2019 Perceptions About the Practice of Pharmacy\nOBJECTIVE: To identify pharmacists perspectives on pharmacy practice in relation to specific areas of importance, such as the provision of community pharmacy services and interprofessional collaboration. METHODS: A qualitative study was conducted with a sample of pharmacists in a metropolitan area in Australia. This was a purposive sample of community pharmacists and ph",
        "label": 1
    },
    "695": {
        "output": "# Rationale\nIn this course, we want to understand clinical trial eligibility determination. Clinical trial eligibility criteria (patient selection criteria) are very critical to the conduct and outcome of clinical trials and clinical research. The definition of eligibility criteria should be based on whether the study is for an intervention, whether the study is for a prevention action, and what is the goal of the clinical trial and what is the target population. Eligibility criteria should be specific and accurate. For example, when designing the clinical trial, if the goal of the trial is to find an antihypertensive drug for hypertension, antihypertensive drugs that can lower blood pressure during the washout period should be excluded.\n\nIf the clinical trial's goal is to find a drug that lowers a specific lipoprotein, the clinical trial will exclude trials that found antihypertensive drugs and metformin. For clinical trials of cardiac drugs, the cardiac disease, especially heart failure, should first be excluded.\nEligibility criteria are classified into inclusion and exclusion criteria. For example, a study may exclude patients with severe cardiovascular disease to avoid complications and adverse events. Patients who did not meet the inclusion criteria should be excluded from the trial. \nThese decisions, together with the informed consent process by the participant, are performed by the clinical research coordinator. In this course, let's take a look at how clinical research coordinators decide the inclusion criteria of clinical trials and the exclusion criteria required for clinical trials.\n\n## Inclusion criteria\nThere are a variety of inclusion criteria and exclusion criteria for a clinical trial and there is no absolute limit to the number of inclusion criteria and exclusion criteria. However, most of all, inclusion criteria and exclusion criteria are based on safety. If an inclusion criteria and exclusion criteria do not seem safe in this process, they can be excluded. For this purpose, physicians and other clinical research coordinators should be well prepared. The study protocol is based on inclusion criteria and exclusion criteria.\nThe clinical research coordinator selects appropriate inclusion criteria based on information such as the type of diseases or symptoms that most need treatment, potential side effects, and the treatment regimen. In our study",
        "label": 1
    },
    "696": {
        "output": "CREDITS: [https://www.kaggle.com/davidhuang010406/trial-eligibility-for-patients/code]\n\n\n\n1. [https://sagepod.com/posts/insta-medicine-clinical-trial-eligibility-using-instasource]\n1. [https://sagepod.com/posts/insta-medicine-clinical-trial-eligibility-using-instasource]\n2. [https://sagepod.com/posts/insta-medicine-clinical-trial-eligibility-using-instasource]\n3. [https://sagemaker.com/blog/insta-medicine-clinical-trial-eligibility-using-instasource]\n4. [https://sagemaker.com/blog/insta-medicine-clinical-trial-eligibility-using-instasource]\nInstaMedicine-Clinical-Trial-Eligibility\n\n\n<EOD> .\nPURPOSE\nPreviously, we reported the superiority of the use of autologous mesenchymal stem cells (MSCs) into endothelial progenitor cells(EPCs) for the differentiation of the EPCs in an in vitro study. We also reported the preliminary clinical study showing the safety of the autologous MSCs/EPCs for the treatment of acute ischemic stroke. In this article, we investigated the prognosis of patients who underwent the treatment with the autologous MSCs/EPCs.\n\n\nMETHODS\nNine patients who were diagnosed with acute ischemic stroke underwent the intraarterial injection of the autologous MSCs/EPCs. Their neurological outcomes were evaluated at the admission and at 1 and 6 months by using the mRS. The mRS, the NIHSS at onset (NHISSO), the functional dependence at onset (FDO), the number of the infarcted lesions, and the number of the patients who had received treatment with M",
        "label": 0
    },
    "697": {
        "output": "<EOD> Risk factors associated with severe dengue in a single tertiary care center of West Bengal, India\n\nIntroductionSevere dengue has become a major public health challenge and needs to be explored.ObjectivesThis study was conducted to identify the risk factors associated with severe dengue in comparison with non-severe dengue.Materials and methodsA cross-sectional study was conducted in a tertiary care center of West Bengal, India. Dengue infections diagnosed from January 2019 to December 2021 on the basis of both NS1 Ag-positivity and significant increase of dengue IgM antibody were included. The patients were classified as severe dengue or non-severe dengue by considering the diagnostic criteria adopted by the World Health Organization (WHO). Data regarding demographic, hematological, and other biochemical parameters as well as the severity of dengue infections were compiled. The risk factors were identified by comparing severe dengue and non-severe dengue cases. The Chi-square test was used to find the association of the variables with severity. A p-value less than 0.05 was considered statistically significant.ResultsThere were 64 cases (11.6%) among 552 dengue patients diagnosed as severe dengue. Males (63.6%) were outnumbered than females. The mean (\u00b1SD; Median) age was 36.4 (\u00b111.9; 36.0) years. The mean (\u00b1SD; Median) duration for development of signs and symptoms was 6.0 (\u00b12.3; 6.0) days. The common clinical symptoms were fever (100%), headache (94.6%), myalgia (87.5%), arthralgia (84.4%), retro-orbital pain (83.3%), vomiting (65.6%), nausea (61.9%), abdominal pain (57.1%), and rash (25.8%). Nine severe dengue patients (14.1%) died in the intensive care unit. The mean platelet count (24723 /mm 3 ) and mean hematocrit (3",
        "label": 1
    },
    "698": {
        "output": "[CLOZY](157)  \nHello You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 157 mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 and 54",
        "label": 0
    },
    "699": {
        "output": "[END]\n\n*\n\n*This is the best practice from @FGI: #clinical-data-management. I learned this way by observing and helping out there.\n*\n\n*It is not an answer from @FGI: #clinical-data-management. In the other ways for the evaluation, we should use other kinds of metrics to describe the precision, recall and f1-score.\n\n*In this exercise, you need to make a decision. The task is to check whether the patient note satisfies the inclusion criteria or not, and you are supposed to fill those decisions into the patient table.\n\n**Instruction**:\n\n*\n\n*You can use any programming language and/or any type of web browser. You should not use any API.\n\n*\n\n*The maximum runtime is 60min. Any solution over the runtime will be graded automatically as not passing.\n\n*\n\n*You should submit the final version of your solution (the script) together with your answer. If your answer is not submitted at all, it will be marked as not passing.\n### Submission\n\nThe deadline of the contest is June 17, 2018 \n<EOD> The Role of Glycogen Synthase in the Regulation of Glucose Transporter and Na+/Glucose Cotransporter in the Rat Retina\n\nThe present study was designed to investigate the mechanisms involving the roles of glycogen synthase kinase-3\u2424 (GSK-3\u2424) and glycogen synthase (GS) in the regulation of glucose transporter (GLUT) 1 and Na \u03e9 /glucose cotransporter (SGLT-1) expression in rat retina. Two doses of N-ethylmaleimide (NEM), a GSK-3 inhibitor, significantly increased the protein abundance of GS; conversely, two doses of lithium (LiCl), a GSK-3 activator, resulted in a decrease in GS protein content. Intravitreal injections of NEM at 5 mM increased the level of GLUT1 in rat retina, whereas LiCl at 5 mM decreased the level of GLUT1. In contrast, inhibition",
        "label": 0
    },
    "700": {
        "output": "<EOD> .\nThe method for analysis of the 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and its analogs in animal and human serum is established, being based not only on the direct determination of the TCDD, but also the determination of 3,6-dichlorodibenzodioxin and their isomers. The TCDD, TCDF, 3,6-dichlorodibenzodioxin were reacted with sodium bisulfate, 1,2-dihydroxybenzene and tetraethylammonium salt. Then we used the column of the mixed-mode resin (CX-8) for the purification of reaction product for analysis by high pressure gas chromatography. The limit of detection (signal to noise) of the TCDD was less than 10 pg which corresponds to 50 fmol. It is proved that the established method is both useful and convenient in the determination of the TCDD and its analogs in animal and human serum.<EOD> A Systematic Review and Meta\u2010Analysis of Randomized Controlled Studies of Combined Oral Contraceptives in Treatment of Acne in Comparison With Combined Oral Contraceptives Alone\nAn increased interest on the role of female sex hormones on acne has been observed.<EOD> The Use of Compression Garments in Athletic Training: A Review of the Literature\n\n\n\n## Conventional compression stockings\nConventional compression stockings (CCS) are generally used in the management of venous insufficiency, and they decrease blood pooling within extremities by increasing venous return [bib_ref]  Intermittent pneumatic compression devices for prevention of deep-vein thrombosis, Segal [/bib_ref]  [bib_ref]  Compression stockings may not affect oxygen uptake or leg blood flow during..., White [/bib_ref] . In the past, CCSs were a popular choice for the prevention of deep vein thrombosis (DVT) in athletes engaging in long duration, unweighted, static activities, such as cycling [bib_ref]  Intermittent pneumatic compression devices for prevention of deep-vein thromb",
        "label": 2
    },
    "701": {
        "output": "<EOD> A comparative study of the effects of L-NAME and lysophosphatidic acid (LPA) on the proliferation and migration of osteoblasts and osteosarcoma cell lines\nObjective: Nitric oxide (NO) and lysophosphatidic acid (LPA) have been described as potential candidates to participate in bone remodeling processes, although little is known about the mechanisms of action of these substances in both normal and cancer cells. This study aimed to determine the proliferation and migration effects of NO and LPA on two cell lines of osteoblastic phenotypes, i.e., osteoblastic cells (OB) and the human osteosarcoma cell line U2OS, and compare them with the effects of LPA and NO on a urothelial carcinoma (HCV-29) cell line of epithelial phenotype. Methods: The proliferation and migration of the cells were evaluated by trypan blue exclusion/counting (TBE), cell density (BD), and cell migration (CM) assays. Nitric oxide was synthesized as a 3 Mm solution (S-nitrosoglutathione, GSNO) or by pre-incubating a lysate of peripheral blood lymphocytes from a pool of young adult donors with sodium nitroprusside (SNP) or S-nitroso-N-acetyl-D,L-penicillamine (SNAP), and LPA was used as a 20 mM solution. Results: The study reveals that OB proliferation is enhanced by NO and LPA, and to a lesser extent also by LPA, while U2OS cell proliferation is inhibited mainly by GSNO, and to a lesser extent by SNAP, NO, and SNP. Similar to the OB pattern, in the TBE tests U87 proliferation was enhanced by NO, and to a lesser extent by LPA. In the BD test, however, the osteosarcoma cell line U2OS showed a marked increase in proliferation with LPA, SNAP, or NO, whereas U87 cells",
        "label": 0
    },
    "702": {
        "output": "<EOD> A 12\u2010hour ultrasound service does not provide a better level of patient satisfaction than an 8\u2010hour service\nTo evaluate patient satisfaction with 2 separate scheduling formats using a single sonography clinic.<EOD> Characteristics of Children Presenting With Suspected COVID-19 at King Abdulaziz Medical City in Jeddah, Saudi Arabia\n\n\n\n# Introduction\nCoronavirus disease 2019 (COVID-19) is defined as an infectious illness caused by a newly discovered virus belonging to the Coronaviridae family. In December 2019, the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) broke and spread throughout the world, leading WHO to announce a pandemic on March, 30, 2020 [bib_ref]  World Health Organization declares global emergency: a review of the 2019 novel..., Sohrabi [/bib_ref] . To date, about 450 million infections and 6 million deaths linked to COVID-19 disease have been recorded globally (2). About 3000 cases and 30 deaths occurred in Saudi Arabia, according to the COVID-19 Data Repository of the Ministry of Health [bib_ref]  Data repository on the coronavirus , 2020. Ministry of Health, Kingdom of..., Health [/bib_ref] . According to CDC, the majority of COVID-19 patients are either asymptomatic or have mild symptoms [bib_ref]  Presenting symptoms of COVID 19 and its management, Farooqui [/bib_ref] . On the other hand, 5% have a severe disease, while 20% have a critical one [bib_ref]  Presenting symptoms of COVID 19 and its management, Farooqui [/bib_ref] . There is considerable variability in the presentation of COVID-19 between different age groups, as well as within the same age group [bib_ref]  Presenting symptoms of COVID 19 and its management, Farooqui [/bib_ref] . According to the National COVID-19 Data, the pediatric population is less frequently affected, accounting for only 0.8% of the confirmed patients [bib_ref]  Evaluation of suspected COVID-19 children by the Saudi Ministry of Health",
        "label": 1
    },
    "703": {
        "output": "___\nWe will continue to talk about the analysis of clinical trials in the next lesson.\n<EOD> The effect of glycerol on human erythrocyte glucose transport.\nIn a series of previous papers we have shown that a small amount, less than 5%, of one type of aminoglycoside antibiotics, gentamicin sulphate, inhibits the glucose transport of human erythrocytes.1-3) In order to prove the fact that the inhibitory action of aminoglycoside was independent of their own structure,2) we chose another group of antibiotics, of chloramphenicol (CM), tetracycline (TC), and doxycycline (DC), and demonstrated that their inhibitory action was also similar to that of gentamicin, while penicillin G (PG) and its derivative, carbenicillin hydrate (CH) did not show any inhibitory action. The question that could be raised from these experiments concerns the possible inhibitory action of other sugar components, such as glycerol for example. Thus, the present study was made on the interaction between glycerol and erythrocyte glucose transport to verify this problem.<EOD> Evolving role of bone marrow mononuclear cells in the therapy of organ failure: basic concepts\n\nBone marrow mononuclear cells (BMMNCs) have the unique ability to home to injured organs and participate in the healing process. Transfusion of these cells may become a novel tool to treat or even prevent multi organ failure. A number of animal studies, using infarcted rats as an experimental model, have shown that autologous and allogeneic BMMNC therapy significantly improved cardiac blood flow and reduced fibrosis. This beneficial effect on cardiac blood flow has also been observed after autologous BMMNC transplantation in patients with acute myocardial infarction. A number of clinically relevant diseases, including heart failure, liver cirrhosis, renal failure, diabetes nephropathy and atherosclerosis, are characterised by significant deterioration of the microcirculation. The restoration of the",
        "label": 1
    },
    "704": {
        "output": "## Task 2. [CrossRef]\nPlease consider this patient in terms of clinical trial inclusion or exclusion criteria based on information provided in the following section, which is also based on the patient's clinical trial eligibility assessment for Task 1. Your evaluation is a sentence and then should be repeated, i.e., a sentence containing both an eligibility assessment and the inclusion criteria information. Each patient has two assessments: one for the trial-level eligibility assessment and the other for trial-level exclusion assessment. You will be given the patient note in the same manner as Task 1, and the same patient note is provided for Task 2.\n[formula]  Patient 1 46-year-old man with a family history of CAD and no risk factors presenting with dizziness \u27a5 Assessment: 2) Eligible. [/formula] \nInclusion criteria: CAD Cohort \u27a5 Study inclusion criteria:\n\n## Patient 2 57-year-old man without CAD \u27a5 Assessment: 2) Eligible.\nInclusion criteria: CAD cohort study \u27a5 Study inclusion criteria:\nAge 50 years or older\nHistory of hypercholesterolemia\n\n## Patient 3 32-year-old man without cad \u27a5 assessment:\n1) Not relevant.\nAge 30-50 years and LDL-C level < 360 mg/dL \u27a5 Inclusion criteria: CAD cohort study \u27a5 Study inclusion criteria:\nAge 30-50 years and LDL-C level <360 mg/dL\n\n## Patient 4 48-year-old man with cad \u27a5 assessment:\n1) Not relevant.\nAge 50 or older and LDL-C level < 360 mg/dL \u27a5 Inclusion criteria: CAD cohort study \u27a5 Study inclusion criteria:\nAge 30-50 years and LDL-C level < 360 mg/dL\n\n## Patient 5 61-year-old woman without cad \u27a5 assessment:\n1) Not",
        "label": 1
    },
    "705": {
        "output": "### Discussion\n> `You might be wondering as to how to decide the eligibility of participants. Generally, the inclusion criteria are the minimum level of evidence required for patients to be included in the trial. In other words, patients who satisfy all inclusion criteria can participate in the trial. Let me explain using the example of two clinical trials.\n> One test was about a new drug (involving n\u2009=\u2009100 participants) for patients with breast cancer. The objective was to detect a difference in the overall and complete responses to treatment. The inclusion criteria included a tumor mass of < 250 grams and no metastasis to organs other than the breast, as estimated radiographically. The exclusion criteria included liver disorder, previous radiation therapy to the breast, previous tumor recurrence, or pregnancy or lactation. The participants in this trial were randomized into the treatment group or control group. Another trial involved a new drug (involving n\u2009=\u2009200 participants) for patients with lung cancer. The objective was to detect a difference in the overall and partial responses to treatment. The inclusion criteria included histologically/cytologically confirmed non-small cell lung cancer, a performance status of 0 to 2, and at least one measurable lesion. The exclusion criteria included previous surgery for cancerous tumors and radiotherapy to the thorax region. This trial used a placebo control and consisted of 4 arms (arm 1: new drug, arm 2: new drug and placebo, arm 3: placebo, and arm 4: placebo). Let's suppose that a participant of each trial had a tumor mass of 900 grams and no metastasis to liver, kidney, or bone. The participant satisfied inclusion in only the first and third trials. Here, the second and fourth trials would exclude the participant. Consequently, you have to make the assessment of eligibility in two trial-levels or trial-level eligibility in each trial. How to do that?` [4] \n> `When you start the eligibility check of a trial, only the data of participants who satisfy all the eligibility criteria are shown in the data input tab. To get the trial-level eligibility for participants who satisfy",
        "label": 0
    },
    "706": {
        "output": "####\n\n`/20 min`<EOD> A retrospective cross-sectional study for epidemiological estimation of the incidence of sexually transmitted infections among HIV patients in Iran\n\n\n\n## To the editor\nStudies have evaluated the association between sexually transmitted infections (STI) and pre-existing HIV infection as well as HIV treatment and STIs among those who are living with HIV. In a study, about the frequency of urethral and cervical infection with pathogenic sexually transmitted viruses among HIV/AIDS patients, Chavoshi et al. showed a 1.4% prevalence of HIV and genital herpes virus (GVH). [bib_ref]  Frequency of Urethral and cervical infection with pathogenic sexually transmitted viruses among..., Chavoshi [/bib_ref]  Furthermore, in a case-control study, the odds of STIs among HIV-positive women with a CD4 cell count of >200, CD4 cell count of 200-499 cell/microl, CD4 cell count <200 cell/microl, and a negative CD4 cell count have been estimated as 3.0, 1.9, 1.7, and 1.7, respectively. [bib_ref]  Sexual and reproductive health of HIV-positive women on antiretroviral therapy: A hospital-based..., Gholamzadeh [/bib_ref]  Recent reports show that the prevalence of curable STIs among those living with HIV is high and, in this respect, Iran, as a country, is no different. Therefore, it is essential to evaluate the trend of these infections among this high-risk group. This study retrospectively evaluated the HIV/AIDS patient data from the HIV/AIDS research center of the Tehran University of Medical Sciences located in Tehran, the capital city of Iran. The data were obtained from January 2001 to December 2015. The HIV/AIDS database was obtained from SIB (Shenas Institute of Health Information Technology), a national health information company. The cases recorded in the SIB were sent by the special units/depart",
        "label": 0
    },
    "707": {
        "output": "### Task 1\n\n##",
        "label": 1
    },
    "708": {
        "output": "Therefore, the output of Trial-level eligibility should be `Trial-level eligibility: 0) Excluded; 1) Not relevant; 2) Eligible`, where the last one indicates that the patient meets inclusion criteria, therefore is eligible for this trial.\nIn the next tutorial, you will know how to create a report in R with the ClinicalTrial package by the clinical trial note and eligibility in this tutorial.\n\n[INST] Here you can obtain the data from the web:\n[EXER] ClinicalTrial/Sep/Sepr_Data.csv\n[INST] Download the file firstly and save your local path: ```wget -T 5 https://github.com/dongzhongchun/ClinicalTrial/raw/master/R/Trial2.csv; wget -T 5 https://github.com/dongzhongchun/ClinicalTrial/raw/master/R/Trial2.csv.zip; unzip Trial2.csv.zip; mv Trial2.csv Trial2.csv.zip; Rscript Trial_report.R Path/to/Trial2.csv.zip 9a29698c11f1de5779a297cb0358464d40fb46e6 2476de5895506cde88bef21cf66fe04281b49a53cc3ca10d79ec3a80c45fa8; rcrawl Trial2.csv.zip # Path of your local, in windows we can run without -e in the R cmd # e.g., rcrawl C:/Users/Xiyu/R_project-jewel/data/Trial2.csv.zip ```[INST] If you use Linux, enter in a terminal `$ wc -l Trial2.csv.zip`, the output: The file size is 16439100 by the command: $ echo $DISKSPACE -s /Users/Xiyu/R_project-jewel/data/Trial2.csv.zip` The root",
        "label": 0
    },
    "709": {
        "output": "# E\n\n## I would like to ask which of the followings apply to your case. please select all that apply.\n\n## Patient note: \\usepackage{amsmath, amssymb}\nThe following \\textgreater{} symbols may also be used to denote a \\textit{NOT} relation:\n\n## Inclusion and exclusion criteria\nPlease indicate which of the criteria in the list below are met by the patient: \n- Clinical characteristics\\+:\n- Diagnosis of coronary artery disease\n- Taking ASA 100 mg/d day\n- Taking Ranitidine 150 mg/day\n- Taking Omeprazole 20 mg/day\n- \\textgreater{} ASA\n- Inclusion and Exclusion criteria\nPlease indicate which of the criteria in the list below are met by the patient: \n- Clinical characteristics\\+:\n- Diagnosis of coronary artery disease\n- Taking ASA 100 mg/d day\n- Taking Ranitidine 150 mg/day\n- Taking Omeprazole 20 mg/day\n- \\textgreater{} ASA\n- Inclusion and Exclusion criteria \nPlease indicate which of the criteria in the list below are met by the patient: \n- Clinical characteristics\\+:\n- Diagnosis of coronary artery disease\n- Taking ASA 100 mg/d day\n- Taking Ranitidine 150 mg/day\n- Taking Omeprazole 20 mg/day\n- Inclusion and Exclusion criteria\nPlease indicate which of the criteria in the list below are met by the patient: \n\\textgreater{} Clinical characteristics\\+:\n- Diagnosis of coronary artery disease\n- Taking ASA 100 mg/d day\n- Taking Ranitidine 150 mg/day\n- Clinical characteristics\\+:\n- \\textgreater{} Diagnosis of coronary artery disease\n- Taking ASA 100 mg/d day\n- Taking Omeprazole 20 mg/day\n\n# F\n\n##",
        "label": 0
    },
    "710": {
        "output": "You should submit your solution in the following box:\n[inst-solution] Your assignment code: YOUR_CODE_HERE\n\nPlease submit your code within 10 days, otherwise a 30% penalty will be applied and you are not allowed to work on it later.\n\nGood luck with this assignment. [END]\n\n**[/COR]**\n\n### `11.9_Assignments`\n\n```r\nassignments <- read.csv(file.choose(), header = TRUE)\n```\n\nYou should have the four files as follows: \n\n- **[Solution code assignment].RData**\n  - You should define a new 'RData' object containing your solution code. Please, see how to create it [here](https://www.rdocumentation.org/packages/rdata).\n  - Write `\"assignments = assignments\"` then the last lines inside `assigment2` function. \n- **Code.txt**\n  - Put your code in an editor and save it as a file in UTF-8 encoding called 'Code.txt'\n- **Trial-level eligibility assignment.xlsx**\n  - This is an Excel file with a worksheet called \"Triallevel eligibility assessment\" with your proposed assessment of eligibility or \"Trial-level eligibility: 0) Excluded; 1) Not relevant; 2) Eligible\" for each patient (rows) and your trial code (columns)\n- **F1_C1.xlsx; etc.**\n  - This is an Excel file with three worksheets called \"Assignee\", \"Patient_code\", and \"Trial_code\" \n  - `Assignee` tab: This is a list of assignments submitted by students. Your assignment code is 'Your code'\n  - `Patient_code` tab: This is a list of patient codes, i.e., the first three digits of the trial code. It is used to avoid double counting patients when the code of the trial is shared.\n  - `Trial_code` tab: This is a list of the codes of clinical trials that are given to students. Each student gets a trial code. You should assign the same trial code to all patients in your assignment.<EOD> Effect of N",
        "label": 1
    },
    "711": {
        "output": "<EOD> Apoptosis in proliferative endometrium: comparison of low dose and high dose of 17 beta-estradiol valerate-cyproterone acetate administration.\nThe aim of the present study was to evaluate the immune response following low dose and high dose regimens of combined estrogen progestin treatment of proliferative endometrial mucosa and compare apoptosis induction in proliferative endometrium resulting from these regimens. The study included twenty three fertile women with abnormal uterine bleeding. Patients were divided into two groups to receive two different regimens which were 50 micrograms estradiol valerate daily for ten days and 5 mg estradiol valerate daily for fifteen days, respectively. In twenty three fertile women, tissue samples were obtained from ten biopsies in each patient. Specimens were classified into three groups: before treatment, low dose estrogen progestin treatment and high dose estrogen progestin treatment. Apoptotic cell morphology was assessed under high power field (HPF) by light microscope. Apoptotic cells were identified by positive results in TUNEL assay. As a result, the mean numbers of apoptosis per HPF (mean+/-SEM) were 0.2 (0.1), 2.1 (2.99), and 1.2 (0.43), and the percentage of apoptosis per total epithelium area (mean+/-SEM) were 0.9+/-0.4%, 7.6+/-1.7% and 4.2+/-1.1% in groups before treatment, low dose estrogen progestin treatment group and high dose estrogen progestin treatment group, respectively. A significant increase was found in high dose estrogen progestin treatment group (p<0.001) when compared to pretreatment group that included only low-dose estrogen progestin treatment group. In conclusion combined estrogen progestin treatment was found to be more effective in induction of apoptosis in proliferative endometrial mucosa, in high dose estrogen progestin group in comparison",
        "label": 1
    },
    "712": {
        "output": "---\n\n# Tip 2\n[[INST] Hello. \nYou are a statistician for clinical trials. A data-management expert asked for statistics of the current trial, and for example, he wants to get the summary statistics of outcome variables from the completed trial. But the current trial design is a multi-period crossover trial where patients perform the treatment period in six conditions: drug A, placebo A, drug B, placebo B, drug A\\'s control, and drug B\\'s placebo. What are the problems when the data are analyzed without considering repeated measures of patients?]] [END]\n\nThe statistician should first analyze whether the crossover design is valid or invalid. In valid crossover designs, patient's responses for the same treatment are expected to be independent. In invalid crossover designs, patient's responses for the same treatment are likely to be correlated. The assumption that the study participants (patients) behave independently is likely to be violated in a crossover study. In such cases, even though there are two experimental groups that are independent, the crossover design must be considered when performing the analysis.\n\n[[INST] The statistician should first analyze whether the trial design is reasonable or not. Even though there are two experimental groups that are independent, the crossover design must be considered whenever performing the analysis.]] [END]\n\n[![INST] Hello. You are a clinical epidemiologist and expert of clinical trials. You are a statistician for clinical trials. The data analyst of a clinical trial is analyzing data based on their experience. You wonder that the data analyst did not consider multi-period crossover trial when performing the analysis, and now he requests for explanation about the analyses without considering crossover trial designs. First, explain how the result might be different when analyzing a multi-period crossover trial without considering the crossover trial design and why, using an example. Next, explain how the result might be different when analyzing a multi-period crossover trial with considering the crossover trial design and why, using an example.]<EOD> Exploring the Effect of the Chemical and Physical Structure of Tannins on Their Extraction from Plum Peel: A",
        "label": 1
    },
    "713": {
        "output": "1. Read the patient note. The important factors you should analyze are the stenosis of the internal carotid artery (ICA) as well as plaque, especially, those that are bulky plates extending to the middle third of the internal coronary arteries (ICAs) and were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs).\n2. Identify the appropriate inclusion criteria for the clinical trial:\n1) Hypertension\n2) Cardiomyopathy/congestive heart failure with an ejection fraction < 40%\n3) Diabetes with fasting glucose > 110 mg/dL or glycosylated hemoglobin (HgbA1c) > 7.0%\n\n4. Identify the factors of the patient's history of stroke or transient ischemic attack (TIA). The trial has listed them as \"Cardiac diseases (e.g., stroke)\".\n5. Identify the factors of the patient's current use of tobacco. The trial has listed them as \"Too many cigarettes. \"\n6. Identify the factors of the patient's poorly controlled cholesterol (LDL > 70 mg/dL or triglycerides > 150 mg/dL). The trial has listed them as \"BAD LDL.\"\n7. Identify the factors of the patient's homocysteine > 12umol/L. The trial has listed them as \"Homocystein > 12umol.\"\n8. Identify whether the age of the patient is>55 years.\n9. Identify whether the patient has a family history of CAD. The trial has listed them as \"Family history of CAD.\"\n10. Identify whether the patient is English speaking. The trial has listed them as \"English-speaking.\"\n\n*11. The patient meets the inclusion criteria of the trial. [?]\n\nB. Evaluate the case\n\n*Given the patient's information, how do you assess his eligibility for the clinical trial? Please consider the Trial eligibility, Trial exclusion, or Trial nonexclusion. Which one is",
        "label": 1
    },
    "714": {
        "output": "## Example\nIn this section, you are given the patient note and clinical trial note as follows. You will determine the patient's eligibility and output eligibility note. \nA 43-year-old male patient presented with dizziness and headaches. He had a 5-year history of CAD, was a smoker, had high blood pressure, elevated LDL, no family history of CAD, and had no diabetes mellitus or other cardiovascular risk factors. There was no previous use of lipid-lowering medications. \nThe patient's LDL and HDL levels were 444 and 69\u2009mg/dL, respectively. He was overweight (BMI: 28), and his FBS and triglyceride levels were normal (105 and 120\u2009mg/dL, respectively). The patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur I+/VI in the neck, which radiated to the skull. Ultrasonography of the carotid arteries revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between",
        "label": 1
    },
    "715": {
        "output": "### [Question] 3 In this patient, find the appropriate answer.  \n- As shown in the medical record, what is the patient's LDL-C?  \n    a. Less than 130 mg/dl  \n    b. 130 to 159 mg/dl  \n    c. At least 160 mg/dl  \n    d. Less than 50 mg/dl  \n-  a. Less than 130 mg/dl   \n-  b. 130 to 159 mg/dl   \n-  c. At least 160 mg/dl   \n-  d. Less than 50 mg/dl   \n\n\n### CORRECT ANSWER\uff1ad",
        "label": 2
    },
    "716": {
        "output": ".\nYou need to calculate the 3-valued scale, i.e.,\nIf the output on the third line in the output box 1 is 2 for both data in the input tab, run the program once again, giving any input data that you like, but do not alter the first row data. When its output is 0 or 1, 2 in the output box 3, the program will provide the trial-level eligibility, otherwise it provides the incorrect trial-level eligibility. When the output is zero, 0. This shows that the output is wrong. You should run the program again. You should repeat that process until you obtain a correct trial-level eligibility.\n\n**Trial-level 3**, trial-level 3 eligibility.\n\nPlease do the following worksheet:\n\n*\n\n*Add two more patients as data to your existing patients (the data entered will be overwritten but the data for your patients are not overwritten).\n\n*Enter the date of entry into the program.\n\n*Enter the patient number.\n\n*Enter hs TnT.\n\n*Enter CAD.\n\n*Enter data into `Patient: 4` data tab of the program.\n\n*Change the date of entry into the program for `Patient: 5` by 5th of March 2017 (instead of 22nd Feb 2017).\n\n*Enter date and ID number into both patient and the trial tab.\n\n*Enter hs TnT, LDL cholesterol and triglyceride values for this patient.\n\n*Enter CAD and ulcerated carotid arteries.\n\n*Select the correct value of LDL cholesterol for this patient.\n\n*Go ahead to the first worksheet of your document and complete the program for 20 patients. The first input tab is Patient 1 and last one is the input for Patient 20. Change the date of entry into the program for this patient by 5th March 2017 (instead of 22nd Feb 2017).\n\n*In this program, enter the ID number of this patient in the data tab.\n\n*Enter date and ID number in both patients and trial.\n\n*Enter hs",
        "label": 1
    },
    "717": {
        "output": "#### Differential Diagnosis\n\n- Inclusion criteria, clinical trial\n- Exclusion criteria, study\n- Clinical trial, inclusion criteria\n- Clinical trial, exclusion criteria\n- Study, exclusion criteria\n- Exclusion criteria, clinical trial\n- Inclusion criteria, clinical trial\n\n### The Problem Statement (the Clinical Problem Statement, the Population, and the Primary Clinical Problem) \nAs the clinical trial information suggests, the target patient is the patient with a carotid stenosis who undergoes the carotid stenting. There are other eligibility criteria, such as medication history, medical history, and laboratory test results. You should analyze those from a clinical perspective to determine what type of patients could be candidates for this trial using the criteria on the patient note.\n\n# Considerations \nSometimes, medical tests are not available for each patient. For example, the ultrasound findings were reported in the patient note. Also, it is rare to conduct blood tests on healthy people. In that case, it might be helpful to consider including healthy people who are eligible for the trial based on other clinical information.\n\n# Approach \n\n### Define the Population\nFirst, define the target population for inclusion and exclusion criteria. It can be a general population but should be defined broadly so that the criteria are applicable to a variety of patients and, with minor variations, to many people. In this study, the patient should be willing to be included in this clinical study. A patient meeting the conditions described above can be included in the trial.\n\n### Consider Which Trial Population Matches the Population\nIt's important to consider how broad the eligibility criteria should be. For example, in some cases, it may be appropriate to allow a variety of populations to receive the trial drug. However, in other trials, a certain population may be needed to ensure safety and effectiveness. \n\n### Assess Current and Prior Criteria\nAn assessment of existing eligibility criteria can determine if they adequately describe a patient population. In some cases, the current eligibility requirements are clear and do not need to be changed. In other cases, current requirements may be too broad or too narrow. Also, criteria may be more easily adaptable to future trial protocols",
        "label": 1
    },
    "718": {
        "output": "# Questions\n\n## Excluded\n\n### When can you conclude a patient is excluded?:\nIf the patient met the inclusion criteria, but was also excluded by the exclusion criteria and the exclusion criteria were clearly stated.\nWhen you can't make the decision yourself, only choose `0: Excluded.` to mark all cases.\n\n### When should you choose the same answer to all trials with the same patient record?:\nIf the trials have the same patient record and you can't make sure the clinical trial is suitable for this patient, choose the same answer to all trials by selecting `0: Excluded.` in each trial.\n\n## Not Relevant\n\n### When do you have to answer `no`?:\nYou must answer `no` to the assessment of `not relevant`.\n\n### When do you have to answer to all trials?:\nIf you answer that the information is not enough to check the eligibility, mark all cases.\n\n## Eligible\n\n### When can a patient be marked eligible?:\nIf the patient met the inclusion criteria and none of the exclusion criteria.\n\n### When can a patient be marked as `not applicable`?:\nIf the exclusion criteria for the present trial did not apply to this patient, indicate which of these applied to the patient. If no appropriate exclusion criteria is found, you need to indicate the `not applicable.` answer.\n\n### When should you choose the same answer to all trials with the same patient record?:\nIf there are multiple trials with the same patient record, check them one by one and decide.\n\n## Questions\n\n### You are given a record of a patient, what actions are you able to do?\nIn this task, you must answer how you perform the clinical trial. Choose multiple answers if necessary.\n\n### The trial has a trial-level answer value, which means that the trial-level eligibility is 2: Eligible.\n\n### The patient note was as follows:\nPlease indicate the trial information needed from the patient note to determine the trial-level eligibility.\n\n### The trial records were as follows:\n\n### The trial notes are as follows:\nPlease indicate the trial information needed from the trial record to determine the trial-level eligibility.",
        "label": 2
    },
    "719": {
        "output": "A: \n(1) I would think that this should be 1) not relevant 2) not relevant 3) not relevant\n\nBecause we see a \"Not for treatment with clinical trial\" at least twice, and none of the other options.\n\nEDIT.\n(1) I would still say \"not for treatment with clinical trial\". Since the clinical trials were not found at all on this person, we don't know their relevance. Thus, the note would simply say \"not for treatment with clinical trial\".\n(2) I would think the person would either be \"excluded\" (the clinical trial did exist, but we know it would not be found if looked for), or \"not relevant\" because the clinical trial no longer excludes people because they have this trait. Both seem appropriate.\n<EOD> Isolation of an anticomplementary fraction from bovine milk. I. Isolation and preliminary characterization.\nSummary The protein and lipid fractions of whole milk were separately separated into their major constituents, globulin and albumin, respectively. These components were subjected to a series of purification steps to produce their respective albumin and globulin. The globulin component was then separated into its two major plasma proteins, \u03b1 - and \u00df -globulins, and into the glycoproteins, \u03b1 -lactalbumin; \u03b2 -lactoglobulin; \u03b3 -lactoglobulin; \u03b1 -caseins; \u03b2 -caseins and \u03ba -caseins. This preparation and the component proteins comprise the basis for the preparation of the fraction anticomplementary to milk. The anticomplementary activity is restricted to the glycoproteins.<EOD> SARS-CoV-2 vaccine and treatment of COVID-19 with antiviral drugs in humans\n\nClinical trials for COVID-19 vaccines are in progress, and some have recently received emergency use authorization or equivalent approval. However, to date, no effective treatment for COVID-19 exists. At the time of writing in March 2021, the number of COVID-19-related deaths exceeds one million worldwide and approximately 28 million people are infected. In this report, we first review the bi",
        "label": 0
    },
    "720": {
        "output": "##### Patient notes\n\n##### Inclusion criteria of a clinical trial:\n\n**Title:** Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia \n\n**Summary:** The goal of this research is to test if the conditioning regimen, fludarabine and total body irradiation (FluTBI), can lead to a safer and more effective stem cell transplant treatment regimen for ALL patients older than 40 years of age and/or younger patients with high risk medical conditions. The primary objective is to establish the efficacy of allo HCT in older ALL patients using myeloablative FluTBI conditioning regimen. The investigators are also assessing the safety and toxicity of allo HCT in older ALL patients using myeloablative FluTBI conditioning regimen.\n\n**Inclusion Criteria:**\n\n**Disease Criteria:**\n\nALL in complete remission (CR) at the time of transplant. Remission is defined as less than 5.0% bone marrow lymphoblasts by morphology, as determined by a bone marrow aspirate obtained within 2 weeks of study registration. \n\nPhiladelphia chromosome positive ALL is allowed. \n\nLymphoid blastic crisis of CML will be included (provided that patients achieve CR).\n\nAge Criteria: Equal or above age 40 and up to",
        "label": 0
    },
    "721": {
        "output": "This example is included in the file ``Example/src/main/resources/TrialCodePilot/AssessmentExample.csv``.\n\n[END]\n\n\n### Example 5: Missing values\n\n> 123-Assessment - Missing Value\n\n[EXP]\n<?xml version=\"1.0\" encoding=\"UTF-8\"?>\n\n<!DOCTYPE ns1 PUBLIC \"-//NS1 Information Systems International//NS1 IS2 Information Systems International//NS1//EN\" \"http://www.ns.one/DataStandards/1.0/ISIS//EN\">\n<ns1>\n  <informationSet>\n    <identifier>\n      <data>123</data>\n    </identifier>\n    <informationSet>\n      <information>\n        <description>Clinical Trial Initiation, Assessment of Eligibility</description>\n        <informationName>\n          <identifier>Answers to assessment of eligibility</identifier>\n        </informationName>\n        <informationType>\n          <data>\n            <xsi:nil>\n              <xsi:boolean></xsi:boolean>\n            </xsi:nil>\n          </data>\n        </informationType>\n        <itemSet>\n          <item xsi:type=\"ClinicalTrialInformation-InclusionCriteria\">\n            <item>\n              <item>\n                <item>\n                  <item xsi:type=\"Code-Element\">\n                    <item xsi:type=\"ClinicalTrialInformation-Element\">\n                      <item xsi:type=\"Code-Element\">\n                        <item xsi:type=\"ClinicalTrialInformation-Element\">\n                          <item xsi:type=\"Code-Element\">\n                            <item xsi:type=\"Code-Element\">\n                              <item xsi:type=\"Code-Element\">\n                              175\n                              </item><commit_msg>Correcting link to page of example 5 - Missing values<commit_after>__[START]__[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical",
        "label": 1
    },
    "722": {
        "output": "## Questions\n[SOL] Hello.You are an experienced clinician and a researcher. Recently, you were invited by the local hospital committee to design a clinical trial on carotid revascularization. The clinical committee wants to start with a short trial with one group of patients. As the researcher, you should review the list of eligibility criteria to select the participants.\n\nList all the essential patient factors for you to eligible for the clinical trial. You may have any type of disease. Only mention the disease that is relevant. For example, the disease that has been mentioned in the clinical trial eligibility criteria. It can be one of these diseases or multiple diseases.\n\nPlease write your answer below and don't be concerned with other patients.\n\n[SOL] Good. You are right. The essential patient factors are mentioned in the eligibility criteria in this format:\n\n[SOL] Good. You are right. The essential patient factors are mentioned in the eligibility criteria in this format:\n\n## Mention three reasons why a patient with diabetes will not be eligible for the clinical trial.\n\n[SOL] Good. You are right. The patient will not be eligible for the clinical trial if the patient with diabetes. There are three reasons why a patient with diabetes will not be eligible for the clinical trial:\n- A 53-year-old woman presents to a clinic for routine screening. Her only health issue is borderline high cholesterol (total cholesterol of 250 mg/dL). The clinician recommends that she begin dietary supplements containing plant sterol esters as part of lifestyle modification for her high cholesterol. She agrees to try it for 4 weeks. At week 5, a nurse reviews labs and finds out that the subject is now overweight and has developed type 2 diabetes based on her latest hemoglobin A1c. The nurse tells the physician that the patient should stop the prescribed dietary supplement.\n\n[SOL] Good. You are right. The patient not be eligible for the clinical trial if the patient in diabetes mellitus of type 2. That is why the",
        "label": 1
    },
    "723": {
        "output": "<commit_msg>reverted -test of patient note <commit_after><?php\n/////////////////////////////////////////////////////////////////////////////////////////////\n// FILE NAME : clinicrecruit.php\n/////////////////////////////////////////////////////////////////////////////////////////////\n// A script to perform test cases. Use this script before running it in production.\n/////////////////////////////////////////////////////////////////////////////////////////////\n// AUTHOR : <NAME> <<EMAIL>>\n/////////////////////////////////////////////////////////////////////////////////////////////\n/////////////////////////////////////////////////////////////////////////////////////////////\n/////////////////////////////////////////////////////////////////////////////////////////////\n/////////////////////////////////////////////////////////////////////////////////////////////\n\n/////////////////////////////////////////////////////////////////////////////////////////////\n// CHECK MESSAGES BEFORE RUNNING THE SCRIPT\n/////////////////////////////////////////////////////////////////////////////////////////////\nif (empty($arg) || $arg == 100) {\n  echo \"ClinicRecruit.php should be run from the top level of the directory. Run ClinicRecruit.php from the root directory (your code, project root, in your home folder).\";\n  echo \"Run the script as follows: php test.php test.php [1] [2]\".\n        \" [1] Run a simple test that calls ClinicRecruit.php.\"\n        \" [2] Run a complex test that includes ClinicRecruit.php.\";\n  echo \"If you have written functions from libraries, they should be run as if you were in any other file.\";\n  echo \"Run your unit test by specifying the name of the class or file.\"\n        . \" The following shows an example how to run one class.\";\n  echo \"php test.php MyFirstPHPclass/myFirstPHPclassTest.php\";\n  echo \"If you are using a class for PHP 5.5 or up, you must specify its' complete\n        namespace with a double \" before the name of your class, e.g,\".\n        echo \"php test.php MyFirstPHPclass/myFirstPHPclassTest.php \" .\n        \"--namespace myfirstPHPclass\\\\MyFirstPHPclassTest\";\n  echo \"If you use a class for PHP 5.4 or down, you must use the\n        PHP_AUTO_LOAD function to load libraries and classes with names\n        starting with a capital letter.\",\n        \"This is a built-in PHP function.\",",
        "label": 0
    },
    "724": {
        "output": "To practice this task you can go to [instructions for the exercise]. You can also see the [real-time solution] if you still cannot finish these assignments alone. After that, you should be able to see what are the other tasks you're expected to accomplish and do them. Good luck.\n\n# [TRAIN] - [EXERCICE] - [INST] - Task 06: Excluded\n[TRAIN]  - [EXERCIS] - [INST] - Task 06: Excluded\n\n## [TRAIN] \ttask 03: [NAME: EXCLUDED]\nWelcome to the Excluded room. You should write what each line in the patient note means.\nPatient note in EXCLUDED:\nA 25-year-old woman presents with dizziness and frequent headaches. She has two children. The patient's previous medical history is uneventful. Her blood biochemical results were all normal. There is no history of drug use or smoking. Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. No neurological problems were detected. Ultrasonography of the carotid arteries revealed a severe stenosis in the left internal carotid artery (LCIC), and as moderate stenosis in the right internal carotid artery (RICA) estimated between 50% and 60%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 258\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 66.08\u2009cm/s and RICA EDV was 26.31\u2009cm/s. An echogenic, moderately stenotic, lesion was found in the right posterior branch of the internal carotid artery, and was estimated to be a 20% or 30% stenosis on the distal wall.\n\n## [TRAIN] \ttask 04: [NAME: EXCLUDED]\nWelcome to the Excluded room. You should",
        "label": 0
    },
    "725": {
        "output": "![<EOD> A new variant of type II herpesvirus of turkeys (HVT) with deletions of BamHI-C and BamHI-W segments in the viral genome.\nEvidence is presented for a deletion 5' to the major late genes in a variant of HVT strain HI. Sequence of the restriction endonuclease BamHI-W fragment of the parent virus, in which the recombination occurred, does not reveal any changes in the primary structure of the DNA due to the deletion.<EOD> Tetraaquabis(N,N\u2032-1-ethylpropane-1,3-diamine-\u03ba2 N,N\u2032)cobalt(II) bis[2-(4-butyl-1H-imidazol-1-yl)acetate] dihydrate\n\nKey indicators: single-crystal X-ray study; T = 298 K; mean (C-C) = 0.006 \u00c5; disorder in solvent or counterion; R factor = 0.062; wR factor = 0.164; data-toparameter ratio = 17.4. Refinement R[F 2 > 2(F 2 )] = 0.062 wR(F 2 ) = 0.164 S = 1.01 4955 reflections 283 parameters H atoms treated by a mixture of independent and constrained refinement \u00c1 max = 0.52 e \u00c5 \u00c03 \u00c1 min = \u00c00.40 e \u00c5 \u00c03\nIn the crystal structure of the title complex, [Co(C 8 H 20 N 3 ) 2 (H 2 O) 4 ](C 12 H 12 N 2 O 2 ) 2 \u00c12H 2 O or [CoCl 2 (C 8 H 18 N 4 ) 2 (H 2 O) 4 ]\u00c12H 2 O, the hexadentate N,N 0 -1-ethylpropane-1,-3-diamine (enpr) ligand bonds to one Co 2+ center, which also exhibits a dist",
        "label": 1
    },
    "726": {
        "output": "*Your name: <NAME>, <EMAIL>  \n*Your IP address: 205.161.121.128  \n*Your session ID: f60a50cd1315b2d2684c1e98323235ad  \n*Your timestamp: 2022-03-27T10:50:20.349-05:00  \n\n# Example\n\nHere is a sample output of clinical trial eligibility assessment:\n\nTrial name: PREDICTION_SAFETY\nTrial description: The purpose of this study is to evaluate the efficacy, safety, and feasibility of the Peripheral Vascular Evaluation Prior to Dermatologic Surgery protocol on patients who require a surgical procedure of the lower limb. The protocol uses a pragmatic design that compares the usual practice of not using an ankle brachial index and duplex scan prior to this kind of surgery to using them. \n\nTrial-level eligibility:\n2) Excluded \n\nPatient-level eligibility:\n2) Excluded \n\nYour name: <NAME>, <EMAIL>  \nYour IP address: 195.164.118.148  \nYour session ID: 794b6ebd208a2be9b8824749d19aa589  \nYour timestamp: 2022-11-01T06:20:36.610-05:00<EOD> Effects of a 269,000 mg/m3 ozone mixture on human lung macrophages. Involvement of hydroxyl radical.\nHuman cultured macrophages challenged with ozone (O3) showed substantial decreases in cytosolic and mitochondrial glutathione (GSH) contents as early as 15 min after challenge; the ratio of cytosolic GSH to mitochondrial GSH was significantly decreased. The cytosolic GSH level did not decrease further with increasing",
        "label": 0
    },
    "727": {
        "output": "<EOD> The Use of Antigens, Toxoids and Toxin-Antitoxin Conjugates for the Immunotherapy of Visceral Leishmaniasis\n\nCitation: Santos-Vasconcelos, J.; Soares, J.V.O.; Santos, J.; Nobre-Pinheiro, C.G.; Faria, S.L.; Saraiva, M.C.; Alves, M.O.; Costa, M.; Santos, P.M.; Nunes, D.M.; et al.Abstract: Visceral leishmaniasis is an endemic disease that is present in several regions of the world, especially in the tropics and subtropics. The treatment of patients suffering from visceral leishmaniasis is difficult and does not lead to complete cure in some cases. Therefore, this disease is a clinical and public health challenge, and an effective preventive vaccine against visceral leishmaniasis has not yet been developed. Due to the lack of a preventive vaccine and the difficulties associated with treating the disease, immunotherapy may represent a promising therapeutic approach, and it is a novel and promising strategy for controlling the disease. In this review, the main molecular aspects of immunotherapy against intracellular protozoan parasites, with particular focus on visceral leishmaniasis, are revised. First, the complexity of the disease and the main immunological aspects concerning macrophages are discussed. Next, the challenges of the immunotherapy of intracellular pathogens are presented. Then, the main immune evasion mechanisms of Leishmania spp. are described. Thereafter, the major aspects of the immunotherapy against visceral leishmaniasis are discussed, and all available strategies of immunotherapy are reviewed, as they seem to be useful in controlling visceral leishmaniasis, along with the use of adjuvants. Finally, an overview of the major antigens and toxoids of the immunotherapy for visceral leishmaniasis, and their conjugates, are discussed.\n\n# Introduction\nAmong the various neglected diseases, leishmaniasis represents one of the most relevant zoonoses",
        "label": 0
    },
    "728": {
        "output": "<EOD> Effect of Sitting Position on the Reliability of Maximum Isometric Muscle Strength Measurements\nGlencross, DCP and Van der Kamp, PW and Hough, PN. Effect of sitting position on the reliability of maximum isometric muscle strength measurements. J Strength Cond Res 26(2): 501-505, 2012. The aim of this research was to investigate the influence of chair height, height of the trunk of the chair, and the hip/knee angle on intratester reliability of maximum upper and lower limb muscle strength measurements, using isokinetic testing as the gold standard. Eight male volunteers with a mean ( \u00b1 SD) age of 48.6 \u00b1 6.3 years were tested on 2 occasions. On both occasions the testing involved repeated maximum voluntary contractions. Testing took place on a HUMAC T250 isokinetic machine in a standardized sitting position in the following groups: (1) normal chair height; trunk and chair height varied (normal testing); (2) normal chair height with the hip/ knee angle adjusted prior to testing; (3) high chair; trunk and chair height were constant (high testing); (4) high chair with the hip/knee angle adjusted prior to testing (high angle testing); (5) low chair; trunk and chair height were constant (low testing); and (6) low chair with the hip/knee angle adjusted prior to testing (low angle testing). Maximum upper limb strength in the shoulder abduction and elbow flexion, and lower limb strength in the knee extension, and hip abduction were measured. The strength variables tested achieved a level of reliability for both normal and high sitting position when compared with the isokinetic machine. The variables for hip abduction in particular were less reliable and should therefore be used with caution when a person cannot position themselves for a high chair. To a great extent the test/retest variability was found to be more associated with the performance of the test than the influence of the sitting position on the reliability of the tests conducted. Practitioners should use the sitting position based on their assessment of their client's ability to perform a test and make no major alterations to sitting",
        "label": 1
    },
    "729": {
        "output": "<NAME><NAME>\n\n= Overview\n\n![](https://img.shields.io/badge/author-<NAME>-lightsteelblue)\n= Objective\n<NAME> is an online text editor that is based on the Jupyter [Notebooks](https://www.jupyter.org) and [Kernel](https://www.kaggle.com/learn/jupyterkernels). When using Kaggle, you can build your notebooks in any language (Python, RST, LaTeX).\nThe objective of this tutorial will be to demonstrate how to extract information from a clinical trial. We will use two main steps:\n- Evaluating the patient's eligibility for the clinical trial\n- Creating new columns from the raw information.\n\n= Learning Path\n* __Data Cleanup__\n\t[Data Cleanup](https://www.kaggle.com/learn/data-cleanup)\n* __Preprocessing__\n\t[Data Preprocessing](https://www.kaggle.com/learn/data-preprocessing)\n* __Baseline Transformations__\n\t[Baseline Transformations](https://www.kaggle.com/learn/baseline-transformations)\n* __Feature Engineering__\n\t[Feature Engineering](https://www.kaggle.com/learn/feature-engineering)\n* __Data Imbalance__\n\t[Data Imbalance](https://www.kaggle.com/learn/data-imbalance)\n* __Supervised Machine Learning__\n\t[Supervised Machine Learning](https://www.kaggle.com/learn/supervised-machine-learning)\n* __Unsupervised or Unsupervised Learning__\n\t[Unsupervised Machine Learning](https://www.kaggle.com/learn/unsupervised-machine-learning)\n* __Cross-validation__\n\t[Cross-validation](https://www.kaggle.com/learn/cross-validation)\n* __Data Transformation__\n\t[Data Transformation](https://www.kaggle.com/learn/data-transformation)\n* __Data Visualization__\n\t[Data Visualization](https://www.kaggle.com/learn/data-visual",
        "label": 0
    },
    "730": {
        "output": "<p style=\"text-align: justify;\">Four different scenarios of the clinical trial analysis for patient 1:</p> <p style=\"text-align: justify;\">Case 1. [CODE]: The exclusion criteria on the previous disease exclude the patient from the trial. [CODE]: Outputs 1. The patient does not qualify because exclusion criteria on the previous disease apply.</p> <p style=\"text-align: justify;\">Case 2. [CODE]: The previous disease has no effect on exclusion from the particular trial. [CODE]: Outputs 0. The patient does not have sufficient information to qualify for this clinical trial.</p> <p style=\"text-align: justify;\">Case 3. [CODE]: The patient has no effect on exclusion from the trial. [CODE]: Outputs 0. The patient does not have sufficient information to qualify for this clinical trial.</p> <p style=\"text-align: justify;\">Case 4. [CODE]: The patient meets inclusion criteria and all the exclusion criteria for the trial are met. [CODE]: Outputs 2. Inputs 2: The trial-level eligibility is eligible. [CODE]: Outputs 2. The patient is eligible for this clinical trial.</p> \nYou should think about the following questions:<P>\u2022 In Case 1, is the patient's exclusion criterion applied? (yes/no)</li> \n\u2022 In the cases 2 and 4, the correct trial-level eligibility output is 0. Why?</li> \n\u2022 In case 3, if the trial-level eligibility output is 2, why?</li> \n\u2022 Now, suppose that the patient does not meet any of the inclusion criteria. Which output does your program give?</li> \n\u2022 If an output of 2 means that the patient is eligible for this clinical trial. What is different between the output for case 4 and Case 1?</li> \n<P>\n<P>The correct answer is <STRONG>(A), (B), (C), and (B)</STRONG> respectively \nA1. <STRONG>The exclusion criteria for the previous disease exclude the patient from the trial.</STRONG>\nA.2. <STRONG",
        "label": 0
    },
    "731": {
        "output": "## Step 3\nUsing the data from Step 1 or 2, import the data into the R environment.\n[INST] R> data=read.table(paste0(\"../data\", filename,\".txt\"), header=T, row.names=FALSE) # Read the trial patient data [INST] R> patient.id<-rownames(data)\n\n## [install]\nR> data <-read.table(paste0(\"../data\", filename,\".txt\"), header=T, row.names=FALSE) # Read the trial patient data R> patient.id<-data[,1] R> gender <-data ,2] R> birth.year <-data[,3] R> birth.month <-data# Add a variable to indicate the patient was excluded by eligibility check R> exclusion <-data[,patient.id %in% excluded ,2]+data[,1] # Add the date of diagnosis of CAD R> cad.",
        "label": 0
    },
    "732": {
        "output": "## Good luck!\n<EOD> A randomised, controlled trial to assess the effect of oral pre\u2010treatment with indomethacin on gastrointestinal complications following coronary angiography and intervention\nObjectiveTo examine whether indomethacin (Indobolet\u00ae, Indocid\u00ae, Indometon\u00ae) administered orally 18 h before and 8 h after coronary angiography and intervention reduces the severity of gastrointestinal complications. DesignProspective, single-centre, randomised, double-blind, placebo-controlled, parallel-group trial. PatientsConsecutive patients booked for elective coronary angiography and intervention within a few days. InterventionAfter randomisation, one group received indomethacin 75 mg twice daily, one group received placebo twice daily. Patients completed questionnaires on gastrointestinal symptoms (symptom score) before and after coronary angiography and intervention, and within 3 days thereafter. Main outcome measuresThe primary outcome was the severity of heartburn as compared to that noted just before cardiac catheterisation. A second gastrointestinal score was calculated after coronary angiography and intervention. Secondary outcomes were the severity of regurgitation, nausea, vomiting, and abdominal pain, and the overall frequency of gastrointestinal symptoms. ResultsSixty-six patients were randomised (34 women, 32 men, age 72.5\u00b111.1 yrs, body mass index 28.4\u00b14.9 kg/m2). Thirty-three received and thirty-three placebo. Ninety out of 132 questionnaires delivered within 3 days after coronary angiography and intervention were returned. Severity scores of heartburn before coronary angiography and intervention were 1 point (52), 1 point (30), for the groups receiving indomethacin, respectively, and placebo (0). Mean severity score of heartburn during catheterisation was 0.7 and 0.9, respectively, postintervention 0.8 and 0.9 for both groups (Wilcoxon analysis). Heartburn severity score",
        "label": 1
    },
    "733": {
        "output": "__NOTE__\nIf you see `0) Excluded, 1) Not relevant or 2) Eligible` by `Trial-level eligibility:` keyword, you should fill in the rest of the assessment of eligibility for the `Trial-level: 2) Eligible` case. [INST]\n[INST] \n\n\n## Exercises:\n[INST] Use exercise3.py and data/patient_data/ to work in this exercise.\n[INST] Exercise 3 -  `Inclusion criteria`\n\n\n[INST]\n`Trial-level eligibility: 2) Eligible, Assessing physician: {NAME} {LAST} Clinical trial-related factor: `Inclusion and Exclusion Criteria`\n\n### Include\nIn the CTA, the following criteria are defined for inclusion in the trial: \n\n**Inclusion Criteria (IC):**\n\n1. 18-60 years of age; 2. Cases of angina pectoris by coronary angiography. \n\n### Exclude\nIn the CTA, the following criteria are defined for exclusion from the trial: \n\n**Exclusion Criteria (EC):**\n\n- Previous myocardial infarction or percutaneous coronary intervention in the last 3 months;\n- Left ventricular ejection fraction < 30% in left ventriculography exam;\n- Left ventricular outflow tract and valvular disease;\n- Other conditions that affect the patient's coronary artery;\n- Patients with any contraindication to treatment with omega 3 (allergies or food intolerance and any other adverse response) \n\n[INST]\n`Trial-level eligibility: 2) Eligible, Assessing physician: {NAME} {LAST}, Clinical trial-related factor: `Excluding inclusion criteria`\n\n### Exclude\nIn the CTA, the following criteria are defined for exclusion from the trial: \n\n**Exclusion Criteria (EC)** \n\n- Not meet the `Inclusion criteria (IC) (in any of them) `\n\n## Exercise 4",
        "label": 0
    },
    "734": {
        "output": "### [/STARTSTEP][ENDSTEP] [INST]\nNow you should input the patient note as follow. First, you should input the patient note in the 'Patient note' section by`Patient note`. You can input the text of the clinical trial note of the patient. You can also add line spacing after 'Patient note' section. And you can input more patient notes by pressing `Enter`. \n[/STARTSTEP][ENDSTEP] [INST]\n```\n\n## Step 5: Patient demographics and patient treatment\nPatient demographics such as age, height, weight, gender, birth date and birth place are required. You can also choose the clinical trial center in the 'Clinical trial center' section.\n\n### [/STARTSTEP] [ENDSTEP] [INST]\nIn the 'Patient demographics' section, you should input the demographics of the patient. You can set the patient's birth date, gender, and ethnicity. [/STARTSTEP] [ENDSTEP] [INST]\n\n### [/STARTSTEP][ENDSTEP] [INST]\nSelect the clinical trial center in the 'Clinical trial center' section and input the clinical trial center name. [/STARTSTEP][ENDSTEP] [INST]\n\n### [/STARTSTEP][ENDSTEP] [INST]\nAfter selecting the Clinical trial center, you should start the selection of the Clinical trial in the 'CINICAL TRIAL' section. You can choose the clinical trial from three levels; National Cancer Institute, Phase I clinical trial, and Phase 2 clinical trial. And you can input the accession number of the protocol of clinical trial from the 'Protocol ID' section. And you can input the type of the clinical trial, treatment arms to which the patient belongs and status with clinical trial. \n\n# Example code\nIn this tutorial, let's implement the previous code (the previous step in this tutorial) in R.\n\n#### Import data\n\ninstall.packages(\"devtools\")\n\ndevtools::install_github (\"michaeltcullen/CINICAL_TRIAL_SELECT)\n\nlibrary(tidyverse)\n\n# Install CIN",
        "label": 0
    },
    "735": {
        "output": "![](https://res.cloudinary.com/v3pv89h28/image/upload/v1636724413/jml2mlhz3c.png)\n\n> ## Your submissions will remain invisible for peer review.\n\n\n[!VIDEO](https://youtu.be/976xMx2zIwA)\n\n- In `Your submissions will remain invisible for peer review` section you can submit your submissions for final peer review.\n\n\n- If you want to submit your final paper on Kaggle without reviewing, click on `Save submissions without reviewing` button.\n\n\n- If you want to submit only training data for your paper, click on `My submissions, Final training only` button.\n\n- A detailed report is sent to your email address.\n\n\n<EOD> .\nThe effect of the thrombodynamin agent on the blood circulation rate in rats has been found to be a dose-dependent increase. The drug at the doses not producing thrombohemorrhagic activity raises the blood flow rate in skin and mucosal membranes.<EOD> Lattice dynamics of crystalline water from the perspective of quantum mechanics, molecular mechanics, and coarse-grained continuum models.\nThe lattice dynamics of a crystalline phase of water has been a longstanding conundrum due to its anomalies, particularly the weakly bound hydroxyl bonds. Traditional density functional theory based on the Born-Oppenheimer approximation is known to be unreliable. This issue is revisited from a purely quantum mechanical perspective. A wave packet method is applied, which incorporates the true vibrational normal modes of a crystalline water phase. It is shown that a well-converged treatment of the lattice vibration modes gives reasoned results and is in agreement with the results of direct dynamics simulations of the quantum dynamics of the water molecule near the crystalline phase. The quantum results can also be compared with those of quantum dynamics using the local harmonic approximation approximation (LH2) and with molecular dynamics simulations (MD) based on the TIP4P/2005 potential functional. LH3 shows considerable improvement compared to the LH2 results. The",
        "label": 0
    },
    "736": {
        "output": "<EOD> Translocation of a liposomal doxorubicin delivery system into multicellular spheroids of human breast carcinomas: effects of cell cycle-synchronization.\nBACKGROUND\nThe potential of doxorubicin-containing liposomes (DXR-LP) to penetrate through the different depths of multicellular spheroids (MCS) of the tumor cell lines MCF-7 and MDA-MB-231 was investigated by means of confocal laser scanning fluorescence microscopy (CLSM).\n\n\nMATERIALS AND METHODS\nCell cycle-specific synchronization of the MCS was achieved using a combination of vinblastine (MCF-7) and nocodazole (MDA-MB-231).\n\n\nRESULTS\nLiposomes displayed increased penetration into all MCS layers when compared with free drug (MCF-7: 56% vs 27%, MDA-MB-231: 66% vs 52%). Cycling cells of all MCS- layers took up more liposomes than non-cycling cells.\n\n\nCONCLUSION\nCell cycle-specific synchronization was a useful approach to improve the penetration of doxorubicin into all MCS-layers.<EOD> PARP Inhibitor and CDK4\u20136 Inhibitor Combination Therapy for the Treatment of Breast Cancer\n\nThe CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib have shown promising efficacy in combination with anti-hormone therapy in patients with hormone-receptor-positive/Her-2-negative metastatic breast cancer in randomized trials. CDK4/6 inhibitors showed promising activity in solid tumors, although clinical trials showed limited effects as single agents. Increasing data have shown that single-agent CDK4/6 inhibitors are able to enhance DNA-damage response and sensitize the cells to DNA damage in many types of solid tumors. Preclinically, CDK4/6 inhibition can enhance the efficacy of",
        "label": 1
    },
    "737": {
        "output": "<EOD> .\nThis paper proposes the use of the electronic tongue for determining an in vitro release from solid dispersions of a hydrophilic tetracycline, i.e. demeclocycline, from a hydrophobic carrier, i.e. PVP, and a model compound, i.e. the non-ionizable indomethacin, from PVP, thus investigating a model of solid dispersion of a poorly water-soluble compound. The influence of particle size on in vitro release, and its correlation with the changes in the electronic tongue pattern, were investigated. The results suggest the use of the electronic tongue as one of the tools for determining a drug release profile for poorly water-soluble compounds from a solid dispersion. The use of high-performance chromatography for the quantitation and calculation of a dissolution profile is not very practical, since a high level of sensitivity is required. The electronic tongue gives a good sensitivity for determining the drug release in vitro and is very easy to run. The data obtained with this method can be related to the dissolution profile for these compounds.<EOD> Infection of the cranial nerves in pediatric patients with bacterial meningitis\n\nBackground: Cranial nerve impairment is an uncommon manifestation of bacterial meningitis. It is unclear what factors influence how severely the cranial nerves are affected by infection, and whether age plays a role in this process. Methods: A retrospective case series from 2001 to 2016. Outcomes of interest included the presence of cranial nerve palsies with or without other associated focal neurologic findings, meningeal irritation signs, intracranial hypertension defined by increased intracranial pressure (> 20 cm H2O), white blood cell count, platelet count, serum sodium, glucose, blood urea nitrogen, creatinine, albumin, and arterial carbon dioxide. All cases were analyzed by a child neurologist. Outcomes were compared in patients younger than 24 months (10 patients, 5 male) and patients older than 24 months (9 patients, 5 male). Data are presented as median",
        "label": 1
    },
    "738": {
        "output": "##[QUESTION]\n\nIn this example, there are three pieces of information that you must input to complete this section: trial's exclusion criteria (trial-level exclusion), patient information that is in the exclusion criteria (patient-level exclusion), and patient information that is not included in exclusion criteria. If any of this missing information exists, you should make a Trial-level exclusion. If all the inputted pieces of information are confirmed, you should submit a Trial-level eligibility of 1) Not relevant.\n\n\n[ANSWER]\n\n1) The exclusion criteria are given only in the trial, and do not refer to patients, e.g., \"Patients \u226518 years old\"; thus, input the first character of the exclusion criteria.\n\n2) If the exclusion criteria mention patients, for example, \"Patients who lack the presence of a specific gene (e.g., CD19, CD20) should be excluded\", you should select the information that is already in your dataset, e.g., Patient ID, Age, Gender, etc.\n\n\n3) If the exclusion criteria do not refer to the patients directly, the character to select is the final character of the exclusion criteria, e.g., 2) Eligible (the last option). You should make a trial-level exclusion only when the patient's characteristics do not meet all the exclusion criteria.\n\n\n##[REFERENCE]\n\nRoth A, et al., Trial-Level Eligibility (TLE) for Clinical Trial Informatics: An Automated Approach for Computational Trial Eligibility. J Innov Clin Dent. 2017, 11(1) \n\n##[SELECTION]\n\nHere is the input file, the `screening_data.txt`, that provides information needed for the algorithm. You should set up the patients' selection with the `screening_data.txt` file, and select appropriate data using the program.\n\n![](\n[REFERENCE]\n\n\n\n## Program Installation and Running\n--------------------------------------\n\n\n\n* Install all the prerequisites\n\n\t```\n\tyum install perl -y\n\tsudo yum install gcc -y",
        "label": 0
    },
    "739": {
        "output": "For more details about eligibility criteria in general, see.\n\n## [[B1: In which line should output the result of the final analysis]] \nWhen you finish the main program, this box appears. In this box, after submitting data, what do you want to obtain? What should you type in this box at the end? \n\nThis is the end of the tutorial. \n\nThe output of the program should be something like in this table. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n[table]  <Tutorial>:  [[T2: In which line should output the final assessment for each patient]]  The next task is to output the final assessment for each patient. To do this, there are 4 factors: Patient name, Age, Sex, Atherosclerosis (0=No, 1=Yes) and final assessment. Final assessment is used in the model that will be described below. [/table] \n<EOD> .\nThe authors discuss the problem of indications to extracorporeal shockwave lithotripsy (ESWL) in patients with nephrolithiasis in the conditions of a specialized center. A total of 158 patients (90 males and 68 females) were treated from 1988 to 1997. At first, a diagnosis was made using ultrasonography, a urography, X-ray, intravenous urography, computerized tomography, retrograde pyelography. After ESWL stone clearance was achieved in 84.4% of the cases. In 1.9% of patients repeated lithotripsy was required during the first month. No statistically significant differences were detected in the frequency of clinical manifestations of renal colic between patients treated by shockwave lithotripsy and nephrolithotomy. Complications during the treatment were registered in 8 patients (5%). They were of the mild and moderate severity, no severe complications were recorded. After treatment patients of groups 3 and 4 received a conservative therapy and were examined yearly. Stone clearance was achieved in 66.7 and 71% of these patients. ESWL is a safe and effective method of tre",
        "label": 2
    },
    "740": {
        "output": "## [/CATEGORY]\n\n\n\n\n[CATEGORY: TOP]   \n\nIf we have a lot of data in the clinical research note, we may not want to repeat all of the information all of the time. That is, if data can be used more than once, we can use the category to make use of this fact. For example, in our example, the disease, the family history of CAD and lifestyle (physically active and so on) can repeatedly make use of the common information through the category.\n\nWe can organize the data into the category through the following way.\n\n*If the data can be recured more than once, we do not need to write the values repeatedly, but we can define these common data as the category.\n    *Note that we do not repeat values again. For instance, `CAD=1` is defined as a category named `Cancer`. [INST]\n*If we are going to use a category data, we need to define a variable, similar to the variable definition. For instance, a category named `Cancer-type` is created through `Cancer cancerType { . . . } = 1`, and we can then define a category variable with the values as follows. Cancer categoryType { . . . }={breast, prostate, lung, and bile duct}\n    *Note that variables and the category are similar concepts to the `Trial-level eligibility` variable. We can create a variable based on other variable with defined value.\n*Also, we should define the values for the category variable. For example, `CANCER.type=lung` and `CANCER.type=bile duct`, etc.\n*If we would like to refer to other values in the note through the category variable, we can use the value. For instance, `Patients with cancer of the lower lung` or `Patients with cancer of the bile duct`.\n*If we need to use an existing variable in our note, we will need to reference other values. For example, we may need to check which patients are patients with CAD. To do that, we will use the value of the category-related variable for each patient.\n\n\n*We can check a patient's value, e.g., `A 33-year old woman",
        "label": 1
    },
    "741": {
        "output": "![INST]: #inst<EOD> .\nOBJECTIVE\nTo develop the surgical approach for reconstruction of the parotid gland in the patients with primary parotid neoplasm located between the parotidectomy line and the mental foramen or passing the foramen.\n\n\nMETHODS\nThe clinical data of 121 cases of primary parotid neoplasms involving the facial nerve trunk from Jan. 2001 to Oct. 2012 were retrospectively analyzed. All these cases were dissected from the buccal fat pad firstly to clear the nerve trunk or sheath and then the facial nerve trunk was dissected up to the main trunk in the parotid gland. The other parotid gland was dissected along the main trunk without the facial nerve.\n\n\nRESULTS\nThere were 47 patients of benign salivary gland tumors (10 of the facial nerve trunk sheath, 6 of the facial nerve trunk passing the foramen, and the other 29 of the buccal fat pad. Among the 74 patients of malignant salivary gland tumors, 27 were located close to the mental foramen, 21 to the facial nerve trunk sheath, 15 passed the foramen, and 11 close to the facial trunk. There was no facial paralysis caused by the facial nerve injury, but obvious paralysis occurred in 5 cases of the buccal fat pad without facial nerve dissection. No mental nerve paresthesia occurred in 17 cases of mental foraminal tumors, and of the 54 cases of extramandibular tumors.\n\n\nCONCLUSION\nThe combination of 2 procedures of tumor resection and facial nerve protection are effective for patients with neoplasms involving facial nerves, as well as the mental foraminal neoplasms without mental nerve paresthesia.<EOD> Prospective Study of Porphyria Cutanea Tarda\nA prospective study of 11 patients with porphyria cutanea tarda is described, and the natural history of the disease is presented and",
        "label": 1
    },
    "742": {
        "output": "> ## # ETHICS\n* The study met all requirements of ethical research.\n* Potential participant understands that withdrawal from the trial will not affect care, and the research team agreed that the individual will not be exposed to any harm or potential risk as a result of the participant's decision to participate in or to withdraw from the study.\n* Potential participant understands that all medical information collected will be kept fully confidential and will be used only for the purpose of research.\n* All data are collected anonymously, will only be accessible by the researchers involved in the study and will be used only for scientific purposes.\n* The patient's data will not be used for any other purpose.\n* The study investigators will ensure, by providing access to appropriate information and resources, that the potential participant's right to make an informed decision about research participation will not be compromised or impeded.\n* The study investigators shall provide appropriate medical care to potential participants even if they refuse to enroll or withdraw from the study.\n* If the individual decides to participate, he will provide written informed consent for participation in the study.\n\n```python\nTrial-level eligibility: 0) Excluded, 1) Not relevant, or 2) Eligible\n```<EOD> Phenytoin\u2010induced hypocalcemia with an abnormal parathyroid hormone level\nA 36\u2010year\u2010old man, 6 weeks after transplantation of the pancreas because of T1DM, was admitted because of generalized tonic\u2010clonic convulsions and coma. Phenytoin was given because of poor blood glucose control and repeated mild hypoglycaemic episodes. The patient received 2\u20133\u2003g phenytoin over the following 28\u2003h with total doses varying from 4 to 6\u2003g. Seventeen hours after the last bolus dose the patient was restless but responsive and phenytoin was therefore reduced to a daily dose. The following day, he remained awake and responsive, but blood calcium was found to be less than 2\u2003mmol/L. Phenytoin treatment was stopped, but calcium was not given because of recent renal transplantation. However, by the next day paresthesia developed",
        "label": 1
    },
    "743": {
        "output": "# Instruction for Phase 3\nNow, please repeat the same three steps (Lines 8 - 10) for each patient note, one by one. That is a total of 13 patient notes and 13 trial-level eligibility assessments. Let us see how it looks! \n\n# Discussion\nYou and your physician are conducting a cross sectional study to gather evidence on the prevalence of obesity of adults of different age groups. As many as 900 participants, equally of each gender were chosen for the study by random sampling. Height, weight, and body mass index (BMI) were measured and recorded for each participant. Your supervisor told you that obesity is a high risk factor for many chronic diseases including diabetes, heart disease, and hypertension, and therefore, it is worthwhile to present the cross sectional study findings in your group. Let us discuss ways on how BMI is affected by factors such as gender, age, and race. \n\n* What is an example of a simple random sampling? (Ans. If you make a list of the members of a class, and pick a name out of the class membership list, and this occurs with every member, then you are performing simple random sampling. \n\n\n![[image:Slide-2.gif]]!\n\nLet's examine a trial-by-trial example based on your trial-level eligibility assessment. You see that all the assessments for patients in Example_1 are 0. It means that patients in Example_1 do not meet the exclusion criteria; consequently, they can participate in a clinical study. On the other hand, we cannot identify all conditions for patients in Example_2, Example_8, and Example_12; therefore, we have to make an exclusion criteria based on the available information. Because conditions in Example_2 and Example_8 are not clearly defined, we mark the Trial-level eligibility 0 for them. We can observe the Trial-level eligibility for patients in Example_12 is 2. Thus, patients in Example_12 should not be excluded, because none of their conditions of exclusion are met. Let us observe a patient note for a particular trial (e.g., patient 12 in Example_1",
        "label": 1
    },
    "744": {
        "output": "[CODE]\nfrom __future__ import annotations\n\n# standard library imports #\nfrom contextlib import contextmanager\nfrom typing import Dict, Iterable, Optional, Union\n\n# external imports #\nimport pandas as pd\n\n# third party imports #\nimport numpy as np\nfrom pprint import pprint\n\n# in-house imports #\nimport eligibility_assessment_interface as eai\nimport path as pth\nimport trial_interface as ti\nimport _interfaces as _inf\n\n\n# ----------------------------------------------------------------------# #\n## Tutorial: Trial Recruitment via Eligibility Checking #\nTrials have to recruit new patients over an extended period of time. After enrolment, patients have to undergo clinical examinations and are followed-up for a period of time. \n\nA lot of time can be saved by identifying patients who have a good prognosis as early as possible by conducting clinical examinations only in the patients who meet the trial eligibility criteria.\nTrials with such an approach are called non-inferior but require a time-consuming screening of many patients.\nTo avoid such an extensive recruitment effort and to save time, trials use so-called eligibility criteria to pre-select patients for enrolment. Eligibility criteria are conditions on demographics, medical history, other medical conditions, risk factors and medication adherence. The goal of this step is to reduce the overall number of patients for further recruitment as much as possible and also to enrich the study population with patients who have a potentially beneficial outcome. \n\nThe assessment of eligibility can be a complex task. It may be based on a complex, multilevel, hierarchical criteria framework that contains exclusion and inclusion criteria. The decision on eligibility is based on multiple pieces of evidence that are to be evaluated individually. \n\nThe eligibility assessment interface (eai) is used to support the clinical assessment of eligibility by the clinical staff.\n\nOne of the most important requirements for eligibility assessment interface systems is to support the user in the time-consuming and complex decision process of the trial recruitment step.\nA system which meets these requirements is the eligibility assessment interface.\n\nPlease note that",
        "label": 1
    },
    "745": {
        "output": "### Questions [Q]{x}\n\n[X]{Q}2 When you are finished with the trial-level eligibility, you are to report results according to the rules provided in the questionnaire. \n\n1) Clinical Trial Screening Results\n\n[/Q]{1}\n\n\n## Submit\nAll your work should be done before you submit it to us. Please make sure you follow all guidelines before submitting. Remember you need to add your answers to the following questions to find the complete assessment.\n\n### \u3010Questionnaire\u3011\u3010Question\u3011\n\n##{Q}1 Q 1 This questionnaire was developed for the purpose of evaluating the ability of your trial-level eligibility model in identifying clinical trial recruiting in a realistic context. The main purpose of this questionnaire is to evaluate the overall accuracy in recruiting clinical trials. Your model should answer the following question: `Is the clinical trial eligible?`\n\nHow do you expect to do?\n\n\n\n### Q 2 Q2 This questionnaire was developed for the purpose of evaluating the ability of your trial-level eligibility model in identifying clinical trial recruiting in a realistic context. The main purpose of this questionnaire is to evaluate the overall accuracy in recruiting clinical trials. Your model should answer the following question: `Is the clinical trial eligible?`\n\n\nHow do you expect to do?\n\n\n\n### Q 3 Q3 This questionnaire was developed for the purpose of evaluating the ability of your trial-level eligibility model in identifying clinical trial recruiting in a realistic context. The main purpose of this questionnaire is to evaluate the overall accuracy in recruiting clinical trials. Your model should answer the following question: `Is the clinical trial eligible?`\n\nHow do you expect to do?\n\n\n\n### Q 4 Q4 This questionnaire was developed for the purpose of evaluating the ability of your trial-level eligibility model in identifying clinical trial recruiting in a realistic context. The main purpose of this questionnaire is to evaluate the overall accuracy in recruiting clinical trials. Your model should answer the following question: `Is the clinical trial elig",
        "label": 0
    },
    "746": {
        "output": "subfolder: subfolder name in the project folder.\n- [] file: file name of your solution.\n- [INST] subfolder: subfolder name in the project folder.\n\n#### :white_check_mark: What did you need? Checkmark what you have implemented correctly.\n\n### [INST] Required\n- [] [INST] \n- [] [INST]\n- [INST] [INST]\n- [INST] [INST]\n- [INST] [INST]\n- [INST] [INST]\n- [INST] [INST]\n- [INST] [INST]\n\n### [INST] Good to have\n![](http://up05.vkontakte.ru/doc/430375492/0b51faf968ea7772d0584443f1a0ec57.png)\n- [INST] [INST]\n- [INST] [INST]\n- [INST] [INST]\n<EOD> A comparison of the clinical characteristics of COVID-19 and seasonal influenza infection\n\n [bib_ref]  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia..., Chen [/bib_ref]  [bib_ref]  Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China, Dong [/bib_ref]  [bib_ref]  The epidemiological and clinical characteristics of 67 cases of coronavirus disease 2019..., Chen [/bib_ref]  [fig_ref]  Table 1: Comparison of features and outcomes of COVID-19 and SARI patients [/fig_ref]  [bib_ref]  Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, Li [/bib_ref]  [bib_ref]  Epidemiological characteristics of 504 cases of pneumonia cases infected by SARS-CoV-2 in..., Zhang",
        "label": 0
    },
    "747": {
        "output": "- Challenge description\n\nThe challenge can be found here.\n\n\n\n- Resources used\n\n- A list of resources that we think you may find helpful\n\n[R1]\n[R1]\n[R1]\n[R1]\n[R1]\n<EOD> Interstitial lung disease in systemic lupus erythematosus\nPurpose of reviewThe purpose of this article is to review recent data regarding the epidemiology, diagnosis and management of interstitial lung disease (ILD) in patients with systemic lupus erythematosus (SLE). Recent findingsThe prevalence of SLE-related ILD is estimated to be 5% based on multiple case series. The most common type of SLE-related ILD is a diffuse alveolar damage-like interstitial pneumonitis with nonspecific interstitial pneumonitis. Although there is no standardized method to diagnose ILD, interstitial pneumonitis is a key criterion for a complete American College of Rheumatology classification of SLE. Although the reported incidence of SLE-related ILD was previously 0.2 to 0.3 cases/100 person-years, a study reported an incidence of 0.6 cases/100 person-years, mainly in patients who fulfilled at least four ACR criteria for SLE. Treatment for SLE-related ILD varies depending on the severity of ILD; if there is only a unilateral and focal ground-glass opacity pattern on high resolution CT or mild restrictive lung function abnormalities, glucocorticoid treatment may prevent progression to diffuse pulmonary fibrosis. However, if there is bilateral lung involvement and widespread ground-glass opacity patterns on high resolution CT, corticosteroid treatment is often sub-optimal. In these situations, immunosuppressive agents could play a key role in ILD therapy. Cyclophosphamide therapy has been used to treat SLE-related ILD and is considered to have an adjuvant role as an immunosuppressant agent, although its effects on improving lung function or decreasing mortality rate are small. SummaryS",
        "label": 0
    },
    "748": {
        "output": "Good job! We did it again!\n<EOD> Association of genes involved in c\u2010MYC gene expression modulation with survival in patients with advanced renal cell carcinoma treated with cytokines or antiangiogenic therapy\nThe c\u2010MYC protooncogene is a transcription factor involved in the induction of cellular proliferation, cell growth, cellular transformation, and apoptosis. In the present study, we examined the role of regulatory regions of c\u2010MYC on overall survival (OS) of advanced renal cell carcinoma (RCC) patients treated either with cytokines (n\u2009=\u200969) or with targeted therapies (n\u2009=\u200962). We found that CpG\u2010methylated patients had 2.3\u2010fold longer OS compared with the unmethylated patients (P\u2009=\u20090.002) and survived significantly longer than unmethylated patients who were treated with cytokines (P\u2009=\u20090.01) or treated with targeted therapy (P\u2009=\u20090.002). Moreover, OS was significantly associated with CpG\u2010hypermethylation of the P1 promoter (P\u2009=\u20090.04). In contrast, OS showed no significant relationship with the expression of c\u2010MYC or its regulatory elements. In conclusion, c\u2010MYC CpG\u2010methylation and P1 CpG\u2010hypermethylation have prognostic value for the OS of advanced RCC patients treated with cytokines, or targeted therapy, or both. \u00a9 2010 Wiley\u2010Liss, Inc.<EOD> Neuron loss and the dynamics of the mating\u2010induced LH surge in virgin guinea pigs.\n1. Guinea pigs were castrated on the day of birth to facilitate hormonal studies. All virgin guinea pigs were examined neurologically and had been previously shown by computer image analysis to be normal. 2. Differential counting of the hypothalamo\u2010preoptic areas (HPOs) disclosed a highly significate reduction in the numbers of vasopressin/oviduct\u2010immunoreactive (ir) neurones at the onset of diestrus in virgin adult guinea",
        "label": 2
    },
    "749": {
        "output": "Here is the Python code:\n\n```python\n# + Python@Run\n# + title: Main\n# title: Main\nclass Eligibility:\n    def __init__(self, scale: str):\n        if scale == \"0\":\n            self.scale = \"Excluded\"\n        elif scale == \"1\":\n            self.scale = \"Not relevant\"\n        elif scale == \"2\":\n            self.scale = \"Eligible\"\n        super().__init__()\n\n    def to_json(self) -> dict:\n        return {\n            \"assessment\" : self.scale,\n            \"trial_id\" : \"F2747\"\n        }\n\n    def from_json(self, json: dict) -> None:\n        json.pop(\"assessment\")\n        self.__init__(json[\"trial_id\"])\n\n    def __repr__(self) -> str:\n        return f\"Eligibility: {self.scale}\"\n```\n\nLet's try the above code: `from clinical_assessment.Eligibility import Eligibility`. and input the note and trial.\n\n```python\n# + Python@Run\n# + Python@title Main\n# + Python@language Python\n\n# + Python@title: Main\n# + Python@index 1\nassessment 0\ntrial_id F2747\n# + colab={\"base_uri\": \"https://localhost:8080/\", \"height\": 762}\n\nassessment 0\ntrial_id F2747\n# + Python@index 2\nassessment 1\ntrial_id F2747\n\nassessment 1\ntrial_id F2747\n# + Python@index 3\nassessment 2\ntrial_id F2747\n\nassessment 2\ntrial_id F2747\n# + Python@index 4\nassessment 0\ntrial_id F2747\n# + Python@index 5\nassessment 1\ntrial_id F2747\n```\n\nSo far, we have only created the Eligibility class; we have",
        "label": 0
    },
    "750": {
        "output": "[INST] Instructions\n\n\nHere is the output in Python 3.6.11. \nfrom random import randint\nfrom random_walk_by_age import random_walk_by_age\nfrom random_walk_by_weight import random_walk_by_weight\n\npatient = \"\"\"\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nHere is the clinical trial:\nTitle: Observational Study to Estimate the Effectiveness of",
        "label": 0
    },
    "751": {
        "output": "## Example input\n```\nName: A 46-year-old man presents with dizziness and frequent headaches. \nHe has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces. \nVascular Reactivity and Metabolic Syndrome\nInclusion Criteria:\n3 or more of the following criteria of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III):\n```\n<EOD> Acute Kidney Inj",
        "label": 1
    },
    "752": {
        "output": "<EOD> Ouabain Inhibits PMA-Induced Macropinocytosis in MDCK Cells by Suppressing PI3 Kinase Activity\nAbstract: Ouabain has been reported to inhibit cell growth, macropinocytosis, and protein synthesis in Madin\u2013Darby canine kidney (MDCK) cells. The present study confirms that ou",
        "label": 1
    },
    "753": {
        "output": "<EOD> Molecular Mechanism of the Inhibitory Activities of Benzenesulfonamide and Quinazolin-4(3H)-one Derived against Multidrug-resistant Gram-negative Bacteria\nThe continuous emergence of antibiotic-resistant Gram-negative bacteria necessitates the search for new antibiotics, which often involve the utilization of natural products (NPs) and their derivatives. In our previous study, we discovered that benzenesulfonamide 1, quinazoline 4(3H)-one 2 and N-acylated 3 were promising against drug-sensible and MDR Gram-negative bacteria. In the present study, the mechanism of antibacterial activity of 3 against E. coli was evaluated. The results indicated that the mechanism of action was consistent with the Gram-negative mechanism, which involves binding to the 3\u2019 end of the 16S rRNA and affecting translation to inhibit bacterial growth. Besides, 1-3 had weak inhibitory activities to human DNA gyrase, which contributed to their negligible hemolytic activity. Moreover, 3 displayed low inhibitory activity against C. elegans, indicating its low toxicity. In brief, these findings provide novel NPs candidate against drug-sensible and MDR Gram-negative bacteria, which can be utilized for the development of new antibiotics. Graphical Abstract 5-N-octanoyl-3-((E)-(4-chlorophenyl)diazenyl)benzenesulfonamide (3) exhibited potent antibacterial activities against drug-sensible and multidrug-resistant Gram-negative bacteria; moreover, it had negligible hemolytic and cytotoxic activities.<EOD> .\nPURPOSE\nTo evaluate the intraoperative and histological characteristics of retinal detachment associated with proliferative diabetic retinopathy in patients submitted to pneumatic retinopexy.\n\n\nMETHODS\nPatients' ages, sex and number of retinal detachments were recorded. The extent of proliferative diabetic retinopathy and its classification were also assessed.\n\n\nRESULT",
        "label": 1
    },
    "754": {
        "output": "[CODE]\ndef recruitment_assistant(patient_text: str, trial_txt: str) -> str:\n    \"\"\"Get trial-level eligibility of patient\n\n    Args:\n        patient_text (str): The text content of the patient note.\n        trial_txt (str): The text content of the clinical trial note.\n\n    Returns:\n        The trial level eligibility of the patient.\n    \"\"\"\n    patient_note_text = preprocess_text(patient_text)\n    trial_note_text = preprocess_text(trial_txt)\n    patient_note_pos_list =  patient_note_text.token_position\n    trial_note_pos_list = trial_note_text.token_position\n    trial_level_eligibility_code = ''\n    trial_level_eligibility_score = 0\n    exclude_conditions = ['Excluded', 'Not relevant']\n    for token in trial_note_text.split(sep=' '):\n        if token.lower() in exclude_conditions:\n            trial_level_eligibility_score = 1\n            trial_level_eligibility_code = 'Excluded'\n        if token in DONT_APPLEND_TOKENS:\n            token = ' ' + token\n        else:\n            token = token + ' '\n        trial_level_eligibility_code += token\n\n    patient_pos_list = [x[0] for x in patient_note_pos_list]\n    for token in patient_note_text.split(sep=' '):\n        if token.lower() in exclude_conditions:\n            patient_level_eligibility_score = 1\n            patient_level_eligibility_code = 'Excluded'\n        patient_level_eligibility_code += token\n\n    return f\"Trial-level eligibility: {trial_level_eligibility_code} \\nPatient-level eligibility: {patient_level_eligibility_code}\"\n    trials_eligibilities = recruitment_assistant('MyNote', trial_txt)\n\n\nWhat should you change if the patient note doesn",
        "label": 1
    },
    "755": {
        "output": "Examples are described at the end of this document.\n\n---\n\n# How to calculate patient level eligibility\n\n* **A person level eligibility score is a 13-bit number**\n  1. The number \"1\" is added for the patient-level eligibility score if the patient satisfied the inclusion criteria. The number \"0\" is added if the patient did not satisfy the inclusion criteria. The number \"1\" is added if the exclusion criteria are met.\n  <p align=\"center\">\n          <img class=\"align-center\" src=\"https://github-images.herokuapp.com/ml4hub-training-guide-docs/images/text-based/ML4_PPE_ClinTri_Inclusion_Exclusion_Condi-tions.png\"/></p>\n  <br><p style=\"text-align:justify;\">\n    The eligibility score is the sum of the score of each condition, i.e. the sum of 0 and 1. In this example, PPE is 0 because we exclude the patient in this clinical trial because he have not been diagnosed with diabetes by physician.\n  </p>\n  <p align=\"center\">\n        <img class=\"align-center\" src=\"https://github-images.herokuapp.com/ml4hub-training-guide-docs/images/text-based/ML4_PPE_ClinTri_Inclusion_Exclusion_Conditions.png\"/></p>\n  <br>\n  2. The result is rounded off by a maximum and minimum integer value.\n  <p align=\"center\">\n        <img class=\"align-center\" src=\"https://github-images.herokuapp.com/ml4hub-training-guide-docs/images/text-based/ML4_PPE_ClinTri_Inclusion_Exclusion_Conditions.png\"/></p>\n  <br><p style=\"text-align:justify;\">\n    The number \"1\" is added in this example if the patient is not eligible. The number \"6\" is added if the patient is eligible. The result is the rounded number 6 and we consider that the patient is eligible for this trial.\n  </",
        "label": 0
    },
    "756": {
        "output": "#### [INST] Exercise 05.2\nExercise 07.1\n\n[INST] The previous exercise was not too difficult, so now let's try to make some minor change. As you know, clinical criteria such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions are important in deciding which candidate would benefit most from a particular drug therapy. Hence, we should be able to make a final decision regarding whether or not a patient is eligible for a clinical trial by considering the clinical criteria as well. What is it worth doing? Let's do it!\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient'",
        "label": 1
    },
    "757": {
        "output": "##<jupyter_code>if __name__ == '__main__':\n    %run 'C:/Users/pav.bakolic/Library/Jupyter/jupyter_client_v1_7.dll' %kernel.path\n    %run 'C:/Users/pav.bakolic/Projects/DataFit/Tutorials/DataFit_Instructor_Tutorials/Tutorial_06_DataFit.ipynb' #this script runs in a new process.\n    %run 'E:/_Projects/DataFit/Sources/DataFitTutorial.ipynb' #this script runs in the new process.\n\n    if __name__ == '__main__':\n        df = pd.read_csv(\"../Examples/data.csv\", sep = ',')\n        column_name = list(df.columns)\n        column_name.sort()\n    else:\n        print (\"This is an incorrect call to runn the script. The script can be run properly as %run E:/_Projects/DataFit/Sources/DataFitTutorial.ipynb\", '\\n')\n        raise RuntimeError(\"This is an incorrect call to runn the script. The script can be run properly as %run E:/_Projects/DataFit/Sources/DataFitTutorial.ipynb\")\n\n    print (\"Please, run the script after you imported the DataFit package.\")\n    print_message(\"DataFit package version: 1.1.0.0.\", \"title\")\n    print_message(\"DataFit package author: Pavle Bakolic (. \", \"subtitle\")\n\n    if __name__ == '__main__':\n        print (\"Please, run the script after you imported the DataFit package.\")\n        print_message(\"DataFit package version: 1.1.0.0.\", \"title\")\n        print_message(\"DataFit package author: Pavle Bakolic (. \", \"subtitle\")\n    else:\n       raise RuntimeError(\"Please, run the script after you imported the DataFit package.\")\n\n\n    data = pd.DataFrame()\n    data['Name'] = 'Peter'\n    data['Age'] =",
        "label": 0
    },
    "758": {
        "output": "## 2.2.1: Assessment of Inclusion Criteria for Clinical Trial in [INST] \n[[INST]] You are a helpful assistant for clinical trial recruitment. Your task is to assess whether the patient's inclusion criteria is met, or not. \n\nLet's think step by step. \n 1. Get input the file of `patientNote.csv` and `trialNote.csv`. \n 2. If the name of patients' gender in the `patientNote.csv` and that of the clinical trial is the same, the patient is assessed for the trial. If the two identifiers are different, the patient is not assessed. \n 3. Get the age of the patients from the patient note. \n 4. If the trial's inclusion criteria for age is same, then it is assessed. \n 5. If the trial's inclusion criteria for cholesterol level is same, then it is assessed. \n 6. If the trial's exclusion criteria for cholesterol level is not met, then stop assessment process. \n 7. If the trial's inclusion criteria for the history of angina is same, then it is assessed. \n 8. If the trial's exclusion criteria for the history of angina is not met, then stop assessment process. \n 9. If the trial's inclusion criteria for gender is the same and the trial's exclusion criteria for gender is not met, then it is assessed. \n 10. If the trial's inclusion criteria for medication use is the same and the trial's exclusion criteria for medication use is not met, then the assessment is continued. \n 11. If the trial's inclusion criteria for systolic murmurs is the same and that of the trial's exclusion criteria is not met, then it is assessed. \n 12. If the trial's inclusion criteria for triglycerides is the same and the trial's exclusion criteria for triglycerides is not met, then it is assessed. \n 13. If the trial's inclusion criteria for carotid artery stenosis is the same and that of the trial's exclusion criteria is not met,",
        "label": 0
    },
    "759": {
        "output": "I think it is best to repeat triallevel eligibility as the last line in the assessment. Otherwise, there is a risk that it gets overlooked.\n<EOD> GIRLS & INTERRUPTION.\nBased in the UK, with international experience, Mia has worked with girls in the South Sudan, Egypt, India, Nigeria and Lebanon in response to gender based and other forms of discrimination. This has included facilitating trainings on gender, human rights and conflict resolution with over 100 organisations, training of trainers and community based participatory research on girls\u2019 education. Mia is a PhD candidate, investigating girls\u2019 participation in the education & work spaces, and has worked with children in conflict zones in Africa, Asia, South America and the Middle East.\nShe has led research and advocacy work on girls\u2019 participation in the education field for more than 17 years with UNICEF. She was recently the Regional Team Lead for Child Protection and Participation in Syria and Lebanon. Here, she also worked on issues of child marriage, as the lead of work in the East Mediterranean region on ending child marriage and the lead expert on children detained in North Africa.\nPreviously, Mia was UNICEF\u2019s Chief Gender Specialist in the UK and Regional Representative in Cairo. Additionally, she was the Education Specialist in the South Sudan, Lebanon and Nigeria, as well as the Humanitarian Chief of Programme in the Ukraine.\nMia was the Lead Programmer and Producer of the award-winning documentary \u2018Plain Jane\u2019. She is now a Film Producer working on projects in Lebanon, Egypt, Brazil and India.<EOD> Erectile dysfunction treated with sildenafil (Viagra)\nSildenafil (Viagra) is currently used by an estimated 150,000-250,000 men, with an estimated total consumption nearing 800 million tablets annually. Despite recent marketing of generic drugs containing sildenafil, the pill continues to be marketed under the Viagra trademark by Pfizer. This article will focus on the pharmacokinetic, pharmacodynamic and adverse effects of sildenafil, the incidence",
        "label": 1
    },
    "760": {
        "output": "## Question\n\nAssume that you are a healthcare professional and your patient is a pregnant woman. You've met a 3-months-old pregnant woman in her first visit to the clinic. Your task is to assess her hemodynamic status. In cases where pregnant women are examined, physiological changes occur in their hemodynamic status. Your assessments should be made on the basis of these pregnancy-induced physiological changes. \n\nTo make an accurate hemodynamic assessment on the basis of these physiological changes, you will use a cardiovascular risk calculator based on the data presented in the patient record and your observations. It takes you approximately 10 minutes to enter all of the information into the model. \n\nHere is the patient information:\nHer name is Mary and she is a 3-months-old pregnant woman who is taking no medications except prenatal vitamins. Her blood pressure is 120/85 mm Hg and her heart rate is 85 beats per minute. She does not have any previous diagnoses concerning the heart or the vascular system.\n\nHere is the cardiovascular risk calculator: \n\n\nHemodynamic assessment: \nRisk level:\nRisk level:\n\nWhat should you write in Hemodynamic assessment by using the cardiovascular risk calculator (i.e., `risk level) in the output? [INDICATOR]\n\nAssume that you are a healthcare professional and want to check your patient's hemodynamic status on the basis of prenatal physiological changes. You've met a 3-months-old pregnant woman in her first visit to the clinic. Your task is to assess her hemodynamic status.\n\n\nTo make an accurate hemodynamic assessment on the basis of these physiological changes, you will use a cardiovascular risk calculator based on the data presented in the patient record and your observations. It takes you approximately 10 minutes to enter all of the information into the model. \n\nHere is the patient information:\nHer name is Mary and she is a 3-months-old pregnant woman who is taking no medications except pren",
        "label": 0
    },
    "761": {
        "output": "Good Luck!<EOD> Long-Term Effects of Childhood Sexual Abuse Exposure on Intimate Partner Aggression and Parenting\nChildhood sexual abuse (CSA) has been associated not only with adult revictimization, but also with an increased risk of adult intimate partner aggression. Few studies have examined the long-term effects of CSA exposure, particularly on the parenting context, which may serve as a mediator for these effects. Data from a large study of U.S. adults (N = 2255) documented that childhood sexual victimization (CSV) exposure was associated with adult intimate partner aggression (IPA) perpetration, and this effect remained significant after controlling for sociodemographic characteristics, substance use, and adult victimization. CSV exposure was additionally associated with psychological aggression perpetration, yet not physical aggression perpetration. Further, CSA-exposed adults were more likely to report that they perpetrated both types of aggression against their own children. There were effects of parental IPA perpetration on young children's externalizing problems, even after controlling for child temperament. Overall, the current findings document that effects of CSA exposure on IPA are long lasting and extend to the next generation.<EOD> Changes in the serum levels of 17 beta-hydroxy-20 alpha-dihydro-4-pregnen-3-one in the prepuberal estradiol-treated puberal baboon.\nTwo prepuberal baboons exposed to estradiol were sacrificed sequentially at approximately 3-week intervals. At each sacrifice, the serum concentration of 17 beta-hydroxy-20 alpha-dihydro-4-pregnen-3-one (estrogen-metabolite; EM), 17 beta-estradiol (E2) and 17-hydroxyprogesterone (17-OH-P) were measured by competitive protein binding assays. Serum EM increases were found in association with an increase in E2. It is suggested that EM levels may reflect 17-ketosteroid side-chain cleavage enzyme activity.<EOD> Prostate carcinoma: imaging evaluation.",
        "label": 1
    },
    "762": {
        "output": "In the following, we describe the evaluation of each term in detail.\n\n## Age\nThe patient's age is 46. To determine a certain age range, refer to the [https://en.wikipedia.org/wiki/Old_Age Wikipedia] article. The age range is often from 60 years old to 70 years old. Therefore, it is 60 years old to 70 years old.\n\n## Gender\nThe patient's gender is male (male).\n\n## Current and previous treatments\nNo use of lipid-lowering medications is used in the patient history, so patient history is used in the condition.\n\n## Laboratory tests and examination\nThere is no need to check whether there are abnormal values in the patient's blood lipid levels since it is known in the inclusion criteria that the patient's LDL-C and HDL-C levels are 545 and 53, respectively. For the patient's neck auscultation, systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA), and moderate stenosis in the right internal carotid artery (RICA) with estimated severity of 42%, 40%, and 70% in the LICA, the right internal carotid artery (RICA), and the left internal carotid artery (LICA), respectively.\n\n## Diagnosis\nWhat is the patient's diagnose? The patient's diagnose is prostatic adenocarcinoma.\n\n## Condition\nIt is unknown whether there is a cardiovascular risk factor such as smoking of the patient. Therefore, the patient's smoking condition is used. And as a result, it is no.\n\n## History of illness\nWhether the patient ever had cardiovascular diseases is not known, so history of illness is used. As a result, the patient did not ever have cardiovascular diseases.\n\n## Family history of disease\nWhether the patient has a family history of cardiovascular diseases is unknown. Since family history of disease is unknown",
        "label": 0
    },
    "763": {
        "output": "<EOD> .\nIn the treatment of cancer, surgical reconstructive procedures which involve removal of bone and/or soft tissue must be associated with procedures which allow bone and/or soft tissue to be grafted in the same operation. On the basis of the experience of last years, the authors report on 10 cases of patients treated in the orthopaedic surgical unit of I.N.O for reconstruction after different surgical procedures. From this experience, the authors conclude that the best type of graft in a single operation is autogenous bone. They have never used autogenous soft tissue. They have found the use of artificial bone to be less advantageous; for example, in the form of a hydroxyapatite compound, the use of which is still experimentally based.<EOD> Anatomy as",
        "label": 1
    },
    "764": {
        "output": "## C1: Exclusion criteria\n\nExclusion criteria can have a positive form: one or more inclusion criteria are missing (for example, age <6\u2009years is missing). If any inclusion criterion is missing, it is better to report the reason with `Exclusion criteria: 0) Not a CANadian resident.` as exclusion criteria. [/C1] Exclusion criteria are in a positive form.\n\n## C2: Exclusion criteria\n\nExclusion criteria can have a negative form: a patient is excluded for some reason. For example, the CPR number provided is invalid so a patient is excluded. If a patient is excluded for some reasons, report the reason in `Trial-level eligibility: 0) Excluded.` [/C2] Exclusion criteria are in a negative form.\n\n## C3: Exclusion criteria\n\nExclusion criteria can also be due to drug contraindication or inaccessibility, but in our dataset, there are no exclusion or inclusion criteria for drug contraindica-tion or inaccessibility. [/C3] Exclusion criteria are not drug contraindication or inaccessibility.\n\n## F: [/F] Patient note 4\nA 69-year-old woman with a history of CAD, hypertension, and diabetes comes in for an annual checkup. She has a family history of heart disease in her mother and brother. She has been on atorvastatin, an antihypertensive and an antidiabetic medication, which she stopped a few years ago.\nHer blood pressure is 149/97\u2009mmHg and her other vital signs within normal limits. Her physical exam is unremarkable, and laboratory testing shows her LDL-C level is 41\u2009mg/dL.\nShe is not taking any lipid-lowering medications. She does not use tobacco, alcohol or illicit drugs, and her blood glucose and triglyceride levels are with normal limits.\n\nHere is the patient note:\nPhysical exam (blood pressure is 110/80\u2009mmHg and otherwise normal vital signs are observed): Normal exam with blood pressure of 116/86\u2009mmHg and heart rate of 80 beats",
        "label": 0
    },
    "765": {
        "output": "], (2018-08-06).\nPlease refer to the following section for a reference list of resources used. The information provided for you may not be sufficient to pass certain test cases. You must use additional resources to pass these test cases.\n\nResources\nPlease find below the list of resources\n\nNote\nPlease find below a note on resources\nThe resources and their links may change in any one of three different ways\n- Changes in their content\n- The URL gets changed in some cases\n- They may not work anymore in the updated GauGan\n- You are referred to another resource\n\n\n[https://gaugan.readthedocs.io/en/_build/html/help_resources.html (in the main page, click on 'Resources')](https://gaugan.readthedocs.io/en/_build/html/help_resources.html \"Help Resources of GauGan\")\n\n\n\n\n[https://gaugan.readthedocs.io/en/latest/faq.html (Click on 'Other FAQ')]  [https://gaugan.readthedocs.io/en/latest/faq.html (Click on 'Other FAQ')](https://gaugan.readthedocs.io/en/latest/faq.html \"Other FAQ of GauGan\")\n\n\n\n\n# Acknowledgements\n\nThanks to the following people, in alphabetical order:\n<NAME> (<EMAIL>)\n<NAME> (<EMAIL>)\n<NAME> (<EMAIL>)\n<NAME> (<EMAIL>)\n</A>\n<NAME> (<EMAIL>)\n<NAME> (<EMAIL>)\n[https://gaugan.readthedocs.io/en/latest/contributors.html (Click on 'Contributors')]  [https://gaugan.readthedocs.io/en/latest/contributors.html (Click on 'Contributors')](https://gaugan.readthedocs.io/en/latest/contributors.html \"Contributors of GauGan\")\n\n\n<EOD> Pretransplant DNase and rt-PA Treatment of Endothelial Thrombi In Vitro.",
        "label": 0
    },
    "766": {
        "output": "![INST](https://www.jianguoyi.com/article/45330.html)\n\n### Output example \n<script type=\"text/javascript\">\n\tvar\n\t\tdata_url = \"https://www2.cnki.net/kns52/default.aspx\", //\u6570\u636e\u4e3b\u7f51\n\t\tdata_url2 = \"https://www.jianguoyi.com/article/22020.html\", //\u6570\u636e\u4e8c\u7f51\n\t\tarticle_data = {code:'data', url:'https://www.jianguoyi.com/article/22020.html'}, //\u53c2\u6570\u6570\u636e\u7ed1\u5b9a\n        input_data = $('#article_data'), //\u6570\u636e\u7f16\u8f91\u533a\n\t\tinput_code = $('#article_code'), //\u7f16\u7801\u8f93\u5165\u533a\n\t\tcontent_url = '', //\u5f39\u51fa\u5c42url\n\t\tpage = 1, //\u6570\u636e\u9875\u7801\n\t\tisLoading = false, //\u662f\u5426\u52a0\u8f7d\u4e2d\u7684\u5e03\u95e8\u6570\n\t\tarticle_index = null, //articleIndex\u662f\u6807\u9898\u662f\u987a\u5e8f\u7684\u7f16\u53f7\u4f9b\u7528\n\t\t$data = $.data, //\u6570\u636e\u96c6\u5408\n\t\t$html = $.html, //\u5b57\u7b26\u4e32\u8fd4\u56de\u6570\u636e\u7684\u83b7\u53d6\u65b9\u6cd5\n\t\t$dataType = $.dataType, //\u6570\u636e\u7c7b\u578b\u8fd4\u56de\u6570\u636e\u7684\u83b7\u53d6\u65b9\u6cd5\n\t\tarticle_data = $.param, //\u6570\u636e\u5b57\u7b26\u4e32\u7f16\u7801\u8fd4\u56de\u6570\u636e\u7684\u83b7\u53d6\u65b9\u6cd5\n\t\t$index = $('#article_index'), //\u663e\u793a\u6570\u636e\u6570\u91cf\n\t\t$articleCount = $('#article_count'), //\u663e\u793a\u8fd4\u56de\u4e2a\u6570\n\t\t$isLoadingEfficiency = $('#isLoadingEfficiency'), //\u52a0\u8f7d\u7387\n\t\t$output_style = $('#output_style').find('li'), //\u8fd4\u56de\u6570\u636e\u683c\u5f0f\u7c7b\u578b\n\t\t$output = $('#output'), //\u8fd4\u56de\u6570\u636e\u5206\u88c5\n\t\t$outputWrap = $('#outputWrap'), //\u6570\u636e\u5206\u88c5\u5c01\u5305\n\t\tinput_url = $('#input_url'), //\u7f16\u8f91\u6570\u636eurl\n        input_url2 = $('#input_url2",
        "label": 0
    },
    "767": {
        "output": "# Examples:\n##### `Clinical trial`\n`c12` 1 2 4 # A trial-level eligibility of 12 for all 3 criteria\n  `n01` 2 2\n##### `Clinical trial` `c4` 1 1 1 # A trial-level eligibility of 4 for the 1 criterium.\n  `n01` 1 1\n##### `Clinical trial` `c8` 4 2 2 # A trial-level eligibility of 8 for all 3 criteria.\n  `n01` 4 2\n\n<EOD> Fertility Preservation Programs in Switzerland\n\nThere is a lack of data on treatment outcomes and costs of fertility preservation programs (FPPs), particularly in countries with multiple FPPs. We analyzed the Swiss Society for Gynaecology and Obstetrics' register (2011)(2012)(2013)(2014)(2015)(2016)(2017)(2018)(2019)) on the numbers and type of FPPs, as well as treatment outcomes and costs. Data for FPPs in 2018 were obtained from their respective websites. A total of 54 FPPs were reported in 2018: 22 were operated by an obstetrician-gynecologist (OB/GYN), 26 by a gynaecologist (GYN), two by both an OB/GYN and a GYN, and four did not report the background of the responsible physician. A comparison of FPPs' websites showed variation in quality of information, number of cycles, number of cryoconserved oocytes, use of ovarian stimulation, and type of insemination. There were 836 ovarian stimulation cycles with the use of either gonadotropins (-77%), clomiphene (-6%), or HMG (n = 12) including two cycles with the use of estrogens. A total of 448 oocytes were cryoconserved and five ova were freeze preserved. The total number of",
        "label": 1
    },
    "768": {
        "output": "<EOD> Diffuse intestinal amyloidosis (AA-amyloidosis) in a patient with rheumatoid arthritis and systemic lupus erythematosus\n\nA 73-year-old woman with a 4-year history of rheumatoid arthritis presented to the outpatient clinic with complaints of loose stools for the past 6 months that failed to resolve with medical therapy or dietary measures. Computed tomography enterography showed diffuse small intestinal dilation and an extensive small-bowel submucosal mass. The patient underwent an exploratory laparotomy and ileocecectomy. Macroscopic examination of the resected ileum displayed diffuse thickening of the intestinal wall. Microscopic examination revealed amyloid deposition in the intestinal mucosa, submucosa, and muscularis propria of the resected terminal ileum. Further immunohistochemical evaluation revealed amyloid A that was positive for serum amyloid A and lambda light chains, as assessed with antibodies against AA and IgG kappa chain. We then diagnosed the patient with amyloidosis of the intestine.\n\n# Background\nAlthough amyloidosis in the gastrointestinal tract mainly manifests as a local infiltration or submucosal mass formation, amyloidosis of the intestine is usually a diagnostic challenge, especially in patients with multiple comorbidities. We present a patient with multiple comorbidities, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), who presented with malnutrition and smallintestinal dilation. The patient was eventually diagnosed with amyloidosis of the intestine based on immunohistochemical staining.\n\n## Case presentation\nA 73-year-old woman presented with a 4-year history of RA with a high erythrocyte sedimentation rate, C-reactive protein, and serum amyloid A levels and 8 years of unexplained lownutrition status despite a daily diet rich",
        "label": 0
    },
    "769": {
        "output": "Let's do it! \n\n```code\n#! /usr/bin/python3\n\nimport string\nimport re\nimport sys\nfrom copy import deepcopy\n\nfrom typing import List\n\nfrom .. import models\nfrom ..app.parsers import ParserBase\n\n\nclass TrialPartitionParser(ParserBase):\n    \"\"\"\n    https://docs.google.com/document/d/1D6571_749xPV5_BNn1Zi6vD64G2RWxUxK6U281ZR1w/edit##pane:id=gqHxXFvvXKk8qD479\n    \"\"\"\n    @property\n    def _parser_tag(self):\n        return \"TrialPartition\"\n\n    @property\n    def _parser_names(self):\n        return \"recruit_eligibility\", \"trial_level_eligibility\"\n\n    @property\n    def _parser_type_names(self):  # types, not tags\n        return \"Boolean\", \"String\"\n\n    def __init__(self, element: models.ModelDict):\n        super(TrialPartitionParser, self).__init__(element, None)\n        if \"participant_eligibility\" in element and \"trial_level_eligibility\" in element:\n            # The eligibility of a person can be considered as 0 if it is excluded or 1 if it is included,\n            # so treat it as a list.\n            self._eligibility = element[\"participant_eligibility\"].as_json_nested_list(models.TrialLevelEligibility)\n\n    def _parse_inputs(self, parser_name: str, values: List[models.TrialLevelEligibility], max_result_list_size: int) -> models.TrialLevelEligibility:\n        # Here we assume 'max_result_list_size: Int' is the default for this class.\n        if len(values):\n            max_result_size = max(value.item().eligibility.keys(), key=value.item().eligibility.keys()).items()\n\n        # Get the",
        "label": 2
    },
    "770": {
        "output": "##### Implementation\n\nLet's start with the implementation of the code. You should save the code in a variable in the notebook by adding code within the curly brackets, e.g.,\n\n%NOTEBOOK%   \n\n\n```python\ntrialDict = {'1' : ['Age>=60, Gender=M, LDL>=160', 'Age>=60, Gender=M, LDL>=190'],\n               '2' : ['Age>=65.5, Gender=F, LDL>=160', 'Age>=65.5, Gender=F, LDL>=190'],\n               '2_1': ['Age>=65.5, Gender=F, LDL>=160', 'Age>=65.5, Gender=F, LDL>=190'],\n               ' 3 : ['Age>=65, Gender=F, LDL>=160', 'Age>=65, Gender=F, LDL>=190'],\n               ' 4 : ['Age>=65.5, Gender=M, LDL>=160', 'Age>=65.5, Gender=M, LDL>=190'],\n               ' 5 : ['Age>=60, Gender=M, LDL>=160', 'Age>=60, Gender=M, LDL>=190'],\n               ' 6 : ['Age>=65.5, Gender=M, LDL>=160', 'Age>=65.5, Gender=M, LDL>=190'],\n               ' 7 : ['Age>=65, Gender=M, LDL>=160', 'Age>=65, Gender=M, LDL>=190'],\n               ' 8 : ['Age>=60, Gender=M, LDL>=160', 'Age>=60, Gender=M, LDL>=190'],\n               ' 9 : ['Age>=65.5, Gender=F, LDL>=160', nil],\n               ' 10 : ['Age>=65.5, Gender=M, LDL>=160",
        "label": 0
    },
    "771": {
        "output": "##[SIDES_INST_01_C]\nClinicalTrials has two options for the calculation of the probability value by Bayesian algorithm of two-sided t-test: The \"A1\" option is for \"symptomatic patients.\" The \"A2\" option is for all cases.\nThis example shows the \"A2\" option for \"symptomatic patients\":\n(A1) Eligibility: The patient is symptomatic according to your research.\nEligible: The patient meets inclusion criteria and exclusion criteria do not apply.\nExcluded: The patient meets inclusion criteria, but is excluded on the grounds of the trial's's exclusion criteria.\nNot Relevant: The patient does not have sufficient information to qualify for the trial.\n\n# METHODS\n\n## The SIDES method\nThe SIDES method is the process that can be implemented to support the assessment of eligibility of a patient in a trial. As the clinical trial recruiters are using the electronic information system for decision making, the steps of the SIDES method can be automated.\nStep 1. The SIDES method begins by gathering patient data and transferring information to the assessment system. For transfer, the data can be automatically extracted through scanning of a patient's chart.\nStep 2. All pertinent data items should be transferred to the assessment system.\nStep 3. In this step, the assessors use the data to determine trial eligibility. In their case the assessors may be the clinicians and research nurses.\nStep 4. All relevant criteria, criteria definitions, and patient data items, are logged at this stage to maintain the assessment process's clarity and traceability.\nStep 5. The assessor makes his/her assessment based on the patient data and criteria definitions.\nStep 6. At the final step, the assessors compare the patient data with the trial's inclusion and exclusion criteria. If the required criteria's thresholds are not met, the patient is excluded or not eligible for the trial. If the patient meets the specified criteria, he/she is eligible for a trial.\nThe use and implementation of the SIDES is shown in [fig_ref]  Figure 1: The flowchart of the SIDES",
        "label": 1
    },
    "772": {
        "output": "## Requirements 1.\nRisk Assessment (RA) must be passed before working on a trial.\n1 You can go to the following link: \n[A] Click on a trial, and you will see a window showing the trial information (the one here is the same as the last example in List).\n[B] Click on Help & Documents and then click on Risk Assessment (RA) at the top of the page.\n[C] The window will appear automatically as a new window, and you will see the RA questionnaire and the answer of the trial. The answer will be filled in the box \"Select Risk Assessment Answer\".\n\n## Requirements 2.\nBefore you start working on trials, you must pass the Assessment module. You can take the following link and choose Assessment from the dropdown menu in the upper right corner.\n\n## Test Cases 1.\nThese are example patient notes for which you must determine and record the scale of the assessment (0, 1, 2) according to the clinical trial listed above. First, find the trial ID (455) by opening a trial, clicking on it by typing 455, and then, choosing the \"View Trial\" option in the top bar. Then, take a look at the Assessment table.\n\n## Requirements 3.\nThis is a quiz in the form of an email for which you will be given one patient (the first one in List) (note that the email ID is also the patient ID 00101 in List). You will find the list of emails in the following link: \nChoose Emails from the dropdown menu in the upper right corner, then choose Messages by Patients. Next, click on the Patient tab, and finally, choose patient 00101 in list. The message will be sent in the following window.\nNote that in emails, you should not only read the text, but also find the eligibility scale of the patient for the clinical trial.\n\n## Requirements 4.\nFirst, take a look at a trial (note that the trial ID is 455). Then, click on Assessments table. Now, choose a patient from the list and click the Check Assessmentbutton. This patient will have C",
        "label": 2
    },
    "773": {
        "output": "A: Let's split this question into more specific questions.\nLet's start with the formatting of the input. You can use the input() function, e.g.: input(\"In what format should the clinical note appear?\", \"Note in which format to appear: [TEXT]\")[s] in the beginning to receive a response with the choice of format: {(text) 'TEXT'.\nThe choice would be validated as {(text) }, which would be converted to text, to then obtain the response as {(text) text}.\nThe variable text must be used in the form text, i.e.: text = {text} to access the variable text.\nIn the next step, let's generate a random letter as a token to access the data. Here it is possible to use the choice() function, e.g.:\nchoice(\"What random letter do you choose as an example of validation for this test?\", \"Select a random letter to use in the beginning to access the data: [A]\").[s]\nYou can use the choice() function, in the same way. It is an alternative for the response variable, if it has only one element, otherwise if it has more than one element, you must select one of the input data with the use of the choice() function.\nIf input of choice() is {a}, then it means to access element \"a\", and if you already have element A, it will fail to access the data.\nIn this case, the letter to be used and the format of the input note is the choice() output. Both should be used later by the command input.\nThe input() commands and function are very similar. In the following command, you can observe the same as the input() command. In this case it is used with all the data and will have an error, until you apply the validation.\nNow let's define the data for the data validation.\nThere is no need to define the random letter, as if it is not the letter chosen in choice(), the function will generate one from scratch.\nIn the following line we will define the data for the input data.\ninput('In what format should the clinical note appear?', \"Note in which format to appear: [TEXT]\")[s]\n\nA: It is recommended to not mix python and bash in bash script. The following is a python code that performs as expected in",
        "label": 0
    },
    "774": {
        "output": "[END]\\n\\n\n  ## Assessment of exclusion criteria \nHere you should enter exclusion criteria for your trial and your clinical trial to obtain trial-level exclusion criteria. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. \nIf the output is empty:\n```\nTriplet [184] exclusion_Criteria:\n```\nIf the output isn't empty:\n```\nTriplet [184] exclusion_Criteria\n\n                        A, age \n                        G, gender \n                        B, Blood pressure \n                        C, BMI (kg/m2)\n                        D, smoking history (pack years)\n                        E, Previous treatment history (days)\n                        F, Medical history\n                        H, comorbidity and compliance\n```\n\n# Author statement \nNohad Ghamari: Conceptualization, Writing -original draft, Writing -review & editing, Methodology, Software; \n<EOD> Evaluation of the effects of different adsorption treatments on the surface texture of dentin.\nBACKGROUND\nThe aim of the present study was to evaluate the effect of different etching protocols on the surface texture of dentin when using an adenosine triphosphate (ATP) scavenger.\n\n\nMATERIAL AND METHODS\nThree kinds of treatments were performed on the dentin surface: (1) 5000 ppm phosphoric etch for 30 s, (2) application of adenosine triphosphate (ATP) for 15 s, and (3) a combination of A and B procedures (15 s ATP and then 30 s of etch with phosphoric acid). The measurements of roughness were recorded before and after three types of treatments and then processed using one-way ANOVA and Tukey's HSD test at a significant level of 0.05. A scanning electric microscopy (SEM) analysis was also performed.\n\n\nRESULTS\nThe etching protocol significantly increased the",
        "label": 0
    },
    "775": {
        "output": "<EOD> Effect of LPS on human neutrophils primed with an N-formyl peptide.\nThe simultaneous effect of phorbol myristate acetate (PMA) and lipopolysaccharide (LPS) on the respiratory burst in human neutrophils primed with f-Met-Leu-Phe was investigated to determine whether the oxidative enzyme system of these cells was activated by LPS alone or in combination with PMA. PMA plus LPS was more effective in enhancing the chemiluminescence response of f-Met-Leu-Phe-primed neutrophils than either of the agents used separately. LPS alone only showed a weak enhancing effect, which was not significantly higher than that seen in the presence of the f-Met-Leu-Phe-primed neutrophil control group. These data indicate that N-formyl peptide-primed neutrophils are capable of reacting with LPS alone. The activation of neutrophils was accompanied by release of a plasma serine esterase, and a platelet-activating factor (PAF)-dependent component was found to be responsible for the LPS/PMA interaction. The release of the serine esterase was suppressed by WEB 2086, a PAF receptor antagonist. The effect of PMA on the PAF receptor was also studied. In contrast to neutrophils, PMA pre-incubation significantly enhanced the chemiluminescence response mediated by PAF itself but not through serine esterase. These findings demonstrate that LPS activates neutrophils when N-formyl peptide primed, through a serine esterase, the activation by PMA alone being sufficient for the oxidative burst.<EOD> A Study of Serum Ferritin Levels in Patient with Chronic Hepatitis C\n\nObjective: The ferritin level is associated with the HCV infection, disease activity, and outcomes of HCV infection. The aim of this study was to investigate an association between the ferritin level and response to therapy or disease progression in patient with chronic hepatitis C.Materials and Methods:One hundred and thirteen patient with chronic HCV were included, and were divided into",
        "label": 0
    },
    "776": {
        "output": "Your output should be in the standardized format of the JSON data file which is shown below.\n{\"trial_id\":\"9000,\"trial_type\":\"clinical\",\n\"protocol\": {\"study_id\":\"Alirocumab\",\n\"title\": \"Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)\",\n\"study_objectives\":[\"Primary: to provide participants with severe hypercholesterolemia at risk for subsequent CV events and not adequately controlled with currently available LMT access to alirocumab ahead of commercial availability and to document the overall safety and tolerability of alirocumab in this participant population.\nSecondary: to document the effect of alirocumab on LDL-C levels as well as non-HDL-C, total-C, HDL-C, and TG levels after 12 weeks of treatment.\",\n\"inclusion_criteria\":\n[{\n\"field_name\":\"Alirocumab APPRISE -Patient Flow Chart (Alirocumab 9000), 5.2. Patient Inclusion Criteria\",\n\"value\":\n\"[inst] Patients were either eligible [elig] ( 0.5) or ineligible [inelig] ( 1.0) for each item.\"\n}],\n\"trial_type\": \"clinical\",\n\"phase\": \"Phase I (safety)\"}],\n\"visit\": [{\"date\": \"2015-01-19T00:00:00.000\",\n\"name\": \"Screening (Patients)\",\n\"baseline\": \"NA\",\n\"end\": \"NA\",\n\"interim\": \"NA\",\n\"observation_type\": \"PtB\",\n\"study_type\": \"Single\",\n\"assessment\":\n[{\"assessment_type\": \"Patient\",\n\"assessment_criteria\":\n[{\n\"assessment_criterion\": \"",
        "label": 2
    },
    "777": {
        "output": "## Assignment instructions\n\n# Assignment requirements\n- Your solution should first test the function of the clinical trial pipeline with example inputs.\n- Your solution should then implement the case study of the patient's clinical trial eligibility assessment.\n- After implementing the case study, your program should include a function to output a score between 0, Excluded, and 2, Eligible, for the patient's clinical trial eligibility as well as for individual input data elements (i.e., LDL-C) using the input shown in the example input [1].\n- Next, your program should output the clinical trial eligibility assessment for all patient note inputs.\n- Submit your solution via Canvas, by uploading it as a zip archive.\n- Name your zip archive with the title of the problem, followed by a unique identifier.\nA description of the solution can follow but is not required as long as the zipped file complies with the above.",
        "label": 1
    },
    "778": {
        "output": "<EOD> Rare cases of neurotoxicity induced by hydroxychloroquine and chloroquine: focus on management\n\nRare cases of neurotoxicity induced by hydroxychloroquine and chloroquine: focus on Management \u0b1dCorresponDence: dr.pavithra.kumari21@gmail.com Braz J Otorhinolaryngol. 2021;87:544-546 Dear Editor,Chloroquine (CQ) and hydroxychloroquine (HCQ) have been identified as potential therapeutic agents against coronavirus disease 2019 (COVID-19) because of their immunosuppressive and anti-inflammatory characteristics 1 . These agents are well tolerated drugs with few toxic side effects. However, the use of these medications is associated with several ocular and neurological side effects. Neurological symptoms commonly appear in patients who have been treated with hydroxychloroquine for less than five years, and the neurotoxic effects of hydroxychloroquine are more common in patients receiving higher daily doses of chloroquine 2 .\nThe patient described herein who recently recovered from COVID-19 on a CQ/HCQ combination protocol presented with a mild, non-specific neurotoxicity during the course of his treatment with this therapeutic regimen.\nA male aged 56 years came to our clinic reporting a loss of vision in the right eye (RE) for the past three days. He had no significant past medical history except diabetes. According to his history, he was treated for COVID-19 by oral CQ, HCQ, azithromycin, naproxen, vitamin C, hydroxychloroquine sulfate, and multivitamins for 14 days one week prior to this visit. He had been symptomatic for one week with the typical respiratory manifestations of COVID-19 (fever, dry cough, and loss of smell) but had recovered without medication. He was treated with the combination protocol of CQ/HCQ as the patients with COVID-19 were not",
        "label": 2
    },
    "779": {
        "output": "**Task 3:** Using your knowledge of the inclusion and exclusion criteria of a clinical trial, decide if the patient met the inclusion criteria given in the original patient note.\n\n<EOD> Assessment of clinical competency in paediatric oncology rotation in residency with 12 months of experience\n\nBackground: A 1-year dedicated paediatric oncology rotation was developed to enhance paediatric postgraduate year 2 (PGY2) resident experiences and evaluate the role of a dedicated rotation in medical competency. The purpose of this study is to assess the perceptions of paediatric resident competency and provide qualitative feedback related to the rotation. Methods: This was a prospective observational study that collected information at the start and end of the paediatric oncology rotation with the PGY2 paediatric resident. The assessments were focused on the residents' perceptions of their knowledge base and clinical competency to manage both solid and hematologic tumors.Results: Twelve residents entered this study, including 11 PGY2 and 1 PGY3. There were 128 assessments at the beginning and end of the rotation. Twenty were solid tumors, and 108 were hematologic tumors. There was a slight improvement in the mean score percentage for most of the hematologic disorders. An improvement was noted with the evaluation of diagnostic cytogenetic/molecular tests (p = 0.0069) and response to therapy (p < 0.0001). However, no improvement in scores was noted for the solid tumors and no difference was found between the clinical competency and knowledge base of residents during the oncology rotation. Conclusions: The PGY2 residents felt prepared to take care of hematologic oncology patients following their time in the rotation. Further studies are needed to ascertain best practices for evaluating residents' competency and to help residents identify areas for improvement.\n\n# Background\nThe residency curriculum was redesigned and a paediatric oncology rotation was added to the general paediatrics rotation for postgraduate year (PGY) 2 residents in October 2008, following the creation of the paediat",
        "label": 1
    },
    "780": {
        "output": "### Examples\n\nThis is clinical trial:\n*Title: A Multi-Center Study to Evaluate Acute Safety and Clinical Performance of Paladin\u00ae Carotid Post-Dilation Balloon System With Integrated Embolic Protection *Summary: The purpose of this study is to assess the safety and clinical performance of Paladin System in patients with carotid artery stenosis.\n\nThis is an example of a patient's patient:\nA. 46-year-old man presents with dizziness and frequent headaches. B. Patient has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus C. He is physically active. D. His LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose level (85 mg/dL) was within normal limits E. Patient reported no use of lipid-lowering medications.\nF. Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA), 80% stenosis in the right anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending<EOD> The effect of posttraumatic stress disorder on pregnancy outcomes and pregnancy-related anxiety in women with substance use disorders\nAbstract Background: Pregnant women have a risk of developing Posttraumatic Stress Disorder (PTSD). Substance use disorders (SUDS) further aggravate the risk of PTSD. Objective: To investigate the effect of PTSD diagnosis in pregnant women with SUDS on pregnancy outcomes and pregnancy-related anxiety and to compare the pregnancy characteristics between pregnant women with SUDS and PTSD and those with SUDS. Method: A cross-sectional study was conducted among 221 pregnant women with SUDS. Socio-demographic",
        "label": 0
    },
    "781": {
        "output": "<EOD> Oligomerization Is Necessary for Protein Trafficking But Dispensable for Transcriptional Activation in Arabidopsis LATERAL ORGAN BOUNDARIES PROTEIN 11\n\nThe latERAL orgANs BOUNDARies proTEin (LATERAL ORGANBOUNDARIES-LIKE (LBO) family and its counterpart the LATERAL ORGAN BOUNDARIES (LOB) family are plant-specific transcription factors and key regulators of embryo patterning, apical-basal axis establishment, organ polarity, and floral organogenesis. LBO/LOB genes have two distinct functional domains: N-terminal domains that participate in protein-protein interactions and C-terminal domains that recognize a specific DNA motif to regulate the expression of their target genes. LBO11, an LBO/LOB family protein in Arabidopsis thaliana, is predominantly localized in the PM with a small percentage (<15%) translocating into the Golgi and predominantly accumulating in vacuoles for degradation. Two LBO11 mutants disrupted at distinct positions, K338A and \u2206C336, were employed to determine the subcellular trafficking of the LBO family. In both LBO11 mutants, the conserved C-terminal protein-protein interaction domain was removed, resulting in a significant increase in Golgi accumulation of LBO11 fusions, but the Golgi localization of LBO/LOB proteins remained normal, demonstrating that oligomerization is important for LBO/LOB trafficking. In addition to the LBO11-T1 construct lacking the C-terminal domain and the LBO11-T5 construct with N-terminal domain disrupted, the remaining three LBO11-T constructs lacking either the full or partial DNA binding region were all unable to rescue the LBO11 knockout phenotype as single transgenes, indicating that functional domains of the LBO11 protein other than the transcription domain, such as the N-or Cterminal domains, are also important for the LBO11 function in development. Moreover, these LBO11-T constructs exhibited various degrees",
        "label": 0
    },
    "782": {
        "output": "- \u2713 The patient notes should use the following format:  `Demographic features: (given name)(given name)(gender). Birth date: (date)(month)(year). Patient ID: (patient ID). Patient diagnosis: [patient diagnosis].` (See the example snippet: [snippet:patients].)\n- \u2713 Include the clinicians' comments in the `Medical notes` of the patient notes. You can use the special tag `_clin_notes:` in `Clinician notes` (in the format of `Clinician notes: [_clin_notes:].` - a snippet: [snippet:clinian_notes].)\n- \u2713 Copy and paste the data of each patient into a patient note. Make sure whether the data are pasted correctly.\n- \u2713 The input data should be processed using an XML editor. You should verify whether the input data are parsed successfully in `Test.py`.\n\n### Steps to Run\n\nThis project includes two steps: `train` and `predict`. Here, `train` means training a model based on input data, and `prediction` means predicting the eligibility using the trained model based on the given data.\n\nTo train an eligibility model:\n\n1. Clone or download the whole project into your preferred folder, e.g., `MyFolder\\clinical-recruitment`.\n2. CD into your selected folder.\n3. Create a new project: `cd ./clinical-recruitment/clinical-recruitment/main.py`\n - The project's name should be changed to the folder name.\n4. Change the script's name to `main.py` in the form of `__main__.main.py`.\n5. Change the path of `main.py` to the current project folder by making the changes of `sys.argv` . To modify the command line input, you can remove it.\n6. Change the `PATH` value to the `train` directory, including the following subfolders: `data`,`train`,`tests`, etc.\n   - Please follow the documentation [here.](https://git-scm.com/book/en/v5-Git-Basics#sec-path-variable)\n7. Open `console",
        "label": 0
    },
    "783": {
        "output": "If you answer these questions correctly, you can proceed to the next step. Good luck.\n\n# Introduction\n\nHi, Dr. Seungjun Kim. You are a professor of internal medicine at Seoul National University College of Medicine in Seoul, South Korea. This is a hypothetical email, although its contents are based on a true case that occurred at Seoul National University College of Medicine. The contents of the email are presented in a story format.\n\nYou are asked by Prof. Jae Hyeok Lee, Head of the Department of Internal Medicine at Eulji General Hospital, to develop a mobile screening system for coronary artery calcification (CAC) because of the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). You are currently working on new systems to apply in medical institutions. Recently, as a member of clinical engineering, you have been conducting research to find a new way to apply artificial intelligence (AI) to medical images and to use the findings to assist clinicians in diagnosing the disease and developing new drugs.\n\n![Coronary Artery Calcification](/figures/images/12.gif)\n\n<p>\nCAC is very common among older people with heart issues. It starts in the intima layer of the coronary artery, where platelets and lipids deposit, which cause inflammation as the calcium accumulates.\nThere are several diseases that cause CAC, such as atherosclerosis, hypertension, and diabetes. The common causes of CAC are cardiovascular diseases, such as heart disease",
        "label": 1
    },
    "784": {
        "output": "[/JR]\n\n\n## [INST] Hello.\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the trial inclusion/exclusion criteria to determine the patient's eligibility. \nThe factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. \n\n\nIn this exercise, you have several trials to perform (see below). To each trial, you should create a data frame as in Example 9.3.1. Below is an example on how to filter a trial: \nFirst, you can see that data frame `df1` contains a column called `Trial-level`, which indicates the code of the trial you are currently on. Based on that column, you can apply the filters to the data set: \n```R\nFilter(get_trial_codes = c(\"CTT234\"), \n      data = df1, \n      select = , \n      x = TRUE)\n``` \n```R\nFilter(get_trial_codes = c(\"CTT234\", \"CTT638\"), \n      data = df1, \n      select = , \n      x = TRUE)\n```\n```R\nFilter(get_trial_codes = c(\"CTT234\"), \n      data = df1, \n      select = c(\"Trial-level\", \"Trial-duration\",\n                  \"Most-severe-symptom\"), \n      x = TRUE)\n``` \n```R\nFilter(get_trial_codes = c(\"CTT234\", \"CTT638\"), \n      data = df1, \n      select = c(\"Trial-level\", \"Trial-duration\",\n                  \"Most-severe-symptom\"), \n      x = TRUE, \n      target = c(\"Trial-code\", \"Trial-duration\", \n                 \"Most-severe-symptom\"))\n```\n```R\nFilter(get_trial_codes = c(\"CTT234\", \"CTT638\"),",
        "label": 0
    },
    "785": {
        "output": "[/CODE]\n\n\n\nWe'll keep going with the code and try to solve it with the following functions: \n\n\n* `trial_recruitment_patient_note()`\nTrial recruiting function for the clinical trial record, which generates a patient note template.\n\n#### Parameter Description\n| Attribute            | Data type | Default Value                                 | Description                                                  |\n| ------------------- |:---------:|:-------------:|:------------------------------------------|:--------------------------------------------------------|\n| trial             | object   | object                                           | A trial with a trial object containing clinicaltrial_id and title                        |\n| include_all_items | integer | 1                                           | Whether to include all items on each recruiting step. Default is 1                         |\n| note_type         | character | `medical_history`                        | Type of note. Default is `medical_history`. If the specified note_type does not exist, the note will be generated automatically                  |\n| patient           | object   | `NULL`                                        | Object containing information such as patient_id and enrollment_status                  |\n\n#### Sample Parameter   \n\n[sample.r](../source/main/code/trial_recruitment/nots/trial_recruitment_patient_note.r)         \n\nThere are no functions to make your code run, but our code makes sure that you get an error if some parameters are missing, so you don't need to set them up for the recoding, but you can edit trial's include_all_items (parameter) to try different items.                                         \n\n`\nThe patient meets inclusion criteria.\n`\nThere are other functions, too.\n  \n#### Other Parameters        \n- [x] `trial_recruitment_patient_id_note()`\n\n#### Sample Parameter\n[sample.r](../source/main/code/trial_recruitment/nots/trial_recruitment_patient_id_note.r)          \n\n**Output example**\n```\ntrial_recruitment_patient_note_example\n```\n    [\n      trial_recruitment_patient_note_example_output, ...",
        "label": 1
    },
    "786": {
        "output": "![[image: 9-7-2.jpg]]\n\n<EOD> The efficacy of acupuncture for nausea and vomiting in paediatric cancer patients: A narrative review\nThis review summarises the literature to evaluate the efficacy of acupuncture for nausea and vomiting in paediatric cancer patients, compared with standard treatment or no treatment. Searches in all languages identified 27 relevant reports encompassing 42 individual trials and 2 reviews, with a date of publication ranging from 1995\u20102019 and a total sample size of 1856 cancer patients and 498 controls. Acupuncture may decrease the risk of delayed, delayed\u2010cumulative and anticipatory nausea for both chemotherapy and radiotherapy regimes when comparing acupuncture with conventional antiemetics. However, the magnitude of the effect and the statistical methodologies used to evaluate the significance of the results are inconclusive, with the results being limited by small sample size, heterogeneous study designs, and lack of placebo\u2010 and sham\u2010controlled reports.<EOD> A Comparison of the Costs of an Extended Access Program and the Standard Schedule for Intrathecal Baclofen for Idiopathic Scoliosis\nThe authors compared the costs of an extended access program with the conventional schedule for administering intrathecal baclofen for the management of intractable spasticity in patients with idiopathic scoliosis. Nine patients were entered on an extended access (EA) program. The average number of intrathecal baclofen infusions per month prior to entry on the EA protocol was similar to the number of infusions per month after entering the EA protocol (1.3 + 1.0 versus 1.6 + 1.1, respectively; P = not significant ). However, the average cost of obtaining and administering an infusion before entering the EA protocol was US $804.08 compared with US $106.81 after entry (P < 0.001). The difference was due to the lower costs in the EA group of drug and catheter and the lower drug costs. Overall, the EA program was about 91% cheaper and approximately",
        "label": 1
    },
    "787": {
        "output": "---\n**1. Please check your answer and fix problems.** It must be the same as the `Output` in the `Instructions.`\n**2. If your answer is correct, you will observe that your program will display only 'Eligible' in one end-line, after this output. ** **3. If your answer is incorrect, it will display the message 'Please fix the problem and try again.'** If you can not solve this section after 2 attempts, it is better to skip this section. **4. Proceed to the next task 'Clinical Trial Assignment' by clicking the button [**Run the App**](/lab/index.html#Examine the result).\n---\n\n### Task #4\n[ **Clinical Trial Assignment** ](#clinical) \n\n\n*Task 4 - Clinical Trial Assignment*\n\n[Run the App](/lab/index.html#Examine the result).\n\n[**Instructions** ](/lab/index.html#Task-4) \n\n[Answers](/lab/answer/_exercise_2_data.html)\n---\n### **Examine your result:**\nAfter clicking the \u201cRun the App\u201d button, you will see how you perform this task.\n\n---\n[**Examine Your Result**](/lab/index.html#Examine-your-result) \n\n---\n*Task 5 - Incrementally Implementing Classes. You can do the section 5 task. \n\n[Run the App](/lab/index.html#Examine the result).\n\n--31%\n![eligible](https://github.com/xelabs/easy-python-project/blob/master/images/e2-1.png)\n![eligible](https://github.com/xelabs/easy-python-project/blob/master/images/e2-2.png)\n![eligible](https://github.com/xelabs/easy-python-project/blob/master/images/e2-3.png)\n\n---\n\n---\n### **Examine your result:**\nAfter clicking the \u201cRun the App\u201d button, you will see how you",
        "label": 1
    },
    "788": {
        "output": "You may need to modify `Tri-eligibility` value in the following lines to match the patient assessment:\nPatient-level eligibility: `Patient-level eligibility: 1) Not relevant`.\n\n### Incomplete Inclusion Criteria\nOne of the problems in clinical trials is the inclusion of ineligible participants in clinical trials. In order to minimize this, clinical studies employ rigid inclusion and exclusion criteria, which can be found in the trial's inclusion and exclusion criteria page. In the following cases, participants should be identified as ineligible and excluded:\n- Age limit, e.g., below 18 years old, - Not smoking or smoking more than a pack of cigarettes per day;\n- Using a prescription drug or drinking alcohol or cannabis;\n- The patient has had a myocardial infarction or heart attack (infarction or angina);\n- Chronically ill;\n- Taking a lot of medication, or in particular, those that affect the heart;\n- The patient has had an artificial heart valve;\n- The patient suffers from arthritis, diabetes, or depression;\n- The patient has heart valve disease;\n- The patient cannot stop smoking or drinking for 5 to 6 months;\n- The patient has a weakened immune system (e.g., caused by chemotherapy or radiation);\n- The patient has poor physical health;\n- The patient is pregnant or thinking of getting pregnant;\n- The patient cannot undergo a physical examination or have an HIV/hepatitis test;\n- HIV or hepatitis positive;\n- Patients with liver, kidney, or heart disease and not on treatment;\n- Uncontrolled diabetes and unable to control diabetes well;\n- The patient is a smoker or is taking medication to treat any disease;\n- The patient is pregnant, is of childbearing age, or is breastfeeding;\n- The patient has the right conditions to participate in the study, but is taking medications to treat their illnesses.\nSome trials also include conditions such as having sexually transmitted diseases or having high blood or high platelet levels. This",
        "label": 0
    },
    "789": {
        "output": "_Remember to write your work in Markdown language if you need to re-edit your work, as the output will be generated from Markdown language._\n# [Ask#\n\n# Tasks of a POC Assistant in Clinical Research:\n1. Recruiting participants from different specialties\n2. Assessment of eligibility of study participants\n3. Creating and updating the trial database\n4. Documenting all procedures in accordance with the procedures and processes at site\n5. Organizing and conducting visits to trial centers on a regular basis\n6. Monitoring enrolled participants - tracking enrolments and tracking exits during study and follow up visits\n7. Tri-monthly monitoring of sites, data checks and review all relevant clinical protocols and SOPs\n8. Trial follow up visits with selected sites\n9. Preparing, reviewing and approving all required regulatory documents.\n10. Collecting, collating and analyzing site visit results and reporting these results via site visit report templates\n11. Monitor and report any adverse events that occur across the trial to ensure their immediate attention in order to ensure the safety of trial participants.\n12. Provide operational and strategic support for clinical projects / studies by providing appropriate feedback and by developing trial and project improvement action plans.\n13. Investigate all adverse events.\n14. Collecting and collating routine study data to be entered into the appropriate CRF\n15. Reviewing CRFs submitted for data entry during the source data verification process to check they are complete, accurate and meet study requirements.\n16. Reviewing all CRFs and all other documents submitted for data entry and query resolution as required to ensure complete and accurate data entry\n17. Reviewing CRFs and all other documents before the site trial close-out visit to ensure complete resolution of any outstanding queries; ensuring the trial database is closed and locked correctly.\n18. Provide a point of contact for site staff for all enquiries relating to study visits and protocol.\n\n##[INTERVIEW]\nHello. You are the program manager of the company Pioneering. Pioneering is a company specialized in medical data acquisition. Its services include collecting real patient data and creating a database to sell.\n\nYour main",
        "label": 0
    },
    "790": {
        "output": "The output must be a table, like below:\nIn the figure above, the patient passed all the eligibility criteria.\nYou should calculate the overall eligibility for the patient. The overall eligibility is a Boolean value derived from the trial-level eligibility. Take the above as an example: 250/250 = TRUE (the patient is overall eligible).\n<EOD> Examining the relationships between parenting stress, social support, maternal self-esteem and child internalizing symptoms\nParenting stress and social support may be associated with psychological symptoms through shared and unique mechanisms, as well as with the child\u2019s symptoms through shared and unique pathways. However, there has been little attempt to examine these associations simultaneously, in both parents of children without disabilities and parents of children with disabilities. In the present study, 161 mothers with and without children with Autism Spectrum Disorder (ASD) and 93 fathers with children with ASD were included in two separate analyses. Structural equation modeling was used to address several gaps in the literature. First, the relative contributions of stress and social support to general psychological distress, and to child internalizing symptoms, was explored. Second, the relative contributions of parenting stress and social support to child internalizing symptoms was assessed. These analyses showed that in mothers without children with ASD, social support was directly associated with lower stress and higher self-esteem leading to lower child internalizing symptoms, in turn leading to lower psychological distress; stress was associated with increased psychological distress. In addition, in these mothers, stress, social support, self-esteem and child internalizing symptoms each exerted unique effects on psychological distress. In contrast, in mothers with children with ASD, stress, social support, self-esteem and child internalizing symptoms exerted unique effects on psychological distress. In fathers with and without children with ASD, stress, social support, and self-esteem were associated respectively with unique and shared effects on psychological distress. The results indicate that a number of factors may account for the unique associations between stress, social support, self-esteem, and child internalizing symptoms.<EOD> 29-Hydroxyproxifolin: a new compound from a marine",
        "label": 2
    },
    "791": {
        "output": "Here is the result:\n\n    [{\"trial_level_eligibility\": 2, \"patient\": \"Snacking should be avoided within one hour before going to bed, to avoid unnecessary and undesirable weight gain.\"},{\"trial_level_eligibility\": 0, \"patient\": \"Exposed to a moderately oxidizing environment for less than one hour per day, such as in an open area or inside an air-conditioned room.\"},{\"trial_level_eligibility\": 1, \"patient\": \"Fruit-flavored, carbonated beverages (fruit nectar, fruit squash, or other carbonated juice drinks)\"},{\"trial_level_eligibility\": 1, \"patient\": \"Fruit-flavored, noncarbonated beverages (eg, fruit juices, fruit squash, fruit cordials, or other juice drinks)\"},{\"trial_level_eligibility\": 2, \"patient\": \"Consumption of 35 g or more of alcohol per day (men) or 25 g or more of alcohol per day (women)\"}]\n\n##### 2.[INST] Good you did!\n\n### Good. Do you have any questions?\n\n  Q: Isn't there a short cut instead of using the if-else for multiple trial-level eligibility?\n\nA: Indeed, there is, you can use `if`, else `else`, and `endif` at once as: `if (if trial_level_eligibility == 1 ){end if; else if (if trial_level_eligibility == 2){end if; end if; else if ( if trial_level_eligibility == 0 ){end if; else printout_text.print_data; end if;}end if;}`\n\nThis code would output eligible patients first, followed by noneligible patients for each patient. [INST]\n\n### 3.[INST] Tutorial of a more complex scenario\n\nAnswers to Questions in Previous Tutorial:\n\n  Q: How? \n\nA: Apart from the main body of the case, there is an additional comment, i.e., the",
        "label": 0
    },
    "792": {
        "output": "___\n\n**Please note:** The R commands and scripts in this guide are tested and validated on the R interpreter. If you want to run the R commands in this guide in your own R session, make sure that you use the same R interpreter or version as presented below.<EOD> .\nThe purpose of the article is to summarize basic achievements in the field of psychiatry in the Ukraine since the XX century and outline the specific features of this discipline in Ukraine. The reviewed studies show the important place of the psychiatric specialty in the medical systems of the Ukraine in the XX century, the development of the theory and practice of the psychiatric care in the country.<EOD> Challenges in the design of a high-dimensional protein-protein interaction modulators discovery screen.\nProtein-protein interaction partners can act as critical nodes that control, or are crucial for, function of proteins they bind to. A number of high-throughput screening methods targeting interactions of proteinprotein domains have emerged over the past decade to identify bioactive small molecules targeting these interfaces. The design of such methods has proven especially challenging as they must accurately recapitulate the structures of protein complexes and control for factors such as avidity of binding. Here we examined proteinprotein interactions involving the N-terminal region of the tumor suppressor protein p53 and three of its direct interacting proteins, murine double minute 2 (MDM2), mouse double homeobox 4 (Mdmx), and E3 ubiquitin-protein ligase RING-box (RINGB) using fluorescence polarization-based fragment screening to determine its technical limitations and to assess the scope of high-throughput screening methods developed to date. A comparison of multiple, established methods with and without specific design elements, revealed that screening for high-affinity ligands to dissociate a complex with the protein-chemistry-based technique called Dissociation Enhanced through Ligand Hydrocarbon Stapling technology (d-DELHI), was most accurate. Furthermore, the robustness of the assay was ass",
        "label": 1
    },
    "793": {
        "output": "## 2. Use of R in Pipelined Data Preprocessing (R/PD)\n\nIn this step, you need to prepare input files for machine learning modeling in the R/PD step. \nAt this step, you are required to use the following files to make your R Pipelined data preprocessing (R/PD) step ready. \nTo build your R/PD step, you need the following inputs: \n- An Excel (.xlsx) file containing patient records in the required format; \n- An empty R file; \n- R packages for reading Excel (.xlsx) files and R pipelines, R scripts for splitting the dataset, and R scripts for feature selection.  \n\n## Feature selection\n\nFeature selection is an important step in machine learning. The goal is to choose the most relevant variables, to avoid a problem with overfitting, and to accelerate the classification. You can choose any of the available variables as the features of the patient records, so there are various combinations. Feature selection methods reduce the number of features and select optimal features. In our case, you will use the wrapper method. \n\nThis step is optional. Please read the Feature Selection section. \n<h5>Create files for the Feature Selection methods</h5>\n\n<pre><code class=\"text\">rm(list=ls()) set.seed(100)</code></pre>\n\n<pre><code class=\"text\"># for split dataset set.seed(100)\n\nfit1 <-crossValidate(\n    formData , \n    typeOfFeature=c'text','classLabel',''',\n    # typeOfFeature=c('text','value','value2','value3','value4'),\n    fitData=NULL,\n    fitData=fitData,\n    testData=fitData,\n    testData=fitData,\n    labelClass=NULL,\n    labelClass=featureVars, # labelClass=classLabel\n    typeOfFeature=c('classLabel','classLabel','classLabel','classLabel','classLabel','classLabel','featureVars','age','sex','treatment','heartDisease','bdi','bdi2','bdi3','bdi4','bmi','weight','height'),\n    cutPoint=NULL,\n    cutPoint",
        "label": 0
    },
    "794": {
        "output": "Write the output with the patient's status in your code, e.g.:\nf = pd.DataFrame(\n    {\n        'patient': patient,\n        'status': f['Trial-level eligibility']\n    }\n)\n\n\n\n##### Task 14\n\n\n\n\n\n\n\n\n\n\n<EOD> .\nObjective: By comparing the efficacy of the modified unilateral eversion technique (USET) and endoscopic endonasal transpterygoid approach (ETA) with microscopic unilateral eversion technique (UTE) for the treatment of refractory nasopharyngeal carcinoma, the optimal method of the nasopharyngeal recurrence of nasopharyngeal carcinoma was explored. Of which, the objective of this study was to analyze the efficacy of treatment of modified USET and ETA with microscopic UTE for nasopharyngeal recurrent carcinoma. Methods: The clinical data of 78 patients with nasopharyngeal recurrent carcinoma treated in the Department of Otolaryngology of Beijing Tongren Hospital from February 2016 to March 2018 whose primary treatment was radiotherapy, whose primary treatment was radiotherapy, and who were diagnosed by pathological examination, were retrospectively analysed. All patients were divided into two groups (N=39 in Group A, n=39 in Group B) according to different surgical approaches, and the efficacy was compared. In Group A, there were 23 males and 16 females, with an average age of (46.7\u00b110.1) years (range: 25 to 64 years); the tumor location was all at the ipsilateral nasopharyngeal side of middle ear; the volume of preoperative tumor was (2.60\u00b11.21) cm\u00d7(2.35\u00b11.14) cm\u00d7(2.16\u00b10.94) cm; the volume of postoperative residual tumor was (1.16\u00b10.56) cm\u00d7(1.46\u00b10.81) cm\u00d7(1.07\u00b10",
        "label": 1
    },
    "795": {
        "output": "##### Examples of the patient's output for the clinical trial {#Examples-section}\n\nExamples:\nHere are examples of patient's output after submitting the patient note and patient's information file to `patient/get.ipynb` [/RUNNING_EXAMPLE_CODE#Patient_Note_1: clinical_trial]:\n\nHere are examples of patient's output after submitting the patient note and patient's information file to `patient/get.ipynb`, where all patients meet all inclusion criteria: \n``# 1 trial-level eligibility = 2 2 trial-level eligibility = 0 3 trial-level eligibility = 2``\n``\n{\n\"PatientNote\": [\n    {\n        \"Name\": \"Father\",\n        \"Age\": 46\n    },\n    {\n        \"Name\": \"Man\",\n        \"Age\": 46\n    }\n],\n\"PATIENT_INFO\": [\n    {\n        \"ID\": 1,\n        \"Name\": \"<NAME>\",\n        \"Phone\": \"9999999999\",\n        \"Email\": \"<EMAIL>\",\n        \"Birth_date\": \"April 2nd, 2000\",\n        \"Birthplace\": \"Tokyo\",\n        \"Birth_sex\": \"Male\",\n        \"Address\": \"Tokyo\",\n        \"Height\": \"173 Cm\",\n        \"Weight\": \"63 KG\",\n        \"Blood_group\": \"A+\",\n        \"Emergency_person\": \"Father\",\n        \"Emergency_address\": \"Tokyo\",\n        \"Emergency_phone\": \"9999999999\",\n        \"History_of_medication\": [ ],\n        \"Allergy\": [ ],\n        \"Medical_History\": [ ],\n        \"Smoking\": [ ],\n        \"Drinking\": [ ],\n        \"History of trauma\": [ ],\n        \"History of surgical operation\": [ ],\n        \"Exercise_habit\": [ ]\n    },\n    {\n        \"ID\": 1",
        "label": 2
    },
    "796": {
        "output": "Good luck!\n\n\n## Problem 3\nSome lines are missing from the output, as a result of the output being split by lines. This problem seems to occur only when the number of variables included in the model is high.\n\n## Potential solution\nRun the following code to merge the three different rows that you have in the output of the command: 'Model 3'.\n\n```python\ndf.rename(columns={\"Model 1\": 'Trial level',\\\n                      \"Model 2\": 'Trial level',\\\n                      \"Model 3\": 'Trial level'},\\\n            inplace=True) \nprint(df)\n```\n\n## Potential problem 4\nBecause several columns of the model are categorical, the dataset may be converted to a binary format. This problem occurs because of the way in which the original code works.\n\n## Potential solution\nYou could modify the dataset by converting all the categorical variables into binary, using the 'df.select()' function. For example, in the dataset where only the model 2 is shown above, the first step is to convert the 'gender' category into a binary format, using the 'df.select()' function. In this command, the first column has already been converted because it represents the patient ID. You should always assign each categorical value a value '1' when you use the 'df.select()' function. In this command, the variable 'Pat' has already been converted into a '1'.\n\n```python\nnew_dataset = df.rename(columns={\"Trial level\":\"Trial level\",\\\n                                \"Pat\":\"Pat\",\\\n                                \"Adult\": \"Adult\",\\\n                                \"Smoking\": \"Smoking\",\\\n                                \"HbA1C\": \"HbA1C\",\\\n                                \"HDL\": \"HDL\",\\\n                                \"LDL\": \"LDL\",\\\n                                \"Age\": \"Age\",\\\n                                \"BMI\":\"BMI\",\\\n                                \"Trial_eligibility': 'Trial eligibility'})\\\n          .select('HbA1C', 'Smoking', 'Adult', 'age', 'BMI', 'gender', 'HDL', 'Pat', 'LDL',  'Trial",
        "label": 0
    },
    "797": {
        "output": "#### Solution\n<EOD> Intravenous administration of the anti-gout medication allopurinol into the lateral tail veins of rats.\nThroughout the history of the treatment of gout, it has been a problem that the long-acting anti-gout preparations often give rise to the patient's discomfort. In a long-term study, the author reported that subcutaneous administration of allopurinol, an anti-gout drug, once a day to patients caused the marked reduction of serum uric acid levels, relieved their gouty symptoms, improved X-ray manifestation, and prolonged their lifespans. The author administered allopurinol orally once a day, subcutaneously or by intramuscular injection twice or thrice a week to rats with arthrodial effusion and hyperuricemia, and observed a therapeutic effect on rats. The author noticed that if the rats were also given intravenous administration of allopurinol through the lateral tail veins, hyperuricemia and arthrodial effusion were also remedied, and the symptoms were much relieved and disappeared in a far shorter time.<EOD> The relationship between dietary diversity and dietary fat intake of adolescents in Malaysia\n\nBackground: To determine the relationship between dietary diversity and the fat content of meals consumed by adolescents in Malaysia. Materials and methods: A correlational survey design was employed to measure 290 adolescents' dietary diversity scores (DDS) and fat intake from 798 food and liquids items based on 24-hour recall information. Data was collected using self-administered questionnaires, while DDS and estimated fat intake data were collected via 24-hour recall. The mean food group intake frequency, the DDS, and estimated fat intake for each food group were calculated and were used as continuous outcomes for the analysis. Data were analysed using the Student t-test and analysis of variance. Correlation analysis and linear regression analysis were performed to determine the relationship and association among the continuous variables. Results: The adolescents achieved mean DDS and daily fat intake in the range of 2.",
        "label": 1
    },
    "798": {
        "output": "<EOD> A study to assess the efficacy of combination of toothpaste and mouthwash in comparison to a single toothpaste in the management of gingivitis\n\nINTRODUCTIONGingivitis is one of the most prevalent oral diseases. It has an incidence of over 90%. According tous, the incidence or the prevalence of periodontitis in the dentate portion of the population is 70%. [1][2]The present-day view on periodontitis is that it represents a spectrum of lesions extending from chronic gingivitis to periodontitis. Both of these pathological changes share the common predisposing factor of microbial plaque.[3]\n\n# Introduction\nGingivitis is one of the most prevalent oral diseases. It has an incidence of over 90%. According tous, the incidence or the prevalence of periodontitis in the dentate portion of the population is 70%. The present-day view on periodontitis is that it represents a spectrum of lesions extending from chronic gingivitis to periodontitis. Both of these pathological changes share the common predisposing factor of microbial plaque. [bib_ref]  Plaque bacterial diversity in experimental gingivitis, Teles [/bib_ref]  [bib_ref]  Clinical and microbiological effects of the adjunctive use of chlorhexidine mouthrinses in..., Marigo [/bib_ref]  [bib_ref]  Management of the dentine-restoration interface, Tyas [/bib_ref]  Periodontal therapy aims at arresting and/or reversing the underlying causes of periodontal disease and thus re-establishing the pre-diseased state. [bib_ref]  Periodontitis prevention and maintenance, Heasman [/bib_ref]  In early periodontal therapy, the most common interventions are scaling/root planing, and in late periodontitis, there is the use of local or systemic antibiotics. [bib_ref]  Current concepts in periodontal therapy, Armitage [/bib_ref]  Recent systematic reviews have demonstrated the efficacy of adjunctive use of 0.12% chlorhexidine mouthrinsing in reducing plaque accumulation and suppressing the growth of oral pathogens. [bib_ref]  Clinical and micro",
        "label": 2
    },
    "799": {
        "output": "If assess- \n0) Apart from the three-point scale, you should indicate whether the patient was recruited in the clinical trial. \nNote 4: Additional Information \nHere are several additional information about the trial: \n--Recruiting centre: \n    Only one center is being assessed (SHENGJING-SICAP-329), where patients can be enrolled in the study.\n--End of recruitment: The end of recruitment is October 2015.\n--Enrollment period: January 2014\u2013October 2015.\n--Start date (enrolment first patient): December 7, 2012.\n--Source of funding (grant funded): This study is supported by the National Science and Technology Support Program of China (NSTSPC) (No.2012BAIC14B01) and the Shenyang Science and Technology Plan (No.F12-116-1-28).\n--Acknowledgement: The manuscript was a collaboration between researchers from the Shengjing Hospital of China Medical University, the Beijing Gen",
        "label": 1
    },
    "800": {
        "output": "__The goal is to determine whether the patient meets the inclusion criteria. If the patient meets the criteria, then the score should be given 1; otherwise, it should be 0. You must compare the patient note with the inclusion criteria carefully. To get the answer, you shouldn't just read the patient's medical history, but also look at the patient's blood test results and the findings (e.g., a murmur) by physical examination. Your ultimate goal is to find a clinical trial for the patient. To do this, you will need to review the exclusion criteria.\nYou should compare the exclusion criteria and the patient data such that you can determine whether the patient fits into the trial data. If a factor is applicable to the patient, but meets one of the exclusion criteria, the score should be given 1, otherwise the patient should receive 0. For example, a patient has high LDL-C, but the LDL-C level falls within the normal range. That is, the exclusion criteria are not met.\n\nThe exclusion criteria are a type of filter that is designed to rule out patients with unrealistic expectations or who are prone to drop out. They include the following points:\n\n> - 50 years and above\n> - LDL-cholesterol \u2265 180 mg/dL\n> - Recent MI \u2264 6 months\n> - Recent PCI\n> - CABG \u2264 3 months\n> - Previous CABG\n> - TIA or stroke\n> - PAD\n> - Current LDL-cholesterol-lowering drug treatment\n> - Other cardiovascular disease, except for stable angina\n__Instructions:__\n\n```python3\nimport pandas as pd\nimport random\nimport numpy as np\n\nfrom sklearn import base\nfrom sklearn.model_selection import StratifiedKFold\n```\nLet's create the patient dataset.\n\n```python3\ndf = pd.DataFrame({'patient_id': np.random.randint(1, 500, size=100)\n                   , 'patient_bmi':np.random.randint(5, 25, size=100)})\ndf2 = df['patient_id",
        "label": 2
    },
    "801": {
        "output": "[INST]\nClosing\nGood job! You have successfully completed this activity!\nPlease find your answers on the following page.\nTo proceed to the next part of the lecture click on the following button.\nNext\nClick here to review the instructions for this trial\nGo back<EOD> Clinical practice. Painful neuroma of digital nerves.\nThis 71-year-old woman was referred by her primary care physician for evaluation of a painful neuroma of the index finger. The patient had undergone neurolysis of the digital nerve near the base of her left index finger 6 years before. She reported that within 1 year, her initial symptoms of paresthesia with numbness resolved, and the sensation of the fingertip returned to normal. However, pain in the region of the nerve repair occurred in the third year after surgery, and the pain persisted with gradual worsening. The patient reported that the pain was aggravated by cold and touching the finger, which would cause sharp shooting pain and burning. She denied any improvement with rest, ice, anti-inflammatory drugs, heat, or numbing agents. Her pain was so extreme that she had to take fentanyl transdermal patches, which caused sleep disturbances. Her past medical history was not contributory; she had no other allergies.<EOD> Ovarian cancer screening in women with Li\u2010Fraumeni syndrome\nWomen with Li\u2010Fraumeni syndrome appear to be at high risk for breast and soft tissue cancer. The present study evaluated ovarian cancer risk, the utility of pelvic examination, and possible approaches for ovarian cancer screening in this group.<EOD> TNF-alpha and IL-1 alpha up-regulate type I interferon receptor expression in hepatocytes; synergism between TNF-alpha and IFN-alpha.\nActivation of the interferon signaling pathway has been implicated in the pathogenesis of immune-mediated hepatitis. This study examined the role of Type I cytokines in regulating the IFN receptor (IFN alphaR) expression in hepatocytes. Rats injected with 200 microliters TNF-alpha showed a 2.5-fold rise in Type I",
        "label": 1
    },
    "802": {
        "output": "End<EOD> Lethargia, hypersomnolence, and sudden mental slowing: An enhancing phenomenon related to cytomegalovirus infection in a liver transplant patient\n\nEnhancing phenomenon of HHV-6 is associated with transplantation and immunodeficiencies, affecting the central nervous system (CNS), and characterized by excessive daytime sleepiness, hypersomnolence, and lethargy. Here we report a case of enhanced HHV-6 infection causing these symptoms in a 25-year-old male after liver transplantation secondary to fulminant autoimmune liver disease in the setting of anti-glomerular basement nephritis secondary to autoimmune hepatitis. On admission, the patient suffered from lethargy and hypersomnolence, leading to delayed recovery, and required supplemental oxygen for hypoxemia. Investigations subsequently revealed positive anti-HHV-6 IgM and IgG (IgG/IgM ratio 2.3). Further analysis on cerebrospinal fluid (CSF) for CNS infection revealed elevated leukocyte count with elevated HHV-6 DNA load: 5 x 105 cp/mL, which improved following foscarnet treatment. Therefore, we conclude that enhanced HHV-6 infection is an underrecognized cause of lethargy, hypersomnolence, and slowed cognition. Further studies should be undertaken to clarify the mechanism of enhanced HHV-6 infection and its relation to the enhancing phenomena and CNS impairments. KEYWORDS cytomegalovirus, enhancing phenomenon, hepatitis-6, psychomotor dysfunction, lethargia Frontiers in Immunology Citation: Chen J, Huang Y-H, Li P, Tian X, Yeh K-J, Huang Y-C and Li CH (2022) Lethargia, hypersomnolence, and sudden mental slowing: An enhancing phenomenon related to cytomegalovirus infection in a liver transplant patient. Front. Immunol. 13:9374",
        "label": 1
    },
    "803": {
        "output": "[CODE] <!DOCTYPE html> <html lang=\"en\"> <title>Clinical Trial Analysis Task</title> <meta charset=\"utf-8\"/> <style type=\"text/css\"> .btn {display: inline-block; position: relative; vertical-align: middle; *vertical-align: top; } .btn table tbody tr th:before {content:'';/*' '*/content:'' !important;} .btn table tbody tr th:after {content:'';/*' '*/content:' \u2610\u00d7\u00d7\u00d7' !important;} .btn table tbody tr td {vertical-align: top !important; padding: 0; } <style type=\"text/css\" media=\"screen\"> .btn {background-color: black !important; padding: 0.125rem !important; border: 1px solid white !important; border-left-width: 3.25rem !important; } .btn label {top: .5rem !important; margin-left: .3rem !important; margin-right: .15rem !important; } .btn #accept {color: rgb(234,239,243); text-decoration: underline; } .btn #decline {color: rgb(253,60,68); } </style> <meta name=\"viewport\" content=\"minimum-scale=1, maximum-scale=1\"> <meta name=\"format-detection\" content=\"telephone=no\"> <meta charset=\"utf-8\"> <meta name=\"description\" content=\"Clinical trial analysis task\"> <meta name=\"keywords\" content=\"eligibility, clinical trial, patient note, patient trial\"> <meta property=\"og:title\" content=\"Clinical Trial Analysis Task\"> <meta property=\"og:description\" content=\"We would like you to assess the eligibility of the patient note.\"> <meta property=\"author\" content=\"M.D\"> <meta property=\"og:image\" content=\"../images/16.png\"/> <link rel=\"stylesheet\" type=\"text/css\" href=\"../style.css\"> <script src=\"//s.stackpath.com/github/discourse/discourse\" data-version=\"1.6\"> (function() { // The body of this function",
        "label": 2
    },
    "804": {
        "output": "# Implementation\n\n### Requirement\n\n* [BioDataPipeline](https://github.com/Bio-DistributedDataPlatform/BioDataPipeline)\n  v0.x\n  (for `create_data`)\n* [dask](https://hub.docker.com/r/dask/dask)\n  v1.7\n  (for `dask.distributed.cpu.Delayed`)\n* `pandas`\n* `xlwrite`\n* `openpyxl`\n  `matlab-m file` \n<EOD> The effects of exercise on metabolism, mood, anxiety and depression in offspring of mice exposed neonatally to nicotine\n\nBackground: Maternal nicotine exposure (MNE) alters nAChR density and functionality in the central nervous system, particularly the dopaminergic brain reward pathway, and may affect emotional regulation. Moreover, the ability of an exercise program to counteract the aforementioned changes may depend on multiple factors, including the type, duration, and dose. The aim of this study was to assess the effects of exercise on the emotional regulation of offspring from mice exposed neonatally to nicotine. Method: Nicotine was administered neonatally to adult female Swiss mice at the beginning of lactation, and exercise was conducted for 14 consecutive days (days 0\u221213). The open field was used on day 4 (OF-4), and the novel object recognition test was conducted on days 4 and 7 (NOR-4 and -7). Results: On OF-4, nicotinetreated offspring exhibited less horizontal exploration and rearing, thus suggesting an anxiogenic effect. On NOR-4, nicotine-treated subjects displayed reduced ability to discriminate between a familiar and a new object (P < 0.01). Nicotine-exposed offspring trained on exercise also displayed anxiogenic response when submitted to OF-4 (P < 0.05) and impaired discrimination response in NOR-4 (P < 0.01), although the anxiogenic effect was more marked in the untrained group. Finally, a significant difference",
        "label": 1
    },
    "805": {
        "output": "[/TRIAL-DETAILS]\n\n[/T1_DOC]\n\n\n[T2_Doc: Cerebral Vasculitis]    [[INST]] \nCerebral vasculitis is commonly diagnosed at the time of brain biopsy but can present similarly to stroke.\n\nYou are tasked to help a busy neurologist manage an outpatient medical clinic, which requires a variety of patient types to be evaluated. This includes adult patients with transient ischemic attacks (TIA), who need to be evaluated for the possibility of a vasculitis etiology, and adult patients with cryptogenic stroke, who need to be evaluated for potential vascular risk factors and etiology. \n\nTo optimize the neurologist's workflow and enhance the patient and physician experience, you would develop a solution to support the diagnosis and treatment monitoring of vasculitis and stroke patients as they proceed through their care. \n\nWe do not have any other details about the patients being evaluated, other than they need to be adult vasculitis and vasculopathy patients, so adult patients being evaluated for a vasculitis etiology.  This could be through a positive result of inflammatory bloodwork (such as a high C-reactive protein or antinuclear antibody); it could also be patients with a negative bloodwork, but suspicious for the presence of TIA without clear explanation. \n\nWhile no actual patient records were provided, we created a variety of clinical patient records in the software to test the proposed solution. From previous research performed in medical record abstraction, we know that clinicians need support to help them better manage patients with multiple comorbidities and the potential side effects of treatment. Because vasculitis patients often may have one or more of these comorbidities, the neurologist will have to create a report to communicate to both colleagues and patients. \n\nThe report would be formatted into a single page of text, and would need to address both the patient's treatment regimen, and the comorbidities that are of note at this time for the patient, allowing neurologists and other physicians to communicate the treatment plan and comorbidities without having to communicate separately through emails and messages with different members of the patient's healthcare team.",
        "label": 2
    },
    "806": {
        "output": "Good luck.\n\n__HIGH_CONTRAST:__\nIt is the last task that a trial assistant has to do to provide a quality review of the eligibility criteria. The main purpose of applying `high contrast` is twofold. The first is to make the text of the document more readable for humans. The second is to allow searching for documents from the set of documents using machine learning methods (for example, natural language processing or deep learning)\n\n\n\n\n__HIGH_CONTRAST:__\n```sql\nupdate trials set trial_document=case when rlike(trial_document, '[A-Z][AC-Z]\\'?$') then right('[A-Z][AC-Z]\\'?$', locate('[A-Z][AC-Z]\\'?$','trial_document',1)-locate('[A-Z][AC-Z]\\'?$','trial_document',1)+length('[A-Z][AC-Z]\\'?$')) else '`[A-Z]\\'?$'`\n```\n\n## Part 3: Check that Trial_document_highContrast is correct\n\nBefore proceeding with the data analysis, it is best to first check whether the generated `trial_document` column is consistent with the original `trial_document` column. Because SQL operations are not completely deterministic, you should not rely on automatic code generation.\n\n\n__Test__: \n```sql\nselect sum(case when rlike(trial_document, '[A-Z][AC-Z]\\'?$') then 1 else 0 end ) as hc_pass sum(case when rlike(trial_document, '[A-Z][AC-Z]\\'?$') then 0 else 1 end ) as hc_fail\n```\n\n__Result__:\n```text\nSELECT sum(cast(case when rlike(trial_document, '[A-Z][AC-Z]\\'?$') then 1 else 0 end as \n                boolean))\n      AS\n    hc_pass,\n    \nCOUNT(1)\n      AS\n    hc_fail\nFROM dtl_11;\n```\n\n\n__Result__:\n```text\n+----------------------+---------+",
        "label": 2
    },
    "807": {
        "output": "### Q1. \nPlease explain to me step by step how to handle the patient note in the task?\n\n### A1.\nThis task is an input-output exercise in which you have to input information from the patient note into the task and output, whether the information is necessary to determine whether the patient meets the inclusion criteria of the clinical trial or not. In this task, it's a little bit tougher than other tasks since clinical note is much longer and there is no standard input form such as in the EHR clinical note exercise. In order to handle the task, I will suggest you to take following tips:\n\n\n* \n \nFirst, review whether information in the task has already been included in the patient note and add missing necessary information. The patient does not have medical history of diabetes mellitus, so, in this case, he might be eligible to the clinical trial. \nIf there is no new information, you can input it in the section `Either...`. For example, in the above example, `Either he has a family history of CAD or he is physically active.`.\n \n* \n \nIn case of the output, it is a good idea to review whether information in the trial note and input patient data match up. For example, in the case of `Trial-level eligibility: Excluded`, is there any information in the input section that contradicts the trial exclusion criteria? 2\n\n* \n \nIn case of any contradictory information, I suggest you to check how to input the contradictory information in the input section of the trial note. For example, in this case, the patient has a family history of CAD, but the trial excludes the patient due to prior CAD. In this case, you can use a dummy variable `Either...` in the input section of the patient noted. If you input the dummy variable `Either...`, it works as the output when the trial note says otherwise or vice versa.\n*\t\t<NAME>, <NAME>, <NAME>, and <NAME>; 5\n<span style=\"color: purple;\" xml:space=\"preserve\">23</span>\n\t<span style=\"color: green;\" xml:space=\"preserve\">3</span>\n\t<span style=\"color: pur",
        "label": 0
    },
    "808": {
        "output": "# Submitting your solution\nSubmission: You are invited to submit your solution (written or recorded, < 10 minutes) to the following address: e-mail: [hidden email]\nYou can submit your solution via the discussion section of the assignment. After submitting your solution, your solution will be reviewed by an instructor. All the feedbacks in the discussion section of the assignment will be replied within one week.\nThe best two solutions will be rewarded with a 10,000 RMB \"Educational Scholarship\". Also, each problem that gets an answer will be rewarded 200 RMB.\n\n## Note:\nThe discussion section of the assignment is not a debate, we will not accept any insult comments, offensive comments, and comments violating any of the Ethics guidelines for instructors which are in the first assignment. There will be no discussion section open after April 10, 2022.\n\n## Ethics:\nThis study was approved by the institutional review board of TMC. All eligible participants signed informed consent.\n\n# Analysis:\nParticipant information was analyzed at the center level. The primary outcomes of patient discomfort levels were recorded by investigators using 5-point Likert scales.\n\n# Discussion\n\n## Interpretation:\nThe findings are consistent with several investigations conducted at the same site, indicating consistency of the data. Higher levels of discomfort observed among patients during the period of drug treatment can be managed by improving current patient education initiatives. There are several methods of analgesia that can provide comparable benefits and lower doses of opioids may be a valuable tool to control pain in this population. It is important to understand that the efficacy of analgesia is dependent on the drug type and dosage administered. All of them contribute to a greater or lesser extent to a patient's level of discomfort. The relationship between drug type and symptomatic state may vary greatly from one medication to the next, and from one patient to the next. Our results are consistent with other studies demonstrating that higher levels of patient discomfort are associated with higher doses of opioids. This may be related to genetic variability and differences in the pharmacokinetics of opioids between",
        "label": 0
    },
    "809": {
        "output": "### Data and code available\n[Data and code for [Ellipsis]: Data and code for \"Inclusion Criteria Assessment\" are available at: UXAI&AI:  Data and code for \"Inclusion Criteria Assessment\" are available at: UXAI&AI.]\n   \n# Acknowledgments\n\n### Copyright\n\n    Copyright \u00a9 2019 The Authors. Creative Commons Attribution 4.0 International License.\n\n### Authors' Contributions\n\n    GD: Conceptualization, investigation, methodology, formal analysis, visualization, writing -original draft. GD, ZQ: methodology, and writing -review and editing. ZQ: methodology, visualization, supervision, project administration.\n\n# Disclosures\n\n### Data Availability Statement\n\n    All data generated or analysed during this study are included in this published article.\n\n# Funding\n\n### Support Statement\n\n    The authors received no specific funding for this work.\n<EOD> .\nObjective: To investigate the value of serum C-reactive protein (CRP) in predicting early clinical remission in patients with ulcerative colitis (UC). Methods: A retrospective analysis was performed on hospitalized UC patients who met the inclusion criteria from November 2011 to December 2014. The blood CRP level was tested within 72 hours of hospitalization and before treatment. According to the blood CRP at the time of the disease was diagnosed, CRP>5 and CRP\u22645 was divided into CRP-high and CRP-low groups. According to the early clinical remission of patients with UC, the CRP-high group and the CRP-low group were divided into remission group and non-remission group. All the patients were divided into mild or moderate and severe groups according to the disease severity at admission. The efficacy of budesonide in early clinical remission assessment was analyzed in patients with UC with differed initial blood CRP levels. The association of CRP with clinical symptoms in patients with UC was evaluated. The receiver operating characteristic (ROC) analysis was used to assess the value of CRP in determ",
        "label": 0
    },
    "810": {
        "output": "If you have a question, raise it in our discussion forum [https://discuss.voc.academy].\n\n__Clinical Guidelines__\n![INST] \nInstructions:\n\n* Consider the following variables for the patient:\n    * Age\n    * Gender\n    * Dizziness\n    * Frequent headaches\n    * Physical activity\n    * High LDL-C and low HDL-C levels\n    * Family history of CAD\n* Assess whether he has any exclusion criteria based on the trial.\n\n* Assess whether he has any eligibility based on the inclusion criteria of the trial.\n\n* Determine the Trial-eligibility scale based on the assessments.\n\n__Clinical Trial Paper__\nThis is the clinical trial paper to follow the same process: (1) Assess your understanding; (2) Make trial-level eligibility determination; and (3) Determine patient-level eligibility determination.\n\n### Assess your understanding\n\n* What is the eligibility determination in the clinical trial?\n- Patient-level eligibility\n- Trial-level eligibility\n\n### Make Patient-level Eligibility Determination\n\n1. Identify the Patient note:\n- The patient note:\n- Patient note:\n\n![INST] \nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal",
        "label": 1
    },
    "811": {
        "output": "Your final report looks like the following:\n1) Patient:\nSex: Male\nAge: 46 Years\nPrevious lipid-lowering medication:\n- \u2714Yes, atorvastatin\nCarotid artery disease:\n- BP (140 to 159): 145\n- BP (160 to 179): 142\n- BP \u2265 180:\n\n# Discussion\nThis is a simple case, but the algorithm for the patient note was a bit complex. A lot of things could be left out, if one wants, because the clinical researcher already knows most of what is in the patient note. For instance, the sex, age, and previous lipid-lowering medication are known from the information table, just as the patient's medical record is available.\nNotice that the patient had a LDL-Cholesterol level of 545. To answer the patient note: the assessment of the eligibility is 0, because the patient meets the inclusion criteria, but does not meet the exclusions criteria. The patient is a person with high cardiovascular risk who is excluded by the trial's exclusion criteria (previous lipid-lowering medication and the LDL-C level). The final assessment should be: `Trial-level eligibility: 2) Eligible.`.\nThere are no inclusion criteria for the age and sex, because the age is above 18 years and the sex is male or female.\nTo assess if a patent is eligible, the trial's exclusion criteria and the patient's information must be taken into consideration.\n\n# Conclusion\nThis tutorial taught how to make a trial-level eligibility for clinical trial recruitment. These tasks help to prevent enrolling a patient with characteristics which are not compatible with the inclusion criteria or even worse, with the exclusion criteria.<EOD> .\nThe frequency of posttraumatic epilepsy was studied on the group of 148 patients who had suffered a craniocephalic traumatism and who were treated a St. Joseph Hospital, Hiroshima, in 1962-71. The patients were classified into 63 of localized brain damage (",
        "label": 2
    },
    "812": {
        "output": "In this situation, we can only judge the eligibility based on the Trial-level eligibility since the patient does not satisfy the inclusion criteria like < 65\u2009years old. We need to continue to check the patient note, until we find the proper patient with matchable patient note in the dataset and the trial note. One of the patient note below is such a case:\n\n\nA 61-year-old man presented with dizziness and difficulty focusing. He reported a positive history of high blood pressure, diabetes mellitus, and smoking. The patient's LDL-C level was 106\u2009mg/dL and his fasting glucose level was 88\u2009mg/dL. No lipid-lowering medication was recorded.\nWe can get the Trial-level eligibility is 1) Eligible because the patient satisfies the trial's inclusion criteria even if the patient is above 65\u2009years old.\n![](./fig/8/4.png)\n\n\n## [INST4]\nWhat if the patient's LDL-C level is < 106\u2009mg/dL?\n\nWe know the LDL-C level should be < 106\u2009mg/dL in the clinical trial. So, the Trial-level eligibility is 1) Eligible.\n[formula]  \\begin{verbatim} Trial-level eligibility:",
        "label": 1
    },
    "813": {
        "output": "[A] Eligibility criteria of the clinical trial** \n\n## Trial name: Ultrasound-guided Intermediate Cervical Plexus Block\n\nInclusion and Exclusion criteria: \nInclusion Criteria:\n- open surgical revascularization\n- age over 18 years\n- written informed consent\n- internal carotid stenosis \n- superficial cervical ansa (facial nerve: cervical branch) is 12 mm \n- ultrasound-guided block",
        "label": 1
    },
    "814": {
        "output": "## [SOLS/SOLU] Solutions to test the patient note\n\nSolutions to test the patient note.\n\n## [INST/SOLS/SOLU] 0: Not Relevant\nWe should have the next result after executing each of the following four steps: the result can be found at the first line of all code.\n\n**Step 1**: Find all the stenosis in different fields and vessels.\n\n```\n// Find all 'stenosis' in carotid artery fields\nvar stenosis_in_CA = patient.dataValues.fieldValue(FLDV.stenosis, fieldType.string);\n\n// Find all the 'stenosis' in 'ICA' and 'CCA' fields\nvar stenosis_in_ICA_and_CCA = patient.dataValues.fieldValue(FLDV.stenosis, fieldType.string)\n\n\n// Find all 'stenosis' in 'carotid artery' fields\nstenosis_in_carotid_artery = patient.fields.carotid_artery.map((carotid_artery, i, arr) => {\n\n    if(carotid_artery.stenosis !== undefined){\n      return {\n        stenosis: carotid_artery.stenosis\n      }\n    }\n  })\n\n// Find all 'stenosis' in 'CX' fields\n//stenosis_in_carotide_X = patient.dataValues.fieldValue(FLDV.stenosis, fieldType.string)\n\n// Find all the stenosis in left and right internal carotid arteries\n// stenosis_in_ICAs = patient.dataValues.fieldValue(FLDV.stenosis, fieldType.string);\n```\n\n **Step 2**: Find the stenosis with different severity and vessel.\n\n```\n// Find the stenosis with a severity of different than zero\nstenosis_in_all_artery_with_severity = patient.fields.carotid_artery.map((carotid_artery, i, arr) => {\n\n        const carotid_artery_stenosis = carotid_artery.stenosis",
        "label": 2
    },
    "815": {
        "output": "[TITLE] Title: Enterprise Stent Implantation in the Treatment of Carotid Artery Stenosis With Ischemic Stroke Summary: To investigate the long-term effects of intracranial implantation of Enterprise stent system versus antiplatelet medication on neurologic deficits, daily living abilities, and carotid artery stenosis in patients with atherosclerotic ischemic stroke\n\n#### Inclusion criteria\nAtherosclerotic plague-caused carotid artery stenosis\nSevere carotid artery stenosis (unilateral stenosis > 70%) diagnosed according to angiography\nAge 18-75 years\nOf either sex\nProvision of informed consent regarding trial procedure\n\n#### Exclusion criteria\nIntra-cranial stenosis\nAortic aneurysm\nAbsence of target artery \nSevere cranial nerve deficit with paralysis\nAbsence of a suitable target vessel (carotid artery, vertebral artery < 2 mm lumen diameter)\nAbsence of a suitable stent for carotid artery obstruction \nPrevious treatment with carotid stent implantation\nCoexistence of peripheral vascular disease, especially below the knee, not with surgery treatment\nAny medical problem that, in the judgment of the physician, might make implantation of a stent unsafe \nNeurological deficit, e.g., stroke, transient ischemic attack, ischemia after angiography \nSevere coexisting systemic disease with 3 years of life expectancy \nUnstable angina \nRestenosis after stent implantation \nIntravenous drug addiction and non-compliance with the follow-up program \n\n## Patient Information\nYour task is to produce patient information according to the specified format and data input. You should follow the instructions carefully.  \n[TITLE] Title: Enterprise Stent Implantation in the Tre",
        "label": 1
    },
    "816": {
        "output": "## Solution\n\n### Detailed instructions\nDetailed Instructions\n\nIn this example, the patient meets some but not all the inclusion criteria of the trial (e.g., gender), whereas the trial-level eligibility is 1. You should output the three-point scale for the assessment of eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\n```python\nTrial-level Eligibility = Trial-level eligibility\nif Trial-level Eligibility is 1:\n    Result of assessment of trial eligibility = 1 \n    Comment of Trial-level assessment of eligibility = \"Exclusion criteria apply\"\nelse:\n    Result of assessment of trial eligibility = 2 \n    Comment of Trial-level assessment of eligibility = \"Patient does not meet inclusion criteria\"\n```\n\nThis code block returns `Comment of Trial-level assessment of eligibility: Exclusion criteria apply` and `Result of assessment of trial eligibility: 1`.\n\n\nYou should always repeat the comment of Trial-Level assessment of eligibility.\n\nThis code block returns `Comment of Trial-level assessment of eligility: The patient has been excluded from the study because the he was 46 years old, has a family history of CAD, physical inactivity, LDL and HDL cholesterol levels of 545 and 53\u2009mg/ dl respectively, and no use of lipid-lowering medications.` and `Result of assessment of trial elligibility: 2`.\n\n# Result of assessment of trial eligibility: 2\n\n# Comment of trial-level assessment of eligibility: The patient has been excluded from the study because the he was 46 years old, has a family history of CAD, physical inactivity, LDL and HDL cholesterol levels of 545 and 53\u2009mg/dl respectively, and no use of li",
        "label": 0
    },
    "817": {
        "output": "23. [ENT] Clinical Trial.\n```python\nimport random\nimport pandas as pd\nfrom sklearn.preprocessing import LabelEncoder\ndef get_patient_note(clin_trial, i=0):\n     \"Gets patient note for clinical trial\"\n    patient_note = ''.join('/'.join(i).split()[:-1])\n    patient_note += '\\n'\n    patient_note += '    Name =  '+clin_trial[0]\n    patient_note += '\\n'\n    patient_note += '    Inclusion_CRITERIA = '+clin_trial[1]\n    patient_note += '\\n'\n    return patient_note\n\ndef get_clinical_trial(i=0, clin_trial):\n    \"Gets the clinical trial for the patient for the given index\"\n    clinical_trial = clin_trial.iloc[i].iloc[:-1]\n    if i == len(clin_trial):\n        clinical_trial = clinical_trial.append(True)\n    else:\n        clinical_trial = clinical_trial.append(False)\n    return clinical_trial\n\ndef patient_note_prep(patient_note):\n     ''A function with the task to prepare all patient notes in a form similar to clinical trial information for evaluation''\n     for i in range(len(patient_note)):\n          if i in range(1, len(patient_note)):\n              patient_note[i+1] = \" \"\n          else:\n                 \"0\"\n          if i == 0 :\n                 patient_note_text[len(patient_note_index)] = patient_note_text.append(get_patient_note(clin_trial, 0))\n                patient_note = patient_note.replace(clin_trial[0], 'Clinical_Trial')\n                 patient_note = patient_note.replace('Inclusion_CRITERIA', 'Inclusion\\nCriteria')\n                 patient_note.replace('Exclusion_CRITERIA', 'Exclusion\\nCriteria').",
        "label": 1
    },
    "818": {
        "output": "## [/TEST]\n<EOD> .\nIn order to analyze the relationship between the level of p53, CD95 and c-erbB-2 expression and clinicopathological parameters and the survival (OS) in patients with esophageal squamous cell carcinoma, p53, CD95 and c-erbB-2 were examined immunohistochemically in paraffin specimens of 156 patients with endoscopically obtained squamous cell carcinoma of the esophagus. A positive CD95 expression was found in 36% of the tumours. Of these, 95% had positive p53 expression and 80% showed positive c-erbB-2 expression. A positive p53 expression was found in 58% of the tumors, in 66% of these tumours there was a positive c-erbB-2 expression and in 91% there was a positive CD95 expression. In Kaplan-Mayer analysis, no statistically significant relationship between CD95 or p53 expression and survival was found. The significant relation of c-erbB-2 expression to survival was revealed. The high frequency of p53 expression in this analysed group of patients corresponds to known data, what suggest that this tumour is associated with a mutation of p53 gene. The high frequency of the c-erbB-2 expression suggest an onedirection of the progression of neoplastic transformation of esophageal squamous epithelium.<EOD> Chaperone-coated pili, a class of adhesins related to P pili.\nA new class of pili (C-pili) produced by two uropathogenic enteric bacteria, Escherichia coli ABU 83972 and serotype W125 of Proteus mirabilis 42, were recently described by Andersen et al. (R. H. Andersen, R. I. Poulsen, R. J. Hardie, P. Moller-Oppegaard, A. H. Viborg, B. J. Andersen, H. Svenstrup, and N. Jann, p. 3713-3718,",
        "label": 1
    },
    "819": {
        "output": "[bib_ref]  A study exploring the eligibility outcomes (assessed as binary variable \"eligible\" versus..., Iversen [/bib_ref]  The file is in.csv format. \n(1) (https://figshare.com/s/9ececf1e53f62b3bb65b) is a data file. (2) (https://figshare.com/s/5ce68253a13298a8a5ba) is an example directory that stores the data file. [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  is an example for output data in the JSON format. [bib_ref]  Efficiently combining clinical judgment and statistical evidence, Vickers [/bib_ref]  In this module, we are going to show you the output that we want in the result. [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  shows the JSON file for training, validation, and test, respectively. [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  shows the training set of the test. Similarly, [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  , [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  , and [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  are the validation set, the training set, and the test set for the model, respectively. [bib_ref]  Clinical trial simulation, Flynn [/bib_ref]  In this module, we are going to show you the confusion matrix for each model. [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  , [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  , [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  , [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  , [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  , [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  , [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  , and [fig_ref]  Figure 1: Screenshot of the terminal window [/fig_ref]  are for the confusion matrix of the training, validation, test, training, validation, test",
        "label": 0
    },
    "820": {
        "output": "[Tutorial/1-10] The next subproblem \n\n## Step-by-step output:\n[Tutorial/1-11] The next subproblem \n\n## Step-by-step output:\n[Tutorial/1-12] The next subproblem \n\n## Step-by-step output:\n[Tutorial/1-13] The next subproblem \n\n## Step-by-step output:\n[Tutorial/1-14] The next subproblem \n\n## Step-by-step output:\n[Tutorial/1-15] The next subproblem \n\n## Step-by-step output:\n[Tutorial/1-16] The next subproblem \n\n## Step-by-step output:\n[Tutorial/1-17]\n\n## Tutorial/2-1\n\n# Exercise\n\n## Exercise-2 \n[Tutorial/2-1] Write a C program for binary search tree using the recursive method.\n\n## Exercise-2.1\nHere is the definition of the recursive binary search tree (BST) algorithm:\n\n## Exercise-2.2\nThe given binary search tree is:\n\n## Exercise-2.3\nRun the code, and the output should be:\n\n## Exercise-2.4\nHere is the definition of an algorithm for the depth-first search tree traversal.\n\n## Exercise-2.5\nUse an empty binary tree.\n\n## Exercise-2.6\nInput an empty binary tree.\n\n## Exercise-2.7\nCreate the output file.\n\n## Exercise-2.8\nWrite a C program for a binary search tree using the depth-firstsearch (DFS) algorithm.\n\n## Exercise-2.9\nHere is the definition of the recursive binary search tree (BST) algorithm:\n\n## Exercise-2.10\nThe given binary search tree is:\n\n## Exercise-2.11\nRun the code and output should be:\n\n## Exercise-2.12\nHere is the definition of an algorithm for the depth-first search tree traversal.\n\n## Exercise-2.",
        "label": 0
    },
    "821": {
        "output": "---\n\n## Implementation note\n\nAs well as using Python 3.x with PyAutoTest, all our modules are written by the following two people:\n- [<NAME>](<EMAIL>): Leavers of [BioMedIA](https://biomedianet.org/blog/author/sidan-tian), and mainly responsible for our modules.\n- [<NAME>](<EMAIL>): the first author of this paper, and mainly responsible for the PyAutoTest.\nThe PyAutoTest's source code is available on [Github](https://github.com/zhenghong-tian/PyAutoTest).\nMoreover, for detailed source codes and how we built and used each module, please visit [BiomedIA](https://biomedianet.org/pylab/bioid/index.html).\n\n---\n```python\n# +\nimport biomedianet as bm\n# -\n```<EOD> .\nOBJECTIVE\nTo study the effect of PAF on platelets after the burn patients treated with the intravascular fibrinolysis or not.\n\n\nMETHODS\nThe concentrations of PAF and TXB2 were determined, and the reactions of the platelets with PAF were observed in burn patients with 3 degrees or more total burn surface area (TBS) without thrombosis and with coagulopathy. Platelets were isolated from the peripheral blood of healthy volunteers and the PAF were incubated with the platelets and washed. The platelets were treated with TXB2 mimicking enzyme, and then they were observed with electron microscopy.\n\n\nRESULTS\nThe concentrations of plasma platelet activating factor in the patients after the intravascular fibrinolysis were significantly higher than that of control subjects. The amount of TXB2 after incubating with PAF were increased significantly than that of control group. The platelets treated with TXB2 after incubating with PAF showed the thrombi and formed the fibrin networks.\n\n\nCONCLUSION\n1. The concentrations of PAF and TXB2 increased significantly than that before intravascular fibrinolysis, which indicated the intravas",
        "label": 0
    },
    "822": {
        "output": "<EOD> .\nThe authors have studied the use of the bone-suturing device they have developed in 75 patients with the bile ducts injured during gallbladder removal. The use of the device allowed to obtain more secure healing of the bile ducts injuries, and resulted in earlier mobilisation of the patients, i.e. decreased risk of purulent complications and aseptic inflammations as well.<EOD> A Study of the Correlation between the E3/19K Fragment Derived from EBV and Autoantibodies to SSA/Ro and SSB/La in Different Disease Conditions\nThe E3/19K fragment derived from the Epstein Barr Virus (EBV) was previously demonstrated to have antigenic crossreactivity with SSA/Ro and SSB/La. In the present study, the possible correlation between anti-p64 and anti-SSA/Ro in adult cases of systemic lupus erythematosus (SLE), and between anti-p64 and anti-SSB/La in Sj\u00f6gren's syndrome (SS) was assessed. Moreover it was tested whether E3/19K fragment antibodies could interfere with anti-SSA/Ro ELISA methodology. The sensitivity of the latter of anti-p64 antibody detection was investigated as well. 156 sera from patients with SLE, RA, SS, Sj\u00f6gren's Disease (SjD) and chronic liver diseases; and 65 sera from healthy controls, were tested simultaneously by ELISA for antibodies to p64, SSA/Ro and SSB/La. Positive anti-p64 antibody sera were tested in a commercially available anti-SSA/Ro ELISA to detect anti-p64 interference. Anti-p64 antibody titre in SLE patients was estimated and correlated with the levels of the other autoantibodies in that group. It was concluded that the presence of anti-p64 did not interfere with the anti-SSA/Ro ELISA methodology, and anti-p64 was mostly detected in SLE sera. Its serum titre was comparable with that of SLE anti-",
        "label": 0
    },
    "823": {
        "output": "[OUT] Good luck!\n\n[H3]\n\n[/H3]\n\n--\n\n-- ****************************************************************\n\n[[NOTE] Included in the {{SE}} and 26 November 2017.]]\n\n{{H2}} A {{NE}} to assess clinical trial eligible\n\nPatients have to fulfill the eligibility criteria to be screened and then enter a clinical trial.\n\nThis {{NE}} will allow you to assess trial eligible of a clinical trial patient based on the eligibility criteria.\n\nThe criteria can be listed to the right (see below) or as a table. To define the criteria in a table, click on the small square at the bottom of the field.\n\n- Type: *String*  - Type of element: *String*\n- Name: *String*  - Name: *String*\n- Criteria ID number: *Number*  - Criteria ID number: *Number*\n- Criteria description: *String*  - Criteria description: String*\n- Table: *Bool*  - Table: *Bool*\n- Table value: \n- Columns : \n  - Label: *String*  - Columns : *Number of columns of table* - Label: *String*  - Rows : *Number of rows of table* - Rows label: *String*\nInputting a value in this column will select a criterion from the table below. If the table contains several criteria, it is then up to you to select one of them. (e.g. if the patient has a total of three criteria, it will automatically select the first one. If a patient has a single criterion, the only way this table will do its job is to simply check which criteria are not satisfied by the patient)\n- Criterion value to exclude: \nIf one of the criteria is not met, one can check this box. In this case the result will be \"1\" (excluded) - Otherwise, the result will be \"0\" (included)*\n- Criterion value to include: \nIf one of the criteria is not met, one can check this box. In this case the result will be \"1\" (included) - Otherwise, the result will be \"0\" (excluded)*\n\n*",
        "label": 0
    },
    "824": {
        "output": "<EOD> A novel CAR\u2010T lymphoma: a challenge to the clinical practice for acral T\u2010cell lymphoma\nDear Editor A 72-year-old man presented with an erythematous blister in the plantar skin of his left foot for 20 days. Histopathological examination showed epidermal atrophy, degeneration of the basal cells, liquefaction degeneration of the dermis, small vessel changes, and infiltration of atypical cells with small-lucent cytoplasm (Figure 1A-D). Immunohistochemistry studies showed the tumor cells to be positive for CD3, CD5, CD7, CD43, CD45RO, CXCR3, Granzyme B, and Ki-67 (~80% positive cells). The tumor cells were negative for CD20, CD30, CD56, CD57, CD68, CD8, CD5, CD34, CD10, Tcl1, EBER, and Ki-67 (Figure 1E,F). Fluorescence in situ hybridization (FISH) tests did not confirm a TCR gene rearrangement. No evidence of Epstein\u2013Barr virus was found in the tumor (EBER test), and tuberculosisspecific polymerase chain reaction results were negative. The patient was diagnosed with peripheral T-cell lymphoma, unclassified. The patient received three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. After the first course of chemotherapy, the lesions decreased in size, the ulcer and blistering were healed, and the patient\u2019s pain symptoms were relieved. Chemotherapy was given 17 months after chemotherapy. FISH examination showed a deletion on the L551-S617 sequence in the CDKN2 gene. The CDKN2A/B protein is a tumor suppressor that regulates the division of mammalian cells and regulates the cell cycle through p21 protein binding; this gene is often deleted and mutated in T-cell",
        "label": 0
    },
    "825": {
        "output": "# C.2 The data file\n\nBefore the exam: This test is for clinical researchers. The patient is 67 years old, male, and has many diseases. Please evaluate whether this patient can participate in this trial, and write a report. Please put all the relevant information you collect in the document we provide for the evaluation, and then you can read the doctoral report and use your logical judgment to make a decision.\n\n## Diseases:\n(A1, A2, ..., A7: Inflammable bowel disease; A8: Allergy; A9: Liver Disease)\nSmell: (S1, S2: Normal; S3: Abnormal)\nTaste: (T1, T2, ..., T5: Normal; T6: Not Good)\n\n## Clinical information:\nEligibility: Tested_for_this_study: Yes\nEligibility: Not Tested_for_this_study: No\n\n## Trial information:\nTitle: Pharmacokinetic Analysis of AbobotulinumtoxinA (Dysport) in Parkinson's Disease\n\n## Phylogenetic tree\n```\n# -*- coding: utf-8 -*-\n\n#\n# Author: <NAME>\n# Date: 2022-01-19\n#\n# A function for producing a phylo tree visualization\n# \nimport seaborn as sns\nimport matplotlib.pyplot as plt\n# from ggtree.tree_view import TreeContourPlot\n# import plotly as py\n#\n\ndef PhyloTree(data,\n             color = 'default',\n             width = 'default',\n             node = 'default',\n             leaf = 'default',\n             x_tip=0 ,\n             y_tip=0 ,\n             x_branch=0 ,\n             y_branch=0):\n    fig = plt.gca()\n    fig.set_size_inches(width, height)  # set width and height\n\n    fig = sns.barplot(x=x_tip,y=y_tip, data=[-5 * np.log10(data.tip.tip_prob),",
        "label": 0
    },
    "826": {
        "output": "Good luck.!\n[INST]\n[INST] If you need to run these two commands simultaneously, you can use the `&` symbol like this: `codex.set_patient(\"M0001\")&codex.set_patient(\"M0002\")`.[INST]\n<EOD> A clinical trial comparing the efficacy and safety of three monoclonal antibody treatment sequences for advanced non-small cell lung cancer.\n18514 Background: Monoclonal antibody (MAB) therapies represent a significant breakthrough in the treatment of non-small cell lung cancer (NSCLC). Two types of MABs have been approved by the US federal drug agency (FDA), each with the potential for an interchangeable positioning of two different agents in the sequence of first-line treatments of lung cancer. There are currently two regimens available, one for the use in all patients (docetaxel + carboplatin - CA) and another (nab-P + PA) allowing treatment in those who are not candidates for this combination.\n\n\nMETHODS\n385 unselected advanced NSCLC patients from 5 major medical centers in Spain were recruited for an open-label, multicenter phase III trial that randomly allocated them at a 2:1 ratio to a CA-based (N = 231 ) or a nab-P + PA-based (N = 154 ) first-line therapy. This analysis evaluates the association between initial therapy and response, time to progression, and time to death.\n\n\nRESULTS\nPatients in the CA or nab-P + PA arms were found to have a similar baseline demographics and disease characteristics with similar 1st Response Rates and time to progression. However, the CA group showed a higher median survival rate and a longer time to progression (median progression-free survival: 5.2 and 4.5 months in the CA and nab-P + PA groups, respectively; p = 0.83), and a similar trend was also observed in the overall survival, with a median survival of 9.6 vs 8.1 months, respectively) (p = 0.25) for the entire patient population. Treatment-emergent",
        "label": 1
    },
    "827": {
        "output": "<EOD> A Rare Case of a Dysphagia Nodi Ventriculi after the Treatment of Recurrent Falls in an Incompetent Patient\nAbstract Dysphagia nodi ventriculi, in English, is the term used for a lump or knob on the posterior wall of the esophagus. It is predominantly asymptomatic, and most often is discovered incidentally on chest or abdominal radiographs, although chest computed tomography and laryngoscopy are preferred to rule out other clinical conditions. Here, we present the case of a 68-year-old non-tetraplegic man who suffered a hyperextension trauma to his cervical spine, which caused spinal cord injury, loss of cerebral and cerebellar functions, and impairments to both vision and proprioception. Over the course of 4\u2009years, the patient received 17 hospitalizations due to frequent episodes of falling. After the hospitalizations, the patient displayed episodes of gastroesophageal reflux, dysphagia, and dysphonia. Eventually, the patient was referred to an otorhinolaryngologist and a gastroenterologist. After a diagnostic workup to rule out other clinical conditions, a radiologic study identified a mass near the esophageal lumen. The patient underwent a gastroscopy with a biopsy for pathological review and immunohistochemistry, which revealed a gastric-type leiomyosarcoma. After the surgical procedure, the patient received postoperative chemotherapy. At 40 months after the procedure, the patient remained alive. The objective of this case is to add to the literature further evidence of an extracranial-originated leiomyosarcoma that can be related to a history of long-term recurrent traumatic falls and to highlight the importance of a multidisciplinary approach to medical care among individuals with cervical disorders.<EOD> Is GDF15 a useful biomarker for predicting the prognosis of colorectal cancer?\nThe Growth Differentiation Factor 15 (GDF15) was identified as the newest member of the transforming growth factor-\u03b2 (T",
        "label": 0
    },
    "828": {
        "output": "You do this in the last line to avoid having multiple outputs one after another.\n\nIn the following, examples using pseudocode is shown in detail:\n\n## Pseudocode:\n\n* [//Instructions] \n\n```python\ninput = raw_input('Input a note: ')\nnote = input\nj = 0\ni = 0\n\n\n\nwhile j <= len(note): \n    #if word1 \n    if [note] == [\"1\"]: \n        output = 'Excluded'    \n        j=j+1 \n        i=i+1 \n        #if word2 \n    if [note] == ['2']: \n        output = 'Not relevant'    \n        j=j+1 \n        i=i+1\n        #if word3 \n    if [note] == ['3']: \n        output = 'Eligible'    \n        j=j+1 \n        i=i+1\n        #if word1, word2 \n    if [note] == {[\"1\", \"2\"]}:\n        output = 'Eligible'    \n        j=j+1 \n        i=i+1\n    #if word1, word1, word2, word3 \n    #if [note] == [\"1\", \"2\", \"3\"]:\n        output = 'Eligible'    \n        j=j+1 \n        i=i+1 \n    #if word1,word2, word3, word4 \n    if [note] == {\"1\", \"2\", \"3\", [\"1\", \"2\"]}:\n        output = 'Eligible'    \n        j=j+1 \n        i=i+1  \n    #if word1,word2,word3,word4,word5 \n    if [note] == {[\"1\", \"2\", \"3\", [\"1\", \"2\"]]:\n        output = 'Eligible'    \n        j=j+1 \n        i=i+1\n    #if word1,word2,word3,word4,word5,word6 \n    if [note] == {\"1\", \"2\", \"3\", [\"1\", \"2\"], [\"1\", \"",
        "label": 0
    },
    "829": {
        "output": "[fig]  [INST]: A: [C] [I] [L] [N] [S] [T] [G] [O] [E] [U] \u00a9 2022 Institute of Electrical and Electronics Engineers Inc. \u00a9 2022 IEEE International Conference on Health Informatics (ICHI) . DOI: [M] Doi: [R] [F] [E] [R] [F] [I] [R] [F] \u00a9 2022 IEEE International Conference on Health Informatics (ICHI) . DOI: [M] doi: [R] .[M] doi: [R] . [/fig] \n[table]  70: [I] 96 [L] 60 [E] 52 [A] 29 [B] 24 [F] 22 [T] 57 [C] 30 [G] 61 [U] 41 [H] 90 [M] 35 [K] [/table] \n<EOD> .\nThe authors report a rare case of intussusception in a newborn of 9 days old with gastric hypertrophy, in which no cause could be detected and the infant died 7 days after operation. The various theories for the mechanism of intussusception in newborn, in particular those of malposition of anatomical structures and an abnormality in the process of intestinal peristalsis are reviewed. As far as the authors are aware of, this would appear to be the first case of isolated ileocolic intussusception in the 9 days old neonate with associated gastric hypertrophy, reported in literature and it certainly gives to the authors interest to speculate on the mechanism of these two apparently unrelated conditions.<EOD> The role of the immune system as a tumor promoter.\nA chronic inflammatory state that is induced by a viral infection or by a chemical substance can potentially lead to development of cancers or other diseases. Inflammatory cytokines may induce the over growth of cancer cells or they might induce the generation of cell types that promote tumor growth or suppress antitumor responses.<EOD> Neuroprotective Effect of Caffeo",
        "label": 0
    },
    "830": {
        "output": "Explanation about the usage of the code.\n\n**1. Assignment of variables.**\nIn the notebook_2_assignment_variables.ipynb, we made three types of variables about the patient, which are the following:\n\n|    Variable Name     |   Descriptions                     |\n|:--------------------|:-----------------------------------|\n|    patientnote      |  This module has your patient note with more details.             |\n|           patientnote    |    In the `Patient' class, the instance variable `patientnote` holds the patient note you submitted.            |\n|                        patientnote                    |                                        |\n|           patient_disease    |    In the `Patient_disease' class, the instance variable `patient_disease` holds all the disease and history data about             |\n|                        patient_disease                    |                                        |\n|         variables          |    The instance variables of `patientname`, `personal_history`, `living_region`, `worked_region`, `blood_profile_note`, `gender`, `age`, `body_temperature`,             `pain_score`, `personal_information`, `systolic_blood_pressure`, `diastolic_blood_pressure`,           `pulse_rate`, `smoking`, `alcohol_drinking`, `history_of_disease`, 'history_of_chemotherapy', 'history_of_diuretic_medications', 'history_of_steroid', 'history_of_antibiotics', **`history_of_antidepressant', `history_of_anxiolytics`, `history_immunosuppressant`, `body_mass_index`, `bodyweight`, `height`, `surgical_treatment`, `'surgery_history', `hospital_location`, and `hospital_date'.            |                                        |\n|                        variables                     |\n\nIn the notebook_2_assignment_variables.ipynb, we made one type of variables about the patient data including body temperature, laboratory data, gender, smoking, alcohol consumption, drug history, and so on. This data is stored in the",
        "label": 0
    },
    "831": {
        "output": "This is the final output that should appear in the trial-level eligibility line, e.g., [Instructions]:\n[formula]  Patient ID: 754136036311 Trial-level eligibility: 0) Excluded Trial-level eligibility: 1) Excluded Trial-level eligibility: 2) Excluded Trial-level eligibility: 2) Elgible [/formula] \n## Exercise 2\nAs a clinical study assistant, your task is to determine patient eligibility for recruitment into a trial for the treatment of hypertension. \nThere are three main data elements you need to consider: age, systolic blood pressure (SBP) \u2265 139 and < 200 mmHg, and pregnancy status. Here are the characteristics of the trial:\nAge: The trial enrolls adult participants aged 20 to 65\u00a0years.\nSBP: The participants should have a measured SBP of > 139 and < 200 mmHg.\n\nParticipants who have chronic kidney disease due to diabetes, liver cirrhosis, or kidney disease due to chronic alcohol consumption.\nParticipants who are currently using antihypertensive drugs.\nParticipants with abnormal blood pressure that does not return to normal after an interval of at least six hours (a second blood pressure measurement).\nYou should make a trial-level eligibility on each participant for the trial, i.e., output the scale Trial-level eligibility for the assessment of eligibility.\nHere is the patients' note:\nA 35-year-old woman presents with hypertension. The patient has a family history of hypertension. Previous blood pressure was 150/100 mmHg, and fasting blood sugar was 140 mg/dL.\nA 62-year-old man presents with hypertension. The patient has a family history of diabetes. Previous blood pressure was 170/90 mmHg, and fasting blood sugar was 200 mg/dL.\nThe patient reported no use of antihypertensive medications",
        "label": 0
    },
    "832": {
        "output": "[[INST]] Hi all! You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient's notes and a clinical trial's patient eligibility criteria to find any similar traits between the  two sources to make a judgment and a final judgement, to decide whether to recruit this patient for clinical trial or not.\n\nIn this case, you should check whether the patient in the notes is eligible for the clinical trial according to the inclusion criteria of the trial. So, you should assess the patient's eligibility with the patient note (and the information above) and the clinical trial's information, for example, age, gender, the type of a disease, previous treatment history, etc. If the patient is eligible according to the clinical trial inclusion criteria (after the examination), you should output `Yes` (1) in the case section and `No` (0) in section 'not a case for trial'. If the patient in the patient notes was not eligible following the inclusion of age, the gender, the type of the disease and the type of the treatment history, you output the 3-level scale for the assessment of eligibility and a final judgement. If the final judgement is `1`,  you should output `Not a case for trial` at the end.<EOD> A Review of the Phytochemistry, Pharmacology, and Toxinology of Lomatogetone: A Traditional Chinese Medicine\n\nCitation: Zhou, B.; Ma, J.; Guan, Y.; Zhang, M.; Yan, W.; Yang, Z.; Liu, X.; Yan, X.; Li, H. A Review of the Phytochemistry, Pharmacology, and Toxinology of Lomatogetone: A Traditional Chinese Medicine.Plants 2023, 12, 305. https:// Abstract: Lomatogetone, also known as Loma citrina, Cibotia barometz, or Bai-sheng, belongs to the Lauraceae family and has been widely used to treat various bacterial and fungal diseases; meanwhile, the species is also used in human and veterinary traditional medicine. Herein, we have described the chemical components, the ph",
        "label": 0
    },
    "833": {
        "output": "You should always repeat the patient's eligibility in one line and the trial eligibility in the last line. If you don't remember what you did, just restart the demo (above this paragraph).\n<EOD> Association of the B4GALNT2 Gene with Body Weight in Children\nGenome wide association studies have identified multiple loci within the human genome that are associated with obesity and obesity-related phenotypes. Obesity is one of the major risk factors for coronary events. We analysed 9 tag SNPs (tSNPs) in a candidate gene, B4GALNT2, that has been proposed as a gene responsible for type 2 diabetes, and showed a relationship with total cholesterol and apolipoprotein B levels. The association of B4GALNT2 with total cholesterol and apolipoprotein B may be mediated by the increased body weight and body mass index of carriers of B4GALNT2. The aim of this study was to examine whether B4GALNT2 is associated with body weight and body fat mass in children. We used allele specific PCR analysis to determine the genotypes of all of the tSNPs. Genotype distribution was in Hardy\u2013Weinberg equilibrium. A total of 221 unrelated Korean children were genotyped for nine tSNPs (rs673991 AA/GA, rs740796 CG/GG, rs7781802 AA/AG, rs1326049 TT/TG, rs2268518 TT/TC, rs9206580 AA/AG, rs7619244 AA/AG, rs2243397 CT/CC, and rs2296349 AC/CC). Total fat, percent fat, height, weight, and body mass index were determined for all the subjects. Two representative SNPs (rs7781802 and rs1326049) showed a significant association with body weight and percent fat. This suggests that B4GALNT2 is associated with both body weight and body fat mass in children. We believe that rs7781802 and rs132",
        "label": 1
    },
    "834": {
        "output": "##\n\n# Related Work\n\nOur approach can be categorized as a rule-based system. Rule-based systems have been widely used in the clinical decision support system because they are capable of reasoning over a set of rules in order to perform an action or to make a decision.  In this paper, we used the semantic web technology, OWL and ROBOT, to represent our rule-based system. \nEvaluation measures for the semantic Web, OWL and ROBOT are generally lacking (see [fig_ref]  Table 1: Evaluation criteria for semantic Web, OWL and ROBOT [/fig_ref] . \nSince our goal is to develop a decision-support system for clinical trial study, we evaluated our approach primarily from the perspective of a human expert's decision. We did not investigate whether our approach is efficient or effective compared with other data mining technology in clinical trial study or evaluation of patients' eligibility.\n\n\n\n![](Figures_in_Review/eligibility_decision_making_with_owl_class.png) \nAn example of our OWL class modeling approach.\n\nHere are some related works: \n- Evaluation of OWL ontology reasoning tools. A number of articles evaluate the performance of OWL ontology reasoning tools in various ontology-based applications. \n-  The semantic web technologies have been applied to many biomedical subdomains in recent years. There are some studies evaluating the semantic web technologies in terms of OWL ontology reasoning efficiency and accuracy. \n-  The OWL RL ontology rule engine (RORE) is a knowledge-based system (knowledge-based engine) for making decisions in rule-based reasoning systems based on OWL ontologies in the clinical domain. \n-  The RORE is also an ontology management system that manages a set of ontologies and reason over the ontologies. \n-  The RORE also has a set of knowledge-based modules that use the inferred knowledge stored inside the RORE knowledgebase for making decisions. \n-  A decision-making method using OWL for medical data. They employed the OWL-DL (Web Ontology Language Description Logic) as the logical language. They showed the effect of a semantic Web ont",
        "label": 2
    },
    "835": {
        "output": "## \u2714\ufe0f A: If you think that you passed all the tests and you want to pass the exam, please press [submit] below. Otherwise, press one of the buttons below.\n[INST][X]: Close\n[INST]: Insufficient\n[INST]: Failure\n[INST]: Unable to reach the internet. Please retest later.\n[END]: You passed! \n\nYou can share and bookmark this page as any other page on [idrlog.com].<EOD> Rituximab-containing chemotherapy in the treatment of follicular lymphoma: a meta-analysis.\nThis meta-analysis was performed to compare different first line chemotherapies of indolent non-Hodgkin lymphoma (iNHL), including the FCR, chemoimmunotherapy, CHOP, R-CHOP. This meta-analysis searched the Cochrane Library, Pub Med, EMBASE database and included 14 trials. Four studies were excluded on account of data repetition and publication bias occurred. Then included 10 trials with 12 groups consisting of 2752 patients. The results of this meta-analysis showed that rituximab-containing chemotherapy significantly improved complete response rate (CR), including remission rate for follicular lymphoma (FL), in comparison to chemotherapy without rituximab. In addition, rituximab-containing chemotherapy significantly improved overall response rate (ORR), event free survival (EFS), disease-free survival (DFS), and 3-year survival rate. Rituximab-CHOP and R-FCR significantly improved DFS. On the other side, the adverse events were evaluated in this meta-analysis, including febrile neutropenia, grade 3-4 neutropenia, and severe infections. The adverse events were not significantly increased in rituximab-containing chemotherapy in induction and maintenance treatments. In summary, the addition of rituximab to chemotherapy improved CR, ORR, EFS, DFS and survival in patients with iNHL. It is significant to apply rituximab-containing chemotherapy in the treatment of iNHL. However, this meta-analysis has several limitations, and therefore future studies with larger patient",
        "label": 1
    },
    "836": {
        "output": "# Conversion from python to R\n\nHere we write the conversion command: r_command <- paste0(\"xeligible_trial = rbind(list_patient_note, list_trial)\"; paste0(\"xeligible = (sum(xeligible_trial$Trial-level eligibility == 2) );\"); #print(xeligible)\n<EOD> Surgical anatomy of aortic arch vessel variations\nObjective: To characterize the range of aortic arch vessel variations and define standard surgical approaches to these vessels for the open and endovascular aortic surgery.<EOD> Diagnostic accuracy of the CBC24: A composite measure of health in the UK biobank and the UK health and retirement survey\n\nObjective: To assess the diagnostic accuracy of the CBC24 as a composite measure of health in two large UK cohorts. Introduction: Researchers often use a combination or aggregation of health indicators to create a single measure of the overall health of individuals. Aggregation is especially common in medical research and geriatric care. Although there are various methods for creating such indices, existing measures of general health often do not perform well in identifying clinical outcomes. Methods: In this cross-sectional study, we evaluated the diagnostic accuracy of the CBC24 in the UK Biobank and UK Household Longitudinal Study (UKHLS), which measures an individual's overall state of health. Diagnostic accuracy metrics, including receiver operating characteristic curves, sensitivity, and specificity, were used to assess the performance of the CBC24 in discriminating individuals with and without self-reported chronic conditions and mortality status for both cohorts. Results: Across both cohorts, the CBC24 performed comparably or better than more complex indices in distinguishing health versus poor health and in predicting mortality using self-reports of chronic conditions. While accuracy was lower for the more comorbid UKHLS sample, results were also somewhat lower even when analyses were restricted to the non-CBC24 components. Nevertheless, the CBC24 continues to demonstrate better performance relative to its individual components and other measures. Conclusions: Given these results, the CBC24 will be a useful predictor of mortality and chronic",
        "label": 0
    },
    "837": {
        "output": "Copyright statement: Copyright \u00a9 Springer Business Media\n[INST] \nReferences: \n<EOD> Association of Serum Uric Acid With Left Ventricular Hypertrophy and Diastolic Dysfunction in Patients With Primary Aldosteronism\nJ Clin Hypertens (Greenwood) 2013;15:635\u2013642. \u00a92013 Wiley Periodicals, Inc.<EOD> The role of the mitochondrial respiratory chain in the induction of drug resistance in ovarian cancer cells\n\nDrug resistance remains a significant obstacle in the successful treatment of ovarian cancer patients. The mechanisms of acquired drug resistance are varied and, as such, can be difficult to predict or to block. The emergence of drug-resistant cells in ovarian cancer, and other diseases, can be associated with various genetic changes including mitochondrial genome alterations, which contribute to the enhanced drug resistance in human cells that harbor multiple genetic mutations and/or polymorphic sequences. Here, we analyzed the role of the mitochondrial respiratory chain (RC) in regulating the cellular sensitivity to platinum-based chemotherapeutics in two human ovarian cancer cell lines. The study revealed that inhibition of the mitochondrial OXPHOS with small molecules can partially sensitize drug resistant ovarian cancer cells to cisplatinum. Our data indicate that inhibition of the NADH-quinone oxidoreductase (NDUFV1), the complex I of the RC, is the most effective approach to reduce cell viability in ovarian cancer cell lines. In contrast, the knockdown of mitochondrially located proteins targeting complexes II-V did not significantly affect the sensitivity of ovarian cells to platinum-based drugs. Collectively, these data indicate that inhibition of the RC may be of therapeutic benefit in ovarian cancer patients, and suggest that the RC is a promising target to overcome cisplatin-based chemotherapeutics resistance.\n\n## Findings\nOvarian cancer is a leading cause of female death and the leading cause of death among all gynecologic tumors. Platinum-based",
        "label": 0
    },
    "838": {
        "output": "# Output\nHere is the command-line output of the script:\n[INST] Running script: /home/sjung/Work/clinical trial/clinical trial2.sh\n[INST] Processing 1 patient, please wait.\n[INST] Comparing the patient's LDL-C 545 and 160.5 to 12.36 mmol/L, 190 mg/dl, indicates that the patient meets the inclusion criterion of lipid levels \n[INST] Comparing the patient's HDL-C 53 and 1.100 mg/dl with 40 mg/dl, 1.170 mmol/L, indicates that the patient meets the inclusion criterion of lipid levels for HDL-C \n[INST] Comparing the patient's glucose and 218 mg/dl with 140 mg/dl, 7.80 mmol/L, indicates that the patient meets the inclusion criterion of glucose \n[INST] Comparing the patient's triglyceride and 158 mg/dl with 150 mg/dl, 1.70 mmol/L, indicates that the patient meets the inclusion criterion of triglyceride \n[INST] Comparing the patient's neck auscultation 3+/6+ to 0 indicates that the patient meets the inclusion criterion of no serious cardiac murmur \n[INST] Comparing the patient's carotid artery 50% to (b) indicates that the patient meets the inclusion criterion of no severe stenosis \n[INST] Comparing the patient's carotid artery 218.5 cm/s to (b) indicates that the patient meets the inclusion criterion of no maximum aortic velocity of >400 cm/s \n[INST] Comparing the patient's carotid artery max PSV 91.72 cm/s to max PSV cutoff of 200 cm/s indicates that the patient meets the trial-level inclusion criterion of plaque \n[INST] Comparing the patient's carotid artery EDV 37.37 cm",
        "label": 1
    },
    "839": {
        "output": "<EOD> The relationship between the quality of life of the caregivers and the quality of life of the elderly\n\nBackground/aim: The objective of this study was to evaluate the relationship between the quality of life of the caregivers (CG) and the quality of life of the elderly (EH) whom they care.Materials and methods:Study consisted of a total of 231 CG and 170 EH, including the caregivers of elderly who live at home. Socio-demographical and clinical features of the CG and EH were recorded during the interview by personal information form. Care burden levels were determined using the Turkish version of the Zarit Burden Interview (ZBI) Scale. Quality of life was evaluated using the World Health Organization Quality of Life Scale.Results: In this study, 68.6% of caregivers were women, and 31.4% were men. The ages were 33-87 years, with a mean age of 62.67 \u00b1 12.38 years. Of the CG, 90.7% were spouses, 4.3% were children, and 4.1% were other relatives. Quality of life of both the caregivers and the elderly significantly decreased with the care burden and was significantly correlated with their relationship status. The quality of life scores of the CG showed a significant correlation with the ZBI scores, and the quality of life scores were evaluated.Conclusion:The results of this study indicated that the quality of life of the CG as well as the EH whom they care is significantly decreased by increasing the care burden. In addition, the quality of life of the CG, who cared for their elderly relatives, was affected by the quality of life, severity of the care burden, and the relationship between them. For this reason, the health and needs of CG whose quality of life is negatively affected should be supported, and social intervention should be made to reduce the care burden.\n\n# Introduction\nTurkey, like many countries, is in a period of unprecedented development and demographic transformation. While the increase in life expectancy is a positive phenomenon in developing countries, the rapid increase in the elderly population is the most important demographic issue in the world today, and the most developed",
        "label": 0
    },
    "840": {
        "output": "__References__\n<EOD> Effect of exercise-induced muscle damage on neuromuscular performance: a brief review\n\nIntroduction: After a high-intensity muscular activity (HIMA), an intense muscle damage appears and persists for a short or long period of time, depending of the type, intensity and duration of HIMA, and it is reflected in neuromuscular fatigue. Aim of this review is to analyze the effect of muscle damage on neuromuscular performance. Methods: A review of the literature was conducted and a total of six databases were searched (PubMed, Medline, Cochrane, Pedro, Embase and SPORTDiscus). All articles written in English and Spanish related to the effect of muscle damage on neuromuscular performance were considered. Included studies must meet three essential criteria: (1) intervention involved exercise (or not); (2) participants were sedentary or engaged in regular exercises that could not influence the results of the study; and (3) the main outcome of interest was the assessment of muscle damage and neuromuscular performance. Results: We found that muscle damage seems to negatively affect the neuromuscular performance after the HIMA. Conclusions: The performance of the HIMA does not seem to be related to the magnitude of muscle damage, but to the recovery of the damaged muscle fibers in order to improve muscle function for further muscular performance.\nResumen. Palabras clave: Neuromuscular performance. Muerte muscular. Efectos del ejercicio intensivo en los m\u00fasculos.\nIntroducci\u00f3n: Despu\u00e9s de una actividad muscular muy intensa (HIMA), una intensa lesi\u00f3n muscular aparece y se prolonga durante un corto o largo periodo, dependiendo del tipo, intensidad y duraci\u00f3n de la HIMA, reflej\u00e1ndose en la fatiga neuromuscular. El objetivo de esta revisi\u00f3n es analizar el efecto de la lesi\u00f3n muscular sobre la percepci\u00f3n de la neuromuscular. Metodolog\u00eda: Se realiz\u00f3 una revisi\u00f3n de la literatura y se analizaron un total de seis bases de datos (PubMed, Medline, Cochrane, Pedro, Embase y SPORTDiscus). Se consideraron los estudios escritos en idioma ingl\u00e9s o cast",
        "label": 1
    },
    "841": {
        "output": "[MOD] Use the following Python function if you must implement your own module instead of installing it as a package. \n\n```\ndef clinical_trial_eligibility(note):\n    '''\n       Return trial-level eligibility from patient note\n    '''\n    # ...\n    return Trial-level eligibility\n```\n\n\n\n\n<p align=\"center\">\n<img src=\"https://raw.githubusercontent.com/pysafety/PYSAFETY/master/instructions/Pictures/python_notes_instructions/6_clinical_trial/5.png\">\n</p>\n<p align=\"center\">\n  <small>\n    <br>\n  </small> \n<p align=\"center\">\n  <small> \n  <br>\n</small> \n    \n<EOD> A retrospective cohort of 100 patients with COVID-19 infection in a low prevalence area in the Netherlands\n\n\n[fig]  Figure 1: (A) ROC curve for age (area under the curve [AUC]: 0.89 [95% CI; 0.82-0.96]), (B) ROC curve for C-reactive protein (CRP; 0.79 [0.67-0.91]) and (C) ROC curve for D-dimer (0.80 [0.70-0.90]) to predict mortality of the patients with COVID-19Fig. 2. Kaplan-Meier curve for mortality, for the different age groups and the cut-off value of 20.5 ng/mL for CRP and 900 ng/L for D-dimer. Data points were censored when patients lost follow-up before admission. [/fig] \n<EOD> Phenotypic and genotypic analyses of Campylobacter, Escherichia coli, and aeromonads isolated from a raw milk cheese\nSUMMARY The presence of Campylobacter, Escherichia coli, and aeromonads in different bricks of a raw milk cheese made from raw cows' milk was investigated in December 2012 and August",
        "label": 1
    },
    "842": {
        "output": "The assessment of risk and disease factors and their values for the patient have been calculated in the second and third steps. The assessment is automatically summarized in the first step so that you can see in the first step which values of the different risk factors in the patient are associated with the patient\u00b4s probability and eligibility.\n\nHere is how it looks like: \nThe patient note is 0.8 points below the trial-level eligibility threshold in this trial.\nFor each trial, we give you all the patient-level assessment of risk and disease factors and their values for the patient, as well as an overall trial-level assessment. The trial-level assessment in this trial is shown below.\n\n![trial-level summary table](https://raw.githubusercontent.com/kaggle/machinelearning-bootcamp/master/images/MIB-MLE_challenge_part2.ipynb.pdf)\n\nThe red lines represent the trial threshold values. Our patient meets all the criteria of the trial. He gets the maximal value in the last line in the table:\n\n\nIn addition, the patient note shows a very similar overall score: \n\n![Overall score](https://raw.githubusercontent.com/kaggle/machinelearning-bootcamp/master/images/MIB-MLE_challenge_part2.ipynb.pdf)\n\nThis is important to help us to understand what the final score is composed of. Our patient is quite similar to the overall score in the trial. Thus, both the patient and the trial are comparable.\n\n# Conclusion\nThis challenge is about evaluating a patient note from a cohort and decide whether this patient is eligible for a clinical study. We trained the classification model on a large amount of patient notes to automatically learn from the data. The model uses a simple classifier which combines the input variables of the patient note to one value. Thus, the final score we create for each challenge is a combination of all the values of these factors:\n\n## Suggestions\nPlease let us know which suggestions you had for the patient note and the eligibility score to get better in the future. Did you have any difficulties which we could help to solve? Please tell us!\nWe will take this into account when developing the next version of the MIB/MLE.",
        "label": 1
    },
    "843": {
        "output": "### Example\n#### A 24-year-old male with a family history of CAD presented to the emergency room in the setting of fever and chills. His vitals were notable for a heart rate of 91.  Fever and chills began the prior night and were associated with a cape with fever followed by a sore throat and cough. He denied chest pain or associated symptoms. Erythema and swelling were present on the tip of his tongue. He was unable to get to sleep due to worsening sore throat and cough. He felt that his voice was changing. His medical history is notable for non-toxic acute ingestion of ibuprofen 8 hours prior to presentation. Past surgical history was unremarkable. Social history was significant for no tobacco use but approximately 3 drinks per day.  He was previously seen in the primary care clinic 9 days ago for a similar viral syndrome with sore throat and fever. There, she was started on azithromycin and acetaminophen and advised to follow up with her primary care provider.\n<EOD> The Drug Candidate for the Management of COVID-19 Cases: Is It Worthy in India?\n\nThe Drug Candidate for the Management of COVID-19 Cases: Is It Worthy in India?\nNov-Dec 2020The Drug Candidate for the Management of COVID-19 Cases: Is It Worthy in India?\nAnn Indian Acad Neurol Ann Indian Acad Natl Med Coll\n236Nov-Dec 202010.4103/aian.AIAN_1084_201\nCorpus callosum, cingulate cortex, and cuneus (visual cortex) has been more affected in acute disseminated encephalomyelitis than other white matter and cortical areas. [bib_ref]  Regional differences in acute disseminated encephalomyelitis: A magnetic resonance imaging-based study, Col [/bib_ref]  The main neurological symptom in children with COVID-19 was encephalopathy. [bib_ref]  Neurologic and radiographic findings associated with COVID-19 in",
        "label": 0
    },
    "844": {
        "output": "##### 4 The trial note\n\n[IN] The investigators want to analyze results of previous RCT and explore the efficiency of carotid artery stenting and carotid endarterectomy on patient eligibility of clinical trial of carotid artery stenting or carotid endarterectomy. Designing a RCT trial to prove the effect and safety. The clinical data is used to explore the patient's clinical characteristics and to explore the impact of plaque and vascular stenosis on patients' eligibility.\n[/IN]\n\n##### 5 Other clinical trials\n\n![]()\n\n### A) Data preparation\n\n### a.1. Raw Data for the Training of 610 Patients and 61 Clinical Trials\n\n![](./Images/fig2418a.png \"Data Preparation\")\n\n\n\n### a.2. Data Cleaning\n\n![](./Images/fig2418b.png \"Data Cleaning\")\n\n\n\n### a.3. Clinical Trials\n\n### a.4. Patients\n\n##### a.4.1 Preprocessing\n\nTrial Note (optional):\n\n```\nInclusion criteria:\n- Stable angina patients who meet the diagnosis criteria of AHA of coronary artery(coronary heart disease)(CHD) according to GENERAL and/or local guidelines with objective evidence of myocardial ischemia;\n- Able to exercise 8-12 minutes on a bicycle exercise test or an equivalent treadmill stress test;\n- LVEF >35% and a maximum LVEDP < 15mm Hg as determined by right heart catheterization with measurements at end cardiac systole.\nExclusion criteria:\n- Acute myocardial infarction <8 weeks;\n- Coronary artery bypass grafting <6 weeks;\n- Left ventricular aneurysm requiring surgical repair;\n- Surgery <6 weeks;\nAge <18 years or >75 years;\n- New York Heart Association Class III-IV or Killip Class III-IV heart failure of non-ischem",
        "label": 1
    },
    "845": {
        "output": "[BACK]\n[CLOSE]\n[/CLOSE]<EOD> .\nBACKGROUND AND PURPOSE\nProliferative vitreoretinopathy (PVR) is a severe complication in rhegmatogenous retinal detachments (RRD). There is still no clear definition of the course of PVR. There are basically two clinical forms: the fibrosis and the traction types. Many studies describe the results of surgical correction of RRD, but there is little known about the natural course of PVR and RRD. The aim of the present study was to evaluate the natural course of PVR and RRD over a 5-year period.\n\n\nPATIENTS AND METHODS\nIn a prospective, observational study from 1995 to 1999, 31 eyes of 30 patients with diagnosis of PVR were included. All patients were initially treated surgically and were followed for at least 5 years. The study was designed to identify prognostic risk factors that may influence the outcome.\n\n\nRESULTS\nOutcome events were defined as the combined incidence of new retinal detachment and persisting vitreoretinal contractions. Prognostic risk factors were identified: young age, poor initial PVR classification, preexistent severe ocular disease, and macular damage.\n\n\nCONCLUSION\nIn view of the natural course of PVR and RRD, our data suggest that young patients, patients with a poor initial PVR classification, preexistent ocular disease and macular damage should be informed about the risk of retinal re-detachment and vitreoretinal contractions postoperatively. This should enable patients to decide early on whether they want to undergo a second operation for retinal re-attachment.<EOD> .\nA case of successful coronary reimplantation (CRA) was reported. This was a 55-year-old-man with Kawasaki disease who has undergone coronary artery bypass grafting (CABG) in 1994. Two main coronary arteries were completely occluded from the ostium to the orifice with the dilated and thinned posterior descending artery",
        "label": 1
    },
    "846": {
        "output": "Please submit your solution using the Submit button at the bottom of the page.\nSadly we need to tell you that this challenge will not be continued. We will offer a new challenge for you soon!\nPlease submit your solution and see if you and other participants made a correct choice. If more people got it right than the average for this challenge, you deserve a virtual badge!\nSadly we need to tell you that this challenge has ended. If you're in a competition, you still have time to compete! There is still time to go for it!\n<EOD> .\nThis is a case report from a 76-year old woman, with a 5+3 years history of psoriasis, which developed a tumor-like verrucous growth on the forehead, of which biopsies showed psoriatic skin. She was referred for surgery, where the diagnosis of xanthogranuloma (an uncommon non-neoplastic disorder of unknown origin) was made. It is of particular clinical interest that a verrucous growth developed on the forehead of a psoriatic patient.<EOD> Rhabdomyoma of the Tongue: A Case Report\nA rare case of a 1-year-old boy diagnosed as having a glossoepiglottic rhabdomyoma is reported. The patient had been submitted to an adenotomy when he was 3 years and 9 months old because of a laryngeal mass, which had been misdiagnosed as a tonsil. The patient was again studied by ENT and an abdominal computer tomography (CT), and was then taken to surgical excision. The excised mass was evaluated histopathologically. The report discusses, among other points, the possible origin of the epiglottis and/or the glossoepiglottic fold as the source of the tumor.<EOD> The Impact of Anorexia Nervosa on Bone Metabolism in Young Women\nAbstract: Bone mass deficits have been widely described in anorexic patients, especially in those with the eating disorder for many years. Bone mass at the hip appears to be better preserved than at the spine. Fat mass has been shown to be an important determinant of bone mineral content in patients with",
        "label": 0
    },
    "847": {
        "output": "<EOD> Highly regioselective arylation of amines, heteroarenes, phosphines, silanes, alcohols and carboxylic acids with aryl halides.\nA method for regioselectively arylating a broad range of organic compounds (amines, heteroarenes, phosphines, silanes, alcohols, carboxylic acids, etc.) with aryl halides in the presence of triphenylphosphine was developed.<EOD> Risk Factors of Dental Caries with Special Reference to Caries-Prone Groups as Seen in an Unorthodox Community in North Malaya.\nDental caries in any population group is a multifactorial disease, as a result of metabolic, social, dietary, hygienic and psychological factors. Different groups such as children, pregnant mothers, diabetics and the elderly are more prone to accumulate dental caries. An effort was made to evaluate the factors contributing to dental caries in a particular population group and determine their contribution to this disease. The study was conducted in the Nganasan and Selkup groups in Central Yakutiia and the Dolgano-Meriam and Selkuper in North Malaya, Russia for a period of one year from 2000 to 2001. Dental caries and other oral manifestations were evaluated and recorded in order to analyze the contribution of each risk factor. The present study highlights the different contributing factors, the role of psychosocial health on caries prevalence and the impact of cultural habits on oral diseases.<EOD> Sensing Tensile Stress in Single Nanowires\nSensitivity Sensors in the form of nanowires have important applications in biomedicine and biosensing, particularly for highly sensitive, miniaturized devices used in point-of-care testing applications. Xie et al. (p. 454) used a scanning electron microscopy technique to measure the change in the electrical resistance of bimetallic Zn (80 percent) Cu (20 percent) nanowires that was induced under an externally applied tensile stress. These nanowires exhibited a sensitive gauge factor of almost 30, more sensitive than bulk materials. Further increases in gauge",
        "label": 0
    },
    "848": {
        "output": "A: You would set eligibility to one or more values, and add an after script to give an appropriate flag.\n\n\n*\n\n*@echo off\n\nrem This script takes two parameters from the command prompt, so you need to\nrem modify the script to work on your environment.\n\nrem Example is for the command prompt \n\nset scriptCommand=runRICscript.exe\nset scriptFile=RICtrialscript.txt\n\nrem The next code will explain the main features of the script runRICscript.exe\n\nrem The script runRICscript.exe looks for a value called Trial_ID in the header\nrem of the .txt file to be able to associate the value it with the .csv file generated.\n\necho Enter the Trial ID: %Trial_ID% &\nset trial_id=%Trial_ID%\n\nrem The file Trial.xml is located in the current directory, and the script verifies\nrem that it exists. If the file Trial.xml does not exist, it will create it.\n\necho Enter the Trial ID: %Trial_ID% &\nset trial_id=%Trial_ID%\n\nrem The script verifies the location of the file to be analyzed, and if it does not\nrem exist, it builds the path with the directory that will be analyzed.\n\necho Enter the Trial ID: %Trial_ID% &\nset trial_id=%Trial_ID%\n\nrem The script sets a variable with the value of the directory that will be passed\nrem as an argument as TrialDirFile in the script runRICscript.exe.\n\necho Enter the Trial ID: %Trial_ID% &\nset trial_id=%Trial_ID%\n\nset TrialDirFile=%C:/Users/Uberaba/ProgramaPython/Trial/Trial1/Trial01\n\nrem The script sets a variable with the directory of the folder with the patient\nrem files that will be analyzed.\n\necho Enter the Trial ID: %Trial_ID% &\nset trial_id=%Trial_ID%\n\nset TrialPatientDir=%TrialDirFile%\n\nrem The script sets a variable with the path name of the file .txt",
        "label": 1
    },
    "849": {
        "output": "[/MARKUP]\n\n\n\n\n<EOD> Folding a novel peptide by single-molecule force spectroscopy.\nThe folding pathways of proteins and peptides are not fully understood. Atomic force spectroscopy (AFS) is known to reveal the dynamics of the unfolding and refolding of unfolded proteins. However, in AFS of proteins, it is hard to find the detailed mechanism of folding by pulling one end of single protein. In this study, we employed AFS to investigate the process of novel peptide folding by pulling the other end of the peptide while monitoring structural changes in real time. We show that a unique force-dependent pathway appears between 6 and 10 nN within the unfolding range of the peptide. The force-dependent pathway corresponds well to the intramolecular hydrogen bonding behavior determined through density functional theory. Moreover, we find that a new force-dependent path appears after the second force jump from 10 to 20 nN within the unfolding range of the peptide. This force-induced path is similar to the folding pathway determined by nuclear magnetic resonance experiments. These results demonstrate that AFS provides an alternative method to directly and quickly unveil the dynamic and complicated folding processes of a peptide.<EOD> A Case Report of Acute Nephrotic Syndrome Due to the Recurrence of Metastatic Colorectal Cancer With Pulmonary and Pleural Dissemination\n\nAcute nephrotic syndrome (ANS) has nonspecific clinical manifestations. We report a case of ANS induced by metastasized colorectal cancer. A 78-year-old male patient was diagnosed with diabetes 10 years previously, and his diabetic level was well controlled. His clinical manifestations were drowsiness, edema of both lower extremities and a swollen chest after he received two cycles of chemotherapy and targeted therapy for rectal cancer. His serum albumin (Alb) was 0.86 g/dL. Total protein, cholesterol, uric acid, serum creatinine (Scr), and serum cystatin C (SCC) levels were greater than the",
        "label": 0
    },
    "850": {
        "output": "Tutorial video to submit a file: [URL]\nTutorial video to modify a file: [URL]<EOD> Conventional Suture for Tendon Repair Results in Abnormal Morphology and Functional Behavior: A Rabbit Patellar Tendon Defect Model\n\nThe aim of this study was to provide physiologic insight to the current understanding of the pathologic findings following tendon repair on the basis of morphology, biomechanical property, histopathologic features, and gene expression, and to reveal the potential effect of conventional suture and augmentation on the tendon repair. Twenty-four knees of Chinese rabbits were randomly assigned to one of four groups: (1) normal, (2) patellar avulsion control (AC), (3) suture repair (SR) with a suturing configuration of 2-3-0 Vicryl in cruciate fashion, and (4) augmentation repair (AR) with a suturing configuration of 2-3-0 Vicryl in cruciate fashion combined with high molecular weight (HMW) PG, in order of suture repairing. Knees from AC group were exposed to patellar tendon avulsion followed by no surgery for one month before sacrifice. All the remaining rabbits were treated surgically with a patellar tendon defect model. All rabbits were sacrificed for patellar tendon and patellar bone biopsies to observe the tissue morphology, mechanical behavior, and expression of tendon related genes. Both the rabbits in surgery group and the AC group had a similar tissue morphology. There were significant differences in the expression of collagen I, II, MMP-1, MMP-2, and biglycan, as well as morphology and biomechanical properties between the experimental group and the normal control group or the AC group. The suture repair technique has poor biocompatibility for tendon healing, leading to a series of disadvantages like abnormal morphology, lower biomechanical properties and abnormal regulation of tendon related genes. However, HMW-PG might potentially enhance the performance of suture repair tendon healing.\nIn the daily practices of sports surgeries, the use of sutures for tendon repair is widely accepted. Suturing",
        "label": 1
    },
    "851": {
        "output": "Closing:\nThe following code will close the session. You should call sess_close() after finishing all your changes. sess_close() is found on the Python library page. \nsess.close()<EOD> Effectiveness of vapourizing the skin (cryotherapy) in the treatment of genital verrucae due to molluscum contagiosum\nMolluscum contagiosum (MC) is a highly contagious, skin infecting pox-virus-related disease, which in immunocompetent patients is clinically benign but which is difficult to clear. It is therefore of interest to identify treatment measures which can be easily performed on an outpatients basis without causing excessive discomfort and in which complete clearance is achieved in the majority of patients with minimal recurrence. Vapourizing the skin (cryotherapy) is a simple, safe, rapid procedure, causing less discomfort than similar therapies. We report our experience using this technique in treating 26 cases of MC and compare this with the responses to other therapies.<EOD> Influence of Cigarette Smoking on Sleep Apnea Severity in the Apnea Positive Pressure Long-Term Efficacy Study (APPLES).\nSTUDY OBJECTIVES\nCigarette smoking and obstructive sleep apnea (OSA) are independently associated with important adverse health consequences. We sought to determine if smoking cigarettes was associated with OSA severity and changes in severity during long-term positive airway pressure (PAP) therapy.\n\n\nMETHODS\nWe performed a post-hoc analysis evaluating baseline smoking status and changes in apnea-hypopnea index (AHI) during long-term PAP therapy in a cohort of 648 participants in the Apnea Positive Pressure Long-Term Efficacy study (APPLES). There were 143 ever-smokers (non-smokers vs. ever-smokers) and 505 never-smokers.\n\n\nRESULTS\nIn univariable analysis, smoking duration and pack-years were not associated with OSA severity. In multivariable analysis, never smokers had an AHI 6.7",
        "label": 0
    },
    "852": {
        "output": "</section><h3><a href=\"/doc/cog/05-05-intro-to-cog/05-08-02-rec_pat.html\">Section 5.8: Generate recruitment criteria</h3>[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply)(In this paper, this step is performed by trial-level eligibility of the Clinical Trial (CTO))\n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the L",
        "label": 0
    },
    "853": {
        "output": "Note that any pre-prints or non-peer-reviewed \"versions\" of your article that you may have posted publicly on prepress servers should be taken down upon online publication of the final, peer-reviewed article.\n\n## Please see below for our manuscript checklist -the final manuscript files (text and figures) should match as closely as possible this checklist.\n\n## Title page\n\n## [inst] manuscript type: basic report\nTitle Page Manuscript Type (Please put N/A if it is not applicable)\n\n## Article category\n\n## Article type\n\n# [inst] abstract\nAbstract Please enter structured abstract according to the following items.\n\n# Introduction\nBackground (1)\n\n## Rationale\n\n## Objectives (1)\n\n# Methods\n\n# Introduction\nBackground (1)\n\n## Rationale (see above)\n\n## Objectives (3)\nStudy design -Setting\n\n## Study design -sampling\n\n## Study design -subjects 4\nStudy design -Sample size 6\n\n## Sample size justification 7\nStudy design -Protocol 8\nData analysis plan -Statistical methods -Plain language summary 9\n\n## Ethical approval and informed consent 10\n\n# Methods\n\n## Data collection process 11\n\n## Data collection tools 12\n\n## Procedures for data extraction 13\nData items 14 [fig_ref]  Table 1: The patient note. [/fig_ref]",
        "label": 1
    },
    "854": {
        "output": "2) Write `END.`: this means this is the end. [/EN].\n\n# The Assembler\nThe Assembler runs the Python code (the Assembler script) as a subprocess (child process) and returns the output to the Python library to be analyzed by the Assembler module. It is a Python script in the Assembler repository. The Assembler script contains all the information required to run the program correctly. \n\n## To run\nThe code to run the assembler script must be added to the following code.  \n```bash\nassembler.py <patient_note.json>\n```\n\n### The Input file\nThe input file contains the patient information, it is in JSON format. The user should select the patient he wishes to analyze from the file. \nAs the program is used for the patients' data, so it must be used inside the work folder. \nThe name of the input file can be changed to \"patient_note.json\" in the same working folder with the assembler script. \nIn an input file this information should be included:\n\n* Patient ID: a string with the patient ID\n* Gender: \"Male\" (when the patient is male) or \"Female\" (when the patient is female)\n* Age (the user can set the age in the input file to give the patient a fictitious age or a real age)\n* Patient_id: a string with the patient ID. \n* Name: patient first name\n* Surname: patient last name\n* Exclusion_status: the status of the patient in clinical trials (0=excluded, 1=not relevant, 2=eligible)\n* Ctrl_id: the ID of the controller. \nIf there is a controller that controls the work on all of the patients, it can be identified, giving its ID in the input file, with \"0\" in the ID column.  \n  `C_ID: 0` gives an ID of 0 to the controller, the user should not change this column\n  but he can create new controllers with \"C_ID: X\" where \"X\" is different from 0. \n  By default, the ID of the controller is \"0\", so it is not necessary to give a controller ID.",
        "label": 0
    },
    "855": {
        "output": "For more information on each data structure, please refer to the 'Help' and `docs` directories of the R package `clinical.trials`. \n\n\n``` r\nclinical.trials(trial=clinical, disease = \"Disease\", recruit = rep(FALSE, 50), subject=subject, disease.title = \"Disease\", disease.note = \"Brief description of Disease\", age_min = 18, age_max = 44, age.note = \"Brief description of Age\", gender.note = \"Gender description\", gender.m = \"Male\", gender.fm = \"Female\", recruit.status = rep(FALSE, 50), recruit.expose.type = rep(c(\"Inclusion criterion\", \"Exclusion criteria\", \"Inclusion criteria\"), 50))```\n\n\n``` r\nclinical.trials(trial=clinical, disease = \"Disease\", recruit = TRUE, subject = NULL, disease.title = \"Disease\", disease.note = \"Brief description of Disease\", age_min = 18, age_max = 55, age.note = \"Brief description of Age\", gender.note = \"Gender description\", gender.m = \"Male\", gender.fm = \"Female\", recruit.status = rep(TRUE, 50), recruit.expose.type = rep(c(\"Inclusion criterion\", \"Exclusion criteria\", \"Inclusion criteria\"), 50)).`````\n\n# Results\nThe results of your work are shown in Output-level eligibility of the data-frame clinical, the `Recruit.Status`, , `Age.Group1` , and `Age.Group_not_eligible.status` variables are also contained in the data-frame output.\n\n\n``` r\nclinical.trials.out[1:5] ```<EOD> Gap junction intercellular communication in rabbit corneal and conjunctival epithelial cells in culture.\nPURPOSE\nIntercellular communication via gap junctions is critical for a variety of in vivo epithelial functions. This study was undertaken to examine the morphologic features",
        "label": 0
    },
    "856": {
        "output": "We have provided four clinical trial cases that you can try as in our article [here]:\n\n## Step 1&2: Input Patient Details\nTo start practicing our tool, you should create input for the required data. \n\n\n### Example 1: Patient Details Using Tabular Data\nThis is the first example. You should prepare patient data. First, we should prepare a trial case-based patient data. Input a patient's data, e.g., ID (case ID), diagnosis, and trial name. You are free to prepare trial data (exclusion criteria). You can also refer that example for more information about the patient details.\n\n### Example 2: Patient Details With a Single Text Box\nThe second example is provided to illustrate the use of one text box for all patient data. \n\n### Example 3: Categorical Data\nThis is the third example. You can also use the categorical data in your input data.\n\n### Example 4: Tabular Data\nThe last example is provided to illustrate the use of multiple text boxes for each patient data.\n\n### Example 2&3: Patient Details Input Form\n<EOD> An open\u2010label, multicenter study to evaluate the effect of azithromycin on the bacterial content in subgingival pockets and on the bacterial composition of subgingival biofilms: Azithromycin in the treatment of periodontitis\nAzithromycin (Zithromax\u00ae, Pfizer, U.S.A.), a macrolide antibiotic with broad\u2010spectrum activity against both anaerobic and aerobic bacteria, has been reported to suppress destructive periodontal disease activity in humans. The purpose of the present study was to investigate the antibacterial effect of azithromycin on the subgingival microflora and to evaluate the short\u2010term effect of the drug on anaerobic bacterial subgingival biofilms. Azithromycin (three 1.0\u2010g doses given at four weeks' intervals) was given to 39 patients with severe chronic periodontitis. Two treatment groups were included. The group A comprised 20 patients, who had not previously been treated with antibiotics, and who were allocated to azithromycin",
        "label": 1
    },
    "857": {
        "output": "[CODE]#!/bin/bash\n\nDATA_DIR=\"$HOME/data\"\nSRC=\"$DATA_DIR/pyspark-3.3.0\"\nJAR=\"$DATA_DIR/spark-3.3.0.dist.zip\"\n\n# Download Spark installation package\nif [ ! -f $JAR ]; then\n    download http://repo1.java.net/maven2/org/apache/spark/spark-core_2.12-3.3.0.jar $JAR & while [ ! [ -f $JAR ] ]; do echo \".\"; sleep 1; done\nfi\n\necho \"Unpacking Spark jars...\"\nunzip $JAR\nrm $JAR\n\n# Download the data to be used in the experiment\nfor FILE_NAME in $DIR/test-data/in$TEST_NAME.txt ;\n    do rm -rf $FILE_NAME && cp $FILE_NAME $DIR/test-data/ ;\ndone\nrm -rf $DIR/test-data\n\necho \"Launching the script...\"\n./scripts/spark-run-main.py -i $SRC/input-data -j $JAR -t $TEST_NAME -o $OUT_DIR -c core.default.job_conf.properties > /dev/null &\necho \"Script has terminated.\"\nsleep 2\n\necho \"Launching the shell script...\"\nsource $SRC/run-scripts/$TEST_NAME/$TEST_NAME;\necho \"Script has terminated.\"\nsleep 2\n\n# Clean up the temporary data\nfor FILE_NAME in $DIR/test-data/in$TEST_NAME;\n    do touch $FILE_NAME;\ndone\nrm -rf $DIR/test-data\n\n# Write the run results\nfor FILE_NAME in $DIR/test-data/out$TEST_NAME/*.json ;\n\t\tdo # Create a new variable to check whether results exist\n\t\t\tif echo $FILE_NAME | grep 'Not run results found' -v > /dev/null;\n\t\t\tthen echo \"Success!\"\n\t\t\tdone\n\n       echo $FILE_NAME # Output test run results if none already exists.\ndone\n\n# Check the output folder for errors \ndir = \"pys",
        "label": 0
    },
    "858": {
        "output": "Now you are ready.\n\n# Testing\n\nRun a test using the command:\n\n`<cd> Tester folder<space> In.clin.test<enter> `\n\n# Results\n\nRunning all tests completes in a few seconds and outputs the following in the terminal.\n`OK`150\n`---`\n`Total tests:   151`\n`Summary`\n  `time      : 93.9s`\n  `memory    : 3534.0MB`\n  `failures  : 0`\n`Failures`\n\nTesting can be done using the command above. The first three lines are headers, and the fourth line is the default output for all tests. It indicates that the time is 93.9 seconds and memroy consumption is 3.5 MB. As no failure occurs, the test can be performed successfully and the entire program can run. The remaining test outputs are summarized here.\n\n```bash\nTests performed: \nTesting In.clin.test\n\n\n\n```\n\nThe test commands can be saved into a file (test file) by using the command below.\n\n`<cd> Tester folder<space> In.clin.test<tab><cr><cr> cat Testing In.clin.test\n\n```bash\nOK\n---\nTotal tests:   151\nSummary\n  time      : 93.9s\n  memory    : 3534.0MB\n  failures  : 0\n...\n```\n\nThe test commands are saved to the file named \"Testing In.clin.test\" by using the command above.\nThe command returns the complete description of the test file, and the size of this file is 34 bytes.<EOD> The role of surgery in the management of oesophageal leiomyoma in children\nIntroduction\u2003 The authors analyse the experience with paediatric oesophageal leiomyoma, with a special emphasis on the use of endoscopy, computed tomography, pre\u2010operative biopsies and surgical management.<EOD> Tuberculin Testing and Diagnosis of Mycobacterium tuberculosis in Drug-resistant Tuberculosis Patients, South Africa.\nWe investigated t",
        "label": 2
    },
    "859": {
        "output": "[END]\n\n\n--\n---\n#### Patients - Inclusion Criteria\n\nPatients presenting a symptomatic (ipsilateral ischemic stroke, TIA located in the carotid artery territory or retinal ischemia) carotid stenosis between 50% and 99% (according to NASCET and ECST criteria)\nPatients presenting an asymptomatic carotid stenosis between 60% and 99% (according to NASCET and ECST criteria)\n\n\n#### Patients - Exclusion Criteria\n\nPatients not presenting a symptomatic (ipsilateral ischemic stroke, TIA located in the carotid artery territory or retinal ischemia) or an asymptomatic carotid stenosis between 50% and 99% (according to NASCET and ECST criteria)\nPatients presenting an asymptomatic carotid stenosis < 60% (according to NASCET and ECST criteria)\nPatients presenting an asymptomatic carotid occlusion 51 Carotids not suitable for intervention due to: e.g., chronic occlusions (>1 month from onset), arteriosclerotic ulcer, kinked, dissecting, or fibrous intimal hyperplasia (>1 cm in diameter), total occlusion, or 2) any other condition at the discretion of the investigator as not suitable for study inclusion 52 Patients presenting an asymptomatic carotid stenosis 53 that are currently experiencing cerebrovascular ischemic events.\nPatients presenting an asymptomatic carotid stenosis 54 < 0.5 mm 1 mm-e.g. patients with stenosis of 60%-99% and more than 0.5 mm < 1 mm in length\nPatients presenting an asymptomatic carotid occlusion < 0.5 mm\n\n#### Treatment - Pre-procedural Pharmacological treatment\n\nPatients that present signs of intraprocedural thromboembolic complications, irrespective of the type of procedure (elective or emergent",
        "label": 2
    },
    "860": {
        "output": "[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level assessment of eligibility using the patient note given initially. \n\nHere is the patient's note:\n\nA 43-year-old obese man presents with an LDL cholesterol level of 90 mg/dL and a triglyceride level of 291 mg/dL. His family history is negative for atherosclerosis, diabetes mellitus, hyperlipidemia, coronary heart disease, and hypertension. The patient has a history of high cholesterol and hypertriglyceridemia. He has used fenofibrate for 10 years and is currently on gemfibrozil 300\u2009mg daily. He does not smoke. His mother died of coronary artery disease at age 71. \nThe patient reported no use of lipid-lowering medications.\nA chest radiograph revealed cardiomegaly.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, of high intensity and extending to the skull. Electrocardiography revealed regular sinus rhythm without any dysrhythmia and without abnormal conduction. Carotid ultrasonography showed no stenosis in any of the internal carotid artery branches. Here is the clinical trial: \n Title: The Relationship Between Morbid Obesity and Carotid Artery Stenosis",
        "label": 1
    },
    "861": {
        "output": "<EOD> In Vitro Characterization of a Potent and Orally Efficacious Inhibitor of Matrix Metalloproteinase-12 Discovered in a Pharmaceutical Collaboration.\nBroad targeting of metalloproteinases to provide clinically active inhibitors with optimal characteristics remains a considerable challenge. We describe the discovery and comprehensive in vitro characterization of a potent and orally efficacious inhibitor of matrix metalloproteinase (MMP)-12, a potential target for the treatment of cancer, inflammatory, and autoimmune diseases, such as rheumatoid arthritis. The inhibitor is generated in our laboratory from a large diverse combinatorial library of potent and selective MMP-12 inhibitors. The most active compound (3, K(i) = 95 pM) exhibits excellent oral efficacy in the mouse collagen-induced arthritis (CIA) model. The inhibitor shows complete inhibition of MMP-12 activity at low \u03bcg/kg levels in rat and NHP plasma with an oral bioavailability of \u223c40 % in rat and \u223c70 % in NHP. It demonstrates excellent physicochemical, metabolic, and formulation properties in vitro. The inhibitor is also expected to achieve high metabolic stability, allowing once-daily dosing in rat and NHP. This study provides a starting point for the lead optimization of this inhibitor series, which is currently underway in our laboratory.<EOD> The relationship between metabolic parameters and body adiposity in healthy children.\nINTRODUCTION\nMetabolic indices assess the metabolic status of patients at high risk of obesity and type 2 diabetes; however, few studies have evaluated their usefulness in children. The aim of this study is explore the relationship between metabolic parameters and body fat in a clinically healthy population.\n\n\nMATERIALS AND METHODS\nNinety-four children were recruited. Total blood lipid profile and metabolic status (triglycerides, HDL, LDL, VLDL, ApoB, Apo A, cholesterol, LDL/HDL",
        "label": 2
    },
    "862": {
        "output": "```python\n[birth_year - 2009.day - 3.month] % 100\n```\n\n## 4. Questioner. \ud83c\udfa9\nQuestioners inquire into a wide variety of aspects including: the patient's medical history such as illnesses, current medical conditions, previous treatments, or symptoms; the social history including such aspects as the patient's general health, family history, and environmental exposures; and the physical examination such as vital signs or weight.\n\n\n## \ud83c\udfa8 Data Types.\n\n\n##### Medical data\n\n- [patient.birth_year.astats], [patient.birth_year.birth_year] <c>Age; int;</c> \n- [patient.birth_year.birth_year_month] <c>Moth</c> \n- [patient.birth_year.birth_year_day] <c>Day</c>; {date} \n- [patient.gender.gender] <c>Gender; male ;female</c> \n- [patient.gender_name] <c>gender_name</c>; {string} \n- [patient.pregnancy] <c>Pregnancy;</c> \n- [patient.race] <c>race; black;white,Cauc</c> \n- [patient.race_name] <c>race_name</c>; {string} \n- [patient.marital_status] <c>Marital_Status; married; divorced</c>; {string} \n- [patient.medical_history.a_history_of_headaches] \n- [patient.medical_history.a_neurological_disorder] \n- [patient.medical_history.an_intrauterine_death] \n- [patient.medical_history.at_least_one_child] \n- [patient.medical_history.bad_diabetes_control] \n- [patient.medical_history.blood_disease] \n- [patient.medical_history.",
        "label": 0
    },
    "863": {
        "output": "[/INFO]\n\n# Example\n\nTo run this example, type the following:\n\n<rst>\n\n:stdin <FILE>\n\n</rst>\n\n> Trial-level eligibility: 1) Not relevant.\n> Trial-level eligibility: 1) Eligible.\n> Trial-level eligibility: 0) Excluded.\n\nHere is how this example looks on the terminal:\nRunning sample_test...\nFinally, you should always repeat Trial-level eligibility in the last line by `Trial-level eligibility:`, e.g., `Trial-level eligibility:1) Eligible.`.<EOD> A Phase 3 Trial of Nusinersen for Spinal Muscular Atrophy Versus Observation: A Second Hypothesis: Commentary\nSpinal muscular atrophy (SMA) is a rare motoneuron disease caused by homozygous deletion of the survival motor neuron 1 gene with loss of a splicing enhancer, resulting in loss of survival motor neuron protein expression.1 The deletion frequency of the splicing enhancer varies by ethnicity, with the highest frequency, >1:10,000 persons, in patients from northern Europe. However, no ethnic group is immune from the disease.<EOD> Evaluation of Intravenous Administration of Carbohydrates Alone or with N-Acetylcysteine to Attenuate Radiation Hepatitis\nAbstractThe aim of this study was to observe the effects of administration of different carbohydrates and N-acetylcysteine (NAC) on the liver after cobalt 60 cGy total body irradiation (TBI) in comparison with no intervention. A total of 150 male rats were divided equally into 15 groups. Groups A-D consisted of rats that underwent 60 cGy TBI. Group A received no intervention, group B received glucose (2 ml/kg), group C received lactose (2 ml/kg), and group D received sucrose (2 ml/kg); then, all were sacrificed at various times",
        "label": 1
    },
    "864": {
        "output": "### Examplary file `example2.pdf`\nFirstly, please download the following file `example2.pdf` by rightclicking the Examplary file [example2.pdf] then clicking `Save As ...` or `Save Target As ...` in your browse window; the file contains 2 patient note and the clinical trial `Sample clinical trial.RIS` and file `Example 2.md`.\n\nSecondly, the following procedure will be displayed to you when running the script, make sure to check the box 'Show detailed help'.\n\nThen, save the file in your default directory. Next, type the command in the terminal.\n\n\t\trdoc_get_relevant.R\n\nFinally, the following contents will be displayed.\n\n```\n---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\nR> library(\"rdoc_get_eligible\")\nR> rdoc_get_relevant(\"example2.pdf\")\nR> head(Trials)\n-------------------------------------------------------------------------------------------------------\nR> Inference based eligibility assessment: 0(Excluded)\nR> Note: the result of eligibility has a one-to-many relationship (e.g., Inference based eligibility assessment: 1(Eligible), 0(Excluded).\n\n                         A: Assessment B: Basis C: Criteria E: Evidence R: Reason\n\n12\n       12\n       \"Fasting Glucose\" \"Glycated Haemoglobin\" \"HDL-C\" \"LDL-C\" \"Neck Auscultation\" \"Peak Systoic Velocity\"\n  \"Incidenece\" \"1.167\" \"1.238\" \"1\" \"1501\" \"4+/6+\", \"1.721\"\n1             \"Incidence\"\n  \"1.167\" \"1\" 12 \"1.238\" \"0.917\" \"4+/6+\", \"1.721\"\n2             \"Hypertension\"\n  \"1559\"  \"0\" 13 \"1609\" \"0\" 13",
        "label": 0
    },
    "865": {
        "output": "##[BLOCK]\n## Coding\n[BLOCK]\nIn general, the following data fields are recommended for coding:\n\nThe following examples are of the coding guidelines:\n\n* A) Assessment of Eligibility: 2) Eligible\n** 1. **`Coding for the `Assessment of eligibility: 2) Eligible` as `2: Eligible`: \n`  `Assessment of eligibility: 0) Excluded` as `0: Excluded`: `1: Not relevant`\nAll the details of your clinical study are provided to us as XML file.\nIn this clinical study, we have only four items of data:\n\nA) Assessment of Eligibility:\n\nB) Trial-level eligibility:\n\nC) Inclusion criteria:\n\nD) Exclusion criteria:\n\nXML format: <assessmentOfEligibility>\n   <0> excluded</0>\n   <1>notrelevant</1>\n   <2:eligible</2> \n </assessmentOfEligibility>\n<trialLevelEligibility> excluded</trialLevelEligibility>\n<InclusionCriteria>\n    <Factor  age  >\u2265 60 years</Factor>   \n</InclusionCriteria>\n\n\n<ExclusionCriteria>\n     <Factor  highsurgicalrisk>high cardiac or pulmonary risk</Factor>\n</ExclusionCriteria>\n\nXML file:\n'<?xml version=\"1.0\"?>\n<assessmentOfEligibility  xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" xsi:schemaLocation=\"http://research.cchmc.org/cchs-xml http://research.cchmc.org/cchs-xml/cchs-xml.xsd\">\n  <0>0<Factor>excluded</Factor></0>\n  <1>notrelevant<Factor>notrelevant</Factor></1>\n  <2>2<Factor>eligible</Factor></2>\n </assessmentOfEligibility>",
        "label": 2
    },
    "866": {
        "output": "In this patient, the clinical trial is not applicable as only one exclusion criterion has been met: the patient is not eligible for the clinical trial due to having previous coronary artery bypass grafting (CABG) surgery [bib_ref]  Outcomes of coronary artery bypass grafting in patients with prior surgical revascularization, Fananapazir [/bib_ref] .\n\n\n\nAs we discussed, there is no simple step-by-step algorithm for assessing whether the patient is suitable to enter a given clinical study. A trial-level assessment of patient eligibility is performed not only based on patient characteristics that we see in his medical profile. One must also consider the clinical trial's eligibility criteria, which are more or less strict than others, which may affect the patient in terms of his or her treatment or recruitment. When the patient's characteristics are consistent with the clinical trial's inclusion criteria, the second checkpoint includes checking of the exclusion criteria in order to determine the patient's eligibility to be in the clinical trial. At this point, the clinicians have also to think outside the box: e.g., the patient was treated in the past for a heart ailment. He meets the trial's inclusion criteria, but his history inhibits him from participating in the trial. If the trial's exclusion criteria were based on medical procedures performed to improve patient condition in the past, this patient would be completely disqualified [bib_ref]  Challenges and solutions in conducting neuroimaging trials in patients with recurrent concussive..., Slobounov [/bib_ref] .\n\n# Implementing the method\n\n\n```python\n# +\nimport numpy as np\nfrom neodataprocessing import *\n\n# +\n# Load in patient data file into DP\npatient_data = load_patient_data(os.path.join(\"/path/to/data\",  # Path of the data ))\n# +\n# Load in patient-specific trial data\nclinical_trial_data = load_trial_data(os.path.join(\"/path/to/data\",  # Path of the data ))\n# +\n# Load in patient-specific DP data\nclinical_trial_patient_",
        "label": 2
    },
    "867": {
        "output": "# Exercise\n\n## Exercise 1: Clinical trial recruitment problem 1\nHere is the patient note: \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\n## Exercise 2: Clinical trial recruitment problem 2\nHere is the patient note: \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\n## Exercise 3: Clinical trial recruitment problem 3\nHere is the patient note: \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\n## Exercise 4: Clinical trial recruitment problem 4\nHere is the patient note: \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\n## Exercise 5: Clinical trial recruitment problem 5\nHere is the patient note: \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\n## Exercise 6: Clinical trial recruitment problem 6\nHere is the patient note: \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\n## Exercise 7: Clinical trial recruitment problem 7\nHere is the patient note: \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n## Solution\n\n## Exercise 1: Clinical trial recruitment problem 1\nLet's think step by step. \nFinally, you should always repeat Trial-level eligibility in the last line by `Trial-level elig",
        "label": 1
    },
    "868": {
        "output": "#### Examples\n\n<h3 align=\"center\">\n\nExamples.\n</h3>\n\nAs you may be aware, your task is to assess eligibility in both individual and clinical studies. To make this easier, we show you patient profiles in the first two examples. The assessment and output of the eligibility scale are based on this patient\u2019s case notes.\n\n**Example 1**:\n\n_Patient_\n\n\n\nThe patient note is below: \nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\n\nThe patient reported no use of lipid-lowering medications. \n\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u00a0cm/s and 54.5\u00a0cm/s, respectively; RICA PSV was 91.72\u00a0cm/s and RICA EDV was 37.37\u00a0cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less",
        "label": 0
    },
    "869": {
        "output": "________________________________________________________________________________________\n\n## <NAME>\n<NAME>\n<EOD> 17\u03b2-Estradiol protects against ischemia/reperfusion injury-induced oxidative stress and cardiac remodeling in the rat heart.\nOxidative stress in the cardiac myocyte induced by ischemia/reperfusion (I/R) injury causes cardiac injury and remodeling, and is the major contributor to the cell death and dysfunction observed before reperfusion. Therefore, the present study aimed to demonstrate the underlying mechanism through which the biological estrogen, estradiol (E2), attenuated I/R-induced cardiac injury and oxidative stress in the rat heart. The hearts of animals were subjected to I/R treatment, and the protective mechanisms of pretreatment with E2 of various doses (10, 50 and 100 \u03bcg/kg) was compared to treatment with E2 only. The effects of E2 intervention were evaluated by determining the cardiac infarct severity and oxidative stress, using reverse transcription-semi-quantitative polymerase chain reaction and Western blot analysis. Furthermore, cardiac remodeling was determined by examining the thickness and weight of the left ventricle (LV). The results of the present study concluded that pretreatment with E2 provided cardioprotection against I/R injury, which was associated with the inhibition of myocardial apoptosis and attenuation of oxidative stress. Furthermore, E2-pretreatment reduced cardiac remodeling after I/R, increased the left ventricular ejection fraction and decreased the LV end-diastolic pressure. The results suggested that E2, acting as a free-radical scavenger, attenuated oxidative stress and myocardial injury, and consequently improved the cardiac recovery from reperfusion.<EOD> Fertility preservation: a guide to a patient-centred counselling in the new Italian law.\nNew guidelines for fertility preservation has been issued by the Italian National Institute for Health (Istituto Superiore di Sanit\u00e0--ISSN) in 2015",
        "label": 1
    },
    "870": {
        "output": "##[END]\n[INST] You are a pharmaceutical industry research specialists. You want to do research in clinical trial with a new oral anticoagulant (NOAC) (Novel Oral Anticoagulant). The novel indication of the NOAC is prevention of systemic embolism at high risk of embolism and reduction of recurrent stroke in patients with atrial fibrillation. You must choose the best NOAC in terms of efficacy/safety. Thus, you need to select the target population. Your task is to do a search of medical documents about NOAC in terms of efficacy, safety using specific web sites [e.g., ]. The documents are medical articles and posters of international conferences. You do a first selection from titles and abstracts, afterward you read full-text article. \n\n##\n[INST] You are a cardiologist at the Lausanne University Hospital (CHUV). Each week, 18 patients consult with an electrode for cardiac ablation for tachyarrhythmias. You want to build an electronic health record (EHR) based on a local database. You can use data from cardiac ablation reports, medical history, medical data sheets, lab tests, etc. and then analyze them with statistical tools. At the same time, you can store and share them with other participants to conduct joint studies with physicians from other hospital centers, clinics and public health organizations. \n\n* [ ] E.g., a physician wants to use a mobile application that provides medical information. The EHR must be stored and exchanged between specialists, patients, clinics and hospitals.\n\n* [ ] EHR: Electronic Health Record\n\n* [ ] [ ] E.g., hospital physician wants to share a medical report with the patient via email, mobile application, or social network.\n\n* [ ] E.g., a patient wants to share his or her medical data with the primary care physician via a specific channel, such as a link in an email or an online shared document. [END]\n[INST] You are a computer scientists at the Lausanne University Hospital (CHUV). You are part of a team that developed an application based on blockchained technology, which gives all patients the flexibility and confidence to access E",
        "label": 0
    },
    "871": {
        "output": "Congratulations! You have finished the assessment of eligibility in this exercise.\n\n[TASK #6] Hello. You are a researcher. Your task is to assess the severity of depression in patients with major depressive disorder. We provide you information on patients' demographics, depression, and anxiety. Please assess their symptoms of depression based on  the Hamilton Depression Rating Scale (HAM-D).<EOD> Efficient In Vivo Delivery Mediated by D-Peptide Transporters.\nD-peptides are a promising class of medication that have the potential to directly interact with their biological target to trigger therapeutic effects. However, the inefficient delivery of D-peptides to their intended target has been a concern and limits the therapeutic application of D-peptides to those that act on extracellular receptors or directly enter the systemic circulation through the oral or rectal routes of administration. In this report, 14 D-peptides (e.g., d-Ser, d-Val, d-Pro, etc.) were evaluated to identify those that are specifically recognized by oral D-peptide transporters in the small intestine. These D-peptide transporter substrates were also found to serve as oral delivery vehicles to transport the macromolecular biomarker Alexa Fluor@ 750 (Mw, \u223c750 Da) to the circulation in vivo. We show that the D-peptide transporters are present exclusively in the epithelial cells of the small intestine as evidenced by the intestinal uptake of lysine-containing D-peptides and the inhibition of intestinal uptake by D-lysine in normal and CD-1 and C57BL/6 mice. A series of lysine-containing D-peptides, such as the 15-mer D-d-lys-d-d-Pro-d-Leu-d-d-Ala-d-Leu-d-d-Leu-d-d-Val-d-Leu-d-d-Ala-d-val and the 2",
        "label": 1
    },
    "872": {
        "output": "<h3>Recommended</h3><div id=\"comment\"></div><h3>BONUS 1: Tips and pitfalls</h3>\n<h5>Tips:</h5>\n<ul><li>Inconsistent triage was observed in the comparison, such as 'Unavailable' and 'Unknown' to 'Not relevant' and vice versa. </li><li>For a more specific result, 'Unavailable' patients, which have incomplete data, or unknown eligibility status should still be included when calculating the percentage match for the assessment eligibility.</li><li>Ensure the correct coding of the patients' gender and the trials' sex requirement. Female should only be coded with \"F\" and Male should only be coded with \"M\"; if a sex preference is required in the trial, then the patient should be excluded if inconsistent to the prefer requirement. If there is no sex preference in the trial, the patient should be excluded if the patient's sex is inconsistent with the trial's requirement.</li><li>Some of the included clinical trial records had wrong criteria; e.g. <span style=\"color: red\">1.4</span><span style=\"color: blue;\">-1</span><span style=\"color: red\">.0 -2.1</span><span style=\"color: blue;\"> -2.3</span><span style=\"color: red\">-7.3</span>.</li></ul><h5>Pitfalls:</h5><ul><li>Do not ignore the 'trial eligibility status of the missing patient' data</li><li>Ensure that the 'status' of the clinical trial and the specific eligibility criteria met in the clinical trials are correct</li><li>Make sure to keep the following variables consistent: Patients' gender, number of gender in each trial, patients' age, number of age groups, and ranges of age groups used, and patients' age range</li><li>There was no need to assess eligibility status when the trial eligibility status was 'unavailable'</li><li>Don't miss records with missing eligibility status or the patients with unknown eligibility status. If the number of patients with missing eligibility status is small, the 'not relevant",
        "label": 1
    },
    "873": {
        "output": "You are already trained on how to calculate clinical trial eligibility, and we'll now cover real-world scenarios to test your knowledge. Remember that a patient note contains five subheadings: Clinical Findings (CFs), Demographics (age and gender), Drug History (name, dosage, duration, and start time), Allergies, and Current Health Status (CHS) and Current Medications (CMed).\n\nYou are a medical resident, and you have to evaluate the patient's eligibility for the clinical trial. There are three scenarios below. For each scenario, only two subheading are required, so you don't want all information. What do you do with the other subheadings? What are your assessment criteria? \n\n**Sc1. Clinical Trial: Insulin Resistance. Patient: Mr. Cao, aged 45 years, male** \n\nMr. Cao has been diagnosed with insulin resistance. A clinical examination indicates diabetes mellitus and lipid metabolism disorder. He currently receives insulin therapy, which is the only treatment in his medical file. He had a previous blood transfusion a week earlier due to diabetes. His clinical findings suggest a 60/90 mmHg BP elevation, accompanied by a body weight of 78\u2009kg and a waist circumference of 20\u2009cm. \n\n**Sc2. Clinical Trial: Diabetes. Patient: Ms. Li, aged 40 years, female** \n\nMs. Li has been diagnosed with insulin resistance. A clinical examination indicates diabetes mellitus and lipid metabolism disorder. He currently receives insulin therapy, which is the only treatment in his medical file. He had a previous blood transfusion a week earlier due to diabetes. Clinical findings indicate a BP of 80/110 mmHg with 74\u2009kg weight and 20\u2009cm waist circumference. \n\n**Sc3. Clinical Trial: Insulin Resistance. Patient: Ms. Li, aged",
        "label": 2
    },
    "874": {
        "output": "<EOD> .\nObjective. To verify the diagnostic value of 300 ms EEG in coma and identify the optimal parameters for the test. Methods. EEGs were performed on 418 patients. According to the duration of coma (with and without 300 ms EEG), the sensitivity and specificity of the two EEG tests were compared. A ROC curve was used to compare the sensitivity of 300 ms and 100 ms EEG at different levels of specificity. Results. For subjects with a duration of coma \u226414 days, the sensitivity of 300 ms EEG (92.0%) was significantly higher than that of 100 ms EEG (31.6%)(\u03c7(2) = 123.19, P < 0.001). For subjects with a duration of coma >14 days, the sensitivity of 300 ms EEG (81.8%) was higher than that of 100 ms EEG (39.7%)(\u03c7(2) = 49.20, P < 0.001). The specificity of short-duration EEG \u2265300 ms (93.5%) was significantly higher than that of 100 ms EEG (76.0%)(\u03c7(2) = 21.05, P < 0.001). Conclusions. EEG coma duration over 14 days can be diagnosed with 100 ms in the coma for diagnosis \u2265300 ms.<EOD> Biodiversity in phospholipase-catalyzed ester cleavage reactions: the effect of different substituents on a common system.\nThe effect of a number of structurally different substrates on the kinetic parameters of different phospholipases C (PLCs) from various sources was investigated. On the basis of the results obtained, our conclusions are as follows: (a) phospholipid-dependent PLCs from Escherichia coli, Bacillus cereus, and snake (Bothrops jararaca) venoms showed a preference for 1,2-diacyl-sn-glycerol-3-phospho",
        "label": 0
    },
    "875": {
        "output": "</details>\n\n\n## Instructions to Contributors\nPlease use these instructions when creating new datasets.\n\n## Datasets for the paper.\n1. Create a new dataset in the Kaggle repository for your study.\n\n[INSERT YOUR DATASET ID HERE]\n2. Include your code to evaluate eligibility.\n\n[INSERT YOUR CODE HERE]\nYou should do the following on that script:\n- Run the script: \n$ [PATH_FROM_YOUR_PROJECT] evaluate_eligibility  \nThis will evaluate eligibility on all patient notes, not just on new patient notes from which you want to get an eligibility score! However, you should see all the outputs on the patient note (trial_level_eligibility, patient_level_eligibility, etc.).\n- Read the patient notes and then return the three-point scale into the same file. You should include the following fields:\npatient_id patient_level_eligibility trial_level_eligibility \nHere is a template for your code.\n\ndef main():\n    dataset = pd.read_csv(\"[DATASET_NAME].csv\")\n    trial_level_eligibility, patient_level_eligibility = dataset.groupby(dataset.patient_id).apply(evaluate_eligibility, axis=0)\n    trial_level_eligibility.to_csv(\"[DATASET_NAME]_trial_level_eligibility.csv\")\n\n    patient_level_eligibility.to_csv(\"[DATASET_NAME]_patient_level_eligibility.csv\")\n\n    return\n\n\nif __name__ == '__main__':\n    main()\n\nTherefore, you should see two output files in the directory of your dataset:\n- trial_level_eligibility.csv\n- patient_level_eligibility.csv\n\n3. Include the dataset in your CV and research papers as the following:\n\n```\n//dataset_name\ndata <- readRDS(file = \"dataset_name.RDS\", sep=\",\")\n\n//dataset_name (1)\ndata <- readRDS(file = \"dataset_name (1).RDS\", sep=\"",
        "label": 2
    },
    "876": {
        "output": "## Exercise 1\nTry to solve all following cases.\n\n## 1)\nWhat is the eligibility in the trial for the following case?\n- A 62 year old is diagnosed with mild hyperlipidemia and he is considering undergoing LDL-lowering therapy. He has recently heard about the benefits of the LDL-lowering therapy over diet and exercise. He has also had several friends go on this therapy and they feel it has greatly improved their health. However, he is very concerned about his eligibility with that therapy. Which drug is given, is it free or has any cost for him (free or not)? What is the eligibility in this case?\n- A 72 year old male is admitted with a myocardial infarction for stenting of the left anterior descending artery. He has previously experienced two silent myoardial infarcts and four silent strokes within the last 10 years due to his asymptomatic vasculitis. Although he is experiencing pain from this infarction, he decides that he does not want to take aspirin due to his bleeding problems from his previous strokes and is hesitant to take more blood thinner for this infarction. Which drug is given, is it free or has any cost for him (free or not). What is the eligibility in this case?\n- A 52 year old woman with diabetes, hypertension, and hyperlipidemia is referred to catheterization lab with an acute ST elevation MI. She has multiple comorbidities, including previous MI 2 years ago, and is being treated with several medications including diuretics and vasodilators. She is given an emergency intervention, but the interventionalist notes that her arteries were severely calcified with large atherosclerotic plaque. During the procedure, the interventionalist is concerned about the stenotic vessel and decides to place an intracoronary stent in the LAD. The stent will not be visible in angiography. After the stent is deployed, the interventionalist notes that the stent is appropriately sized and placed and that no other complications occur. However, the intervention will cost her out of pocket",
        "label": 0
    },
    "877": {
        "output": "The solution is available from [here](https://www.kaggle.com/ml-competitions/challenge-of-examination-of-clinical-trial/), [here](https://github.com/laboratory-of-computing-and-data-analytics/Challenge-of-examination-of-clinical-trial) and is available from [here](https://pubmed.ncbi.nlm.nih.gov/33963224/).\n\nI hope you enjoy solving the Challenge of Clinical Trial Assessment Competition.\nAll the best!\n<EOD> Recombinant DNA products for the delivery of therapeutic agents: patents available.\n\n This news item reprinted from the \"Bulletin of The International Patent Forum\" provides a list of U.S. patents that include recombinant DNA production of therapeutic agents such as tetanus toxoid, human serum albumin, hirudin, interferons, and interleukin 2. The patent numbers are arranged in order by patent number for the ease of finding the patent for the product one is interested in.\n<EOD> \u03b2-Amyloid Peptides Are Released from Cultured Cortical Rat Neurons by Both Exocytic and Non-Exocytic Pathways\nPrevious in vivo and in vitro studies have suggested that Alzheimer's disease is associated with dysfunction of neurotransmitter systems, leading us to postulate that neurotransmitters and their precursors might mediate aspects of the pathology. Accordingly, the present studies investigated the hypothesis that secretion of \u03b2-amyloid is altered in cortical neurons from 8-month-old Alzheimer's disease affected (APP(NL)) and non-affected (APP(N)) transgenic mice using real-time imaging of individual live cortical neurons. Neurons from APP(N) transgenic mice secrete amyloid peptides via the exocytic pathway as well as via a non-exocytic pathway. The data from \u03b2-amyloid secretion in APP(N) neur",
        "label": 0
    },
    "878": {
        "output": "<EOD> Correlated motion of molecule-substrate dipolar vibration in a magnetic field.\nIn this work we analyzed the correlation of molecule-substrate vibration and dipolar vibration in a magnetic field, by studying the Raman spectra of CH_{3}Cl/SiO_{2} samples, deposited on glass substrates, at different CH_{3}Cl exposures, by combining the classical theoretical simulations and empirical analysis.<EOD> A novel MRI imaging modality for visualizing changes in the rat knee joint after transection of intraarticular ligaments.\nThere are a number of disorders of the intraarticular ligaments and articular cartilage that result in osteoarthritis (osteoarthritis). For the assessment of the pathological conditions of articular cartilage which are difficult to detect on conventional radiographs and MR images, we developed a novel MRI imaging modality, termed the \"intracortical cartilage imaging modality (iccMRI)\". iccMRI enables visualization of the cartilage layers in the femoral and tibial condyle and the articular surface of the posterior cruciate ligament separately. We evaluated the sensitivity of iccMRI for detecting the thin degenerative cartilage layer around the site of the posterior cruciate ligament (PCL) in a rat model of osteoarthritis that underwent transection of the intraarticular ligaments. iccMRI clearly discerned the changes in the articular cartilage layers of the posterior condyle and the patellar surface of the rat knees after transection of the intraarticular ligaments, and is expected to be a useful tool for the clinical assessment of intraarticular ligament and articular cartilage diseases.<EOD> Combination chemotherapy and cimetidine in the treatment of severe sepsis.\nSixty-six patients with severe sepsis unresponsive to antibiotic therapy were divided into two groups. Ten patients were given placebo in addition to antibiotics for 10 days. Forty-six patients received daily injections of 500 mg of cimetidine for 10 days with antibiotic and placebo administration as in the previous",
        "label": 2
    },
    "879": {
        "output": "### Solution\n\nIn\nhere, we do the following.\n\n\n\n* * *\n\nlet f = open(\u2018patient-note.txt\u2019, \u2018r+\u2019)\nlet g = open(\u2018eligible.txt\u2019, \u2018w\u2019)\nif f.readline() != \u201c[PATIENT-INFO]\u201d then\nvar a, b, c, d, e = f.readline.split(\u2018\\n\u2019)\nc, b =",
        "label": 0
    },
    "880": {
        "output": "[END]\n\n# Discussion\nThe eligibility test is important to assess the fitness for clinical trials. In this assessment, the inclusion criteria of a clinical trial were compared with the characteristics of patients or patient records.\nCritical reading is needed to ensure patients meet the inclusion criteria. In this case scenario, the reader had to check whether the patient met the clinical trial's specific inclusion criteria or not.\nFurthermore, the assessment is needed in each patient, and the result should be a 3-point assessment, not a binary result.\nTo check the content, read all the patient information, i.e., the \"History of present illness\" section, and the \"Physical examination\" section and check the patient's characteristics thoroughly. In the patient information, check medical history, previous treatments, and comorbidities. In the physical examination section, check the physical condition.\nIf the data are not clear or there is missing data, ask the lecturer. This case involved untreated asymptomatic patients.\nThus, the patient will not be excluded only because they have a current comorbidity. Rather, the patient is excluded because the patient is symptomatic from the condition.\nThe lecturer did not give a list of patients or patient records; thus, the reader must write all information related to patients' assessments; for example, for patient 1, the assessment will be \"Excluded\" (the patient does not meet the clinical trial's inclusion criteria).\nThen, to find out if the patient is eligible or not, the reader has to check the scale and the exclusion criteria for clinical trial 1 on a trial-level.\nIn case the patient has several diseases or comorbidities, the reader should check all the exclusion criteria for clinical trial 1 to find out if the patient's conditions are exclusion criteria for the clinical trial.\nIf the patient has a previous history of symptomatic coronary heart disease (CHD), the condition is excluded when the patient participates in trial-1. \nFor patient 2, the assessment will be \"Not relevant: 0. (The patient does not have sufficient information to be a trial-level eligible.)\".\nAt last, the reader should write the patient assessment and the trial",
        "label": 1
    },
    "881": {
        "output": "Let's begin the first line of the patient evaluation, patient_clinical_assessment. First, the subject_number needs to be given; for example, subject_number=1. Next, you should fill in the rest of the parameters of the patient's clinical assessment, where clinical_assessment_list=<Clinical Assessment List>: <br>\n<br>\n<b>Clinical Assessment List</b><br>\n1 - Age: Age of the patient;\n2 - BMI: Body mass index (BMI);\n3 - WC: Waist Circumferene,\n4 - SBP: Systolic blood pressure",
        "label": 2
    },
    "882": {
        "output": "## Evaluation\n\nIf all criteria were met, then the number of elements was 10 and the maximum number of points was 240. The final result was 40, which is in the 5th quantile of the points of all 1000 participants of the course.\n\n## Example of Task Solution\n\nA patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009 mg/dL, resp.) were within normal limits.\n\nThe patient reported no use of lipid-lowering medications. \nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009 cm/s and 54.5\u2009 cm/s, respectively; RICA PSV was 91.72\u2009 cm/s and RICA EDV was 37.37\u2009 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nTherefore clinical trial eligibility criteria from the clin",
        "label": 2
    },
    "883": {
        "output": "### Examples:\n\n---\n* Patient_ID: 1 * Trial_ID: TREAT05678\n\n<pre class=\"debug\"><code>&lt;!DOCTYPE html></code><code>&lt;html class=\"html-comment\" id=\"html-comment\" lang=\"en\" data-lang-code=\"EN\"> &lt;head&gt; <code>&lt;meta charset=\"UTF-8\"/> </code> &lt;title class=\"html-comment\">Patient Trial-level eligibility 1) Excluded-No</code> &lt;link rel=\"home page\" href=\"/home\"/&gt; <!--[if IE]> <script src=\"http://ajax.googleapis.com/ajax/libs/jquery/1.7.1/jquery.min.js\"></script></script> <!--&gt;  <!--[if !IE]><script src=\"jquery.min.js\"></script> <!--&gt; </head> <body class=\"\" style=\"\"> <!--[if IE]> <div class=\"mceHTMLParser\"></div> <!--&gt; <blockquote class=\"blockquote quote\"><p>Trial-level eligibility 1) Excluded-No</p> <cite class=\"blockquote-author\">- Patient_ID: 1 -   - Trial_ID: TREAT05678 </cite> <p><strong><a href=\"/patient/1\">Patient_ID: 1</a></strong> <a href=\"/trial/TREAT05678\">Trial_ID: TREAT05678</a> <strong>:</strong><br> <em>Title: The Effects of Dietary Intake of Cod Residual Material Meal on Lipid Regulation, Glucose Regulation and Body Composition in Physically Active Adults </em> <em> Summary:</em> A high intake of fish is associated with positive health effects, including prevention and treatment of chronic non-communicable diseases, such as cardiovascular diseases (CVDs) and type 2 diabetes. These health effects have traditionally been attributed to the omega-3 fatty acids in fatty fish, but recent studies have suggested that also fish proteins",
        "label": 2
    },
    "884": {
        "output": "[CORRECT] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 5",
        "label": 0
    },
    "885": {
        "output": "There is no time limit for solving this task, but we don't recommend you to take more than 5 minutes. So, the code will be judged if you get the exact answer at all.\n\nTo do this, you need to understand correctly the task and think through a plan for its solution. In general, there are several ways to do this task, the main points that are important to pay attention to are highlighted in bold. You may use any programming language you like, and even a spreadsheet if you think it is the only way to solve the problem. You can send in as many solutions as you like. One point per task, with the best solution getting a bonus point - make sure you understand everything the solution does.\n\n##### What was tested in this task?\n\n\n*The tester will know when you have understood the task correctly and he/she is not a mathematician and doesn't expect perfect implementation of the algorithm.*\n\nAll the testing for this task are on the task description page. If you want to see the results - check the test results table.\n\nIf you are sure that you know how to solve this task and you just want to see how the judging will work - go down to the bottom of the page, fill the sample submission form correctly and you will see a link `View solution - try now`. But this is all with just 5 minutes!\n\n\n\n#### Examples for the solution\n\nHere are some examples of correct submissions. Please note that there are many more ways to solve this problem; the main point that is important to pay attention to is emphasized in bold and underlined.\n\nYou should always get the same result if you run the examples with the same parameters. Pay attention to the difference between the first and second rows and to the difference between the second and third rows. 500 (10%) are eligible for the ACT study. This means that 500 patients with ischemic chest pain, ST depression or T wave inversion in at least 1 lead, and Troponin values between 5\u201350 were eligible. For the ACE study, 47% (93) of the patients with chest pain with normal troponin levels were eligible.\n\n```\nExample solution 2 with test data\n\nIn case of ACT trial\n{\n  patient",
        "label": 0
    },
    "886": {
        "output": "The correct solution is below. \n```bash\n$ cat data/2_case_5.json\n{\n  \"ID\": \"f88a0ea9-0114-4278-b28d-49b1b747b026\",\n  \"age\": 46,\n  \"gender\": \"male\",\n  \"hypertension\": \"false\",\n  \"high cholesterol\": \"false\",\n  \"cardiac risk factors\": \"true\",\n  \"smoking\": \"false\",\n  \"family history of heart disease\": \"false\",\n  \"exercise level\": \"regularly active\",\n  \"high blood pressure\": \"false\",\n  \"lipid level\": \"true\",\n  \"diabetes\": \"false\",\n  \"cardiovascular\": \"true\",\n  \"exclusion criteria\": {\n    \"use lipid-lowering medications\": \"false\",\n    \"neck auscultation\": 0\n  },\n  \"trial level eligibility\": 2\n}\n\n$ cat data/2_case_6.json\n{\n  \"ID\": \"a00c7bd7-ddf7-4485-bf8e-0be2f77082a6\",\n  \"age\": 46,\n  \"gender\": \"male\",\n  \"hypertension\": \"false\",\n  \"high cholesterol\": \"false\",\n  \"cardiac risk factors\": \"true\",\n  \"smoking\": \"false\",\n  \"family history of heart disease\": \"false\",\n  \"exercise level\": \"regularly active\",\n  \"high blood pressure\": \"false\",\n  \"lipid level\": \"true\",\n  \"diabetes\": \"false\",\n  \"cardiovascular\": \"true\",\n  \"exclusion criteria\": {\n    \"use lipid-lowering medications\": \"false\",\n    \"neck auscultation\": 0\n  },\n  \"trial level eligibility\": 2\n}\n\n$ cat data/2_case_7.json\n{\n  \"ID\": \"b84c266d-25",
        "label": 2
    },
    "887": {
        "output": "<EOD> .\nTo establish the association between infection by H. pylori and gastric ulcer. 1,200 consecutive patients of the Endoscopy Unit of an open Hospital from Cochabamba were studied, in order to find out the percentage of infection by H. pylori and by the association with gastric ulcer. The percentage of gastric ulcer, duodenal and gastric bleeding in the total of patients was 2.0%, 1.6% y 1.0%. To find out the association between H. pylori and gastric ulcer, 100 patients with gastric ulcer, 100 patients with non ulcer dyspepsia and 100 individuals of the control group were studied. The prevalence of H. pylori infection by the urease test for the three groups was of 63%, 45% y 20%. When the group of ulcer is compared to the group of non ulcer dyspeptics; the association was found to be of high degree association between H. pylori and gastric lesions, with a relative risk of 3%, a Pc value 0% and an OR of almost infinite. But when the group of ulcers was compared to the control group, the association is of low degree association between H. pylori and gastric lesion, with a relative risk of 1.89%, a Pc value of 0.05 and an OR of 1.50. H. pylori has been considered by different investigators to be the most common infectious agent and to play a major role in the etiology of gastric ulcer, but the results are not homogenous. Infections by H. pylori is much more prevalent in patients with gastric ulcer than in non ulcer dyspeptics and the prevalence is about four times higher in that with gastric ulcer, than in the control group.<EOD> The role of cytokines, chemokines and matrix degrading enzymes in bovine spongiform encephalopathy associated neuroinflammation.\nThe neuropathological phenotype of bovine spongiform encephalopathy (BSE)",
        "label": 0
    },
    "888": {
        "output": "[INFO]\nThe expected information type of this test is: `scalar`.\nExamples of expected scalar information types include:\n\t1.\t0: `Scalar` information type\n\t2.\t4: `Logical` information\n\t3.\t13: `Real` information\n\t4.\t8: `Float` information\n\t5.\t16: `Int` information\n\t6.\t18: `UInt` information\n\t7.\t32: `Ptr` information\n\t8.\t33: `Array` information\n\t9.\t34: `FlexibleArray` information\n\t10.\t35: `Struct` information\n\t11.\t36: `Tuple` information\n\t12.\t37: `Chan` information\n\t13.\t39: `Range` information\n\t14.\t52: `Function` information\n\t15.\t64: `Method` information\n\t16.\t68: `Type` information\n\t17.\t72: `StructField` information\n\t18.\t75: `StructVariant` information\n\t19.\t79: `Slice` information\n\t20.\t80: `Variable` information\n\t21.\t88: `Channel ` information\n\t22.\t112: `Iterator` information\n\t23.\t117: `Resource` information\n\t24.\t122: `Result` information\n\t25.\t126: `Closure` information\n\t26.\t127: `Extern` information\n\t27.\n\t36.\t640: `Error` information\n\t37.\t680: `UnspecifiedObject` information\n\t42.\n\t650: `TypeMismatch` information\n\t670: `Expected` information\n\t675: `Unexpected` information\n\t677: `Type` information\n\t680: `Error` information\n\t7300: `Value` information\n\t7350: `",
        "label": 0
    },
    "889": {
        "output": "Please check the above notes and revise your code if necessary.\n<Trial-level code> #19[TEST]\npatient$trial_level <-factor(patient$name, levels = c(\"0\") #0: Excluded,\n'1') #1: Not relevant, '2') #2: Eligible)\n\n\n## Evaluation question 2: eligibility assessment-in a hypothetical scenario-what would you do with the note in #2\nA 46-year-old woman presents with dizziness and frequent headaches. She had a medical history of CAD, which is controlled by taking 10 mg of aspirin once a day and 20 mg of atorvastatin once a day. The patient's LDL-C and HDL-C levels were 110 and 53\u2009mg/dL, respectively. Her fasting glucose and triglyceride levels (79 and 147\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the LICA,  as well as moderate stenosis in the RICA estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.",
        "label": 0
    },
    "890": {
        "output": "## Answer\n\n## 18 1 2\n\nThe assessment of eligibility for the clinical trial has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\n### 1. Correct Response: Trial level eligibility: 2) Eligible\n\n### Explanatory\n\n### 1. Trial level eligibility: 2) Excluded\n\n### 2. Trial level eligibility: 1) Not relevant\n\n### 3. Trial level eligibility: 1) Eligible\n\n### Explanatory\n\n### 3. Incorrect\n\n## (a) A 46-year-old man with dizziness and frequent headaches \u2026\n\n### Trial eligibility: 2) Eligible\n\n### Explanatory\n\n## (c) Trial-level eligibility: Eligible\n\n## Unstated information and unexamined assumptions\nThe patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively.\nAccording to CDC, Low-Density Lipoprotein Cholesterol (LDL-C) levels are used to predict heart attack and coronary heart disease (CHD) risk. Your level is considered high if it is 190 mg/dL or higher. Most people should aim for a level of 100-130 mg/dL, but it is OK if your level is somewhat higher than 130 mg/dL. HDL-C, is a \"good\" cholesterol. The higher the HDL-C reading, the lower the risk for heart attack and CHD.\n\n# 1. Trial eligibility: 2) Eligible\n\n### Explanatory\n\n### The correct answer was provided by \"unexamined assumptions\".\n\n### Wrong Answer: Trial-",
        "label": 0
    },
    "891": {
        "output": "# CQ3.4 Data-driven CQA\n[CQ] 100% of records in the data set pass CQA checks\n\n# [DATA]\n\n# Data Examples\n[INST] Check data for:\nIncomplete, duplicate or inconsistent data\nImprove quality by implementing automated methods based on clinical decision support systems\n\n# CQ4. Data Quality Checks\n\n# CQ4.1 Completeness of the Data\n[CQ] 100% records in the data set include 100% required fields\n\n# [DATA]\n- Data set(s) with no mandatory fields\n- Missing field(s) in the data set\nReason for Data Collection:\n[CXO] Is the field absolutely necessary?\nCan you justify that a data entry is mandatory? If not, you should remove the field\n- Yes, a mandatory field\n- No, the field is not mandatory, but it would be helpful, but optional\nRecommendation:\n- Remove the field\n- Change field's attribute to `required true` or `required false` for further processing\nReason:\n- When field is mandatory, data quality goes down\nRemarks:\n- For further processing, field's attribute must be `required true`\n- When field is mandatory and no longer used, data quality is not affected when field's attribute is `required false`\n- In case that some data field must be mandatory, but a data field is not mandatory, you will get an error when running data checks\nRecommendation:\n- Set all fields to be `required`, and create a new column `Reason`\n- Move the value of `required` from `required true` to 'optional true'\n- Move the value of `required true` to `required false`\n- Set all mandatory and nonmandatory fields to be `required field`\n- Check that a mandatory field is really mandatory\nReason:\n- In case that some data field must be mandatory, but a nonmandatory field was set mandatory, you will get an error when running data checks\n- In case that some data field must be mandatory, but a mandatory field was made optional, you will get an error when running data checks\nRe",
        "label": 0
    },
    "892": {
        "output": "__37,328__\n\n__5__\n\n__37,313__\nExplanation. Here is a sample to explain what you expect to see in this challenge. Let's review it together.\n\n````\n\n### Patient #0\n\n#### Patient Report\n\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s.\nPlaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\n\n#### CT-angio result\n\n```ct-angio\n--CT angiography:\n--Multiple severe st",
        "label": 0
    },
    "893": {
        "output": "<EOD> Mixed messages: a qualitative study of mental health problems in young offenders in a young offenders\u2019 institution for girls\n\n \n\n## Reviewer\nEileen McDonnell Leicester University, UK REVIEW RETURNED 26-Mar-2014\n\n## General comments\nA qualitative study of young offenders in a young offenders institution for girls in England.\nThe authors aim to describe the mental health problems experienced, focusing on anxiety, depression, self-harm and suicide, and how these issues impact the quality of life of young offenders and influence the relationships they have with other young people. The findings are based on in depth interviews with a small sample. The findings may, be of interest to mental health professionals working in prisons for young offenders..\nThe paper is well written and it flows very well. The abstract is clearly written, concise and covers the key points. The introduction is nicely structured and presents a clear rationale for the study. The methods section is clear, well structured and provides the needed information to enable the reader to assess the reliability of the study. The conclusion has considered limitations to the research and also provides recommendations to the government.\nThe reference list is up-to-date and the author's have not included a single reference or citation in their paper.\nThere were a number of typos in the text. For example in the abstract on page 4 \"In terms of mental health, young people's experiences, both good and bad, is explored to understand how mental health problems in young offenders influence their quality of life and relationships to other young offenders inside the institution\" is missing the \"a\". The list of references on page 31 is not complete, reference number 38 has not been correctly cited on the reference list.\nThere was no reference section for the qualitative reporting guidelines.\nPage 3, 3rd paragraph: \"It was not until the Prison Reform Trust drew attention to the poor mental health within young offenders institutions and the adverse effect it has on other prisoners that the Government started its public inquiries\". I would suggest the quote \"and the adverse effect it has on other prisoners \u2026\" is removed as it makes the sentence hard to understand. The information is repeated twice on page 4.\nPage 7, 2",
        "label": 2
    },
    "894": {
        "output": "[/CODE]\n\n# Discussion\n\nClinics Trials are prospective trials, designed to test whether a treatment is effective or not. A clinical trial is a research study that prospectively evaluates the effects of an intervention on health outcomes in human participants. They are used to improve patient care, both for specific individual medical problems, and for general care.\nIt is important in a retrospective study to confirm results found in trials of similar designs.\nA retrospective study is a research method that uses secondary data (data that has been previously collected for a separate reason than the current study).\nRetrospective, or historical studies, use real world data (RWD) to look for a correlation between existing patient outcomes and a specific treatment.\n\"These outcomes data are typically collected after an intervention, for example, in the treatment of a condition or disease. Such studies can help researchers evaluate how well or how poorly a therapy works.\"\n\n# Clinical trials\nFor broader information about Clinic trials, click here.<EOD> The role of bone marrow adipose tissue in metabolism and the skeleton\nPurpose of review This review highlights the most recent studies that have explored the links between the adipose tissue deposited within the bone marrow and the skeleton, adipokine production, and energy homeostasis. We also discuss the most recent studies examining the effects of altered bone marrow adipous tissue (BMAT) on skeletal metabolism. Recent findings BMAT adipogenesis is driven initially by bone formation and remodeling processes. Once established, BMAT is a mechanosensitive tissue that responds to changes in loading with increases or decreases in the expression of specific adipocyte and osteogenic genes. The functional effects of BMAT include contributions to energy homeostasis, systemic production of adipokines and support of bone homeostasis. In obesity, BMAT increases prior to that in white adipose tissue depots, and appears to support bone and possibly body metabolism differently, depending on whether bone and body weight gain reflects intracortical remodeling or marrow adipogenesis of adipocyte hyperplasia",
        "label": 1
    },
    "895": {
        "output": ".\n\n## Rarely eligible\nYou can mark this patient as \"Rarely eligible.\" If you marked \"Rarely eligible\", it will result in the patient being eligible from the perspective of the trial. You can still continue to recruit patients for the trial. If you select a patient for randomization and that patient is not randomly selected, i2b2 will present you a list of the randomly selected patients for this specific trial. Please select the patients from this list for randomization. Do not send those who are",
        "label": 0
    },
    "896": {
        "output": "<EOD> .\nMorphological and functional studies were made in 40 patients with different forms of chronic glomerulonephritis (CGN), 18 of them with nephrotic syndrome (NS) and 16 of them with proliferative form of CGN (mixed forms of nephritis). Changes in total number of lymphoid organs cells in CGN patients were observed. A possible relationship between this index and development of NS and activity of CGN was established. This relationship may be used as an index of prognosis and of CGN activity.<EOD> .\nThe purpose of this paper is to present the results of a new method of studying the microcirculation through the use of capillary microscopy with the help of a microscope magnifier. The study was performed in 6 children with chronic glomerulonephritis and 16 healthy children of the same range of age. The obtained results are very promising: capillary density is considerably higher than in the other methods; the results of the quantitative capillaroscopy are more accurate; the method is more precise because the same region of the skin is always used.<EOD> The Impact of Aging on Inferior Vena Cava and Pulmonary Vein Velocities and Strain in Dogs\nObjective: This study was conducted to evaluate the correlation between aging and inferior vena cava (IVC) and pulmonary vein (PV) velocities and strain in canines. Methods: Twenty\u2010five dogs aged 4 to 11 years were included in the study. The IVC and PV diameters and pulmonary flow velocities were measured with the use of 2\u2010dimensional and 3\u2010dimensional (3D) echocardiography. The volume and wall thickness of the IVC were measured with 3D echocardiography. The respiratory variation of IVC diameter, IVC ejection fraction (EF), IVC strain, and the right and left atrial peak emptying velocity were calculated. Results: Right ventricular (RV) EF tended to decrease with aging. The diameter of the IVC and RV tended to increase and the diameter of the PV tended to decrease with aging. The IVC systolic forward flow increased with",
        "label": 0
    },
    "897": {
        "output": "[INST]\nYou should make a Patient-level eligibility on each patient for the clinical trial, i.e., output the patient's eligibility. \n\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nWhat is the trial-level eligibility, given the patient's information? Trial -level eligibility: 0) Excluded (does not have a history of smoking, high blood pressure and diabetes mellitus and is",
        "label": 1
    },
    "898": {
        "output": "###### Input:\n###### Output:\n*Note: It may take some time according to the size of clinical trials file. The output will only be displayed when you press the 'Run' button.*\n##### Exercise 3: Find patients who do not meet the inclusion criteria.\nThis exercise is to detect patients who were excluded due to the exclusion criteria. Use a simple statement of the Exclude column to display all columns for screening. You should press Ctrl+F to search for a word by typing in the Find box and then press Enter. \n\nFor the Exclude column, search `Stroke`, `Mi`, and `Tia`. If one of these cases is selected, then the other two cases will also be displayed automatically. \n\nSelect those cases to display the remaining columns. Then apply the following statement. `Select * from patientdata having Exclude=0 and Trialleveleligibility=1`. \n\nIf you press the 'Run' button or check the 'Run All button, then the patient data matching the selection conditions will be displayed. In this exercise, we want to see which patients meet the criteria of the exclusion section of the clinical trial. \n\nThe result:\n\n###### Input:\n###### Output:\n\n\n###### Exercise 4: Elaborate clinical trial data by calculating the proportion of excluded or eligible patients.\nCreate a statement to calculate a column, called Patient's eligibility proportion, which records the patient's eligibility on a clinical trial. Take the proportion of patients who met eligibility criteria by calculating the proportion of patients belonging to eligibility group, according to the proportion of all eligible patients.\n\n#### Exercise: Calculate the eligible proportion of the trial.\n\nCreate a patient count column to calculate the proportions of patients with eligible or excluded status. We calculate the proportion of patients who are eligible or not. In this situation, we must consider not only how many eligible patients are but also how many patients are being excluded. The statement is as follows:\n`select  * , count(Patienteligibility)=Eligible_Count, count(*)=Total_Count, Total_Count/Eligible_Count*100 from patientdata`.\n\nThe result",
        "label": 1
    },
    "899": {
        "output": "## \u2b0c Q1.2\nYou should now have a list of patients that you should include in the clinical trial. Please report the numbers of patients eligible to participate in the trial, the numbers of patients unwilling to participate in the trial, and the reasons for their unwillingness to participate.\nPlease report these numbers with a statistical test (Fisher's Exact test or t-test) and p value in the `Results` section. If there is no difference between groups, no statistical tests are needed. A simple `There was no significant difference.`. is enough and no need to report the statistical test or p value. Also, if you are doing a multiple hypothesis testing, you need to perform Bonferroni correction.\n\n## \u2b0c Q1.3\nFor a more real-world case, what if the patient in question does not have all the factors for inclusion criteria of the clinical trial? Does the patient have to be excluded if he/she lack certain factors? Or is it all right to include the patient with some missing factors? It is the case that the patient doesn't have 1 type of inclusion criteria. Should this patient be automatically excluded from the trial, or will you conduct an assessment to decide whether this patient should be included? \n```\n```<EOD> 15N isotopic labeling of an antibody Fab fragment by protein in situ refolding\nThe feasibility of selectively labeling in situ refolded antibodies on the protein level in terms of amide 15N\u2010H NMR is demonstrated. Both light and heavy chains were found to be isotopically labeled, which is attributed to the low isotopic shift between 14N\u2010 and 15N\u2010labeled protein. The method will find a particular use in the assessment of the impact of N15\u2010labeling on protein stability and dynamics.<EOD> A novel approach for the detection of mycotoxins at ultra-trace level in grains by high performance liquid chromatography with column-switching.\nColletotrichum dematium is a common fungus which produces the mycotoxin dematiacein. It is a dark-brown pigment whose chemical structural formula was elucidated in 1978. The toxin is known to be",
        "label": 0
    },
    "900": {
        "output": "## \u2728 **Important: Do not forget to set the appropriate value for the `trial-level-eligibility` parameter. \ud83c\udf9e\ud83d\ude80\ud83d\udc4d** \u2728\n\n### Checking\n\n### **Step 1: Checking eligibility by the check-eligibility R function **\nLet us assume a new patient with the following clinical trial's eligibility:\n\n    check-eligibility R2_check # Check patient trial-level eligibility by the check-eligibility R function \n \nChecking trial-level eligibility: 2) Eligible. \n \n \n \nChecking trial-level eligibility: Excluded.\n\n### **Step 2: Checking patient-level eligibility by the clinicaltrial el function**\nLet us assume the following patient-level ineligibility:\n \n    clinicaltrial(clinicaltrial, trial) # Patient-level eligibility by the function clinicaltrial \n\nEligibility is evaluated on each patient-level based on the patient and trial: \n \n    clinicaltrial R1 \n \n \n \nPlease click on the trial, R1. You will be asked to verify the trial-level eligibility. \n\nEligibility: Excluded.\n\n### **Step 3: Checking eligibility by the trial-eligibility R function** \nLet us assume patient-level eligibility by the clinicaltrial function: \n \n    trial-eligibility(clinicaltrial) \n \nEligibility checked on the trial-level: 2) Eligible. \n \n \n \nEligibility checked on the trial-level: Eligible.\n\n### **Step 4: Checking the patient-level eligibility by the trial-eligibility R function** \n \n    trial-eligibility(clinicaltrial, trial-level-eligibility) \n \n \n \nEligibility checked on the patient-level: 2) Eligible. \n \n \n \nEligibility checked on the patient-",
        "label": 0
    },
    "901": {
        "output": "Good luck.<EOD> Coma and electroencephalographic changes associated with bullous acral erythema in a patient on ibrutinib\n\n\n\n## In tro duc ti on\nBullous acral erythema (BAE) is a disease of unknown etiology. BAE is characterized by erythematous papules and plaques with dusky hemorrhagic blisters that occur on the dorsal aspects of the finger pulps, palms, and soles [bib_ref]  Bullous acrodermatitis of hallopeau: clinicopathological features and treatment outcomes, Choi [/bib_ref] .\nIbrutinib is a non-covalent Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK. BTK regulates the humoral immune system through maturation and differentiation of B-cells, which is crucial in the process of autoimmunity; therefore, ibrutinib blocks BTK and ultimately causes immunosuppression [bib_ref]  Management of ibrutinib toxicities: a guide for the oncologist, Al-Shamy [/bib_ref] . Cutaneous toxicities associated with ibrutinib can manifest in the oral mucosa, nail bed, and cutaneous appendages, such as acrokeratoelastosis [bib_ref]  Ibrutinib-induced pseudoacrodermatitis-like lesions and hair disorder: a novel cutaneous adverse effect, Mccartney [/bib_ref] . The use of ibrutinib as a first-line agent in chronic lymphocytic leukemia (CLL) has been associated with new skin manifestations . Ibrutinib has been reported to cause toxic eruptions, rashes, and drug reactions, which can lead to the development of Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) like dermatological disorders. Although SJS was never reported during the development of ibrutinib [bib_ref]  A review of rash and other dermatologic complications associated with BCR-ABL tyrosine..., Mckillop [/bib_ref]  , SJS is associated with drug reactions that are typically accompanied by",
        "label": 1
    },
    "902": {
        "output": "### Tutorial\n\nTutorial for eligibility assessment can be found on the [official page](https://academic.oup.com/bib/article-abstract/48/2-3/298/614063) of the article by S. S. Hsu and J. L. Boushel published in 2018 issue of the _Bibliometrics_.\n\nYou can also use the [R-script](https://github.com/fedich/ClinicalTrials/blob/master/demo.R) to complete the exercise. For running the script, put its file in the working directory, open terminal, and type the following:\n\n```\nRscript demo.R\n```\n\n# Changelog\n## v2.0.0 (publ in 22.05.2021)\n\n- new clinical trial data set\n\n## v1.1.0 (publ in 25.09.2019)\n\n- fixed case of incorrect evaluation of all cases with the correct type answer\n\n## v1.0.0 (publ in 13.10.2018)\n\n- minor bugfixes\n\n## v0.3.0 (publ in 11.05.2018)\n\n- fixed evaluation of all cases with the correct type answer (i.e all cases had been marked as correct)\n\n# Discussion\n\nIf you have any comments or questions to this page, go to the topic discussion here [Discussion][2].\n\nIf you want to report a bug of this solution by the author, please [open new issue][3] on GitHub.\n\n\n   [1]: https://academic.oup.com/bib/article-abstract/48/2-3/298/614063\n   [2]: https://github.com/fedich/ClinicalTrials\n   [3]: https://github.com/fedich/ClinicalTrials/issues\n<EOD> .\nDuring the period from 1983 to 1998, a review of 1410 patients who received treatment at the Department of Thoracic S",
        "label": 0
    },
    "903": {
        "output": "### Notes\n*The task of the patient note in this problem is the assessment of eligibility that includes three factors: LDL, HDL, smoking. The patient note includes the information about the LDL value, HDL value, smoking, age, gender, and the clinical trial includes the information about including criteria for age, gender, and smoking. \n*The clinical trial assessment of eligibility is always 2, because there is no patients or no data to exclude or not relevant.\nTo see the details of the patient note on screen, go to the top page of the notebook, press `Control` \u229b `Z` and then, go to the top page of your notebook again. \n\n## Clinical trial patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (.70, 72, and 21%),  as well as moderate stenosis in the right internal carotid artery (.40, 70, and 25%\n). For the left internal carotid artery,.5 and 9). For the right internal carotid artery(.75, 80, and 22.5%).\nPlaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) (.",
        "label": 0
    },
    "904": {
        "output": "[/DOC]\n\n## Part B: Exercise\n\nIn the following two exercises, you will assess each patient and clinical trial information by yourself and give appropriate answers. For questions with multiple choices, highlight only correct answers.\nFor the exercise part, you should choose the correct answer with the highest percentage on the given question.  \n\n``` python\nprint(\"[Part B]: Exercises\") \nprint(\"============\") \n\n\n##[*] Part_B_Assess_Inclusion_and_Exclusion_criteria_in_Dulaglutide_in_Diabetic_Patients\ninput_file_name = input(\"Enter your file name: \")\nopen(input_file_name, \"r\").read()\n\npatient_note = input(\"Assess the patient's inclusion and exclusion criteria in Dulaglutide in Diabetic Patients: \")\npatient_note = patient_note.split(\", \")\n\nclinical_trial_info = input(\"Assess the clinical trial's inclusion and exclusion criteria in Patient's disease: \")\nclinical_trial_info = clinical_trial_info.split(\", \")\n \ndef Part_B_Assess_Inclusion_and_Exclusion_criteria_in_Dulaglutide_in_Diabetic_Patients( \n        input_file_name, patient_note, and clinical_trial_info \n        ) :\n    def print_help( ) :\n        print(f\"Assess the patient's inclusion and exclusion criteria in Dulaglutide in Diabetic Patients:\")\n        print('\"Assess trial's inclusion and exclusion criteria in Patient's disease:\")\n    def main( ) :\n        with open(input_file_name, \"r\").as_file():\n            patient_note = open(input_file_name, \"r\").read().split(\", \")\n            clinical_trial_info = open(input_file_name, \"r\").read().split(\", \")\n            if len(patient_note) == 2:\n                if len(patient_note[0]) == 2: \n                    print_",
        "label": 0
    },
    "905": {
        "output": "[EXERCISE]\n-  2) `Trial-level eligibility: 2) Eligible.` for the patient.\n-  2) `Trial-level eligibility: 2) Eligible.`\n<nextstep>E3</nextstep>\n[INFO]\n-   `patient_note.jn-s1_exam_data: 46,``patient_note.jn-s1_exam_data: 44,``patient_note.jn-s1_exam_data:`\n    -  patient_note.jn-s1_exam_data: 46,`\n      3.049, 3.1886815596211, 131560, 45, 447, 0.52123153850712, 365, , \n    -  patient_note.jn-s1_exam_data: 44,`\n      4.1664768112053, 4.32348099777166, 5782.6, 44, 339, 0.72796399112799, 364, \n    -  patient_note.jn-s1_exam_data: 44,`\n      4.1664768112053, 4.32348099777166, 5782.6, 44, 339, 0.72796399112799, 364, \n    -  patient_note.jn-s1_exam_data: 44,`\n      4.1664768112053, 4.32348099777166, 5782.6, 44, 339, 0.727963991",
        "label": 0
    },
    "906": {
        "output": "## Instructions for clinical trial recruitment.\nNow let's make a model to answer the following questions.\n\n## How do you think this person will be assessed for eligibility for this clinical trial?\n\nPlease explain why you said this was the clinical trial assessment score. How would you evaluate clinical suitability?\n\n## [discussion]\nWhen making a clinical trial assessment score, in the example of the patient given above, what clinical information (such as stenosis severity, plaque characteristics etc.) will you take into account? Please explain why you said this was the clinical trial assessment score. How would you evaluate clinical suitability?\n\n\n## [instructions to revise]\nYou should revise your answers for the questions above according to the following points.\n\u2022\n- After obtaining enough information about the clinical trial, do you still believe that the patient, given his or her particular clinical profile, meets or does not meet inclusion criteria in terms of the disease? \n\u2022\n- Evaluate whether it is possible to include the person in the trial and if not, why? \n\u2022\n- Based on your analysis, how would you score the patient using the following options: 0: Excluded, 1: Not eligible, 2: Eligible.\n\n## [discussion]\nAccording to your analysis, which clinical information should be analyzed first? What factor plays the most important role in inclusion or exclusion criteria?\n\n## [instructions to revise]\nYou should rewrite your answers for the questions above according to the following points. \n- You should show your reasoning for the inclusion/exclusion of patients in the clinical trial.\n- You should explain why you think this clinical trial is likely to include/exclude this person based on your analysis.\n- You should mention each inclusion/exclusion factor (with score) that may affect the decision of patient inclusion/exclusion from the clinical trial.\n- You should explain why you think the patient will be included (score 2: Eligible) or excluded (score 0: Excluded) from a clinical trial.\n\n##\n\n## [discussion]\nIn the example clinical trial, what information is missing from the patient's medical history? Based on your analysis, what information",
        "label": 1
    },
    "907": {
        "output": "* If you are satisfied with your evaluation, you can press `Submit` button. Your answer will be recorded in the output of your evaluation.\n<EOD> Chrysin inhibits UVB-induced acute inflammation by regulating the NER and MAPK/Erk pathway.\nChrysin is a natural flavonoid with various pharmacological properties, including antiaging, anticarcinogenic, antiangiogenic, and neuroprotective properties. However, the protective effect of chrysin on UVB-induced acute inflammation and the underlying mechanism have not been studied. Thus, UVB irradiated animal models were established to investigate the preventive effects of chrysin on UVB-induced acute inflammatory skin damage. The study showed that oral administration of chrysin can inhibit UVB-induced inflammation. The expression of inflammatory factors in skin tissue, including tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), IL-6, and IL-4, and the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) and p38, and ERK5 after UVB exposure were significantly decreased by chrysin treatment. Additionally, chrysin also increased the expression of nucleotide excision repair (NER) proteins, including excision repair cross-complementing protein 1 (ERCC1), ERCC4, and ERCC5. In keratinocytes and fibroblasts isolated from hairless mice, chrysin inhibited activation of ERK and ERK1/2, p38, and p38, and ERK5 were decreased by pre-treatment with chrysin in HaCaT and NIH/3T3 cells. Activation of ERK and p38 were inhibited by overexpression of ERCC1 in NIH/3T3 cells, while the phosphorylation of ERK1/5 also decreased significantly. These in vivo and in vitro experiments suggested that chrysin may play a certain role in UVB-induced acute skin inflammation by regulating the ERK1/2,",
        "label": 1
    },
    "908": {
        "output": "<EOD> The effect of endotoxin on interferon therapy for chronic hepatitis C. A randomized controlled study of interferon in treatment-naive patients with chronic hepatitis C genotype 1.\nOBJECTIVE\nTo investigate the effect of endotoxin (LPS) on interferon (IFN) therapy.\n\n\nPATIENTS AND METHODS\nIn this prospective, randomized, controlled study, 81 patients chronically infected with hepatitis C virus type 1 (HCV) were treated in a standard 24-week protocol using IFN combination therapy (IFN-alpha2b and pegylated-IFN-alpha2b). The patients, who had previously not received IFN therapy, were randomly divided into groups A and B. Group A patients were treated with IFN for the initial 4 weeks and group B patients were treated with IFN for the initial 2 weeks. Then, the two groups were matched to have similar LSP levels before the randomized intervention commenced. To standardize the LSP levels of the patients, all of the included patients were treated with a LPS binding protein (LBP, 1.5 g/daily) for the first 4 weeks. Sustained responders were reevaluated using a liver biopsy at 3 post-therapy years.\n\n\nRESULTS\nGroup A had a higher percentage of sustained responders than group B (62.5% versus 31.6%; odds ratio = 3.69; 95% confidence interval: 1.29-10.52). Group A patients had a better histological response, as demonstrated by lower necrotic activity index scores (0.60 versus 1.30). A negative correlation was defined between LSP levels at endpoint, and the degree of necroinflammation (r =-0.57, P = 0.0001); LSP levels at endpoint correlated negatively with the degree of fibrosis (r =-0.58, P = 0.01). The LSP changes at 4 or 6 weeks were not significantly different between the two groups. After reevaluation, group A patients were more likely to have more obvious",
        "label": 0
    },
    "909": {
        "output": "# 2.2.3 Sample Size\nThe sample size is calculated before recruiting study participants to ensure that the study has adequate power to detect treatment effects. This is based on the following information. \nA total of 126 participants are expected to finish the study.\n\n\n# 2.2.4 Outcome Measurements\nOutcome measurements should be clearly defined at the beginning of a clinical trial. You should note that a measurement is a value of a certain characteristic of the disease under study. There are many types of outcome measurements, such as clinical parameters, adverse events, and quality of life (QOL).\n### Outcome measurements of clinical parameters \nThe clinical parameters are indicators of the disease state that describe the characteristics of the disease, including the symptoms, results of laboratory",
        "label": 0
    },
    "910": {
        "output": "[INST] ENDIF \n\n\n\n\nA: It's probably not what you're looking for but what you want is the most common answer.\nTo achieve this, I would set the output variable to be the most common value (eg. 2, so that if the answer is 1 then ignore, else 2 is your answer).\n<EOD> .\nMalignant melanoma of the female genital organs is described. As a rule, the tumour first originates in the vulva (88 patients, 86.6% of cases) or the vagina (11 patients, 10.8%). The treatment of choice is radical surgery. Taking into account that only approximately 5% of patients have the opportunity for radical surgery, systemic chemotherapy is also used. Chemotherapy of the tumour may have a promising effect since the drug used in large amounts is able to damage the tumour cell DNA and cause an apoptotic process in it via the p53 gene (a tumour-suppressor gene). One of the promising chemotherapeutic drugs is dacarbazine with its inhibition of the TYR gene, which is overexpressed in melanoma. Dacarbazine is also used alone or in combination with other cytostatics.<EOD> Diagnostic Usefulness of MRI in Fibrous Dysplasia\n\nThis study investigates the usefulness of plain MRI in fibrous dysplasia of rib in detecting the location, the character and the extent of this lesion. Twenty four cases of fibrous dysplasia of rib treated at our institution between March 2004 and May 2014 were retrospectively analyzed. Plain radiographs, CT and MRI were reevaluated to measure the size and location of the lesion. The lesion's location and extent were described as being near the costochondral junction (group 1), the costophrenic angle and the end of rib (group 2), and the diaphysis of the rib (group 3). All patients in group 3 showed no osseous involvement on plain radiograph or CT, whereas 9 patients in group 1 or group 2 showed a demineralized lesion of fibrous",
        "label": 1
    },
    "911": {
        "output": "### Exercise 8: Data cleaning on a real-world dataset\n\nIn this exercise, we will apply some basic data cleaning tasks to this dataset,  in particular:\n\n- 1. Filter out the records if the value of the variable called `type` is in the list `[0 1]`: i.e., if the `type` is either 0 (not diabetic) and 1 (diabetic).\n\n- 2. Drop the first record of all the columns that are empty.\n\n- 3. Remove rows with a missing `type` or `sex` variable.\n\n- 4. Sum the values for `hours_sport_per_week` using `sum()` function, and transform it with `as.numeric()` function, to take only the values and not the names of categories, e.g., like  is not true.\n\n- 5. Transform into binary the variables `hours_sport_per_week` and `body_mass_index`.\n\nNow, we load the dataset from the file `realworld-small-dataset.csv`:\n\n~~~ [INST] {\nimport pandas as pd\ndf = pd.read_csv('realworld-small-dataset.csv',names=['type','sex','alcohol',\n'smoking', 'hour_of_sport', 'week_of_sport', 'sport', 'body_mass',\n'body_mass_index'])\ndf\n~~~\n\nWhat if the type of diabetes is not given? \n\nSometimes it can be interesting to have a look at a variable without giving it at first, since that may tell you something interesting about that column. In this question, instead of the column `type`, we are looking at the column named `gender`. So, let's write again this part of code in this way:\n\n~~~ [INST] {\nimport pandas as pd\ndf = pd.read_csv('realworld-small-dataset.csv',names=['gender','sport','body_mass'])\ndf\n~~~\n\nAnd now, try to guess what that looks like.\n\nThe column `gender` presents the value  `type=1`, which means that  the person is female. Let's see why",
        "label": 0
    },
    "912": {
        "output": "<a href=''><img src='https://avatars1.climateaudit.com/u/867823?s=48&u=3fbf79c27ee1d6ff509c042c010baecd40a27758' width='280' height='300' /></a>\n\n\nI hope my solution helps you.\n\n---\n#### Solution Summary\n\nThe answer can be found in the patient note. \n\n 1. The patient has a heart disease, i.e., family history of CAD.\n 2. His cholesterol level is high, 545 (LDL-C \u2265 190 mg/dL).\n 3. His triglycerides are normal or a little higher, 158 (> 150mg/dL).\n 4. His LDL-C is almost 5 times the limit of 130 mg/dL.\n\nBased on the cholesterol level and the family history, you can conclude that the patient is eligible for the clinical trial. \n\n---\n#### Solution References\n\n<a href=''>https://www.ncbi.nlm.nih.gov/pubmed/?cmd%3Dsearch%26term_key%3D[family_history%20of%20coronary%20%20artery]%2B%26cmd%3Ddopts'>Family History of Coronary Artery Disease</a>\n\n<a href=''>https://www.ncbi.nlm.nih.gov/pubmed/?cmd%3Dsearch%26term_key=cholesterol%20level%20and%20[triglycerides%20or%20triglyceride]'>Cholesterol level and Cholesterol-lowering agents</a>\n\n<a href=''>https://www.healthline.com/health/cholesterol#causes-risk-factors>Cholesterol level and Risk factors for Elevated Cholesterol</a></body>",
        "label": 1
    },
    "913": {
        "output": "# Conclusion\n\nAn efficient and accurate recruitment of eligible patients to a trial is a crucial step for the success of a clinical trial or study. Many criteria must be satisfied to obtain an eligibility for the trial:\n\n## Inclusion criteria:\nThe age from 18 to 67\nThe male gender\nThe history of previous elbow joint fracture, and\nNot meeting the criteria of exclusion.\n\n## Exclusion criteria:\nNot satisfying the three above: the history of previous elbow joint fracture.\n\n## The patients who",
        "label": 0
    },
    "914": {
        "output": "## [/PART TA B LE]\n\n<h3 id=\"LimitedPart2\">Limited Problem 2: Eligibility of Cardio-Vascular Trials: 2-Day 2</h3>\n\n### Recap of Recent Cardiovascular Research\n\nIn this problem, we learned that cardiovascular disease (CVD) is a group of heart and blood vessel conditions.\n\n[1] Incorrect \u2461: You should not have excluded any patient.\n\n[2] Incorrect \u2464\u2463\u2464: \nA 56-year-old man, who has no evidence of carotid artery stenosis, presents with dizziness and frequent head",
        "label": 1
    },
    "915": {
        "output": "<EOD> Molecular detection of Bartonella spp., Coxiella burnetii, and Anaplasma spp. among flea species collected from dogs in Sinaloa, Mexico.\nCanine vector-borne diseases are emerging public health hazards around the globe. Their most important determinants are the animal parasites, which are infected by the vector-borne pathogens. Dermacentor spp. were the most highly infected (flea infestation 45%) and, therefore most likely, may be considered a threat to people and other animal species. In this study, the Bartonella spp. and Anaplasma spp. infections were detected in low numbers. On the contrary, Coxiella burnetii was detected in 124 flea pools and has the highest prevalence (73.5%).<EOD> A method to estimate the effect of alcohol on liver enzyme activity.\nOBJECTIVES\nTo assess whether using serial alcohol measurements in the calculation of the relative liver enzyme activity can improve our diagnostic accuracy for severe forms of alcoholic liver disease (ALD), we investigated the reliability of 2 different calculation methods for the estimation of the effect of alcohol on liver enzyme activities.\n\n\nMETHODS\nOne hundred subjects of both sexes, referred to a gastrointestinal endoscopy outpatient clinic, were asked to perform 10 consecutive 15-minutes sessions of an alcohol intake test. Serum levels of aspartate aminotransferase (SGOT) and alkaline phosphatase (GGT), with and without alcohol intake, were estimated. Liver enzyme activity and the effect of alcohol on enzyme activity (EA) were estimated with 2 widely accepted approaches: the \"simple method\" (SM-EA), in which the enzyme activity is estimated under the assumption that after alcohol intake the liver enzyme levels are the same and there is no time lag with respect to the intake, and the \"long-term calculation\" (LTC-EA), which includes serial measurements of alcohol concentration and assumes a certain time lag after alcohol intake, which was defined to be the time needed to reach 50%",
        "label": 1
    },
    "916": {
        "output": "[INST]\nYou are a physician and you are in charge of a research-focused department. You are trying to conduct a new investigation to treat chronic heart failure (CHF). CHF is a complex condition in which the heart can't pump blood, and the heart fails at low level of stress and requires increased heart load to achieve a normal output and blood pressure.\nYour proposed trial has three arms: two treatment arms (oral standard therapy) and one placebo treatment arm. Your primary endpoint will be the left ventricular ejection fraction (RV-EF) [bib_ref]  Left ventricular ejection fraction: is it as good as we think?, Pond\u00e9 [/bib_ref]  , which is a clinical parameter defining the functional capacity of the left ventricle of heart in a patient with heart failure, and secondary endpoints will be the 6-minute walk test (6MWT) [bib_ref]  Six minute walk test in heart failure: Is it a better prognostic..., Cao [/bib_ref]  and Minnesota Living with Heart Failure Questionnaire (MLHFQ) [bib_ref]  The reliability of the Minnesota Living with Heart Failure questionnaire improved in..., Rector [/bib_ref]  , which define the quality of life. Before the real trial starts, an observational pilot study was conducted to compare the standard treatment and placebo group in three months follow-up. The trial was designed to include 20 participants in each arm: 20 in the placebo group, 20 in the standard treatment group, and 20 in the standard treatment group.\nThe primary endpoint, the average of repeated values, is collected at baseline (t0), after 1 month (t1), and after 3 months (t2) and will be given in percentage.\n\nHere are the clinical and demographic data of the sample in the placebo group. \n\nYou may calculate the sample sizes for your placebo and standard treatment group using the following steps [bib_ref]  Sample-size determination, Dell [/bib_ref]  : \n- Calculate the pooled variance of the sample.\n- Divide it by the pooled SD and multiply by the pooled SD. Then multiply the result by the desired power of\n\n# Exercises\nWrite your code and paste it in the comments.\n\n## Exercise 1\nInput variable `v",
        "label": 1
    },
    "917": {
        "output": "For example, you get a patient report and a clinical trial criteria table as follows:\nThis is the patient report:\n\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.[1]\nHere is the criteria table of a clinical trial:\nInclusion criteria:\n   \n1. Patient is a resident of USA\n   \n2. Patient has a documented history of hypercholesterolemia (elevated LDL of 190 to 400; average LDL > 190 mg/dL, and",
        "label": 1
    },
    "918": {
        "output": "4.2 Inflammation \n[INST] Hello. You have a very important task. Your job title is \"Biostatistics Expert\" and you work in a pharmaceutical company. As a Biostastical Expert, in some of your latest studies, you are asked to analyze the levels of inflammation biomarkers and other biomarkers in blood samples from patients who have diabetes. After measuring, a group of statisticians determines what kind of value it is. You will now look at the levels of these biomarkers and determine their levels by evaluating the charts. The chart below shows the levels of four biomarkers over time for one of your study's patients.\n\nC-reactive protein (CRP): a protein produced by the liver. Its levels gradually rise after inflammation takes place.\nMonocyte chemoattractant protein-1 (MCP-1): a protein found in a person's urine and blood to move white blood cells (WBC) to the site of inflammation.\nVascular cell adhesion molecule-1 (VCAM-1): an adhesion molecule on the surfaces of cells that allows WBC and leukocytes (circulating cell of the immune system) to attach. VCAM-1 is secreted by activated vascular endothelial cells and is a highly specific biomarker for the inflammation of the vascular endothelium.\nErythrocyte sedimentation rate (ESR): is a method to test for inflammation. It is an indirect measure of how fast red blood cells (erythrocytes) fall to the bottom of a tube filled with blood. The result is given in millimeters per hour. The ESR becomes high when body inflammation increases.\nThe following questions need to be answered:\n\n### Q-1. Which of the tests/biomarkers will be significantly increased with the onset of infection? Answer: MCP-1\nThe levels of biomarkers vary from patient to patient. There is no value for all patients. Based on the increase in the biomarker levels (indifference), in general, the biomarker that you think will be increased is MCP-1.",
        "label": 1
    },
    "919": {
        "output": "<EOD> The effects of a physical therapy rehabilitation program with postural training on postural control in school children with cerebral palsy: A randomized controlled trial\n\nBackground: Postural control in children with cerebral palsy (CP) is compromised, increasing the risk of injury. However, there is a paucity of effective interventions for improving postural control in children with CP. Objective: To investigate the effects of a physical therapy rehabilitation program with postural training on postural control in children with CP. Methods: Thirty children aged 2-10 years with spastic diplegia were randomly divided into a physiotherapy treatment and a control group. Both groups received treatment according to routine clinical practice. The therapy group also received the intervention. The outcome measures of this study included the Modified Tardieu Scale (MTS), Gross Motor Function Measure (Gross Motor Function Classification System-GMFCS), the revised version of the Movement Assessment Battery for Children (MAB-II), the Pediatric Reintegration to Daily Existence (PRTEE), the Pediatric Evaluation of Disability Inventory (PEDI), the Bruininks-Oseretsky Test of Motor Proficiency, second edition (BOT-2), the Physical Self-Description Questionnaire (PSDQ) in the physical domain, the Postural Assessment Scale for Stability (PASS), and the Movement Assessment Battery for Children-Postural Assessment (MABC-S). The children were assessed at baseline and after 12 weeks of treatment. Results: The physiotherapy treatment group showed significant improvements in the MTS, MABC-S, GMFCS, PSDQ in the physical domain, MAB-II, BOT-2 gross motor skills: body balance, equilibrium, coordination, flexibility, dynamic motor skills (jumping, hopping, and running), and in the PASS and PEDI physical abilities subscale. Conclusion: The study suggests that treatment with a focus on posture is efficacious for improving the postural control of children with CP. CLINIKA, 2012; 18(2): 175Y187\n\n# Introduction",
        "label": 0
    },
    "920": {
        "output": "This program, `Evaluate.jl` can be downloaded from Github, but I only provide the first step. \n[https://github.com/HungLeDo/AnalogyPhenomenon.jl]\nThe program, you can download from [https://github.com/HungLeDo/AnalogyPhenomenon.jl](https://cran.r-project.org/web/packages/AnalogyPhenomenon.jl/index.html). [INST] [INST]\n\nPlease note that this paper is published in 2016, but the problem in 2019 should be still current. \n[https://doi.org/10.6084/m9.figshare.4480775.v1](https://doi.org/10.6084/m9.figshare.4480775.v1)\n\n\n[INST](https://github.com/HungLeDo/AnalogyPhenomenon.jl): Julia package with Analogy programming\n\n\n[INST](https://github.com/HungLeDo/AnalogyPhenomenon.jl): Julia package with Analogy programming \n\n#### 1. Install the packages\n\nAdd the following code in a `.julia` file in the root folder of your `julia` installation. \n```julia\nusing Pkg;\npkg\"activate\"(\"AnalogyPhenomenon\")\n``` \n\n#### 2. AnalogyPhenomenon package documentation\n\nLet's take a look at the following code. \n```julia\nusing AnalogyPhenomenon\n``` \n\n```julia\nAnalogyPhenomenon.test_analogy_phenomenon()\n``` \n\nWe can see that this is the end of our Julia program. \n\n\n\nThe following code can generate an optimal solution as a list of variables. \n```julia\nAnalogyPhenomenon.eligibility_list(trial, patient_note, Clinical_Trial, Evaluation)\n``` \n\nIf you want to get all, let's take a look at the following code. \n```julia\nAnalogyP",
        "label": 0
    },
    "921": {
        "output": "Happy recruiting! [CIT]\n\n\nA: In python, Pandas is the de facto standard library for data manipulation and analysis in python. It has an extensive documentation and a large user base. It contains numerous data structures and operations suited for work in a broad variety of domains and data sources. It is the primary data structure in Python due to its unique features, such as reading data from text file, sorting, manipulating strings in a fast and efficient manner, reading excel sheets, etc.\nIt also has a very friendly and easy to understand interface and is also very user friendly in terms of operations and workflows. Pandas is also able to handle very large data sets and is a very efficient library with great performance when it comes to handling data in large scale. In particular, it is preferred over other methods by many large companies and institutions. Pandas is often used by data analysts, statisticians, researchers, and people who work with a lot of data.\nHere is a good documentation of Pandas: [https://pandas.pydata.org/pandas-docs/stable/](https://pandas.pydata.org/pandas-docs/stable/), which is quite extensive and has step by step examples to help with the learning process.\nA: \nMy recommendation would be to try Pandas. It is a very comprehensive Library for data. As you can see it can do a lot. As you can see it doesn't do everything. Maybe if you want to get into NLP or sentiment analysis you will need to look for other libraries. But there is a lot of info here:\n\nI have never had a problem with Pandas. I used it a lot as well. It is one of those things that once you start using it, you will use it over and over.\nIn your example the one extra thing you don't do is check that the 2 variables are the same size. In the example that is the difference between a and b. You did not need to use the .isiterable if you know both arrays are the same size. \nLet me know if you have any issues. \nA: For your case\n\nA: I would strongly recommend to use the pandas library because the pandas library can automatically calculate the results for you and plot the graph for you.\nThis is what the pandas library can do:\n\nA: Since you are starting with python so I will take",
        "label": 1
    },
    "922": {
        "output": "Good job! You are doing great!\n\nAs a side note, don't forget to consider the case of tied decision-reaching. Note that tied-decision is very rare, especially in this competition, because usually there is only one right answer. In this case, you have to assign the final mark for your test to the highest grade.\n\n\n\n\n### Solution\n\nYou could solve this problem in a dynamic way by recursively checking if we need to assign additional values in the current stage.\n\n```python\ndef is_eligible(patient_note: str, trials: list) -> int:\n    if len(trials) == 1:\n        if patient_note == f\"S/I\": # This is for patients who will be included\n            return 2\n        else: # This is patients who are excluded\n            return 0\n\n    result = 0\n    for trial in trials:\n        # We only need to check current eligibility status\n        if not is_eligible(patient_note, trial):\n            # We need to increase the score for trial\n            result += 1 \n\n    return result\n```\n<EOD> Exploring the genes and variants involved in the pathogenesis of a case of atraumatic anterior shoulder dislocation. A candidate gene association and RNA-seq-based gene expression analysis\nAtraumatic anterior dislocation of the shoulder joint is an injury of very rare occurrence, accounting for a small percentage of all anterior shoulder dislocations. Due to the rarity of this injury, the pathogenic mechanism of atraumatic dislocation remains unclear. The aim of this research is to better understand the etiopathogenesis of atraumatic anterior shoulder dislocation using a candidate gene association and RNA-seq-based gene expression analysis. A 40-year old male subject of normal constitution experienced sudden, painful reduction of the right shoulder joint while making a shoulder stretch. Magnetic resonance imaging revealed anterior humeral head subluxation. An anterior shoulder exploration was performed, with the humeral head reduced and fixed with a hook plate. A histological sample was collected during the surgical procedure. The patient was included in this research project and gave written informed consent. The sample was stored at -80\u00b0 C for future molecular studies. A",
        "label": 0
    },
    "923": {
        "output": "##[OUT] You are a helpful assistant in a research study of the effects of coffee on the heart of a male rat. your job is to determine whether coffee extract has an effect on the weight of a male rat heart within a specified interval.\nYour task is to compare the ratio of heart weight to body weight of the control and test rats within a specified interval. The control group was given water and the test group was given coffee extract.\nYou input a number in `Weights:`, e.g., `Heart weight: 0.12`. This is the number of the control group. Note that the weights are automatically summed, i.e., weight sum = Heart weight + Body weight. \n`Heart weight: 0.3`. This is the number of the test group. \n\n### 1.23:\nYou are a research assistant in a study assessing the effect of cigarette smoking on blood pressure (BP).\n\n### 1.23.1:\nYour data is structured in three columns: `Time` is a variable that contains BP values over eight time intervals for the two groups. `Group` is a variable that contains a coded variable of one or zero. `Mean` is the variable denoting the mean of `BP over eight time intervals`. Now the values of `Mean` in the two groups `Time 1-8` are shown below (note that `Time 1-8` is also the name of columns, not variables). \n\n### 1.24:\nIn a study, we assess the diabetic neuropathy in type 2 diabetic patients.\n\n### 1.25:\nThe assessment of diabetic neuropathy is in three steps: 1) The measurement of the lower leg and ankle reflexes; 2) the assessment of foot sensation by touch, vibration, temperature and pain; 3) measurements of nerve conductions (e.g., motor and sensory nerves). According to these data, we determine whether each patient is in the stage of normal status, peri-neuropathy or the status of diabetic neuropathy. A complete assessment of these parameters determines the clinical status of the patient.\nHere is a patient record: \nNow",
        "label": 1
    },
    "924": {
        "output": "A: There is a missing \"(\" at the top left. This is probably the result of a copy-paste from your PDF. \nIn\n\n  ` 130 to 150 (mmHg) `\n\nYou can replace the brackets around 130 to 150 (mmHg) by a bracket around 150 as you did in \n\n  ` 80 to 160 (cm/s) `\n\nin the next line.\n\nA: Try to use it as:\n\n\n\n<table width=\"100%\" border=\"1\" class=\"codeblock\">\r\n<caption>Code snippet</caption>\r\n  <tr>\r\n    <th valign=\"top\"><pre class=\"codeblock\">\t\t\t\t\t\t\t\t\t\t\t\t\t\t130 to 150 (mmHg) &#x203F; 130 &#x203F; 150, 150 to 160 (mmHg) &#x203F; </pre>\r\n\t</th>\r\n\t<th valign=\"top\"><pre class=\"codeblock\">\t\t\t\t\t\t\t\t\t\t\t\t\t\t(cm/s) <span class=\"mod\">&#x203F; 80 to 160 (cm/s) &#x203F;</span> </pre>\r\n\t</th>\r\n </tr>\n</table>\n\nI haven't tested it, but the syntax is not fully correct. You should probably correct it beforehand, if you want the <strong>span </strong>tag to work.\n\nA: Please, see my answer to this question\nI also suggest you to use proper HTML tags instead of inline code. This will reduce the space of your posts. The code should look like the following:\n<h4>\n\u00a0\nTitle:\nOptimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) \n\u00a0\nSummary:\nHigh blood pressure (BP) is a major public health concern, especially in low and middle income countries. High BP is a highly",
        "label": 0
    },
    "925": {
        "output": "### Exercises\nFor more exercises about eligibility assessment and others exercises of your first task, you can go back to the last page.\n- 61: Eligibility assessment\n\nHungry for more?\n\nWe invite you to continue the learning experience:  \n- 61: Eligibility assessment\n- 65: 10-year risk of vascular death\n\n## 61: Eligibility assessment\n\n### Scoring\n\nWhen the computer's score is green, it means that both the first and the second options are true, which makes a score of 100% on the first problem. This means that the computer scores you correctly, in case of red, the first one is marked incorrect and that the reason of this mark is described.\n\n#### 1) Check the score\n\nWhen the computer's score is green, it means that both the first and the second options are true, which makes a score of 100% on the first problem. This means that the computer scores you correctly, in case of red, the first one is marked incorrect and that the reason of this mark is described.\n\n### Scoring\n\nWhen the computer's score is green, it means that both the first and the second options are true, which makes a score of 100% on the first problem. This means that the computer scores you correctly, in case of red, the first one is marked incorrect and that the reason of this mark is described.\n\n#### 2) Check the score\n\nWhen the computer's score is green, it means that both the first and the second options are true, which makes a score of 100% on the first problem. This means that the computer scores you correctly, in case of red, the first one is marked incorrect and that the reason of this mark is described.\n\n### Scoring\n\nWhen the computer's score is green, it means that both the first and the second options are true, which makes a score of 100% on the first problem. This means that the computer scores you correctly, in case of red, the first one is marked incorrect and that the reason of this mark is described.\n\n#### 3) Check the score\n\nWhen the computer's score is green,",
        "label": 2
    },
    "926": {
        "output": "[INST] Example: \n```\n# + language: python\n# + title: Step 1. Read in input data\n# +\ndata <- read_txt(\"../data/sample_data.txt\")\ndf_patients_criteria <- data\ndf_patients_criteria <- df_patients_criteria [df_patients_criteria$id %in% data$ID]\ndf_patients_criteria <- df_patients_criteria [ df_patients_criteria[,df_patients_criteria$age]<=65, ]\n\ndf_patients_criteria <- df_patients_criteria\ndf_patients_criteria <- df_patients_criteria [df_patients_criteria$gender~=\"m\", ]\ndf_patients_criteria <- df_patients_criteria [df_patients_criteria$gender~=\"f\", ]\ndf_patients_criteria <- df_patients_criteria\ndf_patients_criteria <- df_patients_criteria [df_patients_criteria$gender  == \"m and age > 65\", ]\ndf_patients_criteria <- df_patients_criteria [df_patients_criteria$gender  == \"f and age > 65\", ]\ndf_patients_criteria <- df_patients_criteria [df_patients_criteria$type_of_study~=\"clinical intervention study\", ]\ndf_patients_criteria <- df_patients_criteria\ndf_patients_criteria <- df_patients_criteria [df_patients_criteria$type_of_study~=\"clinical interventional study\", ]\ndf_patients_criteria <- df_patients_criteria\ndf_patients_criteria <- df_patients_criteria [df_patients_criteria$type_of_study~=\"randomized controlled trial\", ]\ndf_patients_criteria <- df_patients_criteria\ndf_patients_criteria <- df_patients_criteria [df_patients_criteria$id~=\"3\", ]\n\ndf_patients_criteria <-",
        "label": 1
    },
    "927": {
        "output": "> Example\n```python\ndf['Cardio. (last visit)'].max()\n```\n\n#### [/BOLD] Expected Output\n\n```\n1\n```\n\n#### [/BOLD] Explanation\n\nThe patient's last visit date is 24/05/2012, and there are 10 visits in total. \n<EOD> The impact of the COVID-19 quarantine on sleep quality in patients with narcolepsy type 1\n\nThe novel coronavirus disease-19 pandemic forced billions of people into lockdown. Since patients with narcolepsy type 1 (NT1) already have poor sleep, it poses a challenge to study the effects of quarantine time on sleep behavior in these patients. Thus, the purpose of the study was to survey the effects of lockdown and social isolation during the coronavirus (COVID-19) pandemic on sleep quality in patients with narcolepsy type 1 (NT1). In an online survey-based research we used the Pittsburg Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) to collect data, and also asked patients to indicate perceived changes to their sleep",
        "label": 0
    },
    "928": {
        "output": "You might be asked about other questions, such as:\n\n\n*   Are there any exclusion criteria in this clinical trial for the eligibility assessment of a healthy person?\n\n### HINT\nThe exclusion criteria of the clinical trial are the clinical study requirements for the exclusion of the assessed person.\n\n## AORTA SCANNING\nPatients with stenosis of aorta need to be referred for further procedures in the form of treatment, surgery or invasive cardiac procedures. Hence, these patients need to be referred for surgical evaluation and, if possible, surgery (repair with valve replacement, if aortic diameter > 50\u2009mm or > 40\u2009mm for patients with severe echocardiographic AS).\n\nIn severe cases, surgery is recommended at 50, and for patients with symptomatic valve disease at 40.\n\n## ECHOCARDIOGRAPHY\nEchocardiography is a noninvasive imaging procedure to evaluate the heart's structure and function. The device emits soundwaves and produces images of the heart and arteries. Echocardiography may be performed at the bedside, in an office, or in a hospital setting.\n\n## ANCA\nAntineutrophil cytoplasmic antibody (ANCA) is an antibody directed against components of the neutrophil with specificity for cytoplasmic azurophilic granules. This is an antibody of the immunoglobulin G subclass and, in contrast to antiglomerular basement antibodies, is not bound to the kidney.\n\n## ASSOCIATED CONDITIONS\nInfectious endocarditis is an infection of the endothelium of the heart. It may be caused by a primary seeding with a bacterial, fungal, viral, or protozoal microorganism. It is classified as infec1tions caused by gram-positive bacteria (more common), gram-negative bacteria (uncommon; often caused by enteric fever), and acid-fast microorganisms. In all these in1ictions, endocardial vegetations occur, which may lead to the development of infect",
        "label": 0
    },
    "929": {
        "output": "<EOD> A clinical trial of interferon alfa-2b alone or in combination with zidovudine after surgery for recurrent/metastatic cervical carcinoma.\nOBJECTIVES\nTo compare the efficacy and the toxicity of the single agent interferon (IFN) alfa-2b versus combination IFN and zidovudine (AZT) in patients (pts) with recurrent/metastatic squamous cell carcinoma of the cervix after prior cisplatin-based chemotherapy and radiation therapy.\n\n\nMETHODS\nFrom January 1, 1989 to December 31, 1990, 14 pts were entered onto the trial of IFN alfa-2b at 5 MU (i.v.), 3 days/week. The median age was 44 years (range 29-57) and median PPA and PYT were 20.7 and 19.3 cm3, respectively. Six pts received IFN alone and eight pts received IFN plus AZT (200 mg po tid). Responses were evaluated every 3 months after therapy. A response of > or = 50% reduction in pelvic and/or extrapelvic tumor from nadir with no evidence of new tumor lesions was considered a partial response (PR) and progression (PD) was seen when tumor increase by 25% or greater in comparison to nadir.\n\n\nRESULTS\nOf the 14 pts entered on the trial with squamous cell carcinoma of the cervix from January 1989 to December 1990, 2 pts had disease progression after the 1st cycle of IFN and were subsequently taken off the study. The remaining 12 pts completed 8 weeks of IFN therapy with none experiencing clinical PR or CPR. There were, therefore, 9 inevaluable pts among the 14 pts entered.\n\n\nCONCLUSION\nThis study indicates no significant difference in efficacy when either IFN alfa-2b or AZT alone is compared with the combination IFN/AZT in heavily pretreated pts with",
        "label": 0
    },
    "930": {
        "output": "Please check if you have written down the correct answers to the problems. It is good to check your answers with the testers before proceeding to the next section.\n<EOD> .\nTo be recognized of the medical community is very important for an occupational health services, as a step towards integration into the public and hospital health system. The authors analyze the historical development of this specialized service, in particular in regard to its integration into the Hospital Care Network of the \"Azienda Ospedaliera Universitaria Policlinico S. Orsola-Malpighi (Bologna)\" by emphasizing the advantages of the organization and the advantages to the users and to the doctor-patient relationship. Then, the attention is addressed to the future as in the present times one can find only isolated cases where the occupational health service have integrated into hospitals, while other integration experiences are at their start-up.<EOD> Improved Delivery of Antisense Antibiotic Propolionicin\nPropolionicin, a novel antisense compound that inhibits the growth of Gram\u2010negative bacterial pathogens, was evaluated for safety, toxicity, immunogenicity, and pharmacokinetics following i.v. administration of a series of prodrug variants in several murine infection models. These prodrug species included derivatives of the natural antibiotic, propionicin, which is produced by Actinoplanes propionicis, and the semisynthetic analogs 2\u2010methyl\u2010propionicin and 7\u2010oxosemiporpropionicin. These prodrugs were designed to improve the delivery and/or reduce the toxicity of the active drug. Prodrug variants were synthesized as fatty acid ester prodrugs of propionicin or semiporpropionicin and evaluated for in vitro cytotoxicity, pharmacokinetics, and pharmacodynamic",
        "label": 0
    },
    "931": {
        "output": "# References\n- \u2191 1.0 1.1 1.2 1.3 \"Examples of patient notes\". Examples of patient notes. Retrieved 2014-12-22.\n- \u2191 \"Example of Clinical Trial\". Example of Clinical Trial. Retrieved 2014-12-22.\n\n<EOD> HIV-1 reverse transcriptase interacts with RNA in the absence of DNA.\nMany of the early steps of infection are still not clearly understood. We describe here a novel binding of HIV-1 reverse transcriptase (RT) to RNA. The interaction of recombinant HIV-1 RT with RNA could be demonstrated by an RNA-binding assay, by electrophoretic mobility shift assay or by binding studies of RT to oligodeoxyribo(dT). Furthermore, RT was shown to interact with RNA in the absence of ssDNA. Analysis of the interaction behaviour and the possible structural implications is difficult because RT and RNA associate in many different modes. In addition, the different RNA binding sites of RT interfere with each other.<EOD> A rare case of a giant ovarian dermoid cyst\n\na b s t r a c t INTRODUCTION: Mature cystic teratoma of ovary is one of the most common tumor among the population of reproductive age group and have the most benign pathology. Derma tois, the presence of hair follicles and sebaceous glands, epidermal components, adipose tissue are the characteristic features of a mature cystic teratoma. CASE PRESENTATION: Here we present a rare case of 50-year-old Indian woman presenting with huge left ovarian mass of size 28 \u00d7 23 \u00d7 21 cm weighting approximately 7 Kg. She underwent laparotomy where mass adhered to pelvic peritoneum so deroofing and excising the mass was difficult. On histopathology of mass we found hair follicles, sebaceous glands and epidermal components suggestive of a dermoid cyst. CONCLUSION: Mature cystic teratoma",
        "label": 1
    },
    "932": {
        "output": "<EOD> Draft Genome Sequence of a Flavivirus Isolated from a Black Fly in India That Belongs to the Putative Novel Genus Okavirus.\nA novel RNA virus was isolated from female Simulium squamosum black flies in a subtropical ecosystem in India. The virus was designated as Simulium squamosum virus, Indian isolate. Metagenomic analyses revealed that the virus belonged to the proposed novel genus, Okavirus in the family Flaviviridae. Here, we report a draft genome sequence of Simulium squamosum virus, Indian isolate.\n \n\n\n\nS\nquamosum<EOD> Effect of Sodium Channel Inhibitors Tetrodotoxin and Tetraethylammonium Chloride on Neuroendocrine Changes Induced by Hormones in Rat Supraoptic Nucleus Cells in Primary Culture\nThe aim of the study was to characterize the effect of sodium channel blockers on the hormonal control of the rat neurosecretory supraoptic nucleus cells (SONC) primary cultures. SONC primary cultures were obtained from 10-day-old rat pups. Cells were plated on poly-l-ornithine and laminin coated substrate and grown for 7 days in vitro (DIV) in minimum essential medium with fetal calf serum. Neurosecretory cells were identified immunocytochemically as vasopressin containing using the antisera raised against vasopressin. In cultures maintained up to 7 DIV, we have demonstrated spontaneous release of oxytocin (OT) and vasopressin (AVP) at a constant rate for the 4 days of culture. Pulse-chase experiments using L-leucine indicated no significant differences in rates of L-leucine incorporation, maturation and release rates of OT- and AVP-containing nerve terminal fragments between untreated and toxin-treated cells. In addition, hCG, LH, and TRH were found to increase the amount of released OT and AVP. TTX and TEA inhibited hormone-stimulated release of OT and AVP without significantly affecting the hormone-dependent stim",
        "label": 1
    },
    "933": {
        "output": "[INST] **Detailed instructions for each part of the input:\n`Input: Patient note \"The assessment of patient's eligibility for trial on trial level\" A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus, and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications. Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull, ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.*~TITLE:*~Title:*~TITLE:*~Summary:*~Summary:~SUMMARY:~The summary line should include ~~~~and a few keywords so that participants can quickly understand the main question~In the summary line ~~~~the question that the clinical",
        "label": 0
    },
    "934": {
        "output": "The task can be performed in two ways: (1)\n- As simple as possible using the first command, without any intermediate operations. For example, you may want to try and then, if you are satisfied with the results, stop in the last line, which is the same as outputting a result in the same command;\n- As complicated as possible by using a loop. Take the second command with `continue`; it will return you right after checking the first patient's data. Then you will be able to check other patient data on your own. Also use `print(\"Your result for patient {Patient} has been saved. \")` to output the patient number as a separate line. After this loop, you can output the total result once, by using the fourth command, with `if` and `else if`. If one step of the first command fails on a given patient, it will automatically return. In this case, the output result will be generated only if the first command has been successful.\nExample:\n# Simple approach\n\n[IMPORT] Importing patient files; in this example, we only use one file - Patients.csv\n\n[LOOP] Creating the loop, reading each patient one-by-one\n\n(i)  You may want to try to read from the Patients.csv file, if not already there, using with the `head` function, so you can choose your first file. The rest of the files would be loaded automatically\n\n(ii) Assign the patient's number to the variable `Patient`, starting from 1\n\n(iii) Load the file using the `import` command\n\n(iv) Read the file using the `read_csv` command\n\n(v) Read only the fields you require:\n\nIn the above command, `0`-means the row number, `1`-means the column number, and `B` means the raw file name\n\n(vi) Use the loop command, which uses the `for` loop that will iterate over the rows of the data frame and perform the loop logic within \n(vii) Check one field of the patient data, the factor number\n\n(viii)  If it matches, continue with the next row (this will be the next patient)\n\nOtherwise, the error message will be printed and the cycle will be stopped,\nand you will be informed that another patient must be",
        "label": 2
    },
    "935": {
        "output": "You must learn some code for this problem. \n\nThere are many things to know about this section. In general, the code to be used is almost the same each time. In this case, the following code is necessary to complete the task. \n\nYou must learn to understand what the code written in the template of this section is and what it is doing. If you can understand the template, you will be able to know what the code written in the template is and what it is doing.\n\nFirst, you need to learn about `Trial` class.<NAME> provided a very large number of templates that can be useful to most research applications. These templates provide basic functionality needed to solve the problems of various domains, such as the biomedical and clinical domains.~This set of templates is called a framework. \n\n<NAME> wrote a number of important templates to solve common problems encountered in trial design. For instance, these templates include the following:\n\n| Template 1  | Template 2  | Template 3  |\n|:-------------:|          :|         :|\n| Randomized Phase 1| Randomized Phase 2| Randomized Phase 3|\n| Allocation Ratio        | Drop-out rate     | Number of Phases  |\nEach of these templates allows the definition of a very large number of randomized trials with specific design features.<NAME> used an Excel-like interface for writing in trial analysis templates and also for writing their own templates. Each trial analysis template can be written to a file. Once the templates are written to files, they can be shared with others through the web or via email.<strong>In the previous section, <NAME> showed how to solve problems such as `Input file` and `Output`, and <NAME> demonstrated the code for these templates, which are used to define trial attributes. In this section, <NAME> will introduce you to the basic features of the `Trial` class, which can be used to define the trial design features.<strong>This section presents the basic features of the `Trial` class.</strong><br/> \n\n<!-- ============ FOR DEMO ============== -->\n\n```cpp\nvoid demo(QFile& file) {\n  QFile *f = new QFile(\"QMDIDemoTest.txt\");\n  QTextStream stream(f);\n  stream << \"",
        "label": 1
    },
    "936": {
        "output": "```js\ndescribe('TestCardio1', () => {\n  it('should report 2) Eligible in the last line', () => {\n    shouldReport(scenarioPath, '2) Eligible in the last line');\n  });\n});\n```\n\n## [INST] Description (0)\nYour workplace has several recruitment assistants who work on clinical trials in the laboratory. In each trial, they have to create trial reports to summarize the statuses of each clinical trial participant. Their work environment is shown in the [![inst-clin-card-report](https://res.cloudinary.com/dandi-prod/image/upload/v1604490433/github-dandi-prod-clinical-card-report/inst-clin-card-report?version_id=5b416ba3bdf3144c27348482&sig=%2BKYm8yI6HM5Dg/iAJxB1bNJOc%3D)][inst-clin-card-report](https://res.cloudinary.com/dandi-prod/image/upload/v1604490433/github-dandi-prod-clinical-card-report/inst-clin-card-report?version_id=5b416ba3bdf3144c27348482&sig=%2BKYm8yI6HM5Dg/iAJxB1bNJOc%3D))\n\nYou will provide code of assistant #1, #2 and #3 in this scenario. Each helper assistant runs `generateReport` only once. \n\nYour code should read the status of the patient and their assignment in each clinical trial, and then output the patient report for each trial.\n\n\n[![INST] Assistant's workplace](https://res.cloudinary.com/dandi-prod/image/upload/v1604490383/github-dandi-prod-clinical-card-assign-report/inst-card-assign-report?",
        "label": 0
    },
    "937": {
        "output": "What do you think of the risks given to the patient? Why?\nWhy did they assign points of `1`?",
        "label": 0
    },
    "938": {
        "output": "This should also apply to each patient.\n<EOD> The Role of Cyclooxygenase-1 in the Anti-Inflammatory Pharmacology of Diclofenac-Bioflavinoids-Loaded Lipopolymeric Nanosuspension\n\nCitation: El-Allahi, F.M.; Aburayda, M.S.; Shalaby, A.M.; Eid, O.A.; Ali, M.A.; Abu El-Soud, A.M.A.; Salem, S.M.M.; Abdelwahab, A.A. The Role of Cyclooxygenase-1 in the Anti-Inflammatory Pharmacology of Diclofenac-Bioflavinoids-Loaded Lipopolymeric Nanosuspension. Int. J.\n\n\n# Introduction\nInflammation is an initial response of the hostile immune system's components to harmful external (infective) agents and internal (e.g., cancer) infections. It aids tissues self-defense from damage and infection in a way.\nPharmaceutomedic drugs, inflammatory.\nScience. Imamines cells of immunable to immune and inflammatory and anti-drugs and immune's health infection of inflammat the body's immunhe immune's cells.\nEmergency in which canine immune cells which inflammatric\n\nThe patient's health care providers's health of inflammatory\n\nThese drug's immunits immunited. Patient and their.\nThe patient's healthy immune's immune immunhealth care.\nImmunity's drug's patient's bodycare.\ninflammatory immune person's a patient immune care inflammatics the drugs. The care. Pharmacy's healthy's immunhealth care's quality of the role of the immunities immunits ici drugs. (antihealth (h care (patient (eliz health patient care a care to inflam's immune drug's health. The immune patient'health insurance care's immune eligel patient",
        "label": 1
    },
    "939": {
        "output": "Q6: The patient is a 40 year-old woman. She has no previous heart disease and smoked cigarettes from early adolescence which was then replaced by occasional cigar. She has a positive family history for premature CHD. She has a history of hypertension. Her examination is normal. The ECG is normal. The echocardiogram reveals a ejection fraction of about 60% and is otherwise normal. Her fasting glucose, and lipids are normal. She has normal exercise tolerance. Her neck auscultation reveals the absence of murmurs. Her examination does not suggest aortic stenosis. She had a normal angiogram performed a few years ago, showing no abnormal features. Her chest radiograph is normal. The ultrasound of the carotid arteries reveals plaques with a moderate reduction in the lumen of the ICA. Her total calcium, homocysteine, and vitamin B12 levels are normal. There is no history of alcohol or recreational drug abuse. The patient meets the",
        "label": 1
    },
    "940": {
        "output": "The 46-year-old man presented with dizziness and headaches. He had a positive family history of CAD but no other cardiovascular risk factors. His dizziness was described as a continuous sensation of unsteadiness. His LDL-C level was 545 mg/dL, and his HDL-C level was 53 mg/dL. However, he had no cardiovascular",
        "label": 0
    },
    "941": {
        "output": "## ASSIGNMENT 3\nGo to file `example_2.ipynb`.\n\n`1. from IPython.external import rpy2 import sys def execute(): import rpy2 as r import pandas as pd def r2009(): import rpy2 as r import pandas as pd R = r['r2009.xls'] R.set_index('Patient Id') R.index[:] = 0 if 'Patient Id' in R.columns: R['Pre-Tx LDL-C (mg/dL)'] = str_replace_all(R['Pre-Tx LDL-C (mg/dL)'], r'\\n', '') R['Pre-Tx LDL-C (mg/dL)'].add_prefix('Pre-Tx') else: print \"Please specify column with LDL-C before PRE-CATHETERIZATION\" execute () def r2014(): import rpy2 as r import pandas as pd R = r['2014.xls'] R.set_index('Patient Id', drop=True) try: R['ESS'] = R['ESS'].astype(float) except: R['ESS'] = R['Pre-Tx ESS'].astype(float) R[0:9]['SXS'].add_prefix('Pre-Tx') R[0:9] = R[0:9].astype('str') if 'ESS' in R[0:9].columns: R[0:9]['Pre-Tx ESS'] = rpy2.list_cols(R[0:9])[1] R[0:9]['Pre-Tx SXS'] = rpy2.list_cols(R[0:9])[3] if 'SXS' in R[0:9].columns: R[0:9]['ESS'] = rpy2.list_cols(R[0:9])[1] else: R[0:9]['ESS'] = 'Pre-Tx ESS' else: R['ESS'] = R['ESS'].astype(float) if 'LDL-C' in R[0:9].columns:R[0:9]['Pre-Tx",
        "label": 1
    },
    "942": {
        "output": "<EOD> Enzyme Replacement Therapy for Gaucher Disease: Are we there yet? Yes, we are!\nGaucher disease is caused by a deficiency in lysosomal glucocerebrosidase activity. A novel class of enzyme replacement therapy with recombinant human glucocerebrosidase, Genz-565660 (imiglucerase) has dramatically improved the outcomes for patients with this devastating disorder.<EOD> Assessment of gastrointestinal motility in patients with inflammatory bowel diseases (including ulcerative colitis, Crohn's disease) by scintigraphy.\nGastrointestinal motility in patients with inflammatory bowel disease was evaluated by radiogastrography and by radioactivity curves of the abdomen with scintiscanning in order to assess the influence of clinical course and treatment on gastrointestinal motility. The results were evaluated comparatively with the barium tests of gastrointestinal motility. Gastrointestinal motility was disturbed in ulcerative colitis: no contrast medium left the stomach, but a lot of fecal casts appeared in the colon and the contrast was passed slowly to the upper intestine. However, with better treatment and care, gastrointestinal motility improved and the transit time of the contrast to the duodenum was normal, although the patients suffered from severe attacks in the period of the testing. However, with better treatment and care, gastrointestinal motility improved and the transit time of the contrast to the duodenum was normal. In Crohn's disease, gastrointestinal motility was also disturbed, but to a lesser degree than in ulcerative colitis. The scintigraphic studies in patients with Crohn's disease showed better transit through the bowel, but a small bowel length index was significantly disturbed. The results of gastrointestinal motility as measured by scintigraphy are very sensitive for the detection of pathological motility disorders in patients with inflammatory bowel disease, and the method gives information on the transit time through bowel and on the gastric emptying, thus evaluating bowel motility and dysfunctions",
        "label": 0
    },
    "943": {
        "output": "```{python}\nfrom nipype.interfaces import Trait, TraitFile\n\nfrom nipype.interfaces.science.brainh import BrainhEEG\nfrom nipype.pipeline import engine\nfrom nipype.pipeline.datainputs import DataInputSpec\n\nfrom .utils import DataInputSubTool, TraitToFileSpecSubTool\nfrom .utils.injection_time_inputs import InjectionTimeInputSpec\n\n# Inputs\nspec = DataInputSpec(filename=(\"a/b/c.vhdr\",),\n    traits={'injection_times':[\n            ('slice_times',Trait(\"int64\", mandatory=True),),\n           ('voxel_times', Trait(\"int64\", mandatory=True),),\n           ('x0', Trait('int32', mandatory=True),),('sudx',Trait(\"int32\",mandatory=True),),('sudv',Trait(\"int32\",mandatory=True),),('sudx0',Trait(\"float32\",mandatory=True),),('sudv0', Trait(\"float32\",mandatory=True),), ('injcount', Trait(\"int32\", mandatory=True) ),('sud_time',Trait(\"int32\",mandatory=True),)],\n         'voxel': Trait('int8', max = 8552, mandatory = True),\n         'slice':Trait('int8',max = 1024, mandatory=True),\n    )\n)\ninput = BrainhEEG(in_files='A_EEG',subject='00000001',\ndata_prefix=None,\ntrait_prefix=None,\nspec=spec)\n\n\nresult = engine.execute(input)\n\nresult = input.result['output_file']\n\nresult.filepath.datanames['voxel'].attrs['unit'] = 'voxel'\nresult.filepath.datanames['slice'].attrs['unit'] = 'slice'\n\nresult.filepath.datanames['voxel'].vals",
        "label": 0
    },
    "944": {
        "output": "[INST] You are a medical student and the head of your class, and you have been tasked with teaching your classmates to use the AIBO robot for physical examination. This AIBO robot can collect various physiological indicators of patients during physical examination. It can be easily used as a telemedicine device, which has the potential to be used in primary medical institutions. \n\n\n## Clinical Examination of the Skin\n- The robot has been pre-installed with a special app, which can collect and record the human body index, including weight, temperature and blood pressure, before entering the office. It is very convenient for pre-examination.\n\n(a). Examination environment is set up. The screen is cleaned, the screen cover is removed, and the screen is turned on. The computer turns on with Windows at the same time, so as to prevent the computer from being locked. The monitor power switch is set to automatic (turn it on by default). Clean the desk of the examination area.\nPlace two pieces of white paper measuring 10cm\u00d710cm in the left and right corner, respectively, and spread them out 90 cm away from the wall in front of the left leg. The position of two papers is symmetric, and the gap between the two papers is the same. Make sure that other objects do not surround the screen and that the patient is not blocked by other objects. The angle between the examination bed and the desk is approximately 60 degrees, and the angle between the examination bed and the examination chair is approximately 90 degrees.\nMake sure that the examination bed, chair and screen are parallel to the ground. Keep the distance from the patient to the examination bed at 40 cm.\n\n# Inspection method:\nObserve the state of the child: normal or abnormal.\nObserve the state of the child's mouth, including color, moisture, and breathing. Note whether coughing, vomiting, or sniffing occurs. The color of the oral mucosa can be observed by pulling up the lips and chewing on one side.\nObserve feces and genitalia: Color, moistness, and consistency of the feces, the color  of the genitalia (redness, cyanos",
        "label": 1
    },
    "945": {
        "output": "<EOD> Excision of the Incisor. 1\nTHIS operation, performed under chloroform, was done, in order to relieve the irritation and pain caused by an irregularity in the teeth. The pain was referred to the tooth in front, which was so irritated that he would not let his attention be drawn to it. The operation was first mooted by Dr. A. M. Anderson.<EOD> Impact of obesity on perioperative and long-term outcomes of laparoscopic colectomy according to gender\n\nIntroduction:The increasing incidence of obesity in Europe over recent years is a worrying trend. This is a particularly growing issue in postoperative colon cancer patients where the impact of morbid obesity has not previously been extensively reported. The aim of this study was to evaluate the impact of morbid obesity on the perioperative and oncologic outcomes in colon cancer patients undergoing laparoscopic colectomy. Materials and methods: We retrospectively reviewed the data of all morbidly obese and non-obese patients (body mass index (BMI) <40 and \u226540 kg/m 2 , respectively) who successfully underwent laparoscopic colectomy from January 2008 to October 2016. Results: In total, 322 patients were analysed (230 controls and 92 morbidly obese). No mortality was reported; perioperative morbidity was comparable between the two groups, with pneumonia representing the only significant complication. At five years, recurrencefree survival (RFS) was similar between the two groups (70 versus 71%), as was overall survival (OS) (69 versus 74%). Morbid obesity resulted in a higher incidence of positive regional lymph nodes (28 versus 21%). Subanalysis revealed that morbid obesity is associated with improved outcomes in males but not in female patients. Conclusion: Laparoscopic colectomy for the management of colon cancer is a safe option for patients with morbid obesity, with a similar safety profile compared to non-obese patients. Male patients with morbid obesity had less recurrences and mortality, while this effect was",
        "label": 0
    },
    "946": {
        "output": "<EOD> Association Study of PDE4A Polymorphisms with Major Depressive Disorder in Han Population of China\n\nPDE4A, a member of the phosphodiesterase (PDE4) superfamily, is involved in the regulation of cAMP and the pathogenesis of depression. Here, we report an association study examining two single-nucleotide polymorphisms (rs2416867 in PDE4A intron 7-8 and rs2279263 in 39UTR) and major depressive disorder in the Chinese Han population. We genotyped rs2416867 and rs2279263 in 1000 patients with major depressive disorder (MDD), 997 healthy controls, and 83 subjects with recurrent episodes of depression. No statistically significant differences in genotype and allele frequencies were observed between the three groups in the case of PDE4A. A meta-analysis of genetic association studies was performed, including the present and previously published (1006 MDD patients from European cohorts and 449 MDD patients from Asian cohorts) case-control samples. Metaanalysis demonstrated that the MDD risk variant in PDE4A intron 7-8 is present in both European and Asian populations; however, a significant association was only identified in the European population. An analysis of the 39UTR variant identified a significant association between this polymorphism and MDD risk in Asian subjects. The current investigation of both PDE4A intron 7-8 and 39UTR demonstrated an association of MDD risk with genetic variation.\n\n# Introduction and objective\nDepression is a significant psychiatric condition that affects mood, cognition, emotional processing, and behavior [bib_ref]  Changed gene expression profile in adolescent mouse prefrontal cortex upon acute and..., Isgandarova [/bib_ref] . It is an important cause of disability, responsible for more lost years of healthy life than any other disease [bib_ref]  Antidepressants for the prevention of relapse and recurrence after antidepressive Efficacy of..., Spielmans [/bib_ref] . Depression usually runs a chronic course, with symptoms that are exacerbated by stress",
        "label": 0
    },
    "947": {
        "output": "## [Coding example]\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus, and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u200amg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u200amg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA), estimated between 40% and 50% and moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. Peak-Systolic (PSV) and End-diastolic velocity (EDV) cutoff-values were 208.5\u200acm/s and 54.5\u200acm/s, respectively; RICA PSV was 91.72\u200acm/s, and RICA EDV was 37.37\u200acm/s. Here is the clinical trial:\nTitle: A Pilot Study in Severe Patients With Takayasu Arteritis.\nSummary: Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. We classify TAK patients into 3 levels, including mild, moderate, and severe. And the biological agents tocilizumab and adalimumab are randomly prescribed in severe patients, to find out the relatively better treatment strategy, facilitating better intervention strategy in severe TAK patients.\n\n## Inclusion criteria:\nage\u226514 years old;\nactive: Kerr score\u2265 2;\nsevere: Blood pressure > 18",
        "label": 0
    },
    "948": {
        "output": "[STEP 3] Eligibility assessment of all given patients. \nYou should elbow the patients on the basis of the information in the patient note. Patients with sufficient information on both the age and inclusion criteria should be included in the eligibility assessment.\nLet's think step by step. \nFirst, we will check if the patient is 18 years old or older. \n![0][][][][][]\n![0][][][][][]\n```\n\n---\n\n### [115_P05.py](../../../../../python-code/lab42/01.Practice%20with%20code/115/115_P05.py)\n\n[![asciicast](https://asciinema.org/a/43081.svg)](https://asciinema.org/a/43081)\n\n[![](https://github.com/lab42teams/python-code/actions/workflows/build.yml/badge.svg)](https://github.com/lab42teams/python-code/actions/workflows/build.yml)\n\n![](./115_P05.py)\n\n### Rerun\n```python\npython 115_P05.py\n```\n\n---\n\n### [117_P05.py](../../../../../python-code/lab42/02.ClinTrails/117/117_P05.py)\n\n[![asciicast](https://asciinema.org/a/43082.svg)](https://asciinema.org/a/43082)\n\n[![](https://github.com/lab42teams/python-code/actions/workflows/build.yml/badge.svg)](https://github.com/lab42teams/python-code/actions/workflows/build.yml)\n\n![](./117_P05.py)\n\n### Rerun\n```python\npython 117_P05.py\n```",
        "label": 0
    },
    "949": {
        "output": "You are doing great! Your answer matches the example completely! Let's complete this step.\n\n## Part 2. Code in the `data` file\n\nYou have completed the code from the `data` file, see the screenshot of the completion and then save the `.jupyter` file under your working directory as `Part2 _Code.ipynb`. \n\nNext you will create a new directory under your working directory called `work` and then create several new directories under the `work` folder named `data` and `code`. You will save the `data` folder contents under the `work\\data` folder. Here are the contents that need to be created under the `code` folder:\n``` {code}\nfrom pathlib import Path\n\nwork_dir = Path(r\"C:\\MyScripts\\Part2\")\ndata_dir = work_dir / \"data\"\n\ncode_dir = work_dir / \"code\"\ncode_dir / \"demo\" / \"data\" # will create new folder under work_dir called `demo`\ncode_dir / \"demo\" / \"demo1\" # will create new folder under `demo` called `demo1`\ncode_dir / \"demo\" / \"demo1\" / \"data\" # will create new folder under `demo1` called `data`\n\ndata_dir / \"demo1\" / \"data\"  # will create new folder under `demo1` called `data`\n\ncode_dir / \"demo\" / \"demo2\" # will create new folder under `demo` called `demo2`\ncode_dir / \"demo\" / \"demo2\" / \"data\" # will create new folder under `demo2` called `data`\n\ncode_dir / \"demo2\" / \"data\"  # will create new folder under `demo2` called `data`\n\ncode_dir / \"work\" / \"demo\" / \"Part2_Data\"\ncode_dir / \"work\\demo\" / \"Part2_Data\" / fname_in_data_file # will create new folder under `Part2_Data` called `Part2_Data`\nPart2Data_demo_fname_in_data_file = code_dir / \"Part2_Data\" / r\"Demo(1)\" # will create new file under `",
        "label": 1
    },
    "950": {
        "output": "<EOD> A novel SLC26A6 mutation in Pendred syndrome causes early onset of hearing loss and enlargement of the vestibular aqueduct\nPendred syndrome is a recessive disorder comprising untreatable sensorineural hearing loss and enlargement of the inner ear bony labyrinth, including the vestibular aqueduct (EVA). Both features are attributed to a genetic defect affecting the type II anion exchanger pendrin gene (SLC26A4).<EOD> 11th Meeting of the European Atherosclerosis Society: the European Atherosclerosis Research Area Program.\nThe 11th Meeting of the European Atherosclerosis Society (EAS) and the second meeting of the European Atherosclerosis Research Area Program (EARAP) were held in Budapest, Hungary. EAS-EARAP is a joint initiative of the EAS and the European Research Network on Atherosclerosis (EUROSPAN). The aims of EARAP are to provide the funding platform for research ideas and projects contributing to a better understanding and treatment of atherosclerosis, to support new ideas, to promote cooperation between different research groups and societies, to co-ordinate and promote research on emerging methodological and technical approaches, to facilitate young investigator development, and to improve publicity of key issues and of the benefits of basic research. A European research programme is now well developed and the next step is to apply for European structural funds. The 11th meeting presented the latest findings in epidemiology and pathobiology of atherosclerosis. The meeting was also a celebration of the founding of EAS, and of the achievement and dedication of the scientists and clinicians who launched EAS. They formed the nucleus of the Society and now look to the future development of EAS.<EOD> Theoretical framework of the relationship between social exclusion and health\n\n\n\n# Introduction\nThe concept of social exclusion, initially used as a way of describing life conditions of disadvantaged social groups, later became a broader concept that has received great interest from the 1960s, when it started to receive increased attention in social sciences. Social exclusion is used to describe a variety of social problems",
        "label": 0
    },
    "951": {
        "output": "<EOD> Transcriptional activation of the ALDh3A1 gene by the endoplasmic reticulum stress-sensing and transducing kinases IRE1a and PERK\n\nThe ER is an intracellular organelle for the synthesis and posttranslational modifications of secretory and transmembrane proteins. ER stress leads to UPR (unfolded protein response) for the ER-proteome homeostasis. We found that expression of the short-chain alcohol dehydrogenases ALDH3 A member 1 (ALDH3A1) was induced by ER stress through transcriptional activation in several cancer lines. Moreover, an upstream region of ALDH3A1 promoter was bound with IRE1a and inositol requiring enzyme 1 (IRE1), respectively. This is the first paper to report that ALDH3A1 gene is regulated at transcriptional level by IRE1a-XBP1 and PERK-ATF4 axis. Furthermore, the binding site of ATF to the proximal site was detected in the XRCC5 promoter region. To conclude, the present study showed that ALDH3A1 was induced at transcriptional level by ER stress through upstream elements in the proximal promoter region binding IRE1-XBP1 and PERK-ATF.ARTICLE HISTORY\n\n# Introduction\nThe eukaryotic cell cytoplasm contains endoplasmic reticulum (ER), which is a membrane-bound structure with tubular and vesicular compartments. The ER contains a variety of enzymes required for the posttranslational modifications of secretory and transmembrane proteins, such as N-linked glycosylation, lipid modification, calcium regulation and disulfide bond formation [bib_ref]  Stressing out over endoplasmic reticulum-mitochondrial calcium signaling, Steinberg [/bib_ref]  [bib_ref]",
        "label": 0
    },
    "952": {
        "output": "You are given the files 'CSV_Patients.csv', 'CSV_Hypothesis_Trial.csv' and 'CSV_Study_Inclusion_Criteria.csv' for the respective files: `PatientNote.csv`, `Trial_Included_Patients.csv` and `ExclusionReasons.csv`. You also get an XML file of the hypotheses.\n\nThe [*Hypothesis_trial*](https://help.iplantcollaborative.org/p/ipython-notebooks/110317/783100/html/file/hypothesis_trial-1.csv) for the file `Hypothesis_trial.csv` can also be read by the [*PatientNote*](https://help.iplantcollaborative.org/p/ipython-notebooks/110317/783100/html/file/patientnote-1.csv) by the following code. The header for [*Trial_Included_Patients*](https://help.iplantcollaborative.org/p/ipython-notebooks/110317/783100/html/file/trial-included-patients-1.csv) is also shown:\n```python\np = pd.read_csv('hypothesis_trial-1.csv', index_col='Hypothesis' , sep=';')\npatient_id=p.Hypothesis.index[0]\ntrial_id=p.Hypothesis.index[-1] # The last element is always the trial ID\nsample_name=str(trial_id) + '_' + str(patient_id)\npatient_notes=p.drop(f'Hypothesis', axis=1) # remove the hypothesis column first.\nincluded_trial=trial_included_patients[trial_id==trial_id].iloc[0] # the first row in the second data set holds the unique trial ID,\np_data=p.drop(f'Hypothesis', axis=1)[sample_name]\np_data",
        "label": 0
    },
    "953": {
        "output": "![image description](https://user-images.githubusercontent.com/324945/61676620-8a91a180-af5b-11e9-9e16-472f4c73f226.png)\n\n### [02.10.2019 19:24] [kavashadpour](https://github.com/kavashadpour) [original](https://github.com/FarhadArab/AIQA-Final-Report/blob/main/AIQA_19-5.md) [reviewed](https://github.com/FarhadArab/AIQA-Final-Report/ blob/main/AIQA_19-5_rev.md)\n\n## MIMIC (31)\n### [02.10.2019 19:25] [kavashadpour](https://github.com/kavashadpour) [original](https://github.com/FarhadArab/AIQA-Final-Report/ blob/main/AIQA_19-6.md) [reviewed](https://github.com/FarhadArab/AIQA-Final-Report/blob/main/AIQA_19-6.md)\n### [Techniques Used in Deep Learning](http://www.mathworks.com/matlabcentral/fileexchange/50598-deep-learning-techniques-and-tricks)\n### [MIMIC-IV - medical information mart for intensive care - documentation](https://github.com/PhysioNet/MIMIC-III/wiki)\n### [Deep Neural Network for Medical Diagnosis 1](https://github.com/lilyzhong/DeepNeuralNetworkForMedicalDiagnosis/blob/master/dnnmimic.pdf)\n### [MIMIC-IV - medical information mart for intensive care - documentation](https://github.com/PhysioNet/MIMIC-IV/wiki)<EOD> High prevalence of diabetes in a rural Bang",
        "label": 0
    },
    "954": {
        "output": "### \u3010\u6311\u6218\u30114\u3010\u70b9\u3011 \u3010\u5956\u3011 \u3010\u7a7f\u900f\u6c34\u5e73\u3011 \u3010\u7ed3\u679c\u3011 \u3010\u5e73\u5747\u65f6\u95f4\u3011 \u3010\u63ed\u970f\u3011 \n\nChallenge4 is the longest! And we tried more than one hour! It's tough. Because we cannot answer it correctly without all the pieces of information, we have to think what the answer would happen in the case of missing pieces of information. Because we don't know clinical trial's exclusion criteria perfectly, we used some assumptions. These assumptions are written in the comments of trial_level_eligibility \uff1a If the trial participant meets the trial's \"clinical trial exclusion\" condition, then it should be assigned 0 point, instead of exclusion, 1 point should be assigned. In this way, we could think about cases as 1) excluded, 2) included.\n\n#### 12 \u3010\u6311\u6218\u30114.2 Challenge4B\n\n#### 13 \u3010\u6311\u6218\u30114.3 Challenge4C\n\n```\nTrial-level assessment of the patient\n\n1    \nTrial-level assessment of the patient\n\n2    \n\n3\n```\nWe checked the answers using our Python code, but our answers didn't correspond. If it is similar to our responses, we would be happy to learn that our answers were correct.\n\n### \u3010\u6311\u6218\u30114\u3010\u70b9\u3011 \u3010\u5956\u3011 \u3010\u7a7f\u900f\u6c34\u5e73\u3011 \u3010\u7ed3\u679c\u3011 \u3010\u5e73\u5747\u65f6\u95f4\u3011 \u3010\u63ed\u970f\u3011 \n\nChallenge4 is the longest! If we can solve Challenge4 with only one wrong point, we would hope that this point did not influence the answer! So, we would also be pleased to learn that our answers were correct!\n\n\n## C2.11 [\u6311\u6218]5\u3010\u70b9\u3011\"\n\n### \u3010\u6311\u6218\u30115\u3010\u70b9\u3011 \u3010\u5956\u3011 \u3010\u7a7f\u900f\u6c34\u5e73\u3011 \u3010\u7ed3\u679c\u3011 \u3010\u5e73\u5747\u65f6\u95f4\u3011 \u3010\u63ed\u970f",
        "label": 0
    },
    "955": {
        "output": "## Clinician's Report [BGN]\nWhen the patient you just examined for the clinical trial was tested out to be eligible, you will go to another screening room and report the relevant information about the patient as the eligible patient for the trial, including \n - the number of the patient, i.e., the unique number of the patient for the clinical trial that you generate;\n - the gender of the patient, e.g., male;\n - the nationality of the patient, e.g., Taiwan;\n- and the birth month and year of the patient.\nHere are the clinical trial's inclusion criteria.\n\n### Inclusion criteria\n\n- age 18\u2009years or older;\n- have CAD-based disease with symptoms (e.g., chest tightness, dizziness, shortness of breath, and palpitation);\n- be symptomatic, with typical angina;\n- be treated or untreated for hypertension, hyperlipidemia, diabetes, chronic kidney disease, and smoking; and\n- be receiving aspirin, statins, angiotensin, or any anticoagulants.\n\nYou will need to enter the patient number of the patient who is  eligible and use the number to determine the patient's eligibility. The clinical trial's inclusion and exclusion criteria will be used as references to determine the trial-level eligibility of the patient who you just examined. \nLet's think step by step. \n\n### Check trial information\n\n- You use `patients` to retrieve the patient's information on a one-to-one basis.\n- You enter the trial's unique identification number for clinical trial, e.g., `15-61007_MHK_02_20150903`.\n- You use the trial-level eligibility to retrieve the trial information, e.g., `Trial-level eligibility: 0) Excluded`. \n\n\n### Check patient and eligibility\n\n- You enter the unique patient number to retrieve the patient information, e.g., `patients(:[1625], :id, uniqueNumber).` \n- You",
        "label": 0
    },
    "956": {
        "output": "[/formula] \nIf the patient has a systolic murmur in the neck and this patient's gender is male, then output the name of the murmur, which is murmur, within the square brackets, such as `[Murmur]. If the patient's gender is female, then output the name of the murmur, which is femur, within round brackets, such as `[Femur].\n\nIf the carotid ICA, bilaterally, stenosis rate is greater than the trial's cut-offs, then output only the first of the following characters on the scale: \u2018-\u2019: \n[formula]  \uf8f1 \uf8f4 \uf8f2 \uf8f4 \uf8f3 0) Excluded or Not",
        "label": 0
    },
    "957": {
        "output": "To start the task, create a folder for the solution named \"Evaluate Clinical Trial Inclusion Criteria.\" Inside it, create subfolders called \"Code\" and \"Data.\" Put your code in the \"Code\" folder and a copy of the data in the \"Data\" folder. Copy the file \"input.txt\" in your solution folder and also create a file in the \"Test\" folder called \"test.csv\".\n\n\n# Assessing eligibility\n\nTo assess the patient eligibility for a particular clinical trial, we can use the Eligibility package, which is a very useful package for working with clinical trial data. It has three object types:\n\nEl trial.clinical is the most comprehensive and rich object for assessing the eligibility of patients based on their clinical trial inclusion and exclusion characteristics.\nEl.enrollment contains all the information about the trial: the trial\u2019s ID, whether it can be used, the start and end dates of the trial, the enrollment target, and the enrollment status of the patient.\nEl Patient represents a record of assessing a patient for a particular trial and has the attribute trial.clinical, which is a reference to an instance of the El trial.clinical.\nWe need to create objects to work with the data:\n\n```r\n# We work with the data from the file \"input.txt\"\ninp <- read.csv(\"input.csv\")\n\n# We create objects in order to work with the data from the Eligibility package and to assess the eligibility\n\ntrial_clinical <- Eligibility:::create_clinical_trial_data set(inp[1], \"patient\", inp[1]) ,\nenrollment <- Eligibility:::create_clinical_trial_enrollment set(inp[1], \"patient\", inp[2]) ,\neligibility <- Eligibility:::create_clinical_trial_eligibility set(inp, \"patient\") # We are creating the \"eligibility\" object which is the reference to the \"patient\" object of the \"enrollment\" object set of the patient in inp(1)\n\ntrial.clinical <- Eligibility::",
        "label": 0
    },
    "958": {
        "output": "<EOD> FDG\u2010PET imaging in Parkinson disease \u2013 An overview and potential clinical applications\nOver recent years, positron emission tomography (PET) using the ligand \u2010fluorodeoxyglucose (FDG) has been increasingly used to assess Parkinson disease (PD) patients, to confirm or exclude a diagnosis of PD and to identify patients at risk of non\u2010motor complications of the disease, such as dementia. Recent developments in PET instrumentation may allow the use of this imaging technique for clinical practice and to assist with patient management, by identifying patients who may benefit from disease\u2010modifying therapies and by ruling out alternative differential diagnoses.<EOD> Combined oral contraceptive pills to delay menopause.\nI've had a great deal of interest in the question of delaying menopause, given that I have many women who are concerned about what it's going to be like as they get older, are they in good shape? What am I going to be like as an elderly person? So we have several clinical trials underway that look at that problem. We have women here in the study who are taking different hormonal therapies and are being given blood tests and bone density tests to look at the effects of these therapies not only in preventing osteoporosis but to also prevent cognitive decline and a lot of other conditions associated with senescence.<EOD> 1. To identify all possible complications (including late complications) and the risk factors associated with complications and mortality and the influence of anaesthetic techniques on complication rates. 2. Is there a relationship between pre-operative nutritional status and complications? 3. Are there any advantages of early discharge from hospital? 4. To study whether or not discharge to a rehabilitation unit (RU) or convalescence hospital can reduce complications? 5. Should more aggressive treatment be offered to the 'frail elderly'? In this patient group should more conservative treatment be used? There is insufficient evidence to recommend routine use of any new treatment that claims to reduce complication rates, unless the evidence indicates that the treatment may be safe and at least of equal efficacy to the conventional treatment . It is recommended that when dealing with patients under",
        "label": 2
    },
    "959": {
        "output": "# Results\n\n\n\n\n[TARGET] Please see [/TARGET]\n\n### Excluded\nIncluded note ID\n\n### Not relevant\n\n### Eligible\n\n```python\nimport pandas as pd\n```\n\n`df.Trial-level eligibility` is a pandas Series object, and its values are from 0 to 2, as we described above.\n\n\n```python\n```\n\n\n```python\n%pylab inline\ndf.Triall-level eligibility \n```\n\n\n``Not excluded``    0\n```\n\n```python\n\ndf = df[df.Age >= 46]\ndf.Age\n```\n\n```python\n```\n\n```python\n\ndf['Trial-level eligibility'] = 0\n```\n\n\n```python\ndf = df[df.Age >= 46]\ndf.Age\n```\n\n```python\n```\n\n```python\ndf\n```\n\n\n``Not excluded```     0\n```\n\n```python\ndf = df[df.Age >= 46][df.Age <= 46].copy()\ndf.Age\n```\n\n```python\n```\n\n```python\n```\n\n```python\n```\n\n```python\ndf = df[df.age >= 46].copy()\ndf.Age\n```\n\n```python\n```\n\n```python\n```\n\n```python\n```\n\n```python\n# Included note ID\n```\n```\n\n# Excluded\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n### Not relevant\nIncluded note ID\n\n```python\ndf.not_excluded.age\n```\n\n# Excluded\n``The study protocol was submitted and approved by the institution's review board or ethics committee [1]\nNote 1: Patients with a confirmed history of stroke; unstable",
        "label": 0
    },
    "960": {
        "output": "<h3>Examples for this task: <i>\n\t\t<a href=\"https:/testdrive.ai/exercises/inspection/clinical_trial/13061749/\">Example 1 - Paper (pdf)</a> and \n\t\t<a href=\"https:/testdrive.ai/exercises/inspection/clinical_trial/13061749/\">Example 2 - PDF (html)</a> \n  </h3>\n\n### Task Description\n\nExamine a given patient's note to determine whether the patient would be ineligible in a clinical trial. Patients can be ineligible to participate in a clinical trial for various reasons. A patient's notes should be examined to determine whether the patient would be eligible for the clinical trial because any factor that causes the patient to be ineligible needs to be recorded. Therefore, the results of any eligibility examination can contribute to the data for the clinical study. Finally, the recruitment should be evaluated and, if the patient is eligible, the patient should be referred on to the study investigators to receive trial-related treatments.\n\n#### Task Variations\n\nThe patient's notes vary in terms of the number of sentences or paragraphs they contain and the structure of their sentences.\n\nFor instance, some patient notes contain only one paragraph, while others contain three paragraphs. Some notes are structured as questions, such as, \"what is the status of the patient?\".\n\nSome patient notes include one section that describes symptoms along with another section that describes the results of an examination. A patient note may include all the symptoms described in the clinical records that the patient presented, while another may include only a symptom that the clinical record indicates in bold. \n\t\n### Task Objectives\nThe task measures the participants' skills related to the extraction of information from patient notes and to evaluating the eligibility of the patient for a clinical trial.\nAfter completing this task, you should\n\n* Have a good understanding of what information could be used to determine eligibility for a clinical trial.\n* Be able to assess whether a patient is eligible",
        "label": 0
    },
    "961": {
        "output": "[INST] Question 2. Can you determine which of the following is not an exclusion criteria?\n\nYou are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the exclusion criteria of a clinical trial to determine eligibility for a clinical trial. Exclusion criteria should be assessed to determine if a potential trial participant meets the inclusion criteria for the study. Exclusion criteria are reasons why a researcher feels that a person would be inappropriate for entry into a clinical trial.  Exclusion criteria  include having an illness, condition, or disability that would prevent you from complying with the  study protocol,  participating in another clinical trial,  being pregnant, having cancer,  being immunocompromised,   lack of consent to participate in the clinical trial,  being of childbearing age and planning to become pregnant within the duration of the trial,  failure to follow the instructions given by the study teams,  an inability to comply with the visit schedule and  if the person is not able to give informed consent. The following list is an updated catalogue of exclusion criteria:\n\nHypothyroidism, hyperthyroidism  or history of thyroid problems\n\nHistory of alcohol abuse or drug use\n\nHistory of previous or recent breast, prostate or lung cancer<EOD> Improved Survival of 190 Patients with Metastatic Cancer Given Immunotherapy\nThe survival of 190 patients receiving immunotherapy with intravenous, intraperitoneal or topical preparations was studied over a period of 17 years. With survival periods in excess of one month in 90.28 per cent of the patients, and with five survival periods of 19 months or longer, the results approach those achieved with conventional cytotoxic chemotherapy. The patients received immunotherapy as part of an investigational protocol, and no placebo was administered.<EOD> Influence of Cue-based Instruction with Automated Adaptation of Task Difficulty on Cognitive Demand in a Visual Search Task\nThis study examined the influence of adaptive task difficulty and cue-based instruction on attention-controlled search performance. The task consisted of multiple visual search",
        "label": 0
    },
    "962": {
        "output": "### Example 1\nThe following is a patient note as well as criteria for a particular clinical trial. To the left-hand side are the characteristics of our patient. In order to be eligible for this trial, the patient note would need to fit within the specific exclusion and inclusion criteria for the trial. A clinical trial could not be conducted with patients meeting these criteria.\n\n#### Questions\n\n1. Our patient note describes a 58-year old male. What is his age category?\n\n**A: 51-60 Years old.** The trial's eligibility criteria is for ages 18-60 years old. \n\n1. What is the gender of the patient?\n\n**A: Male.** The trial's eligibility criteria is for a male patient.\n\n### Example 2\nThe following is a trial-level eligibility table. To the left is the definition of the trial criteria. In order for the patient to be eligible for this trial, they must meet all the criteria shown to the left. This clinical trial could not be conducted with patients meeting these criteria. \n\n#### Questions\n\n1. Under 2(b) Inclusion criteria, our patient note describes a 58-year old male with a known cranial nerve paralysis. What disease is our patient experiencing?\n\n**A: cranial nerve paralysis is known for Parkinson's disease, Stroke.**\n\n### Conclusion\n<EOD> Changes in the metabolite profile during the process of freezing storage of highbush blueberry (Vaccinium corymbosum L.) using an UHPLC-QTOF MS metabolomics approach.\nThis study investigated the impact of freezing storage on metabolic profiles of highbush blueberry and provided valuable molecular information to reveal the changes in blueberry metabolism during storage. Herein, we evaluated the metabolite changes that occurred during the freezing storage of blueberries via ultra-high performance liquid chromatography-quadrupole time-of-flight tandem mass spectrometry. After 0, 30, 60, 90, and 120 d of storage, we found that the fresh blueberry samples had",
        "label": 0
    },
    "963": {
        "output": "*Examples of patient notes and clinical trials are available here[INST]<EOD> Neuropsychological assessment of the demented for predicting treatment outcome. A longitudinal study in dementia of the Alzheimer type.\nThe present study reports on the course of patients with dementia of the Alzheimer Type (DAT) over up to 18 months treated with donepezil (DPZ, Aricept(R)). Using an initial neuropsychological assessment (NPA) it was tested whether it was possible to predict treatment outcome (e. g. cognitive improvement) with this measurement. Therefore the NPA included all available neuropsychological instruments used in our clinic, ranging from tests of general cognitive function to detailed tests of aphasia or apraxia, as well as personality assessment instruments. Based on the initial evaluation the patients were divided into four groups: severe patients not suitable for any active treatment; moderate patients who received DPZ; slightly less deteriorated patients who received combined therapy (DPZ + donepezil and ginkgo biloba extract (EGb 761, Cerevasc(R)); and the most functional patients not receiving any active therapy. The NPA, including all neuropsychological tests and personality assessment instruments employed, was repeated after intervals of 6 months. It was possible to identify groups of patients showing substantial changes after three, six and eighteen months in almost all neuropsychological tests and personality assessment instruments, but also in terms of clinical characteristics such as general progress of the disease, the global deterioration scale, functional status, activities of daily living (BADL (Norris)), level of care (L.C., Ostergaard-Andersen), and mental behavior (Norris scale of behavioral disturbances (NSD). It was observed that therapy with DPZ resulted in a small but significant positive effect, both in the total scale of MMSE and in the individual tests, though with different time courses. The results of the present study indicate that the neuropsychological assessment offers not only diagnostic information but also information about prognosis for treatment outcome in DAT-patients. If a clinical patient shows a low score at baseline in a neuropsychological test and a small gain in",
        "label": 2
    },
    "964": {
        "output": "[/TEST]\nCourse: Data Science I (part 1) for Medical Doctors \nCourse: Data Science II (part 2) for Medical Doctors \nCourse: Advanced Analysis Tools for Digital Medical Specialists \nCode of Conduct \nCourse Content \nCourse Syllabus 17\nPracticals 31\nData\n\n> data <- read.table(\"data.csv\",header=T) CARDF <-c(\"Trial, Trial_level_eligibility, Patient, Patient_age, Male, Patient_bmi, Patient_bmi_category, History_ of_medical_comorbidity, History_of_diabetes, Smoking_status, Alcohol_use, History_of_cprd, History_of_asthma, History_of_depression, History_of_heart_failure, History_of_atrial_fibrulation, History_of_mitral_valve _disease, History_of_chronic_osteomyelitis, History_of_epidural_ hematoma, History_of_menningothelial_disease, History_of_carotid_artery_sten-osis, History_of_varicose _veins, History_of_other_congenital _ heart_disease, Insurance, Trial\");\nnames(data) <-c(\"Trial\", \"Trial_level_eligibility\",\"Patient\",\"Patient_age\",\"Male\",\"Patient_bmi\",\"Patient_ bmi_category\", \"History_of_medical_comorbidity\",\" History_of_diabetes\",\"Smoking_status\",\"Alcohol_use\",\"History_of_c-prd\",\"History_of_asthma\",\"History_of_depression\",\" History_of_heart_failure\",\"History_of_atrial_fibrulation\",\" History_of_mitral_valve_disease\",\"History_of_chronic_osteomyelitis\", \"History_of_epidural_hematoma\",\"History_of_menningothelial_ disease\",\"History_of_car-otid_artery_st-enosis\",\"History_",
        "label": 0
    },
    "965": {
        "output": "---\n2\\. The second task is to find the median and interquartile range for the number of heartbeat counts. The interquartile range is the range between the first quartile and the third quartile, where the first and third quartiles are percentiles of the data ranked by size. If you need more details, see [Median and IQR](https://colab.research.google.com/github/UBC-ECoG/ECoG-DevNet/blob/master/UBCEcoGDe-vNet/03.IQR.md).\n\nFirst, you should import the following packages:\n\n\n<a href=\"https://colab.research.google.com/github/UBC-ECoG/ECoG-DevNet/blob/master/UBCEcoGDevNet/02.Pandas-Importing.ipynb\" target=\"_blank\" rel=\"nofollow\">Pandas-Importing.ipynb</a>\n\nNext, you should export the relevant metadata:\n\n\n<a href=\"https://colab.research.google.com/github/UBC-ECoG/ ECoG-DevNet/blob/master/UBCEcoGDevNet/02.Pandas-Importing.ipynb\" target=\"_blank\" rel=\"nofollow\">Pandas-Importing.ipynb</a>\n\nThen, you should load the following packages:\n\n\n<a href=\"https://colab.research.google.com/github/UBC-ECoG/ECoG-DevNet/blob/master/UBCEcoGDevNet/03.IQR.md\" target=\"_blank\" rel=\"nofollow\">`03.IQR.md`</a>\n\nThen, you can run the Python function `pandas.DataFrame` to return the object pandas.DataFrame and fill the list with relevant variable and parameter name:\n\n\n<a href=\"https://colab.research.google.com/github/UBC-ECoG/ECoG-DevNet/blob/master/UBC EcoGDevNet/03.IQR.md\" target=\"_blank\" rel=\"nofollow\">03.IQR.ipynb",
        "label": 0
    },
    "966": {
        "output": "## [ /INST]\n__In_Code/TrialInfo/TrialName.txt__\n\n__In_Code/TrialInfo/TrialAcronym.txt__\n__In_Code/TrialInfo/TrialSite.txt__\n__In_Code/TrialInfo/TrialStartDate.txt__\n__In_Code/TrialInfo/FinalStartDate.txt__\n__In_Code/TrialInfo/TrialDuration.txt__\n \n__In_Code/TrialInfo/TrialEndDate.txt__\n__In_Code/TrialInfo/TrialAcc.txt__\n__In_Code/TrialInfo/AgencyApproved.txt__\n__In_Code/TrialInfo/InterviewerApproved.txt__\n__In_Code/TrialInfo/NumberOfPatients.txt__\n__In_Code/TrialInfo/Aim.txt__\n```\n\n__Trial Acronym__\n**`TRIAL ACRONYM`** _string_\n\n__Trial Name__\n**`TRIAL NAME`** _string_\n\n__Trial Site__\n**`TRIAL SITE`** _string_\n\n__Trial Start Date__\n**`TRIAL START DATE`** _object_\n\n __`Trial Start Date.year`__ _string_\n__`Trial Start Date.month`__ _string_\n__`Trial Start Date.day`__ _integer_\n\n __`Trial Start Date.isoYear`__ _string_\n__`Trial Start Date.isoMonth`__ _string_\n__`Trial Start Date.isoDay`__ _integer_\n\n __Trial Start Date.millis_ _integer_\n\n__Trial End Date__\n**`TRIAL END DATE`** _object_\n\n __`Trial End Date.year`__ _string_\n__`Trial End Date.month`__ _string_\n__`Trial End Date.day`__ _integer_\n\n __`Trial End Date.is-oYear`__ _string_\n__`Trial End Date.is-oMonth`__ _string_\n__`Trial End Date.isoDay`",
        "label": 1
    },
    "967": {
        "output": "_\n\n## Output of the patient note:\nThe patient is eligible since the trial medicine shows a scale of 2 by the `Trial-level eligibility` statement. (See the `Examples of the output in the [Evaluate-1-input-note] section.)<EOD> A Phase II trial of irinotecan with 5-fluorouracil bolus and oral leucovorin in patients with advanced colorectal cancer. The GI Study Group.\nA phase II trial to explore the activity and toxicity profile of irinotecan in 33 patients with advanced colorectal cancer was conducted. Patients received irinotecan at a dose of 300 mg/m2 intravenously on Days 1, 8 and 15 with 5-fluorouracil (5-FU) at a dose of 400 mg/m2 as a bolus intravenously on Day 1 and oral leucovorin (LV) at a dose of 50 mg/m2 every 6 hours on Days 1 through 5 and 15 through 19 of a 28-day cycle. Median age was 56 years. All patients had progressed on prior 5-FU-based chemotherapy. Prior 5-FU-containing chemotherapy protocols were delivered either as adjuvant chemotherapy (n = 1) or in the metastatic setting (n = 32); prior irinotecan-based regimens included irinotecan plus LV (n = 22), irinotecan plus LV plus 1 or no prior 5-FU (n = 4), and a combination of irinotecan, LV, and cisplatin (n = 7). Objective responses were observed in 12 (36%) patients including 4 patients (12%) with complete response; median survival of responders was 10 months. Treatment was well tolerated and toxicity, as expected, was mainly hematologic. Non-hematologic toxicities included constipation (n = 12), diarrhea (n",
        "label": 0
    },
    "968": {
        "output": "## General hints \nDo not forget to `strip_tags`.\nCheck the input data and the code for the data you use. See if a patient note contains data of which you are not sure. \n\n### Input data \nYou should check the `Patient_note` tab of the data exploration tab. \n \nIn some cases, the output has a `NaN`-type value. These cases should be examined in detail.\n\n### Code \nAlways check the code! Make sure that there are no errors in the code, i.e., errors and warnings of the type `FatalError` or even `NotFatalError`. \n \nIf an error and/or warning appears, you can skip it if you think that making the necessary corrections is not essential. But you should know what the error and/or warning is for. \n \nYou should work with the full version of Anaconda3. \n \n\n## General hints for the exercise\n\n### The exercise does not have to be finished in one sitting.\nHowever, you will be asked to hand in the final code together with a file of the results, a screenshot of the input data in the data exploration tab, and any other information regarding the exercise that might help a future teacher if s/he has to resolve any kind of issue. \n\n### Always save the output file after each change in the code. \n\n### Before running the exercise on the computer in your lab, you can save the output file in the [Exercises/Input data/Output](https://github.com/vsl-group/exercises/tree/main/Input-data/Output) folder on the GitHub page in a new subfolder with your name. There you need not worry that your output file will be lost at any time if your computer stops working. \nIf possible, save the output file there in an appropriate format, i.e., as a [CSV](https://support.microsoft.com/en-us/documentation/29540436-how-to-export-your-excel-workbook-data-in-",
        "label": 1
    },
    "969": {
        "output": "| Eval 2\n|\n| **A 46-year-old man presents with dizziness and frequent headaches.** He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\n\n| **Clinical trial: Title: Epidemiology and Long-term Outcome of Patients With VHD**\n\n| Summary: Valvular heart diseases are significant problem in Polish population. Coexistence of coronary artery disease in patients with VHD increases the risk of death and affects further therapeutic strategy. The aim of the study is",
        "label": 1
    },
    "970": {
        "output": "[EVALIDATION-2] The second column contains more text about the result. This column can also contain any text such as warnings.\n\n[INST] Hello, you are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nHere is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/mL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively",
        "label": 1
    },
    "971": {
        "output": "### Task 3\nImputity data from a given randomized controlled trial (RCT). \n\n[INST] Here is the example data of one study site: \n![Example_data]()\n\nIf you want to get the data from the real-world example file, it is best to use the file provided with the task, as follows: \n![Example_data]()\n\nIn your Excel file, you should input each patient data as shown below. \n\n\n[INST] Explanations for the variable name are provided below: `Age` is the patient age. `Eligible` is the eligibility criteria. `Excluded` is the patient reasons for being excluded. `Excluded-Eligible-NotEnrolled` is the clinical trial eligibility assessment with the clinical trial eligibility assessment scale shown in Task 1. `Group` is the patient group; the sample size for each group is fixed at 500. `Randomization_group` is the group assignment, in which `0` indicates the control group and `1` indicates the intervention group. `Date` is the randomization date of each site. \n\n\n[PROB] You should include an English description of how you create each variable and describe the meaning of each variable for the readers. \n\n\n[QUESTION] Is it possible to have negative values for variables other than the patient ID? \n\n\n[ANSWER] Patient ID is a required variable, which should be unique. It should be integer. If there is an error, just make sure the variable name is unique, and then correct the value by using MIN and MAX functions.\n\n\n[QUESTION] If you need to have a negative answer, how to implement that? \n\n\n[ANSWER] There is no negative answer to this task, as mentioned above, it should be integer. You can use MIN and MAX functions to handle data with incorrect values. For example, in the above Example_data.xlsx file, the following code can be used to convert the patient ID to the correct value. \n\n\n[INST] Use",
        "label": 2
    },
    "972": {
        "output": "### 1. Check Exclude criteria -  If the patient meets all criteria for exclusion, print on the report the scale for the assessment of eligibility - 2. Check Inclusion criteria - If the patient satisfies all criteria for inclusion, print on the report the scale for the assessment of eligibility - 3. Check Relevant criteria - If criteria for exclusion are not met, also print on the report exclusion criteria that were met. - 4. Add trial-level eligibility - Print the scale for the assessment of eligibility for the clinical trial.\n\nPlease remember that the patient note is stored at the first line of the report.\nTo the next exercise, [CODE] hello.<INST>\nTo the next exercise, [CODE] EVENTS.</INST>\n[[Code: HelloWorld].\n[[Code: Hello World].\n\n# Exercise in Kaggles[INST]\n\n\n**Task1:** Get the Data from Kaggles and Create a Local Model.\n\nThe source code of this problem in Kaggle is available at https://github.com/wangliwei-bio/Kaggle-Get-the-Data-from-Kaggles\n\n[![image](https://upload.wikimedia.org/wikipedia/commons/thumb/b/b1/Python_logo_white.svg/744px-Python_logo_white.svg.png \"Python Logo\")]()\n\n[Teaching note]\nTo learn how to install Kaggles, please refer to the https://github.com/Wangliwei-bio/Scikit-learn-Tutorial/blob/master/kaggle#how-to-install-kaggle.\nTo get the data from Kaggles, please refer to the https://github.com/Wangliwei-bio/Kaggle-Get-the-Data-from-Kaggles#data-in-kaggle.\nTo build a local model from Kaggle, please refer to the [instructions on Kaggle](https://www.kaggle.com/help/overview/python).\nFinally, please refer to the [the source code of this problem in Kaggle](https://github.com/wangliwei-bio/Kaggle",
        "label": 1
    },
    "973": {
        "output": "![INST] Example:\nThis is the output of the algorithm:\n`1 1 2 2 2 2 2 2 2 2 2 2 2 3 2 2 2 2 2 2 3 3 3 0`\nYou can check the output above. Let's explain it carefully.\n[/1 1 2 2 2 2 2 2 2 2 2 2 2 3 2 2 2 2 2 3 3 3 0]\n\n\n\n1) This is the output of the algorithm for the example above:\nTrial-level eligibility: 1) Excluded\nEligibility: 0) Excluded\nEligibility: 1) Not relevant\nEligibility: 2) Eligible\nPatient ID: 1000239\nTrial ID: 1000239_05_2016\nFreq: < 10^9\nFrequency: less than 10 million. It is very, very low, so, very unlikely that we should remove this patient.\n\n### Eligibility: 1) not relevant\n#### The frequency of the term is between 10^6 and 10^9\nThe term Frequency range: less than 10 million to approximately 1 billion. It is relatively reasonable to think like this, because most of the time the patient does not have clear enough information to show whether he participates in the study or not.\n\n### Eligibility: 2) eligible\n#### The frequency of the term is more than 10^9\nThe term Frequency range: greater than 10 billion to 10^15\nAs you can see, the frequency of `the term Frequency` ranged from 10^6 to 10^9. As shown in [11], the term frequency in the training set of the PNNI model is distributed normally around the value 1.5. Hence, the term frequency in the test set of the PNNI model also follows this distribution. This can be expressed by equation (4.1).\n![INST]\nNow, the term frequency is more than 10^9, so",
        "label": 2
    },
    "974": {
        "output": "## Making a decision and submitting a note\n\n# Introduction and Objectives\nNow, it is time to summarize all of the things we learned above. You must decide whether a patient is eligible. The answer you should give to the question [Q01] `Is this patient eligible for the clinical trial?` should be either `0: Excluded` or `1: Not relevant`:\nThe eligibility assessment for entering into a clinical trial involves examining the following characteristics: the age, sex, physical health, disease phase, and previous treatment histories of patients. If there is a mismatch between a patient's characteristics and the selection criteria of a clinical trial, or if a patient has received an experimental drug or treatment protocol that is already known to be ineffective or harmful to the patient's health (e.g., a drug used to treat a specific disease currently under investigation to treat a different disease), then that patient is ineligible for the clinical trial.\n\n## Summary\nBefore we start, it should be noted that this project is a two-round multiple-choice question competition, which means that all the learners have to participate in both rounds. In the first round, which is the learning environment of the MOOC, each learner will try out several times, based on the learning materials, and each patient should be tested with only one trial using the eligibility assessment scale. After the submissions, the leaderboard will be updated (more information about the leaderboard can be found on the leaderboard page). Based on the results of the individual submissions, we will select 40 top-scoring users. The second round of the multiple-choice question competition is the test environment. In this test environment, each of the 40 top-scoring learners will try out again. There will be one correct answer for each question.\nBased on the results, we will select 10 top-scoring learners. For the purpose of providing a quality and fair examination, we will invite only the 40 top-scoring learners to submit their submissions from 22:00, 2022 to 28:00, 2022 (Beijing Time). At 28:00, 2022, the test will be closed. The test",
        "label": 0
    },
    "975": {
        "output": "</aside>\n</main>\n\n[MIT]\n\n## Using NumPy to compute correlations for the carotid artery plaques dataset\n\nSo far, we have been analyzing a given dataset without using any numerical techniques. Now, we shift our focus from `Statistical Analysis of the Carotid Artery Plaques Dataset` to `Computing Correlations for the Carotid Artery Plaques Dataset` section. In this section, we will be using a number of NumPy functions and will compute a correlation matrix and correlation coefficients.\n\n![instasound](/img/instasound.png)\n\nNumPy is a very useful and powerful library for array computation. In this lesson, we will be using a few NumPy features. Therefore, it will be better to have some NumPy basics, such as loading the built-in NumPy array and getting the shape of the built-in NumPy array.\n\n<aside class=\"devpage-skip\" data-skip=\"skip\" data-level=\"0\">\n\n<br><br>\n\n<br><br>\n\n</aside>\n</main>\n\n### Loading in NumPy array\n\nThere are three ways to load NumPy object, i.e., `numpy.loadtxt()`, `numpy.loadtxts()` function, and manual loading.\n<br>\n```python\nimport numpy as np\n\ndef try_load_numpy():\n    \"\"\" Load a NumPy object using `numpy.loadtxt`. \"\"\"\n    try:\n        n_test = np.loadtxt(\"D:/Code/Bioinformatics-Basics/Python/Python 3/NumPy/testData/test_data.txt\",\n                            delimiter=\";\", dtype=np.int32)\n    except:\n        print(\"Unable to load NumPy object.\")\n\ntry_load_numpy()\n\n```\n<br>\n<ul class=\"devpage-bullet\">\n\n    <li class=\"unbullet-left\">\n        <code>loadtxt</code> and <code>loadtxts</code> - Loading using <code>loadtxt</code>.\n    </li>\n    <li class=\"unbullet-left\">\n        <font color=\"red\">NOTE</font>",
        "label": 2
    },
    "976": {
        "output": "After the patient's assessment:\n---  \n!\n---\n\n\n##### Patient note\nThe patient does not meet inclusion criteria, as he does not met the age limit, he has high blood pressure, and he uses anticoagulants. Therefore, he is excluded on the grounds of the trial's exclusion criteria.\n\n* The output of results is also generated in the format of .*\n<EOD> The S252W Mutation in the Epidermal Growth Factor Receptor Does Not Implicate a Mechanism of Sensitivity to Epidermal Growth Factor in Human Glioblastoma Multiforme\nBackground: Glioblastoma multiforme (GBM) is the most frequent and aggressive primary brain tumour in adults. Epidermal growth factor receptor (EGFR) gene amplification is one of the most frequent molecular abnormalities of GBM, although not all GBM display such alterations. Although the S252W mutation is the most frequent non-amplification alteration observed in GBM, its functional effects on transduction pathways are not well defined. We analysed tyrosine phosphorylation levels of the EGFR in glioma cell lines carrying the S252W mutation, the in vitro levels of EGFR-regulated genes, and in vivo tumour growth after treatments with a selective anti-EGFR monoclonal antibody, cetuximab, and an EGFR tyrosine kinase inhibitor, gefitinib. We also analysed mRNA levels of EGFR-regulated genes in primary human tumours with or without amplification. Methods: We analysed the effects of S252W mutation on the level of tyrosine phosphorylation, activation of the phosphatidylinositol kinase (Akt)/mammalian ortholog of the yeast protein kinase (Sch9) signalling pathway, and expression level and activation of EGFR-induced genes like bFGF, cyclin D1 and EGFR in cell lines derived from GBM containing the S252W mutation. Primary human GBM from patients were analysed for expression of EG",
        "label": 0
    },
    "977": {
        "output": "</pre>\n\n<p>So far we have learned how to determine the level of eligibility (trial or patient) and how to extract the final scale for the assessment of eligibility from the extracted triallevel eligibility and input patient-level information to match with trial-level eligibility. We will use these capabilities to prepare our report.\n\nFor our report, you will see in the example code and the corresponding screen shot how to use `for in` and `while loops for the extraction of the list from the JSON data in our report. See Figures 10-16 below for a brief review. Please remember to save your reports to the report folder in your computer.\nFigure 10. How to extract the number of the included and excluded patients from the filtered data by patient-and trial-level eligibility. \nFigure 11. The same as in Figure 10 with the details of the code, including the input parameters to the report for the selection of specific patients. \nFigure 12. How to get more detailed results about the patients who have been excluded from the assessment of eligibility. \nFigure 13. Input data of the patients to the report to perform a patient-level data extraction. \nFigure 14. Display of the detailed results of getting more detailed results about the patients who have been excluded from the assessment of eligibility. \nFigure 15. Result of getting more detailed results about the patients who have been excluded from the assessment of eligibility. This is the more detailed results of those who have been excluded in the results of Figure 13. \nFigure 16. Input of the result data for the patient-level data extraction. \n</p>\n\n\n</div>\n\n<!--   <p style=\"direction:ltr;\"><span class=\"p-caption\">A: Assessment of patient eligibility</span></p>\n\n<p style=\"direction:ltr;\"><b><a class=\"a-name\" href=\"AssessPatientEligaibility_report.html\">Code snippet of Assessment of patient eligibility</a></b> </p>\n<p style=\"direction:ltr;\">\n<b>Code snippet of Assess",
        "label": 2
    },
    "978": {
        "output": "In some cases, a trial-level summary line might be helpful to give a brief look to the results. For example:\n\nEligibility per patient: Eligibility per patient:\nage 32-51 years\nfamily history of CAD, but no other cardiovascular risk factors\n\nEligibility: The mean LDL-C and HDL-C levels were 545.02 and 53.03\u2009mg/dL, respectively. The mean peak-systolic and end diastolic velocity in the left carotid artery were 208.41, 54.51, the mean peak-systolic and end diastolic velocity in the right carotid artery were 91.72, and 36.34\u2009cm/s, respectively. Peaksystolic and end diastolic velocity in common carotid artery were 74.69, 53.47\u2009cm/s, respectively. The plaque in internal carotid artery and common carotid artery were characterized as bulky plates extending to the middle third of the internal coronary arteries and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces. The mean velocity in anterior and posterior walls of internal carotid artery was 208.45, 54.47\u2009cm/s, respectively, and in the common carotid artery was 74.64, 53.89\u2009cm/s, respectively\n\nDemographics:\nmean BMI was 25.18\nEligibility: Bivariate analysis of the association between the eligibility assessment and all the demographics and inclusion criteria for the Trial is shown in Table 2. The eligibility assessment was significantly higher in subjects who: (a) did not smoke (P=0.032); (b) had a diagnosis of nonfamilial hypercholesterolemia (P=0.032); (c) were male (P=0.025); (d) had a diastolic pressure higher than the threshold",
        "label": 0
    },
    "979": {
        "output": "**If you execute the Python script**\n\n`python saveScript.py` [/SUPP]\n\n**If you execute the Python script**\n`python saveScript.py`\n\n#### Verification Result\n\nIn this paper, we focus on verification, not on performance. You may use the notebook `performanceTest.ipynb` to evaluate the execution time [/SUPP]. For more details on verification, see Python Testing.\n\n`s 1:00   1:000   100%` [/SUPP] `0.652`\n\n`s 1:00   1:1000   73.37%` [/SUPP] `0.804` : `44.6561 s` : `100%`\n\n`Trial-level eligibility: 2) Eligible` [/SUPP](https://jupyter.org/services/?url=https%3A%2F%2Fgithub.com%2Fc-feng/AIP-book-en-ch)\n\n\n### Expert\n\nExpert is a method for comparing and merging eligibility judgments using a machine learning algorithm.\nYou should assess the eligibility of a patient note and compare it to the assessment of another expert before making a decision.\n\nExpert-level eligibility indicates if a patient qualifies for a clinical trial. If the evaluation of the patient is identical to the evaluations of the experts, Expert-level eligibility is",
        "label": 1
    },
    "980": {
        "output": "If you have any questions about this tutorial, please, send an email at <EMAIL>.\n\n\n___\n\nTutorial: How to make an assessment of eligibility using Open-CDS?\nAuthor (last update): <NAME>, Institute of Information Technology & Processing, Poznan University of Life Sciences (2020). \nAcknowledgements:\nThis tutorial is dedicated to OLE/IFC expert with a solid background on the Open-CDS system.\n___<EOD> .\nBACKGROUND\nThe increasing number of people in the age group 65 to 80 years and the reduced life-expectancy expectancy in the coming 25 years imply that our health care system will be faced with an increasing number of elderly patients with fractures.\n\n\nQUESTIONS\nWhich are the most common fractures types of older patients and what are the treatment choices? Additionally, what are the effects of different treatment options available?\n\n\nMETHODS\nMedline was searched for literature related to our questions. Furthermore, relevant books were examined for our questions. The selection of the most relevant articles was based on the relevance to one or more of our questions and on their significance.\n\n\nRESULTS\nTreatment for vertebral fractures in elderly patients consist mainly of conservative care or operative therapy, consisting of vertebroplasty, balloon kyphoplasty or osteosynthesis. Operative treatments show better therapeutic results than conservative treatments, especially for intrapedicular compression fractures caused by osteoporosis. In a hip fracture, the treatment depends on the patient's life expectancy, mobility and functional state. For femoral neck and trochanteric fractures, intramedullary nailing is the most frequently used operative technique. For subtrochanteric and per-trochanteric fractures, the most frequently used procedure is trochanteric stabilization. For trochanteric fractures, an unstable subtrochanteric fracture type, or fracture dislocations without an indication for internal fixation, an intramedullary nail with lateral support, an extramedullary skeletal bridge plate or a sliding hip sc",
        "label": 0
    },
    "981": {
        "output": "_Example 2:_ Here is the sample output with the first instance only:  \n 117:\t       4037.2\t\t\t\n 118:\t 0.0\t 0.0\n 119:        2.0\t  2.0\t\t\t\n 120:       40.0\t\t 0.0\t\t\t\n 121:        5.0\t\t\t5.0\t\t\t\n\nTrial-level eligibility\n: 5.0\nOutputs [trial_note]: 1.0.\nOutputs [trial_note_2]: 0.0.\nOutputs [trial_note_3]: 0.5.\n\n_Example 3:_ Here is the sample output with all instances:  \n 117:\t       4037.2\t\t\t\n 118:\t 0.0\t 0.0\n 119:        2.0\t  2.0\t\t\t\n 120:       40.0\t\t 0.0\t\t\t\n 121:        5.0\t\t\t5.0\t\t\t\n       6.0\t\t100.0\t\t90.0\t\t\n 122:       6.0\t\t100.0\t\t90.0\t\t\n 123:       6.0\t\t100.0\t\t90.0\t\t\n 124:       6.0\t\t100.0\t\t90.0\t\t\n 125:       6.0\t\t100.0\t\t90.0\t\t\n       6.0\t\t100.0\t\t90.0\t\t\n\nTrial-level eligibility\n:\n Tally the number of unique inclusion criteria.\n\nTrial-level eligibility\n:\n 1\n\nTrial-level eligibility\n:\n 1\nOutputs [trial_note]:\n   3.0\n   1.0\n   0.0\nOutputs [trial_note_2]:\n   0.0\n   0.",
        "label": 0
    },
    "982": {
        "output": "## CORRECT RESPONSE: \"If one is eligible and one is ineligible, then the correct answer is `No`.\"\n\nCorrect response \u2b50:\n\n\nCORRECT RESPONSE INFORMATION\n\n**The correct answer is:** \n\nCorrect response: `No.`\n\n# Exercises\n\n## Exercise 1\n\n# Exercise 1-A solution\n\n## Exercise 1-B Solution\n\n## Exercise 2\n\n## Exercise 2-A Solution\n\n## Exercise 2-B Solution\n\n## Exercise 3\n\n## Exercise 3-A Solution\n\n## Exercise 3-B Solution\n\n### A.\n\n### B.\n\n## Exercise 4\n\n## Exercise 4.A Solution\n## Exercise 4.B Solution\n## Exercise 5\n\n## Exercise 5-A Solution\n\n### A.\n\n## Exercise 5.B Solution\n## Exercise 6\n\n## Exercise 6-A Solution\n\n## Exercise 6-B Solution\n\n### A.\n\n### B. \n\nExercise 7\n\n## Exercise 7-A Solution\n\n## Exercise 7-B Solution\n\n## Exercise 8\n\n## Exercise 8-A Solution\n\n## Exercise 8-B Solution\n\n## Exercise 9\n\n## Exercise 9.A Solution\n\n## Exercise 9.B Solution\nThis chapter provides a step-by-step explanation of the eligibility process of a patient with a particular medical condition for a clinical trial. It introduces the readers to the problem of trial-level eligibility assessment and then focuses on a description of the eligibility algorithm used to evaluate trials using a step-by-step process. The main content of this chapter is as follows: the concept of trial-level eligibility assessment; the definition of eligibility assessment; the problem that needs to be solved using clinical trial eligibility assessment; the eligibility assessment",
        "label": 0
    },
    "983": {
        "output": "##[EXP] Excluded. \tA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications. Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.  `Clinical-trial : [INST]. The trial-level assessment. \nHere is the clinical trial: \nTitle: The Carotid Artery Multi-modality Imaging Prognostic (CAMP) Study \nSummary: Carotid artery disease is a main cause of ischemic stroke and vascular dementia, and a highly prevalent disease. There is uncertainty about",
        "label": 1
    },
    "984": {
        "output": "[END]\n\u00a9 2016 - 2018 DataCure Inc -- Powered by WordPress Entries (R) 4.7.2\nCopyright (C) 2015-2018 The WordPress Foundation.\n<EOD> .\nThe effect of a long-acting depot formulation of the antidepressant drug zimelidine (ZD) upon the development of tolerance was studies. On the basis of the acute and chronic biochemical experiments performed with rat brain structures in vitro it was found out that the depot formulation of ZD is able to maintain the basal activity of brain serotoninergic (5-HT+) and adrenergic (AD) neuronal systems, preventing the appearance of tolerance to the therapeutic effect of the drug. The development of tolerance in the central serotoninergic and adrenergic nervous system appears to be a result of an inhibition of the initial sensitivity of the 5-HT+ and AD mechanisms to antidepressant drugs caused by changes of the phosphorylation-dephosphorylation status of enzymes regulating the turnover of monoamines, e.g., protein kinases, phosphatases, monoamine oxidase, acetylcholine esterase or GABA transporting carrier.<EOD> Inhibition of A\u03b2\u2010induced neuronal apoptosis via antiapoptotic signalling pathway\nA\u03b2 peptides, as one of the primary pathologic factors in Alzheimer's disease (AD), are cytotoxic to neurons, playing a critical role in the neuronal apoptosis. To clarify the mechanism of A\u03b2\u2010induced neuronal apoptosis, a neuronal apoptosis model in vitro induced by A\u03b2 peptides was used as a neuroprotection study model to search for the active compounds which could exert protective function on neurons. From the screening of crude extracts, a novel quinoline alkaloid (2\u2010aminoquinoline\u20106,7\u2010diol), designated W06, was isolated from a medicinal plant called the seeds of Stemona tuberosa. The biological activities of this comp",
        "label": 0
    },
    "985": {
        "output": "[[SEC:H20_05.0_0_0]] Your role is to analyze the eligibility data of patients at recruiting sites to identify participants who are suitable for the clinical trial.\n\nThe tasks you need to perform are shown on the left-side menu of the [MANAGE] tab. \n\n#### DUTIES\n- [Assembling a Query][INST] Select all the eligibility data from all the patients that participate in the clinical trial. Then export the data to .csv format.\n- [Calculating Eligibility Rates][INST] Analyze the calculated eligibilities.\n- [Viewing Individual Patient Data][INST] Analyze individual patient data and export these to .csv format. \nYour work is done!\n\n[NOTE]\nWhen you are done, close this window and open a new window of your web browser to check if the Exported Files folder is created. You should see .csv files saved inside the Exported Files folder. \n\n\n## SECTION 6: PROFILE SYSTEM\n\n[[SEC:H20_06.0_0_0]] The profile system contains information such as patient visits, baseline data, screening results, etc.\n\n\n### DUTIES\n- [[DESC:MANAGEMENT_SYSTEM]] You can manage screening data and patient visits from the [MANAGE] tab. A trial's patient screening data or patient visits are accessible under the [MANAGE] tab.\n- [[DESC:MANAGEMENT_SYSTEM]] Select [Select All] to transfer screening data and patient visits from all the patients of the trial. You need the data for the export operation [EXPORT] to be performed. You can perform this operation through [ACTION]\n- [[DESC:MANAGEMENT_SYSTEM]] To transfer data, check the box next to each [Patient] record and click on [Export]. Export each of the [Patient] records to .csv format. The file is saved into the Exported Files folder.\n- [[DESC:MANAGEMENT_SYSTEM]] Exported file names take the format ``{Screening Visits} screening-visit_{[001",
        "label": 0
    },
    "986": {
        "output": "![](00-200.png)\n  \n    \n\n## [C]: <NAME>,<NAME>,<NAME>\n[A]: <blink>In my case, my initial guess was actually a lot of the time that I was wrong.<NAME>?<NAME>?<NAME>.</blink>\n[B]: <NAME>.<NAME>, what are the requirements? Can the patients with aortic valve stenosis enroll in a cardiac hypertrophy study if they have mitral regurgitation?<NAME>?<NAME>?<NAME>.</blink>\n\n\n[B]: <NAME>, do we have a mitral valve prolapse for the mitral regurgitation?\n[A]: What was the criteria for mitral valve prolapse for the study design? You had to know the answer before the next question.\n\n[A]: So if it's a mild stenosis, then it's also less than 20% mitral valve calcium?<NAME>.\n\n[B]: <NAME>, it's an interesting answer. If we make a new study, do you think there's a need to look at mitral valve calcium?<NAME>.<NAME>;<NAME>.<NAME>.</blink>\n\n[B]: <NAME>, you said that we have something to look at if the mitral valve regurgitation is less than 3. So, is that something that you would look at in this patient?<NAME>[C]: <NAME>?<NAME>?<NAME>?<NAME>.</blink>\n\n[C]: <NAME>, how do we evaluate that?<NAME>?<NAME>.</blink>\n\n[C]: <NAME>, <NAME>. What would you do in this case if you had a murmur?<NAME>{C}: Yes, this is the one that I was looking at, which is <150> 2016. They did look at mitral valve calcium and mitral valve regurgitation at the same time, which is interesting and actually, not that often is done in medical trials.<NAME>.<NAME>.<NAME>.</blink>\n\n[B]: Do we ever consider the calcifications of aorta or carotid artery",
        "label": 1
    },
    "987": {
        "output": "[fig]  [: MW] Hello. you are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. [MW] Here is the trial record: ID: 36637 Internal ID: 10001 Trial name: Neuro-ultrasound Assessment in Behcet's Disease Title: Neuro-ultrasound Assessment in Behcet's Disease Summary: Assessment of structural changes that occur in large extracranial and intracranial arteries in patients with Behcet's disease Inclusion criteria: Inclusion Criteria: All patients fulfill the modified International Criteria for Beh\u00e7et's Disease Exclusion criteria: Exclusion Criteria: Patients with an age younger than 18 years of age Previous history of stroke or other neurological and psychiatric diseases Patients who are allergic to aspirin, clopidogrel, or dipyridamole Patients who are allergic to iodide-based contrast medium Patients with a history of major surgery in recent 2 weeks Patients who are pregnant or lactating Patients with active pulmonary tuberculosis Patients who are incapable of adhering to all experimental protocols Investigators will exclude any patient who refuses to participate in the study Patients with a history of ischemic stroke or other neurological or psychiatric disease Patients with prior surgical intervention Patients with chronic renal or hepatic dysfunction Patients undergoing dialysis Patients treated with steroids Patients with history of allergic reactions to contrast agents Patients with significant cardiovascular comorbidities including pulmonary tuberculosis Patients who are pregnant or lactating Patients underwent surgery within 2 weeks Patients with severe visual or hearing defects Patients who were incapable of adhering to the protocol",
        "label": 0
    },
    "988": {
        "output": "_**Good Luck**_, \n\n___\n\n\n\n___<NAME></NAME>\n\n***\n\n_This solution has been reviewed using [VTN-1103](https://wiki.vtn.ac.at/display/VTN/VTN+Evaluation+Review+Template)._ \n_For further information please see [VTN-027](https://wiki.vtn.ac.at/display/VTN/VTN-027+Incident+and+VTN-1103_(+VTN+Evaluation+Review+Template))_. _This work will be published under the [VTN License](https://wiki.vtn.ac.at/display/VTN/VTN+License)._ \n \n \n___ \n\n## Related solutions\nYou solved:\n- [Procedure_Patient](https://vtn.ac.at/solutions/59820)<EOD> Genome-Wide SNP-SNP Epistasis Study of the Relationship of Single Nucleotide Polymorphisms in Genes Coding for the Renin-Angiotensin System to Systolic Blood Pressure on the Utrophin Gene.\nThe renin-angiotensin system (RAS) has been shown to affect blood pressure, renal function, and cardiovascular function. The effects of the RAS are mediated by angiotensin-II (Ang II), which is a potent vasoconstrictor, a proinflammatory cytokine and an inducer of both angiotensin type 1 (AT1) and angiotensin type 2 (AT2) receptor expression. The Ang II/AT1 pathway leads to hypertension by promoting sodium and water reabsorption. While the interaction of 3000 SNPs mapping to 23 genes of the RAS in relation to SBP has been investigated by some previous studies, those studies had a modest effect size, and no interaction epistasis study has been undertaken. In this study, we investigated the epistasis of a set of 576 SNPs, which map",
        "label": 0
    },
    "989": {
        "output": "### \u25b6 Trial-level eligibility: 0) Excluded\n\nPatient Note:\nA 67-year-old male has LDL-C 210 mg/dL. He has hypercholesterolemia. He is physically active and has no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. He reported no use of lipid-lowering medications.\n\nNeck auscultation revealed a systolic murmur 2+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed moderate stenosis in the left internal carotid artery (LICA),  as well as severe stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 200.8\u2009cm/s and 50.9\u2009cm/s, respectively; RICA PSV was 151.39\u2009cm/s and RICA EDV was 51.67\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\n\n\n\nTitle: Pullback Pressure Gradient (PPG) Global Registry\n\n\nSummary: The purpose of this study is to determine the predictive capacity of the Pullback Pressure Gradient (PPG) index for post-PCI FFR and to determine the impact of the PPG index on clinical decision making about revascularization and on clinical outcomes.\nInclusion criteria: Consecutive patients with stable coronary artery disease or stabilized acute coronary syndrome and invasive FFR measurement \u22640.80.\n\n### \u25b6 Trial-",
        "label": 0
    },
    "990": {
        "output": "<EOD> .\nThis paper reviews anatomy, biomechanics, and the use of spongy bone or cartilage substitute materials as possible graft materials of the joint endoprosthesis joints and the spinal column. From the standpoint of biomechanics the most suitable graft material is proved to be cancellous bone. Therefore, the replacement materials are tested for their resistance to pressure against compression forces before they can be used clinically in joint and spinal endoprostheses. The results of some of these studies are presented.<EOD> .\nIn a retrospective analysis of 200 cases of thyroid cancer of the papillary type, in all cases with lymph node metastases (343), all other cases (176) were analysed for the number and location of the lymph nodes and also for presence or absence of the metastases in the latter groups, with the aim of developing an algorithm for staging, and establishing a more objective and rational basis for determining the prognosis and planning the therapeutic regime. It is recommended to include lymph nodes in staging and to define the groups as follows: with and without metastases in lymph nodes, and to take into account the group without metastases; this may be considered as a low risk group with a good prognosis (stage I). Stage II includes patients with single lymph node metastases (level VI, VII and IIIb). These groups are to be considered as an intermediate risk group. Stage IIIa also has single nodal metastases in other levels than level VI, but there are also lymph node metastases in level VII and IIIb. Finally, stage IIIb includes multiple lymph node metastases regardless of the level of localisation.--Because of the different prognostic significance of the lymph node metastases in relation to age, patients over 40 years with lymph node metastases are considered as representing the intermediate level of risk. However, lymph node metastases in all other groups are considered as indicative of a general increase in risk and are indicators for the presence of widely spread metastases. In this way, an increased risk in the primary tumour is considered as an indicator of the presence of distant metastases as well.<EOD> Differences of the",
        "label": 0
    },
    "991": {
        "output": "var trialLevelEligibility=1;\n\t\tif (condition) trialLevelEligibility = 2;\n\t\telse trialLevelEligibility = 3;\n\t\tconsole.log(trialLevelEligibility);\n\t\t// Assessment of Patient's Eligibility\n\t\tconsole.log('Assessment of Patient's Eligibility: '+patientNote.condition+' => '+trial_id[condition]+' =>  '+trial_condition[condition]);\n\n\t\t// Create a text message\n\t\tvar message = trial_level_assessment+trial_id[condition]+' was evaluated \\n';\n\t\t// Add the name of the study and your name\n\t\tmessage=message+'Assessing clinical trial eligibility: '+name+', '+trial_description['description']+' ('+trial_description['date']['year']+'-'+(trial_description['date']['month'])+'-'+trial_description['date']['day']+') '+patient_id;\n\t\t// Add the patient's assessment result\n\t\tmessage+=patientLevel_eligibility.patientEligibility + ' ('+trial_condition[condition]+') '+trialLevel_Eligibility + ' ('+ trialeligibility[result]+ ');';\n\t\t/*\n\t\t// Add results for different types of clinical trials\n\t\tmessage+=type+' '+trial_type[cliniCalTrial];\n\t\t*/\n\t\t\n\t\t// Send the SMS message\n\t\tvar sms = SMS_API({\n\t\t\tto: cell,\n\t\t\tmessage:message\n\t\t},{\n\t\t\tsuccess: function(){ },\n\t\t\toutcome: function(){ }\n\t\t}); \n\t\t\n\t}\n</script>\n\n\t\t  </body>\n\n</html> \n<EOD> Development of HCC in livers of Gunn rats undergoing liver regeneration: Implication for carcinogenesis.\nEpidemiological studies have shown that excessive liver regeneration following resection of primary malignant tumors significantly increases the secondary tumor incidence. Moreover,",
        "label": 0
    },
    "992": {
        "output": "## Evaluation metric\nNow, we need to evaluate the performance of an assistant. You must show that the assistant should be assigned as an eligible assistant.\nThe criteria for the assessment of eligibility must include three metrics to evaluate patients' eligibility. They are the accuracy rate, precision, and recall for the assistant.\n\n\nAccuracy-ratio is the number of accurate assistant's evaluation for a patient divided by the total number of trials for the patient. For the assistant in this trial, we have two choices from the total of 50 trials. A correct choice means one of the two trials is eligible and another is a not relevant result so Accuracy-ratio is 33/(33+17), i.e., 0.647. \n\\frac{\\begin{matrix}33 \\\\ 33+17\\end{matrix} } {\\begin{matrix}50 \\\\ 50\\end{matrix}} \\ \\  \\text{(64.7%)}\n\n\nAccuracy measures how correctly an assistant assesses a trial when compared to the ground truth.  While the accuracy gives you an idea of how well the algorithm predicts the ground truth, two more metrics are needed to capture both false positives and false negatives of the model. False positives (FP) and false negatives (FN)  are the two metrics that you must provide with the patient notes while completing the assignment. For this task, FP are the number of assistants who assign trial is unqualified when there was an eligible trial while FN means the number of assistants who assign trial is eligible when there was an unqualified trial. The precision is the ratio of true positives to the sum of true positives and false positives,  while recall is as the ratio of true positives to the sum of true positives and false negatives. \n[Precision=True positive/(True positive+False positive)]\n\n\n[Recall=True positive/True positive+False negative]\n\n## Examples of Trial-level eligibility matrix for Clinical trials \n\nTrial-level eligibility matrix contains 5 columns (or features) in this example of table:\n- Column 1 is the clinical trial ID, which we shall use to",
        "label": 1
    },
    "993": {
        "output": "##[SEC] 3.5) Suggested Solution #5-4\nYou can solve your problem by using the command ``set trial-level-assessor 0.2`` right now. Then, the problem will disappear. You can also modify the trial setting manually. Do not change the trial setting in your code. Make the change in the trial setting file. You can open `master.R` in your local directory to check the code. Also, you can use an `R Studio Console` [https://rstudios.com/products/rstudio-console/(LINK)].\n\n### EX3.5.3. Trial-level assessment and analysis: Trial-level Eligibility\nThis step is the same for `problem solver #5-1`. Please do the same steps from the same starting point, and please confirm that your code does not have the same mistake.\nThere is no answer below for this step.\n\n#[SEC] 3.5) Suggested Solution #6\nYou need to remove ``set trial-level-assessor 0.2`` from your code. If you still get an error on the step, try to set trial-level-assessor 1.0, and confirm again that your code does not have any mistakes.\n\n### EX3.6. Trial-level analysis: Cumulative incidence function\nThis step is the same for `problem solver #6`. Please do the same steps from the same starting point, and please confirm that your code does not have the same mistake.\nThere is no error below for this step.\n\n#[SEC] EX3.7. Suggested Solution (1) Cumulative incidence function for the endpoint\nYou can compute the cumulative incidence for the endpoint.\nI recommend you to create a new R library folder and create a new file in that folder before you import the data.\nNow we import the data into R workspace, and compute the cumulative incidence using `survdiff` from `survival` package. We can also compute the 95% CI of each group by `ggtable`.\n\n## Coding\nlibrary(R.utils)\nlibrary(survival) library(\"table1.ext\") library(survdiff) library(ggtable1.ext) library(ggpubr",
        "label": 0
    },
    "994": {
        "output": "<h2 id=\"data\">Data</h2>\n\n<p class=\"p1\" style=\"text-indent: 3em;\">\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\nThe patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA),  as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\nYou should always repeat Trial-level eligibility = 1) Eligible.`\n</p>\n\n<h2 id=\"data\">Data</h2>\n\n  <table class=\"data\">\n    <thead><tr><th class=\"firstcol\">Pat",
        "label": 0
    },
    "995": {
        "output": "## Tests\nPlease, find here the tests which are passed by this exercise. Each test is evaluated by the corresponding test writer.\n\n### Test I\n\nTest I is the correctness test for the trial-level eligibility.\nThis test is a random selection process, so any correct/incorrect feedback is subjective and depends on the person that takes the Test I.\n\n#### Test output\nOn the _`Test` page_, the tests are displayed and you can click on\nthe\nlinks to see the solutions.\nWhen you click on the link\nyou will reach an answer page in\nwhich the solution of the test is explained. And in order\nto check, whether the submission was valid, click\non the link below.\nIf the solution is correct, then the user is validated.\nIn order to be sure it is the same person, please fill the\nform\nas well.\nThe fields that should be filled are as follows: the\nstudent number,\nthe name and the ID of the clinic.\n\n#### Example\nHere is an example to see the solution page!\n\n|Student ID|Clinic|Stenosis status| Trial-level eligibility|\n|:-----|:------|:-----------|:-----------:|\n|101|3|0|Eligible|\n|101|3|1|Not relevant|\n|201|4|2|Excluded|\n\n|101|3|0|Eligible|\n|102|1|0|Not relevant|\n|201|3|1|Excluded|\n\nPlease, remember to select the correct field!\nAlso, please fill the\nform\n!\n\n#### Solution\n\n\n\n<EOD> An exploration of health professionals' perception of the potential usefulness of an online pain education programme\nAbstract Objective The main aim of this paper is to explore health professionals' perspectives and experiences of using an online education programme for pain management. A secondary aim was to identify how educational requirements could be met to improve the quality management of chronic and acute pain. Methods Focus group interviews were conducted with nurses and doctors between August 2014 and February 2015. They represented the three health disciplines \u2013 nursing, medicine and phys",
        "label": 2
    },
    "996": {
        "output": "<EOD> Influence of Dipyridamole on the Kinetics of Different Pharmaco\u2010Thrombodynamics Parameters\nThe evaluation of the drug induced changes of the thrombus growth and its morphological evolution in different blood concentrations of 3H\u2010fibrinogen is described. For this, a pharmaco\u2010thrombodynamics study was performed with dipyridamole, a drug known to interfere with the platelet\u2010mediated thrombus growth. The time dependent variation in thrombus volume, lag time, maximum absorption and surface tension of thrombi, and their kinetics parameters, in the absence and in the presence of different concentrations of dipyridamole (total plasma concentration from 0.5 \u03bcg mI\u22121 to 1.25 \u03bcg ml\u22121), were determined in an in vitro system. The dose dependent inhibition of thrombus surface tension and of the thrombus volume and the corresponding increase in the lag time and the maximum absorption were observed. A significant modification of the growth velocity was detected indicating a modulation of the morphological stages occurring during the coagulation dependent thrombus formation in the presence of dipyridamole.<EOD> Rhabdomyolysis caused by vigorous aerobic dance\nA fitness instructor developed an unusual pattern of rhabdomyolysis following an aerobic dance session, including delayed presentation, failure of serum CPK kinetic resolution and prolonged muscle stiffness. It is important to be aware of this condition in this setting so that unnecessary investigations or therapeutic procedures, such as cardiopulmonary resuscitation, are avoided.<EOD> A New Innovative Method for Monitoring Mental Health Problems among School-Aged Children during Lockdown (SARS-CoV-2 Pandemic)\n\n\n\n# Introduction\nThe Italian National Health System provides publicly available universal coverage to its entire population, including children. In this context, the National Health Plan 2014-2016 included health promotion in children as a priority and a public health intervention priority for this age group involved a broad approach in which the evaluation of mental health, not addressed in-depth in the previous plan, was proposed [bib_ref]  The First Year of the National Health Plan",
        "label": 1
    },
    "997": {
        "output": "A 44-year-old woman with a history of type 2 diabetes mellitus reports no use of lipid-lowering medications. Her family members have a history of CAD and she is overweight. Her LDL-C and HDL-C levels were 173 and 16\u2009mg/dL. Her fasting glucose and triglyceride levels (94 and 135\u2009mg/dL) were within normal limits.\nThis patient notes exclude criteria; therefore, we should output `0`: Trial-level eligibility: 0) Excluded.\nOne solution is by adding patient note lines with appropriate labels (in our case the label is Exclude) and then the relevant text in the patient note (a part of the label itself) goes into patient notes that should be excluded. Therefore, this patient note is now 0; Exclude: \u2026 The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\nA 44-year-old woman with a history of type 2 diabetes mellitus reports no use of lipid-lowering medications. Her family members have a history of CAD and she is overweight. Her LDL-C and HDL-C levels were 173 and 16\u2009mg/dL. Her fasting glucose and triglyceride levels (94 and 135\u2009mg/dL) were within normal limits.\nThis patient notes exclude criteria; therefore, we should output `0`: Trial-level eligibility: 0) Excluded.\nOne solution is by adding patient note lines with appropriate labels (in our case the label is Exclude) and then the relevant text in the patient note (a part of the label itself) goes into patient notes that should be excluded.\n\nA patient should be considered eligible if they",
        "label": 0
    },
    "998": {
        "output": "**\u2461 If patient does not meet inclusion criteria: Excluded**\n\n\n![INST](inst/4_1_2_1_1_1.png)  \n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the 2022/11/14 12:00:38, by r=regr, session_id=$'b08dcdb8701c7dad', pid=5865, request_id=860862931, user_id=5442315787503587, up_time=102,262,861,383, total_time=2022/11/14 12:06:38, db_query=SELECT \"Patient_Name\".\"Name\".\"eng\", `Trial-level eligibility.` FROM \"patient\" WHERE Patient_ID=1403472342 AND Patient_Name =\"Zakarija\" ORDER BY `Trial-level eligibility`.\n\n[INST] You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\n[INST] Here is the patient note:\nA 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.The patient reported no use of lipid-lowering medications.\nNeck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe",
        "label": 2
    },
    "999": {
        "output": "In other words, if the patient note includes an element that is an inclusion criteria of the clinical trial, print that element in blue like the given example. \nNote that each element that is an inclusion or exclusion criteria of the clinical trial will consist of 4 parts: 1) The inclusion or exclusion criteria; 2) the status information of the clinical trial based on what the patient's element match the one of the clinical trial; 3) the clinical trial whose element will match the patient's one; 4) a list of elements of the patient note that match the clinical trial element. Here, the element of the patient note \"Epigastric pain radiates to the right upper quadrant.\" will match the clinical trial element \"The pain\" while the element of the patient note \"The pain radiates to the right \" will not match. On the other hand, the element of the patient note \"History of hypercholesterolemia\" will not match \"History of Diabetes Mellitus and its compliances\", but the element of the patient note \"2 NVDs\" will.\n\n\n\n![11](../img/img_11.png)\n\nEach element of the patient note that match one of the elements of the clinical trial will be printed in the same line of its corresponding element of the clinical trial with a blue color and will be given the code element_index (e.g., `Epigastric pain radiates to the right upper quadrant_element_index`).\n\nAfter finding an element of the patient note that is an inclusion criteria of the clinical trial, print the corresponding element of the clinical trial with its status information. For example, `the pain radiates to the right` will be printed with the status 0, meaning \"Excluded\" since the element of the clinical trial \"The pain` is \"Pain\"` and `Epigastric pain radiates to the right upper quadrant` is included and not excluded based on the rules. \n\nHere are the rules for the status of elements that are not matched:\n\n\n\n| Elements                                                                                          | Exclusion Criteria                                                     | Inclusion Criteria |\n| ------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------",
        "label": 0
    },
    "1000": {
        "output": "## [/TEAM]\n<p align=\"center\"><strong>[INST] How does the assessment of eligibility lead to trial exclusion?</strong></p>\n\n[TEAM] Here is your task. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a two-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\n\n[SEA] Here is the clin",
        "label": 0
    },
    "1001": {
        "output": "## Trials [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of the a clinical trial to determine the patient's eligibility. Your results of eligibility are recorded as a list to the principal investigator of the corresponding clinical trial. This list is called a trial-level eligibility, and you should repeat it in the last line, e.g., `Trial-level eligibility: 2) Eligible.`.\n\n## Mentioned\n[INST] Here an output example.<EOD> A systematic review of intergenerational participatory research: benefits, challenges, and lessons learned\n\nObjectives: To synthesise the evidence on intergenerational participatory research (IR) projects involving stakeholders of different ages.Methods: We conducted a systematic review of peer-reviewed articles in English and French. We conducted searches between January 2005 to November 2020 in the databases PubMed, CINAHL, Ovid Medline, PsychINFO, ProQuest (Social Sciences Premium Collection), Scopus, and Web of Science. We followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.Results:We identified 1046 articles, included 11 for the final review. Among the 11, 4 (36%) were conducted in North America, 4 (36%) in Europe, 1 (9%) in the Caribbean, and 2 (18%) in Australasia.Interventions most frequently involved children and elderly participants (84% of articles), with family members included in one of two articles. Five articles (45%) reported intergenerational benefits for children (e.g., greater health literacy), 5 (45%) reported educational benefits for intergenerational groups (e.g., greater collaboration and communication skills), and 1 (9%) reported on intergenerational attitudes (e.g., more harmonious relationships). Challenges were reported in 7 (64%) of the articles reviewed. Most common challenges were: facilitating group dynamics (64%), dealing with language barriers (55%), scheduling group meetings (45%), ensuring",
        "label": 0
    },
    "1002": {
        "output": "<EOD> A Study on Torticollis in Children\n\nA Study on Torticollis in Children (Pelvic-Spinal Incompetency with Head Retroversion and Subsequent Horizontal Spinal Curve)\nM.D.A Study on Torticollis in Children (Pelvic-Spinal Incompetency with Head Retroversion and Subsequent Horizontal Spinal Curve)\nARTICLE II.\nWhen the body is in the anatomical position, the superior thoracic vertebrae form an inclination with the vertical.\nIf the position of the head be altered, the inclination of the superior thoracic vertebras will be increased or decreased, according to the position assumed by the head. This statement is made with reference to the head as it was observed during the making of the anthropometric measurements, and the statement is not intended to apply to the position of the head which may be present in the body of the subject, when he stands or when walking. Thus, the head may be tilted so markedly to the backward position that the upper thoracic vertebrae are observed to be perchardly or rather markedly inclined toward the vertical plane. Consequently, in the position observed, the angle which forms the acute angle with the vertical is, as a rule, markedly increased over what is observed in the anatomical position.\nAs a rule, when the head is tilted to one side in children, the superior thoracic inclination and the inclination of the sternum are inclined to the opposite side to a greater or lesser extent ; occasionally the inclinations of the superior thoracic vertebrae, sternum, etc., are in a normal state, but occasionally the inclination of the sternum is increased, the inclination of the superior thoracic vertebrce not being markedly increased, and occasionally the inclination of the upper thoracic vertebra has a marked increase, while the inclination of the sternum is normal. In short words, the superior thoracic curvature is found to incline to the direction in which the head is tilted, while the sternum inclines the opposite way from the tilted head.\nWhen the superior spinal curve is formed due to an excess of inclination of the superior thoracic vertebrce, and the patient keeps his position",
        "label": 0
    },
    "1003": {
        "output": "## Examples\n\nYou have 2 examples to look at in your Jupyter notebook. The first example is `1.input_data.ipython`.\nRun it to visualize the patients. You have a visualization on the left and some of the values on the right. Click on a column and it will highlight the lines according to that column. You can sort the table on any row by clicking the column heading.\n\n\n![](/figures/inst01_input_data.png)\n\nNext, you can run `2.train_test.ipython` to train the NN model. To evaluate, run `3.evaluation.ipython`. Both examples can be found in your Jupyter notebook.\n\n<EOD> Torsin-mediated protein homeostasis is regulated by an intramolecular interaction\n\nEdited by Phyllis HansonDominantly inherited mutations in TOR1AIP1/TOR1A have been linked to earlyonset torsion dystonia and a plethora of neurological disorders suggesting a central role of the encoded TorsinA protein in maintaining neuronal homeostasis. Although implicated in disorders of neuronal maturation and cellular protein homeostasis, the exact molecular function of TorsinA is unclear. The recent discovery of diseasecausing mutations in the intrinsically disordered (ID) C-terminal region of TorsinA suggests that the N-and C-terminal segments have unique roles in protein function. Here, we report on an unanticipated intramolecular interaction between the N-and C-terminal regions of TorsinA. Using nuclear magnetic resonance spectroscopy and an integrated biophysical approach, we dissect the structural interactions of the TorsinA C-terminal region. Through a comparative evaluation of its oligomeric and monomeric states, we provide evidence that the C-terminal region is not essential for oligomerization. Instead, under conditions promoting oligomerization, we observe a specific interaction between the C-terminal region and the N and AAA\u0609 ring domains. We show that the C-terminal interaction with the N and AAA\u0609 ring domains prevents the binding of C-terminal modifiers, thus regulating protein interactions and cellular",
        "label": 0
    },
    "1004": {
        "output": "*Exercises*\n\n1. Create the patient note and the clinical trial on [https://lh3.github.io/diagnostic-code-formatter-interactive/, the interactive HTML page](https://lh3.github.io/diagnostic-code-formatter-interactive/) or [https://lh3.github.io/diagnostic-code-formatter-json/, the JSON page](https://lh3.github.io/diagnostic-code-formatter-json/) and copy-paste in the cells below to continue with the exercise.\n2. Change the patient note by adding new lines and modify it according to your knowledge about diseases. Do the exercise again by using the different patient note.\n3. Change the clinical trial by adding new lines and modify it according to your knowledge about diseases. Do the exercise again by using the different clinical trial.\n4. Change the patient note and/or the clinical trial to fit your need. You must repeat the task and make new assessment for each patient.\n5. Think again and again: Is this new assessment correct? Is it possible to make a mistake? Try to find and solve the mistakes.\n6. Look at the patient's report and the clinicians decision in Examples/02.\n\n[https://lh3.github.io/diagnostic-code-formatter-interactive/exercises/exercises/1/](https://lh3.github.io/diagnostic-code-formatter-interactive/exercises/exercises/1-A-1)(https://lh3.github.io/diagnostic-code-formatter-interactive/exercises/exercises/1-B-A/data/(https://lh3.github.io/diagnostic-code-formatter-interactive/exercises/exercises/1-B-A/data-A) (https://lh3.github.io/diagnostic-code-formatter-interactive/exercises/exercises/1-B-A/json/ (https://lh3.github.io/diagnostic-code-formatter-interactive/exercises/exercises/1",
        "label": 0
    },
    "1005": {
        "output": "<EOD> Evaluation of a new antipyrine method of measuring drug biotransformation activity.\n\nA new method has been developed for the assessment of antipyrine metabolic capacity which makes use of antipyrine binding values, measured by automated high pressure cation exchange chromatography. Preliminary experience in the measurement of this parameter in a limited number of subjects confirms the general expectation that metabolic \"poor\" subjects can be identified reliably by this technique.\nAn important aspect of drug elimination is the role played by the liver in this metabolic process. Assessment of hepatic drug biotransformation capacity has long been accepted as a useful contribution towards an understanding of the inter-subject variability in drug response [bib_ref]  Individual variability in drug metabolism, Meyer [/bib_ref]  [bib_ref]  Individual variation in drug metabolism, Meyer [/bib_ref] . The majority of the assessment techniques which have been employed in clinical practice involve use of the parent drug for such measurements. While this approach has resulted in a satisfactory correlation with drug response, the method has limitations [bib_ref]  Individual variation in drug metabolism, Meyer [/bib_ref]  [bib_ref]  The measurement of hepatic drug metabolizing capacity, Meyer [/bib_ref] . With some drugs, such as theophylline, the parent compound has been found to be essentially inactive as a metabolizing substrate and yet is metabolized to a significant extent.\nIn recent years the use of drugs as probe substrates has been advocated [bib_ref]  Individual variation in drug biotransformation, Bloor [/bib_ref]  [bib_ref]  Substrate markers for enzyme measurement in clinical diagnosis, Bloor [/bib_ref] . As reviewed recently by , the ideal probe should exhibit metabolic stability, no antagonist effect, be capable of assessing several drug metabolizing enzyme systems, be measurable easily and rapidly, preferably by simple non-invasive procedures, be non-toxic when administered parenterally in large amounts and, finally, be cheap on a mass basis. Various types of probe have been proposed for this purpose, one of the earliest being antipyrine (3-hydroxy-5-dimethylaminomethyl phenylpyruvate), which has a long track record in clinical and human experimental",
        "label": 1
    },
    "1006": {
        "output": "<EOD> Evaluation of the SARS-CoV-2 detection by rRT-PCR in different types of clinical specimens\n\nWe evaluated 1251 nasopharyngeal and oropharyngeal swabs (NPOP), bronchoalveolar lavage fluid (BALF) (603), bronchial tissue (24), alveolar lavage fluid (ALF) (21), and 13 sputum samples in all COVID-19 patients who were admitted to the pandemic ward or ICU of the Ondokuz May\u0131s University Medical Faculty between March 16, 2020, and December 30, 2020. 1186/1251 (95.2%) of the samples were",
        "label": 0
    },
    "1007": {
        "output": "##[RST] We've already got a list of patient-level eligibility statuses and the trial-level assessment. Now I want to use that to make a judgment on the whole trial.\n[INSE] First, you will create a trial level eligibility with the `TLE` function. It will give you the same trial-level eligibility function as the `trial-level-eligibility` function. After that, it will output the trial level, where the patient-level eligibility will be assigned. You can also create a list with the same function. \n##[RST] Now, you need to know more about the trial-level eligibility function. \n[INST] Each element of `TLE` contains one of the 2 eligibility assessments for trials.\n[RST] There are more data to be shown on these patients who have met the inclusion criteria for the study. If you look at the patient list, you can see all the patients for whom the trial has met the inclusion criteria and has also met the exclusion criteria. \n##[RST] Let's see!\nTo create an exclusion file, you can use the `list-exclusion` function.\n[INST] The list of possible exclusion criteria in the clinical trial is determined by the clinician before the start of the study. The clinical criteria are provided in the trial-level exclusion file. This file includes codes from the CTCAE scale that describe each patient's symptoms that have affected his or her level of fitness for the trial. These codes form the list of exclusion criteria for this patient that are assigned to the patient when the trial-level eligibility is created. \nThe main problem in this case study is that the assessment of eligibility has been carried out based on the patient level, and now, in the case study analysis, we need the trial-level assessment. You will transform the patient level with the `trial-level-eligibility` function. Here, we assign patient-level eligibility to the trial-level assessment. In patient-level eligibility, there are `no` and `unknown. The results will be `Trial-level eligibility: 2) Eligible.`\nYou will use the 'TrtLvlElig' function to create",
        "label": 0
    },
    "1008": {
        "output": "[INST] You can skip this section if you want. Here, we tell you how we prepared the data to train and evaluate our model. We chose three different datasets based on the available annotations. The first dataset contained annotated patient notes in which all the information about an individual patient was included, i.e., the title, the patient's details (initials, age, and gender), the location, the time, the type of the disorder, and the chief complaints. The 2nd dataset contains title, diagnosis and location information. The last dataset contains diagnosis and chief complaints. \nIn our experiments, the patient notes were tokenized on whitespace and numbers. For example, the token space '15-year-old', 'a 32-year-old woman', '. . ., 70-year-old woman' will be '15year old', ' 32 year old woman', '. . ., 70 year old woman'. The token tokenizer is a lightweight version of the WordPiece-based tokenizer by Google Research. \nIt is worth mentioning that in the first dataset, the tokenization process of the chief complaint was simplified in a way that when the note contained more than one space between the chief complaints, they were tokenized as a separated token.\nSince the number of the notes is high (e.g., more than 60k patient notes), it is more efficient to use the Word Pileup method for training the model. In this model, the Word Pileup method was used with a set of vocabularies with a size of 30 or 100. \nThe vocabulary is generated from the training data by using the Word Pileup technique:\n\n1. Selecting the start token for all words (word_start)\n2. Tokenization of patient notes (tokenization)\n3. Computing the P-value of each word in the patient notes (P_value)\n4. If the P_value is more than 0.1, then the token does not exist in patient notes; otherwise (P_value<0.1), then adding the word to vocabulary V_word\n5. Computing the P-value of each word in the patient notes (P_value)\n6. If the  P_value is more than 0",
        "label": 0
    },
    "1009": {
        "output": "## Case Study Two: \nYou are one of three fellows at the university of Harvard medical school who started a study to estimate the incidence of pulmonary embolism (PE) in hospitalized patients. One of your patients was diagnosed with having pulmonary embolism (PE). One of your first tasks is to estimate the incidence of PE in the inpatient ward to be a part of the larger study. You will determine the incidence as the number of cases of PE cases per 1000 patients admissions. \n[INST] The data file contains data of 1000 patients who were diagnosed by Chest Radiograph (CH) and Echocardiogram (ECG) to determine the clinical state of patients who may show signs of pulmonary embolism.  You need to create a data frame `Patients_data` to store patients data by defining a function Patient_data, then store the results under a data frame named `Data`. The function must take 4 factors as input, which could be a vector or factor. \n\nLet's write your function in one line:\n\n``` {r} \nPatient_data <-function (CH_radiograph_test, ECG_test, CH_radiograph_status_, ECG_status_){ \n\n    Patients <-data.frame()\n\n    Patients <-data.frame(CH_radiograph_test = as.factor(CH_radiograph_test),\n                         ECG_test = as.factor(ECG_test),   CH_radiograph_status_ = as.factor(CH_radiograph_status_), \n                         ECG_status_ = as.factor(CH_radiograph_status_),) \n\n    return(Patients)}\n\n\n```\n\n\n``` r\nCH_radiograph_test <-'CH Radiograph Test' ECG_test <-'Echocardiogram Test'\nCH_radiograph_status_ <-'CH Radiograph Status' ECG_status_ <-'Echocardiogram Status'\n```\n\n###\n\nNow, let's use your newly created function to store the data:\n\n``` r\nYour_data <-Patient_data(",
        "label": 0
    },
    "1010": {
        "output": "### Eligibility\n- If the patient is a potential participant in the clinical trial, a clinical trial-level assessment of eligibility needs to be executed.\n- Let's take the `eligible` case as an example. If the patient fulfills all the inclusion criteria and none of the exclusion criteria, he/she is in the `eligible` assessment of eligibility. In the other 3 cases, patients are `excluded`.\n![FAC]\n- A clinical trial recruiter usually needs to check both trial-level eligibility and patient-level eligibility. For the `eligible` case, the `eligibility` function will print an empty array for lack of an output at the trial-level. [INST]\n\tEven if a clinical trial does not provide a trial-level `eligibility` array, we can still perform a trial-level assessment of eligibility. It is achieved by:\n\t```r\n\tdata <\u2212 trial.recruitment.example()\n\trecruit <- assess.eligibility.clinicalTrail(data)\n\t```\n\t[FAC]\n\t\n### Check the ClinicalTrial object for validity\n\nA well-formed trial is a clinical trial that adheres to the trial schema designed in the ClinTrial package. Checking the validity of a ClinicalTrail object can help a data user with verification.\nThe function that helps users assess the validity of a given ClinicalTrail object is called `validClinTrial`. It returns a boolean, `TRUE`, if the trial can be defined and the trial code appears in the trial schema. In the other example, no valid schema can be assigned for the given trial. [INST]\t\t\n\n### Exclusion Criteria\nOne may wonder why exclusion criteria are important and what the exclusion criteria for clinical trials are, in addition to inclusion criteria. Examining the list of exclusion criteria in the clinical trial provides information about a clinical trial's scope in a nutshell.\nExclusion criteria are essential when it comes to protecting the right to autonomy, i.e., one's ability to decide if one desires to participate in a clinical trial or not",
        "label": 0
    },
    "1011": {
        "output": "You are free to explore what the program says and if needed edit the code. Good luck!\n\n# \u7a81\u7834\u53e3\u764c\u96be\u6cbb\u7684\u9776\u5411\u6cbb\u7597 - \u7f8e\u6d1b\u97e6\u6797 (Paclitaxel) \u4e0e\u963f\u7cd6\u80de\u82f7 (Doxorubicin and Cisplatin)\n\n# 1. [\u7efc\u8ff0](Overview)\n\u3010\u6458\u8981\u3011\u53e3\u8154\u9888\u764c\u662f\u4e00\u79cd\u6bd4\u8f83\u5371\u5bb3\u7684\u6076\u6027\u5316\u7597\u7684\u764c,\u6709\u660e\u663e\u7684\u4e25\u91cd\u6076\u6027\u75c5\u53d8,\u7279\u522b\u662f\u9888\u90e8\u53e3\u8154\u9888\u764c,\u5728\u8fc7\u53bb10\u5e74,\u53e3\u5916\u90e8\u65b9\u6848(extective approach) \u5e94 \u7528\u8bf1\u5bfc\u5316\u7597 \u3001 \u9888\u90e8\u5207\u5f00,\u653e\u7597,\u6839\u6cbb\u672f\u548c\u624b\u672f\u672f\u7684\u65b9\u6848 \u5c1a\u672a\u8fbe\u5230\u4e34\u5e8a\u6cbb\u7597\u6c34\u5e73,\u4f46\u6cbb\u7597\u65b9\u5411\u53d8\u5316\u4e86\u3002\u6700\u8fd1,\u53e3\u8154\u9888\u764c\u60a3\u8005\u7684\u9888\u90e8\u6dcb\u5df4\u7ed3\u6cbb\u7597 \u7684\u7814\u7a76\u5df2\u8fdb\u5c55\u8f83\u5feb.\u8fd1\u5e74\u7684\u7814\u7a76\u5728\u4e34\u5e8a \u5e94\u7528\u4e2d\u4f7f\u7528\u9776\u5411\u8054\u5408\u5316\u7597,\u5305\u62ec\u4ee5\u4e0b\u65b9\u6848: \u4e0e\u957f\u6625\u65b0\u78b1 (Cisplatin) \u65b9\u6848\u8054\u7528 (Paclitaxel/Docetaxel \u548c\u957f\u6625\u65b0\u78b1,\u662f\u4e00\u79cd\u5e38\u7528\u6076\u6027\u80bf\u7624\u5316\u7597\u836f\u7269 [/formula] \n\u3010\u672c\u5feb\u62a5\u53d1\u8868\u7684\u6587\u7ae0\u4ec5\u4ee3\u66ff\u624b\u672f\u6cbb\u7597,\u800c\u4e0d\u5e94\u7528\u4e8e\u5176\u4ed6\u8bca\u65ad\u3002<EOD> In Vitro and In Vivo Anti\u2010cancer Activity of a Silylation Inhibitor of the Human Telomerase Reverse Transcript",
        "label": 0
    },
    "1012": {
        "output": "## [1]\n#Set-Analysis, {Set-up}, {Set-up} (0.9) Set '[set, 7]'.\n\n```jupyter\n    $ grep set input_files/patientsA.txt\nSet: 0\nSet: 1\nSet: 2\nSet-up: (0.9) set '[set, 7]'\nSet-up: (1.0) set '[set, 6]'\nSet-up: (1.1) set '[set, 7]'\nSet-up: (1.2) set '[set, 7]'\nSet-up: (1.3) set '[set, 2]'\nSet-up: \n```\n\n> You see the output of the `Set-up` command is identical with that of the `Set-Analysis` command, except the current set of the patient (i.e., 7 in the first row in the output), which is included in the current analysis.\n\n### Step 2: Focus on the Current Patient Note\n\nThe following steps are shown in Figure 6.1. \n\n<img class=\"align-center\" src=\"../../../../images/jupyter-notebook-images/chapter5/figure4.1.png\">\n\nThe `Set-Analysis` command performs a summary analysis of all eligibility criteria of the current set using 'Natural Language Processing (NLP)'. That is to say, it examines whether all eligibility criteria of the current set are satisfied. And it also uses a similar NLP method to determine the degree to which each criterion is satisfied, i.e., the grade of a criterion that expresses how close the patient data is to the criteria. If the NLP analysis shows that a patient's data completely satisfies a criterion, the corresponding degree of the criteria is calculated as `1.0`, otherwise it is less than `1.0 and` the more inappropriate, the more closer to `0.0` and the more inappropriate the patient data. So you can determine the grade of eligibility in the current trial. \n\nThere are 3 sets of patients, and the degree for each criterion is shown in [fig_ref]  Table",
        "label": 0
    },
    "1013": {
        "output": "### [Tutorial (Quasi_trial_2111)](https://github.com/katacds-deeplab/deeplab_examples/tree/master/tutorials/Quasi_trial_2111)\n_[Tutorial (Quasi_trial_2111)](https://github.com/katacds-deeplab/deeplab_examples/tree/master/tutorials/Quasi_trial_2111)_\n\n[Tutorial (Quasi_trial_2111) tutorial](https://github.com/katacds-deeplab/deeplab_examples/tree/master/Tutorials/Tutorial-Quasi_trial_2111.pdf) \n\n[Tutorial (Quasi_trial_2111) source](https://github.com/katacds-deeplab/deeplab_examples/tree/master/Tutorials/Quasi_trial_2111.ipynb)  \n[Tutorial (Quasi_trial_2111) output](https://github.com/katacds-deeplab/deeplab_examples/tree/master/Tutorials/Quasi_trial_2111_output)\n\nThis code is slightly simplified to a dataset with four patients. It will be shown the way to generate patient notes to the clinical trial data.  \n[Quasi-trial_2111.xls](https://github.com/katacds-deeplab/deeplab_examples/blob/master/Tutorials/Quasi-trial_2111.xls)\n\n\n# TUTORIALS\n\nEach tutorial is given a link. The content is in a separate folder.\n\n| Number                           | Description                                                   |\n| -------------------------------- | ---------------------------------------------------------- |\n| 1. Tutorial 1. Note Generation     | Generation of notepads for clinical trial                   |\n| 2. Tutorial 2. Clinical Trials      | Clinical trial and generation of patient labels for",
        "label": 0
    },
    "1014": {
        "output": "**(2)** You need to specify the number of patients for the assessment of eligibility. `1 patient` or `10 patients` are an example. **(3)** There are 2 outputs of the input/output in the clinical trial. The first output will be shown while entering a Trial ID. However, sometimes you may have two or more output trials shown. Select whichever output is appropriate for your need. You can try the patient note at least several times. **(4)** There is a limit to the number of input patient notes for this trial. `10 patient notes or 50 patient notes` are an example. \n\n## Instruction:\nWe are working with a team of data scientists (data analysts and scientists) who will take some of the data you enter and produce new analyses for academic publications. We also are collaborating with an oncologist who can help us prepare these new analyses for publication.\n\nFor all analyses:\n\n\n*\n\n*The source of the data for these analyses is the dataset we are currently building in our hospital, and not publicly available datasets.\n\nNote: We know and respect the requirement to share these analyses by the publishing journal or other interested parties. However, we unfortunately cannot allow sharing of these files from the team member\u2019s computer systems due to strict hospital security/disclosure laws. Therefore, we will be producing these analyses entirely in-house and will then send them to the requester for verification. Please be advised that it is the data requester\u2019s responsibility to ensure that these analyses meet the journal/group requirements (this can be done with our consultation) and to make sure their team can verify and reproduce these analyses within the given timeframe by the journal/group.\n\nIf the analyses are not in-house then we cannot perform these and therefore cannot help the person obtain them.\n\nPlease let us know if you have any further questions, and have a good day!\n\nThank you,\n\nSara Bar-Shalom\n\nDirector of Advanced Analytics, UCLA Jonsson Comprehensive Cancer Center\n\n#####\n\n\n\n\n**Note (2)**:\n\n**What will be needed for access to the data for publication purposes**:\n\nAs stated",
        "label": 0
    },
    "1015": {
        "output": "The following are some of the patient details (patients with similar attributes, similar symptoms, and similar laboratory findings) that I used for your practice:\n\n[INST] Let's think step by step. Here is the flowcharts of patient eligibility assessment:\n\n\n\n\nHere is the patient with patient characteristics: \n- ID:0000001\n- First_name:Mike\n- Last_name:Wheeler\n- Age:40\n- Sex:Male\n- Birth_country:US\n- Birth_date:12/08/1980\n- Education:MSc\n- Marital status:Married\n- Occupation:Student\n- Nationality:Nigerian\n- Religion:Bah\u00e1'\u00ed\n- Handedness:Right\n- BMI:26.50\n- Height in m:170\n- Weight in kg:59\n- Has diagnosed chronic diseases:0\n- Diagnosed non communicable diseases:0\n- Medical history:0\n- Allergy:0\n- Vaccine history:0\n- Current medication and dose information:0\n- Personal history:0\n- Family history:Psychiatric disorders\n- Exercise habit:0\n- Alcohol, tobacco, drug use history:0\n- Past health conditions:0\n- Has family history of diseases with an uncertain course:0\n- Clinical trial information:0\n- Hospital/Health insurance related information:0\n- Clinical trial ID:0000001\n- Study ID:0000001\n- Study name:STRRIDE I\n- Clinical study name:Exercise in Older Adults with Modest Obesity\n- Trial/Study status:Not recruiting\n- Research type and design:Clinical trial, Randomized trial with a 2arm parallel group design\n- Research phase:Phase 4\n- Research purpose:Primary prevention\n\nAnd here is a patient who does not meet the eligibility criteria for this trial in the study: \n- ID:J0000001\n- First_name:Lara\n- Last",
        "label": 0
    },
    "1016": {
        "output": "If the patient is eligible or excluded, we also need to create a Trial-level exclusion and Trial-level eligibility for the clinical trial, respectively. Let's repeat the process for the second patient. What we should create is:\n[OUT] Trial-level exclusion: ` 0) Excluded.`: Trial-level exclusion criteria\n- First patient:\nThe first step is creating the patient-level eligibility. Like the first patient we should create the three-point scale for the assessment of eligibility. This is based on the same information in the patient report. Therefore, the patient-level eligibility statement from the first patient becomes:\n\n\n\nWe have finished creating the patient-level and trial-level eligibility statements. Let's use the information and make an eligibility statement for the second patient.\n\n## A: \n[OUT] ` 1) Not relevant.: \n[OUT] Patient-level eligibility: ... 1) Not relevant. \n[OUT]\nTrial-level eligibility: ... 1) Eligible. \n[INST]\nIt looks exactly like the first patient. Therefore it is easy to make the second patient-level and trial-level eligibility statements. Patient-level eligibility becomes: And we get trial-level exclusion and trial-level eligibility statements:\n\n## C: \n[INST] Title: Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients Summary: Inhibition of gastric acid is the key to satisfactory relief of symptoms with esomeprazole in NUD patients Inclusion criteria: Inclusion criteria:\nA. Males and females of age 18-55. B. A diagnosis of epigastric pain/discomfort (located in the upper abdomen) rated by the patient as moderate to severe in intensity (on a four-point categorical scale), which has been present at least 3 times per week for 12 weeks, unrelated to exercise.\nC. Patients may have other symptoms of NUD including heartburn, regurgitation, bloating (abdominal distension), early satiety (fe",
        "label": 0
    },
    "1017": {
        "output": "## Example\nExample: This patient is ineligible because he/she has over 120 mg/dL of fasting glucose. \n```\nThis patient is ineligible because he is less than 100: \n| 100_less_",
        "label": 0
    },
    "1018": {
        "output": "[DONE]\n\n# Scoring and Analysis: Summary\nIn this competition, we evaluated the overall quality of the program codes and the performance on the scoring method based on real test data from the clinicaltrials.gov dataset. This scoring method is not an absolute but a relative score to give an approximate ranking on the participants. Also, we evaluate the reproducibility of the program code (and data) and the time spent.\nThe scoring method is the average score over all trial-document-pair where each pair is created by selecting a trial-document from the test data and a program code from the 21 submitted program codes. Also, each program code is weighted equally if no submission is excluded from scoring in this competition. The average score over all documents is (1), if the submitted program output is consistent with the data (2) otherwise (0). Please note that we do not evaluate how to choose which program code is best. The scoring is given by the following equation:\n\\newcommand{\\Sore}[3]{\\texttt{\\texttt{\\scriptsize{\\#Sore}}},$\\mathbf{X}$$\\mathbf{X}^2 \\frac{i}{j}$}\n\\begin{equation}\nScore = 12 \\, \\sum_{j=3}^8 \\sum_{i=1}^{Sore_{j,i}} \\mathbf{X}^2 \\frac{j}{i},\n\\label{score}\n\\end{equation}\nwhere Sore_{j,i} is the score of the jth program code if its 17th code is the i27th code in the 17th program code's data. The i27 line is the first i27 number in the program code.\nIn each competition, the final score was calculated by an average score over all program code submissions and the real test data in that competition. \nSee the real test data, the program code, and their documentation in the ``Program code`` section with a subsection ``Data analysis``\n\\subsection{Data analysis}\n\\label{sec:subsecdataanalysis}\nThis subsection provides the data analysis results. We performed five different experiments to analyze data for scoring.\nIn the first experiment, we only considered the first set and used 4 different trials among 10 trials.\nIn the second experiment, we used six additional trials selected randomly among 10",
        "label": 0
    },
    "1019": {
        "output": "Avoid the use of labels or other descriptors, such as good/poor or positive/negative. Instead, use descriptive terms, such as high/low or positive/negative. \n\n## The output\n<EOD> Mood disorders, depression and alcohol use disorders: A review of shared genetic vulnerabilities\nAims To review the findings regarding the shared genetic vulnerabilities between mood disorders, depression, and alcohol use disorders, and to examine the mechanisms that could contribute to both phenotypes. Method This is a narrative review including original research articles and reviews published in English. The articles retrieved were located via the PubMed and PsycINFO databases. Results The association between depression and alcohol use disorders has been widely studied. However, most of the research on genetic overlap between these two disorders has only focused on major depressive disorder and alcohol use disorders. Several candidate genes and genetic loci involved in the development of both disorders have been described, such as COMT Val158Met and 5-HTTLPR, for example. Candidate genes related to the molecular pathways responsible for the development and maintenance of these disorders have been identified, such as the COMT Val158Met and 5-HTT polymorphisms, both involved in the dopaminergic and serotonergic neurotransmission pathways, respectively. Other genes potentially related to the function of the dopaminergic and glutamatergic systems were found in other studies, namely the DRD2, COMT, NCAM, DRD4, RGS14 and TF genes. CREB genes were also found to be involved in neuroplasticity processes associated with the etiology of these disorders. Conclusions Given the genetic overlap between mood disorders, depression, and alcohol use disorders, future studies should be focused on understanding the pathways that connect common risk genes to those that influence the development and maintenance of alcohol use disorders, as well as on understanding the underlying mechanisms that contribute to both disorders, that is, the common risk factors that may be implicated in the etiology of these disorders. Such studies are essential in the context of precision psychiatry where the objective is to offer tailored treatment strategies and personalized risk prevent",
        "label": 0
    },
    "1020": {
        "output": "## 2. Evaluating eligibility\n\nEvaluating eligibility means finding out if these trials fit with your patient. You should assess inclusion and exclusion criteria as follows: \n### Inclusion criteria\nIn inclusion criteria, some eligibility assessment categories have to be evaluated. Firstly, we assess criteria based on age (AgeCriteria).\n### Exclusion Criteria \u2013 Age\nThen, we evaluate if the age range of both trial and patient is not overlapped. In our case, their age is under 60 and so the age overlapped (< 40 vs. < 60) is not a problem.\n### Exclusion Criteria \u2013 Age\nExclusion with respect to Gender is second criteria (GenderCriteria).\n### Exclusion Criteria \u2013 Gender\nIn third inclusion criteria, we find out how patients' gender and gender in the trial are identical or different (GenderOverLaped).\n### Exclusion Criteria \u2013 Gender\nNext, if a patient is not suffering from hypercholesterolemia based on the given age criteria, she is potentially eligible (disease: hypercholesterolemia; disease: dyslipidemia); but she is excluded in the trial due to the criteria overlapping in terms of age (age: 36-55 and age: 36-57). In the next section, you should assess criteria based on race, gender, height and weight (BodyMassIndexCriteria), disease (hypothyroidismCriteria) and laboratory test (cholesterolCriteria).\n### Exclusion Criteria \u2013 Race\n### Exclusion Criteria \u2013 Gender\n### Exclusion Criteria \u2013 Height and Weight\n### Exclusion Criteria \u2013 Body Mass Index\nNow, you can verify if she has enough height to be included or not (HeightCriteria).\n### Exclusion Criteria \u2013 Height\nLastly, if the patient is not male, the disease may be related with hypothyroidism diagnosed by a physician and thyroid levels may be measured (disease: hypothyroidism; disease: disease: thyroid dysfunction; diseases: thyroid disorder) based on their age, race and height (thyroidLevelsCriteria).\n##",
        "label": 0
    },
    "1021": {
        "output": "### Explanation\nIf you have a question about whether such a patient should be included in the clinical trial, you need the knowledge of the trial's inclusion and exclusion criteria. And then, you check the patient's data against these criteria. \nYou are comparing the 3-option scale for whether the patient has the necessary conditions to be allowed to take part (1 for a clear 'yes' if the patient gets the necessary criteria, 0 meaning that the person does not get these criteria and 2 meaning that you are not sure) and the 3-option scale from the clinical trial. If the patient gets positive answers for all the trial's criteria (2 'yes', all 2 for a 'no' and 0 for a 'not relevant') than it is straightforward to conclude that this patient is eligible for trial participation. \nIf the patient gets positive answers on one or two of the clinical trial's criteria but one of the two criteria (with 'no') is 'does not meet eligibility criteria' the trial-level eligibility is 0 (which means that the patient is excluded). \nIf the patient gets a positive answer and one of the two trial's criteria is 'meets exclusion criteria', but you are still in doubt what the clinical trial includes, you need to repeat the test for every combination of the two possible trial criteria and check if the patient gets a 1 or 2 for inclusion and a 0 for exlusion.\nIf the patient gets positive answers to none of the trial's inclusion criteria (for all 0s) and gets one or two (for all 1 and 2s, for all 'yes' and 'no') criteria as applicable, then you are still not sure about the assessment of individual eligibility. \nIf the patient gets positive answers to none of the trial's inclusion criteria (for all 0, 1 or 2) and also no exclusion criteria (for all 0, 1 or 2), then he is not eligible for trial participation.  \n\nYou repeat the process in every 'not relevant' if they exist.  \n\n\n## Explanation of \"Inclusion criteria\" and \"Exclusion criteria\"\nIt is important to know all inclusion/exclusion criteria because they are the conditions that are needed to be a good candidate for a clinical trial",
        "label": 0
    },
    "1022": {
        "output": "##[RANDOM]\n\nRANDOM_VARIABLE=\n\n`rnd() #random number generator generated number`, #you can just enter an assigned number to make this section optional: '0',\n\n`rand(1,100)` #uniform distribution \n\nIF `RANDOM_VARIABLE>= 1 AND RANDOM_VARIABLE<= 10`\n\n`Trial-level eligibility: 0) Excluded`\n\n`ENDIF`\n\nIF `RANDOM_VARIABLE>= 10 AND RANDOM_VARIABLE<= 20`\n\n`Trial-level eligibility: 1) Not relevant`\n\n`ENDIF`\n\nIF `RANDOM_VARIABLE>= 20 AND RANDOM_VARIABLE<= 60`\n\n`Trial-level eligibility: 2) Eligible`\n\n`ENDIF`\n```<EOD> .\nThe method was based on the inhibition of the thromboplastin-Ca(++)-factor VIII complex in its interaction with the \"tissue\" path in the recalcification of the plasma from guinea-pigs of different age. The method permits determining both the hemostaseologically active and inactive plasmids. Their content depends on the age of the animals, and their changes are most apparent during the formation of plasmatic hemostaseological inactivity and at the end of one day of the postnatal age.<EOD> \nThe COVID-19 pandemic has raised questions about how different health risks are perceived, prioritised and addressed by health decision makers, especially in the absence of effective individual preventive measures. This commentary takes a decision perspective to evaluate scientific evidence about the impact of environmental factors (climate change) and individual behavioural patterns (smoking, low levels of physical activity) on COVID-19 severity and explore their relative importance for the development of health policies and programs. We conclude by reflecting on the consequences of the ongoing health emergency for healthy public policies.<EOD> .\nThis paper reports the authors' experiences of 36 patients with cervical carcinoma and endometrial carcinoma who received treatment with radiation and brachytherapy with HDR Ir-192 source",
        "label": 0
    },
    "1023": {
        "output": "<EOD> A Prognostic Model for Squamous Cell Carcinoma of Hypopharynx\n\nObjective: This study aimed to analyze the clinical, pathological, and other related factors to make an attempt to develop a model for prognostication of squamous cell carcinoma of the hypopharynx (SCHP) patients by multivariate Cox proportional hazard model.Methods: Clinical and pathological characteristics and treatment outcomes with a 5-year follow-up were extracted from the database system of the First Affiliated Hospital of Anhui Medical University and were analyzed by Chi-square tests and Cox proportional hazard model.Results: A total of 202 patients who were histologically diagnosed with SCHP were enrolled in this study. The mean follow-up was 45.4 \u00b1 17.0 months. Survival analysis by Kaplan-Meier survival curve revealed significant relationship between several clinical factors of SCHP such as tumor size, depth of invasion [pT stage (p = 0.041)], lymph node metastasis (LNM; p = 0.027), and distant metastasis (M stage; p = 0.003) and the overall survival of patients. Five characteristics such as sex (p = 0.044), drink (p < 0.001), tumor size (p < 0.001), LNM (p = 0.006), and M stage (p = 0.020) were selected by a multivariate Cox proportional hazard model to build the model. The area under the ROC curve (AUC) was 0.71 for training set and was 0.74 for testing set, respectively, and the C-index was 0.680 on the basis of the model.Conclusion:We developed a prognostic model for SCHP with the five characteristics of sex, drink, tumor size, LNM, and M stage, and the model demonstrated a relatively good prognostic value. Future validation by independent patients would be essential to prove its value before it could be used in clinical practice.\n\n# Introduction\nSquamous cell carcinoma",
        "label": 0
    },
    "1024": {
        "output": "__Hints__ You may want to see trial-level eligibility as the sum of all individual eligibility assessments. You may need to add more `if (inTableRow.Satisfy('condition') && `s for all conditions for the patient. There are also `if (inTableRow.Satisfy('condition') && `s for all conditions of the patient.\n\n---\n\n## [INST] Welcome to the evaluation of an electronic medical records-based clinical trial eligibility assessment for aortic disease in Tanzania. This is an on-line assessment tool. \nHere is the patient note:\n\nA male patient has a history of 2 years of type 1 diabetes. One month ago, this patient developed abdominal distention, which was initially thought to be caused by poor diabetic control. There had been three episodes of vomiting with coffee ground like stomach contents. Cough had occurred over the previous 2 months without haemoptysis. Blood pressure is 120/75mmhg. Body mass index is 24.3kg/m\u00b2. There are neither ankle edema nor pretibial pitting edema. There are no signs of nephropathy or retinopathy. Heart sounds are normal. Peripheral pulses are intact. There is no neurological deficit. The patient takes 20 mcg/day of insulin regular as well as metformin 500mg, twice per day. There is no other drug history.\nAfter the medical consultation and further inquiry, the patient was found to have a history of smoking and consumption of alcohol. He smokes one cigarette per day whereas he takes alcohol 3 times a week. The urine drug screen was negative and he was found to be taking no other medication.\nChest radiograph showed cardiomegaly. The electrocardiogram findings were normal.\nBlood investigations revealed the following:\n[Evaluation of an electronic medical records-based clinical trial eligibility assessment for aortic disease in Tanzania\n\n[INST] Good morning, everybody. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of",
        "label": 0
    },
    "1025": {
        "output": "[NOTE:\nIf the patient is excluded, it should be recorded on patient note as well as written to the file `notQualified.txt`.\nIf the patient is not relevant, it should be recorded on patient note as well as written to the file `notQualified.txt`.\nIf the patient is eligible, both patient note and the file `evaluated.txt` should be written based on the decision according to the clinical trials.\nAfter performing this experiment, you should submit your work in the link below. Please include only the output related to the data in this experiment. \n\n\n# \ud83d\udc6e Results\n\nBelow are the results of three participants. We appreciate any comment or question that you may have. In any case, please let us know whether you finished this problem or you did not submit anything yet. We will wait for your responses for 2 further days. If you do not submit anything, you will automatically be withdrawn automatically from the class. \n\n\n<!-- Submissions-->\n\n\n| # | Status | Participant |\n| --- | --- | --- |\n| 1st | Submitting | 37114 |\n| 2nd | Submitting | 38594 |\n| 3rd | Submitting | 05237 |\n<EOD> Long-time behaviour of a one-dimensional Fokker-Planck equation. On the L\u00e9vy limit of a one-dimensional Fokker-Planck equation.\nWe investigate the asymptotic behaviour of the solution,  , of the one-dimensional Fokker-Planck equation (FPE) when both the diffusion coefficient and the initial densities are L\u00e9vy-stable with arbitrary stability index. An analytical formula for the long-time behavior of the characteristic function, lim t-->infty sin(  ) , is derived based on the results in. Explicit expressions for  and  are then obtained by inverting the asymptotic form of the characteristic function and substituting its L\u00e9vy limit. It is shown, for example, that, for the truncated stable L\u00e9vy PDF with heavy tails, the behavior of  and the convergence rate of the corresponding densities to stable L\u00e9vy densities are all sensitive to . Our approach can easily be extended to a general diffusion-limited reaction system with  a trunc",
        "label": 0
    },
    "1026": {
        "output": "You will start receiving your trials in the `patients:` section from now on. If you are going to get trials from multiple groups at the same time, use a new `patients:` section, e.g., `patients: {{Patients::ClinicalTrials::get_all()}}` or in case that patients are already in the group: `patients: patients_0`:\nYou can also get a patient list from the clinical trial list only, e.g., `patients: patients_ClinicalTrials::get_all(only_trials=True)`, or from all available patients including unassigned and hospitalized patients, i.e., `/api/v1/patients`. Both of the last two parameters are optional:\n![get patients](imagelocation)\n\nLet's get the patient list for the trials that you are going to evaluate. You can simply do it with patients and their trial ids inside the square brackets (`{}`):\nYou can get clinical trials with a certain group as well. In the following example, we are going to give a patient record, and we are going to get trials for this patient. Let's open `patients/patient_1.json` (notice the id of the patient) in your browser:\nYou can see a table where we have a clinical trial id, and we need to send both patient_id and trial_id values to the server:\n![sample patient](imagelocation)\n\nSend the following data to the server:\n\nRequest: $curl -X post -H 'Accept:application/json' -d '$curl_body' -H 'Content-Type:application/json' localhost:5000/api/v1/patients/$patient_id/$trial_id 2# Request: $curl -X post -H 'Accept:application/json' -d '$curl_body' -H 'Content-Type:application/json' localhost:5000/api/v1/patients/$patient_id/$trial_id39\n\nResponse: $\n\nYou will receive a json document, which contains a clinical trial list.\n\nHere is `patients_ClinicalTrials::get_all(only_trials=True)` in case if you",
        "label": 0
    },
    "1027": {
        "output": "> @[GUIDE]# 2. Exclusion criteria\n\nIt is also important to determine if the patient has any exclusion criteria. \n\n### @[INFO]\n\nYou should read an example from Section #7. In the example for the clinical trial, the patients were excluded because of pregnancy or lactation, or oncology or immunosuppressive therapy. This information is very important for the recruitment of the subjects as the patient must be free of all exclusion criteria.\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the exclusion criteria of a clinical trial to determine the patient's exclusion from the study.\n\nA patient must have no pregnancy or lactation, oncology or immunosuppressive therapy.\nA trial can have multiple exclusion criteria and a patient can be excluded from the trial, because of one or several exclusion criteria. \n\nLet's think step by step. \n\n## Trial-level exclusion criteria\n```\nTrial-level exclusion:\n     1 Excluded\n     2 Not relevant\n     3 Eligible\n```\n\n## Trial-level eligibility\n```\nTrial-level eligibility:\n    1 Excluded\n    2 Not relevant\n    3 Eligible\n```\n\nYour task is to store information about the assessment of eligibility for the trial in a table, e.g., an intermediate result `assessment_trial` such as `Trial 1-1-2: Excluded`. \n\n```\npatient_id = '00001'\ntitle = 'Pregnant woman admitted with pregnancy toxemia'\nclinical_trial = '0001'\ntitle_clinical_trial = 'Nulliparous woman pregnant with twin fetuses: an investigation of the safety and feasibility of an induction protocol as a means of reducing preterm delivery'\npatient_exclusion = '2) Not relevant'\npatient_trial_exclusion = 'assessment_trial'\n\nassessment_trial = \"\"\"\nTrial-level exclusion:\n     1",
        "label": 0
    },
    "1028": {
        "output": "```\n\n## \u600e\u4e48\u4f7f\u7528 R \u8bed\u8a00\u5b9e\u73b0\u8fd9\u4e2a\u529f\u80fd\n\n### \u8981\u6c42\n\n- R \u5305 `dplyr` \u7684\u57fa\u672c\u4f7f\u7528\n- `dplyr::filter()` \u7684\u57fa\u672c\u4f7f\u7528\n- \u6ce8\u610f\uff0c\u4f60\u6709\u5fc5\u8981\u8ba4\u771f\u8bfb\u4e00\u7bc7[R \u8bed\u8a00\u7684\u4ecb\u7ecd](https://blog.csdn.net/stella.ya/article/details/67377462)\uff08\u4f60\u53ef\u80fd\u4f1a\u4f7f\u7528\u5230\u5176\u4e2d\u7684\u77e5\u8bc6\u6765\u5b9e\u73b0\u95ee\u5377\uff09\u3002\u6211\u8fd8\u968f\u4fbf\u9488\u5bf9\u4e00\u4e9b\u95ee\u9898\u8fdb\u884c\u4e86 \u6df1\u5165\u7684\u89e3\u6790\u3002\n\n### \u5b9e\u73b0\u65b9\u6cd5\n\n```R\n\n  # R \u8bed\u6cd5 \n  # +--------------------+\n  # | R \u8bed\u8a00\u7684\u53d8\u91cf |\n  # |-------------------+\n  # | \u5b57\u7b26\u4e32\uff1a 'a'\uff0c\u2018b\u2019\uff0c 'c'  |\n  # | \u6570\u5b57\uff1a 20\uff0c 21\uff0c 22  |\n  # | \u5217\u6570\u7ec4\uff1a nums  { 5 , 6 , 7 }\n  # | \u5217\u5217\u5411\u91cf\uff1a matrix { 'a' , 'b' , 'c' }\n  # | \u4e24\u4e2a\u5143\u7d20\u5408\u6210\u4e00\u4e2a\u5217\uff1a cbind{ 'aa' , 'bb' , 'cc' }\n  ###\n  ### \u526a\u88c1\u5305\u542b\u6570\u636e \n  # +--------------------------------------+\n  # | \u5982\u679c\u4f60\u722a\u5b50\u8ddf\u6570\u636e\u6709\u4e00\u70b9\u5c3a\u5ea6\u7684\u5173\u7cfb\uff0c \u90a3\u5c31\u9700\u8981 \u526a\u88c1\u8fd9\u4e9b\u6570\u636e\n  # |--------------------------------____-|\n  ## Select \u5305\u542b\u6570\u636e \n  # +------------------------------------+\n  # | Select \u9009\u5b9a 7 \u5217 \u7684\u6570\u636e(\u7edd\u5bf9\u503c)\n  # +--------------------+\n  # | \u9009\u62e9\u7edd\u5bf9\u503c \n  # +--------------------+\n  # | select(dat = c('Gallstones_smallest', 'Gallstones_largest1",
        "label": 0
    },
    "1029": {
        "output": "`A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile.",
        "label": 0
    },
    "1030": {
        "output": "### Example\n\n```\n#!/usr/bin/env bash\n\n# Assistant for the eligibility assessment in clinical trials\n\n# Parameters\n\n\n\n# Functions\n\n# Utility functions\n\nfunction eli_assess_patient() { \neligibility=2 \necho \"Patient-level eligibility: $eligibility\" \n}\n\nfunction trial_eligibility_all_pat() { \npatients=`ls -t $1` \nfor patient in ${patients}; do \npatient_file=`head -25 $1/$patient` \necho \"$patient_file\" \ntrial_eligibility=`cut -f1 $1/$patient_file` \neligibility=`echo $trial_eligibility` \nif [[ $eligibility == 0 ]]; then \neligibility=1 \nelif [[ $eligibility == 1 ]] && [[ $eligibility_all_patients == 2]]; then \neligibility=2\nelse\neligibility=0\nfi\ncat $1/$patient_file $1/$patient_file\nelif [[ $trial_eligibility == 0 ]] && [[ $eligibility = 1 ]]; then \neligibility=0\ncat $1/$patient_file $1/$patient_file\nelse\ncat $1/$patient_file $1/$patient_file\nelif [[ $trial_eligibility == 1 && $eligibility != 1]]; then \neligibility=1\ntrial_eligibility_all_pat $1\ncat $1/$patient_file $1/$patient_file\nelif [[ $trial_eligibility_all_pat == 2 ]] && [[ $eligibility = 1 ]]; then \neligibility=2\ncat $1/$patient_file $1/$patient_file\nelse\ncat $1/$patient_file $1/$patient_file\nfi\ncat $2 $1/$patient_file $1/$patient_file \n}\n\n### Example\n\n```\n#!/usr/bin/env bash\n\n# Ass",
        "label": 2
    },
    "1031": {
        "output": "### Different Types of Eligibility Checks\nIn general, there are three types of eligibility assessments:\n\n1. Eligibility checks are performed once before the actual protocol execution starts ([INST],[CAL],[OBJ],[PRO]) --these eligibility checks are usually written under [Trial-level eligibility] section of the clinical protocol. (Example: the eligibility check of `Trial-level eligibility:` [2] Eligible is performed by the Assistant [Trial-level eligibility], and its execution is marked in [Trial-level eligibility: `].\n\n2. Eligibility checks are performed during the actual protocol execution --if the subject satisfies the eligibility criteria, the protocol executes the actual protocols. (Example: the eligibility check of `Trial-level eligibility:` [1] Eligible is performed during the actual protocol execution, and this is marked by the execution marks, which is usually written under [Trial-level eligibility: `], like `Executed.` or `Dropped.` (See [INST])\n\n3. Eligibility checks are performed multiple times to maintain eligibility status throughout the entire study, if there are eligibility criteria that are checked multiple times and these checks should be performed during the actual protocol execution and they are usually marked by the execution marks. (Example: the eligibility check of `Trial-level eligibility:` [20] Eligible during 6 - 8 weeks of Treatment is performed multiple times before the actual protocol execution starts to maintain eligibility status throughout the entire study and it is marked just once by `Executed:` or `Dropped.`.\n\n### Rationale\nThere is one rationale per trial-level eligibility check. The rationale of `Trial-level eligibility:` [1] Eligible is `The patient meets inclusion criteria, and exclusion criteria do not apply.`. The rationale of `Trial-level eligibility:` [2] Eligible is `The patient has abdominal pain that started 4 days-ago; is a woman; age of >40; and has BMI >40.` If the rationale is written with multiple lines, then you should concatenate it with the new-line character as follows",
        "label": 0
    },
    "1032": {
        "output": "<EOD> Ophiobolin A and Zearalenone Contamination of Cereals Used for Brewing Traditional Chinese Mead: Risk Assessment for Immunocompromised People\n\nBackground: Foods are likely the most common route of exposure to ochratoxin A (OTA) and zearalenone (ZEA). Ochratoxin A occurs widely in cereals, and its concentration can be increased by brewing traditional Chinese mead. Due to the possible immunosuppressive effects of toxins, immunocompromised people are at a higher risk of secondary fungal infections when they consume food contaminated with ochratoxin A or zearalenone. ophiobolin A (OBA) is a novel sesquiterpenoid mycotoxin produced by various Aspergillus species. The genes that participate in the biosynthesis of OBA have been widely described in A. carbonarius, A. ochraceus, and A. japonicus. ZEA is a mycotoxin that is typically produced by Fusarium fungi. Since ochratoxin A can co-occur with zearalenone in cereals, we investigated the co-contamination of OTA, and ZEA in mead, cocoa, and coffee in the Shanxi Province of China, where traditional cereal-based mead is most popular.Results: The mycotoxins were identified and quantified using LC-MS/MS. Co-contamination with OTA and ZEA was detected in the mead, cocoa, and coffee samples. Zearalenone was detected at concentrations of 2.96 -374.3 \u03bcg/kg, 14.05 -537.3 \u03bcg/kg, and 37.38 -250.58 \u03bcg/kg in the cocoa, coffee, and mead respectively. Zearalenone was also detected in 53.5% of cocoa samples and 21.42% of coffee samples. Ochratoxin A and its metabolites were detected at concentrations of 4.85 -327.86 \u03bcg/kg in the mead, 3",
        "label": 0
    },
    "1033": {
        "output": "# Input Data\n1.\nCopy all the clinical trial characteristics below and paste them here.\n\n## #input-data\nclinical trial characteristics = {\n\"Patient group 1\" : {\"1\"\"Patient group 2\" : {\"\"\u2026\"\"\"\"\nclinical trial characteristics =\"\"\"\"1\"\"\"\"1\nclinical trial characteristics = {\"Patient group 1\":\n{\"\"patient age > 65 years 10/11(91%) 1\", \"\"\"age 65-75 years 9/11(82%) 1\"\", \"\"age > 75 7/11 (64%) 1\"\", \"\"disease\"\":\n\"\"hypercholesterolemia and 2 NVDs 4/11(36.5%),''\"1\",\"\"COPD 4/11(36.5%),''\",\"\"diabetes 4/11 (36.5%)\", \"\"diabetic neuropathy 1/11 (9%)\"\", \"\"hypertension 7/11 (64%)\"\", \"\"hyperlipidemia 3/11 (27%)\",\"\"coronary artery disease 3/11 (27%)\"\", \"\"cardiac arrest 1/11(9%)\"\" ],\n\"age 35-45 years 0/11 0\", \"\"age 45-55 years 7/11(64%) 1\"\", \"\"age 55-65 years 7/11(64%) 1\"\", \"\"age 65-75 years 10/11 (91%) 1\"\", \"\"age > 75 11/11 (100%) 1\"\", \"\"sex 31/39 (79.5%) female\"\", \"\"smoking 6/11 (54.5%) \", \"\"alcoholic\"\", \"\"obese\"\", \"\"metabolic syndrome\"\", \"\"cardiovascular risk\"\", \"\"diabetes mellitus\"\" 3/11 (27%)\", \"\"arteriosclerosis\"\", \"\"congestive heart failure\"\", \"\"cor pulmonale",
        "label": 0
    },
    "1034": {
        "output": "<EOD> The potential of the hernia repair with synthetic, bioglutaraldehyd-based sealants\n\n\n\n## Original paper\nThe potential of the hernia repair with synthetic, bioglutaraldehydbased sealants Vojislav Kovacevic University Clinical Centre Sarajevo, Department of Surgical Disciplines, Sarajevo, Bosnia and Herzegovina\nBackground. Hernioplasty has been the first surgical operation invented by Vincenzo Paretti in 1540. It consists essentially in the closure of the weakest site of the anterior abdominal wall musculoaponeurotic layer to prevent prolapse of peritoneal organs which are responsible for patient's discomfort. Nowadays it is performed with or without prosthesis. Biomechanical characteristics of the abdominal wall musculoaponeurotic layer determines the choice of the material for intraperitoneal patch (IPP) or extraperitoneal patch of the hernial defect (EPIP). Aim. The purpose of this paper is to present the biomechanical analysis and the clinical results of the bioglutaraldheyde (BG)-based sealants (bioglutaraldehyde) from the point of view of the safety for the patient, surgical team and the abdominal wall musculoaponeurotic layer. Methods. In the surgical treatment of complex hernias BG-based tissue glue is used for reinforcement of the weakest site of musculoaponeurotic layer. Tissue adhesives act as a physical barrier between the tissue surfaces that are being adhered, but also function like a scaffold or template to which cells will attach and then proliferate to produce the necessary structural extracellular matrix to aid in wound closure or healing. In our clinical study there was used three-component biological tissue adhesive on the basis of collagen from human placenta and fibrin from human plasma. The materials were made according to the patented formula, technology and process and have obtained the mark of approval in accordance with the World Health Organization's (WHO) standards.",
        "label": 0
    },
    "1035": {
        "output": "There are several other examples in the data set. Good luck!\n\n# References\n[[INST] Hello, Xenia. Welcome to `Assigning labels for the TCGA data set [data link].` The main goal of this activity is to evaluate a given patient note from the TCGA data set and to apply the right labels based on the clinical attributes.\n\nAn important task of a medical practitioner is to obtain medical diagnoses. These diagnoses need to be recorded in computer form for easy communication among other doctors in patient hospitalization, transfer to intensive care units, and so on. In many cases, the medical diagnosis is based on a set of patient characteristics combined with the results of examination procedures and clinical tests. Medical practitioners rely on a standardized vocabulary that is developed by a medical dictionary, known as the International Classification of Diseases (ICD). This vocabulary is used to record and represent disease states according to certain specifications and classifications. The ICD-10 is an updated version of the standardized vocabulary, but the concepts are grouped in an entirely different manner. For a particular diagnosis, several relevant attributes, such as category, subcategory, and subattribute are usually specified. A medical diagnosis is a formal representation of a disease in human beings with a disease that is recognized through signs, symptoms, and other findings that occur in conjunction with a number of laboratory tests and procedures. Thus, medical diagnoses are not simply isolated observations but rather the synthesis of available information regarding a patient's signs and symptoms. Medical diagnoses are defined by using the ICD-10 for recording, storage, and communication of the diagnosis and the severity and prognosis of a given disease.\n\nEach patient in the TCGA data set comes with a complete medical record. However, in some cases, the exact type of cancer or the level of patient classification is not specified. This is due to the fact that the exact subcategories, such as histopathological grading or malignant status, are not recorded accurately in some cases.\n\nLet's take a look at one sample patient note. In total, 22 samples are provided in the data set.\n\nA data point contains information about the patient, such as sex, age, and subcategory (class of cancer and level of classification),",
        "label": 0
    },
    "1036": {
        "output": "<commit_msg>Revised INST<commit_after>#!/usr/bin/env python\n# Copyright 2018 <NAME>\n# Licensed under the Apache License, Version 2.0 (the \"License\");\n# you may not use this file except in compliance with the License.\n# You may obtain a copy of the License at\n#\n#   http://www.apache.org/licenses/LICENSE-2.0\n#\n# Unless required by applicable law or agreed to in writing, software\n# distributed under the License is distributed on an \"AS IS\" BASIS,\n# WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied.\n# See the License for the specific language governing permissions and\n# limitations under the License.\n\nimport collections\nimport csv\nimport itertools\nimport logging\nimport os\nimport pandas as pd\nimport re\nimport json\nimport datetime\nfrom typing import List, Union, Optional, Dict\n\nfrom ...common.configuration import Configuration, DataSourceType, InstanceLevelMetadata, Inputs,\n                                  Outputs, ParameterList, DataElementType,\n                                  FieldsToSkip\nfrom ..common.utils import find_data_type\n\nfrom .data import Data, MetaData, ClinicalData\n\nlogger = logging.getLogger(__name__)\n\n\nclass Rule(list):\n    \"\"\"\n    A rule defines a number of matching elements, and how to generate a new\n    field for the matched elements, based on other fields, for instance a\n    field describing each patient's medication.\n    \"\"\"\n\n    def __init__(self, template, columns, mapping, rules=[]):\n        \"\"\"\n        Create a new Rule.\n\n        :param template: A template of a field.\n        :param columns: A list of columns that will be matched.\n        :param mapping: A dict of a list of mapping, one for each template.\n        :param rules: Either a :class:`RulesRule` or a List of RulesRule.\n        \"\"\"\n        columns = columns if isinstance(columns, list) else [columns]\n        super().__init__()\n\n        template.strip()\n        self.template =",
        "label": 0
    },
    "1037": {
        "output": "## Question\nWhich value should be returned for the `Trial-level eligibility` column when the factor `13` from the `Hypercholesterolemia` is present in `patient_note.csv`?\n\n<!-- MarkDownRendered\n```python\nprint(factor == 13 and is_inclusive)\n``` -->\n### Answer\n\n0 (Excluded).\n\n## Explanation\nThe eligibility assessment is based on factors (e.g. inclusion criteria), their possible values, and their values. A factor is `Hypercholesterolemia` in the above example. A patient note has a factor called `Hypercholesterolemia` with possible values 0, 1, and 2. If we are analyzing all patient notes in a dataset, we would obtain 33% excluded (0), 63% ineligible (1), and 4% not sufficiently documented (2) for this dataset. If the factor 13 from the `Hypercholesterolemia` is present in a specific patient note (`Hypercholesterolemia` = '13' for that dataset), the only possible value will be the 0 in the \n`Trial-level eligibility` column. The factor 13 from the `Hypercholesterolemia` is a factor with possible values 0, 1, and 2 and in this case 13 belongs to the negative values (0). To get \nTrial-level eligibility back we should remove the `Excluded` value from it. As the only possibility to become not Excluded is to become Ineligible, there will be the 2nd possible value in the column and the 4th possible value in the column.\n\n## Question\nWhich combination of values will give the 2nd value for the `Trial-level eligibility`?\n\n<!-- MarkDownRendered\n```python\nis_inclusive[f in [\"Hypercholesterolemia\"]]==2\n``` -->\n### Answer\n\nHypercholesterolemia = '13'.\n\n## Explanation\nIt's a combination that you just observed in your own dataset. Patients with a factor of `Hy",
        "label": 0
    },
    "1038": {
        "output": "___\n\n### Task 1:\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.Here is the clinical",
        "label": 0
    },
    "1039": {
        "output": "## Part 1\nHere are the results of your first eligibility assessment:\n    # A 54-year-old obese woman admitted to the emergency department with...\n    $Triallevel eligible <-NA\n    # She experiences abdominal pain that started...\n    $excluded <-NA\n    # She has clinical trial inclusion criteria:...\n    $excluded <-NA\n    # She has no exclusion criteria for clinical trial:...\n    $excluded <-NA\n    # A 54-year-old woman with abdominal pain, an obese patient...\n    $age <-\"54 years old\"\n    $nv <-\"2 NVDs\"\n    $excluded <-\"150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA\"\n    # This obese patient is not excluded for a clinical trial....\n    $excluded <-\"93.1 mm\"\n    # She is excluded by clinical trial inclusion criteria:...\n    $eligible <-\"2 NVDs, 2 children, and menopausal\"\n    # She does not have other exclusion criteria for clinical trial:...\n    # $eligible <-\"0\")`\n    # Here is the patient note:\n    # A 54-year-old obese woman admitted to the emergency department with abdominal...\n    # A 54-year-old obese woman admitted to the emergency department with...\n    $patient <-\"A 54-year-old obese woman admitted to the emergency department with...\n    $excluded <-\"2 NVDs\"\n    # This patient is not excluded for a clinical trial: 150/85, HR 115, RR...\n    # She has a family history of atherosclerosis, which is an exclusion criteria for...\n    # RFIDs are more effective than standard wristbands because patients are less likely...\n    # She has one of the clinical trial inclusion criteria:\"...\n    # A 54-year-old morbidly obese woman admitted to the emergency department",
        "label": 0
    },
    "1040": {
        "output": "<EOD> .\nSarcoidosis is characterized by the presence of noncaseing granulomas consisting of T lymphocytes, plasmacytes and macrophages. The cause of this granulomatous process has not been finally established, although the presence of an antigen with the ability to produce T cell activation and granuloma formation has been implicated, as has a defect in cell-mediated immunity. The objective of this report is to describe the results obtained by the study of lymphocyte proliferation, lymphocyte cytotoxic activity and spontaneous lymphocyte cytotoxicity in patients with sarcoidosis and their relatives. Lymphocyte proliferation was studied by the use of phytohemagglutinin (PHA); concavalin A (Con A) and lipopolysaccharide (LPS) as stimulating antigens. Spontaneous lymphocyte cytotoxicity was evaluated by incubating 51Cr-labeled lymphocytes from the sarcoid patients, along with lymphocytes from their relatives and healthy individuals, in the presence of autologous peripheral blood lymphocytes. Lymphocyte cytotoxicity was analyzed by measuring 51Cr release from labeled target lymphocytes. No statistically significant differences were found in lymphocyte proliferation among the three groups of patients and their relatives. No signs suggesting cell-mediated cytotoxicity nor spontaneous cytotoxicity were observed in any of the studies. The results obtained in this study do not show a relationship of the sarcoidosis lymphocyte population of cell-mediated cytotoxicity towards autologous lymphocytes.<EOD> Enhancement of tumor-specific immune response by the application of interleukin-2-activated spleen cells as adjuvant to dendritic cell immunization.\nWe compared the immune response induced by dendritic cells and interleukin (IL)-2-activated spleen cells for tumor antigen. Dendritic cells pulsed with tumor antigens efficiently induced primary CTL but failed to induce secondary",
        "label": 0
    },
    "1041": {
        "output": "\u00a9 2021 T. Takayama<EOD> Lactate is one of the contributors in developing muscle lactic fermentation and improves the metabolic state of patients with type 1 diabetes.\nThe present clinical trial was designed to investigate whether lactate or glycerol supplementation improves the metabolic state of patients with type 1 diabetes. Nine patients with type 1 diabetes participated in a randomized, double-blind, cross-over trial. Glycerol and lactate supplementations were completed for 9 weeks. All patients were assessed during the trial. Results showed mean\u00b1SEM for lactate, glycerol and placebo trials were respectively: 0.73\u00b10.06, 0.70\u00b10.08, 0.81\u00b10.09 mmol l\u207b\u00b9 for lactate dehydrogenase; 0.82\u00b10.42, 0.87\u00b10.37, 0.90\u00b10.35 mg dl\u207b\u00b9 for HbA1c; 1.99\u00b11.78, 1.63\u00b11.79, 5.27\u00b11.23 mmol l\u207b\u00b9 for fasting glucose; 3.39\u00b11.29, 2.11\u00b11.35, 4.04\u00b11.15 mmol l\u207b\u00b9 for glucose 2-hour after 75 g glucose load; 0.04\u00b10.01, 0.02\u00b10.01, 0.05\u00b10.01 mmol l\u207b\u00b9 for lactate; 0.10\u00b10.03, 0.12\u00b10.10, 0.09\u00b10.01 mmol l\u207b\u00b9 for glycerol. The results showed that lactate and glycerol supplementations were more effective for lactic dehydrogenase, HbA1c, fasting glucose and glucose 2-hour after a glucose load than placebo. Therefore, lactate supplementation improved the metabolic state of",
        "label": 0
    },
    "1042": {
        "output": "### Pause and discuss.\n\n\nHere are the results of the 30 tasks given to us:\n\n``` r glimpse(data = eligiblity_tasks, target = trial_level_eligibility)\n```\n\n    ## Warning: in getOption(\"date_parsed\"), got \"02-Jul-1990\", called from: \n    ## function (call, env) { parse_date(call$value, envir = env) }\n\n    ## Package 'openxlsx' v0.14.2.9000\n    \n    ## ## data.frame: 30 obs. of 2 variables:\n    ## ##  $ eligibility_tasks: FEMALE\n    ## ##           : FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FEMALE\n    ## ##           : LOGICAL\n    ## ##           : FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE LOGICAL\n    ## ##                 : 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 1\n    ## ##       : FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE",
        "label": 0
    },
    "1043": {
        "output": "Let's visualize the data in the form of the original clinic form, which gives you a better idea of the actual data. The graphic shows columns in the original patient file. We see the patient number, the age of the patient, the gender of the patient",
        "label": 0
    },
    "1044": {
        "output": "## Solution\n\n## Task 1.1\nYou find it difficult to determine which factors are most important to the clinical trial's inclusion criteria. You check a search engine and find a clinical trial titled, `Study of Bimodality vs. Bimodality Followed by Ongoing Hemodialysis for Acute Kidney Injury (BIM-BIO) (NCT01188531),'. You search in clinicaltrials.gov for the key phrase, `inclusion criteria for' in the condition or disease. You find, `inclusion criteria for renal disease: acute kidney injury, renal impairment, acute kidney failure, or chronic kidney disease`, 899 search results. You check the results in detail in Pubmed.\n\n\n\n\n\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\n\n\n\n\n* * Clinical judgment.\n\nThis patient is likely to be eligible. Except a CBC count, the rest of the clinical data are normal. The liver function tests are within normal limits. Moreover,",
        "label": 0
    },
    "1045": {
        "output": "## Conclusion\nIn this tutorial, we tried to explain how to write a useful R code with the `r2win` R package. We showed how to process raw information extracted from a PDF form with only a single input argument and write simple R code that can be used later for various tasks such as the calculation of statistics and statistical tests. The `r2win` package makes it possible for anyone to use the output of the scanning program for their needs. The best way to get to know `r2win` is to try to use the output of the scanning program for your own needs. Then, you will see how useful the `r2win` package can really be.\nWe believe that this article will open a new field of data acquisition, data preprocessing, and data management using machine-readable files based on a paper form.\n[fig]  [NAME]: This survey contains the following subsections (listed below) of the form. Each of these subsections (listed below) contains several questions (listed under `q`). You can start by reading the example below. Then click `S17 Tutorial` and check the example (it is in the pdf form). You can download it (with the `r2win` R package) on this webpage: https://github.com/syoon/r2win_Tutorial. [/fig] \n<EOD> .\nBetween 1981 and 1984, 82 patients operated upon for primary hyperparathyroidism were prospectively studied in order to assess how often they were found to have a non-adrenal hyperplasia of the thymus gland at neck examination. Histologic examination of the removed parathyroid glands showed medullary adenoma in 44 cases, an adenoma in 11 cases, hyperplasia in 18 cases, and a cystic hyperplasia surrounded by atypical nodules in 7 cases. A non-adrenal hyperplasia of the thymus gland was seen in more than half of the patients (45). The average age of those patients is 43.9 years, as opposed to 38.8 years for the patients without thymic hypertrophy. There were more males in the group with thymic hypertrophy as opposed to the group without. B",
        "label": 0
    },
    "1046": {
        "output": "### Example\n\nHere is the full report:\n\n> Trial-level eligibility: 2) Eligible; TL.0 = 2); V04C = 3; V05A = 2; TL.1 = 2; TL.2 = null; TL.3 = null; V04B = null; V01D = null; V07A = null; V09B = null; V04D = null; V06A = null; V12C = 2; V05B = null; V07B = null; V01A = null; S04B = 0; S01D = 0; S03A = null; S03C = 1; S03C = 1; E01A = 2; E01B = null; C01A = 2; C01B = null; C01A = 2; C01B = null; S01C = null; V11C = 1; C05B = null; L02A = null; N04B = 0; L02C = null; N05A = null; L05A = null; L11B = 0; N01C = 0; R01A = 1; R02A = null; L01B = null; R01A = 1; S02A = 0; S11C = null; S03C = 1; S01C = 1; S03C = 1; S21D = null; S21D = null; S11B = 0; D01A = null; D01B = null; S06D = null; S01A = 1; S02C = null; R02C = 0; A01A = 2; A01A = 2; D01C = null; D02C = null; D02C = null; A01B = null; A01B = null; A01B = null; A01C = null; A01C =",
        "label": 0
    },
    "1047": {
        "output": "# Conclusion\n[OUT]\nCongratulations! You have completed the first part. The next step is to identify the differences between your diagnosis and the actual diagnosis.\n\n## #649.\n[INST] You are a helpful assistant for clinical trial recruitment. Your task is to determine the diagnostic outcome of an electrocardiogram (ECG) and compare it to the doctor-diagnosed patient's actual diagnoses. \n\nHere is an ECG: \nA 66-year-old man, with a history of 2 coronary bypass surgeries. His past medical history includes atrial flutter, cardiac insufficiency and congestive heart failure. 3 years ago, a pacemaker was implanted. He is overweight and he smokes occasionally.\nHe has come with dyspnea, and atrial fibrillation (AF). His vitals are BP 120/90, HR 100, RR 25, T 36.5, SpO2 92%\n\nHere is the patient diagnosis report:\nThe ECG showed a first-degree atrioventricular block (PR interval was 183/min), sinus tachycardia, normal sinus rhythm, and left anterior fascicular block. \nIn this part, you analyze electrocardiogram (ECG) for determination of diagnosis, then compare diagnosed cases with diagnosis as reported by the doctor of the patient. Finally, you will identify the differences between the two.\n\n# Conclusion\n<EOD> Role of IL4 genotypic polymorphism in patients with schizophrenia who smoke cigarettes: an ethnically matched case-control study.\nBACKGROUND\nA significant increase in the rate of smoking in people with schizophrenia (PWS) compared to healthy controls has been reported widely. To our knowledge, there have been only a few studies assessing the impact of polymorphic variants in different genes on the smoking behavior in PWS.\n\n\nMETHOD\nIn total 374 patients of Indian origin with schizophrenia were genotyped for the interleukin (IL) 4 (-590 C/T",
        "label": 0
    },
    "1048": {
        "output": "(3) Not relevant because you are unable to evaluate the patient based on the information on the paper. (4) Excluded because although you are able to evaluate the patient based on the information in the paper, the patient does not meet the clinical trial's inclusion criteria.\nThere are some helper functions in patient_recruitment_helper.py to provide extra functionalities. They are defined in PATIENT_RECIPROCATION_HELPERS.py.\n<class 'patient_recruitment_helper.PatientRecruitment'>\n    # You can create a patient_recruitment instance by calling the __init__ method.\n    def __init__(self, patient_record=None, trial_record=None):\n        super(PatientRecruitment, self).__init__()\n        # This creates a set of available methods\n        self._methods_list = helpers.make_method_list(self)\n\n        # Define the patient and trial records\n        self.patient_record = patient_record\n        self.trial_record = trial_record\n\n        # This method can be used to determine eligibility for a particular patient.\n        self.patient_eligible = self.patient_eligibility\n        # This method can be used to determine the clinical trial eligibility by assessing whether a patient meets\n        # the trial's inclusion and exclusion criteria.\n        self.trial_eligible = self.trial_eligibility\n\n\n    def __str__(self):\n    \"\"\"\n        If you have no interest in the internal representation of a class's instance, then you can use this method\n        to return a string-based summary of that object.\n    \"\"\"\n        return self.__dict__.__str__()\n\n    def __repr__(self):\n    \"\"\"\n        If a string representation of the instance is required, then you can use this method to return the \n        object's most descriptive representation. This string value will include the name of the class along with \n        any other values that were contained in the object's `__dict__` attribute.\n    \"\"\"\n        return 'PatientRecruitment(patient_record=%r, trial_record=%r)' % (self.patient_record, self",
        "label": 0
    },
    "1049": {
        "output": "## Making of 3 decision trees\nThis tutorial illustrates step by step how to make a decision tree. To make the decision tree we must define the target values of the model, define the model variables and build the tree. When the tree is not built with R we will use an open source software, WEASEL. The R and WEASEL codes are given below to illustrate the steps. This tutorial is provided from the authors; it is not a R script.\n\n## R code\n\n\n> # defining the model variables\n> model_variables << -\"sex; age; race; cerebral; diabetes; nephropathy;\n> \\            heart_disease; coronary; hepatitis; blood_pressure; bmi",
        "label": 0
    },
    "1050": {
        "output": "<EOD> .\nFor the last eight years we have carried out a follow-up on patients with cerebrovascular disease and diabetes mellitus, in order to evaluate their prognosis and their therapeutic success. Twenty-seven patients, 11 men and 16 women (mean age 65 years) were included in the study. All of them had suffered a cerebral stroke, of arterial aetiology, and all but one were diabetics. During a mean follow-up period of 6.2 years, 6 stroke recurrences and 4 deaths were recorded. Of the survivors, 18 were subject to a functional evaluation, which showed a progressive deterioration of the functional state during the follow-up period in 8 of them and a considerable slowing down of the progression only in 10 patients. The evaluation of the clinical symptomatology after the stroke did not reflect the functional state of the surviving patients. The mean value of the glycosilated haemoglobin was 8.8%, with a great range of values. It is concluded that diabetics with this level of metabolic control and cerebrovascular disease have a serious prognosis which is worsened by the functional deterioration and by the recurrences and death during the follow-up period.<EOD> Cytomegalovirus infection-associated glomerulonephritis in solid organ transplant recipients: a single-centre, retrospective study.\nBACKGROUND\nCytomegalovirus (CMV)-associated glomerulonephritis is a well-known disease in renal transplant patients, particularly those seropositive for CMV (CMV+) and for anti-HLA-DQ antibodies (ADQ+). In our study, we investigated the characteristics and outcome of CMV-associated glomerulonephritis in these high-risk patients.\n\n\nMETHODS\nWe retrospectively reviewed the records of 88 CMV+ and ADQ+ solid organ transplant recipients for 10\u2009years .\n\n\nRESULTS\nAll patients had CMV disease in the graft and 2",
        "label": 0
    },
    "1051": {
        "output": "Please answer:\n\n1. Which is the correct `Trial-level eligibility` line? `0) Excluded.`, `1) Not relevant.`, `2) Eligible.`, or `3) Not eligible.`?\n\n> `2) Eligible.`. \n\n2. Why does it answer `2) Eligible.`?\n\n> The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). Since the patient meets inclusion criteria and has sufficient information to qualify for the current clinical trial, it should output `2) Eligible.`.\n\n3. Which line(s) should be included within the `for` loop in order to output the trial-level eligibility?\n\n> The `for` loop will repeat `Trial-level eligibility:` line based on the trial-level eligibility outputted in the previous step. \n\n4. Which line(s) should be included within the `for` loop in order to assign trial-level eligibility?\n\n> Since the `Trial-level eligibility:` line is the last line within each block, in order to assign trial-level eligibility, it should be assigned to the `print` function in the last line of the `for` loop. \n\n5. How to print the trial-level eligibility and the patient's record id?\n\n> In order to print the trial-level eligibility output, the variable `result` should be assigned to the trial-level eligibility output as the first line of the `for` loop, e.g., `result=[0, 0, 0, 0]` will output `(0, 0, 0, 0)`, `result=[0, 0, 1, 0]` will output `(0, 0, 1, 0)`, etc. Then, the patient's record id can be printed as a comma-separated value by the first argument of the print function inside the `for`",
        "label": 0
    },
    "1052": {
        "output": "} /*\nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n} */\n<EOD> A single injection of a human Bifidobacterium strain enhance memory function in rats\n\nBackground: Growing evidence demonstrates that orally administrated probiotics possess cognitive-protective effects in humans. However, the underlying mechanisms remain largely unclear. In this study, we aimed to examine whether a single injection of a probiotic Bifidobacterium strain would improve memory functions in rats.Methods: Male Wistar rats were randomly allocated to 1 of 4 treatment groups: (a) control vehicle-injected group; (b) 10 10 CFU/animal of Bifidobacterium breve KB290injected group; (c) 10 7 CFU/animal of Bifidobacterium pseudo-gracilis KB177-injected group; (d) normal saline-injected group. Memory function was evaluated by novel object recognition test after a 4 week treatment. Furthermore, immune components in serum were analyzed by a Bio-Plex kit.Results:A single injection of 10 10 CFU/animal of KB290, but not KB177, significantly improved novel object recognition memory function in rats. No major changes in immune response components were observed.Conclusions:A single injection of a high-dose specific probiotic strain into the brain was effective in improving hippocampal-dependent memory function in rats. A low dose of this probiotic strain did not show a memory-enhancing effect, which suggests that a specific dose is needed to obtain memory-modifying effects.Trial registration: This study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR: UMIN000033211, 02/20/2019).\n\n# Background\nProbiotic bacteria have received increasing attention, especially from human nutritionists and medical researchers, in recent years. The Food and Agriculture Organization of the United Nations and the",
        "label": 0
    },
    "1053": {
        "output": "<a id=\"A-1-1-6.md\"></a>A-1-1-6. RS: \n<a href=\"https://github.com/statmodlab/statmodlab/blob/master/_code/rs/problems/A-1-1-6.md\"><code>rs/problems/A-1-1-6.md</code></a>  \n\n\n```r\n# Problem\n```\n```r\nTrialLvlEl <- function(patient){\n  y <- LETTERS[seq(nrow(patient))][paste(1:nrow(patient),sep = \"_\")]\n\n  y <- y[0]\n  y <- as.character(paste0(y, LETTERS[seq(1, ncol(patient) - 2)][paste(1:ncol(patient),sep = \"_\")]))\n\n  y <- y[0]\n  y <- as.character(paste0(y, LETTERS[1:(ncol(patient) - 1)], paste0(2:ncol(patient),paste0(\"_\",rep(c(\"\", LETTERS[seq(ncol(patient))[2]:ncol(patient)])[seq(ncol(patient) - 1)],1),sep = \"_\"))))\n  y <- y[0]\n  y <- as.character(paste0(y, LETTERS[seq(ncol(patient) - 1)], 2:ncol(patient), paste0(\"_\",rep(c(\"\"), LETTERS[seq(ncol(patient))[1]:ncol(patient)])[seq(ncol(patient) - 1)],sep = \"_\"))))\n  y <- y[0]\n  y <- as.character(paste0(y, LETTERS[1:ncol(patient) - 1], paste0(\"_\",L.names[ncol(patient)][1:ncol(patient)], sep = \"_\"))))\n\n  # Letters are used instead of actual patient names\n  eligability <- paste(\"Excluded-\",\n                           Txt2String",
        "label": 2
    },
    "1054": {
        "output": "[INST] \u6f14\u793a\uff1a\u8fd9\u662f\u4e00\u7bc7\u8bba\u6587\uff0c\u8bb2\u4e00\u4e0b\u5173\u4e8e\u708e\u6027\u8102\u80aa\u809d\u8fd9\u79cd\u75c5\uff0c\u603b\u7ed3\u4e86\u53d7\u8bd5\u8005\u63a5\u53d7\u8fc7\u4ec0\u4e48\u6837\u7684\u6cbb\u7597\uff0c\u6700\u7ec8\u6cbb\u7597\u540e\u60a3\u8005\u7684\u8840\u78c0\u6c89\u79ef\u53c8\u600e\u4e48\u6837\u3002\u8fd9\u662f\u4e00\u4e2a\u7814\u7a76\u62a5\u544a\u7684\u7533\u8bf7\u4e66\uff0c\u4e00\u4e2a\u5728\u4e00\u4e2a\u533b\u9662\u7684\u7814\u7a76\u62a5\u544a\u3002\u968f\u540e\u7ffb\u8bd1\u8005\u4eec\u9700\u8981\u5c06\u7ffb\u8bd1\u6587\u770b\u51fa\u6765\u7684\u5bf9\u6bd4\u62a5\u544a\uff0c\u6bd4\u5982\u6211\u4e00\u4e2a\u4f8b\u5b50\u4e2d\u6240\u89c1\u7684\u8840\u78c0\u6c89\u79ef\u3002\u4f46\u662f\u7ffb\u8bd1\u6587\u6587\u4e2d\u8981\u7559\u4fdd\u4e0d\u80fd\u5199\u5b8c\uff0c\u9700\u8981\u91cd\u5199\u62a5\u544a\u5185\u5bb9\u3002\u6211\u4eec\u8bb2\u533b\u62a5\u7684\u67d0\u4e00\u7bc7\u7684\u8bc4\u53d9\u8981\u7559\u4fdd\uff0c\u8fd9\u4e2a\u7bc7\u5b50\u8bb2\u8bc1\u636e\u8981\u8bb2\uff0c\u8bb2\u8bc1\u636e\u7684\u65b9\u6cd5\u662f\u8981\u7528\u201c\u53d7\u8bd5\u8005\u201d\u3001\u201c\u4e34\u5e8a\u7814\u7a76\u201d\u3001\u201c\u5bf9\u7167\u7ec4\u201d\u3001\u201c\u81ea\u4f53\u7ec4\u201d\uff0c\u8fd9\u8bb2\u4ec0\u4e48\u7684\u4e1c\u897f\uff0c\u5728\u8bb2\u4ed6\u7684\u65b9\u6cd5\u3002\u6240\u4ee5\u73b0\u5728\u8fd9\u91cc\u533b\u62a5\u4e2d\u6587\u7684\u4e00\u7bc7\uff0c\u8981\u7559\u4e00\u4e2a\u6587\u5b57\uff0c\u8fd9\u91cc\u8bf4\u5230\u7684\u91c7\u96c6\u7684\u65b9\u6cd5\u662f\u201c\u533b\u62a5\u7684\u6570\u636e\u201d\u3001\u201c\u81ea\u6cbb\u533b\u9662\u7684\u6570\u636e\u201d\u3002\u7136\u540e\u7ffb\u8bd1\u6587\u4e00\u4e0b\uff0c\u5982\u679c\u4f60\u628a\u201c\u5047\u5b9a\u201d\u51fa\u6765\uff0c\u8fd9\u4e2a\u4e5f\u8981\u7559\u4e00\u4e2a\u5b57\uff0c\u8bb2\u4e00\u4e0b\u5047\u5b9a\u7684\u60ef\u7528\u8bed\u662f\u201c\u5e26\u201d\uff0c\u5e26\u5230\u6570\u636e\u3002\u4ece\u5b83\u7684\u7814\u7a76\u7ed3\u679c\u6765\u770b\uff0c\u4f60\u6ce8\u610f\u5230\u60a3\u8005\u4ef0\u8bf8",
        "label": 0
    },
    "1055": {
        "output": "Exercises\n\nExercise 1\n\n1. `python main.py`\n\n2. Do you see a patient (name: <NAME>) who would qualify in your first scenario? What might disqualify this patient from the clinical trial?\n3. Would you include the patient in your second scenario? Why might this patient qualify? Why might this patient qualify?\n4. Check the `Trial-level eligibility` section. Do you agree with your output? <EOD> Evaluation system for monitoring quality during the manufacturing of human albumin in China.\nThe World Health Organization has raised serious concerns about the safety of human albumin after reports of a series of acute allergic reactions. To ensure the safety of therapeutic albumin we conducted a joint evaluation system for monitoring the quality of albumin products being applied in 205 hospitals from January 2011 to December 2013. We assessed the safety of the manufacturing process and stability by sampling albumin from every batch produced. The final quality report was released to the public immediately. To ensure the safety of albumin, we used a standardized evaluation system for risk assessment. If our data analysis indicated the possibility of risk, we retested the batch. A joint quality control team from China Pharmaceutical University, Chinese Center for Disease Control and Prevention, and China Food and Drug Administration designed a standardized evaluation system including laboratory tests, stability tests, and traceability tests. Twenty five albumin manufacturers participated in the evaluation from 2011 to 2013. We analyzed five different albumin types: domestic human albumin (HSA), imported HSA (either domestic or foreign), albumin solution from plasma, albumin solution from whole blood, and albumin liquid (a combination of albumin solution and a stabilizer). We performed 382 quality monitoring tests; 68 of them were traceability tests. The other 214 quality monitoring tests performed to assess the quality and safety included detection of the sterility, endotoxin, and residual antigens; potency tests; and content analysis of the albumin solution. All samples were analyzed according to the standards of the National Pharmacopeia of the People's Republic of China by an accredited",
        "label": 0
    },
    "1056": {
        "output": "<EOD> Effect of Different Mouth Rinses on Prevalence",
        "label": 0
    },
    "1057": {
        "output": "You are done! Your last 10 practice tests are also available under `/practice_test` in the Notebook.\n\n## Learning Goals\nIn the second Notebook, you will familiarize yourselves with the Python version of the Notebook and with several common functions and data types in Python. \n\n## First step: Installing Python and Anaconda.\nYou must follow the instructions on how to install Python and Anaconda.  \nPlease see our [NOTE](https://github.com/sejong-ip/machinelearning-jupyterbook/blob/master/README.md)\n\n## Second step: Python installation and Anaconda installation.\nYou must follow the instructions on how to install Python and Anaconda [NOTE](https://github.com/sejong-ip/machinelearning-jupyterbook/blob/master/README.md#python-install)\n\n## Python Basics \n\nIn this Python Notebook, we discuss a series of Python basic programming concepts. We discuss the following ideas:\n\n### 0) Python Syntax\n\nAn [execution flow](./python_python_syntax.ipynb) for the Python code has been provided. The flow diagram explains a simple process: creating a Python variable, the type of the variable, the Python expression, and printing. \n\nEach cell shows the detailed information for the variables. You can check the comments for specific information.\n\nTo understand Python syntax in more detail, you should watch the tutorial provided on YouTube: [here] .\n\n[Here](./python_python_syntax.ipynb) is the Python expression. \n\n```python\ndef example_function():\n    \"\"\"Example function.\n    \n    \"\"\"\n    print(\"Hello, world!\")\n\n\n# Python basic syntax\nimport pandas as np\nimport numpy as np\nimport random\nimport matplotlib.pyplot as plt\nimport seaborn as sns\nimport seaborn as sns\nimport scipy.stats\nfrom math import factorial\n\nprint(\"print statement\")\nprint(\"print statement\")\n# list\nl = [5, 2, 4, 3]\n# list\nl = [5,2,4,3]\n\nprint(\"List\")\nprint(\"-\")\nprint(\"List\")\nprint(\"-\")\nprint(l",
        "label": 0
    },
    "1058": {
        "output": "### Grading the report\n\n* [CREDITS.md](https://github.com/DME4/TRIALTRAILS/blob/2b89de5d1aee6256e4b94c697e6a765ec13152d9/assignments/1/solutions/2/CREDITS.md) is a mark-scheme/grade-scheme that was created by the course tutor on June 13th, 2020, at 8:10 PM.\n* [TIPOS_SINT\u00c1TICOS.md](https",
        "label": 0
    },
    "1059": {
        "output": "[/FINAL]\n\n[HOLD]\n\n### Eligibility:\n\nExcluded 15\nNot relevant 4\n\n## Assign to treatment\n\n[INST] Let's assume that the patient is eligible for the treatment assignment. \n\nHere the decision is to assign the patient to treatment arm A or B. Treatment arm A is the early surgery with a 3-month delay for treatment arm B. The treatment A is taken for granted as the surgeon decided to perform it. Your job is to decide by which treatment arm we should assign this patient. Should she get early surgery, or could we safely just delay the surgery for another 3 months? The goal is to keep patients from unnecessary early surgery.\n\n[FINAL]\n\n* _Notes to self_:\n\n_Remember that this patient was in clinical trial \"EARLY VERSUS DELAYED SURGERY FOR GALLSTONE PANCREATITIS\" trial_\n\n* The choice between early surgery and delayed surgery is determined based on the patient's symptoms and clinical condition after a minimum of 10 hours. In the case of a waning response to antibiotics, the patient might need to undergo gall bladder removal. This condition warrants a delay in surgical intervention if there is a possibility of improving the patient's condition. However, in the case of sustained severe abdominal pain and high bilirubin level, immediate laparoscopic cholecystectomy is indicated.\n\n* In all but acute cholangitis (wherein a CBD stone is present), post-ERCP pancreatitis should not lead to a delay in laparoscopic cholecystectomy if the patient recovers. A cholecystectomy should be performed 24 hours post-papillary dilatation or ERCP in the absence of biliary stenting.\n\n* A diagnosis of gallstone pancreatitis is confirmed by the presence of gallstones in the ductal structures or by the presence of inflammation associated with the gallstones in the gallbladder bed in one or more of its lobes. Cholecystectomy is then performed lapar",
        "label": 0
    },
    "1060": {
        "output": "Now, you are ready to proceed to the next track.[INST] You are an epidemiologist employed at a hospital. The hospital administrator wants a comprehensive report on the patient characteristics for their general hospital admission (registration, demographic data, length of stay, and readmission). He also is interested in calculating the readmission rates. Below is a hospital admission database table, where you will examine and extract the requested information.\n\nFirst, let's get some information. How often was the readmission happened in the past year? [INST] We want to collect the necessary data in a data frame called `admissions`.\n```python\nimport pandas as pd ```\n\n```python\ndf = pd.read_csv('../../data/README.txt', header=0) ```\n\n```python\nprint(df) ```\n\n```\n   PatientId\n0         1\n1         3\n2           1\n3          24\n```\n\n[!INCLUDE[inst-show-dataframe-values](../includes/inst-show-dataframe-values.md)]\n\n[!INCLUDE[inst-get-value-admission-count](../includes/inst-get-value-admission-count.md)]\n\n```python\ndf\n```\n\n\n     PatientId    Admit_date    Admission    Age Sex Length of stay Readmission \n    0            1          6/1/2020         0        Female    40       Y      \n    1           23          5/22/2020        33        Male     4    N      \n    2          3522      10/30/2019       52        Male      6       N      \n\n[!INCLUDE[inst-show-dataframe-row-values](../includes/inst-show-dataframe-row-values.md)] \n\n[!INCLUDE[inst-get-value-length-of-stay](../includes/inst-get-value-length-of-stay.md)] \n\n```python\ndf['Length of stay']\n```\n\n```python\ndf.groupby(['Admission'])['Length of stay'].mean()\n```\n\n*Admission*:\n\n|Value|",
        "label": 0
    },
    "1061": {
        "output": "![INST]\n[INST]\n\n[INST]\n**C#**\n- class PatientAssistant\n{\n\tpublic string Trial;\n\tpublic int PatientLevel;\n\t\n\tpublic PatientAssistant(string trial, int patientLevel)\n\t{\n\t\t// Constructors\n\t\tthis.Trial = trial;\n\t\tthis.PatientLevel = patientLevel;\n\t}\n}\n**Python**\n- class TrialAssistant\n    def __init__(self, trial_level, patient_level): # TrialAssistant constructor\n        self.trial_level = trial_level\n        self.patient_level = patient_level\n        \n    def _get_trial_level(self): # get trial_level getter method\n        return self.trial_level\n    def _get_patient_level(self): # get patient_level getter method\n        return self.patient_level\n\n\n---\n**Exercise 2**\n![INST]\n[INST]\n\n[INST]\nWrite the code for the method TrialAssistant.evaluate_patient(): it should make a proper Trial-level eligibility for the Clinical Trial and store the results in a dictionary.\n\n---\n**Exercise 3**\n\n![INST]\n[INST]\n\n[INST]\nAfter completing the trial level eligibility, output the results for the entire data set on your screen and make sure that they are in the proper format. \n\n---\n**Exercise 4**\nIn the next exercise, we will make a clinical trial patient for each patient note and enter the results (patient's ID, first name, last name, gender, etc;) to the patient_list dictionary.\n```{hidden}\ndata = patient_notes\nfor patient_note in patient_notes:\n\t# You should create a patient object/variable for each patient\n\tpatient = Patient(data = patient_notes[0], age = 0, gender = 'female')  # the patients need to have a age\n\tfor patient_note in patient_notes[1:]:\n\t\tpatient.data = patient_notes[1]\n\t\tpatient.age = int",
        "label": 0
    },
    "1062": {
        "output": "[PRACTICE] Let's try in our Python code:\n\n    def assess_eligibility(patient_note, clinical_trial):\n        patient_id = patient_note.text.split()[-1:-1][0]\n        clinicaltrial_id = clinical_trial.text.split()  \n\n        trial_id = clinicaltrial_id[:3] .split('\\n')[0]         \n\n        patient_age  =  patient_note.text.split()[1][5:]\n        patient_age  = int(patient_age)  # convert to integer for data type safety\n\n        trial_age  = clinicaltrial.text.split()[3]\n        trial_age  = int(trial_age)  # convert to integer for data type safety\n\n        if trial_age==patient_age:\n            Trial-level eligibility = patient_age\n            if patient_age>=50:\n                if trial_eligibility==1:\n                    print(f\"{patient_id} not qualified for clinical trial\")\n                elif  trial_eligibility==0:\n                    print(f\"{patient_id} excluded from clinical trial\")\n                else: \n                    print(f\"{patient_id} has mixed result of clinical trial\")\n            else:\n                print(f\"{patient_id} not qualified for clinical trial\")\n        else:\n            print(f\"{patient_id} is not qualified for clinical trial\")\n\n\n        # print(f\"Trial-level eligibility: {Trial-level eligibility}\")\n        if Trial-level eligibility==2:\n            Eligibility= Eligibility.append(f\"{patient_id} is Eligible for clinical trial\")\n        else:\n            Eligibility= Eligibility.append(f\"{patient_id} is Not Eligible for clinical trial\")\n        print(f\"Eligibility: {Eligibility}\")\n        return Eligibility\n\n    \n    patient_note = pd.read_csv(\"Patient Noted.csv\")\n    clinical",
        "label": 0
    },
    "1063": {
        "output": "######## IMPORTANT NOTE ABOUT TAGS\n\n### #\nAs a matter of courtesy and to help the other learners read the solutions of the code review in a more organic and less disrupted way we recommend sticky-tags to be included in the solution. Sticky-tags can be recognized by the hashtag `#` (without quotes). They indicate the beginning or end of a code block. You can begin a code block by using a forward slash, e.g., #, and you can end a code block by adding a backslash, e.g., /#. When one solution uses the hashtag and the other solutions does not, then the solution could be identified much easier.\n\n\n### #\nYou will receive the best score if (in addition to the code review) you send a short \"Abstract of your solution (description)\", it's a great idea to share your ideas with other learners. Think about how they could improve the problem. Be bold, it can only help you. \nIf you see any inconsistency or mistake just write to the code in the comments.\n\n## Solution\n\n## The second time \nThe following solution code block is written with `code` tag. It's recommended to make the code block more readable by adding a label. For example, you could change the content of the code block below with: \"Patient age.\" or \"Trial-level eligibility.\" A label should be placed before the \"Begin\" tag.\n\n#### Example for the solution code block:\n\n\n\n\n\n#### Begin Solution Code Block\n\nIn this code block we will show the code, that solves the problem for the next time. There is no need for the learners to copy, and replace the code with the solution code, but in case they would like to implement it on their own system, then we provide a file for the next time here: https://github.com/YasarAlya \n\n\n\n\n\n\nAs stated in the solution from the first time. we will use the `for loop` for the solution from the second time. We will need to collect the name of the patients, the patient's age, and the patient trial-level eligibility. The age of the patient is in patient.age;",
        "label": 0
    },
    "1064": {
        "output": "A: You can check the answer and source by executing the command:  \n$ eval echo $(type <ANSWER>)\nanswers are saved as *.answers file in the user-file-directory\n<EOD> Correlation of the inhibitory effect of 5-fluorouracil on the synthesis of cellular RNA and DNA with that on the incorporation of adenine-8-C14 into ATP.\nSummary and Conclusions 1.The inhibitory effects of 5-fluorouracil on the incorporation of adenine-8-C 14 into cellular RNA and DNA of tumor-bearing or normal mice was almost identical and showed an early onset (2 to 3 hours) and dose dependence. No lag in the inhibition was observed. 5-Fluorouracil (50 mg/kg intraperitoneally) reduced 48 per cent the incorporation of adenine-8-C 14 into DNA after 3 hours\u2014the maximal effect\u2014and had no effect on that into RNA. Higher concentrations (100 mg/kg) were as effective as lower doses after the same time interval of administration. 4.The incorporation of adenine-8-C 14 into the acid-soluble RNA isolated from intestinal epithelial cells of the jejunum of normal mice was inhibited by 5-fluorouracil 1 hour after administration of the drug. The inhibition of the incorporation of adenine-&dquo;-C a4 into the acid-insoluble RNA was maximal only 3 hours after administration of the drug. 5.Although the incorporation of adenine-8-C 14 into the nucleosides of tissue slices of jejunum was completely prevented by 5-fluorouracil after 4 hours (100 mg/kg), no inhibition was observed after 30 micrograms per cubic centimeter of drug. No significant time lag was observed in the prevention of incorporation of adenine-8-CJ 4. A single-cell suspension of the jejunum of mice treated with 5-fluorou",
        "label": 1
    },
    "1065": {
        "output": "* *\n\n[/NOTE]\n<EOD> Comparison of the Effects of Phlorizin and Its Metabolites on the Activity of Mammalian Protein Phosphatase 1\nAbstract The metabolism by rat liver 9000 \u00d7 g supernatant and a purified preparation of protein phosphatase 1 of the phlorizin derivative phloretin-2\u2032-sulphonic acid has been studied. A product was found in the incubation mixture whose behaviour on the chromatographic systems tested, gave an unambiguous identification as phlorizin. Its formation, under the conditions of our experiments, could be accounted for by an initial phlorizin phosphate formation, followed by a second, reversible reaction leading to the phlorizin sulphate. No effect of phlorizin on mammalian protein phosphatase 1 activity was observed; whereas small concentrations of the metabolite phloretin-2'-sulphonic acid inhibited significantly its activity. No effect was observed on the mammalian intestinal alkaline phosphatase activity.<EOD> Effects of Birth Weight, Body Weight, and Feeding Strategy on the Postnatal Development of the Porcine Gastrocnemius Muscle\nPiglets are usually weaned without previous feeding with formula feeds, which may affect the performance of muscle growth and development. Piglets vary in birth weight, and they are then selected either to grow on sows or to be fed by milk only after birth. In this study, the effects of birth weight and the feeding strategy on the performance of muscle growth in an adult life were evaluated. Twenty-seven piglets were allocated into low birth weight (n = 11), high birth weight (HBW; n = 10), and formula feed group (FF; n = 6) on the basis of birth weight. Each birth weight group was divided into two: low birth weight (LBW; n = 5) and high birth weight (HBW; n = 6) and formula feed (FF; n = 6). The body weights of the piglets were measured at birth (BW) and at 21 and 49 days after birth (DBW). After 21 DBW, the p",
        "label": 0
    },
    "1066": {
        "output": "You should make a note of the following to find the trial-level eligibility:\n\n## Procedures\n\n## Trial-level eligibility in the last line by `Trial-level eligibility:`.\nWhat do we include in the note? The trial-level eligibility should include eligibility (EL), reasons for ineligibility (I), and exclusionary criteria (EX).\n\n## Examples\nIn the following example, a clinical study trial-level eligibility is described for a patient who is eligible to enter the trial with 3 scores as [INST] Please see the first example in the previous lesson for more details about notes of patients. \nPatients should not have a history of seizure disorders, clinically or in his or her medical history.\nSeizure disorders, including epilepsy, have been established to occur with the use of ZANUBRUTINIB or other agents with a similar mechanism of action. \nPatients should have a negative pre-study SARS-CoV-2 PCR test. \nPatient should be negative for SARS-CoV-2 at screening/baseline, defined by:\n\\- Two nasal/throat swab SARS-CoV-2 PCR tests obtained within the screening window (which begins 5 days prior to study drug dosing, Day 1 [Day 1 is the day when they start taking Zanubrutinib in the clinical studies]) and separated by \\- Patient is a male, aged between 18 and 95 years. \nPatients should not have known hypersensitivity to anti-CD20 monoclonal antibodies, drugs highly related to Rituximab's structure (e.g., obinutuzumab, ofatumumab, chimer",
        "label": 0
    },
    "1067": {
        "output": "# 3. Exercises\n## 3.1 Data collection script\n\n\n<data-collection-script>\n\n[ELIGILITY: 1]=Excluded;\n[ELIGILITY: 2]=Eligible;\n[DATA-COLLECTION:\n\n<EOD> Efficacy and safety of intermittent lopinavir/ritonavir therapy in children with severe acute malnutrition in a large hospital setting in the Democratic Republic of Congo.\nBackground: Lopinavir in combination with ritonavir (LPV/r) could have a role in the treatment of children with severe acute malnutrition (SAM).A method: We investigated a combination of LPV/r with SAM protocols in 25 children 108 days mean age, under a multidose randomized design with a 5 day intermittent dosing schedule at a dose of 600 mg/ 100 mg, administered in association with a standard antiprotozoal regimen.Results: Plasma K70 concentrations after the third and fourth dosing were below the threshold of quantification (50 ng/ml). Treatment led to the early stabilization of the patient's condition, as highlighted by the reduction in anthropometric parameters, appetite stimulation and improvement of the general clinical condition in comparison to the standard protocol alone.Conclusions: The intermittent dosing protocol was effective in the treatment of acute malnutrition. However, due to the difficulty of ensuring the absorption of protein and lipids in the presence of intestinal edema, our results could not confirm the effectiveness of antiretroviral therapy (ART) in this setting. This could also be attributed to the relatively small sample size.KeywordsLopinavir; malnutrition; antiretroviral therapy; children; Democratic Republic of the Congo.<EOD> Influence of glandular cells in vitro on oocyte activation and embryonic development after sperm nuclear transfer.\nThe mammalian oviduct is a critical site of fertilization, with ciliary beating and oviductal fluid playing roles at the molecular level in preventing polyspermy events. During",
        "label": 0
    },
    "1068": {
        "output": "## Q4. Can we compare and contrast this clinical trial with other clinical trials and the answers you find?\nAnswer. \"Clinical trial is a research done with human participants to analyze how they respond to new treatments or therapies. The focus is to study how the participants respond to the treatment under a safe and controlled environment, such as clinical trial. A clinical trial is conducted using a clinical research protocol. The protocol defines a set of tests, procedures, practices, or methods which have been planned to provide the most reliable information about the safety and effectiveness of the new treatment or therapy. The FDA and other regulatory agencies must approve the protocol (which could take months to do), and the subjects must also give their voluntarily informed consent before participant the clinical trial. A",
        "label": 0
    },
    "1069": {
        "output": "This problem is very useful for programming. You have to choose one of the two branches and keep track of the results, i.e., your `Trial-level eligibility` results may include not only 0 (Excluded), 1 (Not Relevant), or 2 (Eligible), but also something in the format of `Trial-level eligibility: 2) Eligible + T_eligibility_count`. To handle this, you must first use the integer value of `1`. Then, the integer value for `Trial-level eligibility: 2` is just a simple addition of the numbers.\n\nTo solve this problem, we should write first some helper functions and variables to ease things up. \n\n* `count_if`: Auxiliary helper function to add integer values of a string according to a list of numbers\n\n    * input:\n        * _string: String\n        * _numbers: list of integer numbers to add\n        * _start_index: integer to start calculating from\n        * _length: integer to calculate numbers from start_index to\n    * output:\n        * _string to calculate\n\n    * _string: \n        * ````python\n        * from string import ascii_uppercase\n        * \"\"\"\n        * string that will be converted with ascii_uppercase()\n        * \"\"\"\n        * return_string = \"\"\n        * for i in numbers[start_index:length]:\n            return_string += ascii_uppercase(i.encode() % 1000)\n        * return return_string\n        * \"\"\"\n        *\n        *\n    ````\n\n    * _numbers: \n        * ````python\n        * numbers_list = [1, 10, 40, 100]\n        * numbers = list(numbers_list)\n        *````\n\n    * _start_index: \n        * ````python\n        * start_index = 1\n        * ````\n\n    * _length: \n        * ````python\n        * length = 4\n        * ````\n\n    * _string to calculate:\n        * ````python\n        * numbers = [1, 10, 40, 100]",
        "label": 0
    },
    "1070": {
        "output": "[TUT-510/INST] Evaluation of the trial-level eligibility is to find out if the inclusion criteria of the clinical trial include all the relevant patient's data. If it does, you should choose `1) Not Relevant` because it is an inclusion criteria and has not been checked yet. If it does not include all the relevant patient's data, you should choose `2) Eligible`. If the patient data is not included in the inclusion criteria, we consider that the patient is eligible by default. [INST] \n\n![TUT-508][1]\n\n![TUT-509][1]\n\n  [TUT-508]: {{image url=\"images/tutorial/medical/508.png\" defaultHeight=700 crop=30}}\n  [TUT-509]: {{image url=\"images/tutorial/medical/509.png\" defaultHeight=700 crop=30}}\n<EOD> .\nThe effects of the combined treatment with fluorine derivatives (ethyl-5-fluorouracil: E5FUR; picolinyl-6-fluorouracil: P6FUR; or methotrexate: MTX) and 60Co gamma-ray irradiation on growth-inhibition and radiation response were investigated using experimental tumor system; Dalton's lymphosarcoma (LSA) and adenocarcinoma 755 (ADC) of mice. 1) The treatment with fluorine derivatives given intraperitoneally (i.p.) or subcutaneously (subc.) was not effective against LSA growing as a transplantable tumor or against ADC induced by subcutaneous injection of 3-methylcholanthrene, but both the growth of transplanted tumor and the incidence of tumor induced by 3-methylcholanthrene were significantly reduced when irradiation followed the i.p. or subc. administrations of the compounds. 2) In contrast to systemic treatment with fluorine derivatives of both LSA and ADC, the subcutaneous administration of P6FUR showed an effective action against LSA growing as",
        "label": 0
    },
    "1071": {
        "output": "For more details on the format of the results, refer to this issue on data structures.\n<EOD> FAM3G, an Immunoglobulin F-like Apoptotic Cell Molecule, Promotes the Development of Tumor Metastasis\n\nApoptosis has been considered a host protective mechanism against caner. Recently, several studies suggested that tumor cells also utilize the apoptotic machinery to invade, migrate and metastasize. To further understand the impacts of apoptosis on tumor progression, FAM3G, an IgF-like apoptotic cell surface biomarker, was tested to evaluate its functions. The overexpression of FAM3G in human HT1080 fibrosarcomas enhanced the tumor growth, invasion, migration and metastasis compared with empty-vector cells in vitro and in vivo. However, the knockdown of FAM3G by specific siRNA decreased the tumor growth and metastatic activity of A375 melanomas in vivo. We further demonstrated that FAM3G activated Erk1/2, upregulated matrix metalloproteinases (MMPs) gene expression, increased the activation of focal adhesion kinase (FAK) and integrins, and inhibited TNF-\u03b1-induced apoptosis. These results suggest that the overexpression of FAM3G may promote the development of tumor metastasis and inhibit TNF-\u03b1-induced apoptosis through Erk1/2 and FAK pathways. OPEN ACCESS Citation: Liu K-s, Li T, Wang L, Hu K, Yang Z, Liu Y (2014) FAM3G, an Immunoglobulin F-like Apoptotic Cell Molecule, Promotes the Development of Tumor Metastasis. PLoS ONE 9(10): e111295.\n\n# Introduction\nApoptosis plays a critical role in inhibiting metastatic progression, as well as tumor growth [bib_ref]  Evasion of apoptosis as a cellular stress response in cancer, Fulda [/bib_ref] . Recent studies suggested that apoptosis could also be utilized by tumor cells to",
        "label": 0
    },
    "1072": {
        "output": "<jupyter_code>def eligibility_determination():\n    '''A function that return eligibility_test and trial_level_eligibility'''\n    patient = { \n        'Hbp': 140,\n        'Age': 54,\n        'Male': False,\n        'Gender': 'Female',\n        'smoke': False,\n        'drink-alcohol': False,\n        'Use-Illicit_Drugs': False,\n        'NVD': False,\n        'NVD_2': False,\n        'Rheum_disease': False,\n        'Ischemic_heart_disease': False,\n        'Epilepsy': False, \n        'Epigastric_tenderness': True,\n        'Right_Quadrant_tenderness': True,\n        'Bowel_sound': ['normal'],\n        'Leukocytosis': False,\n        'ESR': 40,\n        'C-Peptide': 60,\n        'HbA1C': 20,\n        'OG_BAS_test': [False, False],\n        'SG': False,\n        'SG-tenderness': True,\n        'SG-mass'': True,\n        'Biliary_sludge': False,\n        'Gallbladder_size': False,\n        'Fibrosis': True,\n        'Cholesterol': 320,\n        'Gallstone_no.': 3,\n        'C_G_no.': True,\n        'WBC': 10500,\n        'SpO_2': 98,\n        'BP': {\n            'systolic': 160,\n            'diastolic': 90\n        },\n        'HR': 120,\n        'RR': 15,\n        'Temp': 38.2,\n        'ABG': {\n             'pH': 7.35,\n             'PaO2': 95,\n             'PaCO2':",
        "label": 0
    },
    "1073": {
        "output": "<img src=\"https://github.com/deepRnaseq/papersplus/blob/master/img/image.png\">\n<EOD> .\nWe experienced a case of multiple arterial aneurysms of left renal arteries in a patient with aortic coarctation. A 46-year-old male who had a history of coarctation and an abdominal aortic aneurysm was referred to our department for further evaluation and treatment of a newly discovered renal artery aneurysm. The right renal artery was normal. The left renal artery could not be cannulated by a 5Fr diagnostic catheter and could not be detected by angiography using the antegrade route. Therefore, we decided to cannulate the left renal artery by retrograde route via femoral arteriography. After administration of 5,000 U heparin, we inserted a 5Fr diagnostic catheter into the right femoral artery as well as right femoral vein. The diagnostic catheter was then advanced towards the iliac artery up to the ostium of the left renal artery by manual guidance of the 3.5Fr balloon catheter. A 5Fr diagnostic catheter was then advanced to the left renal artery from the femoral arteriogram. The angiography of the arterial phase was performed by using 2 ml of isosulfin-pentatinate iodine and 10 ml of iopamidol 25 %, 180 mg I/ml. Three fusiform aneurysms, which were 13 mm in diameter in the mid portion of the left kidney were revealed (Fig. 1). The proximal renal artery was normal in size and the aneurysms were located 16 mm distal from the ostium of the renal artery. The ostium of the external iliac artery was normal. No aneurysmal dilatation was observed in the ascending aorta and coarctation site, and the diameter of coarctation site was 24 mm. Therefore, we decided to perform endovascular coil embolization for the renal artery aneurysms. But, because of the severe narrow",
        "label": 0
    },
    "1074": {
        "output": "* * [INST] The number of observations you see per patient varies because the number the patients are available differs across trials. For the first patient, 3 observations are available. The patient has one observation from the clinical trial, no observations from the second trial, and two observations from the patient note. For the second patient, the number of observations is larger -4. For the third patient, the number is much larger -13.\n\n* * [INST] The patient note has a large number of observations -15, while the clinical trial has only two, one for Trial.eligibility and one for Trial.date.<EOD> .\nThis paper explores how women perceive and interpret their pregnancies in urban low-income areas in Mexico City. The analysis is based on in-depth interviews with a sample of 80 indigent women in neighborhoods with the lowest socioeconomic levels in the city. Results confirm that women are aware of the biological nature of pregnancy and that their health behavior is consistent with that knowledge. Pregnancy is seen as an event between the mother and her baby and its meaning is determined by the cultural context that is understood and appreciated in terms of physical and psychosocial changes, and with positive or negative emotions. The women mentioned many social changes during gestation like the need for rest, for the husband's and family's attention, to work less, and to pay less for the family's meals. Health workers should be aware of these changes and try to identify them to better understand the perception of pregnancy to develop health promotion programs.<EOD> Concurrence-induced squeezing in a superconducting circuit.\n\nWe demonstrate experimentally the squeezing effect on the quadrature variance due to the presence of a non-resonant state in a superconducting circuit. We report the measurement of \u223c23 mV, 71% quadrature squeezing of the coherent state for a two-photon detuning of 1.23 MHz. This experiment confirms our earlier predictions that in the presence of a strong non-resonant state, squeezing of the coherent state is possible. This is a key step toward observing photon blockade in circuit QED.\nIntroduction.-Recent years have seen a res",
        "label": 0
    },
    "1075": {
        "output": "**Step 3. Identify possible exclusions with the help of a Clinical Trial Search Guide.**\n\nIf you have identified yourself any possible exclusions or unclear cases, please use the following information on how to do it [16][17][18][19][20][21][22][23][24][25].\n\n**[16]**\n\n### Age\n\n### Inclusion:\n\n> Minimum age limit: 18 years / Maximum age limit: 18 years\n\n### Exclusion:\n\n> Maximum age limit: 70 years / Minimum age limit: 18 years\n\n### Gender\n\n#### Inclusion\n\n> Both sexes / Same sex\n\n#### Exclusion\n\n> Both sexes / Same sex\n\n### Weight\n\n### Inclusion\n\n> Minimum weight limit: 30 kg / Minimum weight limit: 20 kg\n\n### Exclusion\n\n> Maximum weight limit: 200 kg / Minimum weight limit: 80 kg\n\n### Height\n\n### Inclusion\n\n> Minimum height limit: 100 cm / Minimum height limit: 100 cm\n\n### Exclusion\n\n> Maximum height limit: 240 cm / Minimum height limit: 150 cm\n\n### BMI\n\n### Inclusion\n\n> Minimum BMI: 19 kg / Minimum BMI: 19 kg\n\n### Exclusion\n\n> Maximum BMI: 40 kg / Minimum BMI: 19 kg / Maximum BMI: 25 kg / Minimum BMI: 17.5 kg\n\n### Body temperature\n\n### Inclusion\n\n> Allowed to participate with body temperature < 37.5 \u00b0C / Only include participants with no signs of fever at the time of visit and before immunization / Allowed to participate with body temperature \u2265 37.0 \u00b0C / Allowed to participate with body temperature \u2265 37.3 \u00b0C\n\n### Exclusion\n\n> Only include participants with no signs of fever at the time of visit and before imm",
        "label": 0
    },
    "1076": {
        "output": "The [CODE] trial-level eligibility 0\n1\n2 ```\n[/CODE]\n\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The",
        "label": 0
    },
    "1077": {
        "output": "When the trial-level eligibility is equal to 2, the trial is completely eligible. When the trial-level eligibility is equal to 0 and 1, the trial needs to consider some of exclusion criteria to assess the inclusion. The assessment tool for the determination of exclusion criteria is the `Exclusion criteria checker' widget on the dashboard screen. Exclusion criteria are checked on the widget by pressing the `Check exclusion criteria` button on its panel. The widget allows the user to determine exclusion criteria by either pressing\n`Check exclusion criteria` on the dashboard screen or pressing `Check exclusion criteria` on the `trial-detail: trial` view. In the first case, all `Exclusion criteria checker` widgets are checked as shown in [fig_ref]  Figure 27: Fig 27 [/fig_ref] . In the second case, only\n`trial-detail: trial` view has checked `Exclusion criteria checker` widget. When trial-level eligibility is not equal to 2, the screen on the `trial-detail: trial screen` is as shown in . The exclusion criteria to be checked may vary from trial to trial.\n\n## Exclusion criteria checker\n\n## Example 4\nLet's say your trial is of a type where patients are randomly assigned at a 1:4:4 ratio to 3 treatment arms. The first treatment arm is the study arm, and the second and third treatment arms are control arms. We will set the 3 arms to the following: \nLet's use the\n`randomization seed` variable in our\n`trial-detail: patient` screen. We set\n`initial treatment` to study,\n`narm2` to 2, and\n`narm3` to 3, i.e.,  `randomization seed` in the first row of the table, and press `Check exclusion criteria` to see the trial's\n`Exclusion checker` widget on the trial detail screen. The widget is checked as shown in [fig_ref]  Figure 27: Fig 27 [/fig_ref] . The first 5 check buttons (the `B. 1` check buttons) are checked. Click the\n`Check eligibility` button of the check button for 1st treatment arm in the table, and the\nTrial-Level",
        "label": 0
    },
    "1078": {
        "output": "## Exercises\nPlease solve the following questions based on the examples. If you think the answer needs modification, please do the following:\n\n\n##[A]\nPlease submit a Python code to give the patient-level eligibility for this patient. \n\n### Solution:\n```python\nTrial_eligibility_p = \"0\"\nif \"38year\" in note_list[0]:\n\tif \"8m25/f/163cm\" in note_list[0]:\n\t\tif note_list[1] == \"250/250\" and note_list[2] == \"5\":\n\t\t\tif name_list[1] == \"Park\" and name_list[2] == \"JaYook\" and name_list[3] == \"HoJoung\" and note_list[5] == \"9/02/2018\":\n\t\t\t\tTrial_eligibility_p = \"1\"\n\t\t\telse:\n\t\t\t\tTrial_eligibility_p = \"2\"\n\t\t\t\tTrial_eligibility_p = \"2\"\n\t\telse:\n\t\t\tTriall_eligible = \"1\"\n\n\t\tTrial_eligibility_p : str\n\t\tTrial_eligibility : str\n```\n### Efficiency comparison:\n\n```python\nfrom timeit import default_timer\nimport numpy as np\nimport pandas as pd\n\ndf_p = pd.DataFrame((((\"1\",2,3,4,5), (\"1\",5),14)))\ndf_p\ndf_p.shape\ndf_p.index.isin(\"1\")\n```\n\n### Excavate each patient's eligibility:\n```python\nfrom sklearn.feature_extraction.text import CountVectorizer\nimport numpy as np\nimport pandas as pd\nfrom sklearn.neighbors import knearest_neighbors\npd.DataFrame([pd.DataFrame(((('30',70,80,90), ('1',2),27,24))), pd .DataFrame((((\"100\",400,50",
        "label": 0
    },
    "1079": {
        "output": "##\n<EOD> Fatal bullous pemphigoid induced by chemotherapy with platinum salts.\nBullous Pemphigoid (BP) is an extremely rare entity in cancer cases undergoing chemotherapy. We report a 78-year old man with oropharyngeal cancer who after 8 courses of cisplatin chemotherapy in the absence of other treatments was hospitalized for severe neurological and respiratory distress owing to a widespread blistering eruption. The clinical course was rapidly fatal, the patient's death occurring on the 7th hospital day. Post-mortem examination failed to disclose a cutaneous autoimmune disease or a dermatophytosis, and the histological findings strongly suggested a diagnosis of bullous pemphigoid (BP). Therefore it is reasonable to believe that the cisplatin induced BP in our patient, in agreement with previous reports of other cases of chemotherapy-related BP, thus emphasizing an important side effect that should be well known by physicians treating cancer patients.<EOD> Acidic polymers in human urine\nA group of ubiquitous molecules of undisputed biological relevance is the class of structurally similar acidic polymers collectively called polyamines. They have been recognized as very important for cell life. These molecules influence practically all cell functions including proliferation, differentiation, membrane stability, stress tolerance, aging, and death. These polymers have therefore attracted increased interest and studies have shown that these are involved in tumorigenesis, aging, and apoptosis. Although many studies on these molecules have been reported, the role of these molecules in urine is not well known. It is known that polyamines are eliminated into the urine with relatively little modification. Interestingly, the urinary levels of polyamines show great variability in the general population. These may offer a diagnostic tool in certain clinical cases. In this review, we summarize the present knowledge relating to the structure of these molecules, their synthesis, the function and distribution in human tissues, and also focus on their role in some urinary disorders. \u00a9 2010 IUBMB IUBMB Life, 62(6",
        "label": 0
    },
    "1080": {
        "output": "## 7-3. Task 78\n\n[INSTRUT] Hello. You are a helpful assistant to clinical trial recruitment. It is time to evaluate your skills again, so today you will perform additional tasks in this course. You should focus on these subheadings: Clinical Trial ID, Intervention, Primary Outcome, Secondary Outcome, Exclusion Criteria, and Inclusion Criteria. [/INSTRUT] \n[RUN] [CODE] `curl -s \"http://bioinformaticsref.com/TrialIdGenerator.php\" | grep EXAMPLE_A` [/CODE] \n[OUT]  123456789123E894A716E64656C3C316474616E656E67756E2D746C657273742E316B65666972392E327C697374727973\n    \n    \n\n[/OUT]\n\n---\n\n    For example: A Trial-level assessment of eligibility 6 (patient meets inclusion and exclusion criteria) of 12-month-old infant with suspected infectious neonatal sepsis recruited to a phase 2 randomized controlled trial of probiotic Bacillus clausii versus placebo with randomized interim analyses after 65 participants for treatment failure at baseline \n\n---\n\n## Task 79\n\n[INSTRUT] Hello. You are a helpful assistant to clinical trial recruitment. It is time to evaluate your skills again, so today you will perform additional tasks in this course. When you click and play, click on the button ''Play this example'' at the top, right corner of the playback window. If all of your attempts match with all correct, then you will need to solve more training cases to test your understanding. Now, you should choose a clinical trial out of 100 clinical trials randomly chosen to recruitment. \n\nYou should analyze that trial's ID, intervention, and outcome. Moreover, according to the exclusion and inclusion criteria,",
        "label": 0
    },
    "1081": {
        "output": "<pre><code><a href=\"https://repl.it/@xudongliu/EleCtRalizeaBle-v2-2b0n\">xudongliu/EleCtRalizeaBle-v2-2b0n</a>\n\nimport pandas as pd\nimport numpy as np\nimport re\nfrom matplotlib.pyplot import *\nimport gspread\nfrom google.appengine.api import mail\nfrom google.appengine.ext import db\n\nfrom datetime import datetime\n\ndb.connect('MY_BREAST_CANCER_DATABASE')\n\npatients = pd.read_csv('data/patients.csv', sep = \"\\t\")\ntrial_patients = pd.read_csv('data/patients_trials.csv', sep = \"\\t\")\n\n\n#%% The goal function\n(f1 , f2, g1, g2, h) = model_1(patients, trial_patients)\n\npatients.head()\ntrial_patients.head()\nf1_summary(f1, patients, trial_patients)\nf2_summary(f2, patients, trial_patients)\ng1_summary(f1, g1, patients, trial_patients)\ng2_summary(f2, g2, patients, trial_patients)\nh_summary(f1, h, patients, trial_patients)\n\n#%% The parameters of interest\np1_summary(f1, trial_name = \"p1\", index=[\"f1\", \"g1\"])\np2_summary(f1, trial_name = \"p2\")\np3_summary(f1, trial_name = \"p3\", index=[\"f1\", \"g3\"])\nf1_summary_bar(f1, patients, trial_patients)\nf1_summary_bar(f1, g1, trial_patients)\nf1_summary_bar(f1, g3, trial_patients)\nf1_summary_line(f1, patients, trial_patients)\nf1_summary_line(f1, g1, trial_patients)\nf1_summary_line",
        "label": 2
    },
    "1082": {
        "output": "___\n\n### Task 3. Eligible Cases.\nEach patient that fits the inclusion criteria of the clinical trial on their individual level eligible cases. \nYou will determine eligibility at each visit. As in the previous task, you must always repeat `Eligible cases` by `Eligible cases: `, e.g., `Eligible cases: 76`. ___\n\n___\n\n### Task 4. Adverse Events.\nIn trials with interventional study drugs, the occurrence of untoward medical events is evaluated. These events may be due to the effect of the study drug, to an untoward surgical procedure, to trauma, to other medical therapy or events, and/or to spontaneous or spontaneously occurring events, irrespective of the relationship to the study drug.\nUnless otherwise stated in the protocol, the following items should be reported under adverse events.\n\n1. Adverse events with a reasonable possibility of relationship to the study drug, with special reference to possible drug reactions:\n   1. Adverse events occurring during the study before the start of treatment, or which do not have a temporal relationship, are reported as pre-treatment events and, if appropriate, coded as concomitant diseases.\n2. Adverse events possibly related to multiple drug therapy, or with complex or differential causality, must be reported in an appropriate fashion, and coded.\n3. In addition, unforeseen or unusual events and non-complications of other therapies, even without any specified temporal relationship, should always be recorded. In case of multiple events, as appropriate the first event must be named, and, if necessary, the second or third event must be specified.\n4. Important abnormalities and adverse events in blood pressure, pulse and other vital signs not otherwise classified as adverse events, should also be classified in  ___\n\n___\n\n### Task 5. Protocol Deviation Reporting.\nThe objective is to collect data on medication taken by investigational drug trial participants who are receiving trial agent medication, but are not following exactly the protocol-specified dosage and time of administration.\nEligible cases that do not complete the trial in time due to late withdrawal are assessed.",
        "label": 0
    },
    "1083": {
        "output": "2.5.5.4 Exercises\n\n### Excercise 6-7: 2, 3, 5. Evaluating a patient's eligibility for clinical trials.\nAs in the previous exercise 4-6 above.\n\n# Appendix 5. \nA checklist for assessing your learning and evaluation of this unit:\n\n\n1\\. Did you understand the concepts of the module with respect to clinical trials? 2\\. Did you have doubts about any of the concepts that were presented? 3\\. If your answer to #2 is \"yes \", what were they? 4\\. Did you review the material with respect to clinical trials until you understood the concepts? 5\\. Was the material useful to you?\nThe answers to the questions above will be helpful in assessing your personal development, and in guiding the creation and teaching of a further module of this type. Please indicate your answer.\n\n# References\n<EOD> .\nThe paper presents the results of a multifaceted survey carried out to develop the strategy of the regional health policy in the Kola peninsula. The present paper discusses the concept of socio-medical security as well as presents the results of an in-depth socio-medical study of the population of the Murmansk and Monchegorsk municipalities. This paper contains the results of a survey of the health status of the population, the evaluation of the availability and accessibility of health care services and the population's satisfaction with the level of their implementation, evaluation of the availability and accessibility of the population and doctors with sanitation facilities. The paper discusses the efficiency of the preventive and therapeutic health care, the causes of patients' mortality within emergency care and primary care according to the data for the year 2001. The paper presents the methodology of estimating the needs in population health care, as well as evaluation of the population and medical organizations satisfaction with the health care received. The paper also describes the population's demographics, occupational structure, population health by the criteria of prevalence and incidence of diseases, and their economic consequences.<EOD> Development of a multimodal inhibition of apoptosis score and its clinical implications in colorectal cancer\n\nBackground: Colorectal cancer",
        "label": 1
    },
    "1084": {
        "output": "## Examples\n\n\t# -*- mode: python;\n\t# pylint: disable=no-init-with-self\n\n\tdef compute_eligibility(clinical_trial, patient_note):\n\t\tclinical_trial_eligibility()\n\t\tpatient_eligibility()\n\n\t# Include both eligible and excluded by putting 0 and 1 in different ways.\n\tdef clinical_trial_eligibility():\n\t\treturn int([1 for trial in clinical_trial[clinical_trial['Gender'] == 'Female'] if trial['Inclusion_factor'] == 'Hypertension' for trial in clinical_trial]) + \\\n\t\tint([0 for trial in clinical_trial[clinical_trial['Gender'] == 'Female'] if trial['Inclusion_factor'] == 'Hypertension' \\\n\t\tfor trial in clinical_trial]), \\\n\t\tint([1 for trial in clinical_trial[clinical_trial['Gender'] == 'Female'] if trial['Inclusion_factor'] == 'Age' for trial in clinical_trial]) + \\\n\t\tint([1 for trial in clinical_trial[clinical_trial['Intervention'] == 'Toremifene'] if trial['Inclusion_factor'] == 'Age' for trial in clinical_trial]) + \\\n\t\tint([0 for trial in clinical_trial[clinical_trial['Intervention'] == 'Placebo'] if trial['Inclusion_factor'] == 'Age' for trial in clinical_trial]) + \\\n\t\tint([0 for trial in clinical_trial[clinical_trial['Gender'] == 'Female'] if trial['Inclusion_factor'] == 'Age' for trial in clinical_trial]) + \\\n\t\tint([1 for trial in clinical_trial[clinical_trial['Inclusion_factor'] == 'Toremifene' for trial in clinical_trial]]) + \\\n\t\tint([1 for trial in clinical_trial[clinical_trial",
        "label": 0
    },
    "1085": {
        "output": "___\n_______\n\n## How does a patient qualify for a trial?\nYou are the participant, and you qualify if you meet the same inclusion criteria as the ones applied to the trial. If one of the criteria is not met, you will be given an 'X' for that criteria and an eligibility assessment of '0' (for excluded), '1' (not relevant), or again '2' (eligible).\n\n### How the patient was qualified.\nThe inclusion criteria are as follows:\n\n- Age group: 19 to 40 years\n\n- BMI 35 to 45 kg/m2\n\n- Abnormal serum alanine aminotransferase (ALT) (30 IU/L and 50 IU/L for women and men, respectively)\n\n- Alcohol consumption of more than 2 drinks per day for women or 3 drinks/day for men\n\n- Current smoker (or stopped smoking < 6 months)\n\n- No use of dietary supplement (herbal and vitamins)\n\n- No use of other medicines (e.g., statin, metformin)\n\n### Exclusion Criteria:\nThe exclusion criteria are:\n\n- Women pregnant or lactating\n\n- Women on hormonal contraception\n\n- Women who are planning to conceive, are trying to conceive, or wish to avoid pregnancy for duration of 12 weeks\n\n- Men who are planning to conceive, are trying to conceive, or wish to avoid pregnancy for duration 28 days \n\n- Women taking birth control medicines\n\n- Women with severe psychiatric disease\n\n- Women with a current eating disorder or with symptoms of disordered eating\n\n___\n_______\n\n## How should we report these data?\nWe report clinical trials in the format of a patient flow diagram as shown below. It summarizes the flow of participants throughout the trial. The diagram shows the numbers of participants assigned to each group, the number of participants who completed the trial, and the number of participants who dropped out.\n\n# The table for the clinical trial\n\n|- \n|- {{#if:Categories:Clinical",
        "label": 0
    },
    "1086": {
        "output": "## Clinicaltrials_summary\n\n## [INST] # ClinicalTrials_Summary.\nFirst of all you have to load this module:\n> knitr::kable(load(file = \"data/ClinicalTrials_Summary.RData\", quiet = TRUE))\nIn case you are familiar with the `ClinicalTrials`-package, you should skip this. However, I highly recommend going through it once: https://rdrr.io/bioc/crd/man/ClinicalTrials.html\nWithin this package, a file containing all the information you need can be loaded: # Import the data set > data(\"ClinicalTrials_Summary\") > load(file = \"data/ClinicalTrials_Summary.RData\", quiet = TRUE)\nYou can take a look at the function `summary(ClinicalTrials_Summary)' in the console or with `summarize_clinicaltrials_summary (yourData)`. This function produces many data tables, a `summary` file, and a plot table. (See the package's vignette.)\n\n## # Example of clinical trial\n``` r\nClinicalTrials_Summary %>%\n  dplyr::select(Identifier, Summary, Primary, TrialDate, Location, Country, Condition, Sponsor, Type, Disease, Primary, PrimaryReason) %>%\n  dplyr::mutate(PrimaryReason = if_else(PrimaryReason %in% c(\"Potentially life threatening emergency\", \"Important risk of mortality\", \"Life threatening emergency\", \"Serious and immediately life threatening emergency\", \"Critical illness\", \"Serious illness\", \"Serious condition\"), \"Low\", \"High\", \"Very high\")) %>%\n  dplyr::mutate(Location = factor_if(Location, label_from, levels_if(Location, label_from))) %>%\n  dplyr::mutate(Condition = factor_if(Category, fct_relevel(fct_recode(Category), c(\"Cancer\", \"Immunosuppressants\", \"Therapy\", \"Infection\", \"Chronic disease\", \"Pregnancy\"))) %>%\n    factor_colwise()) %>%\n  dply",
        "label": 0
    },
    "1087": {
        "output": "<EOD> Phosphodiesterase inhibitors for the relief of symptoms of urinary tract infection.\nBACKGROUND\nUrinary tract infection (UTI) is a common condition that causes discomfort and distress for patients and consumes large amounts of health care resources. The most commonly used antimicrobials are urinary antibiotics; however, there is evidence that repeated courses of antibiotics lead to antibiotic resistance and adverse events. Several studies have suggested phosphodiesterase inhibitors (PDEI) have an antimicrobial effect and may provide pain relief in patients with symptomatic UTI without inducing antibiotic resistance.\n\n\nOBJECTIVES\nTo assess the effects of phosphodiesterase inhibitor use on the symptoms of urinary tract infection.\n\n\nSEARCH STRATEGY\nWe searched the following electronic databases up to August 2011: CENTRAL; MEDLINE; EMBASE; CINAHL; Science Citation Index; Conference Proceedings Citation Index-Science; Health Systems Evidence Database; National Health Services Economic Evaluation Database; and the Database of Abstracts of Reviews of Effectiveness. For unpublished studies, we searched clinical trial registries. Finally, we contacted experts in the field and PDEI manufacturers.\n\n\nSELECTION CRITERIA\nWe included randomized controlled trials (RCTs) comparing phosphodiesterase inhibitors (PDEI) with placebo or no treatment in individuals with a diagnosis of a lower urinary tract infection.\n\n\nDATA COLLECTION AND ANALYSIS\nIn addition to our review question we also conducted a meta-analysis of the pain and urine symptom scores taken from the included studies. We extracted data on participant characteristics, intervention details, outcomes, and potential mechanisms for the pain and antimicrobial effects of PDEI using the RevMan software. We pooled results using RevMan for Windows, version 5.0 .\n\n\nMAIN RESULTS\nWe identified 13 eligible RCTs, involving 876 participants. None of the included studies reported on our primary outcome of days with symptoms of UTI. We were unable",
        "label": 0
    },
    "1088": {
        "output": "### The data of patient note\n\n\n*\n\n* 1. The id of the clinical trial (e.g., `553`, `562`):\n```python\nfrom lxml import etree\n\npatient_note = element_text(doc, 'clinical-notes', 'patient-notes-id')\npatient_note_id = patient_note.split('id=\"')[1]\n\nclinical_trial = element_text(doc, 'clinical-trials', 'clinical-trial-id')\nclinical_trial_id = patient_note_id.replace('clinical-trial-id=\"', '').replace('\"', '')\n\nclinical_trial.tag[:-1]\n# output: 'clinical-trial-id=553/562'\nclinical_trial.text\n# output: 553 OR 562\nclinical_trial_id\n# output: 553 or 562\n```\n* 2. The title of the clinical trial (e.g., `Antenatal hydronephrosis`).\n```python\nclinical_trial_details = clinical_trial\nclinical_trial_details.findall('title')[0]\nclinical_trial_details.get('title')\n# output: Antenatal hydronephrosis\n```\n* 3. Investigation group (e.g., `Cytotoxic Chemotherapy Versus Placebo or No Intervention in Infiltrating Transitional Cell Carcinoma of the Bladder: A Phase III Multicenter Randomized Controlled Trial`).\n```python\nclinical_trial_details = clinical_trial\nclinical_trial_details.attrs().get('snp')\n# output: [u'cisplatin + carboplatin + gemcitabine -cisplatin + carboplatin + gemcitabine' 'cisplatin plus carboplatin plus gemcitabine placebo placebo ']\n```\n* 4. The date when the patient was admitted to",
        "label": 0
    },
    "1089": {
        "output": "# Difficulty\nDifficulty \nThis assessment is a bit like answering test questions. You know which questions you don\u2019t know that you will answer. Then you will try to answer them. In this exercise, you will try to understand what is needed to determine a patient\u2019s eligibility. To some extent, you will have to think by yourself, just as if you were faced with clinical situations.\n# Question\n\n### Instructions\n\nBefore answering the questions, please look at the clinical trial in. \nWhat are the inclusion criteria of this clinical trial?\nThe clinical trial is entitled \"Self-expandable Metallic Stent Versus Multiple Plastic Stents in Post Orthotopic Liver Transplantation Biliary Stenosis\". Inclusion criteria: post-OLT biliary anastomotic stenosis.\nLet's think in depth about each inclusion criterion. Consider the following case:\na 54-year-old woman.\npost-OLT biliary anastomotic stenosis (1 month post-operative).\njaundice.\ncholestasis.\nbiliary tree dilation on US.\nWhat are the inclusion criteria and the exclusion criteria?\n-Age (>18)\n-Post-OLT biliary anastomotic stenosis\n-Jaundice\n-Cholestasis\n-Biliary tree dilation on US\n-Plastic stent deployment.\n-Fully covered metallic stent deployment.\nIn the case above, the patient qualifies for this clinical trial if she meets the inclusion criteria listed above. Otherwise, she is excluded. \nWhat will you use to assess the eligibility for this clinical trial?\n\n1. Patient Note.\n2. Inclusion Criteria of the clinical trial.\n3. Exclusion Criteria of the clinical trial.\nWhat does the assessment result show? Is the patient eligible for the trial?\n\n## Assessment of eligibility\nThis clinical trial uses a three-point scale for the eligibility assessment, as follows:\n0) Excluded. Patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria.\n1) Not relevant.",
        "label": 0
    },
    "1090": {
        "output": "# Example 2\n<p align=\"center\">\n<img src=\"image/leaderboard-el.png\"/>\n</p>\n\n[INST] The following code sample is an example of an assignment that has been done in class. \n\n# This code sample has been done by <NAME>, [Instructor's name](http://wiki.hkuf.hk/instructor-name/), on 10th April, 2020.\n\n```python\n# +\nname = [i.split('\\')[-1] for i in globals()]\npatient_re = re.compile(r'[0-9]\\.[0-9]\\.[0-9]')\n\ndef main():\n    # Get list of patient notes\n    fichiers_notes = os.listdir(settings['directory_for_notes'])\n\n    for f in fichiers_notes:\n        file = open(settings['directory_for_notes'] + f, 'r')\n        f_lines = file.readlines()\n        df = pd.DataFrame(f_lines)\n        df['ID'] = 1\n        df['ID'] = df['ID'].apply(function_name='assign_unique_id', arguments=(f))\n\n        df['age'] = df['patient'][0].str.contains(r'.*(\\d+)').apply(get_age_from_patient_num, args=(df))\n        df['name'] = f['patient'].str.extract(patient_re, axis=1).str.join(' ').str.replace(patient_re.solve(), '')\n        df['weight'] = df['patient'][0].str.contains(r'.*(\\d+)').apply(get_weight_from_patient_num, args=(df))\n        df['patient'] = df['patient'].str.replace(r'\\N*', '').str.strip().replace('\\n', '')\n\n        df['freq'] = df['patient'].str.count(r'\\d').apply(function_name='calculate_frequency', args=(f))\n\n        for i in range(0, df['freq'].nunique(), 1):",
        "label": 0
    },
    "1091": {
        "output": "## \nTITLE: Effect of Curcumin supplements on blood pressure.\n\n\nDESCRIPTION:\nThe purpose of this trial is to assess the effect of Curcumin supplements on blood pressure. Curcumin has been associated with reducing blood pressure.\n\n\nOUTCOME:\nThis trial will assess the effect of Curcumin on blood pressure in hypertensive postmenopausal women by adding Curcumin and a placebo to the subjects in two parallel groups. Criteria for Participation:\n- Postmenopausal women\n- Aged 45-60 years\n- BMI 30-",
        "label": 0
    },
    "1092": {
        "output": "## Assignment\nYou will be paid 12 Euro if you correctly determine the eligibility of the patients described in this clinical trial.\n\n## Conceptual\n\n## Clinical trial recruitment assistance (task) 1) patient id: ctri_j_229602 2) title: comparison between laparoscopic common bile duct exploration and intraoperative ercp for management of common bile duct stones -trial-level eligibility: 2) eligible\n\n## Pre-evaluation feedback report (task)\nHere is the pre-evaluation feedback report. The overall score of the pre-evaluation feedback is 0/7. In particular:  You did not provide clear Trial-level eligibility for every single entry line. \nTherefore, you need to make adjustments to the answers.\n\n## Evaluation \nThe adjusted evaluation is provided below:\n\n## Conceptual\nYou scored 100%! Conceptual correctness for Task 1. \nFor 15 patients out of 20, you reported the correct clinical trial-level eligibility. Your overall score for Conceptual (Areas) correctness is 70%.\n\n## Pre-evaluation feedback for the task 2.\n\n## Conceptual\nYour Score on Conceptual accuracy: 1\nYou scored 100%! Conceptual correctness for Task 2.\nFor all patients, you reported the correct clinical trial-level eligibility. Your overall score for Conceptual (Areas) correctness is 100%.\n\n## Pre-evaluation feedback for other areas.\n\n## Instructor feedback\nThank you for submitting your conceptual correctness. \nBelow you'll find the instructor feedback on Your submission entitled, \"\n\". Please note that your instructor provides commentary only on the Conceptual Areas (Areas; conceptual correctness is considered 90% or less overall; you scored 91% overall). A score of 100% or greater for one of these concepts is considered 100%. For the first 3 clinical trial patient's notes, below, you have indicated 0/3 in the 90",
        "label": 2
    },
    "1093": {
        "output": "## Question 16(S6)\n\nTo learn more about gallstones, click the \u25b6 button of the right sidebar to be directed to the clinical presentation of gallstones from our online wiki.\n\n\n\n### \u25b6\n\n\n### Question 16(A5)\n[A] The correct response is C since patients who are taking the following medications may increase their risk for gallstones: diuretics, steroids, contraceptive pills, and opioids. Steroids are also sometimes used to suppress inflammation caused by gallstones. As a result, steroids could cause more gallstone episodes in susceptible patients.\nContraceptive pills could also increase the risk for gallstone episodes by changing the levels of certain hormones. Diuretics are also an effective treatment for gallstones in combination with other modalities of treatment, such as cholecystectomy. However, as mentioned in the paragraph above, this does not mean that diuretics are the actual cause of gallstones and could have been effective in preventing future episodes of gallstones. \u2190 A5\n[B] The correct response is A since smoking is associated with gallstones as a result of smoking-related dyslipidemia caused by an increase in the low-density lipoprotein (LDL) cholesterol and triglyceride (TG) levels.\nIn addition, smoking cessation has been associated with improved bile composition by causing a decrease in the TG content of the bile and an increase in the high-density lipoprotein (HDL) cholesterol levels, resulting in a beneficial change to the bile composition.\n[C] The correct response is B since smoking is associated with increased risk of gallstones, decreased cholesterol metabolism, decreased gallbladder emptying, accelerated atheroma formation, and increased risk of cholecystectomy, suggesting adverse effects on the normal function of the gallbladder and possibly on the blood vessels that supply the gallbladder with blood.\n[D] The correct response is D based on the fact that the predominant composition in cholesterol stones involves LDL cholesterol. The risk of",
        "label": 2
    },
    "1094": {
        "output": "## \u2794 Examples of output in this problem \u2794\nOutputs:\n```\nPatient-level eligibility: [\n    \"NOT_ELIGIBLE\" =>  \"Gender (XS)\" \n    \"NOT_ELIGIBLE\" =>  \"Age (G1)\" \n    \"NOT_ELIGIBLE\" =>  \"Absence of previous NVD\" \n    \"RELEVANT\" =>  \"History of SCH (XS)\"\n    \"NOT_ELIGIBLE\" =>  \"Family history of BC (XS)\" \n    \"RELEVANT\" =>  \"Obtained informed consent\" \n    \"NOT_ELIGIBLE\" =>  \"Hypertension (G1)\" \n    \"RELEVANT\" =>  \"Oncogenic mutation (G2)\" \n]\nTrial-level eligibility: [\n    \"NOT_ELIGIBLE\" =>  \"Initial white blood cell count \u2265 20,000/uL\" \n    \"NOT_ELIGIBLE\" =>  \"Murphy stage IV with blast cells in CSF\" \n    \"RELEVANT\" =>  \"Initial white blood cell count < 20,000/uL\" \n    \"RELEVANT\" =>  \"Murphy stage II or III\" \n    \"RELEVANT\" =>  \"AALL0932 is open, and will be used to assign patients to B-ALL risk groups\" \n]\n```\n### 5. Assignment to risk groups \nIn this part, you should assess to which risk group the patient belongs and then report the risk category. \n\n![INST][E5_INST] \n\nHere is an example of output of a trial patient for this problem:\nInput to the `f_aall0932` function:\n```\ninput <- f_aall0932(df = data[1:3])\n```\nOutput of the function `f_aall0932`:\n```\nAssignment to risk groups: [\n\"RELEVANT\" =>  \"Prior AML treatment (XS)\" \n\"",
        "label": 0
    },
    "1095": {
        "output": "### 9. End with a newline\n```\nEnd with a newline by the following code:\n```\n... #END.\n```\n<EOD> Exciton formation in a two-phonon process in CdZnTe photocathodes.\nThe formation of excitons in cadmium zinc telluride (CdZnTe) photocathodes is studied in the frame of a two component plasma model. The analysis of the experimental observations reveals that the excitons in this compound system may be regarded as localized holes. A possible interpretation of the excitons is proposed. Comparisons between real photocorrosion, photoefficiency, and absorption measurements are made. (P.C.H.)<EOD> Prolonged hospitalization, comorbidities, and poor outcomes in COVID\u201019\n\nCOVID-19 is a highly contagious viral illness causing severe respiratory failure. Our study aimed to define the impact of hospital course and concomitant comorbidities on outcomes of patients with COVID-19. A retrospective study was performed in a tertiary hospital in Southern California identifying patients diagnosed with COVID-19 via nasopharyngeal swab RT-PCR, who were admitted from the emergency department between March 19, 2020, and April 27, 2020. Primary outcome was 28-day mortality. Descriptive statistics and multivariable logistic regression were performed. There were 172 patients included in the study. Median age was 67 years, 53.5% were women. Twenty-eight-day mortality was 18.63%. Among COVID-19 admissions, 258 (57.2%) were hospitalized for \u2a7e7 days, 45 had severe COVID-19, and 21 were intubated for >7 days, 14 patients were placed on ventilators >72 hours, and 29 patients died while hospitalized >7 days. Those who prolonged to >7 days had an odds ratio (OR) of 27.108 (95% CI 15.142-48.634) (P < .0",
        "label": 0
    },
    "1096": {
        "output": "[NAME_1] and [NAME_2] have come to the clinic for follow-up and to discuss contraception. They were both tested positive for trichomoniasis, gonorrhea, and chlamydia. They would like to know if they are eligible to initiate therapy for coinfection after 7 days. [INST] If they ask you how you would decide that they are eligible for therapy, you should always start by reassessing their inclusion eligibility with the following questions, e.g. \n\nAre they sexually active and would they be willing to abstain from sexual intercourse",
        "label": 0
    },
    "1097": {
        "output": "If you want to check this example correctly, press `q` or `return` button to confirm and go back one screen. \n\n**[Tutorial (Part 2)]**\n\n```cpp\n#include <vector>\n#include <iostream>\n\nusing std::cout;\nusing std::cin;\nusing std::endl;\nusing namespace std;\n\nvoid test();\n\nint main() {\n    int n, trial_size;\n    cin >> n;\n    cin >> trial_size;\n\n    vector< int > cnt(n);\n    vector< pair <int, int> > arr(trial_size, pair<int, int>(0, 1));\n    for ( int i = 0; i < trial_size; ++i ) {\n        int x; cin >> x;\n        arr[i].first = x;\n    }\n\n    vector< int > dp(trial_size);\n\n    test();\n\n    cout << \n        \"\\n\"\n        \"Minimum: \" << min(dp)\n        \".\"\n        \"\\n\";\n    cout << \"\\n\"\n        \"Maximum: \" << max(dp)\n        \".\"\n        \"\\n\";\n    cout << \"\\n\"\n      << \"Mean: \" << mean(dp)\n      << \".\"\n      \"\\n\"\n      << \"Standard dev.: \" << std::setw(10) << std::setprecision(4)\n      << std::sqrt(\n                      var(dp) / (n - 1))\n        \".\"\n      << std::endl;\n    cout << \n        \"\\n\"\n        \"Variance: \" << var(dp)\n        \".\"\n        \"\\n\";\n    cout << \"\\n\"\n        \"SD of dev.: \" << std::setw(10) << std::setprecision(4)\n        << std::sqrt(\n                var(dp) / (n - 1))\n        \".\\n\";\n    cout << \n        \"\\n\"\n        \"SD of max. and min. difference: \" << std::setw(10) << std::setprecision(4)\n        << std::sqrt(\n                var(dp) / (",
        "label": 0
    },
    "1098": {
        "output": "In the fourth task, you should do the same works as done in the third task. \n\n[INST]\nPatients with initial BP elevations (> 140/90); corrected QTc > 480 msec.\n\n[END]<EOD> Prevalence and Pattern of Cervical Lymph Node Metastasis in Oral Cancer\n\n [bib_ref]  Analysis of 197 recurrent cases of patients with squamous cell carcinoma of..., Chen [/bib_ref]  [bib_ref]  The prognostic significance of cervical metastases in head and neck squamous cell..., Clark [/bib_ref]  [bib_ref]  Metastasis in head and neck cancer: an update, Aljurf [/bib_ref]  [bib_ref]  CNCC-HN: Evaluation of the NCCN Guidelines for Head and Neck Cancer, version..., Balm [/bib_ref]  [bib_ref]  Predictors of occult metastatic nodes in oropharyngeal cancer, Gurney [/bib_ref]  [bib_ref]  The prognostic significance of cervical lymph-node metastases in resectable epidermoid carcinoma of..., Jones [/bib_ref]  [bib_ref]  The prognostic significance of cervical metastases in carcinoma of the oral tongue, Harrison [/bib_ref]  \n\n# Materials and methods\nOne hundred nine patients of buccal mucosa or lip sarcoma admitted between August 2013 and August 2014 at Department of Maxillofacial Surgery of Wenzhou People's Hospital affiliated to Wenzhou Medical College were included in this study. All the patients included in this study had undergone radical resection and neck dissection after being subjected to thorough preoperative evaluation and complete physical examination. [bib_ref]  Oromandibular metastasis from buccal carcinosarcoma, Liu [/bib_ref]  In addition, the patients enrolled in our study underwent clinical treatment. Among these patients, 39 patients were found not to have cervical lymph node metastasis, forming the control group; the other 70 patients were found to have cervical lymph node metastasis and were included in the observation group. The inclusion criteria encompassed the following: The inclusion criteria for the observation",
        "label": 0
    },
    "1099": {
        "output": "#\n\n### Examine the patient note and the clinical trial.\nYour mission is to determine the patients' eligibility for the clinical trial described in a patient case vignette (see below). You need to understand the eligibility requirements for clinical trials and consider whether the patients in the vignette fulfil the eligibility requirements. Based on your considerations, you should determine a trial-level eligibility for each of the patients. Finally, calculate your score according to the scoring criteria. Examine the case vignettes carefully before you proceed (see also Note [E0] at the end of the article) (see also Note [R5] at the end of the article).\nNote: If you need more information as you work through the case, you should use relevant texts or scientific journals that are accessible by you in the library of the university. Refer to Note [U2] below.\n\n**Recommended for experts: Examine several case vignettes; the answers will be discussed in detail during the final exam, as well as the score given. For details, see Note [S1] below.**\n\n### What is an eligibility?\nEligibility is a term often used in clinical trials. It describes the characteristics needed for a person to qualify for a trial. Thus, an eligibility is something that allows that particular person to qualify for a clinical trial. Note that an eligibility may refer to the patient (patient-level eligibility) or the trial (triallevel eligibility).\n\n### Patient-level eligibility\nWhen determining a patient-level eligibility, you need to consider (1) the patient's medical history, (2) the patient's current health status and the clinical findings, (3) the patient's laboratory values, and (4) the other medications, including the over-the-counter medications (Note [B9] will help you to find more information about over-the-counter medicines).\nHere are a few points to remember:\n- Always consider the patient's health status, both overall and with respect to the symptoms stated in the patient case vignette.\n- Consider current medications and past or planned medical procedures.\n- Consider current and past diseases affecting the eligibility",
        "label": 1
    },
    "1100": {
        "output": "<EOD> Effect of Ginkgo Biloba Extract on Rat Platelets and Serum Adenosine\nWe report an investigation of the effect of the flavonoids from the leaves of Ginkgo biloba on adenosine production by rat platelets and also on platelet cyclic AMP levels and aggregation. The flavonoids increased both basal and thrombin-induced adenosine levels in the serum, and stimulated adenosine production by platelets.<EOD> A novel mechanism of RXFP1 regulation in the mouse uterus: RXFP1 desensitisation and its relevance to the female fertility\n\nRXFP1 is a uterine receptor for relaxin-2, and the interaction initiates the uterine relaxation and prepares the female for implantation. The importance of the receptor is highlighted by genetic studies where RXFP1 depletion results in in utero fetal resorption, early embryonic lethality, and abnormal reproductive organs. However, studies on the mechanism by which relaxin regulates uterine RXFP1 remain limited, with many receptor regulatory mechanisms being studied based on relaxin treatment of cell lines. We report here a functional desensitisation of RXFP1 in the mouse uterus, with implications for understanding the mechanism behind the receptor regulation. Treating mice with exogenous intraperitoneal relaxin resulted in desensitisation of RXFP1 on the uterine luminal epithelium, and this was shown by a significant reduction in protein levels of the receptor and intracellular calcium mobilization in response to relaxin in vitro. The desensitisation was found specific for relaxin treatment in vivo, and relaxin administration on consecutive days could not reverse the desensitisation, with a similar timecourse of desensitisation after a single treatment. Relaxin administration on days 1 and 2 of pregnancy induced a partial, and then a complete reduction in the number of implantation sites, which correlated with the level of RXFP1 desensitisation. These findings support a model of physiological RXFP1 regulation in the mouse uterus via receptor desensitisation, induced by relaxin exposure. The significance",
        "label": 0
    },
    "1101": {
        "output": "<EOD> .\nThe paper describes a 464-bp Sma I-Eag I fragment coding the C-terminal part of the protein in the 16,5-lipoxygenase from flax stem. A DNA library of the gene encoding the C-terminal part of the enzyme was obtained. It was found that the gene possesses the following structure: 5'-flanking sequence-coding sequence-3' flanking sequence. The restriction fragments of DNA isolated from the gene library were hybridized with DNA fragments from various flax cultivars to study the polymorphism of the 16,5-lipoxygenase gene. According to the patterns of hybridization of the fragments of DNA they were subdivided into the alleles (a, b, c, d, and e) differing in number and size. Alleles a and b encode the enzyme with the highest activity, allele d-with the lowest activity of the enzyme, whereas alleles c and e display activity lower than the alleles a, b, and D, but higher than that of the allele d. The genetic analysis of enzyme activity distribution among lines of flax has shown that the activity is determined by a polygenic characteristic, whose genotypic factors are alleles a, b, c, d, and e. There is a high correlation between the level of the 16.5-lipoxygenase, its substrate specificity, and enzyme activity. However, the activity of the enzyme depends mainly on the gene, which has the greatest impact on its activity.<EOD> .\nThe authors present the case report outlining a 49-year-old woman who presented with unilateral and transient loss of vision in one eye associated with transient hemianopia. She complained about painless diplopia with lateral deviation of the affected eye. Her past medical history was notable for the right leg deep venous thrombosis treated with low molecular weight heparin (LMWH) one year prior to onset of this episode. There was no evidence of cardiac thrombus, or any other cardio-vascular thrombotic risk factors. Physical examination revealed painless and progressively increasing exophthalmus in the right eye during the following 4 weeks. The diagnostic and therape",
        "label": 0
    },
    "1102": {
        "output": "[/TEST]\n\n</div><!-- Instructions end -->\n</template>'\n      \n<template langs=\"rst\">\n```\n\n### 03_221_clinical_trial_evaluation.edn(1)\n\n*\n\n*The evaluation of a clinical trial is performed by the Clinical Trial Center (CTC) that is based in our department of gastroenterology and hepatology in Leiden, the Netherlands. The Center of Evaluation (COE) is part of the AMC. All studies approved by the COE are performed in a standardized and independent manner. This includes the assessment of: inclusion, exclusion and protocol compliance. Furthermore, the CTRE collects epidemiological information and follow-up data for later meta-analyses of the results. \n\n\n> 03_221_clinical_trial_evaluation.edn(1): \n\n> 03_221_clinical_trial_evaluation.edn(1): # Evaluation of trials\n\n> 03_221_clinical_trial_evaluation.edn(1): # Trial assessments\n\n> 03_221_clinical_trial_evaluation.edn(1): # Evaluation of adverse events\n\n\n``` rst\n\n03_221_clinical_trial_evaluation.edn(1): # Trial descriptions\n\n- Trial N: 'N-of-1 Trial With Pantoprazole and Placebo to Evaluate Gastroesophageal Reflux Disease'\n    \n- Trial M: 'Randomized placebo-controlled trial to study the clinical profile of subjects after pantoprazole withdrawal'\n  \n\n03_221_clinical_trial_evaluation.edn(1): # Inclusion criteria\n\nInclusion criteria for N-of-1 trial A:\n\n- Signs and symptoms of Gastroesophageal reflux disease\n\n- Heartburn during the week before inclusion\n\n- Regurgitation during the week before inclusion\n\n- End",
        "label": 0
    },
    "1103": {
        "output": "<EOD> Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells\n\nBackground: Microarray and RNA-seq represent current best performing technologies for estimating gene expression levels from short sequences of RNA, and each technology has its own set of characteristics and limitations. We performed a comparative study of these technologies in order to explore their efficacy and possible overlapping or complementary applications. Results: In this study, microarray hybridization was performed using 8x60K SurePrint G3 Human Gene Expression platform (Agilent Technologies), while RNA-seq was performed using Illumina NextSeq 500 sequencer. We tested whether these two technologies represent similar approaches to quantifying gene expression with the same data on activated human T cells. RNA-seq technology was generally found to be more sensitive in detecting minor (0.1 fold change) changes in gene expression than the microarray technology. RNA-seq was also more precise (coefficients of variation [CV] < 0.39) and specific (e.g. less false positives and false negatives). We also noted that RNA-seq had significantly higher numbers of detected isoform-specific allelic expression. We further demonstrated that the performance characteristics of the two technologies were different depending on the gene expression level. We also investigated the number of genes detected by both technologies while varying various filtering criteria, such as the number of samples.Conclusions: Overall, we conclude that RNA-seq is a superior tool for mapping transcriptome expression profiling (comprehensive and specific) and isoform-specific expression (allelic alternative splicing). For expression profiles and allelic analysis, we recommend that 10 to 20 samples for microarray and 3 to 5 samples for RNA-seq will be adequate.\n\n# Background\nThe study of transcriptomics is important in multiple areas in biomedicine. Differential gene expression analysis is being widely used by researchers to decipher the molecular basis of several diseases and elucidate the effects of drugs or other treatments [bib_ref]  The use of microarray in pharmacogenomic research, Warrington [/bib_ref] . Microarrays and RNA-seq are currently the most widely utilized methods for transcriptome profil",
        "label": 1
    },
    "1104": {
        "output": "9. Let's create a function to read a new list 2\nFor example, suppose you have a list of patient information like this:\n[\n\nLet's apply that function for a patient example (i.e., the last patient note):\n[[[\"Emergency Dept.\",\"AB,CD\",\"2014-12-01\",\"2014-12-31\"],\"Obesity\",\"51\",\"Male\",\"3\"],[\"Emergency\n\nAnd apply `read_data_from_csv` to read a new list:\n[[\n\n3. Let's show eligible assessment scores for all patients in the trial.\n\nInside the `data` dictionary, we have created the list of patient information. Since there is only one patient information list, we need to access it through the `['patients']` array slice.\n\nHere is the patient list:\n['patients']:\n[{'Patient_ID': 1, 'Visit-Date': '2014-10-01', 'Note_ID': 0, 'Patient_Info': {\"Name\": \"A 25-year-old male\",\"Age\": \"25\"} ,\n'Trial_ID': 11111, 'Eligibility': '1' , 'Status': \"Finalized\"} ,\n'Patient_ID': 2, 'Visit-Date': '2000-10-30', 'Note_ID': 1, 'Patient_Info': {\"Name\": \"Betty J. Johnson\",\"Age\": \"45\"},'Trial_ID': 12345, 'Eligibility': '0' , 'Status': \"Finalized\"} ,\n'Patient_ID': 3, 'Visit-Date': '2014-11-02', 'Note_ID': 1, 'Patient_Info': {\"Name\": \"C J Doe\",\"Age\": \"48\"} ,\n'Trial_ID': 23456, 'Eligibility': '0' , 'Status': \"Finalized\"} ]\n\nSo, we need to find the index of patient number '3' in the 'patients' array, which is `0`. We can",
        "label": 0
    },
    "1105": {
        "output": "# [EXP] EXAMPLE RESPONSE\nHere is another sample file: [EXP_RESPONSE_0]\n\n* This trial-level eligibility: 2; Excluded\nFor assessing trial-level eligibility, you may need to read more than one note\n\nThis trial is for women who meet inclusion criteria and do not meet exclusion criteria for a Phase III Study in Patients with High Blood Lipids. Patients should have a diagnosis of hypercholesterolemia and be receiving a stable dose of 40 mg atorvastatin. Hypercholesterolemia is defined as: (a) total cholesterol  (TC) 220-240 mg/dL, TC .220 mg/dL AND LDL-C .140 mg/dL, LDL-C .130 mg/dL AND TC \\220 mg/dL AND (TC  .220 mg/dL AND TC (TC (TC .220 mg/dL OR LDL-C 130.0-140.0 mg/dL. TC .240 mg/dL. Hypercholesterolemia also includes familial hypercholesterolemia and severe hypercholesterolemia .250 mg/dL. LDL-C.320 mg/dL with documented high risk atherosclerotic cardiovascular disease based on the following criteria: diagnosis of ischemic heart disease (including myocardial infarction and stable angina not due to CAD), diagnosis of coronary or other arterial revascularization by PCI or CABG, history of definite CAD on invasive coronary angiography (ICA) or computer tomographic coronary angiography (CTA), history of abdominal angiography with documented prox occlusive disease, history of percutaneous transluminal angioplasty of the extremities (PTA of the lower or upper extremities, respectively), history of abdominal aortic bypass or extra-anatomic femoral-femoral anastomosis, history of",
        "label": 0
    },
    "1106": {
        "output": "## 4.\n[INSERT] Data for input. This example input file defines four (4) attributes of both patient (Name, BP, and Age) and clinical trial (Title and Summary), and one (1) attribute of output (Trial-level eligibility). [/INSERT]\n\n> patient_note = '[patient_note]'\n> trial = '[trial]'\n\n# The input.\nFile contents can be written to the file for easy sharing and reproductions.\n\n## 5.\n[INSERT] Script for evaluation: The scripting file is located in the same folder as the input file. Each run will start when the user inputs `>> run` and the evaluation results in `0` for any unsuitable input or `1` for the correct one.\n\n# If the result is 1, the case is done.\n\n6. \n<EOD> .\nThis article examines the use of the GnRH test (Gonadotrophin Releasing Hormone) in the assessment of primary ovarian failure. The study included both a clinical and hormonal evaluation in 40 unselected cases of primary amenorrhoea. In order to assess the sensitivity of the GnRH test, patients received 3 doses of 100 mug GnRH (36.5 to 56.5 mg i.v.) over an hour. The results were compared to a clinical and hormonal assessment carried out at the same time. The response pattern and the kinetics were studied in 18 patients with GnRH secretory disturbances using a dose of 100 mug three times daily in the same time as previously.<EOD> The impact of low-dose tizanidine therapy on sleep spindles in OSAS patients: A polysomnographic analysis.\nSTUDY OBJECTIVES\nTizanidine, an \u03b12 adrenergic agonist, improves sleep apnea syndrome (SAS) by decreasing the body's muscle tone. This study examines the effect of tizanidine on sleep spindles, which indicates the therapeutic effects of tizanidine on spindle activity in the central nervous",
        "label": 0
    },
    "1107": {
        "output": "## [GLOBAL] [PRO] Hello, Pro. Your task is to calculate the total number of neurons and oligodendrocytes in individual cortical layers and the total gray and white matter volumes.\nThe brain is the central nervous system (CNS) of the human body. It has a complex architecture that allows it to process information and enable learning. The human brain has many parts including the cerebrum, brainstem, cerebellum and the spinal cord. The cerebrum, is the major portion of the brain that performs a variety of complex functions including speech, thinking, memory, behavior and voluntary movement. This is divided into the left and right hemispheres by a vertical plane on its outer surface. If you cut the brain lengthwise you can observe two large chambers or ventricles, the lateral ventricles and a pair of smaller chambers, the third ventricle. The cavities of the left lateral ventricle (LV) and right lateral ventricle (RV) communicate with the third ventricle. The cerebral cortex is an outer layer of the cerebrum. The cortex consists of 6-layered structure (each layer comprises of different neurons and glial cells). Layer 1, or the innermost layer, is called the molecular layer. It is filled mainly with dendrites of several types of neurons. The layer is followed by Layer 2, or the internal granule layer, which contains neurons originating from the cerebellum. Layer 3, the Purkinje layer, contains the Purkinje cells, which together with the granule cells in layer 2, help control the movement of motor neurons. Layers 4, 5, and 6 compose one-third of the cortex. Layer 4 is called the pyramidal layer, because the majority of neuronal bodies of this layer are pyramid-shaped. Pyramidal cells in layer 4 tend to cluster closer together than cells in the other layers. Cells of the deep cortex in layer 5 and layer 6 are also pyramidal cells, but these are larger and more mature than those in layer 4. The final 5-layer of cortex in the brain is the superficial cortex.",
        "label": 0
    },
    "1108": {
        "output": "[CODE]\n#!/bin/bash -c 'echo \"Hello, Good afternoon. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the [INST] Inclusion criteria of a clinical trial to determine the patient's eligibility.\"'\n#!/bin/bash -c 'echo \"A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty foods. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The largest stone is 14mm. \"'.\n#!/bin/bash -c 'echo \"The assessment of the final clinical trial trial level eligibility is\"'.\n#!/bin/bash -c 'echo \" \"'.\n#!/bin/bash -c '<EMAIL>@<EMAIL> <EMAIL>@<EMAIL>'.\n\n#!/bin/bash -c 'echo  <EMAIL>@<EMAIL> <EMAIL>@<EMAIL>'.\n\n#!/bin/bash -c ''</code>'\n\n\n[CODE]\n\" \n<EMAIL>@<EMAIL> <EMAIL>@<EMAIL>\n</CODE> [END STRIP] <EMAIL>@<EMA",
        "label": 0
    },
    "1109": {
        "output": "<EOD> Tuberculous perforation of the ileum\n\nSUPPLEMENTARY MATERIAL\n2021SUPPLEMENTARY MATERIAL\nJGH Open 5\n61112021Submission Decision: Accepted by Daniel Pua, Associate Editor, July 16, 2020, Editor-in-Chief: Michael Bennedetti\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any Med-Ref platform \u00a9 Med-Media Group Sdn Bhd. All rights reserved.A B\nJGH Open: An open access journal of gastroenterology and hepatology 5 (2021) 112-113 SUPPLEMENTARY MATERIAL Figure A. Computed tomography scan of abdomen showing dilated ascending colon with surrounding inflamed fat stranding (A) and a perforation in the mid-ileum (B).<EOD> Effects of acute and sub-acute exposure to nicotine on cognitive functions in healthy rats\nThe present study evaluated the effects of acute and sub-acute administration of nicotine on cognitive functions in healthy rats, with the focus on the effects of dosage and duration of nicotine administration. In the training phase, rats were trained to find a visible platform by searching for a hole hidden in a wall of a tank. After 5 days of training, the effects of acute and sub-acute administration of 0.0025, 0.01, 0.04, 0.08, 0.16 or 0.32 mg/kg of nicotine dissolved in distilled water (n = 7 per group) were evaluated by measuring the time that the rats took to find the platform after injection of substance. The results showed that the time taken by rats to find the platform was significantly different (P < 0.05) from day to day but did not significantly differ among groups. In the test phase, the effects of 0.1 mg/kg of nicot",
        "label": 0
    },
    "1110": {
        "output": "## 23.2.4.1.13 Expected Value Distribution Plot\n\n__What is the expected value distribution when we sample from the patient note data?__\n\nBefore plotting the distribution, let's load the `R` package of `exvalue`, which plots the `expected value` distribution. \n\nWe can also plot the expected value of a certain cell in any dataset by applying the `plot_expected_value_distribution()` function of `exvalue`.\n\nHere is an example: \n\nWe should plot the expected value distribution for the 200 cells, e.g., \n\n``plot_expected_value_distribution(test_set = test_set, \n                                     dataset = pd.DataFrame({\"cell_id\" : df_1.keys(), \n                                                        \"cell_label\" : df_1.columns, \n                                                        \"expected_value\": test_set.index.values\n                                                        })\n                                     )`` [#no ]\n   ```[R] exvalue [184]: \n    plot_expected_value_distribution(test_set = test_set, \n                                   dataset = pd.DataFrame({\"cell_id\" : df_1.keys(), \n                                                          \"cell_label\" : df_1.columns, \n                                                          \"expected_value\": test_set.index.values\n                                                          }), \n                                   plottitle = \"Expected value distribution\",\n                                   ax = ax_f, \n                                   showtext = True, \n                                   showborder = True, \n                                   xaxislabel = \"Cell index\",\n                                   ylabel = \"$ \\lambda $\", \n                                   xlabel = \"$ \\lambda $\", \n                                   xmax = len(df_1.loc[\"All 100\"][\"Label\"])\n                                  [/1#no ]\n   \n    >>> ax_c.legend(loc =\"best\") [#no ]\n   \n    >>> ax_c.legend(bbox_to_anchor=(0.3,1.0), loc = \"best\")\n    [/2#no ]\n    \n    >>> ax_",
        "label": 0
    },
    "1111": {
        "output": "## Section 2: Evaluation of Inclusion Criteria {section2}\n\nAs you know, the clinical trial is designed to test whether a particular treatment works. In other words, we want to know if some patients get better or how many patients are getting better after the treatment. \nThe clinical trial may have the following three outcomes: \n1) Patients whose condition improved over time (Complete response)\n2) Patients for whom their condition stabilized (Partial response)\n3) Patients whose condition deteriorated (Progression)\nThe assessment of the treatment response (i.e., the treatment outcome) has a three-point scale: 0) Improvement (Condition improved); 1) Stable (Condition did not change); and 2) Deterioration (Condition deteriorated). \nAs you may know, the clinical trial recruits patients with the expectation that the treatment will work in patients. To evaluate the expected effects, we want to analyze patients that were expected to get benefit from the treatment. In other words, eligible patients are the patients who are expected to benefit from the treatment; and ineligible patients are the patients who are not expected to benefit from the treatment (because they are not eligible). To evaluate the expected effects, we want to analyze patients that were expected to get benefit from the treatment. In other words, eligible patients are the patients who are expected to benefit from the treatment; and ineligible patients are the patients who are not expected to benefit from the treatment (because they are not eligible). \n\nThe clinical trial may assess the eligibility by the eligibility-for-benefit analysis. For this clinical trial, we have no information about the patient's response. \nAs you know, a 3-by-3 contingency table is constructed based on binary variable. A 3-by-3 contingency table can easily be used to calculate the chi-square test of goodness of fit. [INST] 3x3 contingency table can be used to calculate chi-square test. In a 3x3 table, there are nine total possible values, given in the following table. \nBased on the table above, we can compute the chi-square values as described in the [RM], using the following code.",
        "label": 0
    },
    "1112": {
        "output": "# Data Visualization\nVisualizing data allows you to quickly draw relevant conclusions from complex datasets. Data visualization is a way of creating visual",
        "label": 0
    },
    "1113": {
        "output": "<EOD> Effect of a High Protein diet on glycaemic and metabolic control in Type\u00a01 diabetes mellitus: a three\u2010way crossover randomized study\nAim: The purpose of this study was to assess the effect of a high\u2010protein diet (HP) on glycaemic and metabolic control in type 1 diabetes mellitus (T1DM).<EOD> A randomized controlled clinical trial to measure the impact of group psychotherapy on the mental health of Chinese female breast cancer patients with metastasis\n\nPurpose: The aim of this study is to assess the effect and feasibility of group psychotherapy in hospitalized Chinese female breast cancer patients with metastasis (BPMs). Patient and methods: In this randomized controlled clinical trial, 118 BPMs with metastasis were recruited from the hospital in China. The patients were randomly assigned to two matched groups: psychotherapy group (32 individuals) or control group (32 individuals). Patients in the psychotherapy group received 12 weeks of intervention, whereas those in the control group received routine treatment. The interventions were conducted by psychotherapists who were blind to patients. Data on psychosocial status were collected before and after the intervention. Data analysis was performed using SPSS19.0. Results: Data analyses revealed significant differences in depression (p = 0.014) and fatigue (p = 0.033) between the two groups at T4 after intervention, but not at T2, T3 or T5. In addition, differences in anxiety, stress, emotional well-being, quality of life, psychological adaptation and pain were nonsignificant.Conclusion:These findings suggest that group psychotherapy is beneficial to female BPMs in controlling their depression and fatigue.\n\n# Introduction\nBreast cancer is common among women worldwide.In 2018, breast cancer alone accounted for 30% of all cancers among women.The prevalence of breast cancer has been increasing in East Asian countries, including China, according to an estimation by GLOBOCAN 2018. In China, breast cancer is the most common cancer among women, accounting for",
        "label": 0
    },
    "1114": {
        "output": "[/HIDE]\n\n## 53 Task 4.2: Finding the most eligible patient\n\nNow you can compute your ranking for each patient. The clinical trial investigators find the most eligible patient with a high priority for their trial.\n\n[MARKDOWN][INST] The most eligible patient is a patient with a high rank of trial-level eligibility. \nYou must use the function `findMostEligiblePatients` of the package `clinicalTrial`. The function calls the algorithm you will find in the source code on the Github repository. \nThe function takes the name of a clinical trial and returns a dataframe `findMostEligiblePatients_DF` with the patients' characteristics according to the clinical trial's eligibility, one column for each variable. Here as an example is the name of the clinical trial: `trial_name = trial`.\n\nFind most eligible patients by the clinical trial name.\n<div class=\"execute_command\" data-run=\"trial_findMostEligiblePatients\">\n<button type=\"button\" class=\"btn btn-light btn-sm\" onclick=\"window.__staticText__.$trial = 'trial';\nwindow.__sessionText$ = JSON.stringify(window.__sandbox$$);\nwindow.__sessionText$ = JSON.parse(window.__sessionText$);\">Find most eligible patients</button>\n</div>\n\nThe output of the function `findMostEligiblePatients_DF` is a dataframe `table`, where every column has the patient's corresponding value. As an example, for the clinical trial we chose `Trial 242`, and the output is in the table below:\n\nTable: `findMostEligiblePa-tients_DF` of the clinical trial numbered `Trial 242`.\n<pre><code>>>\n               id    <NAME>   age    age2  sex     sex2   race   race2  ethnicity ethnicity2 birth_date birth_date2  BMI  ht      bmi_category weight  height  weight2  bmi_2_cat  smoker   lifestyle lifestyle2  zipcode\n    1",
        "label": 0
    },
    "1115": {
        "output": "[TRIAL] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.Here is the clinical trial: \nTitle: Scribes",
        "label": 2
    },
    "1116": {
        "output": "## The third data entry\n[START]\nThe third data entry is the second part of the assessment for eligibility. Each part of the second part of the assessment for eligibility is a column, and your job is to check the data in the assessment of eligibility. \n[/START]\n\n#### 1. Assessment of Eligibility : A, S, E, F, T, C, I, G, and R\n\nHere are the definitions of the variables:\n- 0) Eligible: all the values are 1 except for an observation record that had to be excluded and has values of 0.\n- 1) Not relevant: at least one value is 0.\n- 2) Excluded: at least one value is 1.\n\nHere are the three assessments for `pat1` in Table 4-4.\n \n| Eligibility | A | S | E | F | T | C | I | G | R |\n|--------|---|---|---|---|---|---|---|---|---|---|---|\n| 1+0+2+1+1+0+0+1+1+0+1 | -0+0+2+2+0+0+2+2+0   \n| :++++                     :   \n| :+++               :      :   \n| :---+              :      :   \n| :+      :   :   :       :   \n| :       :    :       :     :   \n| :        :     :          :   \n| :         :      :        :   \n| :          :       :      :   \n|                                3+0    \n\nNow, let's make a logical expression about the assessment of eligibility. \npat1_eval_asschg1 = (eligibility == \"2+0+0+0+1+1+0+0+1+2+2+1\") && (0<=pat1_eval_asschg1 < 10)\n\nFor the first patient of this experiment, the eligibility is set to be 1 and the remaining criteria are 2. The logical expression pat1_eval_asschg1 is created for checking the assessment of",
        "label": 0
    },
    "1117": {
        "output": "<EOD> Tetraethylammonium hydroxide: the proton form of the ion pair formed by tetraethylammonium and bromide.\nA proton in a complex formed by tetraethylammonium (TEA) and bromide (Br) was successfully localized by (1)H NMR spectroscopy. Because the (1)H NMR shift of TEA is sensitive to the hydrogen-bonding environments of its N(+)-H group, the chemical shift was measured in the 200 MHz (1)H and (2)H spectra of TEA/Br solution to identify the localization site. The NMR shift of the N(+)-H group of TEA in TEA/Br solution (1/1 molar ratio) is nearly unchanged by the addition of HBr, indicating that the N(+)-H group is not the hydrogen-bonded donor but is the hydrogen-bonded acceptor of the bromide anion. Therefore, the ion pair formed by TEA and Br in the solution and the neutral ammonium cation can be distinguished. The present results clearly demonstrate that the localization site by NMR spectroscopy is a strong evidence to determine the proton form of the ion pair in the solutions.<EOD> Mucosal healing and serum gastrin in patients with duodenogastric reflux\n\n\n\n# Introduction\nDuodenogastric reflux (DGR) leads to transient lumen obstruction, mucosal inflammation and atrophy. The aim of this study is to evaluate gastric and antral mucosal inflammation, atrophy and mucosal blood flow by using video capsule endoscopy (VCE) in patients with DGR. A further aim is to evaluate the relation between gastric mucosal blood flow and gastric serum gastrin, since serum gastrin was found to decrease with reflux of duodenal contents into the stomach and was postulated to be a reliable marker in clinical practice [bib_ref]  Effect of duodenogastric reflux on gastric mucosa, Shafir [/bib_ref]  [bib_ref]  Duodenogastric reflux: influence on gastric acid",
        "label": 0
    },
    "1118": {
        "output": "[fig]  [RINC]: [INST] [/fig] \n[fig]  [END]: [INST] [/formula] \n<EOD> A critical appraisal of psychosocial interventions for persons with AIDS and their significant others.\nTen randomized clinical trials that tested the effectiveness of psychosocial interventions that benefited persons with AIDS and their significant others are examined. Interventions assessed were: (1) a training seminar that taught the primary care nurse management of the psychosocial effects on the patient and the spouse; (2) a training workshop for professional staff in care of the patient with AIDS; (3) a workshop about AIDS for medical and nursing practitioners; (4) a structured group for patients receiving antibiotic drugs; (5) a training program for psychiatrists on treatment recommendations for AIDS-related depression; (6) a support group for gay individuals with AIDS and for their lovers; (7) a support group for gay men with AIDS and for close others; (8) short-term individual psychotherapy; (9) individual nursing telephone contact within 24 hours of a physician's visit; and (10) a combined medical and nursing intervention approach. The effects of the interventions on patients, their caregivers, and the clinical outcomes of patients with AIDS were assessed. The intervention approaches were generally effective in improving psychosocial outcomes, including quality of life and perceived social support, but the combined intervention had the greatest effect on improving care. This review of AIDS intervention research shows that, although few of the studies are definitive, they each have useful methodological strength.<EOD> Anatomical considerations for implant removal of bone anchored hearing systems\nAbstract Bone anchored hearing aids (BAHAs) have become widely accepted in the treatment of conductive and mixed hearing loss in the pediatric population. One of the few serious complications is the failure of the osseointegrated implant to retain a functional BAHA prosthesis (Baha\u00ae, Ponto\u00ae, BCD\u00ae), necessitating removal. The rate of implant removal due to implant dysfunction was relatively low compared to the rate of",
        "label": 0
    },
    "1119": {
        "output": "This code snippet will produce following answer: \n- `trial=0.1` (2) patient is eligible for the trial because the patient meets inclusion criteria. However, the patient was also excluded by the trial",
        "label": 0
    },
    "1120": {
        "output": "- 10_12_2019_POL_10_15_19_26_A_C_Eligible_498028_V01.pdf\n- 10_14_2019_HEL_10_16_19_29_A_B_Eligible_497562_V01.pdf\n\n\n## Exclusion criteria\n\nExclusion criteria should be listed below. \n- Prenatal examinations are generally considered routine, preventative care, and are usually free to the patient, with the exception of a small fee from the lab for the procedure and the cost of the specimen.\n- The use of the phrase 'routine antenatal examination', if included in the exclusion criteria, may limit the sample to women who are not receiving prenatal care and to those without a registered provider.\n- It is assumed that women, who are pregnant and have access to antenatal providers, would have had at least one prenatal visit.\n- Many prenatal laboratories require women to begin prenatal care during the first trimester in order to have the opportunity to receive preconception care.\n- It is well known that many pregnant women, who do not begin prenatal care during the first trimester, receive care in the second trimester.\n- Since routine testing during the first trimester has not been adopted by health care providers or pregnant women, the phrase in this list is unnecessary, and by eliminating this phrase, the sample size may be increased.\n- 'Prenatal screening tests will be collected between 15-19 weeks of gestation to be eligible for the study'\n- 'Prenatal screening in the first trimester will be collected before 13 weeks of gestation to be eligible for the study'\n- Pregnancy (women are included in the sample of this study, even if they reported having had a negative pregnancy test in the year prior to the study due to the fact that the word \"negative\" was not tested),\n- Non-pregnant (women are not included in the sample of this study, if the woman reported having had a positive pregnancy test within the year prior to the",
        "label": 0
    },
    "1121": {
        "output": "<EOD> .\nThere were examined 87 workers with occupational pulmonary disease and 25 of them were found to be occupational allergic lung. Occupational allergic lung manifests at first as eased and gradually increased respiratory discomfort and productive cough. The patients were exposed to some dusts of chemical agents, as a result of which appeared eased respiratory discomfort and then productive cough. The workers had exposer to 1 in 2-year time to chemical agents for more than 1 in 15 years time.<EOD> The Rate of Increase of Birth Weight and Height in Low- and Very Low-Birth-Weight Infants from Hospital Delivery to 36 Postconceptional Weeks: A Population-Based Cohort Study\nThe goals of this study were to explore the growth rates of infants with low and very low birth weights from birth to 36 postconceptional weeks and to quantify the contributions of gestational age and birth weight to this growth pattern. Data were retrieved from the perinatal database of St. Joseph Mercy Hospital, Oakland County, Michigan, for newborns between January 2\u201315, 2001. Infants with low (501\u20131499 g; n = 78) and very low (<500 g; n = 18) birth weight were included (\u201cLBWIN\u201d). Those with normal birth weights (2500\u20134000 g; n = 423) served as controls (\u201cNBWIN\u201d). Mean birth weights were 1544 \u00b1 498 g, 1372 \u00b1 487g , 3168 \u00b1 168 g, and 2879 \u00b1 154 g for LBWIN, NBWIN, NBWF, and NBWFR (<4000 g and >38 wk gestational age), respectively. The mean gestational age increased significantly through 36 wk in each group (P<.05). NBWFR demonstrated the greatest increase (40), followed by LBWIN (31), NBWF (21), and NBWIN (17). LB",
        "label": 0
    },
    "1122": {
        "output": "## # The pop-up window with a new document in the edit mode\nA new document window will pop up for you, this time, in the edit mode. In the pop-up window you will see four columns. Title: `File Name: Template` appears in the first column. `File Name: Template` should not be changed, unless of course you want to change the name of the project template. Type: If you want to edit the existing file, you can choose it by clicking the arrow symbol in the menu at the top of the window. Click File in the menu and choose New, if you want to add a new file, choose File in the menu and choose New Document, on the main window.\n\n## How to Save/Save as\nClick the File button in the Edit Mode window. The Save menu and File menu appear if you select a menu option from these menus. Click Save in the Save menu and Save As in the File menu. A pop-up window will appear, as shown in [fig_ref]  Figure D: Note: [/fig_ref] .\n[",
        "label": 0
    },
    "1123": {
        "output": "#### Examples\n\n```bash\n$ python clinical_trial_assistant.py\nPatient note:\n```\n\n```json\n{\n  \"Id\": 1,\n  \"PatientId\": 1,\n  \"Age\": 65,\n  \"Female\": false,\n  \"Race\": [\n    [\n      \"White\"\n    ]\n  ],\n  \"Creatinine\": 0.7,\n  \"Phosphate\": 2.0,\n  \"Ca\": 8.8,\n  \"PTH\": 30.0,\n  \"Hgb\": 11.1,\n  \"WBC\": 4.5,\n  \"Platelets\": 153,\n  \"ANC-Cells\": 1.6,\n  \"Lymph Cells\": 1.3,\n  \"Pro B Cells\": 0.304,\n  \"Pro Cells\": 0.144,\n  \"Myeloid Cells\": 0.35,\n  \"Eosinophils\": 0.0506,\n  \"Basophils\": 0.00089,\n  \"Other Cells\": 0.006,\n  \"BUN-Cr\": 14,\n  \"Aspartate Aminotransaminase\": 363,\n  \"Alanine Aminotransaminase\": 448,\n  \"Sodium\": 137,\n  \"Calcium\": 8.6,\n  \"K\": 4.45,\n  \"Chloride\": 107,\n  \"Carbon Dioxide\": 23,\n  \"Bicarbonate\": 21,\n  \"Iron\": 60,\n  \"Total Protein\": 6.28,\n  \"Albumin\": 3.63,\n  \"Urea Nitrogen\": 21,\n  \"Creatinine\": 0.6,\n  \"Calcium (mg%)\": \"10.2269\",\n  \"Calcium (mg/dL)\": 1",
        "label": 0
    },
    "1124": {
        "output": "1 12\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 75-year-old woman presented to the emergency department with progressive abdominal distention, an unintentional 20-pound weight loss, and diffuse abdominal tenderness to palpation. The patient was well prior to 2 weeks prior to this presentation when she presented with a syncopal episode and was found to be hypoglycemic. At that time, she was administered 50 mL 50% dextrose after which she felt better. The patient's medical history is remarkable for coronary artery disease and cerebrovascular accident for which she had a left carotid endarterectomy. She also reports a history of an inguinal hernia 20 years ago that required appendectomy due to acute appendicitis. She is widowed and has 1 child. She does not smoke, drink alcohol, or use illicit drugs. She has no known allergies and is allergic to aspirin. Her BP was 117/62, HR 75, RR 20, BT 97.2, SpO2 97% on RA. The patient is an elderly female who complains of diffuse abdominal dist",
        "label": 0
    },
    "1125": {
        "output": "<EOD> The Impact of Interruptions, Noise, and Social Deprivation on Affect and Performance of Nurses in ICU\nBACKGROUND: Interruptions, high noise levels, and inadequate privacy/social deprivation (ie, social isolation) are common and distressing workplace stressors that can affect nurse staff outcomes, including stress, concentration, and alertness, and may compromise patient care and safety. OBJECTIVE: To improve the workplace by reducing these effects on intensive care unit (ICU) nurses. METHODS: A quasi-experimental intervention study was conducted to evaluate the effects of 4 interventions. Measures taken include the Perceived Stress Scale-14 (PSS), the Hospital Anxiety and Depression Scale (HADS), and the State Anxiety subscale of the Spielberger State-Trait Anxiety Inventory (STAI-S). RESULTS: Ninety-one nurses were included, of whom 50 participated in both the baseline and the postintervention survey (n = 22 baseline/n = 22 intervention; n = 26 baseline/n = 28 intervention). Statistically significant differences were observed in some of the variables under evaluation before and after the completion of the interventions. The results showed that nurses who participated in an intervention programme to reduce stress presented lower depression scores (HADs) and a lower score for state-anxiety (STAI-S). CONCLUSIONS: Improvements in our working environment would support improved quality of patient care, better staff outcomes, and greater job satisfaction. Stress management programmes can enhance stress resilience, reduce mental and physical health problems, promote well-being, improve performance, and provide better patient care.<EOD> A Novel Sensor Platform for Real-Time Determination of Bacterial Contamination in Wounds\nABSTRACT Microbial contamination is among the key barriers for a successful wound healing. Yet so far, real-time determination of bacterial load in wounds remains a dream. We demonstrate the use of a novel sensor platform (Ti3-SRG) based on the selective accumulation of gold nanodots in",
        "label": 2
    },
    "1126": {
        "output": "The output should be similar to the following sample, i.e., \nTrial-level eligibility: 2) Eligible.\n<EOD> Evaluation of an early mobilization strategy after uncomplicated cardiac surgery - a prospective, observational study.\nOBJECTIVES\nIntensive care unit (ICU) physical restraint limits a patient's potential for early mobilization after uncomplicated cardiac surgery. This study aimed to examine the feasibility of a mobilization pathway aimed at early mobilization and to describe mobilization strategies used and physiological responses during mobilization.\n\n\nDESIGN\nA prospective, observational study of consecutive patients who met mobilization criteria from a single ICU.\n\n\nMETHODS\nData were collected on patient demographics, mobilization timing, strategies, and physiological responses. Descriptive statistics are reported as raw data are normal distributed.\n\n\nRESULTS\nOver the study period, 165 patients were included. Intravenous fluids were removed in 152 (91.6%), and 127 patients (76.9%) were mobilized. Median time for mobilization initiation was 0.5 (IQR 0.3-3) day post-operatively. ICU team and therapist were the most frequently cited facilitator and barrier to mobilization, respectively. Fifty-five (43.0%) patients experienced an event of hypotension and tachycardia during mobilization.\n\n\nCONCLUSION\nICU team and therapist facilitate and barriers contribute to early mobilization after major cardiac surgery. Mobilization strategies were based on cardiorespiratory parameters and were undertaken by a multidisciplinary team. Further investigations are needed to clarify the predictors of safe mobilization.<EOD> The Effects of Flap Prep and Injectable Hyaluronan (Juv\u00e9derm) on Implant Stability Using the Periotest Method\n&NA; Although immediate implant placement is a viable technique, the use of such procedures is dependent on a number of variables, each of which may have a negative effect on osteointegration and subsequent implant placement. This study was designed to examine whether flap raising",
        "label": 0
    },
    "1127": {
        "output": "## 11.1  Clinical Trials -Participating in a Clinical Trial\nLearning Objectives\n\n\n- 1. Learn what is a clinical trial.\n\n- 2. Know the definition of eligible, ineligible and never participated in a clinical trial.\n \n\nClinical Trial is research that uses human volunteers. Clinical trials test new interventions such as drugs, medical devices, and procedures for treating disease or injury. Researchers believe the tested intervention will provide benefits, harm, or no significant differences across the different treatment groups.\n\n[\n\n\n\nThe definition comes from NCI dictionary. [NCI Dictionary]\n\nA. Definitely Not Eligible for Clinical Trial: This patient does not meet the inclusion criteria or meets an exclusion criterion.\n\nSome patients do not meet the inclusion criteria; some patients could not meet them because they did not have enough information available to do so.\nA few patients meet an exclusion criterion. A few patients meet exclusion criterion because of an unwished characteristic that makes this patient less likely to profit from the tested intervention. For example, if a particular drug was tested on elderly patients, then this patient could be too young to be eligible to participate.\nOther patients were never invited in a trial.\n\nB. Probably Not Eligible for Clinical Trial: This patient has lessened or conflicting information about the medical history compared with what the trial requires.\n\nSome patient has lessened information about the medical history (e.g., there is no history about drug dosage, type, drug allergies) compared with what the trial requires.\nOne patient has conflicting information with a medical history (e.g. a patient is diagnosed with a particular disease on one occasion and then the doctor changed the diagnosis, so the patient was told something different).\nSome patients do not have information about the previous or current treatment history (e.g., a patient was given a drug 10 years ago, do we know if it was taken according to the instructions, if other drugs were taken, did this drug continue to be used during the time, is the patient willing to adhere to the medication or will the patient buy the drug on the dark market?).\nPatient has",
        "label": 0
    },
    "1128": {
        "output": "IMPORTANT - We use the \"dollar symbol ` and the word-by-word \"command \"` in the following instructions. \n\n\n\n\n\n\n```latex\n1}\n\n\n@manual{ \n@manual{ \n@chapter{Instructions for use}\n    @section{First we use to insert a `Text Box`}\n    @label{Insert a `Text Box`}\n\n    Text Box:\n    `Text Box:`\n\n    \\begin{adjustbox}{just so=bottom center,width=10cm}\n    \\noindent\\makebox[1em][l]{<NAME>}\\\\\n    <EMAIL> \\\\\n    \\begin{verbatim}\n    I am a helpful assistant for the clinical trial recruitment. \n    \\end{verbatim}\n    \\end{adjustbox}\n\n\n    \\label{TextBox_1}\n    @endlabel\n\n    @section{Insert a `List'}\n    @label{Insert a `List`} \n\n    `List:`\n\n    \\begin{adjustbox}{just so=bottom center,width=12cm}\n  \\noindent\\makebox[1em][l]{<NAME>}\\\\\n  <EMAIL> \\\\\n\n    \\begin{verbatim}\n    I am a helpful assistant for the clinical trial recruitment.\n    \\end{verbatim}\n\n    \\end{adjustbox}\n\n    \\label{List_2}\n    @endlabel\n\n    @section{Insert a `Boxed` LaTeX environments}\n\n    @label{Insert a `Boxed LaTeX environments`}\n    \n    Boxed LaTeX environments:\n    `Boxed LaTeX environemtns:`\n\n    \\begin{adjustbox}{just so=bottom center,width=12cm}\n    \\noindent\\makebox[1em][l]{<NAME>}\\\\\n    <EMAIL> \\\\\n    \\begin{verbatim}\n    I am a helpful assistant for the clinical trial recruitment.\n    \\end{verbatim}\n        \\end{adjustbox}\n\n    \\label{Boxed_3}\n    @endlabel\n\n    @subsection{Latex",
        "label": 0
    },
    "1129": {
        "output": "# Example output\nPlease follow the following format. `Your report: ` should display your full results from this exercise, e.g., `Your report: \nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm. Your report:` \nTitle: Common Bile Duct Stones - Natural History and Interventions\n\nSummary: The aims of this study were to~investigate what measures were taken when common bile duct stones (CBDS) were found intraoperatively in Sweden during the period May 2005 to December 2009 by using data from this population-based nationwide registry, and~analyze the outcome in terms of complications and success rates of bile duct clearance in relation to various stone sizes and interventions used. In order to further characterize the natural course of CBDS of various sizes, particular interest was focused on patients with positive findings where no peroperative measures to clear the bile ducts were taken or planned postoperatively.\nInclusion criteria: Inclusion Criteria: >common bile duct stones\n\n```python\nYour report:` A 54-year-old obese",
        "label": 0
    },
    "1130": {
        "output": "[\nA B C D E F G H\n]\n\n#####\n\n\n#####\n\n[A]\n\n[/A]\n\n#####\n##### : [Further_instructions](https://github.com/Assignment4You/Python-Udacity-Instructor-Data/blob/main/Code_Review_Data/Python_Udacy_Instructor_Data/Data/First_Case_Udacit/Further_instructions.md)\n\n\n\n\n\n\n[G]\n\n[/G]\n\n#####\n<EOD> Involvement of CXCL11 and CXCR3 with the development of acute pancreatitis in rats\nPreviously we have reported that CXCL11 and CXCR3 are involved in the development of lung injury due to acute pancreatitis. In this study, we evaluated whether CXCL11/CXCR3 may participate in the pancreatic injury of this syndrome. Adult Sprague\u2010Dawley rats were divided into 4 groups: (a) controls, (b) acute pancreatitis induced by 1 hour",
        "label": 0
    },
    "1131": {
        "output": "## Learning from mistakes: [INST:1] Please answer the question on the screen by pressing a number 1.\nPlease answer the question using the keyboard. \n[4] 6) Patients who are breastfeeding should not take the study medication due to theoretical concerns of potential harm to the nursing infant. \n[END]\n\n## [inst:1]\nPlease answer the question on the screen by pressing a number.\nPlease answer the question using the keyboard. \n3) To minimize the risk of teratogenic effects, oral doses are administered in cycles of 7 days on and 7 days off, in a dose escalation manner over a total of 9 cycles. In each cycle, ontreatment evaluations occur on days 1, . The patients who receive no more than one dose of this treatment will not undergo additional cycles and will receive the comparator treatments. \n[END]\n\n## [inst:1] \nPlease answer the question on the screen by pressing a number 1.\nPlease answer the question using the keyboard.<EOD> Effects of different dietary proteins on growth and bone strength in rats with osteoprotegerin deficiency.\nOsteoprotegerin (OPG) is a member of the tumor necrosis factor receptor superfamily and is a specific decoy protein for receptor activator of NF-\u03baB ligand (RANKL). We have previously shown that the activity of OPG is decreased in vivo with senescence and that deficiency of OPG may alter bone quality as well as bone strength in ageing. In the present study, we investigated the effects of various protein sources on bone strength in the presence of OPG deficiency. Weanling OPGAla -/- rats were randomly allocated to one of the following groups: 1) a regular diet (RD) with 10% of casein, 2) RD + 10% of soybean protein isolate (SPI), 3) RD + 10% of fish protein (FP), 4) RD + 10% of lupin protein (LP), and 5) RD + 10% of cow milk protein (MCP). After 2",
        "label": 0
    },
    "1132": {
        "output": "You learned how to assess the eligibility of a patient using trial information. How does this affect your role of a helpful assistant for clinical trial recruitment?\n\n__Note: The task ends here__\n\n## Practice: \n\n### Practice your eligibility assessment.\n\n### 2. Write Your Thoughts and Answers\n\n\n\n\n<EOD> .\nUNLABELLED\nA new method for detection of immunoglobulins E (IgE) antibodies using monoclonal anti IgE has been used.\n\n\nMATERIALS AND METHODS\nFor IgE measurement, three batches of the Enzyme immunoassay (EIA) kit ImmunoCAP Fluorescence, Pharmacia Diagnostic AB (Sweden) was tested. 10.000 patients, including both adults and children underwent a total of 200.000 blood samplings for IgE determination.\n\n\nRESULTS\nOur results are in agreement with the values reported in the literature.\n\n\nCONCLUSIONS\nWe confirm the very good precision, the accuracy for IgE measurement and we think that this method could be a useful screening tool to be used during mass screening. At the moment it is used to analyse IgE on 25 specimens simultaneously by instrument, for about 10,000 Euro per year, the cost for screening of 25,000,000 persons is approximately 60, 000 Euro. Considering the cost for EAI assay of 2 Euro per test, the total cost for screening of 25,000,000 persons at high risk to develop allergic diseases, is approximately 12.000 Euro per year. The cost for serum IgE determination is about 10 Euro per sample, that is approximately 22,000 Euro per year.<EOD> 1790P Phase I Dose-escalation Study of Bevacizumab Plus Gemcitabine-based Chemotherapy and Radiotherapy as a Multimodality Treatment for Locally advanced Non-metastatic Esophagogastric Adenoc",
        "label": 0
    },
    "1133": {
        "output": "[INST] Let's go! Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese women with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm. \nHere is the clinical trial:",
        "label": 0
    },
    "1134": {
        "output": "### Rules:\n1. Your code will be evaluated only if the output of the last line is exactly the same (see `Rules` page at http://github.com/YuryG/Prizes/blob/master/rules.md)\n2. Your task is to provide your solution in JSON format. \nYou should use the same syntax as [in GitHub](https://github.com/YuryG/Prizes/blob/master/contests/instructions-and-templates/pat_elig.json) (see the sample output below):\n- `data` must be a JSON array containing the objects of your choice.\n- The keys of each object must be the following field names in the input data: `Subject`, `Sex`, `Age`, `Adm1`, `Adm2`, `Adm3`, `Smok`, `Drink`, `CancerType`.\n- Each object should also have the following fields as keys: `Eligible`, `NotEligible`, `Relevant`, `Excluded`.\n- Each object should also have a field called `Score` having the value of 1, 2, or 3, corresponding to the Trial-level eligibility described above. \n- `Score` may be absent.\n- Each object may or may not have fields having keys `Subject`, `Sex`, `Age`, `Admissions`, `Smoking`, `Drinking `, and `Disease`\n- If an object has the field `age`, then you have to provide the patient's age in years, otherwise, your solution will be scored as `False`\n- You may provide more than one object in `data`, but the number of objects you provide should match the number of objects in the input data.\n- All objects should have the following keys:\n    - `Subject`: your solution code\n    - `Age`: the age of the patient in years\n    - `Eligible` (optional): either \"0\" (\"Excluded\") or \"1\" (\"Not Relevant\") or \"2\" (\"Eligible\")\n    - `NotElilgible` (optional): either \"0\" (\"Excluded\") or \"1\" (\"Not Relevant\") or \"2\" (\"Eligible\")\n    - `Relevant` (optional): either \"0\" (\"",
        "label": 0
    },
    "1135": {
        "output": "## Summary\nThis case study presents an example of a trial-level assessment of eligibility.\nIt is essential that participants in a randomized controlled trial meet the inclusion criteria to the extent possible. It is important that, whenever possible, the information on eligibility criteria is recorded on the patients' notes. This will help recruitment teams to understand whether the patient may be eligible for the study. Furthermore, if a patient is eligible for a study, then they should be offered to participate. If they decide not to join the study, they must not be subject to an ethical breach. If the patient is enrolled in the trial, it is important that they continue receiving medical care from the same physicians who assessed their eligibility and ensured care continuity without any breaches in the consent process. This should also facilitate the continuity of treatment and care of the patients in these trials.<EOD> Identification of a new gene encoding a lysophosphatidic acid acyltransferase induced after injury\nLysophosphatidic acid acyltransferase (LPAT) catalyzes the conversion of lysophosphatidic acid (LPA) into phosphatidic acid (PA). To date, only one LPAT has been cloned and shown to be highly expressed in mammalian liver. We report the purification and partial sequencing of rat liver LPAT. This is the first LPAT that is shown to respond to organ injury. Its expression increased \u224850\u2010fold in fatty livers induced by either ethanol feeding or bile duct ligation and returned to normal levels within four to eight weeks. The gene was isolated and shown to have 17 exons and span 2.8 kilobases. Northern analysis indicated that the gene is expressed in multiple tissues with the highest level of expression in adipose tissue. Analysis of 5\u2032 promoter region showed the presence of binding sites for hepatocyte nuclear factors and nuclear respiratory factors.<EOD> Concurrent infection with multiple human papillomavirus genotype in cervix cancer: an important clinical concern\n\nBackground: Concurrent infection of multiple human papillomavirus (HPV) genotypes in cervix cancer patients has been confirmed by many studies, which indicated a greater risk for",
        "label": 0
    },
    "1136": {
        "output": "## The test data of the clinical trial are as follows:\nTo understand the meaning of variables we can use the `?`\nWe can use the `isCriteria` function of the package to confirm if the condition is in compliance with the criteria.\nA simple criterion is the age criteria.\n\nWhat does the criteria (37-60 years) means? `? criteria`?\n\n\n<EOD> Development of a Novel Strain of C. elegans to Study Glia Development, Reproduction, and Neurotoxicity\nC. elegans has many advantages for use as a preclinical model to study neurodegenerative diseases, including the ability to perform phenotype and imaging in live animals. However, it is essential to control potential cytotoxicity from fluorescent labels to enable imaging of mitochondria. Our lab has shown that GFP fluorescence can be toxic to adult worms. In the current study, we took into consideration this prior observation and developed two methods to control this cytotoxicity. First, we established that mitochondria can be labeled with GFP while avoiding toxicity by targeting the GFP solely to the ER, which resides within the mitochondria. In addition, we developed a new non-toxic GFP-tagged C. elegans strain by introducing a mitochondrial localized non-GFP strain as a background control and selecting the non-toxic GFP-labeled strain. This strain is then introduced as a negative control into studies employing C. elegans to test the efficacy of novel drugs or study diseases in which glia are involved.<EOD> .\nA method for the determination of the total chromium content in foodstuffs samples by neutron activation was developed. The method is based on the neutron bombardment of a sample by a neutron flow for a short period of time (in the present work, from 0.25 to 20 min depending on the activity of the sample) to trigger the nuclear fission reaction of the target (sample), then the released nuclides are measured by alpha and gamma spectrometers. This method is a good compromise between the direct method and the preconcentration method because of its relative high sensitivity (detection limit of",
        "label": 0
    },
    "1137": {
        "output": "> Ticket: [INST] C1722506 -[ ] \n> :0|:\n\n# Author(s)\n\n> Ticket: Ticket -Author for tutorial(s) (name and initials): \n> : Ticket -Authorship -Institution: :Ticket -Authorship -Instructions: :Ticket -Authorship -Eligibility: :Ticket -Authorship -Provenance: \n> Ticket -Authorship -Funding source and grant no:\n\n# Previous versions\n\nThis document is a derivative of the original documentation written by [Author 1 and Author 2](https://osf.io/yhv9q/)\n\n### Previous versions\n\n---\n\n### 2022-04\n\nSee 2022-03\n\n---\n\n### 2022-03\n\n- [x] The author(s) were contacted and are willing to update the copy and to provide their [provenance](https://osf.io/yhv9q/, 4th version)\n- [x] The document complies with the author(s)' provenance-related instructions\n- [x] The document complies with the COMPASS instructions\n- [x] The document is made available under a [Creative Commons Zero\u2014No Rights Reserved\u2014Universal](https://creativecommons.org/publicdomain/zero/1.0/) Public Domain Dedication waiver.\n\n### 2022-02\n\nSee 2022-01\n\nCited text from a [previous version](https://osf.io/8f97p/) of this document by [Author 1 and Author 2](https://osf.io/yhv9q/, 3rd version) on 02-06-2022. [Author 1](https://osf.io/jv53q/) added the last item.\n\n---\n\n### 2022-01\n\nSee 2020-12\n\n---\n\n### 2022-01\n\nThis manuscript provides training materials for COMPASS tutors on how",
        "label": 0
    },
    "1138": {
        "output": "# Example outputs\nIf the patient note and clinical trial are given above, `cda1250` and `cds1428`, the output is as follows: \n<EOD> The Association between Peripheral White Blood Cell Count and Arterial Stiffness in General Japanese Women: A Cross-sectional Study\n\nThe purpose of this cross-sectional study was to investigate the relationship between peripheral blood white blood cell (WBC) count and arterial stiffness, as assessed by brachial-ankle pulse wave velocity (baPWV), in general Japanese women. The study was conducted on female patients who visited Kakogawa Municipal Hospital or Kakogawa Central Hospital because of unhealthy conditions. The patients' characteristics, including heart rate, body weight, height, and peripheral blood cell counts, were measured using the automatic analyzer, XN5000-C, and the baPWV results were measured using the VP-2000 instrument. Pearson's correlation analysis was performed to examine the relationship between WBC count and clinical parameters. The study population comprised 339 participants, aged 19-93 years, who underwent both peripheral blood and baPWV measurements. There is a significant positive correlation between WBC count and baPWV in women (correlation coefficient = 0.248, p < .001). However, there was no statistically significant relationship between WBC count and baPWV in the subgroups of all participants, as well as different age (years), height (cm), heart rate (bpm), and blood pressure. WBC count is positively correlated with the baPWV value, and can be considered an important index in assessing arterial stiffness in Japanese women.\n\n# Introduction\nAging is an irreversible process that is characterized by physical and physiological deterioration [bib_ref]  Theories of ageing, Vi\u00f1a [/bib_ref] . The arteries are responsible for 70% to 76% of myocardial oxygen consumption [bib_ref]  Myocardial oxygen consumption and coronary vascular resistance during coronary occlusion in dogs, Effler [/bib_ref]  and the blood pressure in the arterial system is mainly maintained",
        "label": 0
    },
    "1139": {
        "output": "**\u2b50 Question 9\u2b50 \u2753\u2753\u2753**\n\n[Tutor: **Alkan**](https://github.com/alkan0803) \n\n### [Write a Bash Shell script to generate a sample data table according to the random column from 1 to 10 and name it as `randomtable.txt`. How would you print the rows 3 and 6 from this table?][inst]\n\n[EXERCISES] \n\n**Step 1:** Write a Bash script to generate a sample data table according to the random column from 1 to 10 and name it as `randomtable.txt` \n\nWrite the script in your terminal, write the echo statement to check whether your code is working properly or not. \n\n**<sup>[[inst]](https://i.imgur.com/Kf0Y8q4.png)</sup>**\n\n> Output of the echo statement \n\n> output of the cat statement \n\n```bash\ncat randomtable.txt\n```  \n>>> Output of the cat statement from randomtable.txt:\n\n```text\n       6\n    20\n    25\n    8\n    3\n    9\n   14\n    3\n   13\n    7\n   16\n   2\n   23\n   25\n   15\n   10\n   22\n   12\n   17\n   19\n   11\n   21\n   25\n```\n\n![]({{site.baseurl}}/assets/images/q2_ans.jpg)\n\n\n\n**Step.1 output** <sup>[[inst]](https://imgur.com/pVWXDGw)</sup>: `22 \n```\necho A1\necho B1\necho C1\necho D1\necho E1\necho F1\necho G1\necho H1\necho I1\necho J1\necho K1\necho L1 `\n```\n\n**\n**\u2753How would you print the rows 3 and 6 from this table?\n**\u2753How would you print the rows 3 and 6 from this table?\n\n---\n\n**Step",
        "label": 0
    },
    "1140": {
        "output": "| [/GLOSSARY] <a href=\"#patients_eligibility\">next definition</a></div>\n\n<span class=\"term\">Eligibility criteria</span>,<br>\n\n<span class=\"definitionText\">set of criteria to identify a population (clinical trial subjects) eligible to receive the experimental treatment or clinical trial protocol.</span><br><br>\n\n<span class=\"definitionText\">an eligibility assessment is a determination of a patient's eligibility for enrollment in a certain trial, usually based on inclusion/exclusion criteria defined in the study protocol.</span>\n\n<span class=\"definitionText\">eligibility criteria are set of criteria to identify a population (clinical trial subjects) eligible to receive the experimental treatment or clinical trial protocol.</span>\n\n<span class=\"term\">Inclusion criteria</span>,\n<br>\n\n<span class=\"definitionText\">criteria to determine if individual patients can be enrolled in a clinical trial, usually based on patients' characteristics, e.g., age and sex. Exclusion Criteria</span>,\n\n<br>\n\n<span class=\"definitionText\">criteria to determine if individual patients cannot be enrolled in a clinical trial, usually based on specific patient characteristics or general exclusion for the trial, e.g., age and gender.</span>\n\n<br>\n\n\n<!-- End of Glossary -->\n\n---\n\n## Avoiding biases before the actual analysis\n\nIn clinical trials, selection biases can negatively impact external valid",
        "label": 2
    },
    "1141": {
        "output": "<EOD> .\nObjective: To explore the value of 99mTc-MDP Ga-68-PSMA PET/CT in diagnosis of extraprostatic recurrence of prostate cancer and treatment guidance. Methods: Thirty six cases of prostate cancer with extraprostatic recurrence were retrospectively analyzed. All the patients underwent 99mTc-MDP bone scan, 99mTc-MDP Ga-68-PSMA PET/CT, 18F-FDG PET/CT. They were divided into 24 cases of bone recurrence group and 12 cases of visceral recurrence group, and the imaging results were compared and analyzed. The maximum standardized uptake value (SUVmax), disease control rate, patient follow-up and treatment evaluation of 68Ga-PSMA PET/CT (Ga-PET/CT) and 18F-FDG PET/CT under different conditions of PSA level were analyzed. SPSS 23.0 statistical software was used for count data with chi-Square test and Mann-Whitney test. The comparison of count data was performed with Kruskal-Wallis H test. Results: Compared with bone scan, PSMA PET had a higher detection rate of extraprostatic lesions. The lesions found by PSMA PET/CT were more than those by bone scan from the lumbar spine, femur, pelvis, sternum, rib, humerus, skull, cervical and other parts (120 vs 93). Ga-PET/CT had a higher positive rate of extraprostatic lesions than bone scan in different PSA levels. In PSMA PET/CT, the SUVmax of patients with PSA level of \u226520 ng/ml, 11.1, 30.9, and 12.2 times of patients with PSA level of <20 ng/ml, 20-49 ng/ml, 50-99 ng/ml, respectively; the patients with PSA levels of \u226520 ng/ml had more positive of visceral lesions. After the diagnosis, patients underwent follow-up for 3 to",
        "label": 0
    },
    "1142": {
        "output": "Your program should have an output with the name Trial-level eligibility and the scale of the eligibility assessment:\n\nOutput: Trial-level eligibility: 2) Eligible\n\n[/OUTPUT] \n\n\n___\n\n\n[!insert_html file=\"1525760705748\"/]\n\t\t  \n<EOD> The effect of a low potassium diet on the metabolism and excretion of renal tubular constituents in the goat. II. The metabolism of purines\n1. The effect of potassium deficiency on the formation and elimination of purine compounds was studied in two groups of adult goats, given a diet containing 0\u00b736 mEq potassium/l of water, and compared with an untreated group.<EOD> Tocotrienols as inhibitors of sterol O-acyltransferase: in silico molecular docking studies\nAbstract Sterol (steroid) O-acyltransferase regulates the last step of steroid biosynthesis in animals as well as the \u03b2-oxidation of acyl-CoAs, which catalyse the esterification of fatty acids. The present study demonstrates the potential of tocotrienols, the vitamin E isomers found in rice bran oil, as inhibitors of human sterol O-acyltransferase type 1. A computational model for human sterol O-acyltransferase type 1 was generated by docking a previously reported 2P2X crystal structure to sterol O-acyltransferase type 1 homology model. Molecular dynamics simulations of sterol O-acyltransferase type 1 homology model were validated both structurally and mechanically. Tocotrienols exhibit comparable binding affinity, predicted binding mode, and interactions with human sterol O-acyltransferase type 1 residues as compared to a known sterol O-acyltransferase type 1 inhibitor, fenpropimorph. These findings provide a scientific platform for developing tocotrienols as inhibitors of sterol O-acyltransferase type 1. Communicated by Ramaswamy H.",
        "label": 0
    },
    "1143": {
        "output": "[/STYLE] [/INTERNAL] <img src= \"https://userstyles.org/link?id=75850\" border=\"0\">\n[STYLE]\n\n###### AUTHOR CONTRIBUTIONS\n\n[/INTERNAL] <img src= \"https://userstyles.org/link?id=75850\" border=\"0\">\n[STYLE]\n\n###### AUTHOR CONTRIBUTIONS\n\n[/INTERNAL] <img src= \"https://userstyles.org/link?id=75850\" border=\"0\">\n[STYLE]\n\n###### AUTHOR CONTRIBUTIONS\n\n[/INTERNAL] <img src= \"https://userstyles.org/link?id=75850\" border=\"0\">\n[STYLE]\n\n###### AUTHOR CONTRIBUTIONS\n\n[/INTERNAL] <img src= \"https://userstyles.org/link?id=75850\" border=\"0\">\n[STYLE]\n\n###### AUTHOR CONTRIBUTIONS\n\n[/INTERNAL] <img src= \"https://userstyles.org/link?id=75850\" border=\"0\">\n[STYLE]\n\n###### AUTHOR CONTRIBUTIONS\n\n[/INTERNAL] <img src= \"https://userstyles.org/link?id=75850\" border=\"0\">\n[STYLE]\n\n###### AUTHOR CONTRIBUTIONS\n\n[/INTERNAL] <img src= \"https://userstyles.org/link?id=75850\" border=\"0\">\n[STYLE]\n\n###### AUTHOR CONTRIBUTIONS\n\n[/INTERNAL] <img src= \"https://userstyles.org/link?id=75850\" border=\"0\">\n[STYLE]\n\n###### AUTHOR CONT",
        "label": 0
    },
    "1144": {
        "output": "## D[DATA]\nWhen the `Trial-elgibility:` clause is done at a specific patient and a trial, call the `data:` [DATA] module to collect the relevant features of that patient.\n\n\t[DATA]\n\tData-type | Explanation\n\t:-|:-\n\t- PatientAge | The patient's age \n\t- Patient-AgeGroup | One of the 6 age groups: 0-5 years, 6-15 years, 16-59 years, 60-86 years, 85-101 years, and >101 years \n\t- PatientSexID | The patient's gender, `Female`, 'Male'. For a patient who has previously been characterized as female, a \"female\" value is passed in that slot, and a \"male\" value is passed in the slot if the subject is known to be male. \n\t- PatientPatronymic | The patient's patronymic name. A patronymic name is the personal name of an individual derived from, or composed of elements associated with, the individual's father or grandfather (or other male ancestor).\n\t- PatientSuffix | 360 suffix\n\t- PatientPatronymicGroup | The patryonymic group of the patient (in the patient's documentation).\n\t- PatientName |\n\t- PatientSurname | The patient's surname and family name (last name). The surname field of the patient table contains a concatenation of this object, separated by \"_\":<NAME_> \n\t- PatientFamilyName | The patient's surname and family name (last name).\n\t- PatientFirstName | The patient' answer to the question \"How would you prefer to be called?\"; a name to identify the patient, or the person he or she is. The first name is the person's name in the first instance (first name); the first given name (given) in the family name (last); the name used in first use (first); the first given name in the family name (last); the first used in first use (first); first name in the family name (last); first given in the family name (last); and last family name or family name.",
        "label": 0
    },
    "1145": {
        "output": "<EOD> The treatment of gastrooesophageal reflux disease after discharge from hospital: comparison of proton pump inhibitors and combined acid-suppressant therapy\nObjective To compare, in a hospital-to-home setting, the clinical effectiveness of continuing esomeprazole for 4 weeks against omeprazole plus ranitidine given over the first 4 days in patients with gastro-oesophageal reflux disease (GERD). Methods One hundred and twenty-four patients (aged over 50 years with endoscopy-proven erosive oesophagitis) were enrolled into this randomised, double-blind, controlled study. Patients were withdrawn from anti-secretory therapy 48 hours before entering the study. All patients received a standardised hospital diet and were discharged on the same standardised diet continued for 28 days. Symptomatic severity was assessed in terms of the score for heartburn and regurgitation, as measured on a 0\u20133 scale and over the previous 24 hours. Results Improvements in both the heartburn and regurgitation scores were found in both groups: at 2 days, the heartburn scores were 0.022\u00b10.41 in the omeprazole/ranitidine group and 0.069\u00b10.41 in the esomeprazole group (p=0.617), and the regurgitation scores were 0.11\u00b10.40 and 0.01\u00b10.26, respectively (p=0.105). Over the full 28 days of follow-up, the scores remained similar, but on the final day, the regurgitation score remained slightly in favour of patients on esomeprazole (0.4\u00b10.56 versus 0.9\u00b10.58; p=0.013). Conclusion Esomeprazole (20 mg p.o. once daily) was shown to be as effective as a short-term combination treatment with omeprazole and ranitidine (omeprazole 40 mg b.d. and ranitidine 150 mg b.d. for 4 days",
        "label": 0
    },
    "1146": {
        "output": "Hello. You are an experienced clinician who regularly follows patients with anemia. A 70-year-old man who is under your care suffers from anemia. Here are the data:\nAge: 70\nGender: Male;\nMeasurement: Hemoglobin = 10.3; Mean corpuscular volume = 106.8; Hematocrit = 31.1; C-reactive protein = 0.3; Ferritin = 1,464\nPlease, find the most appropriate response to the question with the following options. In your answer, you must select the option closest to reality. \n- The patient's anemia is of inflammatory nature.\n\n## - \nThe patient has increased serum C-reactive protein levels, which means that the body is trying to fight off a viral infection.\n\n## - \nThe low hemoglobin level indicates anemic reticulocytosis with microcytosis due to the body trying to increase the size of the reticulocyte cell. This condition is characteristic for lead poisoning.\n\n## - \nThe patient has increased serum C-reactive protein levels, which means that the body is trying to fight off a bacterial infection.\n\n## - \nThe iron deficiency anemia is related to cancer that caused secondary iron defic",
        "label": 0
    },
    "1147": {
        "output": "![img](./images/trial_level_eligibility.png) \n\n## Expectation-maximization\nYou can expect that the patients are assigned to the eligible, not eligible, and not relevant categories with the 0.3, 0.4, and 0.3 probabilities, respectively. To confirm this expectation, a logistic regression analysis is conducted to identify the factors that could influence the assignment to the trial-level eligibility level. The results of the logistic regression model with eligibility as a dependent variable and factors (age, BMI, gender, NVD, Hx of hypercholesterolemia, HR, RR, T, SpO2, smoker, alcohol, obese, abdominal pain, left, upper quadrant pain, nausea, pain 4-days, epigastric pain, pain on admission, BP, TP, ALT, AST, Alk phosphatase, GGT, HDL, TG, gluteal tenderness, bowel sounds unremarkable, fever, thrombocytopenia, leukocytosis, left shift, neutropenia, anemia, Hgb B12 deficiency, hypothy and hyper T, ANC, Hb, AST, ALT, TP, Creatine, BUN, WBC, WBC, WBC, Fever, hyponatremia, hypoxia, and CBD stones size <20 mm as an independent variable) are summarized in Table 2 below. This table shows that the only variable that significantly influences the assignment of eligibility to the patient was the CBD stones size.\n![img](./images/result1.png)\n\n## Table 2. Result summary of logistic regression for trial-level eligibility as the dependent variable shows no significant variable (p-value>0.05) except CBD stones size less than 20 mm (p-value<0.05) as an independent variable is significant as a predictor in logistic regression\nThese findings indicate that the CBD stones size in patients affect their trial-level eligibility status.\n\n## The result of the logistic regression analyses\nYou use the expectation-maximization (EM",
        "label": 0
    },
    "1148": {
        "output": "There are 2 cases:\nExcluded: the number of `0; Excluded` is greater than the number of `1; Not relevant`: the number of `1; Not relevant` is greater than the number of `0; Eligible: the number of `2; Eligible` is greater than the number of `0; Not eligible`: the number of `0; Excluded` is greater than the number of `2; Eligible` and the number of `1; Not relevant` is greater than the number of `0; Not eligible`. \nYour job is to calculate eligible percentage for patients in each trial and return the calculation result as a number string (e.g., [54.5%]). If a patient was not eligible in a trial, please type in `0.0` into your cell. The eligible patient was determined at the trial level. \n\nAssume that the following data for each trial is shown below:\nClinical trial name: MiniMed 640G\nNo. of patients excluded: 1\nNo. of patients qualified: 43\nNo. of patients not qualified: 0\nEligible percentage (%): 43.00% (43 qualified patients out of 100 qualified patients)\nIf the trial-level eligible percentage is greater than 90.0%, you should return `1` to the end of your output cells. [INST]\n\n[NOTE]\nFor example, if you have 100 patients with available clinical trial data in the clinical trial, and all 100 are trial eligible, you should return `1` in this condition; it's fine with `1; not qualified:` case. The rule is `If one trial-level eligible patient exists among 100 patients, you should return `1;` with no patient`s trial-level exclusion case. If you have more than one trial eligible patient in a trial without trial exclusion, you must return `1;` because you should return `1; no trial-level eligible` case with no patient`s trial-level eligibility.\n\n## Case 2.\n[INST]\n\nThe input text is separated by spaces, without upper and lower cases, and the input values",
        "label": 0
    },
    "1149": {
        "output": "## Exercise_3_4\n\n1. Make a training dataset `patient_data` with 20 records: 10 each with `0 1 0`. 11. Make a testing dataset `test` with 20 records: 10 each with `1 1 0`. 12. Make another testing dataset named `test2` with 20 records: 10 each with `1 0 0`, and 10 each with `1 1 1`.\n\n## Exercise_3_5\n\n1. Make a data frame `patient_too_small` with 20 records. One record has one column `age` with values from the set `{\"0\", \"1\", \"2\", \"3\"}: 10 records each with `age > \"2\"`. 2. Make another data frame `tall_patient` with 20 records. All columns are equal to `-1`. 3. Make another testing dataset `test.age.tall` with 20 records: 10 each with `age > \"2\"`, 10 each with \"age = \"0\". 4. Execute the training in two different ways:\n\n```R\nlibrary(tseries)\nlibrary(forecast)\n\nsapply(x=patient_too_small,\n         FUN=function(x){\nprint(x)$age)\npatient_too_small <-data.frame(age = as.factor(1:length(patient_too_small$age)))\n\ntibs <-training(data = patient_too_small,\n       n.bins = 10,\n       n.folds = 10)\n\ngamfit <-gamm()\n\ngamfit$params$k <-9\ngamfit <-gamfit\n\ngamfit\n\nfitted_gam <-predict(gamfit, tibs = tribble(x=tall_patient, y=as.numeric(as.factor(!tall_patient$age > 2)), data=tibs, seed=12345), n.folds = 10)\nplot(gamfit); points(fitted_gam)",
        "label": 0
    },
    "1150": {
        "output": "Here is the clinical trial:\nTitle: Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients\n\nSummary: While thyroid cancer is generally associated with a favourable prognosis, there is a discrepancy with how important if not traumatic its impact can be on patients. Quality of life (QoL) decreases in the year following a thyroid cancer diagnosis, constituting an optimal period for a preventive intervention. The goal of this study is to evaluate the impact of offering an interdisciplinary team-based care approach for newly diagnosed thyroid cancer patients, including a dedicated nurse who will provide important psychoeducational elements identified in previous focus group studies of thyroid cancer patients, i.e., information on: the physical illness; the emotional impact of being newly diagnosed with thyroid cancer; surgery and its' short- and long-term consequences; radioactive iodine treatments and its associated safety precautions, nutrition and dietary considerations; and how the cancer diagnosis can be an opportunity to make important lifestyle changes and establish new life-priorities.<EOD> Dilated cardiomyopathy with predominant left ventricular systolic dysfunction caused by biallelic truncation mutations in the sarcolipin gene: possible founder effect in eastern Asian populations.\nAIMS\nTo ascertain the genetic etiology of a family in Japan with 4 patients presenting with dilated and predominantly left ventricular systolic dysfunction, the most severely affected among whom died suddenly. We hypothesized that this novel disease might be caused by truncation mutations in the sarcolipin gene (SLN), as this gene has been implicated in another, rare form of dilated cardiomyopathy (DCM) (familial DCM with left ventricular noncompaction ).\n\n\nMATERIALS/METHODS\nSarcolipin gene analysis, histologic examination of cardiac muscle, immunoblotting, and immunolocalization of sarcolipin protein were carried out.\n\n\nRESULTS\nIn trans of the homozygous insertion",
        "label": 0
    },
    "1151": {
        "output": "11. 7-step algorithm of clinical trial data curation. Let's examine the algorithm.\n\n## Repository 2: ClinicalTrials.gov (11)\n- 7-step algorithm of clinical trial data curation\n\n### Preprocessing\n\n\n\n- Read the original raw data, and read patient data with `getPatientsData(trialID: String, outcome: Option[Outcome])`.\n\n\n\n\n\n- Get the corresponding patient note after identifying the patient data with `getClinicPatientData(trialID: String, patientID: String, outcome: Option[Outcome])`.\n\n\n### Extraction Step 1\n\n\n\n- Compute patient eligibility for the clinical trial.\n\n#### Determine if the patient has the information necessary to be eligible for a clinical trial or not.\n- Apply the 3-step algorithm presented above.\n- Generate a corresponding patient eligibility vector for each trial.\n\n### Extraction Step 2\n\n\n\n- For each clinical trial, apply the 3-step algorithm.\n- Generate a corresponding patient eligibility vector for each trial.\n\n## 3. 7-step algorithm of clinical trial data curation\nAs a part of the clinical trial data curation, in this step, we should transform the corresponding patient eligibility vector for each trial to a suitable format and output the data to the MongoDB.\n\n### Preprocessing\n\n\n\n- Make a patienteligibility_vec file with a vector for the corresponding eligibility of a patient for each trial.\n\n#### Patienteligibility_vec is a csv file.\n- Create a trial_eligibility_vec_all_data.csv.\n\n#### Output a data frame of the corresponding eligibility of patients for each trial in a csv file.\n\n### Extraction Step 3\n\n\n\n- Read the corresponding eligibility of patients for each trial from the trial_eligibility_vec_corresponding_clinical_trial.csv output file.\n\n\n\n\n\n### Extraction Step 4\n\n\n\n- Read this row that contains corresponding patient eligibility for each trial in the corresponding patient eligibility vector",
        "label": 0
    },
    "1152": {
        "output": "## What are the exclusion criteria? [21]\nHello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).",
        "label": 0
    },
    "1153": {
        "output": "## [TESTING]\n\n[ELIGIBILITY] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n[STEPS] This is a multiple-choice quiz. You will be presented with a set of statements. The information to answer each statement is hidden in the patient note and the clinical trial. [READ_PATIENT] The following is a summary about the included trials. The following is a summary of the included clinical trials. [READ_CLIN_TRIAL] Clinical trial details: This trial will employ block randomization and intention to treat protocols. The block size must be entered before randomization. Patients will be randomized 1:1 to either methylprednisolone (500 mg IV, 30 minutes before surgical incision.\n[INST] You need to report this note. Type the answer you expect from the system. Then click **Save** button to save the result. After that, you can continue to the next question. [SAVE] [NEXT] The answer is `TRIAL-LEVEL ELIGIBILITY: Eligible`. [SCORE](score.html) [NEXT] [TESTING]\n\n[INST] You should answer in the following manner. Let' s repeat the steps as follows:  \nEnter your first guess. Click **Save**.   \nEnter your second guess. Click **Save** [SAVE]   \nClick **Prev** to go to Trial-level eligibility view again.    \nEnter your third guess. Click **Save**. Click **Prev** to go to Trial-level eligibility view again.   \nEnter your fourth guess. Click **Save**. Click **Prev** to go to Trial-level eligibility view again.   \nEnter your fifth guess. Click **Save**.   \nClick **Prev** to go to Trial-level eligibility view again.",
        "label": 0
    },
    "1154": {
        "output": "[COMMENT] \n**Note**: Before going to the next step, you can easily check what exactly is computed on the patient to determine trial-level eligibility for the patient. That is to say, you can easily understand the patient-level eligibility by looking inside your Trial-level eligibility column where your trial-level eligibility is just copied from, just like the last screenshot. Note that you should check the correctness of what each column computes. \n\n## [/COMMENT]\n\nLet's think what is computed by the Trial level eligibility columns from **triallevel eligibility** to **trial-level eligibility note**. \n\n## From trial level eligibility to Trial-level eligibility Note\n\n- In the next step, you will check the **trial-level eligibility note** column in the same way that you have checked the **trial-level eligibility**.\n- Remember that, from trial-level eligibility column to trial-level eligibility note column, there is just to note whether the patient's current column value is '0' or '1'. So, you will have to check how patient-level information would be copied to trial-level eligibility note column using patient-and trial-level information in that trial. \n\n\n- When you find in [fig_ref]  Table 1: Summary of Patient Example[1][2][3][4][][5][6][7][8][][9][10][11][][] [12][13][14][15][16][][17][18][19][20][21][][] [22][23][24][25][26][] [27][28][30][][31][32][33][34][] [35][36][][37][38][] [[39][40][41][42][][44][45][46][47][48][49][50][51][52][53][54][][56][][57][58][59][60]])",
        "label": 0
    },
    "1155": {
        "output": "**Scoring**: 0 for Excluded, 1 for Not relevant, and 2 for Eligible \n\n\n\n---\n\n## [INST](https://github.com/tpope2/Instructional-Set/blob/master/instructions/Scoring_1_2_3_4_5.ipynb \"Scoring_1_2_3_4_5.ipynb\")\nFor Scoring 1_2_3_4_5 from the [Scores](https://raw.githubusercontent.com/tpope2/Instructional-Set/master/data/Scores/Scoring_1_2_3_4_5.csv) table:\n\n```python\n%pylab inline\nimport csv\nimport os\nimport pandas as pd\ndef download_csv_to_dir(csv_file, filename):\n    d = os.path.dirname(os.path.abspath(__file__))\n    csv_file.seek(0)\n\n    with open(d + '/' + filename, 'wb') as file_handle:\n        file_handle.writelines([csv_file.readline() for csv_file in csv_file.__iter__()])\nos.chdir(os.getcwd())\nnew_header = pd.read_csv(d + '/' + filename)\nnew_header.drop(new_header[new_header.columns].str.contains('*'), axis=1, inplace=True)\nnew_header.columns\n```\n```python\nnew_header = pd.read_csv(d + '/' + filename)\nd1 = new_header.columns[1:(new_header.columns.count(*)+1)]\nn = len(d1)\nd2 = pd.DataFrame(new_header[d1], columns=['Trial_ID'])\n\nd2.info()\n# Source: DataFrame([<KEY>,<KEY>])\n#     Trial_ID    Age    BP_1     BP_2  Pulse      BMI    Sex   DX_1    DX_2_0 DX_2_1 DX_3_0\n#  0   RCT_10",
        "label": 2
    },
    "1156": {
        "output": "# Expected code output\nYour evaluation of a patient should be saved as `trial-level eligibility: 0) Excluded; 1) Not relevant; 2) Eligible.csv.`\nAs output, you would see `patient, eligibility: 0) Excluded; 1) Not relevant; 2) Eligible.csv`.<EOD> Effects of an education program on diet and health: results of a study.\nThe aim of this study was to demonstrate the effectiveness of an education programs for improving diet and health, and thereby lowering the risk of diet-related diseases. The study tested the effectiveness of an education program for children aged 15 to 18, a health and nutrition education program in kindergarten for 4-year-old children, and a diet and health education program for adults who have type 2 diabetes mellitus or hypertension. To evaluate the programs, the participants were given a pretest and a posttest on 12 days in total (15-23 January). The participants were from 3 kindergartens, a secondary and a vocational school in a city in western Sweden, and adults at a diet-and-health center in the same city. Participation in the kindergarten nutrition education program for children between 4 and 6 years of age was voluntary. Participation in the school-based nutrition education program for 15- to 18-year-old children was mandatory. Participation in the diet-and-health education for adults was voluntary. A one-way repeated-measures analysis of variance was used to evaluate the improvements in nutrition knowledge and food habits after education. Pretest nutrition knowledge among the secondary school students was very poor (10.8 of 15 possible points), with no significant changes in the posttest. Although dietary habits did not improve substantially, most students reported that the education had motivated them to eat a nutritionally better diet. The kindergarten education sessions were also successful, with significant improvements in nutrition knowledge among the children. Improvements in the children's food habits and in nutrition knowledge in adults were also highly significant. To evaluate the effects of the program",
        "label": 0
    },
    "1157": {
        "output": "## Exercises & Answers\n\n\n\n## Exercise #1: [inst] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a patient-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\nPatient-level eligibility:  #include 'patient_note.py`\n```\n<EOD> Comorbidity in patients with osteoarthritis and its relationship with health-related quality of life, disability, and pain.\nBACKGROUND\nAlthough osteoarthritis (OA) is associated with numerous comorbidities, no evidence exists regarding their relationship with health-related quality of life (HRQoL), disability, and pain. The aim of the study was to examine the relationships between HRQoL, disability and pain with a range of comorbid health conditions in patients with knee or hip OA.\n\n\nMETHODS\nThe study was a cross-sectional analysis of a population-based sample of 2302 subjects with knee or hip OA from the Chingford Study. Information was collected on 12 comorbid diseases (self-reported), and HRQoL, disability and pain were assessed using validated instruments (EQ-5D, Western Ontario and McMaster Osteoarthritis Index and Visual Analogue Scale). Analysis controlled for potential confounding factors and stratified the analysis by knee or hip OA.",
        "label": 0
    },
    "1158": {
        "output": "You are supposed to fill the blanks, that is, to complete the lines between two dots with all needed information in a patient note. `Trial-level eligibility:` is the variable that has to be set to either 1 or 2 only. It indicates 1 if the patient is deemed eligible for the trial, i.e., eligible for further participation.\n\n## [XSL - FO_1MUL_ELEGIBILITY_ASSESSMENT]\nWhen you have completed the eligibility section, you are to fill out the patient data. \nYou have to set the 'date of creation', 'date of birth', 'sex', 'diagnosis' and 'family history'. \n\nDate of creation, date of birth, and sex have to be completed through 'data entry' field. \n[XSL - FO_1MUL_ELEGIBILITY_ASSESSMENT]\n\n\n## [XSL - FO_1MUL_ELEGIBILITY_ASSESSMENT]\nYou should report 'family history' as \"no\" and 'patient's disease' as \"abdominal pain\". \n\n**Additional Assessments and Interventions Include**:\nThe patient may have several other observations recorded in case notes in addition to those that are already entered using SMART-SOS.\nPlease indicate any other observations recorded in the case notes here. _____________________ \n\n## [XSL - FO_1MUL_ELEGIBILITY_ASSESSMENT]\nAll your data have been updated and saved now. [XSL - FO_1MUL_ELEGIBILITY_ASSESSMENT]\n\n## [XSL - FO_1MUL_ELEGIBILITY_ASSESSMENT]\nLet's imagine three clinical trials and test the eligibility section of each of them. \nThe first trials' name is \"Triage of Abdominal Pain in the",
        "label": 2
    },
    "1159": {
        "output": "Exclusions: `Exclusions: .` \n<EOD> A case of a child with cranial and spinal malformations, with a novel mutation in the EFTUD2 gene\n\nThis case report describes a 6-year-old boy who presented with mental retardation, facial dysmorphism, epilepsy, and abnormal postures affecting both the head and spine. Brain MRI was normal, but cerebellar atrophy was revealed on the brain MRI performed at age four. His older sister also had intellectual disability and was born with macrosomia. No family history of hereditary diseases was noted. After sequencing 41 genes involved in brain and neural development, a novel point mutation was detected in the exon 7 of the EFTUD2 gene. This resulted in the replacement of guanine to adenine at the position 410 (c.410G>A) of messenger RNA (mRNA). This alteration caused the replacement of histidine at the position 137 (p.H137H) of protein to histidine to tyrosine. No mutation was detected in his parents. A point mutation in exon 7 of the EFTUD2 gene (NM_00633.4) was confirmed by Sanger sequencing analysis and was not present in 1,000 Genome browser and ExAC database searches. The described mutation has a potential pathogenic effect on splicing as well as a substitution of an amino acid with a larger polar side chain. EFTUD2 encodes a protein, EFTUI2, which is a key regulator of spliceosome assembly. It has been hypothesized that the absence of this protein blocks the biogenesis of U4/U6 di-snRNP and the splicing of many introns. It also leads to the transcription and processing defects of multiple genes that are critical for neural development.\n\n# Introduction\nA number of neural tube defects are characterized by the fusion of the neural tube, closure of the dorsal defect in the neural tube, or closing of the entire neural tube, and have been shown to be associated with deafness-dystonia (DD) syndrome (OM",
        "label": 0
    },
    "1160": {
        "output": "## Codes\n\nThere are several elements of syntax that are not explained in the documentation. In the following text are listed the more commonly used syntax elements. Some elements are explained in more detail in the following \"Quick reference guide.\"\n\n## Variable\nA `Variable` is used to retrieve an attribute for a patient on a case. The format for naming the variable is `patient.id.<attribute name>();`. \n\nAttributes in the source document are defined in the patient class. The following table contains the attributes of the patient class.\n\n| Attribute   | Description                                                              |                                                                                                                                              |\n|-------------|----------------------------------------------------------------------------------------------------------------------------------------------|\n| `age_yrs`     | Age of the patient in years                                                                                                                                          |\n| `age_mo`     | Age of the woman as a unit of 12 months <p> (month), e.g., 37.</p>                                                                                           |\n| `sex_female` | The variable sex of the patient, with values `1 = Female` and `2` = `Male`. <p>A woman is defined as `Female` regardless of the number of children she has had.</p>                 |\n| `sex_child`  | Specifies the sex of the child. The variable sex, with the values `1`-female and `2`-male.</p>                                                                                     |\n| `gender_male` | The gender of the patient with values `1=male` and `2 = Female`. <p>The word `patient.gender_male` is equivalent to the phrase `patient.sex_male`, because both of these variables contain the same value. </p>                 |\n| `smoker`     | The variable to determine whether or not the patient is a smoker. A smoker is defined as \"one who smokes cigarettes or has smoked cigarettes in the past.\" <p>Smoking status is not restricted to patients who smoke in their current pregnancy and is defined as the current, past or never smoking status of the patient.</p>                                                                                    |\n| `smoke_years` | The age of the patient while a smoker, e",
        "label": 0
    },
    "1161": {
        "output": "<EOD> A comparison of 2 measurement devices for quantifying exercise performance in women with asthma\nWe compared 2 devices to assess their use in measuring exercise testing performance in patients with asthma, and looked for correlations in the results to determine whether the information gained was related to either the method or the degree of asthmatic activity. Twenty\u2010five women with asthma, ages 18\u201347 yr, performed 5 submaximal exercise tests (Ramp test). One test was performed using a conventional system and 2 using a handheld (breath\u2010by\u2010breath) respiratory analysis system. The results showed that both techniques (Ramp and Ramp2 handheld) gave similar results (R2 0.02\u20130.465, p < 0.047), the results differed more with conventional system than the Ramp2 System. In women with varying degrees of asthma activity, some correlations were found between the exercise test variables. These correlations suggest that the degree of asthma activity, as well as the mode of assessment, may be significant factors in evaluating patients' exercise performance.<EOD> Sodium valproate in the treatment of tardive dystonia. A double\u2010blind randomized placebo\u2010controlled trial\nThe present study was designed to evaluate the effect of sodium valproate in tardive dystonia patients. Forty\u2010four patients with tardive dystonia, 15 men and 29 women (mean age 55.5 \u00b1 11.3 years), were included in the 12\u2010week double\u2010blind randomized trial. They received either sodium valproate (200\u2010400 mg/day) or placebo in addition to their neuroleptic medication. All patients were interviewed using the Abnormal Involuntary Movements Scale. Patients were evaluated at baseline and after 4, 8 and 12 weeks of treatment. The Abnormal Involuntary Movements Scale Total score and all individual movement subscores decreased significantly in the sodium valproate group. This decrease was already present after 4 weeks of treatment and continued to diminish over the succeeding 8\u2010week period. In the placebo group, there were no significant changes in the Abnormal Involuntary Mov",
        "label": 0
    },
    "1162": {
        "output": "[INST]\nIf you are given a sample patient note and a trial description, you should first read and extract the patient note and then find its relationship with the trial description. That is, you should check the exclusion criteria which are defined by Boolean operators in the patient note and whether they actually match the conditions in the trial description. For example, if a trial description is \\emph{Hypercholesterolemia and 2 NVDs}, you should find the patient note that satisfies the conditions in the trial description. \n\nThe next step is to repeat the same steps to find the second trial if you are given two trials and a patient note. \n\n[INST]\n\\end{verbatim}\n\n## Question # 4. \nBased on the two trials described in the questionnaire above, the patient note below, and `eligibility`, what is the final eligibility of a patient for Trial 1?\n\nThe patient note and eligibility are as shown below.\n\n\n\n\n\npatient note: Hypertension, Obstructive Sleep Apnea (OSA), and Depression\n\nIf you are given the `Trial`, the `Patient note`, and information about `Eligibility`, what is the `Eligibility` of the patient in the `Trial description`?<EOD> Bacteriology of the nasopharyngeal aspirates from healthy children\nNasopharyngeal swabs from 64 healthy children were inoculated into standard laboratory media. All were grown. Organisms identified were Streptococcus pneumoniae 38\u00b75%; Staph. aureus 21\u00b73%; Hemophilus influenzae 39\u00b71%; Neisseria meningitidis 58\u00b72%; and Branhamella catarrrlis 34\u00b74%. None of the cultures were contaminated. No child had more than one isolate of Haemophilus influenzae: 6.3% had one isolate, and 18.2% two isolates. Bacteriotherapy for acute otitis media with H. influenzae was not considered advisable as most infants had two isolates.<EOD> .\nUNLABELLED\nTumour necrosis factor-alpha (TNF",
        "label": 0
    },
    "1163": {
        "output": "### Difficulty: 2\n\n# [Solo Challenge ##4]\n[INST] Hello. We have a lot patients to meet today. They are all patients with coronary artery disease. One of them has a history of breast cancer. You have to calculate patient's risk of coronary artery diseases. In general, heart disease is caused by the blockage of the main artery. The narrowing of the artery is a result of fat, cholesterol, calcium or fibrin (clots) that accumulates on the artery wall. Narrowed arteries due to high fat, high blood cholesterol, high blood pressure, smoking, diabetes, or excess weight, make it more likely to get blockage or narrowing, called plaque. Accumulation of plaque over time leads to decreased blood flow (ischemia) causing angina (chest pain) or a heart attack. Therefore, you need to extract variables from patients' data to calculate the risk of coronary heart disease.\n\n\nYour patients' data contain the following variables\n\n\nAge\nGender\nBMI\nEthnicity\nSmoker\nHbA1C\nTotal Cholesterol\nHDL\nLDL\nTRG\nHDL Ratio\nTG\n\nBMI <-summary (bcv <-bcv %>% select(-name, -age)) ggplot(bcv, aes(x = BMI)) + geom_vline(aes(xintercept = cutoff / 100, yintercept = 0)) + geom_hline(yintercept = 120, linetype = 'dashed', col = 'gray', lwd = 3) + geom_boxplot(aes(group = bmi.group), col = \"gray\", fill = NA, ylim = c(70, 130)) + geom_point(ylim = c(70, 130), y = cutoff, data = bcv, size = 0.8, aes(x = BMI, y = bmi), lwd = 2) + geom_vline (data = bcv, aes(xintercept = cutoff.1, yintercept = 0)) + geom_point (aes(colour = Age",
        "label": 0
    },
    "1164": {
        "output": "[INST] Let's think about the clinical trial a little bit more. Your task is to assess the patient's eligibility in accordance with the clinical trial's requirements to determine if the patient should be enrolled or excluded from the study. How do I make sure that I choose the patient's name and number correctly? I first read the description of the clinical trial, then read the patient's notes, and then check whether the required characteristics are present in the notes. In terms of eligibility assessment, I always start with patient name. Next, patient number and patient file number appear. I need to compare what information is needed to include or exclude a patient based on that clinical trial. A patient is eligible when fulfilling the inclusion criteria. \n\n\n<div class=\"figure\" width=\"500\"><img class=\"aligncenter size-full wp-image-9356\" src=\"https://upload.wikimedia.org/wikipedia/commons/f/f6/How-does-a-clinical-trial-look-like%3F-US-National-Institutes-of-Health-Blog.jpg\" alt=\"How does a clinical trial look like? (image description)\" width=\"500\"></img></div>\n\n[INST] You can try using the following command sequence to complete the task:\n\n```\n[S1] ClinicalTrial -l #012643\n```\n\n![](https://raw.githubusercontent.com/ehealthresearchgroup/ehealthresearchclinicaltrial/master/images/clinical_tria, ClinicalTrial.png)\n\n![](https://raw.githubusercontent.com/ehealthresearchgroup/ehealthresearchclinicaltrial/master/images/clinical_tria.1, ClinicalTrial.png)\n\n\n*The clinical trial is visible but there are no patient notes.*\n\n# [S2] ClinicalTrial -p #012\n\n```\n[S2] Patient -a #012\n[S3] ClinicalTrial -N 012\n[S4] Patient.Name \"P\"\n[S",
        "label": 0
    },
    "1165": {
        "output": "[CODE]\n# Trials from CSV file data/sample_trial_file.csv\nTrials = pd.DataFrame(pd.read_csv(\"data/sample_trial_file.csv\"))\n\n# Patients from CSV file data/sample_patient_file.csv\nPatients = pd.DataFrame(pd.read_csv(\"data/sample_patient_file.csv\"))\n\n# Patient-level eligibility from clinical trial information\nPatient_level_eligibility = pd.DataFrame(Trials.merge(Patients, on=['ID']))\n\n# Trial-level eligibility from clinical trial information\nTrial_level_eligibility = pd.DataFrame(Patient_level_eligibility.merge(Trials, on=['ID']))\n\nTrial_level_eligibility.to_csv(\"Trial-level_eligibility.csv\", index=False, header=True)\nPatient_level_eligibility.to_csv(\"Patient-level_eligibility.csv\", index=False)\n\n\nA: import time\nfrom datetime import timedelta\nfrom pandas import DataFrame\nimport pandas as pd\nfrom openpyxl import (  # https://github.com/openpyxl/openpyxl/tree/dev#openpyxl-vs-xlsxwriter-py2/py3\n  ExcelWriter, Workbook, \n  xldelta, xltime, xlsread, xlsize, xltsheet, \n  excel_options\n)\nimport numpy as np\nimport scipy\nimport pickle\nimport json\nimport os\n\n\ndf_time_format_string = lambda: r''\"{time: '%b %Y'}\"''\ndf_list_format_string = lambda: r''\"[%d]\n\n\n# Create a list of dictionaries to describe a patient's eligibility level in a clinical trial\neligibilities_dict = { \n    2: r''\"No.\",\n    1: r''\"Yes. The patient meets the inclusion criteria but is excluded on the grounds of the trial's exclusion criteria\",\n    0: r\"\"\"Included. The trial exclusion criteria do not apply\"\"\" \n}",
        "label": 0
    },
    "1166": {
        "output": "### T-7, 15-16\nYou may be confused about the reason of using \"\\\" to specify that there was no result in the patient note for the CPT field. This is to prevent you from considering that the \"Clinical Note\" field is completely empty. You also have to consider the field \"Clinical note: Other\".\n\n### **[T-8, 17-18] CPT**\nEnter the CPT Code/s based on the most recent CPTs for the problem/condition. \nOn a separate note, a CPT code is defined as a numerical code that is assigned to a set of similar healthcare services to help standardize the way the costs associated with those services are tracked and reported. You would find the code(s) to bill from the patient note to ensure billing of the provided services. You will bill for at least the following 3 CPT codes: Evaluation and Management Services, Diagnostic Services, and Procedural Services. The full list of CPT codes to be used in this workshop, including their descriptions, can be found HERE .\n\n## [T-8, 19] **Age**\nEnter the patient's age. \n\n## [T-8, 20-21] **Sex**\nEnter the patient's sex, i.e., male or female. [M]\n\n## [T-9, 22-23] **BMI**\nEnter the patient's BMI in pounds/inches. ENSURE YOUR NOTE INCLUDES THE PATIENT'S WEIGHT! \n\n### [T-11, 4-5] **Medical History**\nEnter the patient's relevant medical history in bullet points. This is how you input your note into the template.\nEnter the patient's diagnosis according to the ICD-10 Code. I believe the ICD-10 Code is a numerical code that you use with other data to classify and catalog diseases. This is a code you can find on the website of this clinic. In theory, you can use the actual numerical code of the disease that the patient has. But remember that the ICD-10 Code is not necessarily the same as the numerical code. For example, if",
        "label": 2
    },
    "1167": {
        "output": "<EOD> Correction: Association of ALS With a 2-Bp Deletion in the Superoxide Dismutase-1 Gene\nIn the article \"Association of ALS With a 2-Bp Deletion in the Superoxide Dismutase-1 Gene\" by Jean-Marc Lemiere, A. David Smith, Anastasios Tzoulis , Gwen R. Vaughan , and Mark A. van der Vliet (Genetics, 150:1323-1328), there is an error on page 1323. In the figure legend for Figure 2, the reference is misprinted: \"References #56, 87. See the erratum on the next page.\" The reference 56 should be \"56. Tzoulis A, . This article is available at / issue-4%2F1\" \"87. . This article is available from the authors.\" The erratum is, therefore, corrected as follows: \"Page 1323. In the figure legend for Figure 2, the reference is misprinted: \"References #56, 87. See the erratum on the next page.\" The reference 56 should be \"56. Tzoulis A, . This article is available at http://genet.sagepub.com/supplemental#87. . This article is available from the authors.\"<EOD> Preventing diabetic end-stage renal disease.\nThe cost of end-stage renal disease resulting from diabetes mellitus is projected to escalate from $7 billion in 2000 to $32-$49 billion by the year 2030. This increased expense has a significant impact on other prevention efforts in health policy. Preventing diabetic end-stage renal disease in the future will require identifying patients who are at higher risk for failure of renal function and treating their comorbid conditions (hypertension, hyperlipidemia, and hyperglycemia), plus tight glycemic, blood pressure, and lipid control when the disease is diagnosed. Nurses, with their holistic approach to patient care, are optimally positioned to provide the early education",
        "label": 0
    },
    "1168": {
        "output": "### Exclusion criteria:\nIf the patient does not meet all of the inclusion criteria stated in the trial note, there are 3 possible results:\n1. Excluded: The patient does not satisfy any of the conditions needed to qualify for a trial.\n2. Not eligible: The patient meets some of the conditions necessary to qualify for a trial, but does not meet all of them. The patient can be included to a trial if the reason for non-eligibility is resolved; if not resolved, the patient does not meet all of the conditions needed to qualify for a trial.\n3. Eligible: The patient satisfies all of the conditions necessary to qualify for a trial.\nHere are some exclusion criteria of the clinical trial:\nHistory of gastrointestinal perforation, gastrointestinal fistulae, gastrointestinal hemorrhage or obstruction; recent surgery (at least 1 month), history of bowel resection.\nIntracranial, intraocular, intraspinal, retroperitoneal, or intrahepatic cancer.\nHistory of grade > 2 autoimmune disease.\nActive central nervous system metastasis.\nActive bleeding or bleeding diathesis.\nAny clinically significant or significant/unstable medical condition, symptom or illness that, in the investigator's opinion, might limit the subject's ability to participate in the study or confound the interpretation of results.\nConcurrent malignancy other than the primary solid tumor malignancy with the following exceptions:\nMelanoma of the skin, in-situ cervical carcinoma, or other carcinoma that has undergone potentially curative therapy and is not currently under active treatment (e.g., surgery, systemic therapy, or radiation).\nSquamous cell carcinoma of the anal canal or patients who have completed potentially curative therapy (e.g., surgery, systemic therapy, or radiation).\nAdenocarcinoma of the rectum (but not anal canal) who have completed potentially curative therapy (surgery, systemic therapy, or radiation).\nProstatic cancer who have completed potentially curative therapy (e.g., surgery, systemic therapy, or radiation) and where",
        "label": 0
    },
    "1169": {
        "output": "```bash\n/bin/bash \n\n\n\n```\n\n\n\n<EOD> Intrahost Evolution of the West Nile Virus Polyprotein\nHost range and virulence are multigenic traits, with the interplay between multiple viral genes and the host immune response governing whether an infection progresses to transmission or to lethal pathology. As part of an investigation into these genes and the underlying molecular mechanism behind their contributions to virulence, intrahost sequence evolution was assessed in a West Nile virus (WNV) lineage 2 polyprotein. Virus was isolated from patients enrolled in a prospective clinical study in 2008 in Israel. We found a relatively low intrahost diversity of the polyprotein at a protein length of 4,029\u2009bp, a rate of 3.1\u2009\u00d7\u200910\u22127 nucleotide substitutions per site per year. Only one sequence of a 15\u2010amino acid sequence had 2 substitutions with the consensus sequence. The overall findings were in agreement with previously identified genetic diversity in WNV populations but demonstrated strong purifying selection pressure in intracellular proteins.<EOD> Cases in Surgery Illustrated by Woodcuts\n\n\n\n## 1864.]\nBronnenhurst and Barnes on Surgery.\n491 by a careful and exhaustive study of the effects which the various instruments produced upon the parts they were to act upon, a work which we believe will have no small weight with the profession, and which we recommend to the attention of surgical students.<EOD> A novel antiemetic agent, granisetron, in cancer chemotherapy.\n\nFive studies compared doses of Granisetron (G) ranging from 0.03-6.0 ug/kg/b.w. to Cisplatin (P), from 20 -80 mg/m 2, in 114 patients (pts) and in two studies 265 pts received single and multiple doses of 10 mg (s.d. 20 mg) daily. G increased the time of nausea-free days from a baseline of 14.4 h (with P)-88 h by",
        "label": 0
    },
    "1170": {
        "output": "# Good Research Practice\n<EOD> The Relationship Between Driving Force, pH, and BMP-2 Release from a Multi-Compartment Ternary Complex.\nThe pH change in a local environment is a crucial factor for the biological activity and transportation of many important proteins, such as enzymes, toxins, antibodies, etc. In this context, we are interested in determining how different stimuli impact multi-compartmental transportation of proteins through a mesoporous structure. In this article, we propose a novel concept of a ternary complex system and the multi-step release of bone morphogenetic protein 2 (BMP-2) from a mesoporous alumina with polyplex-inorganic hybrid mesostructure. To determine how BMP-2 release differs from that of a simple binary complex system, we developed an evaluation method based on the amount of released BMP-2 in solution using surface plasmon resonance (SPR). The pH value also affected the released amount of BMP-2 and we successfully demonstrated that BMP-2 release could be controlled by adjusting the pH value of the solution. Furthermore, the response of BMP-2 release to both the pH of the solution and the driving force was investigated by performing simultaneous SPR measurements for each variable. Both factors were found to affect BMP-2 release from the ternary complex system. However, different results were obtained from the binary system. This ternary complex structure is expected to be a powerful tool for use in drug delivery applications.<EOD> .\nThe effect of hyperbaric oxygenation on the course of diabetic osteochondrosis (DO) was examined in experiments on 30 Wistar rats of the 1st experiment and the same number of rats of the 2nd experiment. Diabetes was created by an intraperitoneal administration of alloxan (Sigma Co. USA) at a dose of 130 mg/kg. After 3 days of experiment, the animals of the 1st experiment were exposed within the chamber at an absolute pressure of 2.5 atm, the fraction of oxygen--40%, the duration of the exposure--3 h per 1 day, for 10 days. The animals of the",
        "label": 0
    },
    "1171": {
        "output": "<EOD> The effect of in vitro gastrointestinal digestion and colonic fermentation on the contents of fructo-oligosaccharides, inulin-type fructans and phytochemicals in wheat bran.\nThe aim of this study was to examine quantitative changes in phytochemicals and carbohydrates in wheat bran during the digestion/fermentation process. Wheat bran with high levels of polyphenols (HP), low levels of polyphenols (LP) and low levels of fructo-oligosaccharides (LOF) were chosen as the materials and each material was divided into LOF, HP, and LP groups. Both HPL and LOP exhibited 10-fold increases in acanthoside, 23-fold increases in oatinoside and 5-fold increases in oatanoside under the fermentation conditions of the colon. The levels of chlorogenic acid were higher for HP and LOP, than for LOP and LOF in the upper intestine. There were no significant differences between HPL and HP. The contents of isoquercitrin, rutin and quercetin were also higher for HP and LOP. There were substantial differences in the levels of fructo-oligosaccharides between HPL and LP at every digestion stage, with increasing changes between HP and LPF. Therefore, HP and LP had the largest amounts of fructo-oligosaccharides in all digestion stages. HPL maintained the highest content of hydroxycinnamic acid derivatives in the large intestine. Therefore, wheat bran with high contents of polyphenols and fructo-oligosaccharides, especially inulin-type fructans, can be a better nutrient for human health and are recommended for nutritional improvement.<EOD> A novel 15q dup14q12q13 syndrome\nThe 15q dup14q12q13 syndrome is a rare chromosomal disorder, which was originally reported as dup15q23 . Affected individuals manifest variable clinical features, the most common being developmental delay and mental retardation, intellectual disability, and macrocephaly. We present a new case of the",
        "label": 0
    },
    "1172": {
        "output": "\u2666 If the [IF] statement is not present. \u2666 Do not copy and paste from the instructions above, instead, create a section called `Patient note `.\n\n\n# Results in SNOMED CT\nA clinical trial is recorded as a single instance. Therefore, if you are asked for Trial-level eligibility, the answer is the eligibility scale of a patient after assessing all the trial criteria. You also need to repeat the process with all patients in the trial to generate a single trial-level eligibility.\n\n\n# Results in OWL\nFor simplicity's sake, assume there is no patient note (or no `Patient note `section).\n\n#### Instructions for the task: \u2666 If you are asked for trial-level eligibility, output the eligibility scale of a patient after assessing all the trial's criteria.\nYou should repeat the process with all patients in the trial to generate a single trial-level eligibility. \u2666 Let's code it as `owl:RealClass, owl:SomeValuesFrom( SNOMEDCT:Trial-level eligibility)`, e.g., `owl:RealClass, owl:SomeValuesFrom( SNOMEDCT:Trial-level eligibility, SNOMEDCT:Excluded ).` [TRANSITION] \u2666 If you are asked for eligibility of a single patient, output the score of that patient's eligibility according to the trial criteria, i.e., use the score(patient note); [TRANSITION] \u2666 If you are asked for the eligibility score of a patient within the trial, return that score after assessing the patient's notes according to the trial criteria, i.e., return score(Patient-trial-patient); [TRANSITION] \u2666 If you are asked for eligibility score of a certain patient within the trial, return that score according to the trial's criteria, i.e., return score(Trial-patient); [TRANSITION]\n#### Code Example:\n<owl:Class rdf:about=\"SNOMEDCT:Trial-level eligibility\"/> <!-- Note The about property of a class has to be unique. --> <owl:ObjectProperty rdf:about=\"SNOMEDCT",
        "label": 0
    },
    "1173": {
        "output": "[INST] **Input to predictions based on the input from the previous step (if input is available). If there is no input, skip this section (including the first sentence below).**\n\nThis model takes the clinical trial and the patient's medical report as input in order to perform the assessment of eligibility. The clinical trial has 3 inputs:\n- title (string) - description (string, also called trial summary in some notebook cells) - inclusion_criteria_map (dict, which stores a list of inclusion criteria as strings and whether a given criterion is 0 (the same as exclusion criteria), 1 (not relevant), or 2 (eligible).\n\nThe medical report of a patient contains 9 inputs (each patient note is represented as strings):\n- disease_codes_list (list) - examination_codes_list (list) - medications_list (list) - symptoms_list (list) - medical_history_list (list) - physical_examination_results_list (list) - laboratory_test_results_list (list) - radiology_test_results_list (list) - notes (string)\n\nAdd `df_patient_notes = df_patient_notes.set_index(patient_id)`, and drop unnecessary columns. Now we only have 9 columns: date_of_med_report, exam_code, disease_code, medication_code, symptoms_code, exam_result_code, medical_history_code, physical_exam_result_code, and notes. Each column can represent a value. For example, date_of_med_report represents the date of the medical visit, exam_results_code represents the result of the exam (e.g., 0 means \"normal\"), disease_codes_list, medical_history_lists, and the others represent the code of the corresponding items. \n\nWe also create a column with numerical values that we can use in later steps as well, so that we can calculate the patient's age: age_in_years = (patient_birthdate.years - patient_birthdate.year) + patient_birthday.year\n\n[INST] **Make a copy of the data table. In each notebook task, the input and output tables should be",
        "label": 0
    },
    "1174": {
        "output": "**Congratulations!*** You are done with the assessment of eligibility!\n\n# Patient-specific eligibility\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\n\nBased on the patient note, you will be asked to perform the patient-specific assessments of eligibility, as follows:\n\n1. Is the patient aged 30-70 years? (Yes or No)\n\n  1 \u21e2 Assessing the patient's age is a part of the patient-specific eligibility assessment.\n\n2. Is the patient a pregnant woman? (Yes or No)\n3. Is the patient a lactating woman? (Yes or No)\n4. Is the patient a severely overweight or morbidly obese adult? (Yes or No)\n\n  1 \u21e2 Assessing the patient's overweight is a part of the patient-specific eligibility assessment.\n   1\u21e2 For the assessment of overweight: calculate body mass index using the formula below and examine the patient status against the established B",
        "label": 0
    },
    "1175": {
        "output": "## Q3\nWhat is the clinical trial's main exclusion criteria?\n\n[BEGIN_SOLUTION]\nFirst, you find the main exclusion criteria in the clinical trial from the summary. The study includes patients who are women pregnant, lactating or trying to conceive; and patients who are severely obese; who have any other history or evidence of severe gastrointestinal disease (e.g. ulcer, ileus); or who have a history of allergy to medications.\n\nThen you find the related information for each criterion from the patient note, for example, 'No severe obesity (BMI >40)' which is one of the main exclusion criteria of the trial.\n[END_SOLUTION]\n\n## Q4\nHow do you determine if a medication would increase risk during a pregnancy?\n\n[BEGIN_SOLUTION]\nFirst, you can use Wikipedia to have initial understanding of the drug, such as whether it is used to treat pain disorders, e.g. cholecystitis. For example, a quick search of Hyoscine Butylbromide will reveal that:\n\"Hyoscine Butylbromide (HBB) is a spasmolytic drug which is used to treat pain or discomfort from irritable bowel syndrome, or to relieve the symptoms of cholecystitis. It acts by relaxing the sphincter tone.\"\nYou can also check Wikipedia about the medication and its associated use, such as:\n\"Hyoscine butylbromide (HBB; also known as hyoscine or Buscopan; INN) is a cholinesterase inhibitor and a spasmolytic drug which is used to relax sphincter muscles. It is used as a medication to relieve spasms.\"\nHere, you can see that:\n- It is used to relieve spasms\n- Its indication to treat pain is cholecystitis\nThen you can check other sources or drug databases, such as Wikipedia about Cholecystitis, for example:\nThe 2009 American Association for the Study of Liver Diseases (AASLD) practice guidelines state that cholecystectomy has been",
        "label": 0
    },
    "1176": {
        "output": "### Cleaning\nAfter finishing the annotation you should clean it. \n\n1. Check the annotations that you have added. (You can check them by [TUT:CheckYourAnnotation](#checkyourannotation))\n\n<!-- [INST] [START GUIDE_CLEANING_CHECKING] -->\n[![Check your annotations with TUT 3.1](img/tut_3_1.png)](TUT:CheckYourAnnotation) [![Check your annotations with TUT 3.1 (Chinese)](img/tut_3_1_chinese.png)](TUT:CheckYourAnnotation/Chinese)\n<!-- [END GUIDE_CLEANING_CHECKING] -->\n\n\n\n### Saving your Annotation\nAs we already noted, you need to write your annotation to a text file with the ***.tsv** extension (e.g., `tut_data_trial3.tsv`). \n\nHere is the sample of a correctly filled tutorial annotation file:\n```\nTrial\n    title Trial name\n    description Trial description\n    inclusionCriteria 0) Excluded 1) Not relevant 2) Eligible\n    exclusionCriteria 0) Excluded 1) Not relevant 2) Eligible\n    inclusionCriteriaPatient 0) Excluded 1) Not relevant 2) Eligible\n    exclusionCriteriaPatient 0) Excluded 1) Not relevant 2) Eligible\n```\n<!-- [INST:TUT:AnnotationSample] -->\n### [TUT:CourseCompletion]\n\nIf you have completed more than half of the tutorial, the next section will let you continue with the final testing:\n* [TUT:CourseCompletion3](#coursecompletion3)\n* [TUT:FinishTutorial](#finishtutorial)\n<!-- [INST:TUT:CourseCompletion3] -->\n\n<a href=\"https://de.kaggle.com/allenai/clinical-annotator\" target=new> \ud83d\udd17\ud83d\udd17\ud83d\udd17\ud83d\udd17 [Go to Kaggle](https://de.kaggle.com/allenai/clinical-annotator)</a>\n<",
        "label": 0
    },
    "1177": {
        "output": "The resulting source code in IPython Notebook format, including the [rst heading], is available online.\n\n### The first approach for comparing a given patient note and the inclusion criteria of a clinical trial\n\nThe first step in the IPython Notebook is `import numpy as np`. We write `numpy` for the Python package `NumPy`. In particular, we imported the `numpy` module from NumPy. The `notebook` is a Python web application. To access it, we first create the folder in the working directory where we store the notebooks (this is the folder we will see in top of Terminal in Mac, and in commandprompt in Windows), then type in the terminal `jupyter notebook`.\n\n    %IPython notebook\n\nFor IPython 5, we can go to File > Open and, instead of choosing the file to open with, we need to select Python notebook, then choose the file jupyter notebook.ipynb. To start the notebook, we then click the file\u2019s icon or press control + shift + o.\n\n[*note]: The terminal in Mac is called Terminal.\n\nThen, we need to import a new module called `pydictools`. Python imports a module by using import module_name from module_name. Here, the import statement `from pydictools import trial` imports the module `pydictools` and allows us to use its functions and methods.\n\n\n![](./images/ipython_notebook/1.jpg)\n\n[*note]: `trial` is the identifier of a module `pydictools` in the Python interpreter. To find this, we type in the interpreter `import pydictools.pydictools` and observe that the identifier appears in uppercase `trial`. Here is the list that comes with the module `pydictools`\n\n      Copyright (c) 2013 <NAME>\n      \n      License: MIT license; see the `pydictools.License` module at\n         http://pythonhosted.org/pydictools/LICENSE.txt\n      \n      Author: <NAME>\n      \n      Author: <NAME>\n      \n      Author: <NAME>\n      \n      Author: <NAME>\n      \n      Author: <",
        "label": 2
    },
    "1178": {
        "output": "Let's continue on the inclusion criteria. Next, we will discuss the inclusion criteria of trials. You will see a new tab called INCLUSION CRITERIA.\nAt the beginning of each section which is called INCLUSION CRITERIA there is a box called `Summary` with a short description of the criterion. Read all sections in this tab if you don't understand something. \nPlease select the checkboxes under the heading `Age` only if your patient meets the inclusion criterion.\nThen you have to select the boxes under the heading `Sex` only if your patient meets the inclusion criterion.\nNow let's think about the criterion `Type of Malignancy`. There are several subcriteria for this criterion. Select the subcriteria corresponding to your patient's cancer. Your patient with a stage II gastric adenocarcinoma has to have the subcriterion gastric cancer.\nThe criterion, `Stage` is a subcriterion for the criterion `Type of Malignancy`. Thus, if you select the box corresponding to your patient's cancer, the boxes for the subcriterion `Stage` will be selected as well (if you did not select the box corresponding to your patient's cancer in the criterion `Type of Malignancy`.).\nTo conclude: the criterion `Disease Stage` is a subcriterion for the criterion `Type of Malignancy`.\n\nNow you must repeat the above steps for the other inclusion criteria. You may have to change the option of selection, because sometimes you have to select the boxes under the heading `Type of Malignancy` only if the boxes under the heading `Disease Stage` are selected. So, repeat the steps that you learned above until you have completed all selected boxes. [INST]\nNow you can go on to the next tab, namely `Sites`, for which you will meet with the patients for every recruitment day. Please remember your patients' names.\nThe patient note that you collected at the previous tab is shown on the first line. On the second line, the patient ID, the recruitment date, and the patient's sex are shown. Check all the criteria corresponding to your patient. Please note that these criteria are only used for the recruitment process. We will show them onscreen, but for the real",
        "label": 0
    },
    "1179": {
        "output": "### \u2714\ufe0f Correct\n\n\nA 56-year-old middle-aged woman with a history of hypertension, hypothyroidism, and hyperlipidemia came to the clinic for her annual physical examination. On reviewing the patient's record, he noted that she had the following abnormal test results in the past year: fasting blood sugar ranged from 160 to 190 mg/dL (normal range, 70 to 110 mg/dL), HbA1c of 8.0%, and C-peptide of 1.0 mcg/L (normal range, 0.8--2.1 mcg/L). The patient was very concerned about the results, and was seeking a better explanation. The clinician explained that her HbA1c test result indicated that her average blood sugar level during the previous six to 12 weeks ranged from 6.5 to 7.5%, which was still well below the normal level of 5.6% (7.0% is the cutoff point for prediabetes). Therefore, this patient probably has impaired blood sugar control, which can usually be improved through diet and exercise. To assess whether her diabetes is caused by insulin resistance, the clinician recommended that she have a C peptide test, which looks at the amount of insulin that she normally produced to test if her diabetes is likely to be type 2 DM. Finally, the clinician recommended that she have an abdominal ultrasound of her pancreas because this is the organ that makes insulin. Since the patient had normal pancreatic size on ultrasound examination, the patient was diagnosed with type 2 DM rather than type 1 DM.\n\n\n\n\n\n    \\section*{Correct Answer with an Explanation}\n    HbA1c and C-peptide tests are valuable for assessing glucose control after patients have been diagnosed with DM and taking medications are usually initiated. These tests are not used to diagnose DM. Other features must be taken into account to diagnose the different types of DM. HbA1c test result indicates that the patient has impaired blood sugar control, and diet and exercise improve her blood sugar",
        "label": 0
    },
    "1180": {
        "output": "### [DATA]\nIn this section, we will create the data tables based on the information presented in the patient's chart and the trial requirements.\nThe list of the data fields is presented in Table 13.16.\n\nTable 13.16. Data table fields.\n\nField | Definition\n---|---\nName | Unique identifier of the patient, patient's identification number\nDate of birth (YMDD) | Date of birth of the patient in the form YY/MM/DD, with 1 st January as reference date\nAge | Age of the patient, expressed in years\nGender | Gender of the patient (male/female)\nPatient's identifier; Internal identifier; A unique identifier of the patient unique for each patient throughout the trial\nDate of examination | Date of examination of the patient\nEpidemiology / sociology | Epidemiology / sociology of the patient\n\nInitiative for participation in the trial and its reason | Initiative for participation in the trial and its reason (consent/authorisation/invited)\nRecruitment | Recruitment channel of the patient to participate in the trial\n\nMother | Initiative for participation in the trial (consent/authorisation/invited)\nFather | Initiative for participation in the trial (consent/authorisation/invited)\nNumber of children | Total number of children of the patient\nAge of children | Total age of the children of the patient\n\nChild 1 | Name of the child 1 of the patient\nAge of child 1 | Age of the child 1 of the patient\nGender of child 1 | Gender of the child 1 of the patient\nAge of child 2 | Age of the child 2 of the patient\nGender of child 2 | Gender of the child 2 of the patient\n\nAge at birth | Age of the child at the time of birth, expressed in years\nBirthweight | Weight of the child at the time of birth, expressed in kilograms\n\nHeight | Height of the child at his/her exam, expressed in centimetres\nWeight | Weight of the child at his/her exam, expressed in kilograms\n\nBlood pressure (mmHg) | Blood pressure of the child measured at his",
        "label": 0
    },
    "1181": {
        "output": "<b><a name=\"Exercise_8\"></a><a name=\"Exercise_8\"></a></b>\nExercise 8\n\n\n[INST] Your boss is a hospital manager trying to hire a new medical expert and he wants to conduct a trial to compare 2 treatments. The study will compare the effects of the use of immuno-chemotherapy for the treatment of gastric metastases with gastrectomy (NCT04609451). The goal of the study is to assess the safety and the effectiveness of the treatment. Safety will be assessed by assessing all the adverse events during and after the treatment. The effectiveness of the treatment will be measured by comparing post-treatment metastasis volume and tumor growth.\n\n\n- [ ] Make a trial-level eligibility for a patient.\n\t- Exclude patients who meet the exclusion criteria.\n\t- Patients who meet the inclusion criteria but not exclusion criteria, mark `1` in the column patient_level_eligibility.\n\n- [ ] Identify each patient by searching on the patient information table.\n- [ ] Create a JSON file to display as a table in the app.\n\n\t[b] Your app will display the table of patients from a JSON file below.\n\t![patients-table](/images/chapter_6/patients-table.PNG)\r\n\n\t[b] In your JSON file, create a key `patients` and save patients' data in a hash of `patients`.\n\n\t\t[b] It should look",
        "label": 0
    },
    "1182": {
        "output": "![](/images/img_15-645x425.png) \n\n\n\nCongratulations! You have successfully created a new trial, and you are ready to practice the eligibility module.\n\n### Checking in the trials\n\nNow, you should be ready for practicing the skills on real trials, let's check out those trials in your dashboard. It is good to check out some trials first, you can check and practice the skills more than once. \n\n![](/images/img_14_practice_trial.png) \n\n\n\n### Practicing the eligibility module \n\n[Go to Practice Trial]()\n\n\n* Click on the icon to start the assessment\n\n![](/images/img_58-6 80x425.png) \n\n\n* Click on the icon to open a new page showing the assessment details\n\n![](/images/img_59-670x425.png) \n\n\n* Check all the checkmarks to complete the assessment and click the icon to view the assessment result\n\n![](/images/img_60-645x425.png) \n\n \nThe result looks like this\n\n![](/images/img_61.png) \n\n\n* Check the mark next to the patient note. The eligibility assessment is correct, so click the mark and click the icon to go to the next trial\n\n![](/images/img_62.png) \n\n\n\n* Click on the icon to get back to the menu, then click on a trial from that list\n\n![](/images/img_63.png) \n\n  \n  \n\n\n\n### Repeat the assessment\n\nIf you think you can do better, you can always try again. You can repeat the eligibility module anytime, just visit the assessment page from the dashboard.\n\n![](/images/img_6_practice_trial.png) \n\n\n\n### [Click to check out the assessment form]()\n\n[Practice Module](/module/practice-module-eligibility-module/3)",
        "label": 0
    },
    "1183": {
        "output": "Here are the output files from the original code:\nHere is the [url=https:-stack overflow-com-users-20481307-56d70470e1-reputation/-answer-2128948#2128948]script source[/url] that I used from stack overflow. It doesn't tell us much, but it's useful, thank you.\n<EOD> Diagnostic criteria for atypical antipsychotic drug poisoning: a systematic review of case reports\nBACKGROUND\nAtypical antipsychotic drug therapy can cause a number of severe adverse events. The lack of internationally agreed criteria to distinguish drug induced events from idiopathic neurological conditions can complicate the diagnosis of these adverse events.\n\n\nAIMS\nTo describe, in cases of atypical antipsychotic drug poisoning, the criteria used in the diagnosis of atypical antipsychotic drug neurological syndromes and to identify the key features associated with an adverse event caused by this treatment.\n\n\nMETHODS\nA systematic search was carried out and 63 publications describing 52 patients met the selection criteria.\n\n\nRESULTS\nOverall, four sets of diagnostic criteria were used and described. In the absence of the criteria set used by the Naranjo nomenclature, clinical features were evaluated as a potential predictor of an adverse event attributable to atypical antipsychotic drugs. Slowing of the EEG predominated (69.2%) followed by cerebral signs such as Parkinsonism-like rigidity (56.6%) and akinesia (51.5%). Adverse drug event-related abnormal liver function was found in 32 patients (61.5%) and electrolyte disturbances were frequent and were observed in 37 (73.4%) patients, especially disturbances in calcium metabolism.\n\n\nCONCLUSIONS\nClinicians should be aware of the diverse neurological manifestations that may occur during atypical antipsychotic treatment. The need to be familiar with the diagnostic criteria set used by Naranjo nomenclature and apply this",
        "label": 2
    },
    "1184": {
        "output": "![INST] \n\n## 5.11 Repeat the last trial of the last session \nGo back to the last trial of session 2 to test the functionality 'trial-specific information and patient eligibility'.\n\n- Eligibility in the upper left corner:\n\n    &trial-level-eligibility: 1) Not relevant\n         &trial-specific-eligibility: Not applicable.\n    &trial-level-eligibility: 1) Excluded\n         &trial-specific-eligibility: Patient does not match trial criteria.\n    &trial-level-eligibility: 2) Eligible\n         &trial-specific-eligibility: Patient matches trial criteria.\n- Eligibility is displayed to",
        "label": 2
    },
    "1185": {
        "output": "By implementing the `column counts()` function you can return the column count without the usage of the `for each` loop.\n\n```cfscript\ntrial_infos = inputBox(fileContent = fileContentToRead, fileDirectory = \"../../Documents\");\n\ncolumnCounts = trial_info.columnCounts();\n\n\n  }\n\n```\n\n## 5. How to display patient note and include more information? \n\nAs you can see, you can print the full results of REDCap in a PDF format. You can do this",
        "label": 0
    },
    "1186": {
        "output": "The question mark at the end of the patient note is called a prompt, not a question. In order to answer the prompts of a patient note, we should answer the questions below based on the information and data recorded in the patient note.\n1) Which type of patient note is it? (2) Which section of the patient note is it?\nIn this patient note, the section is not clear. The title of the patient note is \"Obese woman with abdominal pain: Assessment\", so it is an assessment section. Therefore, the prompt must be answered in assessment subcategories, as \"Is there any past medical history?\" and \"Is the patient on regular medication?\" There are no assessment subcategories in the patient note.\n\nIn addition, the assessment of eligibility is the next step in the procedure. The assessment of eligibility is a series of prompts and subcategories. If a given prompt has 2 or more subcategories (e.g., Assessment of current medication), the first of these subcategories is selected. If a given prompt has only 1 subcategory (e.g., The patient has no past medical history), the patient note is not eligible.\nIt should be noted that this procedure is only done once in this patient note. We must do the following before answering the prompts of the patient note:\n2) Which type of patient note is it? \n\n\n3) Which section of the patient note is it?\n\n\n4) How should I answer the prompts of the patient note?\n\n\n\nPrompt: Is the patient male or female?\n\n\n\nSubcategory: Male\n\n\n\nIf the patient belongs to the male gender, the prompt with the phrase \"The male gender\" under the Trial-level eligibility assessment subcategory is marked, and the scale value is updated. Since all prompts after \"The male gender\" in the Trial-level eligibility assessment subcategory are blank, the patient is not excluded because he/she is a male. This prompt can be answered with the phrase \"The female gender\". \n\nPrompt: Is the patient child or adult?\n\n\n\nSubcategory: Adult\n\n\n\nIf the patient is an adult according to his/her age, the phrase \"patients older than 18\" is selected under Tri",
        "label": 0
    },
    "1187": {
        "output": "<EOD> Listeria monocytogenes: 5-Year Trends in Food Product Recalls and Isolates Associated with Human Post-Hatch Commercial Poultry Product Reports in the United States from 2014 to 2019.\nListeria is an important food-borne pathogen to both public health and the poultry industry. Here we analyzed 5\u00a0years of historical data from the U.S. Food and Drug Administration (FDA), Centers of Disease Control and Prevention (CDC) foodborne outbreak tracings, and the National Poultry Advisory Council (NPAC) to determine the frequency and source of human listeriosis cases associated with commercial poultry products. Since 2014, a median of 137 human cases of listeriosis were reported each year (range: 56-255); most were \u226560\u00a0years old (62% to 68%). For post-hatch poultry products, there has been a yearly overall increase from 3.69 cases/million outbreak-associated poultry products in 2014 to 10.18 cases/million in 2019. In 2019, of the total of 204 products recalled by the FDA, the majority were associated with Listeria monocytogenes (82; 39%) with two (33%) and four (67%) recalled products containing the major poultry products. Most Listeria positive isolates were serotype 1/2a (721 of the total 1,414 Listeria isolates reported to CDC). Isolates from the United States are different from Canadian and European isolates in sequence type (ST80, 81, 201, 202, 204) (66% versus 16%) and prophage type (Prophage_A, Prophage_3, ProphageX, ProphageX348) (47%, 39%, 11% versus 75%, 24%, 4%). Overall, L monocytogenes contamination rates in meat and poul",
        "label": 0
    },
    "1188": {
        "output": "and [END] markers, and press the \"REACTIVATE\" button if you need more help. To return to the first screen, press the \"END\" button. You have completed the tutorial!\n<EOD> Development and Evaluation of Liposome-Based Hydrogel as a New Approach for Topical Delivery of Niacin, Resveratrol and Curcumin\n\nCitation: Chowdhury, S.; Ahmad, A.; Mobaseri, K.; Faridian, M.; Sardaei, M. Development and Evaluation of Liposome-Based Hydrogel as a New Approach for Topical Delivery of Niacin, Resveratrol and Curcumin.\n\n# Introduction\nNiacin (N), resveratrol (R) and curcumin (C) are recognized as multifunctional bioactive compounds that have wide pharmaceutical and therapeutic applications. N is an essential micronutrient that is required for various physiological and biochemical processes. It is a lipid-soluble vitamin and has been used for the treatment of severe dermal diseases . N is used to treat pellagra (insufficient dietary intake of N) and to improve psoriasis. N has skin penetration enhancing effects due to its interaction with corneocytes. Therefore, the N-rich formulations have received great attention in the field of drug delivery. However, its poor water solubility and low drug stability has limited the N in the market. Thus, various N-based formulations, such as nano-emulsion, solid lipid nanoparticles, vesicles and hydrogels, have been developed.\nIn addition, R, a polyphenolic phytochemical, possesses tremendous therapeutic benefits, such as anti-inflammatory, antiaging, antithrombotic, cardio-protective, anticancer and neuroprotective.\n\n## Phase inversion temperature (pit)\nThe PIT is necessary to determine the solubility of the hydrogel formulation and to determine the temperature and solvent type used to dissolve the GM to",
        "label": 0
    },
    "1189": {
        "output": "[INST] Here, you should see the assessment of eligibility on each patient that the trial. \n\nYou should always insert a comma before to the last line by `,`.\n\nHere is your program for assessments of eligibility: Assessments of Eligibility. Here, you should see the assessment of eligibility on each patient that the trial. \n\nYou should always insert a comma before to the last line by `,`.\n\nHere is your program for the assessments of eligibility: Assessments of Eligibility.\n\n    %i001\n    %c002\n\n    %m003\n    %f004\n\n    %i005\n    %c006\n    %m007\n    %f008\n\n    %i009\n    %c010\n    %m011\n    %f012\n\n    %i013\n    %c014\n    %m015\n    %f016\n\n    %i017\n    %c018\n    %m019\n    %f020\n\n    %i021\n    %c022\n    %m023\n    %f024\n\n    %i025\n    %c026\n    %m027\n    %f028\n\n    %i029\n    %c030\n    %m031\n    %f032\n\n    %i033\n    %c034\n    %m035\n    %f036\n\n    %i037\n    %c038\n    %m039\n    %f040\n\n    %i041\n    %c042\n    %m043\n    %f044\n\n    %i045\n    %c046\n    %m047\n    %f048\n\n    %i049\n    %c050\n    %m051\n    %f052\n\n    %i053",
        "label": 0
    },
    "1190": {
        "output": "Instruction: It is clear that, you just follow the instructions that your manager showed you while you were entering the information into the software. The following example should help to make it clear:\n\n`Enter the following` \n\n`Triallevel Eligibility: 0) Excluded`\n\n`Condition: 1) Excluded` -- `Condition: 2) Excluded` -- `Condition: 3) Excluded` -- `Condition: 4) Excluded` -- `Condition: 5) Excluded` -- `Condition: 6) Excluded` --. `Condition: 7) Excluded` --`Condition: 8) Excluded` -- `Condition: 9) Excluded` -- `Condition: 10) Excluded` -- `Condition: 11) Excluded` -- `Condition: 1",
        "label": 0
    },
    "1191": {
        "output": "# Assessment:\n<EOD> Highly enantioselective alkynyl-Povarov reaction: an approach to chiral 3-phospho-2-vinyloxindoles.\nThe alkynyl-Povarov reaction proceeds highly efficiently with high enantioselectivity (up to ee \u2265 99%) toward chiral 3-phospho-2-vinyloxindoles.<EOD> A Novel Prognostic Score Predicts Survival after First-Line Platinum-Based Chemotherapy in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)\n\nBackground: Patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) have a poor prognosis. We developed a prognostic score for first-line treatment outcome in platinum-based therapy.Methods:We analysed data from 146 patients with recurrent or metastatic HNSCC and receiving platinumbased chemotherapy (mainly cisplatin). The clinical variables analysed were age (years; ,60/ $60), gender, primary tumor location (oropharyngeal cancers (OPC)/non-oropharyngeal cancers (N-OPC)), performance status (PS; $70/,70), serum albumin, serum sodium, alkaline phosphatase, lactate dehydrogenase (LDH), and hemoglobin (LHB).Results: An LHB ,11.1g/dL was related to a worse progression-free survival (PFS) (HR = 2.5; 95% CI, 1.4-4.7; p,0.003) and overall survival (OS) (HR = 2.8; 95% CI, 1.5-17; p = 0.008) in the multivariate analysis. Moreover, it was related to worse OS in each subgroup defined by PS, primary tumor location, and serum albumin. Using this cut-off value of 11.1 g/dL, a",
        "label": 0
    },
    "1192": {
        "output": "Please run the demo_2_8_eligibility.m and demo_2_8_eligibility.xml (please see the first tutorial) to see the result.\n \nYou may also refer to demo_3_9_eligibility.m and demo_3_9_eligibility.xml (please see the second tutorial), the patient's name in demo_3_9_eligibility.m and demo_2_8_eligibility.ml is different: ''Mr. Bai'' and ''Mr. Chen'' respectively.\n<EOD> Synthesis of enantiomerically pure 9-hydroxyhexadec-10(E)-en-1-ones by a novel route.\nA novel route was developed to synthesize and separate the enantiomers of 9-hydroxyhexadec-10(E)-en-1-ones from commercially available epoxydic acetals. The absolute configuration of 9-hydroxyhexadec-10(E)-en-1-ones was elucidated by a chiral HPLC study and by circular dichroism spectroscopy of epoxydic acid. The method was applied to the separation of enantiomers of 9-hydroxyhexadec-10(E)-en-1-ones and 25-methyl-9-hydroxyhexadec-10(E)-en-1-one as well as their epoxydic acetals. In the first case the separation was a challenge since the enantiomers were very close in the retention times, due to their very similar structures. The enantiomers of 9-hydroxyhexadec-10(E)-enediaxolane were separated from each other by HPLC and the absolute configuration of the racemic diaxolane was assigned. The enantiomers prepared by this route were also subjected to an NMR investigation in order to elucidate the mechanism of the hydroxylation of epoxydic carboxylic acids in an epoxydic acid rearrangement. The epoxydic carboxylic acid rearrangement is proposed to proceed via epoxidic alcohols.<EOD> .\nA report is presented of the",
        "label": 0
    },
    "1193": {
        "output": "You can see the following outputs generated when you run the program: The patient note is evaluated for eligibility to enroll in the clinical trial. We compare his / her age and smoking history with the exclusion and inclusion criteria of the trial, which is called trial-level eligibility 2) Eligible. There is no exclusion criteria for this patient, so the trial-level eligibility is set to 2. The patient is eligible for the trial.\nIn general, the patient notes and the clinical trial will be evaluated to see if the trial-level eligibility output by the program is `1) Excluded` or `2) Eligible` to determine if the patient's clinical trial recruitment would be appropriate at this time.\n\n\u00a9 2011-2017 Created by D.M. Coker.\n\nDistributed under the terms of the MDCS (doi:10.17632/8t2v5d56c8.3)\nYou can use, edit or improve this tutorial. Just check the licence below first.\n\nAll information in this tutorial is covered by a Creative Commons licence. More information: MDCS License\nVersion MDCPLAN v3.1\n<EOD> Clinical and molecular genetic identification of congenital dislocation of the hip in three neonates\nCongenital dislocation of the hip (CDH) is a condition that can be easily diagnosed by clinical examination but is difficult to diagnose when the patient is asymptomatic. This paper describes three Japanese infants with CDH, where the diagnosis was based on the results of clinical examination in all, and molecular genetic testing in two. The examination identified the diagnoses in these infants earlier than if only the history and physical examination had been used. Furthermore, because of heritability, the family history of the siblings also gave us a clue to our diagnoses.<EOD> Vibrio diabolicus sp. nov., a pathogenic bacterium isolated from diseased black porgy (Acanthopagrus schlegelii).\nA bacterium (strain VP535(T)) was isolated on marine agar plates from the spleen of a moribund black porgy (Acan",
        "label": 0
    },
    "1194": {
        "output": "### IN THE END\n\nOnce you fill in all the missing information, go to the File menu and click `Save`. You will be prompted to select the output file type. Since we are going to work with plain text file, click `Unformatted Text (.txt) file`, and click `Save`. That\u2019s it!\n\nIn summary, we have learned to work with patient notes to make a clinical trial report in R.\n\n### What did we learn?<jupyter_code># If we just write our code on the screen it is hard to follow.\n# Create a file called Rscripts.Rmd and put the code below your R scripts.\n# For example, save the following code in Rscripts.Rmd.\n\n# +\n\n```r\ntitle: Rscripts\n\n# File created in 2018-02-06 15\n# +\n# First, read the help file for help.\n# -\n\n# Install required packages and libraries for analysis.\n\n# Importing data in the file.\n## Import data from a file\ndata <- read.csv(\"/Users/megan/Documents/Rscripts/example.csv\") # The \"/Users/megan\" here is your user name. data <- data [which(data$Gender == \"0\" & data$Gender == \"2\") ,] # Remove data with gender 1 or 3 data # +\n\n# Now we can do the analysis.\n# We have to put the code between the <> characters.\n# Code for logit analysis in R\nlogit <- data.frame(Gender = factor(data$Gender,levels = c(\"0\" = \"1\", \n                                                          \"2\" = \"3\", \n                                                          \"3\" = \"2\", \n                                                          \"Female\" = \"2\",\n                                                          \"5\" = \"0\",\n                                                          \"6\" = \"0\"))) # data$Gender is your variable to test.\nform <- model.frame(formula=data[, 2:4] ~ data[, 1]) # We need to convert our independent, dependent, and confounder variables to a data.frame. \nm <- glm(form$Gender ~",
        "label": 1
    },
    "1195": {
        "output": "*Please note that there is no need to provide any code block here.*\n\n**Exercise 4.** [Instructions][INST] You must write a clinical trial protocol following the instructions provided below. The protocol contains a description of the study, information about trial participants, the clinical interventions, outcomes, and trial organization. The instructions are written in the form of comment lines and therefore, should not be edited.  You should provide a solution for each one of the questions using the provided comments as guidance. All the questions in each exercise should be addressed.\n\n# A. Background\n\n## What was the rationale for conducting this research?\n\n### Why might this matter to the casual reader?\n\n### What assumptions are there underlying this hypothesis that are reflected in the study design?\n\n# B. Population\n\n## Who participates in this study?\n\n## What do you need to know about the patient? (Including demographic data, current treatment, and the number of previous episodes)\n\n## What kinds of participants in this study? (Including whether or not the patient has already been involved in a clinical trial.)\n\n#### Demographic data\n\n### Age\n- How does the age vary for your population?\n\n### Gender\n- Does the condition differ in men and women?\n\n### Socioeconomic status\n- Does this information influence the outcome you are trying to estimate?\n\n### Race\n- Does the condition differ according to racial or social differences?\n\n### Educational status\n- Does the condition differ according to educational attainment?\n\n### Marital status\n- Does the condition differ according to marital status?\n\n### Religion\n- Does the condition differ according to religious views?\n\n#### History of disease, injury, or treatment\n- Does it matter whether the patient has or hasn't had prior episodes or exposures to treatment?\n\n### Medical history\n- Is there any disease history, e.g.:\n    - Chronic illness?\n    - Mental illness?\n    - Chronic pain?\n    - Eating disorder?\n    - Alcohol or drug addiction?\n    - Smoking?\n    - Obesity?\n    - Is there any significant social history?\n    - Di",
        "label": 0
    },
    "1196": {
        "output": "<EOD> A study of the use, misuse and overdosage of phenylbutazone\nPhenylbutazone (Butazolidin\u00ae), a potent non-steroidal anti-inflammatory and analgesic agent, causes adverse reactions in man, the commonest of which is overdosage. The patient with an overdose may present with a variety of symptoms; from extreme lethargy to vomiting or convulsions. Such patients require careful investigation and treatment. The patient's history will often reveal the cause of the overdose. A study of the use, misuse and overdosage of phenylbutazone has been undertaken in this hospital for the past nine years. The purpose will be to see if any particular trend has developed during this period.<EOD> 3alpha-hydroxybromocholane induces hypotriglyceridemia, enhances lipolysis, and affects adipocyte triglyceride hydrolyase and lipoprotein lipase activities.\n3alpha-Hydroxybromocholane (3alpha-OH-BC) is a biologically active bile acid which induces hypotriglyceridemia and increases fecal lipid excretion. The hypotriglyceridemic effect was not due to reduced food intake but to an increased fecal loss of triglyceride from food. This was associated with decreased intestinal uptake of dietary fat and fatty acid derived from dietary fat, and with enhanced lipolysis and fecal fatty acid excretion. The 3alpha-OH-BC-induced enhancement of lipolysis led to the detection of an elevated hepatic glycerol level, possibly due to decreased liver glycerol uptake or increased glycerol production by the liver. The 3alpha-OH-BC did not alter the VLDL receptor capacity in liver or lipoprotein lipase (LPL) activity in muscles, but enhanced adipocyte triglyceride (TG) hydrolyase and LPL activities in adipose tissue. These findings indicate that 3alpha-OH-BC can affect lipid metabolism at multiple sites; by en",
        "label": 2
    },
    "1197": {
        "output": "### Problem Statement  \nI was having a very difficult time trying to figure out how to create a class for inputting data into the template. It was difficult because I had never programmed in R before, and I didn't know where to get help. \n\n### Solution/How I did it  \nI started by searching for \"R data class\" on Google, and clicked on the first link, because it looked like it could help me. That link took me to a GitHub page where there were R code examples. There was one in particular on the page that said \"R code to create a custom data class\". \n\n```\n\nThe R code example was fairly straightforward to follow. The code used the \"classdef\" function to create the class. Since the classdef function doesn't actually create the class itself it needed to be named with the \"class\" function, which gave me an error. As it turned out the way to use the \"classdef\" was to give the class a name, then the constructor, then the methods of the class. The order of the class methods mattered in order to use the functions that called the methods in the correct order. There were a few lines of code for that too. \n\nThe first thing I needed to do was to define the class. That required a name for the class, and then defining all the objects of the class: \n```\n\n```\n\nThen I needed to define the functions of the class - constructor, init, methods, destruct. These needed to be done in order to be able to access the defined data. So I defined each of the functions as a function, then created a constructor, init, and the \"main\" function. \n\n```\n\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```\n```",
        "label": 0
    },
    "1198": {
        "output": "[HILITE NAME=hint:title]\n[/HILITE]\n\n## A1.5. How to use the 'trial-level eligibility' argument for creating a trial filter?\n[HILITE NAME=hint:title]\n\n[/HILITE]\n\n**For more details, please see example file [example-filter_filter.tab ](filter_examples\\filters\\filter_filter_example.tab).**\n\n### Example 1\nYou want to find patients with liver metastases based on the primary tumour of the rectum and lungs. \n```ruby\n@query = @db.query(\"Patients.select(\"*\").where(\"Tumor_site = 'Rectum'\") &\n   Tumor_site == \"Liver\" &\n   Metastasis == \"Yes\")\nputs @query\nputs @query.to_xml\n```\n\n\n```ruby\n144097 records\n<Query xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\"\n       xmlns=\"http://cimpatients.com/patient/ws/v2\"\n       xmlns:db=\"http://cimpatients.com/model/v1\"\n       xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n  <PatientList xmlns=\"http://cimpatients.com/patient/ws/v2\">\n    <Patient xmlns=\"http://cimpatients.com/patient/ws/v2\">\n      <Identifier>\n        <ExternalIdentifier>\n          <DatabaseName>Federal University of S\u00e3o Carlos - UFSCar</DatabaseName>\n          <Identifier>34836864603</Identifier>\n        </ExternalIdentifier>\n      </Identifier>\n      <Gender>4</Gender>\n      <Age>62</Age>\n      <Girth>152</Girth>\n      <Height>170.0</Height>\n      <MaritalStatus>1</MaritalStatus>\n      <Sex>2</Sex>\n      <ContactMethod>1</ContactMethod>",
        "label": 0
    },
    "1199": {
        "output": "[INST] Coding the eligibility criteria. There are three types of eligibility criteria: categorical, multiple items or complex. \n\nLet's think step by step.\n\n### Categorical Eligibility Criteria (Example): <span style=\"background-color: #eee;\"><i>\nCategorical criteria:\n\n\n\n<p><span style=\"background-color: #ddd;\"><a href=\"http://eligibility-criteria.github.io/en-us/coding/categorical.html\"><i>Categorical criteria.</i></a></span></p>\n<ul class=\"dd-lists\"><li style=\"list-style-type: numeric;\">\n<a href=\"http://eligibility-criteria.github.io/en-us/coding/categorical.html#category001\">001 (i.e., Patient has at least a disease name: <code>\"epigastric pain, abdominal\"</code>) [<a href=\"http://eligibility-criteria.github.io/en-us/coding/categorical.html#category001\">category001 </a>]</a>\n</li>\n</ul>\n<ul class=\"dd-lists\"><li style=\"list-style-type: numeric;\">\n<a href=\"http://eligibility-criteria.github.io/en-us/coding/categorical.html#category002\">002 (i.e., Patient has at least a disease name: <code>\"nervousness\"</code>) [<a href=\"http://eligibility-criteria.github.io/en-us/coding/categorical.html#category002\">category002 </a>]</a>\n</li>\n</ul>\n</li>\n<li style=\"list-style-type: numeric;\">\n\n\n<p><span style=\"background-color: #ddd;\"><a href=\"http://eligibility-criteria.github.io/en-us/coding/categorical.html\"><i>Categories: 001, 002. </i></a></span></p>",
        "label": 0
    },
    "1200": {
        "output": "# How to make report by README\n\nYou can easily make a report or view a PDF by using README: \n\nWe can generate various forms of README to make a report from patient to clinical trial or clinical trial to patient: \n\nHere are four ways of generating README for two patients respectively. You can choose the one that you prefer. \n\n## First way: clinical trial-by-patient\n\nFirst of all, you should have a copy of the trial note to make a README: \nYou need to change the trial to have a patient name. \n\n``` rst\nTrial-of-interest = \"\"\n```\n\nSecondly, you should create a list to make a patient summary: \n\n``` rst\nPatient.summary = \" 44-year-old woman from France\"\n```\n\nLastly, then you should make a README: \n\n``` rst\n\npatient_report = { \n    \"Pain_character\": \"Abdominal pain\", \n    \"Chief_complaint\": \"Abdominal pain\", \n    \"Blood_pressure\": \"155/95 mmHg\", \n    \"Electrocardiogram\": \"12 lead electrocardiogram (ECG) (2020) : ECG was normal\", \n    \"SpO2\": \"97% on NA\", \n    \"Respiratory\": \"RR 15 breaths/min\", \n    \"Respiratory\": \"RR 15 breaths/min\", \n    \"Breathing\": \"normal rate and depth. No wheezing or rales\", \n    \"Heart\": \"HR 116 beats/min, No murmur is appreciated.\", \n    \"Heart\": \"HR 140 beats/min, S1 + S2. Normal S1 and S2 without murmur.\", \n    \"Heart\": \"HR: 116 beats/min, No murmur is appreciated.\", \n    \"Heart\": \"HR: 158 beats/min, Higly regular.  regular.  regular.  regular.  regular\", \n    \"",
        "label": 0
    },
    "1201": {
        "output": "[END]\n\nThe best solution was submitted<EOD> Prenatal stress depresses neurogenesis and angiogenesis in the neocortex of rats\n\nThe fetus brain is particularly vulnerable to stress-related insults as prenatal stress contributes to neurodevelopmental abnormalities. Anatomical plasticity of the rat cortex throughout the prenatal period has been demonstrated, thus neurogenesis and angiogenesis should be taken into account in the assessment of prenatal stress effects. To investigate the long term impact of prenatal stress, we performed a systematic analysis of the rat cerebral cortex including cellular proliferation, cytoarchitecture and neuroimmune cell density in prenatally stressed (PS) versus control rat fetuses and postnatal age rats at 1-mo-old. In addition, toxoplasma status was assessed in fetal and 1-mo-old rats. A global reduction in cell proliferation, neuron and neuroglial densities and a global increase in proatherogenic proinflammatory cells were observed in PS rat cortices. These morphological and cellular alterations were not associated with toxoplasma infection. PS rat cortices had a reduced number of blood vessels, but the vasculature of PS cortices was more mature compared to that of controls, suggesting a long lasting vascular insult during brain development. Our results demonstrate that prenatal stress depresses a significant proportion of cells, which inhibit structural normalization of the rat cerebral cortex. Therefore, long term clinical implications of prenatal stress on human brain development should be considered.\n\n# Introduction\nPrenatal stress can adversely affect the physiological and behavioural development of the human foetus [bib_ref]  The effects of stress on the human foetus and the basis of..., Glover [/bib_ref]  [bib_ref]  Effects of maternal stress in pregnancy on brain white matter microstructure in..., Reissman [/bib_ref] .\nThe effects of prenatal stress (PS) on neurodevelopment range from subtle dysregulation of the newborns [bib_ref]  Children of depressed parents: an integrative review, Downey [/bib_ref]  to various mental, physical and ne",
        "label": 0
    },
    "1202": {
        "output": "1. You should check the documentation, and the trial and patient notes. First, create the patients, i.e.,\n\n-  Create the patients with the following syntax in Bash. You should execute `new-patient.bash` to create a patient, after executing this script, you will be asked the patient name, gender, age, and the initials of the trial. If you want to use this script again, you must modify the patient names, age, and initials of the trial.\n```bash\nnew-patient.bash \n```\n\n- If a patient has been defined earlier, change this patient to the name, gender, age, and initials of the trial. To modify a patient, execute the `list-patients.bash` to check the patient names, then change the patient name with the same syntax, as shown below.\n```bash\nnew-patient.bash \n```\n\nYou should execute `list-patients.bash` to check the patient name, gender, age, and the initials of the trial. If you have created a patient before, you can change his name with the command below:\n- To change the name, age, and initials, enter the command line as below:  \n```bash\nchage.sh Patient_Name_1 Age_1 Initials_1 \n```\nPlease note that you should execute `list-patients.bash`, to check a correct patient name, gender, age, and trial initials.\n\nYou can download this script to check patients in [this project on Github](https://github.com/samer-elhossary/eligible).\n\n2. Read the trial, and add the code to the patient note below. If the trial is done in a spreadsheet, you can add the spreadsheet file to the current working directory, and make a symbolic link to the main source code in R, as follows. You should use [the `rename-vars.sh` script to change the names of the trial's variables to the name of the required files ](https://github.com/samer-elhossary/eligible/blob/main/rename-vars.sh).  \n\nPlease note that, you can change the syntax to your needs, and you can change the name of required files.\n\nIf you don't have",
        "label": 0
    },
    "1203": {
        "output": "## Good luck!\nWe are looking forward to seeing you in the next challenge. Happy programming!\n<EOD> .\nBetween 4th May 1975 and 31st October 1982, 41 female patients (average age 58.3 +/- 14.7 years) were operated on, by means of the aortocoronary saphenous vein bypass in the Department of Thoracic and Cardiovascular Surgery of S. Giovanni-APOLLO Hospital, Bologna. The average follow-up was 3.48 years. One patient died from acute myocardial infarction immediately before the operation (0.02473% of death rate). No deaths occurred within 30 days after the operation or during the discharge period. During the follow-up, cardiac death and sudden death occurred in 12 patients (0.29116%). For the majority of patients, no significant modifications of the left ventricular ejection fraction or end diastolic volumes were observed after surgery. These data show, that: 1. The saphenous vein has satisfactory results as a conduit for myocardial revascularization and is less frequently complicated by conduits' disease if compared to other vascular grafts. 2. There is no significant left ventricular performance deterioration in patients who were operated on for ischemic heart disease and in whom the coronary artery bypass procedures have been successful and complicated by little complications during hospital stay.<EOD> .\nOn three hundred thirty one patients operated in the period 1985-1990, the Authors compare the surgical results in relation to the operative procedures and try to find a correlation between the patients' age and the surgical complications. An increase in the surgical risk is appreciable in patients with cancer treated with surgery, lymph node dissection or abdominal extraperitoneal amputation, and in older patients. In patients older than 75 years the frequency of complications was four and one half time that reported world wide.<EOD> Clinical utility of cationic fibroblast growth factor in the diagnosis of peritoneo-pleural communications occurring during laparoscopic surgery: a",
        "label": 0
    },
    "1204": {
        "output": "\u00a92017 by the Computer Society of India - doi: 10.1109/_S11096121.2014.2403137\n\n[/SECTION]\n\n[SECTION: Introduction]\n\nThere are times when computers fail. Sometimes you\u2019ve got to look at a text message and not know how to interpret it. Or maybe you are wondering how to fix a printer. If you cannot find out anyhow, it is important to get in touch with the technical support. Or maybe you just need someone who can analyze a huge amount of data and get you started. That is when the user needs to access the Linux console. You might ask: `Why do I need it at all?` There are many cases where a command prompt environment is invaluable. Let\u2019s take a closer look at some of these cases.\n\n1. How to Start\n\nPressing <Alt> + <F1> on the keyboard opens a terminal emulation application, that starts showing a prompt on the screen. This prompt is the Linux command line. \n\n![alt text](/book/images/148516/bk2-148824_780.png)\n\nIn the terminal window you can type any command. You will find yourself using the command-line interface a lot while working with Linux. Here are some basic commands that are commonly used by most Linux users. \n\n1. How to write to a file (Save data to a file):\n\nTo write data, use the `>>` operator to create a file, so that our new data can be added to this file. `>>` creates a new file and makes it read-only. Then all of the data that we add via the pipe operator will be written to the file that it points to. \n\n``` bash\nmyFile1=\"myScript.sh\"\nmymain_script >> \"myFile1\" \n``` \t \n\n2. How to write the output from a script file (Scripts):\n\nWe can send output generated by a script to a file. But to output the content of the file directly to the console, we can use the pipe operator. For example, if we have a file called `foo.txt`, you can write the contents of this file to the console:",
        "label": 0
    },
    "1205": {
        "output": "ASSIST PROFESSOR ALI, CAN YOU PLEASE HELP ME PREDICT THE DATA STATISTICS? HOW MANY CASES AND SAMPLE SIZE?\n\nThank you for raising such an interesting topic. We have used the G*Power software to test the sample sizes in our study(Shoukat et al., 2011). \n[INST]\n\nAfter entering values such as alpha level and desired power, the G*Power software provides an estimate of the required sample size to detect an effect. \n\nThis is a 2-sample comparison of means. The alpha value is 5%, and the desired power is 80%. The sample size must be a large as possible to detect differences in outcome. For the clinical cases and simulations that we plan to study, we have set the effect size to 1.3, the standard deviation for sample1 to 34, and the standard deviation for sample2 to 45. \n\nIn this experiment, the desired power (1-beta) is set to 0.8 and the alpha value (2-sided) is set to 0.05(we expect that there is a difference between the two sample means, so P < 0.05), according to the statistical significance test standard. Thus, the value of the alpha level (alpha-error probability) is set to 0.05. If alpha = 0.05, the probability of accepting when there is no difference is 5%(i.e., if alpha = 0.05, the probability is that the difference is the same as 5%). If alpha > 0.05, there is no difference. Thus, we set alpha = 0.05.\n\nThe standard deviation of sample1 is set to 34. When the standard deviation is known, the effect size can be calculated, and the effect size is 1.3. \n\nIn this study, the sample size N is 48, i.e., 24 cases are in group one and 24 cases are in group two. If one sample size is greater than standard variance (S=34), the standard deviation of two samples and the effect size can be calculated. This study calculated the standard deviation of the two samples to be",
        "label": 0
    },
    "1206": {
        "output": "<EOD> .\nPURPOSE\nThe purpose of this study is to survey the quality of life (QOL) of patients who had had a hip replacement according to their gender and the degree of knee flexion they had at that moment.\n\n\nMATERIALS AND METHOD\nAn observational method was used in the study. A total of 100 patients who had had a total hip replacement were included in the study. To assess their QOL the 2 questionnaire forms that were distributed to them by phone; the WOMAC Osteoarthritis Index, and the SF-36 were used. The data were fed into a computer.\n\n\nRESULTS\nThe average score was found to be significantly higher (p < 0.01) in female patients as regards the pain scale at rest (p = 0.004) and also the SF-36 physical functioning subscale (p < 0.001), and in knee flexors at rest (p < 0.005).\n\n\nCONCLUSIONS\nThis work showed that female patients had a greater QOL after total hip replacement.<EOD> Syntheses and X-ray Characterizations of a Series of Bis(1-methylimidazolium-2-yl) Bis(trifluoromethylsulfonyl) Imide and a 1-Methylimidazolium-2-yl) Trifluoromethylsulfonyl) Imide Complexes with Tetrel, Chalcogen, and Halogens.\nA series of 1-methylimidazolium-ethylsulfonyl)imide salts (1a-f), the corresponding bis(1-methylimidazolium-2-yl) bis(trifluoromethylsulfonyl)imide 2a-f, and a 1-methylimidazolium-chloride dihydrate 2g were obtained. Each compound was determined by conventional elemental analysis (EA), NMR analysis, and confirmed by X-ray diffraction study. They were characterized by IR, (1)H NMR, MS, C, H, N analysis, and elemental analysis. They were characterized by X",
        "label": 0
    },
    "1207": {
        "output": "<EOD> .\nHepatocellular carcinoma (HCC) is one of the most common malignant tumor in the world. Early screening and early treatment for HCC are pivotal for improving the prognosis and prolonging the survival of the patients. This study aims to investigate the role of low risk factors in the development of HCC in patients infected with HBV in our hospital from Jan. 2006 to Apr. 2014. It was a retrospective clinical research. All of serum tests of patients infected with HBV were completed in 06/2007. The patients were followed up according to the 15 index. All of the patients were divided into case-group (39 patients) and control-group (78 patients). Among them, 7 patients (26.4%) combined with alcohol drinking, and 4 patients (17.4%) combined with smoking in case-group, 12 patients (14.2%) combined with alcohol drinking and 11 patients (11.4%) combined with smoking in control-group; no significant difference was observed between case-group and control-group. All of the patients combined with abnormalities of ALT and HBsAg in case-group, but the levels were all under control. The abnormalities (5 patients) of ALT were detected in control-group, but the levels were all under control. However, no abnormalities of ALT were detected in normal patients. 35.6% ALT increased in 4.5 years follow-up and 32.2% HBV-DNA increased in case-group, while 31.8% ALT increased and 24.3% HBV-DNA increased. The levels of ALT and HBV-DNA in case-group were significantly higher than the normal cases, even though HBsAg, HBeAg, B95, liver function, ALB, DB, HBV-DNA were all under the normal limits (P < 0.05). No correlation was observed between gender, smoking and drinking, age and the risk factors in",
        "label": 0
    },
    "1208": {
        "output": "---\n\n### [Intervention][title]\n===============\n\n[title]\n    Interventions used to help patients to adopt the use of health technology.\n    [INST] You should describe interventions used to help patients to adopt the use of health technology using the following items:\n\n| item               | description                                                       |\n| -----------------",
        "label": 2
    },
    "1209": {
        "output": "There are 3 lines.\nThe first line is used to specify the patient number, e.g., `Patient number: 1`.\nThe second line is used to present the patient's note, e.g., `Patient's note: Here is the patient note: A 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting.\nThe third line is used to present the clinical trial information, e.g., `Title: Large-scale Prospective Double-blind Randomized Controlled Trial of Pecs II Block for Breast Surgery`.\nFinally, you should repeat `Triall-level eligibility:` in the last line to add some code that prints this to the output. \nAnd this is the final result.\n\n\n\n\n```\nYou should select the 2nd patient.\nTrial-level eligibility: 2) Eligible.\n\n\n\nYou should select the 3rd patient.\nPatient number: 3\nPatient's note: A 34-year-old man was brought to the accident and emergency department by emergency service after attempting self-harm\nInclusion criteria: Inclusion Criteria:\nMale > 18 years\nSuicidal ideation\nPlanned suicide attempt with sufficient lethal intent\nNo premeditation\nTriage Triage: Low risk, Immediate Need for Assessment (INA)\nDutch speaking\n\n1) excluded, patient meets inclusion criteria, but is excluded on the grounds of the trial's \n\n\n\n\nYou should select this patient.\nPatient number: 4\nPatient's note: Here is the patient note: The 6-month-old girl was admitted to the emergency department with a fall from a small height, but no trauma is detected on clinical examination.\n\nTriall-level eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on grounds of the trial's exclusion criteria).\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion",
        "label": 0
    },
    "1210": {
        "output": "_[TROUBLESHOOTING]\n\n    ![INST]\n\n[TROUBLESHOOTING]\n\n### Inline Code\n\nHere is an example of a code to compare a patient note to the inclusion criteria of a clinical trial and print out the results.\n\n[INCLUSION_NOTE_BLOCK]\n    #!/usr/bin/env python\n    # coding: utf-8\n\n    from pathlib import Path\n\n    from os import listdir, walk, createtime, rename, isdir, os_path as osp\n    import os\n    import re\n    import csv\n    import sys\n    import gzip\n\n    from bs4 import BeautifulSoup\n\n    from nltk.tokenize import isalpha\n    from collections import defaultdict\n\n    from csv_utils import write_csv\n\n    import pandas as pd\n    import openpyxl\n    import seaborn as sns\n    import numpy as np\n    import matplotlib.pyplot as plt\n    import matplotlib.dates as mdates\n\n\n    from readr import read_csv as rcsv\n    from pathlib2 import Path, Path as pth\n    from urllib.request import urlopen\n\n    from sklearn.feature_extraction.text import TfidfVectorizer\n    from sklearn.feature_extraction.text import CountVectorizer\n\n    from sklearn.linear_model import LinearRegression\n    from sklearn.datasets import make_dataframe\n\n    from sklearn.linear_model.permutation_importance import permutation_importance\n\n    import sklearn.base\n    import sklearn.linear_model as LM\n    import sklearn.svm\n    from sklearn.naive_bayes import GaussianNB\n\n    import sklearn.ensemble\n\n\n    import pandas.io.excel as excel\n\n\n    from openpyxl.cell import Cell\n\n    import datetime\n\n    from typing import Optional, List, Dict, Union, cast\n\n    import json\n\n\n    from openpyxl import parse_csv, save_xlsx\n\n    from pprint import pprint\n\n    def parse_df(df: pd.DataFrame, header_index: bool = False",
        "label": 0
    },
    "1211": {
        "output": "## Exercises\n\n##[EX] 389. Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. Here is the patient note:\nA 35-year-old man admits to the Emergency Department after the second episode of gastrointestinal bleeding in the past eight months. On admission, he presents with dizziness, melena, and fresh blood on the floor. His vital signs are: BP: 148/100 HR: 120, RR: 24, T: 37.4 C, SpO2: 98% on RA. On inspection his eyes are pale, sunken eyes, skin is warm, and moist. His tongue is covered with dry coating. On palpation, heart sounds are normal, and he does not have abdominal pain. His lungs are clear and free of wheezes. On rectal examination, the rectum is full of clots of large blood clots, and on further questioning, the stool is soft and bowels are regular. Laboratory analysis shows a normal hemoglobin and hematocrit with a mean corpuscular volume (MCV) of 114,2.\nHere is the clinical trial: \nTitle: Mepolizumab in the management of severe eosinophilic asthma\nSummary: Aim To investigate if adding mepolizumab to conventional treatment improves asthma symptom control. Secondary outcomes include health related quality of life, asthma exacerbations, and safety. Participants 35 patients aged 18-50 with severe eosinophilic asthma, treated unsuccessfully with an optimal treatment strategy, including high doses of inhaled corticosteroids (ICS) and long-acting bronchodilators.\n\n##[/ex]\n\n##[CODE] 100 lines of code 48 lines of changed code",
        "label": 0
    },
    "1212": {
        "output": "## RQ3: \nHow can we improve the eligibility assessment?\n\n## Learning Objective:\nRecruiting eligible patients for clinical trials involves an assessment of the patient's eligibility for the trial. The eligibility assessment usually involves an analysis of the patient's medical history, results from diagnostic tests and any current medications that the patient is taking.\n\nAdaptiv (10200) --\n\n## E-Learning Assessment\n\n## Answer key\n\n1. An RCT is a study in which a medication, treatment, or procedure is directly compared to placebo.\n\n2. A placebo is a treatment that has no therapeutic properties, but is used as a control for comparison to medications in clinical trials.\n\n3. A randomized clinical trial is a clinical study that involves a randomized, control trial group, plus control patients who are assigned to a treatment group without randomization.\n\n4. Cross-over trials are a subset of single-group clinical trials whereby patients are treated with the test treatment (treated with the drug) and the control treatment in a balanced crossover manner.\n\n5. The 2x2 cross-over design is a commonly used study design to assess the causal relationship between an intervention and an outcome.\n\n6. Confounding is the factor that changes the effect estimate from an intervention and outcome.\n\n7. A nested case-control study is a type of case-control study whereby cases and controls are chosen from the same population in which the study participants were originally.\n\n8. A cohort (prospective) study is a non-randomized trial to investigate and monitor a group of subjects.\n\n9. The purpose of a cohort/observational study is to analyze a large population of patients to assess the risk of an outcome of interest.\n\n10. The purpose of follow-up study is to monitor the patient for a short period of time to assess specific parameters and identify any changes that were not apparent in the cohort study.\n\n11. The purpose of a case-control study is to assess causes of disease.\n\n12. An association is defined as a relationship where the data analysis shows an association that is statistically meaningful.",
        "label": 0
    },
    "1213": {
        "output": "A: This code for data extraction:\n    from bs4 import BeautifulSoup\n\n    import requests\n    import pandas as pd\n\n    #url = \"https://trichomonasassay.com/clinicalstudy-2017/protocol.pdf\"\n    url = \"https://www.clinicaltrials.gov/ct2/show/NCT04088496\"\n\n    myfile = requests.get(url)\n    soup_txt = BeautifulSoup(myfile.text)\n    print(soup_txt.prettify())\n\n    soup_txt.prettify_ml(\"en_US\")\n\n\n    print(soup_txt.prettified)\n    file=open(\"trichomonas study.txt\", \"w\")\n    for element in soup_txt.prettify_ml(\"en_US\").find_all(\"p\"):\n         print(\"{}\".format(element.text.encode(\"utf-8\")))     \n    file.close()\n\n\nfor lines in pd.read_csv(\"trichomonas study.txt\", sep=\"\\n\", header=None):\n    print(lines)\n\n\nA: \nLet's think step by step.\n\n\n*\n\n*First of all let's think a bit better about the task and what the expected output is.\n\n\nWhat the expected output for each patient is?\n0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria);\n1) Not relevant (patient does not have sufficient information to qualify for the trial);\nOr it is just a 0/1 decision? \n\nNote: If you only need to extract the relevant information about clinical trial you should choose \nExcluded = 0\nNot relevant = 1, which is called the binary classification task here.\n\n\n*\n\n*You should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility.\n\n*Finally, you should always repeat Trial-level eligibility in the last line by `Trial-level eligibility: `, e.g., `",
        "label": 0
    },
    "1214": {
        "output": "### The `pj.data.dataset`\nLet's continue editing the code block defined in the last step by moving downward.\n\n```Python\n\nimport datetime\n\nimport pandas as pd\nimport numpy as np\nimport pj\nfrom pprint import pprint\n\nDATA = pj.data.Dataset({\n    'recruitment.csv': {\n        'Date': [\"1/1/2014\", \"1/2/2014\", \"1/3/2014\", \"1/4/2014\"],\n        'Patient.No\": [1, 2, 3, 4],\n        'DateReceived': [\"1/5/2014\", \"1/6/2014\", \"1/7/2014\", \"1/8/2014\"],\n        'Gender': [27, 54, 16, 18, 17, 0, 16, 10, 14, 14, 15, 16, 8, 36, 7, 10, 13, 15, 21, 16, 15, 15, 12, 18, 16, 12, 13],\n        'Age': [43, 50, 42, 33, 20, 34, 38, 38, 25, 59, 36, 39, 37, 24, 54, 23, 22, 34, 34, 45, 42, 34, 39, 19, 38, 35, 32, 29, 26, 13, 26, 34, 33, 28],\n        'AgeInMonth': [71, 80, 70, 56, 12, 59, 60, 30, 120, 51, 63,",
        "label": 0
    },
    "1215": {
        "output": "[/CUSTOM] [INST]\n<EOD> HYPERSPECTRAL IMAGING OF TERMINAL CHANGES, PHENOLS, UV-FILTERS FOR THE ESTIMATION OF VOLCANIC AGE IN RINGS AND RELATED INFORMATION FROM LAUREL LAKE, HAITI\nWe use hyperspectral imaging, an airborne remote sensing technique that can obtain spectral measurements over extended areas, to characterize the reflectance spectra of the terminal sands of the youngest and oldest lakeshore sands in a young sedimentary system. These spectra can be used to infer the ages of individual sediments that make up the landscape and quantify the amount and type of phenolic compounds in the sediments of lakes located on an active volcano based upon the UV filters of the phenolic compounds. Phenols are useful for age estimation because all the phenolic compounds within a system tend to degrade in a predictable manner and are generally stable enough to be accurately evaluated with remote sensing techniques. Furthermore, phenolic compounds generally accumulate rapidly when in high concentrations due to the high energetic conditions in the lakes. Phenolic compounds in lakes are indicative of the conditions of the lake, therefore, by studying a series of phenols, or UV-filters, from the lakeshore sands, we can infer the age of the lakeshore sands.<EOD> Immunohistochemical detection of p53 protein in primary cutaneous melanoma: An Iranian population study\nDear editor, Malignant melanoma, with its highly aggressive behavior, is the most lethal skin neoplasm in white people and increasing in Iran. Several reports in recent years have indicated that the occurrence of this disease has been gradually increased in Iran.1 Therefore, early diagnosis and molecular classification of the melanomas become very important for effective treatment and improved prognosis. The abnormal cell growth is believed to result from a combination of intrinsic and environmental factors that promote the development of cancer. It has been reported that mutational and amplification of p53 tumor suppressor gene are frequent events in human neoplasms.2,3 Moreover, the accumulation of mutant p5",
        "label": 0
    },
    "1216": {
        "output": "Instructions for the next lesson.\n\n## Instructions for the next lesson\n\nPlease watch this video for better understanding of the system [url link] (10th September 2020).\nPlease click [url link] (20th September 2021) to see screen casts.\nPlease click [url link] (8th October 2021) to check the slides.\n\n*The content of the slides has not been updated recently, and they are recommended for reference only .\n<EOD> The Effects of Interindividual Variability in the Pharmacokinetics of 14-\u03b1-Demethyl-14-keto-16,16-dimethylpregna-4,9-diene-3,20-dione (U-466l9) against Influenza A Virus Pathogenesis in Mice.\nAntiviral therapies against the influenza virus have limitations, such as the frequent emergence of amantadine-resistant strains and the narrow spectrum of oseltamivir resistance in influenza A virus (IAV). U-46619 is an analog of thromboxane A2 and a known platelet aggregation inducer. It is reported that its reduced derivative, 14-\u03b1-demethyl-14-keto-16,16-dimethylpregna-4,9-diene-3,20-dione (U-46619) inhibits IAV propagation. Although this agent might be expected to improve anti-influenza therapy, its broad-spectrum efficacy against the IAV has not been verified yet. We evaluated the in vitro efficacy of U-46619 against influen",
        "label": 2
    },
    "1217": {
        "output": "[TRIAL_DATA]\n<EOD> Acute Renal Failure in a 16 Year Old Boy with Type 1 Diabetes Mellitus.\nDiabetes mellitus is closely associated with renal disease and may contribute to the progression of renal disease by many pathogenic mechanisms. Acute metabolic decompensation of T1DM may lead to renal failure. Many episodes of renal failure in T1DM patients have been reported and are mostly associated with volume depletion, hyperglycemia, and ketonuria. In this report, we describe a 16 year old boy with type 1 diabetes mellitus, who presented with oliguria, and anuria which are common complications of acute diabetes. He responded to aggressive medical therapy and continued insulin therapy after discharge to prevent progression into uremia. The patient made an uneventful recovery but later developed a diabetic ketoacidosis and nephrolithiasis.<EOD> Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement\n\n [bib_ref]  Users' guides to the medical literature: XXV. Evidence-based medicine: principles for applying..., Oxman [/bib_ref]  [bib_ref]  Meta-Analysis of Randomized Controlled Trials: A Tutorial, Rice [/bib_ref]  [bib_ref]  Meta-analyses, systematic reviews, and RCTs: implications for evidence-based physical therapy practice, Onesti [/bib_ref]  [bib_ref]  Users' guides to the medical literature: XXV. Evidence-based medicine: principles for applying..., Oxman [/bib_ref]  [bib_ref]  Meta-analysis of randomized clinical trials comparing the effects of two different thiazide..., Li [/bib_ref]  [bib_ref]  Meta-analysis of randomized clinical trials comparing the effects of two different thiazide..., Li [/bib_ref]  [bib_ref]  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, Moher [/bib_ref]  \n\n## Preferred reporting items for systematic reviews (prisma)\nOn January 23, 2009, an electronic version of the 'preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement' was published in the Journal",
        "label": 0
    },
    "1218": {
        "output": "<h3>[Assignment 5] Hello, You are a helpful assistant for clinical trial recruitment. Your task is to make a trial-specific assessment of eligibility, i.e., determine whether the patient would qualify on that specific inclusion criteria based on the given patient's information. </h3> [INST]\n<p>You need to repeat Assignment 4 again, but this time you will only need to perform trial-specific eligibility instead of trial-level eligibility. Please, enter the following codes: This is another important method for calculating the time required for eligibility assessment.</li><li> `Trial-level eligibility` <code>#time.timeit(f=f, trial-level_eligibility_1=f, trial_id=\"1151\", trial_name=\"Garlic as a Therapy for Cardiovascular Risk Factors\", trial_number=\"5061\", trial_code=\"005061\", trial_status=\"Active\", trial_completed=False, trial_phase=\"1\", trial_phase_name=\"Phase 1-II\", trial_phase_number=\"1\", phase_name=u\"Phase 1: Phase 1-II\", phase_number=\"1\", title=\"Garlic Alone and in Combination With Aspirin for the Prevention of Cardiovascular Events in Patients at High Cardiovascular Risk: A Randomized Controlled Trial\", title=u\"Garlic Alone and in Combination With Aspirin for the Prevention of Cardiovascular Events in Patients at High Cardiovascular Risk: A Randomized Controlled Trial\", title=<NAME>. 005061),</li><li> `Trial-specific eligibility` <code>#time.timeit(f=f, trial-specific_eligibility_1=f, trial_id=\"1151\", trial_name=\"Garlic as a Therapy for Cardiovascular Risk Factors\", trial_number=\"5061\", trial_code=\"005061\", trial_status=\"Active\", trial_completed=False, trial_phase=\"1\", trial_phase_",
        "label": 0
    },
    "1219": {
        "output": "---  \n\n__[QUESTION]__[QUIZNAME]__ has been admitted with abdominal pain started 4 days ago. If you make comparisons between this patient note and the inclusion criteria of the clinical trial mentioned above, which of the following statements is CERTAIN, PROBABLE, or UNLIKELY to be his/her eligibility status? (1 point for each CERTAIN answer, \u00bd a point for each PROBABLE answer, and NO points for each UNLIKELY answer)\n\n[BADGER]__Exam_Question1__Inclusion_Criteria_Elizabeth_Clinical_Trial_5.pdf\n[BADGER]:  [B]Exam_Question1__Inclusion_Criteria_Elizabeth_Clinical_Trial_5.pdf[/B]\n\n[/ANSWER]\n\n### Other Resources\n- [MedCalc](https://medicalcalc.org/)\n- [Clep.co](https://www.clep.co/clinical-study-cme/)\n- [UpToDate](https://www.uptodate.com/contents/clinical-studys#search=clinical%20study&source=search&source=guide&view=advanced&search=clinical%20study&search=&f=ds&option5=&search=&source=search&search=clinical%20study&source=search&search=&source5=&search&type=clinical%20study&source=search&text=&source=guide&type=clinical%20study&type5=&text=&source=search&type=clinical%20study&text=&type<EOD> Fatal necrotizing fasciitis of the scrotum.\nA 43-year-old man developed fever and dyspnea within 24 h after spine surgery with anesthesia and prolonged surgery (6 h). He became obtunded, comatose, and hypotensive and required intubation. He was in septic shock. Laboratory results included a white blood cell count (WBC) of 9,900 cells/mm3 with 9",
        "label": 0
    },
    "1220": {
        "output": "<EOD> Molecular mechanism contributing to the neuroprotective effect of curcumin after traumatic spinal cord injury in rats.\nBACKGROUND AIMS\nCurcumin, an extract from the herb turmeric, is a natural antioxidant, anti-inflammatory and free radical scavenger. The purpose of the present study was to investigate the prophylactic effects of chronically administered curcumin on the acute-phase response after spinal cord injury.\n\n\nMETHODS\nThe effects of curcumin on acute inflammation were analyzed by studying the changes in the mRNA expression of C-C motif chemokine ligand 2 (CCL2), C-X-C motif chemokine ligand 9 (CXCL9), C-X-C motif chemokine ligand 10 (CXCL10) and interleukin (IL)-23 after spinal cord injury. The protein expression levels of tumor necrosis factor (TNF)-\u03b1, IL-1\u03b2, NF-\u03baB, IL-6, transforming growth factor (TGF)-\u03b2, C-C chemokine receptor type 2 (CCR2), C-X-C chemokine receptor type 3 (CXCR3), C-C chemokine receptor type 4 (CCR4), C-X-C chemokine receptor type 5(CXCR5), programmed cell death protein (PD-1), platelet-derived growth factor (PDGF)-BB, glial fibrillary acidic protein (GFAP), ionized calcium binding adapter molecule (Iba1), toll-like receptor (TLR)4, TLR3 and RIP1 were evaluated with quantitative polymerase chain reaction and western blot analysis. A quantitative assessment of apoptotic cells was performed using the TUNEL assay.\n\n\nRESULTS\nCCL2, CXCL9, CXCL10, IL-23, CCR2, CXCR3, CCR4, CXCR5, PD-1 and PDGF-BB expression all increased significantly after spinal cord injury. However,",
        "label": 0
    },
    "1221": {
        "output": "## How to convert this into a Python code.\n```bash\n#!/bin/bash\npython3 main.py < your folder path >\n```\nNow go to your computer (Terminal), change your to your folder where your code is put the patient note and clinical trial information and type in\n```bash\npython3 /home/yourfolderpath/main.py\n```\n\n## How to make output.\nThis is where you have a folder in your folder where your code is put. In this folder, create a new subfolder named 'output', put the your newest output file into this folder. Finally, you should use the command, \n\n```text\n    python3 main.py < your folder path > </code>\n```\n<EOD> Fc gamma RIII mediated antibody-dependent cellular cytotoxicity may be a novel mechanism for anti-CD3 monoclonal antibody induced cytokine release.\nIn vitro cellular cytotoxicity of two murine monoclonal antibodies (mAb) anti-CD3 (A2C11 and 145-2C11) was evaluated. In contrast to a variety of murine tumor specific mAb tested for this purpose, these anti-CD3 mAb did not mediate appreciable lysis of their targets by a monocyte/macrophage, murine cell line or a panel of human malignant hematopoietic cells. However, the A2C11 anti-CD3 mAb, but not 145-2C11 anti-CD3 mAb, triggered significant lysis of human peripheral blood lymphocytes. In a two-color flow cytometric cytotoxicity assay, this A2C11 anti-CD3 mAb associated with an increased percentage of monocytes/macrophages, in the presence of the FcgammaRIII(+) THP-1 target cells. The cytotoxicity correlated with the percentage of THP-1 cells with Fc gamma RIII. The 145-2C11 anti-CD3 mAb, but not A2C11 anti-CD3 mAb, mediated enhanced CD3 and CD16 expression and activation of Fc gamma RIII on mon",
        "label": 0
    },
    "1222": {
        "output": "<EOD> Development of a novel method for quantifying the absorption of nutrients, including free fatty acids, in the small intestine of mice using small intestinal contents.\nNutrient absorption in the small intestine (SI) is generally quantified by measuring the amount of nutrient remaining in the SI lumen, but the SI is separated from the rest of the gastrointestinal tract during sampling, which causes underestimation of the nutrients in the SI lumen. Thus, we developed a method for evaluating the absorption of nutrients in the SI by measuring the nutrient concentration in the SI contents (SI-c). We used 12 ICR mice each fed a coarse or fine diet. The mice were anesthetized with sodium pentobarbital and the SI-c was removed. The nutrient absorption rate was calculated from the concentrations of nutrients in SI-c using the following equation: Nutrient absorption rate (%) = 100 - (nutrient amount in SI-c/nutrient amount in SI lumen) \u00d7 100. The nutrient concentration in the SI-c and the amount of nutrients remaining in the SI lumen was calculated. The nutrients remaining in the SI lumen indicated higher amounts of nutrients in all nutrients tested, because the SI was separated from the gastrointestinal tract during sampling. The nutrient absorption rate was comparable in the coarse and fine feeding groups. When the SI-c was removed prior to the sampling in the fine-feeding group, less free fatty acids were remaining in the SI lumen. In conclusion, the method of analyzing the nutrient concentration in the SI-c may be useful for evaluating the absorption of nutrients in the SI and monitoring the nutritional status and nutritional intervention.<EOD> .\nThe paper presents the author's observations in acoustic neuromechanotomy which he has performed with positive results in 32 patients with lesions of the brainstem and cerebellum as regards vestibular apparatus function and its relationship to the facial nerve function, with no damage to the hearing function of the operated ear which has been confirmed by the results of objective examination and patient interview.",
        "label": 0
    },
    "1223": {
        "output": "## ## Problem 7\nYou are a medical expert. You should check the data in patient's electronic medical record. However, the patient information on the hospital's electronic system is in a specific format and organized differently depending on the specific hospital. To achieve your goal, you should transform the structure and format of the hospital's electronic system's data into a uniform format and structure of your data in electronic medical records as well as perform various statistical operations.\n\n## ### Example 1: ###\nYou are an expert in data processing. Hospital I's data format is listed below. As you can see, hospital I has listed the 5 parameters differently:\nage is a float type parameter , height is a string parameter, weight is a float type parameter, duration of diabetes is a float type parameter, number of meals per day is a string parameter. These differences make data transferring difficult. \nYou are an expert in data processing. Hospital II's data format is listed below. As you can see, hospital II has listed the 4 parameters differently: age, height, BMI, and eating status. These differences make data transferring difficult. \nYou are an expert in data processing. Hospital III's data format is",
        "label": 0
    },
    "1224": {
        "output": "You finished the second task `Trial-level eligibility assessment`. Do you feel the same as that before? [INST]\n\n# Tasks\n- [a0] Task: `Effi ciency analysis of the MIPS`\n\n## [a0] Task: `Effi ciency analysis of the MIPS`\nYou have to develop a methodology for the performance evaluation in a medical informatics problem solution. We chose a multicenter trial with more than 400 hospitals as a case for this experiment.\n\nThe hospitals provided services for patients suffering from schizophrenia for several years. In addition to treatment, services also include drug dispensing and monitoring, psychological care, and caregiver training. Services are mainly provided through medical treatment with or without additional education programs. Due to the widespread nature of the disease and the need for long-term treatment, the hospitals and the local health directorates (LHD) provide services to all patients in each region. Thus, to ensure service continuity during the trial, the services to all patients in the region are carried out solely by the hospitals in that region.\nEvery year, the Directorate of Health establishes the number of service hours a schizophrenic patient can receive from the hospitals in the region for services that each hospital would perform. The region where the patient lives (i.e., residence) and the type and duration of service (such as medical treatment, rehabilitation at home, etc.) defined in the Schizophrenia Treatment Program for the following year are considered when determining the service hours.\nEach hospital must apply the treatment program to be performed with health personnel and to receive appropriate reimbursement for the patients they will treat. Health personnel in the hospital should apply the treatment programs of the patients, they should receive certain reimbursements depending on the service they will perform, their experience, and their performance in the service they will perform within the program. The cost of the patient and the hospital and the revenue earned by the hospital is determined in each hospital, depending on which method is adopted in the hospital. This is calculated with the cost-of-service (CoS) and cost-per-patient (CoP). The total net income of the hospital for each program is evaluated to understand the economic profitability of the",
        "label": 0
    },
    "1225": {
        "output": "[SOLVED] How to calculate the AUC from the ROC curve using OpenCV (Python)?\n\n[SOLVED] How to detect an outlier data point within a cluster?\n<EOD> High affinity fluorescent probe for selective catecholamines detection in living mammal cells\n\n\n\n# Introduction\nIn biological and medicinal areas, fluorescence technologies are widely adopted, and they have been used to examine biological events in cells, 1,2 live tissues,and animals.However, the application of fluorescence technology is limited to a specific molecule as it only exhibits a strong emission signal when its molecules are excited at a particular wavelength of light.For example, the biomolecules of adenine and guanine dinucleotides only emit a strong emission signal at 260 nm, while methionine and tryptophan in biomolecules only show a strong emission signal at the 280 nm excitation wavelength.In order to overcome the narrow bandwidth of excitation/emission signals, researchers have developed a large number of \ue104uorophores for multicolor \ue104uorescent bioprobes, but they have several drawbacks, including poor solubility, weak binding ability and high production cost.Apart from the narrow bandwidth limitation, the \ue104uorescence intensity of \ue104uorescent bioprobes is signi\ue103cantly reduced by the presence of quenchers in biological systems.In order to realize the visualization of biological processes with low background signals, the \ue104uorescent probe should have not only a wide excitation wavelength window but also high photostability in biological systems.It is evident from the above discussions that there is a great demand to develop a highly efficient \ue104uorescent probe for multicolor and multiparameter \ue104uorescence imaging and tracking of targets in living mammalian cells without interference from quenching. Furthermore, an aqueousbased probe with a good water solubility and high stability is very desirable, because hydrophilic groups can be introduced to the probe to obtain a good water solution",
        "label": 1
    },
    "1226": {
        "output": "**The evaluation file** \n\nEvaluation files are plain text files. Each column corresponds with the output column header.\n\nYou should provide the output files of your test run, i.e., the evaluation files. You should keep your patient note file intact and edit it for your patient's trial record: patient ID and trial ID, before providing to your teacher.\n\n\n\n\nEvaluation-File-Name\n[formula]  PN-ID-Number-Of-Trials-ID-Number-of-Trials.txt [/formula] \nExample: Patient1-54713-01-100010.txt\n\n### Patient identifier (ID)\nThere are a number of ways that patient identifiers can be used in trial data files and it is important to be consistent. \n\nHere is an example:\n\n    Patient Number: 54713\n(the patient 54713 had 3 encounters in the emergency department) -the patient ID is the same for every encounter record;\n\nthe ID must be the same for all records of the same patient and must be present in all patient records.\n\nThere are several rules that must be met with patient identifier: \n\n1. It is required in all patient records;\n\n2. It is unique within the whole database;\n\n3. It does not contain non-alphanumeric characters;\n\n4. It contains only capital letters, digits, underscores, and hyphens;\n\n5. It is not an obvious key but is used to identify a person.\n\nIt is not possible to make a unique ID from a combination of the components of the medical record because many patients in a given EHR database may have the same first name, last name, gender, and date of birth. Therefore, it is usually necessary to assign a unique ID within each EHR database.\n\n**Exercise-1** Your task is to read the text below and define the patient identifier for each patient in the database, and create a new patient identifier for the test records in each trial.\nNote: You can find the answer for below in the trial-level eligibility output.\n\nThis is the patient-record of the database:\nID (patient identifier) \n---\n\n1-47004-",
        "label": 0
    },
    "1227": {
        "output": "Task 3 (Optional)\nIn the last line of the script by `Trial-level eligibility: `, e.g., `Trial-level eligibility: 2) Eligible.`, you can see information about the eligibility with an example sentence like the one below. You should replace this sentence with the necessary sentence of your own. The required information should be extracted by means of the NLP-models you developed for these competences. `Trial-level eligibility: 2) Eligible. The patient has sufficient medical information to participate in the clinical trial. According to inclusion and exclusion criteria, the patient did not meet any of the exclusion criteria and fulfils the requirements to participate.`[/OPTIONAL] [INST] Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient's history with the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medicalconditions.\n\nThe assessment of eligibility has a threedimension scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply).\nIn order to assess the eligibility of a patient, it is necessary to compare the patient history with the Inclusion and Exclusion Criteria of a Clinical Trial. \n\nHere is the patient's history from the last six months, including visits to other healthcare unit: \nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and",
        "label": 0
    },
    "1228": {
        "output": "<EOD> A preliminary study of the antagonism of chlorambucil (leukeran) and prednisone combination chemotherapy of human lymphoid carcinoma xenografts in nude mice by cytosin arabinoside (Ara-C)\nThe antagonism of combination chemotherapy of human lymphoid carcinoma xenografts, HUT-14C, HUT-14N, RPMI-8402, RPMI-8226, in nude mice by prednisone and chlorambucil (Leukeran, L), was studied by an experimental technique using cytosin arabinoside (Ara-C). The treatment regimen of prednisone and chlorambucil was established previously in our laboratory. The chemotherapeutic regimen consisted of intraperitoneal injection of prednisone and chlorambucil, once a week, from day 0 to day 13. HUT-14C subcutaneous tumor model was used in both the single drug treatment by cytosin arabinoside injection and the combination treatment by prednisone, chlorambucil, and cytosin arabinoside intraperitoneal injection. The tumors were weighed on day 14, following 3 continuous days (day 12-14) of cytosin arabinoside injection. HUT-14N subcutaneous tumor model was similarly treated by Ara-C intraperitoneal injection with prednisone and chlorambucil intraperitoneal injection, and RPMI-8402 and RPMI-8226 intravenous tumor models were treated for evaluation of their sensitivity to the same combination chemotherapy of Ara-C, chlorambucil, prednisone, and cytosin arabinoside. The results indicated that for the tumor model treated with single drug of cytosin arabinoside intraperitoneal injection Ara-C, tumor growth was inhibited 78% and 45% in the HUT-14C and RPMI-8402, respectively. The tumor growth",
        "label": 0
    },
    "1229": {
        "output": "We are back in the Python shell. Try the solution in the Gap Statement below - \"Solution\".\n\n\n#### Gap Statement\n\n\n#### Solut...<EOD> .\nFive hundred and twenty-eight patients with prostate cancer stage D1 according to TNS and NP were treated in a cancer centre from 1973 to 1980 with radical prostatectomy. The 5 -year actuarial survival was 43% and the 10-year actuarial survival was 22%. The results were analysed by univariate and multivariate survival analysis (stepwise Cox-proportion-Hazard method and discrimination of curves) which showed that tumour of the seminal vesicles is associated with worse prognosis than tumour confined to the prostate. In addition, multivariate analysis showed that age and serum PSA did not influence the outcome as they had been stated before. This was found in a smaller series of patients who received irradiation with hormones as palliative therapy. The analysis of the clinicopathological prognostic factors (number of lymph nodes involved, number of tumour-free lymph nodes, tumour grade and depth of prostatic infiltration) showed a stepwise influence of these parameters on survival. Thus, the number of lymph nodes involved had the greatest influence on prognosis followed by the number of tumour-free lymph nodes, the tumour grade and then the depth of prostatic infiltration. In a univariate analysis the number of lymph nodes involved was closely related to the serum PSA, serum testosteron, Gleason grade and tumour volume, however, in a multivariate analysis only the number of lymph nodes involved, was of importance. After a univariate analysis of treatment dependent survival differences one can only state that external radiation had a better long-term survival rate than radiotherapy and chemotherapy.<EOD> Pesticides and Parkinson's Disease\nPesticide exposure is commonplace and, therefore, may pose problems for vulnerable people, especially after long-term exposure; this is especially so for those already suffering from neurological disorders such as Parkinson's disease. The use of p",
        "label": 0
    },
    "1230": {
        "output": "\u00a9 2021 IEEE\n<EOD> The Effects of Exercise on Cognition and Physical Function Following Pediatric Traumatic Brain Injury\nChildren with traumatic brain injury (TBI) represent an at-risk youth population for the development of attention/executive function (EF) deficits, motor and cardiovascular impairments, and other complications of TBI. Physical activity contributes to the development of executive function and cardiovascular capacity in typically developing children, which could improve outcome following TBI. Thus, the aim of this single-case design was to examine whether acute physical activity improves post-concussive symptoms, EF performance, motor performance, and heart rate, and whether these effects vary by sex. We examined 26 TBI-injured youth (14 M, 12 F, age 10\u201317 years), who participated in 10minutes of continuous aerobic exercise after neuropsychological testing. We used generalized estimating equation (GEE) models to examine the impact of exercise on measures of EF, motor performance, and ratings of concentration before and after aerobic exercise versus after neuropsychological testing only. We found moderate-to-large effects (partial eta 2 = 0.11\u20130.26) for post-exercise improvement in self-rated concentration and visual motor performance, and clinically significant improvements (effect size = 1.31) in speed of information processing, visual attention/executive function, and motor performance. For girls, the beneficial effects of exercise on attention/executive function and motor performance were much stronger than for boys. Participants reported beneficial effects on concentration following exercise. Given the relatively small effects of physical activity on the self-reported mental fatigue and frustration scales, we recommend further investigation and refinement of exercise-induced interventions targeting youth with TBI and deficits in attention/executive function.<EOD> Isolation and characterization of a novel antimicrobial peptide from the spider genus Selenops: Identification of GF-17 and its antibacterial activity.\nSpiders inhabit a variety of environments and consequently they are exposed to a wide array of microbes and parasites. Some spiders",
        "label": 0
    },
    "1231": {
        "output": "**_Note_:_** It should be in the same format we described above.\n\nThe trial-level eligibility for each patient in the patient note should be recorded in the clinical trial assessment table. \n```bash\n$ cat clt_trial_eligibility_assessment\nID\ntrial_id\npatient_id\ntrial-level_eligibility\nSUPPORTING ARGUMENT NUMBER\n```\n\n\nHere is the clinical trial assessment table:\n\n| ID                       | trial_id             | patient_id             | trial-level_eligibility |\n| ----------------------- | -------------------- | ---------------------- | ------------------ |\n| 87d7d39b-89a2-4f22-b723-50c8bb8687a0 | 15d10327-065d-432d-9589-f0849f096f8e | 7762464 | 2) Eligible.\n| 87d7d39b-89a2-4f22-b723-50c8bb8687a0 | 15d10327-065d-432d-9589-f0849f096f8e | 135235 | 0) Excluded.\n| 4c2fdb13-4788-42cf-8043-d6e523e16289 | 5bdf66dd-8023-4986-8b19-2d6c273cd95a | 8112682 | 2) Eligible.\n| 87d7d39b-89a2-4f22-b723-50c8bb8687a0 | 15d10327-065d-432d-9589-f0849f096f8e | 151",
        "label": 0
    },
    "1232": {
        "output": "[INST] Your Task: Find and code 50 trialse levels. \n\nHere a dataset is available:\n[USR]/03.02.2015/3275/eligible_codetask.txt\nYou can easily find more examples by using the search page:\n[USR]/eligible_codetask/code_ex.txt\n\n\n\n##### Example\n\n``` python\nimport sys\nsys.path.append('../') # Add path to the folder of the current directory\n\nimport os, subprocess.textfile\nimport time\n\nfrom test_scripts.eligible_codetask import find_trial_levels\n\nprint('Your IP address is:', os.uname[\"nodename\"])\n\nprint(sys.path[-1])  # Add path to the folder of the current folder\n\n# Find the eligible trial levels\nprint('Find the eligible trial levels: ')\neligible_trial_levels = find_trial_levels('eligible_codetask')\n\nfor trial_level in eligible_trial_levels:\n    print('Trial level: {}'.format(trial_level)), \n```\n```\n\n##[EXIT]\n\n### TROUBLESHOOTING\nYou may fix the following problems, if you encounter them at the beginning of the task.\n\n###### Problem 1\n\nIn the following section, it shows that the dataset is not installed.\n\n``` python\nYour IP address is: 114.28.75-56-47.elastic.co.kr-56.193.232.215\nYour IP address is:  114.28.75-56-47.elastic.co.kr-56.193.232.216\nYour IP address is:  114.28.75-56-47.elastic.co.kr-56.193.232.217\n[INST] Your IP address is: 114.28.75-56-47.elastic.co",
        "label": 0
    },
    "1233": {
        "output": "There are three different ways to use the `Trial-level eligibility` function.\n1. If the patient has enough information to be considered eligible for a clinical trial, the `Trial-level eligibility` code should be entered as 1.\n2. If a patient is not eligible due to the lack of information, the `Trial-level eligibility` code should be saved as 2.\n3. For patients who meet the requirements for a trial but have contradictions in their eligibility criteria, the `Trial-level eligibility` code should be written as 0.\n\n## If the patient already has a registered trial, it is possible to use the `Trial-level eligibility` function.\nLet's assume we have a patient with no registered trials. To register a trial, the user enters the `Trial-level eligibility: N` in the first line (Trial_ID=00_001). A new trial, `Trial_ID=00_002`, is created automatically at the same time. To include this patient in the trial, we insert the `Triallevel eligibility: 2` in the last line of the patient's note, since this patient is eligible for the trial according to the assessments. \nLet's analyze the patient with a completed trial, assuming the `Trial-level eligibility` is 1. There is already a trial registered. If the patient is ineligible according to the assessed eligibility criteria, `Triallevel eligibility: N` should be entered in the first line, then, the trial name should be entered in the second line (Trial_ID=07_001), and the `Triallevel eligibility` should be entered 1 in the last line (Trial-level eligibility: 1). If the patient meets all the criteria for the trial, you should change the code in the first line to`Trial-level eligibility: 2` and leave the trial_ID unchanged, since the patient has been included in the trial by the registered data. \nNow let's demonstrate the code for patients who are ineligible according to the exclusion criteria. Assume the value of the first line is `Trial-level",
        "label": 0
    },
    "1234": {
        "output": "![IMAGE: (29)]\n\n\n##[c1]\nHere are the results with all 6 tests in line 14 of the code (see `y`). \n\n[c2]\nLet's see what happens if we compare patients 1 and 2: \n\n```{r}\ncompare_tests = c(1, 2, 1, 1, 1, 5, 7, 1, 2, 1, 3, 1, 2)\nplot(compare_tests, results[\"Triallevel eligibility\"])\n\n```[/c2]\n\n[/c1]\n\n## Solution:\nFirst, we filter the patients who are more than 40 years old, because the inclusion criteria is 9-55 years. Since this study was conducted before 2011, patients were referred to cholecystectomies if gallbladder function was abnormal. \nSo the inclusion criteria were: a) 9-55 years old, b) No previous CBD stone, and c) No gallstones except gallbladder sludge were accepted. Here we show only the patients who have age between 18 to 55 and no stones except gallbladder sludge. If the patient's abdominal pain is secondary to CBD stone, patients still would be excluded due to the inclusion criteria that patients should not be able to lie in flattened position on the table for 1.5 hours.\n\n![IMAGE: (32)][/c3]\n\n**Remarks:** A HIDA scan is an imaging test, it consists of a nuclear medicine, barium meal and ultrasound study.\n\nIt is used to assesses the function of the gallbladder.\nAnother test of bailout like MRCP or ERCP examination is necessary if there are CBD stones detected.\n<EOD> A comparison of the incidence of cerebral ventricular dilation in infants with congenital ventricular septal defects.\nOne hundred infants under the age of one year with isolated ventricular septal defects were examined by cranial tomography, sub-millimetre resolution computerized axial tomographic scanning, or ventriculography",
        "label": 0
    },
    "1235": {
        "output": "<EOD> Comparison of the safety and efficacy of oral and intravenous hydration in neonates with hyperechoic fetal lung after delivery\n\nObjective: The aim of this study was to compare the safety and efficacy of oral and intravenous hydration in neonates with hyperechoic fetal lung after delivery. Materials and methods: A total of 120 healthy neonates were divided into three groups through simple random sampling. There were no significant differences in gender ratio (P>0.05). In Group O, neonates were administered 8 ml/kg of water orally with breast milk every 12 h. In Group I, neonates were administered 8 ml/kg of water intravenously with an umbilical venous catheter (UVC) every 12 h. In Group H, neonates were administered 8 ml/kg of water intravenously with an UVC every 12 h, and hydration was increased to 12 ml/kg per 12 h if the neonate remained dehydrated. The clinical data, including urine output, blood pressure, heart rate, the incidence of diarrhea, and the length of hospital stay were compared among the three groups. Results: The hydration in Group I was started earlier and lasted longer than that in Group O (P<0.05). For neonates in Groups O and I, the urine output was positively correlated with the duration of oral or intravenous hydration (r=0.586, 0.617 respectively, P<0.001). The rates of oliguria, which were used as a measure of dehydration, were significantly lower in Group I than in Group O on days 2, 5, and 7 (P<0.05). No obvious abnormalities were discovered on electrocardiograms, blood pressure, and heart rate. As the infants became older, the blood pressure of the infants in all three groups was gradually decreased. The total hospital stays were 4.49\u00b12.74 days, 4.79\u00b12.88 days and 5.25",
        "label": 0
    },
    "1236": {
        "output": "or EX (on the trial, 73 or for the following and it and\u00a01 and a\nad, which, and 1, where in the [bib_ref]\n\n-or. No or ex \u00a0that we 110 or the patient: and is: if theel, a new [[C, for this and an\u00a0or] due (a, as a clin\nand for a [bib_ref]m ...\u00a0m toll, a 1 to include a \\ [bib_ref]\n( 0 and [bib_ref] [bib_ref] they [ [bib_ref] a test and this el\u00a0 1.\n...or to be, a\u00a0. [bib_ref] and 1\u00a0(s, and we and the el \nor, and to be a\u00a0or and the. and\nor [bib_ref]\u00a0. [bib_ref] 8, in 1. In the 1\ncare [bib_ref] because [bib_ref] (a. It. In terms\u00a0 [fig_ref] (se- [bib_ref] 2. In [bib_ref] and to a clin \u25b6 and 1 as a\n[ 1. [bib_ref] the 1 and 2 and 1, but [bib_ref], with a\nfor a clin and ex for the clin. [bib_ref]\u00a0. [bib_ref]\u00a0on and [bib_ref].\n (or.\nfor the\u00a0. After [bib_ref] [bib_ref] . 1-based. In this, as \nbased^. 5-m in \n \\\n. and 2-a (in and \\\n [bib_ref] for 1. [bib_ref] ? in [fig_ref] a\u00a0. for a\u00a0f for the or for the A1\n [bib_ref]. [fig_ref] . 4.\n [bib_ref] \u25a0 and the disease. and the conditional\\dours 2\u00a0\nthey<EOD>; and \u00a0related and \u2026 \n (for the medical.\nfor the\n-s (the, the :.\n (k 129 4-related  . (di -ass at\nshe-a-specifical, which a. In a _-in [bib_ref] C for a [bib_ref] a 17th for in a\u00a0 a [bib_ref] [bib_ref] and\n and \ufffdand, and [bib_ref] the clin. and an\n\n In which and the [bib_ref] The The The . The in other, or in a [bib_ref] the#^ the _ 0 or a \u00a0\u00a0\n\n in the [bib_ref]_ [bib_ref] 1-the",
        "label": 0
    },
    "1237": {
        "output": "You've learned it in Part 1. In Part 1, we also created a model named `predict_favor_clinical_trial_criteria`. This model makes predictions about the patients' eligibility for a clinical trial. It will be used by the `eligibility_assessment` model defined earlier.\nYou will find it in the following location: `./clinical_trials/main/predict_favor_clinical_trial_criteria`\nLet's check what it does. \n`>>> from sklearn.pipeline import Pipeline >>> from clinical_trials.datasets.test.eligibility_assessment import eligibility_assessment >>> import matplotlib.pyplot as plt >>> pipeline = Pipeline([('train', sklearn.ensemble.RandomForestClassifier(n_features = 3, max_features = \"auto\", max_depth = 9, max_leaves = 50)),('predict', sklearn.ensemble.RandomForestClassifier(n_features = 3, max_features = \"auto\", max_depth = 9, max_leaves = 50))]) >>> pipeline.fit(X_test, Y_test) >>> print(\"Evaluating on test set:\") >>> print(f\"\"\"F1 score: '{f1}', AUC: '{auc}'.\"\"\"\") >>> plot_confusion_matrices(X_test, Y_test, pipeline, n_cols = 2, cbar = False) >>> plt.show() >>> predictions = pipeline.predict(X_test) >>> print(f\"Total number of predictions for random forest based model: {len(predictions)}\") >>> print(f\"True positives: {len(predictions[predictions[:,0]=='excluded'])}\") >>> print(f\"True negatives: {len(predictions[predictions[:,0]=='eligible')}\") >>> plot_roc_curves(X_test, Y_test, [\"excluded\", \"eligible\"], predictions, n_cols = 1, cbar = False)\nNow let's try it again. We've already trained a model (in Part 1). Let's pass the model as parameter. \nYou need to find",
        "label": 0
    },
    "1238": {
        "output": "<EOD> Prenatal sonographic findings in congenital chylothorax.\nCongenital chylothorax in the fetus is an uncommon condition usually resulting in intrauterine fetal death. The sonographic findings in two cases of congenital chylothorax are described. In both cases, the sonographic findings were that of bilateral pleural effusion and fetal ascites. The findings support the hypothesis that this rare condition is associated with multiple anomalies of the abnormal lymphatic system or with constriction of normal lymphatics.<EOD> Correlation between the severity of the initial episode and recurrence pattern of migraine: a prospective study of migraine in children aged 5-15 years.\nIn this prospective study, the results of 59 migraineurs, aged 5-15 years, were analysed: 24 patients were followed up for 1 year and the remaining 35 for a period of 5.5 years, on average. After the 1st month the frequency of attacks was found to be significantly different in the two groups: a high frequency in the group being followed up for 5.5 years correlated with the occurrence of recurrence. The clinical and metabolic data on recurrence in the patients having had attacks characterized by: (a) more than 20 days of attacks, (b) aura, (c) vomiting as a symptom and (d) a low response to metoclopramide, were analysed.<EOD> The Role of the Family in Initiating Behavioral Change in the Adult With Overweight or Obesity\n\nObjectivesPurpose: While many weight loss interventions for treating overweight or obese adults focus on behavior change at an individual level, the family and household environment may be important for behavior change. The purpose of the current study is to explore the role of the family in initiating behavioral changes in the context of obesity.Methods:Interviews were conducted with adults with class-3 obesity and their family members who agreed to participate. Participants (19 adults and 23 family members) with class-3 obesity were asked to reflect on a behavior change, which was then used as a framework to explore the family's",
        "label": 0
    },
    "1239": {
        "output": "```\n\n\n<EOD> .\nOBJECTIVE\nTo investigate the effect of inhibition of TGF-beta on proliferation, migration and invasion of human cervical cancer HeLa cells.\n\n\nMETHODS\nTGF-beta receptor II (TGF-beta RII) inhibitor SB-431542 was used as TGF-beta inhibitor to treat HeLa cells cultured in vitro. The proliferation of HeLa cells was determined by MTT assay, and the invasion of HeLa cells by Transwell assay. The expression of TGF-beta RII, TGF-beta1, Twist, Vimentin, E-cadherin and N-cadherin were detected by Western blot.\n\n\nRESULTS\nSB-431542 inhibited TGF-beta RII expression of HeLa cells, induced HeLa cell cycle arrest at G1/S and G2/M period, decreased the expression of TGF-beta1, and also down-regulated the expression of Twist and N-cadherin. Inhibition of TGF-beta by SB-431542 may increase the expression of E-cadherin. SB-431542 inhibited the invasion and migration of HeLa cells significantly.\n\n\nCONCLUSION\nInhibition of TGF-beta may inhibit proliferation, invasion and migration of HeLa cells, but may induced cell cycle arrest of HeLa cells. Thus, TGF-beta may be associated with carcinoma metastasis.<EOD> Dementia research and caregiving needs: an interdisciplinary research agenda\n\nPurpose: To introduce an interdisciplinary research agenda aimed at reducing the disease and caregiving burden of dementia for patients and caregivers. Design and Methods: A search was conducted in PubMed and Google Scholar for articles published from 1990 to 2016 focusing on dementia research and caregiving needs. We reviewed 68 sources to identify 32 articles to support a research agenda. Results: Our research agenda provides a framework that could be used to develop",
        "label": 0
    },
    "1240": {
        "output": "<EOD> Vascular endothelial growth factor and its involvement in angiogenesis.\nVascular endothelial growth factor (VEGF), a member of the platelet-derived growth factor family, was identified more than a decade ago as a secretory protein primarily expressed by endothelial cells. In contrast to the other platelet-derived growth factor (PDGF) family of polypeptides, VEGF-A binds to a receptor tyrosine kinase designated VEGFR-1 (fms-related tyrosine kinase 1; Flk/KDR). In addition to the high-affinity VEGFR-2 (KDR/Flk-1), which shares high structural similarity with VEGFR-1, VEGF also interacts with several cell surface receptors, including the neuropilins and VEGFR-1 and members of the immunoglobulin family VEGF receptor (VEGFR)-3. The VEGF gene is conserved through evolution and mRNA and protein is transiently present in developing, proliferating, and hypoxic adult cells. The gene is also expressed in tumor cells and a wide variety of embryonic tissues and cancers. In addition, VEGF-C and -D, which are similar to but distinct from VEGF-A, share the receptor VEGFR-3. The VEGF-VEGFR axis plays a critical role during embryonic and tumor angiogenesis.<EOD> An improved procedure for the measurement of protein synthesis rates in small tissues and cells\nThe current technique for measurement of protein synthesis rates in animal tissue specimen is reviewed. The original description of this procedure is given in a protocol entitled \u2018Determination of amino-acid incorporation into protein during tissue culture\u2019. The present review emphasizes the changes in the protocol since 1964, including the use of mature tissue rather than an immature explant and using the total protein synthesis rate rather than the incorporation of a single essential amino acid. Some modifications to the present technique are also described, including a simplified washing procedure and the use of more than one tissue per assay. For small tissue samples or single cells the use of the protein-bound radioactive isotope and",
        "label": 0
    },
    "1241": {
        "output": "* Run your program and obtain its output. Is your output correct?\n\n    * Did you encounter any unexpected behaviors or bugs? If so, how should you troubleshoot and fix them?\n\n3. The program you wrote and ran in the previous exercise returns a list of patient notes. You, in practice, however, need to obtain a list of patients' triallevel eligibility. So, the program that you should implement in this exercise returns `Trial-level eligibility: 2) Eligible.`.\n\n4. The input file is prepared to contain multiple patient notes per row. To keep in real application settings, you will now have one patient note per row in the patient file.\n\nTherefore, you should adjust the patient note as shown in ?. Do not change the values given in the clinical trial value. ? \n\n> You should implement the `Trial-level eligibility: 2) Eligible.`.\n\nIn summary, this subsection covers some features of trial-level eligibility. In the next, and final subsection, all of these subsection's features come together and we will implement the clinical trial algorithm.\n\n\n<EOD> The impact of COVID-19 pandemic on the emergency department of a tertiary hospital and",
        "label": 0
    },
    "1242": {
        "output": "## [MC] 2. The user interface (UI) displays the following screen and some additional information. \n[OPTIONAL] After finishing with the `patient note`, we assume you have a `patients.csv` file in your working directory with following format: ID, Name, Gender, Age, Race, Birth date, Hospital_number, Hospital_ward, and patient_status, in which hospital_number and hospital_ward are integers. \nWe assume you have filled out a patient note to the patient. When you are done with each patient, please close the note and the tab. \nPlease fill out the following patient's note. This is to give our clinician a better understanding of the case and patient.\nIn the text area with `Note:`, fill out the patient info in the following format:\n\n## **Epi.num** Patient ID **Note:** [**firstname**][**initial][**lastname**]\n\n# Tip 2\nWe assume the following example as the first patient to whom you will apply these steps.\nHere is the patient note:\nA 54-year-<NAME> admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.",
        "label": 0
    },
    "1243": {
        "output": "[INV] In the next scenario, you will train in a clinical trial for treating ankylosing spondylitis in a hospital. You are the doctor and the head nurse at the time. You are also a nurse in the ward training other nurses.\n[\nINST] Hello. You are a doctor and the head nurse at the time in the hospital. You are also a nurse in the ward training other nurses. You are required to train 5 interns and 5 experienced nurses in the administration of Ankylosing Spondylitis treatment. The head nurse has already finished the training, and you have read some about the clinical trials and the treatment of ankylosing spondylitis and prepared the instruction manual.\n\nYour task is to train intern nurses by using the standardised procedure described in the instruction manual, while you train the experienced nurses using the manual you created based on the ankylosing spondylitis clinical trials. After the training, you should record the data of the training of the intern nurses and experienced nurses. The data is in your training file.\n\nThe training file and instruction manual are in `data/Ankylosing Spondylitis/`. Read the instruction manual and analyse the data to see how the training is performed so you can use the method for your training. \n\nYou should also train the other intern and experienced nurses who finish their shift and the head nurse. Train the intern nurses according to the procedure that the head nurse recorded in the training file. Train the experienced nurses according to the manual you created. \n[OUT] After the training is over, you should print the report and save it in `data/Ankylosing Spondylitis/report/` directory for future reference. \n\nThe first intern nurse is named as `intern 1`, followed by the names of intern 2, intern 3, intern 4 or intern 5. The first experienced nurse used is named as `experienced 1`, followed by the names of experienced 2, experienced 3 or experienced 4. The head nurse is named with `head nurse`. \n[/INV]\n[OUT] Hello. Please check if you meet the eligibility requirements, and inform us of",
        "label": 0
    },
    "1244": {
        "output": "### Step 2: Prepare patient's report format \nYou should prepare information about the patient using the patient_note template that is in the folder $HOME/piggy/code/inclusion, which has been installed when setting up the Piggy system. In that template, you will prepare patient_details information, which includes many questions that are used to fill in patient demographics, medical history, and family history. However, there are only selected questions required to make a clinical trial entry and there is only one question for the present complaints and three questions for the past medical history. In the present complaints, the patient only complains of abdominal pain. \nIn the following example, we can see the output for the present complaints question, e.g., \"1) Present complaint: Abdominal pain\"; Question 3 for the past medical history, e.g., \"3b) History of previous surgery: yes\"; and Question 5 for the present medication, e.g., \"5) Present medication: paracetamol, ibuprofen\".[INST]\n\nYou are now ready to create a patient based on information that was extracted above. You can add your patient's name through the file `$HOME/piggy/code/inclusion/patient_note/patient_notes_05.txt`. Let's add Mary`s patient_detail_1 from the file `patient_detail_1.txt`. Next, the following example shows how to save the patient demographics to the patient note file: \n``` bash <br>\ncd $HOME/piggy/code/inclusion/patient_note <br>\npython3 piggy.scripts.add_patient.py PATIENT_DEMOGRAPHICS.txt patient_notes_05.txt `\n```\nLet's continue to add patient history. In this step, we should use two questions: \"2) Past hospitalization within last 2 weeks\" (Question 2) and \" \"2) Past hospitalization within last 2 weeks\" (Question 3). Here is how to add Patient_history information, e.g., \"2a) Past hospitalization within last 2 weeks: no\"; \"3a) History of previous surgery: yes\"; \"",
        "label": 0
    },
    "1245": {
        "output": "### Exclude the following conditions\n\nIn this code, we determine the exclusion criteria:\n\n1. If the patient's sex is not male or female.\n2. If the patient's age is not between 18 and 65 years old.\n3. If the patient did not meet the inclusion criteria.\nExamine the following piece of code:\n\n```r\n# The first variable is a boolean.\n## The patient does not have sufficient information to qualify for the trial.\nPatient.eligible <- (Sex == \"F\" | Age < 18 | Age >= 65 | Eligibility == 0 | Eligibility == \"Relevant\") # The second variable is a character\nEligibility <- as. character (Rating)\n\n# The two variables that we are examining are the same.\nEligibility == Rat.eligibile && Patient.eligile == FALSE\n```\n\nThe output of this code section is:\n\n```r\nRating <- TRIAL_INFORMATION %>% COLUMN_TF(RAT)\nEligibility <- PATIENT_INFORMATION %>% COLUMN_TF(Eligibility)\nPatient.eligible <- as.numeric (PATIENT_INFORMATION %>% COLUMN_TF(Rating))\nEligibility.test <as.data.frame(Eligible)\nEligibility.test \n# +--------------------# # +------------------ # # This is Rating # # We want information whether '0' has a meaning of exclusion. # We can obtain it based on the clinical trial's information # # It is noted that when '0' has a meaning of relevance (not exclusion), the '0' value # is not excluded by exclusion criteria, but is retained by inclusion criteria. # Thus, '0' is considered as 'relevant'. # # In R, any integer is defined by R language. The information on the first # clinical trial trial is as follows: # # The first clinical trial trial is available; therefore `0` has a meaning of exclusion. # # When `0` is evaluated, it can be evaluated as both `0` and `1`. # # We can obtain the information based on the clinical trial of the first trial. #",
        "label": 0
    },
    "1246": {
        "output": "##[INT] A patient note is presented below. You are asked to determine a patient's eligibility\nfor a clinical trial. Give the reason(s) for your decision. \n\n# A 27-year-old male presented with back pain and lower limb paresthesia. \nThere is also more evidence for paresthesia, including the clinical symptoms and history. \nSo, the patient does not meet the criteria for paresthesia. \nLet's think step by step.\n\n##[INST] hello again. Here is the last part of the patient examination.\n\n##[CMT1] Clinical examination: \nParesthesia: Yes/No\n\n### Evaluating your decision: \n`Evaluate your results against the above rubric, e.g. for Eligible,`\n``Congratulations! This is a correct response.``\n# A patient note is presented below. You are asked to determine a patient's\n\n## Patient note:\nA 27-year-old male presented with back pain and lower limb paresthesia. \n\n# \n\n### Scenario - A 68-year-old woman has had back pain for three weeks. \nShe also has right hip pain and tenderness to palpation just over the greater trochanter. \nShe has no history of fractures. On presentation, her temperature is 37.7\u00b0C, her blood pressure is 160/87 mm Hg, her heart rate is 94 beats/min, her respiratory rate is 22 breaths/min, and her oxygen saturation is 95% on room air. On examination, the patient is alert and in no acute distress. Her abdomen is soft, but distended. There is dullness to percussion in the left lower quadrant. She has a markedly diminished rectal tone. Rectal examination reveals the prostate is hard and tender and the vagina is flushed with stool.\n\n### Scenario - A 68-year-old woman has had back pain for three weeks. \nshe also has right hip pain and tenderness to palpation just",
        "label": 0
    },
    "1247": {
        "output": "[/END]\n\n# Discussion\nIn this study, we showed that it is possible to extract relevant information from a medical text note. The goal of the clinical trial eligibility information extraction system was to reduce the burden of reading clinical trial eligibility criteria and shorten the registration period. Moreover, given the increasing number of patients and the difficulty in conducting eligibility screening, the automatic assessment of patient eligibility has become an unavoidable task for medical staff.\nUnlike the manual reading of the trial eligibility criteria, the trial eligibility criteria were analyzed using machine-learning methods and the results were visualized.\n\nHere is a screenshot of the web page of the system for the trial and the patient. \n\n[/INCLUDE]\n\n# Conclusion\nThe eligibility criteria used for screening patients were not only extracted but were also assessed, and the results were visualized. The extracted clinical trial eligibility criteria and the evaluation results were visualized.\nThe purpose of using medical text notes is to understand patients' medical information and conduct diagnoses and treatments to diagnose their conditions faster and perform a more accurate assessment. This research provides the conditions to help users find patients quickly using the medical text notes and medical text notes related to information on patients' inclusion criteria to obtain the information on their symptoms. Moreover, in the future, we will use other machine learning algorithms, such as Long Short-Term Memory, for patient eligibility assessment and compare the results. It is planned to conduct research continuously in the future to evaluate the proposed system through various clinical trials.\nAcknowledgments: I would like to thank the people who participated in this research: Kyung Hee University library for collecting the medical text notes, and especially, Dr. Jeong-Hwan Park, a colleague at MATRIX Lab, for his advice and help in preparing clinical trial information.\nPotential conflicts of interest: I declare (for the preceding 12 months) no links to the manufacturers of drugs, supplements, and medical equipment; no stock ownership; and no patents, in the field of research and publication.<EOD> Effect of pH on the thermal stability and oxidation kinetics of the S-layer protein of Rhizobia meliloti.\nIt is",
        "label": 0
    },
    "1248": {
        "output": "## Clinical studies\nThe clinical data and patient information are represented using the clinical study data structure provided by HL7 CDA version 2.\nIn CDA, the clinical data in the Clinical Study are modeled in the Clinical Study Data section in the `Related Health Care Encounters` profile. Clinical Study Data section includes a header and a body. The Clinical Study Header represents administrative information about the clinical study. The Clinical Study Body shows the clinical study details. And we only consider the body here.\nThere are two tables used to encode the Clinical Study Body in the HL7 Implementation Guide for Clinical Study Data Model. The Health Study Element contains basic information about the study, such as study type, contact information and location description. Research Study Element contains additional data, such as eligibility criteria, study design, and patient care items. Health Study Element and Research Study Element are combined into the `Clinical study` in CDA.\nWe list the elements of the CDA `Clinical study` structure and define each element with its attributes in the **Table 7**.\n**Table 7.** The Clinical Study Structure of CDA Clinical Study Template.    \n1 `cstudy`      - `id`, unique identifier (must start with a capital letter and is represented by the Unicode character `A0`)   \n2 `cstudy_type` - The type of study (e.g., `Bioequivalence`) \n3 `cstudy_status`  - The current status of the study \n4 `cstudy_name`  - A descriptive name that identifies the study\n5 `cstudy_desc` - A description of the complete study\n6 `cstudy_sponsor` - A value of `sponsor_type` that identifies the sponsor of the study. If the study is sponsored by a single entity and the entity is a person or group of related persons, or a legal entity, then the `spon\u2010 sor_type` value of `person`, `group`, or `orga\u2010nization`, respectively, is used. If a study is sponsored by multiple entities, e.g., a trial is a multi\u2010center study, then the `spon\u2010 sor_type` value is",
        "label": 0
    },
    "1249": {
        "output": "[INST] Let's see how to process patient information. \n\n[DEF #patient] #define patient {...}\n\n[DEF #patient-note] #define patient-note {...}\n\n[DEF #patient-age] #define patient-age {...}\n\n[DEF #patient-sex] #define patient-sex {...}\n\n[DEF #patient-race] #define patient-race {...}\n\n[DEF #patient-marital-status] #define patient-marital-status {...}\n\n[DEF #patient-high-school-completion] #define patient-high-school-completion {...}\n\n[DEF #patient-income-level] #define patient-income-level {...}\n\n[DEF #patient-drink] #define patient-drink {...}\n\n[DEF #patient-smoke] #define patient-smoke {...}\n\n[DEF #patient-medical-history] #define patient-medical-history {...}\n\n[DEF #patient-fhx] #define patient-fhx {...}\n\n[DEF #patient-med] #define patient-med {...}\n\n[DEF #patient-bmi] #define patient-bmi {...}\n\n[DEF #patient-bpm] #define patint-bpm {...}\n\n[DEF #patient-t-spo2] #define patient-t-spo2 {...}\n\n[DEF #patient-esr] #define patient-esr {...}\n\n[DEF #patient-bab] #define patient-bab {...}\n\n[INST] Let's define the patient-medical-history as a list of the patient's medical history:\n\n#define patient-medical-history { patient-high-cholesterol 1, patient-peptic-ulcer-disease 1, patient-breast-cancer 1, patient-diabetes-1 1, patient-gastric-ulcer 1, patient-hypertension 1 }\n\nAs we mentioned, the number of items describing the patient-medical-history is not limited",
        "label": 0
    },
    "1250": {
        "output": "## Problem-1\nWhat abnormal behavior indicates a diagnosis of dementia? What symptoms are typical for this syndrome?\n\n### [12]\n\n## Problem-2\nWhat are the causes of late-onset dementia?\n\n### [13]\n\n### [14]\n\n# Dementia\nPeople with dementia have problems with their memory, thinking, behavior and their ability to perform daily activites. With dementia the changes are great enough to affect a person's ability to",
        "label": 0
    },
    "1251": {
        "output": "### **Instructions** (instructions.txt)\n<br>[NAME1018] This is a short exercise about eligibility assessment. You are a clinical assistant of trial, and you are assessing the eligibility of a person seeking a clinical trial, from a patient note and a summary of the clinical trial.\n\nThere are 3 criteria to check whether a person is eligible for inclusion in the trial. The assessment of eligibility is based either on the patient note alone (if the case does not mention any trial criteria) or on the patient note along with the trial summary (if the case states the trial criteria for inclusion and is eligible for inclusion). The eligibility assessment is based on a 3-point scale: 0) Excluded (patient satisfies the trial criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient satisfies the trial criteria and the trial's exclusion criteria do not apply). For more information about this exercise, please refer to the instructions below:\n\n    1) Your task is to write 1 line for each step in the sequence of operations. A function (the letter F) is applied to the output of the previous function to create the next function. So we will need at least one function.\n\n    2) Each time that F is applied, a new line may be created by adding the character, or `).`, at the end of the previous line. Your task is to determine when each `)` is to be created by determining whether the argument of F is a reference.\n\n    3) You will be asked for how many F should be applied before creating a new line. You may type, for example, `f2{)`, for 2 applications of F. Once you know how many times you should apply F to return a reference, you may write (using this as an example of notation):\n\n    \n    \n    \n    )).f1(0,3),().f1(0).f2(2,1),(3)f1(2).f1(1).f1(0)\n    \n    4) After your input has terminated correctly (i.e., you have created a reference),",
        "label": 0
    },
    "1252": {
        "output": "# [DATA INPUT]\nA trial report comprises the following sections (from top to bottom) in R: `Design`, `Trial Details`, `Patients enrolled` and `Timing of assessments` sections. \nLet's fill in trial details.\n\n### Patient Trial ID\n\nYou're required to fill in `Patient Trial ID` section in R, which is a variable filled in as an ID number to a patient in the trial. The ID will be given by the trial investigator. Then, all the `Eligibility` variables (e.g., `Eligibility_age` and `Eligibility_gender`,) will be filled in. The following code in R is filled in as an example:\n\n```r\n\n### Eligibility in the \"Trial-level eligibility\" section (Trial-level_eligibility_notrelevant)\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\n\nHere is the clinical trial:\nTitle: A Study of AbGn-107 in Patients With Gastric,",
        "label": 0
    },
    "1253": {
        "output": "[CIT]\n\nInstructions\n\nIn this module, you are going to learn how to make a decision analysis, which is a form of decision-making support that aims to assist in decision-making based on probabilities from decision trees. You will learn how to build decision tree classifiers with a few examples.  \n\n[MODULE]\n\nLet's look at the following problem. The probability table is written from the top and the probability from the left and right cells, and the numbers are written in the order given. First, let's assume that we have a patient with 4 diseases (disease A, disease B, disease C, and disease D). Also, let's assume that we want to determine the probability of whether the patient has any disease (any disease (yes-no)) by creating a decision tree.\n\n![](images/mod_ex2_pic_1.png)\n\nLet's create the first-level decision tree. The top number (10%) indicates that there is a 10% probability that the patient does not have any disease. We can make 0 and 1, but in our case, if the patient has any disease (C), a decision criterion has also been determined. If the patient has any disease (yes-no), the patient has the disease A. We can get a 1.44% (0.144 / 10 = 0.257) in this case. (Note that both numbers are smaller than 1 because the patient may or may not have disease B and disease C.)\n\nLet's create the second-level decision tree. If the patient has any disease (yes-no), the patient has the disease B (0.394%). If the patient has any disease (yes-no), the patient has the disease B (0.188%). (Note that both numbers are smaller than 1 because the patient may or may not have disease A and disease C.)\n\nLet's continue creating the decision tree and repeat the process. Eventually, we get 'C.' When the patient has any disease, the patient has the disease B (0.188%). If the patient has any disease (yes-no), the patient has the disease B (0.188%), then the patient has the disease C, the patient has the disease C",
        "label": 0
    },
    "1254": {
        "output": "## 2. Clinical Trial.jl\nClinical Trial.jl (CT.jl) is a Julia language package that allows you to process clinical trial data and store in a structured manner, along with trial and participant metadata. CT.jl is a Julia package for handling trial and participant data for clinical epidemiology studies. For more information on clinical trial workflow, please see [CT.jl](https://cran.r-project.org/package=CT.jl)!\n\n### Features\n\n- Extract, transform, and load (ETL) trial and patient data\n- A consistent interface for trial and patient data for common analysis pipelines\n- Extract and load patient/patient visit data from R packages pvmet, PVData and PDMeta\n\n\n## Clinicaltrial.io\n[https://clinicaltrials.io](https://clinicaltrials.io 'clinicaltrials.io') is the largest search portal for all available clinical trial information. By combining the search results of 35 different portals, clinicaltrials.io delivers complete search results and provides users access to the latest trial information at any time.\n\n### Discover trials\nSearch for clinical trials on our portal using the search fields below.\n\n### Find trials\nBrowse available clinical trials by location.\n\n### Follow trial\nBrowse available clinical trials that you may want to follow.\n\n### Share trial\nSearch and share information for the trials on our portal.\n\n# Author contributions\n<EOD> Exotic pets\nIn the animal kingdom there are many animal types that are not native to Australia. Many of these animal types have gone extinct in their native habitat, which makes them interesting species for exotic animal keeping. Exotics can range in size from small birds to the lion, and they can include reptiles, fish, horses, primates, and birds of prey to name a few species. There are thousands of species of animals that are not native to Australia, and many of these have become popular pets in Australia.\nIf you're looking for a unique pet experience, then consider an exotic animal. Australian animal welfare societies are now taking on the job of bringing these exotic animals to Australia",
        "label": 0
    },
    "1255": {
        "output": "__Exercise 2__\n\n__[START]__\n\n[Teacher's notes__Please consider an explanation or two about this task]\nThe patient's problem list appears in the input box on top of the screen. The trial-level eligibility should be checked in the check box for each problem.\n\n_Example__\n[Teacher's note__Please consider the following explanation about this task]\n[START]\n\n[Note] The patient's problem list appears in the input box on top of the screen.\n\n[Input](/help/exams/2020)___What is this part of the question?\n\n______Trials:\n___1.__________________[Start].\n___2.__________________[End].\n___3.__________________[Finished].\n\n_____________ Trial-level eligibility for patient note.\n\n______Exercise 1._____The patient note appears in the textbox of the question. Find the eligibility of each problem for this question.\nPlease write or type the scale of the trial-level eligibility in the check box for each problem.\n\n______Exercise 2._____Write the trial-level eligibility for the last input of the first problem 'Hypothyroidism'.\n\n______Exercise 3._____Write the trial-level eligibility for the last input of the third problem 'Chest pain'.\n\n___[END]___\n\n___[START]__\n\n[Note] What is your eligibility for the clinical trial for this question?\n\n______Choose the choice most closely matches your description. The question starts with \"You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria",
        "label": 0
    },
    "1256": {
        "output": "## 4 -Evaluate a Patient's Record\nIn this part, you will use the patient's record from the dataset. If you do not know how to use the patient's record, first click `show_record` in the upper-right corner to see the `patient record` widget. You can observe various information by moving the mouse cursor on a data sample. Try to guess before the data sample is displayed in the UI.\n\n[INST] You are a psychiatrist. Your hospital is setting up a trial focusing on the treatment of adolescents with substance use disorders (SUDs). You are very interested in the trial because substance use disorders are very prevalent in adolescents. In your hospital, two treatments have been used to treat adolescents with SUDs: group parent-based training (PBT) and group psychoeducational group (PEG). However, it is unclear which treatment is more effective in the treatment of adolescents with SUDs. Therefore, the trial aims to assess the efficacy of these two different treatments and to help clinicians make decisions on which treatment is more effective for adolescents with SUD. \n\nHere are exclusion criteria:\n- Patients with mental retardations of the following degrees: A person is judged to be a mental retardation if he/she is able to read, write, and perform a simple arithmetic operation. He/she is not limited to his/her ability to perform a simple arithmetic operation. A person is considered to be an ordinary person. A person with a degree of mental retardation is defined as an ordinary person by the following requirements:\n-He/she can use a basic computer, mobile phone, and other gadgets.\n-He/she can read, write, and perform a simple arithmetic operation.\n-He/she is able to go shopping and do household chores.\nA person is defined as a severe mental retardation if he/she is not limited in the above requirements, he/she is severely limited in the following requirements:\n-He/she cannot learn to read and writing.\n-He/she cannot understand and perform basic math operations.\n-He/she cannot perform a simple shopping mission.\n-He/she cannot understand and follow the instructions in shopping",
        "label": 0
    },
    "1257": {
        "output": "[H] Output the patient-level eligibility as well as a patient note. [/H]\n[INST] Hello. You are a helpful assistant for clinical trial recruitment. Your assignment is to examine the trial's eligibility of each patient for the clinical trial based on their characteristics. \n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\nHere is the clinical trial: \nTitle: Digital SpyGlass Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy\nSummary: This study to evaluated the effectiveness of Digital SpyGlass Cholangioscopy to facilitate common bile duct stone removal without fluoroscopy\nInclusion criteria: Inclusion Criteria:\nPatients with clinically suspected/confirmed CBDS\nCBD caliber 5-15 mm\n\nLet's think step by step. \n\nPatient-Level Eligibility:\n[INST] Patient-Level Eligibility: 3) Ineligible\n\nTrials.Summary.trials_eligibility_summary:",
        "label": 2
    },
    "1258": {
        "output": "<EOD> Effects of dietary fat sources on the gastroduodenal lesions with the use of bile salt reflux test.\nThe effects of dietary fat sources on the gastroduodenal lesions with the bile salt stimulation on 112 patients with bile salt reflux and 32 patients with hiatal hernia were studied. 1. 8 patients with normal endoscopic findings and 14 patients with mild esophagitis were fed with butter, olive oil, corn oil, beef tallow, soybean oil and sesame oil, to assess the direct effects of dietary fat alone on the gastroduodenal lesions. 2. 53 patients with abnormal endoscopic findings (fundic gastritis, pyloric, duodenal gastritis, etc in 36; advanced, active gastric ulcer, duodenal ulcers, etc in 17) and 43 patients without hiatal hernia with normal upper tract with bile salt stimulation were fed with butter, olive oil, corn oil, beef tallow, soybean oil and sesame oil, to assess the effects of fat sources on the gastroduodenal lesions under bile salt stimulation. On endoscopic follow up, butter aggravated the lesions of gastroduodenal mucosa, although sesame oil improved slightly. Butter caused the deteriorated histological gastritis in all instances, while sesame oil produced slight improvement. Olive, corn oil and beef tallow caused mild to moderate worsening of gastroduodenal lesions, while soybean oil caused a slight improvement on the histological scores. Patients with normal upper tract showed a similar and consistent result with those with hiatal hernia. On histological findings, patients without hiatal hernia showed relatively small histological worsening with fat sources feeding, in comparison with patients with hiatal hernia.<EOD> Long-Term Dacarbazine or Diacerein Treatment in Relapsing Polychondritis-Associated Vasculitis: A Case Report\n\nObjective:Rare disease Background:Polychondritis-associated vasculitis (PA",
        "label": 0
    },
    "1259": {
        "output": "[/SC]<EOD> <filename>client-scripts/client-scripts.js\n'use strict';\n\nvar _ = require('lodash');\nconst {\n  BLUE_COLORS,\n  GREEN_COLORS,\n  YELLOW_COLORS,\n  RED_COLORS\n} = require('../../constants/colors.js');\nvar constants = require('../../constants.js');\n\nconst _colors = {\n\n  green: { color: '#1fbd9e' },\n  green_dark: { color: '#0e9581' },\n  yellow_light: {\n    color: '#fbc985',\n    light: true,\n    bg_color: '#fbc985',\n    text_color: '#ffffff'\n  },\n  yellow: { color: '#fbc985' },\n  yellow_dark: {\n    color: '#ffc001',\n    light: true,\n    bg_color: '#ffc001',\n    text_color: '#ffffff'\n  },\n  orange: { color: '#ff9f00' },\n  gray0: '#303030',\n  gray10: '#505050',\n  gray10_dark: '#707070',\n  gray20: '#707070',\n  gray20_dark: '#909090',\n  gray30: '#707070',\n  gray30_dark: '#909090',\n  gray50: '#505050',\n  gray50_dark: '#707070',\n  gray70: '#505050',\n  gray70_dark: '#707070',\n\n  blue0: '#3b5af8',\n  blue10: '#3A84FA',\n  darkcyan0: '#7059ff',\n  darkcyan10: '#7059ff',\n  magenta0: '#ff5E06',\n  red0: '#153653',",
        "label": 2
    },
    "1260": {
        "output": "## Exercise 5.\n[INST] You are asked to prepare yourself to work next to a doctor. You're going to observe her work with patients. \n\nThe doctor is working with a medical team of 3 interns in ward. You have just arrived in time. The doctor should talk to a patient in need of treatment. Let's observe and code how the doctor works with the patient. \n\n![](/assets/images/exercise5.png)\n\nThe doctor examined the patient and found a mass on the left breast and a lump in the right. Breast ultrasound revealed a 49 x 37 mm mass in the right breast.\n\nThe doctor explained that the tumour is non-invasive, and surgery is needed. After the surgery, if pathological examination was found to be invasive, additional chemotherapy would be needed, and if benign histology would be found, no additional therapy would be required, and the patient could be followed-up. She also explained that if the tumour is benign, the patient would be in remission.\n\n\n## PART 2: BUSINESS COURSE: INSURANCE PROBLEMS\n## Exercise 6.\n[INST]  You have worked in a large insurance company. One day, you received a complaint that the insurance amount paid to the patient was incorrect. The insurance company sent an examiner to investigate. You will follow the examiner to the insurance company.\n\nThe examiner visited the insurance company at 11:50 AM. She was greeted kindly by a secretary. She was taken to a room for the interview. After taking her order, the secretary left the room and left. The patient claimed that the insurance company inaccurately calculated the amount of compensation. The examiner asked some questions that she had prepared before. The patient had insufficient proof of having the injury or illness. The examiner found many inconsistencies in the patient's statements. Patient did not provide sufficient and reliable evidence. She did not provide a medical report, or clinical report. The examiner concluded that the patient's claim was groundless, and the insurance did not compensate.\n\n## PART 3 and PART 4: GENERAL",
        "label": 0
    },
    "1261": {
        "output": "__NOTE_\n\nPlease try the Python script to understand our logic.\n\n**_script-2.py__:**\n\n```Python\n\n# +\nimport couchdb\ndef trial():\n    # couchdb.get('data', 'studies', 'PED.K2015009.1')\n    # couchdb.get('data', 'patients', 'V1.K2015009.11')\n\n    trials = couchdb.get('data', 'studies', {'$filter': 'id=?q'})\n    trials.insert()\n    for trial in trials:\n        patients = couchdb.get('data', 'patients', {'$filter': 'studyID= ?q'})\n        for patient in patients:\n            # calculate eligibility of each study\n            trial_level = 0\n            # patients ID\n            patientID = patient['id']\n\n            # trial date\n            trial_date = datetime.datetime.now().strftime(\"%B %d/%Y\")\n\n            if trial['studyDate'] == trial_date: # get study date\n                if 'inclusionCriteriaClinicalTrial' not in patient: # exclude some fields\n                    for c in trial.keys():\n                        if c == 'inclusionCriteriaClinicalTrial':  # get trial inclusion criteria\n                            trialInclusionCriteriaClinicalTrial = couchdb.get('data', 'data_inclusion_criteria', { 'study_id': 'PED.K2015009.1'+patientID, 'study_name': 'Trial A', 'study_studyID': 'PED.K2015009.11'})\n                            if '16 years old' not in trialInclusionCriteriaClinicalTrial.document['value']:\n                                if 'male' not in trialInclusionCriteriaClinicalTrial.document['value'] and 'female' not in trialInclusionCriteriaClinicalTrial.document['value']:\n                                    trial_level = 1\n                            else:\n                                    trial_",
        "label": 0
    },
    "1262": {
        "output": "Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the exclusion criteria of a clinical trial to determine the patient's eligibility. An exclusion criteria is the fact that a patient does not have (at the time of recruitment) a certain characteristic which excludes a person from being eligible. The exclusion criteria of this patient are related to her hobbies and general health history. [/fig] \n<EOD> .\nTo determine possible toxic effects of thiamethoxam (TMX) on german cockroaches Blatella germanica (L. ), we studied the effects of TMX and fipronil (FP) at different concentrations on the insects of various ages. The results showed that TMX exhibited toxicity to B. germanica (L.) and the toxicity was agedependent. At first-instar, LC25 of TMX was 0.02703 mg/ml, the corresponding toxicity of FP was 0.000310 mg/ml. There was no obvious difference between LC25 of FP and LC10 of TMX. At second-instar, LC15 of TMX was 0.00647 mg/ml, the corresponding toxicity of FP was 0.0000710 mg/ ml. There was no obvious difference between LC15 of TMX and LC05 of FP. At third-instar, LC30 of TMX was 0.00220 mg/ml, the corresponding toxicity of FP was 0.0000710 m",
        "label": 0
    },
    "1263": {
        "output": "# Conclusion\nClinical data science aims to improve clinical research by reducing the waste associated with clinical trials.\nThe [Trial-eligibility.jl] package for [julia][julia.jl] enables a consistent set of eligibility tools that can facilitate recruiting patients for clinical trials. It enables consistent workflows that increase the reusability and efficiency of clinical data scientists and enables easy sharing of patient eligibility data and clinical trial protocols.<EOD> Longitudinal Associations between Perceived Relationship Quality and Mental Health in Children with Asthma and Their Parents\n\nBackground: This study examines the longitudinal associations between perceived parent-child relationship quality, and between parent-child relationship quality and child mental health, and asthma-specific quality of life for children with persistent asthma, and between parent-child relationship quality and parent mental health. Methods: Dyads (n = 145) of children with persistent asthma and respective parents completed a longitudinal survey of symptom and quality-of-life domains. Results: Children's perceptions of the quality of the mother-child relationship were associated with children's asthma-specific quality of life for the mother-child dyad (B = 0.67, p = .028) at baseline. Children's perceptions of the quality of their relationship with the father were associated with their mental health status for the father-child dyad 6 months later (B = \u22121.07, p = .009). Children's perception of the mental health status of their parents were significantly associated with child asthma-specific quality of life for the child-parent dyad (B = 0.15, p = .022 and B = \u22120.41, p = .009, for the mother-child and father-child dyads, respectively). Children did not report their asthma-specific quality of life at 6 months. Parents' perceptions of the child's mental health status were found to be associated with their own mental health status 6 months later (B = \u22121.33, p = .011). Conclusion: Intervention programs for improving children's mental health status and asthma-specific",
        "label": 0
    },
    "1264": {
        "output": "You have the choice to choose among different models, depending on your context and your knowledge:\n\n**`Based Model`**. This model is especially suitable for less complex models (fewer factors).\n\nYou are first going to create a list of items for the trial level. You are going to call each item a feature. `Patient-level eligibility: 35)`\nYou can then form the features in one feature vector. `patient-level eligibility: `[`35 2)`\nYou can then fit the feature vector to a Linear Regression model. This is done by calculating an estimation and a p-value for your model in `linear_regression()`, wherein the model parameters are fit using the inverse-logit function from sklearn's `multinomial` wrapper around the scikit-learn logistic regression models. We showcase the use of the linear model with the patient-35 note above.\n\n```\nprint(\"Model parameters:\")\nprint(\"Number of features: {}\".format(len(Trial_Note,)))\nprint(\"Model fit:\")\nprint(\"Estimated regression coefficient: {}\".format(Trial_Note.linreg._multinomial.linreg_out,[\"number_of_firing_channels\"]).params[\"number_of_firing_channels\"]))\nprint(\"Estimated regression coefficient variance: {}\".format(Trial_Note.linreg._multinomial.linreg_out,[\"number_of_firing_channels\"])._multinomial_var['number_of_firing_channels']))\nprint(\"Error: {}\".format(Trial_Note.linreg._multinomial.linreg_out,[\"number_of_firing_channels\"])._multinomial.resid[-1]))\nprint(\"P_value: {}\".format(Trial_Note.linreg._multinomial.linreg_out,[\"number_of_firing_channels\"]).linreg_out.pvalue[2, \"number_of_firing_channels\"]))\nprint(\"<NAME>\")\n```\n\n[Fork this repo](https://github.com/galexia/clinicaltrial/tree/main/clinical/python/inst_trial).",
        "label": 0
    },
    "1265": {
        "output": "[/TUTOR_NOTES]\n\n# E2F1\nA biological model used to describe proliferation processes is the E2F-Rb-E2F1 model. The cell proliferation process can be divided into multiple steps, which can be described as a sequence of states using transitions (e.g., cells go from G1 phase to S phase). The flow between these state sequences is regulated both by negative feedback within a pathway and external cues. In E2F-Rb, the E2F1 protein is regulated, mainly by the Retinoblastoma protein (Rb) (also called pRb). This inhibitory system is part of the G1/S checkpoint controlling the progress of the cell cycle. The Rb gene prevents cell proliferation by regulating cell cycle progression. In inhibitory conditions, Rb binds the E2F1 protein to halt cell cycle progression through the S phase. When the inhibitory signals in the G1/S checkpoint pathway are removed, Rb dissociates from the E2F1-Rb complex allowing the E2F1 protein to bind to E2F sites upstream of transcriptionally active origins of DNA replication. Rb protein function is affected by the cdk4-cyclin D complex, which activates Rb by phosphorylation. When Rb is phosphorylated by the cdk4-6 complex it cannot bind to the E2F1 protein, and the E2F1 protein is not able to bind the E2F-responsive promoters. Inhibitory signals, such as the binding of the p27 protein to the cdk complex, cause Rb to dissociate from the E2F1 protein and promote the cell cycle to move through the S phase. Positive signals, such as the binding of the ppRb protein to the E2F1 protein, stabilize the Rb and stop the cell cycle moving out of G1.\n\n\nA B\nA simple mechanism which regulates this system is given by:\n\n\n\\[ \\begin{align}\n  \\mathrel{\\stackrel{\\text{Inhibition}}{\\rightarrow}} &  Rb\\cdot E2F \\;  \\ mathrel{\\stackrel{\\text{Binding}}{\\rightarrow}}",
        "label": 0
    },
    "1266": {
        "output": "[INST]\n# Exercises\n```\npython clinical.py -n N -i ./clinical_exercises.txt\n```\nwhere, -n -Name of the clinical trial that you want to evaluate,\n    -i -A path to a .tsv file containing the patient note,\n    -./clinical_exercises.txt -A path to the data file with clinical trials, i.e.,\n      <patient-note-of-clinical-trial-A>.tsv, <patient-note-of-clinical-trial-B>.tsv, etc.\nThis command shows the eligibility of all patients in clinical trails Clinical trial A and Clinical trial B. Exercise 1 provides an example for this task.  \nAll the patients who are not eligible, should be listed, e.g.,\n```bash\nclinical.py -n N -i ./clinical_exercises.txt\nEligible: 0\nNot eligible: 139\n```\nThe trial-level eligibility for each patient note, i.e., the eligibility of each clinical trial, can be listed, e.g.,\n```bash\nclinical.py -n N -i ./clinical_exercises.txt -t trial\nEligibility of each trial:\nClinical trial A:\nEligible: 34\nNot eligible: 4 \nClinical trial B:\nEligible: 134\nNot eligible: 36\n```\nMore examples:\nClinical trial A -Clinical trial B.\n\nExercise 1:\nTrial-level eligibility of each trial, i.e., the assessment of trial eligibility of each patient, can be listed, e.g.\n\nExercise 2:\nEligibles by trial ID.\n\nExercise 3:\nEligibles by number of patients.<EOD> The efficacy of intrathecal methotrexate for meningeal dissemination of systemic lymphoproliferative disease--a report of three cases.\nThree patients with",
        "label": 0
    },
    "1267": {
        "output": "[BIN] Let's think step by step.\n\nFirst is the patient note. Here is the patient note in the patient_notes table:\n\n*Note: You have to import the patient_notes table to your local data set by the `import` function first.* \nPatient-level eligibility: 0) Excluded The three-point assessment of patient eligibility is used to identify the relevant information by the model. \nYour function should output the patient-level eligibility as a string rather than binary decision. \nThen, you should store the patient notes and model predictions output to the relevant fields in a dataframe. Finally, you should calculate the probabilities of eligibility for the model: \nCalculate probability of eligibility: Probability of Eligibility = True / (True + False) = 0.21 / (2.71+0.79) = 0.21\n\nIf the probability eligibility is more than 0.5, the patient is eligible, regardless of their patient-level eligibility, with an error of 0.05. \n\nProbability for patients in eligible class:\nTrue: Probability of Eligibility: 0.21\nFalse: Probability of Eligibility: 1-0.21 = 0.79\n\nFinally, you should store these results in a dataframe for use in the trial-level eligibility part. \nYour function should output the results to a dataframe in a row. \nPatients table (p_id, patient-level eligibility, probability_of_eligibility, trial_level_eligibility):\n[0] 0) Excluded 0.7900\n[1] 0) Excluded 0.2100\n[2] 0) Excluded 0.7700\n[3] 0) Excluded 0.7900\n\nThe following lines store patient-level eligibility in the patient_notes table with the probability_of_eligibility column.\npatient_notes <- cbind(patient_notes, triallevel_eligibility = lapply(1:nrow(trial), function (x) \"trial\" + to",
        "label": 0
    },
    "1268": {
        "output": "Hello. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.\n\nThe assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); 1) Not relevant (patient does not have sufficient information to qualify for the trial); and 2) Eligible (patient meets inclusion criteria and exclusion criteria do not apply). \nYou should make a trial-level eligibility on each patient for the clinical trial, i.e., output the scale for the assessment of eligibility. \n\nHere is the patient note:\nA 54-year-old obese woman admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, getting worse after eating fatty food. The patient experienced similar pain twice in the past year. Her past medical history is remarkable for hypercholesterolemia and 2 NVDs. She has 2 children, and she is menopausal. She does not smoke, drink alcohol, or use illicit drugs. She is mildly febrile. Her BP is 150/85, HR 115, RR 15, T 38.2, SpO2 98% on RA. She is an obese woman with no acute distress. On palpation, she experiences epigastric tenderness and tenderness in the right upper quadrant without rebound. Bowel sounds are normal. Laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift. The ultrasound revealed several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\nHere is the clinical trial: \nTitle: The E",
        "label": 0
    },
    "1269": {
        "output": "___\n\n### Subject ID <a id=\"id\"></a>\nYou should repeat the `Subject ID: <id>` a number of times until it matches the number of rows in your CSV file.\n[TUT_BT_03_01_Subject_ID]. \n<EOD> .\nLiver cirrhosis is frequently followed by an increase in portal vein flow and an associated rise in intrahepatic resistance. We studied this increase in 19 cirrhotic patients, 19 noncirrhotic patients, and 19 healthy subjects using Doppler sonography. The intrahepatic resistive index was calculated in one of the portal vein branches by use of two formulas: the area under the velocity tracing curve (AUC) was calculated by 2nd order polynomial regression analysis, and the mean velocity time integrals (TIG) were calculated using a digital timer triggered device and an electromagnetic flow velocity meter in the main portal vein and its branches. Both methods showed a significant increase in intrahepatic resistance in cirrhotic patients compared to patients without liver disease (P<0.001).<EOD> Rheumatization in Patients of Tuberculous Laryngitis: A Prospective Study to Study the Risk Factors\n\n\n\n# Introduction\nTuberculosis is an endemic bacterial infection that has been a major medical problem worldwide for centuries [bib_ref]  The history of myasthenia gravis, Mccahon [/bib_ref]  The World Health Organization (WHO) has estimated that the global incidence of tuberculosis was roughly 12% of the world's population, resulting in 1.7 million deaths in 2017 . The highest reported burden was found in South-East Asian [bib_ref]  The epidemiology and pathogenesis and management of extra-pulmonary tuberculosis, Chang [/bib_ref] . Pulmonary tuberculosis is the most common presentation of tuberculosis infection and accounts for 70-80% of total cases, including sputumpositive and sputum-negative pulmonary TB [bib_ref]  Extrapulmonary tuberculosis: an overview, Golden [/bib_ref] . This systemic condition is characterised by the",
        "label": 0
    },
    "1270": {
        "output": "[fig]  -: Excluded (patient meets inclusion [or exclusion] criteria, but is excluded on the grounds of the trial's exclusion criteria).Not relevant (patient does not have sufficient information to qualify for the trial).Eligible (patient meets inclusion criteria and exclusion criteria do not apply). [/fig] \n<EOD> The Effect of Dapoxetine on Premature Ejaculation With 6-Minute and the Changes in Male Sexual Function for the Long Term\nDapoxetine is a recently approved treatment for premature ejaculation (PE). A pilot study of dapoxetine showed a significant increase in ejaculation latency time (EL) and a significant decrease in premature ejaculation profile (PEP) scores. No study has assessed the effect of dapoxetine on patients who have a baseline EL of less than 6 minutes. This study was aimed at evaluating the effect of dapoxetine on the ejaculatory time as assessed by EL and PEP of patients with both baseline EL greater than 6 and 6 minutes. Fifty-three patients with PE and an inadequate ejaculatory time (IE) were treated with dapoxetine 30 mg for 8 weeks. The patients were subdivided into group I (baseline IE greater than 6 minutes) and group II (baseline IE = 6 minutes). The median EL in both groups progressively increased by a total of 1 min/wk. There was a significant change in IE from baseline to week 8 in group I. Both groups did not show any worsening in IE, and only a few complaints of side effects were reported. These promising data suggest that PE patients with baseline IE less than 6 minutes still have IE at 8 weeks of therapy with dapoxetine 30 mg and are likely to continue the treatment even after they reach the 6-minute IE.<EOD> Eosinophilic Gastroenteritis With Perforated Duodenal Ulcer\n\n\n\n# Background\nEosinophilic gastroenteritis (EGE) is a rare allergic disorder occurring in approximately 1 out of 25 000 cases with the highest population-based incidence observed in Southern countries. It",
        "label": 0
    },
    "1271": {
        "output": "### 4-2.4.8. Trial-patient and Trial-expert. \n\n[INST] Welcome. You are a helpful assistant for clinical trial recruitment. Your task is to compare a given patient note and the inclusion criteria of a clinical trial to determine the patient's eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. The assessment is performed trial by trial.\n\nHere is the patient note:\nA 62-year-old woman, who has experienced 3 NVDs, presented with 24 hours of severe, constant left upper abdominal pain associated with nausea, vomiting, loss of appetite, and poor oral intake. The pain is radiating to her left midback, and improves with flexion. Her vital signs are stable, and abdominal examination yields normal findings other than severe left upper quadrant pain on deep palpation. Her laboratory tests are normal, and her chest x-ray and abdominal CT-scan yield normal findings. Her EGD shows esophagitis and gastritis.\nHere is the clinical trial: \nTitle: Increased Prostate Specific Antigen (PSA): Predictive Value for Prostate Cancer\n\n\nSummary: We are running a prostate cancer incidence study of men >40 years old with increased PSA values on screening. Increased age or abnormal test results are risk factors for cancer and warrant screening. This is a hospital-based observational study. Our research focuses on the value of PSA testing to detect cancer in the earlier stages. We want to know if other clinical tests or risk factors might help to predict early-stage prostate cancer in men with increased PSA levels. The primary outcomes of this study are the frequency, incidence (time of occurrence), and type of cancer in men who did not participate in prostate biopsy. The primary outcomes of the study are the frequency, incidence, and type of cancer in men who did not participate in prostate biopsy.\nInclusion criteria Inclusion criteria:\nAny man >40 years old with increased",
        "label": 2
    },
    "1272": {
        "output": "## \ud83c\udfaf Solution\n\n### Python 3.7\n1. Run `python setup.py install` to install Pyret. Next to it, you can also find documentation, examples, download links, and help.\n\n    _Note:_ Since 3.5.3, the Pyret command-line-interface has been unified under the name 'pyret --' . So if you installed Pyret in Python 3.5.3 and above in `/usr/local/lib/` or other unexpected paths, you may need to install it again using [pip --version 20.7.1](https://pypi.org/packages/pip/20.7.1/).\n\n### Install `pyret` in your Python environment.\n\n    _Note:_ If you install Pyret on your PATH and you have other Python versions on your PATH before, the command below should be put in your `~/.bashrc` file to ensure that the correct version of Pyret is used. You should be aware of your Python version (`import sys`). This way, we will ensure that Pyret is not used in some strange environment.\n\n    ```\n    export PATH=/usr/local/lib/python/3.7/python:${PATH}\n    ```\n\n     \n`pyret -- version` shows what Pyret's version is.\n\n    ```\n    pyret version\n    ```\n\n    ```\n    Pyret 20.10.4\n    +------------------------------------------------------------------------------------------------------------------------------+\n    |                                                                                                                                |\n    |                                                                                                                                |\n    |                                                                                                                                |\n    |  ___                 /_____________________                 ___                         ______________                 |\n    | /         ____/      ____   _   _______ _   _____ ___________________   /                           |\n    |       /        /     /    /  /  /     _  /     _____ __________________________  |\n    |    _/         \\   /  /    /  /     _  |   | _____  _____ ___________  |\n    |       ____    \\/  /    /  /     __  |   | |",
        "label": 0
    },
    "1273": {
        "output": "This solution is suitable for:\n- CRA clinical question type\n- Data type table question\n\nWe hope this solution will give you some useful guidance. Thank you for writing in CRA \ud83d\udc4d\n\n# RESULTS \ud83d\udccc\n\n## CRA Output\n![](../../../.gitbook/assets/img.png)\n\n## Table Output\n![](../../../.gitbook/assets/img.png)\n\n## Clinical Question\n![](../../../.gitbook/assets/img.png)\n\n## Data Type Question\n![](../../../.gitbook/assets/img.png)\n\n## Sample Solutions\nFor each of the clinical questions below, you are expected to evaluate the patient according to the eligibility criteria of a clinical trial. Enter your answer in the box in the left column, taking into account the criteria listed above. Then, scroll to the next part of the question to see its solution.\n\n### [Solution 1](/solutions/inclusion-criteria-helpful.md)\n\n#### CRA\n\n![](../../../.gitbook/assets/img.png)\n\n#### Table\n\n![](../../../.gitbook/assets/img.png)\n\n### [Solution 2](/solutions/eligible.md)\n\n#### CRA\n\n![](../../../.gitbook/assets/img.png)\n\n#### Table\n\n![](../../../.gitbook/assets/img.png)\n\n### [Solution 3](/solutions/inclusion-for-the-patient.md)\n\n#### CRA\n\n![](../../../.gitbook/assets/img.png)\n\n#### Table\n\n![](../../../.gitbook/assets/img.png)\n\n### [Solution 4](/solutions/eligible-the-patient.md)\n\n#### CRA\n\n![](../../../.gitbook/assets/img.png)\n\n#### Table\n\n![](../../../.gitbook/assets/img.png)<EOD> Molecular Docking as a Candidate for Drug Repurposing as a Possible Remedy Against COVID-19\n\nThe COVID-19 pandemic has created a global",
        "label": 2
    },
    "1274": {
        "output": "###### Problem 2\nInconsistent results\nIssue: Inconsistent results are caused by different data frame structures provided by Datalite, e.g., data frames containing patient-level data, trial_data, patient_data, or trial_data2, or not using a data frame.\n\n## Potential solution\nPlease provide a data frame containing patients in the same format as in trial_data, and the patients' trial number in the data frame name: \n\n## Potential solution\nPlease follow the instructions that we provided at https://bio4h.readthedocs.io/en/latest/dev-setup.html#install-submodules-for-tutorials.\n[/PRO]\n\n## # create a new dataset for micafungin\n\n# Copy a patient's note that is included in the trial\nsetDataSheet <- getSheet(getActiveSheet(), \"Patient's Note 3\")$SubjectsetDataSheet(\n    \"pat_micafungin_note\",\n    setCols(setDataSheet),\n    paste0(\"setDataSheet\", \": \", paste0(\"pat_\", \"trial_\", \"patients\")))\n\nLet's think step by step. \n\n## {\n\n# +\n# Create a new data frame named \u00b4pat_micafungin_note\u00b4\n# Copy a patient's note that is included in the trial\n# Copy the column names from the patient's note data frame\nsetDataSheet <- getSheet(getActiveSheet(), \"Patient's Note 3\")\nsetCols(setDataSheet) <- paste0(\"setDataSheet\", \": \")\npaste0(\"setDataSheet\", \": \") <- paste0(\"pat_\", \"trial_\", \"patients\")\n# +\n## {\n\n# +\n# Assign columns' names in the data frame\nsetDataSheet$age <- \"Age\"\nsetDataSheet$smokers <- \"Smokers\"\nsetDataSheet$sex <- \"Sex\"\nsetDataSheet$bmi <- \"BMI\"\nsetDataSheet$diseases <- \"Diseases\"\nsetDataSheet$surgery <- \"Surgery\"\nsetDataSheet$surgery_date <- \"Surgery_date\"\nsetData",
        "label": 0
    },
    "1275": {
        "output": "<EOD> Association between Serum Concentrations of 1,25-Vitamin D and the Risk of Hypertension in the Population with Different Levels of Vitamin D\n\n\n\n# Introduction\nHypertension has become one of the significant threats to mankind. Hypertension is an important risk factor for the occurrence of stroke, ischemic heart disease, and end-stage renal failure [bib_ref]  Evidence-based guideline for the management of high blood pressure in adults: Report..., James [/bib_ref]  [bib_ref]  Epidemiology of hypertension in China and India, Guo [/bib_ref] . It is estimated that from 2000 to 2010, the number of adults (aged 18 or older) with high blood pressure increased from 594.9 million to 1.13 billion worldwide [bib_ref]  Worldwide trends in blood pressure from 1975 to 2015: A pooled analysis..., Ncd-Risc [/bib_ref] . The prevalence of hypertension in different countries was significantly different [bib_ref]  Hypertension in the Philippines: Prevalence, gender and age differences and awareness, treatment..., Labignan [/bib_ref]  [bib_ref]  Global prevalence of hypertension in rural and urban populations in low-and middle-income",
        "label": 0
    },
    "1276": {
        "output": "[RM10]. [INST]\n[RM11]. [INST]\n[RM12]. [INST]\n[RM13]. [INST]\n\n\n## [CONT]\n\n\n---\n\n## _02_ Exercise \n\n\n\nThe following script is part of a notebook which can be loaded from [here](https://notebooks.datanovia.io/notebook/2295638) and can be executed from the commandline: \n```jupyter\n%load_ext autoreload\n%autoreload 2\n%pylab inline\nfrom IPython.display import display, HTML\nfrom IPython.history import get_ipython\nimport datetime\nimport ipywidgets\nimport shutil\nimport glob\nimport jcvi\nimport os\n\njcvi = jcvi.JCvi()\nimport jcvi.interfaces as jcvi_interfaces\nfrom jcvi_interfaces import JCvi_inputtype as JcviInputType\nfrom jcvi_interfaces import JCvi_outputtype as JcviOutputType\nfrom jcvi_interfaces import JCvi_exceptiontype as JcviExceptionType\nfrom jcvi_interfaces import JCvi_variabletype as JcviVarType\njcvi.set_print_all() # set print all\n```\n## Explanation \n\n\n```jcvi\njcvi = jcvi.JCvi()\n```\n\n\n```jupyter\n%matplotlib inline\nimport matplotlib as mplib\nfrom jcvi_mpl import *\n\nfrom notebooks.datanovia_code.2295638_01.jcvi2_code_01_notebook_ipython.py\n```\n\n\n```jupyter\n%%time\n```\n\n```jci\n%time\n```\n\n\n```jupyter\nimport datetime\n```\n\n\n```jupyter\n```\n\n```jupyter\n```\n\n\n```jupyter\n```\n\n\n```jupyter\n```\n\n```jci\n```\n\n```jci\n```\n<EOD> A single molecule magnet built by a su",
        "label": 2
    },
    "1277": {
        "output": "Instructions for the evaluation of the system's final prediction \nPrediction of the system's final result should consider the following:\n\n1) Whether the evaluation is correct.\n2) The probability of correctly predicting the result. \n\n<EOD> Diuretic response to acute low\u2010dose frusemide in anuric type 1 diabetes mellitus: association with duration and type of disease and microvascular complications\nAim:\u2002 The aim was to test the hypothesis that reduced sensitivity to frusemide in diabetic subjects is associated with the duration and type of disease and microvascular complications.<EOD> Interpretable image captioning with memory-guided LSTMs and auxiliary classifier\n\nInterpreting results of a deep learning (DL) model has become a fundamental and practical challenge in current development of DL models. Although in the previous work, human-designed hand-crafted rules and features such as position, size, and color have been considered as an important component to interpret the neural network's results, our purpose is to build a single universal method that can easily interpret deep learning models for arbitrary images in every vision and machine learning (ML) tasks. We proposed an interpretable DL model, named memory guided long short-term memory network (Mem-LSTM) which can be adopted for interpretable video understanding, human activity recognition, image semantic segmentation, image object detection, and other DL tasks. In addition, we proposed an auxiliary DL classifier (ADC) to improve the interpretability of deep learning model, which is essentially a neural network with more parameters than the original model for the task. In doing so, the attention maps can be visualized. The proposed ADCs can use the deep learning features as input and output, and it can be a complementary classifier of the main deep learning architecture. Experimental results proved the effectiveness of our method for the image caption tasks in the large-scale datasets, such as META (N=1,691,512) and IAP (1,731,342) large-scale datasets, a total of 56,207,464.OPEN\nGenerally, deep learning (DL) models have been proven powerful for solving many tasks in computer vision and machine learning (ML)",
        "label": 0
    },
    "1278": {
        "output": "<EOD> Lung cancer in HIV patients: is it the same as in the general population?\n\nBackground: A growing number of HIV patients is developing lung cancer. These patients are not only exposed to a higher risk for developing primary lung cancer as a result from the use of tobacco products, but also to a higher risk for secondary lung cancer. There is evidence that HIV patients have an increased risk for developing lung cancer, but it is not clear to which extent the risk in HIV positives differs from the risk in the general population.Methods: To investigate differences in the characteristics of lung cancer and its management, all lung cancer cases registered with the Utrecht Cancer registry from 1989 to 2007 were selected. Cases with and without a concomitant infection HIV were included and the characteristics of these two patient groups were compared.Results: HIV positive lung cancer patients are more often men (p = 0.02; relative risk (RR), 1.7; 1.1-2.7) and smoke more heavily, as smoking-related tumors accounted for 73.7% (41.0%-100.0%; p < 0.001) of all lung cancer in HIV positives compared to 53.4% (2.8%-100.0%; p = 0.13) in HIV negatives. Patients who are HIV positive have also a lower age at diagnosis with a median of 56.0 years (IQR, 51.0-66.0) compared to 65.0 years (IQR, 54.0-74.0) in HIV negatives (p < 0.001). The treatment regimen also differs between both groups of patients. Although HIV positives also received chemotherapy, it was given at a younger age than in the general population (median, 56.0 years; IQR, 51.0-66.0) compared to 68.0 years (IQR, 58.0-71.7; p < 0.001).Conclusions: Lung cancer in HIV positives is characterized by a high rate of tobacco-associ",
        "label": 2
    },
    "1279": {
        "output": "If you want to add more trials to the input example, add them into the input box. To run example, press ENTER. \n\n\n![\n\n\n# 1) Eligible.\n\n## 2) Excluded\n\n## \n\n# Excluded-2-2\n\n## \n\n# Excluded-2-3\n\n## \n\n# Excluded-2-4\n\n## \n\n# Excluded-2-5\n\n## \n\n# Excluded-2-2\n\n## 3) Excluded\n\n## \n\n# Excluded-1\n\n## \n\n# Excluded-2\n\n## \n\n## \n\n# Excluded-2-3\n\n## \n\n## \n\n# Excluded-2-4\n\n## \n\n## \n\n# Excluded-2-5\n\n## 3) Excluded\n\n## \n\n# Excluded-1\n\n## \n\n# Excluded-2\n\n## \n\n## \n\n# Excluded-2-3\n\n## \n\n# Excluded-2-4\n\n## \n\n## \n\n# Excluded-2-5\n\n## 3) Excluded\n\n## \n\n# Excluded-1\n\n## \n\n# Excluded-2\n\n## \n\n## \n\n# Excluded-2-3\n\n## \n\n# Excluded-2-4\n\n## \n\n## \n\n# Excluded-2-5\n\n## \n\n## 2)\nExcluded\n\n## # Excluded-1\n\n## \n\n## # Excluded-2\n\n## \n\n## # Excluded-2-3\n\n## \n\n## # Excluded-2-4\n\n## \n\n## # Excluded-2-5\n\n## 2)\nExcluded\n\n## # Excluded-1\n\n## \n\n## # Excluded-2\n\n## \n\n## # Excluded-2-3\n\n## \n\n## # Excluded-2-4\n\n## \n\n## # Excluded-2-5\n\n## 2)\nExcluded",
        "label": 0
    },
    "1280": {
        "output": "##[INTER] Hello. You are an attending physician in an internal medicine department of a medical hospital. You have decided to refer a patient to the next outpatient appointment. Here is a patient note:\nA 49-year-old man (Mr. Z), complains about abdominal pain that started 8 days ago that radiates to his right upper quadrant, it is getting worse after eating chili and fatty food. The patient experienced a similar pain twice in the past year. He has 3 children, and he is not married. He smokes 15 cigarettes per day. He does not drink alcohol, does not use illicit drugs, and his BP is normal. His past medical history is remarkable for hypercholesterolemia. He is mildly depressed. He has no weight loss or fever. On palpation, he experiences tenderness and a mass in the right hypochondrium. Bowel sounds are normal. \nLet's think step by step. \n`A 49-year-old man complains (or a 49 year old man is complaining about) the abdominal pain. The pain is severe and has radiates to the right upper quadrant. It begins like 8 days ago and is getting worse after eating chili and fatty foods. The pain was repeated twice in the past year. He is taking drugs for cholesterolemia. He doesn't smoke cigarettes but he smokes one pack of 15 cigarettes per day.` [/INTER] \n##[INTRA] Hello. You are an internal medicine specialist who has a consultation room in a medical school. You have decided to refer a patient to the next outpatient appointment. Here is a patient note:\nA 48-year-old woman with a history of arterial hypertension, depression and GI disorders has complaints for a month. She complains for non-diarrheal cramps in the stomach with no change in bowel movements. She is very worried because her symptoms are disturbing her daily life activities. She takes medication for hypertension and depression and has very good adherence. She has no history of smoking and is not on any illicit drug",
        "label": 0
    },
    "1281": {
        "output": "Note that, since we don't need an output of eligibility in the clinical trial, we will omit the output here, e.g., `The trial-level eligibility of the patient (Cycle Index ID: 203) is 2) Eligible.`. So, we write like `The trial-level eligibility of the patient (Cycle Index ID: 203) is 2) Eligible.`.\n\n## Assessment of eligibility\nNow, we define the patient's assessment of trial eligibility, i.e., the assessment of the patient's eligibility based on the assessment of the current patient note and the clinical trial, via `Eligibility assessment of the patient via Note: `\nEligibility assessment of the patient via Note: \nIf patient is eligible to the trial:\nAdd patient to the \"Recruitment\" list and call the function `Add_to_list()`\nAdd patient to the \"Unmatchable\" list and call the function `Add_to_list()`\nCall the function `Add_to_list()`\nThe trial-level eligibility of the patient (Cycle Index ID: 203) is Eligible.\nThe trial-level eligibility of the patient via Note: (Cycle Index ID: 203) is\nEligible.` Note that we write a code block for the assessment of eligibility since these lines are only for assessing the patient eligibility.\n\n## Summary\nNow we summarize the output, e.g., ` \n```\nCycle Index ID: 203:\n    Patient notes: \n    Note:\n    Eligible\n    Eligible\n```.. .\nEnd of the cycle loop for the trial\nRecruitment:\n\n    Note:\nSame trial\n\n\nUnmatchable:\n\n    Note:\n    same trial\n\n```\nAs we can see, we get only 1 recruitment cycle and no unmatchable cycle. So, this patient is eligible to the trial, i.e., the trial-level assessment of trial eligibility is 2) Eligible.\nIn fact, trial eligibility in this scenario has 3 levels: 1",
        "label": 0
    },
    "1282": {
        "output": "[TUT]\nCopy and save this file named `p07_patient_note_test_3.txt` in your current directory, since you will require it for the next step as mentioned in the section `Instructions for Executing Each Task`. If you run it, you may get the same test set as this example, but randomized.\n\nThe output is the following:\n`Evaluation 1 (Patient_01)`:\n\n        Excluded -- --\n\n    `Evaluation 1 (Patient_02)`:\n\n        Not Relevant    1.0 -- --\n\n\n```\n[TUT]\nIf you do not have a Python development environment, you can simply run `pytest.py` without any inputs.\n```\n\nIf you run `pytest`, all tests and its results will be returned. The test report will display a summary table indicating 'Passed', 'Failed', 'Skipped', and 'Skipped/Not run' test results, while the detail of the test reports is shown in the [TUT].\n\n## Step6: Final assessment report\n\nOnce you run `pytest -v', the results will be shown by [TUT].\n\n\n### Instructions for generating the assessment report\n\n1. Save the generated `finalreport_template.py` file in a subfolder of the same directory as the saved `assessment_tasks.py` files.\n2. Modify the code in the `finalreport_template.py` file to generate a customized assessment report for your submission.\n3. Once you have finalized your report, `pytest -v` with the modified `finalreport_template.py` (i.e., finaltest_example.py in this assessment) file will return the assessment report.\n\n### Assessment Report\n\n\n\n## Task 1: Copy and save the file named `p08_fungi_species_test_3.csv` in current directory.\n\nThis is the file with one instance of the sample dataset. You may get the same file with different values by using the file-sampling options in the `data_preprocessing.py` file.\n\nIn the assessment report, the values in the `Species` column were replaced with `",
        "label": 0
    },
    "1283": {
        "output": "When patients do not have sufficient information to qualify for the trial, you should not assign any value to their Trial Eligibility. Include a separate item to assign 0 (Excluded) to them. \n\n# Example\n### Exclude patient:\n``<td bgcolor=\"#123f7d\"><font style=\"font-family: Cambria, Arial, sans-serif; color:#1684a3; font-size:12px; vertical-align:-8px\">1</font></td>``\n<!--[instructs]: #task=20 -->\n```txt\n# Patient Excluded from Analysis\nPatient excluded: Age 20\nGender: male\nHeight: 185 cm\nWeight: 100 kg\n``<br><br><font color=\"#1684a3\" size=\"14\" style=\"font-weight: bold;\">Age </font>20&nbsp;years </font>\n<br><br>\n\n### Male:\n```txt\n# Male\n```\n\n```txt\n# Height in CM 85\n```\n\n```txt\n# Admission Weight in KG 100\n```\n<EOD> The relationship between self-reported health and the incidence of functional disability.\nOBJECTIVES\nTo evaluate the association between self-reported health and functional disability incidence, after controlling for covariates.\n\n\nMATERIALS AND METHODS\nIn order to obtain nationwide information, we analyzed data from the Korean General Social Survey (n = 3,167), which included a large number of samples from different regions in Korea.\n\n\nRESULTS\nIn this study, 62.8% (n = 1,968) of participants were incident disabled. Using Cox proportional hazard models, we found that compared to participants without any disability, participants with a \"fair\" or \"bad\" health rating were respectively, 74% more likely (HR = 1.74) to become disabled than those with a \"very good\" rating (reference group), after adjusting for covariates.\n\n\nCONCLUSION\nSelf-reported health has stronger effects on the incidence of functional disability than",
        "label": 0
    },
    "1284": {
        "output": "\uf0e0 Click the 'Evaluate' button to evaluate the current patient's inclusion in the trial. You can do so by pressing the `Evaluate` button and input the patient's information below. You should input the information for all 4 patients with the note:\nOnce you complete this task, you will see the result for Patient-level eligibility in the top part of the web page. For the 4 patients, we get the following results:\nPatient-level eligibility: \uf0a8 2) Eligible: All patients met the requirements for inclusion criteria \uf0a8 Excluded: None were found to meet any of the exclusion criteria \uf0a8 Not relevant: None had enough information to determine ineligibility.\nYou can continue your assignment in your user area. You find the link here: <EMAIL>. Click the 'Evaluate' button to evaluate the current patient's inclusion in the trial.\n\n## Part 3: Trial-level eligibility\nThe trial-level eligibility should be entered once for each trial in the entire course. In this part, you will apply this task for trial 1615.\nTrial-level eligibility: 2) Eligible\nTrial-level eligibility will be marked in the Patient-level eligibility page.\nCongratulations! You are going to finish now?\nPlease click the 'Evaluate', then click the 'Send' button in the following page to submit your assignment.\nGood job! Congratulations! \n\n## Task Name:\nTrial-level eligibility\nTrial-level eligibility determines the eligibility for a patient for a clinical trial on both global and per-patient levels. For the patient, it is calculated as the combination of the Patient-level eligibility and Patient-level eligible/not eligible factors. For the trial, it simply combines the above two concepts on the global level.\n\nThis task has two parts:\n1) Calculate Trial-level eligibility for the patient based on global assessment \n2) Compare the information from global assessment to the information from the per-patient assessment\n\nThe steps to complete the task is:\n\n\n1.\nOpen [https://mhealth",
        "label": 0
    },
    "1285": {
        "output": "A: The 11C-CSar PET/CT scans and measurements would require a more complete specification of the scanner and the data collection.\nIt's interesting that the 11C-CSar PET/CT scans are used to evaluate the \"hepatobiliary secretion of cholylsarcosine\"; one would imagine that other modalities (MRCP, EUS, serum tests), would be used to determine the impact of the cholic acid level; is this an error?\nI'd expect that a 11C-CSar PET/CT evaluation is more easily described after the clinical trial is complete; e.g., \"Trial-level eligibility: 2) Eligible.`, rather than before a trial is conducted which implies that there's some unknown risk-benefit ratio.\nIt may be the best approach to only use the 11C-CSar PET/CT scans on those participants in the study that have completed the study; and use them to validate the clinical trial's success on each person by comparing the post versus pre PET/CT scans and measurement results.\n<EOD> Transcriptional activation of the AREs of hNQO1 by sulforaphane: mechanistic studies of the Nrf2 system.\nHuman NAD(P)H:quinone oxidoreductase 1 (hNQO1) is induced by sulforaphane (SFN) and other isothiocyanates. The promoter of human hNQO1 contains multiple AREs and an ARE-related sequence (ARE-RS), to which the transcription factors Nrf2 and OASIS/Nrf1 bind, respectively. In the present study, we demonstrate that SFN is effective in vivo and in vitro to stimulate the ARE/ARE-RS sequences. Furthermore, we demonstrate that the Nrf2-ARE/ARE-RS complex functions cooperatively at the promoter, and we provide a mechanistic model of the response regulation of the human NQO1 promoter by Sulforaphane. An ARE/ARE-RS luciferase reporter plasmid could be used to detect the effects of small molecules on the SFN-induced responses of the Nrf2",
        "label": 0
    },
    "1286": {
        "output": "## \u00a9 2013 by A. Schaefer, M. Kohlbacher\n\u00a9 2014 by M. Kohlbacher - All Rights Reserved \n<EOD> Phenotypic variability and genotypic heterogeneity in oligospermic and azoospermic men in a fertile cohort\n\n\n\n# Introduction\nThe evaluation of reproductive outcomes in men with impaired spermatogenesis has improved with the introduction of genetic tools. This has permitted not only the identification of the pathogenic variant but also more frequently the characterization of the molecular mechanism that leads to male infertility. The diagnosis of the defect and, often, a better follow up of these patients is now possible.\nIn 2010, a group of researchers from the European Academy of Andrology (EAA) generated an aCGH protocol, which has since then led the characterization of complex chromosomal rearrangements (CCRs) [bib_ref]  New insights in the genetics of oligo-terato-azoospermia, Cerv\u00e1n-Mart\u00edn [/bib_ref]  [bib_ref]  Y chromosome microdeletions: why we still count, Krausz [/bib_ref]  [bib_ref]  New approach demonstrates the clinical impact of the Y chromosome and suggests..., Mcauliffe [/bib_ref] . In brief, the protocol combines multiplex genomic screening (Y chromosome short tandem repeats (STRs) and chromosome 18 STRs) and a genomic scan using aCGH, detecting the loss of sequence copy number, on the basis of a normozoospermic reference sample. These studies have suggested that CCRs are a common genotype in infertile men presenting with oligo-, terato-, and/or azoospermia (OTA) and that the combined analysis of multiple loci is a convenient tool to detect the male side of infertility [bib_ref]  New insights in the genetics of oligo-terato-azoospermia, Cerv\u00e1n-Mart\u00edn [/bib_ref]  [bib_ref]  Y chromosome microdeletions: why we still count, Krausz [/bib_ref]  [bib_ref]  New approach demonstrates the clinical impact of the Y chromosome and",
        "label": 0
    },
    "1287": {
        "output": "We hope this solution helped, and we are ready to support you.\n\nPlease share your thoughts about the [#doc-005936] question and its solution.\n<EOD> A Novel Technique for the Production of the \u201cBubbliness Feel\u201d in Acrylic Art\nThis article provides an instruction guide for adding a \u201cbubbly\u201d or \u201cbubbliness\u201d effect to any acrylic painting by the use of air (or hydrogen) bubbles. This new technical technique was developed by the author and has the potential for creating an entirely new effect in acrylic painting. The instructions are well illustrated and simple to follow. A number of sample paintings demonstrating the use of this technique are included.<EOD> Inheritance of resistance to acetaryl in sweet corn.\nAcetyl (AC), an herbicideresistant corn (Zea mays L.) allele at the acrylic acid locus (AA3), was introduced into the Sweet-Maize and Sweet-Bounty commercial hybrids for production of AC corn. Inheritance of this allele may be either monogenic or dually dominant, although it is presently unknown which gene and the degree of dominance are responsible for this resistance to acetyl. To determine whether the resistance to acetyl is codominant, the AA genotypes were characterized in the hybrids and their segregating families. The segregation ratios were similar to that expected for monogenic transmission of resistance to acetyl: the AC plants (resistant) ranged from 22 to 40%, the heterozygous plants (susceptible) from 39 to 60% and the AA homozygous plants (susceptible) from 6 to 33%. The AC and AA plants were further characterized for the inheritance of a dominant AC-resistance trait and dominant AC-response (sensitivity) trait, using the hybrid Sweet-Bounty. The resistant plants (AC) showed only slight morphological differences from other plants, except that they were more vigorous and had greater kernel set than the susceptible plants. The resistant plants were more competitive for light than susceptible plants in plots of Sweet-Maize and Sweet-Bounty due to",
        "label": 0
    },
    "1288": {
        "output": "```R\nlibrary(trial)\n\nsubject2 <- patient_trial(text=get_patient_note(), name=\"a\",\"age_range=c(45,82),\n                      gender=c(\"f\",\"f\",\"f\"), raceA=c(\"white\",\"white\",\"white\"),\n                      raceB=c(\"black\",\"white\",\"white\"), ethnicity=c(\"hispanic\",\"white\",\"white\"),\n                      height_range=c(162,178), weight_range=c(86,145), bmi=c(26,33),\n                      marital_status=c(\"widow\",\"widow\",\"single\"), education=c(\"some_high\",\"graduate_degree\",\"graduate_degree\"),\n                      employment_status=c(\"employed\",\"employed\",\"employed\"), smoking_status=c(\"current_smoker\",\"current_smoker\",\"nonsmoker\"),\n                      comorbidity=c(\"hypercholesterolemia\",\"hypertension\",\"hypertension\"),\n                      clinical_status=c(\"currently_ill\",\"currently_ill\",\"recently_ill\"),\n                      clinical_trial=list(\"<NAME>\",\"<NAME>\",\"<NAME>\",\n                      trial.phase=\"II\"), condition=list(c(\"non-hodgkin_lymphoma\",\"colorectal_cancer\",\"non-hodgkin_lymphoma\"),\n                      condition.stage=list(c(\"relapsed-refractory\"),c(\"relapsed-refractory\"),c(\"IV\")),\n                      site=list(c(\"lymph-node\"),c(\"peritoneal-cavity\"),c(\"peritoneal-cavity\"),\n                      tumor=list(\"Burkitt_lymphoma\",\"colorectal_cancer\",\"non-hodgkin_lymphoma\"),\n                      histology=list(\"lymphoma\",\"non-small_cell_lung\",\"non-hodgkin_lymphoma\"),\n                      diagnosis_status=\"newly_diagnosed\"),\n                      comorbidity=list(\"none\",c(\"hypertension\"),c(\"hy",
        "label": 0
    },
    "1289": {
        "output": "1. Let's add the code to process the patient note.\n[INST]\nThis code extracts the variables from the patient note that you described above, assigns them variables that the patient note used and converts the variables into variables that the clinical trial used.\n[COD]\n{\n  \"Trial_participant_age\" : \"Age\",\n  \"Trial_participant_gender\" : \"Female\",\n  \"Trial_participant_obese\" : \"True\",\n  \"Trial_participant_hyperchole\" : \"True\",\n  \"Trial_participant_histNVD\" : \"True\",\n  \"Trial_participant_menopausal\" : \"True\",\n  \"Body_BMI\" : \"BMI\",\n  \"Hyper_cholest\" : \"Cholest\",\n  \"histNVD\" : \"true\",\n  \"menopausal\": \"true\",\n  \"BMI\" : \"24\",\n  \"Hyper_cholest\": \"True\",\n\n}\n\n2. Let's add the code to process the clinical trial information.\n[INST]. \nThe code above contains all rules that process the clinical trial note. The codes will be explained step by step below, but here is a summary of them:\n(1) If only age is the inclusion criteria, assign the age variable from the patient to the age variable of the clinical trial. This is just an example, there can be other cases.\n(2) If only gender is the inclusion criteria, assign the female variable from the patient to the female variable of the clinical trial. This is a just example, there can be other cases.\n(3) If neither gender nor age is the inclusion criteria, assign the clinical trial's generic \"1\" to the eligibility variable of the patient. That is because this clinical trial's exclusion criteria are so strict that the patient would not pass the assessment stage at all.\n(4) If the trial \"Exclude\" variable of the clinical trial is \"True\", let the trial-level eligibility also be \"Exclude\" and assign the age and gender of the patient to the gender and age variables of the clinical trial. If the trial \"",
        "label": 0
    },
    "1290": {
        "output": "<EOD> Preparations and Appliances\n\nUNDER THE CHARGE OF Preparations and Appliances\nM.DM.DUNDER THE CHARGE OF Preparations and Appliances\n466 PREPARATIONS AND APPLIANCES.\nThe B.A.A.P. has been specially prepared from a number of drugs and active ingredients, so that the physician can administer a cocktail of therapeutic agents to meet all contingencies in a single drink. This includes such powerful therapeutic agents as bromides, paraldehyde, hydrochloric acid, boric acid, and antipyrin. The B.A.A.P. has already been described in these columns (Vol. XCVI., p. 223) and appears to have had a satisfactory reception in practice.A new product of the firm of Messrs. Henry Lamotte is a preparation for the treatment of chlorosis and anaemic states of the blood. Lamotte's Anforderingsriicke is a syrup of wild strawberry flavour with a slightly acid reaction. It contains the following:?Extractum ferri iodidi 0*01, extractum perchloridi ferri 0-01, liq. arseniatis rubri 0'0004, tincturae ex quassia 0-04, tincturae ex quinine 0*01, aquae distillatae 50, aeeticse ad 50, sativae radicles 30, liquoris ex strelitias narnii fermenti 30, syrupus aroniae 260, and syrupus althaeae 25. In addition there are the usual preservatives and sweetenings. It is claimed that the product is specially indicated for all gynaecologicai cases, menorrhagia, dysmenorrheal, metrorrhagia, oligophrenia and chlorosis.Another product for the physician which has lately appeared is a preparation known as ' Fleming's Medical Honey Dew.' This is a form of the honeycomb of the stingless bee",
        "label": 2
    },
    "1291": {
        "output": "### Questions from Classes\n\n*What is the difference between the patient note and patient record? \n*What is the difference between two types of errors? \n*What are the advantages that help us overcome the limitations of a computer? What are the disadvantages that we need to tackle? \n\n\n#### Notes\n<EOD> Role of endogenously synthesized prostaglandins in the regulation of renal Na+ excretion, blood pressure, and Na+ appetite in rats\n\n\n\n# Introduction\nThe kidney is the main site for regulation of body fluid and electrolyte excretion. The primary renal transporter involved in salt handling is the Na + , K + -ATPase, which is located in the luminal membranes of the principal cells in the ascending limb and also the intercalated cells of the connecting tubule and collecting duct [bib_ref]  Mechanisms of salt-sensitive hypertension, Luzardo [/bib_ref] . Prostaglandins (PGE 2 , PGI 2 ) act in the kidney by modulating transport activity of the Na + , K + -ATPase and the sodium chloride cotransporter (NCCT) [bib_ref]  Prostaglandins as modulators of renal tubular transport, Ellison [/bib_ref] . In the kidney, the metabolism of arachidonic acid from the membrane phospholipids, to PGE 2 , PGI 2 and their metabolites is mediated in large part by the enzyme cyclooxygenase (COX), which catalyzes the conversion of arachidonic acid to prostaglandin H 2 (PGH 2 ). PGH 2 is then converted to the final major product PGs which will be the subject of the review.\nThe physiological function of PGs is mediated by G-protein coupled receptors (GPCR) that are coupled via their G a/b subunits to adenylyl cyclase [bib_ref]  Prostaglandin and thromboxane G protein-coupled receptors as drug targets, Breyer [/bib_ref] . Activation of these receptors, also by pharmacological agonists, will lead to their physiological",
        "label": 0
    },
    "1292": {
        "output": "*_INSTRUCTIONS_FOR_USER_*\n\n### TARE\nThese questions refer to the following CQs: \n6.30.4 | Is the use of targeted Treg cell therapy in adults with autoimmune hepatitis more efficacious and safe than placebo or best supportive care for maintaining remission?\n6.37.3 | Is the use of tumour-infiltrating lymphocytes (TILs) for the treatment of colorectal cancer more efficacious and safe than immunotherapy with ipilimumab or nivolumab?\n9.17.1 | Are the use of anti-CD3 monoclonal antibodies (mAbs) or immune checkpoint inhibitors (ICIs) better than placebo or best supportive care for the treatment of acute Graft-versus-Host-Disease (aGVHD)?\n\\_\\_INSTRUCTIONS FOR USER_*\n[*_INSTRUCTIONS_FOR_USER_*]\n\n### TARGETED TREG CELL THERAPY\nPlease answer the respective question on a case-by-case basis. The case may have a number (e.g.~1) for each patient receiving the allocated intervention and may have a description (free text)\nof the patient. 500.\n[*_INSTRUCTIONS_FOR_USER_*]\n\n### TARGETED TREG CELL THERAPY IN ADULTS WITH AUTOIMMUNE HEPATITIS\nTcell treatment\n\n### TARGETED TREG CELL THERAPY IN HUMAN IMMUNE DEFICIENCY\nBacterial infections\n\n### TARGETED TREG CELL THERAPY IN INFANTILE INFLAMMATORY BOWEL DISEASE\nAntimicrobial resistance\n\n### TUMOUR-INFILTRATING LYMPHOCYTES (TILS) THERAPY\nPlease answer the respective question on a case-by-case basis. The case may have a number (e.g.~1) for each patient receiving the allocated intervention and may",
        "label": 0
    },
    "1293": {
        "output": "Note1. Here is the eligibility statement you should complete per trial. Use one statement to be suitable for all eligible subjects. You should not make separate statements for excluded or not relevant patients. You should not use 0) Excluded. 1) Not relevant. 2) Eligible. If you cannot decide whether someone qualifies on the first review, you should mark it 0) Excluded. 1) Not relevant. 2) Eligible. \n\nNote2. As the trial-level assessment of eligibility is the primary outcome, you should write your eligibility assessment in the first line. For example, if you write `Excluded.`, then you should write `Excluded. = 0. Excluded on the grounds of the trial's exclusion criteria`.` in the first line. However, if you write `Not relevant.`, then you should write `Not relevant. = 1. Not relevant on the grounds of insufficient information.` in the first line.\n\n\n\n``` r\n# Write the trial-level assessment you should make for each patient and put a blanket statement by `=2) Eligible` if the statements are all the same in the last line\n\nTrial.assessment <- \" =2) Eligible\"\n```\n\n``` r\n# Make trial-level assessment based on the patient's information you wrote before.\n\nTrial.assessment <- paste(\"Triallevel Assessment:  = \", clinical.trial$Name, \" = \", as.factor(S(trials.eligible))))\nTrial.assessment <- paste(Trial.assessment)\n```\n\n``` r\npar(\"mfrow\")\nwrite.table(Trial.assessment, file = \"table_write.txt\", sep = \";\", quote = FALSE, row.names = FALSE)\n```\n### Additional File \"README.md\"\nTo start an R session. Run the following from an R console or terminal.\n``` r\ninstall.packages(\"readr\")\ninstall.packages(\"tidyverse\")\nlibrary(readr\n```\n# For R sessions in interactive mode\n``` r\ninstall.packages(\"SHINY\")\nlibrary(SHINY)\nshiny::runApp(\"",
        "label": 0
    },
    "1294": {
        "output": "## Examples\n\nWe want to extract and visualize the patient IDs, trial types, and trial titles from both ClinR and ClinV data sources. \n```sql\nSELECT\n  ClinTrial.patient_id,\n  ClinTRail.trial_type,\n  ClinTrial.trial_title\n  FROM ClinTrial\n  WHERE\n    trial_type = 'PROTOCOL'\n  UNION\n  SELECT\n    ClinV.patient_id,\n    ClinTRail.trial_type,\n    ClinTrial.trial_title\n  FROM ClinV\n  WHERE\n    trial_type = 'OVERALL'\n```\nLet's load the dataset with Pandas:\n```python\nimport pandas as pd\n\nprint(pd.set_option('display.max_columns',1000)) print(pd.get_datalink()) print( pd.get_datalink().name() ) print('pd:', pd.get_datalink().name(), '\\n') print(pd.set_option('display.max_rows', 1000))\n\n# pd.set_option('display.max_rows',25)\n# print(pd.get_datalink()) # 'SQLite'\n```\nWe will use the following SQL syntax:\n```sql\nSELECT\n  * FROM ClinTrial\n    WHERE\n      trial_type = 'PROTOCOL'\n    UNION\n    SELECT\n      * FROM ClinTrial\n        WHERE\n          trial_type = '<NAME>'\n    UNION\n    SELECT\n      * FROM ClinV\n        WHERE\n          trial_type = '<NAME>'\n```\nThe following code is used to load the dataset with SQL and return `pandas.DataFrame`.\n```python\nimport pandas as pd\nfrom sqlalchemy.sql import func\nfrom sqlalchemy import create_engine\nimport numpy as np\nsql = \"\"\"\n    SELECT id1.patient_id, id2.trial_type, id2.trial_title\n  FROM ClinTrial\n    as id1\n    LEFT JOIN ClinTRail\n      AS id2\n      WITH LAST\n      ON id1.id = id2.patient",
        "label": 0
    },
    "1295": {
        "output": "[STUPEL] After you successfully run the `h2.028_patient` file, you can test `h2.028_patient` using `filetester.py`. The following text should appear when running `filetester.py`: \n\n```\nYou can also run the following commands which are in the `filetester.py` notebook under the directory `code` to test the `h2.028_patient` file.\n\n1. Copy this code to notepad++. This is the filetester code.\n\n2. Open a command line and change the directory to the `code` directory. Here is the command to use: cd code\n\n3. Run the following commands to test that the `d20_clinicalTrials.csv` file is loaded and that the `d20_clinicalTrials` notebook is opened. This requires the `filetester.py` script.\n> python filetester.py\n> cd ..\n> cd clinicalTrials\n> Python filetester.py\n\n4. After changing the directory to the `code` directory, you can run the filetester script.\n\n>> Filetester.py\n\nThis takes some time, and a prompt will appear asking you to wait.\n5. Check the result to see if successful execution of filetester.py is in the output of Python. If the program is successful, it is displayed on the first line, i.e., `Successful execution of filetester.py`, on the `Screen.txt` file. \n\n\nYou should not press any button except return on the keyboard to continue, because sometimes the result of the filetester.py may show in the output, but the Screen.txt file continues to generate an error message that the `Screen.txt` file does not exist. If the Screen.txt file starts with the number of lines, it is because that means to load the first line from the `Screen.txt` file after executing filetester.py. Let's see if the program is OK, by looking the first line of the `Screen.txt` file. It should show number 1 after the filetester.py was executed successfully. If the `Screen.txt` file contains no data, Python 3.5.",
        "label": 0
    },
    "1296": {
        "output": "# [C] Evaluate Your Output\nEvaluation is the last task in eligibility assessment.\n\n\n## [INST] Evaluation\nAt the end of the eligibility assessment, the program should evaluate the output of you eligibility assessment.\nOn the basis of your eligibility assessment, you are asked to evaluate and justify the result with a 3-stage scale: 0) Excluded (the patient does not meet the inclusion criteria); 1) Not relevant (the patient meets the inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria); and 2) Eligible (the patient meets the inclusion criteria and exclusion criteria do not apply).\n[EXPL] How to Evaluate?\n- There are three cases (0) excluded, (1) not relevant, and (2) eligible.\n- You should evaluate on the basis of your justification and clinical reasoning.\n- Each patient has three possible trials, so repeat these evaluations three times\n\n## [C] Test Your Code\n\n\n## [INST] Test Your Code\nThe program should be tested by two or more experts who have sufficient experience and knowledge in using the clinical trials eligibility assessment tool. You should make a trial-level eligibility on each patient\nTesting of the code is to ensure that the code works as you wanted it to.\nThe purpose of testing is to verify that the code performs the expected task. This verification process determines if the programs work as the creator intended. \n\n## [C] Debugging of the Code\nAs well you have seen in the testing, there are still some problems such as you input error and error in the logic of code. But there is a remedy to solve the problem. This is called debugging.\nDebugging is a process to find and eliminate bugs. It fixes programming bug to make sure that the code running program works as expected. \n\n# Discussion\nYou may develop your coding skills by comparing the code of each of your peers with your own code.<EOD> Prolonged Inhibition of T Follicular Helper Cells and Germinal Center Activity Due to Omicron SARS-CoV-2 BA.1 Infection\n\nBackground: Omicron, the latest SARS-CoV",
        "label": 0
    },
    "1297": {
        "output": "Since each patient has several lines, you should make `Array of sample-level eligibilities: [0 0 NaN 0 0 NaN 0 0 NaN]`. The sample-level eligibility is similar to the trial-level eligibility, since the patient-level eligibility includes all patients with the patient's name. [/",
        "label": 0
    },
    "1298": {
        "output": "># Exercise\n>Above, we learned to apply the rules of eligibility using the patient note. You may do a trial-level eligibility of [EXERCISE](https://cod.es/570f9b63a75d9c5c6b598d0d85b633a2) using the patient note and a clinical trial. Please submit your exercise with the name ```report_exercise_n1.html```.\n\n# Summary\nIn this lecture, we learned to determine patient eligibility using a patient note and a clinical trial. You should always follow the rules and write a rational sentence of eligibility.\n<EOD> Clinical and biological markers of early thymic function\nThe thymus is the major organ in which precursors of T-lymphocytes develop to mature T-lymphocytes. Thymus dysfunction is associated with an increase in early postnatal infection and morbidity as shown by thymic hypoplasia and by congenital atrophy or aplasia of the thymus. Immunological studies of the thymus gland have led to the identification of thymus epithelial cells (TECs) as the most important population of stromal cells in thymus organogenesis. TECs provide the physical environment by cellular interaction. The thymus expresses high levels of cytokines and chemokines that guide the differentiation and maturation of T-lymphocytes from the bone marrow to the thymus and the egress process of mature T-lymphocytes .<EOD> An Analysis of the Bonds of Nucleobases and Their Derivatives with N2 and N3 of Purine/Pyrimidine Using DFT Methods: Implications for the Biological Impact of Chemical Modifications\n\n\n\n# Introduction\nMany fundamental biological processes, including DNA synthesis and mRNA splicing, are regulated by RNA modifications. The main source of natural variability in the functioning of RNA-containing systems is the variety of modified nucleosides and their combinations. These chemical modifications can be introduced at any position of the entire molecule or only at the sugar part",
        "label": 0
    },
    "1299": {
        "output": "### [CASE-1]_QUESTION]\nIn order to reduce the overall error rate for the automated process, in addition to the error of clinical trial assignment, a researcher needs to make sure that each patient is assigned the correct clinical trial. To do that, the researcher creates 3 separate files, an Excel file that contains patient notes, ClinicalTrials.gov (CT) metadata and clinical trials. The Excel file is a CSV file, and the column headings of the data fields are defined in CSV header columns. The file that contains the CT metadata follows a slightly different format. It has column headings that are defined in header paragraphs. The three CSV files should be input into the Python notebook, and processed by the automated process. The script starts by merging the CSV files into a dictionary. It searches for the matching patients among clinical trials using the patient's ID in Patients CSV file. The ID is unique for each patient, so that it will never be used by multiple patients in a clinical trial. Then, the script outputs the ID and the matching trial ID for patients in each CT data file. The output CSV file will contain one patient ID per row, one trial ID per column.\n\nNote: All Python script functions and the notebook (replay) can be found in our GitHub repository ([CLIN] [LINK]):\n![INST]\n\n[CONTINUED] (2.1) Data Cleaning and Mergence:\nThe file that only has trial data will be merged with the file that has patient data. At this point, we have a dictionary with columns named trial ID, type, start_date, and end_date as well as patient ID, trial ID, note.\n[CLIN] \n\n[CONTINUED] (2.2) Clinical Trial Eligibility:\nThe trial IDs form a set, and only the patient IDs that have trial IDs within that set are available for the clinical trial eligibility step. In this step, each patient is compared with each clinical trial that they are known to have. For each clinical trial, the script will count the number of patients who are eligible for each trial, and return the number of patients as results. The following line in the output csv file shows an example for each clinical trial with the same patient ID who was assigned to",
        "label": 0
    },
    "1300": {
        "output": "<EOD> Genomics of bacterial egg-associated pathogens.\nEgg-associated infections can have a significant impact on poultry performance, and the pathogenic bacteria involved may pose a risk for human health. Although the etiology of these infections is multifactorial, bacteria are major constituents of the egg or fertilized egg surface. In this article we review the genetic attributes and potential mechanisms involved in virulence for the genetic determinants of three common species: Campylobacter jejuni, Salmonella enterica, and Escherichia coli.<EOD> Hydrophobic/Lipophilic Properties of a Molecular System with Hydrogen-Bonding-Driven Charge-Transfer Structures.\nA series of organic molecules with hydrogen-bond charge-transfer structures (HBCTs) were theoretically designed and their hydrophobic/lipophilic properties were investigated. Intramolecular HBs were first constructed by cation-\u03c0 interaction and then the hydrogen-bond-driven charge transfer was designed to construct the cation-\u03c0 and n\u2192\u03c0* interactions at the same or different times by introducing C=N/C=O groups between CNs and benzene moieties with different \u03c0 electron densities. The molecules show lipophilicity and the logarithmic values of their partition coefficients of their aqueous solution/dichloromethane (logKSA/DCM) range from -1.634 to -3.600 with the introduction of benzene or pyridine moieties, depending on the electron density of the \u03c0 orbitals. It was found that the lipophilic/hydrophilic properties of the molecules with HBCTs could be tuned by molecule-water interactions (MUIs) from 2 to -122 kJ mol-1 and then hydrophobic/lipophilic properties were modulated by the balance of intramolecular HB energy (IHBE) and MUI. The results also indicated that the charge-transfer properties were mainly regulated by the balance of intramolecular HB energy (IHBE) and MUI under the hydrogen-bonding",
        "label": 0
    }
}